PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	De Wulf, P; McGuire, AM; Liu, XQ; Lin, ECC				De Wulf, P; McGuire, AM; Liu, XQ; Lin, ECC			Genome-wide profiling of promoter recognition by the two-component response regulator CpxR-P in Escherichia coli.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ENVELOPE STRESS; SEQUENCE LOGOS; PROTEINS; MUTATIONS; BINDING; SYSTEM; INVOLVEMENT; SUPPRESSES; ACTIVATION	In Escherichia coli, the two-component Cpx system comprising the CpxA sensor kinase and the CpxR response regulator modulates gene expression in response to a variety of stresses including membrane-protein damage, starvation, and high osmolarity. To date, the few known CpxR-P target operons were mostly identified by genetic screens. To facilitate the discovery of all target operons, we derived a 15-bp weighted matrix for CpxR-P recognition that takes into account the relative base frequency at each nucleotide position. This matrix essentially consists of two tandem 5'-GTAAA-3' motifs separated by a 5-bp linker. All of the 15-bp stretches on both strands of the E. coli MG1655 genome were then scored for their degree of matching with the matrix and classified in statistical deviation groups. The effectiveness of this screening is indicated by the identification of eight new target operons (ung, ompC,psd, mviA, aroK, rpoErseABC, secA, and aer) among eleven candidates tested. Moreover, the matrix score correlates with the likelihood that a site is a true target and with the relative site affinity for CpxR-P in vitro. Our data indicate that some 100 operons are under direct CpxR-P control and that the signal transduction pathway interacts with several other control circuits in manners hitherto unanticipated.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	elin@hms.harvard.edu	Manson, Abigail/B-7132-2016	Manson, Abigail/0000-0002-3800-0714; LIU, XUEQIAO/0000-0001-7652-241X; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; COSMA CL, 1995, MOL MICROBIOL, V18, P491, DOI 10.1111/j.1365-2958.1995.mmi_18030491.x; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Danese PN, 1998, J BACTERIOL, V180, P5875, DOI 10.1128/JB.180.22.5875-5884.1998; Dartigalongue C, 1998, EMBO J, V17, P3968, DOI 10.1093/emboj/17.14.3968; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; De Wulf P, 2000, MICROBIOL-UK, V146, P247, DOI 10.1099/00221287-146-2-247; De Wulf P, 2000, J BACTERIOL, V182, P1423, DOI 10.1128/JB.182.5.1423-1426.2000; Dorel C, 1999, FEMS MICROBIOL LETT, V178, P169, DOI 10.1111/j.1574-6968.1999.tb13774.x; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GROSS CA, 1996, ESCHERICHIA COLI SAL, V2, P1382; Harrison-McMonagle P, 1999, J MOL BIOL, V285, P555, DOI 10.1006/jmbi.1998.2375; JACOBDUBUISSON F, 1994, P NATL ACAD SCI USA, V91, P11552, DOI 10.1073/pnas.91.24.11552; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; MCEWEN J, 1980, P NATL ACAD SCI-BIOL, V77, P513, DOI 10.1073/pnas.77.1.513; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Missiakas Dominique, 1996, P481; NAKAYAMA S, 1995, J BACTERIOL, V177, P5062, DOI 10.1128/jb.177.17.5062-5069.1995; Pogliano J, 1998, J BACTERIOL, V180, P3486, DOI 10.1128/JB.180.13.3486-3490.1998; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; RAINWATER S, 1990, J BACTERIOL, V172, P2456, DOI 10.1128/jb.172.5.2456-2461.1990; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Schneider TD, 1996, METHOD ENZYMOL, V274, P445; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; THORBJARNARDOTTIR SH, 1978, MOL GEN GENET, V161, P89, DOI 10.1007/BF00266619	39	163	167	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26652	26661		10.1074/jbc.M203487200	http://dx.doi.org/10.1074/jbc.M203487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11953442	hybrid			2022-12-25	WOS:000176908700107
J	Laboissiere, MCA; Young, MM; Pinho, RG; Todd, S; Fletterick, RJ; Kuntz, I; Craik, CS				Laboissiere, MCA; Young, MM; Pinho, RG; Todd, S; Fletterick, RJ; Kuntz, I; Craik, CS			Computer-assisted mutagenesis of ecotin to engineer its secondary binding site for urokinase inhibition.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; IN-VITRO SELECTION; PLASMINOGEN-ACTIVATOR; PEPTIDE LIBRARIES; 2-HYBRID SYSTEM; PHAGE DISPLAY; RNA; METASTASIS; MOLECULES; EVOLUTION	Inhibitors of urokinase-type plasminogen activator WPM were selected in vitro from two ecotin phage-display libraries to study the effect on binding of amino acid substitutions at critical positions 108, 110, 112, and 113 within the 100s loop (RNKL, respectively, in wild type ecotin). The first, a focused library, was the result of a computation-assisted approach using the three-dimensional structure of the ecotin-trypsin complex to guide the modeling of amino acid substitutions predicted to increase affinity for uPA. The second, a complete library, allowed for all substitutions at the above identified positions. The consensus sequences selected from the focused, and complete libraries were RRWS and R(R/N)QL, respectively. Inhibition constant determinations showed ecotin variants containing these sequences to be similarly potent (K-i = 1-2 nm). These substitutions were combined with previously identified substitutions in another critical region of ecotin. One of these combinations (D70R/M84R/RRQL) is the tightest (Ki = 50 pm) ecotin variant inhibitor of uPA. The blending of combinatorial methods and computer algorithms designed to predict stronger binders has allowed us to obtain protein derivatives that exhibit greatly increased affinity for a predetermined target. This technology can be applied to select for enhanced binding interactions at protein-protein interfaces and accelerate the process of protease inhibitor development.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Brasilia, Dept Ciencias Farmaceut, Fac Ciencias Saude, BR-70910900 Brasilia, DF, Brazil	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.			Young, Malin/0000-0001-8343-4469	NCI NIH HHS [CA72006] Funding Source: Medline; NIDDK NIH HHS [DK39304] Funding Source: Medline; NIGMS NIH HHS [GM31497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GULBA DC, 1996, ANN HEMATOL S1, V73, P9; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Hoogenboom HR, 1997, TRENDS BIOTECHNOL, V15, P62, DOI 10.1016/S0167-7799(97)84205-9; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; LEE HR, 1991, FEBS LETT, V287, P53, DOI 10.1016/0014-5793(91)80014-T; MCGRATH ME, 1994, EMBO J, V13, P1502, DOI 10.1002/j.1460-2075.1994.tb06411.x; MENG EC, 1992, J COMPUT CHEM, V13, P505, DOI 10.1002/jcc.540130412; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Reuning U, 1998, INT J ONCOL, V13, P893; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; WELLS J A, 1992, Current Opinion in Biotechnology, V3, P355, DOI 10.1016/0958-1669(92)90163-D; Yang SQ, 1998, J MOL BIOL, V279, P945, DOI 10.1006/jmbi.1998.1748; Yang SQ, 1998, J MOL BIOL, V279, P1001, DOI 10.1006/jmbi.1998.1749; Zou XQ, 1999, J AM CHEM SOC, V121, P8033, DOI 10.1021/ja984102p	31	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26623	26631		10.1074/jbc.M203076200	http://dx.doi.org/10.1074/jbc.M203076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11959867	hybrid			2022-12-25	WOS:000176908700104
J	Efron, L; Dagan, A; Gaidukov, L; Ginsburg, H; Mor, A				Efron, L; Dagan, A; Gaidukov, L; Ginsburg, H; Mor, A			Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ANTIMICROBIAL PEPTIDES; PLASMA-MEMBRANE; TARGET; ANTIBIOTICS; MAGAININ; BLOOD	Antiplasmodial activity of the dermaseptin S4 derivative K(4)S4(1-13) (P) was shown to be mediated by lysis of the host cells. To identify antiplasmodial peptides with enhanced selectivity, we produced and screened new derivatives based on P and singled out the aminoheptanoylated peptide (NC7-P) for its improved antiplasmodial properties. Compared with P, NC7-P displayed both increased antiparasitic efficiency and reduced hemolysis, including against infected cells. Antiplasmodial activity of P and its derivative was time-dependent and irreversible, implying a cytotoxic effect. But, whereas the dose dependence of growth inhibition and hemolysis of infected cells overlapped when treated with P, NC7-P exerted more than 50% growth inhibition at peptide concentrations that did not cause hemolysis. Noticeably, NC7-P but not P, dissipated the parasite plasma membrane potential and caused depletion of intraparasite potassium at nonhemolytic conditions. Confocal microscopy analysis of infected cells localized the rhodaminated derivative in association with parasite membranes and intraerythrocytic tubulovesicular structures, whereas in normal cells, the peptide localized exclusively at the plasma membrane. Overall, the data demonstrate that antimicrobial peptides can be engineered to act specifically on the membrane of intracellular parasites and support a mechanism whereby NC7-P crosses the host cell plasma membrane and disrupts the parasite membrane(s).	Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Ginsburg, H (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, IL-91904 Jerusalem, Israel.	hagai@vms.huji.ac.il						Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.3.CO;2-B; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; Dagan A, 2002, ANTIMICROB AGENTS CH, V46, P1059, DOI 10.1128/AAC.46.4.1059-1066.2002; Diaz-Achirica P, 1998, BIOCHEM J, V330, P453, DOI 10.1042/bj3300453; ELFORD BC, 1993, PARASITOL TODAY, V9, P80, DOI 10.1016/0169-4758(93)90205-T; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Feder R, 2001, PEPTIDES, V22, P1683, DOI 10.1016/S0196-9781(01)00504-6; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609; GRELLIER P, 1991, J CELL BIOL, V112, P267, DOI 10.1083/jcb.112.2.267; Gura T, 2001, SCIENCE, V291, P2068, DOI 10.1126/science.291.5511.2068; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; JAYNES JM, 1988, FASEB J, V2, P2878, DOI 10.1096/fasebj.2.13.3049204; Krugliak M, 2000, ANTIMICROB AGENTS CH, V44, P2442, DOI 10.1128/AAC.44.9.2442-2451.2000; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; Lamb HM, 1998, DRUGS, V56, P1047, DOI 10.2165/00003495-199856060-00011; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Levy O, 2000, BLOOD, V96, P2664; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MIKKELSEN RB, 1982, J CELL BIOL, V93, P685, DOI 10.1083/jcb.93.3.685; MILIK M, 1993, PROTEINS, V15, P10, DOI 10.1002/prot.340150104; Mor A, 2000, DRUG DEVELOP RES, V50, P440, DOI 10.1002/1098-2299(200007/08)50:3/4<440::AID-DDR27>3.3.CO;2-W; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOR A, 2001, KIRK OTHMER ENCY CHE; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; Oren Z, 1998, BIOPOLYMERS, V47, P451; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; SOBALLE PW, 1995, INT J CANCER, V60, P280; Sokolov Y, 1999, BBA-BIOMEMBRANES, V1420, P23, DOI 10.1016/S0005-2736(99)00086-3; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; TANABE K, 1989, J PROTOZOOL, V36, P139, DOI 10.1111/j.1550-7408.1989.tb01060.x; Tossi A, 2000, BIOPOLYMERS, V55, P4; Uematsu N, 2000, BIOPHYS J, V79, P2075, DOI 10.1016/S0006-3495(00)76455-1; Vial H., 1998, MALARIA PARASITE BIO, P159; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; White SH, 1998, BBA-REV BIOMEMBRANES, V1376, P339, DOI 10.1016/S0304-4157(98)00021-5; *WHO, 1999, DIS STAT WORLD HLTH; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	49	66	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24067	24072		10.1074/jbc.M202089200	http://dx.doi.org/10.1074/jbc.M202089200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11937508	hybrid			2022-12-25	WOS:000176611800014
J	Miyajima, H; Miyaso, H; Okumura, M; Kurisu, J; Imaizumi, K				Miyajima, H; Miyaso, H; Okumura, M; Kurisu, J; Imaizumi, K			Identification of a cis-acting element for the regulation of SMN exon 7 splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; MOTOR-NEURON GENE; MOLECULAR ANALYSIS; HNRNP A1; SEVERITY; PROTEIN; DUPLICATION; EXPRESSION; ENHANCERS; DELETIONS	Spinal muscular atrophy results from the loss of functional survival motor neuron (SMN1) alleles. Two nearly identical copies of SMN exist and differ only by a single non-polymorphic C to T transition in exon 7. This transition leads to alteration of exon 7 splicing; that is, SMN1 produces a full-length transcript, whereas SMN2 expresses a low level of full-length transcript and predominantly an isoform lacking exon 7. The truncated transcript of SMN encodes a less stable protein with reduced self-oligomerization activity that fails to compensate for the loss of SMN1. In this paper, we identified a cis-acting element (element 1), which is composed of 45 bp in intron 6 responsible for the regulation of SMN exon 7 splicing. Mutations in element 1 or treatment with antisense oligonucleotides directed toward element 1 caused an increase in exon 7 inclusion. An similar to33-kDa protein was demonstrated to associate with a pre-mRNA sequence containing both element 1 and the C to T transition in SMN exon 7 but not with the sequence containing mutated element 1, suggesting that the binding of the similar to33-kDa protein plays crucial roles in the skipping of S3LV exon 7 containing the C to T transition.	NAIST, Div Struct Cellular Biol, Nara 6300101, Japan	Nara Institute of Science & Technology	Imaizumi, K (corresponding author), NAIST, Div Struct Cellular Biol, 8916-5 Takayama, Nara 6300101, Japan.			Miyaso, Hidenobu/0000-0003-2212-1500				Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, ANN NEUROL, V41, P230, DOI 10.1002/ana.410410214; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hertel KJ, 1997, CURR OPIN CELL BIOL, V9, P350, DOI 10.1016/S0955-0674(97)80007-5; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Simard LR, 1997, AM J MED GENET, V72, P51, DOI 10.1002/(SICI)1096-8628(19971003)72:1<51::AID-AJMG11>3.0.CO;2-T; Tange TO, 2001, EMBO J, V20, P5748; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9	30	84	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23271	23277		10.1074/jbc.M200851200	http://dx.doi.org/10.1074/jbc.M200851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956196	hybrid			2022-12-25	WOS:000176475700024
J	Sanchez-Chapula, JA; Navarro-Polanco, RA; Culberson, C; Chen, J; Sanguinetti, MC				Sanchez-Chapula, JA; Navarro-Polanco, RA; Culberson, C; Chen, J; Sanguinetti, MC			Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; POTASSIUM CHANNEL; RECEPTOR-SITE; CARDIAC-ARRHYTHMIA; CHLOROQUINE; RECTIFIER; MECHANISM; BINDING; RECTIFICATION; DOFETILIDE	The structural determinants for the voltage-dependent block of ion channels are poorly understood. Here we investigate the voltage-dependent block of wild-type and mutant human ether-a-go-go related gene (HERG) K+ channels by the antimalarial compound chloroquine. The block of wild-type HERG channels expressed in Xenopus oocytes was enhanced as the membrane potential was progressively depolarized. The IC50 was 8.4 +/- 0.9 muM when assessed during 4-s voltage clamp pulses to 0 mV. Chloroquine also slowed the apparent rate of HERG deactivation, reflecting the inability of drug-bound channels to close. Mutation to alanine of aromatic residues (Tyr-652 or Phe-656) located in the S6 domain of HERG greatly reduced the potency of channel block by chloroquine (IC50 > 1 mM at 0 mV). However, mutation of Tyr-652 also altered the voltage dependence of the block. In contrast to wild-type HERG, block of Y652A HERG channels was diminished by progressive membrane depolarization, and complete relief from block was observed at +40 mV. HERG channel block was voltage-independent when the hydroxyl group of Tyr-652 was removed by mutating the residue to Phe. Together these findings indicate a critical role for Tyr-652 in voltage dependent block of HERG channels. Molecular modeling was used to define energy-minimized dockings of chloroquine to the central cavity of HERG. Our experimental findings and modeling suggest that chloroquine preferentially blocks open HERG channels by cation-pi and v-stacking interactions with Tyr-652 and Phe-656 of multiple subunits.	Univ Utah, Eccles Inst Human Genet, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Colima, Unidad Invest Carlos Mendez, Ctr Univ Invest Biomed, Colima 23000, Mexico; Merck Res Labs, Mol Syst, West Point, PA 19486 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Universidad de Colima; Merck & Company	Sanguinetti, MC (corresponding author), Univ Utah, Eccles Inst Human Genet, Eccles Program Human Mol Biol & Genet, 15 N 2030 E,Rm 4220, Salt Lake City, UT 84112 USA.	michael.sanguinetti@hmbg.utah.edu	Navarro-Polanco, Ricardo/AAQ-6152-2021; Sanguinetti, Michael/AAN-2615-2020		FOGARTY INTERNATIONAL CENTER [R03TW001211] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055236] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW001211] Funding Source: Medline; NHLBI NIH HHS [R01HL55236] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BUSTOS MDG, 1994, TROP MED PARASITOL, V45, P83; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; FAUCHIER JP, 1993, ARCH MAL COEUR VAISS, V86, P757; FURUKAWA T, 1989, J PHARMACOL EXP THER, V251, P756; HARRIS L, 1988, CAN J CARDIOL, V4, P295; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; HONDEGHEM LM, 1984, ANNU REV PHARMACOL, V24, P387, DOI 10.1146/annurev.pa.24.040184.002131; Kamiya K, 2001, MOL PHARMACOL, V60, P244, DOI 10.1124/mol.60.2.244; Kang JS, 2001, MOL PHARMACOL, V59, P122, DOI 10.1124/mol.59.1.122; Kang JS, 2001, J PHARMACOL EXP THER, V299, P290; Katayama Y, 2000, J PHARMACOL EXP THER, V294, P339; Lees-Miller JP, 2000, MOL PHARMACOL, V57, P367; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; MILLER MD, 1994, J COMPUT AID MOL DES, V8, P153, DOI 10.1007/BF00119865; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Roden DM, 1998, AM J CARDIOL, V82, p49I, DOI 10.1016/S0002-9149(98)00472-X; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437; SANGHVI LM, 1965, CIRCULATION, V32, P281, DOI 10.1161/01.CIR.32.2.281; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; STARMER CF, 1985, J THEOR BIOL, V115, P337, DOI 10.1016/S0022-5193(85)80196-X; STARMER CF, 1987, BIOPHYS J, V52, P405, DOI 10.1016/S0006-3495(87)83229-0; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YEH JZ, 1978, NATURE, V273, P387, DOI 10.1038/273387a0; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	41	157	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23587	23595		10.1074/jbc.M200448200	http://dx.doi.org/10.1074/jbc.M200448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960982	hybrid			2022-12-25	WOS:000176475700064
J	Ahamed, J; Ali, H				Ahamed, J; Ali, H			Distinct roles of receptor phosphorylation, G protein usage, and mitogen-activated protein kinase activation on platelet activating factor-induced leukotriene C-4 generation and chemokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); KAPPA-B ACTIVATION; PERIPHERAL-BLOOD MONOCYTES; SIGNAL-REGULATED KINASES; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PROINFLAMMATORY CYTOKINE; CROSS-DESENSITIZATION; ARACHIDONIC-ACID; GENE-EXPRESSION	Platelet activating factor (PAF) interacts with cell surface G protein-coupled receptors on leukocytes to induce degranulation, leukotriene C-4 (LTC4) generation, and chemokine CCL2 production. Using a basophilic leukemia RBL-2H3 cell line expressing wild-type PAF receptor (PAFR) and a phosphorylation-deficient mutant (mPAFR), we have previously demonstrated that receptor phosphorylation mediates desensitization of PAF-induced degranulation. Here, we sought to determine the role of receptor phosphorylation on PAF-induced LTC4 generation and CCL2 production. We found that PAF caused a significantly enhanced LTC4 generation in cells expressing mPAFR when compared with PAFR cells. In contrast, PAF-induced CCL2 production was greatly reduced in mPAFR cells. Pertussis toxin and U0126, which inhibit G(i) and p44/42 mitogen-activated protein kinase (ERK) activation, respectively, caused very little inhibition of PAF-induced CCL2 production (similar to20% inhibition). In contrast, these inhibitors almost completely blocked both PAF-induced ERK phosphorylation and LTC4 generation in PAFR cells. However, in mPAFR cells pertussis toxin only partially inhibited PAF-induced ERK phosphorylation. A Ca2+/calmodulin inhibitor had no effect on PAF-induced ERK phosphorylation in PAFR cells but completely blocked the response in mPAFR cells. These data demonstrate that receptor phosphorylation, which serves to desensitize PAF-induced LTC4, generation, is required for chemokine CCL2 production. They also indicate a previously unrecognized selectivity in G protein usage and ERK activation for PAF-induced responses. Whereas PAF-induced CCL2 production is, in large part, mediated independently of Gi activation or ERK phosphorylation, LTC4 generation requires ERK phosphorylation, which is mediated by different G proteins depending on the phosphorylation status of the receptor.	Univ Penn, Sch Dent Med, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Pathol, 4010 Locust St,346 Levy Bldg, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166, R01HL063372] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54166, HL-63372] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2001, J IMMUNOL, V167, P3559, DOI 10.4049/jimmunol.167.7.3559; Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BRAQUET P, 1987, PHARMACOL REV, V39, P97; Briscoe C, 2001, DEV BIOL, V233, P225, DOI 10.1006/dbio.2001.0217; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jocks T, 1998, NEPHROL DIAL TRANSPL, V13, P37, DOI 10.1093/ndt/13.1.37; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maruoka S, 2000, AM J RESP CRIT CARE, V161, P922, DOI 10.1164/ajrccm.161.3.9906059; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Miura K, 1999, J IMMUNOL, V162, P4198; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nasu K, 1999, MOL HUM REPROD, V5, P548, DOI 10.1093/molehr/5.6.548; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Syrbu SI, 1999, J IMMUNOL, V162, P2334; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VENABLE ME, 1993, J LIPID RES, V34, P691; VERGHESE MW, 1987, J IMMUNOL, V138, P4374	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22685	22691		10.1074/jbc.M110210200	http://dx.doi.org/10.1074/jbc.M110210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934880	hybrid			2022-12-25	WOS:000176313600076
J	Arakawa, R; Yokoyama, S				Arakawa, R; Yokoyama, S			Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELLULAR LIPID EFFLUX; TANGIER-DISEASE; CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; INHIBITION; ALPHA; FIBROBLASTS; MACROPHAGES; GENERATION	ATP-binding cassette transporter (ABC) A1 was increased by apolipoprotein A-I without an increase of its message in THP-1 cells. The pulse label study demonstrated that apoA-I retarded degradation of ABCA1. Similar changes were demonstrated by apoA-II, but the effect of high density lipoprotein was almost negligible on the basis of equivalent protein concentration. Thiol protease inhibitors (leupeptin and N-acetyl-Leu-Leu-norleucinal (ALLN)) increased ABCA1 and slowed its decay in the cells, whereas none of the proteosome-specific inhibitor lactacystin, other protease inhibitors, or the lysosomal inhibitor NH4Cl showed such effects. The effects of apoA-I and ALLN were additive for the increase of ABC.,U,, and the apoA-I-mediated cellular lipid release was enhanced by ALLN. The data suggest that ABCA1 is rapidly degraded by a thiol protease(s) in the cells unless helical apolipoproteins in their lipid-free form stabilize ABCA1 by protecting it from protease-mediated degradation.	Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Grelan Pharmaceut Co Ltd, Div Res & Dev, Tokyo 2050002, Japan	Nagoya City University	Yokoyama, S (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Biochem Cell Biol & Metab, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.							Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2000, J LIPID RES, V41, P1952; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; Costet P, 2000, J BIOL CHEM, V275, P28240; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; Kojima K, 2001, BBA-MOL CELL BIOL L, V1532, P173, DOI 10.1016/S1388-1981(01)00124-X; LIANG HQ, 1995, BBA-LIPID LIPID MET, V1257, P31, DOI 10.1016/0005-2760(95)00055-H; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; TAJIMA S, 1983, J BIOL CHEM, V258, P73; Tomimoto S, 2001, ARTERIOSCL THROM VAS, V21, P394, DOI 10.1161/01.ATV.21.3.394; Tsujita M, 1996, BIOCHEMISTRY-US, V35, P13011, DOI 10.1021/bi960734h; Tsujita M, 2000, BBA-MOL CELL BIOL L, V1485, P199, DOI 10.1016/S1388-1981(00)00061-5; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Von Eckardstein A, 2001, FASEB J, V15, P1555, DOI 10.1096/fj.00-0798com; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	31	173	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22426	22429		10.1074/jbc.M202996200	http://dx.doi.org/10.1074/jbc.M202996200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950847	hybrid			2022-12-25	WOS:000176313600042
J	Lu, ML; Huang, YW; Lin, SX				Lu, ML; Huang, YW; Lin, SX			Purification, reconstitution, and steady-state kinetics of the trans-membrane 17 beta-hydroxysteroid dehydrogenase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 MESSENGER-RNA; EXPRESSION; PROTEINS; CELLS; IDENTIFICATION; TRANSPORTER; ENZYME	Human membrane 17beta-hydroxysteroid dehydrogenase 2 is an enzyme essential in the conversion of the highly active 17beta-hydroxysteroids into their inactive keto forms in a variety of tissues. 17beta-hydroxysteroid dehydrogenase 2 with 6 consecutive histidines at its N terminus was expressed in Sf9 insect cells. This recombinant protein retained its biological activity and facilitated the enzyme purification and provided the most suitable form in our studies. Dodecyl-p-D-maltoside was found to be the best detergent for the solubilization, purification, and reconstitution of this enzyme. The overexpressed integral membrane protein was purified with a high catalytic activity and a purity of more than 90% by nickel-chelated chromatography. For reconstitution, the purified protein was incorporated into dodecyl-beta-D-maltoside-destabilized liposomes prepared from L-alpha-phosphatidylcholine. The detergent was removed by adsorption onto polystyrene beads. The reconstituted enzyme had much higher stability and catalytic activity (2.6 mumol/min/mg of enzyme protein with estradiol) than the detergent-solubilized and purified protein (0.9 mumol/ min/mg of enzyme protein with estradiol). The purified and reconstituted protein (with a 2-kDa His tag) was proved to be a homodimer, and its functional molecular mass was calculated to be 90.4 +/- 1.2 kDa based on glycerol gradient analytical ultracentrifugation and chemical cross-linking study. The kinetic studies demonstrated that 17beta-hydroxysteroid dehydrogenase 2 was an NAD-preferring dehydrogenase with the K-m of NAD being 110 +/- 10 muM and that of NADP 9600 +/- 100 muM using estradiol as substrate. The kinetic constants using estradiol, testosterone, dihydrotestosterone, and 20alpha-dihydroprogesterone as substrates were also determined.	Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, CHUQ, Quebec City, PQ G1V 4G2, Canada	Laval University	Lin, SX (corresponding author), Univ Laval, Med Ctr, Oncol & Mol Endocrinol Res Ctr, CHUQ, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Lin, Sheng-Xiang/0000-0001-9149-375X				Blomquist CH, 1997, J ENDOCRINOL, V153, P453, DOI 10.1677/joe.0.1530453; CASSEY ML, 1994, J CLIN INVEST, V94, P2135; English MA, 2001, MOL CELL ENDOCRINOL, V171, P53, DOI 10.1016/S0303-7207(00)00418-4; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LuuThe V, 1995, J STEROID BIOCHEM, V55, P581, DOI 10.1016/0960-0760(95)00209-X; Michel H., 1991, CRYSTALLIZATION MEMB, P73; Miettinen MM, 1996, BIOCHEM J, V314, P839, DOI 10.1042/bj3140839; Mustonen M, 1997, MOL CELL ENDOCRINOL, V134, P33, DOI 10.1016/S0303-7207(97)00157-3; Mustonen MVJ, 1998, J MOL ENDOCRINOL, V20, P67, DOI 10.1677/jme.0.0200067; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; Puranen TJ, 1999, ENDOCRINOLOGY, V140, P3334, DOI 10.1210/en.140.7.3334; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROMER LCR, 1980, BIOCHIM BIOPHYS ACTA, V601, P123; Schagger H., 1994, PRACTICAL GUIDE MEMB, P59; *SIGM, 1986, TECHN B SIGM; SMITH MH, 1970, HDB BIOCH, pC3; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; VOET D, 1990, BIOCHEMISTRY-US, P577; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WU L, 1993, J BIOL CHEM, V268, P12964	24	27	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22123	22130		10.1074/jbc.M111726200	http://dx.doi.org/10.1074/jbc.M111726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940569	hybrid			2022-12-25	WOS:000176313600005
J	Tanoue, T; Yamamoto, T; Nishida, E				Tanoue, T; Yamamoto, T; Nishida, E			Modular structure of a docking surface on MAPK phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHATASES; SUBSTRATE SELECTIVITY; CRYSTAL-STRUCTURE; IN-VIVO; PTP-SL; ERK2; TRANSCRIPTION	Mitogen-activated protein kinases (MAPKs) must be precisely inactivated to achieve proper functions in the cells. Ten members of dual specificity phosphatases specifically acting on MAPKs, termed MAPK phosphatases (MKPs), have been reported. Each member has its own substrate specificity that should be tightly regulated. However, the molecular mechanism underlying the regulation of the specificity is largely unknown. In the MAPK signaling pathways, docking interactions, which are different from transient enzyme-substrate interaction, are known to regulate the enzymatic specificity. Here we have identified and characterized a docking surface of MKPs. Our results show that a docking surface is composed of a tandem alignment of three subregions (modules): a cluster of positively charged amino acids, a cluster of hydrophobic amino acids, and a cluster of positively charged amino acids (positive-hydrophobic-positive). This modular structure well fits the docking groove on MAPKs that we have previously identified and may contribute to regulating the docking specificity of the MKP family. The position, number, and species of charged amino acids in each module including the central hydrophobic subregion are important factors in regulation of docking to specific MAPKs. This modular structure in the docking interaction may define a novel model of protein-protein interaction that would also regulate other systems.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.	L50174@sakura.kudpc.kyoto-u.ac.jp	Yamamoto, Takuya/H-2792-2017	Yamamoto, Takuya/0000-0002-0022-3947				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen PL, 2001, J BIOL CHEM, V276, P29440, DOI 10.1074/jbc.M103463200; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811; Zhan XL, 2001, CHEM REV, V101, P2477, DOI 10.1021/cr000245u; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	52	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22942	22949		10.1074/jbc.M202096200	http://dx.doi.org/10.1074/jbc.M202096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953434	hybrid			2022-12-25	WOS:000176313600107
J	Diemel, RV; Snel, MME; Waring, AJ; Walther, FJ; van Golde, LMG; Putz, G; Haagsman, HP; Batenburg, JJ				Diemel, RV; Snel, MME; Waring, AJ; Walther, FJ; van Golde, LMG; Putz, G; Haagsman, HP; Batenburg, JJ			Multilayer formation upon compression of surfactant monolayers depends on protein concentration as well as lipid composition - An atomic force microscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL SEGMENT; B SP-B; RESPIRATORY-DISTRESS-SYNDROME; PULMONARY SURFACTANT; LUNG SURFACTANT; SP-C; FILMS; DIPALMITOYLPHOSPHATIDYLCHOLINE; PHOSPHOLIPIDS; SPECTROSCOPY	The determinants for the formation of multilayers upon compression of surfactant monolayers were investigated by compressing films, beyond the squeeze-out plateau, to a surface tension of 22 millinewtons/m. Atomic force microscopy was used to visualize the topography of lipid films containing varying amounts of native surfactant protein B (SP-B). These films were compared with films containing synthetic peptides based on the N terminus of human SP-B: monomeric mSP-B-(1-25) or dimeric dSP-B-(1-25). The formation of typical hexagonal network structures as well as the height of protrusions were shown to depend on the concentration of SP-B. Protrusions of bilayer height were formed from physiologically relevant concentrations of 0.2-0.4 mol % (4.5-8.5 wt %) SP-B upwards. Much higher concentrations of SP-B-(1-25) peptides were needed to obtain network structures, and protrusion heights were not equal to those found for films with native SP-B. A striking observation was that while protrusions formed in films of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)/1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-(1 -glycerol)) (DPPG) (80/20) had single bilayer thickness, those formed in DPPC/1-palmitoyl-2-oleoyl-snglycero-3-(phospho-rac-(l-glycerol)) (80/20) had various heights of multilayers, whereas those seen in DPPC/1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine/DPPG (60/20/20) were mainly of bilayer height. For the first time direct observations by atomic force microscopy show M that a certain minimal concentration of SP-B is required for the formation of layered protrusions upon film compression, (ii) that protrusion height depends on whether the phospholipids contain an unsaturated fatty acyl chain, and (iii) that protrusion height also depends on whether the unsaturated acyl chain is present in phosphatidylcholine or in phosphatidylglycerol.	Univ Utrecht, Fac Vet Med, Grad Sch Anim Hlth, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Fac Vet Med, Grad Sch Anim Hlth, Dept Sci Food Anim Origin, NL-3508 TD Utrecht, Netherlands; Univ Innsbruck, Dept Anaesthesiol & Crit Care Med, A-6020 Innsbruck, Austria; Univ Utrecht, Fac Chem, NL-3584 CH Utrecht, Netherlands; Univ Calif Los Angeles, Dept Med, Div Infect Dis, Los Angeles, CA 90502 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Div Med Genet, Torrance, CA 90502 USA	Utrecht University; Utrecht University; University of Innsbruck; Utrecht University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Batenburg, JJ (corresponding author), Univ Utrecht, Fac Vet Med, Grad Sch Anim Hlth, Dept Biochem & Cell Biol, POB 80176, NL-3508 TD Utrecht, Netherlands.	J.J.Batenburg@vet.uu.nl	Haagsman, Henk P/F-8919-2010	Walther, Frans/0000-0003-1931-159X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055534] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL055534] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amrein M, 1997, EUR BIOPHYS J BIOPHY, V26, P349, DOI 10.1007/s002490050089; BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BANGHAM AD, 1979, BIOCHIM BIOPHYS ACTA, V573, P552, DOI 10.1016/0005-2760(79)90229-7; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CLEMENTS JA, 1977, AM REV RESPIR DIS, V115, P67; Crane JM, 2001, BIOPHYS J, V80, P1863, DOI 10.1016/S0006-3495(01)76156-5; Creuwels LAJM, 1996, BBA-BIOMEMBRANES, V1285, P1, DOI 10.1016/S0005-2736(96)00131-9; Diemel RV, 2001, ARCH BIOCHEM BIOPHYS, V385, P338, DOI 10.1006/abbi.2000.2157; Gordon LM, 2000, J PEPT RES, V55, P330, DOI 10.1034/j.1399-3011.2000.00693.x; Gordon LM, 1996, PROTEIN SCI, V5, P1662, DOI 10.1002/pro.5560050820; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; Gupta M, 2000, EUR RESPIR J, V16, P1129, DOI 10.1034/j.1399-3003.2000.16f19.x; GUPTA M, 2000, AM J RESP CRIT CARE, V161, pA656; Haagsman HP, 2001, COMP BIOCHEM PHYS A, V129, P91, DOI 10.1016/S1095-6433(01)00308-7; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; Krol S, 2000, BIOPHYS J, V79, P904, DOI 10.1016/S0006-3495(00)76346-6; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; Lipp MM, 1998, PHYS REV LETT, V81, P1650, DOI 10.1103/PhysRevLett.81.1650; Marsh D., 2013, HDB LIPID BILAYERS; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; OOSTERLAKENDIJKSTERHUIS MA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P45, DOI 10.1016/0005-2736(92)90292-T; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P10965, DOI 10.1021/bi00109a022; PEREZGIL J, 1995, BIOCHEMISTRY-US, V34, P3964, DOI 10.1021/bi00012a014; Robertson B, 1998, BBA-MOL BASIS DIS, V1408, P346, DOI 10.1016/S0925-4439(98)00080-5; Rodriguez-Capote K, 2001, AM J PHYSIOL-LUNG C, V281, pL231, DOI 10.1152/ajplung.2001.281.1.L231; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Schurch S, 1998, BBA-MOL BASIS DIS, V1408, P180, DOI 10.1016/S0925-4439(98)00067-2; SCHURCH S, 1995, BIOL NEONATE, V67, P61; SEEGER W, 2000, ACP-APPL CARDIOPUL P, V9, P295; Takamoto DY, 2001, BIOPHYS J, V81, P153, DOI 10.1016/S0006-3495(01)75688-3; Tredano M, 1999, HUM MUTAT, V14, P502, DOI 10.1002/(SICI)1098-1004(199912)14:6<502::AID-HUMU9>3.0.CO;2-C; Veldhuizen EJA, 2000, BIOPHYS J, V79, P377, DOI 10.1016/S0006-3495(00)76299-0; Veldhuizen EJA, 2001, CHEM PHYS LIPIDS, V110, P47, DOI 10.1016/S0009-3084(00)00228-0; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1; Walmrath D, 1996, AM J RESP CRIT CARE, V154, P57, DOI 10.1164/ajrccm.154.1.8680699; WALTHER FJ, 2000, AM J RESP CRIT CARE, V161, pA656; WARING A, 1989, Peptide Research, V2, P308; Weaver TE, 1999, BIOL NEONATE, V76, P15, DOI 10.1159/000047041; YU SH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P26, DOI 10.1016/0005-2760(92)90212-E	41	62	62	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21179	21188		10.1074/jbc.M111758200	http://dx.doi.org/10.1074/jbc.M111758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923286	hybrid			2022-12-25	WOS:000176286000010
J	Hong, DP; Gozu, M; Hasegawa, K; Naiki, H; Goto, Y				Hong, DP; Gozu, M; Hasegawa, K; Naiki, H; Goto, Y			Conformation of beta(2)-microglobulin amyloid fibrils analyzed by reduction of the disulfide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; CONSTANT FRAGMENT; KINETIC-MODEL; PROTEIN; BETA-2-MICROGLOBULIN; EXTENSION; DEPOSITS; POLYMERIZATION; HEMODIALYSIS; FORM	beta(2)-Microglobulin (beta2-m), a major component of dialysis-related amyloid fibrils, has an intrachain disulfide bond buried inside the native structure. We examined the conformation of beta2-m amyloid fibrils by analyzing the reactivity of the disulfide bond to a reducing reagent, dithiothreitol. Although the disulfide bond in the native structure was highly protected from reduction, the disulfide bonds in the amyloid fibrils prepared at pH 2.5 were progressively reduced at pH 8.5 by 50 mm dithiothreitol. Because beta2-m amyloid fibrils prepared under acidic conditions have been known to depolymerize at a neutral pH, we examined the relation between depolymerization and reduction of the disulfide bond. The results indicate that the disulfide bonds in the amyloid fibrils were protected from reduction, and the reduction occurred during depolymerization. On the other hand, the disulfide bonds of immature filaments, the thin and flexible filaments prepared under conditions of high salt at pH 2.5, were reduced at pH 8.5 more readily than those of amyloid fibrils, suggesting that the disulfide bonds are exposed to the solvent. Taken together, the disulfide bond once exposed to the solvent upon acid denaturation may be progressively buried in the interior of the amyloid fibrils during its formation.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Fukui Med Univ, Dept Pathol, Fukui 9101193, Japan	Osaka University; University of Fukui	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Campistol JM, 1996, KIDNEY INT, V50, P1262, DOI 10.1038/ki.1996.436; CAPEILLEREBLANDIN C, 1991, BIOCHEM J, V277, P175, DOI 10.1042/bj2770175; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; Davison AM, 1995, NEPHROL DIAL TRANSPL, V10, P48; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; GarciaGarcia M, 1997, NEPHROL DIAL TRANSPL, V12, P1192, DOI 10.1093/ndt/12.6.1192; Gejyo F, 1990, Contrib Nephrol, V78, P47; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; Hashimoto N, 1999, AMYLOID, V6, P256, DOI 10.3109/13506129909007337; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; ISENMAN DE, 1975, P NATL ACAD SCI USA, V72, P548, DOI 10.1073/pnas.72.2.548; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; KINDY MS, 1995, LAB INVEST, V73, P469; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROLL J, 1976, BIOCHIM BIOPHYS ACTA, V434, P490, DOI 10.1016/0005-2795(76)90239-7; LINKE RP, 1989, KIDNEY INT, V36, P675, DOI 10.1038/ki.1989.245; LINKE RP, 1986, BIOCHEM BIOPH RES CO, V136, P665, DOI 10.1016/0006-291X(86)90492-4; MARLEY RW, 1988, SCIENCE, V240, P622; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Naiki H, 1996, LAB INVEST, V74, P374; NAIKI H, 1991, LAB INVEST, V65, P104; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YAMADA T, 1994, ANN CLIN LAB SCI, V24, P243; Yamaguchi I, 2001, BIOCHEMISTRY-US, V40, P8499, DOI 10.1021/bi0027128; Yamaguchi I, 2001, AMYLOID, V8, P30, DOI 10.3109/13506120108993812	39	68	70	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21554	21560		10.1074/jbc.M200188200	http://dx.doi.org/10.1074/jbc.M200188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943769	hybrid, Green Published			2022-12-25	WOS:000176286000058
J	Kishi, H; Krishnamurthy, H; Galet, C; Bhaskaran, RS; Ascoli, M				Kishi, H; Krishnamurthy, H; Galet, C; Bhaskaran, RS; Ascoli, M			Identification of a short linear sequence present in the C-terminal tail of the rat follitropin receptor that modulates arrestin-3 binding in a phosphorylation-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LEYDIG TUMOR-CELLS; FOLLICLE-STIMULATING-HORMONE; HUMAN CHORIO-GONADOTROPIN; BETA-ARRESTIN; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; CHORIOGONADOTROPIN RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; INTRACELLULAR DOMAINS; MEDIATED ENDOCYTOSIS	The rat follitropin receptor (rFSHR) is an unusual G protein-coupled receptor in that agonist-induced activation leads to the phosphorylation of the first and third intracellular loops instead of the C-terminal tail. To determine regions of G protein-coupled receptors that affect internalization independently of phosphorylation we examined the effects of truncations of the C-terminal tail of the rFSHR on agonist-induced internalization. Our studies show that progressive truncations of a region flanked by residues 642 and 651 enhance the internalization of human follicle-stimulating hormone (hFSH). Further characterization of a mutant truncated at residue 649 (designated rFSHR-t649) and another mutant in which the 642-651 region was deleted in the context of the full-length rFSHR, designated rFSHR(Delta642-651), showed that both of them internalized hFSH at rates that were 2-3 times faster than rF-SHR-wild type (wt). Like rFSHR-wt, however, the internalization of hFSH mediated by rFSHR-t649 and rFSHR(Delta642-651) can be inhibited with dominant-negative mutants of the non-visual arrestins or dynamin. Alanine-scanning mutagenesis of the 642-651 region suggests that the effects on internalization are not mediated by a single residue, however. In an attempt to understand the molecular basis of the enhanced internalization of hFSH mediated by these mutants we used an assay that can be readily used to assess the association of the rFSHR with the arrestin-3 in co-transfected cells. Using this assay we were able to show that, when compared with rFSHR-wt, rFSHR(Delta642-651) displays an similar to4-fold enhancement in binding affinity for arrestin-3 and an similar to1.7-fold reduction in maximal arrestin-3 binding capacity. We conclude that a short linear sequence present in the C-terminal tail of the rFSHR ((642)SATHN-FHARK(651)) that is not phosphorylated limits internalization by lowering the affinity of the rFSHR for the endogenous non-visual arrestins.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-319A BSB,51 Newton Rd, Iowa City, IA 52242 USA.	mario-ascoli@uiowa.edu	Bhaskaran, Ravi Sankar/Q-2823-2016; galet, colette/C-4620-2011	Bhaskaran, Ravi Sankar/0000-0002-2003-6276; galet, colette/0000-0002-5931-2143	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28962] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HIPKIN RW, 1995, J BIOL CHEM, V270, P26683, DOI 10.1074/jbc.270.44.26683; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Kishi H, 2000, J BIOL CHEM, V275, P31030, DOI 10.1074/jbc.M005528200; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Nakamura K, 1998, MOL ENDOCRINOL, V12, P580, DOI 10.1210/me.12.4.580; Nakamura K, 1999, J BIOL CHEM, V274, P25426, DOI 10.1074/jbc.274.36.25426; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; PEREIRA ME, 1987, J BIOL CHEM, V262, P6093; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; QUINTANA J, 1993, ENDOCRINOLOGY, V133, P2098, DOI 10.1210/en.133.5.2098; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; WILEY HS, 1982, J BIOL CHEM, V257, P4222; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	49	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21939	21946		10.1074/jbc.M110894200	http://dx.doi.org/10.1074/jbc.M110894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934883	hybrid			2022-12-25	WOS:000176286000106
J	Oudgenoeg, G; Dirksen, E; Ingemann, S; Hilhorst, R; Gruppen, H; Boeriu, CG; Piersma, SR; van Berkel, WJH; Laane, C; Voragen, AGJ				Oudgenoeg, G; Dirksen, E; Ingemann, S; Hilhorst, R; Gruppen, H; Boeriu, CG; Piersma, SR; van Berkel, WJH; Laane, C; Voragen, AGJ			Horseradish peroxidase-catalyzed oligomerization of ferulic acid on a template of a tyrosine-containing tripeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE CROSS-LINKING; SUGAR-BEET PULP; LIGNIN; BIOSYNTHESIS; DEHYDRODIMERS; POLYMERS; GRASSES; COMPLEX; PROTEIN; SUBERIN	Ferulic acid (FA) is an abundantly present phenolic constituent of plant cell walls. Kinetically controlled incubation of FA and the tripeptide Gly-Tyr-Gly (GYG) with horseradish peroxidase and H2O2 yielded a range of new cross-linked products. Two predominant series of hetero-oligomers of FA linked by dehydrogenation to the peptidyl tyrosine were characterized by electrospray ionization (tandem) mass spectrometry. One series comprises GYG coupled with 4-7 FA moieties linked by dehydrogenation, of which one is decarboxylated. In the second series 4-9 FA moieties linked by dehydrogenation, of which two are decarboxylated, are coupled to the tripeptide. A third series comprises three hetero-oligomers in which the peptidyl tyrosine is linked to 1-3 FA moieties of which none is decarboxylated. Two mechanisms for the formation of the FA-Tyr oligomers that result from the dualistic, concentration-dependent chemistry of FA and their possible role in the regulation of plant cell wall tissue growth are presented.	Ctr Prot Technol TNO WU, NL-6700 EV Wageningen, Netherlands; Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Food Chem Lab, NL-6700 EV Wageningen, Netherlands; Univ Amsterdam, Fac Sci, Swammerdam Inst Life Sci, NL-1018 WV Amsterdam, Netherlands; ATO, NL-6708 PD Wageningen, Netherlands; TNO Food & Nutr Res, NL-3700 AJ Zeist, Netherlands	Netherlands Organization Applied Science Research; Wageningen University & Research; Wageningen University & Research; University of Amsterdam; Netherlands Organization Applied Science Research	Voragen, AGJ (corresponding author), Ctr Prot Technol TNO WU, Bomenweg 2, NL-6700 EV Wageningen, Netherlands.	Fons.voragen@chem.fdsci.wag-ur.nl	Oudgenoeg, Gideon/I-6532-2013; van Berkel, Willem J.H./O-2431-2014; Boeriu, Carmen/L-1173-2016	van Berkel, Willem J.H./0000-0002-6551-2782; Boeriu, Carmen/0000-0003-4903-6621; Hilhorst, Riet/0000-0002-8261-1299				ANDERSEN SO, 1964, BIOCHIM BIOPHYS ACTA, V93, P213, DOI 10.1016/0304-4165(64)90289-2; BERNARDS MA, 1995, J BIOL CHEM, V270, P7382, DOI 10.1074/jbc.270.13.7382; Bernards MA, 2001, PHYTOCHEMISTRY, V57, P1115, DOI 10.1016/S0031-9422(01)00046-2; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; Bunzel M, 2001, J SCI FOOD AGR, V81, P653, DOI 10.1002/jsfa.861; Davin LB, 2000, PLANT PHYSIOL, V123, P453, DOI 10.1104/pp.123.2.453; Davin LB, 1997, SCIENCE, V275, P362, DOI 10.1126/science.275.5298.362; Gang DR, 1999, CHEM BIOL, V6, P143, DOI 10.1016/S1074-5521(99)89006-1; Grabber JH, 2000, J AGR FOOD CHEM, V48, P6106, DOI 10.1021/jf0006978; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; LEWIS NG, 1987, SCIENCE, V237, P1344, DOI 10.1126/science.237.4820.1344; Michener Charles D., 1997, Scientific Papers Natural History Museum University of Kansas, V1, P1; Michon T, 1999, BIOTECHNOL BIOENG, V63, P449, DOI 10.1002/(SICI)1097-0290(19990520)63:4<449::AID-BIT8>3.0.CO;2-M; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; Oosterveld A, 2001, CARBOHYD POLYM, V44, P9, DOI 10.1016/S0144-8617(00)00193-4; Oosterveld A, 1997, CARBOHYD RES, V300, P179, DOI 10.1016/S0008-6215(97)00041-4; Oosterveld A, 2000, CARBOHYD RES, V328, P199, DOI 10.1016/S0008-6215(00)00096-3; Ostergaard L, 2000, PLANT MOL BIOL, V44, P231, DOI 10.1023/A:1006442618860; Oudgenoeg G, 2001, J AGR FOOD CHEM, V49, P2503, DOI 10.1021/jf000906o; RALPH J, 1992, J CHEM SOC PERK T 1, P2971, DOI 10.1039/p19920002971; RALPH J, 1992, J CHEM SOC PERK T 1, P2961, DOI 10.1039/p19920002961; RALPH J, 1994, J CHEM SOC PERK T 1, P3485, DOI 10.1039/p19940003485; Wang WC, 1999, BIOCHEM J, V340, P329, DOI 10.1042/0264-6021:3400329; Ward G, 2001, J BIOL CHEM, V276, P18734, DOI 10.1074/jbc.M009785200	25	33	35	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21332	21340		10.1074/jbc.M201679200	http://dx.doi.org/10.1074/jbc.M201679200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925445	Green Published, hybrid			2022-12-25	WOS:000176286000029
J	Powell, DW; Rane, MJ; Chen, QD; Singh, S; McLeish, KR				Powell, DW; Rane, MJ; Chen, QD; Singh, S; McLeish, KR			Identification of 14-3-3 zeta as a protein kinase B/Akt substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT; PHOSPHORYLATION; 14-3-3-PROTEINS; ACTIVATION; INHIBITION; APOPTOSIS; ISOFORMS; SURVIVAL; PKB/AKT; CELLS	Protein kinase B/Akt (PKB/Akt) is a member of the ACG kinase family, which also includes protein kinase C, that phosphorylates a number of 14-3-3-binding proteins. 14-3-3 protein regulation of protein kinase C activity is modulated by 14-3-3 phosphorylation. We examined the hypothesis that PKB/Akt interacts with and phosphorylates 14-3-3zeta, leading to modulation of dimerization. By glutathione S-transferase pull-down, Akt precipitated recombinant 14-3-3zeta and endogenous 14-3-3zeta from HEK293 cell lysates. Recombinant active PKB/ Akt phosphorylated recombinant 14-3-3zeta in an in vitro kinase assay. Transfection of active PKB/Akt into HEK293 cells resulted in phosphorylation of 14-3-3zeta. Based on a motif search of 14-3-3zeta, a potential PKB/Akt phosphorylation site, Ser-58, was mutated to alanine. PKB/Akt was unable to phosphorylate this mutant protein. Incubation of 14-3-3zeta with recombinant active PKB/ Akt resulted in phosphorylation of 45% of the protein, as determined by a pI shift on two-dimensional electrophoresis, but 14-3-3zeta dimerization was not altered. These data indicate that PKB/Akt phosphorylates Ser-58 on 14-3-3zeta both in vitro and in intact cells. The functional relevance of this phosphorylation remains to be determined.	Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McLeish, KR (corresponding author), Univ Louisville, Mol Signaling Grp, Kidney Dis Program, 615 S Preston St, Louisville, KY 40202 USA.		McLeish, Kenneth R./B-9819-2013; Powell, David W/E-9288-2013	McLeish, Kenneth R./0000-0002-7816-3286; 				ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; Autieri MV, 1999, DNA CELL BIOL, V18, P555, DOI 10.1089/104454999315105; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; HAUAAER A, 1999, J BIOL CHEM, V274, P9258; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Lawlor MA, 2001, J CELL SCI, V114, P2903; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Meller N, 1996, MOL CELL BIOL, V16, P5782; Montano X, 2001, FEBS LETT, V507, P237, DOI 10.1016/S0014-5793(01)02903-9; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	23	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21639	21642		10.1074/jbc.M203167200	http://dx.doi.org/10.1074/jbc.M203167200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11956222	hybrid			2022-12-25	WOS:000176286000070
J	Deroo, BJ; Archer, TK				Deroo, BJ; Archer, TK			Proteasome inhibitors reduce luciferase and beta-galactosidase activity in tissue culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; GLUCOCORTICOID RECEPTOR; HEAT-SHOCK; PROTEIN DENATURATION; CHROMATIN STRUCTURE; MAMMALIAN-CELLS; 26S PROTEASOME; DEGRADATION; PROGESTINS; APOPTOSIS	Reporter enzymes are commonly used in cell biology to study transcriptional activity of genes. Recently, reporter enzymes in combination with compounds that inhibit proteasome function have been used to study the effect of blocking transcription factor degradation on gene activation. While investigating the effect of proteasome inhibition on steroid receptor activation of the mouse mammary tumor virus (MMTV) promoter, we found that treatment with proteasome inhibitors enhanced glucocorticoid activation of the promoter attached to a chloramphenicol acetyltransferase (CAT) reporter, but inhibited activation of MMTV attached to a firefly luciferase or beta-galactosidase reporter. MMTV RNA levels under these conditions correlated with the promoter activity observed using the CAT reporter, suggesting that proteasome inhibitor treatment interfered with luciferase or beta-galactosidase reporter assays. Washout experiments demonstrated that the majority of luciferase activity was lost if the proteasome inhibitor was added at the same time luciferase was produced, not once the functional protein was made, suggesting that proteasome inhibition interferes with production of luciferase protein. Indeed, we found that proteasome inhibitor treatment dramatically reduced the levels of luciferase and beta-galactosidase protein produced, as determined by Western blot. Thus, treatment with proteasome inhibitors interferes with luciferase and beta-galactosidase reporter assays, possibly by inhibiting production of a functional reporter protein.	NIEHS, Reprod & Dev Toxicol Lab, Chromatin & Gene Express Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Archer, TK (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Chromatin & Gene Express Sect, NIH, MD E4-06, Res Triangle Pk, NC 27709 USA.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; Bush KT, 1997, J BIOL CHEM, V272, P9086; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DERON BJ, 2002, IN PRESS MOL CELL BI, V22; Fryer CJ, 1998, J BIOL CHEM, V273, P1175, DOI 10.1074/jbc.273.2.1175; Kidd VJ, 2000, SEMIN CELL DEV BIOL, V11, P191, DOI 10.1006/scdb.2000.0165; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee PH, 1998, INT J ROBUST NONLIN, V8, P39; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morley SJ, 2001, FEBS LETT, V503, P206, DOI 10.1016/S0014-5793(01)02735-1; Naylor LH, 1999, BIOCHEM PHARMACOL, V58, P749, DOI 10.1016/S0006-2952(99)00096-9; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; Nollen EAA, 2001, P NATL ACAD SCI USA, V98, P12038, DOI 10.1073/pnas.201112398; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; PINTO M, 1991, J BIOL CHEM, V266, P13941; Roussou I, 2000, CELL STRESS CHAPERON, V5, P8, DOI 10.1379/1466-1268(2000)005<0008:EPDIIT>2.0.CO;2; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	27	42	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20120	20123		10.1074/jbc.C200173200	http://dx.doi.org/10.1074/jbc.C200173200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11959849	hybrid			2022-12-25	WOS:000176204500003
J	Herter, S; Fuchs, G; Bacher, A; Eisenreich, W				Herter, S; Fuchs, G; Bacher, A; Eisenreich, W			A bicyclic autotrophic CO2 fixation pathway in Chloroflexus aurantiacus.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYPROPIONATE CYCLE; CARBON FIXATION; ASSIMILATION; METABOLISM; ACETATE; C-13-NMR	Phototrophic CO2 assimilation by the primitive, green eubacterium. Chloroflexus aurantiacus has been shown earlier to proceed in a cyclic mode via 3-hydroxypropionate, propionyl-CoA, succinyl-CoA, and malyl-CoA. The metabolic cycle could be closed by cleavage of malyl-CoA affording glyoxylate (the primary CO2 fixation product) with regeneration of acetyl-CoA serving as the starter unit of the cycle. The pathway of glyoxylate assimilation to form gluconeogenic precursors has not been elucidated to date. We could now show that the incubation of cell extract with a mixture of glyoxylate and [1,2,3-C-13(3)]propionyl-CoA afforded erythro-beta-[1,2,2'-C-13(3)]methylmalate and [1,2,2'-C-13(3)]citramalate. Similar experiments using a partially purified protein fraction afforded erythro-beta-[1,2,2'-C-13(3)]methylmalyl-CoA and [1,2,2'-C-13(3)]mesaconyl-CoA. Cell extracts of C. aurantiacus were also shown to catalyze the conversion of citramalate into pyruvate and acetyl-CoA in a succinyl-CoA-dependent reaction. The data suggest that glyoxylate obtained by the cleavage of malyl-CoA can be utilized by condensation with propionyl-CoA affording erythro-beta-methylmalyl-CoA, which is converted to acetyl-CoA and pyruvate. This reaction sequence regenerates acetyl-CoA which serves as the precursor of propionyl-CoA in the 3-hydroxypropionate cycle. Autotrophic CO2 fixation proceeds by combination of the 3-hydroxypropionate cycle with the methylmalyl-CoA cycle. The net product of that bicyclic autotrophic CO2 fixation pathway is pyruvate serving as an universal building block for anabolic reactions.	Univ Freiburg, Inst Biol 2, Lehrstuhl Mikrobiol, D-79104 Freiburg, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	University of Freiburg; Technical University of Munich	Fuchs, G (corresponding author), Univ Freiburg, Inst Biol 2, Lehrstuhl Mikrobiol, Schanzlestr 1, D-79104 Freiburg, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Alber BE, 2002, J BIOL CHEM, V277, P12137, DOI 10.1074/jbc.M110802200; BHAT KS, 1985, INDIAN J CHEM B, V24, P509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKEL W, 1976, EUR J BIOCHEM, V64, P255, DOI 10.1111/j.1432-1033.1976.tb10295.x; CASTENHOLZ RW, 1969, BACTERIOL REV, V33, P476, DOI 10.1128/MMBR.33.4.476-504.1969; COX RB, 1976, J GEN MICROBIOL, V95, P121, DOI 10.1099/00221287-95-1-121; DIMROTH P, 1977, EUR J BIOCHEM, V80, P469, DOI 10.1111/j.1432-1033.1977.tb11902.x; EGGERER H, 1964, BIOCHEM Z, V339, P436; EISENREICH W, 1993, EUR J BIOCHEM, V215, P619, DOI 10.1111/j.1432-1033.1993.tb18073.x; Han L, 1997, J BACTERIOL, V179, P5157, DOI 10.1128/jb.179.16.5157-5164.1997; Herter S, 2001, J BACTERIOL, V183, P4305, DOI 10.1128/JB.183.14.4305-4316.2001; HOLO H, 1986, ARCH MICROBIOL, V145, P173, DOI 10.1007/BF00446776; HOLO H, 1989, ARCH MICROBIOL, V151, P252, DOI 10.1007/BF00413138; HOLO H, 1987, ARCH MICROBIOL, V148, P292, DOI 10.1007/BF00456707; Hugler M, 2002, J BACTERIOL, V184, P2404, DOI 10.1128/JB.184.9.2404-2410.2002; IVANOVSKII RN, 1995, MICROBIOLOGY+, V64, P257; IVANOVSKY RN, 1993, ARCH MICROBIOL, V159, P257, DOI 10.1007/BF00248481; Ivanovsky RN, 1997, FEMS MICROBIOL LETT, V153, P399, DOI 10.1016/S0378-1097(97)00280-2; KAKINUMA K, 1993, BIOSCI BIOTECH BIOCH, V57, P1916, DOI 10.1271/bbb.57.1916; KONDRATIEVA EN, 1992, FEMS MICROBIOL LETT, V100, P269, DOI 10.1111/j.1574-6968.1992.tb05714.x; KORKES S, 1956, ANNU REV BIOCHEM, V25, P723; KORNBERG HL, 1957, NATURE, V179, P988, DOI 10.1038/179988a0; Korotkova N, 2002, J BACTERIOL, V184, P1750, DOI 10.1128/JB.184.6.1750-1758.2002; LOKEN O, 1982, ARCH MICROBIOL, V132, P276, DOI 10.1007/BF00407965; Menendez C, 1999, J BACTERIOL, V181, P1088, DOI 10.1128/JB.181.4.1088-1098.1999; NANAKO H, 1970, BIOCHEM BIOPH RES CO, V41, P1605; OSUMI T, 1975, J BIOCHEM-TOKYO, V78, P763, DOI 10.1093/oxfordjournals.jbchem.a130965; RENAUD P, 1987, HELV CHIM ACTA, V70, P292, DOI 10.1002/hlca.19870700204; SIMON E, 1957, BIOCHEM PREP, V5, P30; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; STRAUSS G, 1993, EUR J BIOCHEM, V215, P633, DOI 10.1111/j.1432-1033.1993.tb18074.x; SUBHASH CG, 1984, J BIOL CHEM, V259, P10012; Ugol'kova N. V., 2000, Mikrobiologiya, V69, P175	34	95	104	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20277	20283		10.1074/jbc.M201030200	http://dx.doi.org/10.1074/jbc.M201030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929869	hybrid			2022-12-25	WOS:000176204500025
J	Milutinovic, S; Zhuang, QL; Szyf, M				Milutinovic, S; Zhuang, QL; Szyf, M			Proliferating cell nuclear antigen associates with histone deacetylase activity, integrating DNA replication and chromatin modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC INHERITANCE; FISSION YEAST; COMPLEX; PCNA; TRANSCRIPTION; METHYLATION; INHIBITION; H3	Faithful inheritance of the chromatin structure is essential for maintaining the gene expression integrity of a cell. Histone modification by acetylation and deacetylation is a critical control of chromatin structure. In this study, we test the hypothesis that histone deacetylase 1 (HDAC1) is physically associated with a basic component of the DNA replication machinery as a mechanism of coordinating histone deacetylation and DNA synthesis. Proliferating cell nuclear antigen (PCNA) is a sliding clamp that serves as a loading platform for many proteins involved in DNA replication and DNA repair. We show that PCNA interacts with HDAC1 in human cells and in vitro and that a considerable fraction of PCNA and HDAC1 colocalize in the cell nucleus. PCNA associates with histone deacetylase activity that is completely abolished in the presence of the HDAC inhibitor trichostatin A. Trichostatin A treatment arrests cells at the G(2)-M phase of the cell cycle, which is consistent with the hypothesis that the proper formation of the chromatin after DNA replication may be important in signaling the progression through the cell cycle. Our results strengthen the role of PCNA as a factor coordinating DNA replication and epigenetic inheritance.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cai RL, 2000, J BIOL CHEM, V275, P27909; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Grewal SIS, 1998, GENETICS, V150, P563; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HUFF JP, 1990, J EXP MED, V172, P419, DOI 10.1084/jem.172.2.419; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	23	81	85	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20974	20978		10.1074/jbc.M202504200	http://dx.doi.org/10.1074/jbc.M202504200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929879	hybrid			2022-12-25	WOS:000176204500112
J	Muto, A; Tashiro, S; Tsuchiya, H; Kume, A; Kanno, M; Ito, E; Yamamoto, M; Igarashi, K				Muto, A; Tashiro, S; Tsuchiya, H; Kume, A; Kanno, M; Ito, E; Yamamoto, M; Igarashi, K			Activation of Maf/AP-1 repressor Bach2 by oxidative stress promotes apoptosis and its interaction with promyelocytic leukemia nuclear bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL MAF PROTEINS; ANTIOXIDANT RESPONSIVE ELEMENTS; TRANSCRIPTION FACTOR BACH2; LEUCINE-ZIPPER PROTEIN; LOCUS-CONTROL REGION; ABL TYROSINE KINASE; YA SUBUNIT GENE; INTERACTION MOTIF; DNA-BINDING; BTB/POZ DOMAIN	The oxidative stress response operates by inducing the expression of genes that counteract the stress. We show here that the oxidative stress-responsive transcription factor Bach2 is a generic inhibitor of gene expression directed by the 12-O-tetradecanoylphorbol-13-acetate response element, the Maf recognition element, and the antioxidant-responsive element. The Bach2-enhanced green fluorescent protein bicistronic retrovirus was used to monitor the fate of Bach2-expressing cells at the single cell level. Bach2 exerted an inhibitory effect on NIH3T3 cell proliferation and caused massive apoptosis upon mild oxidative stress in both NIH3T3 and Raji B-lymphoid cells. Interestingly, Bach1, a highly homologous protein, could not induce cell death, demonstrating the specificity for the apoptosis induction. Although both oxidative stress and leptomycin B, an inhibitor of nuclear export, induce nuclear accumulation of Bach2, the leptomycin B-induced nuclear accumulation of Bach2 was not sufficient to elicit apoptosis. Upon oxidative stress, Bach2 formed nuclear foci that associated with promyelocytic leukemia nuclear bodies. Our results suggest that Bach2 constitutes a cell lineage-specific system that couples oxidative stress and cell death and that inhibition of 12-O-tetradecanoylphorbol-13-acetate response element, the Maf recognition element, and the antioxidant-responsive element upon oxidative stress may be critical determinants for apoptosis.	Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 7348551, Japan; Jichi Med Sch, Ctr Mol Med, Div Genet Therapeut, Tochigi 3290498, Japan; Hiroshima Univ, Sch Med, Dept Immunol, Hiroshima 7348551, Japan; Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med, Tsukuba, Ibaraki 3058575, Japan	Hiroshima University; Jichi Medical University; Hiroshima University; Hirosaki University; University of Tsukuba; University of Tsukuba	Igarashi, K (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Kasumi 1-2-3, Hiroshima 7348551, Japan.	igarak@hiroshima-u.ac.jp	Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Kanno, masamoto/0000-0001-9169-3444; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BIGUET C, 1994, J BIOL CHEM, V269, P28865; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kume A, 2000, GENE THER, V7, P1193, DOI 10.1038/sj.gt.3301225; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sasaki S, 2000, ONCOGENE, V19, P3739, DOI 10.1038/sj.onc.1203716; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Sun JY, 2001, J BIOCHEM, V130, P385, DOI 10.1093/oxfordjournals.jbchem.a002997; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vieira SAD, 2001, GENE CHROMOSOME CANC, V32, P353, DOI 10.1002/gcc.1200; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	59	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20724	20733		10.1074/jbc.M112003200	http://dx.doi.org/10.1074/jbc.M112003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923289	hybrid			2022-12-25	WOS:000176204500081
J	Nordin, BE; Schimmel, P				Nordin, BE; Schimmel, P			Plasticity of recognition of the 3 '-end of mischarged tRNA by class I aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BAKERS-YEAST; 3-HYDROXYL GROUP; MIS-ACYLATION; ISOLEUCINE; SIEVE; SITE; DETERMINANTS; THREONINE; MECHANISM	Certain aminoacyl-tRNA synthetases prevent potential errors in protein synthesis through deacylation of mischarged tRNAs. For example, the close homologs isoleucyl-tRNA synthetase (IleRS) and valyl-tRNA synthetase (ValRS) deacylate Val-tRNA(Ile) and Thr-tRNA(Val), respectively. Here we examined the chemical requirements at the 3'-end of the tRNA for these hydrolysis reactions. Single atom substitutions at the 2'- and 3'-hydroxyls of a variety of mischarged RNAs revealed that, while acylation is at the 2'-OH for both enzymes, IleRS catalyzes deacylation specifically from the 3'-OH and not from the 2'-OH. In contrast, ValRS can deacylate non-cognate amino acids from the 2'-OH. Moreover, for IleRS the specificity for a 3'-O location of the scissile ester bond could be forced to the 2'-position by introduction of a 3'-O-methyl moiety. Cumulatively, these and other results suggest that the editing sites of these class I aminoacyl-tRNA synthetases have a degree of inherent plasticity for substrate recognition. The ability to adapt to subtle differences in mischarged RNAs may be important for the high accuracy of aminoacylation.	Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015539, R37GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexander RW, 1998, P NATL ACAD SCI USA, V95, P12214, DOI 10.1073/pnas.95.21.12214; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BRUICE TC, 1962, J AM CHEM SOC, V84, P1973, DOI 10.1021/ja00869a040; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CRAMER F, 1975, FEBS LETT, V56, P212, DOI 10.1016/0014-5793(75)81093-3; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FRANCIS TA, 1983, J BIOL CHEM, V258, P4279; FRASER TH, 1975, P NATL ACAD SCI USA, V72, P3044, DOI 10.1073/pnas.72.8.3044; FREIST W, 1983, EUR J BIOCHEM, V131, P65, DOI 10.1111/j.1432-1033.1983.tb07232.x; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; Glasfeld E, 1996, BIOCHEMISTRY-US, V35, P4139, DOI 10.1021/bi9527810; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hendrickson TL, 2000, BIOCHEMISTRY-US, V39, P8180, DOI 10.1021/bi0004798; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; IGLOI GL, 1977, BIOCHEMISTRY-US, V16, P1696, DOI 10.1021/bi00627a027; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nomanbhoy TK, 2000, P NATL ACAD SCI USA, V97, P5119, DOI 10.1073/pnas.090102197; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; NUREKI O, 1993, TRANSLATIONAL APPARATUS, P59; PAULING L, 1958, FESTSCHRIFT PROF DR; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; SCHIMMEL P, 2002, IN PRESS COLD SPRING; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT E, 1996, THESIS MIT CAMBRIDGE, P160; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; Shi PY, 1998, RNA, V4, P276; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; SPRINZL M, 1975, P NATL ACAD SCI USA, V72, P3049, DOI 10.1073/pnas.72.8.3049; TAIJI M, 1983, BIOCHEMISTRY-US, V22, P3220, DOI 10.1021/bi00282a028; von der Haar F, 1976, Biochemistry, V15, P4131, DOI 10.1021/bi00663a034; VONDERHAAR F, 1975, FEBS LETT, V56, P215, DOI 10.1016/0014-5793(75)81094-5; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722	48	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20510	20517		10.1074/jbc.M202023200	http://dx.doi.org/10.1074/jbc.M202023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923317	hybrid			2022-12-25	WOS:000176204500054
J	Zhang, DW; Cole, SPC; Deeley, RG				Zhang, DW; Cole, SPC; Deeley, RG			Determinants of the substrate specificity of multidrug resistance protein 1 - Role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; BINDING CASSETTE TRANSPORTER; DRUG-RESISTANCE; LEUKOTRIENE C-4; PHARMACOLOGICAL CHARACTERIZATION; ANTICANCER AGENTS; EXPORT PUMP; MRP; GENE; CELLS	Human multidrug resistance protein 1 (MRP1) confers resistance to many natural product chemotherapeutic agents and actively transports structurally diverse organic anion conjugates. We previously demonstrated that two hydrogen-bonding amino acid residues in the predicted transmembrane 17 (TM17) of MRP1, Thr(1242) and Trp(1246), were important for drug resistance and 17beta-estradiol 17-(beta-D-glueuronide) (E(2)17betaG) transport. To determine whether other residues with hydrogen bonding potential within TM17 influence substrate specificity, we replaced Ser(I233), Ser(1235), Ser(1237), Gln(1239), Thr(1241), and Asn(1245) with Ala and Tyr(1236) and Tyr(1243) with Phe. Mutations S1233A, S1235A, S1237A, and Q1239A had no effect on any substrate tested. In contrast, mutations Y1236F and T1241A decreased resistance to vincristine but not to VP-16, doxorubicin, and epirubicin. Mutation Y1243F reduced resistance to all drugs tested by 2-3-fold. Replacement of Asn(1245) with Ala also decreased resistance to VP-16, doxorubicin, and epirubicin but increased resistance to vincristine. This mutation also decreased E(2)17betaG transport similar to5-fold. Only mutation Y1243F altered the ability of MRP1 to transport both leukotriene 4 and E(2)17betaG. Together with our previous results, these findings suggest that residues with side chain hydrogen bonding potential, clustered in the cytoplasmic half of TM17, participate in the formation of a substrate binding site.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Labs, Botterell Hall, Kingston, ON K7L 3N6, Canada.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Zhang, Dawei/ABD-8990-2022	Cole, Susan P.C./0000-0001-6571-6884; Zhang, Dawei/0000-0001-8279-8041				Arkin IT, 1998, BBA-PROTEIN STRUCT M, V1429, P113, DOI 10.1016/S0167-4838(98)00225-8; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; GRANT CE, 1994, CANCER RES, V54, P357; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hooijberg JH, 1999, CANCER RES, V59, P2532; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; KEPPLER D, 2001, J BIOL CHEM, V276, P38636; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Seelig A, 2000, INT J CLIN PHARM TH, V38, P111; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; Stride BD, 1996, MOL PHARMACOL, V49, P962; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; Taniguchi K, 1996, CANCER RES, V56, P4124; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865; Zelcer N, 2001, J BIOL CHEM, V276, P46400, DOI 10.1074/jbc.M107041200; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	51	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20934	20941		10.1074/jbc.M201311200	http://dx.doi.org/10.1074/jbc.M201311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925441	hybrid			2022-12-25	WOS:000176204500107
J	Lin, DY; Shih, HM				Lin, DY; Shih, HM			Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-BINDING-PROTEIN; INTERACTING PROTEIN; INDUCED APOPTOSIS; CELL-DEATH; PML; ACTIVATION; INHIBITION; DOMAINS; TARGET; HELIX	Daxx has been reported to mediate the Fas/JNK-dependent signals in the cytoplasm. However, several lines of evidence have suggested that Daxx is located mainly in the nucleus and functions as a transcriptional regulator. Recent studies have further indicated that Daxx-elicited transcriptional repression can be inhibited by the nuclear body-associated promyelocytic leukemia protein and apoptosis signal-regulating kinase 1 by sequestering Daxx to the nuclear bodies and the cytoplasm, respectively. Here, we further investigated the coordinated molecular mechanism by which Daxx function is regulated through protein-protein interaction. Using yeast two-hybrid screens to identify Daxx-interacting protein(s), three independent clones encoding the 58-kDa microspherule protein (MSP58) fragments were identified. Furthermore, we have demonstrated that Daxx interacts in vitro and in vivo with MSP58 via its NH2-terminal segment, which is distinct from the binding region of Fas, apoptosis signal-regulating kinase 1, and promyelocytic leukemia protein, suggesting a unique modulatory role of MSP58 on Daxx function. Transient transfection experiments revealed that MSP58 relieves the repressor activity of Daxx in a dose-dependent manner in COS-1 and 293 cells but not in HeLa cells, implicating cell type-specific modulation of Daxx function by MSP58. Moreover, immunofluorescence analysis unequivocally demonstrated that MSP58 overexpression results in a translocation of Daxx to the enlarged nucleoli in COS-1 or 293 cells, whereas Daxx exhibited a diffuse nuclear pattern in HeLa cells. Taken together, these findings delineate a network of regulatory signaling pathways that converges on MSP58/Daxx interaction, causally associating Daxx nucleolus targeting with its transcriptional activation function.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11456, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan	National Defense Medical Center; National Health Research Institutes - Taiwan	Shih, HM (corresponding author), 128,Sec 2,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.							AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Eilers AL, 1999, J BIOL CHEM, V274, P32750, DOI 10.1074/jbc.274.46.32750; Everett RD, 1999, J CELL SCI, V112, P3443; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pluta AF, 1998, J CELL SCI, V111, P2029; Ren Y, 1998, EUR J BIOCHEM, V253, P734, DOI 10.1046/j.1432-1327.1998.2530734.x; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	29	86	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25446	25456		10.1074/jbc.M200633200	http://dx.doi.org/10.1074/jbc.M200633200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11948183	hybrid			2022-12-25	WOS:000176747000079
J	Burk, O; Tegude, H; Koch, I; Hustert, E; Wolbold, R; Glaeser, H; Klein, K; Fromm, MF; Nuessler, AK; Neuhaus, P; Zanger, UM; Eichelbaum, M; Wojnowski, L				Burk, O; Tegude, H; Koch, I; Hustert, E; Wolbold, R; Glaeser, H; Klein, K; Fromm, MF; Nuessler, AK; Neuhaus, P; Zanger, UM; Eichelbaum, M; Wojnowski, L			Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; XENOBIOTIC RESPONSE; SMALL-BOWEL; CYTOCHROME-P450; GENE; ACTIVATION; IDENTIFICATION; METABOLISM; PREDICTION; MODULATORS	Human CYP3A enzymes play a pivotal role in the metabolism of many drugs, and the variability of their expression among individuals may have a strong impact on the efficacy of drug treatment. However, the individual contributions of the four CYP3A genes to total CYP3A activity remain unclear. To elucidate the role of CYP3A7, we have studied its expression in human liver and intestine. In both organs, expression of CYP3A7 mRNA was polymorphic. The recently identified CYP3A7*1C allele was a consistent marker of increased CYP3A7 expression both in liver and intestine, whereas the CYP3A7*1B allele was associated with increased CYP3A7 expression only in liver. Because of the replacement of part of the CYP3A7 promoter by the corresponding region of CYP3A4, the CYP3A7*1C allele contains the proximal ER6 motif of CYP3A4. The pregnane X and constitutively activated receptors were shown to bind with higher affinity to CYP3A4-ER6 than to CYP3A7-ER6 motifs and transactivated only promoter constructs containing CYP3A4-ER6. Furthermore, we identified mutations in CYP3A7*1C in addition to the ER6 motif that were necessary only for activation by the constitutively activated receptor. We conclude that the presence of the ER6 motif of CYP3A4 mediates the high expression of CYP3A7 in subjects carrying CYP3A7*1C.	Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; Univ Tubingen, Div Pharmacol, D-72076 Tubingen, Germany; Humboldt Univ, Charite, Dept Surg, D-13353 Berlin, Germany; Epidauros Biotechnol AG, D-82347 Bernried, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Burk, O (corresponding author), Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany.	oliver.burk@ikp-stuttgart.de	Zanger, Ulrich M./A-9364-2012	Zanger, Ulrich M./0000-0002-5276-2002				Bertilsson G, 2001, BIOCHEM BIOPH RES CO, V280, P139, DOI 10.1006/bbrc.2000.4066; Drocourt L, 2001, DRUG METAB DISPOS, V29, P1325; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Gellner K, 2001, PHARMACOGENETICS, V11, P111, DOI 10.1097/00008571-200103000-00002; Gillam EMJ, 1997, ARCH BIOCHEM BIOPHYS, V346, P81, DOI 10.1006/abbi.1997.0286; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Greuet J, 1996, BIOCHEM BIOPH RES CO, V225, P689, DOI 10.1006/bbrc.1996.1231; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; HASHIMOTO H, 1993, EUR J BIOCHEM, V218, P585, DOI 10.1111/j.1432-1033.1993.tb18412.x; Hustert E, 2001, PHARMACOGENETICS, V11, P773, DOI 10.1097/00008571-200112000-00005; Hustert E, 2001, DRUG METAB DISPOS, V29, P1454; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kivisto KT, 1996, BRIT J CLIN PHARMACO, V42, P387, DOI 10.1046/j.1365-2125.1996.42615.x; KOLARS JC, 1992, J CLIN INVEST, V90, P1871, DOI 10.1172/JCI116064; KOMORI M, 1990, BIOCHEMISTRY-US, V29, P4430, DOI 10.1021/bi00470a024; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Lacroix D, 1997, EUR J BIOCHEM, V247, P625, DOI 10.1111/j.1432-1033.1997.00625.x; Lang T, 2001, PHARMACOGENETICS, V11, P399, DOI 10.1097/00008571-200107000-00004; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LOWN KS, 1994, DRUG METAB DISPOS, V22, P947; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; Moore JT, 2000, TOXICOLOGY, V153, P1, DOI 10.1016/S0300-483X(00)00300-0; Ohmori S, 1998, BBA-GEN SUBJECTS, V1380, P297, DOI 10.1016/S0304-4165(97)00156-6; Ozdemir V, 2000, PHARMACOGENETICS, V10, P373, DOI 10.1097/00008571-200007000-00001; Pascussi JM, 1999, BIOCHEM BIOPH RES CO, V260, P377, DOI 10.1006/bbrc.1999.0745; Saito T, 2001, J BIOL CHEM, V276, P38010; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; SCHUETZ JD, 1994, PHARMACOGENETICS, V4, P11, DOI 10.1097/00008571-199402000-00002; Shimada T, 1996, DRUG METAB DISPOS, V24, P515; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; TOM BH, 1976, IN VITRO CELL DEV B, V12, P180; Westlind A, 2001, BIOCHEM BIOPH RES CO, V281, P1349, DOI 10.1006/bbrc.2001.4505; Wilkinson GR, 1996, J PHARMACOKINET BIOP, V24, P475, DOI 10.1007/BF02353475; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; YANG HYL, 1994, MOL PHARMACOL, V46, P922; Zelko I, 2000, BIOCHEM BIOPH RES CO, V277, P1, DOI 10.1006/bbrc.2000.3557	39	153	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24280	24288		10.1074/jbc.M202345200	http://dx.doi.org/10.1074/jbc.M202345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11940601	hybrid			2022-12-25	WOS:000176611800041
J	Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB				Petrescu, AD; Hertz, R; Bar-Tana, J; Schroeder, F; Kier, AB			Ligand specificity and conformational dependence of the hepatic nuclear factor-4 alpha (HNF-4 alpha).	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; ACID-BINDING PROTEIN; ACYL-COENZYME-A; FATTY-ACID; ENERGY-TRANSFER; CIRCULAR-DICHROISM; COA THIOESTERS; LIVER-CELLS; RAT; TRANSCRIPTION	Hepatic nuclear factor-4alpha (HNF-4alpha) controls the expression of genes encoding proteins involved in lipid and carbohydrate metabolism. Fatty acyl-CoA thioesters have recently been proposed to be naturally occurring ligands of HNF-4alpha and to regulate its transcriptional activity as function of their chain length and degree of unsaturation (Hertz, R., Magenheim, J., Berman, I., and Bar-Tana, J. (1998) Nature 392, 512-516). However, the apparent low affinities (p m K-d values) obtained with a radiolabeled fatty acyl-CoA ligand binding assay raised questions regarding the physiological significance of this finding. Furthermore, it is not known whether interaction with fatty acyl-CoA alters the structure of HNF-4alpha. These issues were examined using rat recombinant HNF-4alpha ligand-binding domain (HNF-4alphaLBD) in conjunction with photon counting fluorescence and circular dichroism. First, fluorescence resonance energy transfer between FWF-4alphaLBD tryptophan (Trp) and cis-parinaroyl-CoA yielded an intermolecular distance of less than or equal to42 Angstrom, thus pointing to direct molecular interaction rather than nonspecific coaggregation. Second, quenching of HNF-4alphaLBD intrinsic Trp fluorescence by fatty acyl-CoAs (e.g. pamitoyl-, stearoyl-, linoleoyl-, and arachidonoyl-CoAs) yielded a single binding site with K-d values of 1.6-4.0 nm. These affinities were 2-3 orders of magnitude higher than those previously derived by radiolabeled fatty acyl-CoA ligand binding assay. Third, binding of fatty acyl-CoAs was specific as the binding affinities of the respective free fatty acids or free CoA (K-d values of 421-742 nm) were significantly lower. Fourth, circular dichroism demonstrated that the HNF-4alphaLBD secondary structure was significantly and differentially altered by fatty acyl-CoA binding. The opposite effects of saturated versus polyunsaturated fatty acyl-CoAs on HNF-4alphaLBD secondary structure correlated with their opposite regulatory effects on HNF-4alpha function. Fifth, the CoA thioesters of some hypolipidemic peroxisome proliferators bind with high affinity (K-d values as low as 2.6 nm) to HNF-4alphaLBD, thus indicating that HNF-4alpha may serve as target for these drugs. In summary, these data demonstrate for the first time high affinity binding to HNF-4alpha of fatty and xenobiotic acyl-CoAs in the physiological range, resulting in significantly altered HNF-4alpha conformation.	Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Texas A&M Univ, Dept Physiol & Pharmacol, Texas Vet Med Ctr, College Stn, TX 77843 USA; Hebrew Univ Jerusalem, Dept Human Nutr & Metab, Sch Med, IL-91120 Jerusalem, Israel	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Hebrew University of Jerusalem	Kier, AB (corresponding author), Texas A&M Univ, Dept Pathobiol, Texas Vet Med Ctr, College Stn, TX 77843 USA.	akier@cvm.tamu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIEHS NIH HHS [ES09106] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARTANA J, 1985, J BIOL CHEM, V260, P8404; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; CARTER ME, 1993, J BIOL CHEM, V268, P13805; Cattley RC, 1998, REGUL TOXICOL PHARM, V27, P47, DOI 10.1006/rtph.1997.1163; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Elholm M, 2000, J LIPID RES, V41, P538; FORSTER TH., 1967, COMPREHENSIVE BIOCH, P61; Frolov A, 1998, J BIOL CHEM, V273, P11049, DOI 10.1074/jbc.273.18.11049; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Frolov A, 1997, LIPIDS, V32, P1201, DOI 10.1007/s11745-997-0154-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hertz R, 1998, TOXICOL LETT, V103, P85, DOI 10.1016/S0378-4274(98)00290-2; HERTZ R, 2001, BIOCHEM PHARMACOL, V61, P1507; HUBBELL T, 1994, BIOCHEMISTRY-US, V33, P3327, DOI 10.1021/bi00177a025; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; JUGUELIN H, 1984, ANAL BIOCHEM, V142, P329, DOI 10.1016/0003-2697(84)90472-X; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; Li JX, 2000, GENE DEV, V14, P464; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McArthur MJ, 1999, J LIPID RES, V40, P1371; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; Parker C.A, 1968, PHOTOLUMINESCENCE SO; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis	50	70	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					23988	23999		10.1074/jbc.M201241200	http://dx.doi.org/10.1074/jbc.M201241200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11940586				2022-12-25	WOS:000176611800005
J	Skjerpen, CS; Wesche, J; Olsnes, S				Skjerpen, CS; Wesche, J; Olsnes, S			Identification of ribosome-binding protein p34 as an intracellular protein that binds acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH-REPEAT; FACTOR-I; KINASE CK2; HEPARIN-BINDING; TRANSLOCATION; SYNAPTOTAGMIN-1; PROLIFERATION; INTERACTS; DOMAIN; LOCALIZATION	With the aim of identifying new intracellular binding partners for acidic fibroblast growth factor (aFGF), proteins from U2OS human osteosarcoma cells were adsorbed to immobilized aFGF. One of the adsorbed proteins is a member of the leucine-rich repeat protein family termed ribosome-binding protein p34 (p34). This protein has previously been localized to endoplasmic reticulum membranes and is thought to span the membrane with the N terminus on the cytosolic side. Confocal microscopy of cells transfected with Myc-p34 confirmed the endoplasmic reticulum. localization, and Northern blotting determined p34 mRNA to be present in a multitude of different tissues. Cross-linking experiments indicated that the protein is present in the cell as a dimer. In vitro translated p34 was found to interact with maltose-binding protein-aFGF through its cytosolic coiled-coil domain. The interaction between aFGF and p34 was further characterized by surface plasmon resonance, giving a K-D of 1.4 +/- 0.3 mum. Even though p34 interacted with mitogenic aFGF, it bound poorly to the non-mitogenic aFGF(K132E) mutant, indicating a possible involvement of p34 in intracellular signaling by aFGF.	Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway	University of Oslo	Olsnes, S (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Biochem, N-0310 Oslo, Norway.	sjur.olsnes@labmed.uio.no	Wesche, Jorgen/ABH-7524-2020	Wesche, Jorgen/0000-0002-9200-9162				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Gotz C, 2000, BIOCHEM BIOPH RES CO, V268, P882, DOI 10.1006/bbrc.2000.2230; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; Klingenberg O, 2000, J BIOL CHEM, V275, P11972, DOI 10.1074/jbc.275.16.11972; Klingenberg O, 1999, J BIOL CHEM, V274, P18081, DOI 10.1074/jbc.274.25.18081; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Mizukoshi E, 1999, BIOCHEM J, V343, P461, DOI 10.1042/0264-6021:3430461; OHSUMI T, 1993, BIOCHEM J, V294, P465, DOI 10.1042/bj2940465; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Russo K, 2002, J BIOL CHEM, V277, P1284, DOI 10.1074/jbc.M108858200; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shen B, 1998, BIOCHEM BIOPH RES CO, V252, P524, DOI 10.1006/bbrc.1998.9677; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Wiedlocha A, 1995, J BIOL CHEM, V270, P30680, DOI 10.1074/jbc.270.51.30680; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wiedlocha A, 1996, MOL CELL BIOL, V16, P270	40	33	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23864	23871		10.1074/jbc.M112193200	http://dx.doi.org/10.1074/jbc.M112193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964394	hybrid			2022-12-25	WOS:000176475700100
J	Zhou, TQ; Shen, J; Liu, Y; Rosen, BP				Zhou, TQ; Shen, J; Liu, Y; Rosen, BP			Unisite and multisite catalysis in the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; NUCLEOTIDE-BINDING SITE; ESCHERICHIA-COLI; CONFORMATIONAL-CHANGES; PUMP; MECHANISM; FLUORESCENCE; MUTAGENESIS; SUBSTRATE; SEQUENCE	The ars operon of plasmid R773 encodes an As(III)/Sb(III) extrusion pump. The catalytic subunit, the ArsA ATPase, has two homologous halves, A1 and A2, each with a consensus nucleotide-binding sequence. ATP hydrolysis is slow in the absence of metalloid and is accelerated by metalloid binding. ArsA M446W has a single tryptophan adjacent to the A2 nucleotide-binding site. Tryptophan fluorescence increased upon addition of ATP, ADP, or a nonhydrolyzable ATP analogue. Mg2+ and Sb(III) produced rapid quenching of fluorescence with ADP, no quenching with a nonhydrolyzable analogue, and slow quenching with ATP. The results suggest that slow quenching with ATP reflects hydrolysis of ATP to ADP in the A2 nucleotide-binding site. In an A2 nucleotide-binding site mutant, nucleotides had no effect. In contrast, in an A1 nucleotide-binding mutant, nucleotides still increased fluorescence, but there was no quenching with Mg2+ and Sb(III). This suggests that the A2 site hydrolyzes ATP only when Sb(III) or As(III) is present and when the A1 nucleotide-binding domain is functional. These results support previous hypotheses in which only the A1 nucleotide-binding domain hydrolyzes ATP in the absence of activator (unisite catalysis), and both the A1 and A2 sites hydrolyze ATP when activated (multisite catalysis).	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bhattacharjee H, 2000, BIOMETALS, V13, P281, DOI 10.1023/A:1009200215328; Bhattacharjee H, 2000, BIOCHEM SOC T, V28, P520, DOI 10.1042/0300-5127:0280520; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Rouviere N, 1997, BIOCHEMISTRY-US, V36, P7339, DOI 10.1021/bi962289w; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; Walmsley AR, 2001, BIOCHEM J, V360, P589, DOI 10.1042/0264-6021:3600589; Walmsley AR, 2001, J BIOL CHEM, V276, P6378, DOI 10.1074/jbc.M008105200; WEBER J, 1997, BIOCHIM BIOPHYS ACTA, V1318, P19; Zhou T, 2000, EMBO J, V19, P1; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731; Zhou TQ, 2001, J BIOL CHEM, V276, P30414, DOI 10.1074/jbc.M103671200	29	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23815	23820		10.1074/jbc.M203432200	http://dx.doi.org/10.1074/jbc.M203432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964412	hybrid			2022-12-25	WOS:000176475700094
J	Fisher, TS; Prasad, VR				Fisher, TS; Prasad, VR			Substitutions of Phe(61) located in the vicinity of template 5 '-overhang influence polymerase fidelity and nucleoside analog sensitivity of HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-SYNTHESIS; ANGSTROM RESOLUTION; ERROR SPECIFICITY; CRYSTAL-STRUCTURE; MISPAIR EXTENSION; THUMB SUBDOMAIN; DRUG-RESISTANT; TYPE-1; PROCESSIVITY	Human immunodeficiency virus type I reverse transcriptase (RT) is an error-prone DNA polymerase. Structural determinants of its fidelity are incompletely understood. RT/template primer contacts have been shown to influence its fidelity and sensitivity to nucleoside analog inhibitors. The Phe(61) residue, located within the beta3 sheet of the finger subdomain, is highly conserved among retroviral RTs. The crystal structure of a ternary complex revealed that Phe(61) contacts the first and second bases of the 5'-template overhang. To determine whether such contacts influence the dNTP-binding pocket, we performed a limited vertical scanning mutagenesis (Phe --> Ala, Leu, Trp, or Tyr) at Phe(61). The F61A mutant displayed the highest increase in fidelity, followed by the F61L and F61W variants, which had intermediate phenotypes. F61Y RT had a minimal effect. The increase in fidelity of the F61A mutant was corroborated by a 12-fold decrease in its forward mutation rate. The Phe(61) mutant RTs also displayed large reductions in sensitivity to 2',3'-dideoxythymidine triphosphate and 2',3'-dideohydrothymidine triphosphate. Mutants displaying the largest increase in fidelity (F61A and F61L) were also the most resistant. These results suggest that contacts between the finger subdomain of human immunodeficiency virus type 1 RT and the template 5'-overhang are important determinants of the geometry of the dNTP-binding pocket.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Prasad, VR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave,Rm GB 401, Bronx, NY 10461 USA.		Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NIAID NIH HHS [R01 AI30861] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Jonckheere H, 2000, EUR J BIOCHEM, V267, P2658, DOI 10.1046/j.1432-1327.2000.01272.x; KEW Y, 1994, J BIOL CHEM, V269, P15331; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Omrani AS, 2000, J INFECTION, V41, P5, DOI 10.1053/jinf.2000.0702; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Peletskaya EN, 2001, J VIROL, V75, P9435, DOI 10.1128/JVI.75.19.9435-9445.2001; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; Rezende LF, 1998, J VIROL, V72, P2890, DOI 10.1128/JVI.72.4.2890-2895.1998; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Rubinek T, 1997, EUR J BIOCHEM, V247, P238, DOI 10.1111/j.1432-1033.1997.00238.x; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; TELESNITSKY A, 1998, RETROVIRUSES, P121; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	46	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22345	22352		10.1074/jbc.M200282200	http://dx.doi.org/10.1074/jbc.M200282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948182	hybrid			2022-12-25	WOS:000176313600031
J	Iijima, Y; Laser, M; Shiraishi, H; Willey, CD; Sundaravadivel, B; Xu, L; McDermott, PJ; Kuppuswamy, D				Iijima, Y; Laser, M; Shiraishi, H; Willey, CD; Sundaravadivel, B; Xu, L; McDermott, PJ; Kuppuswamy, D			c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; CAP-DEPENDENT INITIATION; VIVO PRESSURE-OVERLOAD; S6 KINASE; ANGIOTENSIN-II; IN-VIVO; CYCLIC-AMP; RAT-HEART; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION SITE	p70S6 kinase (S6K1) plays a pivotal role in hypertrophic cardiac growth via ribosomal biogenesis. In pressure-overloaded myocardium, we show S6K1 activation accompanied by activation of protein kinase C (PKC), c-Raf, and mitogen-activated protein kinases (MAPKs). To explore the importance of the c-Raf/MAPK kinase (MEK)/MAPK pathway, we stimulated adult feline cardiomyocytes with 12-O-tetradecanoylphorbol-13-acetate (TPA), insulin, or forskolin to activate PKC, phosphatidylinositol-3-OH kinase, or protein kinase A (PKA), respectively. These treatments resulted in S6K1 activation with Thr-389 phosphorylation as well as mammalian target of rapamycin (mTOR) and S6 protein phosphorylation. Thr-421/Ser-424 phosphorylation of S6K1 was observed predominantly in TPA-treated cells. Dominant negative c-Raf expression or a MEK1/2 inhibitor (U0126) treatment showed a profound blocking effect only on the TPA-stimulated phosphorylation of S6K1 and mTOR. Whereas p38 MAPK inhibitors exhibited only partial effect, MAPK-phosphatase-3 expression significantly blocked the TPA-stimulated S6K1 and mTOR phosphorylation. Inhibition of mTOR with rapamycin blocked the Thr-389 but not the Thr-421/Ser-424 phosphorylation of S6K1. Therefore, during PKC activation, the c-Raf/MEK/extracellular signal-regulated kinase-1/2 (ERK1/2) pathway mediates both the Thr-421/Ser-424 and the Thr-389 phosphorylation in an mTOR-independent and -dependent manner, respectively. Together, our in vivo and in vitro studies indicate that the PKC/c-Raf/MEK/ERK pathway plays a major role in the S6K1 activation in hypertrophic cardiac growth.	Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kuppuswamy, D (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, 114 Doughty St, Charleston, SC 29425 USA.	kuppusd@musc.edu		Willey, Christopher/0000-0001-9953-0279	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48788] Funding Source: Medline; NIGMS NIH HHS [GM08716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; Boknik P, 2001, CARDIOVASC RES, V51, P717, DOI 10.1016/S0008-6363(01)00346-7; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUA BHL, 1987, AM J PHYSIOL, V252, pC323, DOI 10.1152/ajpcell.1987.252.3.C323; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COOPER G, 1974, J APPL PHYSIOL, V37, P762, DOI 10.1152/jappl.1974.37.5.762; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Filippa N, 1999, MOL CELL BIOL, V19, P4989; GERARD RD, 1995, DNA CLONING PRACTICA, P285; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Morgan HE, 1997, MOL CELL BIOCHEM, V176, P145, DOI 10.1023/A:1006855818855; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; ROZICH JD, 1995, J MOL CELL CARDIOL, V27, P485, DOI 10.1016/S0022-2828(08)80044-2; SADOSHIMA J, 1995, CIRC RES, V76, P1; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; Senbonmatsu T, 2000, J CLIN INVEST, V106, pR25, DOI 10.1172/JCI10037; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; WATSON PA, 1989, AM J PHYSIOL, V256, pC1257, DOI 10.1152/ajpcell.1989.256.6.C1257; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	76	124	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23065	23075		10.1074/jbc.M200328200	http://dx.doi.org/10.1074/jbc.M200328200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940578	hybrid			2022-12-25	WOS:000176313600122
J	Liedtke, CM; Yun, CHC; Kyle, N; Wang, DD				Liedtke, CM; Yun, CHC; Kyle, N; Wang, DD			Protein kinase C epsilon-dependent regulation of cystic fibrosis transmembrane regulator involves binding to a receptor for activated C kinase (RACK1) and RACK1 binding to Na+/H+ exchange regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIF-CONTAINING PROTEIN; CONDUCTANCE REGULATOR; INTRACELLULAR RECEPTORS; CRYSTAL-STRUCTURE; BETA; DOMAIN; PKC; CFTR; REGION; TRANSLOCATION	Protein kinase C (PKC) regulation of cystic fibrosis transmembrane regulator (CFTR) chloride function has been demonstrated in several cell lines, including Calu-3 cells that express native, wild-type CFTR. We demonstrated previously that PKCepsilon was required for cAMP-dependent CFTR function. The goal of this study was to determine whether PKCepsilon interacts directly with CFTR. Using overlay assay, immunoprecipitation, pulldown and binding assays, we show that PKCepsilon does not bind to CFTR, but does bind to a receptor for activated C kinase (RACK1), a 37-kDa scaffold protein, and that RACK1 binds to Na+/H+ exchange regulatory factor (NHERF1), a binding partner of CFTR. In vitro binding assays demonstrate dose-dependent binding of PKCepsilon to RACK1 which is inhibited by an 8-amino acid peptide based on the sequence of the sixth Trp-Asp repeat in RACK1 or by an 8-amino acid sequence in the V1 region of PKCepsilon, epsilonV1-2. A 4-amino acid sequence INAL (70-73) expressed in CFTR shares 50% homology to the RACK1 inhibitory peptide, but it does not bind PKCepsilon. NHERF1 and RACK1 bind in a dose-dependent manner. Immunofluorescence and confocal microscopy of RACK1 and CFTR revealed colocalization of the proteins to the apical and lateral regions of Calu-3 cells. The results indicate the RACK1 binds PKCepsilon and NHERF1, thus serving as a scaffold protein to anchor the enzyme in proximity to CFTR.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Warren Alan Bernbaum MD Ctr Cyst Fibrosis Res, Cleveland, OH 44106 USA; Emory Univ, Dept Gastroenterol, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Dept Med, Atlanta, GA 30322 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Emory University; Emory University	Liedtke, CM (corresponding author), BRB, Rm 824,2109 Adelbert Rd, Cleveland, OH 44106 USA.	cxl7@po.cwru.edu			NHLBI NIH HHS [HL67190, HL58598] Funding Source: Medline; NIDDK NIH HHS [DK27651, DK44484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067190, R01HL058598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, P01DK044484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Brandon NJ, 1999, J NEUROSCI, V19, P9228; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FranchiGazzola R, 1996, J BIOL CHEM, V271, P26124, DOI 10.1074/jbc.271.42.26124; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liedtke CM, 2001, AM J PHYSIOL-LUNG C, V280, pL739, DOI 10.1152/ajplung.2001.280.4.L739; Liedtke CM, 1998, AM J PHYSIOL-CELL PH, V275, pC1357, DOI 10.1152/ajpcell.1998.275.5.C1357; Liedtke CM, 1997, AM J PHYSIOL-CELL PH, V273, pC1632, DOI 10.1152/ajpcell.1997.273.5.C1632; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; Middleton LM, 1998, AM J PHYSIOL-CELL PH, V275, pC293, DOI 10.1152/ajpcell.1998.275.1.C293; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yeon SW, 2001, BIOCHEM BIOPH RES CO, V280, P782, DOI 10.1006/bbrc.2000.4181; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	52	77	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22925	22933		10.1074/jbc.M201917200	http://dx.doi.org/10.1074/jbc.M201917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956211	hybrid			2022-12-25	WOS:000176313600105
J	Pelletier, B; Beaudoin, J; Mukai, Y; Labbe, S				Pelletier, B; Beaudoin, J; Mukai, Y; Labbe, S			Fep1, an iron sensor regulating iron transporter gene expression in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ENCODING GENE; METAL-ION TRANSPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; USTILAGO-MAYDIS; GATA FACTOR; FERRIC REDUCTASE; SIDEROPHORE BIOSYNTHESIS; PENICILLIUM-CHRYSOGENUM; MOLECULAR-BIOLOGY	Schizosaccharomyces pombe cells acquire iron under high affinity conditions through the action of a cell surface ferric reductase encoded by the frp1(+) gene and a two-component iron-transporting complex encoded by the fip1(+) and fio1(+) genes. When cells are grown in the presence of iron, transcription of all three genes is blocked. A conserved regulatory element, 5'-(A/T)GATAA-3', located upstream of the frp1(+), fip1(+), and fio1(+) genes, is necessary for iron repression. We have cloned a novel gene, termed fep1(+), which encodes an iron-sensing transcription factor. Binding studies reveal that the putative DNA binding domain of Fep1 expressed as a fusion protein in Escherichia coli specifically interacts with the 5'-(A/T)GATAA-3' sequence in an iron-dependent manner. In a fep1Delta mutant strain, the fio1(+) gene is highly expressed and is unregulated by iron. Furthermore, the fep1Delta mutation increases activity of the cell surface iron reductase and renders cells hypersensitive to the iron-dependent free radical generator phleomycin. Mutations in the transcriptional co-repressors tup11(+) and tup12(+) are phenocopies to fep1(+). Indeed, strains with both tup11Delta and tup12Delta deletions fail to sense iron. This suggests that in the presence of iron and Fep1, the Tup11 and Tup12 proteins may act as co-repressors for down-regulation of genes encoding components of the reductive iron transport machinery.	Univ Sherbrooke, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Osaka Univ, Dept Biotechnol, Suita, Osaka 5650871, Japan	University of Sherbrooke; Osaka University	Labbe, S (corresponding author), Univ Sherbrooke, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada.			Mukai, Yukio/0000-0003-1265-0839; Labbe, Simon/0000-0002-4947-523X				Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; ALFA C, 1993, EXPT FISSION YEASTS; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; Andrews NC, 1999, NUTR REV, V57, P114, DOI 10.1111/j.1753-4887.1999.tb06934.x; Ardon O, 2001, J BIOL CHEM, V276, P43049, DOI 10.1074/jbc.M108701200; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DANCIS A, 1998, J PEDIAT 2, V132, P524; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FOX KR, 1987, BIOCHEM J, V243, P847, DOI 10.1042/bj2430847; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1999, J BIOL CHEM, V274, P4613, DOI 10.1074/jbc.274.8.4613; Haas H, 1997, J BIOL CHEM, V272, P22576, DOI 10.1074/jbc.272.36.22576; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hoe KL, 1996, BIOCHEM MOL BIOL INT, V39, P127; KEENEY JB, 1994, GENETICS, V136, P849; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; Koch KA, 1996, MOL CELL BIOL, V16, P724; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Ostling J, 1996, MOL CELL BIOL, V16, P753; Philpott CC, 1998, EMBO J, V17, P5026, DOI 10.1093/emboj/17.17.5026; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; SANTORO N, 1997, YEAST STRESS RESPONS, P165; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VASSAROTTI A, 1985, J BIOL CHEM, V260, P6348; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; Wessling-Resnick M, 2000, ANNU REV NUTR, V20, P129, DOI 10.1146/annurev.nutr.20.1.129; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YAMAGUCHIIWAI Y, 2002, J BIOL CHEM     0304; Yun CW, 2000, J BIOL CHEM, V275, P16354, DOI 10.1074/jbc.M001456200; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Yun CW, 2001, J BIOL CHEM, V276, P10218, DOI 10.1074/jbc.M010065200; Zhou LW, 1998, MOL GEN GENET, V259, P532, DOI 10.1007/s004380050845	67	99	101	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22950	22958		10.1074/jbc.M202682200	http://dx.doi.org/10.1074/jbc.M202682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956219	hybrid			2022-12-25	WOS:000176313600108
J	Cheng, H; Cenciarelli, C; Tao, MY; Parks, WP; Cheng-Mayer, C				Cheng, H; Cenciarelli, C; Tao, MY; Parks, WP; Cheng-Mayer, C			HTLV-1 tax-associated hTid-1, a human DnaJ protein, is a repressor of I kappa B kinase beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; HUMAN-IMMUNODEFICIENCY-VIRUS; IKK-BETA; TRANSFORMING PROTEIN; REL PROTEINS; ACTIVATION; ALPHA; GENE; DROSOPHILA	hTid-1, a human DnaJ protein, is a novel cellular target for HTLV-1 Tax. Here, we show that hTid-1 represses NF-kappaB activity induced by Tax as well as other activators such as tumor necrosis factor alpha (TNFalpha) and Bcl10. hTid-1 specifically suppresses serine phosphorylation of IkappaBalpha by activated IkappaB kinase beta (IKKbeta), but the activities of other serine kinases including p38, ERK2, and JNK1 are not affected. The suppressive activity of hTid-1 on IKKbeta requires a functional J domain that mediates association with heat shock proteins and results in prolonging the half-life of the NF-kappaB inhibitors IkappaBalpha and IkappaBbeta. Collectively, our data suggest that hTid-1, in association with heat shock proteins, exerts a negative regulatory effect on the NF-kappaB activity induced by various extracellular and intracellular activators including HTLV-1 Tax.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; CNR, Ist Neurobiol & Med Mol, I-00137 Rome, Italy; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Dept Pediat, New York, NY 10016 USA	Rockefeller University; Consiglio Nazionale delle Ricerche (CNR); New York University; New York University	Cheng, H (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.		CENCIARELLI, CARLO/AAC-1603-2019	CENCIARELLI, CARLO/0000-0001-7480-4608				Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; BOHNLEIN E, 1989, J VIROL, V63, P1578; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GONZALEZCRESPO S, 1994, SCIENCE, V264, P255, DOI 10.1126/science.8146656; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu BY, 1997, J VIROL, V71, P3161, DOI 10.1128/JVI.71.4.3161-3167.1997; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Yoo CG, 2000, J IMMUNOL, V164, P5416, DOI 10.4049/jimmunol.164.10.5416; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	43	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20605	20610		10.1074/jbc.M201204200	http://dx.doi.org/10.1074/jbc.M201204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927590	hybrid			2022-12-25	WOS:000176204500066
J	Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T				Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T			Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers	ONCOGENE			English	Article						lung cancer; 14-3-3 sigma; methylation; MSP	SIGMA GENE; SMALL-CELL; HYPERMETHYLATION; IDENTIFICATION; INVOLVEMENT; IMPAIRMENT; CHECKPOINT; EXPRESSION; PROTEIN; P53	One isoform of the 14-3-3 family, 14-3-3sigma, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3sigma is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3sigma gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3sigma gene. Among nonsmall cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3sigma (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or significant reduction in 14-3-3sigma expression in vivo, while a loss or reduction of 14-3-3sigma expression was very rare in primary NSCLC specimens (I of 22 tissues, 5%). This is the first description that indicates lung cancers frequently show significant inactivation of the 14-3-3sigma gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3sigma gene in lung tumorigenesis in a histological type-specific manner.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4348681, Japan; Rinku Gen Med Ctr, Osaka 5988577, Japan	Aichi Cancer Center; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Konishi H, 2002, CANCER RES, V62, P271; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Osada H, 2001, CANCER RES, V61, P8331; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Suzuki H, 2000, CANCER RES, V60, P4353; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438	21	132	141	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2418	2424		10.1038/sj.onc.1205303	http://dx.doi.org/10.1038/sj.onc.1205303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948426				2022-12-25	WOS:000174635600015
J	Buhman, KK; Smith, SJ; Stone, SJ; Repa, JJ; Wong, JS; Knapp, FF; Burri, BJ; Hamilton, RL; Abumrad, NA; Farese, RV				Buhman, KK; Smith, SJ; Stone, SJ; Repa, JJ; Wong, JS; Knapp, FF; Burri, BJ; Hamilton, RL; Abumrad, NA; Farese, RV			DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; MONOACYLGLYCEROL ACYLTRANSFERASE; APOLIPOPROTEIN-B; CHOLESTEROL; LIVER; MICE; ACID	Dietary triacylglycerols are a major source of energy for animals. The absorption of dietary triacylglycerols involves their hydrolysis to free fatty acids and monoacylglycerols in the intestinal lumen, the uptake of these products into enterocytes, the resynthesis of triacylgylcerols, and the incorporation of newly synthesized triacylglycerols into nascent chylomicrons for secretion. In enterocytes, the final step in triacylglycerol synthesis is believed to be catalyzed primarily through the actions of acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes. In this study, we analyzed intestinal triacylglycerol absorption and chylomicron synthesis and secretion in DGAT1-deficient (Dgat1(-/-)) mice. Surprisingly, DGAT1 was not essential for quantitative dietary triacylglycerol absorption, even in mice fed a high fat diet, or for the synthesis of chylomicrons. However, Dgat1(-/-)mice had reduced postabsorptive chylomicronemia (1 h after a high fat challenge) and accumulated neutrallipid droplets in the cytoplasm of enterocytes when chronically fed a high fat diet. These results suggest a reduced rate of triacylglycerol absorption in Dgat1(-/-)mice. Analysis of intestine from Dgat1(-/-) mice revealed activity for two other enzymes, DGAT2 and diacylglycerol transacylase, that catalyze triacylglycerol synthesis and apparently help to compensate for the absence of DGAT1. Our findings indicate that multiple mechanisms for triacylglycerol synthesis in the intestine facilitate triacylglycerol absorption.	Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Dept Anat, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Oak Ridge Natl Lab, Nucl Med Program, Oak Ridge, TN 37831 USA; USDA, Western Human Nutr Res Ctr, Davis, CA 95616 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11793 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Agriculture (USDA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Farese, RV (corresponding author), Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA.		Buhman, Kimberly/AAV-3111-2021	Buhman, Kimberly/0000-0002-3784-1028; Repa, Joyce/0000-0001-5740-1954	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056084, R01DK056084] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056084, DK56084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGERMULLER S, 1982, HISTOCHEM J, V14, P823, DOI 10.1007/BF01033631; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; Knapp FF, 1999, INT J CARDIAC IMAG, V15, P1, DOI 10.1023/A:1006147228352; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LEHNER R, 1993, J BIOL CHEM, V268, P8781; MANSBACH CM, 1973, BIOCHIM BIOPHYS ACTA, V296, P386, DOI 10.1016/0005-2760(73)90097-0; Meiner V, 1997, J LIPID RES, V38, P1928; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; RODGERS JB, 1970, BIOCHIM BIOPHYS ACTA, V202, P426, DOI 10.1016/0005-2760(70)90113-X; Schwarz M, 1998, J LIPID RES, V39, P1833; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; WILSON MD, 1994, J LIPID RES, V35, P943; YANG LY, 1991, J LIPID RES, V32, P1173; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	20	187	230	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25474	25479		10.1074/jbc.M202013200	http://dx.doi.org/10.1074/jbc.M202013200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11959864	hybrid			2022-12-25	WOS:000176747000082
J	Gao, L; Cueto, MA; Asselbergs, F; Atadja, P				Gao, L; Cueto, MA; Asselbergs, F; Atadja, P			Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REVERSIBLE ACETYLATION; TRICHOSTATIN-A; PROTEIN SIR2; CLASS-I; YEAST; REPRESSION; RPD3; COMPLEX; SMRT	We have cloned and characterized a human cDNA that belongs to the histone deacetylase family, which we designate as HDAC11. The predicted HDAC11 amino acid sequence reveals an open reading frame of 347 residues with a corresponding molecular mass of 39 kDa. Sequence analyses of the putative HDAC11 protein indicate that it contains conserved residues in the catalytic core regions shared by both class I and 11 mammalian HDAC enzymes. Putative orthologues of HDAC11 exist in primate, mouse, Drosophila, and plant. Epitope-tagged HDAC11 protein expressed in mammalian cells displays histone deacetylase activity in vitro. Furthermore, HDAC11's enzymatic activity is inhibited by trapoxin, a known histone deacetylase inhibitor. Multiple tissue Northern blot and real-time PCR experiments show that the high expression level of HDAC11 transcripts is limited to kidney, heart, brain,, skeletal muscle, and testis. Epitope-tagged HDAC11 protein localizes predominantly to the cell nucleus. Co-immunoprecipitation experiments indicate that HDAC11 may be present in protein complexes that also contain HDAC6. These results indicate that HDAC11 is a novel and unique member of the histone deacetylase family and it may have distinct physiological roles from those of the known HDACs.	Novartis Pharmaceut Corp, Oncol Biol Unit, Dept Oncol, Summit, NJ 07901 USA; Novartis Pharmaceut Corp, Funct Genom, Summit, NJ 07901 USA	Novartis; Novartis	Atadja, P (corresponding author), Novartis Pharmaceut Corp, Oncol Biol Unit, Dept Oncol, Summit, NJ 07901 USA.							Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Buggy JJ, 2000, BIOCHEM J, V350, P199, DOI 10.1042/0264-6021:3500199; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Furukawa Y, 1996, CYTOGENET CELL GENET, V73, P130, DOI 10.1159/000134323; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guenther MG, 2000, GENE DEV, V14, P1048; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Van den Wyngaert I, 2000, FEBS LETT, V478, P77, DOI 10.1016/S0014-5793(00)01813-5; VanLint C, 1996, GENE EXPRESSION, V5, P245; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	43	525	568	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25748	25755		10.1074/jbc.M111871200	http://dx.doi.org/10.1074/jbc.M111871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11948178	hybrid			2022-12-25	WOS:000176747000118
J	Simon, MF; Rey, A; Castan-Laurel, I; Gres, S; Sibrac, D; Valet, P; Saulnier-Blache, JS				Simon, MF; Rey, A; Castan-Laurel, I; Gres, S; Sibrac, D; Valet, P; Saulnier-Blache, JS			Expression of ectolipid phosphate phosphohydrolases in 3T3F442A preadipocytes and adipocytes - Involvement in the control of lysophosphatidic acid production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; SIGNAL-TRANSDUCTION; LYSOPHOSPHOLIPASE-D; ADIPOSE-TISSUE; RAT PLASMA; RECEPTOR; IDENTIFICATION; CLONING; CELLS; GROWTH	Because of its production by adipocytes and its ability to increase preadipocyte proliferation, lysophosphatidic acid (LPA) could participate in the paracrine control of adipose tissue development. The aim of the present study was to determine which enzyme activities are involved in exogenous LPA hydrolysis by preadipocytes and adipocytes. Using a quantitative method, we observed that extracellular LPA rapidly disappeared from the culture medium of 3T3F442A preadipocytes. This disappearance was strongly slowed down in the presence of the phosphatase inhibitors, sodium vanadate and sodium pervanadate. By using [P-33]LPA on intact 3T3F442A preadipocytes, we found that 90% of LPA hydrolysis resulted from LPA phosphatase activity biochemically related to previously described ectolipid phosphate phosphohydrolases (LPPs). Quantitative real time reverse transcriptase-PCR revealed that 3T3F442A preadipocytes expressed mRNAs of three known Lpp gene subtypes (1, 2, and 3), with a predominant expression of Lpp1 and Lpp3. Differentiation of 3T3F442A preadipocytes into adipocytes led to an 80% reduction in ecto-LPA phosphatase activity, with a concomitant down-regulation in Lpp1, Lpp2, and Lpp3 mRNA expression. Despite this regulation, treatment of 3T3F442A adipocytes with sodium vanadate increased LPA production in the culture medium, suggesting the involvement of ecto-LPA phosphatase activity in the control of extracellular production of LPA by adipocytes. In conclusion, these data demonstrate that hydrolysis of extracellular LPA by preadipocytes and adipocytes mainly results from a dephosphorylation activity. This activity M occurs at the extracellular face of cell membrane, (ii) exhibits biochemical characteristics similar to those of the LPP, (iii) is negatively regulated during adipocyte differentiation, and (iv) plays an important role in the control of extracellular LPA production by adipocytes. Ecto-LPA phosphatase activity represents a potential target to control adipose tissue development.	Univ Toulouse 3, CHU Rangueil, INSERM U317, Inst Louis Bugnard, F-31403 Toulouse 04, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Saulnier-Blache, JS (corresponding author), Univ Toulouse 3, CHU Rangueil, INSERM U317, Inst Louis Bugnard, Batiment L3, F-31403 Toulouse 04, France.		Saulnier-Blache, Jean Sebastien/X-7729-2018; Valet, Philippe/N-7472-2017	Valet, Philippe/0000-0001-6520-7393; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				AILHAUD G, 2000, INT J OBES RELAT  S2, V24, P1; Alderton F, 2001, J BIOL CHEM, V276, P13452, DOI 10.1074/jbc.M006582200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GESTA S, 2002, IN PRESS J LIPID RES; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HALDAR D, 1992, METHOD ENZYMOL, V209, P64; Hooks SB, 1998, FEBS LETT, V427, P188, DOI 10.1016/S0014-5793(98)00421-9; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Ishikawa T, 2000, J BIOCHEM-TOKYO, V127, P645, DOI 10.1093/oxfordjournals.jbchem.a022652; JAMAL Z, 1992, INT J OBESITY, V16, P789; JAMDAR SC, 1994, BIOCHEM J, V301, P793, DOI 10.1042/bj3010793; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kai M, 1997, J BIOL CHEM, V272, P24572, DOI 10.1074/jbc.272.39.24572; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; Kanoh H, 1999, CHEM PHYS LIPIDS, V98, P119, DOI 10.1016/S0009-3084(99)00024-9; Liliom K, 1998, J BIOL CHEM, V273, P13461, DOI 10.1074/jbc.273.22.13461; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; MAURIEGE P, 1987, EUR J CLIN INVEST, V17, P156, DOI 10.1111/j.1365-2362.1987.tb02395.x; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; PAGES C, 2001, PROSTAG OTH LIPID M, V1, P1; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tokumura A, 1999, BBA-MOL CELL BIOL L, V1437, P235, DOI 10.1016/S1388-1981(99)00011-6; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; Xu J, 2000, ANN NY ACAD SCI, V905, P81; Xu J, 2000, J BIOL CHEM, V275, P27520; Zhang NA, 2000, GENOMICS, V63, P142, DOI 10.1006/geno.1999.6055	33	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23131	23136		10.1074/jbc.M201530200	http://dx.doi.org/10.1074/jbc.M201530200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956205	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000176475700006
J	Chi, YI; Sadler, I; Jablonski, LM; Callantine, SD; Deobald, CF; Stauffacher, CV; Bohach, GA				Chi, YI; Sadler, I; Jablonski, LM; Callantine, SD; Deobald, CF; Stauffacher, CV; Bohach, GA			Zinc-mediated dimerization and its effect on activity and conformation of staphylococcal enterotoxin type C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC-SHOCK SYNDROME; MHC CLASS-II; CRYSTAL-STRUCTURE; CYSTEINYL LEUKOTRIENES; NUCLEOTIDE-SEQUENCE; SUPERANTIGEN; PROTEINS; BINDING; RESOLUTION; MOLECULES	Staphylococcal enterotoxins are superantigen exotoxins that mediate food poisoning and toxic shock syndrome in humans. Despite their structural and functional similarities, superantigens display subtle differences in biological properties and modes of receptor binding as a result of zinc atoms bound differently in their crystal structures. For example, the crystal structures of the staphylococcal enterotoxins in the type C serogroup (SECs) contain a zinc atom coordinated by one aspartate and two histidine residues from one molecule and another aspartate residue from the next molecule, thus forming a dimer. This type of zinc ligation and zinc-mediated dimerization occurs in several SECs, but not in most other staphylococcal enterotoxin serogroups. This prompted us to investigate the potential importance of zinc in SEC-mediated pathogenesis. Site-directed mutagenesis was used to replace SEC zinc binding ligands with alanine. SEC mutants unable to bind zinc did not have major conformational alterations although they failed to form dimers. Zinc binding was not essential for T cell stimulation, emesis, or lethality although in general the mutants were less pyrogenic. Thus the zinc atom in SECs might represent a non-functional heavy atom in an exotoxin group that has diverged from related bacterial toxins containing crucial zinc atoms.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Idaho, Dept Microbiol Mol Biol & Biochem, Moscow, ID 83843 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Idaho; University of Idaho	Chi, YI (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.	young-in.chi@joslin.harvard.edu						ALBER G, 1990, J IMMUNOL, V144, P4501; BERGDOLL MS, 1988, METHOD ENZYMOL, V165, P324; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BOHACH GA, 1989, INFECT IMMUN, V57, P23, DOI 10.1128/IAI.57.1.23-28.1989; BOHACH GA, 1992, PROTEINS, V13, P152, DOI 10.1002/prot.340130208; BOHACH GA, 1987, INFECT IMMUN, V55, P428, DOI 10.1128/IAI.55.2.428-432.1987; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; Bohach GA, 1995, MOL APPROACHES FOOD, P339; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CUNNINGHAM BC, 1991, SCIENCE, V253, P545, DOI 10.1126/science.1907025; Edwards VM, 1997, INFECT IMMUN, V65, P2346, DOI 10.1128/IAI.65.6.2346-2352.1997; FRASER JD, 1992, P NATL ACAD SCI USA, V89, P5507, DOI 10.1073/pnas.89.12.5507; Hakansson M, 2000, J MOL BIOL, V302, P527, DOI 10.1006/jmbi.2000.4093; HARRIS TO, 1993, INFECT IMMUN, V61, P3175, DOI 10.1128/IAI.61.8.3175-3183.1993; HOVDE CJ, 1990, MOL GEN GENET, V220, P329; HOVDE CJ, 1994, MOL MICROBIOL, V13, P897, DOI 10.1111/j.1365-2958.1994.tb00481.x; Jablonski L. M., 1997, FOOD MICROBIOLOGY FU, P353; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Jarvis K.E., 1991, HDB INDUCTIVELY COUP; JETT M, 1990, INFECT IMMUN, V58, P3494, DOI 10.1128/IAI.58.11.3494-3499.1990; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM Y B, 1970, Journal of Experimental Medicine, V131, P611, DOI 10.1084/jem.131.3.611; KUSHNARYOV VM, 1989, REV INFECT DIS, V11, pS282; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE PK, 1991, J INFECT DIS, V164, P711, DOI 10.1093/infdis/164.4.711; Li YL, 2001, IMMUNITY, V14, P93, DOI 10.1016/S1074-7613(01)00092-9; MARR JC, 1993, INFECT IMMUN, V61, P4254, DOI 10.1128/IAI.61.10.4254-4262.1993; Monday S. R., 1999, COMPREHENSIVE SOURCE, P589; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; Papageorgiou AC, 2000, TRENDS MICROBIOL, V8, P369, DOI 10.1016/S0966-842X(00)01793-5; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; Petersson K, 2001, EMBO J, V20, P3306, DOI 10.1093/emboj/20.13.3306; POINDEXTER NJ, 1985, J INFECT DIS, V151, P65, DOI 10.1093/infdis/151.1.65; SCHAD EM, 1995, EMBO J, V14, P3292, DOI 10.1002/j.1460-2075.1995.tb07336.x; SCHEUBER PH, 1987, INT ARCH ALLER A IMM, V82, P289, DOI 10.1159/000234209; SCHEUBER PH, 1987, EUR J CLIN INVEST, V17, P455, DOI 10.1111/j.1365-2362.1987.tb01142.x; SCHLIEVERT PM, 1982, INFECT IMMUN, V36, P123, DOI 10.1128/IAI.36.1.123-128.1982; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Sundstrom M, 1996, EMBO J, V15, P6832, DOI 10.1002/j.1460-2075.1996.tb01074.x; Sundstrom M, 1996, J BIOL CHEM, V271, P32212, DOI 10.1074/jbc.271.50.32212; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; SWAMINATHAN S, 1995, NAT STRUCT BIOL, V2, P680, DOI 10.1038/nsb0895-680; TONELLO F, 1996, ADV EXP MED BIOL, V89, P251; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	51	28	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22839	22846		10.1074/jbc.M201932200	http://dx.doi.org/10.1074/jbc.M201932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934896	hybrid			2022-12-25	WOS:000176313600094
J	Hsu, HY; Wen, MH				Hsu, HY; Wen, MH			Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NEUTROPHIL NADPH-OXIDASE; GTP-BINDING PROTEINS; SCAVENGER RECEPTOR; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; TNF-ALPHA; CONVERTING-ENZYME	Lipopolysaccharide (LPS) stimulates macrophages to release inflammatory cytokines, interleukin-1beta (IL-1), and tumor necrosis factor (TNF). LPS-induced TNF suppresses scavenger receptor functions in macrophages (van Lenten, B. J., and Fogelman, A. M. (1992) J. Immunol. 148, 112-116), which is regulated by TNF-mediated protein kinases (Hsu, H. Y., and Twu, Y. C. (2000) J. Biol. Chem. 275, 41035-41048). To examine the molecular mechanism for LPS induction of IL-1 in macrophages, we demonstrated that LPS quickly stimulated reactive oxygen species (ROS), and 3 h later induced prointerleukin-1beta (pro-IL-1, precursor of IL-1) production and IL-1 secretion. LPS stimulated pro-IL-1 message/protein between 3 and 10 h; however, there was a 40% reduction of pro-IL-1 in preincubation of the antioxidant, N-acetyl-cysteine (NAC). Moreover, NAC moderated LPS-induced IL-1 secretion partially via interleukin 1-converting enzyme. The maximal activity of LPS-induced ERK, JNK, and p38 was 12- (30 min), 5- (30 min), and 16-fold (15 min), respectively. In contrast, NAC reduced ERK activity to 60% and decreased p38 activity to the basal level, but JNK activity was induced 2-fold. Furthermore, the pharmacological antagonists LY294002, S13203580, curcumin, calphostin C, and PD98059 revealed the diverse roles of LPS-mediated protein kinases in pro-IL-1. On the other hand, NAC and diphenyleneiodonium chloride partially inhibited LPS-induced Rac activity and protein-tyrosine kinase (PTK), indicating that LPS-mediated ROS and NADPH oxidase correspond to Rac activation and IL-1 expression. Our findings establish for the first time that LPS-mediated PTK/phosphatidylinositol 3-kinase/ Rac/p38 pathways play a more important role than pathways of PTK/PKC/MEK/ERK and of PTK/phosphatidylinositol 3-kinase/Rac/JNK in the regulation of pro-IL-1/ IL-1. The findings also further elucidate the critical role of LPS-mediated ROS in signal transduction pathways. Our results suggest that understanding LPS-transduced signals in IL-1 induction upon the antibacterial action of macrophages should provide a therapeutic strategy for aberrant inflammatory responses leading to severe cellular injury or concurrent multiorgan septic damage.	Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Hsu, HY (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, 155 Li Nong St, Taipei 112, Taiwan.	hyhsu@ym.edu.tw						BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Beutler B, 2002, CURR OPIN HEMATOL, V9, P2, DOI 10.1097/00062752-200201000-00002; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Boggs SE, 1998, BIOCHEM BIOPH RES CO, V247, P229, DOI 10.1006/bbrc.1998.8765; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chan ED, 1999, J IMMUNOL, V162, P415; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRAWFORD D, 1988, CANCER RES, V48, P2132; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GEPPERT TD, 1994, MOL MED, V1, P93; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GRAY JG, 1993, MOL CELL BIOL, V13, P6678, DOI 10.1128/MCB.13.11.6678; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HANUKOGLU I, 1993, ARCH BIOCHEM BIOPHYS, V305, P489, DOI 10.1006/abbi.1993.1452; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; Hong YH, 1997, J IMMUNOL, V159, P2418; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 2001, J BIOL CHEM, V276, P28719, DOI 10.1074/jbc.M011117200; Hsu HY, 2000, J BIOL CHEM, V275, P41035, DOI 10.1074/jbc.M003464200; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARLSSON A, 1995, INFECT IMMUN, V63, P4606, DOI 10.1128/IAI.63.12.4606-4612.1995; Kaul N, 1998, ARCH BIOCHEM BIOPHYS, V350, P79, DOI 10.1006/abbi.1997.0487; Koay MA, 2001, INFECT IMMUN, V69, P5991, DOI 10.1128/IAI.69.10.5991-5996.2001; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Loppnow H, 1998, EUR CYTOKINE NETW, V9, P675; LOPPNOW H, 1990, J CLIN INVEST, V85, P731, DOI 10.1172/JCI114498; Manna SK, 1999, J IMMUNOL, V162, P1510; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Matsuno R, 1997, BIOCHEM BIOPH RES CO, V237, P601, DOI 10.1006/bbrc.1997.7195; MIKUNI Y, 2000, J IMMUNOL, V165, P931; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Park LCH, 1999, J NEUROCHEM, V72, P1948, DOI 10.1046/j.1471-4159.1999.0721948.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REIMANN T, 1994, J IMMUNOL, V153, P5740; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Scherle PA, 1998, J IMMUNOL, V161, P5681; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; Wong G H, 1996, EXS, V77, P321; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Xaus J, 2000, BLOOD, V95, P3823; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349	71	409	426	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22131	22139		10.1074/jbc.M111883200	http://dx.doi.org/10.1074/jbc.M111883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940570	hybrid			2022-12-25	WOS:000176313600006
J	Qiao, YM; Prabhakar, S; Coccia, EM; Weiden, M; Canova, A; Giacomini, E; Pine, R				Qiao, YM; Prabhakar, S; Coccia, EM; Weiden, M; Canova, A; Giacomini, E; Pine, R			Host Defense responses to infection by Mycobacterium tuberculosis - Induction of IRF-1 and a serine protease inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; LEUKEMIA-CELL LINE; TRANSCRIPTION FACTOR; REGULATORY FACTOR-1; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN MACROPHAGES; INTERFERON-GAMMA; GENE-EXPRESSION; NUCLEAR FACTOR; I INTERFERON	Alveolar macrophages and newly recruited monocytes are targets of infection by Mycobacterium tuberculosis. Therefore, we examined the expression of interferon regulatory factor 1 (IRF-1), which plays an important role in host defense against M. tuberculosis, in undifferentiated and differentiated cells. Infection induced IRF-1 in both. IRF-1 from undifferentiated, uninfected monocytic cell lines was modified during extraction to produce specific species that were apparently smaller than intact IRF-1. After infection by M. tuberculosis or differentiation, intact IRF-1 was recovered. Subcellular fractions were assayed for the ability to modify IRF-1 or inhibit its modification. A serine protease on the cytoplasmic surface of an organelle or vesicle in the "lysosomal/mitochondrial" fraction from undifferentiated cells was responsible for the modification of IRF-1. Thus, the simplest explanation of the modification is cleavage of IRF-1 by the serine protease. Recovery of intact IRF-1 correlated with induction of a serine protease inhibitor that was able to significantly reduce the modification of IRF-1. The inhibitor was present in the cytoplasm of M. tuberculosis-infected or -differentiated cells. It is likely that induction of both IRF-1 and the serine protease inhibitor in response to infection by M. tuberculosis represent host defense mechanisms.	Publ Hlth Res Inst, Newark, NJ 07103 USA; Ist Super Sanita, I-00161 Rome, Italy; NYU, Sch Med, New York, NY 10016 USA; Bellevue Hosp, New York, NY 10016 USA	Istituto Superiore di Sanita (ISS); New York University; Bellevue Hospital Center	Pine, R (corresponding author), Publ Hlth Res Inst, 225 Warren St, Newark, NJ 07103 USA.		GIACOMINI, ELENA/M-4359-2015; Coccia, Eliana M/B-4752-2013	Coccia, Eliana M/0000-0002-1606-2949	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037877] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37877] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antalis TM, 1998, J EXP MED, V187, P1799, DOI 10.1084/jem.187.11.1799; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636; Bird PI, 1999, IMMUNOL CELL BIOL, V77, P47, DOI 10.1046/j.1440-1711.1999.00787.x; CHANG KJ, 1975, J BIOL CHEM, V250, P488; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Cooper AM, 2000, INFECT IMMUN, V68, P6879, DOI 10.1128/IAI.68.12.6879-6882.2000; de Duve C, 1971, J Cell Biol, V50, P20; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; GAN HX, 1995, J IMMUNOL, V155, P1304; GENTON C, 1987, J CELL BIOL, V104, P705, DOI 10.1083/jcb.104.3.705; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Jin FY, 1998, INFECT IMMUN, V66, P2447, DOI 10.1128/IAI.66.6.2447-2452.1998; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LIN RT, 1994, J BIOL CHEM, V269, P17542; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; Matikainen S, 1996, BLOOD, V88, P114; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PINE R, 1989, MOL CELL BIOL, V9, P3533, DOI 10.1128/MCB.9.8.3533; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Pine R, 2002, J INTERF CYTOK RES, V22, P15, DOI 10.1089/107999002753452629; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Rao J, 1998, J CELL PHYSIOL, V175, P121, DOI 10.1002/(SICI)1097-4652(199805)175:2<121::AID-JCP1>3.0.CO;2-Q; Raupach B, 2001, CURR OPIN IMMUNOL, V13, P417, DOI 10.1016/S0952-7915(00)00236-3; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; SCHMITT E, 1977, BRIT J HAEMATOL, V35, P11, DOI 10.1111/j.1365-2141.1977.tb00557.x; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Weiden M, 2000, J IMMUNOL, V165, P2028, DOI 10.4049/jimmunol.165.4.2028; Zhao BY, 1999, ANTIMICROB AGENTS CH, V43, P661, DOI 10.1128/AAC.43.3.661; Zhu J, 1999, BBA-MOL CELL RES, V1451, P219, DOI 10.1016/S0167-4889(99)00111-1	43	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22377	22385		10.1074/jbc.M202965200	http://dx.doi.org/10.1074/jbc.M202965200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948194	hybrid			2022-12-25	WOS:000176313600035
J	Ruvolo, PP; Clark, W; Mumby, M; Gao, FQ; May, WS				Ruvolo, PP; Clark, W; Mumby, M; Gao, FQ; May, WS			A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; MOLECULAR-CLONING; CANCER-CELLS; APOPTOSIS; KINASE; STRESS; FAMILY; INTERLEUKIN-3; BRYOSTATIN-1; SUPPRESSION	Recently it has been shown that the potent apoptotic agent ceramide activates a mitochondrial protein phosphatase 2A (PP2A) and promotes dephosphorylation of the anti-apoptotic molecule Bcl2 (Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K., and May, W. S. (1999) J. Biol. Chem. 274, 20296-20300). In cells expressing Bcl2, dephosphorylation of Bcl2 appears to be required for ceramide-induced cell death because treatment of cells with low doses of the PP2A inhibitor okadaic acid blocks Bcl2 dephosphorylation and promotes cell survival. Furthermore, the non-phosphorylatable (i.e. PP2A-resistant) gain-of-function S70E mutant Bcl2 can protect cells from ceramide-induced apoptosis. These findings support a model whereby Bcl2 function is regulated by PP2A. PP2A is a heterotrimer that contains a catalytic C-subunit, a structural A-subunit, and a regulatory B-subunit. The A- and C-subunits are fairly conserved and ubiquitously expressed, and they form the catalytic complex of the phosphatase. In contrast, there are at least three families of diverse B-subunit molecules that vary in expression temporally and by tissue type. It is hypothesized that ceramide regulates PP2A via the B-subunit. Thus, understanding the mechanism of how PP2A regulates Bcl2 phosphorylation status and how ceramide might regulate this process requires identification of the regulatory B-subunit of PP2A that comprises the Bcl2 phosphatase. Results indicate that the B56 alpha-subunit is a candidate regulatory subunit of the physiologic Bcl2 phosphatase since (a) B56 a associates with Bcl2 as evidenced by pull-down experiments, (b) B56 alpha co-localizes with Bcl2 in mitochondrial membranes, (c) ceramide promotes translocation of B56 alpha to mitochondrial membranes, and (d) overexpression of B56 a promotes mitochondrial PP2A activity and Bcl2 dephosphorylation and potentiates cell killing with ceramide. These findings suggest a role for B56 alpha in regulating the Bcl2 phosphatase.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ruvolo, PP (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med, IBT 900,2121 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2001, LEUKEMIA, V15, P1153, DOI 10.1038/sj.leu.2402197; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Smyth M J, 1997, Adv Pharmacol, V41, P133, DOI 10.1016/S1054-3589(08)61057-1; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	39	126	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22847	22852		10.1074/jbc.M201830200	http://dx.doi.org/10.1074/jbc.M201830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11929874	hybrid			2022-12-25	WOS:000176313600095
J	Schroeder, JA; Adriance, MC; McConnell, EJ; Thompson, MC; Pockaj, B; Gendler, SJ				Schroeder, JA; Adriance, MC; McConnell, EJ; Thompson, MC; Pockaj, B; Gendler, SJ			ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIN-BUNDLING PROTEIN; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; MOUSE MAMMARY; CELL MOTILITY; CYCLIN D1; PROGNOSTIC MARKER; FACTOR-ALPHA; E-CADHERIN	Simultaneous deregulation of both Wnt and ErbB growth factors has previously been shown to result in the cooperative induction of mammary gland tumors. Using the murine mammary tumor virus (MMTV)-Wnt-1 transgenic model of mammary carcinoma, we have identified an unvarying association between beta-catenin and epidermal growth factor receptor/c-Neu (ErbB1/ErbB2) heterodimers in mammary gland tumors, indicating a requirement for ErbB signaling in Wnt-mediated tumorigenesis. Expansion of these observations to a second transgenic model, MMTV-c-Neu, demonstrated similar tumor-specific interactions, including an ErbB1 ligand-inducible phosphorylation of both beta-catenin and c-Neu. Direct relevance of these findings to human breast cancer was established upon examination of a set of human infiltrating ductal breast adenocarcinoma and lymph node metastasis tissues taken at surgery. These data revealed increased levels of beta-catenin in tumors and metastases versus normal breast as well as an association between beta-catenin and c-Neu that measurably occurs only in neoplasia, most strongly in metastatic lesions. These studies have identified a seemingly indispensable interaction between beta-catenin and epidermal growth factor receptor/c-Neu heterodimers in Wnt-1-mediated breast tumorigenesis that may indicate a fundamental signaling event in human metastatic progression.	Mayo Clin Scottsdale, Mayo Med Grad Sch, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Mayo Med Grad Sch, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Mayo Med Grad Sch, Tumor Biol Program, Scottsdale, AZ 85259 USA.			schroeder, joyce/0000-0003-1277-5172	NCI NIH HHS [CA90204, CA64389, CA81703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA090204, R01CA064389, F32CA081703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Bonvini P, 2001, CANCER RES, V61, P1671; Brandt R, 2000, ONCOGENE, V19, P2129, DOI 10.1038/sj.onc.1203520; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grothey A, 2000, BRIT J CANCER, V83, P870, DOI 10.1054/bjoc.2000.1395; Grothey A, 2000, ONCOGENE, V19, P4864, DOI 10.1038/sj.onc.1203838; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Kumar R, 2000, SEMIN ONCOL, V27, P84, DOI 10.1053/sonc.2000.19893; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Piedra J, 2001, J BIOL CHEM, V276, P20436, DOI 10.1074/jbc.M100194200; Polakis P, 2000, GENE DEV, V14, P1837; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Schroeder JA, 1998, CELL GROWTH DIFFER, V9, P451; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shibata T, 1996, ONCOGENE, V13, P883; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simon R, 2001, J NATL CANCER I, V93, P1141, DOI 10.1093/jnci/93.15.1141; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tomlinson JS, 2001, CANCER RES, V61, P5231; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993	37	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22692	22698		10.1074/jbc.M201975200	http://dx.doi.org/10.1074/jbc.M201975200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950845	hybrid			2022-12-25	WOS:000176313600077
J	Bouche, N; Scharlat, A; Snedden, W; Bouchez, D; Fromm, H				Bouche, N; Scharlat, A; Snedden, W; Bouchez, D; Fromm, H			A novel family of calmodulin-binding transcription activators in multicellular organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT GLUTAMATE-DECARBOXYLASE; REGULATED GENE-EXPRESSION; ARABIDOPSIS-THALIANA; PROTEIN SEQUENCES; PLASMA-MEMBRANE; HUMAN GENOME; DOMAINS; CALCIUM; SITE; LOOP	Screening of cDNA expression libraries derived from plants exposed to stress, with (35)S-labeled recombinant calmodulin as a probe, revealed a new family of proteins containing a transcription activation domain and two types of DNA-binding domains designated the CG-1 domain and the transcription factor immunoglobulin domain, ankyrin repeats, and a varying number of IQ calmodulin-binding motifs. Based on domain organization and amino acid sequence comparisons, similar proteins, with the same domain organization, were identified in the genomes of other multicellular organisms including human, Drosophila, and Caenorhabditis, whereas none were found in the complete genomes of single cell eukaryotes and prokaryotes. This family of proteins was designated calmodulin-binding transcription activators (CAMTAs). Arabidopsis thaliana contains six CAMTA genes (AtCAMTA1-AtCAMTA6). The transcription activation domain of AtCAMTA1 was mapped by testing a series of protein fusions with the DNA-binding domain of the bacterial Lex-A transcription factor and two reporter genes fused to LexA recognition sequences in yeast cells. Two human proteins designated HsCAMTA1 and HsCAMTA2 were also shown to activate transcription in yeast using the same reporter system. Subcellular fractionation of Arabidopsis tissues revealed the presence of CAMTAs predominantly in the nucleus. Calmodulin binding assays identified a region of 25 amino acids capable of binding calmodulin with high affinity (K(d) = 1.2 nM) in the presence of calcium. We suggest that CAMTAs comprise a conserved family of transcription factors in a wide range of multicellular eukaryotes, which possibly respond to calcium signaling by direct binding of calmodulin.	Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; INRA, Stn Genet, F-78026 Versailles, France	University of Leeds; Tel Aviv University; Weizmann Institute of Science; Queens University - Canada; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Fromm, H (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	h.fromm@leeds.ac.uk	FROMM, HILLEL/AAF-6783-2019; Bouchez, David/B-7463-2019	FROMM, HILLEL/0000-0003-1977-1211; Bouchez, David/0000-0003-3545-4339; Bouche, Nicolas/0000-0002-3800-2613				Ach RA, 1997, PLANT CELL, V9, P1595, DOI 10.1105/tpc.9.9.1595; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; Arazi T, 2000, PLANT MOL BIOL, V42, P591, DOI 10.1023/A:1006345302589; Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; BAUM G, 1993, J BIOL CHEM, V268, P19610; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOWNING WL, 1992, PLANT J, V2, P685, DOI 10.1046/j.1365-313X.1992.t01-11-00999.x; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Faiman GA, 1996, J BIOL CHEM, V271, P13829, DOI 10.1074/jbc.271.23.13829; Foster R., 1992, Methods in Arabidopsis research., P378; Gadgil H, 1999, J CHROMATOGR A, V848, P131, DOI 10.1016/S0021-9673(99)00338-6; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HAGMAN J, 1995, EMBO J, V14, P2907, DOI 10.1002/j.1460-2075.1995.tb07290.x; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Heist EK, 1998, CELL CALCIUM, V23, P103; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KINCAID RL, 1982, J BIOL CHEM, V257, P638; Knight H, 2001, TRENDS PLANT SCI, V6, P262, DOI 10.1016/S1360-1385(01)01946-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liu LS, 1999, EUR J BIOCHEM, V262, P247, DOI 10.1046/j.1432-1327.1999.00349.x; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LUTHE DS, 1980, PLANT PHYSIOL, V65, P305, DOI 10.1104/pp.65.2.305; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Reddy ASN, 2000, BIOCHEM BIOPH RES CO, V279, P762, DOI 10.1006/bbrc.2000.4032; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rodriguez-Concepcion M, 1999, EMBO J, V18, P1996, DOI 10.1093/emboj/18.7.1996; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Shannon KB, 2000, CURR BIOL, V10, P727, DOI 10.1016/S0960-9822(00)00539-X; SILVA ODE, 1994, PLANT MOL BIOL, V25, P921, DOI 10.1007/BF00028887; Snedden WA, 1997, PLANT MOL BIOL, V33, P753, DOI 10.1023/A:1005737026289; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; Yanagisawa S, 1998, PLANT CELL, V10, P75, DOI 10.1105/tpc.10.1.75; Yanagisawa S, 2000, PLANT J, V21, P281, DOI 10.1046/j.1365-313x.2000.00685.x; Yang TB, 2000, J BIOL CHEM, V275, P38467, DOI 10.1074/jbc.M003566200; Zegzouti H, 1999, PLANT J, V18, P589, DOI 10.1046/j.1365-313x.1999.00483.x; ZHUANG SB, 1995, BIOCHEM BIOPH RES CO, V209, P12, DOI 10.1006/bbrc.1995.1463; Zik M, 1998, PLANT MOL BIOL, V37, P967, DOI 10.1023/A:1006047623263	60	202	235	4	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21851	21861		10.1074/jbc.M200268200	http://dx.doi.org/10.1074/jbc.M200268200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925432	Green Published, hybrid			2022-12-25	WOS:000176286000095
J	Funahashi, J; Takano, K; Yamagata, Y; Yutani, K				Funahashi, J; Takano, K; Yamagata, Y; Yutani, K			Positive contribution of hydration structure on the surface of human lysozyme to the conformational stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVITY-CREATING MUTATIONS; LOW-HUMIDITY VARIANT; X-RAY-ANALYSIS; STAPHYLOCOCCAL NUCLEASE; WATER-MOLECULES; LOW-TEMPERATURE; HYDROGEN-BONDS; AMINO-ACIDS; BIOLOGICAL MACROMOLECULES; HYDROPHOBIC RESIDUES	Water molecules make a hydration structure with the network of hydrogen bonds, covering on the surface of proteins. To quantitatively estimate the contribution of the hydration structure to protein stability, a series of hydrophilic mutant human lysozymes (Val to Ser, Tyr, Asp, Asn, and Arg) modified at three different positions on the surface, which are located in the a-helix (VaI-110), the beta-sheet (Val-2), and the loop (Val-74), were constructed. Their thermodynamic parameters of denaturation and crystal structures were examined by calorimetry and by x-ray crystallography at 100 K, respectively. The introduced polar residues made hydrogen bonds with protein atoms and/or water molecules, sometimes changing the hydration structure around the mutation site. Changes in the stability of the mutant proteins can be evaluated by a unique equation that considers the conformational changes resulting from the substitutions. Using this analysis, the relationship between the changes in the stabilities and the hydration structures for mutant human lysozymes substituted on the surface could be quantitatively estimated. The analysis indicated that the hydration structure on protein surface plays an important role in determining the conformational stability of the protein.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan	Osaka University; Kumamoto University	Yutani, K (corresponding author), Osaka Univ, Inst Prot Res, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yutani@protein.osaka-u.ac.jp	Yamagata, Yoshiki/T-6489-2019					Biswal BK, 2000, ACTA CRYSTALLOGR D, V56, P1110, DOI 10.1107/S0907444900008866; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; BYRNE MP, 1995, BIOCHEMISTRY-US, V34, P13949, DOI 10.1021/bi00042a029; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Cordes MHJ, 1999, PROTEIN SCI, V8, P318; DOIG AJ, 1995, PROTEIN SCI, V4, P2247, DOI 10.1002/pro.5560041101; DOSTER W, 1986, BIOPHYS J, V50, P213, DOI 10.1016/S0006-3495(86)83455-5; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; EARNEST T, 1991, PROTEINS, V10, P171, DOI 10.1002/prot.340100303; EISENSTEIN M, 1988, ACTA CRYSTALLOGR B, V44, P625, DOI 10.1107/S0108768188004732; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERRAND M, 1993, P NATL ACAD SCI USA, V90, P9668, DOI 10.1073/pnas.90.20.9668; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; Funahashi J, 1996, J BIOCHEM, V120, P1216; Funahashi J, 1999, PROTEIN ENG, V12, P841, DOI 10.1093/protein/12.10.841; Funahashi J, 2000, BIOCHEMISTRY-US, V39, P14448, DOI 10.1021/bi0015717; Garman EF, 1997, J APPL CRYSTALLOGR, V30, P211, DOI 10.1107/S0021889897002677; HAYWARD S, 1993, J MOL BIOL, V234, P100; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; HOPE H, 1988, ACTA CRYSTALLOGR B, V44, P22, DOI 10.1107/S0108768187008632; HOPE H, 1990, ANNU REV BIOPHYS BIO, V19, P107; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JOHNSON CK, 1976, ORTEP2; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; Koehl P, 1999, P NATL ACAD SCI USA, V96, P12524, DOI 10.1073/pnas.96.22.12524; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; Myers JK, 1996, BIOPHYS J, V71, P2033, DOI 10.1016/S0006-3495(96)79401-8; Nagata C, 1996, ACTA CRYSTALLOGR D, V52, P623, DOI 10.1107/S0907444995016623; Nakasako M, 1999, J MOL BIOL, V289, P547, DOI 10.1006/jmbi.1999.2795; Otwinowski Z., 1990, DENZO DATA PROCESSIN; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; PARRY RM, 1969, ARCH BIOCHEM BIOPHYS, V130, P59, DOI 10.1016/0003-9861(69)90009-5; Perl D, 2000, NAT STRUCT BIOL, V7, P380; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; RUPLEY JA, 1991, ADV PROTEIN CHEM, V41, P37; SAENGER W, 1987, ANNU REV BIOPHYS BIO, V16, P93; Schwehm JM, 1998, BIOCHEMISTRY-US, V37, P6939, DOI 10.1021/bi9725069; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; Sukumar N, 1999, ACTA CRYSTALLOGR D, V55, P934, DOI 10.1107/S0907444998015522; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; Takano K, 1997, J MOL BIOL, V274, P132, DOI 10.1006/jmbi.1997.1365; Takano K, 1998, J MOL BIOL, V280, P749, DOI 10.1006/jmbi.1998.1906; Takano K, 1999, BIOCHEMISTRY-US, V38, P12698, DOI 10.1021/bi9910169; Takano K, 1997, BIOCHEMISTRY-US, V36, P688, DOI 10.1021/bi9621829; Takano K, 1999, BIOCHEMISTRY-US, V38, P6623, DOI 10.1021/bi9901228; Takano K, 1999, PROTEIN ENG, V12, P663, DOI 10.1093/protein/12.8.663; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.bb.20.060191.003045; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; Xu JA, 1998, PROTEIN SCI, V7, P158, DOI 10.1002/pro.5560070117; Yamagata Y, 1998, BIOCHEMISTRY-US, V37, P9355, DOI 10.1021/bi980431i; YU MH, 1995, J MOL BIOL, V249, P388, DOI 10.1006/jmbi.1995.0304; Yutani K, 1999, INT CONGR SER, V1194, P175	58	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21792	21800		10.1074/jbc.M110728200	http://dx.doi.org/10.1074/jbc.M110728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927576	hybrid			2022-12-25	WOS:000176286000088
J	Ghosh, SK; Gadiparthi, L; Zeng, ZZ; Bhanoori, M; Tellez, C; Bar-Eli, M; Rao, GN				Ghosh, SK; Gadiparthi, L; Zeng, ZZ; Bhanoori, M; Tellez, C; Bar-Eli, M; Rao, GN			ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; GENE-EXPRESSION; GROWTH-FACTOR; MAP KINASE; C-JUN; HUMAN KERATINOCYTES; RESPONSE ELEMENT; HUMAN-MELANOMA; MITOGEN; PROLIFERATION	Previously we have demonstrated that activation of p38 mitogen-activated protein kinase (MAPK) and induction of DNA synthesis in response to receptor tyrosine kinase (RTK) and G protein-coupled receptor (GPCR) agonists require NADH/NADPH-like oxidase activity in vascular smooth muscle cells (VSMC). Here we tested the role of p38 MAPK in RTK and GPCR agonist-induced DNA synthesis in VSMC. Platelet-derived growth factor (PDGF)-BB and thrombin (RTK and GPCR agonists, respectively) activated p38 MAPK in a time-dependent manner in VSMC. Inhibition of p38 MAPK led to a 50% decrease in the DNA synthesis induced by thrombin but not PDGF-BB. ATF-1 was found to be the predominant member of the cyclic AMP response element (CRE)-DNA complex formed in VSMC in response to PDGF-BB and thrombin, and both agonists induced its phosphorylation. Regardless of this, inhibition of p38 MAPK reduced only thrombin- but not PDGF-BB-induced ATF-1 phosphorylation. Similarly, inhibition of p38 MAPK caused a 50% decrease in thrombin-but not PDGF-BB-induced CRE promoter-dependent transcription. Ectopic expression of an inhibitory anti-ATF-1 single-chain antibody fragment, ScFv, significantly interfered with DNA synthesis induced by thrombin but not PDGF-BB. Together, these results suggest the following conclusions. 1) Both RTK and GPCR agonists activate p38 MAPK and induce CRE promoter-dependent transcription; 2) both RTK and GPCR agonists induce ATF-1 phosphorylation, and ATF-1 is a predominant member in the CRE-DNA complexes formed in response to these agents; and 3) p38 MAPK-dependent ATF-1 phosphorylation and CRE promoter-mediated transcription are associated with GPCR agonist-induced VSMC growth.	Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Rao, GN (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.		Bhanoori, Manjula/ACH-9333-2022					Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; Burns CJ, 2000, BIOCHEM BIOPH RES CO, V268, P541, DOI 10.1006/bbrc.2000.2179; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; De Graeve F, 1999, ONCOGENE, V18, P3491, DOI 10.1038/sj.onc.1202723; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EDELMAN ER, 1995, CIRC RES, V76, P176, DOI 10.1161/01.RES.76.2.176; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Klemm DJ, 2001, J BIOL CHEM, V276, P46132, DOI 10.1074/jbc.M104769200; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; Miao RQ, 2000, CIRC RES, V86, P418, DOI 10.1161/01.RES.86.4.418; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	47	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21325	21331		10.1074/jbc.M201608200	http://dx.doi.org/10.1074/jbc.M201608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925444	hybrid			2022-12-25	WOS:000176286000028
J	Hall, DR; Bond, CS; Leonard, GA; Watt, I; Berry, A; Hunter, WN				Hall, DR; Bond, CS; Leonard, GA; Watt, I; Berry, A; Hunter, WN			Structure of tagatose-1,6-bisphosphate aldolase - Insight into chiral discrimination, mechanism, and specificity of class II aldolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; BINDING; PROGRAM; PHOSPHOGLYCOLOHYDROXAMATE; DIHYDROXYACETONE; COMPLEX	Tagatose-1,6-bisphosphate aldolase (TBPA) is a tetrameric class II aldolase that catalyzes the reversible condensation of dihydroxyacetone phosphate with glyceraldehyde 3-phosphate to produce tagatose 1,6-bisphosphate. The high resolution (1.45 Angstrom) crystal structure of the Escherichia coli enzyme, encoded by the agaY gene, complexed with phosphoglycolohydroxamate (PGH) has been determined. Two subunits comprise the asymmetric unit, and a crystallographic 2-fold axis generates the functional tetramer. A complex network of hydrogen bonds position side chains in the active site that is occupied by two cations. An unusual Na+ binding site is created using a pi interaction with Tyr(183) in addition to five oxygen ligands. The catalytic Zn2+ is five-coordinate using three histidine nitrogens and two PGH oxygens. Comparisons of TBPA with the related fructose-1,6-bisphosphate aldolase (FBPA) identifies common features with implications for the mechanism. Because the major product of the condensation catalyzed by the enzymes differs in the chirality at a single position, models of FBPA and TBPA with their cognate bisphosphate products provide insight into chiral discrimination by these aldolases. The TBPA active site is more open on one side than FBPA, and this contributes to a less specific enzyme. The availability of more space and a wider range of aldehyde partners used by TBPA together with the highly specific nature of FBPA suggest that TBPA might be a preferred enzyme to modify for use in biotransformation chemistry.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; European Synchrotron Radiat Facil, Joint Struct Biol Grp, F-38043 Grenoble, France; Univ Manchester, Dept Chem, Manchester M13 9PL, Lancs, England; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Dundee; European Synchrotron Radiation Facility (ESRF); University of Manchester; University of Leeds	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Bond, Charles S/B-4094-2011; Bond, Charles/AAF-9608-2020; Leonard, Gordon/D-2160-2019; Hunter, William/AAE-3947-2019	Bond, Charles S/0000-0002-9584-6783; Bond, Charles/0000-0002-9584-6783; Leonard, Gordon/0000-0001-5030-0122; Berry, Alan/0000-0003-3502-0426; Hall, David/0000-0002-5333-6136				ANASTASSIS P, 1999, NAT STRUCT BIOL, V7, P458; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; COLLINS KD, 1974, J BIOL CHEM, V249, P136; Cooper SJ, 1996, STRUCTURE, V4, P1303, DOI 10.1016/S0969-2126(96)00138-4; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Erion MD, 1998, J AM CHEM SOC, V120, P3295, DOI 10.1021/ja972906j; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hall DR, 1999, J MOL BIOL, V287, P383, DOI 10.1006/jmbi.1999.2609; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Marrs B, 1999, CURR OPIN MICROBIOL, V2, P241, DOI 10.1016/S1369-5274(99)80042-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Plater AR, 1999, J MOL BIOL, V285, P843, DOI 10.1006/jmbi.1998.2376; Qamar S, 1996, PROTEIN SCI, V5, P154; Reizer J, 1996, MICROBIOL-SGM, V142, P231, DOI 10.1099/13500872-142-2-231; Schoevaart R, 2001, J ORG CHEM, V66, P4559, DOI 10.1021/jo001766k; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Takayama S, 1997, ANNU REV MICROBIOL, V51, P285, DOI 10.1146/annurev.micro.51.1.285; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VONDEROSTEN CH, 1989, J AM CHEM SOC, V111, P3924, DOI 10.1021/ja00193a025; WONG CH, 1995, TETRAHEDRON ORGANIC, V12; Wouters J, 1998, PROTEIN SCI, V7, P2472, DOI 10.1002/pro.5560071127; Zgiby S, 2002, J MOL BIOL, V315, P131, DOI 10.1006/jmbi.2001.5237; Zgiby SM, 2000, EUR J BIOCHEM, V267, P1858, DOI 10.1046/j.1432-1327.2000.01191.x	35	50	52	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22018	22024		10.1074/jbc.M202464200	http://dx.doi.org/10.1074/jbc.M202464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940603	hybrid, Green Published			2022-12-25	WOS:000176286000114
J	Saez-Cirion, A; Nir, S; Lorizate, M; Agirre, A; Cruz, A; Perez-Gil, J; Nieva, JL				Saez-Cirion, A; Nir, S; Lorizate, M; Agirre, A; Cruz, A; Perez-Gil, J; Nieva, JL			Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 ENVELOPE GLYCOPROTEIN; SPIN-LABEL ESR; MEDIATED FUSION; PORE FORMATION; INFLUENZA HEMAGGLUTININ; LIPID-COMPOSITION; MIXED MEMBRANES; PEPTIDE; VESICLES	The interfacial sequence DKWASLWNWFNITNWLWYIK, preceding the transmembrane anchor of gp41 glycoprotein subunit, has been shown to be essential for fusion activity and incorporation into virions. HIVc, a peptide representing this region, formed lytic pores in liposomes composed of the main lipids occurring in the human immunodeficiency virus, type 1 (HIV-1), envelope, i.e. 1-palmitoyl-2-oleoylphosphatidylcholine (POPC):sphingomyelin (SPM):cholesterol (Chol) (1:1:1 mole ratio), at low (>1:10,000) peptide-to-lipid mole ratio, and promoted the mixing of vesicular lipids at >1: 1000 peptide-to-lipid mole ratios. Inclusion of SPM or Chol in POPC membranes had different effects. Whereas SPM sustained pore formation, Chol promoted fusion activity. Even if partitioning into membranes was not affected in the absence of both SPM and Chol, HIVc had virtually no effect on POPC vesicles. Condition; described to disturb occurrence of lateral separation of phases in these systems reproduced the high peptide-dose requirements for leakage as found in pure POPC vesicles and inhibited fusion. Surface aggregation assays using rhodamine-labeled peptides demonstrated that SPM and Chol promoted HIVc self-aggregation in membranes. Employing head-group fluorescent phospholipid analogs in planar supported lipid layers, we were able to discern HIVc clusters associated to ordered domains. Our results support the notion that the pre-transmembrane sequence may participate in the clustering of gp41 monomers within the HIV-1 envelope, and in bilayer architecture destabilization at the loci of fusion.	Univ Basque Country, CSIC, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Seagram Ctr Soil & Water Sci, IL-76100 Rehovot, Israel; Univ Complutense Madrid, Fac Biol, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Hebrew University of Jerusalem; Complutense University of Madrid	Nieva, JL (corresponding author), Univ Basque Country, CSIC, Unidad Biofis, Apartado 644, E-48080 Bilbao, Spain.	gbpniesj@lg.ehu.es	Saez-Cirion, Asier/A-8640-2008; Perez-Gil, Jesus/H-3102-2019; Cruz, Antonio/H-2881-2015; Nieva, Jose L/Q-2063-2019; Lorizate, Maier/S-1151-2018	Saez-Cirion, Asier/0000-0003-2406-7536; Perez-Gil, Jesus/0000-0003-3587-7147; Cruz, Antonio/0000-0002-0465-4111; Nieva, Jose L/0000-0001-6446-5649; Lorizate, Maier/0000-0001-8173-2788				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; ARRONDO JLR, 1989, FEBS LETT, V252, P118, DOI 10.1016/0014-5793(89)80901-9; Ben-Efraim I, 1999, J MOL BIOL, V285, P609, DOI 10.1006/jmbi.1998.2370; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; Cruz A, 2000, EUR BIOPHYS J BIOPHY, V29, P204, DOI 10.1007/PL00006647; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Dimitrov AS, 2001, J BIOL CHEM, V276, P30335, DOI 10.1074/jbc.M103788200; Doms RW, 2000, J CELL BIOL, V151, pF9, DOI 10.1083/jcb.151.2.F9; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; Milhiet PE, 2001, BIOPHYS J, V81, P547, DOI 10.1016/S0006-3495(01)75721-9; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nicol F, 1996, BIOPHYS J, V71, P3288, DOI 10.1016/S0006-3495(96)79521-8; Nicol F, 1999, BIOPHYS J, V76, P2121, DOI 10.1016/S0006-3495(99)77368-6; Nicol F, 2000, BIOPHYS J, V78, P818, DOI 10.1016/S0006-3495(00)76639-2; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; RAPAPORT D, 1991, J BIOL CHEM, V266, P23769; Rapaport D, 1996, BIOPHYS J, V70, P2502, DOI 10.1016/S0006-3495(96)79822-3; Raulin J, 2002, PROG LIPID RES, V41, P27, DOI 10.1016/S0163-7827(01)00019-4; Razinkov VI, 1998, J GEN PHYSIOL, V112, P409, DOI 10.1085/jgp.112.4.409; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Ruano MLF, 1998, BIOPHYS J, V74, P1101, DOI 10.1016/S0006-3495(98)77828-2; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SARIN PS, 1985, NEW ENGL J MED, V313, P1289, DOI 10.1056/NEJM198511143132011; SCHAFFNER CP, 1986, BIOCHEM PHARMACOL, V35, P4110, DOI 10.1016/0006-2952(86)90037-7; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Siegel DP, 1997, BIOPHYS J, V73, P3089, DOI 10.1016/S0006-3495(97)78336-X; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; Suarez T, 2000, FEBS LETT, V477, P145, DOI 10.1016/S0014-5793(00)01785-3; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; TILCOCK CPS, 1982, BIOCHEMISTRY-US, V21, P4596, DOI 10.1021/bi00262a013; Veiga MP, 2000, BIOCHEMISTRY-US, V39, P9876, DOI 10.1021/bi000678r; Veiga MP, 2001, BIOCHEMISTRY-US, V40, P2614, DOI 10.1021/bi0019803; White SH, 1998, METHOD ENZYMOL, V295, P62; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wimley WC, 2000, BIOCHEMISTRY-US, V39, P4432, DOI 10.1021/bi992746j; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	67	106	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21776	21785		10.1074/jbc.M202255200	http://dx.doi.org/10.1074/jbc.M202255200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929877	hybrid			2022-12-25	WOS:000176286000086
J	Das Sarma, J; Wang, FS; Koval, M				Das Sarma, J; Wang, FS; Koval, M			Targeted gap junction protein constructs reveal connexin-specific differences in oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYNTHESIS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; KIN RECOGNITION; PLASMA-MEMBRANE; QUALITY-CONTROL; INTERCELLULAR COMMUNICATION; SECRETORY PATHWAY; GOLGI-APPARATUS; BREFELDIN-A	To define further the mechanisms of gap junction protein (connexin (Cx)) oligomerization without pharmacologic disruption, we have examined the transport and assembly of connexin constructs containing C-terminal di-lysine-based endoplasmic reticulum (ER) (HKKSL) or ER-Golgi intermediate compartment (AKKFF) targeting sequences. By immunofluorescence microscopy, Cx43-HKKSL transiently transfected into HeLa cells showed a predominantly ER localization, although Cx43-AKYFF was localized to the perinuclear region of the cell. Sucrose gradient analysis of Triton X-100-solubilized connexins showed that either Cx43-HKKSL or Cx43-AKKFF expressed alone by HeLa cells was maintained as an apparent monomer. In contrast to Cx43-HKKSL, Cx32-HKKSL was maintained in the ER as stable hexamers, consistent with the notion that Cx32 and Cx43 oligomerization occur in distinct intracellular compartments. Furthermore, Cx43-HKKSL and Cx43-AKKFF inhibited trafficking of Cx43 and Cx46 to the plasma membrane. The inhibitory effect was because of the formation of mixed oligomers between Cx43-HKKSL or Cx43-AKKF and wild type Cx43 or Cx46. Taken together, these results suggest that Cx43-HKKSL and Cx43-AKKFF recirculate through compartments where oligomerization occurs and may be maintained as apparent monomers by a putative Cx43-specific quality control mechanism.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Koval, M (corresponding author), Univ Penn, Sch Med, Dept Physiol, B-400 Richards Bldg,6085,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	mkoval@mail.med.upenn.edu	Koval, Michael/C-6366-2015; Sarma, Jayasri Das/AAS-3837-2020	Koval, Michael/0000-0002-5422-5614; 	NIGMS NIH HHS [GM61012, R01 GM061012, R01 GM061012-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham V, 1999, AM J PHYSIOL-LUNG C, V276, pL825, DOI 10.1152/ajplung.1999.276.5.L825; Ahmad S, 1999, BIOCHEM J, V339, P247, DOI 10.1042/0264-6021:3390247; Ahmad S, 1998, BIOCHEM SOC T, V26, pS304, DOI 10.1042/bst026s304; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Berthoud VM, 2001, EUR J CELL BIOL, V80, P11, DOI 10.1078/0171-9335-00132; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; Cosson P, 1995, COLD SPRING HARB SYM, V60, P113, DOI 10.1101/SQB.1995.060.01.014; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; Cruciani V, 1999, EXP CELL RES, V251, P285, DOI 10.1006/excr.1999.4574; Das Sarma J, 2001, J CELL SCI, V114, P4013; Diez JA, 1999, EUR J BIOCHEM, V262, P142, DOI 10.1046/j.1432-1327.1999.00343.x; Dogic D, 2001, EUR J CELL BIOL, V80, P151, DOI 10.1078/0171-9335-00145; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; George CH, 1999, J BIOL CHEM, V274, P8678, DOI 10.1074/jbc.274.13.8678; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hauri HP, 2000, J CELL SCI, V113, P587; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Jordan K, 2001, J CELL SCI, V114, P763; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Musil LS, 1990, CURR OPIN CELL BIOL, V2, P875, DOI 10.1016/0955-0674(90)90086-T; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Paulson AF, 2000, J CELL SCI, V113, P3037; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; PURANAM KL, 1993, EXP CELL RES, V206, P85, DOI 10.1006/excr.1993.1123; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VanSlyke JK, 2000, METHODS, V20, P156, DOI 10.1006/meth.1999.0933; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Yeager M, 1998, CURR OPIN STRUC BIOL, V8, P517, DOI 10.1016/S0959-440X(98)80131-0; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471	55	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20911	20918		10.1074/jbc.M111498200	http://dx.doi.org/10.1074/jbc.M111498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929864	hybrid			2022-12-25	WOS:000176204500104
J	Kim, JH; Rah, JC; Fraser, SP; Chang, KA; Djamgoz, MBA; Suh, YH				Kim, JH; Rah, JC; Fraser, SP; Chang, KA; Djamgoz, MBA; Suh, YH			Carboxyl-terminal peptide of beta-amyloid precursor protein blocks inositol 1,4,5-trisphosphate-sensitive Ca2+ release in Xenopus laevis oocytes.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; ALZHEIMERS-DISEASE; SECRETORY CLEAVAGE; CORTICAL-NEURONS; LUMINAL CA2+; FRAGMENT; TRISPHOSPHATE; RECEPTOR; CELLS; NEUROTOXICITY	The effects of Alzheimer's disease-related amyloidogenic peptides on inositol 1,4,5-trisphosphate receptor-mediated Ca2+ mobilization were examined in Xenopus laevis oocytes. Intracellular Ca2+ was monitored by electrophysiological measurement of the endogenous Ca2+-activated Cl- current. Application of a hyperpolarizing pulse released intracellular Ca2+ in oocytes primed by pre-injection of a non-metabolizable inositol 1,4,5-trisphosphate analogue. The carboxyl terminus of the amyloid precursor protein inhibited inositol 1,4,5-trisphosphate receptor-mediated intracellular Ca2+ release in a dose-dependent manner. Equimolar beta-amyloid peptides Abeta(1-40) or Abeta(1-42) had no effect, and whereas a truncated carboxyl terminus lacking the Abeta domain was equipotent to the full-length one, a carboxyl terminus fragment lacking the NPTY sequence was less effective than the full-length fragment. The inhibition induced by the carboxyl terminus was not associated with the block of the Ca2+-dependent Cl- channel itself or compromised Ca2+ influx. We conclude that the carboxyl terminus of the amyloid precursor protein inhibits inositol 1,4,5-trisphosphate-sensitive Ca2+ release and could thus disrupt Ca2+ homeostasis and that the carboxyl terminus is much more effective than the P-amyloid fragments used. By perturbing the coupling of inositol 1,4,5-trisphosphate and Ca2+ release, the carboxyl terminus of the amyloid precursor protein can potentially be involved in inducing the neural toxicity characteristic of Alzheimer's disease.	Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Univ London Imperial Coll Sci Technol & Med, Dept Biol, Neurobiol Grp, London SW7 2AZ, England	Seoul National University (SNU); Seoul National University (SNU); Imperial College London	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea.		Suh, Yoo-Hun/J-2761-2012	Rah, Jong-Cheol/0000-0003-3780-0522				Bach JH, 2001, J NEUROCHEM, V78, P109, DOI 10.1046/j.1471-4159.2001.00370.x; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CAPUTO CB, 1992, BIOCHEM BIOPH RES CO, V185, P1034, DOI 10.1016/0006-291X(92)91730-E; CHONG YH, 1994, LIFE SCI, V54, P1259; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; DYRKS T, 1992, J BIOL CHEM, V267, P18210; EINSTEIN G, 1994, J NEUROSCI, V14, P5077; Fraser SP, 1996, J NEUROCHEM, V66, P2034; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; FRASER SP, 1993, ELECTROPHYSIOLOGY PR, P65; FUKUCHI K, 1993, NATURE, V361, P122, DOI 10.1038/361122a0; GEARING M, 1993, J NEUROPATH EXP NEUR, V52, P22, DOI 10.1097/00005072-199301000-00004; GomezHernandez JM, 1997, J PHYSIOL-LONDON, V502, P569, DOI 10.1111/j.1469-7793.1997.569bj.x; Hartell NA, 2000, J NEUROCHEM, V74, P1112; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; Kim HS, 1998, NEUROREPORT, V9, P3875, DOI 10.1097/00001756-199812010-00020; Kim SH, 1996, J NEUROCHEM, V67, P1172; KOZIKOWSKI AP, 1990, J AM CHEM SOC, V112, P7403, DOI 10.1021/ja00176a055; KOZLOWSKI MR, 1992, J NEUROSCI, V12, P1679; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; LEVY S, 1993, J GEN PHYSIOL, V101, P67, DOI 10.1085/jgp.101.1.67; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATSUMOTO A, 1994, BIOCHEM BIOPH RES CO, V175, P361; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MILEDI R, 1989, J PHYSIOL-LONDON, V415, P189, DOI 10.1113/jphysiol.1989.sp017718; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1995, PFLUG ARCH EUR J PHY, V430, P954, DOI 10.1007/BF01837409; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Rah JC, 2001, FASEB J, V15, P1463, DOI 10.1096/fj.00-0724fje; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7319; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Suh YH, 1997, J NEUROCHEM, V68, P1781; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; Thrower EC, 1998, BIOCHEM J, V330, P559; TOKUDA T, 1995, NEUROSCI LETT, V186, P149, DOI 10.1016/0304-3940(95)11307-I; Wilcox RA, 1998, TRENDS PHARMACOL SCI, V19, P467, DOI 10.1016/S0165-6147(98)01260-7; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YAO Y, 1992, J PHYSIOL-LONDON, V458, P319, DOI 10.1113/jphysiol.1992.sp019420; YAO Y, 1993, J PHYSIOL-LONDON, V468, P275, DOI 10.1113/jphysiol.1993.sp019771; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0	57	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20256	20263		10.1074/jbc.M108326200	http://dx.doi.org/10.1074/jbc.M108326200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927572	hybrid			2022-12-25	WOS:000176204500022
J	Kimura, Y; Sakai, F; Nakano, O; Kisaki, O; Sugimoto, H; Sawamura, T; Sadano, H; Osumi, T				Kimura, Y; Sakai, F; Nakano, O; Kisaki, O; Sugimoto, H; Sawamura, T; Sadano, H; Osumi, T			The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; REPLICATIONAL SITES; HNRNP PROTEINS; DNA; ORGANIZATION; CHROMATIN; NUCLEOSKELETON; VISUALIZATION; SPECIFICITIES; PURIFICATION	Using a monoclonal antibody that recognizes a nuclear matrix protein, we selected a cDNA clone from a lambdagt11 human placenta cDNA library. This cDNA encoded a 939-amino acid protein designated nuclear matrix protein NXP-2. Northern blot analysis indicated that NXP-2 was expressed in various tissues at different levels. Forcibly expressed green fluorescent protein-tagged NXP-2 as well as endogenous NXP-2 was localized in the nucleus and distributed to the nuclear matrix. NXP-2 was released from the nuclear matrix when RNase A was included in the buffer for nuclear matrix preparation. Mapping of functional domains was carried out using green fluorescent protein-tagged truncated mutants of NXP-2. The region of amino acids 326-353 was responsible for nuclear matrix binding and contained a cluster of hydrophobic amino acids that was similar to the nuclear matrix targeting signal of acute myeloleukemia protein. The central region (amino acids 500-591) was demonstrated to be required for RNA binding by Northwestern analysis, although NXP-2 lacked a known RNA binding motif. The region of amino acid residues 682-876 was predicted to have a coiled-coil structure. The RNA-binding, nuclear matrix-binding, and coiled-coil domains are structurally separated, suggesting that NXP-2 plays important roles in diverse nuclear functions, including RNA metabolism and maintenance of nuclear architecture.	Himeji Inst Technol, Dept Life Sci, Grad Sch, Kamigori, Hyogo 6781201, Japan; Himeji Inst Technol, Fac Sci, Kamigori, Hyogo 6781201, Japan	University of Hyogo; University of Hyogo	Sadano, H (corresponding author), Himeji Inst Technol, Dept Life Sci, Grad Sch, 3-2-1 Koto, Kamigori, Hyogo 6781201, Japan.							BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; COOK PR, 1984, EMBO J, V3, P1837, DOI 10.1002/j.1460-2075.1984.tb02056.x; DeFranco DB, 2000, CRIT REV EUKAR GENE, V10, P39; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DICKINSON P, 1990, EMBO J, V9, P2207, DOI 10.1002/j.1460-2075.1990.tb07390.x; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; MCCREADY SJ, 1980, J CELL SCI, V46, P365; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; Nickerson JA, 2001, J CELL SCI, V114, P463; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Sadano H, 2000, BIOCHEM BIOPH RES CO, V267, P418, DOI 10.1006/bbrc.1999.1969; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH HC, 1984, J CELL BIOL, V99, P1794, DOI 10.1083/jcb.99.5.1794; Spector DL, 1996, EXP CELL RES, V229, P189, DOI 10.1006/excr.1996.0358; Stein GS, 2000, J CELL SCI, V113, P2527; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tan JH, 2000, MOL BIOL CELL, V11, P1547, DOI 10.1091/mbc.11.5.1547; Tang L, 1999, J BIOL CHEM, V274, P33580, DOI 10.1074/jbc.274.47.33580; TUBO RA, 1987, J BIOL CHEM, V262, P5857; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; XING YG, 1991, J CELL BIOL, V112, P1055, DOI 10.1083/jcb.112.6.1055; YAMASAKI M, 1997, BIOIMAGES, V6, P1; ZANG CM, 1997, P NATL ACAD SCI USA, V94, P6746; ZEITLIN S, 1987, MOL CELL BIOL, V7, P111, DOI 10.1128/MCB.7.1.111; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	44	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20611	20617		10.1074/jbc.M201440200	http://dx.doi.org/10.1074/jbc.M201440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927593	hybrid			2022-12-25	WOS:000176204500067
J	Pu, HX; Scanzano, R; Blostein, R				Pu, HX; Scanzano, R; Blostein, R			Distinct regulatory effects of the Na,K-ATPase gamma subunit.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+-K+-ATPASE; SODIUM-PUMP; IMMUNOCYTOCHEMICAL LOCALIZATION; FUNCTIONAL-ROLE; TRANSPORT; SEQUENCE; FAMILY; KIDNEY; CELLS	The two variants of the gamma subunit of the rat renal sodium pump, gamma(a) and gamma(b), have similar effects on the Na,K-ATPase. Both increase the affinity for ATP due to a shift in the enzyme's E-1 <----> E-2 conformational equilibrium toward E-1. In addition, both increase K+ antagonism of cytoplasmic Na+ activation. To gain insight into the structural basis for these distinct effects, extramembranous N-terminal and C-terminal mutants of gamma were expressed in rat alpha1-transfected HeLa cells. At the N terminus, the variant-distinct region was deleted (gammaNDelta7) or replaced by alanine residues (gammaN7A). At the C terminus, four (gamma(a)CDelta4) or ten (gamma(a)CDelta10) residues were deleted. None of these mutations abrogates the K+/Na+ antagonism as evidenced in a similar increase in K'(Na) seen at high (100 mm) K+ concentration. In contrast, the C-terminal as well as N-terminal deletions (gammaNDelta7, gamma(a)CDelta4, and gamma(a)CDelta10) abolished the decrease in K'(ATP) seen with wildtype gamma(a) or gamma(b). It is concluded that different regions of the gamma chain mediate the distinct functional effects of gamma, and the effects can be long-range. In the transmembrane region, the impact of G41R replacement was analyzed since this mutation is associated with autosomal dominant renal Me2+-wasting in man (Meij, I.C., Koenderink, J. B., van Bokhoven, H., Assink, K. F. H., Groenestege, W. T., de Pont, J. J. H. H. M., Bindels, R. J. M., Monnens, L. A. H., Van den Heuvel, L. P. W. J., and Knoers, N. V. A. M. (2000) Nat. Genet. 26, 265-266). The results show that Gly-41 --> Arg prevents trafficking of gamma but not alphabeta pumps to the cell surface and abrogates functional effects of gamma on alphabeta pumps. These findings underscore a potentially important role of gamma in affecting solute transport, in this instance Me2+ reabsorption, consequent to its primary effect on the sodium pump.	McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Blostein, R (corresponding author), Montreal Gen Hosp, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	Rhoda.Blostein@mcgill.ca						Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BARLETBAS C, 1990, AM J PHYSIOL, V259, pF246, DOI 10.1152/ajprenal.1990.259.2.F246; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; COLLINS JH, 1987, BIOCHEMISTRY-US, V26, P8665, DOI 10.1021/bi00400a026; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2001, BIOPHYS J, V80, p501A; GARTY H, 2002, IN PRESS AM J PHYSL; Jones DH, 2001, PHYSIOL GENOMICS, V6, P129, DOI 10.1152/physiolgenomics.2001.6.3.129; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; SACHS JR, 1988, J PHYSIOL-LONDON, V400, P575, DOI 10.1113/jphysiol.1988.sp017137; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sweadner KJ, 2000, BIOCHEM BIOPH RES CO, V279, P196, DOI 10.1006/bbrc.2000.3907; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	30	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20270	20276		10.1074/jbc.M201009200	http://dx.doi.org/10.1074/jbc.M201009200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929868	hybrid			2022-12-25	WOS:000176204500024
J	Gu, JJ; Kawai, H; Nie, LG; Kitao, H; Wiederschain, D; Jochemsen, AG; Parant, J; Lozano, G; Yuan, ZM				Gu, JJ; Kawai, H; Nie, LG; Kitao, H; Wiederschain, D; Jochemsen, AG; Parant, J; Lozano, G; Yuan, ZM			Mutual dependence of MDM2 and MDMX in their functional inactivation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								MDMX, an MDM2-related protein, has emerged as yet another essential negative regulator of p53 tumor suppressor, since loss of MDMX expression results in p53-ependent embryonic lethality in mice. However, it remains unknown why neither homologue can compensate for the loss of the other. In addition, results of biochemical studies have suggested that MDMX inhibits MDM2-mediated p53 degradation, thus contradicting its role as defined in gene knockout experiments. Using cells deficient in either MDM2 or MDMX, we demonstrated that these two p53 inhibitors are in fact functionally dependent on each other. In the absence of MDMX, MDM2 is largely ineffective in down-regulating p53 because of its extremely short half-life. MDMX renders MDM2 protein sufficiently stable to function at its full potential for p53 degradation. On the other hand, MDMX, which is a cytoplasmic protein, depends on MDM2 to redistribute into the nucleus and be able to inactivate p53. We also showed that MDMX, when exceedingly overexpressed, inhibits MDM2-mediated p53 degradation by competing with MDM2 for p53 binding. Our findings therefore provide a molecular basis for the nonoverlapping activities of these two p53 inhibitors previously revealed in genetic studies.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Harvard University; Harvard T.H. Chan School of Public Health; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Texas System; UTMD Anderson Cancer Center	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.			Kawai, Hidehiko/0000-0003-2213-7166	NATIONAL CANCER INSTITUTE [R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA85679-01A] Funding Source: Medline; NIEHS NIH HHS [T32 ES07155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9	10	204	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19251	19254		10.1074/jbc.C200150200	http://dx.doi.org/10.1074/jbc.C200150200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11953423	hybrid			2022-12-25	WOS:000175894800003
J	Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH				Kim, SS; Chae, HS; Bach, JH; Lee, MW; Kim, KY; Lee, WB; Jung, YM; Bonventre, JV; Suh, YH			P53 mediates ceramide-induced apoptosis in SKN-SH cells	ONCOGENE			English	Article						p53; apoptosis; ceramide; Bcl-2; Bax; caspase	PC12 CELLS; FACTOR WITHDRAWAL; NEURONAL DEATH; BCL-2; BAX; ACTIVATION; PROTEIN; DISTINCT; PATHWAY; HETERODIMERIZES	Ceramide induces apoptotic cell death in a dose- and time-dependent manner in neuroblastoma SKN-SH cells. Pretreatment with caspase inhibitors blocks cell death, suggesting that a set of caspase activities including caspase 1, as well as caspase 3, are involved in ceramide-induced apoptosis in SKN-SH cells. Treatment with a caspase inhibitor 3 h after ceramide addition did not inhibit cell death, although caspase activity was substantially reduced. Ceramide-induced apoptosis is accompanied by accumulation of p53 followed by an increase of Bax and decrease of Bcl-2 levels. Inhibition of p53 expression with p53 antisense oligonucleotides inhibits apoptosis and prevents the increase in Bax and decrease in Bcl-2. Furthermore, pretreatment with p53 antisense oligonucleotides markedly inhibits the induction of caspase activity. These results suggest that p53 regulates the ratio Bcl-2/Bax and the expression/activation of caspases during ceramide-induced apoptosis in SKN-SH cells. Caspase inhibition did not alter the expression of p53, Bcl-2 and Bax. Thus ceramide-induced reduction in the Bcl-2/Bax ratio, increase in caspase activity, and apoptosis is dependent upon increases in cellular p53 levels which play a critical role in the regulation of apoptotic cell death.	Chung Ang Univ, Coll Med, Dept Anat, BioGrand Inc,MRC, Seoul 156756, South Korea; NIH, Biomed Brain Res Ctr, Seoul 122701, South Korea; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Seoul Natl Univ, Coll Med, Dept Pharmacol,Neurosci Res Inst,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea	Chung Ang University; Chung Ang University Hospital; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Harvard University; Harvard Medical School; Seoul National University (SNU)	Bonventre, JV (corresponding author), Massachusetts Gen Hosp E, Suite 4002,149 13th St, Charlestown, MA 02129 USA.	joseph_bonventre@hms.harvard.edu	Suh, Yoo-Hun/J-2761-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039773, P01DK038452, R01DK039773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452, DK39773] Funding Source: Medline; NINDS NIH HHS [NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali ST, 1997, BIOCHEM J, V325, P321, DOI 10.1042/bj3250321; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anjum R, 1998, FEBS LETT, V439, P81, DOI 10.1016/S0014-5793(98)01343-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugg B, 1996, J NEUROCHEM, V66, P733; Choisy-Rossi C, 1998, TOXICOL LETT, V103, P491, DOI 10.1016/S0378-4274(98)00238-0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; El-Assaad W, 1998, BIOCHEM J, V336, P735, DOI 10.1042/bj3360735; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hartfield PJ, 1998, J NEUROCHEM, V71, P161; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kim SS, 1997, BIOCHEM BIOPH RES CO, V237, P583, DOI 10.1006/bbrc.1997.7133; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	38	32	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2020	2028	PII 10.1038/sj/onc/1205037	10.1038/sj.onc.1205037	http://dx.doi.org/10.1038/sj.onc.1205037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960374				2022-12-25	WOS:000174827000008
J	Kohn, EA; Ruth, ND; Brown, MK; Livingstone, M; Eastman, A				Kohn, EA; Ruth, ND; Brown, MK; Livingstone, M; Eastman, A			Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HAMSTER OVARY CELLS; PROTEIN KINASE-C; G(2) CHECKPOINT; RADIOSENSITIZING AGENT; SELECTIVE INHIBITORS; UCN-01; P53; ARREST; REPLICATION	DNA damage causes cell cycle arrest in G(1), S, or G(2) to prevent replication on damaged DNA or to prevent aberrant mitosis. The G(1) arrest requires the p53 tumor suppressor, yet the topoisomerase I inhibitor SN38 induces p53 after the G(1) checkpoint such that the cells only arrest in S or G(2). Hence, SN38 facilitates comparison of p53 wild-type and mutant cells with regard to the efficacy of drugs such as 7-hydroxystaurosporine (UCN-01) that Abrogate S and G(2) arrest. UCN-01 abrogated S and G(2) arrest in the p53 mutant breast tumor cell line MDA-MB-231 but not in the p53 wild-type breast line, MCF10a. This resistance to UCN-01 in the p53 wild-type cells correlated with suppression of cyclins A and B. In the p53 mutant cells, low concentrations of UCN-01 caused S phase cells to progress to G(2) before undergoing mitosis and death, whereas high concentrations caused rapid premature mitosis and death of S phase cells. UCN-01 inhibits Chk1/2, which should activate the mitosis-inducing phosphatase Cdc25C, yet this phosphatase remained inactive during S phase progression induced by low concentrations of UCN-01, probably because Cdc25C is also inhibited by the constitutive kinase, G TAK1. High concentrations of UCN-01 caused rapid activation of Cdc25C, which is attributed to inhibition of C-TAK1, as well as Chk1/2. Hence, UCN-01 has multiple effects depending on concentration and cell phenotype that must be considered when investigating mechanisms of checkpoint regulation.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA	Dartmouth College	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.		Livingstone, Mark/H-1709-2011	Livingstone, Mark/0000-0002-2757-7008	NCI NIH HHS [CA82220, CA23108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082220, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Bunch RT, 1997, CELL GROWTH DIFFER, V8, P779; Busby EC, 2000, CANCER RES, V60, P2108; Cholody WM, 2001, CANCER CHEMOTH PHARM, V47, P241, DOI 10.1007/s002800000234; DARZYNKIEWICZ Z, 1984, CYTOMETRY, V5, P355, DOI 10.1002/cyto.990050411; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Husain A, 1997, CLIN CANCER RES, V3, P2089; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Lammer C, 1998, J CELL SCI, V111, P2445; LAU CC, 1982, P NATL ACAD SCI USA, V79, P2943; Lee SI, 1999, BIOCHEM PHARMACOL, V58, P1713, DOI 10.1016/S0006-2952(99)00258-0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Moser BA, 2000, MOL CELL BIOL, V20, P4288, DOI 10.1128/MCB.20.12.4288-4294.2000; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; POWELL SN, 1995, CANCER RES, V55, P1643; Rhind N, 2000, J CELL SCI, V113, P3889; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shao RG, 1997, CANCER RES, V57, P4029; Shi Z, 2001, CANCER RES, V61, P1065; SORENSON CM, 1988, CANCER RES, V48, P6703; STAUSFELD UP, 1994, J BIOL CHEM, V269, P5989; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; TAKAHASHI I, 1989, J ANTIBIOT, V42, P564, DOI 10.7164/antibiotics.42.564; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Yin XY, 2001, CANCER RES, V61, P6487; Yu Qiang, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P800; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26553	26564		10.1074/jbc.M202040200	http://dx.doi.org/10.1074/jbc.M202040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11953432	hybrid			2022-12-25	WOS:000176908700096
J	Siu, F; Bain, PJ; LeBlanc-Chaffin, R; Chen, H; Kilberg, MS				Siu, F; Bain, PJ; LeBlanc-Chaffin, R; Chen, H; Kilberg, MS			ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; AMINO-ACID REGULATION; EXPRESSION; TRANSCRIPTION; PROTEIN; CELLS; ELEMENTS	Transcription from the asparagine synthetase (A.S.) gene is increased in response to either amino acid (amino acid response) or glucose (endoplasmic reticulum stress response) deprivation. These two independent pathways converge on the same set of genomic cis-elements within the A.S. promoter referred to as nutrient-sensing response elements (NSRE) 1 and 2, both of which are necessary for gene activation. The NSRE-1 sequence was used to screen ATF/CREB family members by electrophoresis mobility shift assays and supershift by specific antibodies. The results indicated that ATF4 binds to the NSRE-1 sequence and that the amount of the ATF4 complex was increased when extracts from amino acid-deprived or glucose-deprived cells were tested. Using electrophoresis mobility shift assay experiments and a probe that contained both NSRE-1 and NSRE-2, mutation of the NSRE-1 sequence completely prevented formation of the ATF4-containing complexes, whereas mutation of the NSRE-2 sequence did not. Overexpression of ATF4 increased A.S. promoter-driven transcription, whereas an inhibitory dominant negative ATF4 mutant blocked both basal and starvation-enhanced transcription. Collectively, the results provide both in vitro and in vivo evidence for a role of ATF4 in the transcriptional activation of the A.S. gene in response to nutrient deprivation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Box 100245, Gainesville, FL 32610 USA.				NIDDK NIH HHS [DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRULIS IL, 1979, J BIOL CHEM, V254, P629; ARFIN SM, 1977, P NATL ACAD SCI USA, V74, P2367, DOI 10.1073/pnas.74.6.2367; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hutson RG, 1996, CLIN NUTR, V15, P327, DOI 10.1016/S0261-5614(96)80009-4; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Jousse C, 1999, Curr Opin Clin Nutr Metab Care, V2, P297, DOI 10.1097/00075197-199907000-00008; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700	22	196	202	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24120	24127		10.1074/jbc.M201959200	http://dx.doi.org/10.1074/jbc.M201959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11960987	hybrid			2022-12-25	WOS:000176611800020
J	Casaus, JL; Navarro, JA; Hervas, M; Lostao, A; De la Rosa, MA; Gomez-Moreno, C; Sancho, J; Medina, A				Casaus, JL; Navarro, JA; Hervas, M; Lostao, A; De la Rosa, MA; Gomez-Moreno, C; Sancho, J; Medina, A			Anabaena sp PCC 7119 flavodoxin as electron carrier from photosystem I to Ferredoxin-NADP(+) reductase - Role of TRP57 and TYR94	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; FLASH ABSORPTION-SPECTROSCOPY; MONONUCLEOTIDE BINDING-SITE; SYNECHOCYSTIS PCC-6803; OXIDIZED FLAVODOXIN; TERTIARY STRUCTURE; KINETIC-ANALYSIS; CYTOCHROME C(6); PCC 7119; RESOLUTION	The influence of the amino acid residues sandwiching the flavin ring in flavodoxin (Fld) from the cyanobacterium Anabaena sp. PCC 7119 in complex formation and electron transfer (ET) with its natural partners, photosystem I (PSI) and ferredoxin-NADP(+) reductase (FNR), was examined in mutants of the key residues Trp(57) and Tyr(94). The mutants' ability to form complexes with either FNR or PSI is similar to that of wild-type Fld. However, some of the mutants exhibit altered kinetic properties in their ET processes that can be explained in terms of altered flavin accessibility and/or thermodynamic parameters. The most noticeable alteration is produced upon replacement of Tyr(94) by alanine. In this mutant, the processes that involve the transfer of one electron from either PSI or FNR are clearly accelerated, which might be attributable to a larger accessibility of the flavin to the reductant. However, when the opposite ET flow is analyzed with FNR, the reduced Y94A mutant transfers electrons to FNR slightly more slowly than wild type. This can be explained thermodynamically from a decrease in driving force due to the significant shift of 137 mV in the reduction potential value for the semiquinone/hydroquinone couple (E-1) of Y94A, relative to wild type (Lostao, A., Gomez-Moreno, C., Mayhew, S. G., and Sancho, J. (1997) Biochemistry 36,14334-14344). The behavior of the rest of the mutants can be explained in the same way. Overall, our data indicate that Trp(57) and Tyr(94) do not play any active role in flavodoxin redox reactions providing a path for the electrons but are rather involved in setting an appropriate structural and electronic environment that modulates in vivo ET from PSI to FNR while providing a tight FMN binding.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, CIC Isla de la Cartuja, Seville 41092, Spain	University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-JA-USE - Centro de Investigaciones Cientificas Isla de La Cartuja (CICIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Medina, A (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	mmedina@posta.unizar.es	Medina, Milagros/F-8310-2012; Sancho, javier/AAA-1225-2019; navarro, jose a/B-6354-2015; Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014; Lostao, Anabel/P-8693-2015	Medina, Milagros/0000-0001-8743-0182; Sancho, javier/0000-0002-2879-9200; navarro, jose a/0000-0002-0536-6074; Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; Lostao, Anabel/0000-0001-7460-5916				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; FUKUYAMA K, 1990, J BIOL CHEM, V265, P15804; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Jenkins CM, 1997, J BIOL CHEM, V272, P22509, DOI 10.1074/jbc.272.36.22509; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Medina M, 1999, BIOPHYS J, V77, P1712, DOI 10.1016/S0006-3495(99)77017-7; MEDINA M, 1992, FEBS LETT, V313, P239, DOI 10.1016/0014-5793(92)81200-6; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; Muhlenhoff U, 1996, BIOCHEMISTRY-US, V35, P1367, DOI 10.1021/bi952381c; NAVARRO JA, 1995, ARCH BIOCHEM BIOPHYS, V321, P229, DOI 10.1006/abbi.1995.1390; NAVARRO JA, 1994, PHOTOCHEM PHOTOBIOL, V60, P231, DOI 10.1111/j.1751-1097.1994.tb05096.x; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Reynolds RA, 2001, ACTA CRYSTALLOGR D, V57, P527, DOI 10.1107/S0907444901002554; Rogers L.J, 1987, CYANOBACTERIA, P35; ROGNER M, 1990, J BIOL CHEM, V265, P6189; Shin M, 1971, METHOD ENZYMOL, V23, P440; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; VANMIERLO CPM, 1990, EUR J BIOCHEM, V194, P185; WALKER MC, 1990, ARCH BIOCHEM BIOPHYS, V281, P76, DOI 10.1016/0003-9861(90)90415-U; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857; Zhou ZM, 1996, BIOCHEMISTRY-US, V35, P15980, DOI 10.1021/bi962124n	30	31	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22338	22344		10.1074/jbc.M112258200	http://dx.doi.org/10.1074/jbc.M112258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950835	hybrid, Green Published			2022-12-25	WOS:000176313600030
J	Keshamouni, VG; Mattingly, RR; Reddy, KB				Keshamouni, VG; Mattingly, RR; Reddy, KB			Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; STEROID-HORMONE RECEPTORS; SIGNAL-TRANSDUCTION; MAP KINASE; ESTROGEN-RECEPTOR; MCF-7 CELLS; DEPENDENT ACTIVATION; ESTRADIOL-RECEPTOR; FACTOR SECRETION	Activation of mitogen-activated protein kinase (Erk/ MAPK) is a critical signal transduction event for estrogen (E-2)-mediated cell proliferation. Recent studies from our group and others have shown that persistent activation of Erk plays a major role in cell migration and tumor progression. The signaling mechanism(s) responsible for persistent Erk activation are not fully characterized, however. In this study, we have shown that E-2 induces a slow but persistent activation of Erk in MCF-7 breast carcinoma cells. The E-2-induced Erk activation is dependent on new protein synthesis, suggesting that E-2-induced growth factors play a major role in Erk activation. When MCF-7 cells were treated with E-2 in the presence of an anti-HER-2 monoclonal antibody (herceptin), 60-70% of E-2-induced Erk activation is blocked. In addition, when untreated MCF-7 cells were exposed to conditioned medium from E-2-treated cells, Erk activity was significantly enhanced. Furthermore Erk activity was blocked by an antibody against HER-2 or by heregulin (HRG) depletion from the conditioned medium through immunoprecipitation. In contrast, epidermal growth factor receptor (Ab528) antibody only blocked 10-20% of E-2-induced Erk activation, suggesting that E-2-induced Erk activation is predominantly mediated through the secretion of HRG and activation of HER-2 by an autoctine/paracrine mechanism. Inhibition of PKC-delta-mediated signaling by a dominant negative mutant or the relatively specific PKC-delta inhibitor rottlerin blocked most of the E-2-induced Erk activation but had no effect on TGFalpha-induced Erk activation. By contrast inhibition of Ras, by inhibition of farnesyl transferase (Ftase-1) or dominant negative (N17)-Ras, significantly inhibited both E-2- and TGFalpha-induced Erk activation. This evaluation of downstream signaling revealed that E-2-induced Erk activation is mediated by a In HRG/HER-2/PKC-delta/Ras pathway that could be crucial for E-2-dependent growth-promoting effects in early stages of tumor progression.	Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reddy, KB (corresponding author), Wayne State Univ, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.			Keshamouni, Venkateshwar/0000-0003-1947-791X	NATIONAL CANCER INSTITUTE [R01CA081150, R01CA083964] Funding Source: NIH RePORTER; NCI NIH HHS [R01 NCA81150, R01 CA 83964-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUBIK D, 1987, CANCER RES, V47, P6517; Elledge RM, 1998, CLIN CANCER RES, V4, P7; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; FABBRO D, 1986, CANCER RES, V46, P2720; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Hornia A, 1999, MOL CELL BIOL, V19, P7672; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kurokawa H, 2000, CANCER RES, V60, P5887; LACROIX H, 1989, ONCOGENE, V4, P145; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPPMAN ME, 1987, J CELL BIOCHEM, V35, P1, DOI 10.1002/jcb.240350102; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mattingly RR, 2001, TOXICOL APPL PHARM, V176, P162, DOI 10.1006/taap.2001.9272; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miles DW, 2001, BREAST CANCER RES, V3, P380, DOI 10.1186/bcr326; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moasser MM, 2001, CANCER RES, V61, P7184; MORRISON P, 1996, J BIOL CHEM, V271, P12691; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Normanno N, 1997, J MAMMARY GLAND BIOL, V2, P143, DOI 10.1023/A:1026351730785; OBRIAN CA, 1989, CANCER RES, V49, P3215; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; REDDY KB, 1992, CANCER RES, V52, P3636; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rusnak DW, 2001, CANCER RES, V61, P7196; Sato J D, 1983, Mol Biol Med, V1, P511; SEGER R, 1992, J BIOL CHEM, V267, P25628; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Tang CK, 1996, CANCER RES, V56, P3350; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Treish I, 2000, AM J HEALTH-SYST PH, V57, P2063, DOI 10.1093/ajhp/57.22.2063; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	78	142	149	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22558	22565		10.1074/jbc.M202351200	http://dx.doi.org/10.1074/jbc.M202351200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960991	hybrid			2022-12-25	WOS:000176313600061
J	Matsui, T; Li, L; Wu, JC; Cook, SA; Nagoshi, T; Picard, MH; Liao, RL; Rosenzweig, A				Matsui, T; Li, L; Wu, JC; Cook, SA; Nagoshi, T; Picard, MH; Liao, RL; Rosenzweig, A			Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GROWTH-FACTOR-I; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3-BETA; SERINE-THREONINE KINASE; P70 S6 KINASE; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; CARDIOMYOCYTE HYPERTROPHY; DEPENDENT PHOSPHORYLATION	The serine-threonine kinase, Akt, inhibits cardiomyocyte apoptosis acutely both in vitro and in vivo. However, the effects of chronic Akt activation in the heart are unknown. To address this issue, we generated transgenic mice (TG+) with cardiac-specific expression of a constitutively active mutant of Akt (myr-Akt) driven by the myosin heavy chain-alpha promoter. Three TG+ founders (9-19 weeks) died suddenly with massive cardiac dilatation. Two viable TG+ lines (TG564 and TG20) derived from independent founders demonstrated cardiac-specific transgene expression as well as activation of Akt and p70S6 kinase. TG564 (n = 19) showed cardiac hypertrophy with a heart/body weight ratio 2.3-fold greater than littermates (n = 17, p < 0.005). TG20 (n = 18) had less marked cardiac hypertrophy with a heart/body weight ratio 1.6-fold greater than littermates (a = 17, p < 0.005). Isolated TG564 myocytes were also hypertrophic with surface areas 1.7-fold greater than littermates (p < 0.000001). Echocardiograms in both lines demonstrated concentric hypertrophy and preserved systolic function. After ischemia-reperfusion, TG+ had a 50% reduction in infarct size versus TG- (17 +/- 3% versus 34 +/- 4%, p < 0.001). Thus, chronic Akt activation is sufficient to cause a spectrum of phenotypes from moderate cardiac hypertrophy with preserved systolic function and cardioprotection to massive cardiac dilatation and sudden death.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Cardiovasc Gene Therapy,CVRC, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02129 USA; Boston Univ, Sch Med, Cardiac Muscle Res Lab, Boston, MA 02118 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp East, Cardiovasc Res Ctr, Program Cardiovasc Gene Therapy, 114 16th St,2nd Floor,Rm 2600, Charlestown, MA 02129 USA.		Cook, Stuart/G-9567-2011; Picard, Michael/F-1567-2013	Picard, Michael/0000-0002-9264-3243; Cook, Stuart/0000-0001-6628-194X	NHLBI NIH HHS [HL59521, HL61557, HL04250] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059521, K08HL004250, R01HL061557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baines CP, 1999, BASIC RES CARDIOL, V94, P188, DOI 10.1007/s003950050142; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Li BS, 1999, CIRC RES, V84, P1007, DOI 10.1161/01.RES.84.9.1007; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nagata K, 2000, CIRC RES, V87, P903, DOI 10.1161/01.RES.87.10.903; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Ozes ON, 1999, NATURE, V401, P82; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Thorell A, 1999, AM J PHYSIOL-ENDOC M, V277, pE733, DOI 10.1152/ajpendo.1999.277.4.E733; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; von Harsdorf R, 1999, CIRC RES, V85, P128, DOI 10.1161/01.RES.85.2.128; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	49	343	353	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22896	22901		10.1074/jbc.M200347200	http://dx.doi.org/10.1074/jbc.M200347200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943770	hybrid, Green Published			2022-12-25	WOS:000176313600101
J	Schwientek, T; Bennett, EP; Flores, C; Thacker, J; Hollmann, M; Reis, CA; Behrens, J; Mandel, U; Keck, B; Schafer, MA; Haselmann, K; Zubarev, R; Roepstorff, P; Burchell, JM; Taylor-Papadimitriou, J; Hollingsworth, MA; Clausen, H				Schwientek, T; Bennett, EP; Flores, C; Thacker, J; Hollmann, M; Reis, CA; Behrens, J; Mandel, U; Keck, B; Schafer, MA; Haselmann, K; Zubarev, R; Roepstorff, P; Burchell, JM; Taylor-Papadimitriou, J; Hollingsworth, MA; Clausen, H			Functional conservation of subfamilies of putative UDP-N-acetylgalactosamine : polypeptide N-acetylgalactosaminyltransferases in Drosophila, Caenorhabditis elegans, and mammals - One subfamily composed of l(2)35Aa is essential in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; ALPHA-D-GALACTOSAMINE; O-LINKED GLYCOSYLATION; CDNA CLONING; GALNAC-TRANSFERASES; 3 MEMBERS; EXPRESSION; FAMILY; GENE; SEQUENCE	The completed fruit fly genome was found to contain up to 15 putative UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetvlgalactosaminyltransferase (GalNAc-transferase) genes. Phylogenetic analysis of the putative catalytic domains of the large GalNAc-transferase enzyme families of Drosophila melanogaster (13 available), Caenorhabditis elegans (9 genes), and mammals (12 genes) indicated that distinct subfamilies of orthologous genes are conserved in each species. In support of this hypothesis, we provide evidence that distinctive functional properties of Drosophila and human GalNAc-tranferase isoforms were exhibited by evolutionarily conserved members of two subfamilies (dGalNAc-T1 (l(2)35Aa) and GalNAc-T11; dGalNAc-T2 (CG6394) and GalNAc-T7). dGalNAc-T1 and novel human GalNAc-T11 were shown to encode functional GalNAc-transferases,with the same polypeptide acceptor substrate specificity, and dGalNAc-T2 was shown to encode a GalNAc-transferase with similar GalNAc glycopeptide substrate specificity as GalNAc-T7. Previous data suggested that the putative GalNAc-transferase encoded by l(2)35Aa had a lethal phenotype (Flores, C., and Engels, W. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 2964-2969), and this was substantiated by sequencing of three lethal alleles l(2)35Aa(HG8), l(2)35Aa(SF12), and l(2)35Aa(SF32). The finding that subfamilies of GalNAc-transferases with distinct catalytic functions are evolutionarily conserved stresses that GalNAc-transferase isoforms may serve unique biological functions rather than providing functional redundancy, and this is further supported by the lethal phenotype of l(2)35Aa.	Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England; Univ Gottingen, Zool Inst entwicklungsbiol, Abt Mol Entwicklungsgenet, D-37073 Gottingen, Germany; Univ Porto, IPATIMUP, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal; Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Guys Hosp, Breast Canc Biol Grp, Imperial Canc Res Fund, London SE1 9RT, England; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Copenhagen; University of Wisconsin System; University of Wisconsin Madison; MRC Harwell; University of Gottingen; Universidade do Porto; University of Southern Denmark; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Nebraska System; University of Nebraska Medical Center	Schwientek, T (corresponding author), Univ Cologne, Fak Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.		Zubarev, Roman A/W-7891-2018; REIS, Celso A/B-9969-2008; Burchell, Joy/G-4560-2012; Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021	Zubarev, Roman A/0000-0001-9839-2089; REIS, Celso A/0000-0002-0286-6639; Bennett, Eric/0000-0002-4976-0647; Behrens, Jane Windfeldt/0000-0002-0136-9681; Burchell, Joy/0000-0003-0413-3823	NCI NIH HHS [1 R01 CA66234] Funding Source: Medline; NIGMS NIH HHS [GM30948] Funding Source: Medline; CIT NIH HHS [FCT-POCTI/36376/99] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030948, R56GM030948] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CIT NIH HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ashburner M, 1999, GENETICS, V153, P179; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1998, GLYCOBIOLOGY, V8, P547, DOI 10.1093/glycob/8.6.547; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BENNETT EP, 2001, GLYCOCONJ J, V18, P113; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; de Haan CAM, 1998, J BIOL CHEM, V273, P29905, DOI 10.1074/jbc.273.45.29905; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Felsenstein J, 1986, PHYLIP PHYLOGENY INF; Flores C, 1999, P NATL ACAD SCI USA, V96, P2964, DOI 10.1073/pnas.96.6.2964; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hassan H., 2000, CARBOHYDRATES CHEM B, P271; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HOMA FL, 1993, J BIOL CHEM, V268, P12609; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Jurado LAP, 1999, GENOMICS, V58, P171, DOI 10.1006/geno.1999.5819; Mandel U, 1999, GLYCOBIOLOGY, V9, P43, DOI 10.1093/glycob/9.1.43; Manzi AE, 2000, GLYCOBIOLOGY, V10, P669, DOI 10.1093/glycob/10.7.669; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Mirgorodskaya E, 2001, ANAL CHEM, V73, P1263, DOI 10.1021/ac001288d; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nehrke K, 1998, GLYCOBIOLOGY, V8, P367, DOI 10.1093/glycob/8.4.367; Rottger S, 1998, J CELL SCI, V111, P45; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Schmidt A, 1996, MOL GEN GENET, V251, P381, DOI 10.1007/BF02172530; SCHWIENTEK T, 2001, GLYCOCONJ J, V18, P44; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG Y, 1993, J BIOL CHEM, V268, P22979; Westerman EL, 1999, GLYCOBIOLOGY, V9, P1121; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WOJCZYK BS, 2002, GLYCOBIOLOGY, V18, P60; WOODRUFF RC, 1979, GENETICS, V92, P117; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	51	153	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22623	22638		10.1074/jbc.M202684200	http://dx.doi.org/10.1074/jbc.M202684200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11925450	hybrid			2022-12-25	WOS:000176313600069
J	Takata, Y; Yamada, T; Huang, YF; Komoto, J; Gomi, T; Ogawa, H; Fujioka, M; Takusagawa, F				Takata, Y; Yamada, T; Huang, YF; Komoto, J; Gomi, T; Ogawa, H; Fujioka, M; Takusagawa, F			Catalytic mechanism of S-adenosylhomocysteine hydrolase - Site-directed mutagenesis of Asp-130, Lys-185, Asp-189, and Asn-190	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; CRYSTAL-STRUCTURE; BINDING; ENZYME	S-Adenosylhomocysteine hydrolase (AdoHeyase) catalyzes the hydrolysis of S-adenosylhomocysteine to form adenosine and homocysteine. On the bases of crystal structures of the wild type enzyme and the D244E mutated enzyme complexed with 3'-keto-adenosine (D244E.Ado*), we have identified the important amino acid residues, Asp-130, Lys-185, Asp-189, and Asn-190, for the catalytic reaction and have proposed a catalytic mechanism (Komoto, J., Huang, Y., Gomi, T., Ogawa, H., Takata, Y., Fujioka, M., and Takusagawa, F. (2000) J. Biol. Chem. 275, 32147-32156). To confirm the proposed catalytic mechanism, we have made the D130N, K185N, D189N, and N190S mutated enzymes and measured the catalytic activities. The catalytic rates (k(cat)) of D130N, K185N, D189N, and N190S mutated enzymes are reduced to 0.7%, 0.5%, 0.1%, and 0.5%, respectively, in comparison with the wild type enzyme, indicating that Asp-130, Lys-185, Asp-189, and Asn-190 are involved in the catalytic reaction. K-m values of the mutated enzymes are increased significantly, except for the N190S mutation, suggesting that Asp-130, Lys-185, and Asp-189 participate in the substrate binding. To interpret the kinetic data, the oxidation states of the bound NAD molecules of the wild type and mutated enzymes were measured during the catalytic reaction by monitoring the absorbance at 340 nm. The crystal structures of the WT and D244E.Ado*, containing four subunits in the crystallographic asymmetric unit, were re-refined to have the same subunit structures. A detailed catalytic mechanism of AdoHcyase has been revealed based on the oxidation states of the bound NAD and the re-refined crystal structures of WT and D244E.Ado*. Lys-185 and Asp-130 abstract hydrogen atoms from 3'-OH and 4'-CH, respectively. Asp-189 removes a proton from Lys-185 and produces the neutral Nzeta (-NH2), and Asn-190 facilitates formation of the neutral Lys-185. His-54 and His-300 hold and polarize a water molecule, which nucleophilically attacks the C5'- of 3'-keto-4',5'-dehydroadenosine to produce 3'-keto-Ado.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Toyama Med & Pharmaceut Univ, Fac Med, Dept Biochem, Toyama 9300194, Japan	University of Kansas; University of Toyama	Takusagawa, F (corresponding author), Univ Kansas, Dept Mol Biosci, 3004 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.				NIGMS NIH HHS [GM37233] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CANTONI GL, 1954, J AM CHEM SOC, V76, P4744, DOI 10.1021/ja01647a081; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; GOMI T, 1989, J BIOL CHEM, V264, P16138; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; Huang YF, 2002, J BIOL CHEM, V277, P7477, DOI 10.1074/jbc.M109187200; Komoto J, 2000, J BIOL CHEM, V275, P32147, DOI 10.1074/jbc.M003725200; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PALMER JL, 1976, J BIOL CHEM, V251, P5817; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VOET D, 1995, BIOCHEMISTRY-US, P353	16	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22670	22676		10.1074/jbc.M201116200	http://dx.doi.org/10.1074/jbc.M201116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11927587	hybrid			2022-12-25	WOS:000176313600074
J	Zhang, LQ; Hartshorn, KL; Crouch, EC; Ikegami, M; Whitsett, JA				Zhang, LQ; Hartshorn, KL; Crouch, EC; Ikegami, M; Whitsett, JA			Complementation of pulmonary abnormalities in SP-D(-/-) mice with an SP-D/conglutinin fusion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TARGETED MICE; CARBOHYDRATE-RECOGNITION DOMAIN; INFLUENZA-A VIRUSES; ALVEOLAR MACROPHAGES; IN-VIVO; TRANSGENIC MICE; HOST-DEFENSE; SURFACTANT; EXPRESSION; BINDING	Surfactant protein D (SP-D) and serum conglutinin are closely related members of the collectin family of host defense lectins. Although normally synthesized at different anatomic sites, both proteins participate in the innate immune response to microbial challenge. To discern the roles of specific domains in the function of SP-D in vivo, a fusion protein (SP-D/Cong(neck+CRD)) consisting of the NH2-terminal and collagenous domains of rat SP-D (rSP-D) and the neck and carbohydrate recognition domains (CRDs) of bovine conglutinin (Cong) was expressed in the respiratory epithelium of SP-D gene-targeted (SP-D(-/-)) mice. While SP-D/Cong(neck+CRD) fusion protein did not affect lung morphology and surfactant phospholipid levels in the lungs of wild type mice, the chimeric protein substantially corrected the increased lung phospholipids in SP-D(-/-) mice. The SP-D/Cong(neck+CRD) fusion protein also completely corrected defects in influenza A clearance and inhibited the exaggerated inflammatory response that occurs following viral infection. However, the chimeric protein did not ameliorate the ongoing lung inflammation, enhanced metalloproteinase expression, and alveolar destruction that characterize this model of SP-D deficiency. By contrast, a single arm mutant (RrSP-D-Ser15,D-20) partially restored antiviral activity but otherwise failed to rescue the deficient phenotype. Our findings directly implicate the CRDs of both SP-D and conglutinin in host defense in vivo. Our findings also strongly suggest that the molecular mechanisms underlying impaired pulmonary host defense and abnormal lipid metabolism are distinct from those that promote ongoing inflammation and the development of emphysema.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Cincinnati Children's Hospital Medical Center; Boston University; Boston University; Washington University (WUSTL)	Whitsett, JA (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@chmcc.org		Hartshorn, Kevan/0000-0002-7196-7433	NHLBI NIH HHS [HL29594, HL5891, HL63329-03, HL44015, HL61646-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL061646, P01HL029594, R01HL044015, R01HL063329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1992, AM J PHYSIOL, V263, pL60, DOI 10.1152/ajplung.1992.263.1.L60; CROUCH E, 1991, AM J RESP CELL MOL, V5, P13, DOI 10.1165/ajrcmb/5.1.13; Crouch EC, 1998, BBA-MOL BASIS DIS, V1408, P278, DOI 10.1016/S0925-4439(98)00073-8; Elhalwagi BM, 1999, AM J RESP CELL MOL, V21, P380, DOI 10.1165/ajrcmb.21.3.3676; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13, DOI 10.1165/ajrcmb.12.1.7811466; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; HARTSHORN KL, 1993, J IMMUNOL, V151, P6265; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156, DOI 10.1152/ajplung.1997.273.6.L1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; Hartshorn KL, 2000, AM J PHYSIOL-LUNG C, V278, pL90, DOI 10.1152/ajplung.2000.278.1.L90; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; HOLMSKOV U, 1993, J BIOL CHEM, V268, P10120; Holmskov UL, 2000, APMIS, V108, P7; HULL W, 2000, AM J RESP CRIT CARE, V161, pA42; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2000, J IMMUNOL, V165, P3934, DOI 10.4049/jimmunol.165.7.3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Madan T, 1997, INFECT IMMUN, V65, P3171, DOI 10.1128/IAI.65.8.3171-3179.1997; Reid KBM, 1998, BBA-MOL BASIS DIS, V1408, P290, DOI 10.1016/S0925-4439(98)00074-X; REID KBM, 1994, SPRINGER SEMIN IMMUN, V15, P307, DOI 10.1007/BF01837363; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589, DOI 10.1177/40.10.1527377; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	35	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22453	22459		10.1074/jbc.M201632200	http://dx.doi.org/10.1074/jbc.M201632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956209	hybrid			2022-12-25	WOS:000176313600046
J	Eaton, P; Fuller, W; Shattock, MJ				Eaton, P; Fuller, W; Shattock, MJ			S-thiolation of HSP27 regulates its multimeric aggregate size independently of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ALPHA-B-CRYSTALLIN; OXIDATIVE STRESS; CREATINE-KINASE; TROPONIN-I; MOLECULAR CHAPERONE; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES; OXIDANT STRESS; RAT-HEART	HSP27 exists as large aggregates that breakdown after phosphorylation. We show rat cardiac HSP27 is S-thiolated during oxidant stress, and this modification, without phosphorylation, disaggregates multimeric HSP27. Biotinylated cysteine acts as a probe for thiolated proteins, which are detected using non-reducing Western blots probed with streptavidin-horseradish peroxidase. Controls show a low level of S-thiolation, which is increased 3.6-fold during post-ischemic reperfusion. S-Thiolated proteins were purified using streptavidin-agarose, and Western immunoblotting showed HSP27 was present. We increased protein S-thiolation 10-fold with 10 mum H2O2 with or without a kinase inhibitor mixture (staurosporine, genistein, bisindolylmaleimide, SB203580, and PD98059). H2O2 alone induced the phosphorylation of HSP27 Ser-86 and Ser-45/Ser-59 of its homologue alphaB crystallin. However, kinase inhibition reduced phosphorylation of these sites below basal. Despite effective kinase inhibition, H2O2 still disaggregated HSP27, but not aB crystallin. This is consistent with the lack of an S-thiolation site on aB crystallin. Thus, we have demonstrated a novel mechanism of HSP27 multimeric size regulation. S-Thiolation must occur at Cys-141, the only cysteine in rat HSP27.	St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Eaton, P (corresponding author), St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England.	philip.eaton@kcl.ac.uk	Eaton, Philip/I-5444-2015	Eaton, Philip/0000-0003-0748-2367; Shattock, Michael/0000-0001-6242-7585; Fuller, William/0000-0002-5883-4433				Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; AUFRICHT C, 1998, AM J PHYSIOL, V43, pF215; Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; Bluhm WF, 1998, AM J PHYSIOL-HEART C, V275, pH2243, DOI 10.1152/ajpheart.1998.275.6.H2243; Bonini MG, 2001, J BIOL CHEM, V276, P9749, DOI 10.1074/jbc.M008456200; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Butt E, 2001, J BIOL CHEM, V276, P7108, DOI 10.1074/jbc.M009234200; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Cheung PY, 1998, ARCH BIOCHEM BIOPHYS, V350, P104, DOI 10.1006/abbi.1997.0496; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; Demasi M, 2001, ARCH BIOCHEM BIOPHYS, V389, P254, DOI 10.1006/abbi.2001.2332; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; DILISA F, 1995, BIOCHEM J, V308, P57, DOI 10.1042/bj3080057; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; Eaton P, 2001, J MOL CELL CARDIOL, V33, P1659, DOI 10.1006/jmcc.2001.1418; Fiebig R, 1996, AGE, V19, P83, DOI 10.1007/BF02434087; GANOTE C, 1993, CARDIOVASC RES, V27, P1387, DOI 10.1093/cvr/27.8.1387; GANOTE CE, 1988, AM J PATHOL, V132, P212; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Hallk HM, 1998, CIRCULATION, V98, P220; HEARSE DJ, 1991, CARDIOVASC DRUG THER, V5, P853, DOI 10.1007/BF00053547; Hook DWA, 1998, INT J BIOL MACROMOL, V22, P295, DOI 10.1016/S0141-8130(98)00027-0; Huot J, 1996, CANCER RES, V56, P273; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; Jiang MT, 2002, BIOPHYS J, V82, p347A; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Landry J, 1999, BIOCHEM SOC SYMP, P79; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; Liu W, 1999, J CELL SCI, V112, P2409; Loktionova SA, 1998, FEBS LETT, V433, P294, DOI 10.1016/S0014-5793(98)00920-X; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Martin JL, 1997, CIRCULATION, V96, P4343; McDonough JL, 1999, CIRC RES, V84, P9; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; Mohr S, 1996, J BIOL CHEM, V271, P4209; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Qin CA, 1996, CURR EYE RES, V15, P719, DOI 10.3109/02713689609003454; Reddy S, 1998, FREE RADICAL BIO MED, V25, pS78; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SEKI N, 1986, B JPN SOC SCI FISH, V52, P1673; SHATTOCK MJ, 1993, CIRC RES, V72, P91, DOI 10.1161/01.RES.72.1.91; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Wang HM, 2001, BIOCHEMISTRY-US, V40, P3316, DOI 10.1021/bi002786j; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Zavialov A, 1998, INT J BIOL MACROMOL, V22, P163, DOI 10.1016/S0141-8130(98)00014-2; Zucchi R, 1998, CIRC RES, V83, P908	66	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21189	21196		10.1074/jbc.M200591200	http://dx.doi.org/10.1074/jbc.M200591200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925435	hybrid			2022-12-25	WOS:000176286000011
J	Tudzynski, B; Rojas, MC; Gaskin, P; Hedden, P				Tudzynski, B; Rojas, MC; Gaskin, P; Hedden, P			The gibberellin 20-oxidase of Gibberella fujikuroi is a multifunctional monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENT-KAURENE OXIDASE; CELL-FREE SYSTEM; BIOSYNTHESIS PATHWAY; MOLECULAR-CLONING; CUCURBITA-MAXIMA; GENE-CLUSTER; EXPRESSION; ENZYME; ENCODES; TRANSFORMATION	The genes for gibberellin (GA) biosynthesis are clustered in the fungus Gibberella fujikuroi. In addition to genes encoding a GA-specific geranylgeranyl diphosphate synthase and a bifunctional ent-copalyl diphosphate/ent-kaurene synthase, the cluster contains four cytochrome P450 monooxygenase genes (P450-1, -2, -3, -4). Recently it was shown that P450-4 and P450-1 encode multifunctional enzymes catalyzing the three oxidation steps from ent-kaurene to ent-kaurenoic acid and the four oxidation steps from ent-kaurenoic acid to GA(14), respectively. Here we describe the functional analysis of the P450-2 gene by gene disruption and by expressing the gene in a mutant that lacks the entire GA biosynthesis gene cluster. Mutants in which P450-2 is inactivated by the insertion of a large piece of DNA accumulated GA(14) and lacked biosynthetically more advanced metabolites, indicating that the gene encodes a 20-oxidase. This was confirmed by incubating lines containing P450-2 in the absence of the other GA biosynthesis genes with isotopically labeled substrates. The P450-2 gene product oxidized the 3beta-hydroxylated intermediate, GA(14), and its non-hydroxylated analogue GA(12) to GA(4) and GA(9), respectively. Expression of P450-2 is repressed by high amounts of nitrogen in the culture medium but is not affected by the presence of biosynthetically advanced GAs, i.e. there is no evidence for feedback regulation. The fact that the GA 20-oxidase is a cytochrome P450 monooxygenase in G. fujikuroi and not a 2-oxoglutarate-dependent dioxygenase as in plants, together with the significant differences in regulation of gene expression, are further evidence for independent evolution of the GA biosynthetic pathways in plants and fungi.	Univ Bristol, Dept Agr Sci, IACR Long Ashton Res Stn, Bristol BS41 9AF, Avon, England; Univ Munster, Inst Bot, D-48149 Munster, Germany; Univ Chile, Fac Ciencias, Dept Quim, Lab Bioorgan, Santiago, Chile	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol; University of Munster; Universidad de Chile	Hedden, P (corresponding author), Univ Bristol, Dept Agr Sci, IACR Long Ashton Res Stn, Bristol BS41 9AF, Avon, England.		ROJAS, MARIA CECILIA/D-8730-2014	ROJAS, MARIA CECILIA/0000-0002-6034-9779	Biotechnology and Biological Sciences Research Council [BBS/E/C/00004161] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASHMAN PJ, 1990, BIOCHIM BIOPHYS ACTA, V1036, P151, DOI 10.1016/0304-4165(90)90027-T; BARENDSE GWM, 1980, J CHROMATOGR, V198, P449, DOI 10.1016/S0021-9673(00)80514-2; Barrero AF, 1999, PHYTOCHEMISTRY, V50, P1133, DOI 10.1016/S0031-9422(98)00699-2; BEARDER JR, 1975, J CHEM SOC PERK T 1, P721, DOI 10.1039/p19750000721; CHAPMAN DJ, 1980, ANNU REV PLANT PHYS, V31, P639, DOI 10.1146/annurev.pp.31.060180.003231; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DESJARDINS AE, 1992, J IND MICROBIOL, V9, P201, DOI 10.1007/BF01569624; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; GASKIN P, 1992, GC MS GIBBERLLINS RE; GEISSMAN TA, 1966, PHYTOCHEMISTRY, V5, P933, DOI 10.1016/S0031-9422(00)82790-9; GRAEBE JE, 1974, PHYTOCHEMISTRY, V13, P1433, DOI 10.1016/0031-9422(74)80304-3; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Helliwell CA, 2001, P NATL ACAD SCI USA, V98, P2065, DOI 10.1073/pnas.041588998; HENDRICK CA, 1964, AUST J CHEM, V17, P915; JENNINGS JC, 1993, PLANT PHYSIOL, V101, P925, DOI 10.1104/pp.101.3.925; KAMIYA Y, 1986, PLANTA, V169, P524, DOI 10.1007/BF00392102; Kawaide H, 1997, J BIOL CHEM, V272, P21706, DOI 10.1074/jbc.272.35.21706; Lange T, 1997, P NATL ACAD SCI USA, V94, P6553, DOI 10.1073/pnas.94.12.6553; LANGE T, 1994, PLANTA, V195, P108; LANGE T, 1994, P NATL ACAD SCI USA, V91, P8552, DOI 10.1073/pnas.91.18.8552; Lange T, 1997, PHYSIOL PLANTARUM, V100, P543, DOI 10.1034/j.1399-3054.1997.1000316.x; Linnemannstons P, 1999, APPL ENVIRON MICROB, V65, P2558; Maniatis T., 1989, MOL CLONING LAB MANU; MUNOZ GA, 1993, APPL ENVIRON MICROB, V59, P4317; PHILLIPS AL, 1995, PLANT PHYSIOL, V108, P1049, DOI 10.1104/pp.108.3.1049; PONTECORVO GV, 1952, ADV GENET, V5, P141; Rojas MC, 2001, P NATL ACAD SCI USA, V98, P5838, DOI 10.1073/pnas.091096298; Sakamoto T, 2001, GENE DEV, V15, P581, DOI 10.1101/gad.867901; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Tudzynski B, 1996, MICROBIOL-SGM, V142, P533, DOI 10.1099/13500872-142-3-533; Tudzynski B, 1998, CURR GENET, V34, P234, DOI 10.1007/s002940050392; Tudzynski B, 2001, APPL ENVIRON MICROB, V67, P3514, DOI 10.1128/AEM.67.8.3514-3522.2001; Tudzynski B, 1998, FUNGAL GENET BIOL, V25, P157, DOI 10.1006/fgbi.1998.1095; Urrutia O, 2001, PHYTOCHEMISTRY, V56, P505, DOI 10.1016/S0031-9422(00)00381-2; Ward JL, 1997, CHEM COMMUN, P13, DOI 10.1039/a606158c; West C. A., 1973, Phytochemical Society Symposia Series, P143; Wu KQ, 1996, PLANT PHYSIOL, V110, P547, DOI 10.1104/pp.110.2.547; XU YL, 1995, P NATL ACAD SCI USA, V92, P6640, DOI 10.1073/pnas.92.14.6640	39	71	81	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21246	21253		10.1074/jbc.M201651200	http://dx.doi.org/10.1074/jbc.M201651200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943776	hybrid			2022-12-25	WOS:000176286000018
J	Bubb, MR; Govindasamy, L; Yarmola, EG; Vorobiev, SM; Almo, SC; Somasundaram, T; Chapman, MS; Agbandje-McKenna, M; McKenna, R				Bubb, MR; Govindasamy, L; Yarmola, EG; Vorobiev, SM; Almo, SC; Somasundaram, T; Chapman, MS; Agbandje-McKenna, M; McKenna, R			Polylysine induces an antiparallel actin dimer that nucleates filament assembly - Crystal structure at 3.5-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; BETA-ACTIN; DIFFRACTION DATA; ARP2/3 COMPLEX; POLYMERIZATION; KINETICS; GELSOLIN; DYNAMICS; MODEL; ASSOCIATION	An antiparallel actin dimer has been proposed to be an intermediate species during actin filament nucleation. We now show that latrunculin A, a marine natural product that inhibits actin polymerization, arrests polylysine-induced nucleation at the level of an antiparallel dimer, resulting in its accumulation. These dimers, when composed of pyrene-labeled actin subunits, give rise to a fluorescent excimer, permitting detection during polymerization in vitro. We report the crystallographic structure of the polylysine-actin-latrunculin A complex at 3.5-Angstrom resolution. The non-crystallographic contact is consistent with a dimeric structure and confirms the antiparallel orientation of its subunits. The crystallographic contacts reveal that the mobile DNase I binding loop of one subunit of a symmetry-related antiparallel actin dimer is partially stabilized in the interface between the two subunits of a second antiparallel dimer. These results provide a potential explanation for the paradoxical nucleation of actin filaments that have exclusively parallel subunits by a dimer containing antiparallel subunits.	Vet Affairs Med Ctr, Malcom Randall Dept, Res Serv, Gainesville, FL 32608 USA; Univ Florida, Coll Med, Gainesville, FL 32608 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University System of Florida; University of Florida; State University System of Florida; University of Florida; Yeshiva University; Albert Einstein College of Medicine; State University System of Florida; Florida State University	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.			Chapman, Michael/0000-0001-8525-8585; Somasundaram, Thayumanasamy/0000-0002-3629-5117	NIGMS NIH HHS [GM53807] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASPENSTROM P, 1993, FEBS LETT, V329, P163, DOI 10.1016/0014-5793(93)80215-G; Blanchoin L, 2000, NATURE, V404, P1007, DOI 10.1038/35010008; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; BUBB MR, 1994, J BIOL CHEM, V269, P25592; BUBB MR, 1994, J BIOL CHEM, V269, P25587; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; CHATELIER RC, 1987, BIOPHYS CHEM, V28, P121, DOI 10.1016/0301-4622(87)80081-9; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; delaTorre JG, 1997, EUR BIOPHYS J BIOPHY, V25, P361, DOI 10.1007/s002490050049; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JOHANNES FJ, 1991, EMBO J, V10, P3951, DOI 10.1002/j.1460-2075.1991.tb04965.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kim E, 2000, BIOPHYS CHEM, V86, P191, DOI 10.1016/S0301-4622(00)00143-5; Kuo SC, 2000, NATURE, V407, P1026, DOI 10.1038/35039544; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; MOCKRIN SC, 1983, J BIOL CHEM, V258, P3215; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P28; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; ORLOVA A, 1993, J MOL BIOL, V232, P334, DOI 10.1006/jmbi.1993.1393; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; SCHACHMAN HK, 1959, ULTRACENTRIFUGATION, P75; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; Terry DR, 1997, J BIOL CHEM, V272, P7841, DOI 10.1074/jbc.272.12.7841; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; WEGNER A, 1982, BIOCHEMISTRY-US, V21, P1909, DOI 10.1021/bi00537a032; WEGNER A, 1975, BIOPHYS CHEM, V3, P215, DOI 10.1016/0301-4622(75)80013-5; Yarmola EG, 2000, J BIOL CHEM, V275, P28120	43	63	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20999	21006		10.1074/jbc.M201371200	http://dx.doi.org/10.1074/jbc.M201371200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11932258	hybrid			2022-12-25	WOS:000176204500115
J	Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H				Kuo, MT; Liu, ZS; Wei, YJ; Lin-Lee, YC; Tatebe, S; Mills, GB; Unate, H			Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappa B signaling	ONCOGENE			English	Article						2-acetylaminofluorene; MDR; P13 kinase; Akt; rac	TUMOR-SUPPRESSOR GENE; MULTIDRUG-RESISTANCE; PHOSPHATIDYLINOSITOL 3-KINASE; P-GLYCOPROTEIN; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; PROMOTER ACTIVITY; NADPH OXIDASE; RHO GTPASES; HEAT-SHOCK	The expression of P-glycoprotein encoded by the multidrug resistance (MDR1) gene is associated with the emergence of the NIDR phenotype in cancer cells. Human MDR1 and its rodent homolog mdr1a and mdr1b are frequently overexpressed in liver cancers. However, the underlying mechanisms are largely unknown. The hepatocarcinogen 2-acetylaminofluorene (2-AAF) efficiently activates rat mdr1b expression in cultured cells and in Fisher 344 rats. We recently reported that activation of rat mdr1b in cultured cells by 2-AAF involves a cis-activating element containing a NF-kappaB binding site located - 167 to - 158 of the rat mdr1b promoter. 2-AAF activates IkappaB kinase (IKK), resulting in degradation of IkappaBbeta and activation of NF-kappaB. In this study, we report that 2-AAF could also activate the human MDR1 gene in human hepatoma and embryonic fibroblast 293 cells. Induction of MDR1 by AAF was mediated by DNA sequence located at -6092 which contains a NF-kappaB binding site. Treating hepatoma cells with 2-AAF activated phosphoinositide 3-kinase (PI3K) and its downstream effectors Rac1, and NAD(P)H oxidase. Transient transfection assays demonstrated that constitutively activated PI3K and Rac1 enhanced the activation of the MDR1 promoter by 2-AAF. Treatment of hepatoma cells with 2-AAF also activated another PI3K downstream effector Akt. Transfection of recombinant encoding a dominant activated Akt also enhanced the activation of MDR1 promoter activation by 2-AAF. These results demonstrated that 2-AAF up-regulates MDR1 expression is mediated by the multiple effectors of the PI3K signaling pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuo, MT (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tkuo@mail.mdanderson.org			NCI NIH HHS [CA16672, CA79085, CA72404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404, P30CA016672, R01CA079085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borst P, 1997, SEMIN CANCER BIOL, V8, P131, DOI 10.1006/scbi.1997.0072; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; Cieslik K, 2001, J BIOL CHEM, V276, P1211, DOI 10.1074/jbc.M005305200; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; DENG LS, 2001, IN PRESS CLIN RELEVA; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujiwara Y, 2000, JPN J CANCER RES, V91, P287, DOI 10.1111/j.1349-7006.2000.tb00943.x; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ng IOL, 2000, AM J CLIN PATHOL, V113, P355, DOI 10.1309/AC1M-4TY4-U0TN-EN7T; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; OZES MN, 2000, NATURE, V406, P307; Ozes ON, 1999, NATURE, V401, P82; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POIRIER MC, 1991, CARCINOGENESIS, V12, P895, DOI 10.1093/carcin/12.5.895; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHEN CJ, 1990, J BIOL CHEM, V265, P506; SILVERMAN JA, 1995, MOL CARCINOGEN, V13, P50, DOI 10.1002/mc.2940130109; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TEETER LD, 1993, MOL CARCINOGEN, V8, P67, DOI 10.1002/mc.2940080202; TEETER LD, 1993, INT J ONCOL, V2, P73; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Verna L, 1996, PHARMACOL THERAPEUT, V71, P83, DOI 10.1016/0163-7258(96)00063-0; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yeh KT, 2000, CANCER INVEST, V18, P123, DOI 10.3109/07357900009038243; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhou G, 1996, CELL GROWTH DIFFER, V7, P1369	72	174	187	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1945	1954		10.1038/sj.onc.1205117	http://dx.doi.org/10.1038/sj.onc.1205117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960367				2022-12-25	WOS:000174827000001
J	Bennin, DA; Don, ASA; Brake, T; McKenzie, JL; Rosenbaum, H; Ortiz, L; DePaoli-Roach, AA; Horne, MC				Bennin, DA; Don, ASA; Brake, T; McKenzie, JL; Rosenbaum, H; Ortiz, L; DePaoli-Roach, AA; Horne, MC			Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B ' subunits in active complexes and induces nuclear aberrations and a G(1)/S phase cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; GROWTH ARREST; TUMOR-ANTIGEN; A-SUBUNIT; IDENTIFICATION; EXPRESSION; FAMILY; KINASE; PP2A	Cyclin G2, together with cyclin G1 and cyclin 1, defines a novel cyclin family expressed in terminally differentiated tissues including brain and muscle. Cyclin G2 expression is up-regulated as cells undergo cell cycle arrest or apoptosis in response to inhibitory stimuli independent of p53 (Horne, M., Donaldson, K., Goolsby, G., Tran, D., Mulheisen, M., Hell, J. and Wahl, A. (1997) J. Biol. Chem. 272, 12650-12661). We tested the hypothesis that cyclin G2 may be a negative regulator of cell cycle progression and found that ectopic expression of cyclin G2 induces the formation of aberrant nuclei and cell cycle arrest in HEK293 and Chinese hamster ovary cells. Cyclin G2 is primarily partitioned to a detergent-resistant compartment, suggesting an association with cytoskeletal elements. We determined that cyclin G2 and its homolog cyclin G1 directly interact with the catalytic subunit of protein phosphatase 2A (PP2A). An okadaic acid-sensitive (<2 nM) phosphatase activity coprecipitates with endogenous and ectopic cyclin G2. We found that cyclin G2 also associates with various PP2A B' regulatory subunits, as previously shown for cyclin G1. The PP2A/A subunit is not detectable in cyclin G2-PP2A-B'-C complexes. Notably, cyclin G2 colocalizes with both PP2A/C and B' subunits in detergent-resistant cellular compartments, suggesting that these complexes form in living cells. The ability of cyclin G2 to inhibit cell cycle progression correlates with its ability to bind PP2A/B' and C subunits. Together, our findings suggest that cyclin G2-PP2A complexes inhibit cell cycle progression.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Indiana Univ, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Iowa; Indiana University System; Indiana University-Purdue University Indianapolis	Horne, MC (corresponding author), Univ Iowa, Dept Pharmacol, 2-530 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	mary-horne@uiowa.edu		Horne, Mary/0000-0002-2799-3212	NIGMS NIH HHS [R01 GM 56900] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Bates S, 1996, ONCOGENE, V13, P1103; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen LJ, 1998, MOL IMMUNOL, V35, P195, DOI 10.1016/S0161-5890(98)00044-3; Cheng AY, 1998, CANCER RES, V58, P3611; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; Galadari S, 1998, BIOCHEMISTRY-US, V37, P11232, DOI 10.1021/bi980911+; Gao CY, 1997, BIOESSAYS, V19, P307, DOI 10.1002/bies.950190408; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Horne MC, 1996, IMMUNITY, V4, P145, DOI 10.1016/S1074-7613(00)80679-2; Jackman MR, 1997, CANCER SURV, V29, P47; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jensen MR, 1999, GENE, V230, P171, DOI 10.1016/S0378-1119(99)00057-8; Jiang W, 2000, GENETICS, V154, P1025; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; KINOSHITA N, 1993, GENE DEV, V7, P1059, DOI 10.1101/gad.7.6.1059; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Mills JC, 1998, J CELL SCI, V111, P625; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piel M, 2001, SCIENCE, V291, P1550, DOI 10.1126/science.1057330; QUINTANS J, 1994, BIOCHEM BIOPH RES CO, V202, P710, DOI 10.1006/bbrc.1994.1988; Reed SI, 1997, CANCER SURV, V29, P7; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; Snaith HA, 1996, J CELL SCI, V109, P3001; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Strack S, 1998, J COMP NEUROL, V392, P515; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAMURA K, 1993, ONCOGENE, V8, P2113; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	93	171	180	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27449	27467		10.1074/jbc.M111693200	http://dx.doi.org/10.1074/jbc.M111693200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11956189	hybrid			2022-12-25	WOS:000177055900095
J	Lemmers, C; Medina, E; Delgrossi, MH; Michel, D; Arsanto, JP; Le Bivic, A				Lemmers, C; Medina, E; Delgrossi, MH; Michel, D; Arsanto, JP; Le Bivic, A			hINADI/PATJ, a homolog of discs lost, interacts with crumbs and localizes to tight junctions in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAIN PROTEIN; ZONULA ADHERENS FORMATION; DROSOPHILA STARDUST; KINASE-C; POLARITY; MEMBRANE; COMPLEX; MUPP1; FORM; INAD	dCrumbs is an apical organizer crucial for the maintenance of epithelial polarity in Drosophila (1). It is known that dCrumbs interacts with Discs lost (Dlt), a protein with four PDZ (PSD95/Dises Large/ZO-1) domains (2), and Stardust (Sdt), a protein of the NIAGUK (membrane-associated guanylate kinase) family (3, 4). We have searched for potential homologs of Dlt in human epithelial cells and characterized one of them in intestinal epithelial cells. Human INAD-like (hINADl) contains 8 PDZ domains, is concentrated in tight junctions, and is also found at the apical plasma membrane. Overexpression of hINADl disrupted the tight junctions localization of ZO-1 and 3. We also identified a partial cDNA coding the transmembrane and cytoplasmic domains of a new human crumbs (CRB3) expressed in Caco-2 cells. This CRB3 was able to interact through its C-terminal end with the N-terminal domain of hINADl. Taken together, the data indicate that hINADl is likely to represent a Dlt homolog in mammalian epithelial cells and might be involved in regulating the integrity of tight junctions. We thus propose to rename hINADl ATJ for protein associated to tight junctions.	Univ Mediterranee, Fac Sci Luminy, Inst Biol Dev Marseille, UMR 6165,Lab Neurogenese & Morphogenese Dev Adult, F-13288 Marseille 09, France	UDICE-French Research Universities; Aix-Marseille Universite	Le Bivic, A (corresponding author), Univ Mediterranee, Fac Sci Luminy, Inst Biol Dev Marseille, UMR 6165,Lab Neurogenese & Morphogenese Dev Adult, Case 907, F-13288 Marseille 09, France.	lebivic@ibdm.univ-mrs.fr						Bachmann A, 2001, NATURE, V414, P638, DOI 10.1038/414638a; Balda MS, 1998, J CELL SCI, V111, P541; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; Delgrossi MH, 1997, J CELL SCI, V110, P2207; den Hollander AI, 1999, NAT GENET, V23, P217, DOI 10.1038/13848; den Hollander AI, 2001, HUM MOL GENET, V10, P2767, DOI 10.1093/hmg/10.24.2767; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GARCIA M, 1993, J CELL SCI, V104, P1281; Grawe F, 1996, DEVELOPMENT, V122, P951; Hong Y, 2001, NATURE, V414, P634, DOI 10.1038/414634a; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Klebes A, 2000, CURR BIOL, V10, P76, DOI 10.1016/S0960-9822(99)00277-8; Knoblich JA, 2000, CURR BIOL, V10, pR791, DOI 10.1016/S0960-9822(00)00761-2; Knust E, 2000, CURR OPIN GENET DEV, V10, P471, DOI 10.1016/S0959-437X(00)00115-5; Kramer H, 2000, J CELL BIOL, V151, pF15, DOI 10.1083/jcb.151.4.F15; LEBIVIC A, 1988, EUR J CELL BIOL, V46, P113; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; Saito H, 2001, J BIOL CHEM, V276, P32051, DOI 10.1074/jbc.C100330200; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Soejima H, 2001, GENOMICS, V74, P115, DOI 10.1006/geno.2001.6527; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WODARZ A, 1993, MECH DEVELOP, V44, P175, DOI 10.1016/0925-4773(93)90066-7; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Zahraoui A, 2000, J CELL BIOL, V151, pF31, DOI 10.1083/jcb.151.5.F31	39	133	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25408	25415		10.1074/jbc.M202196200	http://dx.doi.org/10.1074/jbc.M202196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964389	hybrid			2022-12-25	WOS:000176747000074
J	Kim, J; Kim, JH; Lee, SH; Kim, DH; Kang, HY; Bae, SH; Pan, ZQ; Seo, YS				Kim, J; Kim, JH; Lee, SH; Kim, DH; Kang, HY; Bae, SH; Pan, ZQ; Seo, YS			The novel human DNA helicase hFBH1 is an F-box protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-ACTIVATING KINASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEOLYSIS; IDENTIFICATION; METABOLISM; SEQUENCE; ENGINE; MOTIF; SGS1	We have identified a novel DNA helicase in humans that belongs to members of the superfamily I helicase and found that it contains a well conserved F-box motif at its N terminus. We have named the enzyme hFBH1 (human F-box DNA helicase 1). Recombinant hFBH1, containing glutathione S-transferase at the N terminus, was expressed in Sf9 cells and purified. In this report, we show that hFBH1 exhibited DNA-dependent ATPase and DNA unwinding activities that displace duplex DNA in the 3' to 5' direction. The hFBH1 enzyme interacted with human SKP1 and formed an SCF ((S) under bar KP1/(C) under bar ullin/(F) under bar -box) complex together with human Cullin and ROC1. In addition, the SCF complex containing hFBH1 as an F-box protein displayed ubiquitin ligase activity. We demonstrate that hFBH1 is the first F-box protein that possesses intrinsic enzyme activity. The potential role of the F-box motif and the helicase activity of the enzyme are discussed with regard to regulation of DNA metabolism.	Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, Suwon 440746, Kyunggi, South Korea; Dong A Univ, Coll Med, Dept Pharmacol, Seo Gu, Pusan 602103, South Korea; Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Sungkyunkwan University (SKKU); Dong A University; Icahn School of Medicine at Mount Sinai	Seo, YS (corresponding author), Sungkyunkwan Univ, Sch Med, Natl Creat Res Initiat Ctr Cell Cycle Control, Samsung Biomed Res Inst,Changan Ku, 300 Chunchun Dong, Suwon 440746, Kyunggi, South Korea.	ysseo@med.skku.ac.kr	Kim, Jaehoon/G-2711-2011; Seo, Yeonsoo/C-1605-2011	Kim, Jaehoon/0000-0003-4035-0438; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; KAIS, 1994, METHODS YEAST GENETI, P169; Kang HY, 2000, GENETICS, V155, P1055; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; McVey M, 2001, GENETICS, V157, P1531; Miller J.H., 1972, EXPT MOL GENETICS; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Park JS, 1997, J BIOL CHEM, V272, P18910, DOI 10.1074/jbc.272.30.18910; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Yee A, 1996, J BIOL CHEM, V271, P471, DOI 10.1074/jbc.271.1.471; YEE A, 1995, CANCER RES, V55, P6058	33	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24530	24537		10.1074/jbc.M201612200	http://dx.doi.org/10.1074/jbc.M201612200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956208	hybrid			2022-12-25	WOS:000176611800074
J	Pietsch, M; Gutschow, M				Pietsch, M; Gutschow, M			Alternate substrate inhibition of cholesterol esterase by Thieno[2,3-d][1,3]oxazin-4-ones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; PARA-NITROPHENYL; CATALYZED-HYDROLYSIS; BINDING INHIBITION; SLOW-BINDING; MECHANISM; SITE; LIPASE	In a kinetic study, the interaction of bovine pancreatic cholesterol esterase (CEase) with fused 1,3-oxazin-4-ones and 1,3-thiazin-4-ones was investigated, and the compounds were characterized as alternate substrate inhibitors. Inhibition assays were performed in the presence of sodium taurocholate with p-nitrophenyl butyrate as chromogenic substrate. Strong active site-directed inhibition was detected for 2-diethylaminothieno[2,3-d][1,3]oxazin-4-ones with a cycloaliphatic chain at positions 5,6. The most potent inhibitors, compounds 3 and 4, exhibited K-i values of 0.58 and 1.86 muM, respectively. An exchange of the ring oxygen by sulfur and the removal of the cycloaliphatic moiety as well as the replacement of the thiophene ring by benzene led to a loss of inhibitory potency. CEase has the capability to catalyze the hydrolysis of representatives of fused 1,3-oxazin-4-ones as well as the highly stable 1,3-thiazin-4-ones by using an acylation-deacylation mechanism. Hydrolyses were performed in the presence of a high enzyme concentration, and products were identified spectrophotometrically and by means of high performance liquid chromatography. The kinetic parameters V-max(I) and V-max(I)/K-m(I) for the CEase-catalyzed turnover were determined. The compounds whose enzyme-catalyzed hydrolysis followed first-order kinetics (K-m(I) > 25 muM) failed to inhibit CEase. On the other hand, inhibitors 3 (initial concentration of 25 muM) and 4 (20 muM) were hydrolyzed by CEase under steady-state conditions in the first phase of the reaction. Rate-limiting deacylation was demonstrated in nucleophilic competition experiments with ethanol as acyl acceptor wherein the conversion of compound 3 was accelerated up to an ethanol concentration of 1.5 m. The characterization of these compounds (i.e. 3 and 4) as alternate substrate inhibitors is not only based on the verification of the CEase-catalyzed hydrolysis. It also rests upon the concurrence of corresponding K-i values obtained in the inhibition assay compared with separately determined K-m(I) values of their enzyme-catalyzed consumption, as could be predicted from the kinetic model used in this study.	Univ Bonn, Inst Pharmaceut, D-53115 Bonn, Germany	University of Bonn	Gutschow, M (corresponding author), Univ Bonn, Inst Pharmaceut, Kreuzbergweg 26, D-53115 Bonn, Germany.	guetschow@uni-bonn.de						BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; CYGLER M, 1993, PROTEIN SCI, V2, P366; Deck LM, 1999, J MED CHEM, V42, P4250, DOI 10.1021/jm990309x; Feaster SR, 1996, BIOCHEMISTRY-US, V35, P16723, DOI 10.1021/bi961677v; Feaster SR, 1997, METHOD ENZYMOL, V286, P231; Gutschow M, 1999, J MED CHEM, V42, P5437, DOI 10.1021/jm991108w; Gutschow M, 1998, J MED CHEM, V41, P1729, DOI 10.1021/jm9708341; Gutschow M, 1999, J ORG CHEM, V64, P5109, DOI 10.1021/jo9900634; HLASTA DJ, 1994, ANNU REP MED CHEM, V29, P195; HOSIE L, 1987, J BIOL CHEM, V262, P260; KRANTZ A, 1992, BIOORG MED CHEM LETT, V2, P1327, DOI 10.1016/S0960-894X(00)80507-7; KRANTZ A, 1990, J MED CHEM, V33, P464, DOI 10.1021/jm00164a002; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Lin GL, 1999, BIOCHEMISTRY-US, V38, P9971, DOI 10.1021/bi982775e; Lin GL, 1999, BBA-PROTEIN STRUCT M, V1431, P500, DOI 10.1016/S0167-4838(99)00073-4; Lombardo D, 2001, BBA-MOL CELL BIOL L, V1533, P1, DOI 10.1016/S1388-1981(01)00130-5; LOMBARDO D, 1981, BIOCHIM BIOPHYS ACTA, V657, P425, DOI 10.1016/0005-2744(81)90328-4; Martyn DC, 1999, CURR PHARM DESIGN, V5, P405; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MYERSPAYNE SC, 1995, BIOCHEMISTRY-US, V34, P3942, DOI 10.1021/bi00012a011; NEUMANN U, 1995, BIOORG CHEM, V23, P72, DOI 10.1006/bioo.1995.1006; NEUMANN U, 1994, J BIOL CHEM, V269, P21561; Neumann U, 2001, BIOORGAN MED CHEM, V9, P947, DOI 10.1016/S0968-0896(00)00310-2; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Powers J C, 1993, Agents Actions Suppl, V42, P3; Quinn D. M., 1998, COMPREHENSIVE BIOL C, P455; SINNOTT M, 1998, COMPREHENSIVE BIOL C, V4, P93; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P4126, DOI 10.1021/bi00387a057; STOUT JS, 1985, BIOCHIM BIOPHYS ACTA, V837, P6, DOI 10.1016/0005-2760(85)90079-7; SUTTON LD, 1990, J AM CHEM SOC, V112, P8398, DOI 10.1021/ja00179a025; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G	31	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24006	24013		10.1074/jbc.M112252200	http://dx.doi.org/10.1074/jbc.M112252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959857	hybrid			2022-12-25	WOS:000176611800007
J	Ilari, A; Bonamore, A; Farina, A; Johnson, KA; Boffi, A				Ilari, A; Bonamore, A; Farina, A; Johnson, KA; Boffi, A			The X-ray structure of ferric Escherichia coli flavohemoglobin reveals an unexpected geometry of the distal heme pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DIOXYGENASE; BINDING PROPERTIES; DIFFRACTION DATA; PROGRAM; STRESS; LIGAND	The x-ray structure of ferric unliganded lipid-free Escherichia coli flavohemoglobin has been solved to a resolution of 2.2 Angstrom and refined to an R-factor of 19%. The overall fold is similar to that of ferrous lipid-bound Alcaligenes eutrophus flavohemoglobin with the notable exception of the E helix positioning within the globin domain and a rotation of the NAD binding module with respect to the FAD-binding domain accompanied by a substantial rearrangement of the C-terminal region. An inspection of the heme environment in E. coli flavohemoglobin reveals an unexpected architecture of the distal pocket. In fact, the distal site is occupied by the isopropyl side chain Leu-E11 that shields the heme iron from the residues in the topological positions predicted to interact with heme iron-bound ligands, namely Tyr-B10 and Gln-E7, and stabilizes a pentacoordinate ferric iron species. Ligand binding properties are consistent with the presence of a pentacoordinate species in solution as indicated by a very fast second order combination rates with imidazole and azide. Surprisingly, imidazole, cyanide, and azide binding profiles at equilibrium are not accounted for by a single site titration curve but are biphasic and strongly suggest the presence of two distinct conformers within the liganded species.	Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Boffi, A (corresponding author), Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy.	alberto.boffi@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Bonamore, Alessandra/AAB-2587-2019; Ilari, Andrea/T-5501-2017	Ilari, Andrea/0000-0002-7754-399X; Bonamore, Alessandra/0000-0002-3940-4657; Ilari, Andrea/0000-0002-7754-399X				Boffi A, 1999, BIOPHYS J, V77, P1143, DOI 10.1016/S0006-3495(99)76965-1; Bolognesi M, 1999, J MOL BIOL, V291, P637, DOI 10.1006/jmbi.1999.2975; Bonamore A, 2001, BBA-PROTEIN STRUCT M, V1549, P174, DOI 10.1016/S0167-4838(01)00256-4; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; Collaborative Computational Project No. 4, 1994, ACTA CRYSTALLOGR D, V50, P750; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Giangiacomo L, 2001, BIOCHEMISTRY-US, V40, P9311, DOI 10.1021/bi0101143; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; JAKOB W, 1992, ARCH BIOCHEM BIOPHYS, V292, P29, DOI 10.1016/0003-9861(92)90046-Y; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mansy SS, 1998, BIOCHEMISTRY-US, V37, P12452, DOI 10.1021/bi980516j; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; MembrilloHernandez J, 1996, FEBS LETT, V382, P141, DOI 10.1016/0014-5793(96)00154-8; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	28	115	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23725	23732		10.1074/jbc.M202228200	http://dx.doi.org/10.1074/jbc.M202228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964402	hybrid			2022-12-25	WOS:000176475700082
J	Liu, Y; Li, JL; Kim, BO; Pace, BS; He, JJ				Liu, Y; Li, JL; Kim, BO; Pace, BS; He, JJ			HIV-1 tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear tat-interacting protein of 110 kDa, Tip110	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR TRANSCRIPTION FACTOR; RNA RECOGNITION; HISTONE ACETYLTRANSFERASE; TYPE-1 TAT; IN-VITRO; ELONGATION; BINDING; IDENTIFICATION; ACTIVATION	Human immunodeficiency virus type 1 (HIV-1) gene expression and replication is highly dependent on and modulated by interactions between viral and host cellular factors. Tat protein, encoded by one of the HTV-1 regulatory genes, tat, is essential for HIV-1 gene expression. A number of host cellular factors have been shown to interact with Tat in this process. During our attempts to determine the molecular mechanisms of Tat interaction with brain cells, we isolated a cDNA clone that encodes a novel Tat-interacting protein of 110 kDa or Tip110 from a human fetal brain cDNA library. Gen-Bank(TM) BLAST search revealed that Tip110 was almost identical to a previously cloned KIAA0156 gene with unknown functions. In vivo binding of Tip110 with Tat was confirmed by immunoprecipitation and Western blotting, in combination with mutagenesis. The yeast three-hybrid RNA-protein interaction assay indicated no direct interaction of Tip110 with Tat transactivating response element RNA. Nevertheless, Tip110 strongly synergized with Tat on Tat-mediated chloramphenicol acetyltransferase reporter gene expression and HIV-1 virus production, whereas down-modulation of constitutive Tip110 expression inhibited HIV-1 virus production. Northern blot analysis showed that Tip110 mRNA was expressed in a variety of human tissues and cells. Moreover, digital fluorescence microscopic imaging revealed that Tip110 was expressed exclusively in the nucleus, and within a nuclear speckle structure that has recently been described for human cyclin T and CDK9, two critical components for Tat transactivation function on HIV-1 long terminal repeat promoter. Taken together, these data demonstrate that Tip110 regulates Tat transactivation activity through direct interaction, and suggest that Tip110 is an important cellular factor for HIV-1 gene expression and viral replication.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA; Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of South Alabama	He, JJ (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, R4 302,1044 W Walnut St, Indianapolis, IN 46202 USA.	jjhe@iupui.edu		Pace, Betty/0000-0002-1275-4112	NINDS NIH HHS [R01NS39804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039804] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gu JA, 1998, BBA-GENE STRUCT EXPR, V1399, P1, DOI 10.1016/S0167-4781(98)00082-7; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Herrmann CH, 2001, J CELL SCI, V114, P1491; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KATO H, 1992, GENE DEV, V6, P655, DOI 10.1101/gad.6.4.655; LASPIA MF, 1993, J MOL BIOL, V232, P732, DOI 10.1006/jmbi.1993.1427; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; Li XY, 1998, GENE DEV, V12, P2992, DOI 10.1101/gad.12.19.2992; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MILLER JG, 1972, SHORT COURSE BACTERI; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Pereira LA, 2000, NUCLEIC ACIDS RES, V28, P663, DOI 10.1093/nar/28.3.663; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; Schneider S, 1996, BIOTECHNIQUES, V20, P960; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 2000, GENE THER, V7, P438, DOI 10.1038/sj.gt.3301106; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang D, 1999, CANCER RES, V59, P4056; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605	57	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23854	23863		10.1074/jbc.M200773200	http://dx.doi.org/10.1074/jbc.M200773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959860	hybrid			2022-12-25	WOS:000176475700099
J	Muller, M; Panke, O; Junge, W; Engelbrecht, S				Muller, M; Panke, O; Junge, W; Engelbrecht, S			F-1-ATPase, the C-terminal end of subunit gamma is not required for ATP hydrolysis-driven rotation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; SITE-DIRECTED MUTAGENESIS; ROTARY F-ATPASE; BETA-SUBUNIT; VISCOELASTIC DYNAMICS; NONCATALYTIC SITES; SYNTHASE; CATALYSIS; TRANSPORT; TORQUE	ATP hydrolysis by the isolated F-1-ATPase drives the rotation of the central shaft, subunit gamma, which is located within a hexagon formed by subunits (alphabeta)(3). The C-terminal end of gamma forms an alpha-helix which properly fits into the "hydrophobic bearing" provided by loops of subunits alpha and beta. This "bearing" is expected to be essential for the rotary function. We checked the importance of this contact region by successive C-terminal deletions of 3, 6, 9, 12, 15, and 18 amino acid residues (Escherichia coli F-1-ATPase). The ATP hydrolysis activity of a load-free ensemble of F-1 with 12 residues deleted decreased to 24%, of the control. EF1 with deletions of 15 or 18 residues was inactive, probably because it failed to assemble. The average torque generated by a single molecule of EF1 when loaded by a fluorescent actin filament was, however, unaffected by deletions of up to 12 residues, as was their rotational behavior (all samples rotated during 60 +/- 19% of the observation time). Activation energy analysis with the ensemble revealed a moderate decrease from 54 kJ/mol for EF1 (full-length gamma) to 34 kJ/mol for EF1(gamma-12). These observations imply that the intactness of the C terminus of subunit gamma provides structural stability and/or routing during assembly of the enzyme, but that it is not required for the rotary action under load, proper.	Univ Osnabruck, Fachbereich Biol, Biophys Abt, D-49076 Osnabruck, Germany	University Osnabruck	Engelbrecht, S (corresponding author), Univ Osnabruck, Fachbereich Biol, Biophys Abt, Barbarastr 11, D-49076 Osnabruck, Germany.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; *APPL BIOS, 2000, ABI PRISM BIGD TERM; Boyer PD, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1058, DOI 10.1023/A:1012420610963; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cherepanov DA, 2001, BIOPHYS J, V81, P1234, DOI 10.1016/S0006-3495(01)75781-5; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2000, J EXP BIOL, V203, P9; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Gumbiowski K, 2001, J BIOL CHEM, V276, P42287, DOI 10.1074/jbc.M106884200; Happel, 2012, LOW REYNOLDS NUMBER; Hara KY, 2000, J BIOL CHEM, V275, P14260, DOI 10.1074/jbc.275.19.14260; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Ketchum CJ, 1998, J BIOL CHEM, V273, P22292, DOI 10.1074/jbc.273.35.22292; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 1996, FEBS LETT, V383, P196, DOI 10.1016/0014-5793(96)00246-3; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Panke O, 2001, BIOPHYS J, V81, P1220, DOI 10.1016/S0006-3495(01)75780-3; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHIN K, 1992, J BIOL CHEM, V267, P20835; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1995, J BIOL CHEM, V270, P21045, DOI 10.1074/jbc.270.36.21045; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WISE JG, 1990, J BIOL CHEM, V265, P10403; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	45	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23308	23313		10.1074/jbc.M201998200	http://dx.doi.org/10.1074/jbc.M201998200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964400	hybrid			2022-12-25	WOS:000176475700029
J	Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M				Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M			A novel dual specificity phosphatase SKRP1 interacts with the MAPK kinase MKK7 and inactivates the JNK MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JUN NH2-TERMINAL KINASE; TYROSINE-PHOSPHATASE; CATALYTIC ACTIVATION; SIGNAL-TRANSDUCTION; CELL-LINES; SELECTIVELY DEPHOSPHORYLATES; MOLECULAR-CLONING; STRESS; P38	Mitogen-activated protein kinases (MAPKs) are activated in response to various extracellular stimuli, and their activities are regulated by upstream activating kinases and protein phosphatases such as MAPK phosphatases (MKPs). We report the identification and characterization of a novel MKP termed SKRP1 (SAPK pathway-regulating phosphatase 1). It contains an extended active site sequence motif conserved in all MKPs but lacks a Cdc25 homology domain. Immunoblotting analysis revealed that SKRP1 is constitutively expressed, and its transcripts of 4.0 and 1.0 kb were detected in almost tissues examined. SKRP1 was highly specific for c-Jun N-terminal kinase (JNK) in vitro and effectively suppressed the JNK activation in response to tumor necrosis factor a or thapsigargin. Endogenous SKRP1 was present predominantly in the cytoplasm and colocalized with JNK. However, SKRP1 does not bind directly to its target JNK, but co-precipitation of SKRP1 with the MAPK kinase MKK7, a JNK activator, was found in vitro and in vivo. Furthermore, we found that SKRP1 did not interfere with the co-precipitation of MKK7 with JNK. Together, our findings indicate that SKRP1 interacts with its physiological substrate JNK through MKK7, thereby leading to the precise regulation of JNK activity in vivo.	Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan	Tokyo Medical & Dental University (TMDU); Keio University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dowd S, 1998, J CELL SCI, V111, P3389; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hansson T, 1997, J MOL BIOL, V265, P118, DOI 10.1006/jmbi.1996.0716; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kolmodin K, 2001, FEBS LETT, V498, P208, DOI 10.1016/S0014-5793(01)02479-6; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; QU Z, 1997, MOL CELL BIOL, V17, P7407; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378	64	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23909	23918		10.1074/jbc.M200837200	http://dx.doi.org/10.1074/jbc.M200837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959861	hybrid			2022-12-25	WOS:000176475700105
J	Ziros, PG; Gil, APR; Georgakopoulos, T; Habeos, I; Kletsas, D; Basdra, EK; Papavassiliou, AG				Ziros, PG; Gil, APR; Georgakopoulos, T; Habeos, I; Kletsas, D; Basdra, EK; Papavassiliou, AG			The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE-EXPRESSION; GROWTH-FACTOR BETA-1; PERIODONTAL-LIGAMENT; I COLLAGEN; MORPHOGENETIC PROTEIN-2; CLEIDOCRANIAL DYSPLASIA; MESSENGER-RNA; C-JUN; DIFFERENTIATION; KINASE	A primary goal of bone research is to understand the mechanism(s) by which mechanical forces dictate the cellular and metabolic activities of osteoblasts, the bone-forming cells. Several studies indicate that osteblastic cells respond to physical loading by transducing signals that alter gene expression patterns. Accumulated data have documented the fundamental role of the osteoblast-specific transcription factor Cbfa1 (core-binding factor) in osteoblast differentiation and function. Here, we demonstrate that low level mechanical deformation (stretching) of human osteoblastic cells directly up-regulates the expression and DNA binding activity of Cbfa1. This effect seems to be fine tuned by stretch-triggered induction of distinct mitogen-activated protein kinase cascades. Our novel finding that activated extracellular signal-regulated kinase mitogen-activated protein kinase physically interacts and phosphorylates endogenous Cbfa1 in vivo (ultimately potentiating this transcription factor) provides a molecular link between mechanostressing and stimulation of osteoblast differentiation. Elucidation of the specific modifiers and cofactors that operate in this mechanotranscription circuitry will contribute to a better understanding of mechanical load-induced bone formation which may set the basis for nonpharmacological intervention in bone loss pathologies.	Univ Patras, Sch Med, Dept Biochem, GR-26110 Patras, Greece; Heidelberg Univ, Dept Orthodont, D-69120 Heidelberg, Germany; Natl Ctr Sci Res Demokritos, Inst Biol, GR-15310 Athens, Greece	University of Patras; Ruprecht Karls University Heidelberg; National Centre of Scientific Research "Demokritos"	Papavassiliou, AG (corresponding author), Univ Patras, Sch Med, Dept Biochem, GR-26110 Patras, Greece.	papavas@med.upatras.gr	Karamouzis, Michalis/AAD-2860-2020; Kletsas, Dimitris/F-6953-2010; ziros, panos/C-7289-2009; Gil, Andrea Paola Rojas/AAS-8328-2021	Rojas Gil, Andrea Paola/0000-0002-9812-2131; Kletsas, Dimitris/0000-0002-9828-3963				ARCEO N, 1991, J PERIODONTOL, V62, P499, DOI 10.1902/jop.1991.62.8.499; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASDRA EK, 1995, BBA-MOL CELL RES, V1268, P209, DOI 10.1016/0167-4889(95)00090-F; Basdra EK, 1997, EUR J ORTHODONT, V19, P615, DOI 10.1093/ejo/19.6.615; Bronckers ALJJ, 2001, MECH DEVELOP, V101, P255, DOI 10.1016/S0925-4773(00)00562-1; Carnes DL, 1997, J PERIODONTOL, V68, P701, DOI 10.1902/jop.1997.68.7.701; CARVALHO RS, 1995, ARCH ORAL BIOL, V40, P257, DOI 10.1016/0003-9969(95)98814-F; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Souza RN, 1999, DEVELOPMENT, V126, P2911; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franceschi RT, 1999, CRIT REV ORAL BIOL M, V10, P40, DOI 10.1177/10454411990100010201; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Karsenty G, 1999, GENE DEV, V13, P3037, DOI 10.1101/gad.13.23.3037; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052; Kletsas D, 1998, FEBS LETT, V430, P358, DOI 10.1016/S0014-5793(98)00695-4; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; LANYON LE, 1987, J BIOMECH, V20, P1083, DOI 10.1016/0021-9290(87)90026-1; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lekic P, 1996, ANAT REC, V245, P327; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Massague J, 2000, GENE DEV, V14, P627; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Pavlin D, 2000, CALCIFIED TISSUE INT, V67, P163, DOI 10.1007/s00223001105; Peverali FA, 2001, MOL MED, V7, P68, DOI 10.1007/BF03401840; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Schmidt C, 1998, J BIOL CHEM, V273, P5081, DOI 10.1074/jbc.273.9.5081; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Tsuji K, 1998, BONE, V22, P87, DOI 10.1016/S8756-3282(97)00267-6; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1998, GENE, V214, P187, DOI 10.1016/S0378-1119(98)00227-3; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; ZAMAN G, 1992, CALCIFIED TISSUE INT, V51, P132, DOI 10.1007/BF00298501	59	190	236	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23934	23941		10.1074/jbc.M109881200	http://dx.doi.org/10.1074/jbc.M109881200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960980	hybrid			2022-12-25	WOS:000176475700108
J	Boner, W; Taylor, ER; Tsirimonaki, E; Yamane, K; Campo, MS; Morgan, IM				Boner, W; Taylor, ER; Tsirimonaki, E; Yamane, K; Campo, MS; Morgan, IM			A functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATOR; BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; CAPSID PROTEIN; TYPE-16 E1; COACTIVATOR; REPLICATION; TFIIB	The human papillomavirus (HPV) transcription/replication factor E2 is essential for the life cycle of HPVs. E2 protein binds to DNA target sequences in the viral long control regions to regulate transcription of the viral genome. It also enhances viral DNA replication by interacting with the viral replication factor E1 and recruiting it to the origin of replication and may also play a more direct role in replication. The cellular proteins with which E2 interacts to carry out these functions are largely unknown. To identify these proteins a yeast two-hybrid screen was carried out with the transcription/ replication domain of HPV16 E2. This screen identified several candidate interacting partners for E2 including TopBP1 (topoisomerase IIbeta-binding protein 1). TopBP1 has eight BRCA1 carboxyl-terminal domains that are found in proteins regulating the DNA damage response, transcription, and replication. Here we demonstrate that HPV16 E2 and TopBP1 interact in vitro and in vivo and that TopBP1 can enhance the ability of E2 to activate transcription and replication. This is the first time that TopBP1 has been shown to function as a transcriptional coactivator and that E2 interacts with TopBP1. Removal of the amino-terminal domain of TopBP1 abolishes coactivation of transcription and replication. This interaction may have functional consequences upon the viral life cycle.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan	University of Glasgow; Beatson Institute; University of Tokyo	Morgan, IM (corresponding author), Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.	i.morgan@vet.gla.ac.uk						Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; Bakshi RP, 2001, CRIT REV BIOCHEM MOL, V36, P1, DOI 10.1080/20014091074165; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Day PM, 1998, J VIROL, V72, P142, DOI 10.1128/JVI.72.1.142-150.1998; Desaintes C, 1999, ONCOGENE, V18, P4538, DOI 10.1038/sj.onc.1202818; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gillitzer E, 2000, EMBO J, V19, P3069, DOI 10.1093/emboj/19.12.3069; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 2001, CELL GROWTH DIFFER, V12, P525; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Heino P, 2000, VIROLOGY, V276, P304, DOI 10.1006/viro.2000.0342; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Ilves I, 1999, J VIROL, V73, P4404, DOI 10.1128/JVI.73.5.4404-4412.1999; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; LAMBERT PF, 1989, GENE DEV, V3, P38, DOI 10.1101/gad.3.1.38; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Massimi P, 1999, ONCOGENE, V18, P7748, DOI 10.1038/sj.onc.1203208; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MORRISSEY LC, 1989, J VIROL, V63, P4422, DOI 10.1128/JVI.63.10.4422-4425.1989; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; ROMANCZUK H, 1990, J VIROL, V64, P2849, DOI 10.1128/JVI.64.6.2849-2859.1990; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Shimizu K, 2001, MOL CELL BIOL, V21, P3901, DOI 10.1128/MCB.21.12.3901-3912.2001; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; STEGER G, 1995, EMBO J, V14, P329, DOI 10.1002/j.1460-2075.1995.tb07007.x; Strasswimmer J, 1999, HUM MOL GENET, V8, P1219, DOI 10.1093/hmg/8.7.1219; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; Webster K, 2000, J BIOL CHEM, V275, P87, DOI 10.1074/jbc.275.1.87; Witt E, 2000, J MOL BIOL, V301, P1, DOI 10.1006/jmbi.2000.3959; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997	46	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22297	22303		10.1074/jbc.M202163200	http://dx.doi.org/10.1074/jbc.M202163200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934899	hybrid			2022-12-25	WOS:000176313600025
J	Bouyain, S; Silk, NJ; Fabini, G; Drickamer, K				Bouyain, S; Silk, NJ; Fabini, G; Drickamer, K			An endogenous Drosophila receptor for glycans bearing alpha 1,3-linked core fucose residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LECTIN-LIKE DOMAINS; CARBOHYDRATE-RECOGNITION; HORSERADISH-PEROXIDASE; GRASSHOPPER EMBRYOS; EPITOPE; SEQUENCE; SELECTIN; OLIGOSACCHARIDES; GLYCOPROTEINS	The genome of Drosophila melanogaster encodes several proteins that are predicted to contain Ca2+-dependent, C-type carbohydrate-recognition domains. The CG2958 gene encodes a protein containing 359 amino acid residues. Analysis of the CG2958 sequence suggests that it consists of an N-terminal domain found in other Drosophila proteins, a middle segment that is unique, and a C-terminal C-type carbohydrate-recognition domain. Expression studies show that the full-length protein is a tetramer formed by noncovalent association of disulfide-linked dimers that are linked through cysteine residues in the N-terminal domain. The expressed protein binds to immobilized yeast invertase through the C-terminal carbohydrate-recognition domain. Competition binding studies using monosaccharides demonstrate that CG2958 interacts specifically with fucose and mannose. Fucose binds similar to5-fold better than mannose. Blotting studies reveal that the best glycoprotein ligands are those that contain N-linked glycans bearing alpha1,3-linked fucose residues. Binding is enhanced by the additional presence of alpha1,6-linked fucose. It has previously been proposed that labeling of the Drosophila neural system by anti-horseradish peroxidase antibodies is a result of the presence of difucosylated N-linked glycans. CG2958 is a potential endogenous receptor for such neural-specific carbohydrate epitopes.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Agr Univ Vienna, Inst Chem, Glycobiol Div, A-1190 Vienna, Austria	University of Oxford; University of Natural Resources & Life Sciences, Vienna	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.							Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Blanck O, 1996, J BIOL CHEM, V271, P7289, DOI 10.1074/jbc.271.13.7289; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Bouyain S, 2001, GLYCOBIOLOGY, V11, P989, DOI 10.1093/glycob/11.11.989; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARR SA, 1986, ANAL BIOCHEM, V157, P396, DOI 10.1016/0003-2697(86)90643-3; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DORLAND L, 1981, J BIOL CHEM, V256, P7708; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Drickamer K, 1999, GLYCOBIOLOGY, V9, P1357, DOI 10.1093/glycob/9.12.1357; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GRAYEB J, 1984, EMBO J, V3, P2437; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; Ng KKS, 1997, BIOCHEMISTRY-US, V36, P979, DOI 10.1021/bi962564e; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Raju TS, 2000, GLYCOBIOLOGY, V10, P477, DOI 10.1093/glycob/10.5.477; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SNOW PM, 1987, J NEUROSCI, V7, P4137; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651	36	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22566	22572		10.1074/jbc.M202825200	http://dx.doi.org/10.1074/jbc.M202825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960993	hybrid			2022-12-25	WOS:000176313600062
J	Gascon, I; Carrascosa, JL; Villar, L; Lazaro, JM; Salas, M				Gascon, I; Carrascosa, JL; Villar, L; Lazaro, JM; Salas, M			Importance of the N-terminal region of the phage GA-1 single-stranded DNA-binding protein for its self-interaction ability and functionality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; HELICASE-PRIMASE; SSB PROTEINS; RECA PROTEIN; UL8 SUBUNIT; REPLICATION; PHI-29; POLYMERASE; ORIGIN	The single-stranded DNA-binding protein (SSB) of phage GA-1 displays higher efficiency than the SSBs of the related phages phi29 and Nf. In this work, the self-interaction ability of GA-1 SSB has been analyzed by visualization of the purified protein by electron microscopy, glycerol gradient sedimentation, and in vivo cross-linking of bacterial cultures infected with phage GA-1. GA-1 SSB contains an insert at its N-terminal region that is not present in the SSBs of 029 and Nf. Three deletion mutant proteins have been characterized, DeltaN19, DeltaN26, and DeltaN33, which lack the 19, 26 or 33 amino acids, respectively, that follow the initial methionine of GA-1 SSB. Mutant protein DeltaN19 retains the structural and functional behavior of GA-1 SSB, whereas mutant proteins DeltaN26 and DeltaN33 no longer stimulate viral DNA replication or display helix-destabilizing activity. Analysis of the mutant proteins by ultracentrifugation in glycerol gradients and electron microscopy indicates that deletion of 26 or 33 but not of 19 amino acids of the N-terminal region of GA-1 SSB results in the loss of the oligomerization ability of this protein. Our data support the importance of the N-terminal region of GA-1 SSB for the differential self-interaction ability and functional behavior of this protein.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [2R01 GM27242-23] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARWERT F, 1974, J VIROL, V13, P584, DOI 10.1128/JVI.13.3.584-589.1974; Beernink HTH, 1998, BIOCHEMISTRY-US, V37, P5673, DOI 10.1021/bi9800956; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; CARTHEW RW, 1985, CELL, V43, P438; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CLEAT PH, 1989, EMBO J, V8, P1841, DOI 10.1002/j.1460-2075.1989.tb03579.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; FOLMER RHA, 1994, EUR J BIOCHEM, V224, P663, DOI 10.1111/j.1432-1033.1994.00663.x; Gascon I, 2000, J MOL BIOL, V296, P989, DOI 10.1006/jmbi.2000.3521; Gascon I, 2000, NUCLEIC ACIDS RES, V28, P2034, DOI 10.1093/nar/28.10.2034; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Lazaro JM, 1995, METHOD ENZYMOL, V262, P42; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Mapelli M, 2000, J VIROL, V74, P8812, DOI 10.1128/JVI.74.19.8812-8822.2000; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; Masui R, 1998, BIOCHEMISTRY-US, V37, P14788, DOI 10.1021/bi981296c; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; Pecenkova T, 1999, J MOL EVOL, V48, P197, DOI 10.1007/PL00006458; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; Revzin A., 1990, BIOL NONSPECIFIC DNA; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1999, GENETIC ENG, V21; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SOENGAS MS, 1994, J MOL BIOL, V239, P213, DOI 10.1006/jmbi.1994.1364; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUIVER MH, 1990, J VIROL, V64, P379, DOI 10.1128/JVI.64.1.379-386.1990; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIKAWA H, 1986, J GEN APPL MICROBIOL, V32, P39, DOI 10.2323/jgam.32.39; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	50	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22534	22540		10.1074/jbc.M202430200	http://dx.doi.org/10.1074/jbc.M202430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956216	hybrid			2022-12-25	WOS:000176313600057
J	Kozlenkov, A; Manes, T; Hoylaerts, MF; Millan, JL				Kozlenkov, A; Manes, T; Hoylaerts, MF; Millan, JL			Function assignment to conserved residues in mammalian alkaline phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-BINDING; UNCOMPETITIVE INHIBITION; REACTION-MECHANISM; MUTAGENESIS; CATALYSIS; MUTATIONS	We have probed the structural/functional relationship of key residues in human placental alkaline phosphatase (PLAP) and compared their properties with those of the corresponding residues in Escherichia coli alkaline phosphatase (ECAP). Mutations were introduced in wild-type PLAP, i.e. [E429]PLAP, and in some instances also in [G429]PLAP, which displays properties characteristic of the human germ cell alkaline phosphatase isozyme. All active site metal ligands, as well as residues in their vicinity, were substituted to alanines or to the homologous residues present in ECAP. We found that mutations at Zn2 or Mg sites had similar effects in PLAP and ECAP but that the environment of the Zn1 ion in PLAP is less affected by substitutions than that in ECAP. Substitutions of the Mg and Zn1 neighboring residues His-317 and His-153 increased k(cat) and increased K-m when compared with wild-type PLAP, contrary to what was predicted by the reciprocal substitutions in ECAP. All mammalian alkaline phosphatases (APs) have five cysteine residues (Cys-101, Cys-121, Cys-183, Cys-467, and Cys-474) per subunit, not homologous to any of the four cysteines in ECAP. By substituting each PLAP Cys by Ser, we found that disrupting the disulfide bond between Cys-121 and Cys-183 completely prevents the formation of the active enzyme, whereas the carboxyl-terminally located Cys-467-Cys-474 bond plays a lesser structural role. The substitution of the free Cys-101 did not significantly affect the properties of the enzyme. A distinguishing feature found in all mammalian APs, but not in ECAP, is the Tyr-367 residue involved in subunit contact and located close to the active site of the opposite subunit. We studied the A367 and F367 mutants of PLAP, as well as the corresponding double mutants containing G429. The mutations led to a 2-fold decrease in k(cat), a significant decrease in heat stability, and a significant disruption of inhibition by the uncompetitive inhibitors L-Phe and L-Leu. Our mutagenesis data, computer modeling, and docking predictions indicate that this residue contributes to the formation of the hydrophobic pocket that accommodates and stabilizes the side chain of the inhibitor during uncompetitive inhibition of mammalian APs.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Umea Univ, Dept Med Biosci, S-90185 Umea, Sweden; Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Sanford Burnham Prebys Medical Discovery Institute; Umea University; KU Leuven	Millan, JL (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	millan@burnham.org	Millan, Jose Luis/B-6580-2008	Hoylaerts, Marc/0000-0002-6474-3933				BOSSI M, 1993, J BIOL CHEM, V268, P25409; DIMAURO S, 2002, IN PRESS J BONE MINE; FISHMAN WH, 1971, ENZYMOLOGIA, V41, P141; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x; HUMMER C, 1991, BIOCHEM J, V274, P91, DOI 10.1042/bj2740091; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; MA L, 1994, J BIOL CHEM, V269, P31614; McComb Jr RB, 1979, ALKALINE PHOSPHATASE, DOI 10.1007/978-1-4613-2970-1_4; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200; MURPHY JE, 1995, J MOL BIOL, V253, P604, DOI 10.1006/jmbi.1995.0576; OGATA S, 1988, J BIOL CHEM, V263, P10489; RAMASAMY I, 1975, BIOCHIM BIOPHYS ACTA, V384, P146, DOI 10.1016/0005-2744(75)90104-7; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Tibbitts TT, 1996, J MOL BIOL, V257, P700, DOI 10.1006/jmbi.1996.0195; WATANABE T, 1991, J BIOL CHEM, V266, P21174; XU X, 1994, BIOCHEMISTRY-US, V33, P2279, DOI 10.1021/bi00174a039; XU X, 1993, BIOCHEMISTRY-US, V32, P10683, DOI 10.1021/bi00091a019; XU X, 1992, J BIOL CHEM, V267, P16244	25	63	76	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22992	22999		10.1074/jbc.M202298200	http://dx.doi.org/10.1074/jbc.M202298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937510	hybrid			2022-12-25	WOS:000176313600114
J	Scott, RO; Thelin, WM; Milgram, SL				Scott, RO; Thelin, WM; Milgram, SL			A novel PDZ protein regulates the activity of guanylyl cyclase C, the heat-stable enterotoxin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN-MEDIATED INTERACTION; ESCHERICHIA-COLI; NA+/H+-EXCHANGER; INTESTINAL MEMBRANES; EPITHELIAL-CELLS; STRUCTURAL BASIS; MESSENGER-RNA; KINASE-A; PEPTIDE	Secretory diarrhea is the leading cause of infectious diarrhea in humans. Secretory diarrhea may be caused by binding of heat-stable enterotoxins to the intestinal receptor guanylyl cyclase C (GCC). Activation of GCC catalyzes the formation of cGMP, initiating a signaling cascade that opens the cystic fibrosis transmembrane conductance regulator chloride channel at the apical cell surface. To identify proteins that regulate the trafficking or function of GCC, we used the unique COOH terminus of GCC as the "bait" to screen a human intestinal yeast two-hybrid library. We identified a novel protein, IKEPP (intestinal and kidney-enriched PDZ protein) that associates with the COOH terminus of GCC in biochemical assays and by co-immunoprecipitation. IKEPP is expressed in the intestinal epithelium, where it is preferentially accumulated at the apical surface. The GCC-IKEPP interaction is not required for the efficient targeting of GCC to the apical cell surface. Rather, the association with IKEPP significantly inhibits heat-stable enterotoxin-mediated activation of GCC. Our findings are the first to identify a regulatory protein that associates with GCC to modulate the catalytic activity of the enzyme and provides new insights in mechanisms that regulate GCC activity in response to bacterial toxin.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63755] Funding Source: Medline; NIDDK NIH HHS [R29DK50744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; BENHAROUGA M, 2001, 15 ANN N AM CYST FIB; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carrithers SL, 2000, REGUL PEPTIDES, V95, P65, DOI 10.1016/S0167-0115(00)00139-7; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN MB, 1992, BIOCHEM BIOPH RES CO, V186, P483, DOI 10.1016/S0006-291X(05)80833-2; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DESHMANE SP, 1995, BIOCHEMISTRY-US, V34, P9095, DOI 10.1021/bi00028a019; Deshmane SP, 1997, BIOCHEMISTRY-US, V36, P12921, DOI 10.1021/bi971077b; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Forte LR, 1999, ENDOCRINOLOGY, V140, P1800, DOI 10.1210/en.140.4.1800; FORTE LR, 2000, J PHYSL, V278, pF180; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; HAKKI S, 1993, INT J BIOCHEM, V25, P557, DOI 10.1016/0020-711X(93)90664-Z; HAKKI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P1, DOI 10.1016/0005-2736(93)90224-N; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; Harris BZ, 2001, J CELL SCI, V114, P3219; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; HIRAYAMA T, 1993, MICROB PATHOGENESIS, V15, P283, DOI 10.1006/mpat.1993.1078; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kocher O, 1999, LAB INVEST, V79, P1161; LI ZP, 1993, AM J PHYSIOL, V265, pG394, DOI 10.1152/ajpgi.1993.265.2.G394; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nandi A, 1997, J CELL BIOCHEM, V66, P500, DOI 10.1002/(SICI)1097-4644(19970915)66:4<500::AID-JCB9>3.0.CO;2-P; Pucilowska JB, 2000, AM J PHYSIOL-GASTR L, V279, pG1307, DOI 10.1152/ajpgi.2000.279.6.G1307; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 2001, J CELL BIOL, V153, P191, DOI 10.1083/jcb.153.1.191; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Schulz S, 1997, J CLIN INVEST, V100, P1590, DOI 10.1172/JCI119683; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swenson ES, 1996, BIOCHEM BIOPH RES CO, V225, P1009, DOI 10.1006/bbrc.1996.1286; Trotter KW, 1999, J CELL BIOL, V147, P1481, DOI 10.1083/jcb.147.7.1481; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409; Vijayachandra K, 2000, BIOCHEMISTRY-US, V39, P16075, DOI 10.1021/bi0013849; Wada A, 1996, FEBS LETT, V384, P75; WALDMAN SA, 1986, INFECT IMMUN, V51, P320, DOI 10.1128/IAI.51.1.320-326.1986; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	56	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22934	22941		10.1074/jbc.M202434200	http://dx.doi.org/10.1074/jbc.M202434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950846	hybrid, Green Published			2022-12-25	WOS:000176313600106
J	Werner, AB; de Vries, E; Tait, SWG; Bontjer, I; Borst, J				Werner, AB; de Vries, E; Tait, SWG; Bontjer, I; Borst, J			Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit its collaboration with pro-apoptotic Bak or Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CYTOCHROME-C RELEASE; ALPHA-INDUCED APOPTOSIS; CELL-DEATH; BH3 DOMAIN; MITOCHONDRIAL APOPTOSIS; P53-INDUCED APOPTOSIS; CASPASE ACTIVATION; SIGNALING PATHWAYS	Following caspase-8 mediated cleavage, a carboxyl-terminal fragment of the BH3 domain-only Bcl-2 family member Bid transmits the apoptotic signal from death receptors to mitochondria. In a screen for possible regulators of Bid, we defined Bfl-1/A1 as a potent Bid interacting protein. Bfl-1 is an anti-apoptotic Bcl-2 family member, whose preferential expression in hematopoietic cells and endothelium is controlled by inflammatory stimuli. Its mechanism of action is unknown. We find that Bfl-1 associates with both full-length Bid and truncated (t)Bid, via the Bid BH3 domain. Cellular expression of Bfl-1 confers protection against CD95- and Trail receptor-induced cytochrome c release. In vitro assays, using purified mitochondria and recombinant proteins, demonstrate that Bfl-1 binds full-length Bid, but does not interfere with its processing by caspase-8, or with its mitochondrial association. Confocal microscopy supports that Bfl-1, which at least in part constitutively localizes to mitochondria, does not impede tBid translocation. However, Bfl-1 remains tightly and selectively bound to tBid and blocks collaboration between tBid and Bax or Bak in the plane of the mitochondrial membrane, thereby preventing mitochondrial apoptotic activation. Lack of demonstrable interaction between Bfl-1 and Bak or Bax in the mitochondrial membrane suggests that Bfl-1 generally prevents the formation of a pro-apoptotic complex by sequestering BH3 domain-only proteins.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.			Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOI SS, 1995, ONCOGENE, V11, P1693; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DSaEipper C, 1996, CANCER RES, V56, P3879; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kenny JJ, 1997, ONCOGENE, V14, P997, DOI 10.1038/sj.onc.1200898; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN EY, 1993, J IMMUNOL, V151, P1979; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orlofsky A, 1999, J IMMUNOL, V163, P412; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	140	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22781	22788		10.1074/jbc.M201469200	http://dx.doi.org/10.1074/jbc.M201469200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11929871	hybrid			2022-12-25	WOS:000176313600087
J	Yang, HJ; Chiang, JH; Fitz-Gibbon, S; Lebel, M; Sartori, AA; Jiricny, J; Slupska, MM; Miller, JH				Yang, HJ; Chiang, JH; Fitz-Gibbon, S; Lebel, M; Sartori, AA; Jiricny, J; Slupska, MM; Miller, JH			Direct interaction between uracil-DNA glycosylase and a proliferating cell nuclear antigen homolog in the crenarchaeon Pyrobaculum aerophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE PROCESSIVITY FACTOR; CLAMP-LOADER COMPLEX; REPLICATION FACTOR-C; CRYSTAL-STRUCTURE; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL INTERACTIONS; FLAP ENDONUCLEASE; SLIDING CLAMPS; ARCHAEON; PCNA	Proliferating cell nuclear antigen (PCNA) acts as a sliding clamp on duplex DNA. Its homologs, present in Eukarya and Archaea, are part of protein complexes that are indispensable for DNA replication and DNA repair. In Eukarya, PCNA is known to interact with more than a dozen different proteins, including a human major nuclear uracil-DNA glycosylase (hUNG2) involved in immediate postreplicative repair. In Archaea, only three classes of PCNA-binding proteins have been reported previously: replication factor C (the PCNA clamp loader), family B DNA polymerase, and flap endonuclease. In this study, we report a direct interaction between a uracil-DNA glycosylase (Pa-UDGa) and a PCNA homolog (Pa-PCNA1), both from the hyperthermophilic crenarchaeon Pyrobaculum aerophilum (T-opt = 100 degreesC). We demonstrate that the Pa-UDGa-Pa-PCNA1 complex is thermostable, and two hydrophobic amino acid residues on Pa-UDGa (Phe(191) and Len(192)) are shown to be crucial for this interaction. It is interesting to note that although Pa-UDGa has homologs throughout the Archaea and bacteria, it does not share significant sequence similarity with hUNG2. Nevertheless, our results raise the possibility that Pa-UDGa may be a functional analog of hUNG2 for PCNA-dependent postreplicative removal of misincorporated uracil.	Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; CHUQ, Ctr Rech Cancerol, Quebec City, PQ GIR 2J6, Canada; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Laval University; University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Miller, JH (corresponding author), Univ Calif Los Angeles, Dept Microbiol & Mol Genet, 1602 Mol Sci Bldg,405 Hilgard Ave, Los Angeles, CA 90095 USA.	jhmiller@mbi.ucla.edu	Sartori, Alessandro/AAK-7840-2021	Sartori, Alessandro/0000-0003-2770-0333	NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057917] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09056] Funding Source: Medline; NIGMS NIH HHS [GM 57917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruck I, 2001, GENOME BIOL, V2; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; FUCHS R, 1994, COMPUT APPL BIOSCI, V10, P171; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hinks JA, 2002, J BIOL CHEM, V277, P16936, DOI 10.1074/jbc.M200668200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Iwai T, 2000, EXTREMOPHILES, V4, P357, DOI 10.1007/s007920070005; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; Krude T, 1999, CURR BIOL, V9, pR394, DOI 10.1016/S0960-9822(99)80251-6; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Matsui E, 1999, J BIOL CHEM, V274, P18297, DOI 10.1074/jbc.274.26.18297; Matsumiya S, 2001, PROTEIN SCI, V10, P17, DOI 10.1110/ps.36401; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Rao HGV, 1998, J BACTERIOL, V180, P5406, DOI 10.1128/JB.180.20.5406-5412.1998; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002	41	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22271	22278		10.1074/jbc.M201820200	http://dx.doi.org/10.1074/jbc.M201820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11927597	hybrid, Green Accepted			2022-12-25	WOS:000176313600022
J	Zhu, YH; Mao, XO; Sun, YJ; Xia, ZG; Greenberg, DA				Zhu, YH; Mao, XO; Sun, YJ; Xia, ZG; Greenberg, DA			p38 mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOREGULATORY FEEDBACK LOOP; GROWTH-FACTOR; INDUCED APOPTOSIS; DOWN-REGULATION; UV-RADIATION; PC12 CELLS; DEGRADATION; UBIQUITINATION; PATHWAY; EXPRESSION	The multifunctional tumor suppressor protein, p53, inhibits cell growth and promotes differentiation and programmed cell death. p53 activity is controlled by transcriptional, translational, and post-translational regulation. A major pathway for post-translational regulation of p53 comprises its nucleocytoplasmic transport and subsequent proteasomal degradation, which involves binding to the oncoprotein, murine double minute-2 (Mdm2). Hypoxia and other stress signals cause cellular injury partly through the action of p53. In this study, we show that hypoxia induces down-regulation of Mdm2 as well as serine 15 phosphorylation and nuclear accumulation of p53 in cultured cortical neurons from E16 mice. These effects are diminished by the p38 mitogen-activated protein kinase inhibitors SB203580 and SB202190, but not by the inactive analog SB202474, and by a dominant-interfering mutant of the p38-activating kinase mitogen-activated protein kinase kinase 3 (MKK3). Hypoxic neuronal death was also reduced by p38 inhibitors, by dominant-interfering MKK3, and by a p53-antisense oligodeoxynucleotide and was increased by a constitutively active form of p38 and by an Mdm2-antisense oligodeoxynucleotide. These results demonstrate that p38 and Mdm2 have roles in coupling hypoxic-ischemic neuronal insults to activation of p53 and hypoxic cell death.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA	Buck Institute for Research on Aging; University of Washington; University of Washington Seattle	Greenberg, DA (corresponding author), 8001 Redwood Blvd, Novato, CA 94945 USA.				NINDS NIH HHS [NS35965] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS035965] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alarcon R, 1999, CANCER RES, V59, P6046; Almog Nava, 1998, Biochimica et Biophysica Acta, V1378, pR43; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Haas M, 2000, J BIOL CHEM, V275, P27832; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Tan Z, 2000, CELL DEATH DIFFER, V7, P675, DOI 10.1038/sj.cdd.4400697; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Trinh E, 2001, MOL CELL NEUROSCI, V17, P342, DOI 10.1006/mcne.2000.0928; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 1996, J NEUROSCI, V16, P6753; Zhu YH, 1999, BIOCHEM BIOPH RES CO, V258, P87, DOI 10.1006/bbrc.1999.0586	41	81	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22909	22914		10.1074/jbc.M200042200	http://dx.doi.org/10.1074/jbc.M200042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948180	hybrid			2022-12-25	WOS:000176313600103
J	Kukor, Z; Mayerle, J; Kruger, B; Toth, M; Steed, PM; Halangk, W; Lerch, MM; Sahin-Toth, M				Kukor, Z; Mayerle, J; Kruger, B; Toth, M; Steed, PM; Halangk, W; Lerch, MM; Sahin-Toth, M			Presence of cathepsin B in the human pancreatic secretory pathway and its role in trypsinogen activation during hereditary pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CATIONIC TRYPSINOGEN; HEPATOCYTE LYSOSOMES; PROTON PUMP; IN-VITRO; MUTATIONS; PREMATURE; PRSS1; GENE; SITE; CELL	The lysosomal cysteine protease cathepsin B is thought to play a central role in intrapancreatic trypsinogen activation and the onset of experimental pancreatitis. Recent in vitro studies have suggested that this mechanism might be of pathophysiological relevance in hereditary pancreatitis, a human inborn disorder associated with mutations in the cationic trypsinogen gene. In the present study evidence is presented that cathepsin B is abundantly present in the secretory compartment of the human exocrine pancreas, as judged by immunogold electron microscopy. Moreover, pro-cathepsin B and mature cathepsin B are both secreted together with trypsinogen and active trypsin into the pancreatic juice of patients with sporadic pancreatitis or hereditary pancreatitis. Finally, cathepsin B-catalyzed activation of recombinant human cationic trypsinogen with hereditary pancreatitis-associated mutations N291, N29T, or R122H were characterized. In contrast to a previous report, cathepsin B-mediated activation of wild type and all three mutant trypsinogen forms was essentially identical under a wide range of experimental conditions. These observations confirm the presence of active cathepsin B in the human pancreatic secretory pathway and are consistent with the notion that cathepsin B-mediated trypsinogen activation might play a pathogenic role in human pancreatitis. On the other hand, the results clearly demonstrate that hereditary pancreatitis-associated mutations do not lead to increased or decreased trypsinogen activation by cathepsin B. Therefore, mutation-dependent alterations in cathepsin B-induced trypsinogen activation are not the cause of hereditary pancreatitis.	Univ Calif Los Angeles, HHMI, Dept Physiol, MacDonald Res Labs 5 748, Los Angeles, CA 90095 USA; Univ Munster, Dept Med B, D-48129 Munster, Germany; Univ Rostock, Dept Pathol, Div Med Biol, D-18057 Rostock, Germany; Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1088 Budapest, Hungary; Novartis Pharmaceut, Res Dept, Summit, NJ 07901 USA; Otto von Guericke Univ, Dept Surg, D-39120 Magdeburg, Germany	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Munster; University of Rostock; Semmelweis University; Novartis; Otto von Guericke University	Sahin-Toth, M (corresponding author), Univ Calif Los Angeles, HHMI, Dept Physiol, MacDonald Res Labs 5 748, Box 951662, Los Angeles, CA 90095 USA.	miklos@hhmi.ucla.edu	Lerch, Markus M./E-2206-2016; Mayerle, Julia/W-7907-2019	Lerch, Markus M./0000-0002-9643-8263; Sahin-Toth, Miklos/0000-0003-4513-9922	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58088] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Chen JM, 2000, GASTROENTEROLOGY, V119, P277, DOI 10.1016/S0016-5085(00)70073-4; Chen JM, 2001, HUM GENET, V109, P245, DOI 10.1007/s004390100580; Ferec C, 1999, J MED GENET, V36, P228; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; Grady T, 1998, AM J PHYSIOL-GASTR L, V275, pG1010, DOI 10.1152/ajpgi.1998.275.5.G1010; GREENBAUM LM, 1959, J BIOL CHEM, V234, P2885; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Halangk W, 2002, AM J PHYSIOL-GASTR L, V282, pG367, DOI 10.1152/ajpgi.00315.2001; HIRANO T, 1991, J CLIN INVEST, V87, P865, DOI 10.1172/JCI115091; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; Kruger B, 2001, BIOCHEM BIOPH RES CO, V282, P159, DOI 10.1006/bbrc.2001.4561; KRUGER B, 1990, FRESEN J ANAL CHEM, V337, P101; Kukor Z, 2002, J BIOL CHEM, V277, P6111, DOI 10.1074/jbc.M110959200; Le Marechal C, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-19; Lerch MM, 1997, GASTROENTEROLOGY, V113, P1355, DOI 10.1053/gast.1997.v113.pm9322531; Lerch MM, 2000, MED CLIN N AM, V84, P549, DOI 10.1016/S0025-7125(05)70239-X; LERCH MM, 1993, GASTROENTEROLOGY, V104, P1768, DOI 10.1016/0016-5085(93)90658-Y; Lerch MM, 2000, ADV EXP MED BIOL, V477, P403; Mooren FC, 2001, FASEB J, V15, P659, DOI 10.1096/fj.00-0172com; MORIYAMA Y, 1992, FEBS LETT, V302, P18, DOI 10.1016/0014-5793(92)80274-K; MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423; MYERS BM, 1993, GASTROENTEROLOGY, V105, P1814, DOI 10.1016/0016-5085(93)91080-2; NIEDERAU C, 1988, J CLIN INVEST, V81, P229, DOI 10.1172/JCI113300; NIEDERAU C, 1986, GASTROENTEROLOGY, V91, P1433, DOI 10.1016/0016-5085(86)90197-6; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; Pfutzer R, 2002, GUT, V50, P271, DOI 10.1136/gut.50.2.271; Ren WP, 1996, BIOCHEM J, V319, P793, DOI 10.1042/bj3190793; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 2001, PANCREATOLOGY, V1, P461, DOI 10.1159/000055848; SALUJA A, 1987, AM J PHYSIOL, V253, pG508, DOI 10.1152/ajpgi.1987.253.4.G508; Saluja AK, 1997, GASTROENTEROLOGY, V113, P304, DOI 10.1016/S0016-5085(97)70108-2; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; Simon P, 2002, J BIOL CHEM, V277, P5404, DOI 10.1074/jbc.M108073200; Steed PM, 1998, PROTEIN SCI, V7, P2033, DOI 10.1002/pro.5560070920; STEER ML, 1987, NEW ENGL J MED, V316, P144; Szilagyi L, 2001, J BIOL CHEM, V276, P24574, DOI 10.1074/jbc.M011374200; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; Teich N, 1998, HUM MUTAT, V12, P39, DOI 10.1002/(SICI)1098-1004(1998)12:1<39::AID-HUMU6>3.0.CO;2-P; TOOZE J, 1991, EUR J CELL BIOL, V56, P187; VANDYKE RW, 1992, BIOCHEM BIOPH RES CO, V184, P300, DOI 10.1016/0006-291X(92)91192-S; WATANABE O, 1984, AM J PHYSIOL, V246, pG457, DOI 10.1152/ajpgi.1984.246.4.G457; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	49	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21389	21396		10.1074/jbc.M200878200	http://dx.doi.org/10.1074/jbc.M200878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11932257	hybrid			2022-12-25	WOS:000176286000036
J	Mansy, SS; Wu, G; Surerus, KK; Cowan, JA				Mansy, SS; Wu, G; Surerus, KK; Cowan, JA			Iron-sulfur cluster biosynthesis - Thermatoga maritima IscU is a structured iron-sulfur cluster assembly protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-SERINE MUTANTS; NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; THERMOTOGA-MARITIMA; 2FE-2S FERREDOXIN; SECONDARY STRUCTURE; MEMBRANE PROTEINS; IDENTIFICATION; SPECTROSCOPY	Genetic evidence has indicated that Isc proteins play an important role in iron-sulfur cluster biogenesis. In particular, IscU is believed to serve as a scaffold for the assembly of a nascent iron-sulfur cluster that is subsequently delivered to target iron-sulfur apoproteins. We report the characterization of an IscU from Thermatoga maritima, an evolutionarily ancient hyperthermophilic bacterium. The stabilizing influence of a D40A substitution allowed characterization of the holoprotein. Mossbauer (delta = 0.29 +/- 0.03 mm/s, DeltaE(Q) = 0.58 +/- 0.03 mm/s), UV-visible absorption, and circular dichroism studies of the D40A protein show that T. maritima IscU coordinates a [2Fe-2S](2+) cluster. Thermal denaturation experiments demonstrate that T. maritima IscU is a thermally stable protein with a thermally unstable cluster. This is also the first IscU type domain that is demonstrated to possess a high degree of secondary and tertiary structure. CD spectra indicate 36.7% alpha-helix, 13.1% antiparallel beta-sheet, 11.3% parallel beta-sheet, 20.2% beta-turn, and 19.1% other at 20 degreesC, with negligible spectral change observed at 70 degreesC. Cluster coordination also has no effect on the secondary structure of the protein. The dispersion of signals in H-1-N-15 heteronuclear single quantum correlation NMR spectra of wild type and D40A IscU supports the presence of significant tertiary structure for the apoprotein, consistent with a scaffolding role, and is in marked contrast to other low molecular weight Fe-S proteins where cofactor coordination is found to be necessary for proper protein folding. Consistent with the observed sequence homology and proposed conservation of function for IscU-type proteins, we demonstrate T. maritima IscU-mediated reconstitution of human apoferredoxin.	Ohio State Univ, Evans Lab Chem, Columbus, OH 43210 USA; Univ Wisconsin, Dept Chem, Milwaukee, WI 53201 USA	University System of Ohio; Ohio State University; University of Wisconsin System; University of Wisconsin Milwaukee	Cowan, JA (corresponding author), Ohio State Univ, Evans Lab Chem, 100 W 18th Ave, Columbus, OH 43210 USA.		Mansy, Sheref/E-6266-2010	Mansy, Sheref/0000-0003-2382-198X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008512] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08512-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; AGARWAL A, 1993, BIOCHEM BIOPH RES CO, V197, P1357, DOI 10.1006/bbrc.1993.2626; Bates DM, 2000, J BIOL CHEM, V275, P6234, DOI 10.1074/jbc.275.9.6234; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bocchetta M, 2000, J MOL EVOL, V50, P366, DOI 10.1007/s002399910040; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Hagen WR, 2000, J BIOL INORG CHEM, V5, P527, DOI 10.1007/s007750050013; HALL DO, 1971, NATURE, V233, P136, DOI 10.1038/233136a0; HINDENNACH I, 1975, EUR J BIOCHEM, V59, P207, DOI 10.1111/j.1432-1033.1975.tb02443.x; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P15109, DOI 10.1021/bi972001i; Hwang DM, 1996, J MOL EVOL, V43, P536, DOI 10.1007/PL00006114; Iametti S, 2001, EUR J BIOCHEM, V268, P2421, DOI 10.1046/j.1432-1327.2001.02130.x; JACOBSON MR, 1989, MOL GEN GENET, V219, P45; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Jung YS, 1999, J BIOL CHEM, V274, P2978, DOI 10.1074/jbc.274.5.2978; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Michelini ET, 1999, J BACTERIOL, V181, P4237, DOI 10.1128/JB.181.14.4237-4244.1999; Muller K, 1998, EUR J BIOCHEM, V258, P1001, DOI 10.1046/j.1432-1327.1998.2581001.x; Natarajan K, 1997, J AM CHEM SOC, V119, P4082, DOI 10.1021/ja9639729; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Pfeil W, 1997, J MOL BIOL, V272, P591, DOI 10.1006/jmbi.1997.1278; Pozdnyakova I, 2001, J AM CHEM SOC, V123, P10135, DOI 10.1021/ja016252x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNAITMAN CA, 1974, J BACTERIOL, V118, P442, DOI 10.1128/JB.118.2.442-453.1974; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Verhagen MFJM, 2001, BBA-BIOENERGETICS, V1505, P209, DOI 10.1016/S0005-2728(01)00166-9; Vidakovic MS, 1996, J BIOL CHEM, V271, P14734, DOI 10.1074/jbc.271.25.14734; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Xia B, 1996, BIOCHEMISTRY-US, V35, P9488, DOI 10.1021/bi960467f; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	45	79	79	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21397	21404		10.1074/jbc.M201439200	http://dx.doi.org/10.1074/jbc.M201439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934893	hybrid			2022-12-25	WOS:000176286000037
J	Nair, AK; Kash, JC; Peegel, H; Menon, KMJ				Nair, AK; Kash, JC; Peegel, H; Menon, KMJ			Post-transcriptional regulation of luteinizing hormone receptor mRNA in the ovary by a novel mRNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; INDUCED DOWN-REGULATION; CODING REGION; RIBONUCLEIC-ACID; HALF-LIFE; DEGRADATION; STABILITY; CELLS; SEQUENCE; STEP	Luteinizing hormone (LH) receptor mRNA is post-transcriptionally regulated. An ovarian cytosolic LH receptor mRNA-binding protein (LRBP) identified in our laboratory binds to a polypyrimidine-rich bipartite sequence in the coding region of LH receptor mRNA. The present studies show a role for LRBP in the regulation of LH receptor mRNA. We demonstrated that increased LH receptor mRNA degradation occurs during hormone-induced LH receptor down-regulation. Furthermore, increased degradation of LH receptor mRNA was seen when partially purified LRBP was included in an in vitro mRNA decay reaction. The LH receptor mRNA binding activity of LRBP measured by RNA electrophoretic mobility shift analysis showed an inverse relationship to LH receptor mRNA levels during different physiological states. These results suggest that LRBP is a physiological regulator of LHR mRNA expression in the ovary and provides a novel mechanism for the regulation of LH receptor expression in the ovary.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Obstet Gynecol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Menon, KMJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 6428 Med Sci Bldg I,1301 Catherine, Ann Arbor, MI 48109 USA.		Kash, John/ABE-8280-2021		NICHD NIH HHS [HD-06656, 5-T32-HD-07048] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD006656] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007048, R37HD006656] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMP TA, 1991, MOL ENDOCRINOL, V5, P1405, DOI 10.1210/mend-5-10-1405; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GOLOS TG, 1987, J CLIN INVEST, V80, P896, DOI 10.1172/JCI113149; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HOFFMAN YM, 1991, ENDOCRINOLOGY, V128, P388, DOI 10.1210/endo-128-1-388; Kash JC, 1998, J BIOL CHEM, V273, P10658, DOI 10.1074/jbc.273.17.10658; Kash JC, 1999, BIOCHEMISTRY-US, V38, P16889, DOI 10.1021/bi9915770; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAPOLT PS, 1990, ENDOCRINOLOGY, V126, P3277, DOI 10.1210/endo-126-6-3277; LU DL, 1993, ENDOCRINOLOGY, V132, P235, DOI 10.1210/en.132.1.235; NAKAMURA K, 1990, BIOCHEM BIOPH RES CO, V172, P786, DOI 10.1016/0006-291X(90)90743-7; PEEGEL H, 1994, ENDOCRINOLOGY, V135, P1044, DOI 10.1210/en.135.3.1044; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROSS J, 1993, RNA PROTEIN INTERACT, P459; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; VEYRUNE JL, 1995, ONCOGENE, V11, P2127; Zhang MC, 1999, MOL CELL BIOL, V19, P7314	28	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21468	21473		10.1074/jbc.M111653200	http://dx.doi.org/10.1074/jbc.M111653200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940568	hybrid			2022-12-25	WOS:000176286000046
J	Ninomiya, T; Sugiura, N; Tawada, A; Sugimoto, K; Watanabe, H; Kimata, K				Ninomiya, T; Sugiura, N; Tawada, A; Sugimoto, K; Watanabe, H; Kimata, K			Molecular cloning and characterization of chondroitin polymerase from Escherichia coli strain K4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUCUMBER STICHOPUS-JAPONICUS; CAPSULE GENE-CLUSTER; PASTEURELLA-MULTOCIDA; SEA-CUCUMBER; SULFATE PROTEOGLYCANS; HYALURONAN SYNTHASE; NUCLEOTIDE-SEQUENCE; SQUID CARTILAGE; GLUCURONIC-ACID; ELEMENT IS2	Escherichia coli strain K4 produces the K4 antigen, a capsule polysaccharide consisting of a chondroitin backbone (GlcUA beta(1-3)-GalNAc beta(1-4))(n) to which beta-fructose is linked at position C-3 of the GlcUA residue. We molecularly cloned region 2 of the K4 capsular gene cluster essential for biosynthesis of the polysaccharide, and we further identified a gene encoding a bifunctional glycosyltransferase that polymerizes the chondroitin backbone. The enzyme, containing two conserved glycosyltransferase sites, showed 59 and 61% identity at the amino acid level to class 2 hyaluronan synthase and chondroitin synthase from Pasteurella multocida, respectively. The soluble enzyme expressed in a bacterial expression system transferred GalNAc and GlcUA residues alternately, and polymerized the chondroitin chain up to a molecular mass of 20 kDa when chondroitin sulfate hexasaccharide was used as an acceptor. The enzyme exhibited apparent K-m values for UDP-GlcUA and UDP-GalNAc of 3.44 and 31.6 muM, respectively, and absolutely required acceptors of chondroitin sulfate polymers and oligosaccharides at least longer than a tetrasaccharide. In addition, chondroitin polymers and oligosaccharides and hyaluronan polymers and oligosaccharides served as acceptors for chondroitin polymerization, but dermatan sulfate and heparin did not. These results may lead to elucidation of the mechanism for chondroitin chain synthesis in both microorganisms and mammals.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Hokkaido Univ, Grad Sch Sci, Dept Chem, Sapporo, Hokkaido 0600810, Japan	Aichi Medical University; Seikagaku Corporation; Hokkaido University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@aichi-med-u.ac.jp		Watanabe, Hideto/0000-0001-5291-0696				BOULNOIS GJ, 1989, MOL MICROBIOL, V3, P1819, DOI 10.1111/j.1365-2958.1989.tb00168.x; Boyce JD, 2000, VET MICROBIOL, V72, P121, DOI 10.1016/S0378-1135(99)00193-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAUDE N, 1995, BIOCHEM MOL MED, V56, P1, DOI 10.1006/bmme.1995.1048; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; DAVID G, 1989, J CELL BIOL, V108, P1165, DOI 10.1083/jcb.108.3.1165; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; GHOSAL D, 1979, NUCLEIC ACIDS RES, V6, P1111, DOI 10.1093/nar/6.3.1111; Griffiths G, 1998, J BIOL CHEM, V273, P11752, DOI 10.1074/jbc.273.19.11752; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Hodson N, 2000, J BIOL CHEM, V275, P27311; HU ST, 1988, MOL GEN GENET, V214, P490, DOI 10.1007/BF00330485; HU ST, 1987, GENE, V55, P157, DOI 10.1016/0378-1119(87)90276-9; INOUE Y, 1981, CARBOHYD RES, V97, P263, DOI 10.1016/S0008-6215(00)80672-2; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Kariya Y, 1997, CARBOHYD RES, V297, P273, DOI 10.1016/S0008-6215(96)00258-3; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KIMATA K, 1974, J BIOL CHEM, V249, P1646; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lidholt K, 1997, J BIOL CHEM, V272, P2682, DOI 10.1074/jbc.272.5.2682; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; Prydz K, 2000, J CELL SCI, V113, P193; ROBERTS I, 1986, J BACTERIOL, V168, P1228, DOI 10.1128/jb.168.3.1228-1233.1986; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; RONECKER HJ, 1987, GENE, V59, P291, DOI 10.1016/0378-1119(87)90337-4; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; STAUFFER GV, 1981, GENE, V14, P63, DOI 10.1016/0378-1119(81)90148-7; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Townsend KM, 2001, J CLIN MICROBIOL, V39, P924, DOI 10.1128/JCM.39.3.924-929.2001; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VYNIOS DH, 1990, BIOCHIM BIOPHYS ACTA, V1033, P139, DOI 10.1016/0304-4165(90)90004-G; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Zako M, 1997, J NEUROCHEM, V69, P2155	48	82	98	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21567	21575		10.1074/jbc.M201719200	http://dx.doi.org/10.1074/jbc.M201719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943778	hybrid			2022-12-25	WOS:000176286000060
J	Wilson, IBH				Wilson, IBH			Functional characterization of Drosophila melanogaster peptide O-xylosyltransferase, the key enzyme for proteoglycan chain initiation and member of the core 2/I N-acetylglucosaminyltransferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-D-XYLOSE; BETA-D-XYLOSYLTRANSFERASE; PROTEIN LINKAGE REGION; HEPARAN-SULFATE; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; CHONDROITIN SULFATE; STRUCTURAL-ANALYSIS; TOUT-VELU; GENE	Chondroitin and heparan sulfates are essential players in animal development and are synthesized by a series of glycosyltransferases, the first of which is UDP-alpha-D-xylose:proteoglyean core protein beta-D-xylosyltransferase (EC 2.4.2.26). In the present study, a Drosophila melanogaster gene (CG17771), previously designated as a homologue of core 2 and I beta1,6-N-acetylglucosaminyltransferases, was shown to encode an active peptide O-xylosyltransferase. A novel coupled assay using matrix-assisted laser desorption ionization time-of-flight mass spectrometry demonstrated transfer of xylose to the peptide DDDSIEGSGGR. Analysis of sequences of various peptide O-xylosyltransferase and beta1,6-N-acetyl-glucosaminyltransferase sequences indicates that they are members of a large multifunctional protein family with a range of roles in U-glycosylation of either peptide or glycan substrates. Because in contrast to mammals, there is only one fly peptide O-xylosyltransferase gene, it is anticipated that, given the key roles of proteoglycans, the hereby designated oxt gene is essential for viability.	Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna	Wilson, IBH (corresponding author), Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, Muthgasse 18, A-1190 Vienna, Austria.	iwilson@edv2.boku.ac.at	Wilson, Iain/B-3326-2009	Wilson, Iain/0000-0001-8996-1518				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Benevolenskaya EV, 1998, MOL GEN GENET, V260, P131, DOI 10.1007/s004380050879; BIERHUIZEN MFA, 1995, GLYCOBIOLOGY, V5, P417, DOI 10.1093/glycob/5.4.417; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CAMBIAZO V, 1990, COMP BIOCHEM PHYS B, V97, P307, DOI 10.1016/0305-0491(90)90286-3; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Ebner A, 2002, GENE, V287, P55, DOI 10.1016/S0378-1119(01)00895-2; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; Kim BT, 2002, J BIOL CHEM, V277, P13659, DOI 10.1074/jbc.M111630200; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Krause E, 1999, ANAL CHEM, V71, P4160, DOI 10.1021/ac990298f; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Majewska-Sawka A, 2000, PLANT PHYSIOL, V122, P3, DOI 10.1104/pp.122.1.3; Mirgorodskaya E, 2001, ANAL CHEM, V73, P1263, DOI 10.1021/ac001288d; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Pfeil U, 2000, GLYCOBIOLOGY, V10, P803, DOI 10.1093/glycob/10.8.803; POWERS PA, 1991, GENETICS, V129, P133; SCHWARTZ NB, 1974, CARBOHYD RES, V37, P167, DOI 10.1016/S0008-6215(00)87072-X; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; SEGEEV P, 2001, DEV DYNAM, V220, P122; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Warren CE, 2001, GLYCOBIOLOGY, V11, P979, DOI 10.1093/glycob/11.11.979	43	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21207	21212		10.1074/jbc.M201634200	http://dx.doi.org/10.1074/jbc.M201634200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929872	hybrid			2022-12-25	WOS:000176286000013
J	Englert, RP; Shacter, E				Englert, RP; Shacter, E			Distinct modes of cell death induced by different reactive oxygen species - Amino acyl chloramines mediate hypochlorous acid-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; HUMAN NEUTROPHILS EMPLOY; HYDROGEN-PEROXIDE; N-CHLOROTAURINE; GROWTH ARREST; MYELOPEROXIDASE; TAURINE; CHLORINATION; OXIDATION; CHOLESTEROL	Oxidants derived from inflammatory phagocytes compose a key element of the host immune defense system and can kill mammalian cells by one of several different mechanisms. In this report, we compare mechanisms of cell death induced in human B lymphoma cells by the inflammatory oxidants superoxide, H2O2, and HOCl. The results indicate that the mode of cell death induced depends on the nature of the oxidant involved and the medium in which the cells are treated. When human Burkitt's lymphoma cells are exposed to superoxide anion, generated as a flux from xanthine and xanthine oxidase, the cells die by a non-apoptotic mechanism (pyknosis/necrosis) identical to that seen when cells are treated with a bolus of reagent H2O2. Addition of superoxide dismutase has no effect, whereas catalase is completely protective, indicating that exogenously generated superoxide kills cells entirely through its dismutation into H2O2. In contrast, cells treated in culture media with reagent 1100 die largely by apoptosis. HOCl-induced apoptosis is mediated by aminoacyl chloramines generated in the culture media and can be mimicked by treatment of cells with taurine chloramine or with long lived chloramines generated from modified Lys or Arg. The results suggest that in a physiological milieu in which O-2(-) and H2O2 are the main oxidants being formed, the principal form of cell death may be necrotic, and under inflammatory conditions in which HOCl is generated, apoptotic cell death may predominate.	US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Immunol Lab, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20815 USA	US Food & Drug Administration (FDA); Uniformed Services University of the Health Sciences - USA	Shacter, E (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Immunol Lab, Bldg 29A,Rm 2A-11,29 Lincoln Dr, Bethesda, MD 20892 USA.	shacter@cber.fda.gov						Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CANTIN AM, 1994, J CLIN INVEST, V93, P606, DOI 10.1172/JCI117013; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V332, P63, DOI 10.1006/abbi.1996.0317; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; DALLEGRI F, 1986, J CLIN LAB IMMUNOL, V20, P37; DAVIES JMS, 1994, ARTHRITIS RHEUM, V37, P424, DOI 10.1002/art.1780370317; Eguchi Y, 1997, CANCER RES, V57, P1835; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPERT MB, 1983, BLOOD, V62, P645; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Lee YJ, 1997, BLOOD, V89, P4480, DOI 10.1182/blood.V89.12.4480; Lelli JL, 1998, FREE RADICAL BIO MED, V25, P694, DOI 10.1016/S0891-5849(98)00107-5; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LINDER M, 1992, NUTR BIOCH METABOLIS, P87; MAIER KL, 1989, FEBS LETT, V250, P221, DOI 10.1016/0014-5793(89)80725-2; MONNIER VM, 1991, GERONTOLOGY, V37, P152; Nagl M, 2000, ANTIMICROB AGENTS CH, V44, P2507, DOI 10.1128/AAC.44.9.2507-2513.2000; Palomba L, 1996, EUR J PHARMACOL, V318, P167, DOI 10.1016/S0014-2999(96)00763-7; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; Shacter E, 2000, BLOOD, V96, P307, DOI 10.1182/blood.V96.1.307.013k47_307_313; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; Thomas E L, 1986, Methods Enzymol, V132, P585; THOMAS EL, 1983, J CLIN INVEST, V72, P441, DOI 10.1172/JCI110992; THOMAS EL, 1985, J BIOL CHEM, V260, P3321; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VANDENBERG JJM, 1993, J LIPID RES, V34, P2005; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WRIGHT CE, 1986, ANNU REV BIOCHEM, V55, P427, DOI 10.1146/annurev.bi.55.070186.002235; WYLLIE AH, 1992, OXFORD TXB PATHOLOGY, P141; ZGLICZYNSKI JM, 1968, EUR J BIOCHEM, V4, P540, DOI 10.1111/j.1432-1033.1968.tb00246.x; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819	58	70	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20518	20526		10.1074/jbc.M200212200	http://dx.doi.org/10.1074/jbc.M200212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925431	hybrid			2022-12-25	WOS:000176204500055
J	Fulda, S; Meyer, E; Debatin, KM				Fulda, S; Meyer, E; Debatin, KM			Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression	ONCOGENE			English	Article						TRAIL; apoptosis; caspases; IAP	X-LINKED INHIBITOR; CD95 APO-1/FAS; TUMORICIDAL ACTIVITY; DEATH; NEUROBLASTOMA; PROTEIN; LIGAND; CELLS; ACTIVATION; CHEMOTHERAPY	Primary or acquired resistance to current treatment protocols remains a major concern in clinical oncology and may be caused by defects in apoptosis programs. Since recent data suggest that TRAIL can bypass apoptosis resistance caused by Bcl-2, we further investigated the role of Bcl-2 in TRAIL-induced apoptosis. Here we report that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma or breast carcinoma cell lines. Bcl-2 overexpression reduced TRAIL-induced cleavage of caspase-8 and Bid indicating that caspase-8 was activated upstream and also downstream of mitochondria in a feedback amplification loop. Importantly Bcl-2 blocked cleavage of caspases-9, -7 and -3 into active subunits and cleavage of the caspase substrates DFF45 or PARP. Also, Bcl-2 blocked cleavage of XIAP and overexpression of XIAP conferred resistance against TRAIL indicating that apoptosis was also amplified through a feedforward loop between caspases and XIAP. In contrast, in SKW lymphoblastoid cells, TRAIL-induced activation of caspase-8 directly translated into full activation of caspases, cleavage of XIAP, DFF45 or PARP and apoptosis independent of Bcl-2 overexpression, although Bcl-2 similarly inhibited loss of mitochondrial membrane potential and the release of cytochrome c, AIF and Smac from mitochondria in all cell types. By demonstrating a cell type dependent regulation of the TRAIL signaling pathway at different level, e.g. by Bcl-2 and by XIAP, these findings may have important clinical implication. Thus, strategies targeting the molecular basis of resistance towards TRAIL may be necessary in some tumors for cancer therapy with TRAIL.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				BERTHOLD F, 1990, KLIN PADIATR, V202, P262, DOI 10.1055/s-2007-1025531; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fels C, 2000, J NEURO-ONCOL, V48, P207, DOI 10.1023/A:1006484801654; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2000, CANCER RES, V60, P3947; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; HOEHNER JC, 1995, INT J CANCER, V62, P19, DOI 10.1002/ijc.2910620106; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim EJ, 2001, INT J ONCOL, V18, P187; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mitsiades N, 2000, CANCER RES, V60, P4122; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Sasaki H, 2000, CANCER RES, V60, P5659; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651	45	323	336	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2283	2294		10.1038/sj.onc.1205258	http://dx.doi.org/10.1038/sj.onc.1205258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948412				2022-12-25	WOS:000174635600001
J	Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK				Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK			Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase1 gene	ONCOGENE			English	Article						NQO1; ARE; detoxifying genes; Nrf2; cysteine; redox regulation	GLUTATHIONE S-TRANSFERASES; DT-DIAPHORASE; TRANSCRIPTION FACTOR; ACTIVATION; CANCER; CELLS; FOS; XENOBIOTICS; RADICALS; MAFG	NF-E2 related factor 2 (Nrf2) is a CNC/b-zip protein that regulates antioxidant response element (ARE)mediated expression, and antioxidant induction, of detoxifying enzyme genes, including NAD(P)H:quinone oxidoreductasel (NQO1). A comparison of Nrf2 from different species, and with other b-zip proteins, revealed the presence of a highly conserved cysteine residue at position 506 in the DNA binding domain of Nrf2. Site-directed mutagenesis was used to mutate this cysteine, to serine. Transfection/over expression experiments in human hepatoblastoma (Hep-G2) cells demonstrated that mutant Nrf2 (mNrf2), containing the C506S mutation, was significantly less efficient in activating ARE-mediated gene expression, and induction in response to tert-butyl hydroquinone (t-BHQ), as copmpared with wild-type Nrf2. N-ethyl malemide (NEM), a sulfhydryl cross- linker, inhibited Nrf2 but not mNrf2C506S-mediated expression of NQO1. This further implicated the cysteine at position 506 in Nrf2 regulation of ARE-mediated gene expression. Nuclear localization experiments revealed that C506S mutation did not affect the retention of Nrf2 by INrf2/Keap1 in the cytosol, or its release in response to antioxidants. However, band and supershift assays showed a significant reduction in the binding of mNrf2C506S to the NQO1 gene ARE as compared with wild-type Nrf2. Therefore, the C506S mutation in Nrf2 lowered its affinity for the ARE, leading to decreased expression, and antioxidant induction, of NQO1.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Pl, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BERGELSON S, 1994, CANCER RES, V54, P36; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; Huang HC, 2001, P NATL ACAD SCI USA, V98, P379; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JAYEPAUL J, 2000, BIOCHEM PHARMACOL, V59, P1433; JOSEPH P, 1994, ONCOL RES, V6, P525; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane Venugopal, 1997, P441; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	40	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2191	2200		10.1038/sj.onc.1205288	http://dx.doi.org/10.1038/sj.onc.1205288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948402				2022-12-25	WOS:000174555300008
J	Hurd, C; Waldron, RT; Rozengurt, E				Hurd, C; Waldron, RT; Rozengurt, E			Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus	ONCOGENE			English	Article						protein kinase D; c-Jun N-terminal kinase; c-Jun phosphorylation	NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; INTACT-CELLS; MU; JNK; IDENTIFICATION; INVOLVEMENT; EXPRESSION; SUPPRESS	Protein kinase D (PKD), a downstream effector of protein kinase C (PKC), is implicated in suppression of the c-Jun N-terminal kinase (JNK) signaling pathway, however, its mechanism of action is unclear. Transphosphorylation of the PKD activation loop at serines 744/ 748 by a PKC mediated signal transduction pathway enhances its catalytic activity. Here we show that PKD activation loop phosphorylation at serines 744/748 via PKC, or mutation of these serines to glutamic acid (PKD-S744/748E) also results in complex formation with JNK, indicating that suppression of JNK signaling by PKD involves a direct interaction with JNK. Because catalytically active PKD associates with JNK we determined whether it could phosphorylate the e-Jun N-terminus as a potential mechanism by which it suppresses c-Jun Ser 63 phosphorylation when it complexes with JNK. Purified human PKD and either wild-type PKD from phorbol 12, 13-dibutyrate (PDB)-stimulated cells or unstimulated constitutively active PKD (PKD-S744/ 748E), phosphorylated the c-Jun N-terminus between amino acids 1-89 at sites distinct from those phosphorylated by JNK. These results demonstrate, for the first time, phosphorylation dependent association of PKD with another signaling molecule and reveal a potential mechanism by which PKD could modulate the ability of JNK to phosphorylate e-Jun by phosphorylating alternative sites in the c-Jun N-terminus when it is complexed with JNK.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002834, R01DK056930] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90388-01] Funding Source: Medline; NIDDK NIH HHS [K01 DK 02834-01, DK 55003, DK56930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akkaraju GR, 2000, BIOCHEM BIOPH RES CO, V279, P103, DOI 10.1006/bbrc.2000.3903; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Guo BC, 2001, CELL RES, V11, P101, DOI 10.1038/sj.cr.7290074; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Shinohara H, 2001, BIOCHEM BIOPH RES CO, V284, P1162, DOI 10.1006/bbrc.2001.5104; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZHUKOVA E, 2001, J BIOL CHEM, V20, P20; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	37	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2154	2160		10.1038/sj.onc.1205290	http://dx.doi.org/10.1038/sj.onc.1205290			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948398				2022-12-25	WOS:000174555300004
J	Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M				Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M			Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells	ONCOGENE			English	Article						PPAR-gamma; thiazolidinediones; GADD153; apoptosis; lung carcinoma	PREPROTHYROTROPIN-RELEASING HORMONE; HUMAN BREAST-CANCER; PPAR-GAMMA; BINDING PROTEIN; TERMINAL DIFFERENTIATION; INSULIN-RESISTANCE; IN-VITRO; APOPTOSIS; CHOP; EXPRESSION	Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by the thiazolidinedione (TZD) class of antidiabetic drugs elicits growth inhibition in a variety of malignant tumors. We clarified the effects of TZDs on growth of human non-small cell lung carcinoma (NSCLC) cells that express endogenous PPAR-gamma Troglitazone and pioglitazone caused inhibition of cellular growth and induced apoptosis of NSCLC cells, in a time- and dose-dependent manner. Subtraction, cloning analysis identified that troglitazone stimulated, expression of the growth arrest and DNA-damage inducible (GADD) 153 gene, and the increased expression, of GADD153 mRNA was also confirmed by an array analysis of the 160 apoptosis-related genes. Western blot analysis revealed that troglitazone also increased, GADD153 protein levels in a time-dependent manner., Troglitazone did not stimulate GADD153 mRNA levels in undifferentiated 3T3-L1 cells lacking PPAR-gamma expression, whereas its induction was clearly observed in differentiated adipocytes expressing PPAR-gamma. Activity of the GADD153 promoter occurred in a NSCLC cell line in transient transcription assays and was significantly stimulated by troglitazone, although binding of PPAR/retinoid X receptor heterodimer was not detected in the promoter region in gel retardation assays. Inhibition of GADD153 gene expression by an antisense phosphorothionate oligonucleotide attenuated the troglitazone-induced growth inhibition. These findings collectively indicated that activation of PPAR-gamma by TZDs, could cause growth inhibition and apoptosis of NSCLC cells and that GADD153 might be a candidate factor implicated in these processes.	Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan; Gunma Univ, Sch Med, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718511, Japan	Gunma University; Gunma University	Mori, M (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Maebashi, Gumma 3718511, Japan.	mmori@med.gunma-u.ac.jp						APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang TH, 2000, CANCER RES, V60, P1129; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kameda T, 1999, BBA-GENE STRUCT EXPR, V1445, P31, DOI 10.1016/S0167-4781(99)00018-4; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LEUTHY JD, 1990, J BIOL CHEM, V265, P16251; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Ohtani K, 1998, ENDOCRINOLOGY, V139, P172, DOI 10.1210/en.139.1.172; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Palakurthi SS, 2001, CANCER RES, V61, P6213; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Ren Y, 1998, ENDOCRINOLOGY, V139, P195, DOI 10.1210/en.139.1.195; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SATOH T, 1993, MOL BRAIN RES, V20, P353, DOI 10.1016/0169-328X(93)90062-T; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Ubeda M, 2000, NUCLEIC ACIDS RES, V28, P4987, DOI 10.1093/nar/28.24.4987; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	54	88	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2171	2180		10.1038/sj.onc.1205279	http://dx.doi.org/10.1038/sj.onc.1205279			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948400				2022-12-25	WOS:000174555300006
J	Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA				Wong, JC; Lee, SB; Bell, MD; Reynolds, PA; Fiore, E; Stamenkovic, I; Truong, V; Oliner, JD; Gerald, WL; Haber, DA			Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product	ONCOGENE			English	Article						EWS-WT1; desmoplastic small round cell tumor; Wilms tumor; interleukin-2/15 receptor; microarrays; tumor-stromal interaction	TUMOR-SUPPRESSOR GENE; ROUND-CELL TUMOR; WILMS-TUMOR; IL-2 RECEPTOR; ALPHA-CHAIN; TRANSCRIPTIONAL ACTIVATOR; DNA-BINDING; EXPRESSION; FUSION; PROMOTER	EWS - WT1 is a chimeric transcription factor resulting from fusion of the N-terminal domain of the Ewing sarcoma gene EWS to the three C-terminal zinc fingers of the Wilms tumor suppressor WT1. This translocation underlies desmoplastic small round cell tumor (DSRCT), which is noted for the abundance of reactive stroma surrounding islets of tumor cells, suggestive of paracrine signals contributing to tumor cell proliferation. Hybridization to high-density oligonucleotide microarrays can be used to identify targets of EWS - WT1. Expression of EWS - WT1 from a tetracycline-regulated promoter leads to the induction of growth-associated genes, of which the most remarkable is the beta-chain of the interleukin-2/15 receptor (IL-2/15Rbeta). Potent transcriptional activation by the chimeric protein maps to two bindings sites within the IL-2/15Rbeta promoter. Analysis of primary DSRCT tumor specimens demonstrates high levels of IL-2/15Rbeta within the tumor cells, along with expression of IL-2 and IL-15 by the abundant hyperplastic endothelial cells within the reactive stroma. Activation of this cytokine signaling pathway is consistent with the nuclear localization of its downstream effectors, phosphorylated STAT3 and STAT5. These observations suggest that the transcriptional induction of a cytokine receptor by a tumor-associated translocation product enables a proliferative response of epithelial cancer cells to ligands secreted by the surrounding stroma.	Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Massachusetts General Hospital; Harvard University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Massachusetts General Hospital; Affymetrix	Haber, DA (corresponding author), Massachusetts Gen Hosp, Canc Ctr CNY 7, Mol Genet Lab, Bldg 149,13th St, Charlestown, MA 02129 USA.	Haber@helix.mgh.harvard.edu		Lee, Sean/0000-0001-6211-3498; Reynolds, Paul/0000-0001-8738-1245; Wong, Jenise C./0000-0003-0573-6650	NCI NIH HHS [CA68273, CA58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068273, R37CA058596, R01CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Azzarone B, 1996, EUR CYTOKINE NETW, V7, P27; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; De Giovanni C, 1998, BRIT J CANCER, V78, P1541, DOI 10.1038/bjc.1998.721; Dobbeling U, 1998, BLOOD, V92, P252, DOI 10.1182/blood.V92.1.252.413k08_252_258; Doucet C, 1997, MELANOMA RES, V7, pS7; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Frank DA, 1999, MOL MED, V5, P432; GERALD WL, 1991, AM J SURG PATHOL, V15, P499, DOI 10.1097/00000478-199106000-00001; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hjorth-Hansen H, 1999, BRIT J HAEMATOL, V106, P28, DOI 10.1046/j.1365-2141.1999.01510.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Karnieli E, 1996, J BIOL CHEM, V271, P19304, DOI 10.1074/jbc.271.32.19304; Kim J, 1998, ONCOGENE, V16, P1021, DOI 10.1038/sj.onc.1201616; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LADANYI M, 1994, CANCER RES, V54, P2837; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; LIN WC, 1995, J IMMUNOL, V155, P4805; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miller MJ, 1996, J BIOL CHEM, V271, P23345; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Pileri SA, 1997, J PATHOL, V183, P116; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Suminami Y, 1998, ONCOGENE, V16, P1309, DOI 10.1038/sj.onc.1201640; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Yamada Y, 1998, BLOOD, V91, P4265, DOI 10.1182/blood.V91.11.4265.411k06_4265_4272; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	51	34	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2009	2019		10.1038/sj.onc.1205262	http://dx.doi.org/10.1038/sj.onc.1205262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960373				2022-12-25	WOS:000174827000007
J	Kim, JH; Lee-Kwon, W; Park, JB; Ryu, SH; Yun, CHC; Donowitz, M				Kim, JH; Lee-Kwon, W; Park, JB; Ryu, SH; Yun, CHC; Donowitz, M			Ca2+-dependent inhibition of Na+/H+ exchanger 3 (NHE3) requires an NHE3-E3KARP-alpha-actinin-4 complex for oligomerization and endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-MEDIATED INHIBITION; C-TERMINAL DOMAINS; PROTEIN-KINASE-C; BRUSH-BORDER; ISOFORM 3; PDZ; TRAFFICKING; PHOSPHORYLATION; IDENTIFICATION; STIMULATION	Two PDZ domain-containing proteins, NHERF and E3KARP are necessary for cAMP-dependent inhibition of Na+/H+' exchanger 3 (NHE3). In this study, we demonstrate a specific role of E3KARP, which is not duplicated by NHERF, in Ca2+-dependent inhibition of NHE3 activity. NHE3 activity is inhibited by elevation of intracellular Ca2+ ([Ca2+](i)) in PS120 fibroblasts stably expressing E3KARP but not those expressing NHERF. In addition, this Ca2+-dependent inhibition requires Ca2+-dependent association between alpha-actinin-4 and E3KARP. NHE3 is indirectly connected to alpha-actinin-4 in a protein complex through Ca2+-dependent interaction between alpha-actinin-4 and E3KARP, which occurs through the actin-binding domain plus spectrin repeat domain of alpha-actinin-4. Elevation of [Ca2+](i) results in oligomerization and endocytosis of NHE3 as well as in inhibition of NHE3 activity. Overexpression of alpha-actinin-4 potentiates the inhibitory effect of ionomycin on NHE3 activity by accelerating the oligomerization and endocytosis of NHE3. In contrast, overexpression of the actin-binding domain plus spectrin repeat domain acts as a dominant-negative mutant and prevents the inhibitory effect of ionomycin on NHE3 activity as well as the oligomerization and internalization of NHE3. From these results, we propose that elevated Ca2+ inhibits NHE3 activity through oligomerization and endocytosis of NHE3, which occurs via formation of an NRE3-E3KARP-alpha-actinin-4 complex.	Johns Hopkins Univ, Sch Med, Dept Med, GI Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, GI Div, Baltimore, MD 21205 USA; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Johns Hopkins University; Johns Hopkins University; Pohang University of Science & Technology (POSTECH)	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, GI Div, 925 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu		Ryu, Sung Ho/0000-0003-0913-3048	NIDDK NIH HHS [P01 DK44484, R01 DK26523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Araki N, 2000, J CELL SCI, V113, P3329; Aronson PS, 1997, WIEN KLIN WOCHENSCHR, V109, P435; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Cavet ME, 2001, AM J PHYSIOL-CELL PH, V281, pC2039, DOI 10.1152/ajpcell.2001.281.6.C2039; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DONOWITZ M, 1983, AM J PHYSIOL, V245, pG165, DOI 10.1152/ajpgi.1983.245.2.G165; Donowitz M, 1998, AM J PHYSIOL-GASTR L, V274, pG971, DOI 10.1152/ajpgi.1998.274.6.G971; DONOWITZ M, 1986, REV INFECT DIS, V8, pS188; FLOOD G, 1995, J MOL BIOL, V252, P227, DOI 10.1006/jmbi.1995.0490; GOYAL J, 1987, BIOCHIM BIOPHYS ACTA, V925, P341, DOI 10.1016/0304-4165(87)90200-5; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Jensen ON, 1996, ELECTROPHORESIS, V17, P938, DOI 10.1002/elps.1150170516; Jensen ON, 1997, ANAL CHEM, V69, P4741, DOI 10.1021/ac970896z; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; McSwine RL, 1998, AM J PHYSIOL-CELL PH, V275, pC693, DOI 10.1152/ajpcell.1998.275.3.C693; Morris AP, 1999, AM J PHYSIOL-GASTR L, V277, pG431, DOI 10.1152/ajpgi.1999.277.2.G431; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 2001, KIDNEY INT, V60, P450, DOI 10.1046/j.1523-1755.2001.060002450.x; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	43	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23714	23724		10.1074/jbc.M200835200	http://dx.doi.org/10.1074/jbc.M200835200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11948184	hybrid			2022-12-25	WOS:000176475700081
J	Fujita, T; Meguro, T; Fukuyama, R; Nakamuta, H; Koida, M				Fujita, T; Meguro, T; Fukuyama, R; Nakamuta, H; Koida, M			New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells - Checkpoint of modulation by cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; NERVE GROWTH-FACTOR; B-RAF; OSTEOBLASTIC CELLS; MAP KINASE; PTH/PTHRP RECEPTOR; COUPLED RECEPTORS; TRANSGENIC MICE; IN-VITRO	cAMP signaling, activated by extracellular stimuli such as parathyroid hormone, has cell type-specific effects important for cellular proliferation and differentiation in bone cells. Recent evidence of a second enzyme target for cAMP suggests divergent effects on extracellular-regulated kinase (ERK) activity depending on Epac/Rap1/B-Raf signaling. We investigated the molecular mechanism of the dual functionality of cAMP on cell proliferation in clonal bone cell types. MC3T3-E1 and ATDC5, but not MG63, express a 95-kDa isoform of B-Raf. cAMP stimulated Ras-independent and Rap1-dependent ERK phosphorylation and cell proliferation in B-Raf-expressing cells, but inhibited growth in B-Raf-lacking cells. The mitogenic action of cAMP was blocked by the ERK pathway inhibitor PD98059. In B-Raf-transduced MG63 cells, cAMP stimulated ERK activation and cell proliferation. Thus, B-Raf is the dominant molecular switch that permits differential cAMP-dependent regulation of ERK with important implications for cell proliferation in bone cells. These findings might explain the dual functionality of parathyroid hormone on osteoblastic cell proliferation.	Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Hirakata, Osaka 5730101, Japan	Setsunan University	Fujita, T (corresponding author), Setsunan Univ, Fac Pharmaceut Sci, Dept Pharmacol, Nagaotoge Cho 45-1, Hirakata, Osaka 5730101, Japan.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1983, EMBO J, V14, P3475; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Fujita T, 2001, JPN J PHARMACOL, V86, P405, DOI 10.1254/jjp.86.405; Fujita T, 2001, JPN J PHARMACOL, V86, P86, DOI 10.1254/jjp.86.86; Fujita T, 2001, JPN J PHARMACOL, V85, P278, DOI 10.1254/jjp.85.278; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985; Hilliker S, 1996, BONE, V19, P469, DOI 10.1016/S8756-3282(96)00230-X; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ionescu AM, 2001, J BIOL CHEM, V276, P11639, DOI 10.1074/jbc.M006564200; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1999, MOL CELL BIOL, V19, P6057; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10304; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Takuma K, 2000, EUR J PHARMACOL, V399, P1, DOI 10.1016/S0014-2999(00)00334-4; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WANG ZQ, 1995, CANCER RES, V55, P6244; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	59	103	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22191	22200		10.1074/jbc.M110364200	http://dx.doi.org/10.1074/jbc.M110364200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956184	hybrid			2022-12-25	WOS:000176313600013
J	Lequin, O; Bolbach, G; Frank, F; Convert, O; Girault-Lagrange, S; Chassaing, G; Lavielle, S; Sagan, S				Lequin, O; Bolbach, G; Frank, F; Convert, O; Girault-Lagrange, S; Chassaing, G; Lavielle, S; Sagan, S			Involvement of the second extracellular loop (E2) of the neurokinin-1 receptor in the binding of substance P - Photoaffinity labeling and modeling studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYKININ NK1 RECEPTOR; COMMON AMINO-ACIDS; NK-1 RECEPTOR; TRANSMEMBRANE HELICES; IDENTIFICATION; PEPTIDE; SITE; CELLS; NMR; SEPTIDE	Substance P (SP) interacts with the neurokinin-1 (NR-1) G-protein-coupled receptor, which has been cloned in several species. In the present study, the domains of the NK-1 receptor involved in the binding of SP and SP-(7-11) C-terminal fragment have been analyzed using two peptide analogs containing the photoreactive amino acid para-benzoylphenylalanine ((p-Bz)Phe) in position 8 of their sequence. This study was carried out with [BAPA-Lys(6),(p-Bz)Phe(8),Pro(9),Met(O-2)(11)]SP-(7-11) and [BAPA(0),(p-Bz)Phe(8)]SP on both rat and human NK-1 receptors expressed in CHO cells. Combined trypsin and endo-GluC enzymatic complete digestions and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis led to the identification of the same domain of covalent interaction, (TMPSR177)-T-173, for the two photoactivatable peptides. Further digestion of this fragment with carboxypeptidase Y led to the identification of (TMP175)-T-173 in the second extracellular loop (E2) of the NK-1 receptor as the site of covalent attachment. Models of the conformation of this E2 loop in the human NLK-1 receptor were generated using two different strategies, one based on homology with bovine rhodopsin and the other based on the solution conformation preferences of a synthetic peptide corresponding to the E2 loop.	Univ Paris 06, CNRS, Unite Mixte Rech 7613, F-75252 Paris 05, France; Sanofi Synthelabo, F-31676 Labege, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Sanofi-Aventis; Sanofi France	Sagan, S (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7613, Boite Courrier 182,4 Pl Jussieu, F-75252 Paris 05, France.	sagan@ccr.jussieu.fr	s, s/HIK-1178-2022; s, s/GVS-3323-2022; s, s/HHD-0404-2022; S, SAGAN/I-8132-2013; QI, DANDAN/GVR-9324-2022; s, s/GYR-2278-2022; SAGAN, Sandrine/AAA-8537-2022	S, SAGAN/0000-0003-0083-4411; LEQUIN, Olivier/0000-0001-5307-3068				AYOUB M, 1995, TETRAHEDRON LETT, V36, P4069, DOI 10.1016/0040-4039(95)00683-4; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Beaujouan JC, 2000, J NEUROCHEM, V75, P1015, DOI 10.1046/j.1471-4159.2000.0751015.x; Beujouan JC, 1999, PEPTIDES, V20, P1347, DOI 10.1016/S0196-9781(99)00140-0; Boucard AA, 2000, BIOCHEMISTRY-US, V39, P9662, DOI 10.1021/bi000597v; Bremer AA, 2000, FEBS LETT, V486, P43, DOI 10.1016/S0014-5793(00)02228-6; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHASSAING G, 1985, TETRAHEDRON LETT, V26, P623, DOI 10.1016/S0040-4039(00)89163-7; Ciucci A, 1997, FEBS LETT, V416, P335, DOI 10.1016/S0014-5793(97)01236-2; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Girault S, 1996, EUR J BIOCHEM, V240, P215, DOI 10.1111/j.1432-1033.1996.0215h.x; Girault S, 1996, ANAL CHEM, V68, P2122, DOI 10.1021/ac960043r; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hastrup H, 1996, FEBS LETT, V399, P264, DOI 10.1016/S0014-5793(96)01337-3; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAVIELLE S, 1988, BIOCHEM PHARMACOL, V37, P41, DOI 10.1016/0006-2952(88)90753-8; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; Liu HT, 1999, P NATL ACAD SCI USA, V96, P5286, DOI 10.1073/pnas.96.9.5286; Macdonald D, 2001, BIOCHEMISTRY-US, V40, P2530, DOI 10.1021/bi001880x; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; McNicoll N, 1996, BIOCHEMISTRY-US, V35, P12950, DOI 10.1021/bi960818q; Mills JS, 1998, J BIOL CHEM, V273, P10428, DOI 10.1074/jbc.273.17.10428; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rupniak NMJ, 1999, TRENDS PHARMACOL SCI, V20, P485, DOI 10.1016/S0165-6147(99)01396-6; Sagan S, 1996, J PHARMACOL EXP THER, V276, P1039; Sagan S, 1997, MOL PHARMACOL, V52, P120, DOI 10.1124/mol.52.1.120; Sagan S, 2001, BIOCHEM BIOPH RES CO, V282, P958, DOI 10.1006/bbrc.2001.4687; Sagan S, 2001, EUR J BIOCHEM, V268, P2997, DOI 10.1046/j.1432-1327.2001.02192.x; Sagan S, 1999, J BIOL CHEM, V274, P23770, DOI 10.1074/jbc.274.34.23770; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Wijkhuisen A, 1999, FEBS LETT, V447, P155, DOI 10.1016/S0014-5793(99)00298-7; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2	47	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22386	22394		10.1074/jbc.M110614200	http://dx.doi.org/10.1074/jbc.M110614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950831	hybrid			2022-12-25	WOS:000176313600036
J	Dallas, SL; Rosser, JL; Mundy, GR; Bonewald, LF				Dallas, SL; Rosser, JL; Mundy, GR; Bonewald, LF			Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts - A cellular mechanism for release of TGF-beta from bone matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; EXTRACELLULAR-MATRIX; RABBIT OSTEOCLASTS; ACTIVATION; CELLS; IDENTIFICATION; TGF-BETA-1; COMPLEX; CULTURES; GROWTH-FACTOR-BETA-1	The binding of growth factors to the extracellular matrix (ECM) may be a key pathway for regulation of their activity. We have shown that a major mechanism for storage of transforming growth factor-beta (TGF-beta) in bone ECM is via its association with latent TGF-beta-binding protein-1 (LTBP1). Although proteolytic cleavage of LTBP1 has been reported, it remains unclear whether this represents a physiological mechanism for release of matrix-bound TGF-beta. Here we examined the role of LTBP1 in cell-mediated release of TGF-beta from bone ECM. We first characterized the soluble and ECM-bound forms of latent TGF-beta produced by primary osteoblasts. Next, we examined release of ECM-bound TGF-beta by bone resorbing cells. Isolated avian osteoclasts and rabbit bone marrow-derived osteoclasts released bone matrix-bound TGF-beta via LTBP1 cleavage. 1,25-Dihydroxyvitamin D. enhanced LTBP1 cleavage, resulting in release of 90%, of the ECM-bound LTBP1. In contrast, osteoblasts failed to cleave LTBP1 or release TGF-beta from bone ECM. Cleavage of LTBP1 by avian osteoclasts was inhibited by serine protease and metalloproteinase (MMP) inhibitors. Studies using purified proteases showed that plasmin, elastase, MMP2, and MMP9 were able to cleave LTBP1 to produce 125-165-kDa fragments. These studies identify LTBP1 as a novel substrate for MMPs and provide the first demonstration that LTBP1 proteolysis may be a physiological mechanism for release of TGF-beta from ECM-bound stores, potentially the first step in the pathway by which matrix-bound TGF-beta is rendered active.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, San Antonio, TX 78284 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Manchester; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Dallas, SL (corresponding author), Univ Missouri, Sch Dent, Dept Oral Biol, 650 E 25th St, Kansas City, MO 64108 USA.		Bonewald, Lynda/Q-3638-2019	Bonewald, Lynda/0000-0002-5536-9943	NCI NIH HHS [K01CA75387, R29CA74262] Funding Source: Medline; NIAMS NIH HHS [R01 AR43775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074262, K01CA075387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bonewald LF, 1999, CRIT REV EUKAR GENE, V9, P33, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.30; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; Bonewald LF, 1997, ENDOCRINOLOGY, V138, P657, DOI 10.1210/en.138.2.657; Dallas SL, 2000, METH MOL B, V139, P231; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOKUBO T, 1998, ADV ORG BIO A-C, V5, P359; LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756-3282(96)00351-1; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; OKADA Y, 1995, LAB INVEST, V72, P311; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; Sinha S, 1998, MATRIX BIOL, V17, P529, DOI 10.1016/S0945-053X(98)90106-8; Strehlow David, 1998, Current Opinion in Rheumatology, V10, P572, DOI 10.1097/00002281-199811000-00011; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Tiedemann K, 2001, J BIOL CHEM, V276, P36035, DOI 10.1074/jbc.M104985200; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; YEE JA, 1993, J CELL PHYSIOL, V157, P528, DOI 10.1002/jcp.1041570312; Yu Q, 2000, GENE DEV, V14, P163	46	295	306	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21352	21360		10.1074/jbc.M111663200	http://dx.doi.org/10.1074/jbc.M111663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929865	hybrid			2022-12-25	WOS:000176286000032
J	Loh, E; Hong, WJ				Loh, E; Hong, WJ			Sec34 is implicated in traffic from the endoplasmic reticulum to the Golgi and exists in a complex with GTC-90 and ldlBp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OVARY CELL MUTANTS; MEMBRANE-PROTEIN; VESICLE DOCKING; CIS-GOLGI; SACCHAROMYCES-CEREVISIAE; DEFICIENT MUTANT; REQUIRES USO1P; SNARE COMPLEX; EXIT SITES	Sec34p/Grd20p has been implicated in endoplasmic reticulum. (ER)-to-Golgi transport and/or post-Golgi trafficking events and exists in a protein complex consisting of at least eight subunits in yeast. Although the mammalian counterpart (Sec34) of Sec34p has been molecularly identified, its role and interacting partners remain undefined. In this study, we have prepared antibodies specifically against the recombinant N-terminal fragment of Sec34 that recognize a polypeptide of about 93 kDa and label the Golgi apparatus. In a well-characterized semi-intact cell assay that reconstitutes transport of the envelope glycoprotein (VSVG) of vesicular stomatitis virus from the ER to the Golgi apparatus, anti-Sec34 antibodies inhibited the transport in a dose-dependent manner. The inhibition by anti-Sec34 antibodies could be neutralized by a noninhibitory amount of the antigen. Large-scale immunoprecipitation of rat liver cytosol with immobilized anti-Sec34 antibodies has co-immunoprecipitated GTC-90 and ldlBp, two peripheral Golgi proteins previously shown to exist in separate protein complexes. Two mammalian homologues (Dor1 and Cod1) of the yeast Sec34 complex were similarly recovered in the Sec34 immunoprecipitates. When expressed in transfected cells, epitope-tagged ldlCp and Cod2 were co-immunoprecipitated with anti-Sec34 antibodies with efficiencies comparable to that observed for tagged ldlBp, Dor1, and Cod1. Direct interactions of Sec34 with ldlBp and ldlCp were further demonstrated in vitro. These results suggest that Sec34, GTC-90, and ldlBp/ldlCp are part of the same protein complex(es) that regulates diverse aspects of Golgi function, including transport from the ER to the Golgi apparatus.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.	mcbhwj@imcb.nus.edu.sg	HONG, Wanjin/E-9927-2010					Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chatterton JE, 1999, P NATL ACAD SCI USA, V96, P915, DOI 10.1073/pnas.96.3.915; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo W, 2000, TRENDS CELL BIOL, V10, P251, DOI 10.1016/S0962-8924(00)01754-2; Hauri HP, 2000, J CELL SCI, V113, P587; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Hong WJ, 1998, J CELL SCI, V111, P2831; Kim DW, 1999, MOL BIOL CELL, V10, P3317, DOI 10.1091/mbc.10.10.3317; Kim DW, 2001, TRAFFIC, V2, P820, DOI 10.1034/j.1600-0854.2001.21111.x; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; Lowe SL, 1996, J CELL SCI, V109, P209; MALMSTROM K, 1991, J BIOL CHEM, V266, P24025; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; PODOS SD, 1994, J CELL BIOL, V127, P679, DOI 10.1083/jcb.127.3.679; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; Suvorova ES, 2001, J BIOL CHEM, V276, P22810, DOI 10.1074/jbc.M011624200; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; Tang BL, 2000, J BIOL CHEM, V275, P13597, DOI 10.1074/jbc.275.18.13597; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; Walter DM, 1998, J BIOL CHEM, V273, P29565, DOI 10.1074/jbc.273.45.29565; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wuestehube LJ, 1996, GENETICS, V142, P393; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang T, 2001, J BIOL CHEM, V276, P27480, DOI 10.1074/jbc.M102786200	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21955	21961		10.1074/jbc.M202326200	http://dx.doi.org/10.1074/jbc.M202326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929878	hybrid			2022-12-25	WOS:000176286000108
J	Honda, A; Yamada, M; Saisu, H; Takahashi, H; Mori, KJ; Abe, T				Honda, A; Yamada, M; Saisu, H; Takahashi, H; Mori, KJ; Abe, T			Direct, Ca2+-dependent interaction between tubulin and synaptotagmin I. A possible mechanism for attaching synaptic vesicles to microtubules.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; BINDING-SITES; SNARE COMPLEX; BETA-TUBULIN; C-TERMINUS; C2B DOMAIN; TRANSMITTER RELEASE; MEMBRANE-FUSION; DISTINCT POOLS; EXOCYTOSIS	The synaptic vesicle protein synaptotagmin I probably plays important roles in the synaptic vesicle cycle. However, the mechanisms of its action remain unclear. In this study, we have searched for cytoplasmic proteins that interact with synaptotagmin I. We found that the cytoskeletal protein tubulin directly and stoichiometrically bound to recombinant synaptotagmin L The binding depended on mm Ca2+, and 1 mol of tubulin dimer bound 2 mol of synaptotagmin I with half-maximal binding at 6.6 mum tubulin. The Ca2+ dependence mainly resulted from Ca2+ binding to the Ca2+ ligands of synaptotagmin I. The C-terminal region of beta-tubulin and both C2 domains of synaptotagmin I were involved in the binding. The YVK motif in the C2 domains of synaptotagmin I was essential for tubulin binding. Tubulin and synaptotagmin I were co-precipitated from the synaptosome extract with monoclonal antibodies to tubulin and SNAP-25 (synaptosome-associated protein of 25 kDa), indicating the presence of tubulin/synaptotagmin I complex and tubulin binding to synaptotagmin I in SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complexes. Synaptotagmin I promoted tubulin polymerization and bundled microtubules in the presence of Ca2+. These results suggest that direct interaction between synaptotagmin I and tubulin provides a mechanism for attaching synaptic vesicles to microtubules in high Ca2+ concentrations.	Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata 9518585, Japan; Niigata Univ, Brain Res Inst, Dept Pathol, Niigata 9518585, Japan; Niigata Univ, Fac Sci, Dept Biol, Niigata 9518585, Japan	Niigata University; Niigata University; Niigata University	Abe, T (corresponding author), Niigata Univ, Brain Res Inst, Dept Cellular Neurobiol, Niigata 9518585, Japan.							Augustine GJ, 1999, J PHYSIOL-LONDON, V520, P33, DOI 10.1111/j.1469-7793.1999.00033.x; Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; COHEN MW, 1991, J NEUROSCI, V11, P1032; CROSS D, 1991, BIOCHEMISTRY-US, V30, P4362, DOI 10.1021/bi00231a036; CUMMING R, 1983, NEUROSCI LETT, V37, P215, DOI 10.1016/0304-3940(83)90433-0; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; Earles CA, 2001, J CELL BIOL, V154, P1117, DOI 10.1083/jcb.200105020; Fergestad T, 2001, J NEUROSCI, V21, P1218; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fujiwara T, 1997, BIOCHEM BIOPH RES CO, V231, P352, DOI 10.1006/bbrc.1997.6092; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; GRAY EG, 1982, CELL TISSUE RES, V226, P579; GRAY EG, 1978, PROC R SOC SER B-BIO, V203, P219, DOI 10.1098/rspb.1978.0102; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Harlow ML, 2001, NATURE, V409, P479, DOI 10.1038/35054000; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HONDA A, 2000, SOC NEUR ABSTR, V26, P347; HONDA A, 2000, SOC NEUR ABSTR, V29, P714; Honda Atsuko, 1999, Society for Neuroscience Abstracts, V25, P1742; Ishizuka T, 1999, NEUROSCIENCE, V88, P295, DOI 10.1016/S0306-4522(98)00223-1; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Katz B., 1969, RELEASE NEURAL TRANS; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LIN RC, 1997, NEURON, V19, P1095; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; Morimoto T, 1998, NEUROSCIENCE, V82, P969; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rai SS, 1998, P NATL ACAD SCI USA, V95, P4253, DOI 10.1073/pnas.95.8.4253; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SERRANO L, 1986, J BIOL CHEM, V261, P7076; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SOLOMON F, 1977, BIOCHEMISTRY-US, V16, P358, DOI 10.1021/bi00622a003; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takei Y, 1995, J CELL BIOL, V131, P1789, DOI 10.1083/jcb.131.6.1789; Thomas DM, 1998, J NEUROSCI, V18, P3511; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	74	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20234	20242		10.1074/jbc.M112080200	http://dx.doi.org/10.1074/jbc.M112080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925429	hybrid			2022-12-25	WOS:000176204500019
J	Justman, QA; Clinton, GM				Justman, QA; Clinton, GM			Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EXTRACELLULAR DOMAIN; ERBB RECEPTORS; EGF RECEPTOR; INHIBITION; PHOSPHORYLATION; NETWORK; FAMILY; HETERODIMERIZATION; P185(NEU)	Herstatin is an autoinhibitor of the ErbB family consisting of subdomains I and II of the human epidermal growth factor receptor 2 (ErbB-2) extracellular domain and a novel C-terminal domain encoded by an intron. Herstatin binds to human epidermal growth factor receptor 2 and to the epidermal growth factor receptor (EGFR), blocking receptor oligomerization and tyrosine phosphorylation. In this study, we characterized several early steps in EGFR activation and investigated downstream signaling events induced by epidermal growth factor (EGF) and by transforming growth factor a (TGF-alpha) in NIH3T3 cell lines expressing EGFR with and without herstatin. Herstatin expression decreased EGF-induced EGFR tyrosine phosphorylation and delayed receptor down-regulation despite receptor occupancy by ligand with normal binding affinity. Akt stimulation by EGF and TGF-alpha, but not by fibroblast growth factor 2, was almost completely blocked in the presence of herstatin. Surprisingly, EGF and TGF-alpha induced full activation of MAPK in duration and intensity and stimulated association of the EGFR with She and Grb2. Although MAPK was fully stimulated, herstatin expression prevented TGF-alpha-induced DNA synthesis and EGF-induced proliferation. The herstatin-mediated uncoupling of MAPK from Akt activation was also observed in Chinese hamster ovary cells co-transfected with EGFR and herstatin. These findings show that herstatin expression alters EGF and TGF-alpha signaling profiles, culminating in inhibition of proliferation.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	clinton@ohsu.edu						Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CADENA DL, 1994, J BIOL CHEM, V269, P260; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Christianson TA, 1998, CANCER RES, V58, P5123; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; HACK N, 1993, J BIOL CHEM, V268, P26441; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kumagai T, 2001, P NATL ACAD SCI USA, V98, P5526, DOI 10.1073/pnas.071060598; Lee H, 2001, CANCER RES, V61, P4467; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Maihle N J, 2002, Cancer Treat Res, V107, P247; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SCHLESSINGER J, 1988, COLD SPRING HARB SYM, V53, P515, DOI 10.1101/SQB.1988.053.01.059; SELVA E, 1993, J BIOL CHEM, V268, P2250; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sweeney C, 2000, ONCOGENE, V19, P5568, DOI 10.1038/sj.onc.1203913; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vinos J, 2000, ONCOGENE, V19, P3560, DOI 10.1038/sj.onc.1203702; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao DB, 1999, DEV GENET, V25, P375, DOI 10.1002/(SICI)1520-6408(1999)25:4<375::AID-DVG11>3.0.CO;2-X; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	59	30	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20618	20624		10.1074/jbc.M111359200	http://dx.doi.org/10.1074/jbc.M111359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11934884	hybrid			2022-12-25	WOS:000176204500068
J	Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T				Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T			Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers	ONCOGENE			English	Article						lung cancer; CHFR; hypermethylation; checkpoint; prophase	MITOTIC CHECKPOINT; EPIGENETIC INACTIVATION; EXPRESSION; MUTATION; ABNORMALITIES; GROWTH; HBUB1; P53	The CHFR gene, which was recently cloned by Scolnick and Halazonetis in search for a novel mitotic checkpoint gene with fork-head association motifs, has been suggested to play a key role in the mitotic prophase checkpoint. In this study, we demonstrated tumor-specific aberrant hypermethylation of the promoter region of the CHFR gene in a significant fraction of lung cancers in association with loss of detectable levels of CHFR transcripts. Aberrant hypermethylation was observed in seven of 37 primary lung cancer cases. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored expression of the CHFR gene in lung cancer cell lines exhibiting aberrant hypermethylation and loss of its expression. In contrast, genetic alterations were found to be infrequent in lung cancers. This is the first description of aberrant hypermethylation of the CHFR gene in any type of human cancer, and provides further evidence of the involvement of multiple checkpoint alterations in lung cancer.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678061, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Haruki N, 2000, CANCER RES, V60, P4689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Masuda A, 1997, CANCER RES, V57, P4898; Matsuoka S, 2001, CANCER RES, V61, P5362; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	20	108	115	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2328	2333		10.1038/sj.onc.1205402	http://dx.doi.org/10.1038/sj.onc.1205402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948416				2022-12-25	WOS:000174635600005
J	Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O				Meza-Zepeda, LA; Forus, A; Lygren, B; Dahlberg, AB; Godager, LH; South, AP; Marenholz, I; Lioumi, M; Florenes, VA; Maelandsmo, GM; Serra, M; Mischke, D; Nizetic, D; Ragoussis, J; Tarkkanen, M; Nesland, JM; Knuutila, S; Myklebost, O			Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21	ONCOGENE			English	Article						peptidyl-prolyl isomerase; cyclophilin; breast cancer; sarcoma; amplification; chromosome1	IMMUNOSUPPRESSANT FK506; CYCLOSPORINE-A; HUMAN SARCOMAS; BREAST-CANCER; IMBALANCES; GAINS; DNA; AMPLIFICATION; SEQUENCES; COMPLEX	Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas. By positional cloning of amplified genes by yeast artificial chromosome-mediated cDNA capture using magnetic beads, we have identified three candidate genes (COAS1, -2 and -3) in the amplified region in sarcomas. COAS1 and -2 showed higher amplification levels than COAS3. Most notably, amplification was very common in osteosarcomas, where in particular COAS2 was highly expressed. COAS1 has multiple repeats and shows no homology to previously described genes, whereas COAS2 is a novel member of the cyclosporin-binding peptidylprolyl isomerase family, very similar to cyclophilin A. COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistanti tumours. Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common. All three genes were found to be amplified and over-expressed also in breast carcinomas. The complex nature of the 1q21-23 amplicons and close proximity of the genes make unequivocal determination of the gene responsible difficult. Quite likely, the different genes may give selective advantages to different subsets of tumours.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Klinikum Rudolf Virchow, Inst Expt Onkol Transplantat Med, Berlin, Germany; Univ London Sch Pharm, Ctr Appl Mol Biol, London, England; Guys Hosp, UMDS, Div Med Genet, Genom Lab, London, England; Inst Ortoped Rizzoli, Lab Ricerca Oncol, Bologna, Italy; Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; Univ Oslo, Inst Biochem, N-0316 Oslo, Norway	University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of London; University College London; University of London School of Pharmacy; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oslo; University of Helsinki; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.	ola.myklebost@biokjemi.uio.no	Ragoussis, Ioannis/AAD-9790-2022; Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Nizetic, Dean/F-9509-2015; Myklebost, Ola/E-9335-2010; Serra, Massimo/J-4878-2016	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223; Serra, Massimo/0000-0003-0742-1177; Nizetic, Dean/0000-0001-5486-5761				Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambros PF, 2001, MED PEDIATR ONCOL, V36, P1; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Corton JC, 1998, CANCER LETT, V134, P61, DOI 10.1016/S0304-3835(98)00241-9; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Forus A, 2001, CANCER GENET CYTOGEN, V125, P100, DOI 10.1016/S0165-4608(00)00369-1; Fukuda K, 1998, DEVELOPMENT, V125, P3535; Groet J, 1998, GENOME RES, V8, P385, DOI 10.1101/gr.8.4.385; Gronwald J, 1997, CANCER RES, V57, P481; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; HARDAS BD, 1994, GENOMICS, V21, P359, DOI 10.1006/geno.1994.1277; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; Kiechle M, 2000, AM J PATHOL, V156, P1827, DOI 10.1016/S0002-9440(10)65055-9; Kim JO, 1998, ONCOGENE, V17, P1019, DOI 10.1038/sj.onc.1202006; KOLETSKY AJ, 1986, J IMMUNOL, V137, P1054; Kudoh K, 1999, CLIN CANCER RES, V5, P2526; Larramendy ML, 2000, CANCER GENET CYTOGEN, V119, P132, DOI 10.1016/S0165-4608(99)00226-5; Lioumi M, 1998, GENOMICS, V49, P200, DOI 10.1006/geno.1998.5234; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Malamou-Mitsi VD, 1999, J EXP CLIN CANC RES, V18, P357; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; NIZETIC D, 1994, MAMM GENOME, V5, P801, DOI 10.1007/BF00292017; Ozaki K, 1996, CYTOGENET CELL GENET, V72, P242, DOI 10.1159/000134199; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; Rey O, 1999, ONCOGENE, V18, P827, DOI 10.1038/sj.onc.1202328; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Tarkkanen M, 1999, INT J CANCER, V84, P114, DOI 10.1002/(SICI)1097-0215(19990420)84:2<114::AID-IJC4>3.0.CO;2-Q; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Weber T, 2000, BRAIN PATHOL, V10, P73; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11081, DOI 10.1073/pnas.92.24.11081	49	43	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2261	2269		10.1038/sj.onc.1205339	http://dx.doi.org/10.1038/sj.onc.1205339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948409				2022-12-25	WOS:000174555300015
J	Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D				Barda-Saad, M; Shav-Tal, Y; Rozenszajn, AL; Cohen, M; Zauberman, A; Karmazyn, A; Parameswaran, R; Schori, H; Ashush, H; Ben-Nun, A; Zipori, D			The mesenchyme expresses T cell receptor mRNAs: relevance to cell growth control	ONCOGENE			English	Article						mesenchyme; stroma; TCR; cell growth; tumors	D-MU PROTEIN; STEM-CELLS; GENE; TRANSCRIPTS; MATURATION; SEQUENCE; LACKING; SURFACE; STROMA	The mesenchyme plays a crucial regulatory role in organ formation and maintenance. However, comprehensive molecular characterization of these cells is lacking. We found unexpectedly that primary mesenchyme, as well as mesenchymal cell clones, express T cell receptor (TCR)chibeta mRNAs, lacking the variable region. Immunological and genetic evidence support the expression of a corresponding TCRbeta protein. Additionally, mRNAs encoding TCR complex components including CD3 and chain are present. A relatively higher expression of the mesenchymal TCRbeta mRNA by cultured mesenchymal cell clones correlates with fast growth, whereas poorly expressing cells are slow growers and are contact inhibited. The clones that express relatively higher amount of the TCR mRNA exhibit an increased capacity to form tumors in nude mice. However, the expression of this mRNA in the mesenchyme is not per se leading to tumorigenesis, as demonstrated by primary mesenchyme that does not form tumors in mice while expressing moderate amounts of the TCR transcripts. The expression of mesencymal TCRbeta was confined to the G2/M phases of the cell cycle in the MBA-13 mesenchymal cell line. This cell cycle dependent expression, considered together with the correlation between growth properties and the level of TCR expression by cell clones, implies association of mesenchymal TCR with cell growth control.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Bar Ilan Univ, Dept Life Sci, Ramat Gan, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Bar Ilan University	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	dov.zipori@weizmann.ac.il		Shav-Tal, Yaron/0000-0002-8017-948X				Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; CALMAN AF, 1986, J EXP MED, V164, P1940, DOI 10.1084/jem.164.6.1940; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EISEMANN A, 1991, ONCOGENE, V6, P1195; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; FAGIOLI M, 1991, EUR J IMMUNOL, V21, P1529, DOI 10.1002/eji.1830210629; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Hilyard Katherine L., 1995, P403; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Jacobs H, 1996, ONCOGENE, V12, P2089; Lee BC, 1996, BLOOD, V87, P2283, DOI 10.1182/blood.V87.6.2283.bloodjournal8762283; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; MADRENAS J, 1994, MOL IMMUNOL, V31, P993, DOI 10.1016/0161-5890(94)90094-9; MADRENAS J, 1991, TRANSPLANT P, V23, P837; MADRENAS J, 1992, J IMMUNOL, V148, P612; OSSENDORP F, 1992, J IMMUNOL, V148, P3714; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; QIAN L, 1993, J IMMUNOL, V151, P6801; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Shav-Tal Y, 2000, EXP HEMATOL, V28, P1029, DOI 10.1016/S0301-472X(00)00510-5; Shoham T, 2001, LEUKEMIA, V15, P1102, DOI 10.1038/sj.leu.2402145; Snell R.S., 2000, CLIN ANATOMY MED STU; Sutton KA, 1998, IMMUNOLOGY, V93, P213, DOI 10.1046/j.1365-2567.1998.00410.x; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Wallace, 1981, VERTEBRATE LIMB REGE; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZIPORI D, 1988, BLOOD, V71, P586; ZIPORI D, 1989, HDB HEMOPOIETIC MICR, P287	37	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2029	2036		10.1038/sj.onc.1205269	http://dx.doi.org/10.1038/sj.onc.1205269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960375				2022-12-25	WOS:000174827000009
J	Hekman, M; Hamm, H; Villar, AV; Bader, B; Kuhlmann, J; Nickel, J; Rapp, UR				Hekman, M; Hamm, H; Villar, AV; Bader, B; Kuhlmann, J; Nickel, J; Rapp, UR			Associations of B- and C-raf with cholesterol, phosphatidylserine, and lipid second messengers - Preferential binding of Raf to artificial lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; INTEGRAL MEMBRANE-PROTEINS; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; CELL-SURFACE; H-RAS; CAVEOLAE MEMBRANE; STRUCTURAL BASIS; ZINC-FINGER; KINASE	The serine/threonine kinase C-Raf is a key mediator in cellular signaling. Translocation of Raf to membranes has been proposed to be facilitated by Ras proteins in their GTP-bound state. In this study we provide evidence that both purified B- and C-Raf kinases possess lipophilic properties and associate with phospholipid membranes. In the presence of phosphatidylserine and lipid second messengers such as phosphatidic acid and ceramides these associations were very specific with affinity constants (K-D) in the range of 0.5-50 nM. Raf association with liposomes was accompanied by displacement of 14-3-3 proteins and inhibition of Raf kinase activities. Interactions of Raf with cholesterol are of particular interest, since cholesterol has been shown to be involved, together with sphingomyelin and glycero-phospholipids in the formation of specialized lipid microdomains called rafts. We demonstrate here that purified Raf proteins have moderate binding affinity for cholesterol. However, under conditions of lipid raft formation, Raf association with cholesterol (or rafts) increased dramatically. Since ceramides also support formation of rafts and interact with Raf we propose that Raf may be present at the plasma membrane in two distinct microdomains: in raft regions via association with cholesterol and ceramides and in non-raft regions due to interaction with phosphatidylserine and phosphatidic acid. At either location Raf kinase activity was inhibited by lipid binding in the absence or presence of Ras. Ras-Raf interactions with full-length C-Raf were studied both in solution and in phospholipid environment. Ras association with Raf was GTP dependent as previously demonstrated for C-Raf-RBD fragments. In the presence of liposomes the recruitment of C-Raf by reconstituted Ras-farnesyl was only marginal, since almost 70% of added C-Raf was bound by the lipids alone. Thus Ras-Raf binding in response to activation of Ras-coupled receptors may utilize Raf protein that is already present at the membrane.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Basque Country, Dept Bioquim, Grp Biomembranas, E-48080 Bilbao, Spain; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany	University of Wurzburg; University of Basque Country; Max Planck Society; University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany.	rappur@mail.uni-wuerzburg.de	Villar, Ana/I-5190-2015	Villar, Ana/0000-0003-4588-9598; Bader, Benjamin/0000-0002-5299-396X				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Danelian E, 2000, J MED CHEM, V43, P2083, DOI 10.1021/jm991156g; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Marco MD, 2001, J BIOL CHEM, V276, P23009; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gennis R.B., 1988, BIOMEMBRANES MOL STR; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Kerkhoff E, 2001, ADV ENZYME REGUL, V41, P261, DOI 10.1016/S0065-2571(00)00023-6; KOLCH W, 1990, ONCOGENE, V5, P713; Kranenburg O, 2001, CURR BIOL, V11, P1880, DOI 10.1016/S0960-9822(01)00582-6; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LIU Z, 1995, EUR BIOPHYS J, V24, P31, DOI 10.1007/BF00216828; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Massey JB, 2001, BBA-BIOMEMBRANES, V1510, P167, DOI 10.1016/S0005-2736(00)00344-8; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Morre DJ, 1999, BIOFACTORS, V9, P179, DOI 10.1002/biof.5520090213; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Schulte T, 1997, DEVELOPMENT, V124, P577; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weber CK, 2000, ONCOGENE, V19, P169, DOI 10.1038/sj.onc.1203261; Wiese S, 2001, NAT NEUROSCI, V4, P137, DOI 10.1038/83960; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	77	72	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24090	24102		10.1074/jbc.M200576200	http://dx.doi.org/10.1074/jbc.M200576200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11953426	hybrid			2022-12-25	WOS:000176611800017
J	Lindqvist, A; Andersson, S				Lindqvist, A; Andersson, S			Biochemical properties of purified recombinant human beta-carotene 15,15'-monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; BETA,BETA-CAROTENE 15,15'-DIOXYGENASE; SUBSTRATE-SPECIFICITY; EXPRESSION; CLEAVAGE; IDENTIFICATION; PROTEINS; ENZYMES; CLONING	beta-Carotene 15,15'-monooxygenase (BCO), formerly known as beta-carotene 15,15'-dioxygenase, catalyzes the first step in the synthesis of vitamin A from dietary carotenoids. We have biochemically and enzymologically characterized the purified recombinant human BCO enzyme. A highly active BCO enzyme was expressed and purified to homogeneity from baculovirus-infected Spodoptera frugiperda 9 insect cells. The K-m and V-max of the enzyme for beta-carotene were 7 mum and 10 nmol retinal/mg x min, respectively, values that corresponded to a turnover number (k(cat)) of 0.66 min(-1) and a catalytic efficiency (k(cat)/K-m) of similar to10(5) m(-1.)min(-1). The enzyme existed as a tetramer in solution, and substrate specificity analyses suggested that at least one unsubstituted beta-ionone ring half-site was imperative for efficient cleavage of the carbon 15,15'-double bond in carotenoid substrates. High levels of BCO mRNA were observed along the whole intestinal tract, in the liver, and in the kidney, whereas lower levels were present in the prostate, testis, ovary, and skeletal muscle. The current data suggest that the human BCO enzyme may, in addition to its well established role in the digestive system, also play a role in peripheral vitamin A synthesis from plasma-borne provitamin A carotenoids.	Univ Texas, SW Med Ctr, Dept Obstet Gynecol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Andersson, S (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet Gynecol, F2106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	stefan.andersson@utsouthwestern.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052167] Funding Source: NIH RePORTER; NICHD NIH HHS [HD11149] Funding Source: Medline; NIDDK NIH HHS [DK52167] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENDICH A, 1989, FASEB J, V3, P1927, DOI 10.1096/fasebj.3.8.2656356; Blaner William S., 1994, P229; BLOMSTRA.R, 1967, SCAND J CLIN LAB INV, V19, P339, DOI 10.3109/00365516709090648; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; FIDGE NH, 1969, BIOCHEM J, V114, P689, DOI 10.1042/bj1140689; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; GOODMAN DS, 1967, J BIOL CHEM, V242, P3543; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GRISWOLD MD, 1989, ANN NY ACAD SCI, V564, P154, DOI 10.1111/j.1749-6632.1989.tb25895.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P82; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; KIM KH, 1990, MOL ENDOCRINOL, V4, P1679, DOI 10.1210/mend-4-11-1679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMAN.MR, 1972, J LIPID RES, V13, P477; LAKSHMANAN MR, 1968, BIOCHEM BIOPH RES CO, V33, P347, DOI 10.1016/0006-291X(68)90791-2; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; Moghrabi N, 1997, J CLIN ENDOCR METAB, V82, P3872, DOI 10.1210/jc.82.11.3872; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Rock CL, 1997, PHARMACOL THERAPEUT, V75, P185, DOI 10.1016/S0163-7258(97)00054-5; Sambrook J, 2001, MOL CLONING LAB MANU; SINGH H, 1974, BIOCHIM BIOPHYS ACTA, V370, P49, DOI 10.1016/0005-2744(74)90030-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wirtz GM, 2001, HELV CHIM ACTA, V84, P2301, DOI 10.1002/1522-2675(20010815)84:8<2301::AID-HLCA2301>3.0.CO;2-U; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	32	193	204	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23942	23948		10.1074/jbc.M202756200	http://dx.doi.org/10.1074/jbc.M202756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960992	hybrid			2022-12-25	WOS:000176475700109
J	Lee, MCS; Hamamoto, S; Schekman, R				Lee, MCS; Hamamoto, S; Schekman, R			Ceramide biosynthesis is required for the formation of the oligomeric H+-ATPase Pma1p in the yeast endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; GPI-ANCHORED PROTEINS; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; DOMINANT LETHAL MUTATIONS; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; GOLGI-APPARATUS; COAT PROTEINS; COPII; GENE	The yeast plasma membrane H+-ATPase Pma1p is one of the most abundant proteins to traverse the secretory pathway. Newly synthesized Pma1p exits the endoplasmic reticulum (ER) via COPII-coated vesicles bound for the Golgi. Unlike most secreted proteins, efficient incorporation of Pma1p into COPII vesicles requires the Sec24p homolog Lst1p, suggesting a unique role for Lst1p in ER export. Vesicles formed with mixed Sec24pLst1p coats are larger than those with Sec24p alone. Here, we examined the relationship between Pma1p biosynthesis and the requirement for this novel coat sub. unit. We show that Pma1p forms a large oligomeric complex of >1 MDa in the ER, which is packaged into COPII vesicles. Furthermore, oligomerization of Pma1p is linked to membrane lipid composition; Pma1p is rendered monomeric in cells depleted of ceramide, suggesting that association with lipid rafts may influence oligomerization. Surprisingly, monomeric Pma1p present in ceramide-deficient membranes can be exported from the ER in COPII vesicles in a reaction that is stimulated by Lst1p. We suggest that Lst1p directly conveys Pma1p into a COPII vesicle and that the larger size of mixed Sec24pLst1p COPII vesicles is not essential to the packaging of large oligomeric complexes.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.			Lee, Marcus/0000-0002-4973-0915				Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; DUFOUR JP, 1980, EUR J BIOCHEM, V105, P145, DOI 10.1111/j.1432-1033.1980.tb04484.x; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sutterlin C, 1997, J CELL SCI, V110, P2703; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824	33	114	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22395	22401		10.1074/jbc.M200450200	http://dx.doi.org/10.1074/jbc.M200450200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950838	hybrid			2022-12-25	WOS:000176313600037
J	Molotkov, A; Duester, G				Molotkov, A; Duester, G			Retinol/ethanol drug interaction during acute alcohol intoxication in mice involves inhibition of retinol metabolism to retinoic acid by alcohol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A; ETHANOL INHIBITION; MUTANT MICE; RAT-LIVER; MOUSE; EXPRESSION; HINDBRAIN; IDENTIFICATION; INITIATION; MECHANISM	Substantial evidence indicates that one consequence of alcohol intoxication is a reduction in retinoic acid (RA) levels. Studies on the mechanism have shown that chronic ethanol consumption induces P450 enzymes that increase RA degradation, thus accounting for much but not all of the observed decrease in RA. A reduction in RA synthesis may also be involved as ethanol competitively inhibits retinol oxidation catalyzed by alcohol dehydrogenase (ADH) in vitro. This may be important during acute ethanol intoxication and may contribute to adverse retinol/ethanol drug interactions. Here we have examined mice for the effect of either acute ethanol intoxication or Adh1 gene disruption on RA synthesis and degradation. RA produced following a dose of retinol (50 mg/kg) was reduced 87% by pretreatment with an intoxicating dose of ethanol (3.5 g/kg). RA produced in Adh1-null mutant mice following a 50-mg/kg dose of retinol was reduced 82% relative to wild-type mice, thus similar to wild-type mice pretreated with ethanol. Reduced RA production was associated with increased retinol levels in both ethanol-treated wild-type mice and Adh1-null mutant mice, indicating reduced clearance of the retinol dose. RA degradation following a dose of RA (10 mg/kg) was increased only 42% by ethanol pretreatment (3.5 g/kg) and only 26% in Adh1-null mutant mice relative to wild-type mice. These findings demonstrate that the reduced RA levels observed during acute retinol/ethanol drug interaction are due primarily to a decrease in ADH-catalyzed RA synthesis and secondarily to an increase in RA degradation.	Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Gene Regulat Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Armstrong Robert B., 1994, P545; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Chiang MY, 1998, NEURON, V21, P1353, DOI 10.1016/S0896-6273(00)80654-6; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; De Luca LM, 1997, J NUTR BIOCHEM, V8, P426, DOI 10.1016/S0955-2863(97)00063-6; Deltour L, 1996, FASEB J, V10, P1050, DOI 10.1096/fasebj.10.9.8801166; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; DUESTER G, 1991, ALCOHOL CLIN EXP RES, V15, P568, DOI 10.1111/j.1530-0277.1991.tb00562.x; Eckardt MJ, 1998, ALCOHOL CLIN EXP RES, V22, P998, DOI 10.1111/j.1530-0277.1998.tb03695.x; FROLIK CA, 1984, RETINOIDS, V2, P177; Gavalas A, 2000, CURR OPIN GENET DEV, V10, P380, DOI 10.1016/S0959-437X(00)00100-3; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Helms JA, 1996, DEVELOPMENT, V122, P1385; Kastner P., 1994, Vitamin A in health and disease., P189; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Leo MA, 1999, AM J CLIN NUTR, V69, P1071; Lieber CS, 1997, CLIN CHIM ACTA, V257, P59, DOI 10.1016/S0009-8981(96)06434-0; LINDBLAD B, 1976, JAMA-J AM MED ASSOC, V236, P1600, DOI 10.1001/jama.236.14.1600; Liu C, 2001, GASTROENTEROLOGY, V120, P179, DOI 10.1053/gast.2001.20877; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Malpel S, 2000, DEVELOPMENT, V127, P3057; Mangelsdorf David J., 1994, P319; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Misner DL, 2001, P NATL ACAD SCI USA, V98, P11714, DOI 10.1073/pnas.191369798; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 2000, DEVELOPMENT, V127, P75; Power SC, 1999, DEV DYNAM, V216, P469, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<469::AID-DVDY15>3.0.CO;2-3; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; SATRE MA, 1992, BIOL REPROD, V46, P802, DOI 10.1095/biolreprod46.5.802; Stratford T, 1996, CURR BIOL, V6, P1124, DOI 10.1016/S0960-9822(02)70679-9; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; Wagner E, 2000, DEV BIOL, V222, P460, DOI 10.1006/dbio.2000.9719; Wang XD, 1998, HEPATOLOGY, V28, P744, DOI 10.1002/hep.510280321; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	43	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22553	22557		10.1074/jbc.M201603200	http://dx.doi.org/10.1074/jbc.M201603200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960985	hybrid			2022-12-25	WOS:000176313600060
J	Schreiber, V; Ame, JC; Dolle, P; Schultz, I; Rinaldi, B; Fraulob, V; Menissier-de Murcia, J; de Murcia, G				Schreiber, V; Ame, JC; Dolle, P; Schultz, I; Rinaldi, B; Fraulob, V; Menissier-de Murcia, J; de Murcia, G			Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; LIGASE-III; PROTEIN; DAMAGE; CELLS; GENE; BETA; EXPRESSION; TANKYRASE; INTERACTS	The DNA damage dependence of poly(ADP-ribose) polymerase-2 (PARP-2) activity is suggestive of its implication in genome surveillance and protection. Here we show that the PARP-2 gene, mainly expressed in actively dividing tissues follows, but to a smaller extent, that of PARP-1 during mouse development. We found that PARP-2 and PARP-1 homo- and heterodimerize; the interacting interfaces, sites of reciprocal modification, have been mapped. PARP-2 was also found to interact with three other proteins involved in the base excision repair pathway: x-ray cross complementing factor 1 (XRCC1), DNA polymerase beta, and DNA ligase M, already known as partners of PARP-1. XRCC1 negatively regulates PARP-2 activity, as it does for PARP-1, while being a polymer acceptor for both PARP-1 and PARP-2. To gain insight into the physiological role of PARP-2 in response to genotoxic stress, we developed by gene disruption mice deficient in PARP-2. Following treatment by the alkylating agent N-nitroso-N-methylurea (MNU), PARP-2-deficient cells displayed an important delay in DNA strand breaks resealing, similar to that observed in PARP-1 deficient cells, thus confirming that PARP-2 is also an active player in base excision repair despite its low capacity to synthesize ADP-ribose polymers.	Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CEA, Lab Convent,CNRS,UPR 9003, F-67400 Illkirch Graffenstaden, France; Coll France, ULP, CNRS, INSERM,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	de Murcia, G (corresponding author), Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CEA, Lab Convent,CNRS,UPR 9003, Blvd Sebastian Brant, F-67400 Illkirch Graffenstaden, France.		Schreiber, Valérie/M-5007-2016; Dolle, Pascal/A-8037-2010	Schreiber, Valérie/0000-0003-0507-639X; Dolle, Pascal/0000-0002-9294-9090				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; BAUER PI, 1990, BIOCHEM J, V270, P17, DOI 10.1042/bj2700017; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; CONCHA II, 1989, EXP CELL RES, V180, P353, DOI 10.1016/0014-4827(89)90063-3; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; DeMurcia G., 2000, DNA DAMAGE STRESS SI; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Doucet-Chabeaud G, 2001, MOL GENET GENOMICS, V265, P954, DOI 10.1007/s004380100506; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Ma Q, 2001, BIOCHEM BIOPH RES CO, V289, P499, DOI 10.1006/bbrc.2001.5987; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; MENDOZAALVAREZ H, 1993, J BIOL CHEM, V268, P22575; Menissier De Murcia Josiane, 1997, Proceedings of the National Academy of Sciences of the United States of America, V94, P7303; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Niederreither K, 1998, ONCOGENE, V17, P1577, DOI 10.1038/sj.onc.1202072; Niederreither K, 1998, METH MOL B, V89, P247; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; SCHMID P, 1991, DEVELOPMENT, V113, P857; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 2000, DNA DAMAGE STRESS SI, P151; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wilson TM, 1996, MUTAT RES-DNA REPAIR, V362, P237, DOI 10.1016/0921-8777(95)00053-4	49	547	581	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23028	23036		10.1074/jbc.M202390200	http://dx.doi.org/10.1074/jbc.M202390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948190	hybrid			2022-12-25	WOS:000176313600118
J	Ayoub, MA; Couturier, C; Lucas-Meunier, E; Angers, S; Fossier, P; Bouvier, M; Jockers, R				Ayoub, MA; Couturier, C; Lucas-Meunier, E; Angers, S; Fossier, P; Bouvier, M; Jockers, R			Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN RECEPTOR; HORMONE RECEPTOR; HUMAN MEL1A; DOPAMINE; OLIGOMERIZATION; SURFACE; SOMATOSTATIN; ANTAGONISTS; INHIBITION; ACTIVATION	Several G protein-coupled receptors have been shown to exist as homo-and hetero-oligomeric complexes in living cells. However, the link between ligand-induced receptor activation and its oligomerization state as well as the proportion of the total receptor population that can engage in oligomeric complexes remain open questions. Here, the closely related human MT1 and MT2 melatonin receptors (MT1R, MT2R) were used to address these issues. Bioluminescence resonance energy transfer (BRET) experiments in living HEK 293 cells revealed that these receptors form homo- and hetero-oligomers. Constitutive energy transfer was observed for all receptor combinations at physiological expression levels and could be detected in single cell BRET experiments. Inhibition of the energy transfer by dilution of the BRET partners identified MT1R and MT2R dimers as the predominant receptor species, and this oligomerization state did not change upon agonist and antagonist binding. Agonists, neutral antagonists, and inverse agonists all promoted increases in BRET values for MT2R but not for MT1R homodimers in living cells and isolated plasma membranes. This indicates that no correlation could be inferred between the receptor activation state and the dimerization state of the receptor. This also suggests that ligand-promoted BRET increases represent specific ligand-induced conformational changes of pre-existing dimers rather then increased dimerization. The observation that ligands favored the energy transfer within the hetero-oligomer from MT1R to MT2R but not in the reverse orientation, from MT2R to MT1R, supports this view.	Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR 8104,INSERM,U567, F-75014 Paris, France; CNRS, UPR 9040, Neurobiol Cellulaire & Mol Lab, F-91198 Gif Sur Yvette, France; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universite de Montreal	Jockers, R (corresponding author), Inst Cochin Genet Mol, Dept Cell Biol, CNRS, UMR 8104,INSERM,U567, 22 Rue Mechain, F-75014 Paris, France.	jockers@cochin.inserm.fr	Jockers, Ralf/P-2272-2017; Jockers, Ralf/Q-2100-2019; Couturier, Cyril/ABG-9063-2020; Angers, Stephane/E-1432-2014; Bouvier, Michel/H-2758-2014; Couturier, Cyril CC/I-3020-2016	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750; Angers, Stephane/0000-0001-7241-9044; Bouvier, Michel/0000-0003-1128-0100; AYOUB, Mohammed Akli/0000-0003-0022-578X				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Armstrong D, 2001, J BIOL CHEM, V276, P22621, DOI 10.1074/jbc.M006936200; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Boute N, 2001, MOL PHARMACOL, V60, P640; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; DUBOCOVICH ML, 1983, NATURE, V306, P782, DOI 10.1038/306782a0; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; Dubocovich ML, 1998, FASEB J, V12, P1211, DOI 10.1096/fasebj.12.12.1211; DUBOCOVICH ML, 1987, P NATL ACAD SCI USA, V84, P3916, DOI 10.1073/pnas.84.11.3916; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MORGAN PJ, 1989, J NEUROENDOCRINOL, V1, P1, DOI 10.1111/j.1365-2826.1989.tb00068.x; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Petit L, 1999, BIOCHEM PHARMACOL, V58, P633, DOI 10.1016/S0006-2952(99)00134-3; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; REPPERT SM, 1988, SCIENCE, V242, P78, DOI 10.1126/science.2845576; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Tucek S, 1997, TRENDS PHARMACOL SCI, V18, P414; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; WUCH T, 2001, FEBS LETT, V507, P109; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	36	250	260	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21522	21528		10.1074/jbc.M200729200	http://dx.doi.org/10.1074/jbc.M200729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940583	hybrid			2022-12-25	WOS:000176286000053
J	Carmona, MC; Iglesias, R; Obregon, MJ; Darlington, GJ; Villarroya, F; Giralt, M				Carmona, MC; Iglesias, R; Obregon, MJ; Darlington, GJ; Villarroya, F; Giralt, M			Mitochondrial biogenesis and thyroid status maturation in brown fat require CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; C/EBP-ALPHA; TRANSCRIPTIONAL REGULATION; ADIPOCYTE DIFFERENTIATION; ACTIVATES TRANSCRIPTION; ADRENERGIC REGULATION; RETINOIC ACID; PPAR-ALPHA; BETA	Brown fat differentiation in mice is fully achieved in fetuses at term and entails the acquisition of not only adipogenic but also thermogenic and oxidative mitochondrial capacities. The present study of the mice homozygous for a deletion in the gene for CCAAT/enhancer-binding protein a (C/EBPalpha-null mice) demonstrates that C/EBPalpha is essential for all of these processes. Developing brown fat from C/EBPalpha-null mice showed a lack of uncoupling protein-1 expression, impaired adipogenesis, and reduced size and number of mitochondria per cell when compared with wild-type mice. Furthermore, immature mitochondrial morphology was found in brown fat, but not in liver or heart, from C/EBPalpha-null mice. Concordantly, expression of both nuclear and mitochondrial genome-encoded genes for mitochondrial proteins was reduced in C/EBPalpha-null brown fat, although expression of mitochondrial rRNA and mitochondrial DNA content were unaltered. Expression of nuclear respiratory factor-2, thyroid hormone nuclear receptors, and peroxisome proliferator-activated receptor gamma coactivator-1, was delayed in C/EBPalpha-null brown fat. Iodothyronine 5'-deiodinase activity and thyroid hormone content were also reduced in brown fat from C/EBPalpha-null mice, indicating for the first time a crucial role for C/EBPalpha in controlling thyroid status in developing brown fat, which may contribute to impaired mitochondrial biogenesis and cell differentiation. When survival of C/EBPalpha-null mice was achieved by transgenically expressing C/EBPalpha only in the liver, a substantial recovery in brown fat differentiation was found by day 7 of postnatal age, which is associated with a compensatory overexpression of C/EBPdelta and C/EBPbeta.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Autonoma Madrid, CSIC, Ctr Mixto, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA	University of Barcelona; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Baylor College of Medicine	Giralt, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.	giralt@bio.ub.es	Giralt, Marta/A-4756-2013; OBREGON, Maria Jesus/E-2946-2010; Villarroya, Francesc/K-4357-2014; Iglesias, Roser/C-5561-2017	Giralt, Marta/0000-0001-7968-4190; Iglesias, Roser/0000-0002-7107-8097; Carmona Orozco, Mamen/0000-0001-5911-6938; Villarroya, Francesc/0000-0003-1266-9142				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; BIANCO AC, 1987, J CLIN INVEST, V79, P295, DOI 10.1172/JCI112798; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; Casas F, 1999, MOL CELL BIOL, V19, P7913; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEONA CR, 1991, ENDOCRINOLOGY, V128, P422, DOI 10.1210/endo-128-1-422; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Elberg G, 2000, J BIOL CHEM, V275, P27815; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GIRALT M, 1990, EUR J BIOCHEM, V193, P297, DOI 10.1111/j.1432-1033.1990.tb19336.x; GIRALT M, 1988, BIOCHEM BIOPH RES CO, V156, P493, DOI 10.1016/S0006-291X(88)80868-4; GIRALT M, 1991, J BIOL CHEM, V266, P21991; IZQUIERDO JM, 1995, J BIOL CHEM, V270, P10342, DOI 10.1074/jbc.270.17.10342; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Li R, 1997, MOL CELL ENDOCRINOL, V128, P69, DOI 10.1016/S0303-7207(97)04023-9; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; MANCHADO C, 1994, BIOCHEM J, V302, P695, DOI 10.1042/bj3020695; MARTIN I, 1995, BIOCHEM J, V308, P749, DOI 10.1042/bj3080749; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Nedergaard J., 1986, BROWN ADIPOSE TISSUE, P152; NICHOLLS DG, 1986, BROWN ADIPOSE TISSUE, P52; OBREGON MJ, 1989, AM J PHYSIOL, V257, pE625, DOI 10.1152/ajpendo.1989.257.5.E625; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; REHNMARK S, 1993, FEBS LETT, V318, P235, DOI 10.1016/0014-5793(93)80519-Z; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; Song S, 2000, MOL CELL ENDOCRINOL, V165, P189, DOI 10.1016/S0303-7207(00)00246-X; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TERUEL T, 1995, BIOCHEM J, V310, P771, DOI 10.1042/bj3100771; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUCA A, 1993, ENDOCRINOLOGY, V132, P1913, DOI 10.1210/en.132.5.1913; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEIBEL ER, 1979, STEREOLOGICAL METHOD, V1, P23; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yubero P, 1998, MOL ENDOCRINOL, V12, P1023, DOI 10.1210/me.12.7.1023; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	58	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21489	21498		10.1074/jbc.M201710200	http://dx.doi.org/10.1074/jbc.M201710200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940593	hybrid			2022-12-25	WOS:000176286000049
J	El Kirat, K; Besson, F; Prigent, AF; Chauvet, JP; Roux, B				El Kirat, K; Besson, F; Prigent, AF; Chauvet, JP; Roux, B			Role of calcium and membrane organization on phospholipase D localization and activity - Competition between a soluble and an insoluble substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-CHROMOFUSCUS; PHOSPHATIDIC-ACID; PHOSPHATIDYLCHOLINE; CHOLESTEROL; MONOLAYERS; ACTIVATION; HYDROLYSIS; BINDING; DETERGENT; BILAYERS	The phospholipase D (PLD) from Streptomyces chromofuscus is a soluble enzyme known to be activated by the phosphatidic acid-calcium complexes. PLD-catalyzed hydrolysis of phospholipids in aqueous medium leads to the formation of phosphatidic acid (PA). Previous studies concluded on an allosteric activation of PLD by the PA-calcium complexes. In this work, the role of PA and calcium was investigated in terms of membrane structure and dynamics. The role of calcium in PLD partitioning between the soluble phase and the water-lipid interface was tested. The monomolecular film technique was used to measure both membrane dynamics and PLD activity. These experiments provided information on PLD activity at a water-lipid interface. Moreover, the ability of PA to enhance PLD activity toward phosphatidylcholine was correlated to the physical proper-ties of PA itself, affecting the rheology of the membrane. The effect of calcium was investigated on PLD binding to lipids and on the catalytic process by competition experiments between a soluble and a vesicular substrate. These experiments confirmed the absolute PLD requirement for calcium and pointed out the importance of calcium for PLD catalytic process and for the enzyme location at the water-lipid interface.	Univ Lyon 1, CNRS, UMR 5013, Lab Physicochim Biol, F-69622 Villeurbanne, France; Inst Natl Sci Appl, INSERM, U352, Lab Biochim & Pharmacol, F-69621 Villeurbanne, France; Ecole Cent Lyon, CNRS, UMR 5621, Lab Ingn & Fonct Surfaces, F-69131 Ecully, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Centrale de Lyon	El Kirat, K (corresponding author), Univ Lyon 1, CNRS, UMR 5013, Lab Physicochim Biol, 43 Blvd 11-11-1918, F-69622 Villeurbanne, France.	elkirat@univ-lyon1.fr	KIRAT, Karim EL/C-5136-2009; EL KIRAT, Karim/A-4590-2017	KIRAT, Karim EL/0000-0003-4884-7270; EL KIRAT, Karim/0000-0003-4884-7270				ALBRECHT O, 1981, J COLLOID INTERF SCI, V79, P319, DOI 10.1016/0021-9797(81)90084-9; Bechoua S, 1998, J LIPID RES, V39, P873; Beisson F, 2000, EUR J LIPID SCI TECH, V102, P133, DOI 10.1002/(SICI)1438-9312(200002)102:2<133::AID-EJLT133>3.3.CO;2-O; Davis LL, 1998, LIPIDS, V33, P223, DOI 10.1007/s11745-998-0199-5; Dong GA, 1999, BBA-PROTEIN STRUCT M, V1430, P234, DOI 10.1016/S0167-4838(99)00005-9; Dumaual AC, 2000, BBA-BIOMEMBRANES, V1463, P395, DOI 10.1016/S0005-2736(99)00235-7; Estrela-Lopis I, 2001, BIOPHYS J, V80, P749, DOI 10.1016/S0006-3495(01)76054-7; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; HOLBROOK PG, 1991, BIOCHIM BIOPHYS ACTA, V1084, P155, DOI 10.1016/0005-2760(91)90214-3; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; Iwasaki Y, 1999, EUR J BIOCHEM, V264, P577, DOI 10.1046/j.1432-1327.1999.00669.x; KONDO T, 1994, THIN SOLID FILMS, V244, P887, DOI 10.1016/0040-6090(94)90593-2; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Li XM, 2001, BIOCHEMISTRY-US, V40, P5954, DOI 10.1021/bi002791n; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Ponting CP, 1996, PROTEIN SCI, V5, P914; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; Stieglitz KA, 2001, BIOCHEMISTRY-US, V40, P13954, DOI 10.1021/bi011338o; Vinggaard AM, 1996, BIOCHEM J, V319, P861, DOI 10.1042/bj3190861; YAMAMOTO I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P293, DOI 10.1016/0005-2736(93)90302-G; YAMAMOTO I, 1995, BBA-BIOMEMBRANES, V1233, P21, DOI 10.1016/0005-2736(94)00220-J; Yu CH, 1996, MOL CELL BIOCHEM, V157, P101	22	32	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21231	21236		10.1074/jbc.M106449200	http://dx.doi.org/10.1074/jbc.M106449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940565	hybrid			2022-12-25	WOS:000176286000016
J	Nakayama, T; Matsushita, T; Dong, ZY; Sadler, JE; Jorieux, S; Mazurier, C; Meyer, D; Kojima, T; Saito, H				Nakayama, T; Matsushita, T; Dong, ZY; Sadler, JE; Jorieux, S; Mazurier, C; Meyer, D; Kojima, T; Saito, H			Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb - Importance of structural integrity of the regions flanked by the Cys(1272)-Cys(1458) disulfide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN-IB; VONWILLEBRAND-FACTOR-BINDING; FACTOR A1 DOMAIN; ALANINE-SCANNING MUTAGENESIS; MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; HEMOPHILIA-A; ALPHA-CHAIN; RISTOCETIN; BOTROCETIN	In vitro platelet glycoprotein Ib (GPIb) binding of the human von Willebrand factor (VWF) increases markedly by exogenous modulators such as ristocetin or botrocetin, and the binding does not occur in normal circulation. GPIb binding sites have been assigned in the VWF A1 domain, which consists of a disulfide loop Cys(1272(509))-cys(1458(695)) where amino acid residues are numbered from the starting methionine as + 1. The previous numbering from the N-terminal Ser of the mature processed VWF is indicated in parentheses. In contrast, several gain-of-function mutations have been found in two regions comprised of the disulfide loop and its Nand C-terminal flanking regions. In this study, cys(1222(459))-Tyr(1271(508)), Gln(1238(475))-Tyr(1271(508)), Glu(1260(497))-Tyr(1271(508)), and Asp(1459(696))Asp(1472(709)) were sequentially deleted of full-length multimeric recombinant VWF. Deletions at either side resulted in normal GPIb binding, indicating that the flanking regions are not GPIb binding sites. However, the addition of a mutation at Arg(1308(545)) on each deletion mutant resulted in spontaneous GPIb binding without requiring modulators, suggesting that both regions are important for the inhibition of GPIb binding. Spontaneous binding was completely inhibited by monoclonal antibodies that recognize the GPIb binding sites. Interestingly, mutant proteins with N-terminal but not C-terminal deletions lost binding to monoclonal antibodies 13328, 13710, and 23C7, which selectively inhibit ristocetin-induced GPI binding. Their epitopes were found at His(1268(505)) or Asp(1269(506)). The crystallographic structure of the A1 domain suggests that GPIb binding is influenced by the molecular interface between the two regions and that the antibody binding to the interface inhibits binding.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Ctr Reg Transfus Sanguine, F-59012 Lille, France; LRB, Diveloppement Pri Clin, F-59011 Lille, France; Hop Bicetre, INSERM, U143, F-94275 Le Kremlin Bicetre, France; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Aichi Blood Dis Res Fdn, Moriyama Ku, Nagoya, Aichi 4630074, Japan; Nagoya Natl Hosp, Naka Ku, Nagoya, Aichi 4610001, Japan	Nagoya University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Nagoya University	Matsushita, T (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, 65 Tsurumacho, Nagoya, Aichi 4668550, Japan.	tmatsu@med.nagoya-u.ac.jp	Matsushita, Tadadshi/I-7349-2014; Sadler, Evan/D-8556-2011; Kojima, Tetsuhito/I-6271-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Nakayama, Takayuki/0000-0003-2389-2542				ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; AZUMA H, 1993, THROMB HAEMOSTASIS, V69, P192; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHRISTOPHE O, 1995, BRIT J HAEMATOL, V90, P195, DOI 10.1111/j.1365-2141.1995.tb03400.x; COLLER BS, 1983, BLOOD, V61, P99; De Luca M, 2000, BLOOD, V95, P164; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; FUJIMURA Y, 1992, THROMB HAEMOSTASIS, V68, P464; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; HANDA M, 1986, J BIOL CHEM, V261, P2579; JORIEUX S, 1987, THROMB HAEMOSTASIS, V57, P278; KAWAI Y, 1987, ANN NY ACAD SCI, V509, P60, DOI 10.1111/j.1749-6632.1987.tb30984.x; Kroner PA, 1996, BIOCHEMISTRY-US, V35, P13460, DOI 10.1021/bi9610313; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MASCELLI MA, 1986, BIOCHEMISTRY-US, V25, P6325, DOI 10.1021/bi00368a074; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MURATA M, 1991, J BIOL CHEM, V266, P15474; PIETU G, 1994, THROMB HAEMOSTASIS, V71, P788; RABINOWITZ I, 1992, P NATL ACAD SCI USA, V89, P9846, DOI 10.1073/pnas.89.20.9846; RAINES G, 1990, THROMB RES, V60, P201, DOI 10.1016/0049-3848(90)90181-B; SCHULLEK J, 1984, J CLIN INVEST, V73, P421, DOI 10.1172/JCI111228; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; STEL HV, 1984, BLOOD, V63, P1408; Tessier D C, 1996, Methods Mol Biol, V57, P229; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VICENTE V, 1990, J BIOL CHEM, V265, P274	33	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22063	22072		10.1074/jbc.M201327200	http://dx.doi.org/10.1074/jbc.M201327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943773	hybrid			2022-12-25	WOS:000176286000119
J	Renshaw, PS; Panagiotidou, P; Whelan, A; Gordon, SV; Hewinson, RG; Williamson, RA; Carr, MD				Renshaw, PS; Panagiotidou, P; Whelan, A; Gordon, SV; Hewinson, RG; Williamson, RA; Carr, MD			Conclusive evidence that the major T-cell antigens of the Mycobacterium tuberculosis complex ESAT-6 and CFP-10 form a tight, 1 : 1 complex and characterization of the structural properties of ESAT-6, CFP-10, and the ESAT-6-CFP-10 complex - Implications for pathogenesis and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SEQUENCE; TRANSCRIPTION; DIAGNOSIS; VACCINES; SPECTRA; DOMAIN; FOS; BCG	The proteins ESAT-6 and CFP-10 have been shown to be secreted by Mycobacterium tuberculosis and Mycobacterium bovis cells, to be potent T-cell antigens, and to have a clear but as yet undefined role in tuberculosis pathogenesis. We have successfully overexpressed both ESAT-6 and CFP-10 in Escherichia coli and developed efficient purification schemes. Under in vivo-like conditions, a combination of fluorescence, circular dichroism, and nuclear magnetic resonance spectroscopy have shown that ESAT-6 contains up to 75% helical secondary structure, but little if any stable tertiary structure, and exists in a molten globule-like state. In contrast, CFP-10 was found to form an unstructured, random coil polypeptide. An exciting discovery was that ESAT-6 and CFP-10 form a tight, 1:1 complex, in which both proteins adopt a fully folded structure, with about two-thirds of the backbone in a regular helical conformation. This clearly suggests that ESAT-6 and CFP-10 are active as the complex and raises the interesting question of whether other ESAT-6/CFP-10 family proteins (22 paired genes in M. tuberculosis) also form tight, 1:1 complexes, and if so, is this limited to their genome partner, or is there scope for wider interactions within the protein family, which could provide greater functional flexibility?	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Vet Labs Agcy Weybridge, Dept Bacterial Dis, TB Res Grp, Addlestone KT15 3NB, Surrey, England	University of Leicester; University of Kent; Veterinary Laboratories Agency	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	mdc12@le.ac.uk	Hewinson, Glyn/J-1902-2014; Whelan, Adam O/C-9497-2011; Hewinson, Glyn/F-7077-2010; Hewinson, Glyn/AAA-2364-2019	Carr, Mark/0000-0002-3939-0996; Gordon, Stephen/0000-0002-4833-5542; Hewinson, Glyn/0000-0002-5517-4281				Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brosch R, 1998, INFECT IMMUN, V66, P2221, DOI 10.1128/IAI.66.5.2221-2229.1998; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Cole ST, 1999, FEBS LETT, V452, P7, DOI 10.1016/S0014-5793(99)00536-0; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Ehlers S, 1999, FEMS IMMUNOL MED MIC, V23, P149, DOI 10.1111/j.1574-695X.1999.tb01234.x; FEENEY J, 1991, J MAGN RESON, V91, P607, DOI 10.1016/0022-2364(91)90388-A; Gey van Pittius NC, 2001, GENOME BIOL, V2; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; Skjot RLV, 2000, INFECT IMMUN, V68, P214, DOI 10.1128/IAI.68.1.214-220.2000; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stenger S, 1999, CURR OPIN MICROBIOL, V2, P89, DOI 10.1016/S1369-5274(99)80015-0; Tekaia F., 1999, Tubercle and Lung Disease, V79, P329, DOI 10.1054/tuld.1999.0220; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000; Vordermeier HM, 2001, CLIN DIAGN LAB IMMUN, V8, P571, DOI 10.1128/CDLI.8.3.571-578.2001; Wards BJ, 2000, TUBERCLE LUNG DIS, V80, P185, DOI 10.1054/tuld.2000.0244; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Young DB, 1999, SCIENCE, V284, P1479, DOI 10.1126/science.284.5419.1479; Young DB, 1998, NATURE, V393, P515, DOI 10.1038/31095; Zumla A, 1998, BRIT MED J, V316, P1962, DOI 10.1136/bmj.316.7149.1962	34	257	289	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21598	21603		10.1074/jbc.M201625200	http://dx.doi.org/10.1074/jbc.M201625200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940590	hybrid			2022-12-25	WOS:000176286000064
J	Sano, T; Baker, D; Virag, T; Wada, A; Yatomi, Y; Kobayashi, T; Igarashi, Y; Tigyi, G				Sano, T; Baker, D; Virag, T; Wada, A; Yatomi, Y; Kobayashi, T; Igarashi, Y; Tigyi, G			Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; LYSOPHOSPHOLIPASE-D; PHOSPHOLIPASE A(1); ARACHIDONIC-ACID; XENOPUS OOCYTES; HUMAN-PLASMA; THROMBIN; PHOSPHATIDYLINOSITOL; IDENTIFICATION; MICROVESICLES	Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (Sph1P) production was examined in vitro under conditions that simulated blood clotting. Several approaches were utilized to elucidate the metabolic pathways. 1) Platelet phospholipids were labeled using [P-32]orthophosphate, and the production of [P-32]Sph1P and LPA was examined. Thrombin stimulation of platelets resulted in rapid secretion of Sph1P stored within the platelet. In contrast, LPA was neither stored within nor secreted from platelets. Nonetheless, extracellular levels of LPA gradually increased following stimulation. 2) Stable-isotope dilution mass spectrometry was used to quantify the molecular species of LPA generated from platelets in vitro. Only 10% of the LPA generated following thrombin stimulation was associated with platelets, the remaining 90% was contained within the extracellular medium. The acyl composition of LPA produced by platelets differed depending on the presence or absence of plasma in the incubation. 3) The fate of exogenously added fluorescent phospholipid analogs was determined. Incubation of [(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl-(NDD) -labeled phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine with the supernatant fractions from thrombin-stimulated platelets yielded no LPA production. However, these lipids were converted to the corresponding lysolipids by released PLA(1) and PLA(2) activities. When incubated with plasma or serum the NBD-labeled lysophospholipids were readily converted to LPA. Inhibitors of lysophospholipase D and the biological activity of LPA were detected in plasma. These results suggest that the bulk of LPA produced through platelet activation results from the sequential cleavage of phospholipids to lysophospholipids by released phospholipases A(1) and A(2) and then to LPA by plasma lysophospholipase D.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Sapporo, Hokkaido 060812, Japan; Yamanashi Med Univ, Dept Lab Med, Yamanashi 4093898, Japan; Ochanomizu Univ, Dept Biol, Tokyo 112, Japan	University of Tennessee System; University of Tennessee Health Science Center; Hokkaido University; University of Yamanashi; Ochanomizu University	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu	Sano, Takamitsu/F-9410-2012	Yatomi, Yutaka/0000-0003-1719-4297; Baker, Daniel/0000-0003-1482-0416	NHLBI NIH HHS [HL61469, HL027641] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERGHINA M, 1994, FEBS LETT, V351, P181, DOI 10.1016/0014-5793(94)00811-6; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BILLAH MM, 1981, J BIOL CHEM, V256, P5399; BILLAH MM, 1980, J BIOL CHEM, V255, P227; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; ELLA KM, 1994, ANAL BIOCHEM, V218, P136, DOI 10.1006/abio.1994.1152; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Friedman P, 1996, J BIOL CHEM, V271, P953, DOI 10.1074/jbc.271.2.953; GERRARD JM, 1984, BIOCHIM BIOPHYS ACTA, V795, P487, DOI 10.1016/0005-2760(84)90177-2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GOETZL E, 2000, CYTOKINE REFERENCE, P1407; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; HIRAMATSU T, 2001, 7 INT C PLAT ACT FAC, P146; KATES M, 1986, TECHNIQUES LIPIDOLOG, P404; Kimura Y, 2001, J BIOL CHEM, V276, P15208, DOI 10.1074/jbc.M011588200; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; LAPETINA EG, 1981, J BIOL CHEM, V256, P1984; LAPETINA EG, 1979, BIOCHIM BIOPHYS ACTA, V573, P394, DOI 10.1016/0005-2760(79)90072-9; Le Balle F, 1999, ADV ENZYME REGUL, V39, P275, DOI 10.1016/S0065-2571(98)00024-7; LLOYD JV, 1974, BRIT J HAEMATOL, V26, P243, DOI 10.1111/j.1365-2141.1974.tb00469.x; LLOYD JV, 1972, BRIT J HAEMATOL, V23, P571, DOI 10.1111/j.1365-2141.1972.tb07092.x; MAHADEVAPPA VG, 1982, BIOCHIM BIOPHYS ACTA, V713, P73, DOI 10.1016/0005-2760(82)90168-0; MARCUS AJ, 1972, BLOOD LIPIDS LIPOPRO, P429; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; NACELLIN N, 2002, J BIOL CHEM, V277, P6667; Nakajima K, 2002, J BIOL CHEM, V277, P11329, DOI 10.1074/jbc.M111092200; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; SKIPSKI VP, 1967, BIOCHEM J, V104, P340, DOI 10.1042/bj1040340; SWITZER S, 1965, J LIPID RES, V6, P506; THUMSER AEA, 1994, BIOCHEM J, V301, P801, DOI 10.1042/bj3010801; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; TIGYI GJ, 1999, PHOSPHOLIPID GROWTH, P51; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Yatomi Y, 2000, BLOOD, V96, P3431; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480	48	212	233	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21197	21206		10.1074/jbc.M201289200	http://dx.doi.org/10.1074/jbc.M201289200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929870	hybrid			2022-12-25	WOS:000176286000012
J	Wang, WL; Prince, CZ; Mou, YS; Pollman, MJ				Wang, WL; Prince, CZ; Mou, YS; Pollman, MJ			Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation - Resistance to Fas ligand-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDITION CAUSING STROKE; FATE; INHIBITION; CADASIL; INJURY; MUTATIONS; GRIDLOCK; DOWNSTREAM; REPRESSES; KINASE	Mutations in the Notch3 receptor result in the cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephelopathy (CADASIL) syndrome, a heritable arteriopathy predisposing to early onset stroke. Based upon clinical evidence that CADASIL arteriopathy results in degeneration and loss of vascular smooth muscle cells (VSMC) from the arterial wall, we postulated that Notch3 signaling is a critical determinant of VSMC survival. We initially established that both transient and constitutive Notch3 signaling promoted VSMC survival in response to the proapoptotic Fas ligand (FasL). Resistance to FasL-induced apoptosis was associated with the induction of e-FLIP, a primary inhibitor of the FasL signaling pathway. We determined that Notch3's regulation of c-FLIP was independent of the activity of the classical DNA-binding protein, RBPJk, but dependent upon cross-talk activation of the ERK/MAPK pathway. We extended our observations to the in vivo context by deter-mining a coordinate regulation of Notch3 and c-FLIP within the arterial wall in response to injury. Furthermore, we defined that expression levels of Notch3 and c-FLIP are coordinately up-regulated within the neointima of remodeled arteries. Taken together, these findings provide initial evidence that Notch3 signaling may be a critical determinant of VSMC survival and vascular structure by modulating the expression of downstream mediators of apoptosis via signaling cross-talk with the ERK/MAPK pathway.	Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA	Morehouse School of Medicine	Pollman, MJ (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA.	mpollman@msm.edu						Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Beatus P, 1999, DEVELOPMENT, V126, P3925; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Boyle JJ, 2001, ARTERIOSCL THROM VAS, V21, P1402, DOI 10.1161/hq0901.094279; Cai WJ, 1997, ATHEROSCLEROSIS, V131, P177, DOI 10.1016/S0021-9150(97)06099-1; Chan SW, 2000, CIRC RES, V86, P1038, DOI 10.1161/01.RES.86.10.1038; CHITNIS AB, 1995, MOL CELL NEUROSCI, V6, P311, DOI 10.1006/mcne.1995.1024; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Fitzgerald K, 2000, ONCOGENE, V19, P4191, DOI 10.1038/sj.onc.1203766; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Gibbons GH, 2000, CIRC RES, V86, P1009, DOI 10.1161/01.RES.86.10.1009; Hamada Y, 1999, DEVELOPMENT, V126, P3415; HAN DKM, 1995, AM J PATHOL, V147, P267; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Imanishi T, 2000, AM J PATHOL, V156, P125, DOI 10.1016/S0002-9440(10)64712-8; Imanishi T, 2000, J VASC RES, V37, P523, DOI 10.1159/000054085; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Joutel A, 2000, ANN NEUROL, V47, P388, DOI 10.1002/1531-8249(200003)47:3<388::AID-ANA19>3.3.CO;2-H; Joutel A, 1997, ANN NY ACAD SCI, V826, P213, DOI 10.1111/j.1749-6632.1997.tb48472.x; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; McLaughlin KA, 2000, DEV BIOL, V227, P567, DOI 10.1006/dbio.2000.9913; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; Pollman MJ, 1999, CIRC RES, V84, P113; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Wang WL, 2001, CIRCULATION, V104, P89; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	44	105	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21723	21729		10.1074/jbc.M202224200	http://dx.doi.org/10.1074/jbc.M202224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925448	hybrid			2022-12-25	WOS:000176286000080
J	Yamauchi, S; Tokita, Y; Aono, S; Matsui, F; Shuo, T; Ito, H; Kato, K; Kasahara, K; Oohira, A				Yamauchi, S; Tokita, Y; Aono, S; Matsui, F; Shuo, T; Ito, H; Kato, K; Kasahara, K; Oohira, A			Phosphorylation of neuroglycan C, a brain-specific transmembrane chondroitin sulfate proteoglycan, and its localization in the lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-ACTIVITY; CAVEOLAE-LIKE DOMAINS; MOLECULE HB-GAM; CELL-SURFACE; SIGNAL-TRANSDUCTION; ECTOPROTEIN KINASE; NEURONAL SURVIVAL; NERVOUS-SYSTEM; ZETA/RPTP-BETA; AXON GROWTH	Neuroglycan C (NGC) is a brain-specific transmembrane chondroitin sulfate proteoglycan. In the present study, we examined whether NGC could be phosphorylated in neural cells. On metabolic labeling of cultured cerebral cortical cells from the rat fetus with P-32(i), serine residues in NGC were radiolabeled. Some NGC became detectable in the raft fraction from the rat cerebrum, a signaling microdomain of the plasma membrane, with cerebral development. NGC from the non-raft fraction, not the raft fraction, could be phosphorylated by an in vitro kinase reaction. The phosphorylation of NGC was inhibited by adding to the reaction mixture a recombinant peptide representing the ectodomain of NGC, but not by adding a peptide representing its cytoplasmic domain. NGC could be labeled by an in vitro kinase reaction using [gamma-P-32]GTP as well as [gamma-P-32]ATP, and this kinase activity was partially inhibited by 5,6-dichloro-1-beta-D-ribofaranosylbenzimidazole, a selective inhibitor of casein kinase II. In addition to the intracellular phosphorylation, NGC was also phosphorylated at the cell surface by an ectoprotein kinase. This is the first report to demonstrate that NGC can be phosphorylated both intracellularly and pericellularly, and our findings suggest that a kinase with a specificity similar to that of casein kinase II is responsible for the NGC ectodomain phosphorylation.	Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Kasugai, Aichi 4800392, Japan; Nagoya Univ, Grad Sch Med, Dept Neurochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya City Univ, Grad Sch Nat Sci, Showa Ku, Nagoya, Aichi 4678501, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo Metropolitan Org Med Res, Bunkyo Ku, Tokyo 1138613, Japan	Nagoya University; Nagoya City University; Tokyo Metropolitan Institute of Medical Science	Oohira, A (corresponding author), Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, 713-8 Kagiua Cho, Kasugai, Aichi 4800392, Japan.	oohira@inst-hsc.pref.aichi.jp		Kasahara, Kohji/0000-0001-7010-8365; Ito, Hidenori/0000-0002-6527-477X				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Apasov SG, 1996, J BIOL CHEM, V271, P25677, DOI 10.1074/jbc.271.41.25677; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Carey DJ, 1996, PERSPECT DEV NEUROBI, V3, P331; Chen W, 1996, P NATL ACAD SCI USA, V93, P8688, DOI 10.1073/pnas.93.16.8688; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; CORBIN JD, 1983, METHOD ENZYMOL, V99, P317; EHRLICH YH, 1988, J NEUROCHEM, V50, P295, DOI 10.1111/j.1471-4159.1988.tb13263.x; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Gary SC, 1998, CURR OPIN NEUROBIOL, V8, P576, DOI 10.1016/S0959-4388(98)80083-4; Grumet M, 1996, PERSPECT DEV NEUROBI, V3, P319; HARDWICK JC, 1989, J NEUROCHEM, V53, P1512, DOI 10.1111/j.1471-4159.1989.tb08546.x; HENDLEY ED, 1988, J NEUROCHEM, V50, P263, DOI 10.1111/j.1471-4159.1988.tb13259.x; HOGAN MV, 1995, J NEUROCHEM, V65, P2022; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1989, J BIOL CHEM, V264, P14549; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lander AD, 1996, PERSPECT DEV NEUROBI, V3, P347; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MURATA H, 1994, RAPID COMMUN MASS SP, V8, P205, DOI 10.1002/rcm.1290080216; NAGASHIMA K, 1991, FEBS LETT, V293, P119, DOI 10.1016/0014-5793(91)81165-5; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; OOHIRA A, 1998, CONNECT TISSUE, V30, P49; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAULO E, 1994, J BIOL CHEM, V269, P12999; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; SCOTT MG, 1988, BIOCHEM BIOPH RES CO, V155, P1353, DOI 10.1016/S0006-291X(88)81290-7; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Small DH, 1996, J NEUROCHEM, V67, P889; SNOW AD, 1989, NEUROBIOL AGING, V10, P481, DOI 10.1016/0197-4580(89)90108-5; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WALTER J, 1994, CELL MOL BIOL RES, V40, P473; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Watanabe E, 1996, J NEUROSCI RES, V44, P84, DOI 10.1002/(SICI)1097-4547(19960401)44:1<84::AID-JNR11>3.3.CO;2-V; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	65	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20583	20590		10.1074/jbc.M200909200	http://dx.doi.org/10.1074/jbc.M200909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929867	hybrid			2022-12-25	WOS:000176204500063
J	Ricort, JM; Binoux, M				Ricort, JM; Binoux, M			Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase - Effects on the insulin-like growth factor signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TYPE-1 IGF RECEPTOR; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITION; AFFINITY; GENE	The proliferative action of insulin-like growth factors (IGF-I and -II) is mediated via the type I IGF receptor (IGF-IR) and is modulated by their association with high affinity binding proteins, IGFBP-1 to -6. We recently found that, in addition to its ability to bind IGFs, IGFBP-3 also inhibits IGF-IR activation independently of IGF binding and without interacting directly with IGF-IR. Here, we show that IGFBP-3 is capable of blocking the signal triggered by IGFs. Breast carcinoma-derived cells (MCF-7) were stimulated by des(1-3)IGF-I or [Gln(3),Ala(4),Tyr(15),Leu(16)]IGF-I, two IGF analogues with intact affinity for IGF-IR, but with weak or virtually no affinity for IGFBPs, then incubated with IGFBP-3. The activated IGF-IR was desensitized through reversal of its autophosphorylation, following which both phosphatidylinositol 3-kinase and p42(MAPK) activities were depressed. Direct measurement of phosphotyrosine phosphatase activity and reconstitution experiments using tyrosine-phosphorylated insulin receptor substrate-1 (IRS-1) indicated that IGFBP-3 activated a phosphotyrosine phosphatase (PTPase). This action appeared to be peculiar to IGFBP-3 among the IGFBPs, since neither IGFBP-1 nor IGFBP-5 (structurally the closest to IGFBP-3), had any such effect. Several cell lines derived from normal or tumor cells responsive to IGF-I were used to show that IGFBP-3-stimulated PTPase is cell type-specific. Although the precise nature of the phosphatase remains to be determined, the results of this study demonstrate that IGFBP-3 stimulates a phosphotyrosine phosphatase activity that down-regulates the IGF-I signaling pathway, suggesting a major role for IGFBP-3 in regulating cell proliferation.	Univ Paris 06, INSERM U515, Hop St Antoine, Assistance Publ Hop Paris, F-75571 Paris 12, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite	Ricort, JM (corresponding author), Univ Paris 06, INSERM U515, Hop St Antoine, Assistance Publ Hop Paris, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	ricort@st-antoine.inserm.fr						Baserga R, 1999, CONT ENDOCRINOL, V17, P329; Baxter RC, 1997, ADV MOL CELL ENDOCRI, V1, P123, DOI [10.1016/S1569-2566(97)80036-1, DOI 10.1016/S1569-2566(97)80036-1]; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; Gucev ZS, 1996, CANCER RES, V56, P1545; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Holly JMP, 1999, J ENDOCRINOL, V162, P321, DOI 10.1677/joe.0.1620321; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; MohseniZadeh S, 1997, ENDOCRINOLOGY, V138, P5645, DOI 10.1210/en.138.12.5645; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OH Y, 1993, J BIOL CHEM, V268, P26045; Oh Y, 1999, CONT ENDOCRINOL, V17, P257; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WHITE MF, 1994, J BIOL CHEM, V269, P1	31	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19448	19454		10.1074/jbc.M200439200	http://dx.doi.org/10.1074/jbc.M200439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11940579	hybrid			2022-12-25	WOS:000175894800029
J	Arai, A; Kanda, E; Miura, O				Arai, A; Kanda, E; Miura, O			Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway	ONCOGENE			English	Article						rac; erythropoietin; IL-3; signal transduction; hematopoietic cells	GUANOSINE TRIPHOSPHATASES; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; CELL ADHESION; RHO GTPASES; PROTEIN; RECEPTOR; BINDING; EXCHANGE; CRKL	Previous studies have shown that hematopoietic cytokines, including erythropoietin (Epo) and interleukin (IL)-3, activate the Ras GTPase and the downstream Raf/Erk/Elk-1 signaling pathway. Here we report that Epo or IL-3 rapidly and transiently activates Rac, a Rho family GTPase, in hernatopoietic cell lines, 32D/EpoR-Wt and UT-7. The cytokine-induced activation of Rac was augmented in a 32D/EpoR-Wt clone that inducibly overexpresses the adaptor protein CrkL or the Ras guanine nucleotide exchange factor C3G, which forms a complex with CrkL. Furthermore, the Rac activation was enhanced or inhibited in cells inducibly expressing an activated Ras mutant, H-Ras61L, or a dominant negative Ras mutant, H-Ras17N, respectively. In addition, the cytokine-induced Rac activation was inhibited by a phosphatidyl-inositol 3'-kinase (PI3K) inhibitor, LY294002, which also inhibited the Erk activation. A dominant negative Rac mutant, Rac17N, also inhibited the cytokine-induced activation of Erk as well as Elk-1. On the other hand, activation of Akt downstream of PI3K was found to play an inhibitory role in cytokine activation of Erk/Elk-1. Together, these results indicate that Rac is activated by Epo or IL-3 at downstream of the Ras/PI3K pathway in parallel with Akt and plays a role in activation of the Erk/Elk-1 signaling pathway in hematopoietic cells.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	miura.med1@med.tmd.ac.jp		Miura, Osamu/0000-0002-0981-3054				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Arai A, 2001, J BIOL CHEM, V276, P33282, DOI 10.1074/jbc.M102924200; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chin H, 1998, BLOOD, V91, P3734; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa T, 1996, IEEE T POWER DELIVER, V11, P1776, DOI 10.1109/61.544257; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KOMATSU N, 1991, CANCER RES, V51, P341; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MIURA Y, 1994, J BIOL CHEM, V269, P29962; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; Nosaka Y, 2001, BIOCHEM BIOPH RES CO, V285, P675, DOI 10.1006/bbrc.2001.5222; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; VAN AL, 1997, GENE DEV, V11, P2295; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	40	42	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2641	2651		10.1038/sj.onc.1205346	http://dx.doi.org/10.1038/sj.onc.1205346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965537				2022-12-25	WOS:000174996500004
J	Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R				Billard, LM; Magdinier, F; Lenoir, GM; Frappart, L; Dante, R			MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland	ONCOGENE			English	Article						breast cancer; prenatal developments; methyl binding proteins; RT-PCR	HISTONE DEACETYLASE COMPLEX; BINDING-PROTEIN MECP2; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CHROMATIN; IDENTIFICATION; CANCER	During the last years, a direct link between DNA methylation and repressive chromatin structure has been established. This structural modification is mediated by histone deacetylases targeted to the methylated sequences by Methyl Binding Proteins (MBD). Human cancer cells exhibit both a global hypomethylation and some localized hypermethylations suggesting that the deregulation of the methylation machinery is a central event in tumorigenesis. Therefore, we have investigated in human tissues the expression of two major MBDs, MeCP2 and MBD2, during the proliferation of normal breast and in benign and neoplasic breast tumors. Quantitation of the transcripts indicates that MBD2 mRNAs are 20-30-fold more abundant than MeCP2 transcripts in the adult and fetal human mammary gland. In pathological tissues samples MBD2 mRNA levels are significantly higher (P = 0.001) in benign tumors compared with normal breast tissues, whereas MeCP2 expression is not modified in these specimens. In neoplasic samples a deregulation of the expression of both genes was found. The amounts of MBD2 and MeCP2 transcripts vary greatly between samples in cancer cells compared to normal breast tissues or benign tumors, and in invasive ductal carcinomas the amount of MBD2 mRNA is significantly (P = 0.03) associated with the tumor size. Taken together these data suggest that upregulation of VBD2 might be associated with breast cell proliferation. In line with this hypothesis MBD2 is also upregulated during the prenatal development of the human mammary gland, but in contrast to that observed in tumor cells, MeCP2 is also coordinately upregulated in the fetal breast tissues, suggesting that deregulation of MeCP2 and MBD2 occurs in human breast cancers.	UCBLI, Genet Lab, UMR 5641, F-67373 Lyon 08, France; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Dante, R (corresponding author), UCBLI, Genet Lab, UMR 5641, 8 Ave Rockefeller, F-67373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559				ARNAUD M, 1985, BIOCHEM BIOPH RES CO, V13, P108; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Eads CA, 2001, CANCER RES, V61, P3410; Ehrlich Melanie, 2000, P273; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kanai Y, 1999, BIOCHEM BIOPH RES CO, V264, P962, DOI 10.1006/bbrc.1999.1613; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; POULSEN HE, 1975, INT HISTOLOGICAL CLA, P13; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Russo J., 1987, The mammary gland. Development, regulation, and function., P67; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd, P28; Tate P, 1996, NAT GENET, V12, P205, DOI 10.1038/ng0296-205; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	36	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2704	2712		10.1038/sj/onc/1205357	http://dx.doi.org/10.1038/sj/onc/1205357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965543	Green Published			2022-12-25	WOS:000174996500010
J	Fiucci, G; Ravid, D; Reich, R; Liscovitch, M				Fiucci, G; Ravid, D; Reich, R; Liscovitch, M			Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells	ONCOGENE			English	Article						anchorage-independent growth; anoikis; breast cancer; caveolin; invasiveness; MCF-7 cells; multidrug resistance	PHOSPHOINOSITIDE 3-OH KINASE; MULTIDRUG-RESISTANCE; IN-VIVO; METASTATIC ACTIVITIES; UROKINASE RECEPTOR; UP-REGULATION; EXPRESSION; PROTEIN; MEMBRANE; INTEGRIN	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Caveolin-1 is down-regulated in oncogene-transformed and tumor-derived cells. Antisense suppression of caveolin-1 or expression of a dominant negative form are sufficient for inducing cellular transformation. Expression of recombinant caveolin-1 inhibits anchorage-independent growth in cancer cells. The present study was designed to determine whether this is caused by inhibition of cancer cell survival or cell proliferation, and to test if another important property of cancer cells, i.e. matrix invasion, is modulated by expression of caveolin. Utilizing MCF-7 human breast adenocarcinoma cells stably transfected with caveolin-1 (MCF-7/Cav1), we demonstrate that caveolin-1 expression decreases MCF-7 cell proliferation rate and markedly reduces their capacity to form colonies in soft agar. The loss of anchorage-independent growth is not associated with stimulation of anoikis; in fact, MCF-7/Cav1 cells exhibit increased survival after detachment as compared with MCF-7 cells, indicating that in these cells caveolin-1 inhibits anoikis. Analysis of matrix metalloprotease release and matrix invasion revealed that expression of caveolin-1 inhibits also these important metastasis-related phenomena. Plating MCF-7 cells on a laminin matrix resulted in activation of ERK1/2, which was dramatically inhibited in MCF-7/Cav1 cells. We conclude that high expression level of caveolin-1 in human breast cancer cells exerts a negative modulatory effect on anchorage-independent growth by inhibiting cell proliferation even though matrix-independent cell survival is enhanced. Caveolin-1 expression inhibits also matrix invasion and blocks laminin-dependent activation of ERK1/2. The inhibitory effect of caveolin-1 on these transformation-dependent processes supports the hypothesis that caveolin-1 acts as a tumor suppressor protein which may impose major phenotypic changes when expressed in human cancer cells.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Fac Med, Dept Pharmacol, Jerusalem, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BENARD J, 1989, INT J CANCER, V43, P471, DOI 10.1002/ijc.2910430322; Bender FC, 2000, CANCER RES, V60, P5870; BIEDLER JL, 1994, CANCER METAST REV, V13, P191, DOI 10.1007/BF00689636; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Campbell L, 1999, BIOCHEM BIOPH RES CO, V262, P744, DOI 10.1006/bbrc.1999.1280; Carriero MV, 1999, CANCER RES, V59, P5307; Chao C, 1996, CANCER RES, V56, P4811; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kurata H, 2000, EXP CELL RES, V254, P180, DOI 10.1006/excr.1999.4738; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2001, CANCER RES, V61, P4386; Li WP, 2001, J CELL SCI, V114, P1397; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Lisanti MP, 1999, METH MOL B, V116, P51; Liscovitch M, 2000, TRENDS BIOCHEM SCI, V25, P530, DOI 10.1016/S0968-0004(00)01668-6; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MATTERN J, 1990, ANTICANCER RES, V10, P177; Matveev S, 1999, J LIPID RES, V40, P1647; Mikol DD, 1999, GLIA, V27, P39; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2001, J BIOL CHEM, V276, P38121; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; REICH R, 1989, BIOCHEM BIOPH RES CO, V160, P559, DOI 10.1016/0006-291X(89)92469-8; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1999, ONCOGENE, V18, P739, DOI 10.1038/sj.onc.1202330; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHTIL A, 1994, EXP TOXICOL PATHOL, V46, P257, DOI 10.1016/S0940-2993(11)80096-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Welch DR, 2000, CANCER RES, V60, P1552; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	81	236	253	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2365	2375		10.1038/sj.onc.1205300	http://dx.doi.org/10.1038/sj.onc.1205300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948420				2022-12-25	WOS:000174635600009
J	Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR				Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR			Characterization of the p53-rescue drug CP-31398 in vitro and in living cells	ONCOGENE			English	Article						tumour suppressor; DNA binding; stability; NMR	P53 CORE DOMAIN; DNA-BINDING; RESCUE; MUTATIONS	The Pfizer compound CP-31398 has been reported to stabilize the core domain of the tumour suppressor p53 in vitro and be an effective anti-cancer drug by virtue of rescuing destabilized mutants of p53. We did not detect any interaction between the p53 core domain and CP-31398 in vitro by a wide range of quantitative biophysical techniques over a wide range of conditions. CP-31398 did not stabilize p53 in our experiments. However, we found that CP-31398 intercalated with DNA and also altered and destabilized the DNA-p53 core domain complex. We analysed by NMR TROSY the interaction of the domain with a DNA oligomer and identified the changes in the complex on the binding of CP-31398. CP-31398 also decreased sequence-specific DNA binding of wild-type p53 and His-273 mutant p53. CP-31398 had a non-specific toxic effect independent of mutant p53 expression in several cell lines carrying Tet-regulated mutant p53. CP-31398 caused a small increase in MDM-2 expression and a more pronounced p53-independent increase in Bax expression. CP-31398 did, however, induce the PAb1620 epitope (characteristic of native p53) in cells expressing His-175 mutant p53. This was prevented by cycloheximide, suggesting that,my stabilizing action of CP-31398 would have to be on newly synthesized p53. One of the unstable mutants that was reported to have been rescued by CP-31398, R249S, does not bind DNA when folded at lower temperatures.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; Karolinska Hosp, CCK, Karolinska Inst, Dept Pathol Oncol, SE-17176 Stockholm, Sweden; Cambridge Ctr Prot Engn, MRC Ctr, Cambridge CB2 2QH, England	University of Cambridge; Karolinska Institutet; Karolinska University Hospital; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.	arf10@cam.ac.uk	Fersht, Alan R/B-2189-2008; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942; Selivanova, Galina/0000-0002-8698-4332				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE W, 1994, STRUCT BIOL, V1, P877; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Prives C, 1999, J PATHOL, V187, P112; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438	15	131	141	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2119	2129		10.1038/sj.onc.1205362	http://dx.doi.org/10.1038/sj.onc.1205362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948395				2022-12-25	WOS:000174555300001
J	Ariga, T; Masaike, T; Noji, H; Yoshida, M				Ariga, T; Masaike, T; Noji, H; Yoshida, M			Stepping rotation of F-1-ATPase with one, two, or three altered catalytic sites that bind ATP only slowly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; CHANGE MECHANISM; MOLECULAR MOTOR; SYNTHASE; NUCLEOTIDES; RESOLUTION; EFFICIENCY; HYDROLYSIS; SUBUNITS	F-1-ATPase is an ATP hydrolysis-driven motor in which the gamma subunit rotates in the stator cylinder alpha(3)beta(3). To know the coordination of three catalytic beta subunits during catalysis, hybrid F-1-ATPases, each containing one, two, or three "slow" mutant beta subunits that bind ATP very slowly, were prepared, and the rotations were observed with a single molecule level. Each hybrid made one, two, or three steps per 360degrees revolution, respectively, at 5 muM ATP where the wild-type enzyme rotated continuously without step under the same observing conditions. The observed dwell times of the steps are explained by the slow binding rate of ATP. Except for the steps, properties of rotation, such as the torque forces exerted during rotary movement, were not significantly changed from those of the wild-type enzyme. Thus, it appears that the presence of the slow beta subunit(s) does not seriously affect other normal beta subunit(s) in the same F-1-ATPase molecule and that the order of sequential catalytic events is faithfully maintained even when ATP binding to one or two of the catalytic sites is retarded.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; JSP, Precursory Res Embryon Sci & Technol, Yokohama, Kanagawa 3320012, Japan; JSP, Exploratory Res Adv Technol, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; University of Tokyo	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Ariga, Takayuki/ACM-3092-2022	Masaike, Tomoko/0000-0003-3290-1893; Ariga, Takayuki/0000-0002-2045-5761				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Amano T, 1996, J BIOL CHEM, V271, P18128, DOI 10.1074/jbc.271.30.18128; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; Kinosita K, 2000, PHILOS T R SOC B, V355, P473, DOI 10.1098/rstb.2000.0589; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Milgrom YM, 1998, BIOCHEM J, V330, P1037; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P25480, DOI 10.1074/jbc.M102200200; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Oster G, 2000, J BIOENERG BIOMEMBR, V32, P459, DOI 10.1023/A:1005660807157; Ren HM, 2000, J BIOL CHEM, V275, P10057, DOI 10.1074/jbc.275.14.10057; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	27	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24870	24874		10.1074/jbc.M202582200	http://dx.doi.org/10.1074/jbc.M202582200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964408	hybrid			2022-12-25	WOS:000176747000007
J	Knockaert, M; Wieking, K; Schmitt, S; Leost, M; Grant, KM; Mottram, JC; Kunick, C; Meijer, L				Knockaert, M; Wieking, K; Schmitt, S; Leost, M; Grant, KM; Mottram, JC; Kunick, C; Meijer, L			Intracellular targets of paullones - Identification following affinity purification on immobilized inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; MITOCHONDRIAL MALATE-DEHYDROGENASE; GLYCOGEN-SYNTHASE KINASE-3; REFINED CRYSTAL-STRUCTURE; SMALL-MOLECULE INHIBITORS; LEISHMANIA-MEXICANA; PROTEIN-KINASES; PLASMODIUM-FALCIPARUM; TRYPANOSOMA-BRUCEI; CANCER-THERAPY	Numerous inhibitors of cyclin-dependent kinases and glycogen synthase kinase-3 (GSK-3) are being developed in view of their potential applications against cancers and neurodegenerative disorders. Among these, paullones constitute a family of potent and apparently selective cyclin-dependent kinase and GSK-3 inhibitors. However, their actual intracellular targets remain to be identified. To address this issue we have immobilized a paullone, gwennpaullone, on an agarose matrix. Extracts from various cell types and tissues were screened for proteins interacting with this matrix. This approach validated GSK-3alpha and GSK-3beta as major intracellular paullone targets and also mitochondrial, but not cytoplasmic, malate dehydrogenase (MDH). Mitochondrial MDH was indeed inhibited by micromolar concentrations of paullones. Mitochondrial MDH was the major paullone-binding protein in the parasitic protozoon Leishmania mexicana, and paullones inhibited growth of the parasite. This simple batchwise affinity chromatography approach constitutes a straightforward method for the identification of intracellular targets of this particular class of novel anti-mitotic compounds. It has revealed an unexpected target, mitochondrial MDH, the inhibition of which may participate in the pharmacological effects of paullones.	CNRS, Biol Stn, F-29682 Roscoff, France; Univ Hamburg, Inst Pharm, D-20146 Hamburg, Germany; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	Centre National de la Recherche Scientifique (CNRS); University of Hamburg; University of Glasgow	Meijer, L (corresponding author), CNRS, Biol Stn, BP 74, F-29682 Roscoff, France.	meijer@sb-roscoff.fr		Kunick, Conrad/0000-0001-7041-5322; Mottram, Jeremy/0000-0001-5574-3766; Grant, Karen/0000-0002-0934-3873				Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Anderson SA, 1998, EXP PARASITOL, V89, P63, DOI 10.1006/expr.1998.4260; Anderson SA, 1998, MOL BIOCHEM PARASIT, V96, P185, DOI 10.1016/S0166-6851(98)00116-9; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1989, BIOCHEM SOC T, V17, P301, DOI 10.1042/bst0170301; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Fischer PM, 2000, CURR MED CHEM, V7, P1213, DOI 10.2174/0929867003374048; Garcia-Echeverria C, 2000, MED RES REV, V20, P28, DOI 10.1002/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.3.CO;2-U; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GLEASON WB, 1994, BIOCHEMISTRY-US, V33, P2078, DOI 10.1021/bi00174a014; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; Grant KM, 1998, J BIOL CHEM, V273, P10153, DOI 10.1074/jbc.273.17.10153; Gray N, 1999, CURR MED CHEM, V6, P859; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Gussio R, 2000, ANTI-CANCER DRUG DES, V15, P53; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hooijberg JH, 1999, BRIT J CANCER, V81, P269, DOI 10.1038/sj.bjc.6690687; Hooijberg JH, 1997, FEBS LETT, V413, P344, DOI 10.1016/S0014-5793(97)00940-X; Hunter GR, 2000, MOL BIOCHEM PARASIT, V105, P203, DOI 10.1016/S0166-6851(99)00176-0; JOH T, 1987, J BIOL CHEM, V262, P15127; Kaiser A, 2001, ARCH BIOCHEM BIOPHYS, V386, P179, DOI 10.1006/abbi.2000.2220; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; KNOCKAERT M, 2002, IN PRESS ONCOGENE; KREBS H. A., 1937, Enzymologia, V4, P148; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUNNASCH N, 1995, EXP PARASITOL, V80, P357, DOI 10.1006/expr.1995.1047; LANGUNNASCH N, 1992, MOL BIOCHEM PARASIT, V50, P17, DOI 10.1016/0166-6851(92)90240-K; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Mani S, 2000, EXPERT OPIN INV DRUG, V9, P1849, DOI 10.1517/13543784.9.8.1849; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Meijer L, 2000, DRUG RESIST UPDATE, V3, P83, DOI 10.1054/drup.2000.0129; MOTTRAM JC, 1993, J BIOL CHEM, V268, P21044; MOTTRAM JC, 1985, BIOCHIM BIOPHYS ACTA, V827, P310, DOI 10.1016/0167-4838(85)90216-X; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Musrati RA, 1998, GEN PHYSIOL BIOPHYS, V17, P193; Oikonomakos NG, 2000, J BIOL CHEM, V275, P34566, DOI 10.1074/jbc.M004485200; Primot A, 2000, PROTEIN EXPRES PURIF, V20, P394, DOI 10.1006/prep.2000.1321; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; ROSANIA GR, 2000, EXPERT OPIN THER PAT, V10, P1; Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2001, LEUKEMIA, V15, P1, DOI 10.1038/sj.leu.2401994; SHRAGO E, 1965, ARCH BIOCHEM BIOPHYS, V109, P57, DOI 10.1016/0003-9861(65)90286-9; SHRAGO E, 1963, BIOCHIM BIOPHYS ACTA, V73, P7; Sielecki TM, 2000, J MED CHEM, V43, P1, DOI 10.1021/jm990256j; Smith DG, 2001, BIOORG MED CHEM LETT, V11, P635, DOI 10.1016/S0960-894X(00)00721-6; Sridhar R, 2000, PHARM RES-DORDR, V17, P1345, DOI 10.1023/A:1007507224529; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WIEKING K, 2002, IN PRESS ARCH PHARM; Zaharevitz DW, 1999, CANCER RES, V59, P2566	59	126	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25493	25501		10.1074/jbc.M202651200	http://dx.doi.org/10.1074/jbc.M202651200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964410	hybrid			2022-12-25	WOS:000176747000085
J	Fairley, K; Westman, BJ; Pham, LH; Haymet, ADJ; Harding, MM; Mackay, JP				Fairley, K; Westman, BJ; Pham, LH; Haymet, ADJ; Harding, MM; Mackay, JP			Type I shorthorn sculpin antifreeze protein - Recombinant synthesis, solution conformation, and ice growth inhibition studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINTER FLOUNDER ANTIFREEZE; BIOLOGICAL MACROMOLECULES; MOLECULAR-DYNAMICS; PSEUDOPLEURONECTES-AMERICANUS; DIPOLAR COUPLINGS; BINDING MECHANISM; H-1-NMR SPECTRA; POLYPEPTIDE; SPECTROSCOPY; PRESERVATION	A number of structurally diverse classes of "antifreeze" proteins that allow fish to survive in sub-zero ice-laden waters have been isolated from the blood plasma of cold water teleosts. However, despite receiving a great deal of attention, the one or more mechanisms through which these proteins act are not fully understood. In this report we have synthesized a type I antifreeze polypeptide (AFP) from the shorthorn sculpin Myoxocephalus scorpius using recombinant methods. Construction of a synthetic gene with optimized codon usage and expression as a glutathione S-transferase fusion protein followed by purification yielded milligram amounts of polypeptide with two extra residues appended to the N terminus. Circular dichroism and NMR experiments, including residual dipolar coupling measurements on a N-15-labeled recombinant polypeptide, show that the polypeptides are a-helical with the first four residues being more flexible than the remainder of the sequence. Both the recombinant and synthetic polypeptides modify ice growth, forming facetted crystals just below the freezing point, but display negligible thermal hysteresis. Acetylation of Lys-10, Lys-20, and Lys-21 as well as the N terminus of the recombinant polypeptide gave a derivative that displays both thermal hysteresis (0.4 degreesC at 15 mg/ml) and ice crystal faceting. These results confirm that the N terminus of wild-type polypeptide is functionally important and support our previously proposed mechanism for all type I proteins, in which the hydrophobic face is oriented toward the ice at the ice/water interface.	Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Univ Houston, Dept Chem, Houston, TX 77204 USA	University of Sydney; University of Sydney; University of Houston System; University of Houston	Harding, MM (corresponding author), Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.		FTSE, Tony Haymet PhD/A-9881-2009; Mackay, Joel/D-6834-2011	FTSE, Tony Haymet PhD/0000-0002-5617-2106; Mackay, Joel/0000-0001-7508-8033; Harding, Margaret/0000-0003-1072-3870				Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2001, PROTEIN SCI, V10, P2566, DOI 10.1110/ps.ps.26501; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Brown CJ, 1997, CAN MED ASSOC J, V156, P629; BRYK T, 2002, IN PRESS J CHEM PHYS; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; CHAKRABARTTY A, 1988, CAN J ZOOL, V66, P403, DOI 10.1139/z88-057; Chao HM, 1996, J EXP BIOL, V199, P2071; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; Cheng AL, 1997, BIOPHYS J, V73, P2851, DOI 10.1016/S0006-3495(97)78315-2; Cheng C.C., 1991, P1; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; Dalal P., 2001, PHYSCHEMCOMM, V7, P1; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0; DUMAN JG, 1976, COMP BIOCHEM PHYS B, V54, P375, DOI 10.1016/0305-0491(76)90260-1; Ewart KV, 1999, CELL MOL LIFE SCI, V55, P271, DOI 10.1007/s000180050289; Feeney RE, 1998, TRENDS FOOD SCI TECH, V9, P102, DOI 10.1016/S0924-2244(98)00025-9; FLETCHER GL, 1982, ARCTIC, V35, P302; Fletcher GL, 1999, CHEMTECH, V29, P17; FOURNEY RM, 1984, CAN J ZOOL, V62, P28, DOI 10.1139/z84-006; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Gronwald W, 1996, BIOCHEMISTRY-US, V35, P16698, DOI 10.1021/bi961934w; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; Haymet ADJ, 1999, J AM CHEM SOC, V121, P941, DOI 10.1021/ja9801341; Haymet ADJ, 2001, FEBS LETT, V491, P285, DOI 10.1016/S0014-5793(01)02213-X; Hayward JA, 2001, J CHEM PHYS, V114, P3713, DOI 10.1063/1.1333680; HEW CL, 1985, EUR J BIOCHEM, V151, P167, DOI 10.1111/j.1432-1033.1985.tb09081.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Kowalski K, 1999, J BIOMOL NMR, V13, P249, DOI 10.1023/A:1008309602929; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAL M, 1993, FARADAY DISCUSS, V95, P299; Loewen MC, 1999, BIOCHEMISTRY-US, V38, P4743, DOI 10.1021/bi982602p; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCDONALD SM, 1995, AICHE J, V41, P959, DOI 10.1002/aic.690410426; Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rubinsky B, 2000, ANNU REV BIOMED ENG, V2, P157, DOI 10.1146/annurev.bioeng.2.1.157; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Sonnichsen FD, 1998, BIOCHEM CELL BIOL, V76, P284, DOI 10.1139/bcb-76-2-3-284; Tolman JR, 2001, CURR OPIN STRUC BIOL, V11, P532, DOI 10.1016/S0959-440X(00)00245-1; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wang JH, 2000, CRYOBIOLOGY, V41, P1, DOI 10.1006/cryo.2000.2265; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1993, FEBS LETT, V317, P31, DOI 10.1016/0014-5793(93)81485-I; Wierzbicki A, 1996, BIOPHYS J, V71, P8, DOI 10.1016/S0006-3495(96)79204-4; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zhang W, 1998, J BIOL CHEM, V273, P34806, DOI 10.1074/jbc.273.52.34806	56	24	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24073	24080		10.1074/jbc.M200307200	http://dx.doi.org/10.1074/jbc.M200307200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11940576	hybrid			2022-12-25	WOS:000176611800015
J	Bagai, S; Rubio, E; Cheng, JF; Sweet, R; Thomas, R; Fuchs, E; Grady, R; Mitchell, M; Bassuk, JA				Bagai, S; Rubio, E; Cheng, JF; Sweet, R; Thomas, R; Fuchs, E; Grady, R; Mitchell, M; Bassuk, JA			Fibroblast growth factor-10 is a mitogen for urothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC DEVELOPMENT; HUMAN BLADDER; IN-VITRO; PROLIFERATION; EXPRESSION; INDUCTION; MOUSE; STRATIFICATION; OBSTRUCTION; CYSTITIS	Fibroblast growth factor (FGF)-10 plays an important role in regulating growth, differentiation, and repair of the urothelium. This process occurs through a paracrine cascade originating in the mesenchyme (lamina propria) and targeting the epithelium (urothelium). In situ hybridization analysis demonstrated that (i) fibroblasts of the human lamina propria were the cell type that synthesized FGF-10 RNA and (ii) the FGF-10 gene is located at the 5p12-p13 locus of chromosome 5. Recombinant (r) preparations of human FGF-10 were found to induce proliferation of human urothelial cells in vitro and of transitional epithelium of wild-type and FGF7-null mice in vivo. Mechanistic studies with human cells indicated two modes of FGF-10 action: M translocation of rFGF-10 into urothelial cell nuclei and (ii) a signaling cascade that begins with the heparin-dependent phosphorylation of tyrosine residues of surface transmembrane receptors. The normal urothelial phenotype, that of quiescence, is proposed to be typified by negligible levels of FGF-10. During proliferative phases, levels of FGF-10 rise at the urothelial cell surface and/or within urothelial cell nuclei. An understanding of how FGF-10 works in conjunction with these other processes will lead to better management of many diseases of the bladder and urinary tract.	Univ Washington, Dept Urol, Sch Med, Seattle, WA 98195 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Genome Sci, Berkeley, CA 94720 USA; Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Washington, Childrens Hosp & Med Ctr, Div Pediat Urol, Seattle, WA 98105 USA; Univ Washington, Sch Med, Dept Urol, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of Chicago; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bassuk, JA (corresponding author), Univ Washington, Dept Urol, Sch Med, Box 356510, Seattle, WA 98195 USA.	bassuk@u.washington.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baker LA, 1998, SEMIN NEPHROL, V18, P569; Baskin LS, 1996, LAB INVEST, V75, P157; Bassuk JA, 2000, J UROLOGY, V164, P170, DOI 10.1016/S0022-5347(05)67490-3; BASSUK JA, 2002, BLADDER DIS RES CONC; BIRREN B, 2000, GENOME ANAL LAB MANU; Chai TC, 2000, J UROLOGY, V163, P1440, DOI 10.1016/S0022-5347(05)67638-0; CUNHA GR, 1983, DIFFERENTIATION, V24, P174, DOI 10.1111/j.1432-0436.1983.tb01317.x; Danilenko DM, 1999, TOXICOL PATHOL, V27, P64, DOI 10.1177/019262339902700113; DONJACOUR AA, 1988, DEV BIOL, V128, P1, DOI 10.1016/0012-1606(88)90260-6; Emoto H, 1997, J BIOL CHEM, V272, P23191, DOI 10.1074/jbc.272.37.23191; Freeman MR, 1997, J CLIN INVEST, V99, P1028, DOI 10.1172/JCI119230; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HAINAU B, 1974, CANCER-AM CANCER SOC, V33, P115, DOI 10.1002/1097-0142(197401)33:1<115::AID-CNCR2820330118>3.0.CO;2-V; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LEVIN RM, 1994, WORLD J UROL, V12, P226; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Miyakawa K, 1999, GROWTH FACTORS, V16, P191, DOI 10.3109/08977199909002129; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; Ohuchi H, 2000, BIOCHEM BIOPH RES CO, V277, P643, DOI 10.1006/bbrc.2000.3721; Qiao JZ, 1999, DEVELOPMENT, V126, P547; REBEL JM, 1994, J PATHOL, V173, P283, DOI 10.1002/path.1711730312; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tash JA, 2001, J UROLOGY, V166, P2536, DOI 10.1016/S0022-5347(05)65630-3; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Ulich TR, 1997, CANCER RES, V57, P472; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YI ES, 1995, J UROLOGY, V154, P1566, DOI 10.1016/S0022-5347(01)66930-1; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980; [No title captured]	35	45	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23828	23837		10.1074/jbc.M201658200	http://dx.doi.org/10.1074/jbc.M201658200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11923311	hybrid			2022-12-25	WOS:000176475700096
J	Gannon-Murakami, L; Murakami, K				Gannon-Murakami, L; Murakami, K			Selective association of protein kinase C with 14-3-3 zeta in neuronally differentiated PC12 cells - Stimulatory and inhibitory effect of 14-3-3 zeta in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; ADRENAL CHROMAFFIN CELLS; CALCIUM-DEPENDENT EXOCYTOSIS; HUMAN NEUROBLASTOMA-CELLS; ARACHIDONIC-ACID RELEASE; CIS-FATTY ACID; NEURITE OUTGROWTH; PHOSPHORYLATED FORMS; SHEEP BRAIN; RAT-BRAIN	The 14-3-3 protein is a family of highly conserved acidic proteins found in a wide range of eukaryotes from yeast to mammals. 14-3-3 acts as an adapter protein and interacts with signaling molecules including protein kinase C (PKC). Although 14-3-3 was originally characterized as an endogenous PKC inhibitor, it was reported to activate PKC in vitro, but the in vivo regulation of PKC by 14-3-3 is still not well understood. To examine the regulation of PKC by 14-3-3 in the cell, we have generated a sub-cell line, PC 12-B3, that stably expresses FLAG epitope-tagged 14-3-3 isoform in PC 12 cells. Here we show that PKC-alpha and PKC-epsilon become associated with 14-3-3 when the cells are neuronally differentiated by nerve growth factor. We found that the immunoprecipitate by anti-FLAG antibody contains constitutive and autonomous Ca2+-independent non-classical PKC activity. In contrast, the FLAG immunoprecipitate has no Ca2+-dependent classical PKC activity despite the fact that PKC-a is present in the FLAG immunoprecipitate from differentiated PC12-B3 cells. Our results show that the association with 14-3-3 has distinct effects on classical PKC and non-classical PKC activity.	Univ Vermont, Dept Biol, Burlington, VT 05405 USA	University of Vermont	Murakami, K (corresponding author), Univ Vermont, Dept Biol, 307 Marsh Life Sci Bldg, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH048973] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48973] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACS P, 1995, BIOCHEM BIOPH RES CO, V216, P103, DOI 10.1006/bbrc.1995.2597; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1992, BIOCHEM SOC T, V20, P607, DOI 10.1042/bst0200607; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGOYNE RD, 1993, J ANAT, V183, P309; CHEN SG, 1992, BIOCHEM J, V282, P33, DOI 10.1042/bj2820033; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; DEHAUT F, 1993, NEUROSCI LETT, V161, P133, DOI 10.1016/0304-3940(93)90277-R; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; FINK DW, 1990, J NEUROCHEM, V55, P1716, DOI 10.1111/j.1471-4159.1990.tb04961.x; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; GREENE LA, 1991, CULTURING NERVE CELL, P207; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HARLOW E, 1988, ANTIBODIES LAB MANUA, P41; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Huang XP, 1997, J CELL SCI, V110, P1625; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; Kolkova K, 2000, J NEUROSCI, V20, P2238; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; MARTIN H, 1994, J NEUROCHEM, V63, P2259; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Meller N, 1996, MOL CELL BIOL, V16, P5782; MORGAN A, 1992, BIOCHEM J, V286, P807, DOI 10.1042/bj2860807; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; Murakami K, 1996, GENE, V179, P245, DOI 10.1016/S0378-1119(96)00368-X; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NIELSEN PJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P425, DOI 10.1016/0167-4781(91)90136-A; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; OLIVIER AR, 1992, BIOCHEM SOC T, V20, P603, DOI 10.1042/bst0200603; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Skoulakis EMC, 1998, MOL NEUROBIOL, V16, P269, DOI 10.1007/BF02741386; TANJI M, 1994, J NEUROCHEM, V63, P1908; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1231; Wooten MW, 1998, CELL SIGNAL, V10, P265, DOI 10.1016/S0898-6568(97)00127-7; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAUCHI T, 1981, J BIOL CHEM, V256, P5404; Zheng WH, 1996, J NEUROCHEM, V66, P1868; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4	61	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23116	23122		10.1074/jbc.M201478200	http://dx.doi.org/10.1074/jbc.M201478200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11950841	hybrid			2022-12-25	WOS:000176475700004
J	Han, JH; Hajjar, DP; Zhou, XY; Gotto, AM; Nicholson, AC				Han, JH; Hajjar, DP; Zhou, XY; Gotto, AM; Nicholson, AC			Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression - A new mechanism of action for high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SCAVENGER RECEPTOR; PPAR-GAMMA; CELLULAR CHOLESTEROL; FATTY-ACIDS; IN-VITRO; SR-BI; PROTEIN; CD36; DIFFERENTIATION; BINDING	Cellular cholesterol content reflects a balance of lipid influx by lipoprotein receptors and endogenous synthesis and efflux to cholesterol acceptor particles. The beneficial effect of high density lipoprotein (HDL) in protecting against the development of cardiovascular disease is thought to be mediated predominately through its induction of cellular cholesterol efflux and reverse cholesterol transport" from peripheral tissues to the liver. We tested the hypothesis that HDL could inhibit cellular lipid accumulation by modulating expression of peroxisome proliferator-activated receptor-gamma (PPARgamma)-responsive genes. To this end, we, evaluated expression of two PPARgamma-responsive genes, CD36, a receptor for oxidized low density lipoprotein, and aP2, a fatty acid-binding protein. HDL decreased expression of macrophage CD36 and aP2 in a dose-dependent manner. HDL also decreased aP2 expression in fibroblasts, reduced accumulation of lipid, and slowed differentiation of fibroblasts into adipocytes. HDL stimulated mitogen-activated protein (MAP) kinase activity, and inhibition of CD36 expression was blocked by co-incubation with a MAP kinase inhibitor. HDL increased expression of PPARgamma mRNA and protein, induced translocation of PPARgamma from the cytoplasm to the nucleus, and increased PPARgamma phosphorylation. Our data demonstrate that despite induction and translocation of PPARgamma in response to HDL, ALAP kinase-mediated phosphorylation of PPARgamma inhibited expression of PPARgamma-responsive genes and suggest mechanisms by which HDL may inhibit cellular lipid accumulation.	Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Ctr Vasc Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Nicholson, AC (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol, 1300 York Ave, New York, NY 10021 USA.	nicholso@mail.med.cornell.edu			NHLBI NIH HHS [P50-HL56987] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; AMRI EZ, 1991, J LIPID RES, V32, P1449; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; CALVO D, 1993, J BIOL CHEM, V268, P18929; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Fu YC, 2000, J LIPID RES, V41, P2017; GREENWALT DE, 1992, BLOOD, V80, P1105; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackness MI, 1998, CURR OPIN LIPIDOL, V9, P319, DOI 10.1097/00041433-199808000-00006; Makowski L, 2001, NAT MED, V7, P699, DOI 10.1038/89076; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; Xue JC, 1996, MOL CELL BIOL, V16, P1567; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	45	53	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23582	23586		10.1074/jbc.M200685200	http://dx.doi.org/10.1074/jbc.M200685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953427	hybrid			2022-12-25	WOS:000176475700063
J	Petrucco, S; Volpi, G; Bolchi, A; Rivetti, C; Ottonello, S				Petrucco, S; Volpi, G; Bolchi, A; Rivetti, C; Ottonello, S			A nick-sensing DNA 3 '-repair enzyme from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; STRAND BREAKS; CONFORMATIONAL-ANALYSIS; LIGASE III; REPAIR; DOMAIN; XRCC1; GENE; 3'-PHOSPHATASE; SEQUENCE	DNA single-strand breaks, a major cause of genome instability, often produce unconventional end groups that must be processed to restore terminal moieties suitable for reparative DNA gap filling or ligation. Here, we describe a bifunctional repair enzyme from Arabidopsis (named AtZDP) that recognizes DNA strand breaks and catalyzes the removal of 3'-end-blocking lesions. The isolated C-terminal domain of AtZDP is by itself competent for T-end processing, but not for strand break recognition. The N-terminal domain instead contains three Cys(3)-His zinc fingers and recognizes various kinds of damaged double-stranded DNA. Gapped DNA molecules are preferential targets of AtZDP, which bends them by similar to73degrees upon binding, as measured by atomic force microscopy. Potential partners of AtZDP were identified in the Arabidopsis genome using the human single-strand break repairosome as a reference. These data identify a novel pathway for single-strand break repair in which a DNA-binding 3'-phosphoesterase acts as a "nick sensor" for damage recognition, as the catalyst of one repair step, and possibly as a nucleation center for the assembly of a fully competent repair complex.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy	University of Parma	Petrucco, S (corresponding author), Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy.	petrucco@unipr.it	Bolchi, Angelo/GOJ-9730-2022	Rivetti, Claudio/0000-0003-3775-6779				BABIYCHUK E, 1994, P NATL ACAD SCI USA, V91, P3299, DOI 10.1073/pnas.91.8.3299; Babiychuk E, 1998, PLANT J, V15, P635, DOI 10.1046/j.1365-313x.1998.00240.x; Betti M, 2001, J BIOL CHEM, V276, P18038, DOI 10.1074/jbc.M010648200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britt AB, 1999, TRENDS PLANT SCI, V4, P20, DOI 10.1016/S1360-1385(98)01355-7; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; FRIEDBERG EC, 1995, TRENDS BIOCHEM SCI, V20, P381, DOI 10.1016/S0968-0004(00)89082-9; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Mahajan PB, 1998, PLANT PHYSIOL, V118, P895, DOI 10.1104/pp.118.3.895; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; MINET M, 1992, PLANT J, V2, P417; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Rivetti C, 1996, J MOL BIOL, V264, P919, DOI 10.1006/jmbi.1996.0687; Rivetti C, 1998, J MOL BIOL, V280, P41, DOI 10.1006/jmbi.1998.1830; Sambrook J, 2001, MOL CLONING LAB MANU; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Vance JR, 2001, MOL CELL BIOL, V21, P7191, DOI 10.1128/MCB.21.21.7191-7198.2001; Vance JR, 2001, J BIOL CHEM, V276, P15073, DOI 10.1074/jbc.M011075200; Ward JF, 1998, CONT CANC RES, P65; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wilson DM, 1998, CONT CANC RES, P29	38	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23675	23683		10.1074/jbc.M201411200	http://dx.doi.org/10.1074/jbc.M201411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11948185	hybrid			2022-12-25	WOS:000176475700076
J	Zrachia, A; Dobroslav, M; Blass, M; Kazimirsky, G; Kronfeld, I; Blumberg, PM; Kobiler, D; Lustig, S; Brodie, C				Zrachia, A; Dobroslav, M; Blass, M; Kazimirsky, G; Kronfeld, I; Blumberg, PM; Kobiler, D; Lustig, S; Brodie, C			Infection of glioma cells with sindbis virus induces selective activation and tyrosine phosphorylation of protein kinase C delta - Implications for sindbis virus-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT ALPHAVIRUS INFECTION; PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; PKC-DELTA; TRANSLOCATION; EXPRESSION; PATHWAY; FAMILY; BCL-2	Sindbis virus (SV) is an alpha virus used as a model for studying the role of apoptosis in virus infection. In this study, we examined the role of protein kinase C (PKC) in the apoptosis induced by SVNI, a virulent strain of SV. Infection of C6 cells with SVNI induced a selective translocation of PKCdelta to the endoplasmic reticulum and its tyrosine phosphorylation. The specific PKCdelta inhibitor rottlerin and a PKCdelta kinase-dead mutant increased the apoptosis induced by SVNI. To examine the role of the tyrosine phosphorylation of PKCS in the apoptosis induced by SVNI we used a PKCdelta mutant in which five tyrosine residues were mutated to phenylalanine (PKCdelta5). PKCdelta5-overexpressing cells exhibited increased apoptosis in response to SVNI as compared with control cells and to cells overexpressing PKCdelta. SVNI also increased the cleavage of caspase 3 in cells overexpressing PKCdelta5 but did not induce cleavage of PKCdelta or PKCdelta5. Using single tyrosine mutants, we identified tyrosines 52, 64, and 155 as the phosphorylation sites associated with the apoptosis induced by SVNI. We conclude that PKCdelta exerts an inhibitory effect on the apoptosis induced by SV and that phosphorylation of PKCdelta on specific tyrosines is required for this function.	Bar Ilan Univ, Fac Life Sci, Med Diag Res Ctr, IL-52900 Ramat Gan, Israel; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Israel Inst Biol Res, Dept Infect Dis, IL-74100 Ness Ziona, Israel	Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brodie, C (corresponding author), Bar Ilan Univ, Fac Life Sci, Med Diag Res Ctr, IL-52900 Ramat Gan, Israel.							Appel E, 2000, VIROLOGY, V276, P238, DOI 10.1006/viro.2000.0458; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffin DE, 1999, TRENDS MICROBIOL, V7, P155, DOI 10.1016/S0966-842X(99)01470-5; Griffin DE, 1997, ANNU REV MICROBIOL, V51, P565, DOI 10.1146/annurev.micro.51.1.565; Griffin DE, 1998, NEUROSCI BIOBEHAV R, V22, P721, DOI 10.1016/S0149-7634(98)00010-4; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Jan JT, 1999, J VIROL, V73, P10296, DOI 10.1128/JVI.73.12.10296-10302.1999; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Keenan C, 1997, FEBS LETT, V415, P101, DOI 10.1016/S0014-5793(97)01104-6; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; LUSTIG S, 1992, ARCH VIROL, V122, P237, DOI 10.1007/BF01317186; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Nakatsue T, 1998, BIOCHEM BIOPH RES CO, V253, P59, DOI 10.1006/bbrc.1998.9724; Nava VE, 1998, J VIROL, V72, P452, DOI 10.1128/JVI.72.1.452-459.1998; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Newton AC, 2002, METHOD ENZYMOL, V345, P499; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SAITO S, 1990, MICROBIOL IMMUNOL, V34, P859, DOI 10.1111/j.1348-0421.1990.tb01064.x; Sarid R, 2001, CELL DEATH DIFFER, V8, P1224, DOI 10.1038/sj.cdd.4400926; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; STRAUSS EG, 1976, VIROLOGY, V74, P154, DOI 10.1016/0042-6822(76)90137-9; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	53	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23693	23701		10.1074/jbc.M111658200	http://dx.doi.org/10.1074/jbc.M111658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11927579	hybrid			2022-12-25	WOS:000176475700078
J	Boll, M; Foltz, MT; Rubio-Aliaga, I; Kottra, G; Daniel, H				Boll, M; Foltz, MT; Rubio-Aliaga, I; Kottra, G; Daniel, H			Functional characterization of two novel mammalian electrogenic proton-dependent amino acid cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL-MEMBRANE-VESICLES; CACO-2 CELL MONOLAYERS; ELECTROCHEMICAL GRADIENT; RENAL TRANSPORT; VESICULAR GABA; L-ALANINE; SYSTEM-N; LOCALIZATION; IDENTIFICATION; ABSORPTION	We cloned two cDNAs encoding proton/amino acid co-transporters, designated as mPAT1 and mPAT2, from murine tissues. They were identified by sequence similarity to the amino acid/auxin permease family member of lower eukaryotes. We functionally characterized both transporters by flux studies and electrophysiology after expression in Xenopus laevis oocytes. Both mPAT1 and mPAT2 induced a pH-dependent electrogenic transport activity for small amino acids (glycine, alanine, and proline) that is altered by membrane potential. Direct evidence for amino acid/H+-symport was shown by intracellular acidification, and a flux coupling stoichiometry for proline/H+-symport of 1:1 was determined for both transporters. Besides small apolar L-amino acids, the transporters also recognize their D-enantiomers and selected amino acid derivatives such as gamma-aminobutyric acid. The mPAT1 transporter, the marine orthologue of the recently cloned rat LYAAT-1 transporter, can be considered as a low affinity system when compared with mPAT2. The mRNA of mPAT1 is highly expressed in small intestine, colon, kidney, and brain; the mPAT2-mRNA is mainly found in heart and lung. Phenotypically, the PAT1 transporter possesses the same functional characteristics as the previously described proton-dependent amino acid transport process in apical membranes of intestinal and renal epithelial cells.	Tech Univ Munich, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Daniel, H (corresponding author), Tech Univ Munich, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany.		Daniel, Hannelore/B-8982-2009	Rubio-Aliaga, Isabel/0000-0003-1051-9511				Bockman DE, 1997, INT J PANCREATOL, V22, P221; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; JESSEN H, 1988, BIOCHIM BIOPHYS ACTA, V942, P262; JORGENSEN KE, 1987, BIOCHEM J, V248, P533, DOI 10.1042/bj2480533; Kottra G, 2001, J PHYSIOL-LONDON, V536, P495, DOI 10.1111/j.1469-7793.2001.0495c.xd; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; PISONI RL, 1987, J BIOL CHEM, V262, P6010; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; ROIGAARDPETERSEN H, 1989, BIOCHIM BIOPHYS ACTA, V984, P231, DOI 10.1016/0005-2736(89)90221-6; ROIGAARDPETERSEN H, 1990, AM J PHYSIOL, V258, pF388, DOI 10.1152/ajprenal.1990.258.2.F388; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; Saier MH, 2000, MICROBIOL-SGM, V146, P1775, DOI 10.1099/00221287-146-8-1775; Shen H, 1999, AM J PHYSIOL-RENAL, V276, pF658, DOI 10.1152/ajprenal.1999.276.5.F658; THWAITES DT, 1994, J MEMBRANE BIOL, V140, P143; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5	24	131	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22966	22973		10.1074/jbc.M200374200	http://dx.doi.org/10.1074/jbc.M200374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959859	hybrid			2022-12-25	WOS:000176313600110
J	Cook, SA; Matsui, T; Li, L; Rosenzweig, A				Cook, SA; Matsui, T; Li, L; Rosenzweig, A			Transcriptional effects of chronic Akt activation in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; BETA SUPERFAMILY MEMBER; IGF-BINDING PROTEIN-5; NF-KAPPA-B; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CARDIOVASCULAR-SYSTEM; NEURONAL SURVIVAL; SIGNALING PATHWAY; CARDIAC MYOCYTES	Akt activation reduces cardiomyocyte death and induces cardiac hypertrophy. To help identify effector mechanisms, gene expression profiles in hearts from transgenic mice with cardiac-specific expression of activated Akt (myr-Akt) were compared with littermate controls. 40 genes were identified as differentially expressed. Quantitative reverse transcription-PCR confirmed qualitative results of transcript profiling for 9 of 10 genes examined, however, there were notable quantitative discrepancies between the quantitative reverse transcription-PCR and microarray data sets. Interestingly Akt induced significant up-regulation of insulin-like growth factor-binding protein-5 (IGFBP-5), which could contribute to its anti-apoptotic effects in the heart. In addition, Akt-mediated down-regulation of peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 (PGC-1) and PPAR-alpha may shift myocytes toward glycolytic metabolism shown to preserve cardiomyocyte function and survival during transient ischemia. IGFBP-5 transcripts also increased after adenoviral gene transfer of myr-Akt to cultured cardiomyocytes, suggesting that this represents a direct effect of Akt activation. In contrast, substantial induction of growth differentiation factor-8 (GDF-8), a highly conserved inhibitor of skeletal muscle growth, was observed in transgenic hearts but not after acute Akt activation in vitro, suggesting that GDF-8 induction may represent a secondary effect perhaps related to the cardiac hypertrophy seen in these mice. Thus, microarray analysis reveals previously unappreciated Akt regulation of genes that could contribute to the effects of Akt on cardiomyocyte survival, metabolism, and growth.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Program Cardiovasc Gene Therap, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Program Cardiovasc Gene Therapy, 114 16th St,Rm 2600, Charlestown, MA 02129 USA.	Rosenzweig@helix.mgh.harvard.edu	Cook, Stuart/G-9567-2011	Cook, Stuart/0000-0001-6628-194X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061557, K08HL004250, R01HL059521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-04250, HL-59521, HL-61557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APSTEIN CS, 1983, CIRC RES, V52, P515, DOI 10.1161/01.RES.52.5.515; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cook SA, 1999, CIRC RES, V85, P940; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fishman GI, 1998, CIRC RES, V82, P837; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; Godecke A, 2000, BASIC RES CARDIOL, V95, P492, DOI 10.1007/s003950070026; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jonassen AK, 2001, CIRC RES, V89, P1191, DOI 10.1161/hh2401.101385; Kerr SM, 1996, HUM MOL GENET, V5, P1139, DOI 10.1093/hmg/5.8.1139; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Knight J, 2001, NATURE, V410, P860, DOI 10.1038/35073680; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; Matsui T, 2001, CIRCULATION, V104, P330; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; MATSUI T, 2002, IN PRESS J BIOL CHEM, V277; McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Neville C, 1996, DEV GENET, V19, P157, DOI 10.1002/(SICI)1520-6408(1996)19:2<157::AID-DVG7>3.0.CO;2-8; Ozes ON, 1999, NATURE, V401, P82; Perks CM, 2000, J CELL BIOCHEM, V80, P248; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Proud CG, 1997, BIOCHEM J, V328, P329; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Roschier M, 2001, J NEUROCHEM, V76, P11, DOI 10.1046/j.1471-4159.2001.00002.x; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	44	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22528	22533		10.1074/jbc.M201462200	http://dx.doi.org/10.1074/jbc.M201462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956204	hybrid			2022-12-25	WOS:000176313600056
J	Fisher, AA; Ye, DJ; Sergueev, DS; Fisher, MH; Shaw, BR; Juliano, RL				Fisher, AA; Ye, DJ; Sergueev, DS; Fisher, MH; Shaw, BR; Juliano, RL			Evaluating the specificity of antisense oligonucleotide conjugates - A DNA array analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; P-GLYCOPROTEIN; PHOSPHOROTHIOATE; INHIBITION; OLIGODEOXYNUCLEOTIDES; RESISTANCE; SEQUENCE; CLEAVAGE; DELIVERY; PROTEIN	Antisense oligonucleotides are potentially powerful tools for selective control of cellular and viral gene expression. Crucial to successful application of this approach is the specificity of the oligonucleotide for the chosen RNA target. Here we apply DNA array technology to examine the specificity of antisense oligonucleotide treatments. The molecules used in these studies consisted of phosphorothioate oligomers linked to the Antennapedia (Ant) delivery peptide. The antisense oligonucleotide component was complementary to a site Ranking the AUG of the MDR1 message, which codes for P-glycoprotein, a membrane ATPase associated with multidrug resistance in tumor cells. Using a DNA array of 2059 genes, we analyzed cellular responses to molecules comprised of Ant peptide-oligonucleotide conjugates, as well as to the Ant peptide alone. Besides the expected reduction in MDR1 message level, 37 other genes (similar to2% of those tested) showed changes of comparable magnitude. The validity of the array results was confirmed for selected genes using Northern blots to assess messenger RNA levels. These results suggest that studies using antisense oligonucleotide technology to modulate gene expression need to be interpreted with caution.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Duke Univ, Dept Chem, Durham, NC 27708 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Juliano, RL (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365,1106 Jones Bldg, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [P01 GM59299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM059299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal S, 1999, BBA-GENE STRUCT EXPR, V1489, P53, DOI 10.1016/S0167-4781(99)00141-4; Alahari SK, 1996, MOL PHARMACOL, V50, P808; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5; Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BERGAN R, 1994, NUCLEIC ACIDS RES, V22, P2150, DOI 10.1093/nar/22.11.2150; BROWN DA, 1994, J BIOL CHEM, V269, P26801; Celis JE, 2000, FEBS LETT, V480, P2, DOI 10.1016/S0014-5793(00)01771-3; Cho YS, 2001, P NATL ACAD SCI USA, V98, P9819, DOI 10.1073/pnas.171314398; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GILES RV, 1992, NUCLEIC ACIDS RES, V20, P763, DOI 10.1093/nar/20.4.763; HARKER WG, 1986, CANCER RES, V46, P2369; Juliano RL, 1999, PHARM RES-DORDR, V16, P494, DOI 10.1023/A:1011958726518; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; KRIEG AM, 1995, ANTISENSE RES DEV, V5, P241, DOI 10.1089/ard.1995.5.241; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Notterman DA, 2001, CANCER RES, V61, P3124; Stein CA, 2000, PHARMACOL THERAPEUT, V85, P231, DOI 10.1016/S0163-7258(99)00053-4; Stein CA, 1998, ANTISENSE NUCLEIC A, V8, P129, DOI 10.1089/oli.1.1998.8.129; SZANI P, 2001, NUCLEIC ACIDS RES, V29, P3965; Yoo H, 2000, NUCLEIC ACIDS RES, V28, P4225, DOI 10.1093/nar/28.21.4225	26	56	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22980	22984		10.1074/jbc.M203347200	http://dx.doi.org/10.1074/jbc.M203347200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948195	hybrid			2022-12-25	WOS:000176313600112
J	Musib, R; Wang, GF; Geng, L; Rubenstein, PA				Musib, R; Wang, GF; Geng, L; Rubenstein, PA			Effect of polymerization on the subdomain 3/4 loop of yeast actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; SACCHAROMYCES-CEREVISIAE; MYOSIN; FILAMENTS; DYNAMICS; MODEL; REFINEMENT; STABILITY; MUTATION; TERMINUS	The Holmes F-actin model predicts a polymerization-dependent conformation change of a subdomain 3/4 loop with a hydrophobic tip (residues 266-269), allowing interaction with a hydrophobic surface on the opposing strand of the filament producing filament stabilization. We introduced cysteines in place of Val(266), Leu(267), and Leu(269) in yeast actin to allow attachment of pyrene maleimide. Pyrene at each of these positions produced differing fluorescence spectra in G-actin. Polymerization decreased the fluorescence for the 266 and 267 probes and increased that for the 269 probe. The direction of the fluorescence change was mirrored with a smaller and less hydrophobic probe, acrylodan, when attached to 266 or 269. Following polymerization, increased acrylamide quenching was observed for pyrene at 266 or 267 but not 269. The 267 probe was the least accessible of the three in G- and F-actin. F-actin quenching was biphasic for the 265, 266, and 269 but not 267 probes, suggesting that in F-actin, the pyrene samples multiple environments. Finally, in F-actin the probe at 266 interacts with one at Cys(374) on a monomer in the opposing strand, producing a pyrene excimer band. These results indicate a polymerization-dependent movement of the subdomain 3/4 loop partially consistent with Holmes' model.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Wang, Gufeng/B-3972-2011	Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; GREER C, 1982, MOL CELL BIOL, V2, P1270, DOI 10.1128/MCB.2.10.1270; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1992, P NATL ACAD SCI USA, V89, P4466, DOI 10.1073/pnas.89.10.4466; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P8; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Prochniewicz E, 1997, BIOCHEMISTRY-US, V36, P12845, DOI 10.1021/bi971201r; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; Wriggers W, 1997, BIOPHYS J, V73, P624, DOI 10.1016/S0006-3495(97)78098-6; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0	26	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22699	22709		10.1074/jbc.M203096200	http://dx.doi.org/10.1074/jbc.M203096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959868	hybrid			2022-12-25	WOS:000176313600078
J	Rautavuoma, K; Takaluoma, K; Passoja, K; Pirskanen, A; Kvist, AP; Kivirikko, KI; Myllyharju, J				Rautavuoma, K; Takaluoma, K; Passoja, K; Pirskanen, A; Kvist, AP; Kivirikko, KI; Myllyharju, J			Characterization of three fragments that constitute the monomers of the human lysyl hydroxylase isoenzymes 1-3 - The 30-kDa N-terminal fragment is not required for lysyl hydroxylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; HUMAN PROLYL 4-HYDROXYLASE; COLLAGEN; IDENTIFICATION; CLONING; ISOFORM; TISSUE; GENE; EXPRESSION; CARTILAGE	Lysyl hydroxylase (LH) catalyzes the formation of hydroxylysine in collagens; three human isoenzymes have been cloned so far. We report here on the purification of all three recombinant isoenzymes to homogeneity from the medium of cultured insect cells, and we demonstrate that they are all homodimers. Limited proteolysis experiments identified two main protease-sensitive regions in the monomers of about 80-85 kDa, corresponding to three fragments A-C (from the N to C terminus), with molecular masses of about 30, 37, and 16 kDa, respectively. Fragment A was found to play no role in LH activity as a recombinant B-C polypeptide constituted a fully active hydroxylase with K-m values for cosubstrates and the peptide substrate that were identical to those of the full-length enzyme. LH3, but not LH1 and LH2, has also been reported recently (Heikkinen, J., Risteli, M., Wang, C., Latvala, J., Rossi, M., Valtavaara, M., and Myllyla, R. (2000) J. Biol, Chem. 275, 36158-36163) to possess collagen glucosyltransferase activity. We confirm this highly surprising finding here and extend it by demonstrating that LH3 may also possess trace amounts of collagen galactosyltransferase activity. All the glucosyltransferase and galactosyltransferase activity of LH3 was found to reside in fragment A, which played no role in the hydroxylase activity of the polypeptide. This fragment is about 55% identical and 80% similar to the corresponding fragments of LH1 and LH2. However, the levels of the glycosyltransferase activities are so low that they may be of little biological significance. It is thus evident that human tissues must have additional glycosyltransferases that are responsible for most of the collagen glycosylation in vivo.	Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland	University of Oulu; University of Oulu	Myllyharju, J (corresponding author), Univ Oulu, Dept Med Biochem & Mol Biol, POB 5000, FIN-90014 Oulu, Finland.							ANTTINEN H, 1978, BIOCHEM J, V175, P737, DOI 10.1042/bj1750737; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; BYERS PH, 1995, METABOLIC MOL BASES, P4029; CROSSEN R, 1998, BACULOVIRUS EXPRESSI; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; Krol BJ, 1996, J INVEST DERMATOL, V106, P11, DOI 10.1111/1523-1747.ep12326956; KUUTTISAVOLAINEN ER, 1979, CLIN CHIM ACTA, V96, P53, DOI 10.1016/0009-8981(79)90051-2; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; MYLLYLA R, 1988, BIOCHEM J, V253, P489, DOI 10.1042/bj2530489; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PUISTOLA U, 1980, BIOCHIM BIOPHYS ACTA, V611, P40, DOI 10.1016/0005-2744(80)90040-6; TURPEENNIEMIHUJANEN TM, 1980, BIOCHEM J, V189, P247, DOI 10.1042/bj1890247; TURPEENNIEMIHUJANEN TM, 1981, COLLAGEN REL RES, V1, P355; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Wingfield P. T., 1998, CURRENT PROTOCOLS PR; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; YEOWELL HN, 1992, J INVEST DERMATOL, V99, P864, DOI 10.1111/1523-1747.ep12614840; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	35	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23084	23091		10.1074/jbc.M112077200	http://dx.doi.org/10.1074/jbc.M112077200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956192	hybrid			2022-12-25	WOS:000176313600124
J	van Tiel, CM; Westerman, J; Paasman, MA; Hoebens, MM; Wirtz, KWA; Snoek, GT				van Tiel, CM; Westerman, J; Paasman, MA; Hoebens, MM; Wirtz, KWA; Snoek, GT			The Golgi localization of phosphatidylinositol transfer protein beta requires the protein kinase C-dependent phosphorylation of serine 262 and is essential for maintaining plasma membrane sphingomyelin levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEINS; BOVINE BRAIN; HL-60 CELLS; RAT-BRAIN; YEAST; ALPHA; TRANSPORT; ISOFORM; BINDING	Recombinant mouse phosphatidylinositol transfer protein (PI-TP)beta is a substrate for protein kinase C (PKC)-dependent phosphorylation in vitro. Based on site-directed mutagenesis and two-dimensional tryptic peptide mapping, Ser(262) was identified as the major site of phosphorylation and Ser(165) as a minor phosphorylation site. The phospholipid transfer activities of wild-type PI-TPbeta and PI-TPbeta(S262A) were identical, whereas PI-TPbeta(S165A) was completely inactive. PKC-dependent phosphorylation of Ser(262) also had no effect on the transfer activity of PI-TPbeta. To investigate the role of Ser(262) in the function in of PI-TPO, wtPI-TPbeta and PI-TPbeta(S262A) were overexpressed in NIH3T3 fibroblast cells. Two-dimensional PAGE analysis of cell lysates was used to separate PI-TPbeta from its phosphorylated form. After Western blotting, wtPI-TPbeta was found to be 85% phosphorylated, whereas PI-TPbeta(S262A) was not phosphorylated. In the presence of the PKC inhibitor GF 109203X, the phosphorylated form of wtPI-TPbeta was strongly reduced. Immunolocalization showed that wtPI-TPbeta was predominantly associated with the Golgi membranes. In the presence of the PKC inhibitor, w-tPI-TPbeta was distributed throughout the cell similar to what was observed for PI-TPbeta(S262A). In contrast to wtPI-TPbeta overexpressors, cells overexpressing PI-TPbeta(S262A) were unable to rapidly replenish sphingomyelin in the plasma membrane upon degradation by sphingomyelinase. This implies that PKC-dependent association with the Golgi complex is a prerequisite for PI-TPbeta to express its effect on sphingomyelin metabolism.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Tiel, CM (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Dept Lipid Biochem, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	c.vantiel@chem.uu.nl						Alb JG, 2002, MOL BIOL CELL, V13, P739, DOI 10.1091/mbc.01-09-0457; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; DEVRIES KJ, 1995, BIOCHEM J, V310, P643, DOI 10.1042/bj3100643; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; GEIJTENBEEK TBH, 1994, BBA-LIPID LIPID MET, V1213, P309, DOI 10.1016/0005-2760(94)00063-8; HELMKAMP GM, 1985, CHEM PHYS LIPIDS, V38, P3, DOI 10.1016/0009-3084(85)90053-2; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HUANG KP, 1986, J BIOL CHEM, V261, P2134; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mwanjewe J, 2001, BIOCHEM J, V359, P211, DOI 10.1042/0264-6021:3590211; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Snoek GT, 1999, J BIOL CHEM, V274, P35393, DOI 10.1074/jbc.274.50.35393; SNOEK GT, 1993, BIOCHEM J, V291, P649, DOI 10.1042/bj2910649; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; TIMMERMANSHEREIJGERS JLPM, 1995, J BIOL CHEM, V270, P14263, DOI 10.1074/jbc.270.24.14263; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van Tiel CM, 2000, BIOCHEM J, V346, P537, DOI 10.1042/0264-6021:3460537; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200	30	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22447	22452		10.1074/jbc.M201532200	http://dx.doi.org/10.1074/jbc.M201532200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953429	hybrid			2022-12-25	WOS:000176313600045
J	Baumann, F; Neupert, W; Herrmann, JM				Baumann, F; Neupert, W; Herrmann, JM			Insertion of bitopic membrane proteins into the inner membrane of mitochondria involves an export step from the matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; CHARGED RESIDUES; TARGETING SIGNAL; AAA PROTEASE; NUCLEAR GENE; N-TERMINI; C-TERMINI; YEAST; TRANSLOCATION	The mitochondrial inner membrane contains a large number of polytopic proteins that are derived from prokaryotic ancestors of mitochondria. Little is known about the intramitochondrial sorting of these proteins. We chose two proteins of known topology as examples to study the pathway of insertion into the inner membrane; Mrs2 and Yta10 are bitopic proteins that expose negatively charged loops of different complexity into the intermembrane space. Here we show that both Mrs2 and Yta10 transiently accumulate as sorting intermediates in the matrix before they integrate into the inner membrane. The sorting pathway of both proteins can be separated into two sequential reactions: (i) import into the matrix and (ii) insertion from the matrix into the inner membrane. The latter process was found to depend on the membrane potential and, in this respect, is similar to the insertion of membrane proteins in bacteria. A comparison of the charge distribution of intermembrane space loops in a variety of mitochondrial inner membrane proteins suggests that this mode of "conservative sorting" might be the typical insertion route for polytopic inner membrane proteins that originated from bacterial ancestors.	Inst Physiol Chem, D-81377 Munich, Germany		Herrmann, JM (corresponding author), Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.		Baumann, Frank/F-7737-2016					Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GAVEL Y, 1992, EUR J BIOCHEM, V205, P1207, DOI 10.1111/j.1432-1033.1992.tb16892.x; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; Ii M, 2001, J BIOL CHEM, V276, P24704, DOI 10.1074/jbc.M102584200; KAPUT J, 1982, J BIOL CHEM, V257, P5054; Karlberg O, 2000, YEAST, V17, P170, DOI 10.1002/1097-0061(20000930)17:3<170::AID-YEA25>3.0.CO;2-V; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Lee CM, 1999, J BIOL CHEM, V274, P20937, DOI 10.1074/jbc.274.30.20937; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Rojo EE, 1999, J BIOL CHEM, V274, P19617, DOI 10.1074/jbc.274.28.19617; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Rojo EE, 1998, J BIOL CHEM, V273, P8040, DOI 10.1074/jbc.273.14.8040; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Schuenemann TA, 1999, J BIOL CHEM, V274, P6855, DOI 10.1074/jbc.274.11.6855; SDAINTGEORGES Y, 2001, P NATL ACAD SCI USA, V98, P13814; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200	41	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21405	21413		10.1074/jbc.M201670200	http://dx.doi.org/10.1074/jbc.M201670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11932259	hybrid			2022-12-25	WOS:000176286000038
J	Eicken, C; Sharma, V; Klabunde, T; Lawrenz, MB; Hardham, JM; Norris, SJ; Sacchettini, JC				Eicken, C; Sharma, V; Klabunde, T; Lawrenz, MB; Hardham, JM; Norris, SJ; Sacchettini, JC			Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODOMINANT CONSERVED REGION; TERMINAL INVARIABLE DOMAIN; GENETIC-VARIATION; PROTEIN-C; INFECTIVITY; ANTIBODY; RECOMBINATION; POPULATIONS; EXPRESSION; SPIROCHETE	VlsE is an outer surface lipoprotein of Borrelia burgdorferi that undergoes antigenic variation through an elaborate gene conversion mechanism and is thought to play a major role in the immune response to the Lyme disease borellia. The crystal structure of recombinant variant protein VlsE1 at 2.3-Angstrom resolution reveals that the six variable regions form loop structures that constitute most of the membrane distal surface of VlsE, covering the predominantly a-helical, invariant regions of the protein. The surface localization of the variable amino acid segments appears to protect the conserved regions from interaction with antibodies and hence may contribute to immune evasion.	Texas A&M Univ, Ctr Struct Biol, College Stn, TX 77843 USA; Albert B Alkeck Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77225 USA	Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas System	Sacchettini, JC (corresponding author), Texas A&M Univ, Ctr Struct Biol, College Stn, TX 77843 USA.	sacchett@tamu.edu	Norris, Steven James/K-6586-2019	Norris, Steven James/0000-0002-2501-8034	NIAID NIH HHS [R01 AI037277] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037277] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barbour AG, 2000, EMERG INFECT DIS, V6, P449, DOI 10.3201/eid0605.000502; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bunikis J, 1999, INFECT IMMUN, V67, P2874, DOI 10.1128/IAI.67.6.2874-2883.1999; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Eicken C, 2001, J BIOL CHEM, V276, P10010, DOI 10.1074/jbc.M010062200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hudson CR, 2001, MOL MICROBIOL, V41, P229, DOI 10.1046/j.1365-2958.2001.02511.x; Indest KJ, 2001, INFECT IMMUN, V69, P7083, DOI 10.1128/IAI.69.11.7083-7090.2001; Jones K, 2001, BIOCHEM BIOPH RES CO, V289, P389, DOI 10.1006/bbrc.2001.5983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kumaran D, 2001, EMBO J, V20, P971, DOI 10.1093/emboj/20.5.971; Labandeira-Rey M, 2001, INFECT IMMUN, V69, P446, DOI 10.1128/IAI.69.1.446-455.2001; Lawrenz MB, 1999, J CLIN MICROBIOL, V37, P3997, DOI 10.1128/JCM.37.12.3997-4004.1999; Liang FT, 1999, J IMMUNOL, V163, P5566; Liang FT, 2000, J BACTERIOL, V182, P3597, DOI 10.1128/JB.182.12.3597-3601.2000; Liang FT, 1999, J CLIN MICROBIOL, V37, P3990, DOI 10.1128/JCM.37.12.3990-3996.1999; Liang FT, 2001, INFECT IMMUN, V69, P1337, DOI 10.1128/IAI.69.3.1337-1343.2001; Liang FT, 2001, INFECT IMMUN, V69, P3224, DOI 10.1128/IAI.69.5.3224-3231.2001; Liang FT, 1999, INFECT IMMUN, V67, P6702; Liang FT, 2000, INFECT IMMUN, V68, P2349, DOI 10.1128/IAI.68.4.2349-2352.2000; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; Ohnishi J, 2001, P NATL ACAD SCI USA, V98, P670, DOI 10.1073/pnas.98.2.670; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Purser JE, 2000, P NATL ACAD SCI USA, V97, P13865, DOI 10.1073/pnas.97.25.13865; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; Sung SY, 2001, J BACTERIOL, V183, P5855, DOI 10.1128/JB.183.20.5855-5861.2001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zhang JR, 1998, INFECT IMMUN, V66, P3689, DOI 10.1128/IAI.66.8.3689-3697.1998; Zhang JR, 1998, INFECT IMMUN, V66, P3698, DOI 10.1128/IAI.66.8.3698-3704.1998; Zucker WR, 2001, J BIOL CHEM, V276, P457, DOI 10.1074/jbc.M008449200; [No title captured]	35	100	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21691	21696		10.1074/jbc.M201547200	http://dx.doi.org/10.1074/jbc.M201547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923306	hybrid			2022-12-25	WOS:000176286000077
J	Newell, JG; Dunn, SMJ				Newell, JG; Dunn, SMJ			Functional consequences of the loss of high affinity agonist binding to gamma-aminobutyric acid type A receptors - Implications for receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; MOLECULAR-MECHANISMS; SUBUNIT STRUCTURE; BRAIN; STOICHIOMETRY; PHARMACOLOGY; SITES	We reported previously that tyrosine 62 of the 132 subunit of the gamma-aminobutyric acid, type A (GABA(A)) receptor is an important determinant of high affinity agonist binding and that recombinant alpha1beta2gamma2(L) receptors carrying the Y62S mutation lack measurable high affinity sites for [H-3]muscimol. We have now examined the effects of disrupting these sites on the macroscopic desensitization properties of receptors expressed in Xenopus oocytes. Desensitization was measured by the ability of low concentrations of bath-perfused agonist to reduce the current responses elicited by subsequent challenges with saturating concentrations of GABA. Wild-type receptors were desensitized by pre-perfused muscimol with an IC50 similar to0.7 muM, which correlates well with the lower affinity sites for this agonist that are measured in direct binding studies. Receptors carrying the beta2 Y62S and Y62F mutations desensitized at slightly higher (2-7-fold) agonist concentrations. However, at low perfusate concentrations, the Y62S-containing receptor recovered from the desensitized state even in the continued presence of agonist. The characteristics of desensitization in the wild-type and mutant receptors lead us to suggest that the major role of the high affinity agonist-binding site(s) of the GABAA receptor is not to induce desensitization but rather to stabilize the desensitized state once it has been formed.	Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Dunn, SMJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England.	susan.dunn@bristol.ac.uk						AGEY MW, 1989, BIOCHEMISTRY-US, V28, P4200, DOI 10.1021/bi00436a012; Barnard EA, 1998, PHARMACOL REV, V50, P291; Bartrup JT, 1996, J PHYSIOL-LONDON, V490, P679, DOI 10.1113/jphysiol.1996.sp021177; Belelli D, 1996, BRIT J PHARMACOL, V118, P563, DOI 10.1111/j.1476-5381.1996.tb15439.x; Bianchi MT, 2001, J NEUROSCI, V21, P1127; Chang YC, 1996, J NEUROSCI, V16, P5415; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Corringer PJ, 1998, J NEUROSCI, V18, P648; DAVIES M, 1994, CAN J PHYSL PHARM, V72, P337; Dunn SMJ, 1997, BIOCHEMISTRY-US, V36, P3854, DOI 10.1021/bi9615046; Dunn SMJ, 1997, BIOCHEMISTRY-US, V36, P3846, DOI 10.1021/bi961503d; Dunn SMJ, 2000, BIOCHEM BIOPH RES CO, V279, P358, DOI 10.1006/bbrc.2000.3960; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; EDMONDS B, 1995, ANNU REV PHYSIOL, V57, P495; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Jones MV, 1998, J NEUROSCI, V18, P8590; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Newell JG, 2000, MOL BIOTECHNOL, V14, P25, DOI 10.1385/MB:14:1:25; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; OCHOA ELM, 1989, CELL MOL NEUROBIOL, V9, P141, DOI 10.1007/BF00713026; OLSEN RW, 1981, MOL PHARMACOL, V19, P217; Overstreet LS, 2000, J NEUROSCI, V20, P7914; RAFTERY MA, 1983, COLD SPRING HARB SYM, V48, P21, DOI 10.1101/SQB.1983.048.01.005; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; Scholze P, 1996, EUR J PHARMACOL, V304, P155, DOI 10.1016/0014-2999(96)00088-X; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Tretter V, 1997, J NEUROSCI, V17, P2728; YANG JSJ, 1987, MOL PHARMACOL, V32, P266	31	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21423	21430		10.1074/jbc.M110312200	http://dx.doi.org/10.1074/jbc.M110312200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11932253	hybrid			2022-12-25	WOS:000176286000040
J	Dziegielewski, J; Beerman, TA				Dziegielewski, J; Beerman, TA			Cellular responses to the DNA strand-scission enediyne C-1027 can be independent of ATM, ATR, and DNA-PK kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA CELLS; IONIZING-RADIATION; ANTITUMOR ANTIBIOTICS; DAMAGE; P53; NEOCARZINOSTATIN; BLEOMYCIN; PHOSPHORYLATION; REPLICATION	The current paradigm based upon ionizing radiation (IR) studies states that cells deficient in either ataxiatelangiectasia-mutated kinase (ATM) or related phosphatidylinositol 3 (PI 3) -kinases (ATR and DNA-PK) are hypersensitive to DNA strand breaks because they are unable to rapidly activate downstream effectors such as p53. Here we have contrasted cell responses to IR and C-1027, a radiomimetic antibiotic that induces DNA strand breaks. At equal levels of DNA double strand breaks, cell lines with inactive ATM or other phosphatidylinositol 3-kinases displayed classical hypersensitivity to IR but not to C-1027. Moreover, phosphorylation of p53 Ser-15 induced by C-1027 was independent of ATM, ATR, or DNA-PK function. We have concluded that the model based on IR studies cannot always be directly applied to DNA damage induced by other strand-scission agents.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Beerman, TA (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Charlton Sts, Buffalo, NY 14263 USA.				NCI NIH HHS [CA77491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BECKMANN RP, 1987, BIOCHEMISTRY-US, V26, P5409, DOI 10.1021/bi00391a029; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DiBiase SJ, 1999, INT J RADIAT ONCOL, V45, P743, DOI 10.1016/S0360-3016(99)00229-1; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dziegielewski J, 2001, BIOCHEMISTRY-US, V40, P704, DOI 10.1021/bi002181n; GRIMWADE JE, 1986, MOL PHARMACOL, V30, P358; HENNER WD, 1982, J BIOL CHEM, V257, P1750; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; JASPERS NGJ, 1982, CANCER RES, V42, P335; KHANNA KK, 1995, ONCOGENE, V11, P609; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kirk CA, 1997, BIOPHYS CHEM, V63, P201, DOI 10.1016/S0301-4622(96)02217-X; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Li L, 2001, INT J RADIAT ONCOL, V49, P1157, DOI 10.1016/S0360-3016(00)01524-8; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCHUGH MM, 1995, BIOCHEMISTRY-US, V34, P1805, DOI 10.1021/bi00005a038; McHugh MM, 2001, BIOCHEMISTRY-US, V40, P4792, DOI 10.1021/bi001668t; Miller SD, 1997, MOL CELL BIOL, V17, P2194, DOI 10.1128/MCB.17.4.2194; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SHILOH Y, 1983, CARCINOGENESIS, V4, P917, DOI 10.1093/carcin/4.7.917; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; SUGIMOTO Y, 1990, J ANTIBIOT, V43, P417, DOI 10.7164/antibiotics.43.417; SUGIURA Y, 1993, BIOCHEMISTRY-US, V32, P5548, DOI 10.1021/bi00072a008; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; XU YJ, 1990, CANCER CHEMOTH PHARM, V27, P41, DOI 10.1007/BF00689274; XU YJ, 1994, BIOCHEMISTRY-US, V33, P5947, DOI 10.1021/bi00185a036; Xu YJ, 1997, BIOCHEMISTRY-US, V36, P14975, DOI 10.1021/bi972101o; ZAMPETTIBOSSELER F, 1985, MUTAT RES, V151, P89, DOI 10.1016/0027-5107(85)90187-3; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	45	28	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20549	20554		10.1074/jbc.M109897200	http://dx.doi.org/10.1074/jbc.M109897200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927575	hybrid			2022-12-25	WOS:000176204500059
J	Fessler, MB; Malcolm, KC; Duncan, MW; Worthen, GS				Fessler, MB; Malcolm, KC; Duncan, MW; Worthen, GS			A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GDP DISSOCIATION INHIBITOR; CALCIUM-BINDING PROTEIN; MESSENGER-RNA; RECEPTOR 2; FUNCTIONAL PROTEOMICS; ACTIN CYTOSKELETON; CYTOSOLIC TARGET; EXPRESSION; PHOSPHORYLATION	Bacterial lipopolysaccharide (LPS) evokes several functional responses in the neutrophil that contribute to innate immunity. Although certain responses, such as adhesion and synthesis of tumor necrosis factor-alpha, are inhibited by pretreatment with an inhibitor of p38 mitogen-activated protein kinase, others, such as actin assembly, are unaffected. The aim of the present study was to investigate the changes in neutrophil gene transcription and protein expression following lipopolysaccharide exposure and to establish their dependence on p38 signaling. Microarray analysis indicated expression of 13% of the 7070 Affymetrix gene set in nonstimulated neutrophils, and LPS up-regulation of 100 distinct genes, including cytokines and chemokines, signaling molecules, and regulators of transcription. Proteomic analysis yielded a separate list of up-regulated modulators of inflammation, signaling molecules, and cytoskeletal proteins. Poor concordance between mRNA transcript and protein expression changes was noted. Pretreatment with the p38 inhibitor SB203580 attenuated 23% of LPS-regulated genes and 18% of LPS-regulated proteins by greater than or equal to40%. This study indicates that p38 plays a selective role in regulation of neutrophil transcripts and proteins following lipopolysaccharide exposure, clarifies that several of the effects of lipopolysaccharide are post-transcriptional and post-translational, and identifies several proteins not previously reported to be involved in the innate immune response.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Biochem Mass Spectrometry Facil, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Worthen, GS (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Neustadt Bldg,D403,1400 Jackson St, Denver, CO 80206 USA.	worthens@njc.org	Fessler, Michael B/C-6323-2019	Fessler, Michael B/0000-0002-8262-8613; Duncan, Mark/0000-0001-9256-8274				Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arnott D, 1998, ANAL BIOCHEM, V258, P1, DOI 10.1006/abio.1998.2566; Barraclough R, 1998, BBA-MOL CELL RES, V1448, P190, DOI 10.1016/S0167-4889(98)00143-8; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cohen P, 2000, J BIOL CHEM, V275, P11181, DOI 10.1074/jbc.275.15.11181; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; de Wit H, 1998, LEUKEMIA, V12, P363, DOI 10.1038/sj.leu.2400950; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851; Gilbert PM, 2001, J BIOL CHEM, V276, P8014, DOI 10.1074/jbc.M008845200; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Johnston CJ, 1998, TOXICOL SCI, V46, P300, DOI 10.1006/toxs.1998.2557; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; le Gouvello S, 1998, J IMMUNOL, V161, P1113; LECABEC V, 1994, BIOCHEM J, V303, P481, DOI 10.1042/bj3030481; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MARDIAN JKW, 1978, ANAL BIOCHEM, V91, P1, DOI 10.1016/0003-2697(78)90811-4; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; Nick JA, 1999, CHEST, V116, p54S, DOI 10.1378/chest.116.suppl_1.54S; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Regenhard P, 2001, J LEUKOCYTE BIOL, V69, P651; Rosales JL, 1997, J IMMUNOL, V159, P6195; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; ULICH TR, 1991, AM J PATHOL, V138, P1485; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; VALERIUS NH, 1982, ADV EXP MED BIOL, V141, P19; Vartiainen M, 2000, MOL CELL BIOL, V20, P1772, DOI 10.1128/MCB.20.5.1772-1783.2000; Wagner JG, 1999, J LEUKOCYTE BIOL, V66, P10, DOI 10.1002/jlb.66.1.10; Yan JX, 1999, ELECTROPHORESIS, V20, P723, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<723::AID-ELPS723>3.3.CO;2-H; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	67	142	178	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					31291	31302		10.1074/jbc.M200755200	http://dx.doi.org/10.1074/jbc.M200755200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	11943771	hybrid			2022-12-25	WOS:000177718700004
J	Cox, CJ; Espinoza, HM; McWilliams, B; Chappell, K; Morton, L; Hjalt, TA; Semina, EV; Amendt, BA				Cox, CJ; Espinoza, HM; McWilliams, B; Chappell, K; Morton, L; Hjalt, TA; Semina, EV; Amendt, BA			Differential regulation of gene expression by PITX2 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; RIEGER-SYNDROME; HOMEOBOX GENE; HOMEODOMAIN PROTEIN; SIGNALING PATHWAY; DLX2 EXPRESSION; PITUITARY-GLAND; BRANCHIAL ARCH; HEART; TRANSCRIPTION	Three major PITX2 isoforms are differentially expressed in human, mice, zebrafish, chick, and frog tissues. To demonstrate differential regulation of gene expression by these isoforms we used three different promoters and three cell lines. Transient transfection of Chinese hamster ovary, HeLa, and LS-8 cell lines revealed differences in PITX2A and PITX2C activation of the PLOD1 and Dlx2 promoters, however, PITX2B is inactive. In contrast, PITX2B actives the pituitary-specific Prolactin promoter at higher levels than either PITX2A or PITX2C. Interestingly, co-transfection of either PITX2A or PITX2C with PITX2B results in a synergistic activation of the PLOD1 and Dlx2 promoters. Furthermore, PITX2 isoforms have different transcriptional activity dependent upon the cells used for transfection analysis. We have isolated a fourth PITX2 isoform (PITX2D) expressed only in humans, which acts to suppress the transcriptional activity of the other PITX2 isoforms. Electrophoretic mobility shift assays and glutathione S-transferase pull-down experiments demonstrated that all isoforms interact with PITX2D and that PITX2B forms heterodimeric complexes with PITX2A and PITX2C. Our research provides a molecular basis for differential gene regulation through the expression of PITX2 isoforms. PITX2 isoform activities are both promoter- and cell-specific, and our data reveal new mechanisms for PITX2-regulated gene expression.	Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	University of Tulsa; University of Iowa	Amendt, BA (corresponding author), Univ Tulsa, Dept Biol Sci, 600 S Coll Ave, Tulsa, OK 74104 USA.			Amendt, Brad A./0000-0001-6524-1006; Cox, Carol/0000-0002-1394-3978	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013941] Funding Source: NIH RePORTER; NIDCR NIH HHS [1-R01-DE13941] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Amendt BA, 2000, CELL MOL LIFE SCI, V57, P1652, DOI 10.1007/PL00000647; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Campione M, 1999, DEVELOPMENT, V126, P1225; DAY RN, 1994, MOL ENDOCRINOL, V8, P374, DOI 10.1210/me.8.3.374; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Flomen RH, 1997, J MED GENET, V34, P191, DOI 10.1136/jmg.34.3.191; Gage PJ, 1999, DEVELOPMENT, V126, P4643; Gage PJ, 1999, DEV BIOL, V210, P234; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Green PD, 2001, GENE EXPRESSION, V9, P265, DOI 10.3727/000000001783992515; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Hjalt TA, 2001, J CELL BIOL, V152, P545, DOI 10.1083/jcb.152.3.545; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kitamura K, 1997, MECH DEVELOP, V67, P83, DOI 10.1016/S0925-4773(97)00110-X; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lin CR, 1999, NATURE, V401, P279, DOI 10.1038/45803; Liu CY, 2001, DEVELOPMENT, V128, P2039; Liu JK, 1997, DEV DYNAM, V210, P498, DOI 10.1002/(SICI)1097-0177(199712)210:4<498::AID-AJA12>3.0.CO;2-3; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowen M, 2001, J BIOL CHEM, V276, P42565, DOI 10.1074/jbc.M106536200; Lu MF, 1999, NATURE, V401, P276, DOI 10.1038/45797; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Padanilam B. J., 1992, Human Molecular Genetics, V1, P407, DOI 10.1093/hmg/1.6.407; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; QIU MS, 1995, GENE DEV, V9, P2523, DOI 10.1101/gad.9.20.2523; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Smidt MP, 2000, J NEUROCHEM, V75, P1818, DOI 10.1046/j.1471-4159.2000.0751818.x; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Thomas BL, 2000, DEVELOPMENT, V127, P217; Tremblay JJ, 2000, NEUROENDOCRINOLOGY, V71, P277, DOI 10.1159/000054547; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Yu XY, 2001, DEVELOPMENT, V128, P1005	40	130	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25001	25010		10.1074/jbc.M201737200	http://dx.doi.org/10.1074/jbc.M201737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11948188	hybrid			2022-12-25	WOS:000176747000023
J	Eiraku, M; Hirata, Y; Takeshima, H; Hirano, T; Kengaku, M				Eiraku, M; Hirata, Y; Takeshima, H; Hirano, T; Kengaku, M			Delta/Notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like ReDeat-cont ining protein T ryeted to dendrites of developing and adult central nervous system neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; SORTING SIGNALS; HIPPOCAMPAL-NEURONS; CYTOPLASMIC DOMAIN; ADAPTER COMPLEXES; MICE LACKING; MDCK CELLS; NOTCH; AP-1	We have identified a novel epidermal growth factor (EGF)-like repeat-containing single-pass transmembrane protein that is specifically expressed in the developing and mature central nervous system. Sequence analysis revealed that the 10 EGF-like repeats in the extracellular domain are closely related to those of the developmentally important receptor Notch and its ligand Delta. We thus named the molecule Delta/Notch-like EGF-related receptor (DNER). DNER protein is strongly expressed in several types of post-mitotic neurons, including cortical and hippocampal pyramidal neurons, cerebellar granule cells, and Purkinje cells. DNER protein is localized to the dendritic plasma membrane and endosomes and is excluded from the axons, even when overexpressed. The tyrosine-based sorting motif in the cytoplasmic domain is required for dendritic targeting of DNER. Direct in vivo binding of DNER to the coat-associated protein complex AP-1 strongly suggests that DNER undergoes AP-1-dependent sorting to the somatodendritic compartments from the transGolgi network and subsequent passage through the endosomal system.	Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kyoto University; Japan Science & Technology Agency (JST); Kurume University	Kengaku, M (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan.			Eiraku, Mototsugu/0000-0002-9433-9085; Takeshima, Hiroshi/0000-0003-4525-3725				Baker NE, 2000, BIOESSAYS, V22, P264, DOI 10.1002/(SICI)1521-1878(200003)22:3<264::AID-BIES8>3.0.CO;2-M; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Bradke F, 1998, BBA-MOL CELL RES, V1404, P245, DOI 10.1016/S0167-4889(98)00060-3; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Dwyer ND, 2001, NEURON, V31, P277, DOI 10.1016/S0896-6273(01)00361-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Goslin K., 1998, CULTURING NERVE CELL, P339; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kawaguchi S, 2000, NEURON, V27, P339, DOI 10.1016/S0896-6273(00)00041-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lehman NL, 2001, AM J MED GENET, V100, P179, DOI 10.1002/ajmg.1245; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; Poyatos I, 2000, MOL CELL NEUROSCI, V15, P99, DOI 10.1006/mcne.1999.0807; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Smith M, 2001, CYTOGENET CELL GENET, V94, P15, DOI 10.1159/000048775; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; West AE, 1997, J NEUROSCI, V17, P6038; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9; Yamasaki T, 2001, DEVELOPMENT, V128, P3133; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7	42	79	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25400	25407		10.1074/jbc.M110793200	http://dx.doi.org/10.1074/jbc.M110793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11950833	hybrid			2022-12-25	WOS:000176747000073
J	Adachi, M; Lewis, EJ				Adachi, M; Lewis, EJ			The paired-like homeodomain protein, arix, mediates protein kinase A-stimulated dopamine beta-hydroxylase gene transcription through its phosphorylation status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMPATHETIC NEURON DEVELOPMENT; PHOSPHATASE 2A; DNA-BINDING; CYCLIC-AMP; CAMP-RESPONSE; ACTIVATION; PHOX2A; EXPRESSION; GROWTH; DIFFERENTIATION	The homeodomain transcription factor Arix/Phox2a plays a critical role in the specification of noradrenergic neurons by inducing the expression of dopamine beta-hydroxylase (DBH), the terminal enzyme for noradrenaline biosynthesis. In reporter assays, Arix together with activation of cAMP-dependent protein kinase (PKA) potentiates DBH gene transcription. We have evaluated whether post-translational modification of Arix regulates PKA-mediated DBH gene transcription. We found that Arix is constitutively phosphorylated in vivo at the basal level and that the phosphorylation level is substantially decreased upon stimulation of the PKA pathway. The change in the Arix phosphorylation state coincides with DNA binding activity of Arix. Treatment of cells with forskolin results in a robust enhancement of the DNA binding of Arix, which is reversed by treatment with serine/threonine and tyrosine phosphatase inhibitors. Consistent with the DNA binding activity of Arix, treatment of cultured cells with phosphatase inhibitors diminishes transcriptional activation with Arix plus forskolin. Amino acid analysis demonstrates the presence of phosphoserine within Arix. The results collectively suggest that dephosphorylation of Arix is a necessary event to fully activate PKA-mediated DBH transcription. Thus, the present study demonstrates that Arix can integrate extrinsic signals through post-translational modification, regulating DBH gene transcription in response to activation of the PKA pathway.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lewis, EJ (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, L224, Portland, OR 97201 USA.		Adachi, Megumi/M-7746-2017	Adachi, Megumi/0000-0003-3404-6640	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038696, R01GM038696] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38696] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi M, 2000, DNA CELL BIOL, V19, P539, DOI 10.1089/104454900439773; Berry M, 2000, EMBO J, V19, P2946, DOI 10.1093/emboj/19.12.2946; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DZIENNIS S, 2001, P 31 ANN M SOC NEUR; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Francis NJ, 1999, ANNU REV NEUROSCI, V22, P541, DOI 10.1146/annurev.neuro.22.1.541; Goridis C, 1999, CURR OPIN NEUROBIOL, V9, P47, DOI 10.1016/S0959-4388(99)80006-3; Guo S, 1999, DEV BIOL, V208, P473, DOI 10.1006/dbio.1999.9204; Guo S, 1999, NEURON, V24, P555, DOI 10.1016/S0896-6273(00)81112-5; Gupta IR, 1999, J BIOL CHEM, V274, P26305, DOI 10.1074/jbc.274.37.26305; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kim HS, 1998, J NEUROSCI, V18, P8247; Lee YS, 1997, J CELL PHYSIOL, V170, P153, DOI 10.1002/(SICI)1097-4652(199702)170:2<153::AID-JCP7>3.0.CO;2-N; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Marquardt T, 2001, CELL, V106, P651, DOI 10.1016/S0092-8674(01)00499-8; MAURER RA, 1989, J BIOL CHEM, V264, P6870; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Nakano M, 2001, NAT GENET, V29, P315, DOI 10.1038/ng744; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Patzke H, 2001, MECH DEVELOP, V108, P149, DOI 10.1016/S0925-4773(01)00503-2; Reissmann E, 1996, DEVELOPMENT, V122, P2079; Sabban EL, 2001, TRENDS NEUROSCI, V24, P91, DOI 10.1016/S0166-2236(00)01687-8; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; Stanke M, 1999, DEVELOPMENT, V126, P4087; Stoker AW, 2001, CURR OPIN NEUROBIOL, V11, P95, DOI 10.1016/S0959-4388(00)00179-3; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Swanson DJ, 1998, J BIOL CHEM, V273, P24065, DOI 10.1074/jbc.273.37.24065; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; Usui H, 1998, FEBS LETT, V430, P312, DOI 10.1016/S0014-5793(98)00684-X; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Yang CY, 1998, J NEUROCHEM, V71, P1813	42	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22915	22924		10.1074/jbc.M201695200	http://dx.doi.org/10.1074/jbc.M201695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943777	hybrid			2022-12-25	WOS:000176313600104
J	Dahle, MK; Gronning, LM; Cederberg, A; Blomhoff, HK; Miura, N; Enerback, S; Tasken, KA; Tasken, K				Dahle, MK; Gronning, LM; Cederberg, A; Blomhoff, HK; Miura, N; Enerback, S; Tasken, KA; Tasken, K			Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; HUMAN FORKHEAD GENE; WINGED HELIX PROTEINS; CYCLIC-AMP; BETA SUBUNIT; DNA-BINDING; TRANSLATION INITIATION; INSULIN-RESISTANCE; NUCLEAR EXCLUSION; MESSENGER-RNA	We have reported recently that mice overexpressing the forkhead/winged helix transcription factor FOXC2 are lean and show increased responsiveness to insulin due to sensitization of the beta-adrenergic cAMP-PKA(+) pathway and increased levels of the RIalpha subunit of cAMP-dependent protein kinase (PKA) (Cederberg, A., Gronning, L.M., Ahren, B., Tasken, K., Carlsson, P., and Enerback, S. (2001) Cell 106, 563-573). In this present study, we reveal that FOXC2 and a related factor, FOXD1, specifically activate the 1b promoter of the RIa gene in adipocytes and testicular Sertoli cells, respectively. By deletional mapping, we discovered two different mechanisms by which the Fox proteins activated expression from the RIalpha1b promoter. In 3T3-L1 adipocytes, an upstream region represses promoter activity under basal conditions. Bandshift experiments indicate that overexpression of FOXC2 promotes the release of a potential repressor from this region. In Sertoli cells, sequences downstream of the transcription start sites mediate the activating effect of FOXD1, and protein kinase Balpha/Akt1 strongly induces this effect. Furthermore, we show that an inactive FOXD1 mutant lowers the cAMP-mediated induction of the RIalpha1b reporter construct. In summary, winged helix transcription factors of the FOXC/FOXD families function as regulators of the RIalpha subunit of PKA and may integrate hormonal signals acting through protein kinase B and cAMP in a cell-specific manner.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway; Gothenburg Univ, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Hamamatsu Univ Sch Med, Dept Biochem, Hamamatsu, Shizuoka 4313192, Japan	University of Oslo; University of Gothenburg; Hamamatsu University School of Medicine	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, POB 1112 Blindern, N-0317 Oslo, Norway.	kjetil.tasken@basalmed.uio.no	Dahle, Maria K/AAK-5130-2021	Dahle, Maria K/0000-0003-0380-084X; Tasken, Kjetil/0000-0003-2841-4697				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Barradeau S, 2000, FEBS LETT, V476, P272, DOI 10.1016/S0014-5793(00)01653-7; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cederberg A, 1997, GENOMICS, V44, P344, DOI 10.1006/geno.1997.4864; Cederberg A, 1999, J BIOL CHEM, V274, P165, DOI 10.1074/jbc.274.1.165; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chaudhary J, 2000, ENDOCRINOLOGY, V141, P2758, DOI 10.1210/en.141.8.2758; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Collas P, 1999, J CELL SCI, V112, P1045; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Dahle MK, 2001, EUR J BIOCHEM, V268, P5920, DOI 10.1046/j.0014-2956.2001.02542.x; Dahle MK, 2001, MOL REPROD DEV, V59, P11, DOI 10.1002/mrd.1001; DAHLE MK, 2001, MOL REPROD DEV, V268, P5920; DIRKSEN ML, 1995, DEV GENET, V17, P107, DOI 10.1002/dvg.1020170203; DORRINGTON JH, 1975, MOL CELL ENDOCRINOL, V3, P57, DOI 10.1016/0303-7207(75)90031-3; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Gronning LM, 1999, EUR J ENDOCRINOL, V141, P75, DOI 10.1530/eje.0.1410075; HANSSON V, 1976, VITAM HORM, V34, P187, DOI 10.1016/S0083-6729(08)60076-X; Iida K, 1997, DEVELOPMENT, V124, P4627; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; Kaestner KH, 2000, GENE DEV, V14, P142; Knutsen HK, 1997, MOL CELL ENDOCRINOL, V129, P101, DOI 10.1016/S0303-7207(97)04045-8; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Larsson C, 1995, GENOMICS, V30, P464, DOI 10.1006/geno.1995.1266; Malik TH, 2001, EMBO J, V20, P1715, DOI 10.1093/emboj/20.7.1715; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Miura N, 1997, GENOMICS, V41, P489, DOI 10.1006/geno.1997.4695; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Molnar A, 1996, J IMMUNOL, V156, P585; Nakayama Y, 1999, INT J DEV BIOL, V43, P343; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Planas JV, 1999, J BIOL CHEM, V274, P36281, DOI 10.1074/jbc.274.51.36281; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Shantz LM, 1996, CANCER RES, V56, P3265; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Yanga XL, 2000, FEBS LETT, V470, P29, DOI 10.1016/S0014-5793(00)01285-0	61	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22902	22908		10.1074/jbc.M200131200	http://dx.doi.org/10.1074/jbc.M200131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943768	hybrid			2022-12-25	WOS:000176313600102
J	Gukovskaya, AS; Gukovsky, I; Jung, Y; Mouria, M; Pandol, SJ				Gukovskaya, AS; Gukovsky, I; Jung, Y; Mouria, M; Pandol, SJ			Cholecystokinin induces caspase activation and mitochondrial dysfunction in pancreatic acinar cells - Roles in cell injury processes of pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NECROSIS-FACTOR-ALPHA; PERMEABILITY TRANSITION; INDUCED APOPTOSIS; ENZYME-SECRETION; CYCLOSPORINE-A; UP-REGULATION; DEATH; INDUCTION; CERULEIN	Apoptosis and necrosis are critical parameters of pancreatitis, the mechanisms of which remain unknown. Many characteristics of pancreatitis can be studied in vitro in pancreatic acini treated with high doses of cholecystokinin (CCK). We show here that CCK stimulates apoptosis and death signaling pathways in rat pancreatic acinar cells, including caspase activation, cytochrome c release, and mitochondrial depolarization. The mitochondrial dysfunction is mediated by upstream caspases (possibly caspase-8) and, in turn, leads to activation of caspase-3. CCK causes mitochondrial alterations through both permeability transition pore-dependent (cytochrome c release) and permeability transition pore-independent (mitochondrial depolarization) mechanisms. Caspase activation and mitochondrial alterations also occur in untreated pancreatic acinar cells; however, the underlying mechanisms are different. In particular, caspases protect untreated acinar cells from mitochondrial damage. We found that caspases not only mediate apoptosis but also regulate other parameters of CCK-induced acinar cell injury that are characteristic of pancreatitis; in particular, caspases negatively regulate necrosis and trypsin activation in acinar cells. The results suggest that the observed signaling pathways regulate parenchymal cell injury and death in CCK-induced pancreatitis. Protection against necrosis and trypsin activation by caspases can explain why the severity of pancreatitis in experimental models correlates inversely with the extent of apoptosis.	Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Gukovskaya, AS (corresponding author), Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Med, Bldg 258,Rm 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.			Gukovskaya, Anna/0000-0003-3737-5335	PHS HHS [P50-A11999] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BASTANI B, 1995, BBA-MOL CELL RES, V1269, P307, DOI 10.1016/0167-4889(95)00120-0; Beil M, 2002, AM J PHYSIOL-GASTR L, V282, pG450, DOI 10.1152/ajpgi.00042.2001; Bhatia M, 2000, J PATHOL, V190, P117; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; BROCKEMEIER KM, 1995, BIOCHEMISTRY-US, V34, P16440; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fujimoto K, 1997, DIGESTION, V58, P421, DOI 10.1159/000201478; Gaisano HY, 2001, J CLIN INVEST, V108, P1597; Gorelick FS, 1999, BEST PRACT RES CL GA, V13, P227, DOI 10.1053/bega.1999.0021; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Halangk W, 1998, PANCREAS, V16, P88, DOI 10.1097/00006676-199801000-00014; Han B, 1999, AM J PHYSIOL-CELL PH, V277, pC74, DOI 10.1152/ajpcell.1999.277.1.C74; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LERCH MM, 1994, INT J PANCREATOL, V15, P159; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu D, 2000, J BIOL CHEM, V275, P9244, DOI 10.1074/jbc.275.13.9244; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nguyen NSD, 1999, FREE RADICAL BIO MED, V27, P1267, DOI 10.1016/S0891-5849(99)00160-4; NIEDERAU C, 1990, GASTROENTEROLOGY, V99, P1120, DOI 10.1016/0016-5085(90)90633-C; Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1989, CELL CALCIUM, V10, P255, DOI 10.1016/0143-4160(89)90008-0; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; Pandol SJ, 1999, GASTROENTEROLOGY, V117, P706, DOI 10.1016/S0016-5085(99)70465-8; PANDOL SJ, 1982, J BIOL CHEM, V257, P2024; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; REISINE T, 1995, CIBA F SYMP, V190, P160; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; SALUJA AK, 1989, P NATL ACAD SCI USA, V86, P8968, DOI 10.1073/pnas.86.22.8968; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schild L, 1999, MOL CELL BIOCHEM, V195, P191, DOI 10.1023/A:1006988625831; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Terzian AR, 1996, BIOCHEM PHARMACOL, V52, P569, DOI 10.1016/0006-2952(96)00308-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOPAZIAN M, 1999, TXB GASTROENTEROLOGY, P2121; Vercesi AE, 1997, BIOSCIENCE REP, V17, P43, DOI 10.1023/A:1027335217774; Wank SA, 1998, AM J PHYSIOL-GASTR L, V274, pG607, DOI 10.1152/ajpgi.1998.274.4.G607; WILLEMS PHGM, 1995, CELL CALCIUM, V18, P471, DOI 10.1016/0143-4160(95)90010-1; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zaninovic V, 2000, AM J PHYSIOL-GASTR L, V279, pG666, DOI 10.1152/ajpgi.2000.279.4.G666	63	113	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22595	22604		10.1074/jbc.M202929200	http://dx.doi.org/10.1074/jbc.M202929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964411	hybrid			2022-12-25	WOS:000176313600066
J	Kim, Y; Suh, N; Sporn, M; Reed, JC				Kim, Y; Suh, N; Sporn, M; Reed, JC			An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; PPAR-GAMMA; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; SYNTHETIC OLEANANE; DIRECT INHIBITORS; CANCER-CELLS; DEATH; LIGAND	TRAIL (Apo2 ligand) is a member of the tumor necrosis factor (TNF) family of cytokines that induces apoptosis. Because TRAIL preferentially kills tumor cells, sparing normal tissues, interest has emerged in applying this biological factor for cancer therapy in humans. However, not all tumors respond to TRAIL, raising questions about resistance mechanisms. We demonstrate here that a variety of natural and synthetic ligands of peroxisome proliferator-activated receptor-gamma (PPARgamma) sensitize tumor but not normal cells to apoptosis induction by TRAIL. PPARgamma ligands selectively reduce levels of FLIP, an apoptosis-suppressing protein that blocks early events in TRAIL/TNF family death receptor signaling. Both PPARgamma agonists and antagonists displayed these effects, regardless of the levels of PPARgamma expression and even in the presence of a PPARgamma dominant-negative mutant, indicating a PPARgamma-independent mechanism. Reductions in FLIP and sensitization to TRAIL-induced apoptosis were also not correlated with TNF-kappaB, further suggesting a novel mechanism. PPARgamma modulators induced ubiquitination and proteasome-dependent degradation of FLIP, without concomitant reductions in FLIP mRNA. The findings suggest the existence of a pharmacologically regulated novel target of this class of drugs that controls FLIP protein turnover, and raise the possibility of combining PPARgamma modulators with TRAIL for more efficacious elimination of tumor cells through apoptosis.	Burnham Inst, La Jolla, CA 92037 USA; Dartmouth Coll, Sch Med, Dept Pharmacol, Hanover, NH 03755 USA	Sanford Burnham Prebys Medical Discovery Institute; Dartmouth College	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org	高, 雨莉/HGU-8187-2022		NCI NIH HHS [CA 69381, CA55164, CA78040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, P01CA078040, P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Bonavida B, 1999, INT J ONCOL, V15, P793; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Fulda S, 2000, CANCER RES, V60, P3947; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Honda T, 2000, J MED CHEM, V43, P4233, DOI 10.1021/jm0002230; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Nagata S, 2000, NAT MED, V6, P502, DOI 10.1038/74972; Palakurthi SS, 2001, CANCER RES, V61, P6213; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suh N, 1999, CANCER RES, V59, P5671; Suh NJ, 1999, CANCER RES, V59, P336; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	54	279	317	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22320	22329		10.1074/jbc.M202458200	http://dx.doi.org/10.1074/jbc.M202458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940602	hybrid			2022-12-25	WOS:000176313600028
J	Kisselev, AF; Kaganovich, D; Goldberg, AL				Kisselev, AF; Kaganovich, D; Goldberg, AL			Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes - Evidence for peptide-induced channel opening in the alpha-rings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNITS; MULTICATALYTIC PROTEASE; CORE PARTICLE; INHIBITORS; YEAST; 20-S-PROTEASOME; DEGRADATION; RESOLUTION; ACTIVATION; MECHANISM	The eukaryotic 20 S proteasome contains the following 6 active sites: 2 chymotrypsin-like, 2 trypsin-like, and 2 caspase-like. We previously showed that hydrophobic peptide substrates of the chymotrypsin-like sites allosterically stimulate peptide hydrolysis by the caspase-like sites and their own cleavage. More thorough analysis revealed that these peptides also stimulate peptide hydrolysis by the trypsin-like site. This general activation by hydrophobic peptides occurred even if the chymotrypsin-like sites were occupied by a covalent inhibitor and was highly cooperative, with an average Hill coefficient of 7. Therefore, this stimulation of peptide hydrolysis at all active sites occurs upon binding of hydrophobic peptides to several non-catalytic sites. The stimulation by hydrophobic peptides was not observed in the yeast DeltaNalpha3 mutant 20 S proteasomes, in 20 S-PA26 complexes, or SDS-activated proteasomes and was significantly lower in 26 S proteasomes, all of which appear to have the gated channel in the a-rings in an open conformation and hydrolyze peptides at much faster rates than 20 S proteasomes. Also the hydrophobic peptides altered K-m, V-max. of active sites in a similar fashion as PA26 and the DeltaNalpha3 mutation. The activation by hydrophobic peptides was decreased in K+-containing buffer, which favors the closed state of the channels. Therefore, hydrophobic peptides stimulate peptide hydrolysis most likely by promoting the opening of the channels in the a-rings. During protein breakdown, this peptide-induced channel opening may function to facilitate the release of products from the proteasome.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu		Kaganovich, Daniel/0000-0003-2398-1596				Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; CASCIO P, 2002, IN PRESS EMBO J; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick TP, 1998, J BIOL CHEM, V273, P25637, DOI 10.1074/jbc.273.40.25637; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Kessler BM, 2001, CHEM BIOL, V8, P913, DOI 10.1016/S1074-5521(01)00069-2; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kopp F, 2001, J MOL BIOL, V313, P465, DOI 10.1006/jmbi.2001.5063; Li J, 2001, EMBO J, V20, P3359, DOI 10.1093/emboj/20.13.3359; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Osmulski PK, 2000, J BIOL CHEM, V275, P13171, DOI 10.1074/jbc.C901035199; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Schmidtke G, 2000, J BIOL CHEM, V275, P22056, DOI 10.1074/jbc.M002513200; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wilk S, 1999, ARCH BIOCHEM BIOPHYS, V362, P283, DOI 10.1006/abbi.1998.1034; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; [No title captured]	37	144	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22260	22270		10.1074/jbc.M112360200	http://dx.doi.org/10.1074/jbc.M112360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11927581	hybrid			2022-12-25	WOS:000176313600021
J	Fujioka, Y; Kimata, Y; Nomaguchi, K; Watanabe, K; Kohno, K				Fujioka, Y; Kimata, Y; Nomaguchi, K; Watanabe, K; Kohno, K			Identification of a novel non-structural maintenance of chromosomes (SMC) component of the SMC5-SMC6 complex involved in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SISTER CHROMATIDS; PROTEIN; YEAST; SEPARATION; MUTATION; COHESION; RAD18; CONDENSATION; TRIGGERS	Structural maintenance of chromosomes (SMC) proteins play central roles in chromosome organization and dynamics. They have been classified into six subtypes, termed SMC1 to SMC6, and function as heterodimer components of large protein complexes that also include several non-SMC proteins. The SMC2-SMC4 and SMC1-SMC3 complexes are also known as condensin and cohesin, respectively, but the recently identified SMC5 and SMC6 complex is less well characterized. Here, we report that NSE1 from Saccharomyces cerevisiae encodes a novel non-SMC component of the SMC5(Yo1034wp)SMC6(Rhc18p) complex corresponding to the 2-3-MDa molecular mass. Nse1p is essential for cell proliferation and localizes primarily in the nucleus. nse1 mutants are highly sensitive to DNA-damaging treatments and exhibit abnormal cellular morphologies, suggesting aberrant mitosis as a terminal morphological phenotype. These results are consistent with the reported features of the Schizosaccharomyces pombe SMC6 gene, rad18, which is thought to be involved in recombinational DNA repair. We conclude that Nse1p and the SMC5-SMC6 heterodimer together form a high molecular mass complex that is conserved in eukaryotes and required for both DNA repair and proliferation.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology	Kohno, K (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, 8916-5 Takayama, Nara 6300101, Japan.		Kohno, Kenji/AAZ-6573-2020	Kohno, Kenji/0000-0002-3503-6551				Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Ewaskow SP, 1998, BIOCHEMISTRY-US, V37, P4437, DOI 10.1021/bi972652e; Fousteri MI, 2000, EMBO J, V19, P1691, DOI 10.1093/emboj/19.7.1691; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Higashio H, 2000, J BIOL CHEM, V275, P17900, DOI 10.1074/jbc.M000751200; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Iha H, 1998, BIOTECHNIQUES, V25, P936, DOI 10.2144/98256bm01; Jensen ON, 1999, METH MOL B, V112, P513; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; JONES S, 2001, GENOME BIOL, V2; Kaiser C., 1994, METHODS YEAST GENETI; Kimata Y, 1997, BIOCHEM BIOPH RES CO, V232, P69, DOI 10.1006/bbrc.1997.6235; Kimata Y, 1999, CELL STRUCT FUNCT, V24, P197, DOI 10.1247/csf.24.197; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Mengiste T, 1999, EMBO J, V18, P4505, DOI 10.1093/emboj/18.16.4505; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Taylor EM, 2001, MOL BIOL CELL, V12, P1583, DOI 10.1091/mbc.12.6.1583; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Verkade HM, 1999, MOL BIOL CELL, V10, P2905, DOI 10.1091/mbc.10.9.2905; WATANABE K, 1997, THESIS NARA I SCI TE	29	81	82	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21585	21591		10.1074/jbc.M201523200	http://dx.doi.org/10.1074/jbc.M201523200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927594	hybrid			2022-12-25	WOS:000176286000062
J	Pedersen, LC; Darden, TA; Negishi, M				Pedersen, LC; Darden, TA; Negishi, M			Crystal structure of beta 1,3-glucuronyltransferase I in complex with active donor substrate UDP-GlcUA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; SULFATE BIOSYNTHESIS; N-ACETYLGLUCOSAMINE; MOLECULAR-CLONING; MECHANISM; EXPRESSION; HEPARIN	beta1,3-Glucuronyltransferase (GlcAT-I) is an essential enzyme involved in heparan sulfate and chondroitin sulfate biosynthesis. GlcAT-I is an inverting glycosyltransferase that catalyzes the transfer of glucuronic acid (GlcUA) to the common growing linker region Galbeta1-3Galbeta1-4Xyl that is attached to a serine side chain of a core protein. Previously the structure of GlcAT-I has been solved in the presence of the donor product UDP and an acceptor analog Galbeta1-3GalX1-4Xyl (Pedersen, L. C., Tsuchida, K., Kitagawa, H., Sugahara, K., Darden, T. A. & Negishi, M. (2000) J. Biol. Chem. 275, 34580-34585). Here we report the x-ray crystal structure of GIcAT-I in complex with the complete donor UDP-Glc-UA, thereby providing structures of an inverting glycosyltransferase in which both the complete donor and acceptor substrates are present in the active site. This structure supports the in-line displacement reaction mechanism previously proposed. It also provides information on the essential amino acid residues that determine donor substrate specificity.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005, Z01ES043010, ZIAES043010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Murray BW, 1996, BIOCHEMISTRY-US, V35, P11183, DOI 10.1021/bi961065a; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269	28	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21869	21873		10.1074/jbc.M112343200	http://dx.doi.org/10.1074/jbc.M112343200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11950836	hybrid			2022-12-25	WOS:000176286000097
J	Tanaka, Y; Nakayamada, S; Fujimoto, H; Okada, Y; Umehara, H; Kataoka, T; Minami, Y				Tanaka, Y; Nakayamada, S; Fujimoto, H; Okada, Y; Umehara, H; Kataoka, T; Minami, Y			H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GROWTH-FACTORS; T-CELLS; RAS; BONE; INVOLVEMENT; VCAM-1	We have studied the relevance of H-Ras and its downstream effectors to osteoblast functions. 1) Purified human osteoblasts highly expressed integrins beta(1), alpha(4), alpha(5), alpha(6) and the activation epitope of beta(1), However, these molecules were markedly down-regulated on osteoblasts transfected with expression vector encoding fully activated H-Ras(V12), H-Ras(V12)T35S, activating Raf-1/mitogen-activated protein kinase (MAPK), or an active Raf-1 but not on cells having H-Ras(V12)Y40C, a phosphoinositide 3-kinase (PI3K)-binding mutant. 2) Although osteoblasts spontaneously adhered to fibronectin and laminin in beta(1)-dependent manner, the expression of H-Ras(V12) or H-RaS(V12)T35S, but not H-Ras(V12)Y40C, in osteoblasts reduced their adhesion. 3) Osteoblasts bearing H-Ras(V12), H-Ras(V12)T35S, or Raf-1 failed to proliferate, whereas those with H-Ras(V12)Y40C proliferated well. (4) The up-regulation of Fas and down-regulation of Bcl-2 were observed in osteoblasts expressing H-Ras(V12), H-Ras(V12)T35S, or Raf-1. (5) Most of the cells having H-Ras(V12), H-Ras(V12)T35S, or Raf-1 became annexin-V-(high)/propidium iodide (PI)(high) (or) (low) and terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL)(high)/PIlow after 24 and 72 h incubation, respectively. Thus, we propose that H-Ras signals followed by Raf-1/MAPK pathway but not PI3K not only reduces beta(1)-mediated adhesion of osteoblasts to matrix proteins but induces apoptosis presumably via the Fas up-regulation and Bcl-2 down-regulation.	Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan; Kobe Univ, Sch Med, Dept Biomed Regulat, Kobe, Hyogo 6500017, Japan; Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto 6058507, Japan; Kobe Univ, Sch Med, Dept Physiol 2, Kobe, Hyogo 6500017, Japan	University of Occupational & Environmental Health - Japan; Kobe University; Kyoto University; Kobe University	Tanaka, Y (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan.	tanaka@med.uoeh-u.ac.jp						Bennett JH, 2001, HISTOL HISTOPATHOL, V16, P603, DOI 10.14670/HH-16.603; BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221-8747(84)90064-X; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Caverzasio J, 2000, J BONE MINER RES, V15, P1697, DOI 10.1359/jbmr.2000.15.9.1697; Clohisy DR, 1999, J LAB CLIN MED, V134, P190, DOI 10.1016/S0022-2143(99)90197-X; Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Epler J A, 2000, Dev Immunol, V7, P155; Fujii K, 1999, J IMMUNOL, V162, P2391; Fujimoto H, 2001, GENES CELLS, V6, P337, DOI 10.1046/j.1365-2443.2001.00428.x; Globus RK, 1998, J CELL SCI, V111, P1385; Gomez M, 1997, EUR J IMMUNOL, V27, P8, DOI 10.1002/eji.1830270103; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Karaplis AC, 2001, CURR PHARM DESIGN, V7, P655, DOI 10.2174/1381612013397753; Kido M, 2002, J BIOL CHEM, V277, P3117, DOI 10.1074/jbc.M109526200; Knall C, 1998, J CELL BIOCHEM, P137; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Papaioannou S, 1999, BBA-MOL CELL RES, V1449, P284, DOI 10.1016/S0167-4889(99)00025-7; Quarles LD, 1996, J BONE MINER RES, V11, P1375; Raisz LG, 1999, CLIN CHEM, V45, P1353; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rodan GA, 1998, J CELL BIOCHEM, P55; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; Shimizu Y, 2000, Immunol Today, V21, P597, DOI 10.1016/S0167-5699(00)01783-7; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Tanaka Y, 1997, J IMMUNOL, V158, P3822; Tanaka Y, 1999, J IMMUNOL, V163, P6209; Tanaka Y, 1998, BLOOD, V91, P3909; TANAKA Y, 1995, J BONE MINER RES, V10, P1462; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tanaka Y, 2000, J BONE MINER RES, V15, P1912, DOI 10.1359/jbmr.2000.15.10.1912; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799	38	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21446	21452		10.1074/jbc.M202238200	http://dx.doi.org/10.1074/jbc.M202238200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934900	hybrid			2022-12-25	WOS:000176286000043
J	Baljinnyam, B; Schroth-Diez, B; Korte, T; Herrmann, A				Baljinnyam, B; Schroth-Diez, B; Korte, T; Herrmann, A			Lysolipids do not inhibit influenza virus fusion by interaction with hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; LOW-PH; CONFORMATIONAL-CHANGE; KINETICS; GLYCOPROTEIN; PEPTIDE; VESICLE; BINDING; LIPIDS; STALK	The interaction of a spin-labeled lysophosphatidylcholine analog with intact and bromelain-treated influenza viruses as well as with the bromelain-solubilized hemagglutinin ectodomain has been studied. The inhibition of fusion of influenza viruses with erythrocytes by the lysophosphatidylcholine analog was similar to that observed for non-labeled lysophosphatidylcholine. Only a weak interaction of the lysophosphatidylcholine analog with the hemagglutinin ectodomain was observed even upon triggering the conformational change of the ectodomain at a low pH. A significant interaction of spin-labeled lysophosphatidylcholine with the hemagglutinin ectodomain of intact viruses was observed neither at neutral nor at low pH, whereas a strong interaction of the lipid analog with the viral lipid bilayer was evident. We suggest that the high number of lipid binding sites of the virus bilayer and their affinity compete efficiently with binding sites of the hemagglutinin ectodomain. We conclude that the inhibition of influenza virus fusion by lysolipids is not mediated by binding to the hemagglutinin ectodomain, preventing its interaction with the target membrane. The results unambiguously argue for an inhibition mechanism based on the action of lysolipid inserted into the lipid bilayer.	Humboldt Univ, Math Naturwissensch Fak 1, Inst Biol, D-10115 Berlin, Germany	Humboldt University of Berlin	Herrmann, A (corresponding author), Humboldt Univ, Math Naturwissensch Fak 1, Inst Biol, Invalidenstr 42, D-10115 Berlin, Germany.	andreas.herrmann@rz.hu-berlin.de		Schroth-Diez, Britta/0000-0002-4908-5952				BETHELL RC, 1995, BIOCHEM BIOPH RES CO, V206, P355, DOI 10.1006/bbrc.1995.1049; BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; Bottcher C, 1999, FEBS LETT, V463, P255, DOI 10.1016/S0014-5793(99)01475-1; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; Chernomordik LV, 1999, MOL MEMBR BIOL, V16, P33; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GETHING MJ, 1988, CURR TOP MEMBR TRANS, V32, P337; GuntherAusborn S, 1997, VIROLOGY, V235, P201, DOI 10.1006/viro.1997.8699; GUNTHERAUSBORN S, 1995, J BIOL CHEM, V270, P29279; GUTMAN O, 1993, BIOCHEMISTRY-US, V32, P101, DOI 10.1021/bi00052a014; HARTER C, 1989, J BIOL CHEM, V264, P6459; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; KLENK HD, 1991, CLASSIFICATION NOMEN, P263; Korte T, 1999, J VIROL, V73, P4567, DOI 10.1128/JVI.73.6.4567-4574.1999; Korte T, 1997, J BIOL CHEM, V272, P9764; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; KOZLOV MM, 1989, EUR BIOPHYS J BIOPHY, V17, P121; KRUMBIEGEL M, 1994, BIOPHYS J, V67, P2355, DOI 10.1016/S0006-3495(94)80721-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; STEGMANN T, 1986, J BIOL CHEM, V261, P966; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YEAGLE PL, 1994, BIOCHEMISTRY-US, V33, P1820, DOI 10.1021/bi00173a027; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	42	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20461	20467		10.1074/jbc.M112217200	http://dx.doi.org/10.1074/jbc.M112217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923295	hybrid			2022-12-25	WOS:000176204500047
J	Bianchini, EP; Louvain, VB; Marque, PE; Juliano, MA; Juliano, L; Le Bonniec, BF				Bianchini, EP; Louvain, VB; Marque, PE; Juliano, MA; Juliano, L; Le Bonniec, BF			Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR; RAY CRYSTAL-STRUCTURE; COAGULATION-FACTOR XA; ACTIVE-SITE; BLOOD-COAGULATION; SERINE PROTEASES; TISSUE FACTOR; FACTOR-IXA; PROTEIN-C; PROTHROMBINASE COMPLEX	Factor Xa (FXa) hydrolyzes two peptide bonds in prothrombin having (Glu/Asp)-Gly-Arg-(Thr/Ile) for P-3-P-2- P-1-P-1' residues, but the exact preferences of its catalytic groove remain largely unknown. To investigate the specificity of FXa, we synthesized full sets of fluorescence-quenched substrates carrying all natural amino acids (except Cys) in P-3, P-2, P-1', P-2', and P-3' and determined the k(cat)/K-m values of cleavage. Contrary to expectation, glycine was not the "best" P-2 residue; peptide with phenylalanine was cleaved slightly faster. In fact, FXa had surprisingly limited preferences, barely more pronounced than trypsin; in P-2, the ratio of the k(cat)/K-m values for the most favorable side chain over the least was 289 (12 with trypsin), but in P-1', this ratio was only 30 (versus 80 with trypsin). This unexpected selectivity undoubtedly distinguished FXa from thrombin, which exhibited ratios higher than 19,000 in P-2 and P-1'. Thus, with respect to the catalytic groove, FXa resembles a low efficiency trypsin rather than the highly selective thrombin. The rates of cleavage of the peptidyl substrates were virtually identical whether or not FXa was in complex with factor Va, suggesting that the cofactor did not exert a direct allosteric control on the catalytic groove. We conclude that the remarkable efficacy of FXa within prothrombinase originates from exosite interaction(s) with factor Va and/or prothrombin rather than from the selectivity of its catalytic groove.	Univ Paris 05, Fac Pharm, INSERM, U428, F-75270 Paris 06, France; Escola Paulista Med, Dept Biophys, BR-04044020 Sao Paulo, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidade Federal de Sao Paulo (UNIFESP)	Le Bonniec, BF (corresponding author), Univ Paris 05, Fac Pharm, INSERM, U428, 4 Av Observ, F-75270 Paris 06, France.		Le Bonniec, Bernard/S-5756-2016; Le Bonniec, Bernard/ABA-1366-2020; Juliano, Luiz/D-7204-2012	Le Bonniec, Bernard/0000-0002-8432-7363; Le Bonniec, Bernard/0000-0002-8432-7363; Juliano, Luiz/0000-0002-5589-2822; BIANCHINI, Elsa/0000-0002-1370-5312				Alves LC, 1996, PEPTIDE RES, V9, P92; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, PROTEIN SCI, V1, P426; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; BRANDSTETTER H, 1996, J BIOL CHEM, V271, P29968; Burgering MJM, 1997, J MOL BIOL, V269, P395, DOI 10.1006/jmbi.1997.1029; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; CASTILLO MJ, 1983, BIOCHEMISTRY-US, V22, P1021, DOI 10.1021/bi00274a004; CHO K, 1984, BIOCHEMISTRY-US, V23, P644, DOI 10.1021/bi00299a009; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Fraternali F, 1998, PROTEINS, V30, P264, DOI 10.1002/(SICI)1097-0134(19980215)30:3<264::AID-PROT6>3.0.CO;2-K; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GAILANI D, 1993, BLOOD, V82, P813; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Grahn S, 1999, BBA-PROTEIN STRUCT M, V1431, P329, DOI 10.1016/S0167-4838(99)00059-X; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Jesty J, 1976, Methods Enzymol, V45, P95; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; Kurth T, 1998, BIOCHEMISTRY-US, V37, P11434, DOI 10.1021/bi980842z; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P6970; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; Long GL, 1998, J BIOL CHEM, V273, P11521, DOI 10.1074/jbc.273.19.11521; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Marque PE, 2000, J BIOL CHEM, V275, P809, DOI 10.1074/jbc.275.2.809; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MCRAE BJ, 1981, BIOCHEMISTRY-US, V20, P7196, DOI 10.1021/bi00528a022; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P3; REZAIE AR, 2001, BIOCHIM BIOPHYS ACTA, V1548, P167; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; WALKER RK, 1993, J BIOL CHEM, V268, P13920	57	55	65	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20527	20534		10.1074/jbc.M201139200	http://dx.doi.org/10.1074/jbc.M201139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925440	hybrid			2022-12-25	WOS:000176204500056
J	Groth, G; Hisabori, T; Lill, H; Bald, D				Groth, G; Hisabori, T; Lill, H; Bald, D			Substitution of a single amino acid switches the tentoxin-resistant thermophilic F-1-ATPase into a tentoxinsensitive enzyme.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPLAST F-1-ATPASE; INHIBITION; F1-ATPASE; BINDING; SENSITIVITY; SUBCOMPLEX; SUBUNIT; SITE	In contrast to the homologous bacterial and mitochondrial enzymes the chloroplast F-1-ATPase (CF1) is strongly affected by the phytopathogenic inhibitor tentoxin. Based on structural information obtained from crystals of a CF1-tentoxin co-complex (Groth, G. (2002) Proc. Natt. Acad. Sci. U. S. A. 99, 3464-3468) we have replaced residues betaSer(66) and alphaArg(132) in the alpha(3)beta(3)gamma subcomplex of the thermophilic F-1-ATPase from Bacillus PS3 by the corresponding residues of the chloroplast ATPase to confer tentoxin sensitivity to the thermophilic enzyme. The mutation alphaArg(132)-->Pro, proposed to relieve steric constraints on tentoxin binding, did not have any significant effect. However, mutation betaSer(66)-->Ala, predicted to provide a crucial hydrogen bond with the inhibitor, resulted in tentoxin inhibition of ATP hydrolysis comparable with the situation found with the chloroplast enzyme.	Free Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, NL-1081 HV Amsterdam, Netherlands; Univ Dusseldorf, Dept Plant Biochem, D-40225 Dusseldorf, Germany; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, ERATO, JST, Yoshida ATP Syst Project,Midori Ku, Yokohama, Kanagawa 2260026, Japan	Vrije Universiteit Amsterdam; Heinrich Heine University Dusseldorf; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Bald, D (corresponding author), Free Univ Amsterdam, Fac Earth & Life Sci, Dept Biol Struct, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.		; Hisabori, Toru/E-5205-2014	Lill, H./0000-0001-9336-5428; Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARNTZEN CJ, 1972, BIOCHIM BIOPHYS ACTA, V283, P539, DOI 10.1016/0005-2728(72)90273-3; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; Bald D, 2000, J BIOL CHEM, V275, P12757, DOI 10.1074/jbc.275.17.12757; Groth G, 2002, P NATL ACAD SCI USA, V99, P3464, DOI 10.1073/pnas.052546099; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; Hu DL, 1997, J BIOL CHEM, V272, P5457, DOI 10.1074/jbc.272.9.5457; HU NM, 1993, J BIOL CHEM, V268, P8536; LIEBERMANN B, 1983, Z ALLG MIKROBIOL, V23, P503, DOI 10.1002/jobm.3630230810; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Mochimaru M, 1997, FEBS LETT, V419, P23, DOI 10.1016/S0014-5793(97)01421-X; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Santolini J, 1999, J BIOL CHEM, V274, P849, DOI 10.1074/jbc.274.2.849; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V501, P72, DOI 10.1016/0005-2728(78)90096-8; Stiggall D L, 1979, Methods Enzymol, V55, P308; Tucker WC, 2001, BIOCHEMISTRY-US, V40, P7542, DOI 10.1021/bi0105227; Tucker WC, 2001, EUR J BIOCHEM, V268, P2179, DOI 10.1046/j.1432-1327.2001.02110.x; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	20	6	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20117	20119		10.1074/jbc.C200168200	http://dx.doi.org/10.1074/jbc.C200168200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11943766	Green Published, hybrid			2022-12-25	WOS:000176204500002
J	Savitsky, PA; Finkel, T				Savitsky, PA; Finkel, T			Redox regulation of Cdc25C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; CELL-CYCLE; SUPEROXIDE-DISMUTASE; CHECKPOINT PATHWAY; CRYSTAL-STRUCTURE; PROTEIN-KINASE; ARREST; G(2); PHOSPHATASE; INHIBITION	The Cdc25 family of dual specific phosphatases are critical components of cell cycle progression and checkpoint control. Certain stresses such as ultraviolet light stimulate the rapid and selective destruction of Cdc25A protein through a Chk1 protein kinase-dependent pathway. We demonstrate that in contrast to cellular stresses previously examined, hydrogen peroxide exposure affects Cdc25C but not Cdc25A levels. Pharmacological inhibition of Chk1 activity or a mutant of Cdc25C that lacks the Chk1 phosphorylation site still undergoes degradation in response to oxidants. We also demonstrate that in vitro hydrogen peroxide stimulates an intramolecular disulfide bond between the active site cysteine at position 377 and another invariant cysteine at position 330. The in vivo stability of Cdc25C is substantially reduced by the mutation of either of these two cysteine residues. In contrast, a double (C2) mutant of both cysteine 330 and cysteine 377 results in a protein that is more stable than wild type Cdc25C and is resistant to oxidative stress-induced degradation. In addition, the C2 mutant, which is unable to form an intramolecular disulfide bond, has reduced binding to 14-3-3 in vitro and in vivo. These results suggest that oxidative stress may induce cell cycle arrest in part through the degradation of Cdc25C.	NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Finkel, T (corresponding author), NHLBI, Cardiovasc Branch, NIH, Bldg 10 6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.	finkelt@nih.gov		Savitsky, Pavel/0000-0001-8584-7750				Arrington ED, 2000, FREE RADICAL BIO MED, V29, P1166, DOI 10.1016/S0891-5849(00)00439-1; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; D'Agnillo F, 2001, BLOOD, V98, P3315, DOI 10.1182/blood.V98.12.3315; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; den Boer BGW, 2000, TRENDS CELL BIOL, V10, P245, DOI 10.1016/S0962-8924(00)01765-7; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KUGAMAI A, 1999, GENE DEV, V13, P1067; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; NATSUYAMA S, 1993, BIOCHIM BIOPHYS ACTA, V1176, P90, DOI 10.1016/0167-4889(93)90182-O; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	27	179	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20535	20540		10.1074/jbc.M201589200	http://dx.doi.org/10.1074/jbc.M201589200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925443	hybrid			2022-12-25	WOS:000176204500057
J	Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M				Ueki, T; Walter, KM; Skinner, H; Jaffee, E; Hruban, RH; Goggins, M			Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived	ONCOGENE			English	Article						CpG island methylation; pancreatic adenocarcinoma; cell line	DNA METHYLATION; DENOVO METHYLATION; EPITHELIAL-CELLS; SUPPRESSOR ROLE; INACTIVATION; GENE; HYPERMETHYLATION; CARCINOMA; EXPRESSION; PANCREAS	A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell tine populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be artificially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-specific PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P<0.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu	Skinner, Halcyon/A-1049-2009	Skinner, Halcyon G./0000-0002-0220-9110; Jaffee, Elizabeth/0000-0003-3841-6549	NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 1998, ADV CANCER RES, V72, P141; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 2001, CANCER RES, V61, P3225; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jarrard DF, 1999, CANCER RES, V59, P2957; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Markl IDC, 2001, CANCER RES, V61, P5875; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Schutte M, 1997, CANCER RES, V57, P3126; Toyota M, 1999, CANCER RES, V59, P2307; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Wilentz RE, 1998, CANCER RES, V58, P4740	24	47	49	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2114	2117		10.1038/sj.onc.1205275	http://dx.doi.org/10.1038/sj.onc.1205275			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960385				2022-12-25	WOS:000174827000019
J	Zaganas, I; Plaitakis, A				Zaganas, I; Plaitakis, A			Single amino acid substitution (G456A) in the vicinity of the GTP binding domain of human housekeeping glutamate dehydrogenase markedly attenuates GTP inhibition and abolishes the cooperative behavior of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERINSULINISM/HYPERAMMONEMIA SYNDROME; HYPERAMMONEMIA SYNDROME; NEUROLOGICAL DISORDERS; CASSETTE MUTAGENESIS; REGULATORY MUTATIONS; MISSENSE MUTATIONS; HUMAN-LIVER; GENE; IDENTIFICATION; MECHANISM	Human glutamate dehydrogenase (GDH) exists in two isoforms encoded by the GLUD1 and GLUD2 genes, respectively. Although the two enzymes share in their mature form all but 15 of their 505 amino acids, they differ markedly in their allosteric regulation. To identify the structural basis for these allosteric characteristics, we performed site-directed mutagenesis on the human GLUD1 gene at sites that differ from the GLUD2 gene using a cloned GLUD1 cDNA. Results showed that substitution of Ala for Gly-456, but not substitution of His for Arg-470 or Ser for Asn-498, renders the enzyme markedly resistant to GTP inhibition (IC50 = 2.80 muM) as compared with the wild type GLUD1-derived GDH (IC50 = 0.19 muM). The G456A mutation abolished the cooperative behavior of the enzyme, as revealed by the GTP inhibitory curves. The catalytic and kinetic properties of the G456A mutant and its activation by ADP were comparable with those of the wild type GDH. Gly-456 lies in a very tightly packed region of the GDH molecule, and its replacement by Ala may lead to steric clashes with neighboring amino acids. These, in turn, may affect the conformational state of the protein that is essential for the allosteric regulation of the enzyme by GTP.	Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece	University of Crete	Plaitakis, A (corresponding author), Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece.	plaitak@med.uoc.gr	Zaganas, Ioannis/AAE-5441-2020	Zaganas, Ioannis/0000-0002-0774-5772				Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; Cho SW, 2001, EUR J BIOCHEM, V268, P3205, DOI 10.1046/j.1432-1327.2001.02209.x; COLON AD, 1986, J NEUROCHEM, V46, P1811; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V3rd, DOI [10.1016/B978-0-408-10617-7.50013-4/, DOI 10.1016/B978-0-408-10617-7.50013-4]; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P133; De Lonlay P, 2001, PEDIATR RES, V50, P353, DOI 10.1203/00006450-200109000-00010; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee EY, 2001, J BIOL CHEM, V276, P47930, DOI 10.1074/jbc.M108918200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacMullen C, 2001, J CLIN ENDOCR METAB, V86, P1782, DOI 10.1210/jc.86.4.1782; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; MICHAELIDIS TM, 1993, GENOMICS, V16, P150, DOI 10.1006/geno.1993.1152; Miki Y, 2000, J PEDIATR-US, V136, P69, DOI 10.1016/S0022-3476(00)90052-0; MOON K, 1973, J BIOL CHEM, V248, P3082; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Peterson PE, 1997, J STRUCT BIOL, V120, P73, DOI 10.1006/jsbi.1997.3899; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; Plaitakis A, 2001, J NEUROSCI RES, V66, P899, DOI 10.1002/jnr.10054; PLAITAKIS A, 1984, ANN NEUROL, V15, P144, DOI 10.1002/ana.410150206; Santer R, 2001, HUM GENET, V108, P66, DOI 10.1007/s004390000432; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; SMITH EL, 1975, ENZYMES, P293; Smith TJ, 2001, J MOL BIOL, V307, P707, DOI 10.1006/jmbi.2001.4499; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Yorifuji T, 1999, HUM GENET, V104, P476, DOI 10.1007/s004390050990	30	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					26422	26428		10.1074/jbc.M200022200	http://dx.doi.org/10.1074/jbc.M200022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11950837	hybrid			2022-12-25	WOS:000176908700079
J	Simm, AM; Higgins, CS; Carenbauer, AL; Crowder, MW; Bateson, JH; Bennett, PM; Clarke, AR; Halford, SE; Walsh, TR				Simm, AM; Higgins, CS; Carenbauer, AL; Crowder, MW; Bateson, JH; Bennett, PM; Clarke, AR; Halford, SE; Walsh, TR			Characterization of monomeric L1 metallo-beta-lactamase and the role of the N-terminal extension in negative cooperativity and antibiotic hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STENOTROPHOMONAS-MALTOPHILIA; BACTEROIDES-FRAGILIS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; BACILLUS-CEREUS; CLINICAL ISOLATE; MOLECULAR CHARACTERIZATION; ANGSTROM RESOLUTION; GENE; PURIFICATION	The L1 metallo-beta-lactamase from Stenotrophomonas maltophilia is unique among this class of enzymes because it is tetrameric. Previous work predicted that the two regions of important intersubunit interaction were the residue Met-140 and the N-terminal extensions of each subunit. The N-terminal extension was also implicated in beta-lactam binding. Mutation of methionine 140 to aspartic acid results in a monomeric L1 beta-lactamase with a greatly altered substrate specificity profile. A 20-amino acid N-terminal deletion mutant enzyme (N-Del) could be isolated in a tetrameric form but demonstrated greatly reduced rates of beta-lactam hydrolysis and different substrate profiles compared with that of the parent enzyme. Specific site-directed mutations of individual N terminus residues were made (Y11S, W17S, and a double mutant L5A/L8A). All N-terminal mutant enzymes were tetramers and all showed higher K-m values for ampicillin and nitrocefin, hydrolyzed ceftazidime poorly, and hydrolyzed imipenem more efficiently than ampicillin in contrast to wild-type L1. Nitrocefin turnover was significantly increased, probably because of an increased rate of breakdown of the intermediate species due to a lack of stabilizing forces. K-m values for monomeric L1 were greatly increased for all antibiotics tested. A model of a highly mobile N-terminal extension in the monomeric enzyme is proposed to explain these findings. Tetrameric L1 shows negative cooperativity, which is not present in either the monomer or N-terminal deletion enzymes, suggesting that the cooperative effect is mediated via N-terminal intersubunit interactions. These data indicate that while the N terminus of L1 is not essential for beta-lactam hydrolysis, it is clearly important to its activity and substrate specificity.	Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England; Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA; GlaxoSmithKline, Dept Med Chem, Harlow CM19 5AW, Essex, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University System of Ohio; Miami University; GlaxoSmithKline; University of Bristol	Simm, AM (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Univ Walk, Bristol BS8 1TD, Avon, England.	A.M.Simm@bristol.ac.uk	Walsh, Timothy R/F-6519-2010	Walsh, Timothy/0000-0003-4315-4096				Alonso A, 1997, ANTIMICROB AGENTS CH, V41, P1140, DOI 10.1128/AAC.41.5.1140; Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P879, DOI 10.1093/jac/46.6.879; Avison MB, 2001, ANTIMICROB AGENTS CH, V45, P413, DOI 10.1128/AAC.45.2.413-419.2001; Bellais S, 1999, FEMS MICROBIOL LETT, V171, P127, DOI 10.1111/j.1574-6968.1999.tb13422.x; BICKNELL R, 1985, BIOCHEM J, V229, P791, DOI 10.1042/bj2290791; Boschi L, 2000, ANTIMICROB AGENTS CH, V44, P1538, DOI 10.1128/AAC.44.6.1538-1543.2000; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Cornaglia G, 2000, CLIN INFECT DIS, V31, P1119, DOI 10.1086/317448; Crowder MW, 1996, BIOCHEMISTRY-US, V35, P12126, DOI 10.1021/bi960976h; Crowder MW, 1998, ANTIMICROB AGENTS CH, V42, P921, DOI 10.1128/AAC.42.4.921; Crowder MW, 1999, RRD ANTIMICROB AG  1, V3, P105; Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; Gibbs N, 2001, PROTEINS, V43, P186, DOI 10.1002/1097-0134(20010501)43:2<186::AID-PROT1030>3.0.CO;2-L; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hudson L, 1989, PRACTICAL IMMUNOLOGY, P348; HUSSAIN M, 1985, J BACTERIOL, V164, P223, DOI 10.1128/JB.164.1.223-229.1985; Laue T.M., 1991, ANAL ULTRACENTRIFUGA; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; McManus-Munoz S, 1999, BIOCHEMISTRY-US, V38, P1547, DOI 10.1021/bi9826512; McRorie D. K., 1993, SELF ASSOCIATING SYS; Mokaddas EM, 1999, J CHEMOTHERAPY, V11, P93, DOI 10.1179/joc.1999.11.2.93; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; Poirel L, 2000, ANTIMICROB AGENTS CH, V44, P891, DOI 10.1128/AAC.44.4.891-897.2000; RASMUSSEN BA, 1990, ANTIMICROB AGENTS CH, V34, P1590, DOI 10.1128/AAC.34.8.1590; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Riccio ML, 2000, ANTIMICROB AGENTS CH, V44, P1229, DOI 10.1128/AAC.44.5.1229-1235.2000; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; SAINO Y, 1982, ANTIMICROB AGENTS CH, V22, P564, DOI 10.1128/AAC.22.4.564; SAINO Y, 1984, ANTIMICROB AGENTS CH, V25, P362, DOI 10.1128/AAC.25.3.362; Segel I., 1975, ENZYME KINETICS, P371; Simm AM, 2001, FEBS LETT, V509, P350, DOI 10.1016/S0014-5793(01)03152-0; Spencer J, 2001, J BIOL CHEM, V276, P33638, DOI 10.1074/jbc.M105550200; Suzuki Yumiko, 1995, Japanese Journal of Antibiotics, V48, P1906; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Walsh TR, 1998, ANTIMICROB AGENTS CH, V42, P436; WALSH TR, 1994, BBA-GENE STRUCT EXPR, V1218, P199, DOI 10.1016/0167-4781(94)90011-6; Wang ZG, 1998, J AM CHEM SOC, V120, P10788, DOI 10.1021/ja982621m; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Winston RL, 1998, ANAL BIOCHEM, V262, P83, DOI 10.1006/abio.1998.2754; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524; Yang YJ, 1999, J BIOL CHEM, V274, P15706, DOI 10.1074/jbc.274.22.15706	52	32	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24744	24752		10.1074/jbc.M201524200	http://dx.doi.org/10.1074/jbc.M201524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11940588	hybrid			2022-12-25	WOS:000176611800101
J	Yengo, CM; De la Cruz, EM; Chrin, LR; Gaffney, DP; Berger, CL				Yengo, CM; De la Cruz, EM; Chrin, LR; Gaffney, DP; Berger, CL			Actin-induced closure of the actin-binding cleft of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; X-RAY STRUCTURE; MOTOR DOMAIN; ADP RELEASE; ACTOMYOSIN; COMPLEX; HEAD; SUBFRAGMENT-1; PURIFICATION; CONTRACTION	The putative actin-binding interface of myosin is separated by a large cleft that extends into the base of the nucleotide binding pocket, suggesting that it may be important for mediating the nucleotide-dependent changes in the affinity for myosin on actin. We have genetically engineered a truncated version of smooth muscle myosin containing the motor domain and the essential light chain-binding region (MDE), with a single tryptophan residue at position 425 (F425W-MDE) in the actin-binding cleft. Steady-state fluorescence of F425W-MDE demonstrates that Trp-425 is in a more solvent-exposed conformation in the presence of MgATP than in the presence of MgADP or absence of nucleotide, consistent with closure of the actin-binding cleft in the strongly bound states of MgATPase cycle for myosin. Transient kinetic experiments demonstrate a direct correlation between the rates of strong actin binding and the conformation of Trp-425 in the actin-binding cleft, and suggest the existence of a novel conformation of myosin not previously seen in solution or by x-ray crystallography. Thus, these results directly demonstrate that: 1) the conformation of the actin-binding cleft mediates the affinity of myosin for actin in a nucleotide-dependent manner, and 2) actin induces conformational changes in myosin required to generate force and motion during muscle contraction.	Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Vermont; University of Pennsylvania; University of Pennsylvania	Berger, CL (corresponding author), Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044219] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63798] Funding Source: Medline; NIAMS NIH HHS [AR44219] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHOCK SP, 1976, BIOCHEMISTRY-US, V15, P3244, DOI 10.1021/bi00660a013; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEEVES MA, 1991, BIOCHEM J, V274, P1; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; Onishi H, 1995, P NATL ACAD SCI USA, V92, P11965, DOI 10.1073/pnas.92.26.11965; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers J. R., 1999, MYOSINS; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P2110; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944	28	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24114	24119		10.1074/jbc.M111253200	http://dx.doi.org/10.1074/jbc.M111253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959853	hybrid			2022-12-25	WOS:000176611800019
J	Bres, V; Kiernan, R; Emiliani, S; Benkirane, M				Bres, V; Kiernan, R; Emiliani, S; Benkirane, M			Tat acetyl-acceptor lysines are important for human immunodeficiency virus type-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; RNA-POLYMERASE-II; NF-KAPPA-B; CELLULAR PROTEIN-KINASE; CREB-BINDING-PROTEIN; FACTOR P-TEFB; HIV-1 TAT; T-CELLS; TRANSCRIPTIONAL ACTIVATION; HISTONE-ACETYLTRANSFERASE	The human immunodeficiency virus type-1 trans-activator Tat is a transcription factor that activates the HIV-1 promoter through binding to the trans-activation-responsive region (TAR) localized at the 5'-end of all viral transcripts. We and others have recently shown that Tat is directly acetylated at lysine 28, within the activation domain, and lysine 50, in the TAR RNA binding domain, by Tat-associated histone acetyltransferases p300, p300/CBP-associating factor, and hGCN5. Here, we show that mutation of acetyl-acceptor lysines to arginine or glutamine affects virus replication. Interestingly, mutation of lysine 28 and lysine 50 differentially affected Tat trans-activation of integrated versus nonintegrated long terminal repeat. Our results highlight the importance of lysine 28 and lysine 50 of Tat in virus replication and Tat-mediated trans-activation.	Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Benkirane, M (corresponding author), Inst Genet Humaine, CNRS, UPR 1142, 141 Rue Cardonville, F-34396 Montpellier 5, France.		Kiernan, Rosemary/GXV-8695-2022	Kiernan, Rosemary/0000-0001-6645-0686				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cafaro A, 2000, J MED PRIMATOL, V29, P193, DOI 10.1034/j.1600-0684.2000.290313.x; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Ensoli B, 2000, J BIOL REG HOMEOS AG, V14, P22; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; Garber ME, 1998, COLD SPRING HARB SYM, V63, P371, DOI 10.1101/sqb.1998.63.371; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Harrich D, 1997, EMBO J, V16, P1224, DOI 10.1093/emboj/16.6.1224; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Isel C, 1999, J MOL BIOL, V290, P929, DOI 10.1006/jmbi.1999.2933; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; JOSHI A, 1993, BIOTECHNIQUES, V14, P880; JOSHI A, 1993, BIOTECHNIQUES, V14, P884; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; Osterhaus ADME, 1999, VACCINE, V17, P2713, DOI 10.1016/S0264-410X(98)00498-8; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Secchiero P, 1999, J IMMUNOL, V162, P2427; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	62	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22215	22221		10.1074/jbc.M201895200	http://dx.doi.org/10.1074/jbc.M201895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956210	hybrid			2022-12-25	WOS:000176313600016
J	Cheriyath, V; Desgranges, ZP; Roy, AL				Cheriyath, V; Desgranges, ZP; Roy, AL			c-Src-dependent transcriptional activation of TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; GROWTH-FACTOR; BINDING PROTEIN; SH3 DOMAIN; SIGNAL; EXPRESSION; INTEGRIN; EGF; TRANSFORMATION; REQUIREMENT	TFII-I is a multifunctional transcription factor that is also involved in signal transduction. Here we show that TFII-I undergoes a c-Src-dependent tyrosine phosphorylation on tyrosine residues 248 and 611 and translocates to the nucleus in response to growth factor signaling. Tyrosine-phosphorylated nuclear TFII-l activates a stably integrated c-fos reporter gene. Withdrawal of signal leads to diminution of nuclear TFII-I, suggesting that the signal-dependent translocation is reversible. Antibodies against either TFH-I or c-Src abrogate growth factor-stimulated activation of c-fos. Consistent with the notion that tyrosine phosphorylation of TFII-I is required for its transcriptional activity, phosphorylation-deficient mutants of TFII-I fail to activate the c-fos promoter. These data demonstrate that TFH-I, through a Src-dependent mechanism, reversibly translocates from the cytoplasm to the nucleus, leading to the transcriptional activation of growth-regulated genes.	Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Program Immunol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Genet Program, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu			NIAID NIH HHS [AI45150] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Cheriyath V, 2001, J BIOL CHEM, V276, P8377, DOI 10.1074/jbc.M008411200; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Francke U, 1999, HUM MOL GENET, V8, P1947, DOI 10.1093/hmg/8.10.1947; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2001, MOL CELL BIOL, V21, P3387, DOI 10.1128/MCB.21.10.3387-3397.2000; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	41	46	46	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22798	22805		10.1074/jbc.M202956200	http://dx.doi.org/10.1074/jbc.M202956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934902	hybrid			2022-12-25	WOS:000176313600089
J	Jones, LC; Okino, ST; Gonda, TJ; Whitlock, JP				Jones, LC; Okino, ST; Gonda, TJ; Whitlock, JP			Myb-binding protein 1a augments AhR-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIN RECEPTOR; TRANSCRIPTION; TRANSACTIVATION; DOMAINS; IDENTIFICATION; CLONING; REVEALS; MOTIF; ARNT; PAS	We have studied the mechanism by which an acidic domain (amino acids 515-583) of the aromatic hydrocarbon receptor (AhR) transactivates a target gene. Studies with glutathione S-transferase fusion proteins demonstrate that the wild-type acidic domain associates in vitro with Myb-binding protein la, whereas a mutant domain (F542A, 1569A) does not. AhR-defective cells reconstituted with an AhR containing the wild-type acidic domain exhibit normal AhR function; however, cells reconstituted with an AhR containing the mutant acidic domain do not function normally. Transient transfection of Myb-binding protein la into mouse hepatoma cells is associated with augmentation of AhR-dependent gene expression. Such augmentation does not occur when Myb-binding protein la is transfected into AhR-defective cells that have been reconstituted with an AhR that lacks the acidic domain. We infer that 1) Myb-binding protein la associates with AhR, thereby enhancing transactivation, and 2) the presence of AhR's acidic domain is both necessary and sufficient for Myb-binding protein la to increase AhR-dependent gene expression.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol & Oncol, Los Angeles, CA 90048 USA; Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Stanford University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Institute Medical & Veterinary Science Australia	Whitlock, JP (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.		Gonda, Thomas J/A-3620-2012		NCI NIH HHS [CA 53887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FAVIER D, 1994, ONCOGENE, V9, P305; Fernandez J, 1998, ELECTROPHORESIS, V19, P1036, DOI 10.1002/elps.1150190619; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FISHER JM, 1990, J BIOL CHEM, V265, P9676; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Jones LC, 2001, J BIOL CHEM, V276, P25037, DOI 10.1074/jbc.M102910200; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Ledo F, 2000, MOL CELL BIOL, V20, P9120, DOI 10.1128/MCB.20.24.9120-9126.2000; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; PERDEW GH, 1995, HYBRIDOMA, V14, P279, DOI 10.1089/hyb.1995.14.279; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SCAMMELL JG, 1995, MOL BRAIN RES, V33, P326, DOI 10.1016/0169-328X(95)00161-K; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWIFT S, 1999, CURRENT PROTOCOLS S, V31; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003	36	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22515	22519		10.1074/jbc.M200740200	http://dx.doi.org/10.1074/jbc.M200740200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956195	hybrid			2022-12-25	WOS:000176313600054
J	Lee, D; Kim, JW; Seo, T; Hwang, SG; Choi, EJ; Choe, J				Lee, D; Kim, JW; Seo, T; Hwang, SG; Choi, EJ; Choe, J			SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEXES; SWI-SNF COMPLEX; GLUCOCORTICOID RECEPTOR; HUMAN HOMOLOG; BINDING; PROTEIN; BRG1; GROWTH; DOMAIN; GENE	The SWI/SNF complex is required for the transcription of several genes and has been shown to alter nucleosome structure in an ATP-dependent manner. The tumor suppressor protein p53 displays growth and transformation suppression functions that are frequently lost in mutant p53 proteins detected in various cancers. Using genetic and biochemical approaches, we show that several subunits of the human SWI/SNF complex bind to the tumor suppressor protein p53 in vivo and in vitro. The transactivation function of p53 is stimulated by overexpression of hSNF5 and BRG-1 and dominant forms of hSNF5 and BRG-1 repress p53-dependent transcription. Chromatin immunoprecipitation assay shows that hSNF5 and BRG-1 are recruited to a p53-dependent promoter in vivo. Overexpression of dominant negative forms of either hSNF5 or BRG-1 inhibited p53-mediated cell growth suppression and apoptosis. Molecular connection between p53 and the SWI/SNF complex implicates that (i) the SWI/SNF complex is necessary for p53-driven transcriptional activation, and (ii) the SWI/SNF complex plays an important role in p53-mediated cell cycle control.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea University	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		KIM, JIN WOO/C-1655-2011; Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011	KIM, JIN WOO/0000-0003-0767-1918; Lee, Daeyoup/0000-0003-2006-1823; 				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIYASHITA T, 1995, CELL, V80, P293; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pugh B F, 1995, Methods Mol Biol, V37, P349; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sullivan EK, 2001, MOL CELL BIOL, V21, P5826, DOI 10.1128/MCB.21.17.5826-5837.2001; Tanese N, 1997, METHODS, V12, P224, DOI 10.1006/meth.1997.0475; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	44	176	182	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22330	22337		10.1074/jbc.M111987200	http://dx.doi.org/10.1074/jbc.M111987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950834	hybrid			2022-12-25	WOS:000176313600029
J	Bagorda, A; Guerra, L; Di Sole, F; Hemle-Kolb, C; Cardone, RA; Fanelli, T; Reshkin, SJ; Gisler, SM; Murer, H; Casavola, V				Bagorda, A; Guerra, L; Di Sole, F; Hemle-Kolb, C; Cardone, RA; Fanelli, T; Reshkin, SJ; Gisler, SM; Murer, H; Casavola, V			Reciprocal protein kinase A regulatory interactions between cystic fibrosis transmembrane conductance regulator and Na+/H+ exchanger isoform 3 in a renal polarized epithelial cell model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CHLORIDE PERMEABILITY; APICAL MEMBRANE; A6 CELLS; ARGININE-VASOPRESSIN; MOLECULAR MECHANISM; ANCHORING PROTEIN; CL-/HCO3 EXCHANGE; INTRACELLULAR PH; PROXIMAL TUBULE; PDZ PROTEINS	Although Cystic fibrosis transmembrane conductance regulator (CFTR) has been shown to regulate the activity of NHE3, the potential reciprocal interaction of NHE3 to modulate the protein kinase A (PKA)-dependent regulation of CFTR in epithelial cells is still unknown. In the present work, we describe experiments to define the interactions between CFTR and NHE3 with the regulatory, scaffolding protein, NHERF that organize their PKA-dependent regulation in a renal epithelial cell line that expresses endogenous CFTR. The expression of rat NHE3 significantly decreased PKA-dependent activation of CFTR without altering CFTR expression, and this decrease was prevented by mutation of either of the two rat NHE3 PKA target serines to alanine (S552A or S605A). Inhibition of CFTR expression by antisense treatment resulted in an acute decrease in PKA-dependent regulation of NHE3 activity. CFTR, NHE3, and ezrin were recognized by NHERF-2 but not NHERF-1 in glutathione S-transferase pull-down experiments. Ezrin may function as a protein kinase A anchoring protein (AKAP) in this signaling complex, because blocking the binding of PKA to an AKAP by incubation with the S-Ht31 peptide inhibited the PKA-dependent regulation of CFTR in the absence of NHE3. In the A6-NHE3 cells S-Ht31 blocked the PKA regulation of NHE3 whereas it now failed to affect the regulation of CFTR. We conclude that CFTR and NHE3 reciprocally interact via a shared regulatory complex comprised of NHERF-2, ezrin, and PKA.	Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Gottingen, Dept Physiol & Pathophysiol, Div Vegetat Physiol & Pathophysiol, D-37073 Gottingen, Germany; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	Universita degli Studi di Bari Aldo Moro; University of Gottingen; University of Zurich	Casavola, V (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.		Reshkin, Stephan/AAI-6680-2020	Reshkin, Stephan/0000-0001-9757-5908; GUERRA, Lorenzo/0000-0003-3950-9405; CASAVOLA, Valeria/0000-0003-4471-4948	Telethon [E.1125] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Banderali U, 1999, J PHYSIOL-LONDON, V519, P737, DOI 10.1111/j.1469-7793.1999.0737n.x; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BROCHIERO E, 1995, PFLUG ARCH EUR J PHY, V431, P32, DOI 10.1007/BF00374375; CARR DW, 1992, J BIOL CHEM, V267, P13376; Casavola V, 1997, MOL PHARMACOL, V51, P516; Casavola V, 1996, J MEMBRANE BIOL, V151, P237, DOI 10.1007/s002329900074; CASAVOLA V, 1995, AM J PHYSIOL-CELL PH, V269, pC226, DOI 10.1152/ajpcell.1995.269.1.C226; CASAVOLA V, 1992, PFLUG ARCH EUR J PHY, V420, P282, DOI 10.1007/BF00374460; CHALFANT ML, 1993, AM J PHYSIOL, V264, pC1480, DOI 10.1152/ajpcell.1993.264.6.C1480; Clarke LL, 1996, AM J PHYSIOL-GASTR L, V270, pG259, DOI 10.1152/ajpgi.1996.270.2.G259; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Di Sole F, 2001, FASEB J, V15, pA144; Di Sole F, 1999, J PHYSIOL-LONDON, V515, P829, DOI 10.1111/j.1469-7793.1999.829ab.x; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; ERNST SA, 1994, AM J PHYSIOL-CELL PH, V267, pC990, DOI 10.1152/ajpcell.1994.267.4.C990; FAN PY, 1992, BIOCHIM BIOPHYS ACTA, V1111, P75, DOI 10.1016/0005-2736(92)90276-R; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Jiang QS, 2000, J BIOL CHEM, V275, P13266, DOI 10.1074/jbc.275.18.13266; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Ling BN, 1997, J BIOL CHEM, V272, P594; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Schultz B. D., 1999, Physiological Reviews, V79, pS109; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Singh AE, 1998, AM J PHYSIOL-CELL PH, V275, pC562, DOI 10.1152/ajpcell.1998.275.2.C562; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Walsh DE, 2000, J MEMBRANE BIOL, V177, P209, DOI 10.1007/s002320010004; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 2000, BIOCHEMISTRY-US, V39, P6123, DOI 10.1021/bi000064m; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Wheat VJ, 2000, AM J PHYSIOL-CELL PH, V279, pC62, DOI 10.1152/ajpcell.2000.279.1.C62; Widdicombe JH, 2000, AM J RESP CELL MOL, V22, P11, DOI 10.1165/ajrcmb.22.1.f177; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	55	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21480	21488		10.1074/jbc.M112245200	http://dx.doi.org/10.1074/jbc.M112245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937500	Green Accepted, hybrid			2022-12-25	WOS:000176286000048
J	Ditzel, HJ; Strik, MCM; Larsen, MK; Willis, AC; Waseem, A; Kejling, K; Jensenius, JC				Ditzel, HJ; Strik, MCM; Larsen, MK; Willis, AC; Waseem, A; Kejling, K; Jensenius, JC			Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCLONAL-ANTIBODY; INTERMEDIATE FILAMENTS; CARCINOMA-CELLS; HUMAN KERATIN-18; TUMOR-MARKER; LUNG-CANCER; PLASMINOGEN-ACTIVATOR; MALLORY BODIES; COILED-COIL; EXPRESSION	The intermediate filament network in simple glandular epithelial cells predominantly consists of heterotypic complexes of cytokeratin 8 (K8) and cytokeratin 18 (K18). In contrast to other cytokeratins, K8 and K18 are persistently expressed during malignant transformation, but changes in cell morphology are accompanied by alterations in the intermediate filament network. To study molecular changes, K8 and K18 were purified from surgically removed colon cancer and normal epithelia tissues. Western blotting and amino acid sequencing revealed the presence of abundant K8 and K18 fragments, truncated at the N terminus, from cancerous, but not normal, epithelial cells. The fragmentation pattern indicates proteolysis mediated by several enzymes, including trypsin-like enzymes. The cancer-associated forms of K8 and K18 are specifically recognized by the human antibody, COU-1, cloned from the B cells of a cancer patient. We demonstrate that COU-1 recognizes a unique conformational epitope presented only by a complex between K8 and K18. The epitope is revealed after proteolytic removal of the head domain of either K8 or K18. A large panel of recombinant K8 and K18 fragments, deleted N- or C-terminally, allowed for the localization of the COU-1 epitope to the N-terminal part of the rod domains. Using surface plasmon resonance, the affinity of COU-1 for this epitope was determined to be 10(9) m(-1), i.e. more than 2 orders of magnitude higher than for intact heterotypic K8/K18 complexes. The cellular distribution of truncated K8/K18 heterotypic complexes in viable adenocarcinomas cells was probed using COU-1 showing small fibrillar structures distinct from those of intact K8/K18 complexes. Previously we demonstrated the binding and subsequent internalization of recombinant Fab COU-1 to live cancer cells. We have thus characterized a cancer neoepitope recognized by the humoral immune system. The results have biological as well as clinical implications.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ So Denmark, Biomed Lab, DK-5000 Odense, Denmark; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Kings Coll London, Guys Kings & St Thomas Dent Inst, Head & Neck Canc Res Program, London SE1 9RT, England; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark	Scripps Research Institute; University of Southern Denmark; University of Oxford; University of London; King's College London; Aarhus University	Ditzel, HJ (corresponding author), Scripps Res Inst, Dept Immunol, IMM2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hditzel@scripps.edu		Kobaek-Larsen, Morten/0000-0002-5097-9283; Ditzel, Henrik J./0000-0003-3927-5135				BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; Bodenmueller Heinz, 1994, International Journal of Biological Markers, V9, P75; BORUPCHRISTENSEN P, 1990, APMIS, V98, P674, DOI 10.1111/j.1699-0463.1990.tb04988.x; BROERS JLV, 1988, CANCER RES, V48, P3221; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHAN R, 1986, CANCER RES, V46, P6353; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CRAWFORD C, 1990, BIOCHEM J, V265, P575, DOI 10.1042/bj2650575; Denk H, 1979, Int Rev Exp Pathol, V20, P77; DITZEL H, 1993, CANCER RES, V53, P5920; Ditzel HJ, 1997, P NATL ACAD SCI USA, V94, P8110, DOI 10.1073/pnas.94.15.8110; ERB K, 1992, HYBRIDOMA, V11, P121, DOI 10.1089/hyb.1992.11.121; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GODFROID E, 1991, J CELL SCI, V99, P595; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1994, J CELL SCI, V107, P1959; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HATZFELD M, 1987, J MOL BIOL, V197, P237, DOI 10.1016/0022-2836(87)90122-7; HAZAN R, 1986, LAB INVEST, V54, P543; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; JENSEN K, 1994, HEPATOLOGY, V20, P1330, DOI 10.1016/0270-9139(94)90776-5; JENSEN K, 1994, HEPATOLOGY, V20, P1061, DOI 10.1002/hep.1840200440; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kralovich KR, 1998, J PROTEIN CHEM, V17, P845, DOI 10.1023/A:1020738620817; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Marilley D, 2000, EXP CELL RES, V259, P12, DOI 10.1006/excr.2000.4942; MILLER RK, 1993, J CELL BIOL, V122, P123, DOI 10.1083/jcb.122.1.123; Moll R., 1994, International Journal of Biological Markers, V9, P63; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Moll R, 1998, Subcell Biochem, V31, P205; Nishibori H, 1996, CANCER RES, V56, P2752; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; Oshima RG, 1996, CANCER METAST REV, V15, P445, DOI 10.1007/BF00054012; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; Pankov R, 1997, J CELL SCI, V110, P965; Rydlander L, 1996, EUR J BIOCHEM, V241, P309, DOI 10.1111/j.1432-1033.1996.00309.x; SCHAAFSMA HE, 1990, AM J PATHOL, V136, P329; SCHILLER DL, 1983, CELL BIOL INT REP, V7, P3, DOI 10.1016/0309-1651(83)90098-X; SCHMIDT A, 1994, EUR J CELL BIOL, V65, P229; SHITARA K, 1992, ANTICANCER RES, V12, P1121; SHOEMAN RL, 1990, CELL BIOL INT REP, V14, P583, DOI 10.1016/0309-1651(90)90038-Z; SILEN A, 1994, PROSTATE, V24, P326, DOI 10.1002/pros.2990240609; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGAAST A, 1994, BRIT J CANCER, V69, P525, DOI 10.1038/bjc.1994.95; Waseem A, 1996, EXP CELL RES, V223, P203, DOI 10.1006/excr.1996.0074; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x; Wells MJ, 1997, J BIOL CHEM, V272, P28574, DOI 10.1074/jbc.272.45.28574; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	60	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21712	21722		10.1074/jbc.M202140200	http://dx.doi.org/10.1074/jbc.M202140200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923318	hybrid			2022-12-25	WOS:000176286000079
J	El Mezgueldi, M; Tang, NY; Rosenfeld, SS; Ostap, EM				El Mezgueldi, M; Tang, NY; Rosenfeld, SS; Ostap, EM			The kinetic mechanism of myole (human myosin-IC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1; ATPASE ACTIVITY; ACANTHAMOEBA-CASTELLANII; MUSCLE-CONTRACTION; MOTOR DOMAIN; SH3 DOMAIN; F-ACTIN; EXPRESSION; NUCLEOTIDE; BINDING	Myole is the widely expressed subclass-1 member of the myosin-I family. We performed a kinetic analysis of a truncated myole that consists of the motor and the single IQ motif with a bound calmodulin. We determined the rates and equilibrium constants for the key steps in the ATPase cycle. The maximum actin activated ATPase rate (V-max) and the actin concentration at half-maximum of V-max (K-ATPase) of myole are similar to those of the native protein. The K-ATPase is low (similar to1 muM), however the affinity of myole for actin in the presence of ATP is very weak. A weak actin affinity and a rapid rate of phosphate release result in a pathway under in vitro assay conditions in which phosphate is released while myole is dissociated from actin. Actin activation of the ATPase activity and the low K-ATPase are the result of actin activation of ADP release. We propose that myole is tuned to function in regions of high concentrations of cross-linked actin filaments. Additionally, we found that ADP release from actomyole is > 10-fold faster than other vertebrate myosin-I isoforms. We propose that subclass-1 myosin-Is are tuned for rapid sliding, whereas subclass-2 isoforms are tuned for tension maintenance or stress sensing.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Muscle Inst, Philadelphia, PA 19104 USA; Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA	University of Pennsylvania; University of Pennsylvania; University of Alabama System; University of Alabama Birmingham	Ostap, EM (corresponding author), Univ Penn, Sch Med, Dept Physiol, B400 Richards,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	ostap@mail.med.upenn.edu			NIGMS NIH HHS [GM57247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESI JP, 1983, J BIOL CHEM, V258, P176; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; Coluccio LR, 1999, J BIOL CHEM, V274, P21575, DOI 10.1074/jbc.274.31.21575; Dai JW, 1999, BIOPHYS J, V77, P1168, DOI 10.1016/S0006-3495(99)76968-7; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Geeves MA, 2000, J BIOL CHEM, V275, P21624, DOI 10.1074/jbc.M000342200; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Perreault-Micale C, 2000, J BIOL CHEM, V275, P21618, DOI 10.1074/jbc.M000363200; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Rosenfeld SS, 2000, J BIOL CHEM, V275, P25418, DOI 10.1074/jbc.M002685200; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; Skowron JF, 1998, CELL MOTIL CYTOSKEL, V41, P308, DOI 10.1002/(SICI)1097-0169(1998)41:4<308::AID-CM4>3.3.CO;2-A; Sokac AM, 2000, INT REV CYTOL, V200, P197, DOI 10.1016/S0074-7696(00)00005-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; Stoffler HE, 1998, J BIOL CHEM, V273, P14605, DOI 10.1074/jbc.273.23.14605; Stoffler HE, 1998, J CELL SCI, V111, P2779; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200	43	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21514	21521		10.1074/jbc.M200713200	http://dx.doi.org/10.1074/jbc.M200713200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940582	hybrid			2022-12-25	WOS:000176286000052
J	Grishanin, RN; Klenchin, VA; Loyet, KM; Kowalchyk, JA; Ann, K; Martin, TFJ				Grishanin, RN; Klenchin, VA; Loyet, KM; Kowalchyk, JA; Ann, K; Martin, TFJ			Membrane association domains in Ca2+-dependent activator protein for secretion mediate plasma membrane and dense-core vesicle binding required for Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; INOSITOL PHOSPHATES; PH DOMAINS; CA2+-ACTIVATED EXOCYTOSIS; PHOSPHOINOSITIDE BINDING; NEUROENDOCRINE CELLS; SIGNALING MOLECULES; CYTOPLASMIC DOMAIN; CAPS; PHOSPHORYLATION	Ca2+-dependent activator protein for secretion (CAPS) is a cytosolic protein essential for the Ca2+-dependent fusion of dense-core vesicles (DCVs) with the plasma membrane and the regulated secretion of a subset of neurotransmitters. The mechanism by which CAPS functions in exocytosis and the means by which it associates with target membranes are unknown. We identified two domains in CAPS with distinct membrane-binding properties that were each essential for CAPS activity in regulated exocytosis. The first of these, a centrally located pleckstrin homology domain, exhibited three properties: charge-based binding to acidic phospholipids, binding to plasma membrane but not DCV membrane, and stereoselective binding to phosphatidylinositol 4,5-bisphosphate. Mutagenesis studies revealed that the former two properties but not the latter were essential for CAPS function. The central pleckstrin homology domain may mediate transient CAPS interactions with the plasma membrane during Ca2+-triggered exocytosis. The second membrane association domain comprising distal C-terminal sequences mediated CAPS targeting to and association with neuroendocrine DCVs. The CAPS C-terminal domain was also essential for optimal activity in regulated exocytosis. The presence of two membrane association domains with distinct binding specificities may enable CAPS to bind both target membranes to facilitate DCV-plasma membrane fusion.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Martin, TFJ (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.							Alconada A, 1999, J VIROL, V73, P377, DOI 10.1128/JVI.73.1.377-387.1999; Ann K, 1997, J BIOL CHEM, V272, P19637, DOI 10.1074/jbc.272.32.19637; Avery Leon, 1993, Genetics, V134, P455; Berwin B, 1998, NEURON, V21, P137, DOI 10.1016/S0896-6273(00)80521-8; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; Blomberg N, 1997, FOLD DES, V2, P343, DOI 10.1016/S1359-0278(97)00048-5; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Elhamdani A, 1999, J NEUROSCI, V19, P7375, DOI 10.1523/JNEUROSCI.19-17-07375.1999; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Irvine R, 1996, CURR BIOL, V6, P537, DOI 10.1016/S0960-9822(02)00536-5; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Martin TFJ, 1997, J BIOL CHEM, V272, P14447, DOI 10.1074/jbc.272.22.14447; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Renden R, 2001, NEURON, V31, P421, DOI 10.1016/S0896-6273(01)00382-8; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Rupnik M, 2000, P NATL ACAD SCI USA, V97, P5627, DOI 10.1073/pnas.090359097; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Steveson TC, 2001, J BIOL CHEM, V276, P40326, DOI 10.1074/jbc.M011460200; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Tandon A, 1998, NEURON, V21, P147, DOI 10.1016/S0896-6273(00)80522-X; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	49	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22025	22034		10.1074/jbc.M201614200	http://dx.doi.org/10.1074/jbc.M201614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927595	hybrid			2022-12-25	WOS:000176286000115
J	Hao, CM; Redha, R; Morrow, J; Breyer, MD				Hao, CM; Redha, R; Morrow, J; Breyer, MD			Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL PAPILLARY NECROSIS; PPAR-DELTA; INTERSTITIAL-CELLS; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; DIFFERENTIATION; BRAIN; ALPHA; IMPLANTATION	COX2-selective non-steroidal anti-inflammatory drugs (NSAIDs) cause selective apoptosis of renal medullary interstitial cells (RMIC) in vivo and reduce their ability to tolerate hypertonic stress in vitro. To determine the mechanism by which COX2 activity promotes RMIC viability, we examined the capacity of COX2-derived prostanoids to promote RMIC survival. Although RMICs synthesize prostaglandin E2 (PGE2) >> PGI2 > PGF2a > TxA2, only PGI2 enhanced RMIC viability following hypertonic stress. RMICs do not express the prostacyclin receptor, but they do express the prostacyclin responsive nuclear transcription factor peroxisome proliferator-activated receptor delta (PPARdelta). Hypertonic stress increased PGI2 synthesis 330% above base line and also activated a PPARdelta specific reporter (delta response element (DRE)) by 90% above base line. Conversely DRE activity was only inhibited by the COX2-selective inhibitor SC236 but not by a COX1-selective NSAID (SC560). Overexpression of PPARdelta using an adenovirus not only drove DRE activity but also prevented RMIC death due to COX2 inhibition. These studies are consistent with a model whereby hypertonicity activates COX2-derived prostaglandin production, which promotes RMIC viability through PPARdelta. Inhibition of PPARdelta activity may contribute to the renal papillary necrosis associated with analgesic and/or NSAID use.	Vanderbilt Univ, Div Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Dept Vet Affairs Hosp, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hao, CM (corresponding author), Vet Affairs Med Ctr, F-427 ACRE Bldg, Nashville, TN 37212 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037097, P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37097, P01 DK 38226] Funding Source: Medline; NIGMS NIH HHS [GM 15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach PH, 1998, TOXICOL PATHOL, V26, P73, DOI 10.1177/019262339802600110; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; Dowd NP, 2001, J CLIN INVEST, V108, P585, DOI 10.1172/JCI11334; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lim H, 2000, TRENDS ENDOCRIN MET, V11, P137, DOI 10.1016/S1043-2760(00)00243-5; Matsuura H, 1999, MOL CELL ENDOCRINOL, V147, P85, DOI 10.1016/S0303-7207(98)00214-7; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MOLLAND EA, 1978, KIDNEY INT, V13, P5, DOI 10.1038/ki.1978.2; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; NISSEN HM, 1969, Z ZELLFORSCH MIK ANA, V97, P274, DOI 10.1007/BF00344762; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Satoh T, 1999, EUR J NEUROSCI, V11, P3115, DOI 10.1046/j.1460-9568.1999.00791.x; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1; Zhang JF, 2002, J BIOL CHEM, V277, P11505, DOI 10.1074/jbc.M110580200; ZUSMAN RM, 1977, J CLIN INVEST, V60, P215, DOI 10.1172/JCI108758	28	85	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21341	21345		10.1074/jbc.M200695200	http://dx.doi.org/10.1074/jbc.M200695200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927585	hybrid			2022-12-25	WOS:000176286000030
J	Rashid, KA; Hevi, S; Chen, Y; Le Caherec, F; Chuck, SL				Rashid, KA; Hevi, S; Chen, Y; Le Caherec, F; Chuck, SL			A proteomic approach identifies proteins in hepatocytes that bind nascent apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; LOW-DENSITY LIPOPROTEINS; HEP G2 CELLS; APO-B; MCA-RH7777 CELLS; LIPID-SYNTHESIS; APOPROTEIN-B; RAT-LIVER; SECRETION	The biogenesis of apolipoprotein B is quite complex in view of its huge size, hydrophobicity, obligate association with lipids such as cholesterol and triglycerides prior to secretion, and intracellular degradation of a substantial proportion of newly synthesized molecules. Multiple proteins likely serve roles as molecular chaperones to assist in folding, assembly with lipids, and regulation of the secretion of apolipoprotein B. In these studies, we developed a strategy to isolate proteins associated with apolipoprotein B in rat livers. The purification consisted of two stages: first, microsomes were prepared from rat liver and treated with chemical crosslinkers, and second, the solubilized proteins were coimmunoprecipitated with antibody against apolipoprotein B. We found that several proteins were cross-linked to apolipoprotein B. The proteins were digested with trypsin, and the released peptides were sequenced by tandem mass spectrometry. The sequences precisely matched 377 peptides in 99 unique proteins. We show that at least two of the identified proteins, ferritin heavy and light chains, can directly bind apolipoprotein B. These and possibly other proteins identified by this proteomic approach are novel candidates for proteins that affect apolipoprotein B during its biogenesis.	Beth Israel Deaconess Med Ctr, Mol Med Unit, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Chuck, SL (corresponding author), Beth Israel Deaconess Med Ctr, Mol Med Unit, Dept Med, RW663,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062545] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62545] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1992, J BIOL CHEM, V267, P9858; Chan L, 2000, RECENT PROG HORM RES, V55, P93; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Kang S, 2000, BBA-MOL CELL BIOL L, V1529, P223, DOI 10.1016/S1388-1981(00)00151-7; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOSHIZAKA T, 1988, J BIOL CHEM, V263, P1619; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; PULLINGER CR, 1989, J LIPID RES, V30, P1065; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; WETTERAU JR, 1992, SCIENCE, V258, P999; WU XJ, 1994, J BIOL CHEM, V269, P12375; Wu XJ, 1997, J BIOL CHEM, V272, P11575; WU XW, 1994, P NATL ACAD SCI USA, V91, P742, DOI 10.1073/pnas.91.2.742; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	36	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22010	22017		10.1074/jbc.M112448200	http://dx.doi.org/10.1074/jbc.M112448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934886	hybrid			2022-12-25	WOS:000176286000113
J	Holmes, WB; Appling, DR				Holmes, WB; Appling, DR			Cloning and characterization of methenyltetrahydrofolate synthetase from Saccharomyces cerevisiae.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; HUMAN 5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; GENES ENCODING ISOZYMES; SERINE HYDROXYMETHYLTRANSFERASE; PROTEIN-KINASE; RABBIT LIVER; 5-FORMYLTETRAHYDROFOLATE POLYGLUTAMATES; ESCHERICHIA-COLI; YEAST-CELLS; PURIFICATION	The folate derivative 5-formyltetrahydrofolate (folinic acid; 5-CHO-THF) was discovered over 40 years ago, but its role in metabolism remains poorly understood. Only one enzyme is known that utilizes 5-CHO-THF as a substrate: 5,10-methenyltetrahydrofolate synthetase (MTHFS). A BLAST search of the yeast genome using the human MTHFS sequence revealed a 211-amino acid open reading frame (YER183c) with significant homology. The yeast enzyme was expressed in Escherichia coli, and the purified recombinant enzyme exhibited kinetics similar to previously purified MTHFS. No new phenotype was observed in strains disrupted at MTHFS or in strains additionally disrupted at the genes encoding one or both serine hydroxymethyltransferases (SHMT) or at the genes encoding one or both methylenetetrahydrofolate reductases. However, when the MTHFS gene was disrupted in a strain lacking the de novo folate biosynthesis pathway, folinic acid (5-CHO-THF) could no longer support the folate requirement. We have thus named the yeast gene encoding methenyltetrahydrofolate synthetase FAU1 (folinic acid utilization). Disruption of the FAU1 gene in a strain lacking both 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase isozymes (ADE16 and ADE17) resulted in a growth deficiency that was alleviated by methionine. Genetic analysis suggested that intracellular accumulation of the purine intermediate AICAR interferes with a step in methionine biosynthesis. Intracellular levels of 5-CHO-THF were determined in yeast disrupted at FAU1 and other genes encoding folate-dependent enzymes. In fau1 disruptants, 5-CHO-THF was elevated 4-fold over wild-type yeast. In yeast lacking MTHFS along with both AICAR transformylases, 5-CHO-THF was elevated 12-fold over wild type. 5-CHO-THF was undetectable in strains lacking SHMT activity, confirming SMIT as the in vivo source of 5-CHO-THF. Taken together, these results indicate that S. cerevisiae harbors a single, nonessential, MTHFS activity. Growth phenotypes of multiply disrupted strains are consistent with a regulatory role for 5-CHO-THF in one-carbon metabolism and additionally suggest a metabolic interaction between the purine and methionine pathways.	Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA.	dappling@mail.utexas.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009276] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09276] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Baggott JE, 2000, BIOCHEMISTRY-US, V39, P14647, DOI 10.1021/bi001362m; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; BENKOVIC SJ, 1972, J AM CHEM SOC, V94, P7542, DOI 10.1021/ja00776a043; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; BOCHNER BR, 1982, CELL, V29, P929, DOI 10.1016/0092-8674(82)90455-X; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Cherest H, 2000, J BIOL CHEM, V275, P14056, DOI 10.1074/jbc.275.19.14056; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; DAUM G, 1982, J BIOL CHEM, V257, P3028; DAYAN A, 1995, GENE, V165, P307, DOI 10.1016/0378-1119(95)00321-V; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P394, DOI 10.1006/abio.1993.1346; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; HA TS, 1994, J NUTR BIOCHEM, V5, P522, DOI 10.1016/0955-2863(94)90049-3; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; HUANG T, 1995, J BIOL CHEM, V270, P22296, DOI 10.1074/jbc.270.38.22296; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jolivet J, 1997, METHOD ENZYMOL, V281, P162; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Kim DW, 1997, ANAL BIOCHEM, V253, P201, DOI 10.1006/abio.1997.2388; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; MARAS B, 1994, J BIOL CHEM, V269, P18429; MAY M, 1951, J AM CHEM SOC, V73, P3067, DOI 10.1021/ja01151a028; MCKENZIE KQ, 1977, GENETICS, V86, P85; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; Nardese V, 1996, BIOCHEM BIOPH RES CO, V218, P273, DOI 10.1006/bbrc.1996.0048; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROMAN H, 1956, CR TRAV LAB CARLS P, V26, P299; SABINA RL, 1985, J BIOL CHEM, V260, P6107; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH LV, 1967, BIOCHEMISTRY-US, V6, P253, DOI 10.1021/bi00853a039; Schirch V, 1997, METHOD ENZYMOL, V281, P146; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN F, 1986, METHODS YEAST GENETI, P125; SIDI Y, 1985, J CLIN INVEST, V76, P2416, DOI 10.1172/JCI112255; Stefanelli C, 1998, BIOCHEM BIOPH RES CO, V243, P821, DOI 10.1006/bbrc.1998.8154; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1993, ADV EXP MED BIOL, V338, P679; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tibbetts AS, 1997, ARCH BIOCHEM BIOPHYS, V340, P195, DOI 10.1006/abbi.1997.9919; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wach A, 1998, METHOD MICROBIOL, V26, P67; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6	58	34	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20205	20213		10.1074/jbc.M201242200	http://dx.doi.org/10.1074/jbc.M201242200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923304	hybrid			2022-12-25	WOS:000176204500016
J	Ishmael, FT; Alley, SC; Benkovic, SJ				Ishmael, FT; Alley, SC; Benkovic, SJ			Assembly of the bacteriophage T4 helicase - Architecture and stoichiometry of the gp41-gp59 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DNA-REPLICATION; GENE-59 PROTEIN; BINDING-PROTEIN; CROSS-LINKING; PRIMASE; GP32; GP59; FORK; PURIFICATION	The bacteriophage T4 59 protein (gp59) plays an essential role in recombination and replication by mediating the assembly of the gene 41 helicase (gp41) onto DNA. gp59 is required to displace the gp32 single-stranded binding protein on the lagging strand to expose a site for helicase binding. To gain a better understanding of the mechanism of helicase assembly, the architecture and stoichiometry of the gp41-gp59 complex were investigated. Both the N and C termini of gp41 were found to lie close to or in the gp41-gp41 subunit interface and interact with gp59. The site of interaction of gp41 on gp59 is proximal to Cys-215 of gp59. Binding of gp41 to gp59 stimulates a conformational change in the protein resulting in hexamer formation of gp59, and gp59 likewise stimulates oligomer formation of gp41. The gp59 subunits in this complex are arranged in a head to head orientation, such that Cys-42 of one subunit is in close proximity to Cys-42 on an adjacent subunit, and Cys-215 on one subunit is close to Cys-215 on a neighboring subunit. As the helicase is loaded onto DNA, a conformational change in the gp41-gp59 complex occurs, which may serve to displace gp32 from the lagging strand and load the hexameric helicase in its place.	Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA.							Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KARAM JD, 1994, MOL BIOL BACTERIOP T, V4, P38; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MOSIG G, 1994, MOL BIOL BACTERIOP T, V4; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; San Martin C, 1998, STRUCTURE, V6, P501; Sexton DJ, 1996, J BIOL CHEM, V271, P28045, DOI 10.1074/jbc.271.45.28045; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; YONESAKI T, 1994, J BIOL CHEM, V269, P1284	23	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20555	20562		10.1074/jbc.M111951200	http://dx.doi.org/10.1074/jbc.M111951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927580	hybrid			2022-12-25	WOS:000176204500060
J	Lum, AFH; Green, CE; Lee, GR; Staunton, DE; Simon, SI				Lum, AFH; Green, CE; Lee, GR; Staunton, DE; Simon, SI			Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; I-DOMAIN; INTEGRIN AFFINITY; MAC-1 CD11B/CD18; CELL-ADHESION; E-SELECTIN; LEUKOCYTE; BINDING; ALPHA; CXC	Neutrophil recruitment during acute inflammation is triggered by G-protein-linked chemotactic receptors that in turn activate beta(2) integrin (CD18), deemed a critical step in facilitating cell capture and arrest under the shear force of blood flow. A conformational switch in the I domain allosteric site (IDAS) and in CD18 regulates LFA-1 affinity for endothelial ligands including intercellular adhesion molecule I (ICAM-1). We examined the dynamics of CD18 activation in terms of the efficiency of neutrophil capture of ICAM-1, and we correlated this with the membrane topography of 327C, an antibody that recognizes the active conformation of CD18 I-like domain. Adhesion increased in direct proportion to chemotactic stimulus rising 7-fold over a log range of interleukin-8 (IL-8). A threshold dose of similar to75 pM IL-8, corresponding to ligation of only similar to10-100 receptors, was sufficient to activate similar to20,000 CD18 and a rapid boost in the capture efficiency on ICAM-1. This was accompanied by a rapid redistribution of active LFA-1, but not Mac-1, into membrane patches, a necessary component for optimum adhesion efficiency. Shear-resistant arrest on a monolayer of ICAM-1 was reversed within minutes of chemotactic stimulation correlating with a shift from high to low affinity CD18 and dispersal of patches of active CD18. Mobility of active CD18 into high avidity patches was dependent on phosphatidylinositol 3-kinase activity and not F-actin polymerization. The data reveal that the number of chemotactic receptors bound and the topography and lifetime of high affinity LFA-1 tightly regulate the efficiency of neutrophil capture on ICAM-1.	Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; ICOS Corp, Bothell, WA 98021 USA	University of California System; University of California Davis; Icos Corporation	Simon, SI (corresponding author), Univ Calif Davis, Dept Biomed Engn, 1 Shields Ave, Davis, CA 95616 USA.	sisimon@ucdavis.edu						ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Beals CR, 2001, J IMMUNOL, V167, P6113, DOI 10.4049/jimmunol.167.11.6113; Bleijs DA, 2000, J CELL SCI, V113, P391; Burns AR, 2000, J CELL SCI, V113, P45; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Ding ZM, 1999, J IMMUNOL, V163, P5029; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Gopalan PK, 1997, J IMMUNOL, V158, P367; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Henderson RB, 2001, J EXP MED, V194, P219, DOI 10.1084/jem.194.2.219; Hentzen ER, 2000, BLOOD, V95, P911, DOI 10.1182/blood.V95.3.911.003k36_911_920; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Issekutz AC, 1999, J LEUKOCYTE BIOL, V65, P117, DOI 10.1002/jlb.65.1.117; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Kuijpers TW, 1997, J CLIN INVEST, V100, P1725, DOI 10.1172/JCI119697; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; LAWRENCE MB, 1994, IMMUNITY, V1, P137, DOI 10.1016/1074-7613(94)90107-4; LAWRENCE MB, 1990, BLOOD, V75, P227; Lu HF, 2000, J LEUKOCYTE BIOL, V68, P73; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Lupher ML, 2001, J IMMUNOL, V167, P1431, DOI 10.4049/jimmunol.167.3.1431; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Neelamegham S, 1998, BLOOD, V92, P1626, DOI 10.1182/blood.V92.5.1626.417a02_1626_1638; Pellegatta F, 2001, J CARDIOVASC PHARM, V37, P751, DOI 10.1097/00005344-200106000-00013; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Seo SM, 2001, AM J PHYSIOL-CELL PH, V281, pC1568, DOI 10.1152/ajpcell.2001.281.5.C1568; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; SIMON SI, 1995, J IMMUNOL, V155, P1502; SIMON SI, 1992, J IMMUNOL, V149, P2765; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STACKER SA, 1991, J IMMUNOL, V146, P648; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Tsang YTM, 1997, J IMMUNOL, V159, P4566; Van Damme J, 1990, Cytokine, V2, P106, DOI 10.1016/1043-4666(90)90004-D; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529	49	91	97	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20660	20670		10.1074/jbc.M202223200	http://dx.doi.org/10.1074/jbc.M202223200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929876	hybrid			2022-12-25	WOS:000176204500073
J	Mirza, A; McGuirk, M; Hockenberry, TN; Wu, Q; Ashar, H; Black, S; Wen, SF; Wang, LQ; Kirschmeier, P; Bishop, WR; Nielsen, LL; Pickett, CB; Liu, SX				Mirza, A; McGuirk, M; Hockenberry, TN; Wu, Q; Ashar, H; Black, S; Wen, SF; Wang, LQ; Kirschmeier, P; Bishop, WR; Nielsen, LL; Pickett, CB; Liu, SX			Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway	ONCOGENE			English	Article						survivin; p53; transcription; repression; apoptosis	TATA-BINDING PROTEIN; TRANSCRIPTIONAL REPRESSION; GENE-THERAPY; HISTONE ACETYLATION; TARGET GENES; DNA-BINDING; IN-VIVO; EXPRESSION; ACTIVATION; PROMOTER	Survivin is an inhibitor of apoptosis protein, which is over-expressed in most tumors. Aberrant expression of survivin and loss of wild-type p53 in many tumors prompted us to investigate a possible link between these two events. Here we show that wild-type p53 represses survivin expression at both mRNA and protein levels. Transient transfection analyses revealed that the expression of wild-type p53, but not mutant p53, was associated with strong repression of the survivin promoter in various cell types. The over-expression of exogenous survivin protein rescues cells from p53-induced apoptosis in a dose-dependent manner, suggesting that loss of survivin mediates, at least, in part the p53-dependent apoptotic pathway. In spite of the presence of two putative p53-binding sites in the survivin promoter, deletion and mutation analyses suggested that neither site is required for transcriptional repression of survivin expression. This was confirmed by chromatin immunoprecipitation assays. Further analyses suggested that the modification of chromatin within the survivin promoter could be a molecular explanation for silencing of survivin gene transcription by p53.	Schering Plough Corp, Inst Res, Dept Tumor Biol, Kenilworth, NJ 07033 USA; Canji Inc, San Diego, CA 92121 USA	Merck & Company; Schering Plough Corporation	Liu, SX (corresponding author), Schering Plough Corp, Inst Res, Dept Tumor Biol, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	suxing.liu@spcorp.com						Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hirose S, 1998, J BIOCHEM-TOKYO, V124, P1060, DOI 10.1093/oxfordjournals.jbchem.a022220; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kawasaki H, 1998, CANCER RES, V58, P5071; Kiermaier A, 1997, CURR BIOL, V7, pR505, DOI 10.1016/S0960-9822(06)00249-1; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu CD, 1998, CANCER RES, V58, P1808; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Olie RA, 2000, CANCER RES, V60, P2805; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SANTOSO JT, 1995, GYNECOL ONCOL, V59, P171; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Takahashi Y, 2000, GENE DEV, V14, P804; Tamm I, 1998, CANCER RES, V58, P5315; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2000, CANCER GENE THER, V7, P1469, DOI 10.1038/sj.cgt.7700257; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; YAGINUMA Y, 1992, CANCER RES, V52, P4196	43	452	502	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2613	2622		10.1038/sj.onc.1205353	http://dx.doi.org/10.1038/sj.onc.1205353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965534				2022-12-25	WOS:000174996500001
J	Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS				Frechet, M; Canitrot, Y; Bieth, A; Dogliotti, E; Cazaux, C; Hoffmann, JS			Deregulated DNA polymerase beta strengthens ionizing radiation-induced nucleotidic and chromosomal instabilities	ONCOGENE			English	Article						DNA polymerase beta; ionizing radiations; genetic instability; mutagenesis	STRAND-BREAK REPAIR; MUTATOR PHENOTYPE; SOMATIC MUTATIONS; CANCER-CELLS; OVEREXPRESSION; EXPRESSION; TUMORS; DAMAGE; GENE; SENSITIVITY	DNA polymerase beta (Pol beta) is an error-prone enzyme which has been found to be overexpressed in several human tumors. By using a couple of recombinant CHO cells differing only from the exogenous expression of Pol P, we showed here that cells overexpressing Pol beta are much more sensitive to IR treatments by increasing apoptosis. We also found that the surviving cells displayed an hypermutator phenotype which could be explained by different pathways involving Pol beta, such as (i) an increased capacity to incorporate into DNA the mutagenic dGTP analog, 8-oxo-dGTP, one of the most abundant purine-derived nucleotides exposed to gamma-irradiation, (ii) the induction of IR-induced DNA breaks and (iii) accumulation of chromosome aberrations induced by radiation. Alteration of Pol beta expression in irradiated cells thus appears to strengthen both cell death and genetic changes associated with a malignant phenotype. These data provide new insights into the cellular response to radiations and the associated carcinogenic consequences.	CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, F-31077 Toulouse, France; Ist Super Sanita, Lab Comparat Toxicol & Ecotoxicol, I-00161 Rome, Italy	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Istituto Superiore di Sanita (ISS)	Hoffmann, JS (corresponding author), CNRS, IPBS, Grp Instabilite Genet & Canc, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	cazaux@ipbs.fr; jseb@ipbs.fr	Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X				Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bergoglio V, 2001, ONCOGENE, V20, P6181, DOI 10.1038/sj.onc.1204743; Bouayadi K, 1997, CANCER RES, V57, P110; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; GEDIK CM, 1992, INT J RADIAT BIOL, V62, P313, DOI 10.1080/09553009214552161; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; LOEB LA, 1991, CANCER RES, V51, P3075; Louat T, 2001, MOL PHARMACOL, V60, P553; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; Vamvakas S, 1997, CRIT REV TOXICOL, V27, P155, DOI 10.3109/10408449709021617; VELD CWOH, 1994, CANCER RES, V54, P3001; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YANDELL DW, 1986, SOMAT CELL MOLEC GEN, V12, P255, DOI 10.1007/BF01570784; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	40	25	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2320	2327		10.1038/sj.onc.1205295	http://dx.doi.org/10.1038/sj.onc.1205295			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948415				2022-12-25	WOS:000174635600004
J	Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA				Koul, D; Jasser, SA; Lu, YL; Davies, MA; Shen, RJ; Shi, YX; Mills, GB; Yung, WKA			Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity	ONCOGENE			English	Article						MMAC; PTEN; phosphatidylinositol phosphatase; growth inhibition	FOCAL ADHESION KINASE; GLIOMA-CELLS; AKT PROTOONCOGENE; PDZ DOMAIN; PTEN; GROWTH; ONCOGENE; BREAST; PHOSPHORYLATION; INHIBITION	The tumor suppressor gene, MMAC/PTEN, has phosphatase, C2, and PDZ-binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability. Several obvious and significant motifs were found in MMAC/PTEN, including most notably, a catalytic domain of tyrosine phosphatase (IHCxxGxxRS/T) and several potential tyrosine phosphorylation sites. To examine the functional significance of tyrosine phosphorylation of MMAC/PTEN, retroviral constructs were generated with mutations at two putative tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F). Stable expression of wild-type MMAC/PTEN in U251 human glioma cells (which do not normally produce a functional MMAC/PTEN gene product) resulted in a significant reduction of tumor growth in nude mice, decreased growth rate, saturation density, and colony formation in vitro, as well as dephosphorylation of D3-phosphorylated phosphatidylinositols (PtdIns) in vitro. Mutation of Y240 or Y315 to either alanine or phenylalanine abrogated the ability of MMAC/PTEN to alter growth rate, saturation density, and colony formation in vitro. The ability of MMAC/PTEN to limit tumor growth in nude mice was markedly decreased but not abrogated by mutation of Y240 or Y315 to alanine. Thus, Y240 and Y315 are required for MMAC/PTEN to decrease tumor growth in vitro and in vivo. In contrast to wild-type MMAC/PTEN, mutant MMAC/PTEN containing Y240A or Y315A was unable to dephosphorylate D3-phosphorylated PtdIns in vitro. Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yung, WKA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Brain Tumor Ctr, Box 100,1515 Holcombe Blvd, Houston, TX 77030 USA.	wyung@manderson.org	Davies, Michael/GWV-2527-2022		NCI NIH HHS [R01 CA82716, CA-16672, R01 CA51148] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082716, P30CA016672, R01CA051148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BESSON A, 1999, EUR J BIOCHEM, V263, P237; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; LI DM, 1999, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	38	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2357	2364		10.1038/sj/onc/1205296	http://dx.doi.org/10.1038/sj/onc/1205296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948419				2022-12-25	WOS:000174635600008
J	Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW				Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW			The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model	ONCOGENE			English	Article						prostate cancer; Dunning tumor; metalloproteinases; synthetic inhibitor; animal model	TISSUE INHIBITOR; BATIMASTAT BB-94; TIMP-2; ANGIOGENESIS; PROGRESSION; EXPRESSION; CARCINOMA; SECRETION; CULTURES; BENIGN	The therapeutic efficacy of synthetic inhibitors of matrix-metalloproteinases (MMPs) in various cancers has been demonstrated. A novel inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP was evaluated in an orthotopic prostate cancer rat model. Efficacy was determined by recording tumor growth and survival endpoints. Prostate cancer was induced by inoculating R3327 Dunning tumor cells (MatLyLu) into the ventral lobe of the prostates of 148 Copenhagen rats. Daily oral treatment with Ro 282653 (10-300 mg/kg per day) was started on day 1 or on day 6 after tumor cell injection. Animals were sacrificed on day 20 for determination of tumor weights. For survival studies, rats received daily oral Ro 28-2653 (100 mg/kg per day) or vehicle for up to 30 days. Tumor induction was successful in 100% of the animals. Ro 282653 reproducibly reduced the tumor weights by up to 90% in a dose-dependent manner. In addition, an inhibitory effect in rats with established tumors (treatment start at day 6) was shown. A significantly prolonged survival of Ro 28-2653-treated rats was also demonstrated. Selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with prostate cancer.	Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA USA; Roche Diagnost GmbH, Pharma Res Penzberg, Penzberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard Medical School; Massachusetts General Hospital; Roche Holding	Lein, M (corresponding author), Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany.	Michael.Lein@charite.de	Ortel, Bernhard/AAF-7658-2019; Jung, Klaus/Z-2122-2018; Deger, Serpil Muge/ABG-5774-2021	Jung, Klaus/0000-0001-9797-5362; Stephan, Carsten/0000-0002-3270-258X				ANDERSON IC, 1995, CANCER RES, V55, P4120; BOASBERG P, 1997, P AN M AM SOC CLIN, V16, pA316; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, BRIT J CANCER, V67, P1126, DOI 10.1038/bjc.1993.207; Eccles SA, 1996, CANCER RES, V56, P2815; Festuccia C, 1996, INT J CANCER, V69, P386, DOI 10.1002/(SICI)1097-0215(19961021)69:5<386::AID-IJC6>3.0.CO;2-1; FIELDING J, 2000, P AN M AM SOC CLIN, V19, pA240; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lein M, 2000, INT J CANCER, V85, P801, DOI 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C; Lein M, 2000, UROLOGY, V56, P167, DOI 10.1016/S0090-4295(00)00553-7; Lein M, 2000, PROSTATE, V43, P77; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Lubaroff D M, 1980, Prog Clin Biol Res, V37, P243; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6; Macaulay VM, 1999, CLIN CANCER RES, V5, P513; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Price A, 1999, CLIN CANCER RES, V5, P845; Rabbani SA, 1998, IN VIVO, V12, P135; Rothenberg ML, 1999, STEM CELLS, V17, P237, DOI 10.1002/stem.170237; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; Shalinsky DR, 2000, CANC DRUG DISC DEV, P143; Smith DC, 1999, J CLIN ONCOL, V17, P1664, DOI 10.1200/JCO.1999.17.6.1664; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099; Still K, 2000, PROSTATE, V42, P18; Thomas AL, 2000, EXPERT OPIN INV DRUG, V9, P2913, DOI 10.1517/13543784.9.12.2913; Tierney GM, 1999, EUR J CANCER, V35, P563, DOI 10.1016/S0959-8049(99)00007-6; Walsh PC, 2000, J UROLOGY, V163, P1802, DOI 10.1016/S0022-5347(05)67547-7; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2089	2096		10.1038/sj.onc.1205267	http://dx.doi.org/10.1038/sj.onc.1205267			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960381				2022-12-25	WOS:000174827000015
J	Das, S; Cho, W				Das, S; Cho, W			Roles of catalytic domain residues in interfacial binding and activation of group IV cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; AROMATIC RESIDUES; HIGH-AFFINITY; TRANSLOCATION; SPECIFICITY; MECHANISM; DOCKING; LIPIDS	Group TV cytosolic phospholipase A. (cPLA(2)) has been shown to play a critical role in eicosanoid biosynthesis. cPLA(2) is composed of the C2 domain that mediates the Ca2+-dependent interfacial binding of protein and the catalytic domain. To elucidate the mechanism of interfacial activation of cPLA(2), we measured the effects of mutations of selected ionic and hydrophobic residues in the catalytic domain on the enzyme activity and the membrane binding of cPLA(2). Mutations of anionic residues located on (Glu(419) and Glu(420)) or near (Asp(436), AsP438, Asp(439), and Asp(440)) the active site lid enhanced the affinity for cPLA2 for anionic membranes, implying that the electrostatic repulsion between these residues and the anionic membrane surface might trigger the opening of the active site. This notion is further supported by a biphasic dependence of cPLA(2) activity on the anionic lipid composition of the vesicles. Mutations of a cluster of cationic residues (Lys(541), Lys(543), Lys(544), and Arg(488)), while significantly enhancing the activity of enzyme, abrogated the specific activation effect by phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2). These data, in conjunction with cell activity of cPLA(2) and mutants transfected into HEK293 cells, suggest that the cationic residues form a specific binding site for PtdIns(4,5)P-2 and that the specific PtdIns(4,5)P-2 binding is involved in cellular activation of cPLA(2). Also, three hydrophobic residues at the rim of the active site (Ile(399), Leu(400), and Leu(552)) were shown to partially penetrate the membrane, thereby promoting membrane binding and activation of cPLA(2). Based on these results, we propose an interfacial activation mechanism for cPLA(2) which involves the removal of the active site lid by nonspecific electrostatic repulsion, the interdomain hinge movement induced by specific PtdIns(4,5)P-2 binding, and the partial membrane penetration by catalytic domain hydrophobic residues.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.	wcho@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; BRETSCHER MS, 1972, NATURE-NEW BIOL, V236, P11, DOI 10.1038/newbio236011a0; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 1999, METH MOL B, V109, P7; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Cygler M, 1997, METHOD ENZYMOL, V284, P3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WHITE DA, 1973, PHOSPHOLIPID COMPOSI, P441; Williams SD, 2000, J LIPID RES, V41, P1585	41	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23838	23846		10.1074/jbc.M202322200	http://dx.doi.org/10.1074/jbc.M202322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956215	hybrid			2022-12-25	WOS:000176475700097
J	Dixon, MP; Pau, RN; Howlett, GJ; Dunstan, DE; Sawyer, WH; Davidson, BE				Dixon, MP; Pau, RN; Howlett, GJ; Dunstan, DE; Sawyer, WH; Davidson, BE			The central domain of Escherichia coli TyrR is responsible for hexamerization associated with tyrosine-mediated repression of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; INDUCED SELF-ASSOCIATION; REGULATORY PROTEIN; SECONDARY STRUCTURE; NTRC; DNA; ACTIVATION; ATP; PHENYLALANINE; RECOGNITION	TyrR from Escherichia coli regulates the expression of genes for aromatic amino acid uptake and biosynthesis. Its central ATP-hydrolyzing domain is similar to conserved domains of bacterial regulatory proteins that interact with RNA polymerase holoenzyme associated with the alternative sigma factor, sigma(54). It is also related to the common module of the AAA+ superfamily of proteins that is involved in a wide range of cellular activities. We expressed and purified two TyrR central domain polypeptides. The fragment comprising residues 188-467, called TyrR-(188-467), was soluble and stable, in contrast to that corresponding to the conserved core from residues 193 to 433. TyrR-(188-467) bound ATP and rhodamine-ATP with association constants 2- to 5-fold lower than TyrR and hydrolyzed ATP at five times the rate of TyrR. In contrast to TyrR, which is predominantly dimeric at protein concentrations less than 10 mum in the absence of ligands, or in the presence of ATP or tyrosine alone, TyrR-(188-467) is a monomer, even at high protein concentrations. Tyrosine in the presence of ATP or ATPgammaS promotes the oligomerization of TyrR(188-467) to a hexamer. Tyrosine-dependent repression of gene transcription by TyrR therefore depends on ligand binding and hexamerization determinants located in the central domain polypeptide TyrR-(188-467).	Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia; Univ Melbourne, Cooperat Res Ctr Biophys, Parkville, Vic 3010, Australia	University of Melbourne; University of Melbourne	Pau, RN (corresponding author), Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3010, Australia.		Dunstan, Dave/B-8936-2014	Dunstan, Dave/0000-0002-9931-010X				ARGAET VP, 1994, J BIOL CHEM, V269, P5171; Bailey MF, 1996, J MOL BIOL, V263, P671, DOI 10.1006/jmbi.1996.0607; Bantscheff M, 1999, BIOCHEMISTRY-US, V38, P11012, DOI 10.1021/bi990781k; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CUI JS, 1993, J BIOL CHEM, V268, P13023; CUI JS, 1993, J BIOL CHEM, V268, P5040; Dunstan DE, 2000, MACROMOLECULES, V33, P193, DOI 10.1021/ma9908503; FarezVidal ME, 1996, MOL MICROBIOL, V22, P779, DOI 10.1046/j.1365-2958.1996.01530.x; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; Garmendia J, 2000, MICROBIOL-SGM, V146, P2555, DOI 10.1099/00221287-146-10-2555; HAGMAR P, 1995, BBA-GEN SUBJECTS, V1244, P259, DOI 10.1016/0304-4165(95)00015-4; HAYES DB, 1999, SEDNTERP SEDIMENTATI; Hopper S, 1996, J BACTERIOL, V178, P199, DOI 10.1128/jb.178.1.199-203.1996; Howlett GJ, 2000, METHOD ENZYMOL, V323, P231; Hwang JS, 1997, J BACTERIOL, V179, P1051, DOI 10.1128/jb.179.4.1051-1058.1997; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kristl S, 2001, BIOCHEM BIOPH RES CO, V280, P81, DOI 10.1006/bbrc.2000.4076; Kristl S, 2000, FEBS LETT, V467, P87, DOI 10.1016/S0014-5793(00)01118-2; KWOK T, 1995, MOL MICROBIOL, V17, P471, DOI 10.1111/j.1365-2958.1995.mmi_17030471.x; KWOK T, 1998, THESIS U MELBOURNE V; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; MAROUDAS P, 1999, THESIS U MELBOURNE V; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Neuwald AF, 1999, GENOME RES, V9, P27; NG LC, 1995, J BACTERIOL, V177, P1485, DOI 10.1128/jb.177.6.1485-1490.1995; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Osuna J, 1997, PROTEIN SCI, V6, P543; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; Pittard J, 1996, GENES CELLS, V1, P717, DOI 10.1111/j.1365-2443.1996.tb00012.x; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sawyer WH, 2000, BIOCHEMISTRY-US, V39, P5653, DOI 10.1021/bi0000723; Song J, 1996, MOL MICROBIOL, V22, P497, DOI 10.1046/j.1365-2958.1996.00131.x; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wade JT, 2000, MOL MICROBIOL, V36, P223, DOI 10.1046/j.1365-2958.2000.01850.x; WILSON T, 1995, THESIS U MELBOURNE V; WILSON TJ, 1994, J MOL BIOL, V238, P309, DOI 10.1006/jmbi.1994.1294; WILSON TJ, 1995, MOL MICROBIOL, V17, P483, DOI 10.1111/j.1365-2958.1995.mmi_17030483.x; WNAG Y, 2001, PROTEIN SCI, V10, P592; Womack F C, 1973, Methods Enzymol, V27, P464; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; YANG J, 1993, J BACTERIOL, V175, P6372, DOI 10.1128/JB.175.19.6372-6375.1993; YANG J, 1993, J BACTERIOL, V175, P1767, DOI 10.1128/JB.175.6.1767-1776.1993	49	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23186	23192		10.1074/jbc.M112184200	http://dx.doi.org/10.1074/jbc.M112184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11923293	hybrid			2022-12-25	WOS:000176475700014
J	Maggio, F; King, GF				Maggio, F; King, GF			Scanning mutagenesis of a Janus-faced atracotoxin reveals a bipartite surface patch that is essential for neurotoxic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; SODIUM CURRENT INACTIVATION; MU-CONOTOXIN GIIIA; INSECTICIDAL NEUROTOXIN; POTASSIUM CHANNEL; PEPTIDE BLOCKER; TOXINS; RESIDUES; SITE; CYTOPLASM	The Janus-faced atracotoxins (J-ACTXs) are a family of insect-specific excitatory neurotoxins isolated from the venom of Australian funnel web spiders. In addition to a strikingly asymmetric distribution of charged residues, from which their name is derived, these toxins contain an extremely rare vicinal disulfide bond. To shed light on the mechanism of action of these toxins and to enhance their utility as lead compounds for insecticide development, we developed a recombinant expression system for the prototypic family member, J-ACTX-Hv1c, and mapped the key functional residues using site-directed mutagenesis. An alanine scan using a panel of 24 mutants provided the first complete map of the bioactive surface of a spider toxin and revealed that the entire J-ACTX-Hv1c pharmacophore is restricted to seven residues that form a bipartite surface patch on one face of the toxin. However, the primary pharmacophore, or hot spot, is formed by just five residues (Arg(8), Pro(9), Tyr(31), and the Cys(13)-Cys(14) vicinal disulfide). The Arg(8)-Tyr(31) diad in J-ACTX-Hv1c superimposes closely on the Lys-(Tyr/Phe) diad that is spatially conserved across a range of structurally dissimilar K+ channel blockers, which leads us to speculate that the J-ACTXs might target an invertebrate K+ channel.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06032 USA	University of Connecticut; University of Connecticut	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC3305,263 Farmington Ave, Farmington, CT 06032 USA.	glenn@psel.uchc.edu	King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200				Bernard C, 2001, BIOCHEMISTRY-US, V40, P12795, DOI 10.1021/bi015537j; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BLAKE CCF, 1994, NAT STRUCT BIOL, V1, P102, DOI 10.1038/nsb0294-102; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brogdon WG, 1998, EMERG INFECT DIS, V4, P605, DOI 10.3201/eid0404.980410; Chang NS, 1998, BIOCHEMISTRY-US, V37, P4407, DOI 10.1021/bi9724927; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DiasKadambi BL, 1996, J BIOL CHEM, V271, P23828, DOI 10.1074/jbc.271.39.23828; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Feyereisen R, 1995, TOXICOL LETT, V82-3, P83, DOI 10.1016/0378-4274(95)03470-6; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; Fletcher JI, 1999, EUR J BIOCHEM, V264, P525, DOI 10.1046/j.1432-1327.1999.00659.x; Ganetzky B, 2000, KIDNEY INT, V57, P766, DOI 10.1046/j.1523-1755.2000.00913.x; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Gubler DJ, 1998, EMERG INFECT DIS, V4, P442, DOI 10.3201/eid0403.980326; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; KAO PN, 1986, J BIOL CHEM, V261, P8085; Khera PK, 1996, BIOCHEMISTRY-US, V35, P3503, DOI 10.1021/bi9528457; KING GF, 2002, IN PRESS J TOXICOL T; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P14761, DOI 10.1021/bi001506x; Krittanai C, 1997, ANAL BIOCHEM, V253, P57, DOI 10.1006/abio.1997.2366; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Miller MK, 2000, TOXICON, V38, P409, DOI 10.1016/S0041-0101(99)00171-3; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; OERKE EC, 1994, CROP PRODUCTION CROP, P72; OLIVERA BM, 1995, TRENDS BIOTECHNOL, V13, P422, DOI 10.1016/S0167-7799(00)88996-9; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; SATO K, 1991, J BIOL CHEM, V266, P16989; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Tedford HW, 2001, J BIOL CHEM, V276, P26568, DOI 10.1074/jbc.M102199200; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x; Wang XH, 2001, J BIOL CHEM, V276, P40306, DOI 10.1074/jbc.M105206200; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810	46	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22806	22813		10.1074/jbc.M202297200	http://dx.doi.org/10.1074/jbc.M202297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937509	hybrid			2022-12-25	WOS:000176313600090
J	Lemercier, C; Brocard, MP; Puvion-Dutilleul, F; Kao, HY; Albagli, O; Khochbin, S				Lemercier, C; Brocard, MP; Puvion-Dutilleul, F; Kao, HY; Albagli, O; Khochbin, S			Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLZF-RAR-ALPHA; GERMINAL-CENTER FORMATION; TUMOR-SUPPRESSOR GENE; FINGER ENCODING GENE; FUSION PARTNERS; POZ DOMAIN; LAZ3 BCL6; PROTEIN; EXPRESSION; BINDING	BCL6 is a member of the POZ/zinc finger (POK) family involved in survival and/or differentiation of a number of cell types and in B cell lymphoma upon chromosomal alteration. Transcriptional repression by BCL6 is thought to be achieved in part by recruiting a repressor complex containing two class I histone deacetylases (HDACs). In this study we investigated whether BCL6 could also target members of class II HDACs. Our results indicate that three related class II deacetylases, HDAC4, HDAC5, and HDAC7 can associate with BCL6 in vivo and in vitro. Using electron microscopy, we found that endogenous BCL6 and class II HDACs partially co-localize in the nucleus. Overexpression experiments showed that BCL6 and HDAC4, -5, or -7 are intermingled onto common nuclear substructures and form stable complexes. A highly conserved domain in the N-terminal region of HDAC5 and HDAC7 as well as the zinc finger region of BCL6 were found necessary for the complex formation in vivo and in vitro. Moreover, our data point to the zinc finger region of BCL6 as a multifunctional domain which, beside its known capacity to bind DNA, is involved in the nuclear targeting of the protein and in the recruitment of the class II HDACs, and hence constitutes an autonomous repressor domain. Since PLZF, a BCL6 relative, could also interact with HDAC4, -5, and 7, we suggest that class Il HDACs are largely involved in the control of the POK transcription factors activity.	CNRS, UPR 1983, F-94801 Villejuif, France; Inst Albert Bonniot, Equipe Chromatine & Express Genes, INSERM, U309, F-38706 La Tronche, France; Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Dept Biochem,Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University	Khochbin, S (corresponding author), CNRS, UPR 1983, 7 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.	khochbin@ujf-grenoble.fr	Lemercier, Claudie/F-6759-2015; Khochbin, Saadi/M-8090-2013	Khochbin, Saadi/0000-0002-0455-0857				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Albagli O, 2000, MOL CELL BIOL, V20, P8560, DOI 10.1128/MCB.20.22.8560-8570.2000; Albagli-Curiel O, 1998, DIFFERENTIATION, V64, P33, DOI 10.1046/j.1432-0436.1998.6410033.x; Bereshchenko OR, 2000, BLOOD, V96, p702A; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huang EY, 2000, GENE DEV, V14, P45; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Huynh KD, 2000, GENE DEV, V14, P1810; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kojima S, 2001, DEVELOPMENT, V128, P57; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Numoto M, 1999, BIOCHEM BIOPH RES CO, V256, P573, DOI 10.1006/bbrc.1999.0375; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wen Y, 2000, GENETICS, V156, P195; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	58	135	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22045	22052		10.1074/jbc.M201736200	http://dx.doi.org/10.1074/jbc.M201736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929873	Green Submitted, hybrid			2022-12-25	WOS:000176286000117
J	Leung, JY; Kolligs, FT; Wu, R; Zhai, YL; Kuick, R; Hanash, S; Cho, KR; Fearon, ER				Leung, JY; Kolligs, FT; Wu, R; Zhai, YL; Kuick, R; Hanash, S; Cho, KR; Fearon, ER			Activation of AXIN2 expression by beta-catenin-T cell factor - A feedback repressor pathway regulating Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; OVARIAN CARCINOMAS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; UP-REGULATION; CYCLIN D1; C-MYC; TARGET; APC	The Wnt pathway regulates cell fate, proliferation, and apoptosis, and defects in the pathway play a key role in many cancers. Although Wnts act to stabilize beta-catenin levels in the cytosol and nucleus, a multiprotein complex containing adenomatous polyposis coli, glycogen synthase kinase 3beta, and Axin1 or its homolog Axin2/Axil/conductin promotes beta-catenin phosphorylation and subsequent proteasomal degradation. We found that the rat Axil gene was strongly induced upon neoplastic transformation of RK3E cells by mutant beta-catenin or gamma-catenin or after ligand-induced activation of a beta-catenin-estrogen receptor fusion protein. Expression of Wnt1 in murine breast epithelial cells activated the conductin gene, and human cancers with defective beta-catenin regulation had elevated AXIN2 gene and protein expression. Expression of AXIN2/Axil was strongly repressed in cancer cells by restoration of wild type adenomatous polyposis coli function or expression of a dominant negative form of T cell factor (TCF)-4. TCF binding sites in the AXIN2 promoter played a key role in the ability of beta-catenin to activate AXIN2 transcription. In contrast to AXIN2/Axil, expression of human or rat Axin1 homologs was nominally affected by beta-catenin-TCF. Because Axin2 can inhibit beta-catenin abundance and function, the data implicate AXIN2 in a negative feedback pathway regulating Wnt signaling. Additionally, although Axin1 and Axin2 have been thought to have comparable functions, the observation that Wnt pathway activation elevates AXIN2 but not AXIN1 expression suggests that there may be potentially significant functional differences between the two proteins.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fearon, ER (corresponding author), Univ Michigan, Med Ctr, Div Med Genet, 1500 E Med Ctr Dr,4301 MSRB 3,Box 0638, Ann Arbor, MI 48109 USA.	fearon@umich.edu		Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R01CA085463, U19CA084953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK058771] Funding Source: NIH RePORTER; NCI NIH HHS [CA84953, CA85463] Funding Source: Medline; NIDDK NIH HHS [DK58771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Dahmen RP, 2001, CANCER RES, V61, P7039; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Fujita M, 2001, CANCER RES, V61, P7722; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Howe LR, 1999, CANCER RES, V59, P1572; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	50	304	315	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21657	21665		10.1074/jbc.M200139200	http://dx.doi.org/10.1074/jbc.M200139200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940574	hybrid			2022-12-25	WOS:000176286000073
J	Liu, DM; Dillon, JS				Liu, DM; Dillon, JS			Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to G alpha(i2,3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEOTIDE-BINDING-PROTEINS; SRC TYROSINE KINASE; ESTROGEN-RECEPTOR; MYOCARDIAL-INFARCTION; RAT-LIVER; CALCIUM-CONCENTRATION; BRADYKININ RECEPTOR; INTRACELLULAR CA2+; PEPTIDE RECEPTOR	The adrenal steroid dehydroepiandrosterone (DHEA) has no known cellular receptor or unifying mechanism of action, despite evidence suggesting beneficial vascular effects in humans. Based on previous data from our laboratory, we hypothesized that DHEA binds to specific cell-surface receptors to activate intracellular G-proteins and endothelial nitric-oxide synthase (eNOS). We now pharmacologically characterize a putative plasma membrane DHEA receptor and define its associated G-proteins. The [H-3]DHEA binding to isolated plasma membranes from bovine aortic endothelial cells was of high affinity (K-d = 48.7 pM) and saturable (B-max = 500 fmol/mg protein). Structurally related steroids failed to compete with DHEA for binding. The putative DHEA receptor was functionally coupled to G-proteins, because guanosine 5'-O-(3-thio)triphosphate (GTPgammaS) inhibited [H-3]DHEA binding to plasma membranes by 69%, and DHEA increased [S-35]GTPgammaS binding by 157%. DHEA stimulated [S-35]GTPgammaS binding to Galpha(i2) and Galpha(13), but not to Galpha(i1) or Galpha(o). Pretreatment of plasma membranes with antibody to Galpha(i2) or Galpha(i3), but not to Galpha(i1), inhibited the DREA activation of eNOS. Thus, DHEA receptors are expressed on endothelial cell plasma membranes and are coupled to eNOS activity through Galpha(12) and Galpha(i3). These novel findings should allow us to isolate the putative receptor and reevaluate the physiological role of DHEA activity.	Vet Adm Med Ctr, Iowa City, IA 52246 USA; Univ Iowa, Coll Med, Dept Internal Med, Div Endocrinol, Iowa City, IA 52246 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	Dillon, JS (corresponding author), Vet Adm Med Ctr, 3E10, Iowa City, IA 52246 USA.		Liu, Dongmin/A-8069-2011	Dillon, Joseph/0000-0002-4002-1418	NIA NIH HHS [AG55741, R01 AG018928] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018928] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexandersen P, 1996, ATHEROSCLEROSIS, V125, P1, DOI 10.1016/0021-9150(96)05864-9; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; ARAD Y, 1989, ARTERIOSCLEROSIS, V9, P159, DOI 10.1161/01.ATV.9.2.159; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; CHAN TM, 1993, CLIN EXP IMMUNOL, V91, P110; CHATTERJEE TK, 1993, MOL PHARMACOL, V43, P167; Christ M, 1999, STEROIDS, V64, P35, DOI 10.1016/S0039-128X(98)00103-2; COOPER CL, 1989, J BIOL CHEM, V264, P6202; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DWORKIN CR, 1986, LIFE SCI, V38, P1451, DOI 10.1016/0024-3205(86)90557-6; Eisen C, 1997, CELL MOL BIOL, V43, P165; Fiorelli G, 1996, J STEROID BIOCHEM, V59, P233, DOI 10.1016/S0960-0760(96)00092-1; Furutama D, 1998, BBA-MOL BASIS DIS, V1406, P107, DOI 10.1016/S0925-4439(97)00085-9; GILLONGO J, 1993, EUR J PHARM-MOLEC PH, V247, P119, DOI 10.1016/0922-4106(93)90068-K; GORCZYNSKA E, 1995, ENDOCRINOLOGY, V136, P2052, DOI 10.1210/en.136.5.2052; GORDON GB, 1988, J CLIN INVEST, V82, P712, DOI 10.1172/JCI113652; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Herrington DM, 1995, ANN NY ACAD SCI, V774, P271; HOKLAND B, 1992, J LIPID RES, V33, P1335; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; Jesse RL, 1995, ANN NY ACAD SCI, V774, P281; KALIMI M, 1988, BIOCHEM BIOPH RES CO, V156, P22, DOI 10.1016/S0006-291X(88)80800-3; KAWAI S, 1995, ANTICANCER RES, V15, P427; LACROIX AZ, 1992, CIRCULATION, V86, P1529, DOI 10.1161/01.CIR.86.5.1529; LANTINHERMOSO RL, 1997, AM J PHYSIOL, V273, P119; Laubinger W, 1999, LIFE SCI, V65, pPL183, DOI 10.1016/S0024-3205(99)00394-X; LESZCZYNSKI D E, 1989, Steroids, V54, P37, DOI 10.1016/0039-128X(89)90074-3; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MEIKLE AW, 1992, J STEROID BIOCHEM, V42, P293, DOI 10.1016/0960-0760(92)90132-3; MITCHELL LE, 1994, CIRCULATION, V89, P89, DOI 10.1161/01.CIR.89.1.89; Miyamoto A, 1997, J BIOL CHEM, V272, P19601, DOI 10.1074/jbc.272.31.19601; MOHAN PF, 1992, STEROIDS, V57, P244, DOI 10.1016/0039-128X(92)90109-M; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; Nephew KP, 1998, MOL CELL ENDOCRINOL, V143, P133, DOI 10.1016/S0303-7207(98)00128-2; OKABE T, 1995, J CLIN ENDOCR METAB, V80, P2993, DOI 10.1210/jc.80.10.2993; Picotto G, 1999, BIOCHEM J, V339, P71, DOI 10.1042/0264-6021:3390071; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; REUTER S, 1995, J STEROID BIOCHEM, V54, P227, DOI 10.1016/0960-0760(95)00132-J; Rossato M, 1999, STEROIDS, V64, P168, DOI 10.1016/S0039-128X(98)00104-4; SAKAI T, 1992, CHEM PHARM BULL, V40, P2864, DOI 10.1248/cpb.40.2864; Santos-Alvarez J, 1999, J CELL BIOCHEM, V73, P469, DOI 10.1002/(SICI)1097-4644(19990615)73:4<469::AID-JCB5>3.0.CO;2-U; Sarkar R, 1998, J VASC RES, V35, P135, DOI 10.1159/000025576; Schmidt BMW, 2000, FRONT NEUROENDOCRIN, V21, P57, DOI 10.1006/frne.1999.0189; SCHWARTZ AG, 1988, CANCER RES, V48, P4817; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; Shin WS, 1996, ANN NY ACAD SCI, V786, P233, DOI 10.1111/j.1749-6632.1996.tb39066.x; SHIVAJI S, 1992, BIOCHIM BIOPHYS ACTA, V1108, P99, DOI 10.1016/0005-2736(92)90119-7; SLOWINSKASRZEDNICKA J, 1989, ATHEROSCLEROSIS, V79, P197; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; TRUEBA M, 1991, J MEMBRANE BIOL, V120, P115, DOI 10.1007/BF01872394; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANBOMMEL T, 1987, ANTICANCER RES, V7, P1217; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WEHLING M, 1994, STEROIDS, V59, P160, DOI 10.1016/0039-128X(94)90095-7; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Whiting KP, 2000, LIFE SCI, V67, P743, DOI 10.1016/S0024-3205(00)00669-X; WILLIAMS M, 2001, P 83 ANN M END SOC D; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200; Yoneyama A, 1997, LIFE SCI, V60, P833, DOI 10.1016/S0024-3205(97)00011-8; Yoshimata T, 1999, LIFE SCI, V65, P431, DOI 10.1016/S0024-3205(99)00264-7	77	231	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21379	21388		10.1074/jbc.M200491200	http://dx.doi.org/10.1074/jbc.M200491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934890	hybrid			2022-12-25	WOS:000176286000035
J	Yadava, N; Potluri, P; Smith, EN; Bisevac, A; Scheffler, IE				Yadava, N; Potluri, P; Smith, EN; Bisevac, A; Scheffler, IE			Species-specific and mutant MWFE proteins - Their effect on the assembly of a functional mammalian mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; HAMSTER CELL MUTANTS; QUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; STRUCTURAL-ANALYSIS; DEFICIENT; SUBUNITS; DEFECTS; NDH-1; GENE	The MWFE protein (70 amino acids) is highly conserved in evolution, but the human protein (80% identical to hamster) does not complement a null mutation in Chinese hamster cells. We have identified a small protein segment where significant differences exist between rodents and primates, illustrating very specifically the need for compatibility of the nuclear and mitochondrial genomes in the assembly of complex I. The segment between amino acids 39 and 46 appears to be critical for species-specific compatibility. Amino acid substitutions in this region were tested that caused a reduction of activity of the hamster protein or converted the inactive human protein into a partially active one. Such mutations could be useful in making mice with partial complex I activity as models for mitochondrial diseases. Their potential as dominant negative mutants was explored. More deleterious mutations in the NDUFA1 gene were also characterized. A conservative substitution, R50K, or a short C-terminal deletion makes the protein completely inactive. In the absence of MWFE, no high molecular weight complex was detectable by Blue Native-gel electrophoresis. The MWFE protein itself is unstable in the absence of assembled mitochondrially encoded integral membrane proteins of complex I.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Scheffler, IE (corresponding author), Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA.	ischeffler@ucsd.edu	Smith, Erin/E-5933-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059909] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59909] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Au HC, 1999, P NATL ACAD SCI USA, V96, P4354, DOI 10.1073/pnas.96.8.4354; Au HC, 1997, SOMAT CELL MOLEC GEN, V23, P27, DOI 10.1007/BF02679953; Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BREEN GAM, 1979, SOMAT CELL GENET, V5, P441, DOI 10.1007/BF01538879; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DITTA G, 1976, SOMAT CELL GENET, V2, P331, DOI 10.1007/BF01538838; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; Finel M, 1998, BBA-BIOENERGETICS, V1364, P112, DOI 10.1016/S0005-2728(98)00022-X; FINEL M, 1994, EUR J BIOCHEM, V226, P237, DOI 10.1111/j.1432-1033.1994.tb20046.x; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Kenyon L, 1997, P NATL ACAD SCI USA, V94, P9131, DOI 10.1073/pnas.94.17.9131; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Matsuno-Yagi A, 2001, J BIOENERG BIOMEMBR, V33, P155, DOI 10.1023/A:1010702116348; Moser S, 2000, BIOTECHNOL PROGR, V16, P724, DOI 10.1021/bp000077r; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Robinson BH, 1998, BBA-BIOENERGETICS, V1364, P271, DOI 10.1016/S0005-2728(98)00033-4; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; SCHEFFLER IE, 1986, CARBOHYD METABOL, P77; Schulte U, 1995, METHOD ENZYMOL, V260, P3, DOI 10.1016/0076-6879(95)60126-0; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Smeitink J, 2001, J BIOENERG BIOMEMBR, V33, P259, DOI 10.1023/A:1010743321800; Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573; SODERBERG K, 1979, SOMAT CELL GENET, V5, P225, DOI 10.1007/BF01539163; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; WALKER JE, 1995, BBA-MOL BASIS DIS, V1271, P221, DOI 10.1016/0925-4439(95)00031-X; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Walker JE, 1995, METHOD ENZYMOL, V260, P163, DOI 10.1016/0076-6879(95)60136-8; WALLACE DC, 1979, SOMAT CELL GENET, V5, P373, DOI 10.1007/BF01538849; YAGI T, 1993, J BIOENERG BIOMEMBR, V25, P339, DOI 10.1007/BF00762459; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; YAMAGUCHI M, 1993, BIOCHEMISTRY-US, V32, P1935, DOI 10.1021/bi00059a008; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; Yano T, 1999, J BIOL CHEM, V274, P28606, DOI 10.1074/jbc.274.40.28606; Zhuchenko O, 1996, GENOMICS, V37, P281, DOI 10.1006/geno.1996.0561	51	58	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21221	21230		10.1074/jbc.M202016200	http://dx.doi.org/10.1074/jbc.M202016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937507	hybrid			2022-12-25	WOS:000176286000015
J	Alami, M; Trescher, D; Wu, LF; Muller, M				Alami, M; Trescher, D; Wu, LF; Muller, M			Separate analysis of twin-arginine translocation (Tat)-specific membrane binding and translocation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN TRANSLOCATION; GREEN FLUORESCENT PROTEIN; PLASMA-MEMBRANE; BACTERIAL PROTEIN; EXPORT SYSTEM; TAT PATHWAY; COMPONENTS; COMPLEX; REQUIREMENTS; PROMOTERS	The twin-arginine translocation (Tat) pathway exports those precursor proteins to the periplasmic space of bacteria that harbor a twin-arginine (RR) consensus motif in their signal sequences. We have reproduced translocation of several Tat substrates into inside-out plasma membrane vesicles from Escherichia coli. Translocation proceeding at an efficiency of up to 20% occurs specifically via the Tat pathway as indicated by M its requirement for elevated levels of the TatABC proteins in the membrane vesicles, (ii) competition by an intact twin-arginine signal peptide, and (iii) susceptibility toward dissipation of the transmembrane H+ gradient. The latter treatment, while blocking translocation, still allows for functional membrane association of Tat precursors. This is shown by the finding that translocation of isolated membrane-bound Tat precursor is restored upon re-energization of the vesicles.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; CNRS, Inst Biol Struct & Microbiol, UPR9043, Chim Bacterienne Lab, F-13402 Marseille 20, France	University of Freiburg; Centre National de la Recherche Scientifique (CNRS)	Muller, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herderstr 7, D-79104 Freiburg, Germany.							Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Chanal A, 1998, MOL MICROBIOL, V30, P674, DOI 10.1046/j.1365-2958.1998.01095.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; ERNST F, 1994, J BIOL CHEM, V269, P12840; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; MULLER M, 1987, EMBO J, V6, P3855, DOI 10.1002/j.1460-2075.1987.tb02723.x; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Santini CL, 2001, J BIOL CHEM, V276, P8159, DOI 10.1074/jbc.C000833200; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wexler M, 1998, FEBS LETT, V431, P339, DOI 10.1016/S0014-5793(98)00790-X; WIESELER B, 1993, MOL MICROBIOL, V7, P167, DOI 10.1111/j.1365-2958.1993.tb01108.x; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	30	76	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20499	20503		10.1074/jbc.M201711200	http://dx.doi.org/10.1074/jbc.M201711200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923313	hybrid			2022-12-25	WOS:000176204500052
J	Ji, JZ; Tsuk, S; Salapatek, AMF; Huang, XH; Chikvashvili, D; Pasyk, EA; Kang, YH; Sheu, L; Tsushima, R; Diamant, N; Trimble, WS; Lotan, I; Gaisano, HY				Ji, JZ; Tsuk, S; Salapatek, AMF; Huang, XH; Chikvashvili, D; Pasyk, EA; Kang, YH; Sheu, L; Tsushima, R; Diamant, N; Trimble, WS; Lotan, I; Gaisano, HY			The 25-kDa synaptosome-associated protein (SNAP-25) binds and inhibits delayed rectifier potassium channels in secretory cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNELS; GATED K+ CHANNELS; BOTULINUM NEUROTOXIN; SYNTAXIN 1A; CLOSTRIDIAL NEUROTOXINS; INSULIN-SECRETION; CA2+ CHANNELS; BETA-CELL; KINASE-A; SUBUNIT	Delayed-rectilrier K+ channels (K-DR) are important regulators of membrane excitability in neurons and neuroendocrine cells. Opening of these voltage-dependent K+ channels results in membrane repolarization, leading to the closure of the Ca2+ channels and cessation of insulin secretion in neuroendocrine islet 13 cells. Using patch clamp techniques, we have demonstrated that the activity of the K-DR channel subtype, K(v)1.1, identified by its specific blocker dendrodotoxin-K, is inhibited by SNAP-25 in insulinoma HIT-T15 beta cells. A coprecipitation study of rat brain confirmed that SNAP-25 interacts with the K(v)1.1 protein. Cleavage of SNAP-25 by expression of botulinum neurotoxin A in HIT-T15 cells relieved this SNAP-25-mediated inhibition of KDR. This inhibitory effect of SNAP-25 is mediated by the N terminus of K(v)1.1, likely by direct interactions with K(v)1.1 and/or K(v)beta subunits, as revealed by co-immunoprecipitation performed in the Xenopus oocyte expression system and in vitro binding. Taken together we have concluded that SNAP-25 mediates secretion not only through its participation in the exocytotic SNARE complex but also by regulating membrane potential and calcium entry through its interaction with K-DR channels.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; State Ocean Adm, Inst Oceanog 1, Qingdao 266061, Peoples R China; Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); State Oceanic Administration; Tel Aviv University; Sackler Faculty of Medicine	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Rm 7226,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca			Canadian Institutes of Health Research [42394] Funding Source: Medline; NIDDK NIH HHS [DK55160] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055160] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETSHOLTZ C, 1990, FEBS LETT, V263, P121, DOI 10.1016/0014-5793(90)80719-Y; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Biggin PC, 2000, CURR OPIN STRUC BIOL, V10, P456, DOI 10.1016/S0959-440X(00)00114-7; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P311, DOI 10.1113/jphysiol.1990.sp018024; Bressler R, 1997, ARCH INTERN MED, V157, P836, DOI 10.1001/archinte.157.8.836; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Igarashi M, 1996, J CELL BIOL, V134, P205, DOI 10.1083/jcb.134.1.205; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Jing J, 1999, EMBO J, V18, P1245, DOI 10.1093/emboj/18.5.1245; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Miller C., 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-4-reviews0004.REVIEWS0004, DOI 10.1186/GB-2000-1-4-REVIEWS0004.REVIEWS0004, 10.1186/gb-2000-1-4-reviews0004, DOI 10.1186/GB-2000-1-4-REVIEWS0004]; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Salapatek AMF, 1999, MOL ENDOCRINOL, V13, P1305, DOI 10.1210/me.13.8.1305; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; WAIGNER BJ, 2001, NATURE, V411, P805; WEBER T, 1998, NATURE, V395, P328; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164; Yi BA, 2000, NEURON, V27, P423, DOI 10.1016/S0896-6273(00)00052-0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	53	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20195	20204		10.1074/jbc.M201034200	http://dx.doi.org/10.1074/jbc.M201034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925439	hybrid			2022-12-25	WOS:000176204500015
J	Tate, JJ; Cox, KH; Rai, R; Cooper, TG				Tate, JJ; Cox, KH; Rai, R; Cooper, TG			Mks1p is required for negative regulation of retrograde gene expression in Saccharomyces cerevisiae but does not affect nitrogen catabolite repression-sensitive gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOR; RAPAMYCIN; PROTEIN; LOCALIZATION; PATHWAY; TARGET; GLN3P; YEAST; URE2P	The Tor1/2p signal transduction pathway regulates nitrogen catabolite repression (NCR)-sensitive (GAP1, GAT1, DAL5) and retrograde (CIT2, DLD3, IDH112) gene expression by controlling intracellular localization of the transcription activators, Gln3p and Gat1p, and Rtg1p and Rtg3p, respectively. The accepted pathway for this regulation is NH3 or excess nitrogen + Mks1p + Ure2p + Gln3p --> DAL5, and rapamycin or limiting nitrogen Torp --> Tap42 + Mks1p --> Rtg1/3p --> CIT2, respectively. In current models, Mks1p positively regulates both Gln3p (and DAL5 expression) and Rtg113p (and CIT2 expression). Here, in contrast, we show the following. W Mks1p is a strong negative regulator of CIT2 expression and does not effect NCR-sensitive expression of DAL5 or GAP1. (ii) Retrograde carbon and NCR-sensitive nitrogen metabolism are not linked by the quality of the nitrogen source, i.e. its ability to elicit NCR, but by the product of its catabolism, i.e. glutamate or ammonia. (iii) In some instances, we can dissociate rapamycin-induced CIT2 expression from Mks1p function, i.e. rapamycin does not suppress Mks1p-mediated down-regulation of CIT2 expression. These findings suggest that currently accepted models of Tor1/2p signal transduction pathway regulation require revision.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38120 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38120 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; Cooper T. G., 1996, P139; COOPER TG, 2002, FEMS MICROBIOL REV, V737, P1; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DRILLIEN R, 1972, J BACTERIOL, V109, P203, DOI 10.1128/JB.109.1.203-208.1972; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; Edskes HK, 2000, P NATL ACAD SCI USA, V97, P6625, DOI 10.1073/pnas.120168697; Edskes HK, 1999, GENETICS, V153, P585; Feller A, 1997, YEAST, V13, P1337, DOI 10.1002/(SICI)1097-0061(199711)13:14<1337::AID-YEA186>3.0.CO;2-O; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; MATSUURA A, 1993, MOL GEN GENET, V238, P6, DOI 10.1007/BF00279524; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; RAI R, 1989, MOL CELL BIOL, V9, P602, DOI 10.1128/MCB.9.2.602; RAMOS F, 1985, MOL GEN GENET, V200, P291, DOI 10.1007/BF00425438; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; TUROSCY V, 1987, J BACTERIOL, V169, P2598, DOI 10.1128/jb.169.6.2598-2600.1987; WICKERHAM LJ, 1946, J BACTERIOL, V52, P293, DOI 10.1128/JB.52.3.293-301.1946; ZHEGCHANG L, 1999, MOL CELL BIOL, V19, P6720	32	54	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20477	20482		10.1074/jbc.M200962200	http://dx.doi.org/10.1074/jbc.M200962200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923302	hybrid, Green Accepted			2022-12-25	WOS:000176204500049
J	Leem, JY; Vijayan, S; Han, P; Cai, DM; Machura, M; Lopes, KO; Veselits, ML; Xu, HX; Thinakaran, G				Leem, JY; Vijayan, S; Han, P; Cai, DM; Machura, M; Lopes, KO; Veselits, ML; Xu, HX; Thinakaran, G			Presenilin 1 is required for maturation and cell surface accumulation of nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; SUBCELLULAR-LOCALIZATION; BETA-PROTEIN; CLEAVAGE; APP; INHIBITORS; SITE; A-BETA-40/42; ASSOCIATION	Proteolytic processing of amyloid precursor protein generates beta-amyloid (Abeta) peptides that are deposited in senile plaques in brains of aged individuals and patients with Alzheimer's disease. Presenilins (PS1 and PS2) facilitate the final step in Abeta production, the intramembranous gamma-secretase cleavage of amyloid precursor protein. Biochemical and pharmacological evidence support a catalytic or accessory role for PSI in gamma-secretase cleavage, as well as a regulatory role in select membrane protein trafficking. In this report, we demonstrate that PS1 is required for maturation and cell surface accumulation of nicastrin, an integral component of the multimeric gamma-secretase complex. Using kinetic labeling studies we show that in PS1(-/-)/PS2(-/-) cells nicastrin fails to reach the medial Golgi compartment, and as a consequence, is incompletely glycosylated. Stable expression of human PS1 restores these deficiencies in PS1(-/-) fibroblasts. Moreover, membrane fractionation studies show co-localization of PS1 fragments with mature nicastrin. These results indicate a novel chaperone-type role for PS1 and PS2 in facilitating nicastrin maturation and transport in the early biosynthetic compartments. Our findings are consistent with PS1 influencing gamma-secretase processing at multiple steps, including maturation and intracellular trafficking of substrates and component(s) of the gamma-secretase complex.	Univ Chicago, Ctr Mol Neurobiol, Dept Neurol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	University of Chicago; University of Chicago; Rockefeller University	Thinakaran, G (corresponding author), Univ Chicago, Ctr Mol Neurobiol, Dept Neurol Pharmacol & Physiol, Knapp R212,924 E 57th St, Chicago, IL 60637 USA.		Xu, Huaxi/AAV-7177-2021	Radomski, Kryslaine/0000-0001-9624-623X	NATIONAL INSTITUTE ON AGING [P01AG009464, R01AG019070] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG009464, AG09464, AG19070] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Sato N, 2000, NAT CELL BIOL, V2, P863, DOI 10.1038/35046500; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; Thinakaran G, 2001, J MOL NEUROSCI, V17, P183, DOI 10.1385/JMN:17:2:183; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	30	173	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19236	19240		10.1074/jbc.C200148200	http://dx.doi.org/10.1074/jbc.C200148200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11943765	hybrid			2022-12-25	WOS:000175975800128
J	Theodosiou, A; Ashworth, A				Theodosiou, A; Ashworth, A			Differential effects of stress stimuli on a JNK-inactivating phosphatase	ONCOGENE			English	Article						JNK; phosphatase; tumour promotion; degradation	DUAL-SPECIFICITY PHOSPHATASES; MAP KINASE PHOSPHATASE; N-TERMINAL KINASE; C-JUN; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVATION; GENE FAMILY; DELTA; INHIBITOR; PATHWAY	Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, CRC, Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.	alana@icr.ac.uk						ADLER V, 1994, J BIOL CHEM, V269, P11186; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen YR, 2000, INT J ONCOL, V16, P651; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	48	29	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2387	2397		10.1038/sj.onc.1205309	http://dx.doi.org/10.1038/sj.onc.1205309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948422				2022-12-25	WOS:000174635600011
J	Vikis, HG; Stewart, S; Guan, KL				Vikis, HG; Stewart, S; Guan, KL			SmgGDS displays differential binding and exchange activity towards different Ras isoforms	ONCOGENE			English	Article						Ras; Rac; Rho; dominant negative mutants; smgGDS; guanine nucleotide exchange factor	KINASE SUPPRESSOR; PROTEIN; COMPLEX; SIGNAL; FORMS; PURIFICATION; INHIBITION; MUTANTS; GROWTH	Ras family GTPases play central roles in a wide variety of biological responses, including cell proliferation, differentiation, and oncogenic transformation. We searched for novel guanine nucleotide exchange factors of HRas and isolated small G-protein dissociation stimulator (smgGDS), a guanine nucleotide exchange factor known to act on numerous Ras and Rho family GTPases. SmgGDS specifically interacts with both dominant negative and nucleotide free forms of H and NRas, but not with the corresponding oncogenic forms. An effector domain mutant of HRas, HRasN17G37, selectively lost the ability to bind smgGDS. However, smgGDS does not catalyze guanine nucleotide exchange on either H or NRas in vitro. In contrast, substrates of smgGDS, such as KRas, Rac1, and RhoA, bind to smgGDS in both active and inactive forms which requires the presence of poly-basic residues in the C-termini of the GTPases. Our data suggest that the C-terminal poly-basic region of small GTPases is important for both binding and nucleotide exchange by smgGDS. Furthermore, these data underscore the idea that mammalian Ras isoforms are not functionally equivalent.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWMAN EP, 1995, METHOD ENZYMOL, V256, P246; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKANISHI H, 1994, J BIOL CHEM, V269, P15085; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	24	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2425	2432		10.1038/sj.onc.1205306	http://dx.doi.org/10.1038/sj.onc.1205306			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948427				2022-12-25	WOS:000174635600016
J	Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN				Godfried, MB; Veenstra, M; Von Sluis, P; Boon, K; Von Asperen, R; Hermus, MC; Von Schaik, BDC; Voute, TPA; Schwab, M; Versteeg, R; Caron, HN			The N-myc and c-mjc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2	ONCOGENE			English	Article						nm23-H1; nm23-H2; N-myc; c-myc; chromosome 17; neuroblastoma	I HLA EXPRESSION; CELL-LINES; NEUROBLASTOMA; DIFFERENTIATION; LOCALIZATION; PROGRESSION; NUCLEOSIDE; MELANOMAS	Gain of chromosome 17q material is the most frequent genetic abnormality in neuroblastomas. The common region of gain is at least 375 cR large, which has precluded the identification of genes with a role in neuroblastoma pathogenesis. Neuroblastoma also frequently show amplification of the N-myc oncogene, which correlates closely with 17q gain. Both events are strong predictors of unfavorable prognosis. To identify genes that are part of the N-myc downstream pathway, we constructed SAGE libraries of an N-mjc transfected and a control cell line. This identified the chromosome 17q genes nm23-H1 and nm23-H2 as being 6-10 times induced in the N-myc expressing cells. Northern and Western blot analysis confirmed this up-regulation. Time-course experiment shows that both genes are induced within 4 h after N-myc is switched on. Furthermore, we demonstrate also that c-myc can upregulate nm23-H1 and nm23-H2 expression. Neuroblastoma tumor and cell line panels reveal a striking correlation between N-myc amplification and mRNA and protein expression of both nm23 genes. We show that the nm23 genes are located at the edge of the common region of chromosome 17q gain previously described in neuroblastoma cell lines. Our findings suggest that nm23-H1 and nm23-H2 expression is increased by 17q gain in neuroblastoma and can be further up-regulated by myc overexpression. These observations suggest a major role for nm23-H1 and nm23-H2 in tumorigenesis of unfavorable neuroblastomas.	Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Bioinformat Lab, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Kinderziekenhuis, Dept Pediat Oncol & Hematol, NL-1105 AZ Amsterdam, Netherlands; DKFZ, Berlin, Germany	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Caron, HN (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Genet, POB 22700, NL-1100 DE Amsterdam, Netherlands.	HNCaron@amc.uva.nl	Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388; van Schaik, Barbera/0000-0002-5568-8127				BACKER JM, 1993, ONCOGENE, V8, P497; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Cheng NC, 1996, ONCOGENE, V13, P1737; FLORENES VA, 1992, CANCER RES, V52, P6088; Lastowska M, 1998, GENE CHROMOSOME CANC, V23, P116; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Meddeb M, 1996, GENE CHROMOSOME CANC, V17, P156, DOI 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3; Niitsu N, 2001, BLOOD, V97, P1202, DOI 10.1182/blood.V97.5.1202; Pinon VPB, 1999, EXP CELL RES, V246, P355, DOI 10.1006/excr.1998.4318; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; VANROY N, 1995, EUR J CANCER, V31A, P530, DOI 10.1016/0959-8049(95)00004-3; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x	17	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2097	2101		10.1038/sj.onc.1205259	http://dx.doi.org/10.1038/sj.onc.1205259			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960382				2022-12-25	WOS:000174827000016
J	Friedle, H; Knochel, W				Friedle, H; Knochel, W			Cooperative interaction of Xvent-2 and GATA-2 in the activation of the ventral homeobox gene Xvent-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSOVENTRAL AXIS; XENOPUS EMBRYOS; BETA-CATENIN; WNT; EXPRESSION; INDUCTION; BMP-4; MESODERM; SUPPRESSION; PROTEINS	The Xvent family of homeobox transcription factors is essential for the establishment of the dorsal-ventral body axis during Xenopus embryogenesis. In contrast to Xvent-2B and other members of the Xvent-2 subfamily, Xvent-1B is not a direct response gene of bone morphogenetic protein-4 signaling. Xvent-1B is activated by Xvent-2, but CHX experiments revealed the requirement of additional factors. In this study, we report on the cooperative effect of Xvent-2 and the zinc finger transcription factor GATA-2 on the promoter of the Xvent-1B gene. We show that GATA-2 is a direct target gene of bone morphogenetic protein-4 and that GATA-2 interacts with Xvent-2 to activate transcription of Xvent-1B. Both transcription factors bind to distinct elements within the Xvent-1B promoter, and GATA-2 physically interacts with the C-terminal domain of Xvent-2. Promoter/reporter studies in Xenopus embryos revealed that full activation of Xvent-1B requires both Xvent-2 and GATA-2. Moreover, the two factors are sufficient to direct transcription of Xvent-1B in the presence of CHX at the ventral side of the embryo. The failure of both factors to activate Xvent-1B on the dorsal side suggests the existence of a dorsal inhibitor. This inhibitor is likely a component of the dorsal Wnt signaling pathway because nuclear translocation of beta-catenin before mid-blastula transition results in a suppression of Xvent-1B transcription.	Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Ulm University	Knochel, W (corresponding author), Univ Ulm, Biochem Abt, Albert Einstein Allee 11, D-89081 Ulm, Germany.	walter.knoechel@medizin.uni-ulm.de						Ault KT, 1996, P NATL ACAD SCI USA, V93, P6415, DOI 10.1073/pnas.93.13.6415; Baker JC, 1999, GENE DEV, V13, P3149, DOI 10.1101/gad.13.23.3149; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; Darken RS, 2001, DEV BIOL, V234, P42, DOI 10.1006/dbio.2001.0253; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Friedle H, 1998, EMBO J, V17, P2298, DOI 10.1093/emboj/17.8.2298; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamilton FS, 2001, DEVELOPMENT, V128, P2063; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Henningfeld KA, 2002, J BIOL CHEM, V277, P2097, DOI 10.1074/jbc.M108524200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Imai Y, 2001, DEVELOPMENT, V128, P2407; Kasahara H, 2001, J BIOL CHEM, V276, P4570, DOI 10.1074/jbc.M004995200; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Ladher R, 1996, DEVELOPMENT, V122, P2385; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Lemaire P, 1996, BIOESSAYS, V18, P701, DOI 10.1002/bies.950180904; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Maxam A M, 1980, Methods Enzymol, V65, P499; Moretti PAB, 2001, GENOMICS, V76, P21, DOI 10.1006/geno.2001.6574; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Papalopulu N, 1996, DEV BIOL, V174, P104, DOI 10.1006/dbio.1996.0055; Rastegar S, 1999, MECH DEVELOP, V81, P139, DOI 10.1016/S0925-4773(98)00239-1; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; Schuler-Metz A, 2000, J BIOL CHEM, V275, P34365, DOI 10.1074/jbc.M003915200; Sykes TG, 1998, DEVELOPMENT, V125, P4595; Trindade M, 1999, DEV BIOL, V216, P442, DOI 10.1006/dbio.1999.9507; Xu RH, 1999, DEV BIOL, V208, P352, DOI 10.1006/dbio.1999.9205; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	42	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23872	23881		10.1074/jbc.M201831200	http://dx.doi.org/10.1074/jbc.M201831200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964398	hybrid			2022-12-25	WOS:000176475700101
J	Bakker, J; Lin, XH; Nelson, WG				Bakker, J; Lin, XH; Nelson, WG			Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA METHYLTRANSFERASE; MESSENGER-RNA EXPRESSION; DE-NOVO METHYLATION; HISTONE DEACETYLASE; CANCER-CELLS; COMPLEX; ISLAND; MECP2; HEPATOCARCINOGENESIS; NEOPLASIA	During the pathogenesis of human hepatocellular carcinoma (HCC), the CpG island encompassing the pi-class glutathione S-transferase gene (GSTP1) becomes hypermethylated. Repression of transcription accompanying CpG island hypermethylation has been proposed to be mediated by methyl-CpG binding domain (MBD) proteins. We report here that inhibition of transcription from hypermethylated GSTP1 promoters in Hep3B HCC cells, which fail to express GSTP1 mRNA or GSTP1 polypeptides, appears to be mediated by MBD2. Treatment of Hep3B cells with 5-azadeoxycytidine (5-aza-dC), a methyltransferase inhibitor, activated GSTP1 expression, whereas treatment with trichostatin A, a histone deacetylase inhibitor, had little effect. To more precisely assess the contribution of the pattern of GSTP1 CpG island methylation on GSTP1 mRNA expression, Hep3B cells were treated for 72 h with 5-aza-dC and then subjected to limiting dilution cloning. Bisulfite sequencing was used to map the methylation patterns of the GSTP1 promoter region in GSTP1-expressing and -non-expressing clones. In the clone that expressed GSTP1 mRNA determined by Northern blot analysis and quantitative reverse transcriptase (RT)-PCR, widespread demethylation of at least one GSTP1 allele was evident. Chromatin immunoprecipitation experiments revealed the presence of MBD2, but not Sp1, at the GSTP1 promoter in Hep3B cells. In contrast, Sp1 was detected at the GSTP1 promoter in a GSTP1-expressing Hep3B 5-aza-dC subclone. To test whether MBD2 might be responsible for the inhibition of GSTP1 transcription from hypermethylated GSTP1 promoters, siRNAs were used to reduce MED2 polypeptide levels in Hep3B cells. SssI-catalyzed methylation of GSTP1 promoter sequences resulted in diminished luciferase reporter activity after transfection into Hep3B cells. However, when hypermethylated GSTP1 promoter sequences were transfected into Hep3B cells that had been treated with siRNA-targeting MBD2 mRNA, no repression of luciferase reporter expression was evident. These findings implicate MBD2 in the repression of GSTP1 expression associated with GSTP1 CpG island hypermethylation in HCC cells.	Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Nelson, WG (corresponding author), Rm 151,Bunting Blaustein Canc Res Bldg,1650 Orlea, Baltimore, MD 21231 USA.				NCI NIH HHS [CA 70196] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1999, MOL CELL BIOL, V19, P6690; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 1998, CANCER RES, V58, P4515; Esteller M, 2001, CANCER RES, V61, P3225; Feng Q, 2001, GENE DEV, V15, P827; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338; Kanai Y, 1996, JPN J CANCER RES, V87, P1210, DOI 10.1111/j.1349-7006.1996.tb03135.x; Kanai Y, 1997, INT J CANCER, V71, P355; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee WH, 1997, CANCER EPIDEM BIOMAR, V6, P443; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIN RIS, 1969, ANAL BIOCHEM, V27, P473, DOI 10.1016/0003-2697(69)90061-X; Lin XH, 2001, CANCER RES, V61, P8611; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Tchou JC, 2000, INT J ONCOL, V16, P663; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wong IHN, 1999, CANCER RES, V59, P71; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	47	90	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22573	22580		10.1074/jbc.M203009200	http://dx.doi.org/10.1074/jbc.M203009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960994	hybrid			2022-12-25	WOS:000176313600063
J	Beers, J; Glerum, DM; Tzagoloff, A				Beers, J; Glerum, DM; Tzagoloff, A			Purification and characterization of yeast Sco1p, a mitochondrial copper protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C1; METABOLISM; REQUIRES; GENE	The present studies were undertaken to further characterize the properties of Sco1p, a constituent of the mitochondrial inner membrane implicated in copper transfer to cytochrome oxidase. We report a procedure capable of yielding Sco1p of >95% purity. Sco1p has been purified from strains of Saccharomyces cerevisiae that overexpress the protein. The amino-terminal sequence of purified Sco1p indicates that the first 40 amino acids of the primary translation product constitute a mitochondrial targeting sequence that is proteolytically cleaved during import. We estimate that Sco1p constitutes 0.08% total mitochondrial proteins in wild type yeast and 5% in the transformant used for the purification. Sco1p contains similar to1 mol of copper/mol protein. The copper is not removed by the treatment of Sco1p with EDTA, indicating that it is bound with high affinity. Purified Sco1p sediments identical to Sco1p in crude extracts of mitochondria from wild type yeast or from a strain transformed with SCO1 on a high copy plasmid. Native Sco1p has an estimated mass of 88 kDa, suggesting that it is a homotrimer. Sco1p expressed as a soluble protein lacking the internal 17 amino acids of the membrane-anchoring domain has been localized in the matrix. The protein has also been targeted to the intermembrane space. Neither soluble matrix nor intermembrane-localized Sco1p is able to complement a sco1 mutant, suggesting that only the membrane form with the carboxyl-terminal domain facing the intermembrane space is able to exert its normal function.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Glerum, Moira/AHD-3271-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817	22	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22185	22190		10.1074/jbc.M202545200	http://dx.doi.org/10.1074/jbc.M202545200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948192	hybrid			2022-12-25	WOS:000176313600012
J	Miles, RD; Gorrell, A; Ferry, JG				Miles, RD; Gorrell, A; Ferry, JG			Evidence for a transition state analog, MgADP-aluminum fluoride-acetate, in acetate kinase from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE CONFORMATIONS; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; BINDING; HEXOKINASE; SITE; MECHANISM; FLUOROALUMINATE; IDENTIFICATION; TRANSDUCIN	Aluminum fluoride has become an important tool for investigating the mechanism of phosphoryl transfer, an essential reaction that controls a host of vital cell functions. Planar AlF3 or AlF4- molecules are proposed to mimic the phosphoryl group in the catalytic transition state. Acetate kinase catalyzes phosphoryl transfer of the ATP gamma-phosphate to acetate. Here we describe the inhibition of acetate kinase from Methanosarcina thermophila by preincubation with MgCl2, ADP, AlCl3, NaF, and acetate. Preincubation with butyrate in place of acetate did not significantly inhibit the enzyme. Several NTPs can substitute for ATP in the reaction, and the corresponding NDPs, in conjunction with MgCl2, AlCl3, NaF, and acetate, inhibit acetate kinase activity. Fluorescence quenching experiments indicated an increase in binding affinity of acetate kinase for MgADP in the presence of AlCl3, NaF, and acetate. These and other characteristics of the inhibition indicate that the transition state analog, MgADP-aluminum fluoride-acetate, forms an abortive complex in the active site. The protection from inhibition by a non-hydrolyzable ATP analog or acetylphosphate, in conjunction with the strict dependence of inhibition on the presence of both ADP and acetate, supports a direct in-line mechanism for acetate kinase.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 205 S Frear, University Pk, PA 16802 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ANTHONY RS, 1972, J BIOL CHEM, V247, P2120; ANTONNY B, 1992, J BIOL CHEM, V267, P6710; BLATTLER WA, 1979, BIOCHEMISTRY-US, V18, P3927, DOI 10.1021/bi00585a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buss KA, 2001, J BACTERIOL, V183, P680, DOI 10.1128/JB.183.2.680-686.2001; Buss KA, 1997, PROTEIN SCI, V6, P2659; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FOX DK, 1986, J BIOL CHEM, V261, P3498; GARIN J, 1993, BIOCHEMISTRY-US, V32, P6821, DOI 10.1021/bi00078a004; Graham DL, 1999, BIOCHEMISTRY-US, V38, P14981, DOI 10.1021/bi991358e; Ingram-Smith C, 2000, J BIOL CHEM, V275, P33765, DOI 10.1074/jbc.M005303200; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; JANSON CA, 1974, J BIOL CHEM, V249, P2567; Lipmann F, 1944, J BIOL CHEM, V155, P55; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Miles RD, 2001, J BIOL CHEM, V276, P45059, DOI 10.1074/jbc.M108355200; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; PURICH DL, 1972, ARCH BIOCHEM BIOPHYS, V149, P307, DOI 10.1016/0003-9861(72)90326-8; ROSE IA, 1954, J BIOL CHEM, V211, P737; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SCRUTTON MC, 1965, J BIOL CHEM, V240, P3714; SECNIK J, 1992, BIOCHEMISTRY-US, V31, P2982, DOI 10.1021/bi00126a020; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; Singh-Wissmann K, 2000, BIOCHEMISTRY-US, V39, P3671, DOI 10.1021/bi991998h; Singh-Wissmann K, 1998, J BACTERIOL, V180, P1129, DOI 10.1128/JB.180.5.1129-1134.1998; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPECTOR LB, 1980, P NATL ACAD SCI-BIOL, V77, P2626, DOI 10.1073/pnas.77.5.2626; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; TAKASHI R, 1977, P NATL ACAD SCI USA, V74, P2334, DOI 10.1073/pnas.74.6.2334; TODHUNTER JA, 1974, BIOCHEM BIOPH RES CO, V60, P273, DOI 10.1016/0006-291X(74)90201-0; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e	35	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22547	22552		10.1074/jbc.M105921200	http://dx.doi.org/10.1074/jbc.M105921200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960978	hybrid			2022-12-25	WOS:000176313600059
J	Suhara, W; Yoneyama, A; Kitabayashi, I; Fujita, T				Suhara, W; Yoneyama, A; Kitabayashi, I; Fujita, T			Direct involvement of CREB-binding protein/p300 in sequence-specific DNA binding of virus-activated interferon regulatory factor-3 holocomplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; TRANSCRIPTION FACTOR; GENE-EXPRESSION; BETA GENE; COACTIVATOR P300; IN-VIVO; ACETYLATION; INDUCTION; IRF-3	Infections of bacteria and viruses induce host defense reactions known as innate responses including the activation of interferon regulatory factor-3 (IRF-3), critical for the activation of type I interferon system. Upon immediate early signals triggered by the infection, IRF-3 is phosphorylated and a homodimer results. The homodimer complexes with the coactivator CREB-binding protein (CBP)/p300 in the nucleus; thus, holocomplex of IRF-3 competent in DNA binding is generated. We showed CBP/p300 to be indispensable for the DNA binding activity of the holocomplex and to aid the binding through direct interaction with the DNA. We demonstrated that p300 binds with the IRF-3 homodimer via a Q-rich domain and that an intact histone acetyltransferase (HAT) domain is indispensable for the DNA binding of the holocomplex along with a CH3 domain, which connects the HAT and Q-rich domains. These results highlight a novel function of CBP/p300: direct involvement in sequence-specific DNA binding. Furthermore, the critical function of these domains in virus-induced gene activation was demonstrated in vivo by using p300 mutants.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Fujita, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kitabayashi, Issay/G-2204-2017; Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408; Kitabayashi, Issay/0000-0002-8409-0407				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; De Guzman RN, 2000, J MOL BIOL, V303, P243, DOI 10.1006/jmbi.2000.4141; DEMAEYER E, 1988, INTERFERONS OTHER RE, P1; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Liu L, 1999, MOL CELL BIOL, V19, P1202; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SEN GC, 1992, J BIOL CHEM, V267, P5017; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suhara W, 2000, J BIOCHEM-TOKYO, V128, P301, DOI 10.1093/oxfordjournals.jbchem.a022753; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 1996, J BIOCHEM-TOKYO, V120, P160	40	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22304	22313		10.1074/jbc.M200192200	http://dx.doi.org/10.1074/jbc.M200192200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940575	hybrid			2022-12-25	WOS:000176313600026
J	Warren, CE; Krizus, A; Roy, PJ; Culotti, JG; Dennis, JW				Warren, CE; Krizus, A; Roy, PJ; Culotti, JG; Dennis, JW			The Caenorhabditis elegans gene, gly-2, can rescue the N-acetylglucosaminyltransferase V mutation of Lec4 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; EPITHELIAL INVAGINATION; FUCOSYL-TRANSFERASE; CDNA CLONING; PROTEIN; GLYCOSYLATION; GOLGI; EXPRESSION; OLIGOSACCHARIDES; RECOGNITION	UDP-N-acetylglucosamine:alpha-6-D-mannoside beta-1,6-N-acetylglucosaminyltransferase V (GlcNAc-TV) is a regulator of polylactosamine-containing N-glycans and is causally involved in T cell regulation and tumor metastasis. The Caenorhabditis elegans genome contains a single orthologous gene, gly-2, that is transcribed and encodes a 669-residue type II membrane protein that is 36.7% identical to mammalian GlcNAc-TV (Mgat-5). Recombinant GLY-2 possessed GlcNAc-TV activity when assayed in vitro, and protein truncations demonstrated that the N-terminal boundary of the catalytic domain is Ile-138. gly-2 complemented the Phaseolus vulgaris leucoagglutinin binding defect of Chinese hamster ovary Lec4 cells, whereas GLY-2(L116R), an equivalent mutation to that which causes the Lec4A phenotype, could not. We conclude that the worm gene is functionally interchangeable with the mammalian form. GlcNAc-TV activity was detected in wild-type animals but not those homozygous for a deletion allele of gly-2. Activity was restored in mutant animals by an extrachromosomal array that encompassed the gly-2 gene. Green fluorescent protein reporter transgenes driven by the gly-2 promoter were expressed by developing embryos from the late comma stage onward, present in a complex subset of neurons in larvae and, in addition, the spermathecal and pharyngeal-intestinal valves and certain vulval cells of adults. However, no overt phenotypes were observed in animals homozygous for deletion alleles of gly-2.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	dennis@mshri.on.ca	Culotti, Joseph/G-6467-2013; Dennis, James/E-7268-2013; Roy, Peter/G-5357-2014	Roy, Peter/0000-0003-2959-2276; Culotti, Joseph/0000-0001-6325-4612				Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BRENNER S, 1974, GENETICS, V77, P71; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; De Souza SJ, 1998, P NATL ACAD SCI USA, V95, P5094, DOI 10.1073/pnas.95.9.5094; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Epstein HF, 1995, METHODS CELL BIOL, V48; FITCH DHA, 1997, C ELEGANS, V2, P815; Fullekrug J, 1999, J CELL SCI, V112, P2813; Granovsky M, 2000, NAT MED, V6, P306; Granovsky M, 1995, GLYCOBIOLOGY, V5, P797, DOI 10.1093/glycob/5.8.797; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Harfe BD, 1998, DEVELOPMENT, V125, P421; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Korczak B, 2000, GLYCOBIOLOGY, V10, P595, DOI 10.1093/glycob/10.6.595; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAND M, 1994, J BIOL CHEM, V269, P14820; Liu LX, 1999, GENOME RES, V9, P859, DOI 10.1101/gr.9.9.859; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Riddle DL, 1997, C ELEGANS; Sacchetti A, 2001, FEBS LETT, V492, P151, DOI 10.1016/S0014-5793(01)02246-3; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Warren CE, 2002, GLYCOBIOLOGY, V12, p8G; Warren CE, 2001, GLYCOBIOLOGY, V11, P979, DOI 10.1093/glycob/11.11.979; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; Weinstein J, 1996, J BIOL CHEM, V271, P27462, DOI 10.1074/jbc.271.44.27462; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wood WB, 1988, NEMATODE CAENORHABDI; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	54	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22829	22838		10.1074/jbc.M201390200	http://dx.doi.org/10.1074/jbc.M201390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937505	hybrid			2022-12-25	WOS:000176313600093
J	Filippova, M; Song, H; Connolly, JL; Dermody, TS; Duerksen-Hughes, PJ				Filippova, M; Song, H; Connolly, JL; Dermody, TS; Duerksen-Hughes, PJ			The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; NF-KAPPA-B; FACTOR RECEPTOR; FACTOR-ALPHA; E6-ENHANCED SUSCEPTIBILITY; MEDIATED APOPTOSIS; UBIQUITIN LIGASE; HPV E6; ONCOPROTEIN; DEATH	High risk strains of human papillomavirus (HPV), such as HPV 16, cause human cervical carcinoma. The E6 protein of HPV 16 mediates the rapid degradation of p53, although this is not the only function of E6 and cannot completely explain its transforming potential. Previous work in our laboratory has demonstrated that transfection of HPV 16 E6 into the tumor necrosis factor (TNF)-sensitive LM cell line protects expressing cells from TNF-induced apoptosis in a p53-independent manner, and the purpose of this study was to determine the molecular mechanism underlying this protection. Caspase 3 and caspase 8 activation were significantly reduced in E6-expressing cells, indicating that E6 acts early in the TNF apoptotic pathway. In fact, E6 binds directly to TNF R1, as shown both by co-immunoprecipitation and mammalian two-hybrid approaches. E6 requires the same C-terminal portion of TNF R1 for binding as does TNF R1-associated death domain, and TNF R1/TNF R1-associated death domain interactions are decreased in the presence of E6. HA-E6 also blocked cell death triggered by transfection of the death domain of TNF R1. Together, these results provide strong support for a model in which HPV E6 binding to TNF R1 interferes with formation of the death-inducing signaling complex and thus with transduction of proapoptotic signals. They also demonstrate that HPV, like several other viruses, has developed a method for evading the TNF-mediated host immune response.	Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, Loma Linda, CA 92354 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA	Loma Linda University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Duerksen-Hughes, PJ (corresponding author), Loma Linda Univ, Sch Med, Ctr Mol Biol & Gene Therapy, Dept Biochem & Microbiol, 11085 Campus St,105 Mortensen Hall, Loma Linda, CA 92354 USA.	pdhughes@som.llu.edu	Duerksen-Hughes, Penelope/A-3488-2008	Duerksen-Hughes, Penelope/0000-0002-0998-2157	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIAID NIH HHS [AI50080] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benedict CA, 2001, J BIOL CHEM, V276, P3270, DOI 10.1074/jbc.M008218200; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Connolly JL, 2001, J VIROL, V75, P4029, DOI 10.1128/JVI.75.9.4029-4039.2001; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Fogel S, 1998, VIROLOGY, V244, P97, DOI 10.1006/viro.1998.9086; Gao QS, 1999, MOL CELL BIOL, V19, P733; GLAUSINGER BA, 2001, ONCOGENE, V19, P5270; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; GOODING LR, 1990, J IMMUNOL, V145, P3080; GOODING LR, 1990, CRIT REV IMMUNOL, V10, P53; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HOWLEY PM, 1992, PRINCESS TAKAMATSU S, V22, P239; Inoue T, 1998, MOL CARCINOGEN, V21, P215; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kukimoto I, 1998, BIOCHEM BIOPH RES CO, V249, P258, DOI 10.1006/bbrc.1998.9066; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Rapp L, 1999, ONCOGENE, V18, P607, DOI 10.1038/sj.onc.1202373; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Spitkovsky D, 1996, ONCOGENE, V13, P1027; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; TROSSMESILATY S, 1998, P NATL ACAD SCI USA, V95, P8058; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VAN AD, 1996, SCIENCE, V274, P787; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vikhanskaya F, 2002, INT J CANCER, V97, P732, DOI 10.1002/ijc.10114; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WONG GHW, 1992, ANTIVIRAL PROPERTIES; Yang J, 1998, CARCINOGENESIS, V19, P1117, DOI 10.1093/carcin/19.6.1117; Zhu NL, 2001, VIROLOGY, V283, P178, DOI 10.1006/viro.2001.0896; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	59	142	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21730	21739		10.1074/jbc.M200113200	http://dx.doi.org/10.1074/jbc.M200113200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934887	hybrid			2022-12-25	WOS:000176286000081
J	Kopriva, S; Buchert, T; Fritz, G; Suter, M; Benda, RD; Schunemann, V; Koprivova, A; Schurmann, P; Trautwein, AX; Kroneck, PMH; Brunold, C				Kopriva, S; Buchert, T; Fritz, G; Suter, M; Benda, RD; Schunemann, V; Koprivova, A; Schurmann, P; Trautwein, AX; Kroneck, PMH; Brunold, C			The presence of an iron-sulfur cluster in adenosine 5 '-phosphosulfate reductase separates organisms utilizing adenosine 5 '-phosphosulfate and phosphoadenosine 5 '-phosphosulfate for sulfate assimilation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-ADENYLYLSULFATE REDUCTASE; ESCHERICHIA-COLI; ADENYLYLSULPHATE REDUCTASE; ALLOCHROMATIUM-VINOSUM; CYSTEINE BIOSYNTHESIS; APS REDUCTASES; HIGHER-PLANTS; GENE; ADENOSINE-5'-PHOSPHOSULFATE; ENZYME	It was generally accepted that plants, algae, and phototrophic bacteria use adenosine 5'-phosphosulfate (APS) for assimilatory sulfate reduction, whereas bacteria and fungi use phosphoadenosine 5'-phosphosulfate (PAPS). The corresponding enzymes, APS and PAPS reductase, share 25-30% identical amino acids. Phylogenetic analysis of APS and PAPS reductase amino acid sequences from different organisms, which were retrieved from the GenBank(TM), revealed two clusters. The first cluster comprised known PAPS reductases from enteric bacteria, cyanobacteria, and yeast. On the other hand, plant APS reductase sequences were clustered together with many bacterial ones, including those from Pseudomonas and Rhizobium. The gene for APS reductase cloned from the APS-reducing cyanobacterium Plectonema also clustered together with the plant sequences, confirming that the two classes of sequences represent PAPS and APS reductases, respectively. Compared with the PAPS reductase, all sequences of the APS reductase cluster contained two additional cysteine pairs homologous to the cysteine residues involved in binding an iron-sulfur cluster in plants. Mossbauer analysis revealed that the recombinant APS reductase from Pseudomonas aeruginosa contains a [4Fe-4S] cluster with the same characteristics as the plant enzyme. We conclude, therefore, that the presence of an iron-sulfur cluster determines the APS specificity of the sulfate-reducing enzymes and thus separates the APS- and PAPS-dependent assimilatory sulfate reduction pathways.	Univ Freiburg, Inst Forest Bot & Tree Physiol, D-79085 Freiburg, Germany; Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Univ Freiburg, D-79104 Freiburg, Germany; Univ Neuchatel, Biochim Lab, CH-2000 Neuchatel, Switzerland	University of Freiburg; University of Konstanz; University of Zurich; University of Bern; University of Lubeck; University of Freiburg; University of Neuchatel	Kopriva, S (corresponding author), Univ Freiburg, Inst Forest Bot & Tree Physiol, Georges Kohler Allee Geb 053-054, D-79085 Freiburg, Germany.		Schünemann, Volker/C-6603-2016; Kopriva, Stanislav/C-7401-2013; Fritz, Guenter/E-2933-2013	Kopriva, Stanislav/0000-0002-7416-6551; Fritz, Guenter/0000-0002-4571-8812				Abola AP, 1999, J BACTERIOL, V181, P5280, DOI 10.1128/JB.181.17.5280-5287.1999; BERENDT U, 1995, EUR J BIOCHEM, V233, P347, DOI 10.1111/j.1432-1033.1995.347_1.x; Bick JA, 2000, J BACTERIOL, V182, P135, DOI 10.1128/JB.182.1.135-142.2000; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; BRUNOLD C, 1990, SULFUR NUTRITION AND SULFUR ASSIMILATION IN HIGHER PLANTS, P13; Brunold C., 1990, METHODS PLANT BIOCH, P339; DelicAttree I, 1997, MOL MICROBIOL, V24, P1275, DOI 10.1046/j.1365-2958.1997.4121799.x; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; Friedrich MW, 2002, J BACTERIOL, V184, P278, DOI 10.1128/JB.184.1.278-289.2002; Fritz G, 2000, FEBS LETT, V473, P63, DOI 10.1016/S0014-5793(00)01500-3; Gao Y, 2000, PLANT PHYSIOL, V123, P1087, DOI 10.1104/pp.123.3.1087; Gupta RS, 1998, MICROBIOL MOL BIOL R, V62, P1435, DOI 10.1128/MMBR.62.4.1435-1491.1998; Gupta RS, 2000, FEMS MICROBIOL REV, V24, P367, DOI 10.1111/j.1574-6976.2000.tb00547.x; GutierrezMarcos JF, 1996, P NATL ACAD SCI USA, V93, P13377, DOI 10.1073/pnas.93.23.13377; Hipp WM, 1997, MICROBIOL-UK, V143, P2891, DOI 10.1099/00221287-143-9-2891; JONESMORTIMER MC, 1973, HEREDITY, V31, P213, DOI 10.1038/hdy.1973.76; Kappler U, 2001, FEMS MICROBIOL LETT, V203, P1, DOI 10.1016/S0378-1097(01)00304-4; Kopriva S, 2001, J BIOL CHEM, V276, P42881, DOI 10.1074/jbc.M107424200; KREDICH NM, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P37; KRONE FA, 1991, MOL GEN GENET, V225, P314, DOI 10.1007/BF00269864; LAMPREIA J, 1990, EUR J BIOCHEM, V188, P653, DOI 10.1111/j.1432-1033.1990.tb15447.x; Leustek T, 2000, ANNU REV PLANT PHYS, V51, P141, DOI 10.1146/annurev.arplant.51.1.141; LEUSTEK T, 2000, SULFUR NUTR SULFUR A, P1; LI JY, 1991, BIOCHEM J, V274, P355, DOI 10.1042/bj2740355; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; Martin W, 1999, BIOESSAYS, V21, P99, DOI 10.1002/(SICI)1521-1878(199902)21:2<99::AID-BIES3>3.3.CO;2-2; Marzluf GA, 1997, ANNU REV MICROBIOL, V51, P73, DOI 10.1146/annurev.micro.51.1.73; Neumann S, 2000, MOL BIOL REP, V27, P27, DOI 10.1023/A:1007058421714; Postgate JR, 1984, SULPHATE REDUCING BA, V2nd; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez O, 2001, ARCH MICROBIOL, V176, P301, DOI 10.1007/s002030100327; SCHIFF JA, 1987, METHOD ENZYMOL, V143, P329; SCHMIDT A, 1977, FEMS MICROBIOL LETT, V1, P137, DOI 10.1016/0378-1097(77)90143-4; SCHMIDT A, 1977, EXPERIENTIA, V33, P1008, DOI 10.1007/BF01945936; Setya A, 1996, P NATL ACAD SCI USA, V93, P13383, DOI 10.1073/pnas.93.23.13383; SPEICH N, 1994, MICROBIOL-UK, V140, P1273, DOI 10.1099/00221287-140-6-1273; Suter M, 2000, J BIOL CHEM, V275, P930, DOI 10.1074/jbc.275.2.930; TRAUTWEIN AX, 1991, STRUCT BOND, V78, P1; TRUPER HG, 1982, PHILOS T ROY SOC B, V298, P529, DOI 10.1098/rstb.1982.0095; TSANG MLS, 1975, PLANT SCI LETT, V4, P301, DOI 10.1016/0304-4211(75)90102-9; TUOVINEN OH, 1975, ARCH MICROBIOL, V105, P123, DOI 10.1007/BF00447125; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; Weber M, 2000, EUR J BIOCHEM, V267, P3647, DOI 10.1046/j.1432-1327.2000.01394.x	46	79	84	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21786	21791		10.1074/jbc.M202152200	http://dx.doi.org/10.1074/jbc.M202152200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940598	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000176286000087
J	Montero-Lomeli, M; Morais, BLB; Figueiredo, DL; Neto, DCS; Martins, JRP; Masuda, CA				Montero-Lomeli, M; Morais, BLB; Figueiredo, DL; Neto, DCS; Martins, JRP; Masuda, CA			The initiation factor eIF4A is involved in the response to lithium stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; PROTEIN-SYNTHESIS; TRANSCRIPTIONAL RESPONSE; HELICASE ACTIVITY; TOR PROTEINS; GENES TIF1; YEAST; DEPLETION; ACTIVATOR; TAP42	A gene, TIF2, was identified as corresponding to the translation initiation factor eIF4A and when overexpressed it confers lithium tolerance in galactose medium to Saccharomyces cerevisiae. Incubation of yeast with 6 mm LiCl in galactose medium leads to inhibition of [S-35]methionine incorporation. By polysome analysis we show that translation is inhibited by lithium at the initiation step, accumulating 80 S monosomes. We further show by immunoblot analysis that when cells are incubated with lithium eIF4A does not sediment with ribosomal subunits. Overexpression of TIF2 overcomes inhibition of protein synthesis and restores its sedimentation with the initiation complex. In vivo, eIF4A is induced by lithium stress. We have shown previously that lithium is highly toxic to yeast when grown in galactose medium mainly due to inhibition of phosphoglucomutase, an enzyme responsible for the entry of galactose into glycolysis. We show that conditions that revert inhibition of phosphoglucomutase also revert inhibition of protein synthesis. Interestingly, glucose starvation leads to loss of polysomes but not to dissociation of eIF4A from the preinitiation complexes. Overexpression of SIT4, a protein phosphatase related to the TOR kinase pathway, reverts inhibition of protein synthesis by lithium and association of eIF4A with the initiation complex.	Univ Fed Rio de Janeiro, Dept Bioquim Med, ICB CCS, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Montero-Lomeli, M (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, ICB CCS, CP 68041, BR-21941590 Rio De Janeiro, Brazil.	montero@server.bioqmed.ufrj.br	Montero-Lomeli, Monica/D-9885-2013; Masuda, Claudio A/F-7214-2014	Masuda, Claudio A/0000-0002-0310-7108; Bozaquel Morais, Bruno Leonardo/0000-0001-5477-4851				Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BERG WE, 1968, EXP CELL RES, V50, P133, DOI 10.1016/0014-4827(68)90401-1; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BLUM S, 1989, P NATL ACAD SCI USA, V86, P6043, DOI 10.1073/pnas.86.16.6043; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dominguez D, 1999, J BIOL CHEM, V274, P26720, DOI 10.1074/jbc.274.38.26720; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; LINDER P, 1988, NUCLEIC ACIDS RES, V16, P10359, DOI 10.1093/nar/16.21.10359; LIU HP, 1992, GENETICS, V132, P665; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MartinezPastor MT, 1996, FEBS LETT, V390, P319, DOI 10.1016/0014-5793(96)00683-7; Masuda CA, 2001, J BIOL CHEM, V276, P37794; Masuda CA, 2000, J BIOL CHEM, V275, P30957, DOI 10.1074/jbc.M004869200; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schou M, 1997, ARCH GEN PSYCHIAT, V54, P9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tuite JF, 1988, METHOD MICROBIOL, V26, P351; WOLCOTT DL, 1982, EXP CELL RES, V137, P427, DOI 10.1016/0014-4827(82)90044-1; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	39	36	37	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21542	21548		10.1074/jbc.M201977200	http://dx.doi.org/10.1074/jbc.M201977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940596	hybrid			2022-12-25	WOS:000176286000056
J	Rodriguez, PC; Zea, AH; Culotta, KS; Zabaleta, J; Ochoa, JB; Ochoa, AC				Rodriguez, PC; Zea, AH; Culotta, KS; Zabaleta, J; Ochoa, JB; Ochoa, AC			Regulation of T cell receptor CD3 chain expression by L-arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE-SYNTHASE; SYNTHETASE GENE-EXPRESSION; MESSENGER-RNA STABILITY; AMINO-ACID REGULATION; ZETA-CHAIN; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; LIVER-TRANSPLANTATION; CLINICAL-SIGNIFICANCE; MACROPHAGE FUNCTIONS	L-Arg plays a central role in the normal function of several organ systems including the immune system. L-Arg can be depleted by arginase I produced by macrophages and hepatocytes in several disease states such as trauma and sepsis and following liver transplantation. The decrease in L-Arg levels induces a profound decrease in T cell function through mechanisms that have remained unclear. The data presented here demonstrate that Jurkat T cells cultured in medium without L-Arg (L-Arg-free RPMI) have a rapid decrease in the expression of the T cell antigen receptor zeta chain (CD3zeta), the principal signal transduction element in this receptor, and a decrease in T cell proliferation. This phenomenon is completely reversed by the replenishment Of L-Arg but not other amino acids. These changes are not caused by cell apoptosis; instead, the diminished expression of CD3zeta protein is paralleled by a decrease in CD3zeta mRNA, This change in CD3zeta mRNA expression is not caused by a decrease in the transcription rate but rather by a significantly shorter CD3zeta mRNA half-life. This mechanism is sensitive to cycloheximide. Therefore, the regulation Of L-Arg concentration in the microenvironment could represent an important mechanism to modulate the expression of CD3zeta and the T cell receptor and consequently of T cell function.	Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Tumor Immunol Program, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70112 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ochoa, AC (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Tumor Immunol Program, 533 Bolivar St,Rm 455, New Orleans, LA 70112 USA.	aochoa@lsuhsc.edu	Rodríguez, Paulo/HDM-9539-2022	Rodriguez, Paulo/0000-0001-7480-6566	NCI NIH HHS [CA82689-01, R21 CA831198, CA88885-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082689, R01CA088885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINA JE, 1989, J EXP MED, V169, P1021, DOI 10.1084/jem.169.3.1021; Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; Angele MK, 1999, J TRAUMA, V46, P34, DOI 10.1097/00005373-199901000-00006; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; Aulak KS, 1996, J BIOL CHEM, V271, P29799, DOI 10.1074/jbc.271.47.29799; Bernard AC, 2001, SHOCK, V15, P215, DOI 10.1097/00024382-200115030-00009; Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918; BRITTENDEN J, 1994, SURGERY, V115, P205; Bronstein-Sitton N, 1999, J BIOL CHEM, V274, P23659, DOI 10.1074/jbc.274.33.23659; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Bruhat A, 1999, P NUTR SOC, V58, P625, DOI 10.1017/S0029665199000828; Brzozowski T, 1997, J GASTROENTEROL, V32, P442, DOI 10.1007/BF02934081; Carraway MS, 1998, EXP LUNG RES, V24, P253, DOI 10.3109/01902149809041533; Chang CI, 1998, AM J PHYSIOL-HEART C, V274, pH342, DOI 10.1152/ajpheart.1998.274.1.H342; Chang CI, 2001, CANCER RES, V61, P1100; Chen X, 2000, BRIT J HAEMATOL, V111, P817, DOI 10.1046/j.1365-2141.2000.02415.x; Combadiere B, 1996, J EXP MED, V183, P2109, DOI 10.1084/jem.183.5.2109; Correa MR, 1997, J IMMUNOL, V158, P5292; Curiel RE, 1999, BLOOD, V94, P1782, DOI 10.1182/blood.V94.5.1782.417a04_1782_1789; Diah SK, 2001, BBA-GENE STRUCT EXPR, V1518, P267, DOI 10.1016/S0167-4781(01)00202-0; EIGUN S, 1999, INT UROL NEPHROL, V31, P95; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; GAZZOLA GC, 1972, BIOCHIM BIOPHYS ACTA, V266, P407, DOI 10.1016/0005-2736(72)90097-1; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Heys SD, 1997, BRIT J SURG, V84, P238, DOI 10.1002/bjs.1800840229; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Ikemoto M, 1998, CLIN CHIM ACTA, V271, P11, DOI 10.1016/S0009-8981(97)00226-X; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; KIRK SJ, 1992, JPEN-PARENTER ENTER, V16, P429, DOI 10.1177/0148607192016005429; Kono K, 1996, CLIN CANCER RES, V2, P1825; Kono K, 1996, EUR J IMMUNOL, V26, P1308, DOI 10.1002/eji.1830260620; Kuss I, 1999, CLIN CANCER RES, V5, P329; LANGLE F, 1995, TRANSPLANT P, V27, P2872; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; MENDEZ JD, 1992, BIOCHEM INT, V28, P569; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Morris SM, 1998, AM J PHYSIOL-ENDOC M, V275, pE740, DOI 10.1152/ajpendo.1998.275.5.E740; Munder M, 1998, J IMMUNOL, V160, P5347; MURRAY HW, 1992, J INFECT DIS, V165, P513, DOI 10.1093/infdis/165.3.513; Nambiar MP, 2000, J CELL BIOCHEM, V79, P416, DOI 10.1002/1097-4644(20001201)79:3<416::AID-JCB70>3.0.CO;2-5; NATHAN C, 1991, RES IMMUNOL, V142, P600, DOI 10.1016/0923-2494(91)90117-2; NATHAN C, 1991, Behring Institute Mitteilungen, P200; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Ochoa JB, 2000, SURGERY, V127, P419, DOI 10.1067/msy.2000.104745; Ochoa JB, 2001, JPEN-PARENTER ENTER, V25, P23, DOI 10.1177/014860710102500123; Porembska Z, 2001, CLIN CHIM ACTA, V305, P157, DOI 10.1016/S0009-8981(00)00432-0; Quillard M, 1996, EUR J BIOCHEM, V236, P56, DOI 10.1111/j.1432-1033.1996.00056.x; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROTH E, 1994, TRANSPLANTATION, V57, P665, DOI 10.1097/00007890-199403150-00006; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAINI KS, 1990, MOL CELL BIOCHEM, V96, P15; Schmielau J, 2001, CLIN CANCER RES, V7, p933S; SUER GS, 1999, CANC BIOCH BIOPHYS, V17, P125; Taheri F, 2001, CLIN CANCER RES, V7, p958S; Taylor DD, 2001, BRIT J CANCER, V84, P1624, DOI 10.1054/bjoc.2001.1847; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, J IMMUNOL, V141, P3532; WU CW, 1994, J CLIN GASTROENTEROL, V18, P84, DOI 10.1097/00004836-199401000-00019; WU CW, 2001, CHINESE J MICROBIOL, V20, P279; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zea AH, 1995, CLIN CANCER RES, V1, P1327; Zea AH, 1998, INFECT IMMUN, V66, P499, DOI 10.1128/IAI.66.2.499-504.1998; ZHANG C, 2001, FASEB J	71	334	359	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21123	21129		10.1074/jbc.M110675200	http://dx.doi.org/10.1074/jbc.M110675200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11950832	hybrid			2022-12-25	WOS:000176286000004
J	Bernards, AS; Miller, JK; Bao, KK; Wong, I				Bernards, AS; Miller, JK; Bao, KK; Wong, I			Flipping duplex DNA inside out - A double base-flipping reaction mechanism by Escherichia coli MutY adenine glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; MISMATCH REPAIR ENZYME; MITOCHONDRIAL DECAY; NUCLEOTIDE EXCISION; SUBSTRATE-ANALOGS; CRYSTAL-STRUCTURE; OXIDATIVE DAMAGE; RECOGNITION; FLUORESCENCE; SPECIFICITY	The Escherichia coli MutY adenine glycosylase plays a critical role in repairing mismatches in DNA between adenine and the oxidatively damaged guanine base 8-oxoguanine. Crystallographic studies of the catalytic core domain of MutY show that the scissile adenine is extruded from the DNA helix to be bound in the active site of the enzyme (Guan, Y., Manuel, R. C., Arvai, A. S., Parikh, S. S., Mol, C. D., Miller, J. H., Lloyd, S., and Tainer, J. A (1998) Nat. Struct. Biol. 5,1058-1064). However, the structural and mechanistic bases for the recognition of the 8-oxoguanine remain poorly understood. In experiments using a single-stranded 8-bromoguanine-containing synthetic oligodeoxyribonuclelotide alone and in a duplex construct mismatched to an adenine, we observed UV cross-linking between MutY and the 8-bromoguanine probe. We further observed enhanced cross-linking in the single strand experiments, suggesting that neither the duplex context nor the mismatch with adenine is required for recognition of the 8-oxoguanine moiety. Stopped-flow fluorescence studies using 2-aminopurine-containing oligodeoxyribonucleotides further revealed the sequential extrusion of the 8-oxoguanine at 108 s(-1) followed by the adenine at 16 s(-1). A protein isomerization step following base flipping at 1.9 s(-1) was also observed and is postulated to provide additional stabilization of the extruded adenine thereby facilitating its capture by the active site for excision.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 Agr & Life Sci Bldg, Corvallis, OR 97331 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 58771] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Bao KK, 2002, J BIOL CHEM, V277, P12089, DOI 10.1074/jbc.M111315200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Bulychev NV, 1996, BIOCHEMISTRY-US, V35, P13147, DOI 10.1021/bi960694h; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GANNETT PM, 1993, CHEM RES TOXICOL, V6, P690, DOI 10.1021/tx00035a015; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Hornby DP, 1998, CURR OPIN BIOTECH, V9, P354, DOI 10.1016/S0958-1669(98)80007-4; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; House PG, 2001, PROG NUCLEIC ACID RE, V68, P349; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Li XH, 2000, NUCLEIC ACIDS RES, V28, P4593, DOI 10.1093/nar/28.23.4593; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; Lloyd RS, 1997, BIOPOLYMERS, V44, P139; Lu AL, 2000, METH MOL B, V152, P3; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; Morikawa K, 2000, MUTAT RES-DNA REPAIR, V460, P257, DOI 10.1016/S0921-8777(00)00031-8; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; O'Gara M, 1998, NAT STRUCT BIOL, V5, P872, DOI 10.1038/2312; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WONG I, 2002, IN PRESS J BIOL CHEM, V277	43	48	51	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20960	20964		10.1074/jbc.C200181200	http://dx.doi.org/10.1074/jbc.C200181200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11964390	hybrid			2022-12-25	WOS:000176204500110
J	Brandt, D; Gimona, M; Hillmann, M; Haller, H; Mischak, H				Brandt, D; Gimona, M; Hillmann, M; Haller, H; Mischak, H			Protein kinase C induces actin reorganization via a Src- and Rho-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-ASSOCIATED PROTEINS; CELL-CYCLE PROGRESSION; FOCAL ADHESION KINASE; NIH 3T3 FIBROBLASTS; TYROSINE PHOSPHORYLATION; PHORBOL ESTER; ENDOTHELIAL-CELLS; STRESS FIBERS; P190 RHOGAP; PKC-DELTA	We have investigated the mechanism of PKC-induced actin reorganization in A7r5 vascular smooth muscle cells. PKC activation by 12-O-tetradecanoylphorbol-13-acetate induces the disassembly of actin stress fibers concomitant with the appearance of membrane ruffles. PKC also induces rapid tyrosine phosphorylation in these cells. As we could show, utilizing the Sre-specific inhibitor PP2 and a kinase-deficient c-Sre mutant, actin reorganization is dependent on PKC-induced Src activation. Subsequently, the activity of the small G-protein RhoA is decreased, whereas Rac and Cdc42 activities remain unchanged. Disassembly of actin stress fibers could also be observed using the Rho kinase-specific inhibitor Y-27632, indicating that the decrease in RhoA activity on its own is responsible for actin reorganization. In addition, we show that tyrosine phosphorylation of p190RhoGAP is increased upon 12-O-tetradecanoylphorbol-13-acetate stimulation, directly linking Src activation to a decrease in RhoA activity. Our data provide substantial evidence for a model elucidating the molecular mechanisms of PKC-induced actin rearrangements.	Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany; Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria	Hannover Medical School; Austrian Academy of Sciences	Mischak, H (corresponding author), Hannover Med Sch, Dept Nephrol, Feodor Lynen Str 5, D-30625 Hannover, Germany.		Mischak, Harald/E-8685-2011	Mischak, Harald/0000-0003-0323-0306				Adams JC, 1999, MOL BIOL CELL, V10, P4177, DOI 10.1091/mbc.10.12.4177; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BEUG H, 1978, CELL, V14, P834; Borowski P, 1999, BIOL CHEM, V380, P403, DOI 10.1515/BC.1999.054; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Caloca MJ, 2001, J BIOL CHEM, V276, P18303, DOI 10.1074/jbc.M011368200; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHANG JH, 1993, ONCOGENE, V8, P959; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; Coghlan MP, 2000, MOL CELL BIOL, V20, P2880, DOI 10.1128/MCB.20.8.2880-2889.2000; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Emkey R, 1997, J BIOL CHEM, V272, P31182, DOI 10.1074/jbc.272.49.31182; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Fagerstrom S, 1998, J BIOL CHEM, V273, P2336, DOI 10.1074/jbc.273.4.2336; Fincham VJ, 1999, J CELL SCI, V112, P947; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Haskell MD, 2001, J CELL SCI, V114, P1699; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; NEWTON AC, 1995, J BIOL CHEM, V270, P28496; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Uberall F, 1999, J CELL BIOL, V144, P413, DOI 10.1083/jcb.144.3.413; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; VAN AL, 1997, GENE DEV, V11, P2295; Vincent S, 1999, EUR J CELL BIOL, V78, P539, DOI 10.1016/S0171-9335(99)80019-3; WERTH DK, 1983, J BIOL CHEM, V258, P1423; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	66	116	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20903	20910		10.1074/jbc.M200946200	http://dx.doi.org/10.1074/jbc.M200946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925438	hybrid			2022-12-25	WOS:000176204500103
J	Smith, RWP; Steffen, C; Grosse, F; Nasheuer, HP				Smith, RWP; Steffen, C; Grosse, F; Nasheuer, HP			Species specificity of simian virus 40 DNA replication in vitro requires multiple functions of human DNA polymerase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; PROTEIN-A; COMPLEX-FORMATION; PRIMASE ACTIVITY; P48 CONTROL; INITIATION; SUBUNIT; POLYOMAVIRUS; ORIGIN; BINDING	Human cell extracts support the replication of SV40 DNA, whereas mouse cell extracts do not. Species specificity is determined at the level of initiation of DNA replication, and it was previously found that this requires the large subunit, p180, of DNA polymerase a-primase to be of human origin. Furthermore, a functional interaction between SV40 large T antigen (TAg) and p180 is essential for viral DNA replication. In this study we determined that the N-terminal regions of human p180, which contain the TAg-binding sites, can be replaced with those of murine origin without losing the ability to support SV40 DNA replication in vitro. The same substitutions do not prevent SV40 TAg from stimulating the activity of DNA polymerase a-primase on single-stranded DNA in the presence of replication protein A. Furthermore, biophysical studies show that the interactions of human and murine DNA polymerase a-primase with SV40 TAg are of a similar magnitude. These studies strongly suggest that requirement of SV40 DNA replication for human DNA polymerase a depends neither on the TAg-binding site being of human origin nor on the strength of the binary interaction between SV40 TAg and DNA polymerase a-primase but rather on sequences in the C-terminal region of human p180.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany		Nasheuer, HP (corresponding author), Inst Mol Biotechnol, Biochem Abt, Beutenbergstr 11, D-07745 Jena, Germany.	nasheuer@imb-jena.de	Smith, Richard/J-8117-2019; Nasheuer, Heinz P./B-9025-2008	Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079				BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; EKI T, 1991, J VIROL, V65, P4874, DOI 10.1128/JVI.65.9.4874-4881.1991; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GANNON J V, 1990, New Biologist, V2, P84; Hassell J, 1996, DNA REPLICATION EUKA, P639; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; Kautz AR, 2001, J VIROL, V75, P1751, DOI 10.1128/JVI.75.4.1751-1760.2001; Kautz AR, 2001, J VIROL, V75, P8569, DOI 10.1128/JVI.75.18.8569-8578.2001; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KUHN C, 1998, THESIS F SCHILLER U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Mizuno T, 1999, MOL CELL BIOL, V19, P7886; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; Nesper J, 1997, J VIROL, V71, P7421, DOI 10.1128/JVI.71.10.7421-7428.1997; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider A, 1998, J BIOL CHEM, V273, P21608, DOI 10.1074/jbc.273.34.21608; SCHNEIDER C, 1994, MOL CELL BIOL, V14, P3176, DOI 10.1128/MCB.14.5.3176; Schub O, 2001, J BIOL CHEM, V276, P38076; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; Smith RWP, 2000, REC RES DEV VIROL, V2, P67; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TSENG BY, 1983, J BIOL CHEM, V258, P9845; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang M, 2000, NUCLEIC ACIDS RES, V28, P4742, DOI 10.1093/nar/28.23.4742; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; [No title captured]	59	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20541	20548		10.1074/jbc.M201908200	http://dx.doi.org/10.1074/jbc.M201908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927598	hybrid			2022-12-25	WOS:000176204500058
J	Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC				Jiang, YQ; Harlocker, SL; Molesh, DA; Dillon, DC; Stolk, JA; Houghton, RL; Repasky, EA; Badaro, R; Reed, SG; Xu, JC			Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays	ONCOGENE			English	Article						breast cancer; genes; PCR-based cDNA subtraction; cDNA microarray; quantitative PCR	TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; PROSTATE-CANCER; IDENTIFICATION; MAMMAGLOBIN; TISSUE; IMMUNOTHERAPY; LYMPHOCYTES; MUSCIMOL; KERATIN	Identifying novel and known genes that are differentially expressed in breast cancer has important implications in understanding the biology of breast tumorigenesis and developing new diagnostic and therapeutic agents. In this study we have combined two powerful technologies, PCR-based cDNA subtraction and cDNA microarray, as a high throughput methodology designed to identify cDNA clones that are breast tumor- and tissue-specific and are overexpressed in breast tumors. Approximately 2000 cDNA clones generated from the subtracted breast tumor library were arrayed on the microarray chips. The arrayed target cDNAs were then hybridized with 30 pairs of fluorescent-labeled cDNA probes generated from breast tumors and normal tissues to determine the tissue distribution and tumor specificity. cDNA clones showing overexpression in breast tumors by microarray were further analysed by DNA sequencing, GenBank and EST database searches, and quantitative real time PCR. We identified several known genes, including mammaglobin, cytokeratin 19, fibronectin, and hair-specific type 11 keratin, which have previously been shown to be overexpressed in breast tumors and may play an important rote in the malignance of breast. We also discovered B726P which appears to be an isoform of NY-BR-1, a breast tissue-specific gene. Two additional clones discovered, B709P and GABA(A) receptor pi subunit, were not previously described for their overexpression profile in breast tumors. Thus, combining PCR-based cDNA subtraction and cDNA microarray allowed for an efficient way to identify and validate genes with elevated mRNA expression levels in breast cancer that may potentially be involved in breast cancer progression. These differentially expressed genes may be of potential utility as therapeutic and diagnostic targets for breast cancer.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Hosp Aristides Maltez, Salvador, BA, Brazil; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Jiang, YQ (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	jiang@corixa.com			NATIONAL CANCER INSTITUTE [R43CA075794, R44CA075794] Funding Source: NIH RePORTER; NCI NIH HHS [CA75794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMENTA F, 1988, PHARMACOL RES, V20, P863, DOI 10.1016/0031-6989(88)90003-3; Apostolopoulos V, 1996, IMMUNOL CELL BIOL, V74, P457, DOI 10.1038/icb.1996.76; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Bertin N, 1997, CANCER RES, V57, P396; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; Colpitts TL, 2001, BIOCHEMISTRY-US, V40, P11048, DOI 10.1021/bi010284f; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1997, ADV CANCER RES, V71, P343, DOI 10.1016/S0065-230X(08)60103-7; ERDO SL, 1989, BRIT J PHARMACOL, V96, P313, DOI 10.1111/j.1476-5381.1989.tb11819.x; Fleming TP, 2000, ANN NY ACAD SCI, V923, P78, DOI 10.1111/j.1749-6632.2000.tb05521.x; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Hoch RV, 1999, INT J CANCER, V84, P122; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Jager D, 2001, CANCER RES, V61, P2055; Jones KA, 1995, CANCER SURV, V25, P315; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lopez-Otin C, 1998, ENDOCR REV, V19, P365, DOI 10.1210/er.19.4.365; LORIDONROSA B, 1990, CANCER RES, V50, P1608; MAJEWSKA MD, 1991, J ENDOCRINOL, V131, P427, DOI 10.1677/joe.0.1310427; MCKENZIE IFC, 1990, CANCER CELL-MON REV, V2, P75; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OZTURK M, 1992, BONE MARROW TRANSPL, V9, P164; Regnier CH, 1998, BRIT J CANCER, V78, P1640, DOI 10.1038/bjc.1998.736; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Turner BC, 1998, CANCER RES, V58, P5466; Walker RA, 1997, CANCER METAST REV, V16, P5, DOI 10.1023/A:1005740222307; Watson MA, 1999, CANCER RES, V59, P3028; Watson MA, 1996, CANCER RES, V56, P860; Xu JC, 2000, CANCER RES, V60, P1677	38	66	74	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2270	2282		10.1038/sj.onc.1205278	http://dx.doi.org/10.1038/sj.onc.1205278			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948410				2022-12-25	WOS:000174555300016
J	Yuan, LWC; Giordano, A				Yuan, LWC; Giordano, A			Acetyltransferase machinery conserved in p300/CBP-family proteins	ONCOGENE			English	Article						p300; CBP; PCAT; histone/protein acetyltransferase; protein domains; protein structure	MULTIPLE SEQUENCE ALIGNMENT; TRANSCRIPTIONAL COACTIVATOR; DROSOPHILA CBP; DNA-BINDING; P300; ACETYLATION; CBP/P300; ACTIVATION; CHROMATIN; GENE	CREB-binding protein (CBP) and p300 are highly, conserved and functionally related transcription coactivators and histone/protein acetyltransferases. They are, tumor suppressors, participate in a wide variety of physiological events, and serve as integrators among different signal transduction pathways. In this study, 11 distinct proteins that have a high degree of homology with the amino acid sequence of p300 have been identified in current protein databases. All of these, 11 proteins belong to either animal or plant multicellular organisms (higher eucaryotes). Conservation of p300/ CBP domains among these proteins was examined further by sequence alignment and pattern search. The domains of p300/CBP that are required for the HAT function, including PHD, putative CoA-binding, and ZZ domains, are conserved in all of these 11 proteins. This observation is consistent with the previous functional assays and indicates that they are a family of acetyltransferases, i.e. p300/CBP acetyltransferases (PCAT). TAZ domains (TAZ1 and/or TAZ2) of PCAT proteins may allow them to participate in transcription regulation by either directly recruiting transcription factors, acetylating them subsequently, or directing targeted acetylation of nucleosomal histones.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Jefferson University; Boston University	Giordano, A (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.	agiordan@lac.jci.tju.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P589, DOI 10.1093/nar/29.3.589; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	54	38	42	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2253	2260		10.1038/sj.onc.1205283	http://dx.doi.org/10.1038/sj.onc.1205283			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948408				2022-12-25	WOS:000174555300014
J	Xie, ZJ; Munson, SJ; Huang, NW; Portale, AA; Miller, WL; Bikle, DD				Xie, ZJ; Munson, SJ; Huang, NW; Portale, AA; Miller, WL; Bikle, DD			The mechanism of 1,25-dihydroxyvitamin D-3 autoregulation in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RESPONSIVE ELEMENTS; VITAMIN-D METABOLISM; MOLECULAR-CLONING; DIFFERENTIATION; 24-HYDROXYLASE; GENE; CDNA; PROMOTER; GROWTH; 1-ALPHA,25-DIHYDROXYVITAMIN-D3	The synthesis of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) from its precursor, 25-dihydroxyvitamin D-3 (25(OH)D-3), is catalyzed by the mitochondrial cytochrome P450 enzyme 25-hydroxyvitamin D-3-1alpha-hydroxylase (1alpha-hydroxylase). It has been generally assumed that 1,25(OH)(2)D-3 inhibits the activity of this enzyme by regulating its expression at the genomic level. We confirmed that 1,25(OH)(2)D-3 reduced the apparent conversion of 1,25(OH)D-3 to 1,25(OH)(2)D-3 while stimulating the conversion of 1,25(OH)(2)D-3 and 25(OH)D-3 to 1,24,25(OH)(3)D-3 and 24,25(OH)(2)D-3, respectively. However, 1,25(OH)(2)D-3 failed to reduce the abundance of its mRNA or its encoded protein in human keratinocytes. Instead, when catabolism of 1,25(OH)(2)D-3 was blocked with a specific inhibitor of the 25-hydroxyvitamin D-3-24-hydroxylase (24-hydroxylase) all apparent inhibition of la-hydroxylase activity by 1,25(OH)(2)D-3 was reversed. Thus, the apparent reduction in la-hydroxylase activity induced by 1,25(OH)(2)D-3 is due to increased catabolism of both substrate and product by the 24-hydroxylase. We believe this to be a unique mechanism for autoregulation of steroid hormone synthesis.	Univ Calif San Francisco, Endocrine Unit, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; No Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Xie, ZJ (corresponding author), Univ Calif San Francisco, Endocrine Unit, Vet Affairs Med Ctr, 4150 Clement St 111N, San Francisco, CA 94121 USA.		Miller, Walter L/J-3696-2012; xie, zhongjian/K-7858-2016	xie, zhongjian/0000-0002-4328-1303				BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BIKLE DD, 1993, J INVEST DERMATOL, V101, P713, DOI 10.1111/1523-1747.ep12371681; BIKLE DD, 1986, J CLIN INVEST, V78, P557, DOI 10.1172/JCI112609; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HOSOMI J, 1983, ENDOCRINOLOGY, V113, P1950, DOI 10.1210/endo-113-6-1950; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kong XF, 1999, P NATL ACAD SCI USA, V96, P6988, DOI 10.1073/pnas.96.12.6988; MATSUMOTO K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P311, DOI 10.1016/S0167-4889(97)90006-9; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; PILLAI S, 1988, J BIOL CHEM, V263, P5390; Schuessler M, 2001, STEROIDS, V66, P399, DOI 10.1016/S0039-128X(00)00229-4; Schuster I, 2001, STEROIDS, V66, P451, DOI 10.1016/S0039-128X(00)00166-5; Schuster I, 2001, STEROIDS, V66, P409, DOI 10.1016/S0039-128X(00)00159-8; SHERWOOD LM, 1987, NEW ENGL J MED, V316, P1601, DOI 10.1056/NEJM198706183162511; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Zhang MYH, 2002, ENDOCRINOLOGY, V143, P587, DOI 10.1210/en.143.2.587	26	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36987	36990		10.1074/jbc.M201404200	http://dx.doi.org/10.1074/jbc.M201404200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	11956203	hybrid			2022-12-25	WOS:000178447100012
J	Shimizu, H; Burch, LR; Smith, AJ; Dornan, D; Wallace, M; Ball, KL; Hupp, TR				Shimizu, H; Burch, LR; Smith, AJ; Dornan, D; Wallace, M; Ball, KL; Hupp, TR			The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; TERMINAL REGULATORY DOMAIN; WILD-TYPE P53; DNA-BINDING; P53-DEPENDENT TRANSCRIPTION; MUTANT P53; T-ANTIGEN; SV40-TRANSFORMED CELLS; ONCOPROTEIN MDM2; CYCLIN-A	Although the N-terminal BOX-I domain of the tumor suppressor protein p53 contains the primary docking site for MDM2, previous studies demonstrated that RNA stabilizes the MDM2(.)p53 complex using a p53 mutant lacking the BOX-I motif. In vitro assays measuring the specific activity of MDM2 in the ligand-free and RNA-bound state identified a novel MDM2 interaction site in the core domain of p53. As defined using phage-peptide display, the RNA(.)MDM2 isoform exhibited a notable switch in peptide binding specificity, with enhanced affinity for novel peptide sequences in either p53 or small nuclear ribonucleoprotein-U (snRNP-U) and substantially reduced affinity for the primary p53 binding site in the BOX-I domain. The consensus binding site for the RNA(.)MDM2 complex within p53 is SGXLLGESXF, which links the S9-S10 beta-sheets flanking the BOX-IV and BOX-V motifs in the core domain and which is a site of reversible conformational flexibility in p53. Mutation of conserved amino acids in the linker at Ser(261) and Leu(264), which bridges the S9-S10 beta-sheets, stimulated p53 activity from reporter templates and increased MDM2-dependent ubiquitination of p53. Furthermore, mutation of the conserved Phe(270) within the S10 beta-sheet resulted in a mutant p53, which binds more stably to RNA(.)MDM2 complexes in vitro and which is strikingly hyper-ubiquitinated in vivo. Introducing an Ala(19) mutation into the p53(F270A) protein abolished both RNA(.)MDM2 complex binding and hyper-ubiquitination in vivo, thus indicating that p53(F270A) protein hyper-ubiquitination depends upon MDM2 binding to its primary site in the BOX-I domain. Together, these data identify a novel MDM2 binding interface within the S9-S10 beta-sheet region of p53 that plays a regulatory role in modulating the rate of MDM2-dependent ubiquitination of p53 in cells.	Univ Dundee, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Canc Res UK Labs, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.							Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Berger M, 2001, J BIOL CHEM, V276, P3785, DOI 10.1074/jbc.M008879200; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARSTON NJ, 1995, ONCOGENE, V10, P1709; Mateu MG, 1999, NAT STRUCT BIOL, V6, P191; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; SCHEER U, 1994, CURR OPIN CELL BIOL, V6, P354, DOI 10.1016/0955-0674(94)90026-4; Shieh SY, 2000, GENE DEV, V14, P289; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wasylyk C, 2000, MOL CELL BIOL, V20, P5554, DOI 10.1128/MCB.20.15.5554-5570.2000; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xirodimas DP, 1999, J BIOL CHEM, V274, P28042, DOI 10.1074/jbc.274.39.28042	64	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28446	28458		10.1074/jbc.M202296200	http://dx.doi.org/10.1074/jbc.M202296200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	11925449	hybrid			2022-12-25	WOS:000177342600015
J	Walters, RW; Pilewski, JM; Chiorini, JA; Zabner, J				Walters, RW; Pilewski, JM; Chiorini, JA; Zabner, J			Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ADENOASSOCIATED VIRUS; NONTYPABLE HAEMOPHILUS-INFLUENZAE; AIRWAY EPITHELIA; SIALIC-ACID; FACTOR-IX; GLYCOPROTEINS; TRANSDUCTION; EXPRESSION; BINDING; CLONING	Adeno-associated virus (AAV) is a promising vector for gene transfer in cystic fibrosis. AAV4 and AAV5 both bind to the apical surface of differentiated human airway epithelia, but only AAV5 infects. Both AAV4 and AAV5 require 2,3-linked sialic acid for binding. However, AAV5 interacts with sialic acid on N-linked carbohydrates, whereas AAV4 interacts with sialic acid on O-linked carbohydrates. Because mucin is decorated with O-linked carbohydrates, we hypothesized that mucin binds AAV4 and inhibits gene transfer. To evaluate the effect of secreted mucin, we studied mucin binding and gene transfer to COS cells and the basolateral membrane of well differentiated human airway epithelia. AAV4 bound mucin more efficiently than AAV5, and mucin inhibited gene transfer with AAV4. Moreover, O-glycosidase-pretreated mucin did not block gene transfer with AAV4. Similar to secreted mucin, the transmembrane mucin MUC1 inhibited gene transfer with AAV4 but not AAV5. MUC1 inhibited AAV4 by blocking internalization of the virus. Thus, O-linked carbohydrates of mucin are potent inhibitors of AAV4. Furthermore, whereas mucin plays an important role in innate host defense, its activity is specific; some vectors or pathogens are more resistant to its effects.	NIDCR, Gene Therapeut Branch, NIH, Bethesda, MD 20902 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Iowa; University of Iowa; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zabner, J (corresponding author), NIDCR, Gene Therapeut Branch, NIH, 10-1N113,10 Ctr Dr,MSC 1190, Bethesda, MD 20902 USA.	joseph-zabner@uiowa.edu	Pilewski, Joseph/AAF-5149-2021	Zabner, Joseph/0000-0002-9606-1339	NIDDK NIH HHS [T30DK54759] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alisky JM, 2000, NEUROREPORT, V11, P2669, DOI 10.1097/00001756-200008210-00013; Arcasoy SM, 1997, AM J RESP CELL MOL, V17, P422, DOI 10.1165/ajrcmb.17.4.2714; Auricchio A, 2001, MOL THER, V4, P372, DOI 10.1006/mthe.2001.0462; BAUM GL, 1998, MUCUS MUCOCILIARY IN, P253; Beck SE, 1999, J VIROL, V73, P9446, DOI 10.1128/JVI.73.11.9446-9455.1999; Bernstein JM, 2000, OTOLARYNG HEAD NECK, V122, P514, DOI 10.1016/S0194-5998(00)70093-3; Bisaillon M, 1999, J MOL BIOL, V286, P759, DOI 10.1006/jmbi.1998.2495; CHEN CC, 1993, GASTROENTEROLOGY, V105, P84, DOI 10.1016/0016-5085(93)90013-3; Chiorini JA, 1997, J VIROL, V71, P6823, DOI 10.1128/JVI.71.9.6823-6833.1997; Chiorini JA, 1999, J VIROL, V73, P1309, DOI 10.1128/JVI.73.2.1309-1319.1999; CORFIELD AP, 1991, GLYCOCONJUGATE J, V8, P330, DOI 10.1007/BF00731345; DAVIES J, 1995, INFECT IMMUN, V63, P2485, DOI 10.1128/IAI.63.7.2485-2492.1995; Duan DS, 1998, HUM GENE THER, V9, P2761, DOI 10.1089/hum.1998.9.18-2761; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; FLOTTE TR, 1993, J BIOL CHEM, V268, P3781; FLOTTE TR, 1995, GENE THER, V2, P357; GENTSCH JR, 1985, J VIROL, V56, P356, DOI 10.1128/JVI.56.2.356-364.1985; Hildinger M, 2001, J VIROL, V75, P6199, DOI 10.1128/JVI.75.13.6199-6203.2001; HIRST GK, 1950, J EXP MED, V91, P161, DOI 10.1084/jem.91.2.161; Hofling K, 1997, J GEN VIROL, V78, P567; Kaludov N, 2001, J VIROL, V75, P6884, DOI 10.1128/JVI.75.15.6884-6893.2001; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; KONDO M, 1991, AM J PHYSIOL, V261, pL106, DOI 10.1152/ajplung.1991.261.2.L106; KUBIET M, 1995, INFECT IMMUN, V63, P899, DOI 10.1128/IAI.63.3.899-902.1995; Kurpad C, 1999, J HEMATOTH STEM CELL, V8, P585, DOI 10.1089/152581699319740; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Reddy MS, 1997, OTOLARYNG HEAD NECK, V116, P175, DOI 10.1016/S0194-5998(97)70321-8; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SIMS DE, 1991, BIOTECH HISTOCHEM, V66, P173, DOI 10.3109/10520299109109965; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Teramoto S, 1998, J VIROL, V72, P8904, DOI 10.1128/JVI.72.11.8904-8912.1998; THURSTON RJ, 1976, J ULTRA MOL STRUCT R, V56, P39, DOI 10.1016/S0022-5320(76)80139-6; Wagner JA, 1998, LANCET, V351, P1702, DOI 10.1016/S0140-6736(05)77740-0; Walters RW, 2000, J VIROL, V74, P535, DOI 10.1128/JVI.74.1.535-540.2000; Walters RW, 2001, J BIOL CHEM, V276, P20610, DOI 10.1074/jbc.M101559200; WILLOUGHBY RE, 1993, GLYCOBIOLOGY, V3, P437, DOI 10.1093/glycob/3.5.437; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; YOLKEN RH, 1987, J CLIN INVEST, V79, P148, DOI 10.1172/JCI112775; YOLKEN RH, 1992, J CLIN INVEST, V90, P1984, DOI 10.1172/JCI116078; Zabner J, 2000, J VIROL, V74, P3852, DOI 10.1128/JVI.74.8.3852-3858.2000; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996	43	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23709	23713		10.1074/jbc.M200292200	http://dx.doi.org/10.1074/jbc.M200292200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11925433	hybrid			2022-12-25	WOS:000176475700080
J	Davis, DB; Doherty, KR; Delmonte, AJ; McNally, EM				Davis, DB; Doherty, KR; Delmonte, AJ; McNally, EM			Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; PROTEIN-KINASE-C; MIYOSHI MYOPATHY; CAENORHABDITIS-ELEGANS; DYSFERLIN MUTATION; SYNAPTOTAGMIN-I; MYOBLAST FUSION; SKELETAL-MUSCLE; MEMBRANE; GENE	Mutations in dysferlin, a novel membrane protein of unknown function, lead to muscular dystrophy. Myoferlin is highly homologous to dysferlin and like dysferlin is a plasma membrane protein with six C2 domains highly expressed in muscle. C2 domains are found in a variety of membrane-associated proteins where they have been implicated in calcium, phospholipid, and protein-binding. We investigated the pattern of dysferlin and myoferlin expression in a cell culture model of muscle development and found that dysferlin is expressed in mature myotubes. In contrast, myoferlin is highly expressed in elongated "prefusion" myoblasts and is decreased in mature myotubes where dysferlin expression is greatest. We tested ferlin C2 domains for their ability to bind phospholipid in a calcium-sensitive manner. We found that C2A, the first C2 domain of dysferlin and myoferlin, bound 50% phosphatidylserine and that phospholipid binding was regulated by calcium concentration. A dysferlin point mutation responsible for muscular dystrophy was engineered into the dysferlin C2A domain and demonstrated reduced calcium-sensitive phospholipid binding. Based on these data, we propose a mechanism for muscular dystrophy in which calcium-regulated phospholipid binding is abnormal, leading to defective maintenance and repair of muscle membranes.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland,Rm G611,MC 6088, Chicago, IL 60637 USA.		Davis, Dawn/B-1624-2013; McNally, Elizabeth/W-4909-2019; Sadleir, Katherine R/N-1199-2019	Davis, Dawn/0000-0002-0239-4715; Sadleir, Katherine R/0000-0001-8310-841X; McNally, Elizabeth/0000-0002-1221-719X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007381] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL007381] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achanzar WE, 1997, J CELL SCI, V110, P1073; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; Bashir R, 1998, NAT GENET, V20, P37, DOI 10.1038/1689; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Britton S, 2000, GENOMICS, V68, P313, DOI 10.1006/geno.2000.6290; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; DAVID JD, 1981, DEV BIOL, V82, P297, DOI 10.1016/0012-1606(81)90453-X; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Illa I, 2001, ANN NEUROL, V49, P130, DOI 10.1002/1531-8249(200101)49:1<130::AID-ANA22>3.0.CO;2-0; Illarioshkin SN, 2000, NEUROLOGY, V55, P1931, DOI 10.1212/WNL.55.12.1931; Johnson JE, 1998, BIOCHEMISTRY-US, V37, P12020, DOI 10.1021/bi981107q; KALDERON N, 1979, J CELL BIOL, V81, P411, DOI 10.1083/jcb.81.2.411; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lobo MVT, 1999, HISTOCHEM J, V31, P347, DOI 10.1023/A:1003744007153; Matsuda C, 2001, HUM MOL GENET, V10, P1761, DOI 10.1093/hmg/10.17.1761; Matsumura T, 1999, P JPN ACAD B-PHYS, V75, P207, DOI 10.2183/pjab.75.207; McNally EM, 2000, AM J MED GENET, V91, P305, DOI 10.1002/(SICI)1096-8628(20000410)91:4<305::AID-AJMG12>3.0.CO;2-S; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; MENKE A, 1995, J CELL SCI, V108, P727; Nakagawa M, 2001, J NEUROL SCI, V184, P15, DOI 10.1016/S0022-510X(00)00484-6; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PAPAHADJOPOULOS D, 1978, MEMBRANE FUSION, V5, P766; PAPAHADJOPOULOS D, 1979, METHODS MEMBRANE BIO, V10, P1; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piccolo F, 2000, ANN NEUROL, V48, P902, DOI 10.1002/1531-8249(200012)48:6<902::AID-ANA11>3.3.CO;2-Q; Ponting CP, 1996, PROTEIN SCI, V5, P162; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Selcen D, 2001, NEUROLOGY, V56, P1472, DOI 10.1212/WNL.56.11.1472; Seri M, 1999, AM J HUM GENET, V64, P586, DOI 10.1086/302241; SESSIONS A, 1983, BIOCHIM BIOPHYS ACTA, V728, P103, DOI 10.1016/0005-2736(83)90442-X; SESSIONS A, 1981, FEBS LETT, V134, P75, DOI 10.1016/0014-5793(81)80554-6; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ueyama H, 2001, NEUROMUSCULAR DISORD, V11, P139, DOI 10.1016/S0960-8966(00)00168-1; Wang ZM, 2002, BIOPHYS J, V82, P1338, DOI 10.1016/S0006-3495(02)75489-1; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; Weiler T, 1999, HUM MOL GENET, V8, P871, DOI 10.1093/hmg/8.5.871	45	150	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22883	22888		10.1074/jbc.M201858200	http://dx.doi.org/10.1074/jbc.M201858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959863	hybrid			2022-12-25	WOS:000176313600099
J	Wong, WK; Ou, XM; Chen, K; Shih, JC				Wong, WK; Ou, XM; Chen, K; Shih, JC			Activation of human monoamine oxidase B gene expression by a protein kinase C MAPK signal transduction pathway involves c-Jun and Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAO ACTIVITY; MEK KINASE; PROMOTER; TRANSCRIPTION; SP1; DISEASE; BINDING; RAF-1	Monoamine oxidases (MAO) A and B deaminate a number of biogenic amines. Aberrant expression of MAO is implicated in several psychiatric and neurogenerative disorders. In this study, we have shown that phorbol 12-myristate 13-acetate (PMA) increases human MAO B, but not MAO A, gene expression. The sequence between -246 and -225 bp consists of overlapping binding sites (Sp1/Egr-1/Sp1) that are recognized by Sp1, Sp3, and PMA-inducible Egr-1 is essential for PMA activation. PMA transiently increases egr-1 and c-jun gene expression. Mutation studies show that Egr-1 and c-Jun transactivate the MAO B promoter and increase endogenous MAO B transcripts Via the Sp1/Egr-1/Sp1 overlapping binding sites. Sp3 inhibits Sp1 and Egr-1 activation of MAO B gene expression. c-fos gene expression was increased by PATA but not involved in MAO B gene transcription. Furthermore, protein kinase C inhibitor blocks the PMA-dependent activation of MAO B. Cotransfection of the MAO B promoter with dominant negative forms of Ras, Raf-1,MEKK1, MEK1, MEK3, MEK7, ERK2, JNK1, and p38/RK inhibit the PMA-dependent activation of the MAO B promoter. These results indicate that MAO B expression is selectively induced by the activation of protein kinase C and MAPK signaling pathway and that c-Jun and Egr-1 appear to be the ultimate targets of this regulation.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90089 USA.	jcshih@usc.edu			NIMH NIH HHS [R37 MH39085, R37 MH039085-23, R37 MH039085, R01 MH37020, R01 MH037020-16] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAI Y, 1988, J NEURAL TRANSM, V72, P99, DOI 10.1007/BF01250233; BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CAO XM, 1993, J BIOL CHEM, V268, P16949; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVOR EJ, 1993, AM J MED GENET, V48, P209, DOI 10.1002/ajmg.1320480407; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGASHIRA T, 1976, JPN J PHARMACOL, V26, P493, DOI 10.1254/jjp.26.493; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FOWLER CJ, 1980, J NEURAL TRANSM, V49, P1, DOI 10.1007/BF01249185; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; GRIMSBY J, 1990, J NEUROCHEM, V55, P1166, DOI 10.1111/j.1471-4159.1990.tb03121.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOLSCHNEIDER DP, 1998, PSYCHOPHARMOCOLOGY 4; JOSSAN SS, 1991, NEUROSCIENCE, V45, P1, DOI 10.1016/0306-4522(91)90098-9; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIM SJ, 1989, J BIOL CHEM, V264, P402; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; MANN JJ, 1986, J NEURAL TRANSM, V65, P277, DOI 10.1007/BF01249088; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Oreland L., 1993, MONOAMINE OXIDASE BA, P219; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SCHNEIDER G, 1981, ARCH PSYCHIAT NERVEN, V230, P5, DOI 10.1007/BF00343762; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; SHINGU T, 1994, J BIOL CHEM, V269, P32551; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; ZHU QS, 1992, J NEUROSCI, V12, P4437	41	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22222	22230		10.1074/jbc.M202844200	http://dx.doi.org/10.1074/jbc.M202844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956220	hybrid, Green Accepted			2022-12-25	WOS:000176313600017
J	Billecke, SS; Bender, AT; Kanelakis, KC; Murphy, PJM; Lowe, ER; Kamada, Y; Pratt, WB; Osawa, Y				Billecke, SS; Bender, AT; Kanelakis, KC; Murphy, PJM; Lowe, ER; Kamada, Y; Pratt, WB; Osawa, Y			hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase - Geldanamycin-mediated oxidant generation is unrelated to any action of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; HSP90-BASED CHAPERONE SYSTEM; GLUCOCORTICOID RECEPTOR; IN-VITRO; PROSTHETIC GROUP; STEROID-BINDING; INHIBITION; COMPLEX; TETRAHYDROBIOPTERIN; EXPRESSION	It is established that neuronal NO synthase (nNOS) is associated with the chaperone hsp90, although the functional role for this interaction has not been defined. We have discovered that inhibition of hsp90 by radicicol or geldanamycin nearly prevents the heme-mediated activation and assembly of heme-deficient apo-nNOS in insect cells. This effect is concentration-dependent with over 75% inhibition achieved at 20 pm radicicol. The ferrous carbonyl complex of nNOS is not formed when hsp90 is inhibited, indicating that functional heme insertion is prevented. We propose that the hsp90-based chaperone machinery facilitates functional heme entry into apo-nNOS by the opening of the hydrophobic heme-binding cleft in the protein. Previously, it has been reported that the hsp90 inhibitor geldanamycin uncouples endothelial NOS activity and increases endothelial NOS-dependent O-2(.-) production. Geldanamycin is an ansamycin benzoquinone, and we show here that it causes oxidant production from nNOS in insect cells as well as with the purified protein. At a concentration of 20 mum, geldanamycin causes a 3-fold increase in NADPH oxidation and hydrogen peroxide formation from purified nNOS, whereas the non-quinone hsp90 inhibitor radicicol had no effect. Thus, consistent with the known propensity of other quinones, geldanamycin directly redox cycles with nNOS by a process independent of any action on hsp90, cautioning against the use of geldanamycin as a specific inhibitor of hsp90 in redox-active systems.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Osawa, Y (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; Bender AT, 2000, J BIOL CHEM, V275, P17407, DOI 10.1074/jbc.M000155200; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Feelisch M., 1996, METHODS NITRIC OXIDE, P455; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Kumagai Y, 1998, CHEM RES TOXICOL, V11, P608, DOI 10.1021/tx970119u; MANNO M, 1989, XENOBIOTICA, V19, P1023, DOI 10.3109/00498258909043159; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Schulte TW, 1999, MOL ENDOCRINOL, V13, P1435, DOI 10.1210/me.13.9.1435; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Sugiyama K, 1997, P NATL ACAD SCI USA, V94, P796, DOI 10.1073/pnas.94.3.796; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918	31	61	63	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20504	20509		10.1074/jbc.M201940200	http://dx.doi.org/10.1074/jbc.M201940200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923316	hybrid			2022-12-25	WOS:000176204500053
J	Balla, A; Tuymetova, G; Barshishat, M; Geiszt, M; Balla, T				Balla, A; Tuymetova, G; Barshishat, M; Geiszt, M; Balla, T			Characterization of type II phosphatidylinositol 4-kinase isoforms reveals association of the enzymes with endosomal vesicular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE KINASES; SACCHAROMYCES-CEREVISIAE; MEMBRANE TRAFFICKING; PROTEIN-KINASE; LIPID KINASE; YEAST; WORTMANNIN; CLATHRIN; GENE; REQUIREMENT	Phosphorylation of phosphatidylinositol (PI) to PI 4-phosphate is one of the key reactions in the production of phosphoinositides, lipid regulators of several cellular functions. This reaction is catalyzed by multiple enzymes that belong either to the type II or the type III family of PI 4-kinases. Type III enzymes are structurally similar to PI 3-kinases and are sensitive to PI 3-kinase inhibitors. In contrast, the recent cloning of the first type II PI 4-kinase enzyme defined a novel enzyme family. Here we characterize a new member of this family, the type IIbeta enzyme that has been identified in the NCBI data base based on its homology to the first-cloned type IIalpha enzyme. The type IIbeta enzyme has a primary transcript size of similar to3.8 kb and shows wide tissue distribution. It contains an open reading frame of 1.4 kb, encoding a protein of similar to54 kDa. Sequence comparison reveals a high degree of similarity to the type IIalpha enzyme within the C-terminal catalytic domain but significantly lower homology within the N-terminal region. Expression of both enzyme yields increased PI 4-kinase activity that is associated with the microsomal membrane fractions and is significantly lower for the type IIbeta than the type IIalpha form. Both enzymes use PI as their primary substrate and have no detectable activity on PI monophosphates. Epitope-tagged as well as green fluorescent protein-tagged forms of both enzymes localize primarily to intracellular membranes and show prominent co-localization with early endosomes and recycling endosomes but not with the Golgi. These compartments participate in the processing of both the transferrin receptor and the G protein-coupled AT(1A) angiotensin receptor. Our data indicate the existence of multiple forms of type II PI 4-kinase in mammalian cells and suggest that their functions are related to the endocytic pathway.	Natl Inst Hlth, NIAID, Lab Host Def, Bethesda, MD 20892 USA; NICHHD, Endocrinol & Reprod Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Balla, T (corresponding author), Natl Inst Hlth, NIAID, Lab Host Def, Bldg 49 Rm 6A35 49 Convent Dr, Bethesda, MD 20892 USA.			Balla, Tamas/0000-0002-9077-3335; Balla, Andras/0000-0002-6450-2793	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; BALLA T, 1988, J BIOL CHEM, V263, P4083; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; COCHET C, 1991, J BIOL CHEM, V266, P637; Cremona O, 2001, J CELL SCI, V114, P1041; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin N, 1997, J MATER CHEM, V7, P25, DOI 10.1039/a601628f; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; Pramanik A, 1997, CELL MOL BIOL, V43, P1007; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	34	151	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20041	20050		10.1074/jbc.M111807200	http://dx.doi.org/10.1074/jbc.M111807200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11923287	hybrid			2022-12-25	WOS:000175894800105
J	Guttridge, KL; Luft, JC; Dawson, TL; Kozlowska, E; Mahajan, NP; Varnum, B; Earp, HS				Guttridge, KL; Luft, JC; Dawson, TL; Kozlowska, E; Mahajan, NP; Varnum, B; Earp, HS			Mer receptor tyrosine kinase signaling. Prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ARREST-SPECIFIC GENE-6; EXPRESSION ANALYSIS; C-MER; TRANSFORMING SIGNALS; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; PROTEIN-S; RCS RAT; V-RYK	Mer is a member of the Axl/Mer/Tyro3 receptor tyrosine kinase family, a family whose physiological function is not well defined. We constructed a Mer chimera using the epidermal growth factor receptor (EGFR) extracellular and transmembrane domains and the Mer cytoplasmic domain. Stable transfection of the Mer chimera into interleukin 3 (IL-3)-dependent murine 32D cells resulted in ligand-activable surface receptor that tyrosine autophosphorylated, stimulated intracellular signaling, and dramatically reduced apoptosis initiated by IL-3 withdrawal. However, unlike multiple other ectopically expressed receptor tyrosine kinases including full-length EGFR or an EGFR/Axl chimera, the Mer chimera did not stimulate proliferation. Moreover, and in contrast to EGFR, Mer chimera activation induced adherence and cell flattening in the normally suspension-growing 32D cells. The Mer chimera signal also blocked IL-3-dependent proliferation leading to G(1)/S arrest, dephosphorylation of retinoblastoma protein, and elongation of cellular processes. Unlike other agonists that lead to a slow (4-8 days) ligand-dependent differentiation of 32D cells, the combined Mer and IL-3 signal resulted in differentiated morphology and growth cessation in the first 24 h. Thus the Mer chimera blocks apoptosis without stimulating growth and produces cytoskeletal alterations; this outcome is clearly separable from the proliferative signal produced by most receptor tyrosine kinases.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med & Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; Procter & Gamble Corp, Cincinnati, OH 45202 USA; Amgen Corp, Thousand Oaks, CA 91320 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Procter & Gamble; Amgen	Earp, HS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med & Pharmacol, Sch Med, Chapel Hill, NC 27599 USA.		Kozlowska, Ewa/ABB-8371-2020	Kozlowska, Ewa/0000-0002-8655-851X; Dawson, Thomas/0000-0003-3878-1722	NATIONAL CANCER INSTITUTE [R01CA068346, R01CA049240] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49240, CA-68346] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSIER PS, 1994, GROWTH FACTORS, V11, P125, DOI 10.3109/08977199409001054; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; DAI W, 1994, ONCOGENE, V9, P975; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097; FAUST M, 1992, ONCOGENE, V7, P1287; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KATO JY, 1990, BLOOD, V75, P1780; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LING L, 1995, MOL CELL BIOL, V15, P6582; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200	50	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24057	24066		10.1074/jbc.M112086200	http://dx.doi.org/10.1074/jbc.M112086200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11929866	hybrid			2022-12-25	WOS:000176611800013
J	Sun, Y; Liu, S; Ferguson, S; Wang, LQ; Klepcyk, P; Yun, JS; Friedman, JE				Sun, Y; Liu, S; Ferguson, S; Wang, LQ; Klepcyk, P; Yun, JS; Friedman, JE			Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-BETA; GLYCOGEN-SYNTHASE KINASE-3; GLUCOSE-6-PHOSPHATASE CATALYTIC SUBUNIT; GTP GENE-TRANSCRIPTION; GROWTH-HORMONE GENE; GLUCOSE-PRODUCTION; IN-VIVO; DIABETES-MELLITUS; FATTY-ACIDS; OB/OB MICE	The ability of insulin to suppress gluconeogenesis in type 11 diabetes mellitus is impaired; however, the cellular mechanisms for this insulin resistance remain poorly understood. To address this question, we generated transgenic (TG) mice overexpressing the phosphoenolpyruvate carboxykinase (PEPCK) gene under control of its own promoter. TG mice had increased basal hepatic glucose production (HGP), but normal levels of plasma free fatty acids (FFAs) and whole-body glucose disposal during a hyperinsulinemic-euglycemic clamp compared with wild-type controls. The steady-state levels of PEPCK and glucose-6-phosphatase mRNAs were elevated in livers of TG mice and were resistant to down-regulation by insulin. Conversely, GLUT2 and glucokinase mRNA levels were appropriately regulated by insulin, suggesting that insulin resistance is selective to gluconeogenic gene expression. Insulin-stimulated phosphorylation of the insulin receptor, insulin receptor substrate (IRS)-1, and associated phosphatidylinositol 3-kinase were normal in TG mice, whereas IRS-2 protein and phosphorylation were down-regulated compared with control mice. These results establish that a modest (2-fold) increase in PEPCK gene expression in vivo is sufficient to increase HGP without affecting FFA concentrations. Furthermore, these results demonstrate that PEPCK overexpression results in a metabolic pattern that increases glucose-6-phosphatase mRNA and results in a selective decrease in IRS-2 protein, decreased phosphatidylinositol 3-kinase activity, and reduced ability of insulin to suppress gluconeogenic gene expression. However, acute suppression of HGP and glycolytic gene expression remained intact, suggesting that FFA and/or IRS-1 signaling, in addition to reduced IRS-2, plays an important role in downstream insulin signal transduction pathways involved in control of gluconeogenesis and progression to type II diabetes mellitus.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Ohio Univ, Edison Anim Biotechnol Ctr, Athens, OH 45107 USA	Case Western Reserve University; University System of Ohio; Ohio University	Friedman, JE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat Biochem & Mol Genet, Mail Stop B195,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059767] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; Barthel A, 2001, BIOCHEM BIOPH RES CO, V285, P897, DOI 10.1006/bbrc.2001.5261; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Boden G, 2001, DIABETES, V50, P810, DOI 10.2337/diabetes.50.4.810; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; FERBER S, 1994, METABOLISM, V43, P1346, DOI 10.1016/0026-0495(94)90026-4; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hornbuckle LA, 2001, AM J PHYSIOL-ENDOC M, V281, pE713, DOI 10.1152/ajpendo.2001.281.4.E713; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lewis GF, 1997, DIABETES, V46, P1111, DOI 10.2337/diabetes.46.7.1111; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Lochhead PA, 2001, DIABETES, V50, P937, DOI 10.2337/diabetes.50.5.937; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; PARK EA, 1993, J BIOL CHEM, V268, P613; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; REBRIN K, 1995, DIABETES, V44, P1038, DOI 10.2337/diabetes.44.9.1038; Rebrin K, 1996, J CLIN INVEST, V98, P741, DOI 10.1172/JCI118846; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Roden M, 2001, RECENT PROG HORM RES, V56, P219, DOI 10.1210/rp.56.1.219; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHAFRIR E, 1988, FRONTIERS DIABETES R, V2, P304; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1993, FASEB J, V7, P791, DOI 10.1096/fasebj.7.9.8330686; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Wang LQ, 2000, J BIOL CHEM, V275, P14173, DOI 10.1074/jbc.M000764200; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamashita H, 2001, ENDOCRINOLOGY, V142, P2888, DOI 10.1210/en.142.7.2888; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598	53	136	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23301	23307		10.1074/jbc.M200964200	http://dx.doi.org/10.1074/jbc.M200964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964395	hybrid			2022-12-25	WOS:000176475700028
J	Herbst, R; Ott, C; Jacobs, T; Marti, T; Marciano-Cabral, F; Leippe, M				Herbst, R; Ott, C; Jacobs, T; Marti, T; Marciano-Cabral, F; Leippe, M			Pore-forming polypeptides of the pathogenic protozoon Naegleria fowleri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY AMEBIC MENINGOENCEPHALITIS; ENTAMOEBA-HISTOLYTICA; NK-LYSIN; MOLECULAR CHARACTERIZATION; SECONDARY STRUCTURE; CYTOLYTIC ACTIVITY; CDNA SEQUENCE; PROTEIN; MEMBRANE; PEPTIDES	The free-living amoeboflagellate and potential human pathogen Naegleria fowleri causes the often fatal disease primary amoebic meningoencephalitis. The molecular repertoire responsible for the cytolytic and tissue-destructive activity of this amoeboid protozoon is largely unknown. We isolated two pore-forming polypeptides from extracts of highly virulent trophozoites of N. fowleri by measuring their membrane-permeabilizing activity. N-terminal sequencing and subsequent molecular cloning yielded the complete primary structures and revealed that the two polypeptides are isoforms. Both polypeptides share similar structural properties with antimicrobial and cytolytic polypeptides of the protozoon Entamoeba histolytica (amoebapores) and of cytotoxic natural killer (NK) and T cells of human (granulysin) and pig (NK-lysin), all characterized by a structure of amphipathic alpha-helices and an invariant framework of cysteine residues involved in disulfide bonds. In contrast to the aforementioned proteins, the Naegleria polypeptides both are processed from large precursor molecules containing additional isoforms of substantial sequence divergence. Moreover, biochemical characterization of the isolated polypeptides in combination with mass determination showed that they are N-glycosylated and variably processed at the C terminus. The biological activity of the purified polypeptides of Naegleria was examined toward human cells and bacteria, and it was found that these factors, named naegleriapores, are active against both types of target cells, which is in good agreement with their proposed biological role as a broad-spectrum effector molecule.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Res Ctr Infect Dis, Mol Parasitol Grp, D-97070 Wurzburg, Germany; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA	Bernhard Nocht Institut fur Tropenmedizin; University of Wurzburg; Virginia Commonwealth University	Leippe, M (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	matthias.leippe@mail.uni-wuerzburg.de	Leippe, Matthias/AAP-1677-2020	Herbst, Rosa/0000-0002-2379-7433				AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; ALDAPE K, 1994, EXP PARASITOL, V78, P230, DOI 10.1006/expr.1994.1023; ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; Andersson M, 1999, INFECT IMMUN, V67, P201, DOI 10.1128/IAI.67.1.201-205.1999; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; BOMAN HG, 1974, INFECT IMMUN, V10, P136, DOI 10.1128/IAI.10.1.136-145.1974; Bracha R, 1999, MOL MICROBIOL, V34, P463, DOI 10.1046/j.1365-2958.1999.01607.x; Bruhn H, 1999, BIOL CHEM, V380, P1001, DOI 10.1515/BC.1999.124; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CARTER RF, 1970, J PATHOL, V100, P217, DOI 10.1002/path.1711000402; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; CHANG SL, 1979, FOLIA PARASIT, V26, P195; Faull KF, 1999, J MASS SPECTROM, V34, P1040, DOI 10.1002/(SICI)1096-9888(199910)34:10<1040::AID-JMS863>3.0.CO;2-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULFORD DE, 1985, J PROTOZOOL, V32, P176, DOI 10.1111/j.1550-7408.1985.tb03034.x; FULFORD DE, 1986, J PROTOZOOL, V33, P498, DOI 10.1111/j.1550-7408.1986.tb05649.x; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; Horta MF, 1997, TRENDS MICROBIOL, V5, P363, DOI 10.1016/S0966-842X(97)01109-8; Jacobs T, 1998, MOL MICROBIOL, V27, P269, DOI 10.1046/j.1365-2958.1998.00662.x; JOHN DT, 1982, ANNU REV MICROBIOL, V36, P101, DOI 10.1146/annurev.mi.36.100182.000533; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; LEIPPE M, 1995, CELL, V83, P17, DOI 10.1016/0092-8674(95)90229-5; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; Liepinsh E, 1997, NAT STRUCT BIOL, V4, P793, DOI 10.1038/nsb1097-793; LOWREY DM, 1985, INFECT IMMUN, V50, P478, DOI 10.1128/IAI.50.2.478-482.1985; MA P, 1990, REV INFECT DIS, V12, P490; MARCIANOCABRAL F, 1990, J PROTOZOOL, V37, P138, DOI 10.1111/j.1550-7408.1990.tb05884.x; MARCIANOCABRAL F, 1988, MICROBIOL REV, V52, P114, DOI 10.1128/MMBR.52.1.114-133.1988; MARCIANOCABRAL FM, 1986, APPL ENVIRON MICROB, V51, P1133, DOI 10.1128/AEM.51.5.1133-1137.1986; MUNFORD RS, 1995, J LIPID RES, V36, P1653; Nickel R, 1998, FEBS LETT, V437, P153, DOI 10.1016/S0014-5793(98)01220-4; NORONHA FSM, 1994, BRAZ J MED BIOL RES, V27, P477; Noronha FSM, 1996, INFECT IMMUN, V64, P3975, DOI 10.1128/IAI.64.10.3975-3982.1996; Pena SV, 1997, J IMMUNOL, V158, P2680; RODRIGUEZZARAGOZA S, 1994, CRIT REV MICROBIOL, V20, P225, DOI 10.3109/10408419409114556; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TANNICH E, 1991, J BIOL CHEM, V266, P4798; Tatti M, 1999, EUR J BIOCHEM, V263, P486, DOI 10.1046/j.1432-1327.1999.00521.x; TERRY AS, 1988, J BIOL CHEM, V263, P5745; YOUNG JDE, 1989, J BIOL CHEM, V264, P1077; Zaltash S, 1998, FEBS LETT, V423, P1, DOI 10.1016/S0014-5793(97)01582-2; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U	50	67	70	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22353	22360		10.1074/jbc.M201475200	http://dx.doi.org/10.1074/jbc.M201475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948186	hybrid			2022-12-25	WOS:000176313600032
J	Hsu, CH; Wu, SH; Chang, DK; Chen, CP				Hsu, CH; Wu, SH; Chang, DK; Chen, CP			Structural characterizations of fusion peptide analogs of influenza virus hemagglutinin - Implication of the necessity of a helix-hinge-helix motif in fusion activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MEMBRANE-FUSION; LIPID BILAYERS; PHOSPHOLIPID-VESICLES; PH; SPECTROSCOPY; PROTEINS; CONFORMATION; RESOLUTION; LIPOSOMES; TERMINUS	Infection by enveloped viruses initially involves membrane fusion between viral and host cell membranes. The fusion peptide plays a crucial role in triggering this reaction. To clarify how the fusion peptide exerts this specific function, we carried out biophysical studies of three fusion peptide analogs of influenza virus hemagglutinin HA2, namely E5, G13L, and L17A. E5 exhibits an activity similar to the native fusion peptide, whereas G13L and L17A, which are two point mutants of the E5 analog, possess much less fusion activity. Our CD data showed that the conformations of these three analogs in SDS micelles are pH-dependent, with higher a-helical contents at acidic pH. Tryptophan fluorescence emission experiments indicated that these three analogs insert deeper into lipid bilayers at acidic pH. The three-dimensional structure of the E5 analog in SDS micelles at pH 4.0 revealed that two segments, Leu(2)-Glu(11) and Trp(14)-Ile(18), form amphipathic helical conformations' with Gly(12)-Gly(13) forming a hinge. The hydrophobic residues in the N- and C-terminal helices form a hydrophobic cluster. At neutral pH, however, the C-terminal helix of Trp(14)-Ile(18) reduces dramatically, and the hydrophobic core observed at acidic pH is severely disrupted. We suggest that the disruption of the C-terminal helix renders the E5 analog fusion-inactive at neutral pH. Furthermore, the decrease of the hinge and the reduction of fusion activity in G13L reveal the importance of the hinge in fusion activity. Also, the decrease in the C-terminal helix and the reduction of fusion activity in L17A demonstrates the importance of the C-terminal helix in fusion activity. Based on these biophysical studies, we propose a model that illustrates the structural change of the HA2 fusion peptide analog and explains how the analog interacts with the lipid bilayer at different pH values.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; Acad Sinica, Inst Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Chen, CP (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.		Chen, Chinpan/O-4202-2018; HSU, CHUN-HUA/W-4554-2019; Chang, Ding-Kwo/E-7079-2015	HSU, CHUN-HUA/0000-0002-0008-7383; 				Barker WC, 1998, NUCLEIC ACIDS RES, V26, P27, DOI 10.1093/nar/26.1.27; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; BRUNGER AT, 1998, X PLOR; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CREIGHTON TE, 1993, PROTEINS, P190; Dubovskii PV, 2000, PROTEIN SCI, V9, P786; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Han X, 1999, BIOCHEMISTRY-US, V38, P15052, DOI 10.1021/bi991232h; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; HAYWOOD AM, 1985, P NATL ACAD SCI USA, V82, P4611, DOI 10.1073/pnas.82.14.4611; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LUNEBERG J, 1995, J BIOL CHEM, V270, P27606; Macosko JC, 1997, J MOL BIOL, V267, P1139, DOI 10.1006/jmbi.1997.0931; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Matsumoto T, 1999, BIOPHYS CHEM, V79, P153, DOI 10.1016/S0301-4622(99)00051-4; MIDOUX P, 1995, BBA-BIOMEMBRANES, V1239, P249, DOI 10.1016/0005-2736(95)00163-W; MURATA M, 1993, BIOPHYS J, V64, P724, DOI 10.1016/S0006-3495(93)81432-2; MURATA M, 1992, BIOCHEMISTRY-US, V31, P1986, DOI 10.1021/bi00122a013; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pichon C, 1997, ANTISENSE NUCLEIC A, V7, P335, DOI 10.1089/oli.1.1997.7.335; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; TAKAHASHI S, 1990, BIOCHEMISTRY-US, V29, P6257, DOI 10.1021/bi00478a021; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	36	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22725	22733		10.1074/jbc.M200089200	http://dx.doi.org/10.1074/jbc.M200089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937502	hybrid, Green Published			2022-12-25	WOS:000176313600081
J	Pillutla, RC; Hsiao, KC; Beasley, JR; Brandt, J; Ostergaard, S; Hansen, PH; Spetzler, JC; Danielsen, GM; Andersen, AS; Brissette, RE; Lennick, M; Fletcher, PW; Blume, AJ; Schaffer, L; Goldstein, NI				Pillutla, RC; Hsiao, KC; Beasley, JR; Brandt, J; Ostergaard, S; Hansen, PH; Spetzler, JC; Danielsen, GM; Andersen, AS; Brissette, RE; Lennick, M; Fletcher, PW; Blume, AJ; Schaffer, L; Goldstein, NI			Peptides identify the critical hotspots involved in the biological activation of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; LIGAND-BINDING; PROTEIN HORMONE; MECHANISM; DETERMINANTS; AGONIST; COMPLEX; POTENT	We used phage display to generate surrogate peptides that define the hotspots involved in protein-protein interaction between insulin and the insulin receptor. All of the peptides competed for insulin binding and had affinity constants in the high nanomolar to low micromolar range. Based on competition studies, peptides were grouped into non-overlapping Sites 1, 2, or 3. Some Site 1 peptides were able to activate the tyrosine kinase activity of the insulin receptor and act as agonists in the insulin-dependent fat cell assay, suggesting that Site 1 marks the hotspot involved in insulin-induced activation of the insulin receptor. On the other hand, Site 2 and 3 peptides were found to act as antagonists in the phosphorylation and fat cell assays. These data show that a peptide display can be used to define the molecular architecture of a receptor and to identify the critical regions required for biological activity in a site-directed manner.	DGI Technol, Dept Mol Biol, Edison, NJ 08818 USA; DGI Technol, Dept Screening Technol, Edison, NJ 08818 USA; DGI Technol, Dept Prot Technol, Edison, NJ 08818 USA; Novo Nordisk AS, Dept Insulin Res, DK-2880 Bagsvaerd, Denmark; Novo Nordisk AS, Dept Diabet Biol, DK-2880 Bagsvaerd, Denmark	Novo Nordisk; Novo Nordisk	Goldstein, NI (corresponding author), DGI Technol, Dept Mol Biol, Edison, NJ 08818 USA.		Ostergaard, Soren/B-8123-2019	Ostergaard, Soren/0000-0002-9415-3352				Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; Blume AJ, 2000, BIOPOLYMERS, V55, P347, DOI 10.1002/1097-0282(2000)55:4<347::AID-BIP1007>3.0.CO;2-J; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Hammond BJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE1136, DOI 10.1152/ajpendo.1997.272.6.E1136; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Luo RZT, 1999, SCIENCE, V285, P1077, DOI 10.1126/science.285.5430.1077; MARKUSSEN J, 1991, J BIOL CHEM, V266, P18814; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; Mynarcik DC, 1995, J RECEPT SIGNAL TR R, V15, P887, DOI 10.3109/10799899509049863; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Pillutla R C, 2001, BMC Biotechnol, V1, P6, DOI 10.1186/1472-6750-1-6; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHENKER E, 1988, BIOCHEM BIOPH RES CO, V157, P140, DOI 10.1016/S0006-291X(88)80024-X; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	21	65	96	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22590	22594		10.1074/jbc.M202119200	http://dx.doi.org/10.1074/jbc.M202119200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964401	hybrid			2022-12-25	WOS:000176313600065
J	Yaekashiwa, M; Wang, LH				Yaekashiwa, M; Wang, LH			Transcriptional control of the human thromboxane synthase gene in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BETA-GLOBIN LOCUS; SMALL MAF PROTEINS; LEUCINE ZIPPER PROTEIN; RNA POLYMERASE-II; FACTOR NF-E2; MOLECULAR-CLONING; MESSENGER-RNA; CHROMATIN STRUCTURE; INITIATOR ELEMENT	Thromboxane A(2), a potent mediator of vasoconstriction and platelet aggregation, is synthesized from prostaglandin H-2 by thromboxane synthase (TXAS). We report here on promoter analyses of human TXAS using in vitro transcription and in vivo transfection methods. The 39-bp core promoter, containing both TATA and initiator elements, accurately initiates transcription in an orientation-dependent manner in a cell-free transcription system. Mutation of either TATA or initiator abolished transcriptional activity, but the upstream sequence had no effect on TXAS promoter activities in vitro, suggesting that the core promoter is sufficient for transcriptional activity from a naked DNA template. In contrast, mutation of both elements drastically decreased the promoter activity in vivo. Furthermore, TXAS proximal promoter containing the nucleotides -90 to -56 relative to the transcriptional start site was necessary for promoter transactivation in vivo. Transcriptional activities from 5'-deletion mutants indicated that the effects of the nucleotides -90/-56 were more pronounced in stably transfected cells (a 150-fold difference) than in the transiently transfected cells (an 8-fold difference), reflecting the effects of TXAS transcriptional activation from replicating and nonreplicating DNA templates. Partial micrococcal nuclease digestion indicated that the sequence -90/-56, where the NF-E2 site is located, is associated with alterations of nucleosomal structure at the regions of promoter and reporter gene but not the region further downstream. Mutagenesis and forced expression studies demonstrated a critical role of p45 NF-E2 in controlling TXAS expression under native chromatin conditions. Band shifting and chromatin immunoprecipitation assays indicated that p45 NF-E2 was bound to the TXAS promoter in vitro and in vivo. Indirect end labeling and ligation-mediated PCR analyses further demonstrated that the occupation of TXAS promoter NF-E2 site was associated with disruption of nucleosomal structure. Collectively, these results indicate that binding of NF-E2 is critical both for alteration of the nucleosomal structure and for activation of the TXAS promoter, whereas the TATA and initiator elements are essential for transcription.	Univ Texas, Div Hematol, Dept Internal Med, Houston, TX 77030 USA	University of Texas System	Wang, LH (corresponding author), Univ Texas, Div Hematol, Dept Internal Med, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060625] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60625] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Carey M, 2000, TRANSCRIPTIONAL REGU; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Forsberg EC, 1999, J BIOL CHEM, V274, P26850, DOI 10.1074/jbc.274.38.26850; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gong QH, 1996, MOL CELL BIOL, V16, P6055; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lee KD, 1996, BIOCHEM J, V319, P783, DOI 10.1042/bj3190783; LEE KD, 1994, BIOCHEM BIOPH RES CO, V201, P379, DOI 10.1006/bbrc.1994.1712; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MEHTA JL, 1988, P NATL ACAD SCI USA, V85, P4511, DOI 10.1073/pnas.85.12.4511; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 2000, CELL, V103, P865, DOI 10.1016/S0092-8674(00)00190-2; NEEDLEMAN P, 1977, SCIENCE, V195, P409, DOI 10.1126/science.831285; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NUSING R, 1990, EICOSANOIDS, V3, P175; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OHASHI K, 1992, J BIOL CHEM, V267, P789; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Pao CI, 1996, J BIOL CHEM, V271, P8667, DOI 10.1074/jbc.271.15.8667; REMUZZI G, 1985, J CLIN INVEST, V75, P94, DOI 10.1172/JCI111703; SALZER WL, 1990, J CLIN INVEST, V85, P1135, DOI 10.1172/JCI114545; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Schubeler D, 2000, GENE DEV, V14, P940; SHEN RF, 1994, GENE, V140, P261, DOI 10.1016/0378-1119(94)90555-X; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; Tazawa R, 1996, ARCH BIOCHEM BIOPHYS, V334, P349, DOI 10.1006/abbi.1996.0464; TONE Y, 1994, FEBS LETT, V340, P241, DOI 10.1016/0014-5793(94)80146-0; ULLRICH V, 1990, STROKE, V21, P134; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; WANG LH, 1994, ARCH BIOCHEM BIOPHYS, V315, P273, DOI 10.1006/abbi.1994.1500; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; Zhang LQ, 1997, GENOMICS, V45, P519, DOI 10.1006/geno.1997.4982; ZHANG LQ, 1993, BIOCHEM BIOPH RES CO, V194, P741, DOI 10.1006/bbrc.1993.1884; Zucker TP, 1998, CIRCULATION, V97, P589	67	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22497	22508		10.1074/jbc.M111058200	http://dx.doi.org/10.1074/jbc.M111058200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956185	hybrid			2022-12-25	WOS:000176313600052
J	Borovsky, Z; Mishan-Eisenberg, G; Yaniv, E; Rachmilewitz, J				Borovsky, Z; Mishan-Eisenberg, G; Yaniv, E; Rachmilewitz, J			Serial triggering of T cell receptors results in incremental accumulation of signaling intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; KINASE ACTIVATION; TYROSINE KINASE; TCR ENGAGEMENT; MAP KINASE; ANTIGEN; COMPLEXES; AFFINITY; TRANSDUCTION; MODULATION	Triggering of the T cell receptor (TCR) leads to the production of intracellular intermediates with half-life of a few minutes. Signaling kinetics of events originating from serial TCR triggering and its relation to antigen dose was investigated. In this study we documented incremental accumulation of short-lived intermediates of the extracellular signal-regulated kinase (ERK) family, produced during successive TCR triggering. The rate and extent of the intermediate accumulation are essentially determined by the level of TCR engagement and are augmented by costimulation. ERK-1 and ERK-2 exhibit different rates of accumulation following serial receptor triggering. The data indicate that the quantitative kinetic differences in downstream signaling pathways induce qualitatively distinct biological outcomes. Although CD69, interleukin-2, and interferon-gamma (IFN-gamma) were primarily produced by high antigen doses that supported high MAPK phosphorylation, maximal interleukin-5 expression is induced by low and intermediate stimulus doses that do not support significant accumulation of activated ERK. We further demonstrated that the rate of phosphorylated ERK accumulation correlates with the duration of delay between T cell stimulation and the onset of IFN-gamma response, with stronger stimuli giving a more rapid IFN-gamma response. This delay might reflect the time required for the accumulation of signaling intermediates up to a threshold level that is necessary for activation. Thus, the data suggest that signaling events originating from serially triggered TCR are not simply sustained but are gradually accumulated and are integrated in a corresponding response.	Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Rachmilewitz, J (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene Therapy, POB 12000, IL-91120 Jerusalem, Israel.	rjacob@hadassah.org.il						Alcover A, 2000, CRIT REV IMMUNOL, V20, P325; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bachmann MF, 1997, EUR J IMMUNOL, V27, P2195, DOI 10.1002/eji.1830270912; Beeson C, 1996, J EXP MED, V184, P777, DOI 10.1084/jem.184.2.777; Ben-Sasson SZ, 2001, J IMMUNOL, V166, P112, DOI 10.4049/jimmunol.166.1.112; Berg NN, 1998, J IMMUNOL, V161, P2919; DING L, 1993, J IMMUNOL, V151, P1224; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dumont FJ, 1998, J IMMUNOL, V160, P2579; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Gunzer M, 2000, IMMUNITY, V13, P323, DOI 10.1016/S1074-7613(00)00032-7; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; Hardy K, 1997, IMMUNOL CELL BIOL, V75, P528, DOI 10.1038/icb.1997.84; Hashemi BB, 1996, J IMMUNOL, V156, P3660; Hemmer B, 1998, J IMMUNOL, V160, P5807; Hudrisier D, 1998, J IMMUNOL, V161, P553; Itoh Y, 1999, J IMMUNOL, V162, P2073; Lee JE, 1997, J IMMUNOL, V159, P61; Lezzi G, 1998, IMMUNITY, V8, P89, DOI 10.1016/S1074-7613(00)80461-6; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MOLLICK JA, 1991, J IMMUNOL, V146, P463; Muller S, 1999, IMMUNOLOGY, V97, P287; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; Redpath S, 1999, J IMMUNOL, V163, P6; Rogers PR, 2000, J IMMUNOL, V164, P2955, DOI 10.4049/jimmunol.164.6.2955; Rogers PR, 1999, J IMMUNOL, V163, P1205; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wei XB, 1999, P NATL ACAD SCI USA, V96, P8471, DOI 10.1073/pnas.96.15.8471; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1987, J IMMUNOL, V138, P2169; Wulfing C, 1997, J EXP MED, V185, P1815, DOI 10.1084/jem.185.10.1815	36	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21529	21536		10.1074/jbc.M201613200	http://dx.doi.org/10.1074/jbc.M201613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940589	hybrid			2022-12-25	WOS:000176286000054
J	Chen, J; Kaul, S; Simons, SS				Chen, J; Kaul, S; Simons, SS			Structure/activity elements of the multifunctional protein, GMEB-1 - Characterization of domains relevant for the modulation of glucocorticoid receptor transactivation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; ESTROGEN-REGULATED RNAS; TRANSCRIPTION FACTOR; AGONIST ACTIVITY; BINDING PROTEIN; KDWK FAMILY; INDUCTION PROPERTIES; BIOLOGICAL-ACTIVITY; HORMONE RECEPTORS; NUCLEAR RECEPTORS	GMEB-1 was initially described as a component of a 550-kDa heteromeric DNA binding complex that is involved in the modulation of two properties of glucocorticoid receptor (GR) transactivation, the dose-response curve of agonists and the partial agonist activity of antagonists. Subsequently, GMEB-1 was also found to bind to hsp27, to associate with the coactivator TIF2 in yeast cells, and to participate in Parvovirus replication. To understand these multiple activities of GMEB-1 at a molecular level, we have now determined which regions are associated with the various activities associated with the modulation of GR transactivation properties. These activities include, homooligomerization, heterooligomerization, DNA binding, binding to GR and the transcriptional cofactor CBP, and GR modulation. Complex activities such as DNA binding and GR modulation, are found to require the physical combination of those domains that would be predicted from the involved biochemical processes. We have previously documented that GMEB-1 possesses both GR modulatory and intrinsic transactivation activity. However, the domains for these two activities of GMEB-1 are found not to overlap. This separation of activities provides a structural basis for our prior biological observations that the modulation of the dose-response curve and partial agonist activity of GR complexes is independent of the total levels of gene activation by the same GR complexes.	NIDDK, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDK, Steroid Hormones Sect, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057800, ZIADK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1987, ENDOCRINOLOGY, V120, P264, DOI 10.1210/endo-120-1-264; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; BENOR S, 1993, MOL CELL BIOL, V13, P331, DOI 10.1128/MCB.13.1.331; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Christensen J, 1997, J VIROL, V71, P5733, DOI 10.1128/JVI.71.8.5733-5741.1997; Christensen J, 1999, MOL CELL BIOL, V19, P7741; Christensen J, 2001, J VIROL, V75, P7009, DOI 10.1128/JVI.75.15.7009-7017.2001; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; EVANS MI, 1987, P NATL ACAD SCI USA, V84, P8493, DOI 10.1073/pnas.84.23.8493; Garrido C, 1998, CANCER RES, V58, P5495; Giannoukos G, 2001, MOL ENDOCRINOL, V15, P255, DOI 10.1210/me.15.2.255; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Glass CK, 2000, GENE DEV, V14, P121; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Jackson DA, 1998, J STEROID BIOCHEM, V66, P79, DOI 10.1016/S0960-0760(98)00048-X; Jimenez-Lara AM, 2000, FEBS LETT, V468, P203, DOI 10.1016/S0014-5793(00)01209-6; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAY FEB, 1988, J BIOL CHEM, V263, P12901; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MUNCK A, 1984, J BIOL CHEM, V259, P820; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROUSSEAU GG, 1977, J STEROID BIOCHEM, V8, P911, DOI 10.1016/0022-4731(77)90187-X; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; Theriault JR, 1999, FEBS LETT, V452, P170, DOI 10.1016/S0014-5793(99)00634-1; TURCOTTE B, 1990, MOL CELL BIOL, V10, P5002, DOI 10.1128/MCB.10.9.5002; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WESTLEY BR, 1989, J STEROID BIOCHEM, V32, P365, DOI 10.1016/0022-4731(89)90208-2; Zeng HW, 2000, NUCLEIC ACIDS RES, V28, P1819, DOI 10.1093/nar/28.8.1819; Zeng HW, 2000, MOL CELL ENDOCRINOL, V162, P221, DOI 10.1016/S0303-7207(99)00208-7; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756; ZHANG HY, 1993, P NATL ACAD SCI USA, V90, P3880, DOI 10.1073/pnas.90.9.3880	65	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22053	22062		10.1074/jbc.M202311200	http://dx.doi.org/10.1074/jbc.M202311200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934901	hybrid			2022-12-25	WOS:000176286000118
J	Lim, IA; Hall, DD; Hell, JW				Lim, IA; Hall, DD; Hell, JW			Selectivity and promiscuity of the first and second PDZ domains of PSD-95 and synapse-associated protein 102	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; POSTSYNAPTIC DENSITY PROTEIN; D-ASPARTATE RECEPTORS; TUMOR-SUPPRESSOR PROTEIN; ER RETENTION SIGNAL; SINGLE-AMINO-ACID; GUANYLATE KINASE; SODIUM-CHANNELS; INTERACTING PROTEIN; NEURONAL SYNAPSES	PDZ domains typically interact with the very carboxyl terminus of their binding partners. Type I PDZ domains usually require valine, leucine, or isoleucine at the very COOH-terminal (PO) position, and serine or threonine 2 residues upstream at P-2. We quantitatively defined the contributions of carboxyl-terminal residues to binding selectivity of the prototypic interactions of the PDZ domains of postsynaptic density protein 95 (PSD-95) and its homolog synapse-associated protein 90 (SAP102) with the NR2b subunit of the N-methyl-D-aspartate-type glutamate receptor. Our studies indicate that all of the last five residues of NR2b contribute to the binding selectivity. Prominent were a requirement for glutamate or glutamine at P-3 and for valine at P-o for high affinity binding and a preference for threonine over serine at P-2, in the context of the last 11 residues of the NR2b COOH terminus. This analysis predicts a COOH-terminal (E/Q)(S/T)XV consensus sequence for the strongest binding to the first two PDZ domains of PSD-95 and SAP102. A search of the human genome sequences for proteins with a COOH-terminal (E/Q)(S/T)XV motif yielded 50 proteins, many of which have not been previously identified as PSD-95 or SAP102 binding partners. Two of these proteins, brain-specific angiogenesis inhibitor 1 and protein kinase Calpha, co-immunoprecipitated with PSD-95 and SA-P102 from rat brain extracts.	Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison	Hell, JW (corresponding author), Univ Iowa, Dept Pharmacol, 2-512 BSB,51 Newton Rd, Iowa City, IA 52242 USA.		Hell, Johannes W./P-5085-2019; Hall, Duane/ACD-6815-2022	Hall, Duane/0000-0003-2228-0966	NIA NIH HHS [AG00213] Funding Source: Medline; NIDDK NIH HHS [DK07759] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; El-Hussein AE, 2000, SCIENCE, V290, P1364; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Furuyashiki T, 1999, J NEUROSCI, V19, P109, DOI 10.1523/JNEUROSCI.19-01-00109.1999; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Gee SH, 2000, BIOCHEMISTRY-US, V39, P14638, DOI 10.1021/bi001633t; Gee SH, 1998, J NEUROSCI, V18, P128; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Hartmann HA, 1999, NAT NEUROSCI, V2, P593, DOI 10.1038/10147; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Hunt CA, 1996, J NEUROSCI, V16, P1380; Inagaki S, 2001, J BIOL CHEM, V276, P9174, DOI 10.1074/jbc.M009051200; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Katsanis N, 2001, NAT GENET, V29, P88, DOI 10.1038/ng0901-88; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kim TJ, 1996, MICROPOROUS MATER, V7, P35, DOI 10.1016/0927-6513(96)00024-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Koh JT, 2001, MOL BRAIN RES, V87, P223, DOI 10.1016/S0169-328X(01)00004-3; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuwahara H, 1999, J BIOL CHEM, V274, P32204, DOI 10.1074/jbc.274.45.32204; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leonard AS, 1999, P NATL ACAD SCI USA, V96, P3239, DOI 10.1073/pnas.96.6.3239; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Liu TF, 2001, J BIOL CHEM, V276, P35768, DOI 10.1074/jbc.M103585200; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Lynch BA, 1997, ANAL BIOCHEM, V247, P77, DOI 10.1006/abio.1997.2042; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Schultze W, 2001, J NEUROCHEM, V78, P482, DOI 10.1046/j.1471-4159.2001.00447.x; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stathakis DG, 1997, GENOMICS, V44, P71, DOI 10.1006/geno.1997.4848; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Vaccaro P, 2001, J BIOL CHEM, V276, P42122, DOI 10.1074/jbc.M104208200; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	81	115	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21697	21711		10.1074/jbc.M112339200	http://dx.doi.org/10.1074/jbc.M112339200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937501	hybrid			2022-12-25	WOS:000176286000078
J	Raschle, M; Dufner, P; Marra, G; Jiricny, J				Raschle, M; Dufner, P; Marra, G; Jiricny, J			Mutations within the hMLH1 and hPMS2 subunits of the human MutL alpha mismatch repair factor affect its ATPase activity, but not its ability to interact with hMutS alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPOLYPOSIS COLON-CANCER; HSP90 MOLECULAR CHAPERONE; DNA HELICASE-II; ESCHERICHIA-COLI; BINDING-SITE; TUMOR-CELLS; GENETIC INSTABILITY; MUTATOR MUTATIONS; CRYSTAL-STRUCTURE; TOPOISOMERASE-II	The MutL family of mismatch repair proteins belongs to the GHKL class of ATPases, which contains also type II topoisomerases, HSP90, and histidine kinases. The nucleotide binding domains of these polypeptides are highly conserved, but this similarity has failed to help us understand the biological role of the ATPase activity of the MutL proteins in mismatch repair. hMutLalpha is a heterodimer of the human MutL homologues hMLH1 and hPMS2, and we decided to exploit its asymmetry to study this function. We now show that although the two subunits contribute differently to the ATPase activity of the heterodimer, hMutLalpha variants in which one subunit was able to bind but not hydrolyze ATP displayed similarly reduced mismatch repair activities in vitro. In contrast, variants in which either subunit was unable to bind the nucleotide were inactive. Mutation of the catalytic sites of both subunits abolished repair without altering the ability of these peptides to interact with one another. Since the binding of the nucleotide in hMutLalpha was not required for the formation of ternary complexes with the mismatch recognition factor hMutSalpha bound to a heteroduplex substrate, we propose that the ATPase activity of hMutLalpha is required downstream from this process.	Inst Med Radiobiol, CH-8008 Zurich, Switzerland		Jiricny, J (corresponding author), Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.							Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; AU KG, 1992, J BIOL CHEM, V267, P12142; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; De Rosa M, 2000, ONCOGENE, V19, P1719, DOI 10.1038/sj.onc.1203447; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jiricny J, 2000, NAT GENET, V24, P6, DOI 10.1038/71698; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kampranis SC, 1998, J BIOL CHEM, V273, P26305, DOI 10.1074/jbc.273.41.26305; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Nystrom-Lahti M, 2002, GENE CHROMOSOME CANC, V33, P160, DOI 10.1002/gcc.1225; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; ODea MH, 1996, J BIOL CHEM, V271, P9723, DOI 10.1074/jbc.271.16.9723; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	64	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21810	21820		10.1074/jbc.M108787200	http://dx.doi.org/10.1074/jbc.M108787200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11948175	hybrid, Green Accepted			2022-12-25	WOS:000176286000090
J	Widlak, P; Palyvoda, O; Kumala, S; Garrard, WT				Widlak, P; Palyvoda, O; Kumala, S; Garrard, WT			Modeling apoptotic chromatin condensation in normal cell nuclei - Requirement for intranuclear mobility and actin involvement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; NUCLEOSOME CORE PARTICLE; CASPASE-ACTIVATED DNASE; CHROMOSOME CONDENSATION; ATTACHMENT SITES; LAEVIS OOCYTES; BINDING-SITES; CLEAVAGE; FRAGMENTATION; ORGANIZATION	Hallmarks of the terminal stages of apoptosis are genomic DNA fragmentation and chromatin condensation. Here, we have studied the mechanism of condensation both in vitro and in vivo. We found that DNA fragmentation per se of isolated nuclei from non-apoptotic cells induced chromatin condensation that closely resembles the morphology seen in apoptotic cells, independent of ATP utilization, at physiological ionic strengths. Interestingly, chromatin condensation was accompanied by release of nuclear actin, and both condensation and actin release could be blocked by reversibly pretreating nuclei with Ca2+, Cu2+, diamide, or low pH, procedures shown to stabilize internal nuclear components. Moreover, specific inhibition of nuclear F-actin depolymerization or promotion of its formation also reduced chromatin condensation. Chromatin condensation could also be inhibited by exposing nuclei to reagents that bind to the DNA minor groove, disrupting native nucleosomal DNA wrapping. In addition, in cultured cells undergoing apoptosis, drugs that inhibit depolymerization of actin or bind to the minor groove also reduced chromatin condensation, but not DNA fragmentation. Therefore, the ability of chromatin fragments with intact nucleosomes to form large clumps of condensed chromatin during apoptosis requires the apparent disassembly of internal nuclear structures that may normally constrain chromosome subdomains in nonapoptotic cells.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Ctr Oncol, Dept Expt & Clin Radiobiol, PL-44100 Gliwice, Poland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Garrard, WT (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	william.garrard@utsouthwestern.edu	Widlak, Piotr/AAL-8075-2021	Widlak, Piotr/0000-0001-5099-4726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059809] Funding Source: NIH RePORTER; NIGMS NIH HHS [GMR01-59809] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ARENDS MJ, 1990, AM J PATHOL, V136, P593; Barinaga M, 1998, SCIENCE, V280, P32, DOI 10.1126/science.280.5360.32; Belmont HM, 1999, BIODRUGS, V11, P7, DOI 10.2165/00063030-199911010-00002; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Cimbora DM, 2001, CELL, V104, P643, DOI 10.1016/S0092-8674(01)00260-4; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLARK TG, 1979, CELL, V18, P1101, DOI 10.1016/0092-8674(79)90223-X; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Durrieu F, 2000, CURR BIOL, V10, P923, DOI 10.1016/S0960-9822(00)00620-5; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hancock R, 2000, CHROMOSOMA, V109, P219, DOI 10.1007/s004120000077; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Hughes FM, 2000, METHOD ENZYMOL, V322, P47; JAIN SC, 1977, J MOL BIOL, V114, P317, DOI 10.1016/0022-2836(77)90253-4; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; Kass GEN, 1996, BIOCHEM J, V318, P749, DOI 10.1042/bj3180749; Kaufmann S H, 1986, Methods Achiev Exp Pathol, V12, P141; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; KIM SK, 1993, FEBS LETT, V315, P61, DOI 10.1016/0014-5793(93)81133-K; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAWSON GM, 1982, J BIOL CHEM, V257, P6576; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P309, DOI 10.1016/0022-2836(82)90331-X; Leforestier A, 2001, BIOPHYS J, V81, P2414, DOI 10.1016/S0006-3495(01)75888-2; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lupo R, 2001, MOL CELL, V7, P127, DOI 10.1016/S1097-2765(01)00161-7; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; Miralles F, 2000, J CELL BIOL, V148, P271, DOI 10.1083/jcb.148.2.271; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; OLINS AL, 1976, NUCLEIC ACIDS RES, V3, P3271, DOI 10.1093/nar/3.12.3271; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; RADIC MZ, 1987, CELL, V50, P1101, DOI 10.1016/0092-8674(87)90176-0; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 2001, J BIOL CHEM, V276, P45427, DOI 10.1074/jbc.M108844200; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; Strick R, 2001, J CELL BIOL, V155, P899, DOI 10.1083/jcb.200105026; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Travers A, 1999, TRENDS BIOCHEM SCI, V24, P4, DOI 10.1016/S0968-0004(98)01339-5; Turner PR, 1996, MUTAT RES-FUND MOL M, V355, P141, DOI 10.1016/0027-5107(96)00027-9; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Uhlmann F, 2001, CURR BIOL, V11, pR384, DOI 10.1016/S0960-9822(01)00214-7; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VANDYKE MW, 1983, BIOCHEMISTRY-US, V22, P2373, DOI 10.1021/bi00279a011; VANHOLDE KE, 1988, CHROMATIN, P27; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wolffe AP, 2001, CELL, V104, P631, DOI 10.1016/S0092-8674(02)01453-8; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wright WE, 1999, EXP CELL RES, V251, P492, DOI 10.1006/excr.1999.4602	85	36	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21683	21690		10.1074/jbc.M201027200	http://dx.doi.org/10.1074/jbc.M201027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927586	hybrid			2022-12-25	WOS:000176286000076
J	Xu, Y; Mellgren, RL				Xu, Y; Mellgren, RL			Calpain inhibition decreases the growth rate of mammalian cell colonies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; FAMILY; ACTIVATION; ADHESION; GENE; DIFFERENTIATION; PROLIFERATION; CALPASTATIN; MIGRATION; DISTINCT	The calpains, a family of calcium-requiring intracellular proteases, are proposed regulators of cell proliferation. However, ablation of the calpain small subunit gene necessary for function of the conventional calpains did not result in decreased rate of proliferative growth of mouse stem cells under routine culture conditions. To address the reasons for this discrepancy, Chinese hamster ovary cell lines were established that overexpress the calpain inhibitor protein, calpastatin, under control of the ecdysone congener, ponasterone A. Overexpression of calpastatin in these cell lines resulted in a decreased growth of isolated colonies adhering to tissue culture plates. However, when cells were plated at higher density, calpastatin overexpression had no influence on proliferative growth rate. Growth of colonies in soft agar was not inhibited by calpastatin overexpression. Cell adhesion, cell de-adhesion, and cell motility all appeared to be normal after calpastatin overexpression. Differential display analysis was initiated to detect possible alteration of gene expression upon calpastatin overexpression. Analysis of similar to3000 differential display PCR signals resulted in identification of one band that was underexpressed. Northern blot analysis confirmed a decreased amount of similar to1 kb mRNA in cells overexpressing calpastatin. Sequence analysis identified a putative protein, Csr, containing a region homologous to two ubiquitin transferases and a putative cation channel protein.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA		Mellgren, RL (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA.							Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; FUKAI F, 1993, BIOCHEM MOL BIOL INT, V30, P225; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakamura Y, 1999, EXP EYE RES, V69, P155, DOI 10.1006/exer.1998.0686; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; Patel YM, 1999, P NATL ACAD SCI USA, V96, P1279, DOI 10.1073/pnas.96.4.1279; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; Shiraha H, 1999, J CELL BIOL, V146, P243; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Suzuki M, 1998, BIOCHEM BIOPH RES CO, V242, P191, DOI 10.1006/bbrc.1997.7931; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	29	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21474	21479		10.1074/jbc.M111689200	http://dx.doi.org/10.1074/jbc.M111689200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937499	hybrid			2022-12-25	WOS:000176286000047
J	Lambot, M; Fretier, S; De Beeck, AO; Quatannens, B; Lestavel, S; Clavey, W; Dubuisson, J				Lambot, M; Fretier, S; De Beeck, AO; Quatannens, B; Lestavel, S; Clavey, W; Dubuisson, J			Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; VESICULAR STOMATITIS-VIRUS; ENDOPLASMIC-RETICULUM; RECOMBINANT VACCINIA; E2 GLYCOPROTEINS; HUMAN SERA; VERY-LOW; BINDING; PROTEIN; CD81	The envelope glycoproteins, E1 and E2, of hepatitis C virus (HCV) assemble intracellularly to form a noncovalent heterodimer that is expected to be essential for viral assembly and entry. However, due to the lack of a cell culture system supporting efficient HCV replication, it is very difficult to obtain relevant information on the functions of this glycoprotein oligomer. To get better insights into its biological and biochemical properties, HCV envelope glycoprotein heterodimer expressed by a vaccinia virus recombinant was purified by immunoaffinity. Purified E1E2 heterodimer was recognized by conformation-dependent monoclonal antibodies, showing that the proteins were properly folded. In addition, it interacted with human CD81, a putative HCV receptor, as well as with human low and very low density lipoproteins, which have been shown to be associated with infectious HCV particles isolated from patients. Purified E1E2 heterodimer was also reconstituted into liposomes. E1E2-liposomes were recognized by a conformation-dependent monoclonal antibody as well as by human CD81. Together, these data indicate that E1E2-liposomes are a valuable tool to study the molecular requirements for HCV binding to target cells.	Inst Biol Lille, CNRS, UPR2511, Unite Hepatite C, F-59021 Lille, France; Univ Lille 2, Fac Pharm, Inst Pasteur, INSERM,U545, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UPR2511, Unite Hepatite C, 1 Rue Calmette,BP447, F-59021 Lille, France.	jean.dubuisson@ibl.fr	Lestavel, Sophie/B-4658-2017; Dubuisson, Jean/E-6813-2016	Lestavel, Sophie/0000-0001-7839-4757; Dubuisson, Jean/0000-0003-1626-7693				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Allander T, 2000, VIROLOGY, V277, P358, DOI 10.1006/viro.2000.0617; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; CORNET B, 1992, AIDS RES HUM RETROV, V8, P1823, DOI 10.1089/aid.1992.8.1823; CURMAN B, 1980, J BIOL CHEM, V255, P7820; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; DUBJISSON J, 1996, J VIROL, V70, P778; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088; EIDELMAN O, 1984, J BIOL CHEM, V259, P4622; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Flint M, 2001, Clin Liver Dis, V5, P873, DOI 10.1016/S1089-3261(05)70199-9; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Francki RIB, 1991, ARCH VIROL         S, V2, P223; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293; Harlow E., 1988, ANTIBODIES LAB MANUA; HARMSEN MC, 1985, EUR J BIOCHEM, V149, P591, DOI 10.1111/j.1432-1033.1985.tb08966.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000; HELENIUS A, 1981, EUR J BIOCHEM, V116, P27, DOI 10.1111/j.1432-1033.1981.tb05296.x; HELENIUS A, 1977, J CELL BIOL, V75, P866, DOI 10.1083/jcb.75.3.866; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HUANG RTC, 1980, VIROLOGY, V104, P294, DOI 10.1016/0042-6822(80)90334-7; Lagging LM, 1998, J VIROL, V72, P3539, DOI 10.1128/JVI.72.5.3539-3546.1998; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; MADDEN TD, 1988, INT J BIOCHEM, V20, P889, DOI 10.1016/0020-711X(88)90172-3; MADDEN TD, 1986, CHEM PHYS LIPIDS, V40, P207, DOI 10.1016/0009-3084(86)90071-X; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; METSIKKO K, 1986, EMBO J, V5, P3429, DOI 10.1002/j.1460-2075.1986.tb04665.x; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; Monazahian M, 2000, MED MICROBIOL IMMUN, V188, P177, DOI 10.1007/s004300000032; NUSSBAUM O, 1987, J VIROL, V61, P2245, DOI 10.1128/JVI.61.7.2245-2252.1987; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Patel AH, 2000, J GEN VIROL, V81, P2873, DOI 10.1099/0022-1317-81-12-2873; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; PETRI WA, 1979, J BIOL CHEM, V254, P4313; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Prince AM, 1996, J VIRAL HEPATITIS, V3, P11, DOI 10.1111/j.1365-2893.1996.tb00075.x; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; THOMSSEN R, 1993, MED MICROBIOL IMMUN, V182, P329; THOMSSEN R, 1992, MED MICROBIOL IMMUN, V181, P293, DOI 10.1007/BF00198849; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840	55	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20625	20630		10.1074/jbc.M111020200	http://dx.doi.org/10.1074/jbc.M111020200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11937498	hybrid			2022-12-25	WOS:000176204500069
J	Yahagi, N; Shimano, H; Hasty, AH; Matsuzaka, T; Ide, T; Yoshikawa, T; Amemiya-Kudo, M; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N				Yahagi, N; Shimano, H; Hasty, AH; Matsuzaka, T; Ide, T; Yoshikawa, T; Amemiya-Kudo, M; Tomita, S; Okazaki, H; Tamura, Y; Iizuka, Y; Ohashi, K; Osuga, J; Harada, K; Gotoda, T; Nagai, R; Ishibashi, S; Yamada, N			Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; TRANSCRIPTION FACTOR; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; TARGETED DISRUPTION; DIABETES-MELLITUS; ACID SYNTHESIS; MOUSE; DIFFERENTIATION	Obesity is a common nutritional problem often associated with diabetes, insulin resistance, and fatty liver (excess fat deposition in liver). Leptin-deficient Lep(ob)/Lep(ob) mice develop obesity and those obesity-related syndromes. Increased lipogenesis in both liver and adipose tissue of these mice has been suggested. We have previously shown that the transcription factor sterol regulatory element-binding protein-1 (SREBP-1) plays a crucial role in the regulation of lipogenesis in vivo. To explore the possible involvement of SREBP-1 in the pathogenesis of obesity and its related syndromes, we generated mice deficient in both leptin and SREBP-1. In doubly mutant Lep(ob/ob) x Srebp-1(-/-) mice, fatty livers were markedly attenuated, but obesity and insulin resistance remained persistent. The mRNA levels of lipogenic enzymes such as fatty acid synthase were proportional to triglyceride accumulation in liver. In contrast, the mRNA abundance of SREBP-1 and lipogenic enzymes in the adipose tissue of Lep(ob)/Lep(ob) mice was profoundly decreased despite sustained fat, which could explain why the SREBP-1 disruption had little effect on obesity. In conclusion, SREBP-1 regulation of lipogenesis is highly involved in the development of fatty livers but does not seem to be a determinant of obesity in Lep(ob)/Lep(ob) mice.	Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan	University of Tsukuba; University of Tokyo	Shimano, H (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Internal Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.		Shimano, Hitoshi/AAI-5648-2020; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019; Hasty, Alyssa/AAA-2757-2020	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Hasty, Alyssa/0000-0001-7302-8045				BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CLANDININ MT, 1996, LIPIDS, V31, P13, DOI DOI 10.1007/BF02637045; Flier JS, 1999, P NATL ACAD SCI USA, V96, P14191, DOI 10.1073/pnas.96.25.14191; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; HEMS DA, 1975, BIOCHEM J, V150, P167, DOI 10.1042/bj1500167; HERBERG L, 1977, METABOLISM, V26, P59, DOI 10.1016/0026-0495(77)90128-7; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; KAPLAN ML, 1981, AM J PHYSIOL, V240, pE101, DOI 10.1152/ajpendo.1981.240.2.E101; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lee J H, 1998, Korean J Intern Med, V13, P12; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; MAYER J, 1951, SCIENCE, V113, P746, DOI 10.1126/science.113.2948.746; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	38	281	289	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19353	19357		10.1074/jbc.M201584200	http://dx.doi.org/10.1074/jbc.M201584200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11923308	hybrid			2022-12-25	WOS:000175894800016
J	Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N				Chazal, M; Marionnet, C; Michel, L; Mollier, K; Dazard, JE; Della Valle, V; Larsen, CJ; Gras, MP; Basset-Seguin, N			P16(INK4A) is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation	ONCOGENE			English	Article						p16(INK4A); keratinocyte; UVB	P53 TUMOR SUPPRESSION; HUMAN CANCER-CELLS; ULTRAVIOLET-RADIATION; G(1) ARREST; HUMAN SKIN; INK4A LOCUS; DNA-DAMAGE; EXPRESSION; PROTEIN; GENE	The P16(INK4A-ARF) locus plays a crucial role in the control of cellular proliferation via both the Rb and P53 pathways. We previously demonstrated that this locus is altered in human skin carcinomas. In the present study we have studied the expression of the p16(INK4A-ARF) locus following UVB irradiation of normal human keratinocytes both at the mRNA (RT-PCR) and at the protein (Western blotting) levels. Our data confirmed that P16(INK4A) protein is induced by UVB at low (30 mJ cm(2)) and high (100 mJ cm(2)) doses and is observed after a single or repeated exposure implying that this response is involved in both the immediate and adaptative response to UVB. The apparent absence of induction p16(INK4A) mRNA suggested that P16(INK4A) protein is upregulated at the post-transcriptional level. Analysis by flow cytometry and BrdU staining indicated that the highest protein level of P16(INK4A) in the cells was associated with a G(2) cell cycle arrest. Comparative analysis of P16(INK4A) and P53 showed that they were differentially modulated in keratinocytes according to the UVB dose and regimen. Low, acute or repeated UVB exposures led to accumulation of both P16(INK4A) and p53, whereas at high UVB doses, P53 and P53-dependent genes were not induced or even downregulated and only a slight but reproducible stabilization of P16(INK4A) protein was observed. In our conditions, P14(ARF) did not seem to participate in the UV response in these cells as P14(ARF) protein did not vary. These results infer that P16(INK4A) plays a role in cell cycle regulation of keratinocytes submitted to UVB irradiation. They also reinforce our previous demonstration of the importance of inactivation of this gene in UV-induced skin carcinogenesis.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Inst Genet Mol, CNRS, UMR 5535, F-34090 Montpellier, France; Inst Genet Mol, INSERM, U434, F-75010 Paris, France; IBMIG, Oncol Mol Lab, F-86022 Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave C Vellefaux, F-75010 Paris, France.		Michel, Laurence/E-8605-2017					AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahmed NU, 1999, J DERMATOL SCI, V19, P175, DOI 10.1016/S0923-1811(98)00068-1; BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, P102; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enders GH, 1996, ONCOGENE, V12, P1239; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; HALL PA, 1993, ONCOGENE, V8, P203; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; Inohara S, 1996, BRIT J DERMATOL, V135, P717; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; Liefer KM, 2000, CANCER RES, V60, P4016; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1995, CELL, V80, P293; Nielsen GP, 1999, LAB INVEST, V79, P1137; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Parker C.A, 1968, PHOTOLUMINESCENCE SO; Pavey S, 1999, CANCER RES, V59, P4185; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Reznikoff CA, 1996, CANCER RES, V56, P2886; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soufir N, 2000, J NATL CANCER I, V92, P1841, DOI 10.1093/jnci/92.22.1841; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XQ, 1996, CANCER RES, V56, P2510; WEINBERG WC, 1994, CANCER RES, V54, P5584; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2652	2661		10.1038/sj.onc.1205349	http://dx.doi.org/10.1038/sj.onc.1205349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965538				2022-12-25	WOS:000174996500005
J	Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA				Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA			The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation	ONCOGENE			English	Article						radiation; MDM2; E2F-1; medullary thyroid carcinoma	TRANSCRIPTION FACTOR E2F-1; DOWN-REGULATION; DNA-DAMAGE; WILD-TYPE; P53; ONCOGENE; APOPTOSIS; CYCLE; OVEREXPRESSION; SUPPRESSION	We have analysed the radiation response of a human medullary thyroid carcinoma cell line (MTT), characterized by the absence of a functional p53 protein, and the consequences of MDM2 overexpression in this process. We show that the product of the mdm2 proto-oncogene is able to sensitize MTT cells to ionizing radiation. After radiation treatment, MTT cells display histograms consistent with a G2M arrest. MTT cells expressing MDM2 (MTT-mdm2) are unable to respond to DNA damage with G2M arrest, and display a high percentage of apoptosis. MTT-mdm2 cells show high levels of E2F-1 protein, suggesting that the induction of apoptosis observed upon MDM2 overexpression could be dependent on E2F-1. This observation is further supported with assays showing that E2F-1 binding to specific DNA sequences is enhanced in MTT-mdm2 cells. Likewise, transactivation of reporter constructs exclusively dependent on E2F-1 is also elevated after transfection with MDM2. This effect can be reverted by transient transfection with p19(ARF). To link the expression of E2F-1 with the induction of apoptosis, we generated clonal cell lines overexpressing E2F-1. Transfection with E2F-1 results in a low number of outgrowing colonies with reduced proliferation rates, indicating that E2F-1 is deleterious for cell growth. This negative regulation correlates with an increase in the percentage of the cell population with DNA content below 2N, suggesting that E2F-1 promotes apoptosis. Finally, overexpression of E2F-1 sensitizes MTT cells to radiation exposure. We conclude that the effects observed by MDM2 overexpression could be mediated by E2F-1.	CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Puerta Hierro, Dept Oncol Radioterap, Madrid, Spain; Ctr Nacl Invest Oncol Carlos III, Mol Oncol Lab, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda	Sanstisteban, P (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	psantisteban@iib.uam.es	Romero, Jesús/AAE-1899-2021	Romero, Jesús/0000-0001-8778-1388				ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerjee D, 1998, CANCER RES, V58, P4292; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CACHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dilla T, 2000, ENDOCRINOLOGY, V141, P420, DOI 10.1210/en.141.1.420; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Giuffrida D, 1998, ANN ONCOL, V9, P695, DOI 10.1023/A:1008242302749; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Heshmati HM, 1997, AM J MED, V103, P60, DOI 10.1016/S0002-9343(97)00024-7; Hunt KK, 1997, CANCER RES, V57, P4722; Hwang A, 1998, RADIAT RES, V150, pS52, DOI 10.2307/3579808; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KELLE DE, 1995, CELL, V83, P993; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leong S, 1981, ADV THYROID NEOPLASI, P95; Lin WC, 2001, GENE DEV, V15, P1833; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSWALD F, 1994, ONCOGENE, V9, P2029; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; Velasco JA, 1997, INT J CANCER, V73, P449, DOI 10.1002/(SICI)1097-0215(19971104)73:3<449::AID-IJC21>3.0.CO;2-6; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2376	2386		10.1038/sj.onc.1205307	http://dx.doi.org/10.1038/sj.onc.1205307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948421				2022-12-25	WOS:000174635600010
J	Oneyama, C; Nakano, H; Sharma, SV				Oneyama, C; Nakano, H; Sharma, SV			UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug	ONCOGENE			English	Article						UCS15A; SH3; proline-rich domains; Src; Sam68; Grb2	GLUTATHIONE-S-TRANSFERASE; RECEPTOR TYROSINE KINASES; SRC HOMOLOGY-3 DOMAIN; BINDING-PROTEIN; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE EXCHANGE; E-CADHERIN; GRB2; FAMILY; SAM68	Protein-protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein-protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src-SH3 with Sam68, both in vivo and in vitro. This ability of UCS15A was not restricted to Src-SH3 mediated protein-protein interactions, since the drug was capable of disrupting the in vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCgamma. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein-protein interactions such as Grb2-Sos1, cortactin-ZO1, as well as atypical SH3-mediated protein-protein interactions such as Grb2-Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein-protein interactions of P-catenin, with E-cadherin and g-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein-protein interactions appeared to be restricted to SH3-mediated protein-protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein-protein interactions. In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 194, Japan	Kyowa Kirin Ltd	Sharma, SV (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahi Cho,Machida Shi, Tokyo 194, Japan.	ssharma@kyowa.co.jp						Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Combs AP, 1996, J AM CHEM SOC, V118, P287, DOI 10.1021/ja953750v; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jabado N, 1998, J IMMUNOL, V161, P2798; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sharma SV, 2001, ONCOGENE, V20, P2068, DOI 10.1038/sj.onc.1204296; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Summy JM, 2000, ONCOGENE, V19, P155, DOI 10.1038/sj.onc.1203265; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhu T, 1998, J BIOL CHEM, V273, P33864, DOI 10.1074/jbc.273.50.33864	67	48	54	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2037	2050		10.1038/sj.onc.1205271	http://dx.doi.org/10.1038/sj.onc.1205271			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960376				2022-12-25	WOS:000174827000010
J	Doring, F; Wischmeyer, E; Kuhnlein, RP; Jackle, H; Karschin, A				Doring, F; Wischmeyer, E; Kuhnlein, RP; Jackle, H; Karschin, A			Inwardly rectifying K+ (Kir) channels in Drosophila - A crucial role of cellular milieu factors for Kir channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; EXPRESSION; GENE; ENCODES; CLONING; SUBUNITS; RECEPTOR; BARTTER; SHAKER	Three cDNAs encoding inwardly rectifying potassium (Kir) channels were isolated from Drosophila melanogaster. The protein sequences of Drosophila KirI (dKirI) and dKirII are moderately (<44%) and dKirIII sequence is weakly (<27%) identical to human Kir channel subunits. During fly development, five dKir channel transcripts derived from three genes are differentially expressed. Whole mount in situ hybridizations revealed dKirI transcripts absent from embryos, but dKirII and dKirIII are expressed in the embryonic hind gut and in Malpighian tubules, respectively, thus covering the entire osmoregulatory system of the developing fly. In the head of adult flies, predominantly dKirII transcripts were detected. When expressed in Xenopus oocytes, dKir channel activity was only observed after amino acid substitutions in their cytosolic tails (e.g. exchange of a unique valine in the NH2 terminus). In contrast, heterologous expression of wild type dKirI and dYirII in Drosophila S2 cells readily evoked typical inwardly rectifying K+ currents, which were weakly sensitive to Ba2+. Thus, the specific milieu of insect cells provides a crucial cellular environment for proper function of dKir channels.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	University of Wurzburg; Max Planck Society	Doring, F (corresponding author), Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany.	fdoering@mail.uni-wuerzburg.de		Doring, Frank/0000-0003-1017-1498				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Derst C, 1998, J BIOL CHEM, V273, P23884, DOI 10.1074/jbc.273.37.23884; Doring F, 1998, J NEUROSCI, V18, P8625; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; Forsyth SE, 1997, FEBS LETT, V409, P277, DOI 10.1016/S0014-5793(97)00514-0; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Ishii M, 1997, J NEUROSCI, V17, P7725; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; Kuhnlein RP, 1996, DEVELOPMENT, V122, P2215; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; METZLER M, 2001, EUR J NEUROSCI, V13, P477; Nakamura N, 1999, BIOCHEM J, V342, P329, DOI 10.1042/0264-6021:3420329; Nasonkin I, 1999, J BIOL CHEM, V274, P29420, DOI 10.1074/jbc.274.41.29420; Nichols CG, 1996, CIRC RES, V78, P1, DOI 10.1161/01.RES.78.1.1; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Rodriguez-Soriano J, 1998, PEDIATR NEPHROL, V12, P315, DOI 10.1007/s004670050461; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Schmidt A, 1996, MOL GEN GENET, V251, P381, DOI 10.1007/BF02172530; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; SHEPHER RM, 2000, DIABETES ANN, V13, P43; Stobbart R.H., 1974, P361; Takashima S, 2001, MECH DEVELOP, V101, P79, DOI 10.1016/S0925-4773(00)00555-4; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	41	43	45	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25554	25561		10.1074/jbc.M202385200	http://dx.doi.org/10.1074/jbc.M202385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964404	hybrid, Green Submitted			2022-12-25	WOS:000176747000092
J	Fusetti, F; von Moeller, H; Houston, D; Rozeboom, HJ; Dijkstra, BW; Boot, RG; Aerts, JMFG; van Aalten, DMF				Fusetti, F; von Moeller, H; Houston, D; Rozeboom, HJ; Dijkstra, BW; Boot, RG; Aerts, JMFG; van Aalten, DMF			Structure of human chitotriosidase - Implications for specific inhibitor design and function of mammalian chitinase-like lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; X-RAY STRUCTURE; SERRATIA-MARCESCENS; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; ALLOSAMIDIN; PROTEIN; RESOLUTION; FAMILY; IDENTIFICATION	Chitin hydrolases have been identified in a variety of organisms ranging from bacteria to eukaryotes. They have been proposed to be possible targets for the design of novel chemotherapeutics against human pathogens such as fungi and protozoan parasites as mammals were not thought to possess chitin-processing enzymes. Recently, a human chitotriosidase was described as a marker for Gaucher disease with plasma levels of the enzyme elevated up to 2 orders of magnitude. The chitotriosidase was shown to be active against colloidal chitin and is inhibited by the family 18 chitinase inhibitor allosamidin. Here, the crystal structure of the human chitotriosidase and complexes with a chitooligosaccharide and allosamidin are described. The structures reveal an elongated active site cleft, compatible with the binding of long chitin polymers, and explain the inactivation of the enzyme through an inherited genetic deficiency. Comparison with YM1 and HCgp-39 shows how the chitinase has evolved into these mammalian lectins by the mutation of key residues in the active site, tuning the substrate binding specificity. The soaking experiments with allosamidin and chitooligosaccharides give insight into ligand binding properties and allow the evaluation of differential binding and design of species-selective chitinase inhibitors.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	University of Dundee; University of Amsterdam; Academic Medical Center Amsterdam	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	dava@davapc1.bioch.dundee.ac.uk	Dijkstra, Bauke W./H-4308-2019; Aerts, Johannes/A-1028-2009	Dijkstra, Bauke W./0000-0001-9731-6586; Aerts, Johannes/0000-0001-8168-2565; Houston, Douglas/0000-0002-3469-1546; Rozeboom, Henriette/0000-0002-1656-6477; van Aalten, Daan/0000-0002-1499-6908; Boot, Rolf/0000-0002-7031-3390				BARRANGER JA, 1988, GLUCOSYLCERAMIDE LIP, P1677; Blattner R, 1997, PESTIC SCI, V50, P312, DOI 10.1002/(SICI)1096-9063(199708)50:4&lt;312::AID-PS594&gt;3.0.CO;2-O; Bokma E, 2000, FEBS LETT, V478, P119, DOI 10.1016/S0014-5793(00)01833-0; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brurberg MB, 1996, MICROBIOL-SGM, V142, P1581, DOI 10.1099/13500872-142-7-1581; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HAWTIN RE, 1995, VIROLOGY, V212, P673, DOI 10.1006/viro.1995.1525; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NISHIMOTO Y, 1991, J ANTIBIOT, V44, P716, DOI 10.7164/antibiotics.44.716; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; SAKUDA S, 1987, J ANTIBIOT, V40, P296, DOI 10.7164/antibiotics.40.296; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Sami L, 2001, J GEN APPL MICROBIOL, V47, P201, DOI 10.2323/jgam.47.201; Spindler-Barth M, 1998, PESTIC SCI, V52, P47, DOI 10.1002/(SICI)1096-9063(199801)52:1&lt;47::AID-PS672&gt;3.0.CO;2-Y; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	43	176	187	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25537	25544		10.1074/jbc.M201636200	http://dx.doi.org/10.1074/jbc.M201636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960986	Green Published, hybrid			2022-12-25	WOS:000176747000090
J	Amir, RE; Iwai, K; Ciechanover, A				Amir, RE; Iwai, K; Ciechanover, A			The NEDD8 pathway is essential for SCF beta-TrCp-mediated ubiquitination and processing of the NF-kappa B precursor p105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-RICH REGION; COP9 SIGNALOSOME; P50 SUBUNIT; PROTEIN; LIGASE; CONJUGATION; IDENTIFICATION; DEGRADATION; E3; BINDING	The p50 subunit of NF-kappaB is generated by limited processing of the precursor p105. IkappaB kinase-mediated phosphorylation of the C-terminal domain of p105 recruits the SCFbeta-TrCP ubiquitin ligase, resulting in rapid ubiquitination and subsequent processing/degradation of p105. NEDD8 is known to activate SCF ligases following modification of their cullin component. Here we show that NEDDylation is required for conjugation and processing of p105 by SCFbeta-TrCP following phosphorylation of the molecule. In a crude extract, a dominant negative E2 enzyme, UBC12, inhibits both conjugation and processing of p105, and inhibition is alleviated by an excess of WT-UBC12. In a reconstituted cell-free system, ubiquitination of p105 was stimulated only in the presence of all three components of the NEDD8 pathway, El, E2, and NEDD8. A Cul-1 mutant that cannot be NEDDylated could not stimulate ubiquitination and processing of p105. Similar findings were observed also in cells. It should be noted that NEDDylation is required only for the stimulated but not for basal processing of p105. Although the mechanisms that underlie processing of p105 are largely obscure, it is clear that NEDDylation and the coordinated activity of SCFbeta-TrCP on both p105 and IkappaBalpha serve as an important regulatory mechanism controlling NF-kappaB activity.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Osaka Metropolitan University	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.		IWAI, KAZUHIRO/GSN-7385-2022; Ciechanover, Aaron J/C-9166-2017	Iwai, Kazuhiro/0000-0001-5620-5951				Betts JC, 1996, MOL CELL BIOL, V16, P6363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Foo SY, 1999, TRENDS GENET, V15, P229; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; OSKA F, 1998, GENE DEV, V12, P2263; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	50	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23253	23259		10.1074/jbc.M200967200	http://dx.doi.org/10.1074/jbc.M200967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953428	hybrid			2022-12-25	WOS:000176475700022
J	Morris, MC; Gondeau, C; Tainer, JA; Divita, G				Morris, MC; Gondeau, C; Tainer, JA; Divita, G			Kinetic mechanism of activation of the Cdk2/cyclin A complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; INK4 INHIBITORS; CDK COMPLEX; SPECIFICITY	Eukaryotic cell cycle progression is controlled by the ordered action of cyclin-dependent kinases, activation of which occurs through the binding of the cyclin to the Cdk followed by phosphorylation of a conserved threonine in the T-loop of the Cdk by Cdk-activating kinase (CAK). Despite our understanding of the structural changes, which occur upon Cdk/cyclin formation and activation, little is known about the dynamics of the molecular events involved. We have characterized the mechanism of Cdk2/cyclin A complex formation and activation at the molecular and dynamic level by rapid kinetics and demonstrate here that it is a two-step process. The first step involves the rapid association between the PSTAIRE helix of Cdk2 and helices 3 and 5 of the cyclin to yield an intermediate complex in which the threonine in the T-loop is not accessible for phosphorylation. Additional contacts between the C-lobe of the Cdk and the N-terminal helix of the cyclin then induce the isomerization of the Cdk into a fully mature form by promoting the exposure of the T-loop for phosphorylation by CAK and the formation of the substrate binding site. This conformational change is selective for the cyclin partner.	The Scripps Res Inst, La Jolla, CA 92037 USA; Ctr Rech Biochim Macromol, Dept Biochem, UPR 1086 CNRS, F-34293 Montpellier, France	Scripps Research Institute; Universite de Montpellier	Divita, G (corresponding author), The Scripps Res Inst, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gilles@scripps.edu	MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021; Tainer, John/GWQ-4878-2022	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728; Tainer, John/0000-0003-1659-2429				Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Card GL, 2000, EMBO J, V19, P2877, DOI 10.1093/emboj/19.12.2877; ENDICOTT JA, 1994, PROTEIN ENG, V7, P243, DOI 10.1093/protein/7.2.243; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Goda T, 2001, J BIOL CHEM, V276, P15415, DOI 10.1074/jbc.M011101200; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris MC, 1998, BIOCHEMISTRY-US, V37, P14257, DOI 10.1021/bi980913u; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; PICHKAM KM, 1994, J MOL BIOL CELL, V5, P587; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0	21	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23847	23853		10.1074/jbc.M107890200	http://dx.doi.org/10.1074/jbc.M107890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959850	Green Published, hybrid			2022-12-25	WOS:000176475700098
J	Grolleau, A; Bowman, J; Pradet-Balade, B; Puravs, E; Hanash, S; Garcia-Sanz, JA; Beretta, L				Grolleau, A; Bowman, J; Pradet-Balade, B; Puravs, E; Hanash, S; Garcia-Sanz, JA; Beretta, L			Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MESSENGER-RNA; INTERNAL INITIATION; PROTEASOME ACTIVITY; PROTHYMOSIN-ALPHA; INTERLEUKIN-2 STIMULATION; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; EXPRESSION; ACTIVATION	Rapamycin has been shown to affect translation. We have utilized two complementary approaches to identify genes that are predominantly affected by rapamycin in Jurkat T cells. One was to compare levels of polysome-bound and total RNA using oligonucleotide microarrays complementary to 6,300 human genes. Another was to determine protein synthesis levels using two-dimensional PAGE. Analysis of expression changes at the polysome-bound RNA levels showed that translation of most of the expressed genes was partially reduced following rapamycin treatment. However, translation of 136 genes (6% of the expressed genes) was totally inhibited. This group included genes encoding RNA-binding proteins and several proteasome subunit members. Translation of a set of 159 genes (7%) was largely unaffected by rapamycin treatment. These genes included transcription factors, kinases, phosphatases, and members of the RAS superfamily. Analysis of [S-35]methionine-labeled proteins from the same cell populations using two-dimensional PAGE showed that the integrated intensity of 111 of 830 protein spots changed in rapamycin-treated cells by at least 3-fold (70 increased, 41 decreased). We identified 22 affected protein spots representing protein products of 16 genes. The combined microarray and proteomic approach has uncovered novel genes affected by rapamycin that may be involved in its immunosuppressive effect and other genes that are not affected at the level of translation in a context of general inhibition of cap-dependent translation.	Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Beretta, L (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.		Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019; Julius, Annabelle/A-7276-2010	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; Laura, Beretta/0000-0002-2054-684X	NIAID NIH HHS [1R01-AI50896] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050896] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BAXEVANIS CN, 1988, IMMUNOPHARMACOLOGY, V15, P73, DOI 10.1016/0162-3109(88)90054-9; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; BUSTELO XR, 1991, J BIOL CHEM, V266, P1443; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CARLSON RP, 1993, ANN NY ACAD SCI, V685, P86, DOI 10.1111/j.1749-6632.1993.tb35855.x; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; CORDERO OJ, 1992, LYMPHOKINE CYTOK RES, V11, P277; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; DUMONT FJ, 1990, J IMMUNOL, V144, P251; Forre O, 2000, SCAND J RHEUMATOL, V29, P73; FRUMAN DA, 1995, EUR J IMMUNOL, V25, P563, DOI 10.1002/eji.1830250239; GRUNBERG E, 1997, INT J THYMOL, V5, P415; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Ingle GR, 2000, ANN PHARMACOTHER, V34, P1044, DOI 10.1345/aph.19380; Jackson RJ, 1995, RNA, V1, P985; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JIANG W, 1997, P NATL ACAD SCI USA, V94, P133; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kanaan N, 2001, J CELL BIOCHEM, V81, P347, DOI 10.1002/1097-4644(20010501)81:2<347::AID-JCB1049>3.0.CO;2-3; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUICK RD, 1991, ELECTROPHORESIS, V12, P736, DOI 10.1002/elps.1150121007; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, P457; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ponticelli C, 1999, Drugs R D, V1, P55, DOI 10.2165/00126839-199901010-00020; Pradet-Balade B, 2001, BIOTECHNIQUES, V30, P1352, DOI 10.2144/01306rr03; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Saunders RN, 2001, KIDNEY INT, V59, P3, DOI 10.1046/j.1523-1755.2001.00460.x; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; STRAHLER JR, 1989, PROTEIN STRUCTURE PR, P65; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Vuckovic-Dekic Ljiljana, 1997, International Journal of Thymology, V5, P399; Wang X, 1998, J IMMUNOL, V160, P788; Wang X, 1997, EUR J IMMUNOL, V27, P2781, DOI 10.1002/eji.1830271106; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	58	160	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22175	22184		10.1074/jbc.M202014200	http://dx.doi.org/10.1074/jbc.M202014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943782	hybrid			2022-12-25	WOS:000176313600011
J	Wang, JX; Su, M; Fan, J; Seth, A; McCulloch, CA				Wang, JX; Su, M; Fan, J; Seth, A; McCulloch, CA			Transcriptional regulation of a contractile gene by mechanical forces applied through integrins in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ALPHA-ACTIN; SERUM RESPONSE FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; C-FOS GENE; SMOOTH-MUSCLE; CARDIAC MYOCYTES; CARG ELEMENTS; IN-VITRO; PROMOTER; EXPRESSION	We examined mechanotranscriptional regulation of the contractile gene, alpha-smooth muscle actin (SMA), in osteoblastic cells. Tensile forces were applied through collagen-coated magnetite beads to ROS17/2.8 cells. These cells were desmin -, vimentin + and expressed low levels of SMA. After force application (480 piconewton/ cell), SMA protein and mRNA were increased but beta-actin was unchanged. Beads coated with bovine serum albumin or poly-L-lysine produced no change of SMA. In cells transiently transfected with plasmids containing the SMA promoter fused to beta-galactosidase or green fluorescent protein coding sequences, SMA promoter activity was increased by similar to60% after 4 h of force, whereas control (Rous sarcoma virus) promoter activity was unaffected. Transfections with beta-galactosidase or green fluorescent protein reporter constructs showed that force-loaded cells exhibited higher beta-galactosidase activity than cells without force. Cytochalasin D and latrunculin B inhibited force-induced increases of SMA promoter activity. Deletion analyses showed that SMA promoter activity was increased similar to70% after force with a minimal construct containing 155 bp upstream of the translation start site. The force effect on the SMA promoter was abrogated in cells transfected with CArG-B box mutants. Gel mobility shift analyses of nuclear extracts showed strong binding to the CArG-B motif after force. We conclude that the CArG-B box is a force-responsive element in the SMA promoter.	Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Fac Dent, Toronto, ON M5S 3E8, Canada	University of Toronto	McCulloch, CA (corresponding author), Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Fac Dent, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E8, Canada.							AOYAGI T, 1993, J BIOL CHEM, V268, P27176; Arora PD, 1999, AM J PATHOL, V155, P2087, DOI 10.1016/S0002-9440(10)65527-7; AUSUBEL FM, 2001, CURRENT PROTOCOLS MO; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Dugina V, 1998, EXP CELL RES, V238, P481, DOI 10.1006/excr.1997.3868; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; Glogauer M, 1998, PFLUG ARCH EUR J PHY, V435, P320; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; Hautmann MB, 1998, J BIOL CHEM, V273, P8398, DOI 10.1074/jbc.273.14.8398; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; Kinner B, 2001, J ORTHOP RES, V19, P233, DOI 10.1016/S0736-0266(00)00081-4; Komuro I, 2000, JPN HEART J, V41, P117, DOI 10.1536/jhj.41.117; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Menard C, 2000, BIOMATERIALS, V21, P1867, DOI 10.1016/S0142-9612(00)00062-4; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKANO Y, 1991, GENE, V99, P285; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wang J, 2001, TISSUE CELL, V33, P86, DOI 10.1054/tice.2000.0160; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776	39	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22889	22895		10.1074/jbc.M203130200	http://dx.doi.org/10.1074/jbc.M203130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953441	hybrid			2022-12-25	WOS:000176313600100
J	Abeyrathne, PD; Lalev, AI; Nazar, RN				Abeyrathne, PD; Lalev, AI; Nazar, RN			A RAC protein-binding site in the internal transcribed spacer 2 of pre-rRNA transcripts from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; STRUCTURAL FEATURES; FUNCTIONAL-ANALYSIS; DNA; SEQUENCE; COMPLEX; MUTAGENESIS; MATURATION; MRP	The interdependence of steps in the processing of the eukaryotic preribosomal rRNA transcripts indicate that rRNA processing, at least in part, acts as a quality control mechanism to help ensure that only functional rRNA is incorporated into mature ribosomes. In search of structural components that underlie this interdependence, we have isolated a large protein complex or RAC that contains an independent binding site for all four of the transcribed spacers in the nascent pre-rRNA. In this study the RAC-binding site in the internal transcribed spacer 2 sequence of Schizosaccharomyces pombe rRNA transcripts was identified, and the influence of this site on rRNA maturation was assessed. Modification exclusion analyses indicate that the protein complex interacts with a helical domain previously shown to contain features common to both the internal transcribed spacer 1 and the 3'-external transcribed spacer. Mutagenic analyses in vitro confirm an interaction with this sequence, and parallel analyses in vivo indicated a critical role in both the maturation of the rRNA components of the large subunit as well as the 18 S rRNA component of the small subunit. Hybridization analyses also indicated greatly elevated levels of unprocessed nascent RNA. These effects are contrasted with mutations in other regions of the secondary structure that resulted in some reduction of plasmid-derived mature rRNA but no elevated levels of the precursor molecules. The significance with respect to rRNA maturation and the interdependences in rRNA processing are discussed.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Nazar, RN (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	rnnazar@UoGuelph.CA						Abeyrathne PD, 2000, BIOTECHNIQUES, V29, P1172, DOI 10.2144/00296bm03; ABOUELELA S, 1995, BBA-GENE STRUCT EXPR, V1262, P164, DOI 10.1016/0167-4781(95)00074-Q; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; BACHELLERIE JP, 1983, MOL BIOL REP, V9, P79, DOI 10.1007/BF00777477; Chaconas G, 1980, Methods Enzymol, V65, P75; Chamberlain JR, 1998, GENE DEV, V12, P1678, DOI 10.1101/gad.12.11.1678; CHOI YC, 1974, CELL NUCLEUS, V3, P109; ELELA SA, 1994, NUCLEIC ACIDS RES, V22, P686, DOI 10.1093/nar/22.4.686; GOOD L, 1992, NUCLEIC ACIDS RES, V20, P4934, DOI 10.1093/nar/20.18.4934; Good L, 1997, J MOL BIOL, V273, P782, DOI 10.1006/jmbi.1997.1351; Hitchen J, 1997, J MOL BIOL, V274, P481, DOI 10.1006/jmbi.1997.1376; Intine RVA, 1999, J MOL BIOL, V286, P695, DOI 10.1006/jmbi.1998.2502; Lalev AI, 1999, NUCLEIC ACIDS RES, V27, P3071, DOI 10.1093/nar/27.15.3071; Lalev AI, 2001, J BIOL CHEM, V276, P16655, DOI 10.1074/jbc.M101157200; Lalev AI, 1998, J MOL BIOL, V284, P1341, DOI 10.1006/jmbi.1998.2222; Lalev AI, 2000, J MOL BIOL, V302, P65, DOI 10.1006/jmbi.2000.4015; LEE Y, 1995, J BIOL CHEM, V270, P28003; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; MUSTERS W, 1990, RIBOSOME, P435; MUSTERS W, 1990, EMBO J, V9, P3989, DOI 10.1002/j.1460-2075.1990.tb07620.x; NAZAR RN, 1987, J BIOL CHEM, V262, P7523; NAZAR RN, 1982, CELL NUCLEUS, V11, P1; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PEATTIE DA, 1981, P NATL ACAD SCI-BIOL, V78, P2273, DOI 10.1073/pnas.78.4.2273; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RAUE HA, 1995, GENE EXPRESSION, V5, P71; RAUE HA, 1991, PROG NUCLEIC ACID RE, V41, P89; SAMBROOK J, 1982, MOL CLONING LAB MANU, P133; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spasov K, 2002, MOL CELL, V9, P433, DOI 10.1016/S1097-2765(02)00461-6; STOHL LL, 1992, MOL CELL BIOL, V12, P2561, DOI 10.1128/MCB.12.6.2561; SUBRAHMANYAM CS, 1982, NUCLEIC ACIDS RES, V10, P3667, DOI 10.1093/nar/10.12.3667; VANDERSANDE CAFM, 1992, J MOL BIOL, V223, P899, DOI 10.1016/0022-2836(92)90251-E; VANNUES RW, 1995, J MOL BIOL, V250, P24, DOI 10.1006/jmbi.1995.0355; VANRYK DI, 1992, J MOL BIOL, V226, P1027, DOI 10.1016/0022-2836(92)91050-Y; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587; YEH LCC, 1990, J MOL BIOL, V211, P699, DOI 10.1016/0022-2836(90)90071-S	40	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21291	21299		10.1074/jbc.M201751200	http://dx.doi.org/10.1074/jbc.M201751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923314	hybrid			2022-12-25	WOS:000176286000024
J	Hausmann, S; Shuman, S				Hausmann, S; Shuman, S			Characterization of the CTD phosphatase Fcp1 from fission yeast - Preferential dephosphorylation of serine 2 versus serine 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TERMINAL DOMAIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; PHOSPHOSERINE PHOSPHATASE; ELONGATION COMPLEXES; CAPPING ENZYMES; TRANSCRIPTION; PHOSPHORYLATION; PURIFICATION	The C-terminal domain (CTD) of RNA polymerase II undergoes extensive phosphorylation and dephosphorylation at positions Ser(2) and Ser(5) during the transcription cycle. A single CTD phosphatase, Fcp1, has been identified in yeast and metazoans. Here we conducted a biochemical characterization of Fcp1 from the fission yeast Schizosaccharomyces pombe. The 723-amino acid Fcp1 protein was expressed at high levels in bacteria. Recombinant Fcp1 catalyzed the metal-dependent hydrolysis of para-nitrophenyl phosphate with a pH optimum of 5.5 (k(cat) = 2 s(-1); K-m = 19 mm). Deletion analysis showed that 139- and 143-amino acid segments could be deleted from the N and C termini of Fcp1, respectively, without affecting phosphatase activity. A segment containing amino acids 487-580, deletion of which abolished activity, embraces a BRCT domain present in all known Fcp1 orthologs. Mutations of residues Asp(170) and ASp(172) abrogated Fcp1 phosphatase activity; the essential aspartates are located within a (DXDXT172)-D-170 motif that defines a superfamily of metal-dependent phosphotransferases. We exploited defined synthetic CTD phosphopeptide substrates to show for the first time that: (i) Fcp1 CTD phosphatase activity is not confined to native polymerase II and (ii) Fcp1 displays an inherent preference for a particular CTD phosphorylation array. Using equivalent concentrations (25 gm) of CTD peptides of identical amino acid sequence and phosphoserine content, which differed only in the positions of phosphoserine within the heptad, we found that Fcp1 was 10-fold more active in dephosphorylating Ser(2)-PO4 than Ser(5)-PO4.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Chambers RS, 1996, J BIOL CHEM, V271, P24498, DOI 10.1074/jbc.271.40.24498; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1999, J BIOL CHEM, V274, P33985, DOI 10.1074/jbc.274.48.33985; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	30	82	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21213	21220		10.1074/jbc.M202056200	http://dx.doi.org/10.1074/jbc.M202056200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934898	hybrid			2022-12-25	WOS:000176286000014
J	Khan, H; Harris, RJ; Barna, T; Craig, DH; Bruce, NC; Munro, AW; Moody, PCE; Scrutton, NS				Khan, H; Harris, RJ; Barna, T; Craig, DH; Bruce, NC; Munro, AW; Moody, PCE; Scrutton, NS			Kinetic and structural basis of reactivity of pentaerythritol tetranitrate reductase with NADPH, 2-cyclohexenone, nitroesters, and nitroaromatic explosives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; ESTROGEN-BINDING PROTEIN; MORPHINONE REDUCTASE; 2,4,6-TRINITROTOLUENE; SEQUENCE; DEGRADATION; TRINITRATE; CLONING; FLAVIN	The reaction of pentaerythritol tetranitrate reductase with reducing and oxidizing substrates has been studied by stopped-flow spectrophotometry, redox potentiometry, and X-ray crystallography. We show in the reductive half-reaction of pentaerythritol tetranitrate (PETN) reductase that NADPH binds to form an enzyme-NADPH charge transfer intermediate prior to hydride transfer from the nicotinamide coenzyme to FMN. In the oxidative half-reaction, the two-electron-reduced enzyme reacts with several substrates including nitroester explosives (glycerol trinitrate and PETN), nitroaromatic explosives (trinitrotoluene (TNT) and picric acid), and alpha,beta-unsaturated carbonyl compounds (2-cyclohexenone). Oxidation of the flavin by the nitroaromatic substrate TNT is kinetically indistinguishable from formation of its hydride-Meisenheimer complex, consistent with a mechanism involving direct nucleophilic attack by hydride from the flavin N5 atom at the electron-deficient aromatic nucleus of the substrate. The crystal structures of complexes of the oxidized enzyme bound to picric acid and TNT are consistent with direct hydride transfer from the reduced flavin to nitroaromatic substrates. The mode of binding the inhibitor 2,4-dinitrophenol (2,4-DNP) is similar to that observed with picric acid and TNT. In this position, however, the aromatic nucleus is not activated for hydride transfer from the flavin N5 atom, thus accounting for the lack of reactivity with 2,4-DNP. Our work with PETN reductase establishes further a close relationship to the Old Yellow Enzyme family of proteins but at the same time highlights important differences compared with the reactivity of Old Yellow Enzyme. Our studies provide a structural and mechanistic rationale for the ability of PETN reductase to react with the nitroaromatic explosive compounds TNT and picric acid and for the inhibition of enzyme activity with 2,4-DNP.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Ctr Chem Biol, Leicester LE1 7RH, Leics, England; Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England	University of Leicester; University of Leicester; University of Cambridge	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	Munro, Andrew/G-5639-2019; Moody, Peter/A-6832-2008; barna, terez/R-1357-2018	Munro, Andrew/0000-0002-4642-180X; Moody, Peter/0000-0003-1762-9238; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Blehert DS, 1997, J BACTERIOL, V179, P6912, DOI 10.1128/jb.179.22.6912-6920.1997; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; Buckman J, 2000, BIOCHEMISTRY-US, V39, P10521, DOI 10.1021/bi0006520; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; Dutton P L, 1978, Methods Enzymol, V54, P411; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; French CE, 1999, NAT BIOTECHNOL, V17, P491, DOI 10.1038/8673; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Gutierrez A, 2001, BIOCHEMISTRY-US, V40, P1964, DOI 10.1021/bi001719m; Hooker BS, 1999, NAT BIOTECHNOL, V17, P428, DOI 10.1038/8596; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1986, J BIOL CHEM, V261, P1215; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; SAITO K, 1991, J BIOL CHEM, V266, P20720; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; VORBECK C, 1994, J BACTERIOL, V176, P932, DOI 10.1128/jb.176.3.932-934.1994; Williams RE, 2001, BIOCHEM SOC SYMP, V68, P143; WILLIAMS RE, 1999, FLAVINS FLAVOPROTEIN, P663	34	70	73	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21906	21912		10.1074/jbc.M200637200	http://dx.doi.org/10.1074/jbc.M200637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923299	hybrid			2022-12-25	WOS:000176286000102
J	Lin, F; Kolluri, SK; Chen, GQ; Zhang, XK				Lin, F; Kolluri, SK; Chen, GQ; Zhang, XK			Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; THYROID-HORMONE RECEPTOR; ACTIVATOR PROTEIN-1 ACTIVITY; HUMAN LUNG-CANCER; FACTOR COUP-TF; A-I GENE; X-RECEPTOR; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR	Retinoids are therapeutically effective in the treatment of various cancers, and some of the therapeutic action of retinoids can be ascribed to their potent inhibition of AP-1 activity that regulates transcription of genes associated with cell growth. We recently reported that the expression of orphan receptor chicken ovalbumin upstream promoter-transcription factor (COUP-TF) plays a role in mediating the growth inhibitory effect of trans-retinoic acid (trans-RA) in cancer cells. To gain insight into the molecular mechanism by which COUP-TF regulates trans-RA activity, we evaluated the effect of COUP-TF on antagonism of AP-1 activity by trans-RA. Our results demonstrated a positive correlation between COUP-TF expression and the ability of trans-RA to inhibit AP-1 activity in various cancer cell lines. In transient transfection assay, expression of COUP-TF strongly inhibited tumor promoter 12-O-tetradecanoylphorbol-13-acetate-induced AP-1 transactivation activity and transactivation of c-Jun/c-Fos in both a trans-RA-dependent and -independent manner. In vitro studies demonstrated that the addition of COUP-TF inhibited c-Jun DNA binding through a direct protein-protein interaction that is mediated by the DNA binding domain of COUP-TF and the leucine zipper of c-Jun. Stable expression of COUP-TF in COUP-TF-negative MDA-MB231 breast cancer cells restored the ability of trans-RA to inhibit 12-O-tetradecanoylphorbol-13-acetate-induced c-Jun expression. The effect of COUP-TF in enhancing the trans-RA-induced antagonism of AP-1 activity required expression of retinoic acid receptors (RARs), since stable expression of COUP-TF in COUP-TF-negative HT-1376 bladder cancer cells, which do not express RARalpha and RARbeta, failed to restore trans-RA-induced AP-1 repression. Thus, COUP-TF, through its physical interaction with AP-1, promotes anticancer effects of retinoids by potentiating their anti-AP-1 activity.	Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Zhang, XK (corresponding author), Burnham Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Agadir A, 1997, CANCER RES, V57, P3444; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Gudas Lorraine J., 1994, P443; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; Klinge CM, 1999, J STEROID BIOCHEM, V71, P1, DOI 10.1016/S0960-0760(99)00124-7; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lee HY, 1996, CELL GROWTH DIFFER, V7, P997; Li JJ, 1996, CANCER RES, V56, P483; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lin F, 2000, CANCER RES, V60, P3271; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; Robinson CE, 1999, ENDOCRINOLOGY, V140, P1586, DOI 10.1210/en.140.4.1586; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Soprano DR, 1996, ONCOGENE, V12, P577; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Yang L, 1999, BREAST CANCER RES TR, V56, P277, DOI 10.1023/A:1006219411078; Yang LM, 1997, CANCER RES, V57, P4652; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; Zhang XK, 1996, MUTAT RES-FUND MOL M, V350, P267, DOI 10.1016/0027-5107(95)00102-6; ZHANG XK, 1993, RECEPTOR, V3, P183; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	55	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21414	21422		10.1074/jbc.M201885200	http://dx.doi.org/10.1074/jbc.M201885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934895	hybrid			2022-12-25	WOS:000176286000039
J	Solovyan, VT; Bezvenyuk, ZA; Salminen, A; Austin, CA; Courtney, MJ				Solovyan, VT; Bezvenyuk, ZA; Salminen, A; Austin, CA; Courtney, MJ			The role of topoisomerase II in the excision of DNA loop domains during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CELL-DEATH; INTERNUCLEOSOMAL FRAGMENTATION; NEUROBLASTOMA-CELLS; CLEAVAGE; INHIBITOR; ORGANIZATION; INVOLVEMENT; MECHANISMS; ETOPOSIDE	Disintegration of nuclear DNA into high molecular weight (HMW) and oligonucleosomal DNA fragments represents two major periodicities of DNA fragmentation during apoptosis. These are thought to originate from the excision of DNA loop domains and from the cleavage of nuclear DNA at the internucleosomal positions, respectively. In this report, we demonstrate that different apoptotic insults induced apoptosis in NB-2a neuroblastoma cells that was invariably accompanied by the formation of HMW DNA fragments of about 50-100 kb but proceeded either with or without oligonucleosomal DNA cleavage, depending on the type of apoptotic inducer. We demonstrate that differences in the pattern of DNA fragmentation were reproducible in a cell-free apoptotic system and develop conditions that allow in vitro separation of the RAW and oligonucleosomal DNA fragmentation activities. In contrast to apoptosis associated with oligonucleosomal DNA fragmentation, the HMW DNA cleavage in apoptotic cells was accompanied by down-regulation of caspase-activated DNase (CAD) and was not affected by z-VAD-fmk, suggesting that the caspase/CAD pathway is not involved in the excision of DNA loop domains. We further demonstrate that nonapoptotic NB-2a cells contain a constitutively present nuclease activity located in the nuclear matrix fraction that possessed the properties of topoisomerase (topo) II and was capable of reproducing the pattern of HMW DNA cleavage that occurred in apoptotic cells. We demonstrate that the early stages of apoptosis induced by different stimuli were accompanied by activation of topo II-mediated HMW DNA cleavage that was reversible after removal of apoptotic inducers, and we present evidence of the involvement of topo II in the formation of HMW DNA fragments at the advanced stages of apoptosis. The results suggest that topo II is involved in caspase-independent excision of DNA loop domains during apoptosis, and this represents an alternative pathway of apoptotic DNA disintegration from CAD-driven caspase-dependent oligonucleosomal DNA cleavage.	Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Ukrainian Acad Sci, Inst Mol Biol & Genet, UA-252627 Kiev, Ukraine; Univ Kuopio, Kuopio Univ Hosp, FIN-70211 Kuopio, Finland; Univ Newcastle Upon Tyne, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Eastern Finland; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Kuopio University Hospital; University of Eastern Finland; Newcastle University - UK	Solovyan, VT (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland.		Courtney, Michael J/D-6648-2016	Courtney, Michael J/0000-0001-8693-3933; Austin, Caroline/0000-0002-1921-5947				Bezvenyuk Z, 2000, MOL BRAIN RES, V81, P191, DOI 10.1016/S0169-328X(00)00174-1; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COOK PR, 1976, J CELL SCI, V22, P287; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hinck L, 2001, BIOL REPROD, V64, P555, DOI 10.1095/biolreprod64.2.555; JACKSON DA, 1992, CELL BIOL INT REP, V16, P687, DOI 10.1016/S0309-1651(05)80013-X; Jackson DA, 1995, INT REV CYTOL, V162A, P125; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAGARKOVA MA, 1995, J BIOL CHEM, V270, P20239, DOI 10.1074/jbc.270.35.20239; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; LIU LF, 1983, CRC CR REV BIOCH MOL, V15, P1, DOI 10.3109/10409238309102799; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Solovyan V, 1999, NEUROCHEM INT, V34, P465, DOI 10.1016/S0197-0186(99)00017-0; Solovyan V, 1998, MOL BRAIN RES, V62, P43, DOI 10.1016/S0169-328X(98)00234-4; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Tsutsui K, 2001, J BIOL CHEM, V276, P5769, DOI 10.1074/jbc.M008517200; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Widlak P, 2000, J BIOL CHEM, V275, P8226, DOI 10.1074/jbc.275.11.8226; Willmore E, 1998, MOL PHARMACOL, V54, P78, DOI 10.1124/mol.54.1.78; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	37	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21458	21467		10.1074/jbc.M110621200	http://dx.doi.org/10.1074/jbc.M110621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940566	hybrid			2022-12-25	WOS:000176286000045
J	Suzuki-Inoue, K; Tulasne, D; Shen, Y; Bori-Sanz, T; Inoue, O; Jung, SM; Moroi, M; Andrews, RK; Berndt, MC; Watson, SP				Suzuki-Inoue, K; Tulasne, D; Shen, Y; Bori-Sanz, T; Inoue, O; Jung, SM; Moroi, M; Andrews, RK; Berndt, MC; Watson, SP			Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; COLLAGEN RECEPTOR; TYROSINE PHOSPHORYLATION; PLATELET ACTIVATION; SH3 DOMAIN; PHOSPHOLIPASE C-GAMMA-2; ZETA-CHAIN; SRC; EXPRESSION; BINDING	The glycoprotein VI (GPVI)-Fc receptor (FcR) gamma-chain complex, a key activatory receptor for collagen on platelet surface membranes, is constitutively associated with the Src family kinases Fyn and Lyn. Molecular cloning of GPVI has revealed the presence of a proline-rich domain in the sequence of GPVI cytoplasmic tail which has the consensus for interaction with the Src homology 3 (SH3) domains of Fyn and Lyn. A series of in vitro experiments demonstrated the ability of the SH3 domains of both Src kinases to bind the proline-rich domain of GPVI. Furthermore, depletion of the proline-rich domain in GPVI (Pro(-)-GPVI) prevented binding of Fyn and Lyn and markedly reduced phosphorylation of FcR gamma-chain in transiently transfected COS-7 cells, but did not affect the association of the gamma-chain with GPVI. Jurkat cells stably transfected with wild type GPVI show robust increases in tyrosine phosphorylation and intracellular Ca2+ in response to the snake venom convulxin that targets GPVI. Importantly, convulxin is not able to activate cells transfected with Pro(-)-GPVI, even though the association with the immunoreceptor tyrosine-based activation motif-containing chains is maintained. These findings demonstrate that the proline-rich domain of GPVI mediates the association with Fyn/Lyn via their SH3 domain and that this interaction initiates activation signals through GPVI.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, Melbourne, Vic 8008, Australia; Med Sch Edgbaston, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan; Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3168, Australia	University of Oxford; Baker Heart and Diabetes Institute; Kurume University; Monash University	Suzuki-Inoue, K (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	katsue.inoue@pharm.ox.ac.uk	Watson, Stephen P/Q-6292-2016; Tulasne, David/AAR-5287-2020; Berndt, Michael C/D-5580-2012; Tulasne, David/A-8705-2008	Watson, Stephen P/0000-0002-7846-7423; Tulasne, David/0000-0002-6764-7242; Andrews, Robert Keith/0000-0001-9577-8082				Andrews RK, 2001, J BIOL CHEM, V276, P28092, DOI 10.1074/jbc.M011352200; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Berlanga O, 2000, BLOOD, V96, P2740; BERLANGA O, 2002, IN PRESS EUR J BIOCH; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kehrel B, 1998, BLOOD, V91, P491; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Quek LS, 2000, BLOOD, V96, P4246; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200; zurHausen JD, 1997, EUR J IMMUNOL, V27, P2643, DOI 10.1002/eji.1830271025	40	137	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21561	21566		10.1074/jbc.M201012200	http://dx.doi.org/10.1074/jbc.M201012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943772	hybrid			2022-12-25	WOS:000176286000059
J	Celie, PHN; van Stempvoort, G; Fribourg, C; Schurgers, LJ; Lenting, PJ; Mertens, K				Celie, PHN; van Stempvoort, G; Fribourg, C; Schurgers, LJ; Lenting, PJ; Mertens, K			The connecting segment between both epidermal growth factor-like domains in blood coagulation factor IX contributes to stimulation by factor VIIIa and its isolated A2 Domain.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; X-RAY STRUCTURE; ACTIVE-SITE; HEMOPHILIA-B; LIGHT-CHAIN; INTERACTIVE SITES; CHRISTMAS FACTOR; ENZYME-ACTIVITY; BINDING-SITE; SUBUNIT	The light chain of activated factor IX comprises multiple interactions between both epidermal growth factor-like domains that contribute to enzymatic activity and binding of factor IXa to its cofactor factor VIIIa. To investigate the association between factor IXa-specific properties and surface-exposed structure elements, chimeras were constructed in which the interconnection between the modules Leu(84)-Thr(87) and the factor IX-specific loop Asn(89)-Lys(91) were exchanged for corresponding regions of factor X and factor VII. In absence of factor VIIIa, all chimeras displayed normal enzymatic activity. In the presence of factor VIIIa, replacement of loop Asn(89)-Lys(91) resulted in a minor reduction in factor IXa activity. However, chimeras with substitutions or insertions in the spacer between the epidermal growth factor-like domains showed a major defect in response to factor VIIIa. Of these chimeras, some displayed a normal response to isolated factor VIII A2 domain as a cofactor in factor X activation. Surprisingly, chimeras containing elongated inter-domain spacers from factor X or VII displayed reduced response to both complete factor VIIIa and the isolated A2 domain. Moreover, these chimeras still displayed effective association with immobilized A2 domain as assessed by surface plasmon resonance. We conclude that both sequence and length of the junction Leu(84)-Thr(87) between both epidermal growth factor-like domains contribute to the enhancement of factor IXa enzymatic activity that occurs upon assembly with factor VIIIa.	Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, NL-1066 CX Amsterdam, Netherlands; Maastricht Univ, Dept Biochem, NL-6200 MD Maastricht, Netherlands; Univ Utrecht, UIPS, Dept Pharmaceut, NL-3584 CA Utrecht, Netherlands	Maastricht University; Utrecht University	Mertens, K (corresponding author), Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Schurgers, Leon/AAT-7100-2021; Celie, Patrick/AAY-9559-2021; Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Schurgers, Leon/0000-0001-7867-6957				Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; Banner DW, 1997, THROMB HAEMOSTASIS, V78, P512; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Celie PHN, 2000, J BIOL CHEM, V275, P229, DOI 10.1074/jbc.275.1.229; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Johnson DJD, 1999, J STRUCT BIOL, V125, P90, DOI 10.1006/jsbi.1998.4078; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; OLSEN ENH, 2001, THROMB HAEMOSTASIS S, V86; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; TAO BY, 1994, PCR TECHNOLOGY CURRE, P71; Wilkinson FH, 2002, J BIOL CHEM, V277, P5734, DOI 10.1074/jbc.M107753200	35	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20214	20220		10.1074/jbc.M108446200	http://dx.doi.org/10.1074/jbc.M108446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925427	hybrid			2022-12-25	WOS:000176204500017
J	Filipek, A; Jastrzebska, B; Nowotny, M; Kwiatkowska, K; Hetman, M; Surmacz, L; Wyroba, E; Kuznicki, J				Filipek, A; Jastrzebska, B; Nowotny, M; Kwiatkowska, K; Hetman, M; Surmacz, L; Wyroba, E; Kuznicki, J			Ca2+-dependent translocation of the calcyclin-binding protein in neurons and neuroblastoma NB-2a cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; KINASE-C; SUBCELLULAR-LOCALIZATION; HIPPOCAMPAL-NEURONS; IN-VITRO; S100; FAMILY; TARGET; ASSOCIATION; EXPRESSION	The calcyclin-binding protein (CacyBP) binds calcyclin (S100A6) at physiological levels of [Ca2+] and is highly expressed in brain neurons. Subcellular localization of CacyBP was examined in neurons and neuroblastoma NB-2a cells at different [Ca2+](i). Immunostaining indicates that CacyBP is present in the cytoplasm of unstimulated cultured neurons in which resting [Ca2+](i) is known to be similar to50 nm. When [Ca2+]i was increased to above 300 nm by KCl treatment, the immunostaining was mainly apparent as a ring around the nucleus. Such perinuclear localization of CacyBP was observed in untreated neuroblastoma NB-2a cells in which [Ca2+]. is similar to120 nm. An additional increase in [Ca2+](i) to above 300 nm by thapsigargin treatment did not change CacyBP localization. However, when [Ca2+](i) in NB-2a cells dropped to 70 nm, because of BAPTA/AM treatment, perinuclear localization was diminished. Ca2+-induced translocation of CacyBP was confirmed by immunogold electron microscopy and by fluorescence of NB-2a cells transfected with an EGFP-CacyBP vector. Recombinant CacyBP can be phosphorylated by protein kinase C in vitro. In untreated neuroblastoma NB-2a cells, CacyBP is phosphorylated on a serine residue(s), but exists in the dephosphorylated form in BAPTA/AM-treated cells. Thus, phosphorylation of CacyBP occurs in the same [Ca2+](i) range that leads to its perinuclear translocation.	M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Filipek, A (corresponding author), M Nencki Inst Expt Biol, 3 Pasteur St, PL-02093 Warsaw, Poland.	anfil@nencki.gov.pl	Kwiatkowska, Katarzyna/ABE-9713-2021; Wyroba, Elzbieta/R-7525-2016; Kuznicki, Jacek/AAW-9239-2020; Surmacz, Liliana/I-3458-2016; Wyroba, Elzbieta/P-4434-2019	Kwiatkowska, Katarzyna/0000-0002-0550-8394; Kuznicki, Jacek/0000-0001-6486-0657; Filipek, Anna/0000-0001-9484-9555; Surmacz, Liliana/0000-0002-9517-1608				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARANSKA J, 1995, CELL CALCIUM, V17, P207, DOI 10.1016/0143-4160(95)90035-7; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Filipek A, 1998, J NEUROCHEM, V70, P1793, DOI 10.1046/j.1471-4159.1998.70051793.x; Filipek A, 1996, BIOCHEM J, V320, P585, DOI 10.1042/bj3200585; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GRYNKIEWICZ G, 1982, J BIOL CHEM, V60, P3440; Hayashi T, 1997, J NEURAL TRANSM, V104, P811, DOI 10.1007/BF01285550; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jastrzebska B, 2000, J HISTOCHEM CYTOCHEM, V48, P1195, DOI 10.1177/002215540004800903; Kaminska B, 2001, BRIT J PHARMACOL, V133, P997, DOI 10.1038/sj.bjp.0704177; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KUZNICKI J, 1996, GUIDEBOOK CALCIUM BI, P143; Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Narita K, 1998, J GEN PHYSIOL, V112, P593, DOI 10.1085/jgp.112.5.593; Nowotny M, 2000, J BIOL CHEM, V275, P31178, DOI 10.1074/jbc.M001622200; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; RANDALL RD, 1992, J NEUROSCI, V12, P1882; REGGIO H, 1983, METHOD ENZYMOL, V98, P379; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; Wang LJ, 1998, DEV BRAIN RES, V105, P227, DOI 10.1016/S0165-3806(97)00180-6; Xia ZB, 2000, J HEMATOTH STEM CELL, V9, P651, DOI 10.1089/15258160050196696; Zhao XQ, 2000, BIOCHEM BIOPH RES CO, V267, P77, DOI 10.1006/bbrc.1999.1918; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	38	47	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21103	21109		10.1074/jbc.M111010200	http://dx.doi.org/10.1074/jbc.M111010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927578	hybrid			2022-12-25	WOS:000176204500126
J	Hernandez-Acosta, P; Schmid, DG; Jung, G; Culianez-Macia, FA; Kupke, T				Hernandez-Acosta, P; Schmid, DG; Jung, G; Culianez-Macia, FA; Kupke, T			Molecular characterization of the Arabidopsis thaliana flavoprotein AtHAL3a reveals the general reaction mechanism of 4 '-phosphopantothenoylcysteine decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A BIOSYNTHESIS; OXIDATIVE DECARBOXYLATION; MASS-SPECTROMETRY; ESCHERICHIA-COLI; SUBSTRATE; PEPTIDES; EPIDERMIN; PROTEINS; BACTERIA; ENZYME	The Arabidopsis thaliana flavoprotein AtHAL3a, which is linked to plant growth and salt and osmotic tolerance, catalyzes the decarboxylation of 4'-phosphopantothenoyleysteine to 4'-phosphopantetheine, a key step in coenzyme A biosynthesis. AtHAL3a is similar in sequence and structure to the LanD enzymes EpiD and MrsD, which catalyze the oxidative decarboxylation of peptidylcysteines. Therefore, we hypothesized that the decarboxylation of 4'-phosphopantothenoylcysteine also occurs via an oxidatively decarboxylated intermediate containing an aminoenethiol group. A set of AtHAL3a mutants were analyzed to detect such an intermediate. By exchanging Lys(34), we found that AtHAL3a is not only able to decarboxylate 4'-phosphopantothenoylcysteine but also pantothenoyleysteine to pantothenoylcysteamine. Exchanging residues within the substrate binding clamp of AtHAL3a (for example of Gly(179)) enabled the detection of the proposed aminoenethiol intermediate when pantothenoylcysteine was used as substrate. This intermediate was characterized by its high absorbance at 260 and 280 nm, and the removal of two hydrogen atoms and one molecule of CO2 was confirmed by ultrahigh resolution mass spectrometry. Using the mutant AtHAL3a C175S enzyme, the product pantothenoyleysteamine was not detectable; however, oxidatively decarboxylated pantothenoylcysteine could be identified. This result indicates that reduction of the aminoenethiol intermediate depends on a redox-active cysteine residue in AtHAL3a.	Univ Tubingen, Lehrstuhl Mikrobiol Genet, D-72076 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, Valencia 46022, Spain	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobiol Genet, Morgenstelle 15,Verfugungsgebaude, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Audi G, 1995, NUCL PHYS A, V595, P409, DOI 10.1016/0375-9474(95)00445-9; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; Kempter C, 1996, ANGEW CHEM INT EDIT, V35, P2104, DOI 10.1002/anie.199621041; Kupke T, 1997, J BIOL CHEM, V272, P4759, DOI 10.1074/jbc.272.8.4759; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; Majer F, 2002, J BACTERIOL, V184, P1234, DOI 10.1128/JB.184.5.1234-1243.2002; Marshall AG, 1998, MASS SPECTROM REV, V17, P1, DOI 10.1002/(SICI)1098-2787(1998)17:1<1::AID-MAS1>3.0.CO;2-K; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Strauss E, 2001, J AM CHEM SOC, V123, P6449, DOI 10.1021/ja016020y; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200	21	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20490	20498		10.1074/jbc.M201557200	http://dx.doi.org/10.1074/jbc.M201557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923307	hybrid			2022-12-25	WOS:000176204500051
J	Kang, SG; Ortega, J; Singh, SK; Wang, N; Huang, NN; Steven, AC; Maurizi, MR				Kang, SG; Ortega, J; Singh, SK; Wang, N; Huang, NN; Steven, AC; Maurizi, MR			Functional proteolytic complexes of the human mitochondrial ATP-dependent protease, hClpXP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CLPP; SACCHAROMYCES-CEREVISIAE; SPASTIC PARAPLEGIA; BACTERIAL CLPX; PIM1 PROTEASE; HUMAN HOMOLOG; PROTEINS; DEGRADATION; CHAPERONE; SEQUENCE	Human mitochondrial ClpP (hClpP) and ClpX (hClpX) were separately cloned, and the expressed proteins were purified. Electron microscopy confirmed that hClpP forms heptameric rings and that hClpX forms a hexameric ring. Complexes of a double heptameric ring of hClpP with hexameric hClpX rings bound on each side are stable in the presence of ATP or adenosine 5'-(3-thiotriphosphate) (ATPgammaS), indicating that a symmetry mismatch is a universal feature of Clp proteases. hClpXP displays both ATP-dependent proteolytic activity and ATP- or ATPgammaS-dependent peptidase activity. hClpXP cannot degrade lambdaO protein or GFP-SsrA, specific protein substrates recognized by Escherichia coli (e) ClpXP. However, eClpX interacts with hClpP, and, when examined by electron microscopy, the resulting heterologous complexes are indistinguishable from homologous eClpXP complexes. The hybrid eClpX-hClpP complexes degrade eClpX-specific protein substrates. In contrast, eClpA can neither associate with nor activate hClpP. hClpP has an extra C-terminal extension of 28 amino acids. A mutant lacking this C-terminal extension interacts more tightly with both hClpX and eClpX and shows enhanced enzymatic activities but still does not interact with eCIpA. Our results establish that human ClpX and ClpP constitute a bone fide ATP-dependent protease and confirm that substrate selection, which differs between human and E. coli ClpX, is dependent solely on the Clp ATPase. Our data also indicate that human ClpP has conserved sites required for interaction with eClpX but not eCIpA, implying that the modes of interaction with ClpP may not be identical for ClpA and ClpX.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37 Room 1B09,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR027015, Z01AR027015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Corydon TJ, 2000, MAMM GENOME, V11, P899, DOI 10.1007/s003350010173; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; de Sagarra MR, 1999, J MOL BIOL, V292, P819, DOI 10.1006/jmbi.1999.3121; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Majeran W, 2000, PLANT CELL, V12, P137; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Pearce DA, 1999, HUM GENET, V104, P443, DOI 10.1007/s004390050985; Santagata S, 1999, J BIOL CHEM, V274, P16311, DOI 10.1074/jbc.274.23.16311; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; STUART RA, 1994, EXPERIENTIA, V50, P1002, DOI 10.1007/BF01923454; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; van Dyck L, 1998, FEBS LETT, V438, P250, DOI 10.1016/S0014-5793(98)01310-6; Van Dyck L, 1999, CELL MOL LIFE SCI, V56, P825, DOI 10.1007/s000180050029; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957	41	100	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21095	21102		10.1074/jbc.M201642200	http://dx.doi.org/10.1074/jbc.M201642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923310	hybrid			2022-12-25	WOS:000176204500125
J	Wakasugi, K; Slike, BM; Hood, J; Ewalt, KL; Cheresh, DA; Schimmel, P				Wakasugi, K; Slike, BM; Hood, J; Ewalt, KL; Cheresh, DA; Schimmel, P			Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; HUMAN INTERLEUKIN-8 RECEPTOR; INDUCIBLE PROTEIN-10 IP-10; CELL LUNG-CANCER; CXC CHEMOKINES; GAMMA; BINDING; ANTAGONISTS; NEUTROPHILS; RESIDUES	The first step of protein synthesis is catalyzed by aminoacyl-tRNA synthetases. In addition, certain mammalian tRNA synthetases link protein synthesis to cytokine signaling pathways. In particular, human tyrosyl-tRNA synthetase (TyrRS) can be split by proteolysis into two fragments having distinct cytokine activities. One of the TyrRS fragments (mini TyrRS) contains features identical to those in CXC chemokines (like interleukin-8) that also act as angiogenic factors. Here mini TyrRS (but not full-length TyrRS) is shown to stimulate chemotaxis of endothelial cells in vitro and stimulate angiogenesis in each of two in vivo animal models. The angiogenic activity of mini TyrRS can be opposed by anti-angiogenic chemokines like IP-10. Thus, a biological fragment of human tyrosyl-tRNA synthetase links protein synthesis to regulation of angiogenesis.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616	NATIONAL CANCER INSTITUTE [R01CA092577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NCI NIH HHS [CA92577] Funding Source: Medline; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Arenberg DA, 1997, J LEUKOCYTE BIOL, V62, P554, DOI 10.1002/jlb.62.5.554; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Brooks PC, 1999, METH MOL B, V129, P257; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gasperini S, 1999, J IMMUNOL, V162, P4928; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Keane MP, 1997, J IMMUNOL, V159, P1437; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEE J, 1992, J BIOL CHEM, V267, P16283; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Nicolaou KC, 1998, BIOORGAN MED CHEM, V6, P1185, DOI 10.1016/S0968-0896(98)00090-X; Norrby K, 1996, CELL PROLIFERAT, V29, P315, DOI 10.1111/j.1365-2184.1996.tb01583.x; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; STRIETER RM, 1992, AM J PATHOL, V141, P1279; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; Turpaev KT, 1996, EUR J BIOCHEM, V240, P732, DOI 10.1111/j.1432-1033.1996.0732h.x; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	34	103	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20124	20126		10.1074/jbc.C200126200	http://dx.doi.org/10.1074/jbc.C200126200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11956181	hybrid			2022-12-25	WOS:000176204500004
J	Jain, RG; Lenhard, JM				Jain, RG; Lenhard, JM			Select HIV protease inhibitors alter bone and fat metabolism ex vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; MESENCHYMAL STEM-CELLS; MINERAL LOSS; DIFFERENTIATION; OSTEONECROSIS; DENSITY; MEN	Human immunodeficiency virus (HIV) therapies have been associated with alterations in fat metabolism and bone mineral density. This study examined the effects of HIV protease inhibitors (PIs) on bone resorption, bone formation, and adipocyte differentiation using ex vivo cultured osteoclasts, osteoblasts, and adipocytes, respectively. Osteoclast activity, measured using a rat neonatal calvaria assay, increased in the presence of nelfinavir (NFV; 47.2%, p = 0.001), indinavir (34.6%, p = 0.001), saquinavir (24.3%, p = 0.001), or ritonavir (18%, p < 0.01). In contrast, lopinavir (LPV) and amprenavir did not increase osteoclast activity. In human mesenchymal stem cells (hMSCs), the PIs LPV and NFV decreased osteoblast alkaline phosphatase enzyme activity and gene expression significantly (p < 0.05). LPV and NFV diminished calcium deposition and osteoprotegrin expression (p < 0.05), whereas the other PIs investigated did not. Adipogenesis of hMSCs was strongly inhibited by saquinavir and NFV (>50%,p < 0.001) and moderately inhibited by ritonavir and LPV (40%,p < 0.01). Expression of diacylglycerol transferase, a marker of adipocyte differentiation, decreased in hMSCs treated with NFV. Amprenavir and indinavir did not affect adipogenesis or lipolysis. These results suggest that bone and fat formation in hMSCs of bone marrow may be coordinately down-regulated by some but not all PIs.	GlaxoSmithKline Inc, Dept Metab Dis, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Lenhard, JM (corresponding author), GlaxoSmithKline Inc, Dept Metab Dis, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	jml29514@gsk.com						Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145; Beach JW, 1998, CLIN THER, V20, P2; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Carr A, 2001, AIDS, V15, P703, DOI 10.1097/00002030-200104130-00005; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; DUBE MP, 2002, IN PRESS CLIN INFECT; Huang JS, 2001, AIDS, V15, P975, DOI 10.1097/00002030-200105250-00005; Jain RG, 2001, ANTIVIR RES, V51, P151, DOI 10.1016/S0166-3542(01)00148-6; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lenhard JM, 2000, ANTIVIR RES, V47, P121, DOI 10.1016/S0166-3542(00)00102-9; Lenhard JM, 2000, ARTERIOSCL THROM VAS, V20, P2625, DOI 10.1161/01.ATV.20.12.2625; Major NM, 1997, RADIOL CLIN N AM, V35, P1167; Meyer D, 1999, AIDS, V13, P1147, DOI 10.1097/00002030-199906180-00025; Nolan D, 2001, AIDS, V15, P1275, DOI 10.1097/00002030-200107060-00009; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Scribner AN, 2000, J ACQ IMMUN DEF SYND, V25, P19, DOI 10.1097/00126334-200009010-00003; Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005; VARGAS SJ, 1990, BONE, V11, P61, DOI 10.1016/8756-3282(90)90073-8; Weiel JE, 2000, AIDS, V14, P2218, DOI 10.1097/00002030-200009290-00028; White AJ, 2001, SEX TRANSM INFECT, V77, P158, DOI 10.1136/sti.77.3.158; Zhang B, 1999, J CLIN ENDOCR METAB, V84, P4274, DOI 10.1210/jc.84.11.4274	22	113	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19247	19250		10.1074/jbc.C200069200	http://dx.doi.org/10.1074/jbc.C200069200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11937496	hybrid			2022-12-25	WOS:000175894800002
J	Rose, T; Di Cera, E				Rose, T; Di Cera, E			Substrate recognition drives the evolution of serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; GEOMETRY	A method is introduced to identify amino acid residues that dictate the functional diversity acquired during evolution in a protein family. Using over 80 enzymes of the chymotrypsin family, we demonstrate that the general organization of the phylogenetic tree and its functional branch points are fully accounted for by a limited number of residues that cluster around the active site of the protein and define the contact region with the P1-P4 residues of substrate.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231,660 S Euclid Ave, St Louis, MO 63110 USA.			ROSE, Thierry/0000-0001-8863-0207	NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BODE W, 1992, PROTEIN SCI, V1, P426; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FELSENSTEIN J, 1994, PHYLIP PACKAGE VERSI; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Gu X, 1999, MOL BIOL EVOL, V16, P1664, DOI 10.1093/oxfordjournals.molbev.a026080; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Landgraf R, 2001, J MOL BIOL, V307, P1487, DOI 10.1006/jmbi.2001.4540; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MATTEWS II, 1994, BIOCHEMISTRY-US, V33, P3266; RICHARDS FM, 1985, METHOD ENZYMOL, V115, P440; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	15	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19243	19246		10.1074/jbc.C200132200	http://dx.doi.org/10.1074/jbc.C200132200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11925426	hybrid			2022-12-25	WOS:000175894800001
J	Nemergut, ME; Lindsay, ME; Brownawell, AM; Macara, IG				Nemergut, ME; Lindsay, ME; Brownawell, AM; Macara, IG			Ran-binding protein 3 links Crm1 to the Ran guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; EXPORT; RCC1; TRANSPORT; REGULATOR; GTPASE; CHROMOSOME; RECEPTOR; COFACTOR; SIGNAL	Ran-binding protein 3 (RanBP3) is an similar to55-kDa protein that functions as a cofactor for Crm1-mediated nuclear export. RanBP3 stimulates export by enhancing the affinity of Crm1 for Ran-GTP and cargo. However, important additional functions for this cofactor may exist. We now report that RanBP3 associates with the Ran-specific guanine nucleotide exchange factor, regulator of chromosome condensation 1 (RCC1). This interaction was stimulated by the addition of Ran; moreover, Ran.GDP, Ran.TP, and Ran without nucleotide could all stimulate complex formation between RanBP3 and RCC1 even though binding of Ran.GDP to RanBP3 alone was undetectable. RanBP3 could also promote binding of Crm1 to RCC1 in the presence of Ran. Binding of RanBP3 to RCC1 increased the catalytic activity of RCC1 toward Ran, and importantly, the ability of RanBP3 to stimulate RCC1 was not affected by the presence of Crm1. These data indicate that RanBP3 acts as a scaffold protein to promote the efficient assembly of export complexes. By tethering Crm1 to catalytically enhanced RCC1, RanBP3 may lower the entropic barrier for the loading of Ran.GTP onto Crm1. We propose that this provides an additional mechanism by which RanBP3 facilitates export.	Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Brownawell, AM (corresponding author), Univ Virginia, Ctr Cell Signaling, HSC Box 800577, Charlottesville, VA 22908 USA.	amb7c@virginia.edu		Nemergut, Michael/0000-0002-6803-1765	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Black BE, 2001, J CELL BIOL, V152, P141, DOI 10.1083/jcb.152.1.141; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Englmeier L, 2001, EMBO REP, V2, P926, DOI 10.1093/embo-reports/kve200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Lindsay ME, 2001, J CELL BIOL, V153, P1391, DOI 10.1083/jcb.153.7.1391; Macara LG, 1999, CURR BIOL, V9, pR436, DOI 10.1016/S0960-9822(99)80275-9; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Mueller L, 1998, FEBS LETT, V427, P330, DOI 10.1016/S0014-5793(98)00459-1; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Noguchi E, 1999, J BIOCHEM-TOKYO, V125, P574, DOI 10.1093/oxfordjournals.jbchem.a022323; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Plafker SM, 2000, EMBO J, V19, P5502, DOI 10.1093/emboj/19.20.5502; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Sazer S, 2000, J CELL SCI, V113, P1111; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877	32	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17385	17388		10.1074/jbc.c100620200	http://dx.doi.org/10.1074/jbc.c100620200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11932251	hybrid			2022-12-25	WOS:000175685100003
J	Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U				Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U			Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes	ONCOGENE			English	Article						anoikis; epidermal growth factor; epithelial cells	EPIDERMAL-GROWTH-FACTOR; BCL-X-L; FACTOR RECEPTOR; BCL-X(L) EXPRESSION; MONOCLONAL-ANTIBODY; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE; MTA1; MATRIX	The human metastasis-associated gene (MTA1), a member of the nucleosome remodeling complex with histone deacetylase activity, is frequently overexpressed in biologically aggressive epithelial neoplasms. Here, we extend this observation to squamous carcinoma cells, which express high levels of MTA1 relative to normal or immortalized keratinocytes. To address functional aspects of MTA1 expression, we established variants of human immortalized keratinocytes (HaCaT cells) by expressing MTA1 cDNA in both the sense and antisense orientations. We demonstrate that (1) forced MAT1 expression enhances migration and invasion of immortalized keratinocytes; (2) MTA1 expression is necessary but not sufficient for cell survival in the anchorage independent state; (3) MTA1 contributes to expression of the anti-apoptotic Bcl-2 family member Bcl-x(L); (4) MTA1 expression in immortalized keratinocytes depends, in part, on activation of the epidermal growth factor receptor (EGFR). These results establish that, in keratinocytes, MTA1 expression contributes to several aspects of the metastatic phenotype including survival in the anchorage independent state, migration, and invasion.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Mahoney, MG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	My.Mahoney@mail.tju.edu	Mahoney, My/A-2716-2009					Ahmed NU, 1997, BRIT J DERMATOL, V136, P908, DOI 10.1111/j.1365-2133.1997.tb03932.x; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BASU A, 1987, CANCER RES, V47, P2531; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Herman MA, 1999, DEVELOPMENT, V126, P1055; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Jost M, 1997, NUCLEIC ACIDS RES, V25, P3131, DOI 10.1093/nar/25.15.3131; KAWAHARA E, 1995, J CANCER RES CLIN, V121, P133, DOI 10.1007/BF01198094; Kleene R, 1999, J CELL SCI, V112, P2539; LEJEUNE S, 1993, CANCER RES, V53, P3597; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MUKAIDA H, 1991, CANCER, V68, P142, DOI 10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, CANCER RES, V47, P3692; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Simpson A, 2001, GENE, V273, P29, DOI 10.1016/S0378-1119(01)00563-7; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; YONEDA T, 1991, CANCER RES, V51, P4430; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu Z, 2000, CANCER RES, V61, P1707	39	83	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2161	2170		10.1038/sj.onc.1205277	http://dx.doi.org/10.1038/sj.onc.1205277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948399				2022-12-25	WOS:000174555300005
J	Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T				Katsuda, K; Kataoka, M; Uno, F; Murakami, T; Kondo, T; Roth, JA; Tanaka, N; Fujiwara, T			Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells	ONCOGENE			English	Article						p16; adenovirus vector; apoptosis; caspase-3	RETINOBLASTOMA GENE-PRODUCT; KINASE-4 INHIBITOR GENE; S-PHASE ENTRY; POLY(ADP-RIBOSE) POLYMERASE; PROTEIN; EXPRESSION; P53; P16(INK4A); MDM2; P16	The p16 tumor suppressor gene is frequently inactivated in human cancer tissues and cell lines. We previously reported that wild-type p16 expression from an adenovirus vector (Adv/p16) induced p53-dependent apoptotic cell death in non-small cell lung cancer (NSCLC) cell fines. Here we show the potential mechanism of apoptosis induced by Adv/p16 infection. Infection of human NSCLC cell line A549, which carries the wild-type p53 gene, with Adv/p16 resulted in activation of caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP), on day 3 of infection. The retinoblastoma (Rb) cell cycle regulator protein was also cleaved after activation of caspase-3; when the levels of Rb significantly diminished, apoptosis began. When A549 cells were pretreated with the caspase-inhibitory peptide N-acetyl-asp-Glu-Val-Asp-CHO (aldehyde) (Ac-DEVD-CHO), Adv/p16-mediated apoptosis and Rb cleavage were greatly inhibited. Furthermore, MDM2, a negative regulator of p53 expression was upregulated 3 days after Adv/p16 infection, and MDM2 was subsequently cleaved by caspase-3; MDM2 cleavage was inhibited by Ac-DEVD-CHO treatment. These data implied that cleavage of Rb, in addition to activation of caspase-3, represented a mechanism by which Adv/p16 induced apoptotic cell death in human NSCLC cells. Our results support the clinical relevance of Adv/p16 as a treatment for p16-null human NSCLC that express wild-type p53.	Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Tokyo 1040045, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA	Okayama University; National Cancer Center - Japan; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Surg, Div Surg Oncol, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp			NATIONAL CANCER INSTITUTE [P01CA078778, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1996, CANCER RES, V56, P438; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; Herman JG, 1996, CANCER RES, V56, P722; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hu YX, 1997, CLIN CANCER RES, V3, P1473; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JEN J, 1994, CANCER RES, V54, P6353; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kawabe S, 2000, ONCOGENE, V19, P5359, DOI 10.1038/sj.onc.1203935; Kim M, 2000, CELL DEATH DIFFER, V7, P706, DOI 10.1038/sj.cdd.4400703; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAO L, 1995, CANCER RES, V55, P2995; McConkey DJ, 1996, ONCOGENE, V13, P1693; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Steiner MS, 2000, CANCER GENE THER, V7, P360, DOI 10.1038/sj.cgt.7700151; Takeuchi H, 1997, CLIN CANCER RES, V3, P2229; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	50	53	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2108	2113		10.1038/sj.onc.1205272	http://dx.doi.org/10.1038/sj.onc.1205272			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960384	Green Submitted			2022-12-25	WOS:000174827000018
J	Swart-Mataraza, JM; Li, ZG; Sacks, DB				Swart-Mataraza, JM; Li, ZG; Sacks, DB			IQGAP1 is a component of Cdc42 signaling to the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO GTPASES; ACTIN POLYMERIZATION; ACTIVATING PROTEINS; BINDING PROTEIN; GTP-HYDROLYSIS; CELL-POLARITY; TARGET; RAC; IDENTIFICATION; ARGININE	The Ras-GAP related protein IQGAP1 binds several proteins, including actin, calmodulin, E-cadherin and the Rho family GTPase Cdc42. To gain insight into its in vivo function, IQGAP1 was overexpressed in mammalian cells. Transfection of IQGAP1 significantly increased the levels of active, GTP-bound Cdc42, resulting in the formation of peripheral actin microspikes. By contrast, transfection of an IQGAP1 mutant lacking part of the (G) under bar AP-(r) under bar elated (d) under bar omain (IQGAP1DeltaGRD) substantially decreased the amount of GTP-bound Cdc42 in cell lysates. Consistent with these findings, IQGAP1DeltaGRD blocked Cdc42 function in cells that stably overexpress constitutively active Cdc42 and abrogated the effect of bradykinin on Cdc42. In cells transfected with IQGAP1DeltaGRD, bradykinin was unable to activate Cdc42, translocate Cdc42 to the membrane fraction, or induce filopodia production. IQGAP1DeltaGRD transfection altered cellular morphology, producing small, round cells that closely resemble Cdc42(-/-) cells. Some insight into the mechanism was provided by in vitro analysis, which revealed that IQGAP1DeltaGRD increased the intrinsic GTPase activity of Cdc42, thereby increasing the amount of inactive, GDP-bound Cdc42. These data imply that IQGAP1 has a crucial role in transducing Cdc42 signaling to the cytoskeleton.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St,Thorn 530, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735	NCI NIH HHS [CA75205] Funding Source: Medline; NHLBI NIH HHS [HL07627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA075205, R01CA075205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; McCallum SJ, 1998, J BIOL CHEM, V273, P22537, DOI 10.1074/jbc.273.35.22537; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Sokol SY, 2001, J BIOL CHEM, V276, P48425, DOI 10.1074/jbc.M107975200; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999	49	119	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24753	24763		10.1074/jbc.M111165200	http://dx.doi.org/10.1074/jbc.M111165200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11948177	hybrid			2022-12-25	WOS:000176611800102
J	Endo, A; Nagashima, KI; Kurose, H; Mochizuki, S; Matsuda, M; Mochizuki, N				Endo, A; Nagashima, KI; Kurose, H; Mochizuki, S; Matsuda, M; Mochizuki, N			Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES TYROSINE PHOSPHORYLATION; PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; ADAPTER PROTEIN; LYSOPHOSPHATIDIC ACID; DEPENDENT ACTIVATION; KINASE INHIBITORS; SIGNALING PATHWAY; SURFACE-RECEPTOR; ANGIOTENSIN-II	Sphingosine 1-phosphate (S1P), a ligand for endothelial differentiation gene family proteins, is one of the most potent signal mediators released from activated platelets. Here, we report that S1P induces membrane ruffling of human umbilical vein endothelial cells (HUVECs) via the vascular endothelial growth factor receptor (VEGFR), Src family tyrosine kinase(s), and the CrkII adaptor protein. S1P induced prominent phosphorylation of CrkII in HUVECs, indicating that CrkII was involved in the S1P-induced signaling pathway. S1P-induced CrkII phosphorylation was blocked by pertussis toxin and overexpression of the carboxyl terminus of beta-adrenergic receptor kinase, indicating that the betagamma subunit of G(i) was required for the phosphorylation. Notably, the S1P-induced CrkII phosphorylation was also abolished by inhibitors of VEGFR or Sre family tyrosine kinases. By using Picchu, a real time monitoring protein for CrkII phosphorylation, we found that S1P induced rapid CrkII phosphorylation at membrane ruffles. Finally, we observed that expression of a dominant negative mutant of CrkII inhibited the S1P-induced membrane ruffling and cell migration. These results delineated a novel S1P signaling pathway that involves sequential activation of G(i)-coupled receptor(s), VEGFR, Sre family tyrosine kinase(s), and the CrkII adaptor protein, and which is responsible for both the induction of membrane ruffling and the increase in cell motility.	Natl Cardiovasc Ctr, Inst Res, Dept Struct Anal, Suita, Osaka 5658565, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Bunkyo Ku, Tokyo 1130033, Japan; Jikei Univ, Sch Med, Div Cardiol, Minato Ku, Tokyo 1058461, Japan; Osaka Univ, Dept Tumor Virol, Microbial Dis Res Inst, Osaka 5650871, Japan	National Cerebral & Cardiovascular Center - Japan; University of Tokyo; Jikei University; Osaka University	Mochizuki, N (corresponding author), Natl Cardiovasc Ctr, Inst Res, Dept Struct Anal, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.			Matsuda, Michiyuki/0000-0002-5876-9969				BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kovala AT, 2000, FASEB J, V14, P2486, DOI 10.1096/fj.00-0147com; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Ohmori T, 2001, J BIOL CHEM, V276, P5274, DOI 10.1074/jbc.M005405200; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Panetti TS, 2000, ARTERIOSCL THROM VAS, V20, P1013, DOI 10.1161/01.ATV.20.4.1013; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Strawn LM, 1996, CANCER RES, V56, P3540; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291	60	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23747	23754		10.1074/jbc.M111794200	http://dx.doi.org/10.1074/jbc.M111794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956190	hybrid			2022-12-25	WOS:000176475700085
J	Malfait, AM; Liu, RQ; Ijiri, K; Komiya, S; Tortorella, MD				Malfait, AM; Liu, RQ; Ijiri, K; Komiya, S; Tortorella, MD			Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL COLLAGENASE MMP-8; HUMAN SYNOVIAL-FLUID; MATRIX-METALLOPROTEINASE; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; CLEAVAGE-SITE; KNEE CARTILAGE; PROTEOGLYCAN; CATABOLISM; FRAGMENTS	Osteoarthritis is a degenerative joint disorder characterized by breakdown of articular cartilage. Degradation of aggrecan, which together with type 11 collagen provides cartilage with its unique characteristics of compressibility and elasticity, is an early and sustained feature of osteoarthritis. The present work was set up to identify the enzyme(s) responsible for aggrecan breakdown in osteoarthritis. We found that the two cartilage aggrecanases, ADAM-TS4 and ADAM-TS5, are present in osteoarthritic cartilage and that they are responsible for aggrecan degradation without the participation of matrix metalloproteinases. This is based on 1) neoepitopes found on aggrecan fragments in osteoarthritis (OA) cartilage explants in vitro, 2) aggrecan fragments detected in synovial fluid of OA patients, 3) the observation that an aggrecanase inhibitor, BB-16, blocked aggrecan degradation in OA cartilage in vitro, whereas the matrix metalloproteinase inhibitor XS309 did not, and 4) the presence of mRNA and protein for ADAM-TS4 and ADAM-TS5 in OA cartilage. These results suggest that ADAM-TS4 and ADAM-TS5 represent a potential target for the treatment of osteoarthritis.	DuPont Pharmaceut Co, Wilmington, DE 19880 USA; Imperial Coll Sch Med, London W6 8LH, England; Kagoshima Univ, Fac Med, Kagoshima 8908520, Japan	DuPont; Imperial College London; Kagoshima University	Malfait, AM (corresponding author), Pharmacia Corp, Skikie Discovery Biol, 4901 Searle Pky, Skokie, IL 60077 USA.	anne-marie.malfait@pharmacia.com		Malfait, Anne-Marie/0000-0003-1428-0384				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P553, DOI 10.1053/joca.2001.0425; BENDELE AM, 1988, ARTHRITIS RHEUM, V31, P561, DOI 10.1002/art.1780310416; Billinghurst RC, 2000, ARTHRITIS RHEUM, V43, P664, DOI 10.1002/1529-0131(200003)43:3<664::AID-ANR24>3.0.CO;2-D; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Burton-Wurster N, 1993, JOINT CARTILAGE DEGR, P347; Buttner FH, 1998, BIOCHEM J, V333, P159, DOI 10.1042/bj3330159; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DUNHAM J, 1989, AGENTS ACTIONS, V28, P93, DOI 10.1007/BF02022987; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1995, BIOCHEM J, V310, P337, DOI 10.1042/bj3100337; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Greenwald RA, 1999, ANN NY ACAD SCI, V878, P413, DOI 10.1111/j.1749-6632.1999.tb07699.x; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Ilic MZ, 1998, J BIOL CHEM, V273, P17451, DOI 10.1074/jbc.273.28.17451; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kaushal GP, 2000, J CLIN INVEST, V105, P1335, DOI 10.1172/JCI10078; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MOSKOWITZ RW, 1979, ARTHRITIS RHEUM, V22, P155, DOI 10.1002/art.1780220208; PALMOSKI M, 1979, ARTHRITIS RHEUM, V22, P508, DOI 10.1002/art.1780220511; Patwari P, 2000, ARCH BIOCHEM BIOPHYS, V374, P79, DOI 10.1006/abbi.1999.1538; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; Sandy JD, 2000, BIOCHEM J, V351, P161, DOI 10.1042/0264-6021:3510161; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, BIOCHEM J, V358, P615, DOI 10.1042/0264-6021:3580615; Shaw T, 2000, EXPERT OPIN INV DRUG, V9, P1469, DOI 10.1517/13543784.9.7.1469; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Yao WQ, 2001, J MED CHEM, V44, P3347, DOI 10.1021/jm015533c	46	245	267	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22201	22208		10.1074/jbc.M200431200	http://dx.doi.org/10.1074/jbc.M200431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956193	hybrid			2022-12-25	WOS:000176313600014
J	Sarno, S; Ghisellini, P; Pinna, LA				Sarno, S; Ghisellini, P; Pinna, LA			Unique activation mechanism of protein kinase CK2 - The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; BETA-SUBUNIT; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; ZEA-MAYS; II-ALPHA; PROLIFERATION; MUTANTS; PROVIDES; COMPLEX	CK2 is an essential, ubiquitous, and highly pleiotropic protein kinase whose catalytic subunits (alpha and alpha') and holoenzyme (composed by two catalytic and two regulatory beta-subunits) are both constitutively active, a property that is suspected to contribute to its pathogenic potential. Extensive interactions between the N-terminal segment and the activation loop are suspected to underlie the high constitutive activity of the isolated catalytic subunit. Here we show that a number of point mutations (Tyr(26) --> Phe, Glu(180) --> Ala, Tyr(182) --> Phe) and deletions (Delta2-6, Delta2-12, Delta2-18, Delta2-24, Delta2-30) expected to affect these interactions are more or less detrimental to catalytic activity of the a-subunit of human CK2, the deleted mutants Delta2-24 and Delta2-30 being nearly inactive under normal assay conditions. Kinetic analyses showed that impaired catalytic activity of mutants Delta2-12, Delta2-18, Delta2-24, and Y182F is mainly accounted for by dramatic increases in the K-m values for ATP, whereas a drop in K-cat with K-m values almost unchanged was found with mutants Y26F and E180A. Holoenzyme reconstitution restored the activity of mutants Delta2-12, Delta2-18, Y26F, E180A, and Y182F to wild type level and also conferred catalytic activity to the intrinsically inactive mutants, Delta2-24 and Delta2-30. These data demonstrate that specific interactions between the N-terminal segment and the activation loop are essential to provide a fully active conformation to the catalytic subunits of CK2; they also show that these interactions become dispensable upon formation of the holoenzyme, whose constitutive activity is conferred by the beta-subunit through a different mechanism.	Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Venetian Inst Mol Med, Padua, Italy; Univ Genoa, Dept Biophys M&O Sci & Technol, I-16132 Genoa, Italy	University of Padua; Veneto Institute Molecular Medicine; University of Genoa	Pinna, LA (corresponding author), Univ Padua, Dept Biol Chem, Viale G Colombo 3, I-35121 Padua, Italy.	lorenzo.pinna@unipd.it						Ahmed K, 2000, J CELL BIOCHEM, P130; Battistutta R, 2000, EUR J BIOCHEM, V267, P5184, DOI 10.1046/j.1432-1327.2000.01587.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kobe B, 1999, NATURE, V402, P373, DOI 10.1038/46478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; Marin O, 1999, J BIOL CHEM, V274, P29260, DOI 10.1074/jbc.274.41.29260; Marks Friedrich, 1996, P1, DOI 10.1002/9783527615032.ch1; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; RUZZENE M, 1999, PROTEIN PHOSPHORYLAT, P221; Sarno S, 2000, BIOCHEMISTRY-US, V39, P12324, DOI 10.1021/bi0011431; Sarno S, 1998, FEBS LETT, V441, P29, DOI 10.1016/S0014-5793(98)01516-6; Sarno S, 1996, J BIOL CHEM, V271, P10595, DOI 10.1074/jbc.271.18.10595; Sarno S, 2001, MOL CELL BIOCHEM, V227, P13, DOI 10.1023/A:1013136117395; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SARNO S, 2001, IN PRESS PHARM THER; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEMPLICI F, 2002, IN PRESS ONCOGENE	37	69	69	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22509	22514		10.1074/jbc.M200486200	http://dx.doi.org/10.1074/jbc.M200486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956194	hybrid			2022-12-25	WOS:000176313600053
J	Chen, A; Kleiman, FE; Manley, JL; Ouchi, T; Pan, ZQ				Chen, A; Kleiman, FE; Manley, JL; Ouchi, T; Pan, ZQ			Autoubiquitination of the BRCA1-BARD1 RING ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; HISTONE H2AX; IN-VIVO; BRCA1; DOMAIN; FINGER; GENE; RECRUITMENT; MUTATIONS; RADIATION	The RING finger of BRCA1 confers ubiquitin ligase activity that is markedly enhanced when complexed with another RING-containing protein, BARD1, and is required for the function of this tumor suppressor protein in protecting genomic integrity. Here, we report that co-expression of BRCA1-(1-639) and BARD1 in bacteria can assemble a potent ubiquitin ligase activity. Purified BRCA1-(1-639).BARD1 stimulated the Ubc5c-mediated monoubiquitination of histone H2A/H2AX in vitro, suggesting a possible role for BRCA1.BARD1 in modifying chromatin structure. Moreover, the truncated BRCA1.BARD1 complex exhibited efficient autoubiquitination activity in vitro capable of assembling non-lysine 48-linked polyubiquitin chains on both BRCA1-(1-639) and BARD1. When co-expressed in cells by transient transfection, the recombinant BRCA1-(1-300).BARD1 complex was found to be associated with polyubiquitin chains, suggesting that BRCA1-(2-300).BARD1 was ubiquitinated in vivo as well. These results raise the possibility that BRCA1.BARD1 acts to assemble non-lysine 48-linked polyubiquitin chains that may serve as part of a signaling platform required for coordinating DNA repair-related events.	Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Icahn School of Medicine at Mount Sinai; Columbia University	Pan, ZQ (corresponding author), Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, 1 Gustave L Levy Pl, New York, NY 10029 USA.	zhen-qiang.pan@mssm.edu		Manley, James/0000-0002-8341-1459	NATIONAL CANCER INSTITUTE [T32CA078207, R01CA079892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061051, R01GM028983] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79892, CA78207] Funding Source: Medline; NIGMS NIH HHS [GM28983, GM61051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; CHAN AML, 1994, ONCOGENE, V9, P1057; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; DAVIE JR, 1991, BIOCHEM CELL BIOL, V69, P66, DOI 10.1139/o91-009; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DUCKWORTHRYSIECKI G, 1985, CANCER RES, V45, P416; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; Venkitaraman Ashok R., 2000, Biochimica et Biophysica Acta, V1470, pR41, DOI 10.1016/S0304-419X(00)00007-X; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	38	169	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22085	22092		10.1074/jbc.M201252200	http://dx.doi.org/10.1074/jbc.M201252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927591	hybrid			2022-12-25	WOS:000176286000121
J	Cheng, ZF; Deutscher, MP				Cheng, ZF; Deutscher, MP			Purification and characterization of the Escherichia coli exoribonuclease RNase R - Comparison with RNase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-MECHANISM; 3 TERMINUS; RIBONUCLEASE; VIRULENCE; VACB	Escherichia coli RNase R, a 3' --> 5' exoribonuclease homologous to RNase II, was overexpressed and purified to near homogeneity in its native untagged form by a rapid procedure. The purified enzyme was free of nucleic acid. It migrated upon gel filtration chromatography as a monomer with an apparent molecular mass of similar to95 kDa, in close agreement with its expected size based on the sequence of the rnr gene. RNase R was most active at pH 7.5-9.5 in the presence of 0.1-0.5 mm Mg2+ and 50-500 mm KCl. The enzyme shares many catalytic properties with RNase II. Both enzymes are nonspecific processive ribonucleases that release 5'-nucleotide monophosphates and leave a short undigested oligonucleotide core. However, whereas RNase R shortens RNA processively to di- and trinucleotides, RNase II becomes more distributive when the length of the substrate reaches similar to10 nucleotides, and it leaves an undigested core of 3-5 nucleotides. Both enzymes work on substrates with a 3'-phosphate group. RNase R and RNase II are most active on synthetic homopolymers such as poly(A), but their substrate specificities differ. RNase II is more active on poly(A), whereas RNase R is much more active on rRNAs. Neither RNase R nor RNase II can degrade a complete RNA-RNA or DNA-RNA hybrid or one with a 4-nucleotide 3'-RNA overhang. RNase R differs from RNase II in that it cannot digest DNA oligomers and is not inhibited by such molecules, suggesting that it does not bind DNA, Although the in vivo function of RNase R is not known, its ability to digest certain natural RNAs may explain why it is maintained in E. coli together with RNase II.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	mdeutsch@med.miami.edu			NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHA PK, 1983, P NATL ACAD SCI-BIOL, V80, P3301, DOI 10.1073/pnas.80.11.3301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cannistraro VJ, 1999, BBA-PROTEIN STRUCT M, V1433, P170, DOI 10.1016/S0167-4838(99)00136-3; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; Cheng ZF, 1998, J BIOL CHEM, V273, P14077, DOI 10.1074/jbc.273.23.14077; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; CUDNY H, 1980, P NATL ACAD SCI-BIOL, V77, P837, DOI 10.1073/pnas.77.2.837; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; EVANS JA, 1976, J BIOL CHEM, V251, P6646; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P4372, DOI 10.1073/pnas.96.8.4372; GUPTA RS, 1977, J BIOL CHEM, V252, P8945; KASAI T, 1977, J BIOL CHEM, V252, P8950; Kevil CG, 1997, BIOCHEM BIOPH RES CO, V238, P277, DOI 10.1006/bbrc.1997.7284; PIEDADE J, 1995, FEMS MICROBIOL LETT, V127, P187; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	20	152	161	11	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21624	21629		10.1074/jbc.M202942200	http://dx.doi.org/10.1074/jbc.M202942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11948193	hybrid			2022-12-25	WOS:000176286000068
J	Nakanishi, T; Sekimizu, K				Nakanishi, T; Sekimizu, K			SDT1/SSM1, a multicopy suppressor of S-II null mutant, encodes a novel pyrimidine 5 '-nucleotidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION ELONGATION; 6-AZAURACIL SENSITIVITY; YEAST; GENE; RESISTANCE; EXPRESSION; PROTEIN; SUBUNIT	SDT1 (suppressor of disruption of TFIIS 1, YGL224c, also known as SSM1, suppressor of S-II null mutant 1) is Saccharomyces cerevisiae gene identified as a multicopy suppressor of 6-azauracil sensitivity in a null mutant of the transcription elongation factor S-II. We found that overproduction of SDT1 caused hyposensitivity to not only 6-azauracil but also 5-fluorouracil and 5-fluorocytosine. This hyposensitivity was limited to pyrimidine derivatives, and no effect was observed for non-pyrimidine drugs including such clinically used anti-fungal drugs as amphotericin B and fluconazole. Purified recombinant SDT1 protein specifically dephosphorylated 5'-UMP and 5'-CMP. These results suggested that SDT1 conferred pyrimidine-specific hyposensitivity by dephosphorylating active metabolites of 6- or 5-modified pyrimidines, i.e. 6- or 5-modified UMP. This is the first description of a highly specific pyrimidine 5'-nucleotidase in S. cerevisiae.	Daiichi Pharmaceut Co Ltd, Discovery Res Labs, Edogawa Ku, Tokyo 1348630, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Daiichi Sankyo Company Limited; University of Tokyo	Nakanishi, T (corresponding author), Daiichi Pharmaceut Co Ltd, Discovery Res Labs, Edogawa Ku, Tokyo 1348630, Japan.							Amici A, 1999, NUCLEOS NUCLEOT, V18, P853, DOI 10.1080/15257779908041580; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Costa PJ, 2000, GENETICS, V156, P535; Denis CL, 2001, GENETICS, V158, P627; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; HANDSCHUMACHER RE, 1958, BIOCHIM BIOPHYS ACTA, V30, P451, DOI 10.1016/0006-3002(58)90088-X; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; KERN L, 1990, GENE, V88, P149, DOI 10.1016/0378-1119(90)90026-N; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; OHYA Y, 1991, J BIOL CHEM, V266, P12356; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shimoaraiso M, 2000, J BIOL CHEM, V275, P29623, DOI 10.1074/jbc.M910371199; SIKORSKI RS, 1989, GENETICS, V122, P19; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Widnell C C, 1974, Methods Enzymol, V32, P368; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	22	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22103	22106		10.1074/jbc.M200573200	http://dx.doi.org/10.1074/jbc.M200573200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934891	hybrid			2022-12-25	WOS:000176286000123
J	Pummill, PE; DeAngelis, PL				Pummill, PE; DeAngelis, PL			Evaluation of critical structural elements of UDP-sugar substrates and certain cysteine residues of a vertebrate hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE BETA-GLUCOSYLTRANSFERASE; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; IN-VITRO; GLYCOSYLTRANSFERASES; PROTEIN; BINDING; XENOPUS; DG42; GENE	The hyaluronan (HA) synthases catalyze the addition of two different monosaccharides from UDP-sugar substrates to the linear heteropolysaccharide chain. To accomplish this task, the HA synthases must be able to bind and to transfer from both UDP-sugar substrates. Until now, it has been impossible to distinguish between these two abilities. We have created a mutant of xlHAS1, a HA synthase from Xenopus laevis, that allows for the examination of the enzyme's ability to bind substrate only. The ability of different compounds to protect the xlHAS1(C337S) mutant enzyme from loss of activity due to treatment with N-ethylmaleimide, a cysteine-modifying reagent, yields information on the relative affinity of a variety of nucleotides and nucleotide-sugars. We have observed that the substrate binding selectivity is more relaxed than the specificity of catalytic transfer. The only attribute that appears to be absolutely required for binding is a nucleotide containing two phosphates complexed with magnesium ion. The role of certain cysteine residues in catalysis was also evaluated. Cys(307) Of xl-HAS1 may play a role in catalysis or in maintaining structure. Mutation of Cys(337). raises the UDP-GlcUA Michaelis constant (K-m), suggesting that this residue participates in UDP-GlcUA substrate binding or in catalytic complex formation.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.				NIGMS NIH HHS [GM56497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Heldermon CD, 2001, GLYCOBIOLOGY, V11, P1017, DOI 10.1093/glycob/11.12.1017; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Kumari K, 2002, J BIOL CHEM, V277, P13943, DOI 10.1074/jbc.M110638200; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; Morera S, 2001, J MOL BIOL, V311, P569, DOI 10.1006/jmbi.2001.4905; Morera S, 1999, J MOL BIOL, V292, P717, DOI 10.1006/jmbi.1999.3094; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	30	7	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21610	21616		10.1074/jbc.M202456200	http://dx.doi.org/10.1074/jbc.M202456200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943783	hybrid			2022-12-25	WOS:000176286000066
J	Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H				Izutsu, K; Kurokawa, M; Imai, Y; Ichikawa, M; Asai, T; Maki, K; Mitani, K; Hirai, H			The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP	ONCOGENE			English	Article						AML1/Evi-1; CtBP; AML1; dominant negative	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; STIMULATING FACTOR-RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; AML1 GENE; TRANSCRIPTIONAL REGULATION; CELL-DIFFERENTIATION; GROWTH-FACTOR; CO-REPRESSOR; RUNT DOMAIN	AML1/Evi-1 is a chimeric protein that is derived from t(3;21), found in blastic transformation of chronic myelogenous leukemia. It is composed of the N-terminal AML1 portion with the DNA-binding Runt domain and the C-terminal Evi-1 portion. It has been shown to dominantly repress AML1-induced transactivation. The mechanism for it has been mainly attributed to competition with AML1 for the DNA-binding and for the interaction with PEBP2beta (CBFbeta), a partner protein which heterodimerizes with AML1 It was recently found that Evi-1 interacts with C-terminal binding protein (CtBP) to repress TGFbeta-induced transactivation. Here, we demonstrate that AML1/Evi-1 interacts with CtBP in SKH1 cells, a leukemic cell fine which endogenously overexpresses AML1/Evi-1 and that AML1/Evi-1 requires the interaction with CtBP to repress AML1-induced transactivation. The association with CtBP is also required when AML1/Evi-1 blocks myeloid differentiation of 32Dcl3 cells induced by granulocyte colony-stimulating factor. Taken together, it is suggested that one of the mechanisms for AML1/Evi-1-associated leukemogenesis should be an aberrant recruitment of a corepressor complex by the chimeric protein.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	University of Tokyo; Dokkyo Medical University	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp	Izutsu, Koji/AAI-1125-2019	Izutsu, Koji/0000-0001-9129-8057; Ichikawa, Motoshi/0000-0001-6497-0848; Imai, Yoichi/0000-0002-2938-6133				BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferrara FF, 2001, CANCER RES, V61, P2; Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imai Y, 2000, BLOOD, V96, P3154, DOI 10.1182/blood.V96.9.3154.h8003154_3154_3160; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Mitani K, 1997, LEUKEMIA, V11, P863, DOI 10.1038/sj.leu.2400666; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Zent C, 1996, CURR TOP MICROBIOL, V211, P243; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	58	27	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2695	2703		10.1038/sj.onc.1205356	http://dx.doi.org/10.1038/sj.onc.1205356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965542				2022-12-25	WOS:000174996500009
J	Hedayati, MA; Steffen, SE; Bryant, FR				Hedayati, MA; Steffen, SE; Bryant, FR			Effect of the Streptococcus pneumoniae MmsA protein on the RecA protein-promoted three-strand exchange reaction - Implications for the mechanism of transformational recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-PROTEIN; ESCHERICHIA-COLI; BRANCH MIGRATION; 3-STRAND RECOMBINATION; PURIFICATION; RESISTANCE; SEQUENCE; LOCUS	Streptococcus pneumoniae is a naturally transformable bacterium that is able to incorporate DNA from its environment into its own chromosome. This process, known as transformational recombination, is dependent in part on the mmsA gene, which encodes a protein having a sequence that is 40% identical to that of the Escherichia coli RecG protein, a junction-specific DNA helicase believed to be involved in the branch migration of recombinational intermediates. We have developed an expression system for the MmsA protein and have purified the MmsA protein to more than 99% homogeneity. The MmsA protein has DNA-dependent ATP hydrolysis and DNA junction-helicase activities that are similar to those of the E. coli RecG protein. The effect of the MmsA protein on the S. pneumoniae RecA protein-promoted three-strand exchange reaction was also investigated. In the standard direction (circular single-stranded (ss) DNA + linear double-stranded (ds) DNA --> linear ssDNA + nicked circular dsDNA), the MmsA protein appears to promote the branch migration of partially exchanged intermediates in a direction opposite of the RecA protein, resulting in a nearly complete inhibition of the overall strand exchange reaction. In the reverse direction (linear ssDNA + nicked circular dsDNA --> circular ssDNA + linear dsDNA), however, the MmsA protein appears to facilitate the conversion of partially exchanged intermediates into fully exchanged products, leading to a pronounced stimulation of the overall reaction. These results are discussed in terms of the molecular mechanism of transformational recombination.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bryant, FR (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Claverys JP, 2000, MOL MICROBIOL, V35, P251, DOI 10.1046/j.1365-2958.2000.01718.x; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Dowson Christopher G., 1994, Trends in Microbiology, V2, P361, DOI 10.1016/0966-842X(94)90612-2; Dubnau D, 1999, ANNU REV MICROBIOL, V53, P217, DOI 10.1146/annurev.micro.53.1.217; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hakenbeck R, 1999, MOL MICROBIOL, V33, P673, DOI 10.1046/j.1365-2958.1999.01521.x; LACKS S, 1962, J MOL BIOL, V5, P119, DOI 10.1016/S0022-2836(62)80067-9; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARTIN B, 1992, NUCLEIC ACIDS RES, V20, P6412, DOI 10.1093/nar/20.23.6412; Martin B, 1996, MOL MICROBIOL, V19, P1035, DOI 10.1046/j.1365-2958.1996.445975.x; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; Mortier-Barriere I, 1998, MOL MICROBIOL, V27, P159, DOI 10.1046/j.1365-2958.1998.00668.x; MortierBarrere I, 1997, MICROB DRUG RESIST, V3, P233, DOI 10.1089/mdr.1997.3.233; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; Steffen SE, 2000, ARCH BIOCHEM BIOPHYS, V382, P303, DOI 10.1006/abbi.2000.2029; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Steffen SE, 2001, ARCH BIOCHEM BIOPHYS, V388, P165, DOI 10.1006/abbi.2001.2286; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729	25	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					24863	24869		10.1074/jbc.M202041200	http://dx.doi.org/10.1074/jbc.M202041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960988	hybrid			2022-12-25	WOS:000176747000006
J	Chen, Q; Dowhan, DH; Liang, DC; Moore, DD; Overbeek, PA				Chen, Q; Dowhan, DH; Liang, DC; Moore, DD; Overbeek, PA			CREB-binding protein/p300 co-activation of crystallin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A-CRYSTALLIN; TRANSCRIPTION FACTORS; NUCLEAR-RECEPTOR; LENS DEVELOPMENT; DIFFERENTIAL LOCALIZATION; INSITU HYBRIDIZATION; REGULATORY ELEMENTS; CBP; ACTIVATION; ACETYLTRANSFERASE	Although some of the transcription factors that are required for expression of crystallins during lens development have been identified, the molecular interactions that contribute to enhanced crystallin expression are not yet well defined. In this study, we designed experiments to test whether the co-activators CREB-binding protein (CBP) and/or p300 interact with c-Maf, Prox-1, or Sox-1 to enhance transcription of crystallin genes. Promoter regions from the mouse alphaA-, betaB2-, and gammaF-crystallin genes were linked to a luciferase reporter. Expression of c-Maf transactivated each of these promoters. Of particular interest, co-expression of CBP or p300 with c-Maf was found to synergistically co-activate each promoter. CBP and p300 were less effective or ineffective at co-activation with Prox-1 or Sox-1. Co-immunoprecipitation and mammalian two-hybrid experiments revealed that CBP and p300 bind to c-Maf and Prox-1 but not to Sox-1. The co-activation of c-Maf by CBP/p300 requires histone acetyltransferase activity. Our results suggest that c-Maf recruits CBP and/or p300 to crystallin promoters leading to up-regulation of crystallin gene expression through localized histone acetylation and consequent chromatin re-modeling. In a promoter-specific fashion, co-activation can be modulated by Prox-1 and/or Sox-1. This modulation may help to specify the endogenous levels of crystallin gene expression.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Overbeek, PA (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	overbeek@bcm.tmc.edu		Overbeek, Paul/0000-0001-9784-2084	NEI NIH HHS [EY10448, EY11348, EY10803] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010803, R01EY010448, R01EY011348] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBEAU D, 1994, ONCOGENE, V9, P359; Chambers C, 1995, GENE, V166, P287, DOI 10.1016/0378-1119(95)00615-X; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen Q, 2002, ONCOGENE, V21, P1028, DOI 10.1038/sj.onc.1205050; Chen SL, 2000, GENE DEV, V14, P1209; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Dirks RPH, 1996, EUR J BIOCHEM, V239, P23, DOI 10.1111/j.1432-1033.1996.0023u.x; Doerwald L, 2001, EXP EYE RES, V73, P703, DOI 10.1006/exer.2001.1077; Goodman RH, 2000, GENE DEV, V14, P1553; Graw J, 1997, BIOL CHEM, V378, P1331; Gregory PD, 1998, EUR J BIOCHEM, V251, P9, DOI 10.1046/j.1432-1327.1998.2510009.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kondoh H, 1999, CURR OPIN GENET DEV, V9, P301, DOI 10.1016/S0959-437X(99)80045-8; Lengler J, 2001, NUCLEIC ACIDS RES, V29, P515, DOI 10.1093/nar/29.2.515; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; LOK S, 1985, MOL CELL BIOL, V5, P2221, DOI 10.1128/MCB.5.9.2221; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; Moore DD, 1995, GLOB MOB SURV; Nishiguchi S, 1998, GENE DEV, V12, P776, DOI 10.1101/gad.12.6.776; Ogino H, 2000, DEV GROWTH DIFFER, V42, P437; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Ring BZ, 2000, DEVELOPMENT, V127, P307; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6417; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRETON JA, 1991, DIFFERENTIATION, V47, P143, DOI 10.1111/j.1432-0436.1991.tb00232.x; UEDA Y, 2001, INVESTIG OPHTHALMOL, V43, P205; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANLEEN RW, 1987, DEV BIOL, V123, P338, DOI 10.1016/0012-1606(87)90392-7; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	41	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24081	24089		10.1074/jbc.M201821200	http://dx.doi.org/10.1074/jbc.M201821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11943779	hybrid			2022-12-25	WOS:000176611800016
J	Etheridge, KT; Banik, SSR; Armbruster, BN; Zhu, YS; Terns, RM; Terns, MP; Counter, CM				Etheridge, KT; Banik, SSR; Armbruster, BN; Zhu, YS; Terns, RM; Terns, MP; Counter, CM			The nucleolar localization domain of the catalytic subunit of human telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; TERMINAL DOMAINS; YEAST TELOMERASE; RNA COMPONENT; HUMAN-CELLS; EXPRESSION; PROTEIN; GENE	Telomerase is the enzyme essential to complete the replication of the terminal DNA of most eukaryotic chromosomes. In humans, this enzyme is composed of the telomerase reverse transcriptase (hTERT) and telomerase RNA (hTR) subunits. hTR has been found in the nucleolus, a site of assembly of ribosomes as well as other ribonucleoproteins (RNPs). We therefore tested whether the hTERT component is also found in the nucleolus, where it could complex with the hTR RNA to form a functional enzyme. We report here that hTERT does indeed localize to the nucleolus, and we mapped the domain responsible for this localization to the hTR-binding region of the protein by deletion analysis. Substitution mutations in two of the three conserved hTR-binding domains in this nucleolar localization domain (NoLD) abolished nucleolar localization. However, another mutation that impeded hTR binding did not alter this subcellular localization. Additionally, wild type hTERT was detected in the nucleolus of cells that failed to express hTR. Taken together, we propose that the nucleolar localization of hTERT involves more than just the association with the hTR subunit. Furthermore, the coincidental targeting of both the hTR and hTERT subunits to the nucleolus supports the premise that the assembly of telomerase occurs in the nucleolus.	Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Duke University; Duke University; Duke University; University System of Georgia; University of Georgia	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol, Box 3813, Durham, NC 27710 USA.		Terns, Michael/N-6435-2016	Counter, Christopher M/0000-0003-0748-3079; Zhu, Yusheng/0000-0002-0666-7127	NATIONAL CANCER INSTITUTE [R01CA082481] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Bachand F, 1999, J BIOL CHEM, V274, P38027, DOI 10.1074/jbc.274.53.38027; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Chapon C, 1997, RNA, V3, P1337; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GARCIABLANCO MA, 1995, J CELL BIOL, V128, P15, DOI 10.1083/jcb.128.1.15; GOU C, 2001, J UROLOGY, V166, P694; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Guo W, 2001, INT J MOL MED, V8, P73; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kuramoto M, 2001, GENE, V277, P101, DOI 10.1016/S0378-1119(01)00684-9; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lukowiak AA, 2001, RNA, V7, P1833; Malik HS, 2000, GENE, V251, P101, DOI 10.1016/S0378-1119(00)00207-9; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Takenaka Y, 2001, GENE, V264, P153, DOI 10.1016/S0378-1119(01)00337-7; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000	49	112	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24764	24770		10.1074/jbc.M201227200	http://dx.doi.org/10.1074/jbc.M201227200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956201	hybrid			2022-12-25	WOS:000176611800103
J	Brosh, RM; Waheed, J; Sommers, JA				Brosh, RM; Waheed, J; Sommers, JA			Biochemical characterization of the DNA substrate specificity of Werner syndrome helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALLED REPLICATION FORKS; SINGLE-STRANDED-DNA; SYNDROME PROTEIN; SYNDROME CELLS; SYNDROME GENE; FLAP ENDONUCLEASE-1; POLYMERASE-DELTA; REPEAT SEQUENCE; HOLLIDAY JUNCTIONS; S-PHASE	Werner syndrome is a hereditary premature aging disorder characterized by genome instability. The product of the gene defective in WS, WRN, is a helicase/exonuclease that presumably functions in DNA metabolism. To understand the DNA structures WRN acts upon in vivo, we examined its substrate preferences for unwinding. WRN unwound a 3'-single-stranded (ss)DNA-tailed duplex substrate with streptavidin bound to the end of the 3'-ssDNA tail, suggesting that WRN does not require a free DNA end to unwind the duplex; however, WRN was completely blocked by streptavidin bound to the 3'-ssDNA tail 6 nucleotides upstream of the single-stranded/double-stranded DNA junction. WRN efficiently unwound the forked duplex with streptavidin bound just upstream of the junction, suggesting that WRN recognizes elements of the fork structure to initiate unwinding. WRN unwound two important intermediates of replication/repair, a 5'-ssDNA flap substrate and a synthetic replication fork. WRN was able to translocate on the lagging strand of the synthetic replication fork to unwind duplex ahead of the fork. For the 5'-flap structure, WRN specifically displaced the 5'-flap oligonucleotide, suggesting a role of WRN in Okazaki fragment processing. The ability of WRN to target DNA replication/repair intermediates may be relevant to its role in genome stability maintenance.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.							Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	51	109	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23236	23245		10.1074/jbc.M111446200	http://dx.doi.org/10.1074/jbc.M111446200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956187	hybrid			2022-12-25	WOS:000176475700020
J	Barendt, WM; Wright, SH				Barendt, WM; Wright, SH			The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CONTRALUMINAL TRANSPORT; FUNCTIONAL EXPRESSION; CLONING; ANIONS; SYSTEMS; TUBULE; OCT1; PH	The organic cation transporter, OCT2, plays a role in renal secretion of a broad array of weak bases. To determine whether the degree of ionization of these compounds plays a role in their interaction with OCT2, we examined the influence of external pH values on the activity of the human ortholog of OCT2, as expressed in Chinese hamster ovary-K1 cells. Importantly, changing the pH value from 7.0 to 8.0 had no effect on the rate of transport of the fixed cations, tetraethylammonium and 1-methyl-4-phenylpyridinium, i.e. the pH value did not have an effect upon the transporter itself. Cimetidine (pK(a) 6.92), a competitive inhibitor of hOCT2, displayed a 3.5-fold increase in IC50 as pH values increased from 7 to S. hOCT2-mediated cimetidine transport decreased over this pH range, the consequence of an increase in K-t and decrease in J(max) at the higher pH value. The weak bases trimethoprim and 4-phenylpyridine showed a similar pattern of pH-sensitive interaction with hOCT2. The non-ionizable sterol, corticosterone, also inhibited hOCT2 activity, although it was neither competitive in nature nor was it sensitive to pH in the manner observed with weak bases. We conclude that the degree of ionization plays a critical role in binding of substrate to organic cation transporters.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA	University of Arizona	Wright, SH (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL07249] Funding Source: Medline; NIDDK NIH HHS [DK58251] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058251, R01DK058251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Budiman T, 2000, J BIOL CHEM, V275, P29413, DOI 10.1074/jbc.M004645200; Burckhardt G, 2000, AM J PHYSIOL-RENAL, V278, pF853, DOI 10.1152/ajprenal.2000.278.6.F853; Dresser MJ, 2000, J PHARMACOL EXP THER, V292, P1146; Dzekunov SM, 1998, J MEMBRANE BIOL, V166, P9, DOI 10.1007/s002329900443; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Karbach U, 2000, AM J PHYSIOL-RENAL, V279, pF679, DOI 10.1152/ajprenal.2000.279.4.F679; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Koepsell H, 1998, ANNU REV PHYSIOL, V60, P243, DOI 10.1146/annurev.physiol.60.1.243; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; MOTOHASHI H, 2002, J AM SOC NEPHROL, V13; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; ROCHRAMEL F, 1992, HDB PHYSL, V2; Segel I.H., 1975, ENZYME KINETICS; Segel IH, 1976, BIOCH CALCULATIONS; SOMOGYI A, 1983, CLIN PHARMACOKINET, V8, P463, DOI 10.2165/00003088-198308060-00001; ULLRICH KJ, 1992, PFLUG ARCH EUR J PHY, V421, P286, DOI 10.1007/BF00374841; ULLRICH KJ, 1993, PFLUG ARCH EUR J PHY, V425, P300, DOI 10.1007/BF00374180; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	24	63	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22491	22496		10.1074/jbc.M203114200	http://dx.doi.org/10.1074/jbc.M203114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953440	hybrid			2022-12-25	WOS:000176313600051
J	Corsi, B; Cozzi, A; Arosio, P; Drysdale, J; Santambrogio, P; Campanella, A; Biasiotto, G; Albertini, A; Levi, S				Corsi, B; Cozzi, A; Arosio, P; Drysdale, J; Santambrogio, P; Campanella, A; Biasiotto, G; Albertini, A; Levi, S			Human mitochondrial ferritin expressed in HeLa cells incorporates iron and affects cellular iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN H-FERRITIN; ERYTHROID-CELLS; OXIDATIVE STRESS; SKELETAL-MUSCLE; MESSENGER-RNA; L-CHAIN; GENE; OVEREXPRESSION; MUTATION; HYPERFERRITINEMIA	Mitochondrial ferritin (MtF) is a newly identified ferritin encoded by an intronless gene on chromosome 5q23.1. The mature recombinant MtF has a ferroxidase center and binds iron in vitro similarly to H-ferritin. To explore the structural and functional aspects of MtF, we expressed the following forms in HeLa cells: the MtF precursor (similar to28 kDa), a mutant MtF precursor with a mutated ferroxidase center, a truncated MtF lacking the similar to6-kDa mitochondrial leader sequence, and a chimeric H-ferritin with this leader sequence. The experiments show that all constructs with the leader sequence were processed into similar to22-kDa subunits that assembled into multimeric shells electrophoretically distinct from the cytosolic ferritins. Mature MtF was found in the matrix of mitochondria, where it is a homopolymer. The wild type MtF and the mitochondrially targeted H-ferritin both incorporated the Fe-55 label in vivo. The mutant MtF with an inactivated ferroxidase center did not take up iron, nor did the truncated MtF expressed transiently in cytoplasm. Increased levels of MtF both in transient and in stable transfectants resulted in a greater retention of iron as MtF in mitochondria, a decrease in the levels of cytosolic ferritins, and up-regulation of transferrin receptor. Neither effect occurred with the mutant MtF with the inactivated ferroxidase center. Our results indicate that exogenous iron is as available to mitochondrial ferritin as it is to cytosolic ferritins and that the level of MtF expression may have profound consequences for cellular iron homeostasis.	Hosp San Raffaele, IRCCS, Prot Engn Unit, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Brescia, Fac Med, Sect Chem, I-25100 Brescia, Italy; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia; Tufts University	Levi, S (corresponding author), Hosp San Raffaele, IRCCS, Prot Engn Unit, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Campanella, Alessandro/N-8315-2015; arosio, paolo/S-3272-2019; Biasiotto, Giorgio/Z-3660-2019; arosio, paolo/E-6817-2010; levi, sonia/A-3161-2015; Santambrogio, Paolo/AAN-3837-2020; Cozzi, Anna/AAN-3821-2020	Campanella, Alessandro/0000-0002-3463-1199; arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; Biasiotto, Giorgio/0000-0001-7495-7807; albertini, alberto/0000-0002-7989-649X	Telethon [GP0075Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBAS A, 1993, J BIOL CHEM, V268, P8541; Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1071; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Chasteen ND, 1999, J STRUCT BIOL, V126, P182, DOI 10.1006/jsbi.1999.4118; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Curtis ARJ, 2001, NAT GENET, V28, P350, DOI 10.1038/ng571; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Ferreira GC, 1999, INT J BIOCHEM CELL B, V31, P995, DOI 10.1016/S1357-2725(99)00066-7; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1987, GENE, V51, P267; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LUZZAGO A, 1986, BIOCHIM BIOPHYS ACTA, V872, P61, DOI 10.1016/0167-4838(86)90147-0; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Ponka P, 1997, BLOOD, V89, P1; RADEMAKERS LHPM, 1993, EUR J CLIN INVEST, V23, P130, DOI 10.1111/j.1365-2362.1993.tb00752.x; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; Tan G, 2001, HUM MOL GENET, V10, P2099, DOI 10.1093/hmg/10.19.2099; THOMPSON CH, 1993, J INTERN MED, V234, P149, DOI 10.1111/j.1365-2796.1993.tb00724.x; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	35	125	132	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22430	22437		10.1074/jbc.M105372200	http://dx.doi.org/10.1074/jbc.M105372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953424	hybrid			2022-12-25	WOS:000176313600043
J	Dominici, P; Caffarri, S; Armenante, F; Ceoldo, S; Crimi, M; Bassi, R				Dominici, P; Caffarri, S; Armenante, F; Ceoldo, S; Crimi, M; Bassi, R			Biochemical properties of the PsbS subunit of photosystem II either purified from chloroplast or recombinant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PIGMENT-BINDING PROPERTIES; RESOLVED FLUORESCENCE ANALYSIS; SPINACH THYLAKOID MEMBRANES; CHLOROPHYLL-A/B-PROTEINS; IN-VITRO RECONSTITUTION; ANTENNA PROTEINS; DICYCLOHEXYLCARBODIIMIDE-BINDING; ENERGY-DISSIPATION; CHLORINA MUTANTS	The biochemical properties of PsbS protein, a nuclear-encoded Photosystem H subunit involved in the high energy quenching of chlorophyll fluorescence, have been studied using preparations purified from chloroplasts or obtained by overexpression in bacteria. Despite the homology with chlorophyll a/b/xanthophyll-binding proteins of the Lhc family, native PsbS protein does not show any detectable ability to bind chlorophylls or carotenoids in conditions in which Lhc proteins maintain fall pigment binding. The recombinant protein, when refolded in vitro in the presence of purified pigments, neither binds chlorophylls nor xanthophylls, differently from the homologous proteins LHCII, CP26, and CP29 that refold into stable pigment-binding complexes. Thus, it is concluded that if PsbS is a pigment-binding protein in vivo, the binding mechanism must be different from that present in other Lhc proteins. Primary sequence analysis provides evidence for homology of PsbS helices I and III with the central 2-fold symmetric core of chlorophyll a/b-binding proteins. Moreover, a structural homology owed to the presence of acidic residues in each of the two lumen-exposed loops is found with the dicyclohexylearbodiimide/Ca2+ binding domain of CP29. Consistently, both native and recombinant PsbS proteins showed [C-14]dicyclohexylcarbodiimide binding, thus supporting a functional basis for its homology with CP29 on the lumen-exposed loops. This domain is suggested to be involved in sensing low luminal pH.	Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy	University of Verona	Bassi, R (corresponding author), Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy.		Caffarri, Stefano/AAX-8913-2021	Caffarri, Stefano/0000-0002-4729-7679; bassi, roberto/0000-0002-4140-8446				ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; BASSI R, 1985, CARLSBERG RES COMMUN, V50, P145, DOI 10.1007/BF02907142; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BERGANTINO E, 1995, J BIOL CHEM, V270, P8474, DOI 10.1074/jbc.270.15.8474; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Bossmann B, 1997, PHOTOSYNTH RES, V52, P127, DOI 10.1023/A:1005823711838; BRIANTAIS JM, 1979, BIOCHIM BIOPHYS ACTA, V548, P128, DOI 10.1016/0005-2728(79)90193-2; BRIANTAIS JM, 1996, NATO ASI SERIES A, P113; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; FUNK C, 1995, J BIOL CHEM, V270, P30141; FUNK C, 1995, BIOCHEMISTRY-US, V34, P11133, DOI 10.1021/bi00035a019; GABELLINI N, 1988, BIOCHIM BIOPHYS ACTA, V934, P227, DOI 10.1016/0005-2728(88)90186-7; GHANOTAKIS DF, 1984, BIOCHIM BIOPHYS ACTA, V765, P388, DOI 10.1016/0005-2728(84)90180-4; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Harrer R, 1998, EUR J BIOCHEM, V255, P196, DOI 10.1046/j.1432-1327.1998.2550196.x; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; HOPPE J, 1980, EUR J BIOCHEM, V112, P17, DOI 10.1111/j.1432-1033.1980.tb04981.x; JAHNS P, 1990, EUR J BIOCHEM, V193, P731, DOI 10.1111/j.1432-1033.1990.tb19393.x; Jansson S, 1999, TRENDS PLANT SCI, V4, P236, DOI 10.1016/S1360-1385(99)01419-3; Jegerschold C, 2000, J BIOL CHEM, V275, P12781, DOI 10.1074/jbc.275.17.12781; KIM S, 1992, FEBS LETT, V314, P67, DOI 10.1016/0014-5793(92)81463-V; Kuttkat A, 1996, EUR J BIOCHEM, V242, P288, DOI 10.1111/j.1432-1033.1996.0288r.x; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Nield J, 2000, PHILOS T R SOC B, V355, P1337, DOI 10.1098/rstb.2000.0695; Nield J, 2000, NAT STRUCT BIOL, V7, P44; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; RUBAN AV, 1992, FEBS LETT, V309, P175, DOI 10.1016/0014-5793(92)81089-5; SANTINI C, 1994, EUR J BIOCHEM, V221, P307, DOI 10.1111/j.1432-1033.1994.tb18742.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; SIMPSON DJ, 1985, CARLSBERG RES COMMUN, V50, P223, DOI 10.1007/BF02907148; Walters RG, 1996, P NATL ACAD SCI USA, V93, P14204, DOI 10.1073/pnas.93.24.14204; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7	55	130	134	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22750	22758		10.1074/jbc.M200604200	http://dx.doi.org/10.1074/jbc.M200604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934892	hybrid			2022-12-25	WOS:000176313600084
J	Messenger, MM; Saulnier, RB; Gilchrist, AD; Diamond, P; Gorbsky, GJ; Litchfield, DW				Messenger, MM; Saulnier, RB; Gilchrist, AD; Diamond, P; Gorbsky, GJ; Litchfield, DW			Interactions between protein kinase CK2 and Pin1 - Evidence for phosphorylation-dependent interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II-ALPHA; PEPTIDYL-PROLYL ISOMERASE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DNA TOPOISOMERASE; BETA-SUBUNIT; C-MYC; MITOTIC PHOSPHORYLATION; EXPRESSION; BINDING	The peptidyl-prolyl isomerase Pin1 interacts in a phosphorylation-dependent manner with several proteins involved in cell cycle events. In this study, we demonstrate that Pin1 interacts with protein kinase CK2, an enzyme that generally exists in tetrameric complexes composed of two catalytic CK2alpha and/or CK2alpha' subunits together with two regulatory CK2beta subunits. Our results indicate that Pin1 can interact with CK2 complexes that contain CK2alpha. Furthermore, Pin1 can interact directly with the C-terminal domain of CK2alpha that contains residues that are phosphorylated in vitro by p34(Cdc2) and in mitotic cells. Substitution of the phosphorylation sites of CK2alpha with alanines resulted in decreased interactions between Pin1 and CK2. The other catalytic isoform. of CK2, designated CK2alpha', is not phosphorylated in mitotic cells and does not interact with Pin1, but a chimeric protein consisting of CK2alpha' with the C terminus of CK2alpha was phosphorylated in mitotic cells and interacts with Pin1, further implicating the phosphorylation sites in the interaction. In vitro, Pin1 inhibits the phosphorylation of Thr-1342 on human topoisomerase IIalpha by CK2. Topoisomerase Ha also interacts with Pin1 suggesting that the effect of Pin1 on the phosphorylation of Thr-1342 could result from its interactions with CK2 and/or topoisomerase IIalpha. As compared with wild-type Pin1, isomerase-deficient and WW domain-deficient mutants of Pin1 are impaired in their ability to interact with CK2 and to inhibit the CK2-catalyzed phosphorylation of topoisomerase IIalpha. Collectively, these results indicate that Pin1 and CK2a interact and suggest a possible role for Pin1 in the regulation of topoisomerase IIalpha. Furthermore, these results provide new insights into the functional role of the mitotic phosphorylation of CK2 and provide a new mechanism for selectively regulating the ability of CK2 to phosphorylate one of its mitotic targets.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Oklahoma, Hlth Sci Ctr, Ctr Biomed Res, Dept Cell Biol, Oklahoma City, OK 73104 USA	Western University (University of Western Ontario); University of Oklahoma System; University of Oklahoma Health Sciences Center	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.		Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; Gorbsky, Gary/0000-0003-3076-4725				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; BOSE DG, 1995, J BIOL CHEM, V270, P25872; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; HECK MMS, 1989, J BIOL CHEM, V264, P15161; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; KRIEG J, 1995, ONCOGENE, V10, P2221; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1995, BBA-MOL CELL RES, V1269, P69, DOI 10.1016/0167-4889(95)00100-7; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; WELLS NJ, 1995, EUR J BIOCHEM, V231, P491, DOI 10.1111/j.1432-1033.1995.tb20723.x; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	65	76	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23054	23064		10.1074/jbc.M200111200	http://dx.doi.org/10.1074/jbc.M200111200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940573	hybrid			2022-12-25	WOS:000176313600121
J	Thabut, G; El-Benna, J; Samb, A; Corda, S; Megret, J; Leseche, G; Vicaut, E; Aubier, M; Boczkowski, J				Thabut, G; El-Benna, J; Samb, A; Corda, S; Megret, J; Leseche, G; Vicaut, E; Aubier, M; Boczkowski, J			Tumor necrosis factor-alpha increases airway smooth muscle oxidants production through a NADPH oxidase-like system to enhance myosin light chain phosphorylation and contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE 1B; LUNG EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; NITRIC-OXIDE; ENDOTHELIAL-CELLS; SUPEROXIDE ANION; GROWTH-FACTOR; NAD(P)H OXIDASE; IN-VITRO; NEUTROPHILS	Tumor necrosis factor plays a critical role in airway smooth muscle hyperresponsiveness observed in asthma. However, the mechanisms underlying this phenomenon are poorly understood. We investigated if tumor necrosis factor-stimulated airway smooth muscle produced reactive oxygen species, leading to muscular hyperresponsiveness. Tumor necrosis factor increased intracellular and extracellular oxidants production in guinea pig airway smooth muscle cells and tissue homogenates. This production was abolished by inhibitors of NADPH oxidase (diphenylene iodinium or apocynin) and was enhanced by NADPH, whereas inhibitors of mitochondrial respiratory chain, nitric-oxide synthase, cyclooxygenase, and xanthine oxidase had no effect. NADPH oxidase subunits p22(phox) and p47(phox) were detected in smooth muscle cells and tissue homogenates by Western blot, immunohistochemistry, and spectral analysis. Furthermore., oxidants production was significantly reduced by transient transfection of smooth muscle cells with p22(phox) antisense oligonucleotides. Intracellular antioxidants and diphenylene iodinium abolished tumor necrosis factor-induced muscular hyperresponsiveness and increased in phosphorylation of the myosin light chain. Finally, NADPH oxidase subunits p22(phox) and p47(phox) were also detected in human airway smooth muscle. Collectively, these results demonstrate that tumor necrosis factor-stimulated airway smooth muscle produces oxidants through a NADPH oxidase-like system, which plays a pivotal role in muscle hyperresponsiveness and myosin light chain phosphorylation.	Fac Xavier Bichat, INSERM, U408, F-75870 Paris 18, France; Fac Xavier Bichat, INSERM, U479, F-75870 Paris, France; Fac Xavier Bichat, Inst Federat Rech Claude Bernard 02, F-75870 Paris 18, France; Hop Fernand Widal, Lab Etud Microcirculat, F-75010 Paris, France; Hop Beaujon, Serv Chirurg Thorac, F-92110 Clichy, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Boczkowski, J (corresponding author), Fac Xavier Bichat, INSERM, U408, BP416, F-75870 Paris 18, France.		Boczkowski, Jorge/S-7474-2018	Boczkowski, Jorge/0000-0001-6619-5785				Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barnes PJ, 1998, AM J RESP CRIT CARE, V158, pS123, DOI 10.1164/ajrccm.158.supplement_2.13tac800; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BASS DA, 1983, J IMMUNOL, V130, P1910; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; Davis AR, 1998, J LEUKOCYTE BIOL, V64, P114, DOI 10.1002/jlb.64.1.114; De Boer J, 1998, AM J RESP CRIT CARE, V158, P1784, DOI 10.1164/ajrccm.158.6.9711005; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HANCOCK JT, 1991, FREE RADICAL BIO MED, V11, P25, DOI 10.1016/0891-5849(91)90184-5; JOHNSTON RB, 1984, METHOD ENZYMOL, V105, P365; Kashiwagi A, 1999, AM J PHYSIOL-ENDOC M, V277, pE976, DOI 10.1152/ajpendo.1999.277.6.E976; KINNULA VL, 1992, AM J PHYSIOL, V262, pL708, DOI 10.1152/ajplung.1992.262.6.L708; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lopez-Ongil S, 1999, FREE RADICAL BIO MED, V26, P501, DOI 10.1016/S0891-5849(98)00223-8; Luo XP, 1999, FREE RADICAL BIO MED, V26, P1357, DOI 10.1016/S0891-5849(98)00334-7; McFarlane SM, 2001, BIOCHEM PHARMACOL, V61, P749, DOI 10.1016/S0006-2952(01)00530-5; MOORE KP, 1991, EICOSANOIDS, V4, P115; Nakatani Y, 2000, EUR J PHARMACOL, V392, P175, DOI 10.1016/S0014-2999(00)00087-X; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Parris JRM, 1999, J PHYSIOL-LONDON, V518, P561, DOI 10.1111/j.1469-7793.1999.0561p.x; Pavlovic D, 1998, EUR RESPIR J, V11, P575; Pennings HJ, 1998, EUR RESPIR J, V12, P45, DOI 10.1183/09031936.98.12010045; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; PYNE S, 1993, BIOCHEM PHARMACOL, V45, P593, DOI 10.1016/0006-2952(93)90132-G; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Sadeghi-Hashjin G, 1998, MEDIAT INFLAMM, V7, P35, DOI 10.1080/09629359891360; Samb A, 2001, AM J RESP CRIT CARE, V164, P149, DOI 10.1164/ajrccm.164.1.2004030; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Teshima S, 1998, GASTROENTEROLOGY, V115, P1186, DOI 10.1016/S0016-5085(98)70090-3; YAMAGUCHI T, 1989, J BIOL CHEM, V264, P112	47	35	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22814	22821		10.1074/jbc.M200315200	http://dx.doi.org/10.1074/jbc.M200315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940577	hybrid			2022-12-25	WOS:000176313600091
J	Trivier, E; Ganesan, TS				Trivier, E; Ganesan, TS			RYK, a catalytically inactive receptor tyrosine kinase, associates with EphB2 and EphB3 but does not interact with AF-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL OVARIAN-CANCER; H-RYK; POSTTRANSLATIONAL MODIFICATION; EXTRACELLULAR DOMAINS; ECTODOMAIN CLEAVAGE; DOWN-REGULATION; CDNA SEQUENCE; IN-VITRO; PROTEIN; DROSOPHILA	RYK is an atypical orphan receptor tyrosine kinase that lacks detectable kinase activity. Nevertheless, using a chimeric receptor approach, we previously found that RYK can signal via the mitogen-activated protein kinase pathway. Recently, it has been shown that murine Ryk can bind to and be phosphorylated by the ephrin receptors EphB2 and EphB3. In this study, we show that human RYK associates with EphB2 and EphB3 but is not phosphorylated by them. This association requires both the extracellular and cytoplasmic domains of RYK and is not dependent on activation of the Eph receptors. It was also previously shown that AF-6 (afadin), a PDZ domain-containing protein, associates with murine Ryk. We show here that AF-6 does not bind to human RYK in vitro or in vivo. This suggests that there are significant functional differences between human and murine RYK. Further studies are required to determine whether RYK modulates the signaling of EphB2 and EphB3.	John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Mol Oncol Labs, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Ganesan, TS (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK, Mol Oncol Labs, Oxford OX3 9DS, England.		GANESAN, Trivadi Sundaram/AAU-1499-2020	GANESAN, Trivadi Sundaram/0000-0002-4671-8099				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bonkowsky JL, 1999, MECH DEVELOP, V82, P181, DOI 10.1016/S0925-4773(99)00007-6; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; Dierks T, 1998, FEBS LETT, V423, P61, DOI 10.1016/S0014-5793(98)00065-9; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Feng GP, 2000, NEURON, V25, P295, DOI 10.1016/S0896-6273(00)80895-8; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; Halford MM, 1999, J BIOL CHEM, V274, P7379, DOI 10.1074/jbc.274.11.7379; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Jardine LJ, 1999, ONCOGENE, V18, P7602, DOI 10.1038/sj.onc.1203137; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Katso RMT, 1999, CANCER RES, V59, P2265; Katso RMT, 2000, CLIN CANCER RES, V6, P3271; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; McCarthy MJ, 1999, LAB INVEST, V79, P889; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Patthy L, 2000, TRENDS BIOCHEM SCI, V25, P12, DOI 10.1016/S0968-0004(99)01504-2; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAMAGNONE L, 1993, ONCOGENE, V8, P2009; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wang XC, 1996, MOL MED, V2, P189, DOI 10.1007/BF03401616; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991	49	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23037	23043		10.1074/jbc.M202486200	http://dx.doi.org/10.1074/jbc.M202486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956217	hybrid			2022-12-25	WOS:000176313600119
J	Deo, DD; Axelrad, TW; Robert, EG; Marcheselli, V; Bazan, NG; Hunt, JD				Deo, DD; Axelrad, TW; Robert, EG; Marcheselli, V; Bazan, NG; Hunt, JD			Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells - Evidence for a dual kinase mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INDUCED IN-VIVO; FACTOR RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; PHOSPHOLIPASE-C; LIPID MEDIATORS; PERTUSSIS-TOXIN	Platelet-activating factor (PAF) is a potent proinflammatory phospholipid with multiple pathological and physiological effects. We have shown that basic fibroblast growth factor (bFGF) supplementation induces rapid proliferation of human umbilical vein endothelial cells (HUVEC), which is reduced upon removal of bFGF or by bFGF immunoneutralization. The PAF receptor antagonist LAU-8080 inhibited bFGF-stimulated HUVEC proliferation, indicating the involvement of PAF in the bFGF-mediated signaling of HUVEC. Although FGF receptor phosphorylation was not affected by]LAU-8080, the bFGF-mediated prolonged phosphorylation, and activation of Erk-1 and -2 were attenuated. Phosphorylation of STAT-3 was observed in the presence of PAF or bFGF, which was attenuated by PAFR antagonists. PAF-induced STAT-3 phosphorylation observed in HUVEC pretreated with either Src inhibitor PR1 or JAK-2 inhibitor AG-490 indicated M immediate (1 min) phosphorylation of STAT-3 is dependent on Src, (ii) JAK-2-dependent STAT-3 phosphorylation occurs after the delayed (30 min) PAF exposure, and (iii) prolonged (60 min) STAT-3 phosphorylation may be either through Src and/or JAK-2. Attenuation of the STAT-3 phosphorylation by the PAFR antagonists indicated signaling through the PAF receptor. Taken together, these findings suggest the production of PAF is important for bFGF-mediated signaling and that a dual kinase mechanism is involved in the PAF-mediated signal transduction cascade.	Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hunt, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Biochem & Mol Biol, 533 Bolivar St,CSB-4-18, New Orleans, LA 70112 USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Hunt, Jay/0000-0002-8838-201X				Bazan HEP, 1997, CURR EYE RES, V16, P372, DOI 10.1076/ceyr.16.4.372.10699; BOUTHERINFALSON O, 1990, BIOCHEM BIOPH RES CO, V172, P306, DOI 10.1016/S0006-291X(05)80210-4; Brizzi MF, 1999, CIRC RES, V84, P785; Camussi G, 1997, J IMMUNOL, V158, P1302; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DeCoster MA, 1998, J NEUROSCI RES, V53, P297, DOI 10.1002/(SICI)1097-4547(19980801)53:3<297::AID-JNR3>3.0.CO;2-5; DHAR A, 1994, J BIOL CHEM, V269, P9123; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ihida K, 1999, J CELL SCI, V112, P285; Jackson JR, 1998, BBA-LIPID LIPID MET, V1392, P145, DOI 10.1016/S0005-2760(98)00012-5; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLEIN S, 1997, REGULATION ANGIOGENE; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KORNECKI E, 1988, SCIENCE, V260, P315; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEPRINCE C, 1991, LIPIDS, V26, P1204, DOI 10.1007/BF02536532; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Miao HQ, 1996, J BIOL CHEM, V271, P4879; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Montrucchio G, 1997, AM J PATHOL, V151, P557; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Predescu D, 1996, EUR J CELL BIOL, V69, P86; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RUI H, 1994, J BIOL CHEM, V269, P5364; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SA G, 1994, J BIOL CHEM, V269, P3219; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; Shimizu T, 1996, ADV EXP MED BIOL, V416, P79; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; THURSTON AW, 1993, J PHARMACOL EXP THER, V266, P1106; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VENABLE ME, 1993, J LIPID RES, V34, P691; Wang H, 1997, BIOCHEM J, V322, P603, DOI 10.1042/bj3220603; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392	56	100	102	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21237	21245		10.1074/jbc.M110955200	http://dx.doi.org/10.1074/jbc.M110955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940567	hybrid			2022-12-25	WOS:000176286000017
J	Archer, DA; Graham, ME; Burgoyne, RD				Archer, DA; Graham, ME; Burgoyne, RD			Complexin regulates the closure of the fusion pore during regulated vesicle exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; PROTEIN; SNAP-25; BINDING; ROLES	Membrane fusion during exocytosis and throughout the cell is believed to involve members of the SNARE (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors) family of proteins. The assembly of these proteins into a four-helix bundle may be part of the driving force for bilayer fusion. Regulated exocytosis in neurons and related cell types is specialized to be fast and Ca2+-dependent suggesting the involvement of other regulatory proteins specific for regulated exocytosis. Among these are the complexins, two closely related proteins that bind only to the assembled SNARE complex. We have investigated the function of complexin by analysis of single vesicle release events in adrenal chromaffin cells using carbon fiber amperometry. These cells express complexin II, and overexpression of this protein modified the kinetics of vesicle release events so that their time course was shortened. This effect depended on complexin interaction with the SNARE complex as introduction of a mutation of Arg-59, a residue that interacts with synaptobrevin in the SNARE complex, abolished its effects. The data are consistent with a function for complexin in stabilizing an intermediate of the SNARE complex to allow kiss-andrun recycling of the exocytosed vesicle.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Burgoyne, Robert/C-6706-2008; Burgoyne, Robert D/P-6641-2019	Burgoyne, Robert/0000-0002-9219-0387; Burgoyne, Robert D/0000-0002-9219-0387				Burgoyne RD, 2002, TRENDS NEUROSCI, V25, P176, DOI 10.1016/S0166-2236(00)02126-3; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Criado M, 1999, P NATL ACAD SCI USA, V96, P7256, DOI 10.1073/pnas.96.13.7256; Elhamdani A, 1999, J NEUROSCI, V19, P7375, DOI 10.1523/JNEUROSCI.19-17-07375.1999; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2001, J CELL SCI, V114, P4397; GRAHAM ME, 2002, IN PRESS P NATL ACAD; Harata N, 2001, TRENDS NEUROSCI, V24, P637, DOI 10.1016/S0166-2236(00)02030-0; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; ISHIZUKA T, 1995, BIOCHEM BIOPH RES CO, V213, P1107, DOI 10.1006/bbrc.1995.2241; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Machado JD, 2001, MOL PHARMACOL, V60, P514; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Pyle JL, 2000, NEURON, V28, P221, DOI 10.1016/S0896-6273(00)00098-2; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Takahashi S, 1999, EUR J NEUROSCI, V11, P2359, DOI 10.1046/j.1460-9568.1999.00652.x; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4	36	100	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18249	18252		10.1074/jbc.C200166200	http://dx.doi.org/10.1074/jbc.C200166200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11929859	hybrid			2022-12-25	WOS:000175975800002
J	Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K				Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K			Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors	ONCOGENE			English	Article						cell cycle; gene expression; CIMP; chromatin; acetylation	DEPENDENT KINASE INHIBITOR; ISLAND METHYLATOR PHENOTYPE; BECKWITH-WIEDEMANN-SYNDROME; CPG-ISLAND; ABERRANT METHYLATION; GASTRIC-CANCER; CHROMOSOME 11P15; PROTEIN MBD1; P57(KIP2); GENE	To clarify the role of DNA methylation in the silencing of the expression of cyclin-dependent kinase inhibitor p57KIP2 seen in certain tumors, we investigated the methylation status of its 5' CpG island in various tumor cell lines and primary cancers. Dense methylation of the region around the transcription start site was detected in I out of 10 colorectal, 2 out of 8 gastric, and 6 out of 14 hematopoietic tumor cell lines and in 5 out of 35 (14%) gastric, 6 out of 20 (30%) hepatocellular, and 2 out of IS (11%) pancreatic cancers; 7 out of 25 (28%) acute myeloid leukemia cases also showed methylation of the p57KIP2 gene, which strongly correlated with the CpG island methylator phenotype (P < 0.001). Detailed mapping revealed that dense methylation of the region around the transcription start site (-300 to +400), but not of the edges of the CpG island, was closely associated with gene silencing. 5-aza-2'-deoxycytidine, a methyltransferase inhibitor, restored expression of p57KIP2, and chromatin immunoprecipitation using anti-histone H3 and H4 antibodies showed histone to be deacetylated in cell lines where p57KIP2 was methylated at the transcription start site. Regional methylation and histone deacetylation thus appear to be crucially involved in the silencing of p57KIP2 expression in human tumors.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Sapporo Medical University; Sapporo Medical University; University of Texas System; UTMD Anderson Cancer Center	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Tokino, Takashi/AAI-9887-2021	Issa, Jean-Pierre/0000-0003-2258-5030				Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Herman JG, 1996, CANCER RES, V56, P722; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jackson SM, 2000, WILDLIFE RES, V27, P39, DOI 10.1071/WR98045; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Krskova-Honzatkova L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Sherr CJ, 2000, CANCER RES, V60, P3689; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ueki T, 2000, CANCER RES, V60, P1835; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WINQVIST R, 1993, CANCER RES, V53, P4486; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	48	101	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2741	2749		10.1038/sj.onc.1205376	http://dx.doi.org/10.1038/sj.onc.1205376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965547				2022-12-25	WOS:000174996500014
J	Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H				Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H			Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431	ONCOGENE			English	Article						squamous cell carcinoma; the patched gene; retrovirus vector; human gene therapy; Sonic hedgehog; A431	PSEUDOTYPED RETROVIRUS VECTOR; HEDGEHOG SIGNAL-TRANSDUCTION; SONIC-HEDGEHOG; HUMAN HOMOLOG; GORLIN-SYNDROME; DEVELOPMENTAL DEFECTS; MESSENGER-RNA; MUTATIONS; PATHWAY; INDUCTION	Defects in a developmental signaling pathway involving the mammalian homologue of the Drosophila segment polarity gene, patched are associated with human tumors such as basal cell carcinoma, medulloblastoma and squamous cell carcinoma. Loss of heterozygosity (LOH) in some of these tumor cells suggests that patched functions as a tumor suppressor gene. To evaluate the biological significance of patched mutations in human sporadic tumor cells, we constructed a VSV-G pseudotyped retrovirus vector carrying the wild-type patched gene and transduced it into two human squamous cell carcinoma (SCC) cell lines, A431 and KA, that express only mutant patched mRNA. When SSC cells were transduced with Ptc virus, colony forming activity in soft agar was drastically reduced and these cells recovered anchorage independent growth when Sonic hedgehog (Shh), the ligand of Patched (Ptc), was added into the soft agar culture. Expression of exogenous patched, however, had no effect on anchorage independent growth of Ras-transformed NIH3T3 cells or SCC cell line, NA, which expresses wild-type patched mRNA. Cyclopamine, a specific inhibitor of the Shh/Ptc/Smo signaling pathway, efficiently suppressed anchorage independent growth of A431 and KA cells. These results indicate that loss of patched function plays a major role in the acquisition of oncogenic potential in these SCCs and further that Ptc virus would be an effective reagent for suppressing tumorigenicity of such SCCs.	Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Hiroshima Univ, Dept Mol Oral Med & Maxillofacial Surg 1, Fac Dent, Minami Ku, Hiroshima 7348553, Japan	University of Tokyo; Hiroshima University	Iba, H (corresponding author), Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bale AE, 2000, NATURE, V406, P944, DOI 10.1038/35023197; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DAHMANE N, 1997, NATURE, V389, P870; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KWOK TT, 1994, CANCER RES, V54, P2834; Lee J, 1997, DEVELOPMENT, V124, P2537; Lench NJ, 1997, HUM GENET, V100, P497, DOI 10.1007/s004390050541; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; Michimukai E, 2001, IN VITRO CELL DEV-AN, V37, P459; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; OKUNO H, 1991, ONCOGENE, V6, P1491; Palm K, 2000, MOL BRAIN RES, V78, P192, DOI 10.1016/S0169-328X(00)00075-9; Pietsch T, 1997, CANCER RES, V57, P2085; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Unden AB, 1997, CANCER RES, V57, P2336; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Vorechovsky I, 1997, CANCER RES, V57, P4677; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wetmore C, 2000, CANCER RES, V60, P2239; WOLTER M, 1997, CANCER RES, V57, P2582; Xie JW, 1997, CANCER RES, V57, P2369; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	62	24	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2670	2678		10.1038/sj.onc.1205370	http://dx.doi.org/10.1038/sj.onc.1205370			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965540				2022-12-25	WOS:000174996500007
J	Janz, C; Susse, S; Wiesmuller, L				Janz, C; Susse, S; Wiesmuller, L			p53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation	ONCOGENE			English	Article						exonuclease; genomic stability; mispairing; oligomerization; protein-DNA complex formation; tumor suppressor	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; BINDING DOMAIN PEPTIDES; HOLLIDAY JUNCTIONS; HUMAN RAD51; PROTEIN; REPLICATION; INSTABILITY; DAMAGE; OLIGOMERIZATION; INACTIVATION	Heteroduplex joints represent intermediates of Rad51-dependent recombination processes, which are recognized by p53 with extremely high affinities, in a manner independent of the DNA sequence content. To determine the structural elements required for complex formation, we monitored DNA-binding by protection against restriction endonuclease cleavage. We show that wild-type (wt) p53 interacts with heteroduplex joints in the proximity of the flexible junction. Association of p53 within this junction region was also observed with preformed Rad51-heteroduplex complexes, whereas SSB counteracted p53 binding. At a distance of 31 bp from the junction p53 established very few contacts with the heteroduplex, despite the presence of an A - G mismatch. Consistently, p53-dependent exonucleolytic degradation decreased when we raised the distance between the junction and the heteroduplex terminus by 27 bp. Different from the cancer-related mutant p53(273H), which did not recognize the junction, tetramerization defective p53-1262 was protection competent but displayed reduced complex stability in gel shifts. Moreover, p53-1262 performed exonucleolytic activities towards ssDNA like wtp53, but reduced degradation of heteroduplex joints. These results suggest that during recombination wild-type p53, as a tetramer, stably binds to strand transfer regions, enabling the protein to exonucleolytically correct heteroduplex intermediates early after strand invasion.	Univ Ulm, Frauenklin & Poliklin, D-89075 Ulm, Germany	Ulm University	Wiesmuller, L (corresponding author), Univ Ulm, Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.	Lisa.Wiesmueller@medizin.uni-ulm.de						Ahrendt SA, 2000, CANCER RES, V60, P2488; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Atz J, 2000, J CELL BIOCHEM, V76, P572, DOI 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Chene P, 1999, J MOL BIOL, V288, P891, DOI 10.1006/jmbi.1999.2738; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cleaver JE, 1999, CANCER RES, V59, P1102; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Honma M, 1997, MUTAT RES-FUND MOL M, V374, P89, DOI 10.1016/S0027-5107(96)00223-0; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Janus F, 1999, MOL CELL BIOL, V19, P2155; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jean D, 1997, NUCLEIC ACIDS RES, V25, P4004, DOI 10.1093/nar/25.20.4004; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Schwartz JL, 1999, RADIAT RES, V151, P385, DOI 10.2307/3579824; SHAKKED Z, 2000, J BIOMOL STRUCT DYN; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Tarunina M, 1996, ONCOGENE, V13, P589; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	51	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2130	2140		10.1038/sj.onc.1205292	http://dx.doi.org/10.1038/sj.onc.1205292			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948396				2022-12-25	WOS:000174555300002
J	Ren, ZY; Schaefer, TS				Ren, ZY; Schaefer, TS			ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; TYROSINE KINASE-ACTIVITY; CONSTITUTIVE ACTIVATION; C-ERBB-2 GENE; NEU ONCOGENE; LUNG-CANCER; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; STAT ACTIVATION	Stats (signal transducer and activator of transcription) are latent transcription factors that translocate from the cytoplasm to the nucleus. Constitutive activation of Stat3alpha by upstream oncoproteins and receptor tyrosine kinases has been found in many human tumors and tumor-derived cell lines. Constitutively activated Stat3alpha is often correlated with the activation of ErbB-2, a member of the EGFR family. To explore the involvement of ErbB-2 in the activation of Stat3 and the mechanism underlying this event, an ErbB-2 point mutant was used as a model of constitutively activated receptor. Phenylalanine mutations (Y-->F) were made in the autophosphorylation sites of the receptor, and their ability to activate Stat3alpha was evaluated. Our results suggest that Stat3alpha and JAK2 associates with ErbB-2 prior to phosphorylation of the receptor and that full activation of Stat3alpha by ErbB-2 requires the participation of other non-receptor tyrosine kinases. Both Src and Jak2 kinases contribute to the activation of Stat3alpha but Src binds to ErbB-2 only when the receptor is phosphorylated. Our results also suggest that tyrosine 1139 may be important for Src homology 2 domain association because a mutant lacking this tyrosine reduces the ability of the Src homology 2 domain to bind to ErbB-2 and significantly decreases its ability to activate Stat3alpha.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Schaefer, TS (corresponding author), Meso Scale Discovery, 9238 Gaither Rd, Gaithersburg, MD 20877 USA.	tschaefer@meso-scale.com						AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Ali MS, 2000, J BIOL CHEM, V275, P15586, DOI 10.1074/jbc.M908931199; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BECHHARDT RN, 1995, ARCH OTOLARYNGOL, V121, P1265; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Giani C, 1998, ONCOGENE, V17, P425, DOI 10.1038/sj.onc.1201954; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lenferink AEG, 2001, CANCER RES, V61, P6583; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MORIYAMA M, 1991, J UROLOGY, V145, P423, DOI 10.1016/S0022-5347(17)38356-8; NATALI PG, 1994, INT J CANCER, V56, P341, DOI 10.1002/ijc.2910560308; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHLEGEL J, 1993, ACTA NEUROPATHOL, V86, P473; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tan M, 1997, CANCER RES, V57, P1199; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359	56	93	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38486	38493		10.1074/jbc.M112438200	http://dx.doi.org/10.1074/jbc.M112438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	11940572	hybrid			2022-12-25	WOS:000178529600064
J	Yang, Y; Li, LX; Wong, GW; Krilis, SA; Madhusudhan, MS; Sali, A; Stevens, RL				Yang, Y; Li, LX; Wong, GW; Krilis, SA; Madhusudhan, MS; Sali, A; Stevens, RL			RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs - Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE SPLICE VARIANTS; PROTOONCOGENE C-KIT; EXCHANGE FACTOR; PERIPHERAL-BLOOD; PLASMA-MEMBRANE; MOUSE; LINE; ACTIVATION; MICE; EXPRESSION	A cDNA was isolated from interleukin 3-developed, mouse bone marrow-derived mast cells (MCs) that contained an insert (designated mRasGRP4) that had not been identified in any species at the gene, mRNA, or protein level. By using a homology-based cloning approach, the similar to2.6-kb hRasGRP4 transcript was also isolated from the mononuclear progenitors; residing in the peripheral blood of normal individuals. This transcript information was then used to locate the RasGRP4 gene in the mouse and human genomes, to deduce its exon/intron organization, and then to identify 10 single nucleotide polymorphisms in the human gene that result in 5 amino acid differences. The > 15-kb hRasGRP4 gene consists of 18 exons and resides on a regdon of chromosome 19q13.1 that had not been sequenced by the Human Genome Project. Human and mouse MCs and their progenitors selectively express RasGRP4, and this new intracellular protein contains all of the domains present in the RasGRP family of guanine nucleotide exchange factors even though it is <50% identical to its closest homolog. Recombinant RasGRP4 can activate H-Ras in a cation-dependent manner. Transfection experiments also suggest that RasGRP4 is a diacylglycerollphorbol ester receptor. Transcript analysis of an asthma patient, a mastocytosis patient, and the HMC-1 cell line derived from a MC leukemia patient revealed the presence of substantial amounts of non-functional forms of hRasGRP4 due to an inability to remove intron 5 in the precursor transcript. Because only abnormal forms of hRasGRP4 were identified in the HMC-1 cell line, this immature MC progenitor was used to address the function of RasGRP4 in MCs. HMC-1 leukemia cells differentiated and underwent granule maturation when induced to express a normal form of RasGRP4. Thus, RasGRP4 plays an important role in the final stages of MC development.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ New S Wales, Dept Med, Kogarah, NSW 2217, Australia; St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW 2217, Australia; Rockefeller Univ, Pels Family Ctr Biochem & Struct Biol, Lab Mol Biophys, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of New South Wales Sydney; St George Hospital; Rockefeller University	Stevens, RL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506	NHLBI NIH HHS [HL-63284, HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIGMS NIH HHS [GM-54762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamas SP, 1997, LIFE SCI, V61, P1105, DOI 10.1016/S0024-3205(97)00243-9; Atamas SP, 1996, J IMMUNOL, V156, P435; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bottorff D, 1999, MAMM GENOME, V10, P358, DOI 10.1007/s003359901001; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUTTERFIELD JH, 1990, J LEUKOCYTE BIOL, V47, P409, DOI 10.1002/jlb.47.5.409; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GORDON JR, 1990, BLOOD, V75, P1637; Graham TE, 1998, J IMMUNOL, V161, P6733; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KLEIN SC, 1995, IMMUNOGENETICS, V41, P57, DOI 10.1007/BF00188440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LEVISCHAFFER F, 1987, J IMMUNOL, V139, P3431; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lorenzo PS, 2001, CANCER RES, V61, P943; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marone G, 2001, J ALLERGY CLIN IMMUN, V107, P22, DOI 10.1067/mai.2001.111589; Marsh DG, 1997, NAT GENET, V15, P389; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; OBERHAUSER AF, 1994, FEBS LETT, V339, P171, DOI 10.1016/0014-5793(94)80409-5; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Rashidi Hooman H., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P175; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1984, J IMMUNOL, V132, P1479; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN SCI, V3, P1582, DOI 10.1002/pro.5560030923; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHRADER JW, 1981, P NATL ACAD SCI-BIOL, V78, P323, DOI 10.1073/pnas.78.1.323; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; Song JS, 1999, J IMMUNOL, V163, P802; Song JS, 1996, J BIOL CHEM, V271, P26962, DOI 10.1074/jbc.271.43.26962; SWANN PG, 1999, SIGNAL TRANSDUCTION, P152; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	68	83	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25756	25774		10.1074/jbc.M202575200	http://dx.doi.org/10.1074/jbc.M202575200			19	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11956218	hybrid			2022-12-25	WOS:000176747000119
J	Le Ferrec, E; Lagadic-Gossmann, D; Rauch, C; Bardiau, C; Maheo, K; Massiere, F; Le Vee, M; Guillouzo, A; Morel, F				Le Ferrec, E; Lagadic-Gossmann, D; Rauch, C; Bardiau, C; Maheo, K; Massiere, F; Le Vee, M; Guillouzo, A; Morel, F			Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; ANTIOXIDANT RESPONSE ELEMENT; PROTEIN-DNA INTERACTIONS; REPUBLIC-OF-CHINA; DIOXIN RECEPTOR; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOL-3-THIONE OLTIPRAZ; GLUTATHIONE TRANSFERASES; PHENOBARBITAL INDUCTION; INDUCIBLE EXPRESSION; INTRACELLULAR CA2+	Oltipraz, a synthetic derivative of the cruciferous vegetable product 1,2-dithiole-3-thione, is considered as one of the most potent chemoprotectants. It modulates both cytochrome P-450 (CYP) and glutathione S-transferase expression and activities in rat tissues. Its effects, however, are variable according to the enzyme, tissue, and species. We show here that, as previously found in rat lung and kidney, CYP1A1 is inducible by oltipraz in both rat intestine and Caco-2 cells, a cell line originated from a human colon adenocarcinoma. In these cells, a 50 pm oltipraz treatment increased CYP1A1 mRNA (similar to30-fold), protein and activity. mRNA level was augmented as early as 2 h after the beginning of treatment, suggesting a transcriptional activation, and was maximal between 8 and 12 h. Transient transfection of Caco-2 cells with constructs containing different sizes of the 5'-flanking region of the CYP1A1 gene upstream of the luciferase reporter gene showed an increase in luciferase activity in oltipraz-treated cells, which correlates with the presence of the xenobiotic responsive element (XRE). Furthermore we demonstrated that resveratrol, an antagonist of the aryl hydrocarbon (Ah) receptor, inhibited the induction of both CYP1A1 promoter activity and mRNA by oltipraz, supporting the involvement of the Ah receptor in this induction. In an attempt to further characterize the mechanism of CYP1A1 induction, we showed a rapid increase in intracellular calcium concentration upon treatment of Caco-2 cells with oltipraz. Moreover, the effect of this compound on CY-P1A1 was strongly abolished in the presence of BAPTA-AM, a well known chelator of intracellular calcium, and 2-aminoethyl diphenylborate, an inhibitor of store-operated calcium channels. These results bring the first demonstration that oltipraz activates transcription of the CYP1A1 gene through the Ah receptor-XRE pathway in Caco-2 cells and that CYP1A1 induction relies upon an increase of intracellular calcium concentration.	Univ Rennes 1, INSERM, U456, F-35043 Rennes, France; Biopred, F-35000 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Morel, F (corresponding author), Univ Rennes 1, INSERM, U456, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.		LAGADIC-GOSSMANN, Dominique/I-5079-2015; Le FERREC, Eric/K-1374-2015; GUILLOUZO, Andre/Z-2373-2019; Maheo, Karine/AAC-3259-2022; Le Vee, Marc/U-8843-2019; LE VÉE, Marc/AAP-6961-2020	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Le FERREC, Eric/0000-0002-2015-2779; 				ANSHER SS, 1986, FOOD CHEM TOXICOL, V24, P405, DOI 10.1016/0278-6915(86)90205-X; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOONE CW, 1990, CANCER RES, V50, P2; BOULENC X, 1992, J PHARMACOL EXP THER, V263, P1471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243; Casper RF, 1999, MOL PHARMACOL, V56, P784; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciolino HP, 1998, CANCER RES, V58, P5707; Corchero J, 2001, PHARMACOGENETICS, V11, P1, DOI 10.1097/00008571-200102000-00001; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Corcos L, 1998, FEBS LETT, V425, P293, DOI 10.1016/S0014-5793(98)00246-4; Daujat M, 1996, EUR J BIOCHEM, V237, P642, DOI 10.1111/j.1432-1033.1996.0642p.x; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DEWAZIERS I, 1990, J PHARMACOL EXP THER, V253, P387; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Guigal N, 2000, BIOCHEM BIOPH RES CO, V267, P572, DOI 10.1006/bbrc.1999.1959; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; Heist EK, 1998, CELL CALCIUM, V23, P103; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Kensler T W, 1995, J Cell Biochem Suppl, V22, P101; LANGOUET S, 1995, CANCER RES, V55, P5574; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; Le Ferrec E, 2001, CARCINOGENESIS, V22, P49, DOI 10.1093/carcin/22.1.49; LESCA P, 1995, BIOCHEM BIOPH RES CO, V209, P474, DOI 10.1006/bbrc.1995.1526; LIU YL, 1988, TOXICOL APPL PHARM, V93, P442, DOI 10.1016/0041-008X(88)90047-6; Long WP, 1999, J BIOL CHEM, V274, P12391, DOI 10.1074/jbc.274.18.12391; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Maheo K, 1998, HEPATOLOGY, V28, P1655, DOI 10.1002/hep.510280627; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; Primiano T, 1997, Adv Pharmacol, V38, P293; Putney JW, 2001, J CELL SCI, V114, P2223; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; RAO CV, 1993, CANCER RES, V53, P2502; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sadar MD, 1996, J BIOL CHEM, V271, P17635, DOI 10.1074/jbc.271.30.17635; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Tannheimer SL, 1999, MOL CARCINOGEN, V25, P48, DOI 10.1002/(SICI)1098-2744(199905)25:1<48::AID-MC6>3.0.CO;2-6; Tannheimer SL, 1997, CARCINOGENESIS, V18, P1177, DOI 10.1093/carcin/18.6.1177; Vargas M, 1998, DRUG METAB DISPOS, V26, P91; Wang JS, 1996, CANCER EPIDEM BIOMAR, V5, P253; WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545	51	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24780	24787		10.1074/jbc.M111319200	http://dx.doi.org/10.1074/jbc.M111319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959854	hybrid			2022-12-25	WOS:000176611800105
J	Nybakken, KE; Turck, CW; Robbins, DJ; Bishop, JM				Nybakken, KE; Turck, CW; Robbins, DJ; Bishop, JM			Hedgehog-stimulated phosphorylation of the kinesin-related protein Costal2 is mediated by the serine/threonine kinase fused	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CUBITUS-INTERRUPTUS PROTEIN; BASAL-CELL CARCINOMAS; DROSOPHILA PATCHED GENE; HUMAN SONIC HEDGEHOG; HUMAN HOMOLOG; IN-VIVO; MOLECULAR-ORGANIZATION; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN	The Hedgehog (Hh) signaling molecule is required for the development of numerous tissues in Drosophila. Within the cell, Hh signal transduction utilizes a large protein complex consisting of the Fused (Fu), Costal2 (Cos2), and Cubitis interruptus (Ci) proteins, but the functional interactions between these proteins are still largely uncharacterized. Using a baculovirus system, we demonstrate that the serine/threonine kinase Fu phosphorylates the kinesin-like protein Cos2 when coexpressed with Cos2. Coexpression of Cos2 and a kinase-inactive version of Fu eliminates the majority of Cos2 phosphorylation. We then show that the primary Fu-induced phosphorylation site of Cos2 is serine 572, whereas serine 931 is phosphorylated to a lesser extent. Mutation of serine 572 to alanine eliminates most, but not all, specific phosphopeptides of Cos2 when coexpressed with Fu. We also demonstrate that the phosphorylation pattern of Cos2 produced by baculovirus coexpression with kinase-dead Fu is almost identical to the phosphorylation pattern of Cos2 isolated from unstimulated S2 cells. Finally, the phosphorylation pattern of Cos2 produced by baculovirus coinfection with wildtype Fu is almost identical to that of Cos2 isolated from S2 cells stimulated by Hh, indicating that phosphorylation of serines 572 and 931 is a genuine Hh signaling event. This study clarifies the unique functions of Fu and Cos2 in Hh signal transduction and identifies only the second known phosphorylation site of a kinesin-like molecule.	Univ Calif San Francisco, Hooper Fdn, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Nybakken, KE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Warren Alpert Bldg 412,200 Longwood Ave, Boston, MA 02115 USA.	knybakke@genetics.med.harvard.edu			NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FIETZ MJ, 1994, DEV S, V5, P43; FORBES AJ, 1993, DEV S, V4, P115; Frolova LY, 1998, EUR J BIOCHEM, V256, P36, DOI 10.1046/j.1432-1327.1998.2560036.x; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hepker J, 1997, DEVELOPMENT, V124, P549; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; Lin RT, 1999, MOL CELL BIOCHEM, V191, P169, DOI 10.1023/A:1006850009017; Lindesmith L, 1997, J BIOL CHEM, V272, P22929, DOI 10.1074/jbc.272.36.22929; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; OKADA Y, 1995, J NEUROSCI, V15, P3053; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PHAM A, 1995, GENETICS, V140, P587; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PREAT T, 1992, GENETICS, V132, P725; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Price MA, 1999, DEVELOPMENT, V126, P4331; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Rosenberg SJ, 1998, CELL SIGNAL, V10, P131, DOI 10.1016/S0898-6568(97)00117-4; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wicking C, 1998, ONCOGENE, V16, P1091, DOI 10.1038/sj.onc.1201644; Witthuhn BA, 1999, LEUKEMIA LYMPHOMA, V32, P289, DOI 10.3109/10428199909167389; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	74	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24638	24647		10.1074/jbc.M110730200	http://dx.doi.org/10.1074/jbc.M110730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11934882	hybrid			2022-12-25	WOS:000176611800088
J	Mogensen, JE; Wimmer, R; Larsen, JN; Spangfort, MD; Otzen, DE				Mogensen, JE; Wimmer, R; Larsen, JN; Spangfort, MD; Otzen, DE			The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; POLLEN-TUBE GROWTH; BINDING-PROTEIN; CHERRY ALLERGEN; RIBONUCLEASE-ACTIVITY; NMR-SPECTROSCOPY; PR-10 PROTEIN; CDNA CLONING; FATTY-ACIDS; GENE FAMILY	Bet v 1 is a 17-kDa protein abundantly present in the pollen of the White birch tree and is the primary cause of birch pollen allergy in humans. Its three-dimensional structure is remarkable in that a solvent-accessible cavity traverses the core of the molecule. The biological function of Bet v 1 is unknown, although it is homologous to a family of pathogenesis-related proteins in plants. In this study we first show that Bet v 1 in the native state is able to bind the fluorescent probe 8-anilino-1-naphthalenesulfonic acid (ANS). ANS binds to Bet v 1 with 1:1 stoichiometry, and NMR data indicate that binding takes place in the cavity. Using an ANS displacement assay, we then identify a range of physiologically relevant ligands, including fatty acids, flavonoids, and cytokinins, which generally bind with low micromolar affinity. The ability of these ligands to displace ANS suggests that they also bind in the cavity, although the exact binding sites seem to vary among different ligands. The cytokinins, for example, seem to bind at a separate site close to ANS, because they increase the fluorescence of the ANS.Bet v 1 complex. Also, the fluorescent sterol dehydroergosterol binds to Bet v 1 as demonstrated by direct titrations. This study provides the first qualitative and quantitative data on the ligand binding properties of this important pollen allergen. Our findings indicate that ligand binding is important for the biological function of Bet v 1.	Univ Aalborg, Dept Biotechnol, Inst Life Sci, DK-9000 Aalborg, Denmark; ALK Abello AS, Biochem Allergy Res, DK-2970 Horsholm, Denmark	Aalborg University; ALK-Abello AS	Otzen, DE (corresponding author), Univ Aalborg, Dept Biotechnol, Inst Life Sci, Sohngaardsholmsvej 49, DK-9000 Aalborg, Denmark.		Larsen, Jørgen Nedergaard/AAI-3423-2020; Wimmer, Reinhard/M-2346-2019; Wimmer, Reinhard/A-7901-2012	Wimmer, Reinhard/0000-0001-6942-5056; Otzen, Daniel/0000-0002-2918-8989				Bantignies B, 2000, PLANT MOL BIOL, V42, P871, DOI 10.1023/A:1006475303115; Billeter M, 1995, J BIOMOL NMR, V5, P1; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; ENGELHARD M, 1995, PROTEIN SCI, V4, P1553, DOI 10.1002/pro.5560040813; Franklin-Tong VE, 1999, PLANT CELL, V11, P727, DOI 10.1105/tpc.11.4.727; Fujimoto Y, 1998, EUR J BIOCHEM, V258, P794, DOI 10.1046/j.1432-1327.1998.2580794.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P115, DOI 10.1159/000024367; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; Iyer LM, 2001, PROTEINS, V43, P134, DOI 10.1002/1097-0134(20010501)43:2<134::AID-PROT1025>3.3.CO;2-9; Kane CD, 1996, ANAL BIOCHEM, V233, P197, DOI 10.1006/abio.1996.0028; Kirk WR, 1996, BIOPHYS J, V70, P69, DOI 10.1016/S0006-3495(96)79592-9; Kobayashi K, 2000, PLANT CELL PHYSIOL, V41, P148, DOI 10.1093/pcp/41.2.148; KRESBECH GC, 1975, SURFACTANTS WATER CO, P95; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LARSEN JN, 1995, ACI NEWS, V7, P141; Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245, DOI 10.1007/BF02668748; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MO YY, 1992, P NATL ACAD SCI USA, V89, P7213, DOI 10.1073/pnas.89.15.7213; Moiseyev GP, 1997, FEBS LETT, V407, P207, DOI 10.1016/S0014-5793(97)00337-2; NESSLER CL, 1990, PLANTA, V180, P487, DOI 10.1007/BF02411445; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Ory JJ, 1999, BIOPHYS J, V77, P1107, DOI 10.1016/S0006-3495(99)76961-4; Osman H, 2001, FEBS LETT, V489, P55, DOI 10.1016/S0014-5793(01)02078-6; Osmark P, 1998, PLANT MOL BIOL, V38, P1243, DOI 10.1023/A:1006060224012; OSMARK P, 1996, THESIS U COPENHAGEN; OSSIPOV V, 1995, BIOCHEM SYST ECOL, V23, P213, DOI 10.1016/0305-1978(94)00092-U; Peters T. J., 1995, ALBUMIN BIOCH GENETI; Petitpas I, 2001, J MOL BIOL, V314, P955, DOI 10.1006/jmbi.2000.5208; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Poupard P, 2001, AUST J PLANT PHYSIOL, V28, P57; POZUETAROMERO J, 1995, PLANT MOL BIOL, V28, P1011, DOI 10.1007/BF00032663; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 1996, J BIOL CHEM, V271, P31068, DOI 10.1074/jbc.271.49.31068; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1990, LIPIDS, V25, P669, DOI 10.1007/BF02544032; Schweimer K, 1999, APPL MAGN RESON, V17, P449, DOI 10.1007/BF03162177; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; Spangfort MD, 1996, PROTEIN EXPRES PURIF, V8, P365, DOI 10.1006/prep.1996.0112; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SWOBODA I, 1994, BBA-GENE STRUCT EXPR, V1219, P457, DOI 10.1016/0167-4781(94)90072-8; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; Swoboda I, 1996, PHYSIOL PLANTARUM, V96, P433, DOI 10.1111/j.1399-3054.1996.tb00455.x; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Utriainen M, 1998, PLANT CELL ENVIRON, V21, P821, DOI 10.1046/j.1365-3040.1998.00326.x; Van Damme EJM, 2000, PLANT PHYSIOL, V122, P433, DOI 10.1104/pp.122.2.433; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Vanderheeren G, 1998, BIOPHYS J, V75, P2195, DOI 10.1016/S0006-3495(98)77663-5; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Wassenberg JJ, 2000, J BIOL CHEM, V275, P22806, DOI 10.1074/jbc.M001476200; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Wilhelmi LK, 1999, CURR OPIN PLANT BIOL, V2, P18, DOI 10.1016/S1369-5266(99)80004-1; Wimmer R, 1997, J BIOMOL NMR, V9, P101, DOI 10.1023/A:1018631903764; Wolters-Arts M, 1998, NATURE, V392, P818, DOI 10.1038/33929	71	199	213	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23684	23692		10.1074/jbc.M202065200	http://dx.doi.org/10.1074/jbc.M202065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953433	hybrid			2022-12-25	WOS:000176475700077
J	Ribeiro, CS; Carneiro, K; Ross, CA; Menezes, JRL; Engelender, S				Ribeiro, CS; Carneiro, K; Ross, CA; Menezes, JRL; Engelender, S			Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; LEWY BODIES; PRESYNAPTIC PROTEIN; HIPPOCAMPAL-NEURONS; PRECURSOR PROTEIN; BODY FORMATION; BRAIN; MUTATION; GENE	a-Synuclein is the major component of Lewy bodies in patients with Parkinson's disease, and mutations in the a-synuclein gene are responsible for some familial forms of the disease. a-Synuclein is enriched in the presynapse, but its synaptic targets are unknown. Synphilin-1 associates in vivo with a-synuclein promoting the formation of intracellular inclusions. Additionally synphilin-1 has been found to be an intrinsic component of Lewy bodies in patients with Parkinson's disease. To understand the role of synphilin-1 in Parkinson's disease, we sought to define its localization and function in the brain. We now report that, like a-synuclein, synphilin-1 was enriched in neurons. In young rats, synphilin-1 was prominent in neuronal cell bodies but gradually migrated to neuropil during development. Immunoelectron microscopy of adult rat cerebral cortex demonstrated that synphilin-1 was highly enriched in presynaptic nerve terminals. Synphilin-1 co-immunoprecipitated with synaptic vesicles, indicating a strong association with these structures. In vitro binding experiments demonstrated that the N terminus of synphilin-1 robustly associated with synaptic vesicles and that this association was resistant to high salt washing but was abolished by inclusion of a-synuclein in the incubation medium. Our data indicated that synphilin-1 is a synaptic partner of a-synuclein, and it may mediate synaptic roles attributed to a-synuclein.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Johns Hopkins Univ, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Univ Fed Rio de Janeiro, Dept Anat, BR-21941590 Rio De Janeiro, Brazil	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Johns Hopkins University; Johns Hopkins University; Universidade Federal do Rio de Janeiro	Engelender, S (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Pharmacol, POB 4696, IL-31096 Haifa, Israel.		Carneiro, Katia/AAQ-3415-2020; Menezes, João R. L./D-5668-2012; Ross, Christopher A/H-8395-2013; Carneiro, Katia/I-6014-2015	Carneiro, Katia/0000-0001-5915-5486; Engelender, Simone/0000-0001-7401-6855	NINDS NIH HHS [NS38377] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038377] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Engelender S, 2000, MAMM GENOME, V11, P763, DOI 10.1007/s003350010123; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Hsu LJ, 1998, J NEUROCHEM, V71, P338; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; LEE G, 2001, SOC NEUR ABSTR, V27; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nagano Y, 2001, NEUROSCI LETT, V316, P103, DOI 10.1016/S0304-3940(01)02330-8; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2000, BRAIN PATHOL, V10, P520; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6	32	88	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23927	23933		10.1074/jbc.M201115200	http://dx.doi.org/10.1074/jbc.M201115200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956199	hybrid			2022-12-25	WOS:000176475700107
J	Sugiura, M; Kono, K; Liu, H; Shimizugawa, T; Minekura, H; Spiegel, S; Kohama, T				Sugiura, M; Kono, K; Liu, H; Shimizugawa, T; Minekura, H; Spiegel, S; Kohama, T			Ceramide kinase, a novel lipid kinase - Molecular cloning and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PROTEIN-COUPLED RECEPTOR; LEUKEMIA HL-60 CELLS; MARINE BACTERIUM; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE; APOPTOSIS; 1-PHOSPHATE; BINDING; EDG-1	Ceramide-1-phosphate is a sphingolipid metabolite that has been implicated in membrane fusion of brain synaptic vesicles and neutrophil phagolysosome formation. Ceramide-l-phosphate can be produced by ATP-dependent ceramide kinase activity, although little is known of this enzyme because it has not yet been highly purified or cloned. Based on sequence homology to sphingosine kinase type 1, we have now cloned a related lipid kinase, human ceramide kinase (hCERK). hCERK encodes a protein of 537 amino acids that has a catalytic region with a high degree of similarity to the diacylglycerol kinase catalytic domain. hCERK also has a putative N-myristoylation site on its NH2 terminus followed by a pleckstrin homology domain. Membrane but not cytosolic fractions from HEK293 cells transiently transfected with a hCERK expression vector readily phosphorylated ceramide but not sphingosine or other sphingoid bases, diacylglycerol. or phosphatidylinositol. This activity was clearly distinguished from those of bacterial or human diacylglycerol. kinases. With natural ceramide as a substrate, the enzyme had a pH optimum of 6.0-7.5 and showed Michaelis-Menten kinetics, with K-m values of 187 and 32 muM for ceramide and ATP, respectively. Northern blot analysis revealed that hCERK mRNA expression was high in the brain, heart, skeletal muscle, kidney, and liver. A BLAST search analysis using the hCERK sequence revealed that putative ceramide kinases (CERKs) exist widely in diverse multicellular organisms including plants, nematodes, insects, and vertebrates. Phylogenetic analysis revealed that CERKs are a new class of lipid kinases that are clearly distinct from sphingosine and diacylglycerol kinases. Cloning of CERK should provide new molecular tools to investigate the physiological functions of ceramide-1-phosphate.	Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Daiichi Sankyo Company Limited; Virginia Commonwealth University	Kohama, T (corresponding author), Sankyo Co Ltd, Pharmacol & Mol Biol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.	kohama@shina.sankyo.co.jp		Kohama, Takafumi/0000-0002-6822-8170				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bajjalieh S, 2000, METHOD ENZYMOL, V311, P207; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; Kono K, 2000, J ANTIBIOT, V53, P753, DOI 10.7164/antibiotics.53.753; Kono K, 2000, J ANTIBIOT, V53, P459, DOI 10.7164/antibiotics.53.459; Kono K, 2000, J ANTIBIOT, V53, P759, DOI 10.7164/antibiotics.53.759; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; LIU H, 2002, IN PRESS PROG NUC RE; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	46	236	249	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23294	23300		10.1074/jbc.M201535200	http://dx.doi.org/10.1074/jbc.M201535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956206	hybrid			2022-12-25	WOS:000176475700027
J	Swinney, DC; Xu, YZ; Scarafia, LE; Lee, I; Mak, AY; Gan, QF; Ramesha, CS; Mulkins, MA; Dunn, J; So, OY; Biegel, T; Dinh, M; Volkel, P; Barnett, J; Dalrymple, SA; Lee, S; Huber, M				Swinney, DC; Xu, YZ; Scarafia, LE; Lee, I; Mak, AY; Gan, QF; Ramesha, CS; Mulkins, MA; Dunn, J; So, OY; Biegel, T; Dinh, M; Volkel, P; Barnett, J; Dalrymple, SA; Lee, S; Huber, M			A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SIGNAL-INDUCED UBIQUITINATION; SCF-BETA-TRCP; RHEUMATOID-ARTHRITIS; PROTEASOME PATHWAY; CARRIER PROTEIN; IN-VITRO; PHOSPHORYLATION; DEGRADATION; IDENTIFICATION	A small molecule inhibitor of NF-kappaB-dependent cytokine expression was discovered that blocked tumor necrosis factor (TNF) alpha-induced IkappaBalpha degradation in MM6 cells but not the degradation of beta-catenin in Jurkat cells. Ro106-9920 blocked lipopolysaccharide (LPS)-dependent expression of TNFalpha, interieukin-1beta, and interleukin-6 in fresh human peripheral blood mononuclear cells with IC50 values below 1 muM. Ro106-9920 also blocked TNFalpha production in a dose-dependent manner following oral administration in two acute models of inflammation (air pouch and LPS challenge). Ro106-9920 was observed to inhibit an ubiquitination activity that does not require betaTRCP but associates with IkappaBalpha and will ubiquitinate IkappaBalpha S32E,S36E (IkappaBalphaee) specifically at lysine 21 or 22. Ro106-9920 was identified in a cell-free system as a time-dependent inhibitor of IkappaBalphaee ubiquitination with an IC50 value of 2.3 +/- 0.09 muM. The ubiquitin E3 ligase activity is inhibited by cysteine-alkylating reagents, supported by E2UBCH7, and requires cLAP2 or a cLAP2-associated protein for activity. These activities are inconsistent with what has been reported for SCFbetaTRCP, the putative E3 for IkappaBalpha ubiquitination. Ro106-9920 was observed to be selective for IkappaBalphaee ubiquitination over the ubiquitin-activating enzyme (El), E2UBCH7, nonspecific ubiquitination of cellular proteins, and 97 other molecular targets. We propose that Ro106-9920 selectively inhibits an uncharacterized but essential ubiquitination activity associated with LPS-and TNFalpha-induced IkappaBalpha degradation and NF-kappaB activation.	Roche Biosci, Inflamatory & Viral Dis Unit, Palo Alto, CA 94304 USA	Roche Holding	Swinney, DC (corresponding author), Roche Biosci, Inflamatory & Viral Dis Unit, M-S S3-1, Palo Alto, CA 94304 USA.			VOLKEL, Pamela/0000-0001-8582-1550				ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baert FJ, 1999, GASTROENTEROLOGY, V116, P22, DOI 10.1016/S0016-5085(99)70224-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannwarth W, 1996, BIOORG MED CHEM LETT, V6, P2141, DOI 10.1016/0960-894X(96)00387-3; Bondeson J, 1999, P NATL ACAD SCI USA, V96, P5668, DOI 10.1073/pnas.96.10.5668; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; EUGUI EM, 1994, INT IMMUNOL, V6, P409, DOI 10.1093/intimm/6.3.409; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13258; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang HK, 2000, J BIOL CHEM, V275, P26661; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KIAS EA, 1991, HELV CHIM ACTA, V74, P1314; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; LUI P, 2000, SHOCK, V13, P217; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rodriguez MS, 1996, ONCOGENE, V12, P2425; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SEGEL IH, 1975, ENZYME KINETICS, P127; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	48	75	83	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23573	23581		10.1074/jbc.M200842200	http://dx.doi.org/10.1074/jbc.M200842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11950839	hybrid			2022-12-25	WOS:000176475700062
J	Takei, Y; Kadomatsu, K; Itoh, H; Sato, W; Nakazawa, K; Kubota, S; Muramatsu, T				Takei, Y; Kadomatsu, K; Itoh, H; Sato, W; Nakazawa, K; Kubota, S; Muramatsu, T			5 '-,3 '-Inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; PROTEIN-KINASE; GROWTH-FACTOR; WILMS-TUMOR; ISIS 2302; EXPRESSION; INHIBITION; DNA; CELLS	Oligodeoxynucleotides modified at both 5'- and 3'-ends with inverted thymidine (5'-,3'-inverted T) were introduced as new reagents for antisense strategies. These modifications were performed to make the oligodeoxynucleotides resistant to nucleases. The effectiveness of these oligodeoxynucleotides was evaluated in terms of inhibition of synthesis of midkine (MK), a heparin-binding growth factor, and consequent inhibition of growth of CMT-93 mouse rectal carcinoma cells. 5'-,3'-Inverted T antisense AM suppressed synthesis of MK by CMT-93 cells and their growth in culture. Furthermore, 5'-,3'-inverted T oligodeoxynucleotides exhibited less cytotoxicity and better stability than phosphorothioate oligodeoxynucleotides. When 5'-,3'-inverted T antisense MK was mixed with atelocollagen, and injected into CMT-93 tumors pregrown in nude mice, tumor growth was markedly suppressed as compared with tumors injected with sense controls. The suppressive effect of 5'-,3'-inverted T antisense MK on tumor growth was stronger than that of phosphorothioate antisense MK. These findings indicated the usefulness of inverted thymidine-modified antisense oligodeoxynucleotides as a new reagent instead of phosphorothioate-modified oligodeoxynucleotides.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Koken Biosci Inst, Shinjuku Ku, Tokyo 1690072, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol Chem & Metab, Tokyo 1130033, Japan	Nagoya University; University of Tokyo	Muramatsu, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai cho, Nagoya, Aichi 4668550, Japan.	tmurama@med.nagoya-u.ac.jp	Kadomatsu, Kenji/G-8083-2012; TAKEI, Yoshifumi/I-7260-2014					AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; AGRAWAL S, 1995, CLIN PHARMACOKINET, V28, P7, DOI 10.2165/00003088-199528010-00002; ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; Flaherty KT, 2001, CURR OPIN ONCOL, V13, P499, DOI 10.1097/00001622-200111000-00013; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P473, DOI 10.1089/oli.1.1997.7.473; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Henry SP, 1997, TOXICOLOGY, V116, P77, DOI 10.1016/S0300-483X(96)03532-9; Henry SP, 1997, TOXICOLOGY, V120, P145, DOI 10.1016/S0300-483X(97)03661-5; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P395; HORNER MJ, 1996, FUNDAM APPL TOXICO S, V36, P147; IDZIAK I, 1993, TETRAHEDRON LETT, V34, P5417, DOI 10.1016/S0040-4039(00)73923-2; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kandimalla ER, 1997, NUCLEIC ACIDS RES, V25, P370, DOI 10.1093/nar/25.2.370; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; Monteith DK, 1999, TOXICOL PATHOL, V27, P8, DOI 10.1177/019262339902700103; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; OBrien T, 1996, CANCER RES, V56, P2515; Ochiya T, 1999, NAT MED, V5, P707, DOI 10.1038/9560; Owada K, 1999, J NEUROCHEM, V73, P2084; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Robins MJ, 2000, NUCLEOS NUCLEOT NUCL, V19, P69, DOI 10.1080/15257770008032997; Roth CM, 1999, ANNU REV BIOMED ENG, V1, P265, DOI 10.1146/annurev.bioeng.1.1.265; SANDS H, 1994, MOL PHARMACOL, V45, P932; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; SARIN PS, 1988, P NATL ACAD SCI USA, V85, P7448, DOI 10.1073/pnas.85.20.7448; SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99; Sioud M, 2000, J MOL BIOL, V296, P937, DOI 10.1006/jmbi.2000.3491; SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787; SPROAT BS, 1995, J BIOTECHNOL, V41, P221, DOI 10.1016/0168-1656(95)00012-F; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Takei Y, 2001, CANCER RES, V61, P8486; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Tari AM, 2000, METHOD ENZYMOL, V313, P372; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TSUTSUI J, 1993, CANCER RES, V53, P1281; Uhlmann E, 1998, ANGEW CHEM INT EDIT, V37, P2797; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZHANG RW, 1995, BIOCHEM PHARMACOL, V49, P929, DOI 10.1016/0006-2952(95)00010-W	51	44	56	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23800	23806		10.1074/jbc.M112100200	http://dx.doi.org/10.1074/jbc.M112100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959856	hybrid			2022-12-25	WOS:000176475700092
J	Vanoye, CG; MacGregor, GG; Dong, K; Tang, LQ; Buschmann, AS; Hall, AE; Lu, M; Giebisch, G; Hebert, SC				Vanoye, CG; MacGregor, GG; Dong, K; Tang, LQ; Buschmann, AS; Hall, AE; Lu, M; Giebisch, G; Hebert, SC			The carboxyl termini of K-ATP channels bind nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; ADENOSINE-TRIPHOSPHATE; CONFORMATIONAL-CHANGES; SULFONYLUREA RECEPTOR; GASTRIC H+,K+-ATPASE; CYTOPLASMIC DOMAIN; ESCHERICHIA-COLI; KIR6.2 SUBUNIT; INHIBITION; SITE	ATP-sensitive potassium (K-ATP) channels are expressed in many excitable, as well as epithelial, cells and couple metabolic changes to modulation of cell activity. ATP regulation of K-ATP channel activity may involve direct binding of this nucleotide to the pore-forming inward rectifier (Kir) subunit despite the lack of known nucleotide-binding motifs. To examine this possibility, we assessed the binding of the fluorescent ATP analogue, 2',3'-O-(2,4,6-trinitrophenylcyclo-hexadienylidene)adenosine 5'triphosphate (TNP-ATP) to maltose-binding fusion proteins of the NH2- and COOH-terminal cytosolic regions of the three known K-ATP channels (Kirl.1, Kir6.1, and Kir6.2) as well as to the COOH-terminal region of an ATP-insensitive inward rectifier K+ channel (Kir2.1). We show direct binding of TNP-ATP to the COOH termini of all three known K-ATP channels but not to the COOH terminus of the ATP-insensitive channel, Kir2.1. TNP-ATP binding was specific for the COOH termini of K-ATP channels because this nucleotide did not bind to the NH2 termini of Kirl.1 or Kir6.1. The affinities for TNP-ATP binding to K-ATP COOH termini of Kirl.1, Kir6.1, and Kir6.2 were similar. Binding was abolished by denaturing with 4 m urea or SDS and enhanced by reduction in pH. TNP-ATP to protein stoichiometries were similar for all KATp COOH-terminal proteins with 1 mol of TNP-ATP binding/ mole of protein. Competition of TNP-ATP binding to the Kirl.1 COOH terminus by MgATP was complex with both Mg2+ and MgATP effects. Glutaraldehyde cross-linking demonstrated the multimerization potential of these COOH termini, suggesting that these cytosolic segments may directly interact in intact tetrameric channels. Thus, the COOH termini of K-ATP tetrameric channels contain the nucleotide-binding pockets of these metabolically regulated channels with four potential nucleotide-binding sites/channel tetramer.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Vanderbilt Univ, Sch Med, Div Genet Med, Dept Med, Nashville, TN 37232 USA	Yale University; Vanderbilt University	Hebert, SC (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St,SHM B147,POB 208026, New Haven, CT 06520 USA.				NIDDK NIH HHS [DK54999, DK54998] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054998, R01DK054999] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Collins A, 1996, J NEUROSCI, V16, P1; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; DEUTSCH N, 1994, J GEN PHYSIOL, V104, P773, DOI 10.1085/jgp.104.4.773; DIVITA G, 1993, J BIOL CHEM, V268, P13178; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; HILGEMANN DW, 2001, SCI STKE; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; KLINGENBERG M, 1984, BIOCHEMISTRY-US, V23, P2442, DOI 10.1021/bi00306a019; Koster JC, 1999, J PHYSIOL-LONDON, V515, P19, DOI 10.1111/j.1469-7793.1999.019ad.x; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200; MacGregor GG, 2002, P NATL ACAD SCI USA, V99, P2726, DOI 10.1073/pnas.042688899; Markworth E, 2000, DIABETES, V49, P1413, DOI 10.2337/diabetes.49.9.1413; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Misler S, 1992, Curr Opin Nephrol Hypertens, V1, P21, DOI 10.1097/00041552-199210000-00005; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tanabe K, 2000, BIOCHEM BIOPH RES CO, V272, P316, DOI 10.1006/bbrc.2000.2780; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; Trapp S, 1997, P NATL ACAD SCI USA, V94, P8872, DOI 10.1073/pnas.94.16.8872; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	59	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23260	23270		10.1074/jbc.M112004200	http://dx.doi.org/10.1074/jbc.M112004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956191	hybrid			2022-12-25	WOS:000176475700023
J	Cragg, RA; Christie, GR; Phillips, SR; Russi, RM; Kury, S; Mathers, JC; Taylor, PM; Ford, D				Cragg, RA; Christie, GR; Phillips, SR; Russi, RM; Kury, S; Mathers, JC; Taylor, PM; Ford, D			A novel zinc-regulated human zinc transporter, hZTL1, is localized to the enterocyte apical membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MTF-1; BRUSH-BORDER MEMBRANE; CELL-LINE CACO-2; SACCHAROMYCES-CEREVISIAE; ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL EXPRESSION; NATURAL-RESISTANCE; CONFERS RESISTANCE; METAL TRANSPORTER; DIETARY ZINC	Zinc is essential to a wide range of cellular processes; therefore, it is important to elucidate the molecular mechanisms of zinc homeostasis. To date, no zinc transporters expressed at the enterocyte apical membrane, and so essential to mammalian zinc homeostasis, have been discovered. We identified hZTL1 as a human expressed sequence tag with homology to the basolateral enterocyte zinc transporter ZnT1 and deduced the full-length cDNA sequence by PCR. The protein of 523 amino acids belongs to the cation diffusion facilitator family of membrane transporters. Unusually, the predicted topology comprises 12 rather than 6 transmembrane domains. ZTL1 mRNA was detected by reverse transcription-PCR in a range of mouse tissues. A Myc-tagged hZTL1 clone was expressed in transiently transfected polarized human intestinal Caco-2 cells at the apical membrane. Expression of hZTL1 mRNA in Caco-2 cells increased with zinc supplementation of the nutrient medium; however, in the placental cell line JAR hZTL1 appeared not to be regulated by zinc. Heterologous expression of hZTL1 in Xenopus laevis oocytes increased zinc uptake across the plasma membrane. The localization, regulatory properties, and function of hZTL1 indicate a role in regulating the absorption of dietary zinc across the apical enterocyte membrane.	Univ Newcastle, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Newcastle, Human Nutr Res Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Dundee, Sch Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Fac Med, ADN, Lab Etud Polymorphisme, F-44035 Nantes, France	Newcastle University - UK; Newcastle University - UK; University of Dundee	Ford, D (corresponding author), Univ Newcastle, Dept Biol & Nutr Sci, Kings Rd, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.		KÜRY, Sébastien/G-5971-2015; Taylor, Peter M/A-4667-2010	KÜRY, Sébastien/0000-0001-5497-0465; Mathers, John/0000-0003-3406-3002	Biotechnology and Biological Sciences Research Council [D18271] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; BARNES PM, 1973, P ROY SOC MED, V66, P327, DOI 10.1177/003591577306600411; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Goswami T, 2001, BIOCHEM J, V354, P511, DOI 10.1042/0264-6021:3540511; Grotz N, 1998, P NATL ACAD SCI USA, V95, P7220, DOI 10.1073/pnas.95.12.7220; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Liuzzi JP, 2001, J NUTR, V131, P46, DOI 10.1093/jn/131.1.46; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Milon B, 2001, FEBS LETT, V507, P241, DOI 10.1016/S0014-5793(01)02950-7; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PASSMORE R, 1955, BRIT J NUTR, V9, P20, DOI 10.1079/BJN19550006; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Persson B, 1996, PROTEIN SCI, V5, P363; Peter GJ, 1999, BIOCHEM J, V343, P169, DOI 10.1042/0264-6021:3430169; PINTO M, 1983, BIOL CELL, V47, P323; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; SOLOVYEV VV, 1995, P 3 INT C INT SYST M, P367; TACNET F, 1993, J PHYSIOL-LONDON, V465, P57, DOI 10.1113/jphysiol.1993.sp019666; Tandy S, 2000, J BIOL CHEM, V275, P1023, DOI 10.1074/jbc.275.2.1023; Thwaites DT, 1999, EXP PHYSIOL, V84, P275, DOI 10.1017/S0958067099018436; Van Dokkum W., 1995, Nutrition Research Reviews, V8, P271, DOI 10.1079/NRR19950016; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Walker D, 1998, J PHYSIOL-LONDON, V507, P697, DOI 10.1111/j.1469-7793.1998.697bs.x; Wang K, 2001, AM J HUM GENET, V68, P1055, DOI 10.1086/319514; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	47	113	120	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22789	22797		10.1074/jbc.M200577200	http://dx.doi.org/10.1074/jbc.M200577200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937503	hybrid, Green Accepted			2022-12-25	WOS:000176313600088
J	Mulugeta, S; Gray, JM; Notarfrancesco, KL; Gonzales, LW; Koval, M; Feinstein, SI; Ballard, PL; Fisher, AB; Shuman, H				Mulugeta, S; Gray, JM; Notarfrancesco, KL; Gonzales, LW; Koval, M; Feinstein, SI; Ballard, PL; Fisher, AB; Shuman, H			Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FETAL LUNG; RAT GRANULAR PNEUMOCYTES; FATTY-ACID SYNTHESIS; PULMONARY SURFACTANT; EPITHELIAL-CELLS; HORMONAL-REGULATION; SP-A; MESSENGER-RNA; B DEFICIENCY; BINDING	Lamellar bodies are the specialized secretory organelles of alveolar type II (ATII) epithelial cells through which the cell packages pulmonary surfactant and regulates its secretion. Surfactant within lamellar bodies is densely packed as circular arrays of lipid membranes and appears to be the product of several trafficking and biosynthetic processes. To elucidate these processes, we reported previously on the generation of a monoclonal antibody (3C9) that recognizes a unique protein of the lamellar body membrane of 180 kDa, which we named LBM180. We report that mass spectrometry of the protein precipitated by this antibody generated a partial sequence that is identical to the ATP-binding cassette protein, ABCA3. Homology analysis of partial sequences suggests that this protein is highly conserved among species. The ABCA3 gene transcript was found in cell lines of human lung origin, in ATII cells of human, rat, and mouse, as well as different tissues of rat, but the highest expression of ABCA3 was observed in ATII cells. Expression of this transcript was at its maximum prior to birth, and hormonal induction of ABCA3 transcript was observed in human fetal lung at the same time as other surfactant protein transcripts were induced, suggesting that ABCA3 is developmentally regulated. Molecular and biochemical studies show that ABCA3 is targeted to vesicle membranes and is found in the limiting membrane of lamellar bodies. Because ABCA3 is a member of a subfamily of ABC transporters that are predominantly known to be involved in the regulation of lipid transport and membrane trafficking, we speculate that this protein may play a key role in lipid organization during the formation of lamellar bodies.	Univ Penn, Sch Med, Dept Physiol, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Neonatol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Shuman, H (corresponding author), Univ Penn, Sch Med, Dept Physiol, Inst Environm Med, 3700 hamilton Walk,Richards Bldg, Philadelphia, PA 19104 USA.		Koval, Michael/C-6366-2015	Koval, Michael/0000-0002-5422-5614	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053566, P01HL019737, T32HL007748] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL019737-270018, P01 HL019737, T32HL-07748, HL-19737, HL-53566] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Alcorn JL, 1997, AM J RESP CELL MOL, V17, P672, DOI 10.1165/ajrcmb.17.6.2858; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; Batenburg JJ, 1998, PROG LIPID RES, V37, P235, DOI 10.1016/S0163-7827(98)00011-3; Batenburg JJ, 1990, PULMONARY PHYSL FETU, P106; Beers MF, 1998, J BIOL CHEM, V273, P15287, DOI 10.1074/jbc.273.24.15287; BEERS MF, 1995, PEDIATR RES, V38, P668, DOI 10.1203/00006450-199511000-00007; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; CHANDER A, 1987, J CLIN INVEST, V79, P1133, DOI 10.1172/JCI112929; CHANDER A, 1983, BIOCHIM BIOPHYS ACTA, V753, P119, DOI 10.1016/0005-2760(83)90105-4; CHEVALIER G, 1972, ANAT RECORD, V174, P289, DOI 10.1002/ar.1091740303; Childs S, 1994, Important Adv Oncol, P21; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Cockshutt AM, 1992, PULMONARY SURFACTANT, P339; Connors TD, 1997, GENOMICS, V39, P231, DOI 10.1006/geno.1996.4500; CRYSTAL RG, 1999, LUNG, P564; Cutz E, 2000, AM J RESP CRIT CARE, V161, P608, DOI 10.1164/ajrccm.161.2.9905062; DAS DK, 1980, BIOCHEM BIOPH RES CO, V92, P867, DOI 10.1016/0006-291X(80)90783-4; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dean M, 2001, J LIPID RES, V42, P1007; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; DEMELLO DE, 1994, J PEDIATR-US, V125, P43, DOI 10.1016/S0022-3476(94)70119-9; DEMELLO DE, 1994, AM J RESP CELL MOL, V11, P230, DOI 10.1165/ajrcmb.11.2.8049084; DOBBS LG, 1994, AM J RESP CRIT CARE, V150, pS31, DOI 10.1164/ajrccm/150.5_Pt_2.S31; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; Elferink RPJO, 1997, FASEB J, V11, P19, DOI 10.1096/fasebj.11.1.9034162; FISHER AB, 1985, ANNU REV PHYSIOL, V47, P789; Gonzales Linda W., 2001, Pediatric Research, V49, p262A; GONZALES LW, 1990, BIOCHIM BIOPHYS ACTA, V1042, P1, DOI 10.1016/0005-2760(90)90049-4; GONZALES LW, 1994, BBA-LIPID LIPID MET, V1215, P49, DOI 10.1016/0005-2760(94)90090-6; Gonzales LW, 2001, PEDIATR PATHOL MOL M, V20, P387, DOI 10.1080/15513810109168622; HALLMAN M, 1981, J CLIN INVEST, V68, P742, DOI 10.1172/JCI110310; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HENNING SJ, 1978, AM J PHYSIOL, V235, P451; Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JOBE A, 1981, BIOCHIM BIOPHYS ACTA, V666, P47, DOI 10.1016/0005-2760(81)90089-8; Kaminski WE, 2000, BIOCHEM BIOPH RES CO, V273, P532, DOI 10.1006/bbrc.2000.2954; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; KRESCH MJ, 1987, CLIN PERINATOL, V14, P481, DOI 10.1016/S0095-5108(18)30747-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; MAGOON MW, 1983, BIOCHIM BIOPHYS ACTA, V750, P18, DOI 10.1016/0005-2760(83)90200-X; MENDELSON CR, 1991, J DEV PHYSIOL, V15, P61; MULLER WJ, 1995, AM J PHYSIOL-LUNG C, V269, pL11, DOI 10.1152/ajplung.1995.269.1.L11; Mulugeta S, 2001, FASEB J, V15, pA496; MULUGETA S, 2000, AM J RESP CRIT CARE, V161, P43; OGASAWARA Y, 1991, BIOCHIM BIOPHYS ACTA, V1083, P252, DOI 10.1016/0005-2760(91)90079-W; POST M, 1988, BIOCHIM BIOPHYS ACTA, V947, P249, DOI 10.1016/0304-4157(88)90011-1; Robinson JM, 2001, HISTOCHEM CELL BIOL, V116, P119; ROONEY SA, 1986, PEDIATR RES, V20, P545, DOI 10.1203/00006450-198606000-00013; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; RYAN US, 1975, TISSUE CELL, V7, P587, DOI 10.1016/0040-8166(75)90028-2; SA G, 1990, INDIAN J BIOCHEM BIO, V27, P43; Schaller-Bals S, 2000, AM J PHYSIOL-LUNG C, V279, pL631, DOI 10.1152/ajplung.2000.279.4.L631; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schriml LM, 2000, GENOMICS, V64, P24, DOI 10.1006/geno.1999.6102; SHAPIRO DL, 1978, BIOCHIM BIOPHYS ACTA, V530, P197, DOI 10.1016/0005-2760(78)90005-X; Tryka AF, 2000, PEDIATR DEVEL PATHOL, V3, P335, DOI 10.1007/s100249910048; VANGOLDE LMG, 1995, BIOL NEONATE, V67, P2; VOORHOUT WF, 1992, AM J PHYSIOL, V263, pL479, DOI 10.1152/ajplung.1992.263.4.L479; Wagle S, 1999, AM J PHYSIOL-LUNG C, V277, pL381, DOI 10.1152/ajplung.1999.277.2.L381; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; XIE JX, 1995, J BIOL CHEM, V270, P28084; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336; YOUNG SL, 1981, J APPL PHYSIOL, V51, P248, DOI 10.1152/jappl.1981.51.2.248; YOUNG SL, 1993, AM J PHYSIOL, V265, pL19, DOI 10.1152/ajplung.1993.265.1.L19; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	77	158	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22147	22155		10.1074/jbc.M201812200	http://dx.doi.org/10.1074/jbc.M201812200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940594	hybrid			2022-12-25	WOS:000176313600008
J	Ventura, A; Luzi, L; Pacini, S; Baldari, CT; Pelicci, PG				Ventura, A; Luzi, L; Pacini, S; Baldari, CT; Pelicci, PG			The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-LINES; SIGNALING PATHWAY; DNA METHYLATION; MAMMALIAN BRAIN; MESSENGER-RNA; EGF RECEPTOR; SHC ADAPTER; PROTEIN; EXPRESSION; ACTIVATION	The mammal Shc locus encodes three overlapping isoforms (46, 52, and 66 kDa) that differ in the length of their N-terminal regions. p46/p52Shc and p66Shc have been implicated, respectively, in the cytoplasmic propagation of growth and apoptogenic signals. Levels of p66Shc expression correlate with life span duration in mice. p46Shc and p52Shc are ubiquitously expressed, whereas p66Shc is expressed in a cell lineage-specific fashion. However, the mechanisms underlying the regulation of Shc protein expression are unknown. Here we report the identification of two alternative promoters, driving the transcription of two mRNAs coding for p46/p52Shc and p66Shc. We show that treatment with an inhibitor of histone deacetylases or with a demethylating agent results in induction of p66Shc expression in cells that normally do not express this isoform but leaves the levels of the two other isoforms unchanged. Moreover, analysis of the methylation pattern of the p66Shc promoter in a panel of primary and immortalized human cells showed inverse correlation between p66Shc expression and methylation density of its promoter. These results identify histone deacetylation and cytosine methylation as the mechanisms underlying p66Shc silencing in nonexpressing cells.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Fdn Italiana Ric Canc, Inst Mol Oncol, I-20139 Milan, Italy; Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Siena	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Luzi, Lucilla/K-4350-2018; Ventura, Andrea/F-1789-2011	Luzi, Lucilla/0000-0002-8746-4179; Ventura, Andrea/0000-0003-4320-9907; Baldari, Cosima/0000-0002-4414-6744				Ahuja N, 1998, CANCER RES, V58, P5489; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Archey WB, 1999, CANCER RES, V59, P2292; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COLBERT MC, 1988, DEV BIOL, V130, P392, DOI 10.1016/0012-1606(88)90444-7; Conti L, 1997, P NATL ACAD SCI USA, V94, P8185, DOI 10.1073/pnas.94.15.8185; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dhulipala PDK, 1998, ONCOGENE, V17, P1149, DOI 10.1038/sj.onc.1202030; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; ISHIKAWA Y, 1990, J BIOL CHEM, V265, P8458; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Kraus J, 1998, FEBS LETT, V428, P165, DOI 10.1016/S0014-5793(98)00520-1; Lai KMV, 2000, GENE DEV, V14, P1132; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559	37	140	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22370	22376		10.1074/jbc.M200280200	http://dx.doi.org/10.1074/jbc.M200280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948181	hybrid			2022-12-25	WOS:000176313600034
J	Yik, JHN; Saxena, A; Weigel, PH				Yik, JHN; Saxena, A; Weigel, PH			The minor subunit splice variants, H2b and H2c, of the human asialoglycoprotein receptor are present with the major subunit H1 in different hetero-oligomeric receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; GALACTOSYL RECEPTORS; MEMBRANE-PROTEIN; SUBPOPULATION; INACTIVATION; DEGRADATION; MONENSIN; GENES; FORMS; CONSERVATION	The hepatic asialoglycoprotein receptor (ASGP-R) is an endocytic receptor that mediates the internalization of desialylated glycoproteins and their delivery to lysosomes. The human ASGP-R is a hetero-oligomeric complex composed of H1 and H2 subunits. There are three naturally occurring H2 splice variants, designated H2a, H2b, and H2c, although the expression of the H2c protein had not been reported. Following deglycosylation of purified ASGP-R, we detected the H2b and H2c proteins in HepG2 and HuH-7 hepatoma cells, using an antibody directed against a COOH-terminal peptide common to all H2 isoforms (anti-H2-COOH) and another antibody against a 19-amino acid cytoplasmic insert found only in H2b (anti-H2-Cyto19). H1 and both H2b and H2-c were co-purified by affinity chromatography, using asialoorosomucoid (ASOR)-, anti-H1-, or anti-H2-COOH-Sepharose, whereas only H1 and H2b were immunoprecipitated with anti-H2-Cyto19. These results indicate that H2b and Me are not present in the same ASGP-R complexes with H1. Similar to the H2b isoform, H2c was also palmitoylated, indicating that the 19-residue cytoplasmic insert does not regulate palmitoylation. Stably transfected SK-Hep-1 cell lines expressing ASGP-R complexes containing H1 and either H2b or H2c had similar binding affinities for ASOR and endocytosed and degraded ASOR at similar rates. The pH dissociation profiles of ASOR-ASGP-R complexes were also identical for complexes containing either H2b or H2c. We conclude that the H2b and H2c isoforms are both functional but are not present with H1 in the same hetero-oligomeric ASGP-R complexes. This structural difference between two functional subpopulations of ASGP-Rs may provide a molecular basis for the existence of two different pathways, designated State 1 and State 2, by which several types of recycling receptors mediate endocytosis.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu	Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIGMS NIH HHS [GM49695] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAENZIGER JU, 1980, J BIOL CHEM, V255, P4607; Bider MD, 1996, J BIOL CHEM, V271, P31996, DOI 10.1074/jbc.271.50.31996; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CLARKE BL, 1989, BIOCHEM J, V262, P277, DOI 10.1042/bj2620277; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; Huang TM, 2001, MOL BIOL CELL, V12, p330A; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LEE RT, 1987, BIOCHEMISTRY-US, V26, P6320, DOI 10.1021/bi00394a005; LEE RT, 1984, BIOCHEMISTRY-US, V23, P4255, DOI 10.1021/bi00313a037; LEE YC, 1989, CIBA FDN S, V145, P80; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OKA JA, 1983, J BIOL CHEM, V258, P253; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; PAIETTA E, 1992, HEPATOLOGY, V15, P395, DOI 10.1002/hep.1840150307; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Pinna LA, 1997, INT J BIOCHEM CELL B, V29, P551, DOI 10.1016/S1357-2725(96)00142-2; SANFORD JP, 1990, BIOCHIM BIOPHYS ACTA, V1087, P259, DOI 10.1016/0167-4781(90)90216-O; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1991, TARGETED DIAGN THER, V1, P3; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; STOCKERT RJ, 1990, J BIOL CHEM, V265, P1841; TAKEZAWA R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P220, DOI 10.1016/0167-4781(93)90300-3; Tolchinsky S, 1996, J BIOL CHEM, V271, P14496, DOI 10.1074/jbc.271.24.14496; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; Weigel PH, 1998, BIOCHEM BIOPH RES CO, V246, P563, DOI 10.1006/bbrc.1998.8491; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; Yik JHN, 2001, GLYCOBIOLOGY, V11, P919; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388; Zeng FY, 1996, BIOCHEM BIOPH RES CO, V218, P325, DOI 10.1006/bbrc.1996.0057; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454	53	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23076	23083		10.1074/jbc.M202748200	http://dx.doi.org/10.1074/jbc.M202748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943787	hybrid			2022-12-25	WOS:000176313600123
J	Cappellen, D; Luong-Nguyen, NH; Bongiovanni, S; Grenet, O; Wanke, C; Susa, M				Cappellen, D; Luong-Nguyen, NH; Bongiovanni, S; Grenet, O; Wanke, C; Susa, M			Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT BONE-MARROW; FACTOR-I; TYROSINE PHOSPHORYLATION; OSTEOPROTEGERIN LIGAND; HUMAN OSTEOBLASTS; GROWTH-FACTOR; MICE LACKING; C-FOS; RANK; FAMILY	Cytokines macrophage colony stimulating factor (M-CSF) and the receptor activator of NFkappaB ligand (RANKL) induce differentiation of bone marrow hematopoietic precursor cells into bone-resorbing osteoclasts without the requirement for stromal cells of mesenchymal origin. We used this recently described mouse cell system and oligonucleotide microarrays representing about 9,400 different genes to analyze gene expression in hematopoietic cells undergoing differentiation to osteoclasts. The ability of microarrays to detect the genes of interest was validated by showing expression and expected regulation of several osteoclast marker genes. In total 750 known transcripts were up-regulated by greater than or equal to2-fold, and 91% of them at an early time in culture, suggesting that almost the whole differentiation program is defined already in pre-osteoclasts. As expected, M-CSF alone induced the receptor for RANKL (RANK), but also, unexpectedly, other RANK/NFkappaB pathway components (TRAF2A, PI3-kinase, MEKK3, RIPK1), providing a molecular explanation for the synergy of M-CSF and RANKL. Furthermore, interleukins, interferons, and their receptors (IL-1alpha, IL-18, IFN-16, IL-11Ralpha2, IL-6/ 11R gp130, IFNgammaR) were induced by M-CSF. Although interleukins are thought to regulate osteoclasts via modulation of M-CSF and RANKL expression in stromal cells, we showed that a mix of IL-1, IL-6, and IL-11 directly increased the activity of osteoclasts by 8.5-fold. RANKL induced about 70 novel target genes, including chemokines and growth factors (RANTES (regulated on activation, normal T cell expressed and secreted), PDGFalpha, IGF1), histamine, and alpha1A-adrenergic receptors, and three waves of distinct receptors, transcription factors, and signaling molecules. In conclusion, M-CSF induced genes necessary for a direct response to RANKL and interleukins, while RANKL directed a three-stage differentiation program and induced genes for interaction with osteoblasts and immune and nerve cells. Thus, global gene expression suggests a more dynamic role of osteoclasts in bone physiology than previously anticipated.	Novartis Pharma Res, Arthrit & Bone Metab Therapeut Area, CH-4002 Basel, Switzerland; Novartis Pharma Dev, Pharmacogen Area, CH-4002 Basel, Switzerland	Novartis; Novartis	Susa, M (corresponding author), Novartis Pharma Res, Arthrit & Bone Metab Therapeut Area, WKL-125-9-12, CH-4002 Basel, Switzerland.	mira.susa_spring@pharma.novartis.com						Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Atkins GJ, 2000, BONE, V26, P653, DOI 10.1016/S8756-3282(00)00280-5; BARON R, 1999, PRIMER METABOLIC BON, P3; Battaglino R, 2001, J BONE MINER RES, V16, pS153; Cannons JL, 2001, J IMMUNOL, V167, P1313, DOI 10.4049/jimmunol.167.3.1313; CENTRELLA M, 1990, ENDOCRINOLOGY, V126, P39, DOI 10.1210/endo-126-1-39; Csar XF, 2001, J BIOL CHEM, V276, P26211, DOI 10.1074/jbc.M100213200; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730; Dobigny C, 1997, J CELL PHYSIOL, V173, P10, DOI 10.1002/(SICI)1097-4652(199710)173:1<10::AID-JCP2>3.3.CO;2-A; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; FULLER K, 1995, J IMMUNOL, V154, P6065; HaraIrie F, 1996, BONE, V18, P29, DOI 10.1016/8756-3282(95)00425-4; Hiraoka A, 1997, P NATL ACAD SCI USA, V94, P7577, DOI 10.1073/pnas.94.14.7577; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1999, J IMMUNOL, V163, P434; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kozawa O, 1997, AM J PHYSIOL-ENDOC M, V272, pE208, DOI 10.1152/ajpendo.1997.272.2.E208; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lesclous P, 1999, CELLS TISSUES ORGANS, V164, P23, DOI 10.1159/000016639; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li XD, 2000, ENDOCRINOLOGY, V141, P2054, DOI 10.1210/en.141.6.2054; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Miyamoto T, 2000, BLOOD, V96, P4335, DOI 10.1182/blood.V96.13.4335.h8004335_4335_4343; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Nomura F, 2000, GENES CELLS, V5, P191; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Schoor M, 1999, MECH DEVELOP, V85, P73, DOI 10.1016/S0925-4773(99)00090-8; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767; Steingrimsson E, 1998, MAMM GENOME, V9, P250, DOI 10.1007/s003359900736; Suda T, 1997, METHOD ENZYMOL, V282, P223; SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Togari A, 2000, BRAIN RES, V878, P204, DOI 10.1016/S0006-8993(00)02700-1; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Wegner M, 2001, TRENDS GENET, V17, P286, DOI 10.1016/S0168-9525(01)02275-2; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; XU LX, 1995, J CELL PHYSIOL, V165, P624, DOI 10.1002/jcp.1041650321; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZHANG L, 1991, AM J PHYSIOL, V261, pC348, DOI 10.1152/ajpcell.1991.261.2.C348; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	61	150	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21971	21982		10.1074/jbc.M200434200	http://dx.doi.org/10.1074/jbc.M200434200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923298	hybrid			2022-12-25	WOS:000176286000110
J	Warnmark, A; Treuter, E; Gustafsson, JA; Hubbard, RE; Brzozowski, AM; Pike, ACW				Warnmark, A; Treuter, E; Gustafsson, JA; Hubbard, RE; Brzozowski, AM; Pike, ACW			Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ER-ALPHA; ACTIVATION; PROTEIN; DOMAIN; BETA; MOTIF; ACETYLTRANSFERASE; COOPERATIVITY; DETERMINANTS	The activation function 2/ligand-dependent interaction between nuclear receptors and their coregulators is mediated by a short consensus motif, the so-called nuclear receptor (NR) box. Nuclear receptors exhibit distinct preferences for such motifs depending both on the bound ligand and on the NR box sequence. To better understand the structural basis of motif recognition, we characterized the interaction between estrogen receptor a and the NR box regions of the p160 coactivator TIF2. We have determined the crystal structures of complexes between the ligand-binding domain of estrogen receptor a and 12-mer peptides from the Box 2 and Box 3 regions of TIF2. Surprisingly, the Box 3 module displays an unexpected binding mode that is distinct from the canonical LXXLL interaction observed in other ligand-binding domain/NR box crystal structures. The peptide is shifted along the coactivator binding site in such a way that the interaction motif becomes LXXLL rather than the classical LXXLL. However, analysis of the binding properties of wild type NR box peptides, as well as mutant peptides designed to probe the Box 3 orientation, suggests that the Box 3 peptide primarily adopts the "classical" LXXLL orientation in solution. These results highlight the potential difficulties in interpretation of protein-protein interactions based on co-crystal structures using short peptide motifs.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	University of York - UK; Karolinska Institutet	Pike, ACW (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England.			Treuter, Eckardt/0000-0002-4147-8989				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Brandt ME, 1997, J BIOL CHEM, V272, P4843, DOI 10.1074/jbc.272.8.4843; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cenni B, 1999, TRENDS ENDOCRIN MET, V10, P41, DOI 10.1016/S1043-2760(98)00121-0; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Glass CK, 2000, GENE DEV, V14, P121; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hegy GB, 1996, STEROIDS, V61, P367, DOI 10.1016/0039-128X(96)00042-6; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Wong CW, 2001, BIOCHEMISTRY-US, V40, P6756, DOI 10.1021/bi010379h; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; [No title captured]	42	142	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21862	21868		10.1074/jbc.M200764200	http://dx.doi.org/10.1074/jbc.M200764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937504	hybrid			2022-12-25	WOS:000176286000096
J	Zhang, MY; Smith, EP; Kuroda, H; Banach, W; Chernausek, SD; Fagin, JA				Zhang, MY; Smith, EP; Kuroda, H; Banach, W; Chernausek, SD; Fagin, JA			Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-4; GROWTH-FACTOR-I; NEURONAL CELL-LINE; IGF-BINDING; PLASMA-PROTEIN; PROTEOLYTIC ACTIVITY; GENE-EXPRESSION; CLEAVAGE SITE; BONE-CELLS; RAT	The insulin-like growth factor-binding protein 4 (IG-FBP-4), the most abundant IGF-binding protein produced by rodent smooth muscle cells (SMC), is degraded by specific protease(s) potentially releasing IGF-I for local bioactivity. IGFBP-4 protease(s) recognizes basic residues within the midregion of the molecule. We constructed a mutant IGFBP-4 with the cleavage domain substitution 119-KHMAKVRDRSKMK-133 to 119-AAMAAVADASAMA-133. Myc-tagged native and IGFBP-4.7A retained equivalent IGF-I binding affinity. Whereas native IGFBP-4 was cleaved by SMC-conditioned medium, IGFBP-4.7A was completely resistant to proteolysis. To explore the function of the protease-resistant IGFBP-4 in vivo, expression of the mutant and native proteins was targeted to SMC of transgenic mice by means of a smooth muscle a-actin promoter. Transgene expression was confined to SMC-rich tissues in all lines. Bladder and aortic immunoreactive IGFBP-4/transgene mRNA ratios in SMP8-BP4.7A mice were increased by 2- to 4-fold relative to SMP8-BP4 mice, indicating that the IGFBP-4.7A protein was stabilized in vivo. SMP8-BP4.7A mice had lower aortic, bladder, and stomach weight and intestinal length relative to SMP8-BP4 counterparts matched for protein expression by Western blotting. Thus, IGFBP-4.7A results in greater growth inhibition than equivalent levels of native IGFBP-4 in vivo, demonstrating a role for IGFBP-4 proteolysis in the regulation of IGF-I action.	Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Div Endocrinol & Metab, 3125 Eden Ave, Cincinnati, OH 45267 USA.			, steven/0000-0003-4538-8793	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054216] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54216] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anwar A, 2000, ARTERIOSCL THROM VAS, V20, P370, DOI 10.1161/01.ATV.20.2.370; ANWAR A, 1994, HYPERTENSION, V24, P679, DOI 10.1161/01.HYP.24.6.679; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Bayes-Genis A, 2001, ARTERIOSCL THROM VAS, V21, P335, DOI 10.1161/01.ATV.21.3.335; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Besnard N, 1997, BIOL REPROD, V56, P1050, DOI 10.1095/biolreprod56.4.1050; BOES M, 1992, ENDOCRINOLOGY, V131, P327, DOI 10.1210/en.131.1.327; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; Byun D, 2000, J CLIN ENDOCR METAB, V85, P373, DOI 10.1210/jc.85.1.373; Byun D, 2001, J ENDOCRINOL, V169, P135, DOI 10.1677/joe.0.1690135; Byun DW, 2001, J CLIN ENDOCR METAB, V86, P847, DOI 10.1210/jc.86.2.847; Chelius D, 2000, GROWTH HORM IGF RES, V10, P360, DOI 10.1054/ghir.2000.0177; CHEN Y, 1995, GROWTH REGULAT, V5, P45; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CHERNAUSEK SD, 2000, END SOC 82 ANN M TOR, P240; CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1006, DOI 10.1210/endo-129-2-1006; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Conover CA, 1999, J CLIN ENDOCR METAB, V84, P4742, DOI 10.1210/jc.84.12.4742; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Delafontaine P, 1995, CARDIOVASC RES, V30, P825, DOI 10.1016/0008-6363(95)00163-8; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; Imai Y, 1997, J CLIN INVEST, V100, P2596, DOI 10.1172/JCI119803; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; Knudtson KL, 2001, ENDOCRINOLOGY, V142, P3749, DOI 10.1210/en.142.9.3749; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/en.142.6.2641; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; MYERS SE, 1993, ENDOCRINOLOGY, V133, P1525, DOI 10.1210/en.133.4.1525; ORLOWSKI CC, 1989, J CELL PHYSIOL, V139, P469, DOI 10.1002/jcp.1041390304; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Pintar John E., 1995, Progress in Growth Factor Research, V6, P437, DOI 10.1016/0955-2235(95)00029-1; Qin XZ, 1999, J BONE MINER RES, V14, P2079, DOI 10.1359/jbmr.1999.14.12.2079; Qin XZ, 2000, ARCH BIOCHEM BIOPHYS, V379, P209, DOI 10.1006/abbi.2000.1872; Qin XZ, 1998, J BIOL CHEM, V273, P23509, DOI 10.1074/jbc.273.36.23509; Rajah R, 1996, ENDOCRINOLOGY, V137, P2676, DOI 10.1210/en.137.7.2676; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Rees C, 1998, ENDOCRINOLOGY, V139, P4182, DOI 10.1210/en.139.10.4182; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; SHIMASAKI S, 1990, MOL ENDOCRINOL, V4, P1451, DOI 10.1210/mend-4-10-1451; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Smith EP, 2001, ENDOCRINOLOGY, V142, P4420, DOI 10.1210/en.142.10.4420; Wang JW, 1998, ENDOCRINOLOGY, V139, P2605, DOI 10.1210/en.139.5.2605; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; ZESIAWSKI W, 2001, EMBO J, V20, P3638	48	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21285	21290		10.1074/jbc.M112082200	http://dx.doi.org/10.1074/jbc.M112082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923290	hybrid			2022-12-25	WOS:000176286000023
J	Liu, GZ; Pit, LY; Walker, JC; Ronald, PC; Song, WY				Liu, GZ; Pit, LY; Walker, JC; Ronald, PC; Song, WY			Biochemical characterization of the kinase domain of the rice disease resistance receptor-like kinase XA21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; HYPERSENSITIVE RESPONSE; GENE; PTO; PLANT; TOMATO; AVRPTO; AUTOPHOSPHORYLATION; ENCODES	The rice disease resistance gene, Xa21, encodes a receptor kinase-like protein consisting of leucine-rich repeats in the putative extracellular domain and a serine/threonine kinase in the putative intracellular domain. The putative XA21 kinase domain was expressed as maltose-binding and glutathione S-transferase fusion proteins in Escherichia coli. The fusion proteins are capable of autophosphorylation. Phosphoamino acid analysis of the glutathione S-transferase fusion protein indicates that only serine and threonine residues are phosphorylated. The relative phosphorylation rate of the XA21 kinase against increasing enzyme concentrations follows a first-order rather than second-order kinetics, indicating an intramolecular phosphorylation mechanism. Moreover, the active XA21 kinase cannot phosphorylate a kinase-deficient mutant of XA21 kinase. The enzymatic activity of the XA21 kinase in a buffer containing Mn2+ is at least 15 times higher than that with Mg2+. The K-m and V-max of XA21 kinase for ATP are 0.3 mum and 8.4 nmol/mg/min, respectively. Tryptic phosphopeptide mapping reveals that multiple sites on the XA21 kinase are phosphorylated. Finally, our data suggest that the region of XA21 kinase corresponding to the RD kinase activation domain is not phosphorylated, revealing a distinct mode of action compared with the tomato Pto serine/threonine kinase conferring disease resistance.	Univ Florida, Dept Plant Pathol, Gainesville, FL 32611 USA; Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA; Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA	State University System of Florida; University of Florida; University of Missouri System; University of Missouri Columbia; University of California System; University of California Davis	Song, WY (corresponding author), Univ Florida, Dept Plant Pathol, 1453 Fifield Hall, Gainesville, FL 32611 USA.		Ronald, Pamela/AAK-7664-2020	Walker, John/0000-0002-2050-1641				Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Oh MH, 2000, PLANT PHYSIOL, V124, P751, DOI 10.1104/pp.124.2.751; Rathjen JP, 1999, EMBO J, V18, P3232, DOI 10.1093/emboj/18.12.3232; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; Ronald PC, 1997, PLANT MOL BIOL, V35, P179, DOI 10.1023/A:1005750811983; SchulzeMuth P, 1996, J BIOL CHEM, V271, P26684, DOI 10.1074/jbc.271.43.26684; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Sessa G, 1998, J BIOL CHEM, V273, P15860, DOI 10.1074/jbc.273.25.15860; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; SONG W, 1995, SCIENCE, V270, P661; Staskawicz BJ, 2001, SCIENCE, V292, P2285, DOI 10.1126/science.1062013; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; Wang GL, 1998, PLANT CELL, V10, P765, DOI 10.1105/tpc.10.5.765; Xiao SY, 2001, SCIENCE, V291, P118, DOI 10.1126/science.291.5501.118; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	24	58	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20264	20269		10.1074/jbc.M110999200	http://dx.doi.org/10.1074/jbc.M110999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927577	Green Published, hybrid			2022-12-25	WOS:000176204500023
J	Maekawa, A; Austen, KF; Kanaoka, Y				Maekawa, A; Austen, KF; Kanaoka, Y			Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PASSIVE CUTANEOUS ANAPHYLAXIS; HUMAN MAST-CELLS; MOLECULAR-CLONING; MEMBRANE-PROTEIN; C-4 SYNTHASE; IN-VIVO; EXPRESSION; 5-LIPOXYGENASE; IDENTIFICATION; ZYMOSAN	The cysteinyl leukotrienes (cysLTs), leukotriene (LT) C-4, LTD4, and LTE4, are proinflammatory lipid mediators generated in the mouse by hematopoietic cells such as macrophages and mast cells. There are two mouse receptors for the cysLTs, CysLT, receptor (CysLT(1)R) and CysLT(2)R, which are 38% homologous and are located on mouse chromosomes X and 14, respectively. To clarify the different roles of the CysLT1R and CysLT2R in inflammatory responses in vivo, we generated CysLT,R-deficient mice by targeted gene disruption. These mice developed normally and were fertile. In an intracellular calcium mobilization assay with fura-2 acetoxymethyl ester, peritoneal macrophages from wild-type littermates, which express both CysLT(1)R and CysLT(2)R, responded substantially to 1 X 10(-6) M LTD4 and slightly to 1 x 10(-6) M LTC4, whereas the macrophages from CysLT(1)R-deficient mice did not respond to either LTD4 or LTC4. Plasma protein extravasation, but not neutrophil infiltration, was significantly reduced in CysLT(1)R-deficient mice subjected to zymosan A-induced peritoneal inflammation. Plasma protein extravasation was also significantly diminished in CysLT(1)R-deficient mice undergoing IgE-mediated passive cutaneous anaphylaxis as compared with the wild-type mice. Thus, the cysLTs generated in vivo by either monocytes/macrophages or mast cells utilize CysLT(1)R for the response of the microvasculature in acute inflammation.	Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kanaoka, Y (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 626C,1 Jimmy Fund Way, Boston, MA 02115 USA.	ykanaoka@rics.bwh.harvard.edu			NIAID NIH HHS [AI-31599, AI-36610] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI036610, U01AI031599, U19AI031599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Byrum RS, 1999, J IMMUNOL, V163, P6810; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FEINBERG JG, 1961, NATURE, V191, P712, DOI 10.1038/191712a0; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; INAGAKI N, 1986, INT ARCH ALLER A IMM, V81, P58, DOI 10.1159/000234108; INAGAKI N, 1984, INT ARCH ALLER A IMM, V74, P91, DOI 10.1159/000233523; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Menard G, 2000, AM J RESP CELL MOL, V23, P572, DOI 10.1165/ajrcmb.23.4.4152; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mollerup J, 2001, BBA-GENE STRUCT EXPR, V1517, P455, DOI 10.1016/S0167-4781(00)00271-2; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Shi ZZ, 2001, MOL CELL BIOL, V21, P5389, DOI 10.1128/MCB.21.16.5389-5395.2001; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; Thivierge M, 2000, J IMMUNOL, V165, P5221, DOI 10.4049/jimmunol.165.9.5221; Thivierge M, 2001, J IMMUNOL, V167, P2855, DOI 10.4049/jimmunol.167.5.2855; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	46	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20820	20824		10.1074/jbc.M203163200	http://dx.doi.org/10.1074/jbc.M203163200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11932261	hybrid			2022-12-25	WOS:000176204500092
J	Orr, AW; Pallero, MA; Murphy-Ullrich, JE				Orr, AW; Pallero, MA; Murphy-Ullrich, JE			Thrombospondin stimulates focal adhesion disassembly through G(i)- and phosphoinositide 3-kinase-dependent ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE CALRETICULIN; RECEPTOR-RELATED PROTEIN; EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; KINASE PATHWAYS; BINDING; TENASCIN; PEPTIDES	The matricellular protein thrombospondin (TSP) stimulates stress fiber and focal adhesion disassembly through a sequence (hep I) in its heparin-binding domain. TSP/hep I signals focal adhesion disassembly by binding cell surface calreticulin (CRT) and activating phosphoinositide 3-kinase (PI3K). However, other components of this signaling pathway have not been identified. We now show that TSP induces focal adhesion disassembly through activation of pertussis toxin (PTX)sensitive G proteins and ERK phosphorylation. PTX pretreatment inhibits TSP/hep I-mediated focal adhesion disassembly as well as PI3K activation. In addition, membrane-permeable Galpha(i2)- and Gbetagamma-blocking peptides inhibit hep I-mediated focal adhesion disassembly. Hep I stimulates a transient increase in ERK activation, which is abrogated by both PTX and PI3K inhibitors. Inhibiting ERK activation with MEK inhibitors blocks hep I-mediated focal adhesion disassembly, indicating that ERR activation is required for cytoskeletal reorganization. G protein signals and ERK phosphorylation are induced by TSP binding to cell surface CRT, because CRT null mouse embryonic fibroblasts (MEF) fail to stimulate ERK phosphorylation in response to TSP/hep I treatment. These data show that G(i) protein and ERK, in concert with PI3K, are stimulated by TSP-CRT interactions at the cell surface to induce de-adhesive changes in the cytoskeleton.	Univ Alabama, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama, Cell Adhes & Matrix Res Ctr, VH G038D,1530 3rd Ave S, Birmingham, AL 35294 USA.		Orr, Anthony/P-8927-2015	Orr, Anthony/0000-0002-2377-213X	NHLBI NIH HHS [T 32 HL07918-04, HL44575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007918, R01HL044575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Berrou E, 2001, J BIOL CHEM, V276, P39303, DOI 10.1074/jbc.M011751200; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Boulay F, 1997, ANN NY ACAD SCI, V832, P69, DOI 10.1111/j.1749-6632.1997.tb46238.x; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; CHANG MSS, 2000, SCI STKE; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Cho JH, 1999, EUR J BIOCHEM, V266, P878, DOI 10.1046/j.1432-1327.1999.00920.x; Cho JH, 2001, CELL STRESS CHAPERON, V6, P148, DOI 10.1379/1466-1268(2001)006<0148:AOHMCL>2.0.CO;2; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DUNLEVY JR, 1993, J CELL SCI, V105, P489; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gahtan V, 1999, SURGERY, V126, P203, DOI 10.1067/msy.1999.98781; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GRAY AJ, 1995, J BIOL CHEM, V270, P25602; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Gutkind J.S, 2000, SCI STKE; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V372, P238, DOI 10.1006/abbi.1999.1521; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Reuveni H, 2000, J CELL BIOL, V151, P1179, DOI 10.1083/jcb.151.6.1179; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Suchard SJ, 1996, J CELL PHYSIOL, V168, P217, DOI 10.1002/(SICI)1097-4652(199607)168:1<217::AID-JCP26>3.0.CO;2-2; Sugiura T, 1996, INT J CANCER, V68, P774; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; TETI A, 1992, J AM SOC NEPHROL, V2, P582; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; Xie H, 1998, J CELL SCI, V111, P615	60	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20453	20460		10.1074/jbc.M112091200	http://dx.doi.org/10.1074/jbc.M112091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923291	hybrid			2022-12-25	WOS:000176204500046
J	Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T				Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T			Anti-neovascular therapy using novel peptides homing to angiogenic vessels	ONCOGENE			English	Article						anti-neovascular therapy; phage-displayed peptide library; liposome; PRP	ALPHA-V INTEGRINS; DRUG-DELIVERY; BINDING; CANCER; CELLS; LIGANDS; TUMORS	Cancer chemotherapy targeted to angiogenic vessels is expected to cause indirect tumor regression through the damage of the neovasculature without the induction of drug resistance. To develop a tool for neovasculature-specific drug delivery, we isolated novel peptides homing to angiogenic vessels formed by a dorsal air sac method from a phage-displayed peptide library. Three distinct phage clones that markedly accumulated in murine tumor xenografts presented PRPGAPLAGSWPGTS-, DRWRPALPVVLFPLH- or ASSSYPLIHWRPWAR-peptide respectively. After the determination of the epitope sequences of these peptides, we modified liposomes with epitope penta-peptides. Liposome modified with APRPG-peptide showed high accumulation in murine tumor xenografts, and APRPG-modified liposome encapsulating adriamycin effectively suppressed experimental tumor growth. Finally, specific binding of APRPG-modified liposome to human umbilical endothelial cells, and that of PRP-containing peptide to angiogenic vessels in human tumors, i.e., islet cell tumor and glioblastoma, were demonstrated. The present study indicates the usefulness of APRPG-peptide as a tool for anti-neovascular therapy, a novel modality of cancer treatment.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Shizuoka 4228526, Japan; Otsuka Pharmaceut Co Ltd, Inst Mol Sci Med, Tokushima 7710192, Japan; Hamamatsu Photon KK, Shizuoka 4340041, Japan; Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan	University of Shizuoka; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Otsuka Pharmaceutical; Hamamatsu Photonics; Shinshu University; Shinshu University	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp						Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asai T, 1998, BIOL PHARM BULL, V21, P766; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Browder T, 2000, CANCER RES, V60, P1878; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Brown JM, 1998, CANCER RES, V58, P1408; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Gho YS, 1997, CANCER RES, V57, P3733; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7; Ito H, 1999, CANCER RES, V59, P5875; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X; Langer R, 1998, NATURE, V392, P5; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Nishi T, 1996, FEBS LETT, V399, P237, DOI 10.1016/S0014-5793(96)01329-4; Oku N, 1999, ADV DRUG DELIVER REV, V37, P53, DOI 10.1016/S0169-409X(98)00110-0; Oku N, 1999, ADV DRUG DELIVER REV, V40, P63, DOI 10.1016/S0169-409X(99)00040-X; OKU N, 1994, INT J CANCER, V58, P415, DOI 10.1002/ijc.2910580318; OKU N, 1992, BIOCHIM BIOPHYS ACTA, V1126, P255, DOI 10.1016/0005-2760(92)90238-Q; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; St Croix B, 2000, SCIENCE, V289, P1197; Takikawa M, 2000, FEBS LETT, V466, P381, DOI 10.1016/S0014-5793(00)01110-8; Viti F, 1999, CANCER RES, V59, P347; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	34	101	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2662	2669		10.1038/sj.onc.1205347	http://dx.doi.org/10.1038/sj.onc.1205347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965539				2022-12-25	WOS:000174996500006
J	Suzukawa, K; Colburn, NH				Suzukawa, K; Colburn, NH			AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers	ONCOGENE			English	Article						AP-1; JB6 cells; retinoic acid; transrepression; GAL4 transactivation assay	ANCHORAGE-INDEPENDENT GROWTH; TRANSCRIPTIONAL ACTIVATION; INDUCED TRANSFORMATION; PROMOTION-RESISTANT; TUMOR PROMOTERS; EPIDERMAL-CELLS; KAPPA-B; TRANSACTIVATION; INHIBITION; EXPRESSION	Retinoic acid (RA) inhibits tumor promotion in many models in vivo and in vitro, among them mouse epidermal JB6 cells. RA treatment suppresses 12-O-tetradecanoyl-phorbol-13-acetate (TPA) induced AP-1 activity, an activity that is required for transformation of JB6 P+ cells. The molecular mechanism of AP-1 transrepression by retinoids is unclear, especially as related to inhibition of transformation. Overexpression of AP-1 components did not rescue TPA induced AP-1 activation nor did a GST pull down experiment implicate direct binding, thus rendering unlikely both a Jun/Fos-RA-RAR direct interaction and a Jun/Fos sequestration mechanism. Overexpression of p300, SRC-1 or pCAF did not abrogate AP-1 suppression by RA, thus arguing against coactivator competition. Overexpression of the corepressor silencing mediator for retinoic acid and thyroid hormone receptors (SMRT) suppressed AP-1 activity. However, SMRT but not RA inhibited cJun transactivation, suggesting SMRT does not mediate RA transrepression. RA treatment also did not block TPA induced ERK phosphorylation, Jun/Fos family protein expression except for cFos, or DNA binding of the AP-1 complex. The transcriptional activities of full-length JunB and full-length Fra-1, but not the transactivation domain fusions, were increased by TPA treatment and suppressed by RA. Since these full-length fusions have bzip domains, the results suggest that JunB and/or Fra-1-containing dimers may constitute one target of RA for transrepression of AP-1.	Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Colburn, NH (corresponding author), Natl Canc Inst Frederick, Basic Res Lab, Gene Regulat Sect, Bldg 560 Rm 21-89 POB B, Ft Detrick, MD 21702 USA.	Colburn@ncifcrf.gov		Suzukawa, Kazumi/0000-0001-9904-3905				Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bernstein LR, 1999, BBA-GENE STRUCT EXPR, V1489, P263, DOI 10.1016/S0167-4781(99)00191-8; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOLLAG W, 1992, ANN ONCOL, V3, P513, DOI 10.1093/oxfordjournals.annonc.a058252; Boutwell R K, 1989, Prog Clin Biol Res, V298, P3; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COLBURN NH, 1982, J CELL BIOCHEM, V18, P261, DOI 10.1002/jcb.1982.240180302; COLBURN NH, 1981, ANN NY ACAD SCI, V359, P251, DOI 10.1111/j.1749-6632.1981.tb12751.x; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DiSepio D, 1999, Mol Cell Biol Res Commun, V1, P7, DOI 10.1006/mcbr.1999.0101; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Fukasawa H, 2000, BIOL PHARM BULL, V23, P1414; Goyette P, 2000, J BIOL CHEM, V275, P16497, DOI 10.1074/jbc.M909382199; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KAKIZAWA T, 2000, J BIOL CHEM, V27, P27; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SIMONSON MS, 1994, AM J PHYSIOL-RENAL, V267, pF805, DOI 10.1152/ajprenal.1994.267.5.F805; SMITH SE, 1992, CELL GROWTH DIFFER, V3, P523; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VERMA AK, 1977, CANCER RES, V37, P2196; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	58	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2181	2190		10.1038/sj.onc.1205281	http://dx.doi.org/10.1038/sj.onc.1205281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948401				2022-12-25	WOS:000174555300007
J	Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H				Bhat-Nakshatri, P; Sweeney, CJ; Nakshatri, H			Identification of signal transduction pathways involved in constitutive NF-kappa B activation in breast cancer cells	ONCOGENE			English	Article						breast cancer; NF-kappa B; oncogenes; ErbB	TUMOR PROGRESSION; INDUCED APOPTOSIS; C-MYC; TRANSFORMATION; HEREGULIN; GROWTH; DIFFERENTIATION; PHOSPHORYLATION; PARTHENOLIDE; CONTRIBUTES	Nuclear factor-kappaB (NF-kappaB) is usually maintained in an, inactive form in the cytoplasm through its association with inhibitor of kappaB (IkappaB) proteins, and is activated upon stimulation of cells with a variety of signals. However, constitutive activation of NF-kappaB is observed in a number of cancers including breast cancer. The signaling pathways that are involved in constitutive NF-kappaB activation remain largely unknown. Using breast cancer cell lines derived from transgenic mice that overexpress specific oncogene/growth factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a major role in constitutive NT-kappaB activation. Her2/neu potentiated tumor necrosis factor alpha (TNFchi)-inducible NF-kappaB activation whereas c-Myc potentiated 12-o-tetracecanyolphorbol-13-acetate (TPA)-induced NT-kappaB activation. Heregulin-mediated NF-kappaB activation correlated with phosphorylation of epidermal growth factor receptor (EGFR) and ErbB3 but not her2/neu. Tryphostin AG1517, which inhibits heregulin-mediated phosphorylation of EGFR, her2/neu and ErbB3 reduced NF-kappaB activation. In contrast, emodin, which blocks phosphorylation of her2/neu by heregulin, failed to reduce NF-kappaB activation. These results suggest that heregulin induces NF-kappaB independent of her2/neu. PI3 kinase/AKT, protein kinase A (PKA) and IkappaB kinase appear to be downstream signaling molecules involved in NF-kappaB activation as specific inhibitors of these kinases but not inhibitors of ERK/MAP kinase or protein kinase C reduced heregulin-mediated NF-kappaB activation. Based on these results, we propose that heregulin increases the expression of pro-invasive, prometastatic and anti-apoptotic genes in cancer cells through autocrine activation of NF-kappaB, which leads to invasive and drug-resistant growth of breast cancer.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong G, 1999, CANCER RES, V59, P3495; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hehner SP, 1999, J IMMUNOL, V163, P5617; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozes ON, 1999, NATURE, V401, P82; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; ZHANG LS, 1995, CANCER RES, V55, P3890; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	100	107	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2066	2078		10.1038/sj.onc.1205243	http://dx.doi.org/10.1038/sj.onc.1205243			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960379				2022-12-25	WOS:000174827000013
J	Chang, YJ; Wu, HL; Hamaguchi, N; Hsu, YC; Lin, SW				Chang, YJ; Wu, HL; Hamaguchi, N; Hsu, YC; Lin, SW			Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis - Residues Asn(89)-Gly(93) are critical for binding factor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-IX; SOLUBLE TISSUE FACTOR; BLOOD-COAGULATION; HEMOPHILIA-B; FACTOR-X; ENZYME-ACTIVITY; LIGHT-CHAIN; PROTEIN-C; ACTIVATION; COFACTOR	This paper describes the consequences of alanine-scanning mutagenesis on 28 positions of the second epidermal growth factor (EGF-2) domain of factor IX. We identified four positions of Gln(97), Phe(98), Tyr(115), and Leu(117) that are critical for secretion of factor IX. Of the remaining mutations, 4 mutants (V86A, E113A, K122A, and S123A) are as active as wild-type factor IX (lXwt); 16 (D85A, K100A, N101A, D104A, N105X R116A, E119A, T87A, 190A, K91A, R94A, E96A, S102A, K106A, T112A, and N120A) retain reduced but detectable activity, and 4 (N89A, N92A, G93A, and V107A) are nearly inert in the clotting assay. Both factor XIa and the factor VIIa-tissue factor complex effectively catalyzed the activation of these mutants except N89A. The mutant V107A failed to form the factor tenase complex with factor VIIIa because of a 35-fold increase in K,. The mutants N89A and N92A did not compete with factor lXwt for factor VIIIa binding, and G93A exhibited a 6-fold increase in K-i values in the competitive binding assay. It appears that mutations at these positions have significantly affected the interaction between factor IX and factor VIIIa, although other mutations had little effect on the binding of factor IX to factor VIIIa. Mutations in two regions, Thr(87)-Gly(93) and Asn(101)-Val(107), significantly increased the K-m value of factor IXa (2-10-fold) in cleavage of factor X in the absence of factor VIIIa. In the presence of factor VIIIa, the catalytic efficiency of each mutant toward factor X paralleled its clotting activity. Briefly, we propose two relatively distinctive functions of factor IX for two adjacent regions in the EGF-2 domain; the first loop region (residues 89-94) is involved with the binding of its cofactor, factor VIIIa, and the third loop with connected 13-sheets (residues 102-108) is involved in the proper binding to the substrate, factor X.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Brandeis Univ, Rosensteil Basic Med Res Ctr, Waltham, MA 02119 USA; Natl Taiwan Univ Hosp, Grad Inst Med Technol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan	National Cheng Kung University; Brandeis University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lin, SW (corresponding author), Natl Taiwan Univ, Grad Inst Med Technol, Sch Med, Taipei, Taiwan.			LIN, SHU-WHA/0000-0001-6748-5581; Chang, Yu-Jia/0000-0003-3978-3244				AHMAD SS, 1995, BIOCHEM J, V310, P427, DOI 10.1042/bj3100427; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Benham AM, 2000, CRIT REV BIOCHEM MOL, V35, P433, DOI 10.1080/10409230091169258; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Celie PHN, 2000, J BIOL CHEM, V275, P229, DOI 10.1074/jbc.275.1.229; Chang JY, 1997, J CLIN INVEST, V100, P886, DOI 10.1172/JCI119604; Chang YJ, 1999, BIOCHEMISTRY-US, V38, P10940, DOI 10.1021/bi990055h; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; Giannelli F, 1998, NUCLEIC ACIDS RES, V26, P265, DOI 10.1093/nar/26.1.265; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; Himber J, 2001, THROMB HAEMOSTASIS, V85, P475; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Hsu YC, 2001, BIOCHEMISTRY-US, V40, P11261, DOI 10.1021/bi010262t; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Larson PJ, 1996, J BIOL CHEM, V271, P3869; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LIN SW, 1990, J BIOL CHEM, V265, P144; LIN SW, 1994, BLOOD, V84, P1866; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MANN KG, 1990, BLOOD, V76, P1; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; Wong MY, 1999, BIOCHEMISTRY-US, V38, P8948, DOI 10.1021/bi982835g; Wu DH, 2001, J BIOL CHEM, V276, P15025, DOI 10.1074/jbc.M005935200; Wu PC, 2000, THROMB HAEMOSTASIS, V84, P626, DOI 10.1055/s-0037-1614078; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	42	32	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25393	25399		10.1074/jbc.M105432200	http://dx.doi.org/10.1074/jbc.M105432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960977	hybrid			2022-12-25	WOS:000176747000072
J	McCarthy, RA; Barth, JL; Chintalapudi, MR; Knaak, C; Argraves, WS				McCarthy, RA; Barth, JL; Chintalapudi, MR; Knaak, C; Argraves, WS			Megalin functions as an endocytic sonic hedgehog receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PROXIMAL TUBULE CELLS; MICE LACKING; ALPHA-2-MACROGLOBULIN RECEPTOR; CRANIOFACIAL MORPHOGENESIS; MEDIATES ENDOCYTOSIS; ANIMAL DEVELOPMENT; LIGAND-BINDING; PROTEIN	Embryos deficient in the morphogen Sonic hedgehog (Shh) or the endocytic receptor megalin exhibit common neurodevelopmental abnormalities. Therefore, we have investigated the possibility that a functional relationship exists between the two proteins. During embryonic development, megalin was found to be expressed along the apical surfaces of neuroepithelial cells and was co-expressed with Shh in the ventral floor plate of the neural tube. Using enzyme-linked immunosorbent assay, homologous ligand displacement, and surface plasmon resonance techniques, it was found that the amino-terminal fragment of Shh (N-Shh) bound to megalin with high affinity. Megalin-expressing cells internalized NShh through a mechanism that was inhibited by antagonists of megalin, viz. anti-receptor-associated protein and anti-megalin antibodies. Heparin also inhibited NShh endocytosis, implicating proteoglyeans in the internalization process, as has been described for other megalin ligands. Use of chloroquine to inhibit lysosomal proteinase activity showed that N-Shh endocytosed via megalin was not efficiently targeted to the lysosomes for degradation. The ability of megalin-internalized N-Shh to bypass lysosomes may relate to the finding that the interaction between N-Shh and megalin was resistant to dissociation with low pH. Together, these findings show that megalin is an efficient endocytic receptor for NShh. Furthermore, they implicate megalin as a new regulatory component of the Shh signaling pathway.	Med Univ S Carolina, Dept Cell Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Argraves, WS (corresponding author), Med Univ S Carolina, Dept Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA.	argraves@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061873] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61873, R01 HL061873] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwala S, 2001, SCIENCE, V291, P2147, DOI 10.1126/science.1058624; Ahlgren SC, 1999, CURR BIOL, V9, P1304, DOI 10.1016/S0960-9822(00)80052-4; Argraves WS, 2001, FRONT BIOSCI, V6, pD406, DOI 10.2741/Argraves; Balinsky, 1975, INTRO EMBRYOLOGY; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Charrier JB, 2001, DEVELOPMENT, V128, P4011; Chen WB, 2001, DEVELOPMENT, V128, P2385; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Gritli-Linde A, 2001, DEV BIOL, V236, P364, DOI 10.1006/dbio.2001.0336; Hammad SM, 1997, J BIOL CHEM, V272, P18644, DOI 10.1074/jbc.272.30.18644; Helms JA, 1997, DEV BIOL, V187, P25, DOI 10.1006/dbio.1997.8589; Hu D, 1999, DEVELOPMENT, V126, P4873; Hynes M, 2000, NAT NEUROSCI, V3, P41, DOI 10.1038/71114; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kounnas M Z, 1994, In Vivo, V8, P343; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KOUNNAS MZ, 1994, ANN NY ACAD SCI, V737, P114, DOI 10.1111/j.1749-6632.1994.tb44305.x; Lewis KE, 1999, DEV BIOL, V208, P14, DOI 10.1006/dbio.1998.9169; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Marino M, 2001, J AM SOC NEPHROL, V12, P637, DOI 10.1681/ASN.V124637; Marino M, 2000, THYROID, V10, P461, DOI 10.1089/thy.2000.10.461; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Miller LAD, 2001, J HISTOCHEM CYTOCHEM, V49, P1593, DOI 10.1177/002215540104901213; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Nielsen R, 2001, J AM SOC NEPHROL, V12, P1099, DOI 10.1681/ASN.V1261099; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schneider RA, 2001, DEVELOPMENT, V128, P2755; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; STEFANSSON S, 1995, J CELL SCI, V108, P2361; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Varga ZM, 2001, DEVELOPMENT, V128, P3497; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Williams KP, 1999, J CELL SCI, V112, P4405; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1998, BIOL CHEM, V379, P1025; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Ying LT, 2000, DEV DYNAM, V219, P143, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1050>3.3.CO;2-H; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zhang XM, 2001, DEV BIOL, V233, P271, DOI 10.1006/dbio.2000.0195	54	149	158	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25660	25667		10.1074/jbc.M201933200	http://dx.doi.org/10.1074/jbc.M201933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11964399	hybrid			2022-12-25	WOS:000176747000105
J	Kakonen, SM; Selander, KS; Chirgwin, JM; Yin, JJ; Burns, S; Rankin, WA; Grubbs, BG; Dallas, M; Cui, Y; Guise, TA				Kakonen, SM; Selander, KS; Chirgwin, JM; Yin, JJ; Burns, S; Rankin, WA; Grubbs, BG; Dallas, M; Cui, Y; Guise, TA			Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; TUMOR-SUPPRESSOR GENE; TGF-BETA; EXPRESSION; RECEPTOR; INHIBITION; INDUCTION; INVASION; MATRIX; RAS	Transforming growth factor (TGF)-beta promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-beta, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-beta type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibody-treated mice. TGF-beta can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-beta-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-beta-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-beta-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-beta-stimulated PTHrP production. Furthermore, TGF-beta treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-beta and may provide a new molecular target for anti-osteolytic therapy.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Drug Dev,Canc Therapy & Res Ctr, San Antonio, TX 78245 USA; Vet Adm Res Serv, San Antonio, TX 78245 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Guise, TA (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Drug Dev,Canc Therapy & Res Ctr, 14960 Omicron Dr, San Antonio, TX 78245 USA.	guise@uthscsa.edu	Selander, Katri/GWM-8685-2022	Kakonen, Sanna-Maria/0000-0001-9393-6235; Rankin, Wayne/0000-0002-4427-9547	NCI NIH HHS [CA69158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069158, R01CA069158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benitez-Verguizas J, 1999, LIFE SCI, V65, P1807, DOI 10.1016/S0024-3205(99)00437-3; BUNDRED NJ, 1991, BRIT MED J, V303, P1506, DOI 10.1136/bmj.303.6816.1506; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fink SP, 2001, CANCER RES, V61, P256; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Hunt KK, 1998, CANCER RES, V58, P5656; Iddon J, 2000, J PATHOL, V191, P170; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KIRIYAMA T, 1993, MOL CELL ENDOCRINOL, V92, P55, DOI 10.1016/0303-7207(93)90074-T; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li J, 1998, J BIOL CHEM, V273, P31009, DOI 10.1074/jbc.273.47.31009; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; MERRYMAN JI, 1994, ENDOCRINOLOGY, V134, P2424, DOI 10.1210/en.134.6.2424; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; POWELL GJ, 1991, CANCER RES, V51, P3059; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Southby J, 1996, ENDOCRINOLOGY, V137, P1349, DOI 10.1210/en.137.4.1349; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Usui T, 1998, INVEST OPHTH VIS SCI, V39, P1981; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Werkmeister JR, 1998, ENDOCRINE, V8, P291, DOI 10.1385/ENDO:8:3:291; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	65	206	214	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24571	24578		10.1074/jbc.M202561200	http://dx.doi.org/10.1074/jbc.M202561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964407	hybrid			2022-12-25	WOS:000176611800079
J	Yu, LG; Andrews, N; Weldon, M; Gerasimenko, OV; Cambpell, BJ; Sing, R; Grierson, I; Petersen, OH; Rhodes, JM				Yu, LG; Andrews, N; Weldon, M; Gerasimenko, OV; Cambpell, BJ; Sing, R; Grierson, I; Petersen, OH; Rhodes, JM			An N-terminal truncated form of Orp150 is a cytoplasmic ligand for the anti-proliferative mushroom Agaricus bisporus lectin and is required for nuclear localization sequence-dependent nuclear protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-REGULATED PROTEIN; ENDOPLASMIC-RETICULUM; STRESS-PROTEIN; IN-VITRO; TRANSPORT; BINDING; EXPRESSION; RAN; GLYCOSYLATION; INHIBITION	Nuclear localization sequence-dependent nuclear protein import is essential for maintaining cell function and can be selectively blocked in epithelial cells by mushroom (Agaricus bisporus) lectin. Here we report that a major intracellular ligand for this lectin is an N-terminally truncated form of oxygen-regulated protein 150 (Orp150), which lacks the endoplasmic reticulum translocation signal peptide of full-length Orp150. This cytoplasmic form of Orp150 expresses the lectin carbohydrate ligand (sialyl-2,3-galactosyl-,61,3-N-acetyl-galactosamine-alpha) and is shown to be essential for nuclear localization sequence-dependent nuclear protein import.	Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Physiol, Liverpool L69 3GA, Merseyside, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Liverpool; University of Liverpool; University of Cambridge	Rhodes, JM (corresponding author), Univ Liverpool, Henry Wellcome Lab Mol & Cellular Gastroenterol, Dept Med, Liverpool L69 3GA, Merseyside, England.	rhodesjm@liv.ac.uk	Petersen, Ole H/E-8708-2010; Rhodes, Jonathan M/C-2496-2009; Gerasimenko, Oleg/A-6622-2010	Gerasimenko, Oleg/0000-0003-2573-8258				Adam SA, 1999, CURR OPIN CELL BIOL, V11, P402, DOI 10.1016/S0955-0674(99)80056-8; Bando Y, 2000, AM J PHYSIOL-CELL PH, V278, pC1172, DOI 10.1152/ajpcell.2000.278.6.C1172; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Chen X, 1996, FEBS LETT, V380, P68, DOI 10.1016/0014-5793(96)00011-7; CHEN YX, 1995, GLYCOCONJUGATE J, V12, P55, DOI 10.1007/BF00731869; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; DUVERGER E, 1993, EXP CELL RES, V207, P197, DOI 10.1006/excr.1993.1181; Duverger E, 1996, GLYCOBIOLOGY, V6, P381, DOI 10.1093/glycob/6.4.381; DUVERGER E, 1995, J CELL SCI, V108, P1325; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HART GW, 1999, ESSENTIALS GLYCOBIOL, P171; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kaneda S, 2000, J BIOCHEM-TOKYO, V128, P529, DOI 10.1093/oxfordjournals.jbchem.a022783; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MILLER MW, 1994, J BIOL CHEM, V269, P9289; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; PRESANT CA, 1972, J BIOL CHEM, V247, P6937; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; Saris N, 1997, J CELL BIOL, V137, P813, DOI 10.1083/jcb.137.4.813; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Steggerda SM, 2000, MOL BIOL CELL, V11, P703, DOI 10.1091/mbc.11.2.703; SUEYOSHI S, 1988, CARBOHYD RES, V178, P213, DOI 10.1016/0008-6215(88)80113-7; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tsukamoto Y, 1998, LAB INVEST, V78, P699; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; YU LG, 1993, CANCER RES, V53, P4627; Yu LG, 1999, J BIOL CHEM, V274, P4890, DOI 10.1074/jbc.274.8.4890	53	28	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24538	24545		10.1074/jbc.M203550200	http://dx.doi.org/10.1074/jbc.M203550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11960996	hybrid			2022-12-25	WOS:000176611800075
J	Pope, MA; Porello, SL; David, SS				Pope, MA; Porello, SL; David, SS			Escherichia coli apurinic-apyrimidinic endonucleases enhance the turnover of the adenine glycosylase MutY with G : A substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; DNA-POLYMERASE-BETA; C-TERMINAL DOMAIN; STRUCTURAL GENE APN1; HUMAN HOMOLOG; EXONUCLEASE-III; ABASIC SITES; MAJOR HUMAN; IN-VITRO; APURINIC/APYRIMIDINIC ENDONUCLEASES	The DNA repair enzyme MutY plays an important role in the prevention of DNA mutations resulting from the presence of the oxidatively damaged lesion 7,8-dihydro8-oxo-2'-deoxyguanosine (OG). MutY is a base excision repair (BER) glycosylase that removes misincorporated adenine residues from OG:A mispairs, as well as G:A and C:A mispairs. We have previously shown that, under conditions of low MutY concentrations relative to an OG:A or G:A substrate, the time course of the adenine glycosylase reaction exhibits biphasic kinetic behavior due to slow release of the DNA product by MutY. The dissociation of MutY from its product may require the recruitment of other proteins from the BER pathway, such as an apurinic-apyrimidinic (AP) endonuclease, as turnover-enhancing cofactors. The effect of the AP endonucleases endonuclease IV (Endo M, exonuclease III (Exo III), and Ape1 on the reaction kinetics of MutY with G:A- and OG:A.containing substrates was investigated. The effect of the glycosylases UDG and MutM and the DNA polymerase pol I was also characterized. Endo IV and Exo III, unlike Ape1, UDG, and pol I, greatly enhance the rate of product release with a G:A substrate, whereas the rate constant for the adenine removal step remains unchanged. Furthermore, the turnover rate with a truncated form of MutY, Stop 225, which lacks 125 amino acids of the C terminus, is unaffected by the presence of Endo IV or Exo III. These results constitute the first evidence of an interaction between the MutY-product DNA complex and Endo IV or Exo III. Furthermore they suggest a role for the C-terminal domain of MutY in mediating this interaction.	Univ Utah, Dept Chem, Salt Lake City, UT 84103 USA	Utah System of Higher Education; University of Utah	David, SS (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84103 USA.	david@chemistry.chem.utah.edu			NCI NIH HHS [CA 67985] Funding Source: Medline; NIGMS NIH HHS [GM08537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067985, R29CA067985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CAREY J, 1991, METHOD ENZYMOL, V208, P103; Chepanoske CL, 2000, ARCH BIOCHEM BIOPHYS, V380, P11, DOI 10.1006/abbi.2000.1890; Chepanoske CL, 1999, NUCLEIC ACIDS RES, V27, P3197, DOI 10.1093/nar/27.15.3197; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Demple B, 1999, NATO ADV SCI I A-LIF, V302, P59; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOESTCH PW, 1990, MUTAT RES, V236, P173; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Leipold MD, 2000, BIOCHEMISTRY-US, V39, P14984, DOI 10.1021/bi0017982; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Masson JY, 1996, GENE, V179, P291, DOI 10.1016/S0378-1119(96)00375-7; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; NASH HM, 1996, CURR BIOL, V6, P1230; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Porello SL, 1996, J AM CHEM SOC, V118, P10684, DOI 10.1021/ja9602206; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Ramotar D, 1998, BBA-GENE STRUCT EXPR, V1396, P15, DOI 10.1016/S0167-4781(97)00160-7; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sambrook J., 2002, MOL CLONING LAB MANU; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Sung JS, 2001, J BIOL CHEM, V276, P2276, DOI 10.1074/jbc.M008147200; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Williams SD, 2000, BIOCHEMISTRY-US, V39, P10098, DOI 10.1021/bi0004652; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743	76	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22605	22615		10.1074/jbc.M203037200	http://dx.doi.org/10.1074/jbc.M203037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11960995	hybrid			2022-12-25	WOS:000176313600067
J	Konstas, AA; Dabrowski, M; Korbmacher, C; Tucker, SJ				Konstas, AA; Dabrowski, M; Korbmacher, C; Tucker, SJ			Intrinsic sensitivity of Kir1.1 (ROMK) to glibenclamide in the absence of SUR2B - Implications for the identity of the renal ATP-regulated secretory K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; POTASSIUM-CHANNEL; EXPRESSION; DETERMINES; SUBUNIT; KIDNEY; STOICHIOMETRY; ASSOCIATION; TRANSPORTER; INHIBITION	The precise molecular identity of the renal ATP-regulated secretory K+ channel is still a matter of some controversy. The inwardly rectifying K+ channel, Kir1.1 (ROMK) appears to form the pore of the channel, and mutations in Kir1.1 are responsible for Bartter syndrome. The native channel is sensitive to inhibition by the sulfonylurea glibenclamide, and it has been proposed that an accessory protein is required to confer glibenclamide sensitivity to Kir1.1. Several recent studies have suggested that the native channel is composed of the splice variant Kir1.1b (ROMK2) and the sulfonylurea receptor isoform. SUR2B and that there is a direct physical interaction between these subunits. In this study, we have monitored the interaction between Kir1.1b and SUR2B. We find that SUR2B reaches the plasma membrane when coexpressed with Kir6.1 or Kir6.2 but not when coexpressed with Kir1.1b. Furthermore, we find that Kir1.1b exhibits an intrinsic sensitivity to inhibition by glibenclamide with an affinity similar to the native channel. These results demonstrate that SUR2B does not traffic to the membrane in the presence of Kir1.1b and is not required to confer glibenclamide sensitivity to Kir1.1b. This has important implications for the presumed structure of the renal ATP-regulated secretory K+ channel.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Tucker, SJ (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		Tucker, Stephen J./ABE-6741-2020; Tucker, Stephen J./ABE-7468-2020	Tucker, Stephen J./0000-0001-8996-2000; Tucker, Stephen J./0000-0001-8996-2000				Anzai N, 1997, Jpn J Physiol, V47 Suppl 1, pS10; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; Beesley AH, 1999, PFLUG ARCH EUR J PHY, V438, P1, DOI 10.1007/s004240050872; Best L, 1998, BRIT J PHARMACOL, V125, P874, DOI 10.1038/sj.bjp.0702148; Chraibi A, 1999, J PHARMACOL EXP THER, V290, P341; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Devuyst O, 1996, AM J PHYSIOL-RENAL, V271, pF723, DOI 10.1152/ajprenal.1996.271.3.F723; Dong K, 2001, J BIOL CHEM, V276, P44347, DOI 10.1074/jbc.M108072200; Giebisch G, 2001, KIDNEY INT, V60, P436, DOI 10.1046/j.1523-1755.2001.060002436.x; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; Gribble FM, 1997, J PHYSIOL-LONDON, V498, P87, DOI 10.1113/jphysiol.1997.sp021843; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Gros L, 1999, BIOCHEM BIOPH RES CO, V257, P766, DOI 10.1006/bbrc.1999.0529; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; KONSTAS AA, 2002, J BIOL CHEM     0506; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Mennitt PA, 1997, J AM SOC NEPHROL, V8, P1823; Morales MM, 1996, AM J PHYSIOL-RENAL, V270, pF1038, DOI 10.1152/ajprenal.1996.270.6.F1038; Palmer LG, 1997, AM J PHYSIOL-RENAL, V273, pF404, DOI 10.1152/ajprenal.1997.273.3.F404; Ruknudin A, 1998, J BIOL CHEM, V273, P14165, DOI 10.1074/jbc.273.23.14165; Russ U, 1999, MOL PHARMACOL, V56, P955, DOI 10.1124/mol.56.5.955; SCHWANSTECHER M, 1994, BRIT J PHARMACOL, V113, P903, DOI 10.1111/j.1476-5381.1994.tb17078.x; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Tanemoto M, 2000, AM J PHYSIOL-RENAL, V278, pF659, DOI 10.1152/ajprenal.2000.278.4.F659; VOLK T, 1995, CELL PHYSIOL BIOCHEM, V5, P222, DOI 10.1159/000154757; WANG T, 1995, RENAL PHYSIOL BIOCH, V18, P169; Wang WH, 1997, ANNU REV PHYSIOL, V59, P413, DOI 10.1146/annurev.physiol.59.1.413; Yao XQ, 1996, J CLIN INVEST, V97, P2525, DOI 10.1172/JCI118700; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	37	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21346	21351		10.1074/jbc.M202005200	http://dx.doi.org/10.1074/jbc.M202005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927600	hybrid			2022-12-25	WOS:000176286000031
J	Boehm, JE; Singh, U; Combs, C; Antonyak, MA; Cerione, RA				Boehm, JE; Singh, U; Combs, C; Antonyak, MA; Cerione, RA			Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; RETINOIC-ACID; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; DIFFERENTIATION; CYCLE; IDENTIFICATION; ACTIVATION	Tissue transglutaminase (TGase) is involved in the regulation of several biological events including cellular differentiation and apoptosis. The expression and activation of TGase are up-regulated in response to retinoic acid (RA), leading to the protection of several cell lines against N-(4-hydroxyphenyl)retinamide (HPR)-induced apoptosis. The anti-apoptotic mechanisms of TGase are poorly understood at this time. We examined the interaction of TGase with the retinoblastoma (Rb) protein, a substrate of TGase that is also implicated in cell survival functions. In cells undergoing HPR-induced apoptosis, Rb is degraded. This degradation is blocked when cells are pretreated with RA, an important regulator of TGase. In vitro studies revealed that TGase protects Rb from caspase-induced degradation in a transamidation-dependent manner. Experiments performed with fibroblasts from Rb-/- mice further demonstrated that the presence of Rb was required for TGase to exhibit antiapoptotic activity in response to RA treatment. Microinjection of Rb-/- cells with a transamidation-defective TGase mutant and Rb afforded no protection from HPR-induced apoptosis. Taken together, these findings suggest that the ability of TGase to modify Rb via transamidation underlies the ability of TGase to provide protection against apoptotic insults and to ensure that cells remain viable during differentiation.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA; Texas A&M Univ, Vet Affairs Hosp, Cardiovasc Res Inst, Dept Mol Cardiol, Temple, TX 76504 USA	Cornell University; Cornell University; Texas A&M University System	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762, F32GM063320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61762, GM63320] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHIOCCA EA, 1989, J CELL BIOCHEM, V39, P293, DOI 10.1002/jcb.240390309; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Facchiano F, 2001, EXP CELL RES, V271, P118, DOI 10.1006/excr.2001.5356; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FINK ML, 1980, P NATL ACAD SCI-BIOL, V77, P4564, DOI 10.1073/pnas.77.8.4564; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hebert SS, 2000, J BIOL CHEM, V275, P32482, DOI 10.1074/jbc.M006528200; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Ou HS, 2000, CIRC RES, V87, P881, DOI 10.1161/01.RES.87.10.881; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; PIACENTINI M, 1988, BIOCHEM J, V253, P33, DOI 10.1042/bj2530033; Singh US, 1998, J BIOL CHEM, V273, P1946, DOI 10.1074/jbc.273.4.1946; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SPORN MB, 1983, CANCER RES, V43, P3034; SUEDHOFF T, 1990, CANCER RES, V50, P7830; Szegezdi E, 2000, CELL DEATH DIFFER, V7, P1225, DOI 10.1038/sj.cdd.4400751; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	34	98	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20127	20130		10.1074/jbc.C200147200	http://dx.doi.org/10.1074/jbc.C200147200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11956182	hybrid			2022-12-25	WOS:000176204500005
J	Fulda, S; Debatin, KM				Fulda, S; Debatin, KM			IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway	ONCOGENE			English	Article						caspase-8; apoptosis; interferon; drugs; resistance	DRUG-INDUCED APOPTOSIS; CD95 APO-1/FAS SYSTEM; INTERFERON-GAMMA; DEATH; ACTIVATION; CELLS; METHYLATION; RECEPTORS; PROTEINS; PROMOTER	Resistance of tumors to cytotoxic therapy may be due to disrupted apoptosis programs and remains a major obstacle in cancer treatment. Here, we report that IFNgamma sensitizes resistant tumor cells with absent or low caspase-8 expression for apoptosis induced by death-inducing ligands or cytotoxic drugs by upregulating caspase-8 through a Stat1/IRF1 dependent pathway. Combined treatment using IFNgamma with TRAIL, APO1 TNFalpha or cytotoxic drugs cooperated to trigger apoptosis in various resistant tumor cell lines derived from Ewing tumor, neuroblastoma or medulloblastoma, while single agents exerted only a minimal effect. Importantly, IFN- induced caspase-8 expression also in cells with inactivation of the caspase-8 gene by hypermethylation, although no direct effect of IFNgamma on the methylation status of regulatory sequences of the caspase-8 gene was found. IFNgamma-mediated facilitation of apoptosis was inhibited by the caspase-8 specific inhibitor zIETD.fmk or in caspase8 mutant Jurkat cells implying a prominent role of caspase-8 in mediating sensitization by IFNgamma. Upregulation of caspase-8 and sensitization for apoptosis by IFNgamma was blocked by overexpression of dominant-negative mutants of Stat1 or in Stat1-deficient U3A cells, while complementation of Statl-deficient U3A cells with wildtype Stat1 restored the IFNgamma effect. Moreover, ectopic expression of IRFI induced caspase-8 expression thereby sensitizing cells for TRAIL-, APO1- or doxorubicin-induced apoptosis. These findings provide evidence that the Stat1/IRF1 pathway is involved in induction of caspase-8 expression and apoptosis initiated by IFN- and indicate that IFNgamma might be an effective strategy to sensitize various resistant tumor cells with deficient caspase-8 expression for chemotherapy- or death receptor-induced apoptosis.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hendrich B, 2000, CURR TOP MICROBIOL, V249, P55; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MONTALDO PG, 1994, J NATL CANCER I, V86, P1694, DOI 10.1093/jnci/86.22.1694; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANVALEN F, 1999, EWINGS SARCOMA FAMIL, P55; WADLER S, 1990, CANCER RES, V50, P3473	44	213	223	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2295	2308		10.1038/sj.onc.1205255	http://dx.doi.org/10.1038/sj.onc.1205255			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948413				2022-12-25	WOS:000174635600002
J	Hsiang, CH; Straus, DS				Hsiang, CH; Straus, DS			Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells	ONCOGENE			English	Article						MCF-7 breast cancer cells; cyclopentenone; cyclin D1; BTEB	GROWTH-FACTOR-I; NF-KAPPA-B; GENE-EXPRESSION; GENOMIC ORGANIZATION; PROSTAGLANDIN A(2); CARCINOMA CELLS; KINASE-ACTIVITY; SERUM-ALBUMIN; TRANSCRIPTION; PROTEIN	Evidence indicates that overexpression of cyclin D1 is an important event in malignant transformation of breast cancer cells. Therefore, cyclin D1 is a potential target for mechanistically-based chemoprevention/treatment of breast cancer. Treatment of serum-stimulated quiescent MCF-7 breast cancer cells with cyclopentenone (2-cyclopenten-1-one) blocked progression through G(1) and into S phase. Growth arrest of the cyclopentenone-treated cells in G(1) was associated with changes in the levels of several proteins that control the cell cycle, including a dramatic decrease in cyclin D1 protein expression. Cyclopentenone also decreased the abundance of cyclin D1 mRNA and nuclear transcripts, indicating that it regulated cyclin D1 expression at the transcriptional level. Cyclopentenone selectively inhibited the activity of the cyclin D1 and cyclin A promoters but not the activity of several other control promoters. Deletion analysis indicated that the cyclopentenone response element was located in the cyclin D1 core promoter. Additional functional studies showed that a sequence within the core promoter (CycY, located downstream from the initiator element) played an important role in activation of the cyclin D1 promoter in MCF-7 cells. Electrophoretic mobility shift assays demonstrated specific binding of the transcription factor BTEB to the CycY site. The cyclopentenone response element did not correspond to the CycY site but rather mapped to the initiator element itself The overall results suggest that cyclopentenone interferes with the transcription initiation complex that assembles over the cyclin D1 initiator element, leading to selective inhibition of cyclin D1 gene transcription.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Straus, DS (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	daniel.straus@ucr.edu						Alle KM, 1998, CLIN CANCER RES, V4, P847; BAKER RT, 1989, AM J HUM GENET, V44, P534; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bui T, 1997, ENDOCRINOLOGY, V138, P985, DOI 10.1210/en.138.3.985; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Ciufolini MA, 1998, J ORG CHEM, V63, P1668, DOI 10.1021/jo972073f; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukami-Kobayashi J, 1998, EXP CELL RES, V241, P435, DOI 10.1006/excr.1998.4079; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Gillett CE, 1998, J PATHOL, V184, P396; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAYDEN JM, 1994, ENDOCRINOLOGY, V134, P760, DOI 10.1210/en.134.2.760; HERBER B, 1994, ONCOGENE, V9, P1295; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hsiang CH, 1999, BIOCHEM J, V338, P241, DOI 10.1042/0264-6021:3380241; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marten NW, 1999, BBA-GENE STRUCT EXPR, V1447, P160, DOI 10.1016/S0167-4781(99)00165-7; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nenoi M, 1996, GENE, V175, P179, DOI 10.1016/0378-1119(96)00145-X; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simpson JF, 1997, AM J PATHOL, V151, P161; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; SMITH R, 1995, GENOMICS, V25, P85, DOI 10.1016/0888-7543(95)80112-Y; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; STRAUS DS, 1994, J NUTR, V124, P1041, DOI 10.1093/jn/124.7.1041; Suh NJ, 1999, CANCER RES, V59, P336; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	58	21	22	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2212	2226		10.1038/sj.onc.1205293	http://dx.doi.org/10.1038/sj.onc.1205293			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948404				2022-12-25	WOS:000174555300010
J	Niu, GL; Wright, KL; Huang, M; Song, LX; Haura, E; Turkson, J; Zhang, SM; Wang, TH; Sinibaldi, D; Coppola, D; Heller, R; Ellis, LM; Karras, J; Bromberg, J; Pardoll, D; Jove, R; Yu, H				Niu, GL; Wright, KL; Huang, M; Song, LX; Haura, E; Turkson, J; Zhang, SM; Wang, TH; Sinibaldi, D; Coppola, D; Heller, R; Ellis, LM; Karras, J; Bromberg, J; Pardoll, D; Jove, R; Yu, H			Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis	ONCOGENE			English	Article						Stat3 activation; VEGF; tumor angiogenesis	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING; SUPPRESSES GROWTH; IN-VIVO; C-SRC; ACTIVATION; CANCER; GENE; INDUCTION; TRANSCRIPTION	Non-receptor and receptor tyrosine kinases, such as Src and EGF receptor (EGFR), are major inducers of vascular endothelial growth factor (VEGF), one of the most potent mediators of angiogenesis. While tyrosine kinases signal through multiple pathways, signal transducer and activation of transcription 3 (Stat3) is a point of convergence for many of these and is constitutively activated with high frequency in a wide range of cancer cells. Here, we show that VEGF expression correlates with Stat3 activity in diverse human cancer cell lines. An activated Stat3 mutant (Stat3C) up-regulates VEGF expression and stimulates tumor angiogenesis. Stat3C-induced VEGF up-regulation is abrogated when a Stat3-binding site in the VEGF promoter is mutated. Furthermore, interrupting Stat3 signaling with dominant-negative Stat3 protein or Stat3 antisense otigonucleotide in tumor cells down-regulates VEGF expression. Consistent with an important role of Stat3 in VEGF up-regulation induced by various oncogenic tyrosine kinases, v-Src-mediated VEGF expression is inhibited when Stat3 signaling is blocked. Moreover, chromatin immunoprecipitation assays indicate that Stat3 protein binds to the VEGF promoter in vivo and mutation of a Stat3-binding site in the VEGF promoter abrogates v-Src-induced VEGF promoter activity. These studies provide evidence that the VEGF gene is regulated directly by Stat3 protein, and indicate that Stat3 represents a common molecular target for blocking angiogenesis induced by multiple signaling pathways in human cancers.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Immunol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Clin Invest Program, Tampa, FL 33612 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Isis Pharmaceut Inc, Antisense Drug Discovery, Carlsbad, CA 92008 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center; Isis Pharmaceuticals Inc; Memorial Sloan Kettering Cancer Center	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA.	richjove@moffitt.usf.edu	Heller, Richard/ABF-1445-2020; Heller, Richard/I-6605-2012	Heller, Richard/0000-0003-1899-3859; YU, Hua/0000-0003-0931-1000	NATIONAL CANCER INSTITUTE [R01CA055652, R01CA089693, R29CA075243, P01CA082533] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652, CA75243, CA82533, CA89693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Y, 1998, CANCER RES, V58, P4008; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Coughlin CM, 1998, IMMUNITY, V9, P25, DOI 10.1016/S1074-7613(00)80585-3; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dong ZY, 1999, CANCER RES, V59, P872; Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grunstein J, 1999, CANCER RES, V59, P1592; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Pages G, 2000, ANN NY ACAD SCI, V902, P187; PASSANITI A, 1992, LAB INVEST, V67, P519; Petit AMV, 1997, AM J PATHOL, V151, P1523; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wiener JR, 1999, CLIN CANCER RES, V5, P2164; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503	49	965	1081	2	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2000	2008		10.1038/sj.onc.1205260	http://dx.doi.org/10.1038/sj.onc.1205260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960372				2022-12-25	WOS:000174827000006
J	Lee, V; Chen, LW; Paiwand, F; Cao, L; Wu, YJ; Inman, R; Adamsi, ME; Yang, BB				Lee, V; Chen, LW; Paiwand, F; Cao, L; Wu, YJ; Inman, R; Adamsi, ME; Yang, BB			Cleavage of the carboxyl tail from the G3 domain of aggrecan but not versican and identification of the amino acids involved in the degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MOTIFS; ARTICULAR-CARTILAGE; INTERGLOBULAR DOMAIN; G1 DOMAIN; MATRIX METALLOPROTEINASE; CELL-PROLIFERATION; PRODUCT SECRETION; SYNOVIAL-FLUID; LINK PROTEIN; CORE PROTEIN	Aggrecan, a major structural proteoglycan in cartilage, contains three globular domains, G1, G2, and G3, as well as sequences for glycosaminoglycan modification. A large number of proteases are implicated in aggrecan cleavage in normal metabolism, aging, and arthritis. These proteases are known to cleave at the IGD, KS, and CS domains. Here we report for the first time evidence of cleavage at a novel site, the carboxyl tail of aggrecan. Results from deletion mutants of the tail indicated that the likely cleavage sites were two consensus sequences, RRLXK and RSPR, present in the aggrecan analogs of many species. This was confirmed by site-directed mutagenesis. A construct containing two G3 domains (G3G3) was also found to cleave between the G3 duplicates. When G3 tail was linked to a glycosaminoglycan-modifying sequence, it was protected from cleavage. Furin inhibitor also reduced the levels of tail cleavage. The carboxyl tails of chicken and human versican were not cleaved, despite the presence of the consensus sequence. Our studies indicate that the basic amino acids present in the tail play an important role in cleavage, and this mechanism is specific to aggrecan.	Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada; Toronto Western Hosp, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med & Immunol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Yang, BB (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	burton.yang@swchsc.on.ca		Inman, Robert/0000-0002-4750-1422				Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BINETTE F, 1994, J BIOL CHEM, V269, P19116; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; Chen LW, 2002, J BIOL CHEM, V277, P2657, DOI 10.1074/jbc.M101153200; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; Dufour EK, 2001, J BIOL CHEM, V276, P38971, DOI 10.1074/jbc.M102959200; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; Fosang AJ, 1996, J CLIN INVEST, V98, P2292, DOI 10.1172/JCI119040; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LI H, 1993, J BIOL CHEM, V268, P23504; LOHMANDER LS, 1995, J RHEUMATOL, V22, P75; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; LOULAKIS P, 1992, BIOCHEM J, V284, P589, DOI 10.1042/bj2840589; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MANICOURT DH, 1999, DYNAMICS BONE CARTIL, P301; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SAXNE T, 1992, ARTHRITIS RHEUM, V35, P385, DOI 10.1002/art.1780350404; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; WATANABE T, 1992, J BIOL CHEM, V267, P8270; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; Yang BB, 1998, MATRIX BIOL, V16, P541, DOI 10.1016/S0945-053X(98)90066-X; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	42	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22279	22288		10.1074/jbc.M110227200	http://dx.doi.org/10.1074/jbc.M110227200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11932252	hybrid			2022-12-25	WOS:000176313600023
J	Ma, XR; Hu, JB; Lindner, DJ; Kalvakolanu, DV				Ma, XR; Hu, JB; Lindner, DJ; Kalvakolanu, DV			Mutational analysis of human thioredoxin reductase 1 - Effects on p53-mediated gene expression and interferon and retinoic acid-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; REDOX REGULATION; GROWTH ARREST; DNA-BINDING; SCHIZOSACCHAROMYCES-POMBE; CYSTEINE-SELENOCYSTEINE; TARGETED DISRUPTION; SUPPRESSES GROWTH; HUMAN LEUKEMIA; FISSION YEAST	The interferon (IFN-)-beta and all-trans-retinoic acid combination suppresses tumor growth by inducing apoptosis in several tumor cell lines. A genetic technique permitted the isolation of human thioredoxin reductase (TR) as a critical regulator of IFN/all-trans-retinoic acid-induced cell death. Our recent studies have shown that TR1:thioredoxin 1-regulated cell death is effected in part through the activation of p53-dependent responses. To understand its death regulatory function, we have performed a mutational analysis of TR. Human TR1 has three major structural domains, the FAD binding domain, the NADPH binding domain, and an interface domain (ID). Here, we show that the deletion of the C-terminal interface domain results in a constitutive activation of TR-dependent death responses and promotes p53-dependent gene expression. TR mutant without the ID still retains its dependence on thioredoxin for promoting these responses. Thus, our data suggest that TR-ID acts as a regulatory domain.	Univ Maryland, Sch Med, Greenebaum Canc Ctr,Dept Microbiol & Immunol, Mol & Cellular Biol Program, Baltimore, MD 21201 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr,Dept Microbiol & Immunol, Mol & Cellular Biol Program, 665 W Baltimore St,BRB 9th Floor, Baltimore, MD 21201 USA.		Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 78282, CA 71401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chen YQ, 1999, CANCER RES, V59, P3985; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; Dai SD, 1996, J MOL BIOL, V264, P1044, DOI 10.1006/jmbi.1996.0695; Dal-Pizzol F, 2001, FREE RADICAL RES, V34, P395, DOI 10.1080/10715760100300331; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DiPaolo RS, 1999, J CLIN ONCOL, V17, P2213, DOI 10.1200/JCO.1999.17.7.2213; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FAN SJ, 1995, CANCER RES, V55, P1649; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fujiwara N, 2001, J BIOCHEM-TOKYO, V129, P803, DOI 10.1093/oxfordjournals.jbchem.a002923; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gladyshev VN, 1999, BIOCHEM BIOPH RES CO, V259, P244, DOI 10.1006/bbrc.1999.0765; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HAINAUT P, 1993, CANCER RES, V53, P4469; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; KEM SE, 1992, SCIENCE, V256, P827; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000; Lindner Daniel J., 1997, Seminars in Oncology, V24, P99; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Merrill GF, 1999, CANCER RES, V59, P3175; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; MIYASHITA T, 1995, CELL, V80, P293; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 2002, J INTERF CYTOK RES, V22, P145, DOI 10.1089/107999002753452755; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; Wen Y, 2001, CANCER RES, V61, P7142; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	81	14	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22460	22468		10.1074/jbc.M202286200	http://dx.doi.org/10.1074/jbc.M202286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953436	hybrid			2022-12-25	WOS:000176313600047
J	Tu, HM; Sasaki, T; Snellman, A; Gohring, W; Pirila, P; Timpl, R; Pihlajaniemi, T				Tu, HM; Sasaki, T; Snellman, A; Gohring, W; Pirila, P; Timpl, R; Pihlajaniemi, T			The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; ELECTRON-MICROSCOPY; BASEMENT-MEMBRANES; ALPHA(2)BETA(1) INTEGRINS; PROLYL 4-HYDROXYLASE; CALCIUM-BINDING; HUMAN-PLACENTA; CELL-ADHESION; DOMAINS; EXPRESSION	Type XIII collagen consists of a short N-terminal intracellular domain, a transmembrane domain, and a collagenous ectodomain, and it is found at many sites of cell adhesion. We report on the characterization of recombinant type XIII collagen. The shed ectodomain was purified from insect cell culture medium and shown to form 240-kDa trimers with a T-m of 42 degreesC. Correct chain association into a triple-helical conformation was confirmed by limited pepsin digestion and CD spectroscopy. Rotary shadowing electron microscopy of the ectodomain revealed it to be a 150-nm rod with two flexible hinges separating 31-, 52-, and 68-nm portions. The rods represent the collagenous domains 1-3, and the hinges coincide with the non-collagenous domains 2 and 3. By using surface plasmon resonance analysis, the ectodomain showed interaction with immobilized fibronectin, nidogen-2, and perlecan with K-D values in the nanomolar range. The binding sites of type XIII collagen for fibronectin were localized to the collagenous domains, whereas the binding activities for nidogen-2 and perlecan resided in the pepsin-sensitive portions of the ectodomain. Furthermore, the ectodomain bound significantly to heparin, which also inhibited shedding of the ectodomain in insect cell cultures. The results reveal that type XIII collagen is notably distinct in its structure compared with other cell-surface proteins, and the in vitro binding with fibronectin, heparin, and two basement membrane components is indicative of multiple cell-matrix interactions in which this ubiquitously expressed protein participates.	Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90220 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; Max Planck Society	Pihlajaniemi, T (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, Aapistie 7, FIN-90220 Oulu, Finland.	Taina.Pihlajaniemi@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hynes RO, 1990, FIBRONECTINS; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JUVONEN M, 1992, J BIOL CHEM, V267, P24693; JUVONEN M, 1992, J BIOL CHEM, V267, P24700; JUVONEN M, 1993, LAB INVEST, V69, P541; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Lander A D, 1994, Chem Biol, V1, P73, DOI 10.1016/1074-5521(94)90043-4; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; Nokelainen M, 2001, YEAST, V18, P797, DOI 10.1002/yea.730; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; Peltonen S, 1997, DNA CELL BIOL, V16, P227, DOI 10.1089/dna.1997.16.227; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; REISFELD RA, 1962, NATURE, V195, P281, DOI 10.1038/195281a0; Sandborn WJ, 2000, INFLAMM BOWEL DIS, V6, P70, DOI 10.1097/00054725-200002000-00019; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Snellman A, 2000, J BIOL CHEM, V275, P8936, DOI 10.1074/jbc.275.12.8936; Sund M, 2001, EMBO J, V20, P5153, DOI 10.1093/emboj/20.18.5153; Sund M, 2001, MATRIX BIOL, V20, P215, DOI 10.1016/S0945-053X(01)00134-2; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	49	80	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23092	23099		10.1074/jbc.M107583200	http://dx.doi.org/10.1074/jbc.M107583200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956183	hybrid			2022-12-25	WOS:000176313600125
J	Mans, BJ; Louw, AI; Neitz, AWH				Mans, BJ; Louw, AI; Neitz, AWH			Savignygrin, a platelet aggregation inhibitor from the soft tick Ornithodoros savignyi, presents the RGD integrin recognition motif on the Kunitz-BPTI fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FACTOR XA INHIBITOR; SALIVARY-GLANDS; FIBRINOGEN RECEPTOR; PROTEIN STRUCTURES; CELL-ADHESION; VIPER VENOMS; ANTAGONIST; MOUBATA; ARGASIDAE	Savignygrin, a platelet aggregation inhibitor that possesses the RGD integrin recognition motif, has been purified from the soft tick Ornithodoros savignyi. Two isoforms with similar biological activities differ because of R52G and N60G in their amino acid sequences, indicating a recent gene duplication event. Platelet aggregation induced by ADP (IC50,130 nM), collagen, the thrombin receptor-activating peptide, and epinephrine was inhibited, although platelets were activated and underwent a shape change. The binding of alpha-CD41 (P2) to platelets, the binding of purified alpha(IIb)beta(3) to fibrinogen, and the adhesion of platelets to fibrinogen was inhibited, indicating a targeting of the fibrinogen receptor. In contrast, the adhesion of osteosarcoma cells that express the integrin alpha(v)beta(3) to vitronectin or fibrinogen was not inhibited, indicating the specificity of savignygrin toward alpha(IIb)beta(3). Savignygrin shows sequence identity to disagregin, a platelet aggregation inhibitor from the tick Ornithodoros moubata that lacks an RGD motif. The cysteine arrangement of savignygrin is similar to that of the bovine pancreatic trypsin inhibitor family of serine protease inhibitors. A homology model based on the structure of the tick anticoagulant peptide indicates that the RGD motif is presented on the substrate-binding loop of the canonical BPTI inhibitors. However, savignygrin did not inhibit the serine proteases fXa, plasmin, thrombin, or trypsin. This is the first report of a platelet aggregation inhibitor that presents the RGD motif using the Kunitz-BPTI protein fold.	Univ Pretoria, Dept Biochem, ZA-0002 Pretoria, South Africa	University of Pretoria	Neitz, AWH (corresponding author), Univ Pretoria, Dept Biochem, ZA-0002 Pretoria, South Africa.	albert.neitz@bioagric.up.ac.za	Louw, Abraham I/A-5726-2008; Mans, Ben J./M-2427-2017	Mans, Ben J./0000-0002-0177-0029; Neitz, Albert/0000-0001-9248-8469; Louw, Abraham/0000-0002-8036-1513				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; ANTUCH W, 1994, FEBS LETT, V352, P251, DOI 10.1016/0014-5793(94)00941-4; BEDNAR B, 1995, THROMB RES, V77, P453, DOI 10.1016/0049-3848(95)93881-Y; BEER JH, 1992, BLOOD, V79, P117; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRANDT WF, 1984, FEBS LETT, V174, P228, DOI 10.1016/0014-5793(84)81163-1; CALVETE JJ, 1995, P SOC EXP BIOL MED, V208, P346; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CATTANEO M, 1987, BLOOD, V70, P221; CHEN CS, 1991, BIOCHIM BIOPHYS ACTA, V1075, P237, DOI 10.1016/0304-4165(91)90272-I; Clemetson KJ, 1998, CELL MOL LIFE SCI, V54, P499, DOI 10.1007/s000180050178; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FAHEY RC, 1977, J MOL EVOL, V10, P155, DOI 10.1007/BF01751808; Gaspar ARMD, 1996, EXP APPL ACAROL, V20, P583, DOI 10.1007/BF00052809; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Grundy WN, 1999, BIOINFORMATICS, V15, P463, DOI 10.1093/bioinformatics/15.6.463; Huang TF, 1998, CELL MOL LIFE SCI, V54, P527, DOI 10.1007/s000180050181; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Joubert AM, 1998, EXP APPL ACAROL, V22, P603, DOI 10.1023/A:1006198713791; KARCZEWSKI J, 1995, BIOCHEM BIOPH RES CO, V208, P532, DOI 10.1006/bbrc.1995.1371; KARCZEWSKI J, 1994, J BIOL CHEM, V269, P6702; Karczewski J, 1997, BIOCHEM BIOPH RES CO, V241, P744, DOI 10.1006/bbrc.1997.7881; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; KUNITANI M, 1986, J CHROMATOGR, V371, P313, DOI 10.1016/S0021-9673(01)94716-8; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAW JH, 1992, ANNU REV BIOCHEM, V61, P87, DOI 10.1146/annurev.bi.61.070192.000511; LIU CZ, 1994, THROMB HAEMOSTASIS, V72, P919; Mans BJ, 1998, COMP BIOCHEM PHYS B, V120, P617, DOI 10.1016/S0305-0491(98)10061-5; Mans BJ, 2001, ELECTROPHORESIS, V22, P1739, DOI 10.1002/1522-2683(200105)22:9&lt;1739::AID-ELPS1739&gt;3.0.CO;2-7; Mans BJ, 1998, EXP APPL ACAROL, V22, P353, DOI 10.1023/A:1024517209621; Mans BJ, 2000, EXP APPL ACAROL, V24, P271, DOI 10.1023/A:1006440714276; MANS BJ, 2002, IN PRESS INSECT BIOC; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nienaber J, 1999, EXP PARASITOL, V93, P82, DOI 10.1006/expr.1999.4448; PAN YCE, 1984, J CHROMATOGR, V297, P13, DOI 10.1016/S0021-9673(01)89024-5; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Plow EF, 2001, THROMB HAEMOSTASIS, V86, P34; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; RIBEIRO JMC, 1991, COMP BIOCHEM PHYS A, V100, P109, DOI 10.1016/0300-9629(91)90190-N; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; Stuiver I, 1996, J CELL PHYSIOL, V168, P521, DOI 10.1002/(SICI)1097-4652(199609)168:3<521::AID-JCP4>3.0.CO;2-R; SUTCLIFFE MJ, 1994, NAT STRUCT BIOL, V1, P802, DOI 10.1038/nsb1194-802; TARR GE, 1986, MICROCHARACTERIZATIO, P155; vandeLocht A, 1996, EMBO J, V15, P6011, DOI 10.1002/j.1460-2075.1996.tb00989.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wang XN, 1996, J BIOL CHEM, V271, P17785, DOI 10.1074/jbc.271.30.17785; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285; ZUCKER MB, 1989, METHOD ENZYMOL, V169, P117	65	100	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21371	21378		10.1074/jbc.M112060200	http://dx.doi.org/10.1074/jbc.M112060200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11932256	hybrid			2022-12-25	WOS:000176286000034
J	Moody, JE; Millen, L; Binns, D; Hunt, JF; Thomas, PJ				Moody, JE; Millen, L; Binns, D; Hunt, JF; Thomas, PJ			Cooperative, ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ABC TRANSPORTER; HISTIDINE PERMEASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ACTIVE-SITE; SUBUNIT; CONSEQUENCES; PURIFICATION; HYDROLYSIS	ATP-binding cassette (ABC) tran porters harvest the energy present in cellular ATP to drive the translocation of a structurally diverse set of solutes across the membrane barriers of eubacteria, archaebacteria, and eukaryotes. The positively cooperative ATPase activity (Hill coefficient, 1.7) of a model soluble cassette of known structure, MJ0796, from Methanococcus jannaschii indicates that at least two binding sites participate in the catalytic reaction. Mutation of the catalytic base in MJ0796, E171Q, produced a cassette that can bind but not efficiently hydrolyze ATP. The equivalent mutation (E179Q) in a homologous cassette, MJ1267, had an identical effect. Both mutant cassettes formed dimers in the presence of ATP but not ADP, indicating that the energy of ATP binding is first coupled to the tran port cycle through a domain association reaction. The non-hydrolyzable nucleotides adenosine 5'-(beta,gamma-imino)triphosphate and adenosine 5'-3-O-(thio)triphosphate were poor analogues of ATP in terms of their ability to promote dimerization. Moreover, inclusion of MgCl2, substitution of KCl for NaCl, or alterations in the polarity of the side chain at the catalytic base all weakened the ATP-dependent dimer, suggesting that electrostatic interactions are critical for the association reaction. Thus, upon hydrolysis of bound ATP and the release of product, both electrostatic and conformational changes drive the cassettes apart, providing a second opportunity to couple free energy changes to the transport reaction.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75290 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75290 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Thomas, PJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75290 USA.	philip.thomas@utsouthwestern.edu	Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [R01 DK049835, R37 DK049835, DK49835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049835, R37DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bliss JM, 1996, GLYCOBIOLOGY, V6, P445, DOI 10.1093/glycob/6.4.445; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Davidson AL, 1996, J BIOL CHEM, V271, P4858; Dean M, 2001, J LIPID RES, V42, P1007; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kennedy KA, 1999, J BIOL CHEM, V274, P6259, DOI 10.1074/jbc.274.10.6259; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; MINTON AP, 1990, ANAL BIOCHEM, V190, P1, DOI 10.1016/0003-2697(90)90125-S; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSING J, 1975, BIOCHIM BIOPHYS ACTA, V376, P13, DOI 10.1016/0005-2728(75)90201-7; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Thomas PJ, 2001, NAT STRUCT BIOL, V8, P920, DOI 10.1038/nsb1101-920; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	29	274	279	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21111	21114		10.1074/jbc.C200228200	http://dx.doi.org/10.1074/jbc.C200228200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11964392	hybrid, Green Accepted			2022-12-25	WOS:000176286000001
J	Berlot, CH				Berlot, CH			A highly effective dominant negative alpha(s) construct containing mutations that affect distinct functions inhibits multiple G(s)-coupled receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CALCITONIN RECEPTOR; G-PROTEINS; PLASMA-MEMBRANE; ADENYLYL-CYCLASE; LIGAND-BINDING; LIVING CELLS; ACTIVATION; SUBUNITS; LOCALIZATION; G(S)	To investigate the subcellular organization of receptor-G protein signaling pathways, a robust dominant negative a. mutant containing substitutions that alter distinct functions was produced and tested for its effects on G.-coupled receptor activity in HEK-293 cells. Mutations in the alpha3beta5 loop region, which increase receptor affinity, decrease receptor-mediated activation, and impair activation of adenylyl cyclase, were combined with G226A, which increases affinity for betagamma, and A366S, which decreases affinity for GDP. This triple a. mutant can inhibit signaling to G. from the luteinizing hormone receptor by 97% and from the calcitonin receptor by 100%. In addition, this alpha(s) mutant blocks all signaling from the calcitonin receptor to G(q). These results lead to two conclusions about receptor-G protein signaling. First, individual receptors have access to multiple types of G proteins in HEK-293 cell membranes. Second, different G protein a subunits can compete with each other for binding to the same receptor. This dominant negative a. construct will be useful for determining interrelationships among distinct receptor-G protein interactions in a wide variety of cells and tissues.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Berlot, CH (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	catherine.berlot@yale.edu			NIGMS NIH HHS [GM50369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050369, R29GM050369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; DELEAN A, 1980, J BIOL CHEM, V255, P7108; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; GRAESER D, 1993, MOL PHARMACOL, V43, P434; Grishina G, 2000, MOL PHARMACOL, V57, P1081; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; LEE E, 1992, J BIOL CHEM, V267, P1212; LEVINE MA, 1983, AM J MED, V74, P545, DOI 10.1016/0002-9343(83)91008-2; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; Min L, 2000, MOL ENDOCRINOL, V14, P1797, DOI 10.1210/me.14.11.1797; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; Neubig RR, 1998, SEMIN NEUROSCI, V9, P189, DOI 10.1006/smns.1997.0117; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Ostrom RS, 2000, J PHARMACOL EXP THER, V294, P407; OTT S, 1989, J NEUROCHEM, V52, P619, DOI 10.1111/j.1471-4159.1989.tb09164.x; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SIMMONS MA, 1991, J NEUROSCI, V11, P2130; Skoglund G, 2000, DIABETES, V49, P1156, DOI 10.2337/diabetes.49.7.1156; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Vezza R, 2001, MOL PHARMACOL, V59, P1506, DOI 10.1124/mol.59.6.1506; Wade SM, 1999, MOL PHARMACOL, V56, P1005, DOI 10.1124/mol.56.5.1005; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang Q, 1997, J BIOL CHEM, V272, P26040, DOI 10.1074/jbc.272.41.26040; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71	55	38	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21080	21085		10.1074/jbc.M201330200	http://dx.doi.org/10.1074/jbc.M201330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927592	hybrid			2022-12-25	WOS:000176204500123
J	Ishikawa, S; Core, L; Perego, M				Ishikawa, S; Core, L; Perego, M			Biochemical characterization of aspartyl phosphate phosphatase interaction with a phosphorylated response regulator and its inhibition by a pentapeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; SIGNAL-TRANSDUCTION; SPORULATION; 2-COMPONENT; PROTEINS; REPEAT; SPO0F; IGG	The RapA and RapB proteins are aspartyl phosphate phosphatases that specifically dephosphorylate the Spo0Fsimilar toP intermediate response regulator of the phosphorelay signal transduction system for sporulation initiation in Bacillus subtilis. The similar to48-kDa His-tag derivative proteins were purified by metal affinity chromatography, and their molecular and biochemical characteristics were studied. RapA and RapB were found to be dimers in solution. Enzymatic activity was strongly dependent upon maintaining reducing conditions during purification and storage. RapA phosphatase activity on Spo0Fsimilar toP is inhibited in vivo by a pentapeptide generated from the phrA gene. Native gel assays demonstrated that the RapA dimer forms a stable complex with two molecules of Spo0Fsimilar toP or with its PhrA pentapeptide inhibitor. The pentapeptide was shown to displace Spo0Fsimilar toP from a preformed complex with RapA. The structural organization of Rap phosphatases in tetratricopeptide repeats provides insights on the mechanisms of RapA interaction with its substrate and its inhibitor.	Scripps Res Inst, Res Inst, Dept Mol & Expt Med, Div Cellular Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Perego, M (corresponding author), Scripps Res Inst, Res Inst, Dept Mol & Expt Med, Div Cellular Biol, MEM-116,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mperego@scripps.edu	Ishikawa, Shu/K-5383-2017	Ishikawa, Shu/0000-0002-2239-1116	NIGMS NIH HHS [GM55594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERG A, 1989, J BIOL CHEM, V264, P12249; [Anonymous], 1982, MOL CLONING LAB MANU; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Core LJ, 2001, PEPTIDES, V22, P1549, DOI 10.1016/S0196-9781(01)00491-0; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hanly W. Carey, 1995, ILAR J, V37, P93; Harlow E., 1988, ANTIBODIES LAB MANUA; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jiang M, 2000, J BACTERIOL, V182, P303, DOI 10.1128/JB.182.2.303-310.2000; Jiang M, 2000, MOL MICROBIOL, V38, P535, DOI 10.1046/j.1365-2958.2000.02148.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; MUELLER JP, 1992, J BACTERIOL, V174, P4361, DOI 10.1128/JB.174.13.4361-4373.1992; Perego M, 1998, TRENDS MICROBIOL, V6, P366, DOI 10.1016/S0966-842X(98)01350-X; Perego M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/pnas.94.16.8612; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego M, 2001, PEPTIDES, V22, P1541, DOI 10.1016/S0196-9781(01)00490-9; Perego Marta, 1993, P615; RUSSO C, 1983, J IMMUNOL METHODS, V65, P269, DOI 10.1016/0022-1759(83)90324-1; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P701; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; TRACH K, 1990, GENETICS BIOTECHNOLO, V3, P357; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; Tzeng YL, 1998, BIOCHEMISTRY-US, V37, P16538, DOI 10.1021/bi981340o; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	30	42	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20483	20489		10.1074/jbc.M201086200	http://dx.doi.org/10.1074/jbc.M201086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923303	hybrid			2022-12-25	WOS:000176204500050
J	Rief, N; Lobrich, M				Rief, N; Lobrich, M			Efficient rejoining of radiation-induced DNA double-strand breaks in centromeric DNA of human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGY-DIRECTED REPAIR; RIBOSOMAL-RNA GENES; LIGASE-IV; CHROMOSOME-ABERRATIONS; RESTRICTION FRAGMENTS; ALPHA-SATELLITE; END; RECOMBINATION; DAMAGE; HETEROGENEITY	Although major efforts in elucidating different DNA double-strand break (DSB) repair pathways and their contribution to accurate repair or misrepair have been made, little is known about the influence of chromatin structure on the fidelity of DSB repair. Here, the repair of ionizing radiation-induced DSBs was investigated in heterochromatic centromeric regions of human cells in comparison with other genomic locations. A hybridization assay was applied that allows the quantification of correct DSB rejoining events in specific genomic regions by measuring reconstitution of large restriction fragments. We show for two primary fibroblast lines (MRC-5 and 1801311) and an epithelial tumor cell line that restriction fragment reconstitution is considerably more efficient in the centromere than in average genomic locations. Importantly, however, DNA ligase IV-deficient 1801311 cells show, compared with repair-proficient MRC-5 cells, impaired restriction fragment reconstitution both in average DNA and in the centromere. Thus, the efficient repair of DSBs in centromeric DNA is dependent on functional non-homologous end joining. It is proposed that the condensed chromatin state in the centromere limits the mobility of break ends and leads to enhanced restriction fragment reconstitution by increasing the probability for rejoining correct break ends.	Univ Saarland, Fachrichtung Biophys, D-66421 Homburg, Germany	Saarland University	Lobrich, M (corresponding author), Univ Saarland, Fachrichtung Biophys, D-66421 Homburg, Germany.	markus.loebrich@uniklinik-saarland.de						Badie C, 1997, CANCER RES, V57, P4600; BARTHOLDI MF, 1991, J CELL SCI, V99, P255; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Choo KHA., 1997, CENTROMERE; CORNFORTH MN, 1993, ADV RADIAT BIOL, V17, P423; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DARROUDI F, 1987, MUTAT RES, V177, P149, DOI 10.1016/0027-5107(87)90030-3; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DEVILEE P, 1986, CYTOGENET CELL GENET, V41, P193, DOI 10.1159/000132229; DEVILEE P, 1986, NUCLEIC ACIDS RES, V14, P2059, DOI 10.1093/nar/14.5.2059; Dibiase SJ, 2000, CANCER RES, V60, P1245; DIKOMEY E, 1993, INT J RADIAT BIOL, V64, P659, DOI 10.1080/09553009314551901; DIKOMEY E, 1988, INT J RADIAT BIOL, V73, P269; Evans JW, 1996, RADIAT RES, V145, P39, DOI 10.2307/3579193; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; Fouladi B, 2000, RADIAT RES, V153, P795, DOI 10.1667/0033-7587(2000)153[0795:CORODD]2.0.CO;2; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Gilbert N, 2001, P NATL ACAD SCI USA, V98, P11949, DOI 10.1073/pnas.211322798; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; ICHIKAWA H, 1992, P NATL ACAD SCI USA, V89, P23, DOI 10.1073/pnas.89.1.23; ILIAKIS GE, 1990, INT J RADIAT BIOL, V57, P1213, DOI 10.1080/09553009014551301; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KEMP LM, 1986, MUTAT RES, V166, P255, DOI 10.1016/0167-8817(86)90025-8; Kuhne M, 2000, INT J RADIAT BIOL, V76, P891, DOI 10.1080/09553000050050909; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lobrich M, 2000, GENE CHROMOSOME CANC, V27, P59; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; MADEN BEH, 1987, BIOCHEM J, V246, P519, DOI 10.1042/bj2460519; MANUELIDIS L, 1976, NUCLEIC ACIDS RES, V3, P3063, DOI 10.1093/nar/3.11.3063; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MUHLMANNDIAZ MC, 1994, CHROMOSOMAL ALTERATI, P125; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; Overhauser J., 1992, PULSED FIELD GEL ELE, P129; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Rothkamm K, 1999, MUTAT RES-DNA REPAIR, V433, P193, DOI 10.1016/S0921-8777(99)00008-7; Rothkamm K, 2001, CANCER RES, V61, P3886; Sax K, 1938, GENETICS, V23, P494; Schwartz L M, 1995, Methods Cell Biol, V46, pxv; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; SLIJEPCEVIC P, 1994, INT J RADIAT BIOL, V66, P747; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; SRIVASTAVA AK, 1993, MAMM GENOME, V4, P445, DOI 10.1007/BF00296819; Sullivan KF, 1999, METHOD CELL BIOL, V58, P183; Surralles J, 1997, GENE CHROMOSOME CANC, V20, P173, DOI 10.1002/(SICI)1098-2264(199710)20:2<173::AID-GCC8>3.3.CO;2-A; Tabocchini MA, 2000, MUTAT RES-DNA REPAIR, V461, P71, DOI 10.1016/S0921-8777(00)00041-0; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Willard HF, 1991, CURR OPIN GENET DEV, V1, P509, DOI 10.1016/S0959-437X(05)80200-X; WORTON RG, 1988, SCIENCE, V239, P64, DOI 10.1126/science.3336775; Xiao Y, 1999, INT J RADIAT BIOL, V75, P419, DOI 10.1080/095530099140339	61	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20572	20582		10.1074/jbc.M200265200	http://dx.doi.org/10.1074/jbc.M200265200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927583	hybrid			2022-12-25	WOS:000176204500062
J	Pelletier, N; Champagne, N; Stifani, S; Yang, XJ				Pelletier, N; Champagne, N; Stifani, S; Yang, XJ			MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; Runx1; Runx2	ACUTE MYELOID-LEUKEMIA; RECEPTOR COACTIVATOR; DOSAGE COMPENSATION; MONOCYTIC LEUKEMIA; HUMAN GENES; CELL-CYCLE; PROTEIN; CBP; YEAST; MLL	The monocytic leukemia zinc finger protein MOZ and its homologue MORF have been implicated in leukemogenesis. Both MOZ and MORF are histone acetyltransferases with weak transcriptional repression domains and strong transcriptional activation domains, suggesting that they may function as transcriptional coregulators. Here we describe that MOZ and MORF both interact with Runx2 (or Cbfa1), a Runt-domain transcription factor that is known to play important roles in T cell lymphomagenesis and bone development. Through its C-terminal SM (serine- and methionine-rich) domain, MORF binds to Runx2 in vitro and in vivo. Consistent with this, the SM domain of MORF also binds to Runx1 (or AML1), a Runx2 homologue that is frequently altered by leukemia-associated chromosomal translocations. While MORF does not acetylate Runx2, its SM domain potentiates Runx2-dependent transcriptional activation. Moreover, endogenous MORF is required for transcriptional activation by Runx2. Intriguingly, Runx2 negatively regulates the transcriptional activation potential of the SM domain. Like that of MORF, the SM domain of MOZ physically and functionally interacts with Runx2. These results thus identify Runx2 as an interaction partner of MOZ and MORF and suggest that both acetyltransferases are involved in regulating transcriptional activation mediated by Runx2 and its homologues.	McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University	Yang, XJ (corresponding author), McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	yangxj@molonc.mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; John S, 2000, GENE DEV, V14, P1196; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Panagopoulos I, 2000, GENE CHROMOSOME CANC, V28, P415, DOI 10.1002/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Scott EK, 2001, CURR BIOL, V11, P99, DOI 10.1016/S0960-9822(01)00020-3; SEMENZA GL, 1998, MED GENETICS; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Speck NA, 1999, CANCER RES, V59, p1789S; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas T, 2000, DEVELOPMENT, V127, P2537; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	77	109	118	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2729	2740		10.1038/sj.onc.1205367	http://dx.doi.org/10.1038/sj.onc.1205367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965546				2022-12-25	WOS:000174996500013
J	Lerner, LE; Gribanova, YE; Whitaker, L; Knox, BE; Farber, DB				Lerner, LE; Gribanova, YE; Whitaker, L; Knox, BE; Farber, DB			The rod cGMP-phosphodiesterase beta-subunit promoter is a specific target for Sp4 and is not activated by other Sp proteins or CRX.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINITIS-PIGMENTOSA; HOMEOBOX GENE; TRANSCRIPTIONAL ACTIVATION; NONSENSE MUTATION; RD MOUSE; PHOTORECEPTOR; EXPRESSION; BINDING; NRL; IDENTIFICATION	The beta-subunit of cGMP-phosphodiesterase (beta-PDE) is a key protein in phototransduction expressed exclusively in rod photoreceptors. It is necessary for visual function and for structural integrity of the retina. beta-PDE promoter deletions showed that the -45/-23 region containing a consensus Crx-response element (CRE) was necessary for low level transcriptional activity. Overexpressed Crx modestly transactivated this promoter in 293 human embryonic kidney cells; however, mutation of CRE had no significant effect on transcription either in transfected Y79 retinoblastoma cells or Xenopus embryonic heads. Thus, Crx is unlikely to be a critical beta-PDE transcriptional regulator in vivo. Interestingly, although the beta/GC element (-59/-49) binds multiple Sp transcription factors in vitro, only Sp4, but not Sp1 or Sp3, significantly enhanced beta-PDE promoter activity. Thus, the Sp4-mediated differential activation of the beta-PDE transcription defines the first specific Sp4 target gene reported to date and implies the importance of Sp4 for retinal function. Further extensive mutagenesis of the beta-PDE upstream sequences showed no additional regulatory elements. Although this promoter lacks a canonical TATA box or Inr element, it has the (T/A)-rich beta/TA sequence located within the -45/-23 region. We found that it binds purified TBP and TFIIB in gel mobility shift assays with cooperative enhancement of binding affinity.	Univ Calif Los Angeles, Sch Med, Dept Ophthalmol, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Inst Mol Biol, Los Angeles, CA 90095 USA; SUNY Syracuse, Upstate Med Univ, Dept Ophthalmol, Syracuse, NY 13210 USA; SUNY Syracuse, Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Farber, DB (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Ophthalmol, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.			Farber, Debora/0000-0002-3207-697X	NEI NIH HHS [K08 EY00367, EY02651, EY11256] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002651, R01EY011256, R37EY002651, K08EY000367] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Batni S, 2000, METHOD ENZYMOL, V316, P50; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DANCIGER M, 1995, GENOMICS, V30, P1, DOI 10.1006/geno.1995.0001; DiPolo A, 1997, NUCLEIC ACIDS RES, V25, P3863, DOI 10.1093/nar/25.19.3863; DiPolo A, 1996, INVEST OPHTH VIS SCI, V37, P551; FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B; Freund CL, 1998, NAT GENET, V18, P311, DOI 10.1038/ng0498-311; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1999, NAT GENET, V23, P466, DOI 10.1038/70591; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Lerner LE, 2000, METHOD ENZYMOL, V315, P617; Mani SS, 2001, J BIOL CHEM, V276, P36557, DOI 10.1074/jbc.M101685200; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000	30	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	2002	277	29					25877	25883		10.1074/jbc.M201407200	http://dx.doi.org/10.1074/jbc.M201407200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	574UV	11943774	hybrid			2022-12-25	WOS:000176908700010
J	Desmyter, A; Spinelli, S; Payan, F; Lauwereys, M; Wyns, L; Muyldermans, S; Cambillau, C				Desmyter, A; Spinelli, S; Payan, F; Lauwereys, M; Wyns, L; Muyldermans, S; Cambillau, C			Three Camelid VHH domains in complex with porcine pancreatic alpha-amylase - Inhibition and versatility of binding topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANTIBODY FRAGMENT; LOOP STRUCTURES; RECOGNITION; ENZYME; IMMUNOGLOBULINS; CONFORMATIONS	Camelids produce functional antibodies devoid of light chains and CH1 domains. The antigen-binding fragment of such heavy chain antibodies is therefore comprised in one single domain, the camelid heavy chain antibody VH (VHH). Here we report on the structures of three dromedary VHH domains in complex with porcine pancreatic a-amylase. Two VHHs bound outside the catalytic site and did not inhibit or inhibited only partially the amylase activity. The third one, AMD9, interacted with the active site crevice and was a strong amylase inhibitor (K-i = 10 nM). In contrast with complexes of other proteinaceous amylase inhibitors, amylase kept its native structure. The water-accessible surface areas of VHHs covered by amylase ranged between 850 and 1150 Angstrom(2), values similar to or even larger than those observed in the complexes between proteins and classical antibodies. These values could certainly be reached because a surprisingly high extent of framework residues are involved in the interactions of VHHs with amylase. The framework residues that participate in the antigen recognition represented 25-40% of the buried surface. The inhibitory interaction of AMD9 involved mainly its complementarity-determining region (CDR) 2 loop, whereas the CDR3 loop was small and certainly did not protrude as it does in cAb-Lys3, a VHH-inhibiting lysozyme. AMD9 inhibited amylase, although it was outside the direct reach of the catalytic residues; therefore it is to be expected that inhibiting VHHs might also be elicited against proteases. These results illustrate the versatility and efficiency of VHH domains as protein binders and enzyme inhibitors and are arguments in favor of their use as drugs against diabetes.	Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, UMR 60998, Architecture & Fonct Macromol Biol, F-13402 Marseille 20, France	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Muyldermans, S (corresponding author), Free Univ Brussels VIB, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	svmuylde@vub.ac.be; cambillau@afmb.cnrs-mrs.fr	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1998, SPOCK CTR MACROMOLEC; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Desmyter A, 2001, J BIOL CHEM, V276, P26285, DOI 10.1074/jbc.M102107200; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Kabat EA, 1991, US PUBLIC HLTH SERVI; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MINXIE Q, 1993, J MOL BIO, V231, P785; MINXIE Q, 1994, BIOCHEMISTRY-US, V33, P6284; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Muyldermans S, 2001, TRENDS BIOCHEM SCI, V26, P230, DOI 10.1016/S0968-0004(01)01790-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nguyen VK, 1999, MOL IMMUNOL, V36, P515, DOI 10.1016/S0161-5890(99)00067-X; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; ROUSSEL A, 1991, SILICON GRAPHICS GEO, V81, P77; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Spinelli S, 2001, J MOL BIOL, V311, P123, DOI 10.1006/jmbi.2001.4856; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; WIEGAND G, 1995, J MOL BIOL, V247, P99, DOI 10.1006/jmbi.1994.0125; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; Woolven BP, 1999, IMMUNOGENETICS, V50, P98, DOI 10.1007/s002510050694	33	138	153	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23645	23650		10.1074/jbc.M202327200	http://dx.doi.org/10.1074/jbc.M202327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960990	hybrid			2022-12-25	WOS:000176475700071
J	Fujitani, N; Kawabata, S; Osaki, T; Kumaki, Y; Demura, M; Nitta, K; Kawano, K				Fujitani, N; Kawabata, S; Osaki, T; Kumaki, Y; Demura, M; Nitta, K; Kawano, K			Structure of the antimicrobial peptide tachystatin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; 3-DIMENSIONAL SOLUTION STRUCTURE; CELLULOSE-BINDING DOMAIN; BOVINE NEUTROPHILS; CLOTTING FACTORS; BETA-DEFENSINS; HEMOCYTES; PROTEINS; SPECTROSCOPY; MOTIF	The solution structure of antimicrobial peptide tachystatin A from the Japanese horseshoe crab (Tachypleus tridentatus) was determined by two-dimensional nuclear magnetic resonance measurements and distance-restrained simulated annealing calculations. The correct pairs of disulfide bonds were also confirmed in this study. The obtained structure has a cysteine-stabilized triple-stranded beta-sheet as a dominant secondary structure and shows an amphiphilic folding observed in many membrane-interactive peptides. Interestingly, tachystatin A shares structural similarities with the calcium channel antagonist omega-agatoxin IVA isolated from spider toxin and mammalian defensins, and we predicted that omega-agatoxin IVA also have the antifungal activity. These structural comparisons and functional correspondences suggest that tachystatin A and omega-agatoxin IVA may exert the antimicrobial activity in a manner similar to defensins, and we have confirmed such activity using fungal culture assays. Furthermore, tachystatin A is a chitin-binding peptide, and omega-agatoxin IVA also showed chitin-binding activities in this study. Tachystatin A and omega-agatoxin IVA showed no structural homology with well known chitin-binding motifs, suggesting that their structures belong to a novel family of chitin-binding peptides. Comparison of their structures with those of cellulose-binding proteins indicated that Phe(9) of tachystatin A might be an essential residue for binding to chitin.	Hokkaido Univ, Div Biol Sci, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan; Kyushu Univ, Dept Mol Biol, Grad Sch Med Sci, Fukuoka 8128582, Japan; Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1010062, Japan	Hokkaido University; Kyushu University; Kyushu University; University of Toyama; Japan Science & Technology Agency (JST)	Nitta, K (corresponding author), Hokkaido Univ, Div Biol Sci, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan.		Demura, Makoto/F-5272-2011; Kawano, Keiichi/F-5265-2011; Fujitani, Naoki/A-4072-2012	Demura, Makoto/0000-0003-0912-9284; Osaki, Tsukasa/0000-0002-9487-3253; Fujitani, Naoki/0000-0002-4035-7317				ANDERSEN NH, 1993, BIOCHEMISTRY-US, V32, P1407, DOI 10.1021/bi00057a004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEINTEMA JJ, 1994, FEBS LETT, V350, P159, DOI 10.1016/0014-5793(94)00753-5; Billeter M, 1995, J BIOMOL NMR, V5, P1; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HYBERTS SG, 1987, EUR J BIOCHEM, V164, P625, DOI 10.1111/j.1432-1033.1987.tb11173.x; Iwanaga S, 1998, J BIOCHEM, V123, P1; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; Nagy T, 1998, FEBS LETT, V429, P312, DOI 10.1016/S0014-5793(98)00625-5; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Osaki T, 1999, J BIOL CHEM, V274, P26172, DOI 10.1074/jbc.274.37.26172; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGAN LJ, 1991, J NEUROSCI, V11, P2259; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Simpson PJ, 2000, J BIOL CHEM, V275, P41137, DOI 10.1074/jbc.M006948200; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; Wang P, 1997, J BIOL CHEM, V272, P16663, DOI 10.1074/jbc.272.26.16663; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	47	38	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23651	23657		10.1074/jbc.M111120200	http://dx.doi.org/10.1074/jbc.M111120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959852	hybrid			2022-12-25	WOS:000176475700072
J	Huebert, RC; Splinter, PL; Garcia, F; Marinelli, RA; LaRusso, NF				Huebert, RC; Splinter, PL; Garcia, F; Marinelli, RA; LaRusso, NF			Expression and localization of aquaporin water channels in rat hepatocytes - Evidence for a role in canalicular bile secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL PLASMA-MEMBRANE; TRANSPORT WATER; CYCLIC-AMP; LIVER; COUPLETS; IMMUNOLOCALIZATION; CHOLANGIOCYTES; VESICLE; TESTIS; PERMEABILITY	Although bile formation requires that large volumes of water be rapidly transported across liver epithelia, including hepatocytes, the molecular mechanisms by which water is secreted into bile are obscure. The aquaporins are a family of 10 channel-forming, integral membrane proteins of similar to28 kDa numbered 0-9 that allow water to rapidly traverse epithelial barriers in several organs including kidney, eye, and brain. We found transcripts of three of 10 aquaporins in hepatocytes (aquaporin 8 >> aquaporin 9 > aquaporin 0) by reverse transcription-polymerase chain reaction and quantitative ribonuclease protection assays; immunohistochemistry confirmed the presence of these three proteins in liver. Immunoblots of subcellular fractions of hepatocytes showed enrichment of aquaporins 0 and 8 in microsomes and canalicular plasma membranes, aquaporin 9 was enriched only in basolateral plasma membranes. Immunofluoreseence of hepatocyte couplets confirmed the intracellular/canalicular localization of aquaporins 0 and 8 and the basolateral localization of aquaporin 9. Upon exposure of couplets to a choleretic stimulus (i.e. dibutyryl cAMP), aquaporin 8 redistributed to the canalicular plasma membrane; the subcellular distributions of aquaporins 0 and 9 were unaffected. In addition, exposure of couplets to dibutyryl cAMP caused an increase in canalicular water transport in the presence and absence of an osmotic gradient, an effect that was blocked by aquaporin inhibitors. These results provide evidence that aquaporins are present in hepatocytes and that aquaporins are involved in agonist-stimulated canalicular bile secretion.	Mayo Med Sch Clin & Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Med Sch Clin & Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Med Sch Clin & Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Consejo Nacl Invest Cient & Tecn, Inst Fisiol Expt, RA-2000 Rosario, Santa Fe, Argentina	Mayo Clinic; Mayo Clinic; Mayo Clinic; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario	LaRusso, NF (corresponding author), Mayo Med Sch Clin & Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.			Huebert, Robert/0000-0002-9812-7573	NIDDK NIH HHS [DK24031] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENEDETTI A, 1994, P NATL ACAD SCI USA, V91, P792, DOI 10.1073/pnas.91.2.792; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Boyer James L., 1993, P597; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BOYER JL, 1979, YALE J BIOL MED, V52, P61; Cefaratti C, 2000, J BIOL CHEM, V275, P3772, DOI 10.1074/jbc.275.6.3772; Cova E, 2001, HEPATOLOGY, V34, P456, DOI 10.1053/jhep.2001.27092; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Elkjaer ML, 2001, AM J PHYSIOL-RENAL, V281, pF1047, DOI 10.1152/ajprenal.0158.2001; Ford P, 2000, J MEMBRANE BIOL, V176, P151, DOI 10.1007/s002320001084; Fotiadis D, 2000, J MOL BIOL, V300, P779, DOI 10.1006/jmbi.2000.3920; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Gerloff T, 1999, GASTROENTEROLOGY, V117, P1408, DOI 10.1016/S0016-5085(99)70291-X; GRAF J, 1990, J HEPATOL, V10, P387, DOI 10.1016/0168-8278(90)90152-H; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; HAYAKAWA T, 1990, AM J PHYSIOL, V259, pG727, DOI 10.1152/ajpgi.1990.259.5.G727; Hurley PT, 2001, AM J PHYSIOL-GASTR L, V280, pG701, DOI 10.1152/ajpgi.2001.280.4.G701; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; Ishikawa Y, 1999, BIOCHEM BIOPH RES CO, V265, P94, DOI 10.1006/bbrc.1999.1630; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; Koyama Y, 1997, J BIOL CHEM, V272, P30329, DOI 10.1074/jbc.272.48.30329; Lazaridis KN, 2000, P NATL ACAD SCI USA, V97, P11092, DOI 10.1073/pnas.200325297; MARINELLI R, 1999, AM J PHYSIOL, V39, pG280; Marinelli RA, 2000, HEPATOLOGY, V31, P1313, DOI 10.1053/jhep.2000.7986; Marinelli RA, 1997, J BIOL CHEM, V272, P12984, DOI 10.1074/jbc.272.20.12984; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; MEIER PJ, 1988, SEMIN LIVER DIS, V8, P293, DOI 10.1055/s-2008-1040551; Meier PJ, 2000, NEWS PHYSIOL SCI, V15, P89; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Roelofsen H, 1998, J CELL SCI, V111, P1137; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Soroka CJ, 1999, J BIOL CHEM, V274, P26416, DOI 10.1074/jbc.274.37.26416; Tani T, 2001, ARCH HISTOL CYTOL, V64, P159, DOI 10.1679/aohc.64.159; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; VANHOEK AN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P203, DOI 10.1016/0005-2736(90)90296-Z; Verkman AS, 1999, J AM SOC NEPHROL, V10, P1126; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	40	121	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22710	22717		10.1074/jbc.M202394200	http://dx.doi.org/10.1074/jbc.M202394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11932260	hybrid			2022-12-25	WOS:000176313600079
J	Johnson, MD; Wu, XW; Aithmitti, N; Morrison, RS				Johnson, MD; Wu, XW; Aithmitti, N; Morrison, RS			Peg3/Pw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; IMPRINTED GENE PEG3; INDUCED CELL-DEATH; HUMAN HOMOLOG; P53-MEDIATED APOPTOSIS; PROXIMAL CHROMOSOME-7; TUMOR SUPPRESSION; ACTIVATION; PROTEIN; TRANSLOCATION	Neuronal cell death after DNA damage requires p53 and Bax, but the mechanism by which p53 activation leads to Bax translocation and cell death in neurons is not known. We report here that Peg3/Pw1 is up-regulated after DNA damage in cortical neurons in a p53-dependent manner. Overexpression of Peg3/Pw1 leads to decreased neuronal viability. The deleterious effect of Peg3/Pw1 on neuronal survival is abrogated by deletion of either p53 or Bax, indicating an essential role for both in Peg3/Pw1-mediated neuronal death. Moreover, overexpression of a Peg3/Pw1 dominant negative protein inhibits Bax translocation and neuronal cell death after DNA damage. These findings implicate Peg3/Pw1 as a mediator between p53 and Bax in a neuronal cell death pathway activated by DNA damage.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Huffington Ctr Aging, Houston, TX 77030 USA	University of Washington; University of Washington Seattle; Baylor College of Medicine	Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA073678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA73678] Funding Source: Medline; NINDS NIH HHS [NS35533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; CHOPP M, 1992, BIOCHEM BIOPH RES CO, V182, P1201, DOI 10.1016/0006-291X(92)91859-O; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Johnson MD, 1999, J NEUROSCI, V19, P2996; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kim J, 1997, GENOME RES, V7, P532, DOI 10.1101/gr.7.5.532; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; Ledgerwood EC, 2000, LAB INVEST, V80, P1509, DOI 10.1038/labinvest.3780160; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Li LL, 2000, GENOMICS, V63, P333, DOI 10.1006/geno.1999.6103; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MIYASHITA T, 1995, CELL, V80, P293; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Murphy SK, 2001, GENOMICS, V71, P110, DOI 10.1006/geno.2000.6419; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Relaix F, 1996, DEV BIOL, V177, P383, DOI 10.1006/dbio.1996.0172; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Stefanis L, 1999, J NEUROSCI, V19, P6235; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; Watanabe H, 1999, BRAIN RES, V837, P38, DOI 10.1016/S0006-8993(99)01652-2; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamaguchi A, 2002, J BIOL CHEM, V277, P623, DOI 10.1074/jbc.M107435200; ZHANG WW, 1993, BIOTECHNIQUES, V15, P869	41	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23000	23007		10.1074/jbc.M201907200	http://dx.doi.org/10.1074/jbc.M201907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943780	hybrid			2022-12-25	WOS:000176313600115
J	Kiely, PA; Sant, A; O'Connor, R				Kiely, PA; Sant, A; O'Connor, R			RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; MOTIF-CONTAINING PROTEIN; KINASE-C; TYROSINE-PHOSPHATASE; BETA-SUBUNIT; CAENORHABDITIS-ELEGANS; SIGNAL-TRANSDUCTION; RESISTANCE; APOPTOSIS; SRC	The insulin receptor and insulin-like growth factor 1 receptor UGF-1R), activated by their ligands, control metabolism, cell survival, and proliferation. Although the signaling pathways activated by these receptors are well characterized, regulation of their activity is poorly understood. To identify regulatory proteins we undertook a two-hybrid screen using the IGF-1R beta-chain as bait. This screen identified Receptor for Activated C Kinases (RACK1) as an IGF-1R-interacting protein. RACK1 also interacted with the IGF-1R in fibroblasts and MCF-7 cells and with endogenous insulin receptor in COS cells. Interaction with the IGF-1R did not require tyrosine kinase activity or receptor autophosphorylation but did require serine 1248 in the C terminus. Overexpression of RACK1 in either R+ fibroblasts or MCF-7 cells inhibited IGF-1-induced phosphorylation of Akt, whereas it enhanced phosphorylation of Erks and Jnks. Src, the p85 subunit of phosphatidylinositol 3-kinase, and SHP-2 were all associated with RACK1 in these cells. Interestingly, the proliferation of MCF-7 cells was enhanced by overexpression of RACK1, whereas IGF-1-mediated protection from etoposide killing was greatly reduced. Altogether the data indicate that RACK1 is an IGF-1R-interacting protein that can modulate receptor signaling and suggest that RACK1 has a particular role in regulating Akt activation and cell survival.	Natl Univ Ireland, Dept Biochem, Cell Biol Lab, Lee Maltings Cork, Ireland; Natl Univ Ireland, Inst Biosci, Lee Maltings Cork, Ireland; ImmunoGen Inc, Cambridge, MA 02139 USA	ImmunoGen, Inc.	O'Connor, R (corresponding author), Natl Univ Ireland, Dept Biochem, Cell Biol Lab, Lee Maltings Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hongo A, 1996, ONCOGENE, V12, P1231; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; Ligensa T, 2001, J BIOL CHEM, V276, P33419, DOI 10.1074/jbc.M104509200; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Liu YM, 1998, CANCER RES, V58, P570; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Morrione A, 1996, CANCER RES, V56, P3165; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; O'Connor Rosemary, 1998, V62, P137; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Resnicoff M, 1998, INT J MOL MED, V1, P883; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Siddle K, 2001, BIOCHEM SOC T, V29, P513, DOI 10.1042/BST0290513; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; TREADWAY JL, 1989, J BIOL CHEM, V264, P21450; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Urso B, 1999, FEBS LETT, V460, P423, DOI 10.1016/S0014-5793(99)01388-5; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Venkatesan AM, 2001, RECENT PROG HORM RES, V56, P295, DOI 10.1210/rp.56.1.295; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Zabolotny JM, 2001, P NATL ACAD SCI USA, V98, P5187, DOI 10.1073/pnas.071050398; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	60	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22581	22589		10.1074/jbc.M201758200	http://dx.doi.org/10.1074/jbc.M201758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11964397	hybrid			2022-12-25	WOS:000176313600064
J	Lin, AP; McAlister-Henn, L				Lin, AP; McAlister-Henn, L			Isocitrate binding at two functionally distinct sites in yeast NAD(+)-specific isocitrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BRANCH POINT; MOLECULAR-CLONING; SUBUNIT STRUCTURE; KINETIC-ANALYSIS; PHOSPHORYLATION; ENZYME; EXPRESSION	Yeast NAD(+)-specific isocitrate dehydrogenase (IDH) is an octamer containing two types of homologous subunits. Ligand-binding analyses were conducted to examine effects of residue changes in putative catalytic and regulatory isocitrate-binding sites respectively contained in IDH2 and IDH1 subunits. Replacement of homologous serine residues in either subunit site, S98A in IDH2 or S92A in IDH1, was found to reduce by half the total number of holoenzyme isocitrate-binding sites, confirming a correlation between detrimental effects on isocitrate binding and respective kinetic defects in catalysis and allosteric activation by AMP. Replacement of both serine residues eliminates isocitrate binding and measurable catalytic activity. The putative isocitrate-binding sites of IDH1 and IDH2 contain five identical and four nonidentical residues. Reciprocal replacement of the four nonidentical residues in either or both subunits (A108R, F136Y, T241D, and N245D in IDH1 and/or R114A, Y142F, D248T, and D252N in IDH2) was found to be permissive for isocitrate binding. This provides further evidence for two types of binding sites in IDH, although the authentic residues have been shown to be necessary for normal kinetic contributions. Finally, the mutant enzymes with residue replacements in the IDH1 site were found to be unable to bind AMP, suggesting that allosteric activation is dependent both upon binding of isocitrate at the IDH1 site and upon the changes in the enzyme normally elicited by this binding.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	McAlister-Henn, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	henn@uthscsa.edu			NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BARNES LD, 1972, BIOCHEMISTRY-US, V11, P4322, DOI 10.1021/bi00773a019; BURKE WF, 1974, BIOCHIM BIOPHYS ACTA, V351, P333, DOI 10.1016/0005-2795(74)90196-2; CHEN FR, 1963, BIOCHEMISTRY-US, V2, P1023, DOI 10.1021/bi00905a020; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DEAN AM, 1989, J BIOL CHEM, V264, P20482; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; Huh TL, 1997, FASEB J, V11, pA892; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ILLINGWORTH JA, 1972, BIOCHEM J, V129, P1119, DOI 10.1042/bj1291119; KEYS DA, 1990, J BACTERIOL, V172, P4280, DOI 10.1128/jb.172.8.4280-4287.1990; KUEHN GD, 1971, BIOCHEMISTRY-US, V10, P3945, DOI 10.1021/bi00797a023; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; NICHOLS BJ, 1995, BIOCHEM J, V310, P917, DOI 10.1042/bj3100917; NICHOLS BJ, 1993, BIOCHEM J, V295, P347, DOI 10.1042/bj2950347; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Panisko E.A., 2000, THESIS U TEXAS SAN A; Panisko EA, 2001, J BIOL CHEM, V276, P1204, DOI 10.1074/jbc.M005056200; Przybyla-Zawislak B, 1999, GENETICS, V152, P153; RABIN BR, 1967, BIOCHEM J, V102, pC22, DOI 10.1042/bj1020022C; REEVES HC, 1972, BIOCHIM BIOPHYS ACTA, V258, P27, DOI 10.1016/0005-2744(72)90964-3; RICARD J, 1974, EUR J BIOCHEM, V49, P195, DOI 10.1111/j.1432-1033.1974.tb03825.x; Rice DW, 1997, J MOL BIOL, V267, P1026, DOI 10.1006/jmbi.1997.0924; ROST B, 1995, 3 INT C INT SYST MOL, P314; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; WALSH K, 1984, J BIOL CHEM, V259, P9646; WALSH K, 1985, J BIOL CHEM, V260, P8430; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zhao WN, 1997, J BIOL CHEM, V272, P21811, DOI 10.1074/jbc.272.35.21811	39	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22475	22483		10.1074/jbc.M202534200	http://dx.doi.org/10.1074/jbc.M202534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953438	hybrid			2022-12-25	WOS:000176313600049
J	Tyagi, S; Korkaya, H; Zafrullah, M; Jameel, S; Lal, SK				Tyagi, S; Korkaya, H; Zafrullah, M; Jameel, S; Lal, SK			The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST 2-HYBRID SYSTEM; READING FRAME-2 PROTEIN; STRUCTURAL PROTEINS; MACAQUE HEPATOCYTES; MOLECULAR-CLONING; SELF-ASSOCIATION; INSECT CELLS; EXPRESSION; HEV; RNA	Hepatitis E virus (HEV) is a human RNA virus containing three open reading frames. Of these, ORF1 encodes the viral nonstructural polyprotein; ORF2 encodes the major capsid protein, which exists in a glycosylated and non-glycosylated form; and ORF3 codes for a phosphoprotein of undefined function. Using fluorescence-based colocalization, yeast two-hybrid experiments, transiently transfected COS-1 cell co-immunoprecipitation, and cell-free coupled transcription-translation techniques, we have shown that the ORF3 protein interacts with the ORF2 protein. The domains involved in this ORF2-ORF3 association have been identified and mapped. Our deletion analysis showed that a 25-amino acid region (residues 57-81) of the ORF3 protein is required for this interaction. Using a Mexican REV isolate, site-directed mutagenesis of ORF3, and a phosphatase digestion assay, we showed that the ORF2-ORF3 interaction is dependent upon the phosphorylation at Ser(80) of ORF3. Finally, using COS-1 cell immunoprecipitation experiments, we found that the phosphorylated ORF3 protein preferentially interacts with the non-glycosylated ORF2 protein. These findings were confirmed using tunicamycin inhibition, point mutants, and deletion mutants expressing only non-glycosylated ORF2. ORF3 maps in the structural region of the HEV genome and now interacts with the major capsid protein, ORF2, in a post-translational modification-dependent manner. Such an interaction of ORF2 with ORF3 suggests a possible well regulated role for ORF3 in HEV structural assembly.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 1100067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 1100067, India.		Korkaya, Hasan/ABD-6282-2020; Korkaya, Hasan/GRY-1016-2022; Korkaya, Hasan/C-2201-2009	Korkaya, Hasan/0000-0002-0719-5862; 				Ansari IH, 2000, J MED VIROL, V60, P275, DOI 10.1002/(SICI)1096-9071(200003)60:3<275::AID-JMV5>3.3.CO;2-0; AYE TT, 1992, NUCLEIC ACIDS RES, V20, P3512, DOI 10.1093/nar/20.13.3512; Bai C, 1996, METHOD ENZYMOL, V273, P331; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; HARPER JW, 1993, CELL, V75, P805; HE JK, 1993, J CLIN MICROBIOL, V31, P2167, DOI 10.1128/JCM.31.8.2167-2173.1993; HUANG CC, 1992, VIROLOGY, V191, P550, DOI 10.1016/0042-6822(92)90230-M; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; James P, 1996, GENETICS, V144, P1425; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KHUDYAKOV YE, 1994, VIROLOGY, V198, P390, DOI 10.1006/viro.1994.1048; KHUDYAKOV YE, 1993, VIROLOGY, V194, P89, DOI 10.1006/viro.1993.1238; KOONIN EV, 1992, P NATL ACAD SCI USA, V89, P8259, DOI 10.1073/pnas.89.17.8259; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Lal SK, 1997, GENE, V190, P63, DOI 10.1016/S0378-1119(96)00698-1; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Panda SK, 2000, J VIROL, V74, P2430, DOI 10.1128/JVI.74.5.2430-2437.2000; Purcell R. H., 1996, FIELDS VIROLOGY, P2831; Reyes G R, 1993, Arch Virol Suppl, V7, P15; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; TAKACS AM, 1993, P NATL ACAD SCI USA, V90, P10375, DOI 10.1073/pnas.90.21.10375; Tam AW, 1997, VIROLOGY, V238, P94, DOI 10.1006/viro.1997.8817; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; Tam AW, 1996, VIROLOGY, V215, P1, DOI 10.1006/viro.1996.0001; Torresi J, 1999, J GEN VIROL, V80, P1185, DOI 10.1099/0022-1317-80-5-1185; TSAREV SA, 1992, P NATL ACAD SCI USA, V89, P559, DOI 10.1073/pnas.89.2.559; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; Tyagi S, 2001, BIOCHEM BIOPH RES CO, V284, P614, DOI 10.1006/bbrc.2001.5017; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; Tyagi S, 2000, BIOCHEM BIOPH RES CO, V277, P589, DOI 10.1006/bbrc.2000.3720; Xing L, 1999, VIROLOGY, V265, P35, DOI 10.1006/viro.1999.0005; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997; Zafrullah M, 1999, J VIROL, V73, P4074, DOI 10.1128/JVI.73.5.4074-4082.1999	37	93	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22759	22767		10.1074/jbc.M200185200	http://dx.doi.org/10.1074/jbc.M200185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934888	hybrid			2022-12-25	WOS:000176313600085
J	Besson, A; Wilson, TL; Yong, VW				Besson, A; Wilson, TL; Yong, VW			The anchoring protein RACK1 links protein kinase C epsilon to integrin beta chains - Requirement for adhesion and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; MOTIF-CONTAINING PROTEIN; FOCAL ADHESIONS; TYROSINE PHOSPHORYLATION; INTRACELLULAR RECEPTOR; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PKC; ALPHA; INVOLVEMENT	Integrin affinity is modulated by intracellular signaling cascades, in a process known as "inside-out" signaling, leading to changes in cell adhesion and motility. Protein kinase C (PKC) plays a critical role in integrin-mediated events; however, the mechanism that links PKC to integrins remains unclear. Here, we report that PKCepsilon positively regulates integrin-dependent adhesion, spreading, and motility of human glioma cells. PKCepsilon activation was associated with increased focal adhesion and lamellipodia formation as well as clustering of select integrins, and it is required for phorbol 12-myristate 13-acetate-induced adhesion and motility. We provide novel evidence that the scaffolding protein RACK1 mediates the interaction between integrin beta chain and activated PKCepsilon. Both depletion of RACK1 by antisense strategy and overexpression of a truncated form of RACK1 which lacks the integrin binding region resulted in decreased PKCepsilon-induced adhesion and migration, suggesting that RACK1 links PKCepsilon to integrin beta chains. Altogether, these results provide a novel mechanistic link between PKC activation and integrin-mediated adhesion and motility.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Yong, VW (corresponding author), Univ Calgary, Dept Oncol, 3330 Hosp Dr NW,HMRB 191, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca	Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943; Yong, V. Wee/0000-0002-2600-3563				Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Croze E, 2000, J IMMUNOL, V165, P5127, DOI 10.4049/jimmunol.165.9.5127; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIMOND C, 1995, EXP CELL RES, V216, P232, DOI 10.1006/excr.1995.1029; Haller H, 1998, CIRC RES, V82, P157; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Perez-Moreno M, 1998, J CELL SCI, V111, P3563; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; VUORI K, 1993, J BIOL CHEM, V268, P21459; WOODS A, 1992, J CELL SCI, V101, P277; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; YONG VW, 1987, J NEUROSCI METH, V21, P9, DOI 10.1016/0165-0270(87)90098-7	47	155	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22073	22084		10.1074/jbc.M111644200	http://dx.doi.org/10.1074/jbc.M111644200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934885	hybrid			2022-12-25	WOS:000176286000120
J	Lachance, G; Levasseur, S; Naccache, PH				Lachance, G; Levasseur, S; Naccache, PH			Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils - Implication of phosphatidylinositol 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; PLECKSTRIN HOMOLOGY DOMAIN; T-CELL-ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASES; SIGNAL-TRANSDUCTION; CROSS-LINKING; PHOSPHORYLATION; RECEPTOR; BINDING	The importance of the tyrosine phosphorylation cascades in the initiation and regulation of the functional responsiveness of human neutrophils is well established. On the other hand, the link between the G protein-coupled receptors (to which the receptors for chemotactic factors belong) and the activation of tyrosine kinases is very poorly characterized. Based on previous observations indicating that the stimulation of tyrosine phosphorylation was sensitive to inhibition by the phosphatidylinositol 3-kinase inhibitor wortmannin and the recent description of pleckstrin homology domain-containing tyrosine kinases (the Tee family), we have examined the potential implication of the latter in the responses of human neutrophils to chemotactic factors. The results obtained indicate firstly that several members of the Tee family of tyrosine kinases are expressed in human neutrophils, including Tee, Btk, and Bmx. Stimulation of the cells with fMet-Leu-Phe led to a rapid activation of Tee as indicated by its translocation to a membrane fraction and to increases in its in situ level of tyrosine phosphorylation and its capacity to tyrosine phosphorylate itself or an exogenous substrate (SAM68-GST) in in vitro kinase assays. The activation of Tee was inhibited by pertussis toxin as well as by wortmannin. The results of this study provide direct evidence for the implication of Tee family kinases in the responses of human neutrophils to chemotactic factors. They also suggest that one of the links between G protein-coupled receptors and tyrosine kinases depends on the activation of phosphatidylinositol 3-kinase and the generation of phosphatidylinositol 3,4,5-trisphosphate.	Univ Laval, Ctr Hosp Univ Laval, Ctr Rech,Ctr Rech Rhumatol & Immunol,Dept Med, Canadian Inst Hlth Res Grp Mol Mechanisms Inflamm, Quebec City, PQ G1V 4G2, Canada	Laval University	Naccache, PH (corresponding author), CHUQ, CHUL, Room T 1-49,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	paul.naccache@crchul.ulaval.ca						Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; BERKOW RL, 1991, J LEUKOCYTE BIOL, V49, P599, DOI 10.1002/jlb.49.6.599; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Funaki M, 2000, CELL SIGNAL, V12, P135, DOI 10.1016/S0898-6568(99)00086-8; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GAUDRY M, 1991, J LEUKOCYTE BIOL, V51, P103; GERARD C, 1994, ANN REV IMMUNOL; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRINSTEIN S, 1991, AM J PHYSIOL, V260, pC1019, DOI 10.1152/ajpcell.1991.260.5.C1019; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; KRAFT AS, 1987, BLOOD, V70, P356; Laffargue M, 1999, FEBS LETT, V443, P66, DOI 10.1016/S0014-5793(98)01680-9; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; LU DJ, 1993, BLOOD CELLS, V19, P343; Lu YL, 1998, J IMMUNOL, V161, P5404; Mano H, 1999, INT J HEMATOL, V69, P6; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Miura Y, 2000, BLOOD, V96, P1733, DOI 10.1182/blood.V96.5.1733.h8001733_1733_1739; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Naccache PH, 2000, J BIOL CHEM, V275, P23636, DOI 10.1074/jbc.M001780200; NACCACHE PH, 1993, LAB INVEST, V69, P19; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; Oda A, 2000, BLOOD, V95, P1663; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; ROLLET E, 1994, J IMMUNOL, V153, P353; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; Siddiqui RA, 2000, BBA-MOL CELL BIOL L, V1483, P161, DOI 10.1016/S1388-1981(99)00172-9; Sommers CL, 1999, J EXP MED, V190, P1427, DOI 10.1084/jem.190.10.1427; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Welch H, 1997, ONCOGENE, V15, P2021, DOI 10.1038/sj.onc.1201356; Welch H, 1997, J BIOL CHEM, V272, P102; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; Xiao YQ, 1998, EUR J PHARMACOL, V360, P195, DOI 10.1016/S0014-2999(98)00681-5; Yan SR, 1999, FEBS LETT, V451, P33, DOI 10.1016/S0014-5793(99)00539-6; Yang WC, 2001, J IMMUNOL, V166, P387, DOI 10.4049/jimmunol.166.1.387; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	64	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21537	21541		10.1074/jbc.M201903200	http://dx.doi.org/10.1074/jbc.M201903200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940595	hybrid			2022-12-25	WOS:000176286000055
J	Scholze, P; Norregaard, L; Singer, EA; Freissmuth, M; Gether, U; Sitte, HH				Scholze, P; Norregaard, L; Singer, EA; Freissmuth, M; Gether, U; Sitte, HH			The role of zinc ions in reverse transport mediated by monoamine transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEROTONIN TRANSPORTER; HUMAN DOPAMINE TRANSPORTER; FACILITATED EXCHANGE DIFFUSION; NEUROTRANSMITTER TRANSPORTERS; GABA TRANSPORTER-1; MAMMALIAN-CELLS; MOLECULAR-BASIS; RELEASE; COCAINE; LOCALIZATION	The human dopamine transporter (hDAT) contains an endogenous high affinity Zn2+ binding site with three coordinating residues on its extracellular face (His(193), His(375), and Glu(396)). Upon binding to this site, Zn2+ causes inhibition of [H-3]1-methyl-4-phenylpyridinium ([H-3]MPP+) uptake. We investigated the effect of Zn2+ on outward transport by superfusing hDAT-expressing HEK-293 cells preloaded with [H-3]MPP+. Although Zn2+ inhibited uptake, Zn2+ facilitated [H-3]MPP+ release induced by amphetamine, MPP+, or K+-induced depolarization specifically at hDAT but not at the human serotonin and the norepinephrine transporter (hNET). Mutation of the Zn2+ coordinating residue His(193) to Lys (the corresponding residue in hNET) eliminated the effect of Zn2+ on efflux. Conversely, the reciprocal mutation (K189H) conferred Zn2+ sensitivity to hNET. The intracellular [H-3]MPP+ concentration was varied to generate saturation isotherms; these showed that Zn2+ increased V-max for efflux (rather than KM-Efflux-intracellular). Thus, blockage of inward transport by Zn2+ is not due to a simple inhibition of the transporter turnover rate. The observations provide evidence against the model of facilitated exchange-diffusion and support the concept that inward and outward transport represent discrete operational modes of the transporter. In addition, they indicate a physiological role of Zn2+, because Zn2+ also facilitated transport reversal of DAT in rat striatal slices	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark	University of Vienna; University of Copenhagen	Sitte, HH (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	harald.sitte@univie.ac.at	Sitte, Harald/O-7025-2019; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Scholze, Petra/0000-0003-4984-6034; Freissmuth, Michael/0000-0001-9398-1765; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER; NIDA NIH HHS [P01-DA-12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BERNEIS KH, 1969, NATURE, V224, P281, DOI 10.1038/224281a0; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CESURA AM, 1987, J NEUROCHEM, V49, P138, DOI 10.1111/j.1471-4159.1987.tb03405.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; FISCHER JF, 1979, J PHARMACOL EXP THER, V208, P203; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; FREDERICKSON CJ, 1984, NEUROLOGY NEUROBIOLO; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; HEXUM TD, 1974, BIOCHEM PHARMACOL, V23, P3441, DOI 10.1016/0006-2952(74)90347-5; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Iversen L, 2000, MOL PSYCHIATR, V5, P357, DOI 10.1038/sj.mp.4000728; JAVITCH JA, 1984, EUR J PHARMACOL, V106, P455, DOI 10.1016/0014-2999(84)90740-4; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LAUBE B, 1995, J PHYSIOL-LONDON, V483, P613, DOI 10.1113/jphysiol.1995.sp020610; LEVI G, 1993, TRENDS NEUROSCI, V16, P415, DOI 10.1016/0166-2236(93)90010-J; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; Pifl C, 1999, MOL PHARMACOL, V56, P1047, DOI 10.1124/mol.56.5.1047; PIFL C, 1995, MOL PHARMACOL, V47, P368; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RICHFIELD EK, 1993, MOL PHARMACOL, V43, P100; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2001, NEUROSCI LETT, V309, P173, DOI 10.1016/S0304-3940(01)02058-4; SEIDEN LS, 1993, ANNU REV PHARMACOL, V33, P639, DOI 10.1146/annurev.pa.33.040193.003231; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; VALENTA B, 1988, J PHARMACOL EXP THER, V245, P944; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0	44	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21505	21513		10.1074/jbc.M112265200	http://dx.doi.org/10.1074/jbc.M112265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940571	hybrid			2022-12-25	WOS:000176286000051
J	Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M				Folberg-Blum, A; Sapir, A; Shilo, BZ; Oren, M			Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila	ONCOGENE			English	Article						Mdm2; apoptosis; Drosophila	ONCOPROTEIN MDM2; P53-INDEPENDENT ROLE; S PHASE; P53; EXPRESSION; IDENTIFICATION; REGULATOR; CLEAVAGE; PROMOTES; HOMOLOG	The Mdm2 proto-oncogene is amplified and overexpressed in a variety of tumors. One of the major functions of Mdm2 described to date is its ability to modulate the levels and activity of the tumor suppressor protein p53. Mdm2 binds to the N-terminus of p53 and, through its action as an E3 ubiquitin ligase, targets p53 for rapid proteasomal degradation. Mdm2 can also bind to other cellular proteins such as hNumb, E2F1, Rb and Akt; however, the biological significance of these interactions is less clear. To gain insight into the function of Mdm2 in vivo, we have generated a transgenic Drosophila strain bearing the mouse Mdm2 gene. Ectopic expression of Mdm2, using the UAS/GAL4 system, causes eye and wing phenotypes in the fly. Analysis of wing imaginal discs from third instar larvae showed that expression of Mdm2 induces apoptosis. Crosses did not reveal genetic interactions between Mdm2 and the Drosophila homolog of E2F, Numb and Akt. These transgenic flies may provide a unique experimental model for exploring the molecular interactions of Mdm2 in a developmental context.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Sapir, Amir/C-5758-2015	Sapir, Amir/0000-0001-9888-1800; Oren, Moshe/0000-0003-4311-7172; Shilo, Ben Zion/0000-0003-4903-8889	NCI NIH HHS [R01 CA40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; CHANG HC, 1994, COLD SPRING HARB SYM, V59, P147, DOI 10.1101/SQB.1994.059.01.018; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; GOTTLIEB TM, 2002, IN PRESS ONCOGENE; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	37	22	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2413	2417		10.1038/sj.onc.1205305	http://dx.doi.org/10.1038/sj.onc.1205305			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948425				2022-12-25	WOS:000174635600014
J	Tasumi, S; Ohira, T; Kawazoe, I; Suetake, H; Suzuki, Y; Aida, K				Tasumi, S; Ohira, T; Kawazoe, I; Suetake, H; Suzuki, Y; Aida, K			Primary structure and characteristics of a lectin from skin mucus of the Japanese eel Anguilla japonica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CARBOHYDRATE-RECOGNITION DOMAIN; AMINO-ACID-SEQUENCE; C-TYPE LECTINS; CONGER-MYRIASTER; ANIMAL LECTINS; SERINE-PROTEASE; PURIFICATION; COMPLEMENT; GALECTINS	Two types of lactose-binding lectins, AJL-1 and AJL-2, were purified from the skin mucus extract of the Japanese eel Anguilla japonica by lactose,affinity chromatography and subsequent gel filtration. The molecular masses of AJL-1 and AJL-2 were 16,091 and 31,743 Da, respectively. Intact AJL-1 was comprised of two identical 16-kDa subunits having blocked N termini and no disulfide bonds. AJL-2 was a homodimer with, disulfide bonds. Based on the N-terminal amino acid sequence of the AJL-2 monomer, the nucleotide sequence of cDNA encoding this lectin was determined by 3'- and 5'-rapid amplification of cDNA ends. The deduced amino acid sequence showed similar to30% homology with C-type lectins, which bind to carbohydrates in a Ca2+-dependent manner. In addition, AJL-2 exhibited highly conserved consensus amino acid residues of the C-type carbohydrate recognition domain, although this lectin showed Ca2+ independent activity. Gene expression of AJL-2 was detected only in the skin by Northern blot analysis, and this lectin localization was demonstrated in the club cells by immunohistochemistry. These results indicate that AJL-2 is secreted on the body surface and function as a component of skin mucus. AJL-2 agglutinated Escherichia coli and suppressed its growth, suggesting that this lectin is involved in host defense.	Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan; Univ Tokyo, Grad Sch Agr & Agr Life Sci, Dept Aquat Biosci, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Suzuki, Y (corresponding author), Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan.			Tasumi, Satoshi/0000-0003-3047-6942				ALHASSAN JM, 1986, COMP BIOCHEM PHYS B, V85, P31, DOI 10.1016/0305-0491(86)90217-8; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GEWURZ H, 1995, CURR OPIN IMMUNOL, V7, P54, DOI 10.1016/0952-7915(95)80029-8; GIGA Y, 1987, J BIOL CHEM, V262, P6197; GOTONANCE R, 1995, FISHERIES SCI, V61, P137, DOI 10.2331/fishsci.61.137; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P2320; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; JI YH, 1993, J IMMUNOL, V150, P571; KAMIYA H, 1988, DEV COMP IMMUNOL, V12, P309, DOI 10.1016/0145-305X(88)90007-9; KAMIYA H, 1980, BIOCHIM BIOPHYS ACTA, V622, P171, DOI 10.1016/0005-2795(80)90028-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LIM BL, 1994, J BIOL CHEM, V269, P11820; MALHOTRA R, 1990, BIOCHEM SOC T, V18, P1145, DOI 10.1042/bst0181145; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Muramoto K, 1999, COMP BIOCHEM PHYS B, V123, P33, DOI 10.1016/S0305-0491(99)00037-1; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SASTRY K, 1991, J IMMUNOL, V147, P692; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHIOMI K, 1990, NIPPON SUISAN GAKK, V56, P119; SHIOMI K, 1989, COMP BIOCHEM PHYS B, V92, P255, DOI 10.1016/0305-0491(89)90275-7; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; SUZUKI Y, 1985, Nippon Suisan Gakkaishi, V51, P2083; SUZUKI Y, 1986, DEV COMP IMMUNOL, V10, P509, DOI 10.1016/0145-305X(86)90172-2; TAKAMATSU N, 1993, GENE, V128, P251; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TIFFOCHE C, 1993, EUR J BIOCHEM, V213, P901, DOI 10.1111/j.1432-1033.1993.tb17834.x; Toda M, 1996, FISHERIES SCI, V62, P138, DOI 10.2331/fishsci.62.138; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Yuasa HJ, 1998, COMP BIOCHEM PHYS B, V119, P479, DOI 10.1016/S0305-0491(98)00008-X	45	131	140	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	2002	277	30					27305	27311		10.1074/jbc.M202648200	http://dx.doi.org/10.1074/jbc.M202648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	577HR	11959866	hybrid			2022-12-25	WOS:000177055900078
J	Ternes, P; Franke, S; Zahringer, U; Sperling, P; Heinz, E				Ternes, P; Franke, S; Zahringer, U; Sperling, P; Heinz, E			Identification and characterization of a sphingolipid Delta 4-desaturase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; FATTY-ACID DESATURASE; SACCHAROMYCES-CEREVISIAE; DEGENERATIVE SPERMATOCYTE; OLEATE 12-HYDROXYLASE; SIGNAL-TRANSDUCTION; EGF RECEPTOR; GENE; BIOSYNTHESIS; SPHINGOSINE	Sphingolipids desaturated at the Delta4-position are important signaling molecules in many eukaryotic organisms, including mammals. In a bioinformatics approach, we now identified a new family of protein sequences from animals, plants, and fungi and characterized these sequences biochemically by expression in Saccharomyces cerevisiae. This resulted in the identification of the enzyme sphingolipid Delta4-desaturase (dihydroceramide desaturase) from Homo sapiens, Mus musculus, Drosophila melanogaster, and Candida albicans, in addition to a bifunctional sphingolipid Delta4-desaturase/C-4-hydroxylase from M. musculus. Among the sequences investigated are the Homo sapiens membrane lipid desaturase, the M. musculus degenerative spermatocyte, and the Drosophila melanogaster degenerative spermatocyte proteins. During spermatogenesis, but not oogenesis of des mutant flies, both cell cycle and spermatid differentiation are specifically blocked at the entry into the first meiotic division, leading to male sterility. This mutant phenotype can be restored to wild-type by complementation with a functional copy of the des gene (Endo, K., Akiyama, T., Kobayashi S., and Okada, M. (1996) Mol. Gen. Genet. 253, 157-165). These results suggest that Delta4-desaturated sphingolipids provide an early signal necessary to trigger the entry into both meiotic and spermatid differentiation pathways during Drosophila spermatogenesis.	Univ Hamburg, Inst Allgemeine Bot, D-22609 Hamburg, Germany; Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Forschungszentrum Borstel, Lab Grp Immunochem, D-23845 Borstel, Germany	University of Hamburg; University of Hamburg; Forschungszentrum Borstel	Heinz, E (corresponding author), Univ Hamburg, Inst Allgemeine Bot, Ohnhorstr 18, D-22609 Hamburg, Germany.			Ternes, Philipp/0000-0003-0886-5474				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Broadwater JA, 2002, J BIOL CHEM, V277, P15613, DOI 10.1074/jbc.M200231200; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Cadena DL, 1997, BIOCHEMISTRY-US, V36, P6960, DOI 10.1021/bi970091l; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Clancy MJ, 1998, CURR BIOL, V8, pR461, DOI 10.1016/S0960-9822(98)70293-3; CROSSMAN MW, 1984, BIOCHIM BIOPHYS ACTA, V795, P411, DOI 10.1016/0005-2760(84)90092-4; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Endo K, 1997, DEV GROWTH DIFFER, V39, P399, DOI 10.1046/j.1440-169X.1997.00015.x; Endo K, 1996, MOL GEN GENET, V253, P157, DOI 10.1007/s004380050308; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; Gurtu VE, 2002, GENETICS, V160, P271; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; KISIC A, 1995, J LIPID RES, V36, P787; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lin TY, 1996, DEVELOPMENT, V122, P1331; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; Napier JA, 1999, TRENDS PLANT SCI, V4, P2, DOI 10.1016/S1360-1385(98)01357-0; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Qiu X, 2001, J BIOL CHEM, V276, P31561, DOI 10.1074/jbc.M102971200; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sperling P, 2001, EUR J LIPID SCI TECH, V103, P158, DOI 10.1002/1438-9312(200103)103:3<158::AID-EJLT158>3.0.CO;2-1; Sperling P, 2001, FEBS LETT, V494, P90, DOI 10.1016/S0014-5793(01)02332-8; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1531, DOI 10.1515/bchm2.1971.352.2.1531; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TRECO DA, 1993, CURRENT PROTOCOLS MO; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743	46	202	216	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25512	25518		10.1074/jbc.M202947200	http://dx.doi.org/10.1074/jbc.M202947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11937514	hybrid			2022-12-25	WOS:000176747000087
J	D'Alonzo, RC; Kowalski, AJ; Denhardt, DT; Nickols, GA; Partridge, NC				D'Alonzo, RC; Kowalski, AJ; Denhardt, DT; Nickols, GA; Partridge, NC			Regulation of collagenase-3 and osteocalcin gene expression by collagen and osteopontin in differentiating MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST PHENOTYPE; PARATHYROID-HORMONE; BONE-RESORPTION; IN-VITRO; INTERSTITIAL COLLAGENASE; MESSENGER-RNA; PROGRESSIVE DEVELOPMENT; INTEGRIN EXPRESSION; ACTIVATOR PROTEIN-1; MATRIX PROTEINS	Both collagenase-3 and osteocalcin mRNAs are expressed maximally during the later stages of osteoblast differentiation. Here, we demonstrate that collagenase-3 mRNA expression in differentiating MC3T3-E1 cells is dependent upon the presence of ascorbic acid, is inhibited in the presence of the collagen synthesis inhibitor, 3,4-dehydroproline, and is stimulated by growth on collagen in the absence of ascorbic acid. Transient transfection studies show that collagenase-3 promoter activity increases during cell differentiation and requires the presence of ascorbic acid. Additionally, we show that, in differentiating MC3T3-E1 cells, collagenase-3 gene expression increases in the presence of an anti-osteopontin monoclonal antibody that binds near the RGD motif of this protein, whereas osteocalcin expression is inhibited. Furthermore, an RGD peptidomimetic compound, designed to block interaction of ligands to the alpha(v) integrin subunit, increases osteocalcin expression and inhibits collagenase-3 expression, suggesting that the RGD peptidomimetic initiates certain alpha(v) integrin signaling in osteoblastic cells. Overall, these studies demonstrate that stimulation of collagenase-3 expression during osteoblast differentiation requires synthesis of a collagenous matrix and that osteopontin and alpha(v) integrins exert divergent regulation of collagenase-3 and osteocalcin expression during osteoblast differentiation.	Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Pharmacia Co, Dept Arthrit & Inflammat Pharmacol, St Louis, MO 63198 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Pfizer	Partridge, NC (corresponding author), Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Ln, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu		Partridge, Nicola/0000-0002-5406-4814	NIAMS NIH HHS [AR44439] Funding Source: Medline; NIDDK NIH HHS [DK47420, DK48109, R01 DK047420] Funding Source: Medline; NIEHS NIH HHS [ESO6897] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047420, R01DK047420, R01DK048109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006897] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; Balbin M, 1998, J BIOL CHEM, V273, P23959, DOI 10.1074/jbc.273.37.23959; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Borden P, 1996, J BIOL CHEM, V271, P23577, DOI 10.1074/jbc.271.38.23577; Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756-3282(98)00092-1; Carron CP, 2000, J ENDOCRINOL, V165, P587, DOI 10.1677/joe.0.1650587; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; CLOVER J, 1992, J CELL SCI, V103, P267; Crippes BA, 1996, ENDOCRINOLOGY, V137, P918, DOI 10.1210/en.137.3.918; Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4; Davis BA, 1998, CALCIFIED TISSUE INT, V63, P416, DOI 10.1007/s002239900550; DELAISSE JM, 1988, ENDOCRINOLOGY, V123, P264, DOI 10.1210/endo-123-1-264; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTER LV, 1995, ENDOCRINOLOGY, V136, P528, DOI 10.1210/en.136.2.528; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEDA K, 1993, J CELL PHYSIOL, V156, P130, DOI 10.1002/jcp.1041560118; Ivaska J, 2000, CELL MOL LIFE SCI, V57, P16, DOI 10.1007/s000180050496; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; KIRK MD, 1995, J BONE MINER RES, V10, P1203; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; KUBOTA T, 1993, ARCH ORAL BIOL, V38, P23, DOI 10.1016/0003-9969(93)90150-K; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; LYNCH MP, 1995, EXP CELL RES, V216, P35, DOI 10.1006/excr.1995.1005; MASI L, 1992, CALCIFIED TISSUE INT, V51, P202, DOI 10.1007/BF00334548; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Miles RR, 1998, J CELL BIOCHEM, V68, P355, DOI 10.1002/(SICI)1097-4644(19980301)68:3<355::AID-JCB6>3.0.CO;2-T; Moursi AM, 1997, J CELL SCI, V110, P2187; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nanci A, 1999, J STRUCT BIOL, V126, P256, DOI 10.1006/jsbi.1999.4137; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PARTRIDGE NC, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P269; Partridge NC, 1996, CRIT REV EUKAR GENE, V6, P15, DOI 10.1615/CritRevEukarGeneExpr.v6.i1.20; Partridge Nicola C., 1996, P207; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Pistone M, 1996, CELL BIOL INT, V20, P471, DOI 10.1006/cbir.1996.0062; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; QUARLES LD, 1992, J BONE MINER RES, V7, P683; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Shapses SA, 2000, J BONE MINER RES, V15, pS474; Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749-6632.1995.tb44633.x; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; Winchester SK, 1999, J CELL PHYSIOL, V181, P479, DOI 10.1002/(SICI)1097-4652(199912)181:3<479::AID-JCP12>3.0.CO;2-D; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WONG GL, 1980, ARTHRITIS RHEUM, V23, P1081, DOI 10.1002/art.1780231003; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Yamada S, 1999, REV HETEROATOM CHEM, V19, P203; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	84	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24788	24798		10.1074/jbc.M202604200	http://dx.doi.org/10.1074/jbc.M202604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964409	hybrid			2022-12-25	WOS:000176611800106
J	Linseman, DA; McClure, ML; Bouchard, R; Laessig, TA; Ahmadi, FA; Heidenreich, KA				Linseman, DA; McClure, ML; Bouchard, R; Laessig, TA; Ahmadi, FA; Heidenreich, KA			Suppression of death receptor signaling in cerebellar Purkinje neurons protects neighboring granule neurons from apoptosis via an insulin-like growth factor I-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; CELL-DEATH; IGF-I; GENE-EXPRESSION; RAT CEREBELLUM; NERVOUS-SYSTEM; FAS LIGAND; SURVIVAL; BCL-2	Neuronal apoptosis contributes to the progression of neurodegenerative disease. Primary cerebellar granule neurons are an established in vitro model for investigating neuronal death. After removal of serum and depolarizing potassium, granule neurons undergo apoptosis via a mechanism that requires intrinsic (mitochondrial) death signals; however, the role of extrinsic (death receptor-mediated) signals is presently unclear. Here, we investigate involvement of death receptor signaling in granule neuron apoptosis by expressing adenoviral, AU1-tagged, dominant-negative Fas-associated death domain (Ad-AU1-DeltaFADD). Ad-AU1-DeltaFADD decreased apoptosis of granule neurons from 65 +/- 5 to 27 +/- 2% (n = 7, p < 0.01). Unexpectedly, immunocytochemical staining for AU1 revealed that <5% of granule neurons expressed DeltaFADD. In contrast, DeltaFADD was expressed in >95% of calbindin-positive Purkinje neurons (similar to2% of the cerebellar culture). Granule neurons in proximity to DeltaFADD-expressing Purkinje cells demonstrated markedly increased survival. Both granule and Purkinje neurons expressed insulin-like growth factor-I (IGF-I) receptors, and DeltaFADD-mediated survival of granule neurons was inhibited by an IGF-I receptor blocking antibody. These results demonstrate that the selective suppression of death receptor signaling in Purkinje neurons is sufficient to rescue neighboring granule neurons that depend on Purkinje cell-derived IGF-I. Thus, the extrinsic death pathway has a profound but indirect effect on the survival of cerebellar granule neurons.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80220 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Heidenreich, KA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E Ninth Ave, Denver, CO 80262 USA.		Linseman, Daniel/L-3846-2019		NINDS NIH HHS [NS38619-01A1] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON IK, 1988, ACTA PHYSIOL SCAND, V132, P167, DOI 10.1111/j.1748-1716.1988.tb08314.x; Baker NL, 1999, DEV BRAIN RES, V118, P109, DOI 10.1016/S0165-3806(99)00136-4; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BONDY CA, 1991, J NEUROSCI, V11, P3442; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHRISTAKOS S, 1987, METHOD ENZYMOL, V139, P534; Clarkson ED, 2001, EXP NEUROL, V168, P183, DOI 10.1006/exnr.2000.7593; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Doughty ML, 2000, J NEUROSCI, V20, P3687; Fan HB, 2001, J COMP NEUROL, V436, P82; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; GALLI C, 1995, J NEUROSCI, V15, P1172; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Ghoumari AM, 2000, EUR J NEUROSCI, V12, P2935, DOI 10.1046/j.1460-9568.2000.00186.x; Gleichmann M, 2000, NEUROSCI LETT, V282, P69, DOI 10.1016/S0304-3940(00)00857-0; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; HOCKBERGER PE, 1994, NEUROIMAGE, V1, P276, DOI 10.1006/nimg.1994.1012; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Lin X, 1997, DEV BRAIN RES, V99, P234, DOI 10.1016/S0165-3806(97)00015-1; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; Pinkoski MJ, 1999, CELL DEATH DIFFER, V6, P1174, DOI 10.1038/sj.cdd.4400611; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Selimi F, 2000, J NEUROSCI, V20, P992, DOI 10.1523/JNEUROSCI.20-03-00992.2000; Selimi F, 2000, J NEUROSCI, V20, P5339, DOI 10.1523/JNEUROSCI.20-14-05339.2000; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; VOGEL MW, 1995, J NEUROBIOL, V26, P537, DOI 10.1002/neu.480260407; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zanjani HS, 1996, J COMP NEUROL, V374, P332, DOI 10.1002/(SICI)1096-9861(19961021)374:3<332::AID-CNE2>3.0.CO;2-2; Zawada WM, 2001, BRAIN RES, V891, P185; Zhang W, 1997, DEV BRAIN RES, V98, P164, DOI 10.1016/S0165-3806(96)00168-X; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	52	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24546	24553		10.1074/jbc.M201098200	http://dx.doi.org/10.1074/jbc.M201098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964396	hybrid			2022-12-25	WOS:000176611800076
J	Zhang, WB; Navenot, JM; Haribabu, B; Tamamura, H; Hiramatu, K; Omagari, A; Pei, G; Manfredi, JP; Fujii, N; Broach, JR; Peiper, SC				Zhang, WB; Navenot, JM; Haribabu, B; Tamamura, H; Hiramatu, K; Omagari, A; Pei, G; Manfredi, JP; Fujii, N; Broach, JR; Peiper, SC			A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C axe weak partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; LYMPHOCYTE CHEMOATTRACTANT; CHEMOKINE RECEPTORS; INHIBITOR; LIGAND; SDF-1; PHOSPHORYLATION; IDENTIFICATION	CXCR4 is a G protein-coupled receptor for stromal-derived factor 1 (SDF-1) that plays a critical role in leukocyte trafficking, metastasis of mammary carcinoma, and human immunodeficiency virus type-1 infection. To elucidate the mechanism for CXCR4 activation, a constitutively active mutant (CAM) was derived by coupling the receptor to the pheromone response pathway in yeast. Conversion of Asn-119 to Ser or Ala, but not Asp or Lys, conferred autonomous CXCR4 signaling in yeast and mammalian cells. SDF-1 induced signaling in variants with substitution of Asn-119 to Ser, Ala, or Asp, but not Lys. These variants had similar cell surface expression and binding affinity for SDF-1. CXCR4-CAMs were constitutively phosphorylated and present in cytosolic inclusions. Analysis of antagonists revealed that exposure to AAM3100 or ALX40-4C induced G protein activation by CXCR4 wild type, which was greater in the CAM, whereas T140 decreased autonomous signaling. The affinity of AAM3100 and ALX40-4C binding to CAMs was less than to wild type, providing evidence of a conformational shift. These results illustrate the importance of transmembrane helix 3 in CXCR4 signaling. Insight into the mechanism for CXCR4 antagonists will allow for the development of a new generation of agents that lack partial agonist activity that may induce toxicities, as observed for AMD3100.	Univ Louisville, Henry Vogt Canc Res Inst, Louisville, KY 40202 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan; Chinese Acad Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Myriad Genet, Salt Lake City, UT 84108 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Louisville; Kyoto University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Myriad Genetics, Inc; Princeton University	Peiper, SC (corresponding author), Univ Louisville, Henry Vogt Canc Res Inst, Louisville, KY 40202 USA.	speiper@mail.mcg.edu	Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294; Broach, James/0000-0003-1197-0312	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041346] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI41346] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Arthos J, 2000, J VIROL, V74, P6418, DOI 10.1128/JVI.74.14.6418-6424.2000; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Gerlach LO, 2001, J BIOL CHEM, V276, P14153, DOI 10.1074/jbc.M010429200; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Klein C, 1998, NAT BIOTECHNOL, V16, P1334, DOI 10.1038/4310; Labrosse B, 1998, J VIROL, V72, P6381, DOI 10.1128/JVI.72.8.6381-6388.1998; Leeb-Lundberg LMF, 2001, J BIOL CHEM, V276, P8785, DOI 10.1074/jbc.M007396200; Liles WC, 2001, BLOOD, V98, p737A; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Navenot JM, 2001, J MOL BIOL, V313, P1181, DOI 10.1006/jmbi.2001.5086; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Petit I, 2001, BLOOD, V98, p811A; Quitterer U, 1996, BIOCHEMISTRY-US, V35, P13368, DOI 10.1021/bi961163w; REN Q, 1993, J BIOL CHEM, V268, P16483; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; Tao YX, 2000, MOL ENDOCRINOL, V14, P1272, DOI 10.1210/me.14.8.1272; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	39	208	217	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24515	24521		10.1074/jbc.M200889200	http://dx.doi.org/10.1074/jbc.M200889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11923301	hybrid			2022-12-25	WOS:000176611800072
J	Koipally, J; Georgopoulos, K				Koipally, J; Georgopoulos, K			Ikaros-CtIP interactions do not require C-terminal binding protein and participate in a deacetylase-independent mode of repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; CTBP; BRCA1; GENE; COREPRESSOR; MECHANISM; FAMILY; EXPRESSION; COMPLEXES	Ikaros and Aiolos are Kruppel zinc finger proteins that play key roles in hemo-lymphoid development and homeostasis. We have previously shown that they can repress transcription through the recruitment of histone deacetylases (HDACs). Here, we provide the first functional evidence that these proteins can also repress gene function in a manner that does not require deacetylase activity. This functionality can be attributed in part to Ikaros interactions with the HDAC-independent corepressor, C-terminal binding protein (CtBP). However, mutations that block Ikaros-CtBP interactions do not abolish Ikaros's repression activity, implicating the involvement of additional corepressors. Consistent with this expectation, we show that Ikaros can interact with a CtBP-interacting protein (CUP), which has also been linked to a deacetylase-independent strategy of repression. Despite being a CtBP interactor, CUP's association with Ikaros does not require CtBP but instead relies upon its Rb interaction domain. Significantly, Ikaros can interact with Rb, which itself can repress gene function in a deacetylase-independent manner. A mutation in Ikaros that abrogates CUP interactions significantly reduces repression, and a double mutation that prevents interaction with both CtIP and CtBP even further alleviates repression. Finally, we show that CtIP and CtBP can interact with the general transcription factors, TATA binding protein and transcription factor IIB, which suggests a possible mechanism for their deacetylase-independent mode of repression.	Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Med Sch, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Georgopoulos, K (corresponding author), Massachusetts Gen Hosp East, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	katia.georgopoulos@cbrc2.mgh.harvard.edu			NIAID NIH HHS [R01-AI380342] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Courey AJ, 2001, GENE DEV, V15, P2786; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang QH, 2002, SCIENCE, V295, P1895; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	42	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23143	23149		10.1074/jbc.M202079200	http://dx.doi.org/10.1074/jbc.M202079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959865	hybrid			2022-12-25	WOS:000176475700008
J	Hoffmeister, A; Ropolo, A; Vasseur, S; Mallo, GV; Bodeker, H; Ritz-Laser, B; Dressler, GR; Vaccaro, MI; Dagorn, JC; Moreno, S; Iovanna, JL				Hoffmeister, A; Ropolo, A; Vasseur, S; Mallo, GV; Bodeker, H; Ritz-Laser, B; Dressler, GR; Vaccaro, MI; Dagorn, JC; Moreno, S; Iovanna, JL			The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXPRESSION; ACTIVATION; CLONING; PANCREAS	p8 is a nuclear DNA-binding protein, which was identified because its expression is strongly activated in response to several stresses. Biochemical and biophysical studies revealed that despite a weak sequence homology p8 is an HMG-I/Y-like protein, suggesting that p8 may be involved in transcription regulation. Results reported here strongly support this hypothesis. Using a pull-down approach, we found that p8 interacts with the general co-activator p300. We also found that, similar to the HMG proteins, p300 was able to acetylate recombinant p8 in vitro, although the significance of such modification remains to be determined. Then a screening by the two-hybrid system, using p8 as bait, allowed us to identify the Pax2 trans-activation domain-interacting protein (PTIP) as another partner of p8. Transient transfection studies revealed that PTIP is a strong inhibitor of the trans-activation activities of Pax2A and Pax2B on the glucagon gene promoter, which was chosen as a model because it is a target of the Pax2A and Pax2B transcription factors. This effect is completely abolished by co-transfection of p8 in glucagon-producing InRIG9 cells, indicating that p8 binding to PTIP prevents inhibition of the glucagon gene promoter. This was not observed in NIH3T3 fibroblasts that do not express glucagon. Finally, expression of p8 enhances the effect of p300 on Pax2A and Pax2B transactivation of the glucagon gene promoter. These observations suggest that in glucagon-producing cells p8 is a positive cofactor of the activation of the glucagon gene promoter by Pax2A and Pax2B, both by recruiting the p300 cofactor to increase the Pax2A and Pax2B activities and by binding the Pax2,interacting protein PTIP to suppress its inhibition.	INSERM, EMI 0116, Ctr Rech, F-13276 Marseille 9, France; Univ Buenos Aires, Fac Med, Dept Fisiol, RA-1121 Buenos Aires, DF, Argentina; Ctr Med Univ Geneva, Diabet Unit, CH-1211 Geneva 4, Switzerland; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Buenos Aires; University of Geneva; University of Michigan System; University of Michigan; University of Buenos Aires	Iovanna, JL (corresponding author), INSERM, EMI 116, Ctr Rech, 163 Ave Luminy,Campus Luminy,BP 172, F-13009 Marseille, France.	iovanna@inserm-adr.univ-mrs.fr	Iovanna, Juan/M-9805-2017; Vaccaro, Maria I./L-8348-2017; vasseur, sophie/O-9803-2017	Iovanna, Juan/0000-0003-1822-2237; vasseur, sophie/0000-0002-2339-8854; Vaccaro, Maria/0000-0002-2456-747X				ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Garcia-Montero A, 2001, EUR J CELL BIOL, V80, P720, DOI 10.1078/0171-9335-00209; Garcia-Montero AC, 2001, BIOCHEM J, V357, P249, DOI 10.1042/0264-6021:3570249; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lechner MS, 1996, J BIOL CHEM, V271, P21088, DOI 10.1074/jbc.271.35.21088; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Ree AH, 1999, CANCER RES, V59, P4675; Ritz-Laser B, 2000, J BIOL CHEM, V275, P32708, DOI 10.1074/jbc.M005704200; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200	16	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22314	22319		10.1074/jbc.M201657200	http://dx.doi.org/10.1074/jbc.M201657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940591	hybrid			2022-12-25	WOS:000176313600027
J	Lawrence, AJ; Coote, JG; Kazi, YF; Lawrence, PD; MacDonald-Fyall, J; Orr, BM; Parton, R; Riehle, M; Sinclair, J; Young, J; Price, NC				Lawrence, AJ; Coote, JG; Kazi, YF; Lawrence, PD; MacDonald-Fyall, J; Orr, BM; Parton, R; Riehle, M; Sinclair, J; Young, J; Price, NC			A direct pyrophosphatase-coupled assay provides new insights into the activation of the secreted adenylate cyclase from Bordetella pertussis by calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN; PURIFICATION; IDENTIFICATION; BINDING; TRANSFERASE; PROTEINS; CA-2+; SITE	Continuous recording of the activity of recombinant adenylate cyclase (CyaA) of Bordetella pertussis (EC 4.6.1.1) by conductimetric determination of enzyme-coupled pyrophosphate cleavage has enabled us to define a number of novel features of the activation of this enzyme by calmodulin and establish conditions under which valid activation data can be obtained. Activation either in the presence or absence of calcium is characterized by a concentration-dependent lag phase. The rate of formation and breakdown of the activated complex can be determined from an analysis of the lag phase kinetics and is in good agreement with thermodynamic data obtained by measuring the dependence of activation on calmodulin concentration, which show that calcium increases k(on). by about 30-fold. The rate of breakdown of the activated complex, formed either in the presence or absence of calcium, has been determined by dilution experiments and has been shown to be independent of the presence of calcium. The coupled assay is established as a rapid, convenient and safe method which should be readily applicable to the continuous assays of most other enzymes that catalyze reactions in which inorganic pyrophosphate is liberated.	Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Ctr Cell Engn, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Lawrence, AJ (corresponding author), Univ Glasgow, Div Infect & Immun, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.		Hu, Ruogu/B-2203-2008; Riehle, Mathis O/A-3427-2011; Riehle, Mathis/Q-4528-2019	Riehle, Mathis O/0000-0001-7988-1514; Riehle, Mathis/0000-0001-7988-1514				BESSON C, 1994, ANAL CHIM ACTA, V294, P305, DOI 10.1016/0003-2670(94)80314-5; COOTE JG, 1992, FEMS MICROBIOL LETT, V88, P137, DOI 10.1016/0378-1097(92)90688-K; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; Fersht A., 1999, STRUCTURE MECH PROTE, P143; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GOLDHAMMER AR, 1983, ANAL BIOCHEM, V124, P45; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HEWLETT EL, 1979, J BIOL CHEM, V254, P5602; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; Hormozi K, 1999, FEMS IMMUNOL MED MIC, V23, P273, DOI 10.1016/S0928-8244(98)00146-1; KILHOFFER MC, 1983, EUR J BIOCHEM, V133, P111; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; Lawrence A, 1998, BIOCHEM EDUC, V26, P56, DOI 10.1016/S0307-4412(97)00129-5; LAWRENCE AJ, 1972, EUR J BIOCHEM, V24, P538, DOI 10.1111/j.1432-1033.1972.tb19716.x; MASURE HR, 1988, J BIOL CHEM, V263, P6933; MEZNA M, 1994, ANAL BIOCHEM, V218, P370, DOI 10.1006/abio.1994.1194; Mock M, 1993, Trends Microbiol, V1, P187, DOI 10.1016/0966-842X(93)90089-A; MONNERON A, 1988, BIOCHEMISTRY-US, V27, P536, DOI 10.1021/bi00402a005; NAGAI M, 1994, FEMS MICROBIOL LETT, V116, P169, DOI 10.1111/j.1574-6968.1994.tb06696.x; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Tu XL, 2001, FEMS MICROBIOL LETT, V205, P119, DOI 10.1111/j.1574-6968.2001.tb10934.x; Westrop GD, 1996, GENE, V180, P91, DOI 10.1016/S0378-1119(96)00412-X; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	28	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22289	22296		10.1074/jbc.M106701200	http://dx.doi.org/10.1074/jbc.M106701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11934879	hybrid			2022-12-25	WOS:000176313600024
J	Linden, D; Lindberg, K; Oscarsson, J; Claesson, C; Asp, L; Li, L; Gustafsson, M; Boren, J; Olofsson, SO				Linden, D; Lindberg, K; Oscarsson, J; Claesson, C; Asp, L; Li, L; Gustafsson, M; Boren, J; Olofsson, SO			Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; HEP G2 CELLS; TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; CULTURED RAT HEPATOCYTES; LOW-DENSITY LIPOPROTEINS; CHAIN FATTY-ACIDS; GROWTH-HORMONE; GENE-EXPRESSION; B-100-CONTAINING LIPOPROTEINS	The peroxisome proliferator-activated receptor (PPAR) alpha agonist WY 14,643 increased the secretion of apolipoprotein (apo) B-100, but not that of apoB-48, and decreased triglyceride biosynthesis and secretion from primary rat hepatocytes. These effects resulted in decreased secretion of apoB-100-very low density lipoprotein (VLDL) and an increased secretion of apoB-100 on low density lipoproteins/intermediate density lipoproteins. ApoB-48-VLDL was also replaced by more dense particles. The proteasomal inhibitor lactacystin did not influence the recovery of apoB-100 or apoB-48 in primary rat hepatocytes, indicating that co-translational (proteasomal) degradation is of less importance in these cells. Treatment with WY 14,643 made the recovery of apoB-100 sensitive to lactacystin, most likely reflecting the decreased biosynthesis of triglycerides. The PPARalpha agonist induced a significant increase in the accumulation of pulse-labeled apoB-100 even after a short pulse (2-5 min). There was also an increase in apoB-100 nascent polypeptides, indicating that the co-translational degradation of apoB-100 was inhibited. However, a minor influence on an early posttranslation degradation cannot be excluded. This decreased co-translational degradation of apoB-100 explained the increased secretion of the protein. The levels of apoB-48 remained unchanged during these pulse-chase experiments, and albumin production was not affected, indicating a specific effect of PPARalpha agonists on the co-translational degradation of apoB-100. These findings explain the difference in the rate of secretion of the two apoB proteins seen after PPARalpha activation. PPARalpha agonists increased the expression and biosynthesis of liver fatty acid-binding protein (LFABP). Increased expression of LFABP by transfection of McA-RH7777 cells increased the secretion of apoB-100, decreased triglyceride biosynthesis and secretion, and increased PPARalpha mRNA levels. These findings suggest that PPARalpha and LFABP could interact to amplify the effect of endogenous PPARalpha agonists on the assembly of VLDL.	Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Physiol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Wallenberg Lab Cardiovasc Res, SE-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Olofsson, SO (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, SE-40530 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011	Andersson, Karin/0000-0002-9475-3040				Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ANDERSSON M, 1994, J LIPID RES, V35, P535; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1034, P53, DOI 10.1016/0304-4165(90)90152-M; BURRIER RE, 1987, BIOCHIM BIOPHYS ACTA, V919, P221, DOI 10.1016/0005-2760(87)90261-X; Carlsson L, 2001, AM J PHYSIOL-ENDOC M, V281, pE772, DOI 10.1152/ajpendo.2001.281.4.E772; Carlsson L, 1998, ENDOCRINOLOGY, V139, P2699, DOI 10.1210/en.139.6.2699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAMB RG, 1993, BIOCHIM BIOPHYS ACTA, V1165, P299, DOI 10.1016/0005-2760(93)90140-5; Lawrence JW, 2000, J LIPID RES, V41, P1390; Leung KC, 1997, J CLIN ENDOCR METAB, V82, P4208, DOI 10.1210/jc.82.12.4208; Linden D, 2000, AM J PHYSIOL-ENDOC M, V279, pE1335, DOI 10.1152/ajpendo.2000.279.6.E1335; Luxon BA, 1999, AM J PHYSIOL-GASTR L, V277, pG361, DOI 10.1152/ajpgi.1999.277.2.G361; Luxon BA, 2000, BBA-MOL CELL BIOL L, V1487, P309, DOI 10.1016/S1388-1981(00)00104-9; Luxon BA, 1996, AM J PHYSIOL-GASTR L, V271, pG113, DOI 10.1152/ajpgi.1996.271.1.G113; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; McArthur MJ, 1999, J LIPID RES, V40, P1371; MeunierDurmort C, 1996, BIOCHEM J, V319, P483, DOI 10.1042/bj3190483; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; MOON A, 1987, J CLIN INVEST, V79, P59, DOI 10.1172/JCI112808; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Niot I, 1997, BIOCHIMIE, V79, P129, DOI 10.1016/S0300-9084(97)81504-0; Okochi E, 1999, BBA-MOL CELL BIOL L, V1437, P393, DOI 10.1016/S1388-1981(99)00024-4; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; PIND S, 1993, METHOD ENZYMOL, V221, P222, DOI 10.1016/0076-6879(93)21019-5; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Rees S, 1996, BIOTECHNIQUES, V20, P102; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Schoonjans K, 1996, J LIPID RES, V37, P907; Sjoberg A, 1996, J LIPID RES, V37, P275; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Taskinen MR, 2001, EXP CLIN ENDOCR DIAB, V109, pS180, DOI 10.1055/s-2001-18580; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898	52	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23044	23053		10.1074/jbc.M110416200	http://dx.doi.org/10.1074/jbc.M110416200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11925428	hybrid			2022-12-25	WOS:000176313600120
J	Abu Dayyeh, BK; Quan, TK; Castro, M; Ruby, SW				Abu Dayyeh, BK; Quan, TK; Castro, M; Ruby, SW			Probing interactions between the U2 small nuclear ribonucleoprotein and the DEAD-box protein, Prp5.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION FACTOR-4A; RNA-DEPENDENT ATPASE; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; YEAST HOMOLOG; BRANCHPOINT RECOGNITION; FACTOR 4A; MESSENGER; SPLICEOSOME; SNRNP	Pre-mRNA binding to the yeast U2 small nuclear ribonucleoprotein (snRNP) during prespliceosome formation requires ATP hydrolysis, the highly conserved UACUAAC box of the branch point region of the pre-mRNA, and several factors. Here we analyzed the binding of a radiolabeled 2'-O-methyl oligonucleotide complementary to U2 small nuclear RNA to study interactions between the UACUAAC box, U2 snRNP, and Prp5p, a DEAD box protein necessary for prespliceosome formation. Binding of the 2'-O-methyl oligonucleotide to the U2 snRNP in yeast cell extract was assayed by gel electrophoresis. Binding was rapid, enhanced by ATP, and dependent on the integrity and conformation of the U2 snRNP. It was also stimulated by Prp5p that was found to associate physically with U2 snRNP. In vitro heat inactivation of the temperature-sensitive prp5-1 mutant extract decreased oligonucleotide binding to U2 and the ATP enhancement of binding by 3-fold. Furthermore, the temperature-sensitive prp5-1 mutation maps to the ATP-binding motif I within the helicase-like domain. Thus the catalytic activity of Prp5p likely promotes a conformational change in the U2 snRNP.	Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Ruby, SW (corresponding author), Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Mol Genet & Microbiol, 900 Camino Salud NE, Albuquerque, NM 87131 USA.	sruby@unm.edu						ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; [Anonymous], 1991, Methods Enzymol, V194, P1; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; Ast G, 1997, RNA, V3, P371; Ast G, 2001, NUCLEIC ACIDS RES, V29, P1741, DOI 10.1093/nar/29.8.1741; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; BARABINO SML, 1992, NUCLEIC ACIDS RES, V20, P4457, DOI 10.1093/nar/20.17.4457; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Burge CB, 1999, RNA WORLD, P525; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; Cody R.P., 1991, APPL STAT SAS PROGRA; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V20, P3625, DOI 10.1093/nar/20.14.3625; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Farabaugh PJ, 2000, PROG NUCLEIC ACID RE, V64, P131, DOI 10.1016/S0079-6603(00)64004-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gottschalk A, 2001, RNA, V7, P1554; Guth S, 2000, J BIOL CHEM, V275, P38059, DOI 10.1074/jbc.M001483200; Hotz HR, 1998, GENETICS, V149, P807; Igel H, 1998, RNA, V4, P1; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIM SH, 1993, P NATL ACAD SCI USA, V90, P888, DOI 10.1073/pnas.90.3.888; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A, 1999, J CELL BIOL, V145, P1355, DOI 10.1083/jcb.145.7.1355; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LESSER CF, 1993, GENETICS, V133, P851; LIAO XLC, 1992, NUCLEIC ACIDS RES, V20, P4237, DOI 10.1093/nar/20.16.4237; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; LUSTIG AJ, 1986, CELL, V47, P953, DOI 10.1016/0092-8674(86)90810-X; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; NEWHAM CM, 2001, RNA NEW YORK, V7, P1298; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Pauling MH, 2000, MOL CELL BIOL, V20, P2176, DOI 10.1128/MCB.20.6.2176-2185.2000; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Perriman R, 2000, GENE DEV, V14, P97; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Ruby SW, 1997, J BIOL CHEM, V272, P17333, DOI 10.1074/jbc.272.28.17333; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; Ruby SW, 1999, METH MOL B, V118, P365; Ruby SW, 1999, METH MOL B, V118, P323; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; Rutz B, 1999, RNA, V5, P819, DOI 10.1017/S1355838299982286; RYMOND BC, 1990, METHOD ENZYMOL, V181, P122; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; Sambrook J, 1989, MOL CLONING; SCHMID SR, 1991, MOL CELL BIOL, V11, P3463, DOI 10.1128/MCB.11.7.3463; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WELLS SE, 1994, MOL CELL BIOL, V14, P6337, DOI 10.1128/MCB.14.9.6337; Wells SE, 1996, GENE DEV, V10, P220, DOI 10.1101/gad.10.2.220; Wiest DK, 1996, J BIOL CHEM, V271, P33268, DOI 10.1074/jbc.271.52.33268; Will CL, 2001, SCIENCE, V291, P1916, DOI 10.1126/science.1059682; Winer B.J., 1991, STAT PRINCIPLES EXPT; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; Yan D, 1998, MOL CELL BIOL, V18, P5000, DOI 10.1128/MCB.18.9.5000; Yan D, 1996, MOL CELL BIOL, V16, P818; ZAVANELLI MI, 1994, MOL CELL BIOL, V14, P1689, DOI 10.1128/MCB.14.3.1689; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhou W, 2001, P NATL ACAD SCI USA, V98, P1531, DOI 10.1073/pnas.98.4.1531	86	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20221	20233		10.1074/jbc.M109553200	http://dx.doi.org/10.1074/jbc.M109553200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927574	hybrid			2022-12-25	WOS:000176204500018
J	Austin, J; First, EA				Austin, J; First, EA			Potassium functionally replaces the second lysine of the KMSKS signature sequence in human tyrosyl-tRNA synthetase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; SP I; INHIBITOR; CATALYSIS; AMINOACYLATION; FERMENTATION; MECHANISM; SB-219383; BACTERIA	Unlike their bacterial homologues, a number of eukaryotic tyrosyl-tRNA synthetases require potassium to catalyze the aminoacylation reaction. In addition, the second lysine in the class I-specific KMSKS signature motif is absent from all known eukaryotic tyrosyl-tRNA synthetase sequences, except those of higher plants. This lysine, which is the most highly conserved residue in the class I aminoacyl-tRNA synthetase family, has been shown to interact with the pyrophosphate moiety of the ATP substrate in the Bacillus stearothermophilus tyrosyl-tRNA synthetase. Equilibrium dialysis and pre-steady-state kinetic analyses were used to determine the role that potassium plays in the tyrosine activation reaction in the human tyrosyl-tRNA synthetase and whether it can be replaced by any of the other alkali metals. Kinetic analyses indicate that potassium interacts with the pyrophosphate moiety of ATP, stabilizing the E.Tyr.ATP and E.[Tyr-ATP](double dagger) complexes by 2.3 and 4.3 kcal/mol, respectively. Potassium also appears to stabilize the asymmetric conformation of the human tyrosyl-tRNA synthetase dimer by 0.7 kcal/mol. Rubidium is the only other alkali metal that can replace potassium in catalyzing tyrosine activation, although the forward rate constant is half of that observed when potassium is present. The above results are consistent with the hypothesis that potassium functionally replaces the second lysine in the KMSKS signature sequence. Possible implications of these results with respect to the design of antibiotics that target bacterial aminoacyl-tRNA synthetases are discussed.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	First, EA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053693, F31GM020928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53693, GM20928-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin J, 2002, J BIOL CHEM, V277, P14812, DOI 10.1074/jbc.M103396200; BEIKIRCH H, 1972, EUR J BIOCHEM, V26, P182, DOI 10.1111/j.1432-1033.1972.tb01755.x; Brown MJB, 2000, BIOCHEMISTRY-US, V39, P6003, DOI 10.1021/bi000148v; Bush K, 1997, CURR OPIN CHEM BIOL, V1, P169, DOI 10.1016/S1367-5931(97)80006-3; CAPOBIANCO JO, 1989, ANTIMICROB AGENTS CH, V33, P156, DOI 10.1128/AAC.33.2.156; Cotton F.A., 1972, ADV INORG CHEM, P52; ENGEL PC, 1996, ENZYMOLOGY LABFAX, P200; FARMER TH, 1992, J ANTIMICROB CHEMOTH, V30, P587, DOI 10.1093/jac/30.5.587; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; FIRST EA, 1998, COMPREHENSIVE BIOL C, V1, P573; FISHER PA, 1976, BIOCHEMISTRY-US, V15, P4065, DOI 10.1021/bi00663a023; Houge-Frydrych CSV, 2000, J ANTIBIOT, V53, P351, DOI 10.7164/antibiotics.53.351; Kirillov S, 1997, RNA, V3, P905; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KOCH GLE, 1974, NATURE, V249, P316, DOI 10.1038/249316a0; KOCH GLE, 1974, BIOCHEMISTRY-US, V13, P2307, DOI 10.1021/bi00708a011; LODISH H, 1995, MOL CELL BIOL, P640; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; QUIVY JP, 1988, J BIOL CHEM, V263, P15277; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Stefanska AL, 2000, J ANTIBIOT, V53, P345, DOI 10.7164/antibiotics.53.345; Stefanska AL, 2000, J ANTIBIOT, V53, P357, DOI 10.7164/antibiotics.53.357; Stefanska AL, 2000, J ANTIBIOT, V53, P1346, DOI 10.7164/antibiotics.53.1346; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; WELLS TNC, 1991, BIOCHEMISTRY-US, V30, P5151, DOI 10.1021/bi00235a006; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	34	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20243	20248		10.1074/jbc.M201923200	http://dx.doi.org/10.1074/jbc.M201923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927599	hybrid			2022-12-25	WOS:000176204500020
J	Clyne, CD; Speed, CJ; Zhou, J; Simpson, ER				Clyne, CD; Speed, CJ; Zhou, J; Simpson, ER			Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE STROMAL CELLS; ORPHAN NUCLEAR RECEPTOR; BREAST-CANCER PATIENTS; TISSUE-SPECIFIC EXPRESSION; P450 CYP19 GENE; ESTROGEN BIOSYNTHESIS; TRANSCRIPTION FACTOR; PROXIMAL PROMOTER; HORMONE-RECEPTOR; CYTOCHROME-P450	Estrogen biosynthesis from C-19 steroids is catalyzed by aromatase cytochrome P450. Aromatase is expressed in breast adipose tissue through the use of a distal, cytokine-responsive promoter (promoter 1.4). Breast tumors, however, secrete soluble factors that stimulate aromatase expression through an alternative proximal promoter, promoter II. In other estrogenic tissues such as ovaries, transcription from promoter II requires the presence of the Ftz-F1 homologue steroidogenic factor-1 (SF-1); adipose tissue, however, does not express SF-1. We have explored the hypothesis that in adipose tissue, an alternative Ftz-F1 family member, liver receptor homologue-1 (LRH-1), substitutes for SF-1 in driving transcription from promoter II. In transient transfection assays using 3T3-L1 preadipocytes, promoter II reporter constructs were modestly (2-3-fold) stimulated by either treatment with activators of protein kinases A or C (PKA/C) or by cotransfection with LRH-1. In combination, these treatments synergistically activated promoter II (>30-fold). Induction by LRH-1 (but not PKA/C) required an AGGTCA motif at -130 base pair to which LRH-1 bound in gel shift assays. Activity of GAL4-LRH-1 fusion proteins was not altered by activators of PKA or PKC. Quantitative real-time PCR revealed that LRH-1 (but not SF-1) is expressed in the preadipocyte fraction of human adipose tissue at levels comparable with that of liver. Differentiation of cultured human preadipocytes into mature adipocytes was associated with a time-dependent induction of peroxisome proliferator-activated receptor-gamma (PPARgamma), an rapid loss of LRH-1 and aromatase expression. We conclude that LRH-1 is a preadipocyte-specific nuclear receptor that regulates expression of aromatase in adipose tissue. Alterations in LRH-1 expression and/or activity in adipose tissue could therefore have considerable effects on local estrogen production and breast cancer development.	Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research	Clyne, CD (corresponding author), Prince Henrys Inst Med Res, 246 Clayton Rd, Clayton, Vic 3168, Australia.	Colin.Clyne@med.monash.edu.au						ACKERMAN GE, 1981, J CLIN ENDOCR METAB, V53, P412, DOI 10.1210/jcem-53-2-412; Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Auwerx J, 1999, CELL, V97, P161; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; BULUN SE, 1994, BREAST CANCER RES TR, V30, P19, DOI 10.1007/BF00682738; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CASTILLOOLIVARE.A, 2000, J BIOL CHEM, V275, P17793; CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Harada N, 1997, J STEROID BIOCHEM, V61, P175; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; HARADA N, 1990, BIOCHEM BIOPH RES CO, V166, P365, DOI 10.1016/0006-291X(90)91954-Q; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MEANS GD, 1989, J BIOL CHEM, V264, P19385; Michael MD, 1997, MOL CELL ENDOCRINOL, V134, P147, DOI 10.1016/S0303-7207(97)00178-0; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Munster P N, 2001, Cancer Control, V8, P478; Murata Y, 2000, ONCOL REP, V7, P1299; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Okubo T, 2001, CANCER RES, V61, P1338; Paganini-Hill A, 2000, BREAST CANCER RES TR, V64, P165, DOI 10.1023/A:1006426132338; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PINTO HC, 1995, J HEPATOL, V23, P95, DOI 10.1016/0168-8278(95)80316-5; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shamay M, 2001, ONCOGENE, V20, P6811, DOI 10.1038/sj.onc.1204879; Shozu M, 1998, MOL CELL ENDOCRINOL, V139, P117, DOI 10.1016/S0303-7207(98)00069-0; SIITERI PK, 1973, HDB PHYSL, P619; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; SIMPSON ER, 1994, ENDOCR REV, V15, P342, DOI 10.1210/er.15.3.342; Simpson ER, 1997, RECENT PROG HORM RES, V52, P185; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; STEINKAMPF MP, 1987, MOL ENDOCRINOL, V1, P465, DOI 10.1210/mend-1-7-465; Sun TJ, 1998, ENDOCRINOLOGY, V139, P1684, DOI 10.1210/en.139.4.1684; THORSEN T, 1982, EUR J CANCER CLIN ON, V18, P333, DOI 10.1016/0277-5379(82)90002-5; TODA K, 1993, EUR J BIOCHEM, V213, P383, DOI 10.1111/j.1432-1033.1993.tb17772.x; TODA K, 1990, EUR J BIOCHEM, V193, P559, DOI 10.1111/j.1432-1033.1990.tb19372.x; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VANLANDEGHEM AAJ, 1985, CANCER RES, V45, P2900; Wang ZN, 2001, J MOL ENDOCRINOL, V27, P255, DOI 10.1677/jme.0.0270255; Yang C, 1998, CANCER RES, V58, P5695; Zhang CK, 2001, GENE, V273, P239, DOI 10.1016/S0378-1119(01)00586-8; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449; Zhao Y, 1997, J STEROID BIOCHEM, V61, P203, DOI 10.1016/S0960-0760(97)80013-1; Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350; Zhou DJ, 1997, J STEROID BIOCHEM, V61, P273	59	202	206	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20591	20597		10.1074/jbc.M201117200	http://dx.doi.org/10.1074/jbc.M201117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927588	hybrid			2022-12-25	WOS:000176204500064
J	LeClere, S; Tellez, R; Rampey, RA; Matsuda, SPT; Bartel, B				LeClere, S; Tellez, R; Rampey, RA; Matsuda, SPT; Bartel, B			Characterization of a family of IAA-amino acid conjugate hydrolases from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-MAX L; INDOLEACETIC-ACID; QUANTITATIVE-ANALYSIS; PHASEOLUS-VULGARIS; ESCHERICHIA-COLI; PLANT-TISSUES; GENE; IDENTIFICATION; THALIANA; AMIDOHYDROLASE	The mechanisms by which plants regulate levels of the phytohormone indole-3-acetic acid (IAA) are complex and not fully understood. One level of regulation appears to be the synthesis and hydrolysis of IAA conjugates, which function in both the permanent inactivation and temporary storage of auxin. Similar to free LAA certain LAA-amino acid conjugates inhibit root elongation. We have tested the ability of 19 IAA-L-amino acid conjugates to inhibit Arabidopsis seedling root growth. We have also determined the ability of purified glutathione S-transferase (GST) fusions of four Arabidopsis IAA-amino acid hydrolases (ILR1, LAM, ILL1, and ILL2) to release free IAA by cleaving these conjugates. Each hydrolase cleaves a subset of IAA-amino acid conjugates in vitro, and GST-ILR1, GST-IAR3, and GST-ILL2 have K-m values that suggest physiological relevance. In vivo inhibition of root elongation correlates with in vitro hydrolysis rates for each conjugate, suggesting that the identified hydrolases generate the bioactivity of the conjugates.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Rice University; Rice University	Bartel, B (corresponding author), Rice Univ, Dept Biochem & Cell Biol, 6100 S Main St, Houston, TX 77005 USA.	bartel@rice.edu	Bartel, Bonnie/O-8119-2019; Bartel, Bonnie/D-3550-2011	Bartel, Bonnie/0000-0002-6367-346X; Bartel, Bonnie/0000-0002-6367-346X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008362, R29GM054749] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29 GM054749-04, R29 GM054749-05, R29 GM54749, T32 GM08362] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barlier I, 2000, P NATL ACAD SCI USA, V97, P14819, DOI 10.1073/pnas.260502697; BARTEL B, 1995, SCIENCE, V268, P1745, DOI 10.1126/science.7792599; Bartel B, 2001, J PLANT GROWTH REGUL, V20, P198, DOI 10.1007/s003440010025; BIALEK K, 1986, PLANT PHYSIOL, V80, P99, DOI 10.1104/pp.80.1.99; BIALEK K, 1983, PLANT PHYSIOL, V73, P130, DOI 10.1104/pp.73.1.130; BIALEK K, 1992, PLANT PHYSIOL, V100, P2002, DOI 10.1104/pp.100.4.2002; Campanella JJ, 1996, PLANT PHYSIOL, V112, P735, DOI 10.1104/pp.112.2.735; Chou JC, 1996, PLANT PHYSIOL, V112, P1281, DOI 10.1104/pp.112.3.1281; Chou JC, 1998, MOL GEN GENET, V259, P172, DOI 10.1007/s004380050802; COHEN JD, 1982, PLANT PHYSIOL, V70, P749, DOI 10.1104/pp.70.3.749; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COLOMBO S, 1995, J BACTERIOL, V177, P5561, DOI 10.1128/jb.177.19.5561-5566.1995; Davies Peter J., 1995, P1; Davies RT, 1999, PLANT CELL, V11, P365, DOI 10.1105/tpc.11.3.365; DENAPOLI L, 1993, PHYTOCHEMISTRY, V33, P13, DOI 10.1016/0031-9422(93)85388-8; EHMANN A, 1977, J CHROMATOGR, V132, P267, DOI 10.1016/S0021-9673(00)89300-0; EPSTEIN E, 1980, PLANT PHYSIOL, V65, P415, DOI 10.1104/pp.65.3.415; EPSTEIN E, 1986, PLANT PHYSIOL, V80, P256, DOI 10.1104/pp.80.1.256; HANGARTER RP, 1980, PLANT PHYSIOL, V65, P761, DOI 10.1104/pp.65.5.761; HANGARTER RP, 1981, PLANT PHYSIOL, V68, P1424, DOI 10.1104/pp.68.6.1424; HANI EK, 1995, J BACTERIOL, V177, P2396, DOI 10.1128/jb.177.9.2396-2402.1995; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; Hussein MJ, 1998, J BACTERIOL, V180, P6260; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; Kowalczyk M, 2001, PLANT PHYSIOL, V127, P1845, DOI 10.1104/pp.010525; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; Lasswell J, 2000, PLANT CELL, V12, P2395, DOI 10.1105/tpc.12.12.2395; LudwigMuller J, 1996, PHYSIOL PLANTARUM, V97, P627, DOI 10.1111/j.1399-3054.1996.tb00525.x; MAGNUS V, 1992, J PLANT GROWTH REGUL, V11, P67, DOI 10.1007/BF00198017; MICHALCZUK L, 1990, PLANT BIOL, V9, P93; Normanly J, 1997, PHYSIOL PLANTARUM, V100, P431, DOI 10.1034/j.1399-3054.1997.1000304.x; Ostin A, 1998, PLANT PHYSIOL, V118, P285, DOI 10.1104/pp.118.1.285; OSTIN A, 1992, BIOL MASS SPECTROM, V21, P292, DOI 10.1002/bms.1200210605; PERCIVAL FW, 1976, PLANT PHYSIOL, V58, P60, DOI 10.1104/pp.58.1.60; PISKORNIK Z, 1972, PLANT PHYSIOL, V50, P176, DOI 10.1104/pp.50.1.176; SAKANYAN V, 1993, APPL ENVIRON MICROB, V59, P3878, DOI 10.1128/AEM.59.11.3878-3888.1993; Swofford D.L., 2001, PAUP PHYLOGENETIC AN; SZERSZEN JB, 1994, SCIENCE, V265, P1699, DOI 10.1126/science.8085154; Tam YY, 2000, PLANT PHYSIOL, V123, P589, DOI 10.1104/pp.123.2.589; Titarenko E, 1997, PLANT PHYSIOL, V115, P817, DOI 10.1104/pp.115.2.817; Walz A, 2002, P NATL ACAD SCI USA, V99, P1718, DOI 10.1073/pnas.032450399	42	200	213	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20446	20452		10.1074/jbc.M111955200	http://dx.doi.org/10.1074/jbc.M111955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923288	hybrid			2022-12-25	WOS:000176204500045
J	Strack, S; Ruediger, R; Walter, G; Dagda, RK; Barwacz, CA; Cribbs, JT				Strack, S; Ruediger, R; Walter, G; Dagda, RK; Barwacz, CA; Cribbs, JT			Protein phosphatase 2A holoenzyme assembly - Identification of contacts between B-family regulatory and scaffolding A subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E4ORF4 PROTEIN; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; TUMOR-ANTIGEN; T-ANTIGENS; CARBOXYL METHYLATION; DNA-REPLICATION; A-SUBUNIT; ASSOCIATION	Protein serine/threonine phosphatase (PP) 2A is a ubiquitous enzyme with pleiotropic functions. Trimeric PP2A consists of a structural A subunit, a catalytic C subunit, and a variable regulatory subunit. Variable subunits (B, B', and B" families) dictate PP2A substrate specificity and subcellular localization. B-family subunits contain seven WD repeats predicted to fold into a beta-propeller structure. We carried out mutagenesis of Bgamma to identify domains important for association with A and C subunits in vivo. Several internal deletions in Bgamma abolished coimmunoprecipitation of A and C subunits expressed in COS-M6 cells. In contrast, small N- and C-terminal By deletions had no effect on incorporation into the PP2A heterotrimer. Thus, holoenzyme association of B-family subunits requires multiple, precisely aligned contacts within a core beta-propeller domain. Charge-reversal mutagenesis of By identified a cluster ;of conserved critical residues in Bgamma WD repeats 3 and 4. Acidic substitution of paired basic residues in By (RR165EE) abolished association with wild-type A and C subunits, while fostering incorporation of Bgamma into a PP2A heterotrimer containing an A subunit with an opposite charge-reversal mutation (EE100RR). Thus, binding of A and B subunits requires electrostatic interactions between conserved pairs of glutamates and arginines. By expressing complementary charge-reversal mutants in neuronal PC6-3 cells, we further show that holoenzyme incorporation protects By from rapid degradation by the ubiquitin/proteasome pathway.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of Iowa; University of California System; University of California San Diego	Strack, S (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-432 BSB 51 Newton Rd, Iowa City, IA 52242 USA.			Strack, Stefan/0000-0002-6175-7280; Dagda, Ruben/0000-0002-9946-9591	NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HOROWITZ M, 1983, Journal of Molecular and Applied Genetics, V2, P147; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kleinberger T, 2000, APOPTOSIS, V5, P211, DOI 10.1023/A:1009644210581; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 1998, J COMP NEUROL, V392, P515; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	54	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20750	20755		10.1074/jbc.M202992200	http://dx.doi.org/10.1074/jbc.M202992200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929880	hybrid			2022-12-25	WOS:000176204500084
J	Martin, V; Bredoux, R; Corvazier, E; van Gorp, R; Kovacs, T; Gelebart, P; Enouf, J				Martin, V; Bredoux, R; Corvazier, E; van Gorp, R; Kovacs, T; Gelebart, P; Enouf, J			Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms - Expression, regulation, and function of the members of the SERCA3 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP EXPRESSION; MEMBRANE CA2+ PUMP; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; SARCOPLASMIC-RETICULUM; CALCINEURIN CONTROLS; DIFFERENTIAL MODULATION; DEPENDENT RELAXATION; TISSUE DISTRIBUTION; LYMPHOID-CELLS	Sarco/endoplasmic reticulum Ca2+-ATPases (SERCAs) pump Ca2+ into the endoplasmic reticulum. Recently, three human SERCA3 (h3a-c) proteins and a previously unknown rat SERCA3 (r3b/c) mRNA have been described. Here, we (i) document two novel human SERCA3 splice variants h3d and h3e, (ii) provide data for the expression and mechanisms regulating the expression of all known SERCA3 variants (r3a, r3b/c, and h3a-e), and (iii) show functional characteristics of the SERCA3 isoforms. h3d and h3e are issued from the insertion of an additional penultimate exon 22 resulting in different carboxyl termini for these variants. Distinct distribution patterns of the SERCA3 gene products were observed in a series of cell lines of hematopoietic, epithelial, embryonic origin, and several cancerous types, as well as in panels of rat and human tissues. Hypertension and protein kinase C, calcineurin, or retinoic acid receptor signaling pathways were found to differently control rat and human splice variant expression, respectively. Stable overexpression of each variant was performed in human embryonic kidney 293 cells, and the SERCA3 isoforms were fully characterized. All SERCA3 isoforms were found to pump Ca-2+ with similar affinities. However, they modulated the cytosolic Ca2+ concentration ([Ca2+](c)) and the endoplasmic reticulum Ca2+ content ([Ca2+ ](er)) in different manners. A newly generated polyclonal antibody and a pan-SERCA3 antibody proved the endogenous expression of the three novel SERCA3 proteins, h3d, h3e, and r3b/c. All these data suggest that the SERCA3 gene products have a more widespread role in cellular Ca2+ signaling than previously appreciated.	Hop Lariboisiere, Circulat Lariboisiere IFR6, INSERM, U348, F-75475 Paris 10, France; Natl Med Ctr, Inst Haematol & Immunol, H-1113 Budapest, Hungary	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Enouf, J (corresponding author), Hop Lariboisiere, Circulat Lariboisiere IFR6, INSERM, U348, 8 Rue Guy Patin, F-75475 Paris 10, France.	jocelyne.enouf@inserm.lrb.ap-hop-paris.fr	Gelebart, Pascal/AAI-1439-2020; Kovács, Tünde/O-6020-2017	Gelebart, Pascal/0000-0003-2434-8987; Kovács, Tünde/0000-0003-1064-2616				BabaAissa F, 1996, MOL BRAIN RES, V41, P169, DOI 10.1016/0169-328X(96)00088-5; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BOBE R, 1994, J BIOL CHEM, V269, P1417; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; BURK SE, 1989, J BIOL CHEM, V264, P18561; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guerini D, 2000, J BIOL CHEM, V275, P3706, DOI 10.1074/jbc.275.5.3706; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264, DOI 10.1152/ajplung.1999.277.2.L264; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; KOVACS T, 1994, J BIOL CHEM, V269, P6177; Kovacs T, 2001, BIOCHEM J, V358, P559, DOI 10.1042/0264-6021:3580559; Lacabaratz-Porret C, 2000, BIOCHEM J, V350, P723, DOI 10.1042/0264-6021:3500723; Launay S, 1999, BLOOD, V93, P4395, DOI 10.1182/blood.V93.12.4395.412k06_4395_4405; Launay S, 1997, J BIOL CHEM, V272, P10746; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; Liu LH, 2001, J BIOL CHEM, V276, P26737, DOI 10.1074/jbc.C100275200; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; Martin V, 2000, HYPERTENSION, V35, P91, DOI 10.1161/01.HYP.35.1.91; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Ozog A, 1998, FEBS LETT, V427, P349, DOI 10.1016/S0014-5793(98)00464-5; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; Rooney E, 1996, J BIOL CHEM, V271, P29304, DOI 10.1074/jbc.271.46.29304; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	49	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24442	24452		10.1074/jbc.M202011200	http://dx.doi.org/10.1074/jbc.M202011200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11956212	hybrid			2022-12-25	WOS:000176611800063
J	Montaville, P; Neumann, JM; Russo-Marie, F; Ochsenbein, F; Sanson, A				Montaville, P; Neumann, JM; Russo-Marie, F; Ochsenbein, F; Sanson, A			A new consensus sequence for phosphatidylserine recognition by annexins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HETERONUCLEAR NMR; MEMBRANE-BINDING; CALCIUM; PROTEIN; AGGREGATION; MECHANISM; DOMAINS; CELLS; IV	Annexins are abundant and ubiquitous proteins that bind, by their four structurally identical domain cores, to phosphatidylserine-containing membranes in the presence of Ca2+. Using molecular simulation and mutagenesis, we have identified a new phosphatidylserine-binding site in annexin V domain 1 and established its structure. The residues involved in this site constitute a consensus sequence highly conserved in all annexins. Remarkably, this consensus sequence is exclusively found in domains 1 or 2, sometimes in both, but never in domains 3 and 4. Such a pattern actually delineates three classes of annexins, shedding new light on the role played by the four-domain core of annexins that could encode specific information discriminating the different annexins that compete within a given cell for membrane binding. Our findings thus provide new strategies for understanding the regulation of the cellular functions of annexins.	CEA Saclay, Dept Biol Joliot Curie, Serv Biophys Fonct Membrainaires, F-91191 Gif Sur Yvette, France; URA CNRS 2096, F-91191 Gif Sur Yvette, France; Inst Cochin Genet Mol, Unite INSERM U332, F-75014 Paris, France; Univ Paris 06, F-75005 Paris, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite	Sanson, A (corresponding author), CEA Saclay, Dept Biol Joliot Curie, Serv Biophys Fonct Membrainaires, F-91191 Gif Sur Yvette, France.			montaville, Pierre/0000-0002-9931-3482				Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Benz J, 1996, J MOL BIOL, V260, P638, DOI 10.1006/jmbi.1996.0426; Bitto E, 1998, BIOCHEMISTRY-US, V37, P10231, DOI 10.1021/bi980479w; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; DUBOIS T, 1995, BIOCHEM J, V310, P243, DOI 10.1042/bj3100243; FADOK VA, 1992, J IMMUNOL, V148, P2207; FavierPerron B, 1996, BIOCHEMISTRY-US, V35, P1740, DOI 10.1021/bi952092o; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GILMANSHIN R, 1994, BIOCHEMISTRY-US, V33, P8225, DOI 10.1021/bi00193a008; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HAKA AJ, 1985, J MAGN RESON, V64, P547; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JUNKER M, 1993, BIOCHEMISTRY-US, V32, P9968, DOI 10.1021/bi00089a012; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; Mira JP, 1997, J BIOL CHEM, V272, P10474; Morgan RO, 1999, GENE, V227, P33, DOI 10.1016/S0378-1119(98)00597-6; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MOSER C, 1991, J MOL BIOL, V217, P241; Moss S. E, 1992, ANNEXINS; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; NELSON MR, 1995, BIOCHEMISTRY-US, V34, P3121, DOI 10.1021/bi00009a044; NEUMANN JM, 1994, EUR J BIOCHEM, V225, P819, DOI 10.1111/j.1432-1033.1994.0819b.x; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; OUDINET JP, 1993, BIOCHEM J, V292, P63, DOI 10.1042/bj2920063; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PIGAULT C, 1994, J MOL BIOL, V236, P199, DOI 10.1006/jmbi.1994.1129; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Rosengarth A, 2001, J MOL BIOL, V306, P489, DOI 10.1006/jmbi.2000.4423; ROUH A, 1993, J MAGN RESON SER A, V102, P357, DOI 10.1006/jmra.1993.1117; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; SOPKOVA J, 1993, J MOL BIOL, V234, P816, DOI 10.1006/jmbi.1993.1627; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P62; VERMES IC, 1995, J IMMUNOL METHODS, V180, P38; Vetterling W.T., 1988, NUMERICAL RECIPES C; WENG XW, 1993, PROTEIN SCI, V2, P448; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101; ZWAAL RFA, 1977, NATURE, V268, P358, DOI 10.1038/268358a0	43	56	59	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24684	24693		10.1074/jbc.M109595200	http://dx.doi.org/10.1074/jbc.M109595200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11948176	hybrid			2022-12-25	WOS:000176611800094
J	Ouyang, YB; Crawley, JTB; Aston, CE; Moore, KL				Ouyang, YB; Crawley, JTB; Aston, CE; Moore, KL			Reduced body weight and increased postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE O-SULFATION; MOLECULAR-CLONING; CHOLECYSTOKININ; PROTEIN; RECEPTORS; GENES	Tyrosine sulfation is mediated by one of two Golgi isoenzymes, called tyrosylprotein sulfotransferases (TPST-1 and TPST-2). A relatively small number of proteins are known to undergo tyrosine sulfation, including certain adhesion molecules, G-protein-coupled receptors, coagulation factors, serpins, extracellular matrix proteins, and hormones. As one approach to explore the role of these enzymes in vivo and how they might interact in biological systems, we have generated TPST-1-deficient mice by targeted disruption of the Tpst1 gene. Tpst1(+/-) mice appear normal and, when interbred, yield litters of normal size with a Mendelian genetic distribution and an equal sex distribution. Tpst1(-/-) mice appear healthy but have approximate to5% lower average body weight than Tpst1(+/+) controls. In addition, we show that although fertility of Tpst1(-/-) males and females per se is normal, Tpst1(-/-) females have significantly smaller litters because of fetal death between 8.5 and 15.5 days postcoitum. These findings suggest that there are proteins involved in regulation of body weight and reproductive physiology, which require tyrosine sulfation for optimal function that are yet to be described. Our findings also strongly support the conclusion that TPST-1 and TPST-2 have distinct biological roles that may reflect differences in their macromolecular substrate specificity.	Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Arthrit & Immunol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Moore, KL (corresponding author), Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, 825 NE 13th St,Mailstop 45, Oklahoma City, OK 73104 USA.	kevin-moore@omrf.ouhse.edu	Crawley, James TB/A-9290-2008	Crawley, James TB/0000-0002-6723-7841	NHLBI NIH HHS [HL63152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Gigoux V, 1998, J BIOL CHEM, V273, P14380, DOI 10.1074/jbc.273.23.14380; Hansen CP, 2000, AM J PHYSIOL-GASTR L, V279, pG903, DOI 10.1152/ajpgi.2000.279.5.G903; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; Kopin AS, 1999, J CLIN INVEST, V103, P383, DOI 10.1172/JCI4901; Lacourse KA, 1999, AM J PHYSIOL-GASTR L, V276, pG1302, DOI 10.1152/ajpgi.1999.276.5.G1302; MOORE KL, 2001, WILEY ENCY MOL MED; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nicholas HB, 1999, ENDOCRINE, V11, P285, DOI 10.1385/ENDO:11:3:285; Ouyang YB, 1998, J BIOL CHEM, V273, P24770, DOI 10.1074/jbc.273.38.24770; Ouyang YB, 1998, P NATL ACAD SCI USA, V95, P2896, DOI 10.1073/pnas.95.6.2896; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; Rehfeld JF, 1998, PHYSIOL REV, V78, P1087, DOI 10.1152/physrev.1998.78.4.1087; RENSDOMIANO S, 1989, J BIOL CHEM, V264, P899; STEIGERWALT RW, 1981, ENDOCRINOLOGY, V109, P1746, DOI 10.1210/endo-109-5-1746; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yoshinari K, 2001, J BIOCHEM MOL TOXIC, V15, P67, DOI 10.1002/jbt.1	23	60	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23781	23787		10.1074/jbc.M202420200	http://dx.doi.org/10.1074/jbc.M202420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964405	hybrid			2022-12-25	WOS:000176475700089
J	Robichaud, GA; Barbeau, B; Fortin, JF; Rothstein, DM; Tremblay, MJ				Robichaud, GA; Barbeau, B; Fortin, JF; Rothstein, DM; Tremblay, MJ			Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NF-KAPPA-B; PROTEIN-TYROSINE-PHOSPHATASE; HUMAN LYMPHOCYTES-T; GENE-EXPRESSION; INTERLEUKIN-2 PRODUCTION; DIFFERENTIAL REGULATION; TRANSCRIPTION FACTORS; VIRAL REPLICATION	Human immunodeficiency virus type-1 (HIV-1) preferentially replicates in CD4-expressing T cells bearing a "memory" (CD45RO+) rather than a "naive" (CD45RA+/CD62L+) phenotype. Yet the basis for the higher susceptibility of these cells to HIV-1 infection remains unclear. Because the nature of the CD45 isoform itself can affect biochemical events in T cells, we set out to determine whether these isoforms could differently modulate HIV-1 long terminal repeat (LTR) activity and thereby replication. Through the use of CD4+ Jurkat T cells specifically expressing distinct CD45 isoforms (i.e. CD45RABC or CD45RO), we demonstrated that a difference in CD45 isoform expression conferred preferential replication of HIV-1 to CD45RO-expressing T cell clones following a physiological CD3/CD28 stimulation. Closer analysis indicated that higher HIV-1 LTR activation levels were consistently observed in CD45RO-positive cells, which was paralleled by more pronounced nuclear factor of activated T cells (NFAT) activation in these same cells. Specific involvement of NFAT1 was revealed in studied Jurkat clones by mobility shift analyses. In addition, preferential activation of the LTR and viral replication in CD45RO T cells was FK506- and cyclosporin A-sensitive. These results underscore the importance of NFAT in HIV-1 regulation and for the first time identify the role of the CD45 isoform in limiting productive HIV-1 replication to the human CD4 memory T cell subset.	CHU Quebec, CHU Laual, Lab Immunoretorvirol Humaine, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, St Foy, PQ G1V 4G2, Canada; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	Laval University; Laval University; Stanford University; Yale University	Tremblay, MJ (corresponding author), CHU Quebec, CHU Laual, Lab Immunoretorvirol Humaine, Ctr Rech Infectiol, RC709,2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.		Barbeau, Benoit/A-1174-2010	Barbeau, Benoit/0000-0002-4108-8155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045485, R01AI036317] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36317, AI45485] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGEMATSU K, 1995, J IMMUNOL, V154, P3627; ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Barbeau B, 2001, J IMMUNOL, V167, P2700, DOI 10.4049/jimmunol.167.5.2700; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Cayota A, 1996, CLIN EXP IMMUNOL, V104, P11, DOI 10.1046/j.1365-2249.1996.d01-652.x; CAYOTA A, 1990, LANCET, V336, P941, DOI 10.1016/0140-6736(90)92311-5; CAYOTA A, 1993, CLIN EXP IMMUNOL, V91, P241; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Cron RQ, 2000, CLIN IMMUNOL, V94, P179, DOI 10.1006/clim.1999.4831; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; FORTIN JF, 1999, CAN J INFECT DIS, V10, pC25; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hall SR, 1999, EUR J IMMUNOL, V29, P2098, DOI 10.1002/(SICI)1521-4141(199907)29:07<2098::AID-IMMU2098>3.3.CO;2-2; Helbert MR, 1997, CLIN EXP IMMUNOL, V107, P300, DOI 10.1111/j.1365-2249.1997.280-ce1170.x; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; Jacque JM, 1996, J VIROL, V70, P2930; Johnson KG, 2000, P NATL ACAD SCI USA, V97, P10138, DOI 10.1073/pnas.97.18.10138; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 1999, MOL CELL BIOL, V19, P3645, DOI 10.1128/mcb.19.5.3645; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24249; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; PICKER LJ, 1993, J IMMUNOL, V150, P1105; PULIDO R, 1994, J EXP MED, V179, P1035, DOI 10.1084/jem.179.3.1035; Roederer M, 1997, J CLIN INVEST, V99, P1555, DOI 10.1172/JCI119318; ROTHSTEIN DM, 1991, J IMMUNOL, V146, P1175; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TEDDER TF, 1985, J IMMUNOL, V134, P2983; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Tsunetsugu-Yokota Y, 2000, J LEUKOCYTE BIOL, V67, P432, DOI 10.1002/jlb.67.3.432; Wang Y, 2000, J IMMUNOL, V164, P2557, DOI 10.4049/jimmunol.164.5.2557; Woods TC, 1997, BLOOD, V89, P1635, DOI 10.1182/blood.V89.5.1635.1635_1635_1641	62	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23733	23741		10.1074/jbc.M201563200	http://dx.doi.org/10.1074/jbc.M201563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956207	hybrid			2022-12-25	WOS:000176475700083
J	Valentini, G; Chiarelli, LR; Fortin, R; Dolzan, M; Galizzi, A; Abraham, DJ; Wang, CQ; Bianchi, P; Zanella, A; Mattevi, A				Valentini, G; Chiarelli, LR; Fortin, R; Dolzan, M; Galizzi, A; Abraham, DJ; Wang, CQ; Bianchi, P; Zanella, A; Mattevi, A			Structure and function of human erythrocyte pyruvate kinase - Molecular basis of nonspherocytic hemolytic anemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOSTERIC REGULATION; RABBIT MUSCLE; POINT MUTATIONS; ENZYME; GENE; SITE; SUBSTITUTION; DEFICIENCY; INTERFACES; RESOLUTION	Deficiency of human erythrocyte isozyme (RPK) is, together with glucose-6-phosphate dehydrogenase deficiency, the most common cause of the nonspherocytic hemolytic anemia. To provide a molecular framework to the disease, we have solved the 2.7 Angstrom resolution crystal structure of human RPK in complex with fructose 1,6-bisphosphate, the allosteric activator, and phosphoglycolate, a substrate analogue, and we have functionally and structurally characterized eight mutants (G332S, G364D, T384M, D390N, R479H, R486W, R504L, and R532W) found in RPK-deficient patients. The mutations target distinct regions of RPK structure, including domain interfaces and catalytic and allosteric sites. The mutations affect to a different extent thermostability, catalytic efficiency, and regulatory properties. These studies are the first to correlate the clinical symptoms with the molecular properties of the mutant enzymes. Mutations greatly impairing thermostability and/or activity are associated with severe anemia. Some mutant proteins exhibit moderate changes in the kinetic parameters, which are sufficient to cause mild to severe anemia, underlining the crucial role of RPK for erythrocyte metabolism. Prediction of the effects of mutations is difficult because there is no relation between the nature and location of the replaced amino acid and the type of molecular perturbation. Characterization of mutant proteins may serve as a valuable tool to assist with diagnosis and genetic counseling.	Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, I-27100 Pavia, Italy; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Osped Maggiore, Div Ematol, IRCCS, I-20122 Milan, Italy	University of Pavia; Virginia Commonwealth University; University of Pavia; IRCCS Ca Granda Ospedale Maggiore Policlinico	Mattevi, A (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol A Buzzati Travers, Abbiategrasso 207, I-27100 Pavia, Italy.	mattevi@ipvgen.unipv.it	Chiarelli, Laurent Roberto/J-8368-2016; mattevi, andrea/K-5464-2012; Mattevi, Andrea/R-4469-2019; Bianchi, Paola/L-2531-2016	Chiarelli, Laurent Roberto/0000-0003-0348-9764; mattevi, andrea/0000-0002-9523-7128; Mattevi, Andrea/0000-0002-9523-7128; Bianchi, Paola/0000-0001-5976-5233				Allen SC, 1996, ACTA CRYSTALLOGR D, V52, P499, DOI 10.1107/S0907444995016040; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beutler E., 1984, GLUTATHIONE RED CELL; Bianchi P, 2000, BLOOD CELL MOL DIS, V26, P47, DOI 10.1006/bcmd.2000.0276; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Demina A, 1998, BLOOD, V92, P647, DOI 10.1182/blood.V92.2.647.414k13_647_652; Fenton AW, 2002, ARCH BIOCHEM BIOPHYS, V397, P28, DOI 10.1006/abbi.2001.2634; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; Friesen RHE, 1998, J BIOL CHEM, V273, P14772, DOI 10.1074/jbc.273.24.14772; GUPTA RK, 1976, BIOCHEMISTRY-US, V15, P2881, DOI 10.1021/bi00658a028; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KANNO H, 1994, BLOOD, V84, P3505; KANNO H, 1994, BLOOD, V83, P2311; KANNO H, 1991, P NATL ACAD SCI USA, V88, P8218, DOI 10.1073/pnas.88.18.8218; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOMEK M, 1994, ANN HEMATOL, V69, P253, DOI 10.1007/BF01700280; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; Larsen TM, 1997, ARCH BIOCHEM BIOPHYS, V345, P199, DOI 10.1006/abbi.1997.0257; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENZNER C, 1994, BLOOD, V83, P2817, DOI 10.1182/blood.V83.10.2817.2817; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6792, DOI 10.1021/bi962869t; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEUBAUER B, 1991, BLOOD, V77, P1871; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; Valentin G, 2000, J BIOL CHEM, V275, P18145, DOI 10.1074/jbc.M001870200; vanSolinge WW, 1997, BLOOD, V90, P4987, DOI 10.1182/blood.V90.12.4987.4987_4987_4995; Wang CQ, 2001, BLOOD, V98, P3113, DOI 10.1182/blood.V98.10.3113; Wooll JO, 2001, J MOL BIOL, V312, P525, DOI 10.1006/jmbi.2001.4978; Zanella A, 1997, BLOOD, V89, P3847, DOI 10.1182/blood.V89.10.3847.3847_3847_3852; Zanella A, 2000, BEST PRACT RES CL HA, V13, P57, DOI 10.1053/beha.1999.0057	38	102	105	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23807	23814		10.1074/jbc.M202107200	http://dx.doi.org/10.1074/jbc.M202107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960989	hybrid			2022-12-25	WOS:000176475700093
J	Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M				Zama, T; Aoki, R; Kamimoto, T; Inoue, K; Ikeda, Y; Hagiwara, M			Scaffold role of a mitogen-activated protein kinase phosphatase, SKRP1, for the JNK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; NECROSIS-FACTOR RECEPTOR; JUN NH2-TERMINAL KINASE; MAP-KINASE; C-JUN; TYROSINE-PHOSPHATASE; MOLECULAR-CLONING; CELL-LINES; SELECTIVELY DEPHOSPHORYLATES; TRANSDUCTION PATHWAY	Stress-activated protein kinase (SAPK) pathway-regulating phosphatase 1 (SKRP1) has been identified as a member of the mitogen-activated protein kinase (MAPK) phosphatase (MKP) family that interacts physically with the MAPK kinase (MAPKK) MKK7, a c-Jun N-terminal kinase (JNH) activator, and inactivates the MAPK JNK pathway. Although these findings indicated that SKRP1 contributes to the precise regulation of JNK signaling, it remains to be elucidated how SKRP1 is integrated into this pathway. We report that SKRP1 also plays a scaffold role for the JNK signaling, judged by the following observations. SKRP1 selectively formed the stable complexes with MKK7 but not with MKK4 and biphasically regulated the MKK7 activity and MKK7-induced gene transcription in vivo. Co-precipitation analysis between SKRP1 and MKK7-activating MAPKK kinases (MAPKKKs) revealed that SKRP1 also interacted with the MAPKKK, apoptosis signal-regulating kinase 1 (ASK1), but not with MAP kinase kinase kinase 1 (MEKK1). Consistent with these findings, SKRP1 expression increased the ASK1-MKK7 complexes in a dose-dependent manner and specifically enhanced the activation of MKK7 by ASK1. Thus, our findings are, to our knowledge, the first evidence to show that an MKP also functions as a scaffold protein for the particular MAPK signaling.	Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Dept Med, Shinjuku Ku, Tokyo 1600016, Japan	Tokyo Medical & Dental University (TMDU); Keio University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Funct Genomics Dept, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Dowd S, 1998, J CELL SCI, V111, P3389; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200	92	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23919	23926		10.1074/jbc.M200838200	http://dx.doi.org/10.1074/jbc.M200838200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959862	Green Submitted, hybrid			2022-12-25	WOS:000176475700106
J	Belogurov, GA; Turkina, MV; Penttinen, A; Huopalahti, S; Baykov, AA; Lahti, R				Belogurov, GA; Turkina, MV; Penttinen, A; Huopalahti, S; Baykov, AA; Lahti, R			H+-Pyrophosphatase of Rhodospirillum rubrum - High yield expression in Escherichia coli and identification of the Cys residues responsible for inactivation by mersalyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING PYROPHOSPHATASE; SUBSTRATE-BINDING SUBUNIT; INORGANIC PYROPHOSPHATE; PUMPING PYROPHOSPHATASE; ORTHO-PHOSPHATE; INHIBITION; PROTEINS; SYNTHASE; ATP; K+	H+-translocating pyrophosphatase (H+-PPase) of the photosynthetic bacterium Rhodospirillum rubrum was expressed in Escherichia coli C43(DE3) cells. Recombinant H+-PPase was observed in inner membrane vesicles, where it catalyzed both PPi hydrolysis coupled with H+ transport into the vesicles and PPi synthesis. The hydrolytic activity of H+-PPase in E. coli vesicles was eight times greater than that in R. rubrum chromatophores but exhibited similar sensitivity to the H+-PPase inhibitor, aminomethylenediphosphonate, and insensitivity to the soluble PPase inhibitor, fluoride. Using this expression system, we showed that substitution of Cys(185), Cys(222), or Cys(573) with aliphatic residues had no effect on the activity of H+-PPase but decreased its sensitivity to the sulfhydryl modifying reagent, mersalyl. H+-PPase lacking all three Cys residues was completely resistant to the effects of mersalyl. Mg2+ and MgPPi protected Cys(185) and Cys(573) from modification by this agent but not Cys(222) Phylogenetic analyses of 23 nonredundant H+-PPase sequences led to classification into two subfamilies. One subfamily invariably contains Cys(222) and includes all known K+-independent H+-PPases, whereas the other incorporates a conserved Cys(573) but lacks Cys(222) and includes all known K+-dependent H+-PPases. These data suggest a specific link between the incidence of Cys at positions 222 and 573 and the K+ dependence of H+-PPase.	Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Turku; Lomonosov Moscow State University	Baykov, AA (corresponding author), Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland.	baykov@genebee.msu.su; reijo.lahti@utu.fi	Baykov, Alexander/AAH-5301-2021; Baykov, Alexander A/C-7981-2012	Baykov, Alexander/0000-0002-2495-8200; Belogurov, Georgiy/0000-0002-3070-6843; Kauko, Anni/0000-0003-1131-3865				BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; BALTSCHEFFSKY H, 1986, CHEM SCRIPTA, V26B, P259; Baltscheffsky M, 1995, PHOTOSYNTH RES, V46, P87, DOI 10.1007/BF00020419; BALTSCHEFFSKY M, 1967, NATURE, V216, P241, DOI 10.1038/216241a0; Baltscheffsky M, 1999, FEBS LETT, V452, P121, DOI 10.1016/S0014-5793(99)00617-1; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; BAYKOV AA, 1993, FEBS LETT, V327, P199, DOI 10.1016/0014-5793(93)80169-U; BAYKOV AA, 1993, EUR J BIOCHEM, V217, P755, DOI 10.1111/j.1432-1033.1993.tb18303.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTEN CJ, 1989, FEBS LETT, V256, P200, DOI 10.1016/0014-5793(89)81748-X; DALEY LA, 1986, ANAL BIOCHEM, V157, P385, DOI 10.1016/0003-2697(86)90642-1; DAVIES JM, 1992, P NATL ACAD SCI USA, V89, P11701, DOI 10.1073/pnas.89.24.11701; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drozdowicz YM, 1999, FEBS LETT, V460, P505, DOI 10.1016/S0014-5793(99)01404-0; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; Drozdowicz YM, 2000, PLANT PHYSIOL, V123, P353, DOI 10.1104/pp.123.1.353; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; Guillory R J, 1972, Biochem J, V129, P571; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; KIM EJ, 1995, J BIOL CHEM, V270, P2630, DOI 10.1074/jbc.270.6.2630; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo SH, 1999, FEBS LETT, V460, P217, DOI 10.1016/S0014-5793(99)01353-8; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mitsuda N, 2001, FEBS LETT, V488, P29, DOI 10.1016/S0014-5793(00)02400-5; MOYLE J, 1972, FEBS LETT, V23, P233, DOI 10.1016/0014-5793(72)80349-1; Nakanishi Y, 2001, J BIOL CHEM, V276, P7654, DOI 10.1074/jbc.M009743200; NYREN P, 1991, BIOCHEMISTRY-US, V30, P2883, DOI 10.1021/bi00225a022; NYREN P, 1985, ANAL BIOCHEM, V151, P504, DOI 10.1016/0003-2697(85)90211-8; NYREN P, 1986, BIOCHIM BIOPHYS ACTA, V851, P276, DOI 10.1016/0005-2728(86)90135-0; NYREN P, 1991, FEMS MICROBIOL LETT, V77, P265, DOI 10.1016/0378-1097(91)90563-P; Perez-Castineira JR, 2001, FEBS LETT, V496, P6, DOI 10.1016/S0014-5793(01)02390-0; RANDAHL H, 1979, EUR J BIOCHEM, V102, P251, DOI 10.1111/j.1432-1033.1979.tb06287.x; REA PA, 1992, TRENDS BIOCHEM SCI, V17, P348, DOI 10.1016/0968-0004(92)90313-X; Rodrigues CO, 2000, BIOCHEM J, V349, P737, DOI 10.1042/bj3490737; ROS R, 1995, J BIOL CHEM, V270, P4368, DOI 10.1074/jbc.270.9.4368; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO MH, 1994, J BIOL CHEM, V269, P6725; SATO MH, 1991, FEBS LETT, V290, P177, DOI 10.1016/0014-5793(91)81254-6; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; STRID A, 1987, ACTA CHEM SCAND B, V41, P116, DOI 10.3891/acta.chem.scand.41b-0116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JJ, 1991, FEBS LETT, V283, P57, DOI 10.1016/0014-5793(91)80552-E; ZHEN RG, 1994, J BIOL CHEM, V269, P23342; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340	55	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22209	22214		10.1074/jbc.M202951200	http://dx.doi.org/10.1074/jbc.M202951200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956221	hybrid			2022-12-25	WOS:000176313600015
J	Kim, HU; Hsieh, K; Ratnayake, C; Huang, AHC				Kim, HU; Hsieh, K; Ratnayake, C; Huang, AHC			A novel group of oleosins is present inside the pollen of Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED OIL BODIES; GLYCINE-RICH PROTEINS; BRASSICA-NAPUS; LIPID BODIES; NUCLEOTIDE-SEQUENCE; THALIANA; GENES; TAPETUM; EXPRESSION; COAT	In plants, subcellular triacylglycerol granules in seeds (oil bodies) and floral tapetum (tapetosomes) are stabilized by amphipathic structural protein called oleosin. We hereby report a novel group of oleosins that is present inside the pollen of Arabidopsis thaliana. We have used the conserved sequence of oleosins to locate, via the DNA database, all 16 oleosin genes in the Arabidopsis genome. The oleosin genes can be divided into three groups according to their sequences and tissue-specific expressions, as probed by RNA blot hybridization and reverse transcriptase-PCR. The first group includes eight genes specifically expressed in the floret tapetum. The second group includes five genes specifically expressed in maturing seeds. The third, novel group includes three genes expressed in both maturing seeds and floral microspores, which will become pollen. Transgenic study using the promoter of one of these genes attached to a reporter gene has provided corroborative evidence for the specific expression of the gene in the microspores in the florets. One of the pollen oleosins can be identified by microsequencing and specific immunoblotting. Pollen oleosins synthesized by recombinant bacteria can collaborate with phospholipids in stabilizing reconstituted oil bodies. Thus, pollen has oleosins to stabilize the abundant subcellular oil bodies. Seed oil bodies and floret tapetosomes have been isolated from the miniature Arabidopsis plants, and the success indicates that the organelles can be subjected to future biochemical and genetic studies.	Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside	Huang, AHC (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA.	Anthony.Huang@ucr.edu	KIM, HYUN UK/AAJ-1055-2021	KIM, HYUN UK/0000-0002-4566-3057				Bowman J., 1994, ARABIDOPSIS ATLAS MO, V102, P117; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Davis R.A., 1996, BIOCH LIPIDS LIPOPRO, P473; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEOLIVEIRA DE, 1993, PLANT J, V3, P495, DOI 10.1046/j.1365-313X.1993.03040495.x; DERUERE J, 1994, PLANT CELL, V6, P119, DOI 10.1105/tpc.6.1.119; Hanley SZ, 1999, FEBS LETT, V447, P99, DOI 10.1016/S0014-5793(99)00235-5; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kim HU, 2001, PLANT PHYSIOL, V126, P330, DOI 10.1104/pp.126.1.330; Kirik V, 1996, PLANT MOL BIOL, V31, P413, DOI 10.1007/BF00021803; Leber R, 1998, MOL BIOL CELL, V9, P375, DOI 10.1091/mbc.9.2.375; LEE K, 1991, PLANT PHYSIOL, V96, P1395, DOI 10.1104/pp.96.4.1395; LEE KY, 1994, PLANT MOL BIOL, V26, P1981, DOI 10.1007/BF00019508; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Mather IH, 1998, J MAMMARY GLAND BIOL, V3, P259, DOI 10.1023/A:1018711410270; Mayfield JA, 2000, NAT CELL BIOL, V2, P128, DOI 10.1038/35000084; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; McDowell JM, 1996, GENETICS, V142, P587; MURPHY DJ, 1993, PROG LIPID RES, V32, P247, DOI 10.1016/0163-7827(93)90009-L; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; ROBERT LS, 1994, PLANT J, V6, P927, DOI 10.1046/j.1365-313X.1994.6060927.x; Ross JHE, 1996, PLANT J, V9, P625, DOI 10.1046/j.1365-313X.1996.9050625.x; Ruiter RK, 1997, PLANT CELL, V9, P1621, DOI 10.1105/tpc.9.9.1621; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT R, 1991, PLANT MOL BIOL, V17, P195, DOI 10.1007/BF00039494; STAIGER D, 1994, PLANTA, V192, P221, DOI 10.1007/BF01089038; STANLEY RG, 1974, POLLEN; Ting JTL, 1997, J BIOL CHEM, V272, P3699, DOI 10.1074/jbc.272.6.3699; Ting JTL, 1998, PLANT J, V16, P541, DOI 10.1046/j.1365-313x.1998.00325.x; TZEN JTC, 1993, PLANT PHYSIOL, V101, P267, DOI 10.1104/pp.101.1.267; TZEN JTC, 1992, J CELL BIOL, V117, P327, DOI 10.1083/jcb.117.2.327; VANCE VB, 1987, J BIOL CHEM, V262, P11275; VANROOIJEN GJH, 1992, PLANT MOL BIOL, V18, P1177, DOI 10.1007/BF00047721; Wang TW, 1997, PLANT J, V11, P475, DOI 10.1046/j.1365-313X.1997.11030475.x; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711; ZOU JT, 1995, PLANT PHYSIOL, V108, P563, DOI 10.1104/pp.108.2.563	40	125	135	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22677	22684		10.1074/jbc.M109298200	http://dx.doi.org/10.1074/jbc.M109298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11929861	hybrid			2022-12-25	WOS:000176313600075
J	Tachibana, T; Astumi, S; Shioda, R; Ueno, M; Uritani, M; Ushimaru, T				Tachibana, T; Astumi, S; Shioda, R; Ueno, M; Uritani, M; Ushimaru, T			A novel non-conventional heat shock element regulates expression of MDJ1 encoding a DnaJ homolog in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST METALLOTHIONEIN GENE; TRANSCRIPTION FACTOR CONTAINS; PROTEIN-KINASE-C; STRESS-RESPONSE; IN-VIVO; COOPERATIVE BINDING; OXIDATIVE STRESS; LEUCINE ZIPPER; ACTIVATION; DROSOPHILA	The heat shock factor (HSF) is a pivotal transcriptional factor that regulates the expression of genes encoding heat shock proteins (HSPs) via heat shock elements (HSEs). nGAAnnTTCnnGAAn functions as the minimum consensus HSE (cHSE) in vivo. Here we show that the expression of Saccharomyces cerevisiae MDJ1 encoding a mitochondrial DnaJ homolog is regulated by HSF,via a novel non-consensus HSE (ncHSE(MDJ1)), which consists of three separated pentameric nGAAn motifs, nTTCn-(11 bp)-nGAAn-(5 bp)-nGAAn. This is the first evidence to show that the immediate contact of nGAAn motifs is dispensable for regulation by HSF in vivo. ncH-SEMDJ1 confers different heat shock responses versus cHSE and, unlike cHSE, definitively requires a carboxyl-terminal activation domain of HSF in the expression. ncHSE(MDJ1)-like elements are found in promoter regions of some other DnaJ-related genes. The highly conserved HSF/HSE system suggests that similar ncHSEs may be used for the expression of HSP genes in other eukaryotes including humans.	Shizuoka Univ, Fac Sci, Dept Biol & Geosci, Shizuoka 4228529, Japan; Shizuoka Univ, Fac Sci, Dept Chem, Shizuoka 4228529, Japan	Shizuoka University; Shizuoka University	Ushimaru, T (corresponding author), Shizuoka Univ, Fac Sci, Dept Biol & Geosci, Shizuoka 4228529, Japan.	sbtushi@ipe.shizuoka.ac.jp	Ueno, Masaru/G-3990-2019					AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; Brachmann CB, 1998, YEAST, V14, P115; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4; ERKINE AM, 1995, NUCLEIC ACIDS RES, V23, P1822, DOI 10.1093/nar/23.10.1822; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KAWAKAMI K, 1992, GENETICS, V131, P821; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1995, BIOL HEAT SHOCK PROT, P53; Lin JT, 1999, MOL CELL BIOL, V19, P3237; Liu HD, 1996, GENE DEV, V10, P592; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; MAGER WH, 1993, BIOCHEM J, V290, P1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORISHIMA N, 1990, J BIOL CHEM, V265, P15189; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Raitt DC, 2000, MOL BIOL CELL, V11, P2335, DOI 10.1091/mbc.11.7.2335; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Santoro N, 1998, MOL CELL BIOL, V18, P6340, DOI 10.1128/MCB.18.11.6340; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Treger JM, 1998, J BIOL CHEM, V273, P26875, DOI 10.1074/jbc.273.41.26875; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Westermann B, 1996, MOL CELL BIOL, V16, P7063; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013; Zhong T, 1996, J BIOL CHEM, V271, P1349, DOI 10.1074/jbc.271.3.1349; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	80	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22140	22146		10.1074/jbc.M201267200	http://dx.doi.org/10.1074/jbc.M201267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940587	hybrid			2022-12-25	WOS:000176313600007
J	Taoka, S; Banerjee, R				Taoka, S; Banerjee, R			Stopped-flow kinetic analysis of the reaction catalyzed by the full-length yeast cystathionine beta-synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; HEME PROTEIN; PYRIDOXAL 5'-PHOSPHATE; HUMAN ENZYME; HOMOCYSTEINE; HOMOCYSTINURIA; MECHANISM; DISEASE	Cystathionine beta-synthase found in yeast catalyzes a pyridoxal phosphate-dependent condensation of homocysteine and serine to form cystathionine. Unlike the homologous mammalian enzymes, yeast cystathionine beta-synthase lacks a second cofactor, heme, which facilitates detailed kinetic studies of the enzyme because the different pyridoxal phosphate-bound intermediates can be followed by their characteristic absorption spectra. We conducted a rapid reaction kinetic analysis of the full-length yeast enzyme in the forward and reverse directions. In the forward direction, we observed formation of the external aldimine of serine (14 mM(-1) s(-1)) and the aminoacrylate intermediate (15 s(-1)). Homocysteine binds to the aminoacrylate with a bimolecular rate constant of 35 mm(-1) s(-1) and rapidly converts to cystathionine (180 s(-1)), leading to the accumulation of a 420 nm absorbing species, which has been assigned as the external aldimine of cystathionine. Release of cystathionine is slow (k = 2.3 s(-1)), which is similar to k(cat) (1.7 s(-1)) at 15 degreesC, consistent with this being a rate-determining step. In the reverse direction, cystathionine binds to the enzyme with a bimolecular rate constant of 1.5 nM(-1) s(-1) and is rapidly converted to the aminoacrylate without accumulation of the external aldimine. The kinetic behavior of the full-length enzyme shows notable differences from that reported for a truncated form of the enzyme lacking the C-terminal third of the protein.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Jhee KH, 2001, BIOCHEMISTRY-US, V40, P10873, DOI 10.1021/bi011087j; Jhee KH, 2000, J BIOL CHEM, V275, P11541, DOI 10.1074/jbc.C000056200; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kabil O, 2001, J BIOL CHEM, V276, P19350, DOI 10.1074/jbc.M100029200; KERY V, 1994, J BIOL CHEM, V269, P25283; Kraus JP, 1999, HUM MUTAT, V13, P362; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MUDD SH, 1985, AM J HUM GENET, V37, P1; Ojha S, 2002, BIOCHEMISTRY-US, V41, P4649, DOI 10.1021/bi011827o; Ojha S, 2000, BIOCHEMISTRY-US, V39, P10542, DOI 10.1021/bi000831h; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Tai CH, 2001, ACCOUNTS CHEM RES, V34, P49, DOI 10.1021/ar990169l; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 2001, J INORG BIOCHEM, V87, P253, DOI 10.1016/S0162-0134(01)00336-1; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2001, J INORG BIOCHEM, V87, P245, DOI 10.1016/S0162-0134(01)00335-X	25	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22421	22425		10.1074/jbc.M202513200	http://dx.doi.org/10.1074/jbc.M202513200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948191	hybrid			2022-12-25	WOS:000176313600041
J	Woodcock, EA; Wang, BH; Arthur, JF; Lennard, A; Matkovich, SJ; Du, XJ; Brown, JH; Hannan, RD				Woodcock, EA; Wang, BH; Arthur, JF; Lennard, A; Matkovich, SJ; Du, XJ; Brown, JH; Hannan, RD			Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL DNA-TRANSCRIPTION; ACTIVE ALPHA(1B)-ADRENERGIC RECEPTORS; RAT NEONATAL CARDIOMYOCYTES; PROTEIN-KINASE-C; CARDIAC-HYPERTROPHY; VENTRICULAR MYOCYTES; PHOSPHATE RELEASE; PHOSPHOLIPASE-C; MYOCARDIAL HYPERTROPHY; RDNA TRANSCRIPTION	Activation of G(q)-coupled alpha(1)-adrenergic receptors leads to hypertrophic growth of neonatal rat ventricular cardiomyoeytes that is associated with increased expression of hypertrophy-related genes, including atrial natriuretic peptide (ANP) and myosin light chain-2 (MLC), as well as increased ribosome synthesis. The role of inositol phosphates in signaling pathways involved in these changes in gene expression was examined by overexpressing inositol phosphate-metabolizing enzymes and determining effects on ANP, MLC, and 45 S ribosomal gene expression following co-transfection of appropriate reporter gene constructs. Overexpression of enzymes that metabolize inositol 1,4,5-trisphosphate did not reduce ANP or MLC responses, but overexpression of the enzyme primarily responsible for metabolism of inositol 4,5-bisphosphate (Ins(1,4)P-2), inositol polyphosphate 1-phosphatase (INPP), reduced ANP and MLC responses associated with alpha(1)-adrenergic receptor-mediated hypertrophy. Similarly overexpressed INPP reduced ANP and MLC responses associated with contraction-induced hypertrophy. In addition, overexpression of MPP reduced the increase in ribosomal DNA transcription associated with both hypertrophic models. Hypertrophied cells from both cell models as well as ventricular tissue from mouse hearts hypertrophied by pressure overload in vivo contained heightened levels of Ins(1,4)P-2, suggesting reduced INPP activity in three different models of hypertrophy. These studies provide evidence for an involvement of Ins(1,4)P-2 in hypertrophic signaling pathways in ventricular myocytes.	Baker Med Res Inst, Gene Transcript Lab, Melbourne, Vic 8008, Australia; Baker Med Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia; Baker Med Res Inst, Expt Cardiol Lab, Melbourne, Vic 8008, Australia; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92037 USA	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; University of California System; University of California San Diego	Woodcock, EA (corresponding author), Baker Med Res Inst, Gene Transcript Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@baker.edu.au	Matkovich, Scot J/B-9077-2009; ARTHUR, JANE/AAW-9983-2020; Matkovich, Scot J/AFP-0908-2022	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857; Hannan, Ross/0000-0002-2166-4493				Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ANDERSON KE, 1995, CIRC RES, V76, P261, DOI 10.1161/01.RES.76.2.261; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Autelitano DJ, 1998, J MOL CELL CARDIOL, V30, P1515, DOI 10.1006/jmcc.1998.0717; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1988, COLD SPRING HARB SYM, V53, P927, DOI 10.1101/SQB.1988.053.01.107; Bogoyevitch MA, 1996, INT J BIOCHEM CELL B, V28, P1, DOI 10.1016/1357-2725(95)00142-5; Brandenburger Y, 2001, FASEB J, V15, P2051, DOI 10.1096/fj.00-0853fje; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; DU XJ, 1995, CIRCULATION, V91, P2712, DOI 10.1161/01.CIR.91.11.2712; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Harrison SN, 1998, CIRC RES, V83, P1232, DOI 10.1161/01.RES.83.12.1232; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; Homcy CJ, 1998, CIRCULATION, V97, P1890, DOI 10.1161/01.CIR.97.19.1890; INHORN RC, 1987, P NATL ACAD SCI USA, V84, P2170, DOI 10.1073/pnas.84.8.2170; Jacobsen AN, 1996, CIRCULATION, V93, P23, DOI 10.1161/01.CIR.93.1.23; Kent RL, 1996, CIRC RES, V78, P829, DOI 10.1161/01.RES.78.5.829; KENTISH JC, 1990, AM J PHYSIOL, V258, pH610, DOI 10.1152/ajpheart.1990.258.2.H610; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lin G, 2001, CIRC RES, V89, P343, DOI 10.1161/hh1601.095912; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Lorell BH, 1997, CIRCULATION, V96, P3824; Matkovich SJ, 2000, J BIOL CHEM, V275, P10845, DOI 10.1074/jbc.275.15.10845; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wang BH, 2000, AM J PHYSIOL-HEART C, V279, pH1079, DOI 10.1152/ajpheart.2000.279.3.H1079; WOODCOCK EA, 1995, J MOL CELL CARDIOL, V27, P867, DOI 10.1016/0022-2828(95)90036-5; Woodcock EA, 1997, J MOL CELL CARDIOL, V29, P449, DOI 10.1006/jmcc.1996.0287; Woodcock EA, 1998, CARDIOVASC RES, V40, P251, DOI 10.1016/S0008-6363(98)00187-4; WOODCOCK EA, 1995, CIRC RES, V76, P252, DOI 10.1161/01.RES.76.2.252; Wu GY, 2000, J BIOL CHEM, V275, P29927, DOI 10.1074/jbc.C000380200; YORK JD, 1994, J BIOL CHEM, V269, P19992; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 1993, P NATL ACAD SCI USA, V90, P5833, DOI 10.1073/pnas.90.12.5833	50	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22734	22742		10.1074/jbc.M110405200	http://dx.doi.org/10.1074/jbc.M110405200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11932254	hybrid			2022-12-25	WOS:000176313600082
J	Fabbro, M; Rodriguez, JA; Baer, R; Henderson, BR				Fabbro, M; Rodriguez, JA; Baer, R; Henderson, BR			BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; RNA-POLYMERASE-II; INTERACT IN-VIVO; SUBCELLULAR-LOCALIZATION; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; BREAST; PROTEIN; GENE; ASSOCIATION	BRCA1 is a tumor suppressor with several important nuclear functions. BRCA1 has no known cytoplasmic functions. We show here that the two previously identified nuclear localization signals (NLSs) are insufficient for nuclear localization of BRCA1 due to the opposing action of an N-H-2-terminal nuclear export signal. In transfected breast cancer cells, BRCA1 nuclear localization requires both the NLSs and NH2-terminal RING domain region; mutating either of these sequences shifts BRCA1 to the cytoplasm. The BRCA1 RING element mediates nuclear import via association with BARDI, and this is not affected by cancer-associated RING mutations. Moreover, BARDI directly masks the BRCA1 nuclear export signal, and the resulting block to nuclear export is requisite for efficient import and nuclear localization of ectopic and endogenous BRCA1. Our results explain why BRCA1 exon 11 splice variants, which lack the NLSs but retain the RING domain, are frequently detected in the nucleus and in nuclear foci in vivo. In fact, co-expression of BARD1 promoted formation of DNA damage-induced nuclear foci comprising ectopic wild-type or NLS-deficient BRCA1, implicating BARD1 in nuclear targeting of BRCA1 for DNA repair. Our identification of BARD1 as a BRCA1 nuclear chaperone has regulatory implications for its reported effects on BRCA1 protein stability, ubiquitin ligase activity, and DNA repair.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Columbia Univ Coll Phys & Surg, Dept Pathol, Inst Canc Genet, New York, NY 10032 USA	University of Sydney; Westmead Institute for Medical Research; Columbia University	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au	Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	52	146	153	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21315	21324		10.1074/jbc.M200769200	http://dx.doi.org/10.1074/jbc.M200769200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925436	hybrid			2022-12-25	WOS:000176286000027
J	Panni, S; Dente, L; Cesareni, G				Panni, S; Dente, L; Cesareni, G			In vitro evolution of recognition specificity mediated by SH3 domains reveals target recognition rules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; SH3-LIGAND INTERACTIONS; PEPTIDE APTAMERS; ABL-SH3 DOMAIN; PROTEIN; BINDING; SRC; SELECTION; LIBRARIES; DISPLAY	We have designed a repertoire of 10(7) different SH3 domains by grafting the residues that are represented in the binding surfaces of natural SH3 domains onto the scaffold of the human Abl-SH3 domain. This phage-displayed library was screened by affinity selection for SH3 domains that bind to the synthetic peptides, APTYPP-PLPP and LSSRPLPTLPSP, which are peptide ligands for the human Abl or Src SH3 domains, respectively. By characterizing the isolates, we have observed that as few as two or three amino acid substitutions lead to dramatic changes in recognition specificity. We propose that the ability to shift recognition specificity with a small number of amino acid replacements is an important evolutionary characteristic of protein binding modules. Furthermore, we have used the information obtained by these in vitro evolution experiments to generate a scoring matrix that evaluates the probability that any SH3 domain binds to the peptide ligands for the Abl and Src SH3 domains. A table of predictions for the 28 SH3 domains of baker's yeast is presented.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	University of Rome Tor Vergata	Cesareni, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	cesareni@uniroma2.it	Cesareni, Gianni/AAW-1382-2020	DENTE, LUCIANA/0000-0002-9617-0922; panni, simona/0000-0002-7500-4028				Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; Castagnoli L, 2001, COMB CHEM HIGH T SCR, V4, P121; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fazi B, 2002, J BIOL CHEM, V277, P5290, DOI 10.1074/jbc.M109848200; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Geyer CR, 1999, P NATL ACAD SCI USA, V96, P8567, DOI 10.1073/pnas.96.15.8567; Hoffmuller U, 2000, EMBO J, V19, P4866, DOI 10.1093/emboj/19.18.4866; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kay BK, 2000, FEBS LETT, V480, P55, DOI 10.1016/S0014-5793(00)01778-6; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keefe AD, 2001, NATURE, V410, P715, DOI 10.1038/35070613; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Malabarba MG, 2001, ONCOGENE, V20, P5186, DOI 10.1038/sj.onc.1204654; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 2002, SH3 DOMAINS RECOGNIZ, P61; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pisabarro MT, 1998, J MOL BIOL, V281, P513, DOI 10.1006/jmbi.1998.1932; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Santi E, 2000, J MOL BIOL, V296, P497, DOI 10.1006/jmbi.1999.3471; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Zucconi A, 2001, J MOL BIOL, V307, P1329, DOI 10.1006/jmbi.2001.4572	40	34	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21666	21674		10.1074/jbc.M109788200	http://dx.doi.org/10.1074/jbc.M109788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11929862	hybrid			2022-12-25	WOS:000176286000074
J	Sanchez, MA; Tryon, R; Green, J; Boor, J; Landfear, SM				Sanchez, MA; Tryon, R; Green, J; Boor, J; Landfear, SM			Six related nucleoside/nucleobase transporters from Trypanosoma brucei exhibit distinct biochemical functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; NUCLEOSIDE TRANSPORTER; LEISHMANIA-ENRIETTII; TUBULIN GENES; CLONING; FAMILY; EXPRESSION; ADENOSINE; AFFINITY; PURINE	Purine nucleoside and nucleobase transporters are of fundamental importance for Trypanosoma brucei and related kinetoplastid parasites because these protozoa are not able to synthesize purines de novo and must salvage the compounds from their hosts. In the studies reported here, we have identified a family of six clustered genes in T. brucei that encode nucleoside/nucleobase transporters. These genes, TbNT2/927, TbNT3, TbNT4, TbNT5, TbNT6, and TbNT7, have predicted amino acid sequences that show high identity to each other and to TbNT2, a PI type nucleoside transporter recently identified in our laboratory. Expression in Xenopus laevis oocytes revealed that TbNT2/927, TbNT5, TbNT6, and TbNT7 are high affinity adenosine/inosine transporters with K-m values of <5 &mu;M. In addition, TbNT5, and to a limited degree TbNT6 and TbNT7, also mediate the uptake of the nucleobase hypoxanthine. Ribonuclease protection assays showed that mRNA from all of the six members of this gene family are expressed in the bloodstream stage of the T. brucei life cycle but that TbNT2/927 and TbNT5 mRNAs are also expressed in the insect stage of the life cycle. These results demonstrate that T. brucei expresses multiple purine transporters with distinct substrate specificities and different patterns of expression during the parasite life cycle.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Sanchez, MA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd,L220, Portland, OR 97201 USA.				NIAID NIH HHS [R01 AI044138, AI44138] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044138] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BRINGAUD F, 1994, MOL BIOL EVOL, V11, P220; Burchmore RJS, 1998, J BIOL CHEM, V273, P29118, DOI 10.1074/jbc.273.44.29118; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, BIOCHEM CELL BIOL, V76, P853, DOI 10.1139/bcb-76-5-853; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; DeKoning HP, 1997, EUR J BIOCHEM, V247, P1102, DOI 10.1111/j.1432-1033.1997.01102.x; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; Sambrook J., 2002, MOL CLONING LAB MANU; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; SEEBECK T, 1983, P NATL ACAD SCI-BIOL, V80, P4634, DOI 10.1073/pnas.80.15.4634; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; van Deursen FJ, 2001, MOL BIOCHEM PARASIT, V112, P163, DOI 10.1016/S0166-6851(00)00359-5; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873	32	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21499	21504		10.1074/jbc.M202319200	http://dx.doi.org/10.1074/jbc.M202319200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937511	hybrid			2022-12-25	WOS:000176286000050
J	Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP				Tommasi, S; Dammann, R; Jin, SG; Zhang, XF; Avruch, J; Pfeifer, GP			RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1	ONCOGENE			English	Article						RASSF1; tumor suppressor gene; Ras association domain; Nore1	COMPARATIVE GENOMIC HYBRIDIZATION; EPIGENETIC INACTIVATION; CPG ISLAND; DNA METHYLATION; FAMILY; BREAST; CANCER; LUNG; HYPERMETHYLATION; 3P21.3	RASSF1A, one of the two major isoforms of the putative tumor suppressor gene RASSF1, located at 3p21.3, is inactivated in a variety of human cancers including lung, breast, bladder and renal cell carcinomas. We have isolated and cloned two human homologues of this gene, RASSF3 and NORE1, located at 12q14.1 and 1q32.1, respectively. Both RASSF3 and NORE1 share almost 60% homology, at the amino acid level, with RASSF1. The RASSF3 gene contains five exons and encodes a 247 amino acid protein (MW of 28.6 kDa) with a highly conserved Ras association (RalGDS/AF-6) (RA) domain at the C-terminus. RASSF3 is ubiquitously expressed in all normal tissues and cancer cell tines analysed. NORE1, which is homologous to the previously described mouse Nore1 gene, exists in at least two spliced isoforms, A and B. Transcript A encodes a protein of 418 amino acids (MW or 47 kDa) while transcript B contains an ORF of 265 aa (MW of 30.5 kDa). Both share a RA domain, encoded by exons 3 through 6. NORE1A and NORE1B are expressed in most of the normal tissues analysed but they appear to be down-regulated in several cancer cell lines. However, contrary to RASSF1A, gene silencing by methylation of the CpG islands at which the two NORE1 transcripts initiate is not a common event in human primary tumors. RASSF3 and NORE1B are very similar, at the N-terminus, to the splice variant C of RASSF1 (RASSF1C), which does not seem to be involved in tumorigenesis. NORE1A is most closely related to RASSF1A, for sequence homology and genomic organization. However, aberrations in tumors have so far not been found. The presence of a Ras association domain common to NORE1, RASSF1, and RASSF3 suggests their possible involvement in Ras-like signaling pathways.	Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle An Der Saale, Germany; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Harvard University; Massachusetts General Hospital	Tommasi, S (corresponding author), Beckman Res Inst, Dept Biol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	stommasi@coh.org		Tommasi, Stella/0000-0001-6897-4985; Jin, Seung-Gi/0000-0001-5041-0559	NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER; NCI NIH HHS [CA88873] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Almeida A, 1998, ONCOGENE, V16, P2997, DOI 10.1038/sj.onc.1201828; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOKHLATCHEV A, 2002, IN PRESS CURR BIOL; Kros JM, 1999, J PATHOL, V188, P282; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; ORTIZVEGA S, 2002, IN PRESS ONCOGENE; Petersen C, 2000, J BIOL CHEM, V275, P4081, DOI 10.1074/jbc.275.6.4081; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIED T, 1995, CANCER RES, V55, P5415; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Thompson L, 1994, Work, V4, P22, DOI 10.3233/WOR-1994-4104; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wistuba II, 2000, CANCER RES, V60, P1949; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	41	89	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2713	2720		10.1038/sj.onc.1205365	http://dx.doi.org/10.1038/sj.onc.1205365			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965544				2022-12-25	WOS:000174996500011
J	Coles, LC; Shaw, PE				Coles, LC; Shaw, PE			PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway	ONCOGENE			English	Article						Rho proteins; PAKs; MEKs; phospho-specific antibodies; regulatory phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; RAS; SERINE; BINDING; IDENTIFICATION; INHIBITION; RESIDUES; COMPLEX; SITES	The serine/threonine kinase Raf-1 acts downstream of Ras in the MAPK pathway leading to ERK activation in response to mitogens. Raf-1 has oncogenic potential, but is normally controlled by a complex interplay of inhibitory and activating mechanisms. Although Raf-1 is phosphorylated in unstimulated cells, mitogens cause its membrane recruitment by Ras and subsequent phosphorylation on additional sites. Some of these events modulate Raf-1 kinase activity while others determine interactions with other proteins. These changes regulate the ability of Raf-I to phosphorylate its downstream targets MEK1 and MEK2. Rho family small G proteins act synergistically with Raf-I to stimulate the ERK pathway by a cross-cascade mechanism that enhances MEK phosphorylation by Raf-1. Here we show that both Raf-1 and MEK1 are phosphorylated by PAK1 and that mutations at PAK1 phosphorylation sites in either protein prevent cross-cascade activation. In contrast, MEK1 activation by constitutively-active Raf-1 is refractory to mutations at PAK1 phosphorylation sites. Phosphorylation of MEK1 on serine 298 does not appear to regulate the interaction between Raf-1 and MEK1, but rather the ability of Raf-I to phosphorylate MEK1 with which it is complexed in vivo. Our findings indicate that PAK1 primes MEK1 for activation by Raf-1 and imply another level of regulation in the ERK cascade.	Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	33	91	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2236	2244		10.1038/sj.onc.1205302	http://dx.doi.org/10.1038/sj.onc.1205302			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948406				2022-12-25	WOS:000174555300012
J	Dubois, E; Scherens, B; Vierendeels, F; Ho, MMW; Messenguy, F; Shears, SB				Dubois, E; Scherens, B; Vierendeels, F; Ho, MMW; Messenguy, F; Shears, SB			In Saccharomyces cerevisiae, the inositol polyphosphate kinase activity of Kcs1p is required for resistance to salt stress, cell wall integrity, and vacuolar morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METABOLISM; PHOSPHOLIPASE-C; LEUCINE-ZIPPER; YEAST; ARGRIII; FAMILY; GROWTH; IDENTIFICATION; BIOGENESIS; COATOMER	A problem for inositol signaling is to understand the significance of the kinases that convert inositol hexakisphosphate to diphosphoinositol polyphosphates. This kinase activity is catalyzed by Kcs1p in the yeast Saccharomyces cerevisiae. A kcs1Delta yeast strain that was transformed with a specifically "kinase-dead" kcs1p mutant did not synthesize diphosphoinositol polyphosphates, and the cells contained a fragmented vacuolar compartment. Biogenesis of the yeast vacuole also required another functional domain in Kcs1p, which contains two leucine heptad repeats. The kinase activity of Kcs1p was also found to sustain cell growth and integrity of the cell wall and to promote adaptive responses to salt stress. Thus, the synthesis of diphosphoinositol polyphosphates has wide ranging physiological significance. Furthermore, we showed that these phenotypic responses to Kcs1p deletion also arise when synthesis of precursor material for the diphosphoinositol polyphosphates is blocked in arg82Delta cells. This metabolic block was partially bypassed, and the phenotype was partially rescued, when Kcs1p was overexpressed in the arg82Delta cells. This was due, in part, to the ability of Kcs1p to phosphorylate a wider range of substrates than previously appreciated. Our results show that diphosphoinositol polyphosphate synthase activity is essential for biogenesis of the yeast vacuole and the cell's responses to certain environmental stresses.	Free Univ Brussels, Inst Rech Microbiol Jean Marie Wiame, B-1070 Brussels, Belgium; NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Dubois, E (corresponding author), Free Univ Brussels, Inst Rech Microbiol Jean Marie Wiame, 808 Route Lennik, B-1070 Brussels, Belgium.	fanarg@ulb.ac.be	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; Alonso-Monge R, 2001, MOL MICROBIOL, V41, P717, DOI 10.1046/j.1365-2958.2001.02549.x; Amar N, 2000, MOL CELL BIOL, V20, P2087, DOI 10.1128/MCB.20.6.2087-2097.2000; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Brachmann CB, 1998, YEAST, V14, P115; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Darley CP, 2000, BIOCHEM J, V351, P241, DOI 10.1042/0264-6021:3510241; DUBOIS E, 1994, MOL GEN GENET, V243, P315, DOI 10.1007/BF00301067; Dubois E, 2000, FEBS LETT, V486, P300, DOI 10.1016/S0014-5793(00)02318-8; El Bakkoury M, 2000, MOL MICROBIOL, V35, P15, DOI 10.1046/j.1365-2958.2000.01665.x; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; HUANG KN, 1995, GENETICS, V141, P1275; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MESSENGUY F, 1971, EUR J BIOCHEM, V22, P277, DOI 10.1111/j.1432-1033.1971.tb01542.x; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; NASS R, 2001, MICROBIOLOGY, V145, P3221; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; QIU HF, 1990, MOL GEN GENET, V222, P192, DOI 10.1007/BF00633817; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, J BIOL CHEM, V276, P39179, DOI 10.1074/jbc.M106842200; Shaw JD, 2001, EXP CELL RES, V271, P1, DOI 10.1006/excr.2001.5373; Shears SB, 2000, BIOESSAYS, V22, P786, DOI 10.1002/1521-1878(200009)22:9<786::AID-BIES3>3.3.CO;2-S; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; Stolz LE, 1998, GENETICS, V148, P1715; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	43	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23755	23763		10.1074/jbc.M202206200	http://dx.doi.org/10.1074/jbc.M202206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956213	hybrid			2022-12-25	WOS:000176475700086
J	Kridel, SJ; Sawai, H; Ratnikov, BI; Chen, EI; Li, WZ; Godzik, A; Strongin, AY; Smith, JW				Kridel, SJ; Sawai, H; Ratnikov, BI; Chen, EI; Li, WZ; Godzik, A; Strongin, AY; Smith, JW			A unique substrate binding mode discriminates membrane type-1 matrix metalloproteinase from other matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; PROGELATINASE-A; EXTRACELLULAR-MATRIX; CELL-SURFACE; PLASMINOGEN-ACTIVATOR; RAPID IDENTIFICATION; TUMOR-CELLS; SPECIFICITY; DISPLAY	In our study, we characterized the substrate recognition properties of membrane type-1 matrix metalloproteinase (MT1-MMP; also known as MMP-14), a key enzyme in tumor cell invasion and metastasis. A panel of optimal peptide substrates for MT1-MMP was identified using substrate phage display. The substrates can be segregated into four groups based on their degree of selectivity for MT1-MMP. Substrates with poor selectivity for MT1-MMP are comprised predominately of the Pro-X-X- down arrow -X-HY motif that is recognized by a number of MMP's. Highly selective substrates lack the characteristic Pro at the P-3 position; instead they contain an Arg at the P-4 position. This P-4 Arg is essential for efficient hydrolysis and for selectivity for MT1-MMP. Molecular modeling indicates that the selective substrates adopt a linear conformation that extends along the entire catalytic pocket of MT1-MMP, whereas non-selective substrates are kinked at the conserved P-3 Pro residue. Importantly, the selective substrates can be made nonselective by insertion of a proline kink at P-3, without significantly reducing overall k(cat)/K-m values. Altogether the study provides a structural basis for selective and non-selective substrate recognition by MT1-MMP. The findings in this report are likely to explain several aspects of MT1-MMP biology.	Burnham Inst, Program Cell Adhes, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Program Cell Adhes, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jsmith@burnham.org	Li, Weizhong/A-9735-2008; Godzik, Adam/A-7279-2009; Strongin, Alex/R-6609-2019; Godzik, Adam/AAW-1467-2020	Li, Weizhong/0000-0003-1804-9403; Godzik, Adam/0000-0002-2425-852X; Strongin, Alex/0000-0003-3765-3016; Godzik, Adam/0000-0002-2425-852X	NCI NIH HHS [CA69306, CA82713, CA77471, CA83017] Funding Source: Medline; NIAMS NIH HHS [AR42750, AR08505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069306, R01CA083017, R29CA077471, P01CA082713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1192; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; DERYUGINA EI, 2001, J BIOL CHEM, V263, P209; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Imai K, 1996, CANCER RES, V56, P2707; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KNIGHT CG, 1995, METHOD ENZYMOL, P248; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kridel SJ, 2001, ANAL BIOCHEM, V294, P176, DOI 10.1006/abio.2001.5167; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Short SM, 1998, MOL BIOL CELL, V9, P1969, DOI 10.1091/mbc.9.8.1969; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, GENE, V128, P1, DOI 10.1016/0378-1119(93)90145-S; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STOCKER W, 1995, PROTEIN SCI, V4, P823; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	52	80	85	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23788	23793		10.1074/jbc.M111574200	http://dx.doi.org/10.1074/jbc.M111574200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11959855	hybrid			2022-12-25	WOS:000176475700090
J	Potter, MD; Nicchitta, CV				Potter, MD; Nicchitta, CV			Endoplasmic reticulum-bound ribosomes reside in stable association with the translocon following termination of protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE RECOGNITION; MICROSOMAL-MEMBRANES; ER MEMBRANE; NASCENT POLYPEPTIDES; CONDUCTING CHANNEL; SECRETORY PROTEIN; SEC61P COMPLEX; BINDING; CHAIN; SITE	In current views, translation-coupled ribosome binding to the endoplasmic reticulum (ER) membrane is transient, with association occurring via the signal recognition particle pathway and dissociation occurring upon the termination of protein synthesis. Recent studies indicate, however, that ribosomal subunits remain membrane-bound following the termination of protein synthesis. To define the mechanism of post-termination ribosome association with the ER membrane, membrane-bound ribosomes were detergent-solubilized from tissue culture cells at different stages of the protein synthesis cycle, and the composition of the ribosome-associated membrane protein fraction was determined. We report that ribosomes reside in stable association with the Sec61alpha-translocon following the termination stage of protein synthesis. Additionally, in vitro experiments revealed that solubilized, gradient-purified ribosome-translocon complexes were able to initiate the translation of secretory and cytosolic proteins and were functional in assays of signal sequence recognition. Using this experimental system, synthesis of signal sequence-bearing polypeptides yielded a tight ribosome-translocon junction; synthesis of nascent polypeptides lacking a signal sequence resulted in a disruption of this junction. On the basis of these data, we propose that in situ, ribosomes reside in association with the translocon throughout the cycle of protein synthesis, with membrane release occurring upon translation of proteins lacking topogenic signals.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047897] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47897] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bastisch I, 2000, CLIN EXP IMMUNOL, V122, P49, DOI 10.1046/j.1365-2249.2000.01350.x; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; BLOBEL G, 1967, J MOL BIOL, V26, P279, DOI 10.1016/0022-2836(67)90297-5; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Blobel G, 2000, BIOSCIENCE REP, V20, P303, DOI 10.1023/A:1010318832604; Chevet E, 1999, EMBO J, V18, P3655, DOI 10.1093/emboj/18.13.3655; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Gruss OJ, 1999, EUR J BIOCHEM, V260, P785, DOI 10.1046/j.1432-1327.1999.00215.x; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Heritage D, 2001, J BIOL CHEM, V276, P22655, DOI 10.1074/jbc.M102409200; HIGH S, 1993, J BIOL CHEM, V268, P26745; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MECHLER B, 1975, J CELL BIOL, V67, P25, DOI 10.1083/jcb.67.1.25; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2000, J BIOL CHEM, V275, P2037, DOI 10.1074/jbc.275.3.2037; Potter MD, 2001, TRENDS CELL BIOL, V11, P112, DOI 10.1016/S0962-8924(00)01905-X; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Seiser RM, 2000, J BIOL CHEM, V275, P33820, DOI 10.1074/jbc.M004462200; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WADA I, 1991, J BIOL CHEM, V266, P19599; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	40	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23314	23320		10.1074/jbc.M202559200	http://dx.doi.org/10.1074/jbc.M202559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964406	hybrid			2022-12-25	WOS:000176475700030
J	Wehage, E; Eisfeld, J; Heiner, I; Jungling, E; Zitt, C; Luckhoff, A				Wehage, E; Eisfeld, J; Heiner, I; Jungling, E; Zitt, C; Luckhoff, A			Activation of the cation channel long transient receptor potential channel 2 (LTRPC2) by hydrogen peroxide - A splice variant reveals a mode of activation independent of ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CA2+ RELEASE; NEUTROPHIL GRANULOCYTES; RYANODINE RECEPTOR; PC12 CELLS; PROTEIN; HYDROLYSIS; INHIBITION; KINASES; INFLUX	LTRPC2 is a cation channel recently reported to be activated by adenosine diphosphate-ribose (ADP-ribose) and NAD. Since ADP-ribose can be formed from NAD and NAD is elevated during oxidative stress, we studied whole cell currents and increases in the intercellular free calcium concentration ([Ca2+](i)) in long transient receptor potential channel 2 (LTRPC2)-transfected HEK 293 cells after stimulation with hydrogen peroxide (H2O2). Cation currents carried by monovalent cations and Ca2+ were induced by H2O2 (5 mm in the bath solution) as well as by intracellular ADP-ribose (0.3 mm in the pipette solution) but not by NAD (1 mm). H2O2-induced currents developed slowly after a characteristic delay of 3-6 min and receded after wash-out of H2O2. [Ca2+](i) was rapidly increased by H2O2 in LTRPC2-transfected cells as well as in control cells; however, in LTRPC2-transfected cells, H2O2 evoked a second delayed rise in [Ca2+](i). A splice variant of LTRPC2 with a deletion in the C terminus (amino acids 1292-1325) was identified in neutrophil granulocytes. This variant was stimulated by H2O2 as the wild type. However, it did not respond to ADP-ribose. We conclude that activation of LTRPC2 by H2O2 is independent of ADP-ribose and that LTRPC2 may mediate the influx of Na+ and Ca2+ during oxidative stress, such as the respiratory burst in granulocytes.	Rhein Westfal TH Aachen, Med Fak, Inst Physiol, D-52057 Aachen, Germany	RWTH Aachen University	Luckhoff, A (corresponding author), Rhein Westfal TH Aachen, Med Fak, Inst Physiol, Paulwelsstr 30, D-52057 Aachen, Germany.							Berthelier V, 1998, BIOCHEM J, V330, P1383, DOI 10.1042/bj3301383; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; COHEN MS, 1994, CLIN INFECT DIS   S2, V18, P170; COLLINS SJ, 1987, BLOOD, V70, P1233; Conrad PW, 2000, ADV EXP MED BIOL, V475, P293; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Herson PS, 1997, J PHYSIOL-LONDON, V501, P59, DOI 10.1111/j.1469-7793.1997.059bo.x; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Ito Y, 1997, J NEUROCHEM, V69, P729; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRAUSE KH, 1993, BLOOD CELLS, V19, P165; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schorr W, 1999, EUR J IMMUNOL, V29, P897, DOI 10.1002/(SICI)1521-4141(199903)29:03<897::AID-IMMU897>3.3.CO;2-X; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	34	279	291	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23150	23156		10.1074/jbc.M112096200	http://dx.doi.org/10.1074/jbc.M112096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960981	hybrid			2022-12-25	WOS:000176475700009
J	Chai, WG; Beeson, JG; Lawson, AM				Chai, WG; Beeson, JG; Lawson, AM			The structural motif in chondroitin sulfate for adhesion of Plasmodium falciparum-infected erythrocytes comprises disaccharide units of 4-O-sulfated and non-sulfated N-acetylgalactosamine linked to glucuronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; MEMBRANE PROTEIN-1 PFEMP1; HUMAN-PLACENTA; HYALURONIC-ACID; MALARIA; ADHERENCE; THROMBOMODULIN; RECEPTOR; IDENTIFICATION; PROTEOGLYCANS	An important characteristic of malaria parasite Plasmodium falciparum-infected red blood cells (IRBCs) is their ability to adhere to host endothelial cells and accumulate in various organs. Sequestration of IRBCs in the placenta, associated with excess perinatal and maternal mortality, is mediated in part by adhesion of parasites to the glycosaminoglyean chondroitin sulfate A (CSA) present on sncytiotrophoblasts lining the placental blood spaces. To define key structural features for parasite interactions, we isolated from CSA oligosaccharide fractions and established by electrospray mass spectrometry and high performance liquid chromatography disaccharide composition analysis their differing chain length, sulfate content, and sulfation pattern. Testing these defined oligosaccharide fragments for their ability to inhibit IRBC adhesion to immobilized CSA revealed the importance of non-sulfated disaccharide units in combination with 4-O-sulfated disaccharides for interaction with IRBCs. Selective removal of 6-O-sulfates from oligo- and polysaccharides to increase the proportion of non-sulfated disaccharides enhanced activity, indicating that 6-O-sulfation interferes with the interaction of CSA with IRBCs. Dodecasaccharides with four or five 4-O-sulfated and two or one non-sulfated disaccharide units, respectively, comprise the minimum chain length for effective interaction with IRBCs. Comparison of the activities of CSA and CSB oligo- and polysaccharides with a similar sulfation pattern and content achieved from partial desulfation demonstrated that glucuronic acid rather than iduronic acid residues are important for IRBC binding.	Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, MRC, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia	Imperial College London; Royal Melbourne Hospital; University of Melbourne	Chai, WG (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, MRC, Glycosci Lab, Harrow HA1 3UJ, Middx, England.	w.chai@ic.ac.uk						Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; Barragan A, 2000, BLOOD, V95, P3594, DOI 10.1182/blood.V95.11.3594.011k21_3594_3599; Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Beeson JG, 1998, INFECT IMMUN, V66, P3397, DOI 10.1128/IAI.66.7.3397-3402.1998; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Chai WG, 1996, ANAL BIOCHEM, V237, P88, DOI 10.1006/abio.1996.0205; Chai WG, 1998, EUR J BIOCHEM, V251, P114, DOI 10.1046/j.1432-1327.1998.2510114.x; Chai WG, 2001, INFECT IMMUN, V69, P420, DOI 10.1128/IAI.69.1.420-425.2001; Chai WG, 1998, ANAL CHEM, V70, P2060, DOI 10.1021/ac9712761; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040; Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7; JUVANI M, 1975, BIOCHIM BIOPHYS ACTA, V411, P1, DOI 10.1016/0304-4165(75)90279-2; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; Maubert B, 2000, PARASITE IMMUNOL, V22, P191, DOI 10.1046/j.1365-3024.2000.00292.x; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X; RODEN L, 1989, CIBA F SYMP, V143, P60; Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; TOIDA T, 1992, ANAL SCI, V8, P799, DOI 10.2116/analsci.8.799; ZHANG WJ, 1992, TETRAHEDRON LETT, V33, P1177, DOI 10.1016/S0040-4039(00)91889-6	35	60	60	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22438	22446		10.1074/jbc.M111401200	http://dx.doi.org/10.1074/jbc.M111401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956186	hybrid			2022-12-25	WOS:000176313600044
J	Cronan, JE				Cronan, JE			Interchangeable enzyme modules - Functional replacement of the essential linker of the biotinylated, subunit of acetyl-CoA carboxylase with a linker from the lipoylated subunit of pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; FATTY-ACID SYNTHESIS; ESCHERICHIA-COLI; MULTIENZYME COMPLEX; POSTTRANSLATIONAL MODIFICATION; CARRIER PROTEIN; 3-DIMENSIONAL STRUCTURE; POLYPEPTIDE-CHAIN; EXCEPTIONAL SPECIFICITY	Biotin carboxbiotinylated subunit of Escherichia coli acetyl-CoA carboxylase, the enzyme that catalyzes the first committed step of fatty acid synthesis. E. coli BCCP is a member of a large family of protein domains modified by covalent attachment of biotin. In most biotinylated proteins, the biotin moiety is attached to a lysine residue located about 35 residues from the carboxyl terminus of the protein, which lies in the center of a strongly conserved sequence that forms a tightly folded anti-parallel beta-barrel structure. Located upstream of the conserved biotinoyl domain sequence are proline/alanine-rich sequences of varying lengths, which have been proposed to act as flexible linkers. In E. coli BCCP, this putative linker extends for about 42 residues with over half of the residues being proline or alanine. I report that deletion of the 30 linker residues located adjacent to the biotinoyl domain resulted in a BCCP species that was defective in function in vivo, although it was efficiently biotinylated. Expression of this BCCP species failed to restore normal growth and fatty acid synthesis to a temperature-sensitive E. coli strain that lacks BCCP when grown at nonpermissive temperatures. In contrast, replacement of the deleted BCCP linker with a linker derived from E. coli pyruvate dehydrogenase gave a chimeric BCCP species that had normal in vivo function. Expression of BCCPs having deletions of various segments of the linker region of the chimeric protein showed that some deletions of up to 24 residues had significant or full biological activity, whereas others had very weak or no activity. The inactive deletion proteins all lacked an APAAAAA sequence located adjacent to the tightly folded biotinyl domain, whereas deletions that removed only upstream linker sequences remained active. Deletions within the linker of the wild type BCCP protein also showed that the residues adjacent to the tightly folded domain play an essential role in protein function, although in this case some proteins with deletions within this region retained activity. Retention of activity was due to fusion of the domain to upstream sequences. These data provide new evidence for the functional and structural similarities of biotinylated and lipoylated proteins and strongly support a common evolutionary origin of these enzyme subunits.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BARKER DF, 1980, J BACTERIOL, V143, P789, DOI 10.1128/JB.143.2.789-800.1980; BEST EA, 1993, J BACTERIOL, V175, P6881, DOI 10.1128/jb.175.21.6881-6889.1993; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Cronan JE, 2001, J BIOL CHEM, V276, P37355, DOI 10.1074/jbc.M106353200; CRONAN JE, 1988, J BIOL CHEM, V263, P10332; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; GREEN JDF, 1992, J BIOL CHEM, V267, P23484; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; HASAN N, 1989, GENE, V82, P305, DOI 10.1016/0378-1119(89)90055-3; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; MARINI P, 1995, J BACTERIOL, V177, P7003, DOI 10.1128/jb.177.23.7003-7006.1995; MILES JS, 1988, J MOL BIOL, V202, P97, DOI 10.1016/0022-2836(88)90522-0; MILES JS, 1987, BIOCHIM BIOPHYS ACTA, V913, P117, DOI 10.1016/0167-4838(87)90319-0; MORRIS TW, 1994, THESIS U ILLINOIS UR; MURTIF VL, 1987, J BIOL CHEM, V262, P11813; Ohlrogge J, 2000, BIOCHEM SOC T, V28, P567, DOI 10.1042/BST0280567; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1981, NATURE, V292, P474, DOI 10.1038/292474a0; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RADFORD SE, 1989, J BIOL CHEM, V264, P767; RADFORD SE, 1987, BIOCHEM J, V247, P641, DOI 10.1042/bj2470641; RADFORD SE, 1989, FEBS LETT, V250, P336, DOI 10.1016/0014-5793(89)80750-1; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; Ricaud PM, 1996, J MOL BIOL, V264, P179, DOI 10.1006/jmbi.1996.0632; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; TEXTER FL, 1988, BIOCHEMISTRY-US, V27, P289, DOI 10.1021/bi00401a044; TURNER SL, 1993, PROTEIN ENG, V6, P101, DOI 10.1093/protein/6.1.101; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	43	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22520	22527		10.1074/jbc.M201249200	http://dx.doi.org/10.1074/jbc.M201249200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956202	hybrid			2022-12-25	WOS:000176313600055
J	Giuffre, A; Barone, MC; Brunori, M; D'Itri, E; Ludwig, B; Malatesta, F; Muller, HW; Sarti, P				Giuffre, A; Barone, MC; Brunori, M; D'Itri, E; Ludwig, B; Malatesta, F; Muller, HW; Sarti, P			Nitric oxide reacts with the single-electron reduced active site of cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; RHODOBACTER-SPHAEROIDES; PROTON-TRANSFER; BINUCLEAR CENTER; HELIX-VIII; SUBUNIT-I; K-PATHWAY; INHIBITION; MECHANISM; RESPIRATION	The reduction kinetics of the mutants K354M and D124N of the Paracoccus denitrificans cytochrome oxidase (heme aa(3)) by ruthenium hexamine was investigated by stopped-flow spectrophotometry in the absence/presence of NO. Quick heme a reduction precedes the biphasic heme a(3) reduction, which is extremely slow in the K354M mutant (k(1) = 0.09 +/- 0.01 s(-1); k(2) = 0.005 +/- 0.001 s(-1)) but much faster in the D124N aa(3) (k(1) = 21 +/- 6 s(-1); k(2) = 2.2 +/- 0.5 s(-1)). NO causes a very large increase (>100-fold) in the rate constant of heme as reduction in the K354M mutant but only a similar to5-fold increase in the D124N mutant. The K354M enzyme reacts rapidly with O-2 when fully reduced but is essentially inactive in turnover; thus, it was proposed that impaired reduction of the active site is the cause of activity loss. Since at saturating [NO], heme as reduction is similar to100-fold faster than the extremely low turnover rate, we conclude that, contrary to O-2, NO can react not only with the two-electron but also with the single-electron reduced active site. This mechanism would account for the efficient inhibition of cytochrome oxidase activity by NO in the wild-type enzyme, both from P. denitrificans and from beef heart. Results also suggest that the H+-conducting K pathway, but not the D pathway, controls the kinetics of the single-electron reduction of the active site.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, CNR, Inst Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Frankfurt, Biozentrum, Inst Biochem Mol Genet, D-60439 Frankfurt, Germany; Univ Aquila, Dept Pure & Appl Biol, I-67100 Laquila, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; Goethe University Frankfurt; University of L'Aquila	Giuffre, A (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, CNR, Inst Biol & Patol Mol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Sarti, Paolo/D-2946-2009; Giuffrè, Alessandro/K-4341-2015; Malatesta, Francesco/AAT-4757-2020	Giuffrè, Alessandro/0000-0001-5301-0681; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				Adelroth P, 1998, BIOCHEMISTRY-US, V37, P2470, DOI 10.1021/bi971813b; Branden M, 2001, P NATL ACAD SCI USA, V98, P5013, DOI 10.1073/pnas.081088398; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Brunori M, 1997, J BIOL CHEM, V272, P19870, DOI 10.1074/jbc.272.32.19870; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; Giuffre A, 1998, J BIOL CHEM, V273, P32475, DOI 10.1074/jbc.273.49.32475; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Hosler JP, 1996, BIOCHEMISTRY-US, V35, P10776, DOI 10.1021/bi9606511; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Junemann S, 1997, BIOCHEMISTRY-US, V36, P14456, DOI 10.1021/bi971458p; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; Ruitenberg M, 2000, P NATL ACAD SCI USA, V97, P4632, DOI 10.1073/pnas.080079097; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; SVENSSON M, 1995, BIOCHEMISTRY-US, V34, P5252, DOI 10.1021/bi00015a040; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; Verkhovsky MI, 2001, BIOCHEMISTRY-US, V40, P7077, DOI 10.1021/bi010030u; Vygodina TV, 1998, BIOCHEMISTRY-US, V37, P3053, DOI 10.1021/bi971876u; Wikstrom M, 2000, BBA-BIOENERGETICS, V1459, P514, DOI 10.1016/S0005-2728(00)00191-2; Zaslavsky D, 1998, BIOCHEMISTRY-US, V37, P3062, DOI 10.1021/bi971877m; Zaslavsky D, 1999, BIOCHEMISTRY-US, V38, P16016, DOI 10.1021/bi9916675; Zaslavsky D, 2000, BBA-BIOENERGETICS, V1458, P164, DOI 10.1016/S0005-2728(00)00066-9	31	33	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22402	22406		10.1074/jbc.M201514200	http://dx.doi.org/10.1074/jbc.M201514200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950842	hybrid			2022-12-25	WOS:000176313600038
J	Henricksen, LA; Veeraraghavan, J; Chafin, DR; Bambara, RA				Henricksen, LA; Veeraraghavan, J; Chafin, DR; Bambara, RA			DNA ligase I competes with FEN1 to expand repetitive DNA sequences in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAG REPEAT TRACTS; HUMAN GENETIC-DISEASE; SACCHAROMYCES-CEREVISIAE; TRINUCLEOTIDE REPEAT; MISMATCH REPAIR; TRIPLET REPEATS; REPLICATION MUTATIONS; SECONDARY STRUCTURE; POLYMERASE-DELTA; TRANSGENIC MICE	Repeat sequences in various genomes undergo expansion by poorly understood mechanisms. By using an oligonucleotide system containing such repeats, we recapitulated the last steps in Okazaki fragment processing, which have been implicated in sequence expansion. A template containing either triplet or tandem repeats was annealed to a downstream primer containing complementary repeats at its 5'-end. Overlapping upstream primers, designed to strand-displace varying numbers of repeats in the downstream primer, were annealed. Human DNA ligase I joined overlapping segments of repeats generating an expansion product from the primer strands. Joining efficiency decreased with repeat length. Flap endonuclease 1 (FEN1) cleaved the displaced downstream strand and together with DNA ligase I produced non-expanded products. However, both expanded and non-expanded products formed irrespective of relative nuclease and ligase concentrations tested or enzyme addition order, suggesting the preexistence and persistence of intermediates leading to both outcomes. FEN1 activity decreased with the length of repeat segment displaced presumably because the flap forms structures that inhibit cleavage. Increased MgCl2 disfavored ligation of substrate intermediates that result in expansion products. Examination of expansion in vitro enables dissection of substrate and replication enzyme dynamics on repeat sequences.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441, GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Balakumaran BS, 2000, HUM MOL GENET, V9, P93, DOI 10.1093/hmg/9.1.93; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bennett P, 2000, J CLIN PATHOL-MOL PA, V53, P177; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; Chastain PD, 1998, J MOL BIOL, V275, P405, DOI 10.1006/jmbi.1997.1502; Fortune MT, 2000, HUM MOL GENET, V9, P439, DOI 10.1093/hmg/9.3.439; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; Ireland MJ, 2000, GENETICS, V155, P1657; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jankowski C, 2000, P NATL ACAD SCI USA, V97, P2134, DOI 10.1073/pnas.040460297; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Jin YH, 2001, P NATL ACAD SCI USA, V98, P5122, DOI 10.1073/pnas.091095198; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kovtun IV, 2001, NAT GENET, V27, P407, DOI 10.1038/86906; Kovtun IV, 2000, HUM MOL GENET, V9, P2767, DOI 10.1093/hmg/9.18.2767; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Pearson CE, 1998, NUCLEIC ACIDS RES, V26, P816, DOI 10.1093/nar/26.3.816; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; Rolfsmeier ML, 2000, MOL CELL BIOL, V20, P173, DOI 10.1128/MCB.20.1.173-180.2000; Rolfsmeier ML, 2001, GENETICS, V157, P1569; Rolfsmeier ML, 2000, MOL CELL, V6, P1501, DOI 10.1016/S1097-2765(00)00146-5; Saenger W., 1984, PRINCIPLES NUCL ACID; Schweitzer JK, 1999, GENETICS, V152, P953; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Usdin K, 2000, CELL MOL LIFE SCI, V57, P914, DOI 10.1007/PL00000734; White PJ, 1999, MOL CELL BIOL, V19, P5675	42	41	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22361	22369		10.1074/jbc.M201765200	http://dx.doi.org/10.1074/jbc.M201765200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948189	hybrid			2022-12-25	WOS:000176313600033
J	Sasaki, A; Masuda, Y; Iwai, K; Ikeda, K; Watanabe, K				Sasaki, A; Masuda, Y; Iwai, K; Ikeda, K; Watanabe, K			A RING finger protein praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Needin family protein, Dlxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SUPPRESSOR NECDIN; PRADER-WILLI-SYNDROME; MAGE GENE FAMILY; P53; MDM2; IDENTIFICATION; COMPLEX; LYMPHOCYTES; DISRUPTION; EXPRESSION	Msx2 and Dlx5 are homeodomain proteins that play an important role in osteoblast differentiation and whose expression is induced by bone morphogenetic proteins. Recently we have identified a novel protein, Dlxin-1, that associates with these homeodomain proteins and regulates Dlx5-dependent transcriptional function (Masuda, Y., Sasaki, A., Shibuya, H., Ueno, N., Ikeda, K., and Watanabe, K. (2001) J. Biol. Chem. 276, 5331-5338). In an attempt to elucidate the molecular function of Dlxin-1, two closely related RING finger proteins, Prajal and Neurodap-1, were isolated by yeast two-hybrid screening using the C-terminal necdin homology domain of Dlxin-1 as bait. Glutathione S-transferase pull-down and immunoprecipitation/Western blotting assays following co-transfection of Dlxin-1 and Prajal revealed that Prajal binds to the C-terminal necdin homology domain of Dlxin-1 in vitro and in vivo, respectively. Overexpression of Prajal caused a decrease in Dlxin-1 protein level, which was reversed when a proteasome inhibitor was added. Overexpression of Prajal with a mutation in the RING finger inhibited the decrease in Dlxin-1 protein, pointing to the importance of ubiquitin-protein isopeptide ligase (E3) activity associated with RING finger. Wild-type Prajal, but not its RING finger mutant, promoted ubiquitination of Dlxin-1 in vivo. Finally, expression of Prajal down-regulated Dlx5-dependent transcriptional activity in a GAL4-dependent assay. These results suggest that Prajal regulates the transcription function of the homeodomain protein Dlx5 by controlling the stability of Dlxin-1 via an ubiquitin-dependent degradation pathway.	NILS, Dept Geriatr Res, Aichi 4748522, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Abeno Ku, Osaka 5458585, Japan	Osaka Metropolitan University	Watanabe, K (corresponding author), NILS, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.		Watanabe, Ken/I-3960-2013; IWAI, KAZUHIRO/GSN-7385-2022	Watanabe, Ken/0000-0003-0664-3915; Iwai, Kazuhiro/0000-0001-5620-5951				Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chomez P, 2001, CANCER RES, V61, P5544; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gerard M, 1999, NAT GENET, V23, P199, DOI 10.1038/13828; Hennuy B, 2000, ENDOCRINOLOGY, V141, P3821, DOI 10.1210/en.141.10.3821; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lucas S, 1999, CANCER RES, V59, P4100; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Muscatelli F, 2000, HUM MOL GENET, V9, P3101, DOI 10.1093/hmg/9.20.3101; NAKAYAMA M, 1995, J NEUROSCI, V15, P5238; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	35	82	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22541	22546		10.1074/jbc.M109728200	http://dx.doi.org/10.1074/jbc.M109728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11959851	hybrid			2022-12-25	WOS:000176313600058
J	Sawa, C; Yoshikawa, T; Matsuda-Suzuki, F; Delehouzee, S; Goto, M; Watanabe, H; Sawada, J; Kataoka, K; Handa, H				Sawa, C; Yoshikawa, T; Matsuda-Suzuki, F; Delehouzee, S; Goto, M; Watanabe, H; Sawada, J; Kataoka, K; Handa, H			YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GA-BINDING-PROTEIN; UTROPHIN PROMOTER; POLYCOMB COMPLEX; E4TF1 SUBUNITS; RB GENE; ETS; ACTIVATION; EXPRESSION; INTERACTS; SITE	The transcription factor hGABP/E4TF1 is a heterotetrameric complex composed of two DNA-binding subunits (hGABPalpha/E4TF1-60) and two transactivating subunits (hGABPbeta/E4TF1-53). In order to understand the molecular mechanism of transcriptional regulation by hGABP, we searched for proteins that interact with the non-DNA-binding subunit, hGABPbeta, using yeast two-hybrid screening. We identified a human cDNA encoding a protein related to YAF-2 (YY1-associated factor 2), which was previously isolated as an interacting partner of the Ying-Yang-1 (YY1) transcription factor. Reflecting this similarity, both YAF-2 and this novel protein (named YEAF1 for YY1- and E4TF1/hGABP-associated factor-1) interacted with hGABPbeta and YY1 in vitro and in vivo, indicating that YEAF1 and YAF-2 constitute a cofactor family for these two structurally distinct transcription factors. By using yeast three-hybrid assay, we demonstrated that hGABPbeta and YY1 formed a complex only in the presence of YEAF1, indicating that YEAF1 is a bridging factor of these two transcription factors. These cofactors are functionally different in that YAF-2 positively regulates the transcriptional activity of hGABP but YEAF1 negatively regulates this activity. Also, YAF-2 mRNA is highly expressed in skeletal muscle, whereas YEAF1 mRNA is highly expressed in placenta. We speculate that the transcriptional activity of hGABP is in part regulated by the expression levels of these tissue-specific cofactors. These results provide a novel mechanism of transcriptional regulation by functionally distinct cofactor family members.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Okazaki Natl Res Inst, Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Tokyo Institute of Technology; Tokyo Institute of Technology; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Handa, H (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Watanabe, Hajime/S-8957-2019; WATANABE, Hajime/AAJ-8904-2021	Watanabe, Hajime/0000-0001-9657-6554				Avots A, 1997, MOL CELL BIOL, V17, P4381, DOI 10.1128/MCB.17.8.4381; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Genuario R. Robert, 1993, Gene Expression, V3, P279; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Morii E, 2001, BLOOD, V97, P3032, DOI 10.1182/blood.V97.10.3032; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Sawa C, 1996, NUCLEIC ACIDS RES, V24, P4954, DOI 10.1093/nar/24.24.4954; Sawada J, 1999, J BIOL CHEM, V274, P35475, DOI 10.1074/jbc.274.50.35475; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sowa Y, 1997, CANCER RES, V57, P3145; Suzuki F, 1998, J BIOL CHEM, V273, P29302, DOI 10.1074/jbc.273.45.29302; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Vassias I, 1998, J BIOL CHEM, V273, P8287, DOI 10.1074/jbc.273.14.8287; Villena JA, 1998, BIOCHEM J, V331, P121, DOI 10.1042/bj3310121; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	34	43	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22484	22490		10.1074/jbc.M203060200	http://dx.doi.org/10.1074/jbc.M203060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953439	hybrid			2022-12-25	WOS:000176313600050
J	Akache, B; Turcotte, B				Akache, B; Turcotte, B			New regulators of drug sensitivity in the family of yeast zinc cluster proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; MULTIDRUG-RESISTANCE TRANSPORTER; 4-NITROQUINOLINE N-OXIDE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATOR; PLEIOTROPIC DRUG; GENE-EXPRESSION; ENCODING GENE; METAL RESISTANCE; ABC PROTEINS	The Gal4p family of yeast zinc cluster proteins comprises over 50 members that are putative transcriptional regulators. For example, Pdr1p and Pdr3p activate multidrug resistance genes by binding to pleiotropic drug response elements (PDREs) found in promoters of target genes such as PDR5, encoding a drug efflux pump involved in resistance to cycloheximide. However, the role of many zinc cluster proteins is unknown. We tested a panel of strains carrying deletions of zinc cluster genes in the presence of various drugs. One deletion strain (Deltardr1) was resistant to cycloheximide, whereas eight strains showed sensitivity to the antifungal ketoconazole or cycloheximide. Unnamed zinc cluster genes identified in our screen were called RDS for regulators of drug sensitivity. RNA levels of multidrug resistance genes such as PDR16, SNQ2, and PDR5 were decreased in many deletion strains. For example, cycloheximide sensitivity of a Deltastb5 strain was correlated with decreased RNA levels and promoter activity of the PDR5 gene. We tested if activation of PDR5 is mediated via a PDRE by inserting this DNA element in front of a minimal promoter linked to the lacZ gene. Strikingly, activity of the reporter was decreased in a Deltastb5 strain. The purified DNA binding domain of Stb5p bound to a PDRE in vitro. Mutations in the PDRE known to affect binding of Pdr1p/Pdr3p showed similar effects when assayed with Stb5p. These results strongly suggest that Stb5p is a transcriptional activator of multidrug resistance genes. Thus, we have identified new regulators of drug sensitivity in the family of zinc cluster proteins.	McGill Univ, Royal Victoria Hosp, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, Ctr Hlth, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	turcotte@lan1.molonc.mcgill.ca		Akache, Bassel/0000-0002-5377-7193				Adams A, 1997, METHODS YEAST GENETI; Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Angus-Hill ML, 2001, MOL CELL, V7, P741, DOI 10.1016/S1097-2765(01)00219-2; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Brachmann CB, 1998, YEAST, V14, P115; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; Cui Z, 1998, MOL MICROBIOL, V29, P1307, DOI 10.1046/j.1365-2958.1998.01027.x; Cui ZF, 1999, BIOSCI BIOTECH BIOCH, V63, P162, DOI 10.1271/bbb.63.162; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GOMPELKLEIN P, 1990, CURR GENET, V18, P93, DOI 10.1007/BF00321122; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Groom KR, 1998, YEAST, V14, P77, DOI 10.1002/(SICI)1097-0061(19980115)14:1<77::AID-YEA201>3.0.CO;2-P; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Hellauer K, 2001, J BIOL CHEM, V276, P13587, DOI 10.1074/jbc.M011196200; HELLAUER K, 2002, IN PRESS J BIOL CHEM, V277; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; Iraqui I, 1999, MOL CELL BIOL, V19, P3360; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL GEN GENET, V256, P376, DOI 10.1007/s004380050581; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; LEPPERT G, 1990, GENETICS, V125, P13; Lesage P, 1996, MOL CELL BIOL, V16, P1921, DOI 10.1128/mcb.16.5.1921; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; NEEDLEMAN R, 1991, MOL MICROBIOL, V5, P2079, DOI 10.1111/j.1365-2958.1991.tb02136.x; NISHIMURA H, 1992, FEBS LETT, V297, P155, DOI 10.1016/0014-5793(92)80349-L; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; SCHNELL N, 1991, EUR J BIOCHEM, V200, P487, DOI 10.1111/j.1432-1033.1991.tb16209.x; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SIKORSKI RS, 1989, GENETICS, V122, P19; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; VIK A, 2000, MOL CELL BIOL, V20, P4381; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; WU AL, 1993, J BIOL CHEM, V268, P18850	61	60	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21254	21260		10.1074/jbc.M202566200	http://dx.doi.org/10.1074/jbc.M202566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943786	hybrid			2022-12-25	WOS:000176286000019
J	Lin, YQ; Hwang, WC; Basavappa, R				Lin, YQ; Hwang, WC; Basavappa, R			Structural and functional analysis of the human mitotic-specific ubiquitin-conjugating enzyme, UbcH10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; PROTEIN; ANAPHASE; E2-C; DESTRUCTION; COMPLEX; IDENTIFICATION; EXPRESSION	Cell cycle progression is controlled at several different junctures by the targeted destruction of cell cycle regulatory proteins. These carefully orchestrated events include the destruction of the securin protein to permit entry into anaphase, and the destruction of cyclin B to permit exit from mitosis. These destruction events are mediated by the ubiquitin/proteasome system. The human ubiquitin-conjugating enzyme, UbcH10, is an essential mediator of the mitotic destruction events. We report here the 1.95-Angstrom crystal structure of a mutant UbcH10, in which the active site cysteine has been replaced with a serine. Functional analysis indicates that the mutant is active in accepting ubiquitin, although not as efficiently as wild-type. Examination of the crystal structure reveals that the NH2-terminal extension in UbcH10 is disordered and that a conserved 3(10)-helix places a lysine residue near the active site. Analysis of relevant mutants demonstrates that for ubiquitin-adduct formation the presence or absence of the NH2-terminal extension has little effect, whereas the lysine residue near the active site has significant effect. The structure provides additional insight into UbcH10 function including possible sites of interaction with the anaphase promoting complex/cyclosome and the disposition of a putative destruction box motif in the structure.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Basavappa, R (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.	Ravi_Basavappa@urmc.rochester.edu	Basavappa, Ravi/AAF-7385-2021		NIGMS NIH HHS [GM 57536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amon A, 2001, NAT CELL BIOL, V3, pE12, DOI 10.1038/35050642; Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Armon A, 2001, J MOL BIOL, V307, P447, DOI 10.1006/jmbi.2000.4474; ARNOLD JE, 1990, BIOCHEM J, V267, P751, DOI 10.1042/bj2670751; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Funabiki H, 1997, EMBO J, V16, P5977, DOI 10.1093/emboj/16.19.5977; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Osaka F, 1997, MOL CELL BIOL, V17, P3388, DOI 10.1128/MCB.17.6.3388; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICKART CM, 1985, J BIOL CHEM, V260, P1573; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; RUSSELL RB, 1999, STAMP VERSION 4 2 MA; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; Tokumoto M, 1999, FEBS LETT, V458, P375, DOI 10.1016/S0014-5793(99)01189-8; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wada H, 2000, J BIOL CHEM, V275, P17008, DOI 10.1074/jbc.275.22.17008; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Yamanaka A, 2000, MOL BIOL CELL, V11, P2821, DOI 10.1091/mbc.11.8.2821; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zhang C, 2000, J MOL BIOL, V299, P1075, DOI 10.1006/jmbi.2000.3678; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	56	52	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21913	21921		10.1074/jbc.M109398200	http://dx.doi.org/10.1074/jbc.M109398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927573	hybrid			2022-12-25	WOS:000176286000103
J	Sakaguchi, T; Gu, XB; Golden, HM; Suh, ER; Rhoads, DB; Reinecker, HC				Sakaguchi, T; Gu, XB; Golden, HM; Suh, ER; Rhoads, DB; Reinecker, HC			Cloning of the human claudin-2 5 '-flanking region revealed a TATA-less promoter with conserved binding sites in mouse and human for caudal-related homeodomain proteins and hepatocyte nuclear factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINE-SPECIFIC TRANSCRIPTION; PHLORHIZIN HYDROLASE GENE; SUCRASE-ISOMALTASE GENE; TIGHT JUNCTION STRANDS; EPITHELIAL-CELL LINE; NF-KAPPA-B; HOMEOBOX GENE; FACTOR-I; EXPRESSION; HNF-1-ALPHA	Claudin-2 is a structural component of tight junctions in the kidneys, liver, and intestine, but the mechanisms regulating its expression have not been defined. The 5'-flanking region of the claudin-2 gene contains binding sites for intestine-specific Cdx homeodomain proteins and hepatocyte nuclear factor (HNF)-1, which are conserved in human and mouse. Both Cdx1 and Cdx2 activated the claudin-2 promoter in the human intestinal epithelial cell line Caco-2. HNF-1alpha augmented the Cdx2-induced but not Cdx1-induced transcriptional activation of the human claudin-2 promoter. In mice, HNF-1alpha was required for claudin-2 expression in the villus epithelium of the ileum and within the liver but not in the kidneys, indicating an organ-specific function of HNF-1alpha in the regulation of claudin-2 gene expression. Tight junction structural components, which determine epithelial polarization and intestinal barrier function, can be regulated by homeodomain proteins that control the differentiation of the intestinal epithelium.	Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat, Pediat Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Penn, Sch Med, Dept Internal Med, Philadelphia, PA 19104 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Reinecker, HC (corresponding author), Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Dept Med, Gastrointestinal Unit, 32 Fruit St, Boston, MA 02114 USA.				NIDDK NIH HHS [DK51003, DK54399, DK54427, DK33506] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R01DK054427, R01DK051003, R01DK054399] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama TE, 2000, J BIOL CHEM, V275, P27117; ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Awane M, 1999, J IMMUNOL, V162, P5337; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Charite J, 1998, DEVELOPMENT, V125, P4349; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; Drummond FJ, 1998, FEBS LETT, V423, P218, DOI 10.1016/S0014-5793(98)00103-3; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; JAMES R, 1994, J BIOL CHEM, V269, P15229; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; ORKIN SH, 1992, BLOOD, V80, P575; Park J, 2000, GASTROENTEROLOGY, V119, P89, DOI 10.1053/gast.2000.8520; Pontoglio M, 2000, J AM SOC NEPHROL, V11, pS140; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; Whyte DA, 1999, AM J PHYSIOL-RENAL, V277, pF587, DOI 10.1152/ajprenal.1999.277.4.F587; WU GD, 1994, J BIOL CHEM, V269, P17080; Xu FH, 1999, J BIOL CHEM, V274, P34310, DOI 10.1074/jbc.274.48.34310	55	143	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21361	21370		10.1074/jbc.M110261200	http://dx.doi.org/10.1074/jbc.M110261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934881	hybrid			2022-12-25	WOS:000176286000033
J	Duchesne, L; Pellerin, I; Delamarche, C; Deschamps, S; Lagree, V; Froger, A; Bonnec, G; Thomas, D; Hubert, JF				Duchesne, L; Pellerin, I; Delamarche, C; Deschamps, S; Lagree, V; Froger, A; Bonnec, G; Thomas, D; Hubert, JF			Role of C-terminal domain and transmembrane helices 5 and 6 in function and quaternary structure of major intrinsic proteins - Analysis of aquaporin/glycerol facilitator chimeric proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNELS; MIP FAMILY; OLIGOMERIZATION STATE; ESCHERICHIA-COLI; GLYCEROL CHANNEL; XENOPUS OOCYTES; FREEZE-FRACTURE; AQUAPORIN-1; PERMEATION; MEMBRANES	We previously observed that aquaporins and glycerol facilitators exhibit different oligomeric states when studied by sedimentation on density gradients following nondenaturing detergent solubilization. To determine the domains of major intrinsic protein (MIP) family proteins involved in oligomerization, we constructed protein chimeras corresponding to the aquaporin AQPcic substituted in the loop E (including the proximal part of transmembrane domain (TM) 5) and/or the C-terminal part (including the distal part of TM 6) by the equivalent domain of the glycerol channel aquaglyceroporin (GlpF) (chimeras called AGA, AAG, and AGG). The analogous chimeras of GlpF were also constructed (chimeras GAG, GGA, and GAA). cRNA corresponding to all constructs were injected into Xenopus oocytes. AQPcic, GlpF, AAG, AGG, and GAG were targeted to plasma membranes. Water or glycerol membrane permeability measurements demonstrated that only the AAG chimera exhibited a channel function corresponding to water transport. Analysis of all proteins expressed either in oocytes or in yeast by velocity sedimentation on sucrose gradients following solubilization by 2% n-octyl glucoside indicated that only AQPcic and AAG exist in tetrameric forms. GlpF, GAG, and GAA sediment in a monomeric form, whereas GGA and AGG were found mono/dimeric. These data bring new evidence that, within the MIP family, aquaporins and GlpFs behave differently toward nondenaturing detergents. We demonstrate that the C-terminal part of AQPcic, including the distal half of TM 6, can be substituted by the equivalent domain of GlpF (AAG chimera) without modifying the transport specificity. Our results also suggest that interactions of TM 5 of one monomer with TM 1 of the adjacent monomer are crucial for aquaporin tetramer stability.	Univ Rennes 1, UMR 6026, CNRS, F-35042 Rennes, Bretagne, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Hubert, JF (corresponding author), Univ Rennes 1, UMR 6026, CNRS, Campus Beaulieu,Batiment 13, F-35042 Rennes, Bretagne, France.		THOMAS, Danniel/AAJ-5033-2020; DELAMARCHE, Christian/A-2138-2010	THOMAS, Danniel/0000-0002-9650-0434; DELAMARCHE, Christian/0000-0002-8963-0062; Duchesne, Laurence/0000-0003-1985-6266				BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; Borgnia MJ, 2001, P NATL ACAD SCI USA, V98, P2888, DOI 10.1073/pnas.051628098; Bron P, 1999, J STRUCT BIOL, V128, P287, DOI 10.1006/jsbi.1999.4196; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Delamarche C, 2000, BIOTECHNIQUES, V29, P100, DOI 10.2144/00291bc01; Duchesne L, 2001, KIDNEY INT, V60, P422, DOI 10.1046/j.1523-1755.2001.060002422.x; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Heymann JB, 2000, J MOL BIOL, V295, P1039, DOI 10.1006/jmbi.1999.3413; Ishibashi K, 1998, NEWS PHYSIOL SCI, V13, P137; Jensen MO, 2001, STRUCTURE, V9, P1083, DOI 10.1016/S0969-2126(01)00668-2; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 2000, NEPHROL DIAL TRANSPL, V15, P26, DOI 10.1093/ndt/15.suppl_6.26; Kuwahara M, 1999, BIOCHEMISTRY-US, V38, P16340, DOI 10.1021/bi9916776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagree V, 1998, J BIOL CHEM, V273, P12422, DOI 10.1074/jbc.273.20.12422; Lagree V, 1998, J BIOL CHEM, V273, P33949, DOI 10.1074/jbc.273.51.33949; Lagree V, 1999, J BIOL CHEM, V274, P6817, DOI 10.1074/jbc.274.11.6817; LeCaherec F, 1996, EUR J BIOCHEM, V241, P707, DOI 10.1111/j.1432-1033.1996.00707.x; Manley DM, 2000, BIOCHEMISTRY-US, V39, P12303, DOI 10.1021/bi000703t; Mathai JC, 1999, BIOCHEMISTRY-US, V38, P923, DOI 10.1021/bi9823683; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mulders SM, 1998, PFLUG ARCH EUR J PHY, V436, P599, DOI 10.1007/s004240050677; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nollert P, 2001, FEBS LETT, V504, P112, DOI 10.1016/S0014-5793(01)02710-7; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; Ren G, 2000, J STRUCT BIOL, V130, P45, DOI 10.1006/jsbi.2000.4211; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Tsiuriupa G P, 1994, Mol Biol (Mosk), V28, P725; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Zhu FQ, 2001, FEBS LETT, V504, P212, DOI 10.1016/S0014-5793(01)02749-1	36	27	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20598	20604		10.1074/jbc.M201179200	http://dx.doi.org/10.1074/jbc.M201179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927589	hybrid			2022-12-25	WOS:000176204500065
J	Gonzales, M; Bowden, GT				Gonzales, M; Bowden, GT			The role of PI 3-kinase in the UVB-induced expression of c-fos	ONCOGENE			English	Article						UVB; c-fos; PI 3-kinase; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; KERATINOCYTE CELL-LINE; P38 MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; AP-1 TRANSACTIVATION; PROTEIN-1 ACTIVATION; BINDING PROTEIN; GENE-EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS	The role of the PI 3-kinase signaling pathway in UVB-induced c-fos gene expression was investigated in a human keratinocyte cell line, HaCaT. The enzymatic activity of PI 3-kinase was increased threefold by 250 J/m(2) UVB. Inhibition of PI 3-kinase activity, via expression of a mutant p85 subunit or treatment with wortmannin, resulted in decreased levels of c-fos promoter activity and c-fos protein. Two members of the PI 3-kinase signaling pathway, Akt and GSK-3beta, were also found to affect c-fos transactivation. Expression of dominant negative Akt or wild-type GSK-3beta significantly inhibited UVB-induced c-fos promoter activity. In addition, when GSK-3beta activity was inhibited by lithium chloride, both c-fos promoter activity and protein levels increased. These results demonstrate that both Akt activation and GSK-3beta inactivation are required in the UVB-induction of c-fos. Our results demonstrate for the first time that UVB induction of c-fos is in part mediated by the PI 3-kinase signaling pathway in the HaCaT cell line. By identifying the multiple signaling pathways that are induced by UVB and contribute to the induction of c-fos expression, more drug targets may be identified to aid attempts to prevent and treat skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), 1515 N Campbell,Radiat 1,Rm 4999, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CANCER RES, V58, P711; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Funakoshi M, 2001, INT IMMUNOPHARMACOL, V1, P595, DOI 10.1016/S1567-5769(00)00035-7; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Ibuki Y, 2000, BIOCHEM BIOPH RES CO, V279, P872, DOI 10.1006/bbrc.2000.4018; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; POWIS G, 1994, CANCER RES, V54, P2419; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang QB, 2001, CANCER RES, V61, P4329; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wan YS, 2001, INT J ONCOL, V18, P461; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	45	35	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2721	2728		10.1038/sj.onc.1205366	http://dx.doi.org/10.1038/sj.onc.1205366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965545				2022-12-25	WOS:000174996500012
J	Tomicic, MT; Thust, R; Kaina, B				Tomicic, MT; Thust, R; Kaina, B			Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation	ONCOGENE			English	Article						apoptosis; Bcl-2 cleavage; caspase-9; ganciclovir; DNA breakage; suicide gene therapy	CYTOCHROME-C; GENE-THERAPY; CANCER-CELLS; VIRUS; DEATH; P53; PROTEASE; SIGNALS; RELEASE; DAMAGE	Although ganciclovir (GCV) is most often used in suicide anticancer gene therapy, the mechanism of GCV-induced cell killing and apoptosis is not fully understood. We analysed the mechanism of apoptosis triggered by GCV using a model system of CHO cells stably transfected with HSV-1 thymidine kinase (HSVtk). GCV-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Further decline in the Bcl-2 level was due to cleavage of the protein by caspase-9 as demonstrated by use of caspase inhibitors and transfection with trans-dominant negative caspase expression vectors. Bcl-2 cleavage resulted in the appearance of a pro-apoptotic 23 kDa Bcl-2 fragment and in excessive cytochrome c release, dephosphorylation of BAD, cleavage of PARP and finally DNA degradation. Since Fas/CD95 and caspase-8 were only slightly activated we conclude GCV-induced apoptosis to occur in this cell system mainly by activating the mitochondrial damage pathway. This process is independent of p53 for which the cells are mutated. Caspase-9 mediated cleavage of Bel-2 accelerates the apoptotic process and may explain the high potential of GCV to induce apoptosis. Data are also discussed as to implications for HSVtk gene therapy utilizing GCV.	Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany; Univ Jena, Fac Med, Inst Antiviral Chemotherapy, D-07745 Jena, Germany	Johannes Gutenberg University of Mainz; Friedrich Schiller University of Jena	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@mail.uni-mainz.de	Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Craperi D, 1999, HUM GENE THER, V10, P679, DOI 10.1089/10430349950018751; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Feinmesser M, 1999, HUM PATHOL, V30, P1367, DOI 10.1016/S0046-8177(99)90070-9; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO;2-R; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Halloran PJ, 1998, CANCER RES, V58, P3855; Hamel W, 1996, CANCER RES, V56, P2697; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; Izquierdo M, 1996, GENE THER, V3, P491; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; MOOLTEN FL, 1986, CANCER RES, V46, P5276; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBE G, 1985, MUTAT RES, V150, P359; Ochs K, 2000, CANCER RES, V60, P5815; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; OLIVE PL, 1991, CANCER RES, V51, P4671; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; Rubsam LZ, 1998, CANCER RES, V58, P3873; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thust R, 2000, CANCER GENE THER, V7, P107, DOI 10.1038/sj.cgt.7700106; Thust R, 2000, MUTAGENESIS, V15, P177, DOI 10.1093/mutage/15.2.177; Tomicic M, 1997, MUTAT RES-DNA REPAIR, V383, P155, DOI 10.1016/S0921-8777(96)00055-9; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Tomicic MT, 2000, BIOCHEM BIOPH RES CO, V275, P899, DOI 10.1006/bbrc.2000.3386; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XN, 1997, EXP CELL RES, V235, P210, DOI 10.1006/excr.1997.3667; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053	53	102	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2141	2153		10.1038/sj.onc.1205280	http://dx.doi.org/10.1038/sj.onc.1205280			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948397				2022-12-25	WOS:000174555300003
J	Saur, D; Seidler, B; Paehge, H; Schusdziarra, V; Allescher, HD				Saur, D; Seidler, B; Paehge, H; Schusdziarra, V; Allescher, HD			Complex regulation of human neuronal nitric-oxide synthase Exon 1c gene transcription - Essential role of Sp and ZNF family members of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; ZINC-FINGER PROTEIN; RNA-POLYMERASE-III; REPRESS TRANSCRIPTION; PYLORIC-STENOSIS; MINIMAL PROMOTER; CIS-ELEMENTS; ACTIVATION; EXPRESSION; DOMAINS	Neuronal nitric-oxide synthase (nNOS) is expressed in a variety of human tissues and shows a complex transcriptional regulation with the presence of nine alternative first exons (1a-1i) resulting in nNOS transcripts with differing 5'-untranslated regions. We previously demonstrated that nNOS exon 1c, one of the predominant transcripts in the human gastrointestinal tract, is driven by a separate promoter (Saur, D., Paehge, H., Schusdziarra, V., and Allescher, H. D. (2000) Gastroenterology 118, 849-858). The present study focused on the quantitative expression of nNOS first exon variants in different human tissues and the characterization of the basal nNOS exon le promoter. In human brain, skeletal muscle, colon, and TGW-nu-I neuroblastoma cells, first exon expression patterns were analyzed by quantitative real-time reverse transcription-PCR. In these tissues/cells exon 1c was one of the most abundant first exons of nNOS. By transient transfections of TGW-nu-I and HeLa cells with reporter plasmids containing a series of 5' and 3' deletions in the exon 1c regulatory region, the minimal TATA-less promoter was localized within 44 base pairs. Gel mobility shift assays of this cis-regulatory region revealed a high complexity of the basal promoter with a cooperative binding of several transcription factors, like Sp and ZNF family members. When the Sp binding site of the minimal promoter construct was mutated, promoter activity was completely abolished in both cell lines, whereas mutation Of the common binding site of ZNF76 and ZNF143 resulted in a decrease of 53% in TGW-nu-I and 37% in HeLa cells. In Drosophila Schneider cells expression of Sp1, the long Sp3 isoform, ZNF76 and ZNF143 potently transactivated the nNOS exon le promoter. These results identify the critical regulatory region for the nNOS exon 1c basal promoter and stress the functional importance of multiple protein complexes involving Sp and ZNF families of transcription factors in regulating nNOS exon le transcription.	Tech Univ Munich, Med Klin & Poliklin 2, Dept Internal Med 2, D-81675 Munich, Germany	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf	Saur, D (corresponding author), Tech Univ Munich, Med Klin & Poliklin 2, Dept Internal Med 2, Ismaninger Str 22, D-81675 Munich, Germany.		Saur, Dieter/O-8355-2015; Saur, Dieter/G-4629-2011	Saur, Dieter/0000-0001-5874-0210; 				Allescher HD, 1996, AM J PHYSIOL-GASTR L, V271, pG568, DOI 10.1152/ajpgi.1996.271.4.G568; AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bakovic M, 2000, J LIPID RES, V41, P583; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chung E, 1996, AM J HUM GENET, V58, P363; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Deans Z, 1996, J BIOL CHEM, V271, P32153, DOI 10.1074/jbc.271.50.32153; Forstermann U, 1998, FASEB J, V12, P773; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huber A, 1998, AM J PHYSIOL-GASTR L, V275, pG1146, DOI 10.1152/ajpgi.1998.275.5.G1146; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mashimo H, 2000, GASTROENTEROLOGY, V119, P766, DOI 10.1053/gast.2000.16509; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Ogura T, 1996, NEUROSCI LETT, V204, P89, DOI 10.1016/0304-3940(96)12324-7; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Parks CL, 1996, J BIOL CHEM, V271, P4417; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Saur D, 2000, GASTROENTEROLOGY, V118, P849, DOI 10.1016/S0016-5085(00)70171-5; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; Sivarao DV, 2001, GASTROENTEROLOGY, V121, P34, DOI 10.1053/gast.2001.25541; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; STARK ME, 1992, GASTROENTEROLOGY, V103, P1928, DOI 10.1016/0016-5085(92)91454-C; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Terzano S, 2000, J BIOL CHEM, V275, P41495, DOI 10.1074/jbc.M006197200; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Watkins CC, 2000, J CLIN INVEST, V106, P373, DOI 10.1172/JCI8273; Weber JRM, 1997, J NEUROSCI, V17, P7583; WERNERFELMAYER G, 1993, BIOCHEM J, V289, P357, DOI 10.1042/bj2890357; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	60	63	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25798	25814		10.1074/jbc.M109802200	http://dx.doi.org/10.1074/jbc.M109802200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11960979	hybrid			2022-12-25	WOS:000176747000123
J	Boukhvalova, M; VanBruggen, R; Stewart, RC				Boukhvalova, M; VanBruggen, R; Stewart, RC			CheA kinase and chemoreceptor interaction surfaces on CheW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; ASPARTATE RECEPTOR; COVALENT MODIFICATION; THERMOTOGA-MARITIMA; CYTOPLASMIC DOMAIN; COMPLEX; SYSTEM	Chemotactic responses of Escherichia coli to aspartic acid are initiated by a ternary protein complex composed of Tar (chemoreceptor), CheA (kinase), and CheW (a coupling protein that binds to both Tar and CheA and links their activities). We used a genetic selection based on the yeast two-hybrid assay to identify nine cheW point mutations that specifically disrupted CheW interaction with CheA but not with Tar. We sequenced these single point mutants and purified four of the mutant CheW proteins for detailed biochemical characterizations that demonstrated the weakened affinity of the mutant CheW proteins for CheA, but not for Tar. In the three-dimensional structure of CheW, the positions affected by these mutations cluster on one face of the protein, defining a potential binding interface for interaction of CheW with CheA. We used a similar two-hybrid approach to identify four mutation sites that disrupted CheW binding to Tar. Mapping of these "Tar-sensitive" mutation sites and those from previous suppressor analysis onto the structure of CheW defined an extended surface on a face of the protein that is adjacent to the CheA-binding surface and that may serve as an interface for CheW binding to Tar.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Univ Maryland, Grad Program Mol & Cellular Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Stewart, RC (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052853] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52853] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1972, NATURE, V239, P500, DOI 10.1038/239500a0; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOUKHVALOVA M, 2002, J BIOL CHEM, V10; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Bren A, 2000, J BACTERIOL, V182, P6865, DOI 10.1128/JB.182.24.6865-6873.2000; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; Griswold IJ, 2002, NAT STRUCT BIOL, V9, P121, DOI 10.1038/nsb753; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hirschman A, 2001, BIOCHEMISTRY-US, V40, P13876, DOI 10.1021/bi0113622; Inouye C, 1997, GENETICS, V147, P479; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Leung DW, 1989, TECHNIQUE, V1, P11; Levit MN, 1998, MOL MICROBIOL, V30, P459, DOI 10.1046/j.1365-2958.1998.01066.x; Levit MN, 1999, BIOCHEMISTRY-US, V38, P6651, DOI 10.1021/bi982839l; Li GY, 2000, CELL, V100, P357, DOI 10.1016/S0092-8674(00)80671-6; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LUBYPHELPS K, 1994, CURR OPIN CELL BIOL, V6, P3, DOI 10.1016/0955-0674(94)90109-0; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MADDOCK JR, 1993, SCIENCE, V259, P1717; Manson MD, 1998, J BACTERIOL, V180, P1009, DOI 10.1128/JB.180.5.1009-1022.1998; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUTOH N, 1986, J BACTERIOL, V167, P992, DOI 10.1128/jb.167.3.992-998.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; Osborn M J, 1974, Methods Enzymol, V31, P642; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RUSSELL I, 1987, BIOL RES IND YEASTS, V1, P1; SANDERS DA, 1989, J BACTERIOL, V171, P6271, DOI 10.1128/jb.171.11.6271-6278.1989; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Shimizu TS, 2000, NAT CELL BIOL, V2, P792, DOI 10.1038/35041030; Skidmore JM, 2000, J BACTERIOL, V182, P967, DOI 10.1128/JB.182.4.967-973.2000; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STEWART RC, 1990, J BACTERIOL, V172, P3388, DOI 10.1128/jb.172.6.3388-3399.1990; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Swanson RV, 1996, J BACTERIOL, V178, P484, DOI 10.1128/jb.178.2.484-489.1996; Usher KC, 1998, PROTEIN SCI, V7, P403; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WOLFE AJ, 1989, P NATL ACAD SCI USA, V86, P6973, DOI 10.1073/pnas.86.18.6973; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Yi TM, 2000, P NATL ACAD SCI USA, V97, P4649, DOI 10.1073/pnas.97.9.4649	61	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23596	23603		10.1074/jbc.M202288200	http://dx.doi.org/10.1074/jbc.M202288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11964403	hybrid			2022-12-25	WOS:000176475700065
J	David, G; Neptune, MA; DePinho, RA				David, G; Neptune, MA; DePinho, RA			SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; REPRESS TRANSCRIPTION; PROTEIN; COMPLEX; P53; GROWTH; CANCER; DIFFERENTIATION; CONJUGATION; ACTIVATION	Histone deacetylation plays a central role in the regulation of genes linked to virtually all biological processes. This modification reaction is dependent on a family of related histone deacetylases (HDACs), which function as key components of large multiprotein complexes involved in the development of normal and neoplastic cells. The mechanisms regulating HDACs and their roles in such processes are not understood, and these form the major focus for the current study. Here, in the course of assessing possible post-translational modifications of HDAC1, we demonstrated that HDAC1 is a substrate for SUMO-1 (small ubiquitin-related modifier) modification in vitro and in vivo. The HDAC1 lysines targeted for modification were identified as C-terminal Lys-444 and Lys-476, which are also present in mammalian HDAC2 and lower vertebrate HDAC1/2 orthologs yet absent from other HDAC family members, pointing to a means of differential regulation among HDAC proteins. Mutation of these target residues (lysine to arginine substitution) profoundly reduced HDAC1-mediated transcriptional repression in reporter assays without affecting HDAC1 ability to associate with mSin3A and eliminated HDAC1-induced cell cycle and apoptotic responses upon overexpression. Together, the results demonstrate that HDAC1 is modified by SUMO-1, and this modification can dramatically affect HDAC1 activity in a number of surrogate biological assays.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	36	181	187	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23658	23663		10.1074/jbc.M203690200	http://dx.doi.org/10.1074/jbc.M203690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960997	hybrid			2022-12-25	WOS:000176475700073
J	Hofmann, S; Rothbauer, U; Muhlenbein, N; Neupert, W; Gerbitz, KD; Brunner, M; Bauer, MF				Hofmann, S; Rothbauer, U; Muhlenbein, N; Neupert, W; Gerbitz, KD; Brunner, M; Bauer, MF			The C66W mutation in the deafness dystonia peptide 1 (DDP1) affects the formation of functional DDP1 center dot TIM13 complexes in the mitochondrial intermembrane space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; PREPROTEIN TRANSLOCASE; MENTAL DEFICIENCY; CARRIER PROTEINS; TIM COMPLEXES; IMPORT; TRANSPORT; BIOGENESIS; BLINDNESS; MACHINERY	Mohr-Tranebjaerg syndrome is a progressive, neurodegenerative disorder caused by loss-of-function mutations in the DDP1/TIMM8A gene. DDP1 belongs to a family of evolutionary conserved proteins that are organized in hetero-oligomeric complexes in the mitochondrial intermembrane space. They mediate the import and insertion of hydrophobic membrane proteins into the mitochondrial inner membrane. All of them share a conserved Cys(4) metal binding site proposed to be required for the formation of zinc fingers. So far, the only missense mutation known to cause a full-blown clinical phenotype is a C66W exchange directly affecting this Cys(4) motif. Here, we show that the mutant human protein is efficiently imported into mitochondria and sorted into the intermembrane space. In contrast to wild-type DDP1, it does not complement the function of its yeast homologue Tim8. The C66W mutation impairs binding of Zn2+ ions via the Cys4 motif. As a consequence, the mutated DDP1 is incorrectly folded and loses its ability to assemble into a hetero-hexameric 70-kDa complex with its cognate partner protein human Tim13. Thus, an assembly defect of DDP1 is the molecular basis of Mohr-Tranebjaerg syndrome in patients carrying the C66W mutation.	Akad Lehrkrankenhaus Munchen Schwabing, Inst Diabetesforsch & Metab Dis Ctr, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, D-80804 Munich, Germany; Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany; Univ Heidelberg, Biochem Zentrum, D-69120 Heidelberg, Germany	University of Munich; Ruprecht Karls University Heidelberg	Bauer, MF (corresponding author), Akad Lehrkrankenhaus Munchen Schwabing, Inst Diabetesforsch & Metab Dis Ctr, Inst Klin Chem Mol Diagnost & Mitochondriale Gene, Koelner Pl 1, D-80804 Munich, Germany.		Rothbauer, Ulrich/C-7712-2018	Rothbauer, Ulrich/0000-0001-5923-8986				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 1999, J MOL BIOL, V289, P69, DOI 10.1006/jmbi.1999.2751; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Jin H, 1996, NAT GENET, V14, P177, DOI 10.1038/ng1096-177; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; Leon O, 2000, BIOL RES, V33, P21; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rothbauer U, 2001, J BIOL CHEM, V276, P37327, DOI 10.1074/jbc.M105313200; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; TRANEBJAERG L, 1995, J MED GENET, V32, P257, DOI 10.1136/jmg.32.4.257; Tranebjaerg L, 2000, EUR J HUM GENET, V8, P464, DOI 10.1038/sj.ejhg.5200483	31	70	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23287	23293		10.1074/jbc.M201154200	http://dx.doi.org/10.1074/jbc.M201154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956200	hybrid			2022-12-25	WOS:000176475700026
J	Saito, Y; Hojo, Y; Tanimoto, T; Abe, J; Berk, BC				Saito, Y; Hojo, Y; Tanimoto, T; Abe, J; Berk, BC			Protein kinase C-alpha and protein kinase C-epsilon are required for Grb2-associated binder-1 tyrosine phosphorylation in response to platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL MORPHOGENESIS DOWNSTREAM; SIGNAL-REGULATED KINASE; GAB1 DOCKING PROTEIN; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSIN-II; PHOSPHOINOSITIDE 3-KINASE; FOCAL ADHESIONS; PH DOMAIN; RECEPTOR	Grb2-associated binder-1 (Gab1) is an adapter protein related to the insulin receptor substrate family. It is a substrate for the insulin receptor as well as the epidermal growth factor (EGF) receptor and other receptor-tyrosine kinases. To investigate the role of Gab1 in signaling pathways downstream of growth factor receptors, we stimulated rat aortic vascular smooth muscle cells (VSMC) with EGF and platelet-derived growth factor (PDGF). Gab1 was tyrosine-phosphorylated by EGF and PDGF within 1 min. AG1478 (an EGF receptor kinase-specific inhibitor) failed to block PDGF-induced Gab1 tyrosine phosphorylation, suggesting that transactivated EGF receptor is not responsible for this signaling event. Because Gab1 associates with phospholipase Cgamma (PLCgamma), we studied the role of the PLCgamma pathway in Gab1 tyrosine phosphorylation. Gab1 tyrosine phosphorylation by PDGF was impaired in Chinese hamster ovary cells expressing mutant PDGFbeta receptor (Y977F/Y989F: lacking the binding site for PLCgamma). Pretreatment of VSMC with U73122 (a specific PLCgamma inhibitor) inhibited Gab1 tyrosine phosphorylation as well, indicating the importance of the PLCgamma pathway. Gab1 was tyrosine-phosphorylated by phorbol ester to the same extent as PDGF stimulation. Studies using antisense protein kinase C (PKC) oligonucleotides and specific inhibitors showed that PKCalpha and PKCepsilon are required for Gab1 tyrosine phosphorylation. Binding of Gab1 to the protein-tyrosine phosphatase SHP2 and phosphatidylinositol 3-kinase was significantly decreased by PLCgamma and/or PKC inhibition, suggesting the importance of the PLCgamma/PKC-dependent Gab1 tyrosine phosphorylation for the interaction with other signaling molecules. Because PDGF-mediated ERK activation is enhanced in Chinese hamster ovary cells that overexpress Gab1, Gab1 serves as an important link between PKC and ERK activation by PDGFbeta receptors in VSMC.	Univ Rochester, Ctr Cardiolvasc Res, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Ctr Cardiolvasc Res, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL49192, HL63462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063462, R01HL049192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Giardina JB, 2001, HYPERTENSION, V37, P561, DOI 10.1161/01.HYP.37.2.561; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Haller H, 1998, CIRC RES, V82, P157; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 2001, J BIOL CHEM, V276, P12257, DOI 10.1074/jbc.M010590200; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200	35	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23216	23222		10.1074/jbc.M200605200	http://dx.doi.org/10.1074/jbc.M200605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11940581	hybrid			2022-12-25	WOS:000176475700017
J	Thoden, JB; Firestine, SM; Benkovic, SJ; Holden, HM				Thoden, JB; Firestine, SM; Benkovic, SJ; Holden, HM			PurT-encoded glycinamide ribonueleotide transformylase - Accommodation of adenosine nucleotide analoges within the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; MYOSIN MOTOR DOMAIN; X-RAY STRUCTURES; CRYSTAL-STRUCTURE; ATP-BINDING; B-DOMAIN; P-LOOP; PROTEINS; MGADP; SUPERFAMILY	PurT-encoded glycinamide ribonucleotide transformylase, or PurT transformylase, functions in purine biosynthesis by catalyzing the formylation of glycinamide ribonucleotide through a catalytic mechanism requiring Mg(2+)ATP and formate. From previous x-ray diffraction analyses, it has been demonstrated that PurT transformylase from Escherichia coli belongs to the ATP-grasp superfamily of enzymes, which are characterized by three structural motifs referred to as the A-, B-, and C-domains. In all of the ATP-grasp enzymes studied to date, the adenosine nucleotide ligands are invariably wedged between the B- and C-domains, and in some cases, such as biotin carboxylase and carbamoyl phosphate synthetase, the B-domains move significantly upon nucleotide binding. Here we present a systematic and high-resolution structural investigation of PurT transformylase complexed with various adenosine nucleotides or nucleotide analogs including Mg(2+)ATP, Mg2+-5'-adenylylimidodiphosphate, Mg2+-beta,gamma-methyleneadenosine 5'-triphosphate, Mg(2+)ATPgammaS, or Mg(2+)ADP. Taken together, these studies indicate that the conformation of the so-called "T-loop," delineated by Lys-155 to Gln-165, is highly sensitive to the chemical identity of the nucleotide situated in the binding pocket. This sensitivity to nucleotide identity is in sharp contrast to that observed for the "P-loop"-containing enzymes, in which the conformation of the binding motif is virtually unchanged in the presence or absence of nucleotides.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Duquesne Univ, Mylan Sch Pharm, Pittsburgh, PA 15282 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Duquesne University	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM55513, GM24129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024129, R01GM024129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Fan C, 1997, BIOCHEMISTRY-US, V36, P2531, DOI 10.1021/bi962431t; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HARA T, 1996, BIOCHEMISTRY-US, V35, P11963; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Marolewski AE, 1997, BIOCHEMISTRY-US, V36, P6709, DOI 10.1021/bi962961p; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009	22	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23898	23908		10.1074/jbc.M202251200	http://dx.doi.org/10.1074/jbc.M202251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953435	hybrid			2022-12-25	WOS:000176475700104
J	Mizel, SB; Snipes, JA				Mizel, SB; Snipes, JA			Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; TUMOR-NECROSIS-FACTOR; CUTTING EDGE; ENDOTOXIN TOLERANCE; BACTERIAL FLAGELLIN; SIGNAL-TRANSDUCTION; DOWN-REGULATION; LIPOPOLYSACCHARIDE; GENE; MACROPHAGES	Flagellin from a number of Gram-negative bacteria induces cytokine and nitric oxide production by inflammatory cell types. In view of the evidence that flagellin responsiveness is subject to modulation, we explored the possibilities that a prior exposure to flagellin might result in a state of reduced flagellin responsiveness or tolerance and that lipopolysaccharide (LPS) and flagellin may induce a state of cross-tolerance to each other. Our results demonstrate that a prior exposure to flagellin results in a subsequent state of flagellin tolerance in human monocytes, THP1 cells, Jurkat cells, and COS-1 cells. Tolerance occurs within 2 h after addition of flagellin and does not require protein synthesis. Flagellin did not induce tolerance to LPS in monocytes and THP1 cells; however, LPS treatment of monocytes and THP1 cells resulted in a state of flagellin cross-tolerance. Flagellin-induced self-tolerance is not the result of a decrease in the steady-state level of toll-like receptor 5 (TLR5) or interleukin-1 receptor associated kinase (IRAK), but it is associated with a block in the release of IRAK from the TLR5 complex in flagellin-tolerant cells. Release is essential for IRAK activity because the TLR5-associated IRAK lacks kinase activity. LPS-induced cross-tolerance to flagellin is also associated with a block in IRAK release from TLR5. These results provide evidence for a novel mechanism of TLR signaling control.	Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Mizel, SB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	smizel@wfubmc.edu			NIAID NIH HHS [AI-51319, AI-38670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038670, R01AI051319, R01AI038670] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GREISMAN SE, 1969, J IMMUNOL, V103, P1223; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Riedel DD, 2000, MICROBES INFECT, V2, P463, DOI 10.1016/S1286-4579(00)00319-1; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Tominaga K, 1999, BBA-MOL CELL RES, V1450, P130, DOI 10.1016/S0167-4889(99)00037-3; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wilson CS, 1997, J SURG RES, V69, P101, DOI 10.1006/jsre.1997.5040; Wyant TL, 1999, INFECT IMMUN, V67, P1338, DOI 10.1128/IAI.67.3.1338-1346.1999; YAMIN TT, 1997, J EXP MED, V187, P2073; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang RB, 1999, J IMMUNOL, V163, P639; Yoza B, 1998, PROG CLIN BIOL RES, V397, P209	41	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22414	22420		10.1074/jbc.M201762200	http://dx.doi.org/10.1074/jbc.M201762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953430	hybrid			2022-12-25	WOS:000176313600040
J	Xie, JX; Adams, LM; Zhao, JY; Gerken, TA; Davis, PB; Ma, JJ				Xie, JX; Adams, LM; Zhao, JY; Gerken, TA; Davis, PB; Ma, JJ			A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CL-CHANNEL; PHOSPHORYLATION; ACTIVATION; PROTEINS; BINDING; STATES	The regulatory (R) domain of the cystic fibrosis transmembrane conductance regulator (CFTR) contains con. sensus phosphorylation sites for cAMP-dependent protein kinase (PKA) that are the basis for physiological regulation of the CFTR chloride channel. A short peptide segment in the R domain with a net negative charge of B9 (amino acids 817-838, NEG2) and predicted helical tendency is shown to play a critical role in CFTR chloride channel function. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of channel activity. Exogenous NEG2 peptide interacts with CFTR to exert both stimulatory and inhibitory effects on the channel function. The NEG2 peptide with sequence scrambled to remove helical tendencies also inhibits channel function, but does not stimulate. Similar results are found for a NEG2 peptide whose helical structure is disrupted by a proline residue. When six of the negatively charged carboxylic acid residues are replaced by their cognate amides, reducing net negative charge to B3, but increasing helical propensity as assessed by circular dichroism, the peptide stimulates CFTR channel function, but does not inhibit. We speculate that the NEG2 region interacts with other cytosolic domains of CFTR to control opening and closing transitions of the chloride channel.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Ma, JJ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maj2@umdnj.edu			NHLBI NIH HHS [T32 HL07415, R01 HL/DK 49003] Funding Source: Medline; NIDDK NIH HHS [R01 DK51770, P30 DK27651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007415, R01HL049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK051770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG DJ, 1993, BIOCHEM BIOPH RES CO, V192, P1380, DOI 10.1006/bbrc.1993.1569; Baldursson O, 2001, J BIOL CHEM, V276, P1904, DOI 10.1074/jbc.M006934200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cotten JF, 1997, J BIOL CHEM, V272, P25617, DOI 10.1074/jbc.272.41.25617; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Iakoucheva LM, 2001, PROTEIN SCI, V10, P1353, DOI 10.1110/ps.40101; IKUMA M, 1999, PEDIATR PULM, V19, P176; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; King SA, 2000, BIOCHEMISTRY-US, V39, P9868, DOI 10.1021/bi992807d; Ma JJ, 2000, NEWS PHYSIOL SCI, V15, P154; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Ma JJ, 1998, CLIN CHEST MED, V19, P459, DOI 10.1016/S0272-5231(05)70093-9; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; PERCZELL A, 1992, PROTEIN-STRUCT FUNCT, V13, P7; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; Tasch JE, 1999, FEBS LETT, V445, P63, DOI 10.1016/S0014-5793(99)00086-1; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1997, AM J PHYSIOL-LUNG C, V273, pL127, DOI 10.1152/ajplung.1997.273.1.L127; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; XIE JX, 1995, J BIOL CHEM, V270, P28084; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23019	23027		10.1074/jbc.M201661200	http://dx.doi.org/10.1074/jbc.M201661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950844	hybrid			2022-12-25	WOS:000176313600117
J	Budworth, H; Dianova, II; Podust, VN; Dianov, GL				Budworth, H; Dianova, II; Podust, VN; Dianov, GL			Repair of clustered DNA lesions - Sequence-specific inhibition of long-patch base excision repair by 8-oxoguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; DOUBLE-STRAND BREAK; POLYMERASE-BETA; IONIZING-RADIATION; ESCHERICHIA-COLI; MAMMALIAN-CELLS; URACIL RESIDUES; OGG1 PROTEIN; GAPPED DNA; DAMAGE	Ionizing radiation induces clustered DNA damage where two or more lesions are located proximal to each other on the same or opposite DNA strands. It has been suggested that individual lesions within a cluster are removed sequentially and that the presence of a vicinal lesion(s) may affect the rate and fidelity of DNA repair. In this study, we addressed the question of how 8-oxoguanine located opposite to normal or reduced abasic sites would affect the repair of these sites by the base excision repair system. We have found that an 8-oxoguanine located opposite to an abasic site does not affect either the efficiency or fidelity of repair synthesis by DNA polymerase beta. In contrast, an 8-oxoguanine located one nucleotide 3'-downstream of the abasic site significantly reduces both strand displacement synthesis supported by DNA polymerase beta or delta and cleavage by flap endonuclease of the generated flap, thus inhibiting the long-patch base excision repair pathway.	MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37232 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	Vanderbilt University; University of Oxford	Dianov, GL (corresponding author), MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England.		Budworth, Helen/A-1327-2013		NIGMS NIH HHS [GM52948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; Cunniffe S, 1999, RADIAT RES, V152, P421, DOI 10.2307/3580227; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P11811, DOI 10.1021/bi0112356; David-Cordonnier MH, 2001, NUCLEIC ACIDS RES, V29, P1107, DOI 10.1093/nar/29.5.1107; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; Dianov GL, 2001, BIOESSAYS, V23, P745, DOI 10.1002/bies.1104; DIANOV GL, 1986, MUTAT RES, V159, P41, DOI 10.1016/0027-5107(86)90110-7; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GOODHEAD DT, 1993, INT J RADIAT BIOL, V63, P543, DOI 10.1080/09553009314450721; GOODHEAD DT, 1994, INT J RADIAT BIOL, V61, P7; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOKONTIS JM, 1993, CARCINOGENESIS, V14, P645, DOI 10.1093/carcin/14.4.645; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Miller H, 2000, BIOCHEMISTRY-US, V39, P1029, DOI 10.1021/bi991789x; Milligan JR, 2000, INT J RADIAT BIOL, V76, P1475; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Tomkinson AE, 2001, PROG NUCLEIC ACID RE, V68, P151; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WARD JF, 1985, RADIAT RES, V104, P103; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2	36	43	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21300	21305		10.1074/jbc.M201918200	http://dx.doi.org/10.1074/jbc.M201918200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923315	hybrid			2022-12-25	WOS:000176286000025
J	Lee, HS; Kim, MS; Cho, HS; Kim, JI; Kim, TJ; Choi, JH; Park, C; Lee, HS; Oh, BH; Park, KH				Lee, HS; Kim, MS; Cho, HS; Kim, JI; Kim, TJ; Choi, JH; Park, C; Lee, HS; Oh, BH; Park, KH			Cyclomaltodextrinase, neopullulanase, and maltogenic amylase are nearly indistinguishable from each other	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-ENCODING CYCLOMALTODEXTRINASE; ALPHA-AMYLASE; CYCLODEXTRIN; ENZYME; PURIFICATION; SPECIFICITY; DOMAIN	Over 20 enzymes denoted as cyclomaltodextrinase, maltogenic amylase, or neopullulanase that share 40-86% sequence identity with each other are found in public data bases. These enzymes are distinguished from typical alpha-amylases by containing a novel N-terminal domain and exhibiting preferential substrate specificities for cyclomaltodextrins (CDs) over starch. In this research field, a great deal of confusion exists regarding the features distinguishing the three groups of enzymes from one another. Although a different enzyme code has been assigned to each of the three different enzyme names, even a single differentiating enzymatic property has not been documented in the literature. On the other hand, an outstanding question related to this issue concerns the structural basis for the preference of these enzymes for CDs. To clarify the confusion and to address this question, we have determined the structures of two enzymes, one from alkalophilic Bacillus sp. 1-5 and named cyclomaltodextrinase and the other from a Thermus species and named maltogenic amylase. The structure of the Bacillus enzyme reveals a dodecameric assembly composed of six copies of the dimer, which is the structural and functional unit of the Thermus enzyme and an enzyme named neopullulanase. The structure of the Thermus enzyme in complex with beta-CD led to the conclusion that Trp(47), a well conserved N-terminal domain residue, contributes greatly to the preference for beta-CD. The common dimer formation through the novel N-terminal domain, which contributes to the preference for CDs by lining the active-site cavity, convincingly indicates that the three groups of enzymes are not different enough to preserve the different names and enzyme codes.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea; Pohang Accelerator Lab, Pohang 790784, Kyungbuk, South Korea; Seoul Natl Univ, New Biomat Agr Res Ctr, Suwon 441744, South Korea; Seoul Natl Univ, Dept Food Sci & Technol, Suwon 441744, South Korea; Kyung Hee Univ, Dept Food Sci & Technol, Suwon 449701, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University (SNU); Kyung Hee University	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Creat Res Initiat Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Oh, Byung-Ha/C-2061-2011					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENDER H, 1993, APPL MICROBIOL BIOT, V39, P714, DOI 10.1007/BF00164455; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fiedler G, 1996, J MOL BIOL, V256, P279, DOI 10.1006/jmbi.1996.0085; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; Fujiwara S, 1996, GENE, V179, P165, DOI 10.1016/S0378-1119(96)00428-3; Hashimoto Y, 2001, J BACTERIOL, V183, P5050, DOI 10.1128/JB.183.17.5050-5057.2001; HONDOH H, 2001, 1 S ALPH AM FAM SEPT, P48; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim JS, 1999, J BIOL CHEM, V274, P26279, DOI 10.1074/jbc.274.37.26279; Kim MJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P277, DOI 10.1006/abbi.1999.1423; Kim TJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P221, DOI 10.1006/abbi.1998.0639; Kim TJ, 2001, BIOCHEMISTRY-US, V40, P14182, DOI 10.1021/bi015531u; KITAHATA S, 1983, AGR BIOL CHEM TOKYO, V47, P1441, DOI 10.1080/00021369.1983.10865801; Kondo S, 2001, J BIOCHEM, V129, P423, DOI 10.1093/oxfordjournals.jbchem.a002873; OGUMA T, 1990, BIOCHIM BIOPHYS ACTA, V1036, P1, DOI 10.1016/0304-4165(90)90205-B; Ohdan K, 2000, APPL MICROBIOL BIOT, V53, P430, DOI 10.1007/s002530051637; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park KH, 2000, BBA-PROTEIN STRUCT M, V1478, P165, DOI 10.1016/S0167-4838(00)00041-8; PODKOVYROV SM, 1992, J BACTERIOL, V174, P5400, DOI 10.1128/JB.174.16.5400-5405.1992; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; Tibbot BK, 2000, J PROTEIN CHEM, V19, P663, DOI 10.1023/A:1007148202270; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986	24	122	130	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21891	21897		10.1074/jbc.M201623200	http://dx.doi.org/10.1074/jbc.M201623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923309	hybrid			2022-12-25	WOS:000176286000100
J	Phillips, RS; Demidkina, TV; Zakomirdina, LN; Bruno, S; Ronda, L; Mozzarelli, A				Phillips, RS; Demidkina, TV; Zakomirdina, LN; Bruno, S; Ronda, L; Mozzarelli, A			Crystals of tryptophan indole-lyase and tyrosine phenol-lyase form stable quinonoid complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; STOPPED-FLOW SPECTROPHOTOMETRY; CARBON CARBON LYASES; ESCHERICHIA-COLI; CITROBACTER-FREUNDII; PYRIDOXAL-PHOSPHATE; MECHANISTIC DEDUCTIONS; SUBSTRATE-SPECIFICITY; PROTEUS-VULGARIS; LINEAR DICHROISM	The binding of substrates and inhibitors to wild-type Proteus vulgaris tryptophan indole-lyase and to wild type and Y71F Citrobacter freundii tyrosine phenol-lyase was investigated in the crystalline state by polarized absorption microspectrophotometry. Oxindolyl-L-alanine binds to tryptophan indole-lyase crystals to accumulate predominantly a stable quinonoid intermediate absorbing at 502 nm with a dissociation constant of 35 mum, approximately 10-fold higher than that in Solution. L-Trp or L-Ser react with tryptophan indole-lyase crystals to give, as in solution, a mixture of external aldimine and quinonoid intermediates and gem-diamine and external aldimine intermediates, respectively. Different from previous solution studies (Phillips, M S., Sundararju, B., & Faleev, N. G. (2000) J. Am Chem Soc. 122, 1008-1114), the reaction of benzimidazole and L-Trp or L-Ser with tryptophan indole-lyase crystals does not result in the formation of an a-aminoacrylate intermediate, suggesting that the crystal lattice might prevent a ligand-induced conformational change associated with this catalytic step. Wildtype tyrosine phenol-lyase crystals bind L-Met and L-Phe to form mixtures of external aldimine and quinonoid intermediates as in solution. A stable quinonoid intermediate with lambda(max) at 502 nm is accumulated in the reaction of crystals of Y71F tyrosine phenol-lyase, an inactive mutant, with 3-F-L-Tyr with a dissociation constant of 1 mM, approximately 10-fold higher than that in solution. The stability exhibited by the quinonoid intermediates formed both by wild-type tryptophan indole-lyase and by wild type and Y71F tyrosine phenol-lyase crystals demonstrates that they are suitable for structural determination by x-ray crystallography, thus allowing the elucidation of a key species of pyridoxal 5'-phosphate-dependent enzyme catalysis.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Natl Inst Phys Matter, I-43100 Parma, Italy	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Parma	Phillips, RS (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.	rsphillips@chem.uga.edu	Mozzarelli, Andrea/C-3615-2014; Ronda, Luca/E-5214-2012; Bruno, Stefano/A-4582-2011; Demidkina, Tatyana/AAD-9427-2019	Mozzarelli, Andrea/0000-0003-3762-0062; Bruno, Stefano/0000-0002-7890-2472; Ronda, Luca/0000-0002-5389-2669; Phillips, Robert/0000-0001-8710-562X	FIC NIH HHS [TW-00106] Funding Source: Medline; NIGMS NIH HHS [GM-42588] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; Bruno S, 2001, J BIOL CHEM, V276, P16, DOI 10.1074/jbc.C000588200; CHEN HY, 1995, BIOCHEMISTRY-US, V34, P12276, DOI 10.1021/bi00038a023; CHEN HY, 1995, EUR J BIOCHEM, V229, P540, DOI 10.1111/j.1432-1033.1995.tb20496.x; CHEN HY, 1993, BIOCHEMISTRY-US, V32, P11591, DOI 10.1021/bi00094a016; DEMENTIEVA IS, 1994, J MOL BIOL, V235, P783; DEMIDKINA TV, 1989, BIOCHIMIE, V71, P565, DOI 10.1016/0300-9084(89)90188-0; FALEEV NG, 1988, EUR J BIOCHEM, V177, P395, DOI 10.1111/j.1432-1033.1988.tb14388.x; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; Isupov MN, 1998, J MOL BIOL, V276, P603, DOI 10.1006/jmbi.1997.1561; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7333, DOI 10.1021/bi00419a023; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7339, DOI 10.1021/bi00419a024; KUMAGAI H, 1970, J BIOL CHEM, V245, P1767; Mozzarelli A, 1998, J MOL BIOL, V283, P135, DOI 10.1006/jmbi.1998.2038; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; Mozzarelli A, 2000, J BIOL CHEM, V275, P6956, DOI 10.1074/jbc.275.10.6956; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Mozzarelli A, 2001, ADVANCED FUNCTIONAL MOLECULES AND POLYMERS, VOL 4, P55; MURO T, 1978, J BIOCHEM-TOKYO, V84, P633, DOI 10.1093/oxfordjournals.jbchem.a132168; PHILLIPS RS, 1987, ARCH BIOCHEM BIOPHYS, V256, P302, DOI 10.1016/0003-9861(87)90450-4; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; PHILLIPS RS, 1985, J BIOL CHEM, V260, P4665; PHILLIPS RS, 1991, BIOCHEMISTRY-US, V30, P5927, DOI 10.1021/bi00238a017; Phillips RS, 2000, J AM CHEM SOC, V122, P1008, DOI 10.1021/ja991647q; PHILLIPS RS, 2002, BIOCHEMISTRY-US, V41, P4348; Sloan MJ, 1996, BIOCHEMISTRY-US, V35, P16165, DOI 10.1021/bi961211c; SUELTER CH, 1976, FEBS LETT, V66, P230, DOI 10.1016/0014-5793(76)80510-8; Sundararaju B, 1997, BIOCHEMISTRY-US, V36, P6502, DOI 10.1021/bi962917+; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; VINCENT MG, 1984, CHEM BIOL ASPECTS VI, P233; VonTersch RL, 1996, ACS SYM SER, V639, P95; WATANABE T, 1977, J BIOCHEM, V82, P733, DOI 10.1093/oxfordjournals.jbchem.a131750; ZAKOMIRDINA LN, 1990, EUR J BIOCHEM, V193, P243, DOI 10.1111/j.1432-1033.1990.tb19329.x	35	26	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21592	21597		10.1074/jbc.M200216200	http://dx.doi.org/10.1074/jbc.M200216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934889	hybrid			2022-12-25	WOS:000176286000063
J	Solbiati, J; Chapman-Smith, A; Cronan, JE				Solbiati, J; Chapman-Smith, A; Cronan, JE			Stabilization of the biotinoyl domain of Escherichia coli Acetyl-CoA carboxylase by interactions between the attached biotin and the protruding "thumb" structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; POSTTRANSLATIONAL MODIFICATION; MULTIFUNCTIONAL ENZYMES; SWINGING ARMS; MOLECULAR RECOGNITION; CARRIER PROTEIN; TERMINAL DOMAIN; BIOTINYLATION; REPRESSOR; SUBUNIT	We previously reported (Chapman-Smith, A., Forbes, B. E., Wallace, J. C., and Cronan, J. E., Jr. (1997) J. Biol. Chem. 272, 26017-26022) that the biotinylated (holo) species of the biotin carboxyl carrier protein (BCCP) biotinoyl domain is much more resistant to chemical modification and proteolysis than the unbiotinylated (apo) form. We hypothesized that the increased stability was due to a conformational change engendered by interaction of the domain with biotin protein ligase, the enzyme that attaches the biotin moiety. We now report that a BCCP-87 species to which the biotin moiety was attached by chemical acylation rather than by biotin protein ligase showed the characteristically greater stability of the holo biotinoyl domain. This result demonstrates that our hypothesis was incorrect; the attached biotin is solely responsible for the increased stability. The bacteria] and chloroplast multisubunit acetyl-CoA carboxylases are unusual in that the highly symmetrical and conserved structure of the biotinoyl domain of the BCCP subunit is disrupted by a structured loop called the "thumb" that protrudes from body of the domain. Prior structural work showed that the thumb interacts with uriedo ring of the attached biotin moiety. We have tested whether the thumb-biotin interactions are responsible for the greater holo form stability by examination of two BCCP-87 species that lack the thumb. These BCCP species were produced in both the apo and holo forms, and their sensitivities to trypsin digestion were compared. The holo forms of these proteins were found to be only marginally more stable than their apo forms and much more sensitive to trypsin digestion than the wild type holo-BCCP-87. Therefore, removal of the thumb has an effect similar to lack of biotinylation, indicating that thumb-biotin interactions are responsible for most (but not all) of the increased stability of the holo biotinoyl domain. In the course of these experiments we demonstrated that treatment of Escherichia coli with the peptide deformylase inhibitor, actinonin, results in the expected (but previously unreported) accumulation of an N-formylated protein species.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERTS AW, 1972, ENZYMES, V6, P37; Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; Beckett D, 1998, METHOD ENZYMOL, V295, P424; Blanchard CZ, 1999, J BIOL CHEM, V274, P31767, DOI 10.1074/jbc.274.45.31767; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Chen DZ, 2000, BIOCHEMISTRY-US, V39, P1256, DOI 10.1021/bi992245y; CRONAN JE, 1995, FEMS MICROBIOL LETT, V130, P221, DOI 10.1016/0378-1097(95)00210-V; Cronan JE, 2001, J BIOL CHEM, V276, P37355, DOI 10.1074/jbc.M106353200; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; FALL RR, 1976, J BIOL CHEM, V251, P2063; FALL RR, 1973, J BIOL CHEM, V248, P2078; Fontana A, 1997, J MOL BIOL, V266, P223, DOI 10.1006/jmbi.1996.0787; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; LI SJ, 1992, J BIOL CHEM, V267, P855; Means G.E., 1971, CHEM MODIFICATION PR; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Perham RN, 1998, BIOCHEM SOC T, V26, P299, DOI 10.1042/bst0260299; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; REED KE, 1991, J BIOL CHEM, V266, P11425; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; Schmitt E, 1996, BIOCHIMIE, V78, P543, DOI 10.1016/S0300-9084(96)80001-0; SINGER M, 1989, MICROBIOL REV, V53, P1; Solbiati J, 1999, J MOL BIOL, V290, P607, DOI 10.1006/jmbi.1999.2913; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010; Xu Y, 1996, BIOCHEMISTRY-US, V35, P1783, DOI 10.1021/bi952269e; Yao X, 1997, BIOCHEMISTRY-US, V36, P15089, DOI 10.1021/bi971485f; Yao X, 1999, PROTEIN SCI, V8, P307	32	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21604	21609		10.1074/jbc.M201928200	http://dx.doi.org/10.1074/jbc.M201928200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11943781	hybrid			2022-12-25	WOS:000176286000065
J	Stark, JM; Hu, P; Pierce, AJ; Moynahan, ME; Ellis, N; Jasin, M				Stark, JM; Hu, P; Pierce, AJ; Moynahan, ME; Ellis, N; Jasin, M			ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SISTER-CHROMATID EXCHANGES; ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; CHROMOSOME STABILITY; BRC REPEATS; RECOMBINATION; PROTEIN; MOUSE; EXPRESSION	Disruption of the gene encoding RAD51, the protein that catalyzes strand exchange during homologous recombination, leads to the accumulation of chromosome breaks and lethality in vertebrate cells. As RAD51 is implicated in BRCA1- and BRCA2-mediated tumor suppression as well as cellular viability, we have begun a functional analysis of a defined RAD51 mutation in mammalian cells. By using a dominant negative approach, we generated a mouse embryonic stem cell line that expresses an ATP hydrolysis-defective RAD51 protein, hRAD51-K133R, at comparable levels to the endogenous wild-type RAD51 protein, whose expression is retained in these cells. We found that these cells have increased sensitivity to the DNA-damaging agents mitomycin C and ionizing radiation and also exhibit a decreased rate of spontaneous sister-chromatid exchange. By using a reporter for the repair of a single chromosomal double-strand break, we also found that expression of the hRAD51-K133R protein specifically inhibits homology-directed double-strand break repair. Furthermore, expression of a BRC repeat from BRCA2, a peptide inhibitor of an early step necessary for strand exchange, exacerbates the inhibition of homology-directed repair in the hRAD51-K133R expressing cell line. Thus, ATP hydrolysis by RAD51 has a key role in various types of DNA repair in mammalian cells.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org		Moynahan, Mary Ellen/0000-0002-0167-1020; Pierce, Andrew/0000-0001-9062-0307	NCI NIH HHS [R01 CA085867-02, R01 CA085867] Funding Source: Medline; NIGMS NIH HHS [GM54688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Chanet R, 1996, MOL CELL BIOL, V16, P4782; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2000, PROG NUCLEIC ACID RE, V63, P311, DOI 10.1016/S0079-6603(08)60726-6; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Fasullo M, 2001, GENETICS, V158, P959; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Jasin M., 2001, CONT CANC RES, VIII, P207; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; Kang LE, 2000, MOL CELL BIOL, V20, P9162, DOI 10.1128/MCB.20.24.9162-9172.2000; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Maniatis T., 1982, MOL CLONING LAB MANU; MIYAZAKI J, 1989, GENE, V79, P269; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; Robu ME, 2001, P NATL ACAD SCI USA, V98, P8211, DOI 10.1073/pnas.131022698; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	58	100	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20185	20194		10.1074/jbc.M112132200	http://dx.doi.org/10.1074/jbc.M112132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923292	hybrid			2022-12-25	WOS:000176204500014
J	Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T				Nakamura, S; Gomyo, Y; Roth, JA; Mukhopadhyay, T			C-terminus of p53 is required for G(2) arrest	ONCOGENE			English	Article						p53; p21; G(2) arrest	DNA-DAMAGE; CELL-CYCLE; PHOSPHORYLATION; INHIBITION; APOPTOSIS; CANCER; MDM2; CHECKPOINTS; ACETYLATION; EXPRESSION	Mutation of four lysine residues in the p53 C-terminal domain inhibits MDM2-dependent ubiquitination of p53 and alters its subcellular distribution. This implies that modification (such as acetylation and phosphorylation) of amino acid residues in p53 C-terminal domain, regulate the biological functions of p53. In this study, we demonstrated that p53 with lysine residues 372, 373, 381, and 382 mutated to alanine (the A4 mutant) retained the transactivation activity of wild-type p53, although the transactivation activity of p21 promoter by the A4 mutant was slightly reduced. The inducible expression of wild-type p53 and the A4 mutant in H1299 cells caused growth inhibition due to cell-cycle arrest. Consistent with previous studies, the expression of wild-type p53 elicited G(1) and G(2) arrests. However, the cells expressing the A4 mutant underwent G(1) arrest but not G(2) arrest. Cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53 but not A4, when the cells underwent G(2) arrest. This suggests that modification of the p53 C-terminal domain might inhibit p53-mediated G(2) arrest. In other words, p53 requires an intact C-terminus to induce G(2) arrest.	Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Box 109,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmukhopa@mail.mdanderson.org			NCI NIH HHS [2P50 CA70970-04, P50-CA70907, P01 CA78778-01A1, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, P01CA078778, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; STEWART N, 1995, ONCOGENE, V10, P109; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	31	13	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2102	2107		10.1038/sj.onc.1205251	http://dx.doi.org/10.1038/sj.onc.1205251			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960383				2022-12-25	WOS:000174827000017
J	Fujiyama, S; Yanagida, M; Hayano, T; Miura, Y; Isobe, T; Takahashi, N				Fujiyama, S; Yanagida, M; Hayano, T; Miura, Y; Isobe, T; Takahashi, N			Isolation and proteomic characterization of human parvulin-associating preribosomal ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL CIS/TRANS ISOMERASES; FORKHEAD-ASSOCIATED DOMAIN; NUCLEOLAR PROTEIN; BINDING-PROTEIN; KI-67 ANTIGEN; GENE; CYCLOPHILIN; SEQUENCE; ESS1; MUTATIONS	Human parvulin (hParvulin; Par14/EPVH) belongs to the third family of peptidylprolyl cis-trans isomerases that exhibit an enzymatic activity of interconverting the cis-trans conformation of the prolyl peptide bond, and shows sequence similarity to the regulator enzyme for cell cycle transitions, human Pin1. However, the cellular function of hParvulin is entirely unknown. Here, we demonstrate that hParvulin associates with the preribosomal ribonucleoprotein (pre-rRNP) complexes, which contain preribosomal RNAs, at least 26 ribosomal proteins, and 26 trans-acting factors involved in rRNA processing and assembly at an early stage of ribosome biogenesis. Since an amino-terminal domain of hParvulin, which is proposed to be a putative DNA-binding domain, was alone sufficient to associate in principle with the pre-rRNP complexes, the association is probably through protein-RNA interaction. In addition, hParvulin co-precipitated at least 10 proteins not previously known to be involved in ribosome biogenesis. Coincidentally, most of these proteins are implicated in regulation of microtubule assembly or nucleolar reformation during the mitotic phase of the cell. Thus, these results, coupled with the preferential nuclear localization of hParvulin, suggest that hParvulin may be involved in ribosome biogenesis and/or nucleolar re-assembly of mammalian cells.	Tokyo Univ Agr & Technol, Dept Biotechnol, Fuchu, Tokyo 1838509, Japan; Minist Educ Culture Sports Sci & Technol Japan, Integrated Proteom Syst Project, Hachioji, Tokyo, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Biochem Lab, Hachioji, Tokyo, Japan	Tokyo University of Agriculture & Technology; Tokyo Metropolitan University	Takahashi, N (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	ntakahas@cc.tuat.ac.jp	Miura, Yutaka/C-5457-2013; TAKAHASHI, Nobuhiro/G-1129-2013; Isobe, Toshiaki/Q-9279-2017	Uchida, Takafumi/0000-0003-3665-4906				Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; BABLER J, 2001, MOL CELL, V8, P517; BELLE R, 1989, FEBS LETT, V255, P101, DOI 10.1016/0014-5793(89)81069-5; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dousset T, 2000, MOL BIOL CELL, V11, P2705, DOI 10.1091/mbc.11.8.2705; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; HIGHTOWER MJ, 1980, J CELL PHYSIOL, V105, P93, DOI 10.1002/jcp.1041050112; Hill KL, 2000, J BIOL CHEM, V275, P39369, DOI 10.1074/jbc.M006907200; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; Kops O, 1998, J BIOL CHEM, V273, P31971, DOI 10.1074/jbc.273.48.31971; Kressler D, 1999, MOL CELL BIOL, V19, P7897; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Loyer P, 1998, J CELL SCI, V111, P1495; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maleszka R, 1997, GENE, V203, P89, DOI 10.1016/S0378-1119(97)00522-2; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; McCornack MA, 1997, FEBS LETT, V414, P84, DOI 10.1016/S0014-5793(97)00974-5; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pennisi E, 1996, SCIENCE, V274, P1613, DOI 10.1126/science.274.5293.1613; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; Rulten S, 1999, BIOCHEM BIOPH RES CO, V259, P557, DOI 10.1006/bbrc.1999.0828; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Sekerina E, 2000, J MOL BIOL, V301, P1003, DOI 10.1006/jmbi.2000.4013; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Streblow DN, 1998, VIROLOGY, V245, P197, DOI 10.1006/viro.1998.9155; Sueishi M, 2000, J BIOL CHEM, V275, P28888, DOI 10.1074/jbc.M003879200; Takagi M, 2001, J BIOL CHEM, V276, P25386, DOI 10.1074/jbc.M102227200; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKAHASHI N, 2002, IN PRESS MACROLIDE A; TANIDA I, 1991, TRANSPL P, V23, P2856; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Terada T, 2001, J MOL BIOL, V305, P917, DOI 10.1006/jmbi.2000.4293; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Uchida T, 1999, FEBS LETT, V446, P278, DOI 10.1016/S0014-5793(99)00239-2; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; XIANG JL, 1994, BIOCHEM BIOPH RES CO, V199, P1167, DOI 10.1006/bbrc.1994.1353; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yanagida M, 2000, ELECTROPHORESIS, V21, P1890; ZARDI L, 1979, CELL, V18, P649, DOI 10.1016/0092-8674(79)90120-X	62	48	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23773	23780		10.1074/jbc.M201181200	http://dx.doi.org/10.1074/jbc.M201181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960984	hybrid			2022-12-25	WOS:000176475700088
J	Kozak, KR; Gupta, RA; Moody, JS; Ji, C; Boeglin, WE; DuBois, RN; Brash, AR; Marnett, LJ				Kozak, KR; Gupta, RA; Moody, JS; Ji, C; Boeglin, WE; DuBois, RN; Brash, AR; Marnett, LJ			15-lipoxygenase metabolism of 2-arachidonylglycerol - Generation of a peroxisome proliferator-activated receptor alpha agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; ARACHIDONIC-ACID; ARACHIDONYLETHANOLAMIDE ANANDAMIDE; KERATINOCYTE DIFFERENTIATION; MAMMALIAN LIPOXYGENASES; EPIDERMAL-KERATINOCYTES; PPAR-ALPHA; OXYGENATION; ENDOCANNABINOIDS; 2-ARACHIDONOYLGLYCEROL	The recent demonstrations that cyclooxygenase-2 and leukocyte-type 12-lipoxygenase (LOX) efficiently oxygenate 2-arachidonylglycerol (2-AG) prompted an investigation into related oxygenases capable of metabolizing this endogenous cannabinoid receptor ligand. We evaluated the ability of six LOXs to catalyze the hydroperoxidation of 2-AG. Soybean 15-LOX, rabbit reticulocyte 15-LOX, human 15-LOX-1, and human 15-LOX-2 oxygenate 2-AG, providing 15(S)-hydroperoxyeicosatetraenoic acid glyceryl ester. In contrast, potato and human 5-LOXs do not efficiently metabolize this endocannabinoid. Among a series of structurally related arachidonyl esters, arachidonylglycerols serve as the preferred substrates for 15-LOXs. Steady-state kinetic analysis demonstrates that both 15-LOX-1 and 15-LOX-2 oxygenate 2-AG comparably or preferably to arachidonic acid. Furthermore, 2-AG treatment of COS-7 cells transiently transfected with human 15-LOX expression vectors or normal human epidermal keratinocytes results in the production and extracellular release of 15-hydroxyeicosatetraenoic acid glyceryl ester (15-HETE-G), establishing that lipoxygenase metabolism of 2-AG occurs I. in an eukaryotic cellular environment. Investigations into the potential biological actions of 15-HETE-G indicate that this lipid, in contrast to its free-acid counterpart, acts as a peroxisome proliferator-activated receptor a agonist. The results demonstrate that 15-LOXs are capable of acting on 2-AG to provide 15-HETE-G and elucidate a potential role for endocannabinoid oxygenation in the generation of peroxisome proliferator-activated receptor a agonists.	Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Chem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med & Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	marnett@toxicology.mc.vanderbilt.edu	DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [P01CA068484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R01GM053638, T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA68484] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347, GM53638, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brash AR, 1999, ADV EXP MED BIOL, V447, P29; BRYANT RW, 1985, J BIOL CHEM, V260, P3548; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Gaffney BJ, 1996, ANNU REV BIOPH BIOM, V25, P431, DOI 10.1146/annurev.bb.25.060196.002243; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; HAMPSON AJ, 1995, BBA-LIPID LIPID MET, V1259, P173, DOI 10.1016/0005-2760(95)00157-8; Hanley K, 2000, J BIOL CHEM, V275, P11484, DOI 10.1074/jbc.275.15.11484; Hanley K, 1997, J CLIN INVEST, V100, P705, DOI 10.1172/JCI119583; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; HENNEICKEVONZEPELIN HH, 1991, J INVEST DERMATOL, V97, P291; Hillard CJ, 2000, J PHARMACOL EXP THER, V294, P27; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2001, J BIOL CHEM, V276, P30072, DOI 10.1074/jbc.M104467200; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Moody JS, 2001, BIOCHEMISTRY-US, V40, P861, DOI 10.1021/bi002303b; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; Schewe T, 1981, Methods Enzymol, V71 Pt C, P430; Schmid PC, 2000, CHEM PHYS LIPIDS, V104, P185, DOI 10.1016/S0009-3084(99)00124-3; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Sjursen W, 2000, CYTOKINE, V12, P1189, DOI 10.1006/cyto.1999.0727; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; Tijet N, 2000, LIPIDS, V35, P709, DOI 10.1007/s11745-000-0577-z; UEDA N, 1995, ADV PROSTAG THROMB L, V23, P163; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; van Zadelhoff G, 1998, BIOCHEM BIOPH RES CO, V248, P33, DOI 10.1006/bbrc.1998.8910; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	53	150	151	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23278	23286		10.1074/jbc.M201084200	http://dx.doi.org/10.1074/jbc.M201084200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956198	hybrid			2022-12-25	WOS:000176475700025
J	Kryndushkin, DS; Smirnov, VN; Ter-Avanesyan, MD; Kushnirov, VV				Kryndushkin, DS; Smirnov, VN; Ter-Avanesyan, MD; Kushnirov, VV			Increased expression of Hsp40 chaperones, transcriptional factors, and ribosomal protein Rpp0 can cure yeast prions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHOPROTEINS P1; ESCHERICHIA-COLI; PSI+ PRION; HSP104; HSP70; PROPAGATION; GENE; PSI(+); SUP35	The SuP35 (eRF3) translation termination factor of Saccharomyces cerevisiae can undergo a prion-like conformational conversion, thus resulting in the [PSI+] nonsense-suppressor determinant. In vivo this process depends critically on the chaperone Hsp104, whose lack or overexpression can cure [PSI+]. The use of artificial prion [PSIPS+] based on a hybrid Sup35PS with prion domain from the yeast Pichia methanolica allowed us to uncover three more chaperones, Ssb1, Ssa1, and Ydj1, whose overexpression can cure prion determinants. Here, we used the [PSIPS+] to search a multicopy yeast genomic library for novel factors able to cure prions. It was found that overexpression of the Hsp40 family chaperones Sis1 and Yn1077w, chaperone Stil, transcriptional factors SfI1 and Ssn8, and acidic ribosomal protein Rpp0 can interfere with propagation and manifestation of [PSIPS+] in a prion strain-specific manner. Some of these factors also affected the manifestation and propagation of conventional [PSI+]. Excess of SfI1, Ssn8, and Rpp0 influenced at least one of the tested chaperone-specific promoters, SSA4, HSP104, and model promoters, with either the heat shock or stress response elements. Thus, the induction of chaperone expression by these proteins could explain their prion-curing effects.	Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia	National Medical Research Center of Cardiology	Kushnirov, VV (corresponding author), Cardiol Res Ctr, Inst Expt Cardiol, 3rd Cherepkovskaya St 15A, Moscow 121552, Russia.	vita@cardio.ru	Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1984, GENETICS, V107, P19; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Chacinska A, 2001, CURR GENET, V39, P62, DOI 10.1007/s002940000180; Chai YH, 1999, J NEUROSCI, V19, P10338; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; Cooper KF, 1999, GENE EXPRESSION, V8, P43; Derkatch IL, 1996, GENETICS, V144, P1375; Dul JL, 2001, J CELL BIOL, V152, P705, DOI 10.1083/jcb.152.4.705; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; FUJITA A, 1989, GENE, V85, P321; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Jung G, 2000, GENETICS, V156, P559; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Lorenz MC, 1998, GENETICS, V150, P1443; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PIPER P, 1997, YEAST STRESS RESPONS; Raitt DC, 2000, MOL BIOL CELL, V11, P2335, DOI 10.1091/mbc.11.7.2335; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTOS C, 1994, J BIOL CHEM, V269, P15689; SAROKIN L, 1985, MOL CELL BIOL, V5, P2521, DOI 10.1128/MCB.5.10.2521; Sherman F., 1986, METHODS YEAST GENETI; Sondheimer N, 2001, EMBO J, V20, P2435, DOI 10.1093/emboj/20.10.2435; Song WJ, 1998, EMBO J, V17, P5757, DOI 10.1093/emboj/17.19.5757; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Trotter EW, 2001, P NATL ACAD SCI USA, V98, P7313, DOI 10.1073/pnas.121172998; Urakov V N, 2001, BMC Mol Biol, V2, P9, DOI 10.1186/1471-2199-2-9; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Yan W, 1999, MOL CELL BIOL, V19, P7751	48	70	72	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23702	23708		10.1074/jbc.M111547200	http://dx.doi.org/10.1074/jbc.M111547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11923285	hybrid			2022-12-25	WOS:000176475700079
J	Mougin, A; Torterotot, F; Branlant, C; Jacobson, MR; Huang, Q; Pederson, T				Mougin, A; Torterotot, F; Branlant, C; Jacobson, MR; Huang, Q; Pederson, T			A 3 '-terminal minihelix in the precursor of human spliceosomal U2 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; POLYMERASE-III; HELA-CELLS; RIBONUCLEOPROTEIN ORGANIZATION; EUKARYOTIC RNA; END FORMATION; U5 RNAS; U1; CYTOPLASM; RAT	U2 RNA is one of five small nuclear RNAs that participate in the majority of mRNA splicing. In addition to its role in mRNA splicing, the biosynthesis of U2 RNA and three of the other spliceosomal RNAs is itself an intriguing process involving nuclear export followed by 5'-cap hypermethylation, assembly with specific proteins, 3' end processing, and then nuclear import. Previous work has identified sequences near the 3' end of pre-U2 RNA that are required for accurate and efficient processing. In this study, we have investigated the structural basis of U2 RNA 3' end processing by chemical and enzymatic probing methods. Our results demonstrate that the 3' end of pre-U2 RNA is a minihelix with an estimated stabilization free energy of -6.9 kcal/mol. Parallel RNA structure mapping experiments with mutant pre-U2 RNAs revealed that the presence of this 3' minihelix is itself not required for in vitro 3'-processing of pre-U2 RNA, in support of earlier studies implicating internal regions of pre-U2 RNA. Other considerations raise the possibility that this distinctive structural motif at the 3' end of pre-U2 RNA plays a role in the cleavage of the precursor from its longer primary transcript or in its nucleocytoplasmic traffic.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; Univ H Poincare Nancy 1, CNRS, UMR 7567, F-54506 Vandoeuvre Les Nancy, France	University of Massachusetts System; University of Massachusetts Worcester; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Pederson, T (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	thoru.pederson@umassmed.edu	Immel, Françoise/N-7079-2019; Immel, Françoise/GNP-4167-2022	Immel, Françoise/0000-0002-2028-902X; Branlant, Christiane/0000-0003-4728-5499	NIGMS NIH HHS [GM-21595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BRANLANT C, 1983, NUCLEIC ACIDS RES, V11, P8359, DOI 10.1093/nar/11.23.8359; BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; CALVET JP, 1987, J MOL BIOL, V197, P543, DOI 10.1016/0022-2836(87)90563-8; Cuello P, 1999, EMBO J, V18, P2867, DOI 10.1093/emboj/18.10.2867; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELICEIRI GL, 1974, CELL, V3, P11, DOI 10.1016/0092-8674(74)90031-2; ELICEIRI GL, 1976, BIOCHEM BIOPH RES CO, V72, P507, DOI 10.1016/S0006-291X(76)80070-8; GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; Huang Q, 1999, NUCLEIC ACIDS RES, V27, P1025, DOI 10.1093/nar/27.4.1025; Huang Q, 1997, MOL CELL BIOL, V17, P7178, DOI 10.1128/MCB.17.12.7178; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; KONINGS DAM, 1987, EXP CELL RES, V172, P329, DOI 10.1016/0014-4827(87)90391-0; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; KROL A, 1981, NUCLEIC ACIDS RES, V9, P2699, DOI 10.1093/nar/9.12.2699; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; Kuwabara T, 2001, NUCLEIC ACIDS RES, V29, P2780, DOI 10.1093/nar/29.13.2780; LIN WL, 1984, J MOL BIOL, V180, P947, DOI 10.1016/0022-2836(84)90265-1; LIU MH, 1984, NUCLEIC ACIDS RES, V12, P1529, DOI 10.1093/nar/12.3.1529; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; MADORE SJ, 1984, J CELL BIOL, V98, P188, DOI 10.1083/jcb.98.1.188; MADORE SJ, 1984, J CELL BIOL, V99, P1140, DOI 10.1083/jcb.99.3.1140; MYSLINSKI E, 1984, J MOL BIOL, V180, P927, DOI 10.1016/0022-2836(84)90264-X; REDDY R, 1987, J BIOL CHEM, V262, P75; TANI T, 1983, J MOL BIOL, V168, P579, DOI 10.1016/S0022-2836(83)80303-9; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; WIEBEN ED, 1985, J MOL BIOL, V183, P69, DOI 10.1016/0022-2836(85)90281-5; YUO CY, 1985, CELL, V42, P193, DOI 10.1016/S0092-8674(85)80115-X; ZIEVE G, 1976, CELL, V8, P19, DOI 10.1016/0092-8674(76)90181-1; ZIEVE GW, 1990, CRIT REV BIOCHEM MOL, V25, P1, DOI 10.3109/10409239009090604; ZIEVE GW, 1988, J MOL BIOL, V199, P259, DOI 10.1016/0022-2836(88)90312-9; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	39	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23137	23142		10.1074/jbc.M202258200	http://dx.doi.org/10.1074/jbc.M202258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11956214	hybrid			2022-12-25	WOS:000176475700007
J	Amayed, P; Pantaloni, D; Carlier, MF				Amayed, P; Pantaloni, D; Carlier, MF			The effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; DESTABILIZING ACTIVITY; DYNAMIC INSTABILITY; INTACT-CELLS; PROTEIN; ONCOPROTEIN-18; OP18/STATHMIN; MITOSIS; DISSOCIATION; TRANSITION	Stathmin is a phosphorylation-regulated tubulin-binding protein. In vitro and in vivo studies using nonphosphorylatable and pseudophosphorylated mutants of stathmin have questioned the View that stathmin might act only as a tubulin-sequestering factor. Stathmin was proposed to effectively regulate microtubule dynamic instability by increasing the frequency of catastrophe (the transition from steady growth to rapid depolymerization), without interacting with tubulin. We have used a noninvasive method to measure the equilibrium dissociation constants of the T2S complexes of tubulin with stathmin, pseudophosphorylated (4E)-stathmin, and diphosphostathmin. At both pH 6.8 and pH 7.4, the relative sequestering efficiency of the different stathmin variants depends on the concentration of free tubulin, Le. on the dynamic state of microtubules. This control is exerted in a narrow range of tubulin concentration due to the highly cooperative binding of tubulin to stathmin. Changes in pH affect the stability of tubulin-stathmin complexes but do not change stathmin function. The 4E-stathmin mutant mimics inactive phosphorylated stathmin at low tubulin concentration and sequesters tubulin almost as efficiently as stathmin at higher tubulin concentration. We propose that stathmin acts solely by sequestering tubulin, without affecting microtubule dynamics, and that the effect of stathmin phosphorylation on microtubule assembly depends on tubulin critical concentration.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.							Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Diaz JF, 2000, J BIOL CHEM, V275, P26265, DOI 10.1074/jbc.M003120200; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; Gavet O, 1998, J CELL SCI, V111, P3333; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GRADIN HM, 1997, MOL BIOL CELL, V6, P3459; HILL TL, 1987, LINEAR AGGREGATION T, P244; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McNally FJ, 1998, MOL BIOL CELL, V9, P1847, DOI 10.1091/mbc.9.7.1847; MENDES E, 1995, EUROPHYS LETT, V32, P273, DOI 10.1209/0295-5075/32/3/014; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Quarmby LM, 1999, CELL MOTIL CYTOSKEL, V43, P1; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Saoudi Y, 1998, J CELL BIOL, V142, P1519, DOI 10.1083/jcb.142.6.1519; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; Vorobjev IA, 1999, J CELL SCI, V112, P2277; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	51	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22718	22724		10.1074/jbc.M111605200	http://dx.doi.org/10.1074/jbc.M111605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11956188	hybrid			2022-12-25	WOS:000176313600080
J	Burchett, SA; Flanary, P; Aston, C; Jiang, LX; Young, KH; Uetz, P; Fields, S; Dohlman, HG				Burchett, SA; Flanary, P; Aston, C; Jiang, LX; Young, KH; Uetz, P; Fields, S; Dohlman, HG			Regulation of stress response signaling by the N-terminal disshevelled/EGL-10/pleckstrin domain of Sst2, a regulator of G protein signaling in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; COUPLED RECEPTOR KINASE; OSMOLARITY GLYCEROL PATHWAY; ALPHA-INTERACTING PROTEIN; PLASMA-MEMBRANE ATPASE; GENE-EXPRESSION; RGS-DOMAIN; SELECTIVE REGULATION; SYNTAXIN HOMOLOG; FINGER PROTEINS	All members of the regulator of G protein signaling (RGS) family contain a conserved core domain that can accelerate G protein GTPase activity. The RGS in yeast, Sst2, can inhibit a G protein signal leading to mating. In addition, some RGS proteins contain an N-terminal domain of unknown function. Here we use complementary whole genome analysis methods to investigate the function of the N-terminal Sst2 domain. To identify, a signaling pathway regulated by N-Sst2, we performed genome-wide transcription profiling of cells expressing this fragment alone and found differences in 53 transcripts. Of these, 40 are induced by N-Sst2, and nearly all contain a stress response element (STRE) in the promoter region. To identify components of a signaling pathway leading from N-Sst2 to STREs, we performed a genome-wide two-hybrid analysis using N-Sst2 as bait and found 17 interacting proteins. To identify the functionally relevant interacting proteins, we analyzed all of the available gene deletion mutants and found three (vps36Delta, pep12Delta, and tlg2Delta) that induce STRE and also repress pheromone-dependent transcription. We selected VPS36 for further characterization. A vps36Delta mutation diminishes signaling by pheromone as well as by downstream components including the G protein, effector kinase (Ste11), and transcription factor (Ste12). Conversely, overexpression of Vps36 enhances the pheromone response in sst2Delta cells but not in wild type. These findings indicate that Vps36 and Sst2 have opposite and opposing effects on the pheromone and stress response pathways, with Vps36 acting downstream of the G protein and independently of Sst2 RGS activity.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Wyeth Ayerst Res, Neurosci Res, Princeton, NJ 08543 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Yale University; Pfizer; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.	henrik_dohlman@med.unc.edu	Uetz, Peter/A-7119-2012	Uetz, Peter/0000-0001-6194-4927; Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055316, R01GM059167] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055316, R01 GM059167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1998, J BIOL CHEM, V273, P11719, DOI 10.1074/jbc.273.19.11719; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apanovitch DM, 1998, BIOCHEMISTRY-US, V37, P4815, DOI 10.1021/bi9729965; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Benzing T, 2000, J BIOL CHEM, V275, P28167; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Cagney G, 2000, METHOD ENZYMOL, V328, P3, DOI 10.1016/S0076-6879(00)28386-9; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chen TS, 1997, MOL CELL BIOL, V17, P3429, DOI 10.1128/MCB.17.6.3429; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; DULIC V, 1990, J CELL SCI, V97, P517; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gerrard SR, 2000, TRAFFIC, V1, P259, DOI 10.1034/j.1600-0854.2000.010308.x; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoffman GA, 2000, J BIOL CHEM, V275, P37533, DOI 10.1074/jbc.M005751200; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LATTERICH M, 1991, MOL MICROBIOL, V5, P2417, DOI 10.1111/j.1365-2958.1991.tb02087.x; LATTERICH M, 1993, BIOCHEM BIOPH RES CO, V191, P1111, DOI 10.1006/bbrc.1993.1331; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Moskvina E, 1999, MOL MICROBIOL, V32, P1263, DOI 10.1046/j.1365-2958.1999.01438.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; Nothwehr SF, 1996, MOL CELL BIOL, V16, P2700; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Schmidt AE, 1999, J BIOL CHEM, V274, P21981, DOI 10.1074/jbc.274.31.21981; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tadi D, 1999, YEAST, V15, P1733, DOI 10.1002/(SICI)1097-0061(199912)15:16<1733::AID-YEA490>3.0.CO;2-L; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Usui K, 2000, INT J MOL MED, V5, P335; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Xu BE, 2001, GENETICS, V159, P1559; YEGHIAYAN P, 1995, YEAST, V11, P219, DOI 10.1002/yea.320110304; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	93	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22156	22167		10.1074/jbc.M202254200	http://dx.doi.org/10.1074/jbc.M202254200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940600				2022-12-25	WOS:000176313600009
J	Yao, XY; Nguyen, V; Wriggers, W; Rubenstein, PA				Yao, XY; Nguyen, V; Wriggers, W; Rubenstein, PA			Regulation of yeast actin behavior by interaction of charged residues across the interdomain cleft	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERELY DECREASED HYDROPHOBICITY; IN-VITRO; MUTATION; POLYMERIZATION; DYNAMICS; MECHANISM; FILAMENT; LOOP	His(73) participates in the regulation of the nucleotide binding cleft conformation in yeast actin. Earlier molecular dynamics studies suggested that Asp(184) interacts with His(73) thereby stabilizing a "closed-cleft" G-actin. However, beta-actin in the open-cleft state shows a closer interaction of His(73) with Asp(179) than with Asp(184). We have thus assessed the relative importance of Asp(184) and Asp(179) on yeast actin stability and function. Neutral substitutions at 184 or 179 alone had little adverse effect on the monomer and polymerization behavior of actin. Arg or His at 184 in H73E actin partially rescued the monomeric properties of H73E actin, as demonstrated by near-normal thermostability and wild-type (WT)-like protease digestion patterns. ATP exchange was still considerably faster than with WT-actin although slower than that of H73E alone. However, polymerization of H73E/D184R and H73E/D184H is worse than with H73E alone. Conversely, D179R rescued all monomeric properties of H73E to near WT values and largely restored polymerization rate and filament thermostability. These results and new simulations of G-actin in the "open" state underscore the importance of the His(73)-Asp(179) interaction and suggest that the open and not the closed state of yeast actin may be favored in the absence of the methyl group of His(73).	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Iowa; Scripps Research Institute	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.			Wriggers, Willy/0000-0001-5326-3152; Rubenstein, Peter/0000-0003-1225-4414	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NCRR NIH HHS [P41RR12255] Funding Source: Medline; NIGMS NIH HHS [GM33689] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASATOOR AM, 1967, BIOCHEM BIOPH RES CO, V26, P168, DOI 10.1016/0006-291X(67)90229-X; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; CHEN X, 1995, J BIOL CHEM, V270, P11415, DOI 10.1074/jbc.270.19.11415; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COOK RK, 1992, J BIOL CHEM, V267, P9430; COOK RK, 1991, J BIOL CHEM, V266, P16825; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JOHNSON P, 1967, BIOCHEM J, V105, P361, DOI 10.1042/bj1050361; Kalhor HR, 1999, ARCH BIOCHEM BIOPHYS, V370, P105, DOI 10.1006/abbi.1999.1370; Kim E, 1996, BIOCHEMISTRY-US, V35, P16566, DOI 10.1021/bi9623892; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILLER CJ, 1995, BIOPHYS J S, V68, P50; Orlova A, 1997, J MOL BIOL, V271, P235, DOI 10.1006/jmbi.1997.1163; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pollard TD, 2001, J CELL SCI, V114, P3; SUSSMAN DJ, 1984, J BIOL CHEM, V259, P7349; Wriggers W, 1999, PROTEINS, V35, P262, DOI 10.1002/(SICI)1097-0134(19990501)35:2<262::AID-PROT11>3.0.CO;2-N; Yao XY, 2001, J BIOL CHEM, V276, P25598, DOI 10.1074/jbc.M011797200; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	25	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22875	22882		10.1074/jbc.M201685200	http://dx.doi.org/10.1074/jbc.M201685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940592	Green Submitted, hybrid			2022-12-25	WOS:000176313600098
J	Szaszak, M; Gaborik, Z; Turu, G; McPherson, PS; Clark, AJL; Catt, KJ; Hunyady, L				Szaszak, M; Gaborik, Z; Turu, G; McPherson, PS; Clark, AJL; Catt, KJ; Hunyady, L			Role of the proline-rich domain of dynamin-2 and its interactions with Src homology 3 domains during endocytosis of the AT(1) angiotensin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PROTEIN-COUPLED RECEPTORS; SIGNAL-TRANSDUCTION; BETA-ARRESTIN; SH3 DOMAIN; VESICLE FORMATION; BINDING PARTNERS; COATED PITS; AMPHIPHYSIN; INTERNALIZATION	In nonneural tissues, the dynamin-2 isoform. participates in the formation of clathrin-coated vesicles during receptor endocytosis. In this study, the mechanism of dynamin-2 action was explored during endocytosis of the G protein-coupled AT(1A) angiotensin receptor expressed in Chinese hamster ovary cells. Dynamin-2 molecules with mutant pleckstrin homology domains or deleted proline-rich domains (PRD) exerted dominant negative inhibition on the endocytosis of radiolabeled angiotensin II. However, only the PRD mutation interfered with the localization of the dynamin-2 molecule to clathrin-coated pits and reduced the inhibitory effect of the GTPase-deficient K44A mutant dynamin-2. Green fluorescent protein-tagged Src homology 3 (SH3) domains of endophilin I and amphiphysin II, two major binding partners of dynamins, also inhibited AT(1A) receptor-mediated endocytosis of angiotensin II. These effects were partially or fully, respectively, restored by the overexpression of dynamin-2. Transient overexpression of these SH3 domains also reduced the localization of dynamin-2 to clathrin-coated pits. These data indicate that, similar to the recruitment of dynamin-1 during the recycling of synaptic vesicles, interaction of the dynamin-2 PRD with SH3 domains of proteins such as the amphiphysins and endophilins is essential for AT(1A) receptor endocytosis. This mechanism could be of general importance in dynamin-dependent endocytosis of other G protein-coupled receptors in nonneural tissues.	Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest 8, Hungary; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ London, Queen Mary, Barts & London, Dept Endocrinol, London EC1A 7BE, England; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	Semmelweis University; McGill University; University of London; Queen Mary University London; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hunyady, L (corresponding author), Semmelweis Univ, Fac Med, Dept Physiol, PBO 259, H-1444 Budapest 8, Hungary.	Hunyady@puskin.sote.hu	Szaszak, Marta/G-7957-2011	Turu, Gabor/0000-0002-4421-3812	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000193, ZIAHD000193] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Balla T, 2000, TRENDS PHARMACOL SCI, V21, P238, DOI 10.1016/S0165-6147(00)01500-5; Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Berk BC, 1999, J AM SOC NEPHROL, V10, pS62; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Celli M, 1999, J PHYS-CONDENS MAT, V11, P10229, DOI 10.1088/0953-8984/11/50/315; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; de Gasparo M, 2000, PHARMACOL REV, V52, P415; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Eguchi S, 2000, REGUL PEPTIDES, V91, P13, DOI 10.1016/S0167-0115(00)00126-9; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; Hunyady L, 2001, J RENIN-ANGIO-ALDO S, V2, pS16, DOI 10.1177/14703203010020010301; Hunyady L, 2000, REGUL PEPTIDES, V91, P29, DOI 10.1016/S0167-0115(00)00137-3; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Thomas WG, 1999, REGUL PEPTIDES, V79, P9, DOI 10.1016/S0167-0115(98)00140-2; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	64	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21650	21656		10.1074/jbc.M200778200	http://dx.doi.org/10.1074/jbc.M200778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925437	hybrid			2022-12-25	WOS:000176286000072
J	Valerius, O; Brendel, C; Duvel, K; Braus, GH				Valerius, O; Brendel, C; Duvel, K; Braus, GH			Multiple factors prevent transcriptional interference at the yeast ARO4-HIS7 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; GENE; TERMINATION; PROMOTER; REGION; DNA; INITIATION; BINDING; ABF1P	Increased transcriptional activity may cause transcriptional interference in organisms with compact genomes such as the Yeast Saccharomyces cerevisiae. Replacement of the yeast ARO4 promoter by the stronger ACTI promoter increases ARO4 transcription and simultaneously reduces the basal transcription of the downstream HIS7 gene. The open reading frames of ARO4 and HIS7 are tandemly transcribed and are separated by 416 bp. In wild-type cells, a nuclease-resistant site suggests that the two genes are separated by a single positioned nucleosome. Transcriptional interference correlates with Micrococcus nuclease accessibility of this otherwise nuclease-resistant site. Deletion analyses of the region between the two open reading frames revealed that transcriptional interference increases upon removal of either parts of the ARO4 3' end or HIS7 promoter sequences. The abolishment of the Abf1p-binding site within the HIS7 promoter significantly enhances transcriptional interference, resulting in a histidine auxotrophic strain. Our data suggest that the yeast cell prevents transcriptional interference by the combined action of efficient ARO4 transcription termination, the positioning of a fixed nucleosome, and transcription factor binding to the HIS7 promoter.	Univ Gottingen, Inst Microbiol & Genet, D-37077 Gottingen, Germany	University of Gottingen	Braus, GH (corresponding author), Univ Gottingen, Inst Microbiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.		Braus, Gerhard H/G-3999-2012; Braus, Gerhard/ABC-6293-2021	Braus, Gerhard H/0000-0002-3117-5626; Braus, Gerhard/0000-0002-3117-5626				CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DEWINDE JH, 1993, YEAST, V9, P847, DOI 10.1002/yea.320090805; DORSMAN JC, 1990, NUCLEIC ACIDS RES, V18, P2769, DOI 10.1093/nar/18.9.2769; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Greger IH, 1998, EMBO J, V17, P4771, DOI 10.1093/emboj/17.16.4771; Greger IH, 1998, NUCLEIC ACIDS RES, V26, P1294, DOI 10.1093/nar/26.5.1294; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; Jansa P, 2001, NUCLEIC ACIDS RES, V29, P423, DOI 10.1093/nar/29.2.423; KUNZLER M, 1993, J BACTERIOL, V175, P5548; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; Lascaris RF, 2000, NUCLEIC ACIDS RES, V28, P1390, DOI 10.1093/nar/28.6.1390; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; PARAVICINI G, 1988, MOL GEN GENET, V214, P165, DOI 10.1007/BF00340197; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Puig S, 1999, CURR MICROBIOL, V39, P369, DOI 10.1007/s002849900474; Rose MD., 1990, METHODS YEAST GENETI; Springer C, 1997, MOL GEN GENET, V256, P136, DOI 10.1007/s004380050555; Springer C, 1997, J BIOL CHEM, V272, P26318, DOI 10.1074/jbc.272.42.26318; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Thoma F, 1996, METHOD ENZYMOL, V274, P197; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	23	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21440	21445		10.1074/jbc.M201841200	http://dx.doi.org/10.1074/jbc.M201841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937506	hybrid			2022-12-25	WOS:000176286000042
J	Brett, PJ; Tiwana, H; Feavers, IM; Charalambous, BM				Brett, PJ; Tiwana, H; Feavers, IM; Charalambous, BM			Characterization of oligopeptides that cross-react with carbohydrate-specific antibodies by real time kinetics, in-solution competition enzyme-linked immunosorbent assay, and immunological analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEISSERIA-MENINGITIDIS SEROGROUP; CAPSULAR POLYSACCHARIDE; PEPTIDE MIMOTOPES; IMMUNE-RESPONSE; ANTICARBOHYDRATE ANTIBODIES; CLONAL CHARACTERIZATION; MONOCLONAL-ANTIBODIES; B POLYSACCHARIDE; OLIGOSACCHARIDE; EPITOPES	Phage displaying random cyclic 7-mer, and linear 7-mer and 12-mer peptides at the N terminus of the coat protein, pIII, were panned with the murine monoclonal antibody, 9-2-L379 specific for meningoeoccal lipo-oligosaccharide. Five cyclic peptides with two sequence motifs, six linear 7-mers, and five linear 12-mers with different sequence motifs were identified. Only phage displaying cyclic peptides were specifically captured by and were antigenic for 9-2-L379. Monoclonal antibody 9-2-L379 exhibited "apparent" binding affinities to the cyclic peptides between 11 and 184 nm, comparable with lipo-oligosaccharide. All cyclic peptides competed with the binding of 9-2-L379 to lipo-oligosaccharide with EC50 values in the range 10-105 pm, which correlated with their apparent binding affinities. Structural modifications of the cyclic peptides eliminated their ability to bind and compete with monoclonal antibody 9-2-L379. Mice (C3H/HeN) immunized with the cyclic peptide with optimal apparent binding affinity and EC50 of competition elicited cross-reactive antibodies to meningococcal lipo-oligosaccharide with end point dilution serum antibody titers of 3200. Cyclic peptides were converted to T-cell-dependent immunogens without disrupting these properties by C-terminal biotinylation and complexing with NeutrAvidin(R). The data indicate that constrained peptides can cross-react with a carbohydrate-specific antibody with greater specificity than linear peptides, and critical to this specificity is their structural conformation.	UCL, Royal Free & Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England; Natl Inst Biol Stand & Controls, Div Bacteriol, S Mimms EN6 3QG, Herts, England	University of London; University College London; National Institute for Biological Standards & Control	Charalambous, BM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Med Microbiol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	b.charalambous@rfc.ucl.ac.uk						Agadjanyan M, 1997, NAT BIOTECHNOL, V15, P547, DOI 10.1038/nbt0697-547; Charalambous BM, 1999, CLIN DIAGN LAB IMMUN, V6, P838, DOI 10.1128/CDLI.6.6.838-843.1999; Charalambous BM, 2001, J MED MICROBIOL, V50, P937, DOI 10.1099/0022-1317-50-11-937; Charalambous BM, 2000, FEMS MICROBIOL LETT, V191, P45, DOI 10.1016/S0378-1097(00)00368-2; De Berardinis P, 2000, NAT BIOTECHNOL, V18, P873, DOI 10.1038/78490; De Bolle X, 1999, J MOL BIOL, V294, P181, DOI 10.1006/jmbi.1999.3248; ESTABROOK MM, 1993, J INFECT DIS, V167, P966, DOI 10.1093/infdis/167.4.966; Evans JS, 1996, MICROBIOL-UK, V142, P57, DOI 10.1099/13500872-142-1-57; GIEBEL LB, 1995, BIOCHEMISTRY-US, V34, P15430, DOI 10.1021/bi00047a006; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; GRIFFISS JM, 1984, J INFECT DIS, V150, P71, DOI 10.1093/infdis/150.1.71; Grothaus MC, 2000, VACCINE, V18, P1253, DOI 10.1016/S0264-410X(99)00390-4; GU XX, 1993, INFECT IMMUN, V61, P1873, DOI 10.1128/IAI.61.5.1873-1880.1993; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Hutchins WA, 1999, HYBRIDOMA, V18, P121, DOI 10.1089/hyb.1999.18.121; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JONES D, 1995, MENINGOCOCCAL DIS, P147; Kieber-Emmons T, 1998, IMMUNOL RES, V17, P95, DOI 10.1007/BF02786435; KieberEmmons T, 1997, HYBRIDOMA, V16, P3, DOI 10.1089/hyb.1997.16.3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; MACKINNON FG, 1993, MICROB PATHOGENESIS, V15, P359, DOI 10.1006/mpat.1993.1085; Moe GR, 1999, FEMS IMMUNOL MED MIC, V26, P209; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Phalipon A, 1997, EUR J IMMUNOL, V27, P2620, DOI 10.1002/eji.1830271022; Pincus SH, 1998, J IMMUNOL, V160, P293; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; Preston A, 1996, CRIT REV MICROBIOL, V22, P139, DOI 10.3109/10408419609106458; Qiu JP, 1999, HYBRIDOMA, V18, P103, DOI 10.1089/hyb.1999.18.103; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; Schulz-Utermoehl T, 2000, DRUG METAB DISPOS, V28, P544; SCOTT MG, 1989, J IMMUNOL, V143, P293; TARRAND JJ, 1989, J IMMUNOL, V142, P2519; TZITZILONIS C, 2000, 12 INT PATH NEISS C; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; Venkatesh N, 1999, EUR J BIOCHEM, V265, P1061, DOI 10.1046/j.1432-1327.1999.00828.x; VERHEUL AFM, 1991, INFECT IMMUN, V59, P3566, DOI 10.1128/IAI.59.10.3566-3573.1991; VERHEUL AFM, 1993, MICROBIOL REV, V57, P34, DOI 10.1128/MMBR.57.1.34-49.1993; VERHEUL AFM, 1994, CLIN DIAGN LAB IMMUN, V1, P729, DOI 10.1128/CDLI.1.6.729-736.1994; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; WESTERINK MAJ, 1988, INFECT IMMUN, V56, P1120, DOI 10.1128/IAI.56.5.1120-1127.1988; WESTERINK MAJ, 1992, MICROB PATHOGENESIS, V12, P19, DOI 10.1016/0882-4010(92)90062-S	45	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20468	20476		10.1074/jbc.M200387200	http://dx.doi.org/10.1074/jbc.M200387200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923297	hybrid			2022-12-25	WOS:000176204500048
J	Kuemmerle, JF; Zhou, HP				Kuemmerle, JF; Zhou, HP			Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL PROMOTER ACTIVITY; BREAST-CANCER CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSGENIC MICE; EXON-2 PROMOTER; GENE; INHIBITION; PROLIFERATION; RECEPTOR; BETA	Insulin-like growth factor-binding protein-5 (IGFBP-5) and insulin-like growth factor-I (IGF-I) are produced by human intestinal smooth muscle cells. Endogenous IGF-I stimulates growth and increases IGFBP-5 secretion. IGFBP-5 augments the effects of IGF-I by facilitating interaction of IGF-I with the IGF-I receptor tyrosine kinase. Andress (Andress, D. L. (1998) Aim J. Physiol. 274, E744-E750) and Berfield et al. (Berfield, A. K., Andress, D. L., and Abrass, C. K. (2000) Kidney Int. 57, 1991-2003) have shown that in osteoblasts and kidney mesangial cells, IGFBP-5 stimulates proliferation and filopodia formation independently of IGF-I, presumably by activating a distinct IGFBP-5 receptor serine kinase. The present study determined whether IGFBP-5 exerts direct effects on growth in human intestinal smooth muscle cells and identified the intracellular signaling pathways involved. IGFBP-5 caused a concentration-dependent increase in [H-3]thymidine incorporation and an increase in IGF-I secretion that occurred independently of IGF-I and the IGF-I receptor tyrosine kinase. IGFBP-5-induced phosphorylation of p38 ALAP kinase, which was abolished by SB203580, or expression of a dominant negative Pas mutant, Ras(S17N), and phosphorylation of Erk1/2, which was abolished by a Raf1 kinase inhibitor, U1026, or expression of Ras(S17N). IGFBP-5-stimulated [H-3]thymidine incorporation and IGF-I secretion were partly inhibited by SB203580 or U1026 and abolished by the combination of the two inhibitors or by expression of Ras(S17N). These data show that IGFBP-5 stimulates growth and IGF-I secretion in human intestinal smooth muscle cells by activation of p38 MAP kinase-dependent and Erk1/2-dependent pathways that are independent of IGF-I. A positive feedback mechanism therefore links IGFBP-5 and IGF-I secretion that reinforces their individual effects on growth.	Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol, Dept Physiol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Kuemmerle, JF (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Gastroenterol, Dept Med, POB 980711, Richmond, VA 23298 USA.	jkuemmerle@hsc.vcu.edu	Zhou, Huiping/J-3639-2015; Zhou, Huiping/H-6875-2019	Zhou, Huiping/0000-0002-0050-372X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049691, R56DK049691, R01DK049691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Bushman TL, 1998, AM J PHYSIOL-GASTR L, V275, pG1282, DOI 10.1152/ajpgi.1998.275.6.G1282; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; DAUGHADAY WH, 1987, J LAB CLIN MED, V109, P355; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Hou YT, 2000, BIOCHEM BIOPH RES CO, V275, P422, DOI 10.1006/bbrc.2000.3283; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kuemmerle JF, 2000, AM J PHYSIOL-GASTR L, V279, pG975, DOI 10.1152/ajpgi.2000.279.5.G975; Kuemmerle JF, 2000, AM J PHYSIOL-GASTR L, V278, pG710, DOI 10.1152/ajpgi.2000.278.5.G710; Kuemmerle JF, 1998, AM J PHYSIOL-GASTR L, V275, pG151, DOI 10.1152/ajpgi.1998.275.1.G151; Kuemmerle JF, 1997, GASTROENTEROLOGY, V113, P817, DOI 10.1016/S0016-5085(97)70176-8; Lackey K, 2000, BIOORG MED CHEM LETT, V10, P223, DOI 10.1016/S0960-894X(99)00668-X; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; Murthy KS, 2001, GASTROENTEROLOGY, V120, pA201, DOI 10.1016/S0016-5085(01)80997-5; OH YM, 1993, J BIOL CHEM, V268, P14964; Ohneda K, 1997, GASTROENTEROLOGY, V112, P444, DOI 10.1053/gast.1997.v112.pm9024298; Parrizas M, 1997, J BIOL CHEM, V272, P154; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; RUBIN R, 1995, LAB INVEST, V73, P311; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Wang L, 2000, ENDOCRINOLOGY, V141, P1118, DOI 10.1210/en.141.3.1118; Wang X, 1998, ENDOCRINOLOGY, V139, P1054, DOI 10.1210/en.139.3.1054; Wang X, 1997, ENDOCRINOLOGY, V138, P1528, DOI 10.1210/en.138.4.1528; Zeeh JM, 2001, EUR J GASTROEN HEPAT, V13, P851, DOI 10.1097/00042737-200107000-00014; Zimmermann EM, 1997, AM J PHYSIOL-GASTR L, V273, pG875, DOI 10.1152/ajpgi.1997.273.4.G875; Zimmermann EM, 2001, AM J PHYSIOL-GASTR L, V280, pG1022, DOI 10.1152/ajpgi.2001.280.5.G1022	44	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20563	20571		10.1074/jbc.M200885200	http://dx.doi.org/10.1074/jbc.M200885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923300	hybrid			2022-12-25	WOS:000176204500061
J	Oubrahim, H; Chock, PB; Stadtman, ER				Oubrahim, H; Chock, PB; Stadtman, ER			Manganese(II) induces apoptotic cell death in NIH3T3 cells via a caspase-12-dependent pathway.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; DOUBLE-STRANDED-RNA; HYDROGEN-PEROXIDE; ACTIVATION; PROTEASE; MECHANISM; CASPASES; COMPLEX; ROLES	Under physiological conditions, manganese(II) exhibits catalase-like activity. However, at elevated concentrations, it induces apoptosis via a non-mitochondria-mediated mechanism (Oubrahim, H., Stadtman, E. R., and Chock, P. B. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 9505-9510). In this study, we show that the Mn(II)-induced apoptosis, as monitored by caspase-3-like activity, in NIH3T3 cells was inhibited by calpain inhibitors I and II or the p38 MAP kinase inhibitor, SB202190. The control experiments showed that each of these inhibitors in the concentration ranges used exerted no effect on activated caspase-3-like activity. Furthermore, caspase-12 was cleaved in Mn(II)-treated cells, suggesting that the Mn(II)-induced apoptosis is mediated by caspase-12. This notion is confirmed by the observations that pretreatment of NIH3T3 cells with either caspase-12 antisense RNA or dsRNA corresponding to the full-length caspase-12 led to a dramatic decrease in caspase-3-like activity induced by Mn(II). The precise mechanism by which Mn(II) induced the apoptosis is not clear. Nevertheless, Mn(II), in part, exerts its effect via its ability to replace Ca(II) in the activation of m-calpain, which in turn activates caspase-12 and degrades Bcl-xL. In addition, the dsRNA, method serves as an effective technique for knocking out caspase-12 in NIH3T3 cells without causing apoptosis.	NHLBI, LB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Stadtman, ER (corresponding author), NHLBI, LB, NIH, Bldg 10,Rm 2140,50 South Dr,MSC-8012, Bethesda, MD 20892 USA.	erstadtman@nih.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000202, Z01HL000211, ZIAHL000202] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERLETT BS, 1990, P NATL ACAD SCI USA, V87, P389, DOI 10.1073/pnas.87.1.389; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Kerr J.F.R., 1987, P93; Lander F, 1999, INT ARCH OCC ENV HEA, V72, P546, DOI 10.1007/s004200050414; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Oubrahim H, 2001, P NATL ACAD SCI USA, V98, P9505, DOI 10.1073/pnas.181319898; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; TEKLE E, 1991, P NATL ACAD SCI USA, V88, P4230, DOI 10.1073/pnas.88.10.4230; Troy CM, 1996, J NEUROSCI, V16, P253; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; VARANI J, 1991, INFLAMMATION, V15, P291, DOI 10.1007/BF00917314; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	27	64	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20135	20138		10.1074/jbc.C200226200	http://dx.doi.org/10.1074/jbc.C200226200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11964391	hybrid			2022-12-25	WOS:000176204500007
J	van Tienhoven, M; Atkins, J; Li, Y; Glynn, P				van Tienhoven, M; Atkins, J; Li, Y; Glynn, P			Human neuropathy target esterase catalyzes hydrolysis of membrane lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDEPENDENT PHOSPHOLIPASE A(2); LYSOPHOSPHOLIPASE ACTIVITY; TRIFLUOROMETHYL KETONES; DELAYED NEUROTOXICITY; LYSOPHOSPHATIDIC ACID; CLONING; BRAIN; NEURODEGENERATION; PURIFICATION; INHIBITION	A neuronal membrane protein, neuropathy target esterase (NTE), reacts with those organophosphates that initiate a syndrome of axonal degeneration. NTE has homologues in Drosophila and yeast and is detected in vitro by assays with a non-physiological ester substrate, phenyl valerate. We report that NEST, the recombinant esterase domain of NTE (residues 727-1216) purified from bacterial lysates, can catalyze hydrolysis of several naturally occurring membrane-associated lipids. The active site regions of NEST and calcium-independent phospholipase A(2) (iPlA(2)) share sequence similarity, and the phenyl valerate hydrolase activity of NEST is inhibited by low concentrations of iPLA(2) inhibitors. However, on incubation with NEST, fatty acid was liberated only extremely slowly from the sn-2 position of phospholipids (V-max similar to0.01 mumol/min/mg and K-m similar to0.4 mm for 1-palmitoyl, 2-oleoylphosphatidyleholine). Comparison of the NEST-mediated generation of C-14-labeled products from two differentially labeled C-14-phospholipid substrates suggested that a rate-limiting sn-2 cleavage was followed very rapidly by hydrolysis of the resulting lysophospholipid. Among the various naturally occurring lipids tested with NEST, lysophospholipids were by far the most avidly hydrolyzed substrates (V-max similar to20 mumol/ min/mg and k(m) similar to0.05 mm for 1-palmitoyl-lysophosphatidyleholine). NEST also catalyzed the hydrolysis of monoacylglycerols, preferring the 1-acyl to the 2-acyl isomer (V-max similar to1 mumol/min/mg and K-m similar to0.4 mm for 1-palmitoylglycerol). NEST did not catalyze hydrolysis of di- or triacylglycerols or fatty acid amides. This demonstration that membrane lipids are its putative cellular substrates raises the possibility that NTE and its homologues may be involved in intracellular membrane trafficking.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Glynn, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.	pg8@le.ac.uk		Li, Yong/0000-0001-6266-8717				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atkins J, 2002, BIOCHEM J, V361, P119, DOI 10.1042/0264-6021:3610119; Atkins J, 2000, J BIOL CHEM, V275, P24477, DOI 10.1074/jbc.M002921200; CHEMOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; Dessen A, 2000, BBA-MOL CELL BIOL L, V1488, P40, DOI 10.1016/S1388-1981(00)00108-6; Glynn P, 1998, NEUROSCIENCE, V83, P295, DOI 10.1016/S0306-4522(97)00388-6; Glynn P, 2000, PROG NEUROBIOL, V61, P61, DOI 10.1016/S0301-0082(99)00043-X; JOHNSON MK, 1969, BIOCHEM J, V114, P711, DOI 10.1042/bj1140711; JOHNSON MK, 1977, ARCH TOXICOL, V37, P113, DOI 10.1007/BF00293860; JOHNSON MK, 1982, REV BIOCHEM TOXICOL, V4, P141; JOHNSON MK, 1975, BIOCHEM PHARMACOL, V24, P797, DOI 10.1016/0006-2952(75)90123-9; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Kuroiwa N, 2001, BIOCHEM BIOPH RES CO, V281, P582, DOI 10.1006/bbrc.2001.4381; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; Lin QS, 2000, BIOCHEMISTRY-US, V39, P9335, DOI 10.1021/bi000017u; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; Loo RW, 1997, J BIOL CHEM, V272, P19214, DOI 10.1074/jbc.272.31.19214; Lush MJ, 1998, BIOCHEM J, V332, P1; Moser M, 2000, MECH DEVELOP, V90, P279, DOI 10.1016/S0925-4773(99)00239-7; Pete MJ, 1996, J BIOL CHEM, V271, P18114, DOI 10.1074/jbc.271.30.18114; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; RICHARDSON RJ, 1979, J NEUROCHEM, V32, P607, DOI 10.1111/j.1471-4159.1979.tb00391.x; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; SHIMIZU S, 1980, ANAL BIOCHEM, V107, P193, DOI 10.1016/0003-2697(80)90511-4; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THOMAS TC, 1990, BIOCHEM PHARMACOL, V40, P2587, DOI 10.1016/0006-2952(90)90575-6; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1437, P157, DOI 10.1016/S1388-1981(99)00012-8; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WU SY, 1992, CHEM RES TOXICOL, V5, P680, DOI 10.1021/tx00029a014; Yokoyama K, 2000, J LIPID RES, V41, P142; ZAMBRANO F, 1975, BIOCHIM BIOPHYS ACTA, V380, P357, DOI 10.1016/0005-2760(75)90104-6	37	135	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20942	20948		10.1074/jbc.M200330200	http://dx.doi.org/10.1074/jbc.M200330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11927584	hybrid			2022-12-25	WOS:000176204500108
J	Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB				Chesire, DR; Ewing, CM; Gage, WR; Isaacs, WB			In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis	ONCOGENE			English	Article						beta-catenin; prostate cancer; nuclear staining; T cell factor; androgen receptor	ANDROGEN RECEPTOR; CANCER-CELLS; TRANSCRIPTIONAL ACTIVITY; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CARCINOMA CELLS; MAMMARY-GLAND; UP-REGULATION; E-CADHERIN; MUTATIONS	Understanding the molecular etiology of prostate cancer (CaP) progression is paramount for broadening current diagnostic and therapeutic modalities. Current interest in the role of wnt pathway signaling in prostate tumorigenesis was generated with the finding of beta-catenin mutation and corresponding nuclear localization in primary lesions. The recent finding of beta-catenin-induced enhancement of androgen receptor (AR) function potentially ties beta-catenin to key regulatory steps of prostate cell growth, differentiation, and transformation. By immunohistological analysis of metastatic tumors, we detected nuclear beta-catenin in 20% of lethal CaP cases, suggesting a more common role for beta-catenin in advanced disease than would be predicted by its mutation rate. Interestingly, beta-catenin nuclear localization was found to occur concomitantly with androgen-induced regrowth of normal rat prostate. These in vivo observations likely implicate beta-catenin involvement in both normal and neoplastic prostate physiology, thus prompting our interest in further characterizing modes of beta-catenin signaling in prostate cells. Extending our previous findings, we demonstrate that transient beta-catenin over-expression stimulates T cell factor (TCF) signaling in most CaP cell lines. Further, this activity is not subject to cross- regulation by phosphoinositide-3-kinase (PI3-K)/Akt signaling, a stimulatory pathway often upregulated in CaP upon PTEN inactivation. Consistent with a previous report, we observed that transient beta-catenin overexpression enhances AR-mediated transcription off two natural target gene promoters. However, we were unable to recapitulate beta-catenin-induced stimulation of ectopically expressed AR in AR-negative cells, suggesting that other AR-associated factors are required for this activity. Although LNCaP cells are capable of this mode of AR co-stimulation, stable expression of mutant beta-catenin did not alter their proliferative response to androgen. In total, our characterization of beta-catenin signaling in CaP reveals the complex nature of its activity in prostate tissue, indicating that beta-catenin potentially contributes to multiple stimulatory inputs required for disease progression.	Johns Hopkins Med Inst, Brady Urol Inst Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@mail.jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bubendorf L, 1999, CANCER RES, V59, P803; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Duval A, 2000, CANCER RES, V60, P3872; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hayes SA, 2001, CANCER RES, V61, P2112; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; Kinoshita H, 2000, CANCER RES, V60, P3623; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KYPRIANOU N, 1987, PROSTATE, V11, P41, DOI 10.1002/pros.2990110106; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lin DL, 2001, CLIN CANCER RES, V7, P1773; Linja MJ, 2001, CANCER RES, V61, P3550; LUKE MC, 1994, J ANDROL, V15, P41; Luo J, 2001, CANCER RES, V61, P4683; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park WS, 1999, CANCER RES, V59, P4257; Planz B, 1998, J UROLOGY, V160, P1850, DOI 10.1016/S0022-5347(01)62431-5; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shih IM, 2000, CANCER RES, V60, P1671; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Truica CI, 2000, CANCER RES, V60, P4709; UMBAS R, 1992, CANCER RES, V52, P5104; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voeller HJ, 1998, CANCER RES, V58, P2520; Wen Y, 2000, CANCER RES, V60, P6841; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	73	143	148	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2679	2694		10.1038/sj.onc.1205352	http://dx.doi.org/10.1038/sj.onc.1205352			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965541				2022-12-25	WOS:000174996500008
J	Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M				Kontou, M; Adelfalk, C; Ramirez, MH; Ruppitsch, W; Hirsch-Kauffmann, M; Schweiger, M			Overexpressed thioredoxin compensates Fanconi anemia related chromosomal instability	ONCOGENE			English	Article						Fanconi anemia; thioredoxin; oxidoreduction potential	REDOX REGULATION; TRANSCRIPTION FACTOR; ACTIVATION; CELLS; ANTIOXIDANTS; SECRETION; PREVENTS; PROTEINS	The cause of the molecular defect of Fanconi anemia (FA) remains unknown. Cells from patients with FA exert an elevated spontaneous chromosomal instability which is further triggered by mitomycin C. The induced lability is reduced by overexpression of thioredoxin which is not the case for spontaneous instability. However, both are eliminated by overexpression of thioredoxin cDNA with an added nuclear localization signal. This implies that thioredoxin is lacking in the nuclei of FA cells. The total thioredoxin content in all FA cells tested is reduced. The resultant lack of nuclear thioredoxin can be the explanation for the major symptomatology in FA. Since thioredoxin is known to be the reactive cofactor of ribonucleotid reductase its shortcoming reduces the supply of deoxyribonucleotides thus hindering the DNA and replication repair with resultant chromosomal breaks. Furthermore, depression of tyrosine hydroxylase, the key enzyme of melanine synthesis, could be the basis for the pathognomotic 'cafe au lait' spots of FA. The observation of thioredoxin reduction in FA cells permits insight into the molecular phathophysiology of FA.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Univ Innsbruck, Inst Med Biol & Humangenet, A-6020 Innsbruck, Austria	Free University of Berlin; University of Innsbruck	Schweiger, M (corresponding author), Free Univ Berlin, Inst Biochem, Thielallee 63, D-14195 Berlin, Germany.	mschweig@chemie.fu-berlin.de	Ruppitsch, Werner/AAC-9295-2019	Ruppitsch, Werner/0000-0001-9940-3333				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; DALLAPICCOLA B, 1985, HUM GENET, V69, P62, DOI 10.1007/BF00295530; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; FUJII S, 1991, VIRCHOWS ARCH A, V419, P317, DOI 10.1007/BF01606523; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GILLE JJP, 1987, HUM GENET, V77, P28; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; KORKINA LG, 1992, J LEUKOCYTE BIOL, V52, P357, DOI 10.1002/jlb.52.3.357; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; Ramirez MH, 1999, BIOCHEM BIOPH RES CO, V264, P518, DOI 10.1006/bbrc.1999.1482; RUBARTELLI A, 1995, CANCER RES, V55, P675; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Ruppitsch W, 1998, FEBS LETT, V422, P99, DOI 10.1016/S0014-5793(97)01608-6; SAMBROOK J, 1989, MOL CLONING LAB MANU, P712; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sittler A, 1996, HUM MOL GENET, V5, P95, DOI 10.1093/hmg/5.1.95; WOOD JM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P378, DOI 10.1016/0304-4165(91)90088-X	26	26	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2406	2412		10.1038/sj.onc.1205299	http://dx.doi.org/10.1038/sj.onc.1205299			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948424				2022-12-25	WOS:000174635600013
J	Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R				Bartholin, L; Maguer-Satta, V; Hayette, S; Martel, S; Badoux, M; Corbo, L; Magaud, JP; Rimokh, R			Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function	ONCOGENE			English	Article						FLRG; follistatin; activin; TGF beta; Smad	BONE MORPHOGENETIC PROTEINS; BINDING-PROTEIN; TGF; CELL; EXPRESSION; PROMOTER; RECEPTOR; GROWTH; GENE; ANTAGONIST	Signaling of TGFbeta family members such as activin is tightly regulated by soluble binding proteins. Follistatin binds to activin A with high affinity, and prevents activin binding to its own receptors, thereby blocking its signaling. We previously identified FLRG gene from a B-cell leukemia carrying a t(11;19)(q13;p13) translocation. We and others have already shown that FLRG, which is highly homologous to follistatin, may be involved in the regulation of the activin function through its binding to activin. In this study, we found that, like follistatin, FLRG protein inhibited activin A signaling as demonstrated by the use of a transcriptional reporter assay, and blocked the activin A-induced growth inhibition of HepG2 cells. We have recently shown that the TGFbeta-induced expression of FLRG occurs at a transcriptional level through the action of Smad proteins. Here we show that activin A increases FLRG and follistatin at both the mRNA and protein levels. We found that Smad proteins are involved in the activin A-induced transcription activation of FLRG and follistatin. Finally we demonstrate that FLRG protein regulates its own activin-induced expression. In conclusion, activin A induces FLRG and follistatin expression. This observation, in conjunction with the antagonistic effect of FLRG and follistatin on activin signaling, indicates that these two proteins participate in a negative feedback loop which regulates the activin function.	Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France; Ctr Leon Berard, INSERM U453, F-69373 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM U453, F-69373 Lyon, France.	rimokh@lyon.fnclcc.fr	Bartholin, Laurent/Q-6655-2017; HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Maguer-Satta, Veronique/U-8857-2019	Bartholin, Laurent/0000-0002-5637-3223; Maguer-Satta, Veronique/0000-0002-1556-068X				Bartholin L, 2001, ONCOGENE, V20, P5409, DOI 10.1038/sj.onc.1204720; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Maguer-Satta V, 2001, EXP HEMATOL, V29, P301, DOI 10.1016/S0301-472X(00)00675-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pereira RC, 2000, ENDOCRINOLOGY, V141, P4558, DOI 10.1210/en.141.12.4558; Phillips DJ, 2000, BIOESSAYS, V22, P689, DOI 10.1002/1521-1878(200008)22:8<689::AID-BIES2>3.0.CO;2-5; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reddi AH, 2001, ARTHRITIS RES, V3, P1; Russell CE, 1999, MOL CELL ENDOCRINOL, V148, P129, DOI 10.1016/S0303-7207(98)00226-3; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; YAMASHITA T, 1992, BLOOD, V79, P304; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yu J, 1997, CYTOKINES CELL MOL T, V3, P169; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhang YQ, 1997, BBA-GENE STRUCT EXPR, V1354, P204, DOI 10.1016/S0167-4781(97)00085-7	44	68	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2227	2235		10.1038/sj.onc.1205294	http://dx.doi.org/10.1038/sj.onc.1205294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948405				2022-12-25	WOS:000174555300011
J	Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS				Schaefer, LK; Ren, ZY; Fuller, GN; Schaefer, TS			Constitutive activation of Stat3 alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2)	ONCOGENE			English	Article						brain tumor; receptor tyrosine kinase; endothelial cells; VEGF; angiogenesis	GROWTH-FACTOR EXPRESSION; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; SIGNALING PATHWAY; STAT3 ACTIVATION; SRC; GENE; AMPLIFICATION; INDUCTION; APOPTOSIS	Members of the normally latent family of transcription factors signal/inducers and activators of transcription (Stat) are activated in a number of human tumors and tumor-derived cell lines. In the case of Stat3, it is believed that this activation leads to the induction of survival signals as well as increased proliferation. In this study, we demonstrate that Stat3 is constitutively activated in glioma and medulloblastoma tumors and that the activated protein localizes predominantly to the tumor endothelial cells in the highly vascularized glioma tumors. Our efforts to elucidate potential mechanism(s) for this activated protein have shown that coexpression of Stat3)c and the vascular endothelial growth factor receptor-2 (VEGFR-2) result in ligand-independent activation of Stat3chi tyrosine phosphorylation and subsequent transcriptional activation in non-endothelial cells. We also show that activated Stat3alpha can increase transcription from the vascular endothelial growth factor (VEGF) gene. Taken together, these results suggest that the activated Stat3chi found in brain tumors may be due to the endothelial tyrosine kinase VEGFR-2 and that Stat3chi may play a central role in autocrine VEGF activation.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Schaefer, TS (corresponding author), Box 064,1515 Holcombe Blvd, Houston, TX 77030 USA.	tschaefe@jmdanderson.org		Fuller, Gregory/0000-0001-9447-2647				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Carroll RS, 1999, CANCER-AM CANCER SOC, V86, P1335, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO;2-Z; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V131, P207, DOI 10.1016/0006-291X(85)91790-5; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HATVA E, 1995, AM J PATHOL, V146, P368; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIBERMANN TA, 1984, CANCER RES, V44, P753; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Ni Z, 2000, CANCER RES, V60, P1225; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; Schaefer LK, 2000, CELL SIGNAL, V12, P143, DOI 10.1016/S0898-6568(99)00077-7; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Theurillat JP, 1999, AM J PATHOL, V154, P581, DOI 10.1016/S0002-9440(10)65303-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WeberNordt RM, 1996, BLOOD, V88, P809; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Xia Z, 1998, CANCER RES, V58, P3173; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	39	154	167	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2058	2065		10.1038/sj.onc.1205263	http://dx.doi.org/10.1038/sj.onc.1205263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960378				2022-12-25	WOS:000174827000012
J	Pafumi, Y; Lairon, D; de la Porte, PL; Juhel, C; Storch, J; Hamosh, M; Armand, M				Pafumi, Y; Lairon, D; de la Porte, PL; Juhel, C; Storch, J; Hamosh, M; Armand, M			Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-TO-CORE; LINGUAL LIPASE; CYSTIC-FIBROSIS; FAT DIGESTION; SERUM-ALBUMIN; PANCREATIC LIPASE; LIPID-COMPOSITION; ENZYME-ACTIVITY; DROPLET SIZES; HUMAN STOMACH	In the human stomach, gastric lipase hydrolyzes only 10 to 30% of ingested triacylglycerols because of an inhibition process induced by the long chain free fatty acids generated, which are mostly protonated at gastric pH. The aim of this work was to elucidate the mechanisms by which free fatty acids inhibit further hydrolysis. In vitro experiments examined gastric lipolysis of differently sized phospholipid-triolein emulsions by human gastric juice or purified human gastric lipase, under close to physiological conditions. The lipolysis process was further investigated by scanning electron microscopy, and gastric lipase and free fatty acid movement during lipolysis were followed by fluorescence microscopy. The results demonstrate that: 1) free fatty acids generated during lipolysis partition between the surface and core of lipid droplets with a molar phase distribution coefficient of 7.4 at pH 5.40; 2) the long chain free fatty acids have an inhibitory effect only when generated during lipolysis; 3) inhibition of gastric lipolysis can be delayed by the use of lipid emulsions composed of small-size lipid droplets; 4) the release of free fatty acids during lipolysis induces a marked increase in droplet surface area, leading to the formation of novel particles at the lipid droplet surface; and 5) the gastric lipase is trapped in these free fatty acid-rich particles during their formation. In conclusion, we propose a model in which the sequential physicochemical events occurring during gastric lipolysis lead to the inhibition of further triacylglycerol lipolysis.	Univ Mediterranee, U476, INSERM, Natl Inst Hlth & Med Res, F-13009 Marseille, France; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Georgetown Univ, Med Ctr, Dept Pediat, Div Dev Biol & Nutr, Washington, DC 20007 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Rutgers State University New Brunswick; Georgetown University	Armand, M (corresponding author), Univ Mediterranee, U476, INSERM, Natl Inst Hlth & Med Res, 18 Ave Mozart, F-13009 Marseille, France.	armand@marseille.inserm.fr	ARMAND, Martine/O-5780-2016	ARMAND, Martine/0000-0002-8712-6620; Storch, Judith/0000-0001-5482-1777; Lairon, Denis/0000-0001-9941-3742	NIDDK NIH HHS [R01 DK038389] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMS CK, 1984, J CLIN INVEST, V73, P374, DOI 10.1172/JCI111222; Armand M, 1996, PEDIATR RES, V40, P429, DOI 10.1203/00006450-199609000-00011; ARMAND M, 1992, J NUTR BIOCHEM, V3, P333, DOI 10.1016/0955-2863(92)90024-D; Armand M, 1999, AM J CLIN NUTR, V70, P1096; Armand M, 1996, AM J PHYSIOL-GASTR L, V271, pG172, DOI 10.1152/ajpgi.1996.271.1.G172; ARMAND M, 1994, AM J PHYSIOL, V266, pG372, DOI 10.1152/ajpgi.1994.266.3.G372; BALASUBRAMANIAN K, 1992, PANCREAS, V7, P305, DOI 10.1097/00006676-199205000-00006; BELFRAGE P, 1969, J LIPID RES, V10, P341; BITMAN J, 1981, J LIQ CHROMATOGR, V4, P1023, DOI 10.1080/01483918108059602; BOREL P, 1994, J NUTR BIOCHEM, V5, P124, DOI 10.1016/0955-2863(94)90083-3; Borel P, 1996, J LIPID RES, V37, P250; Boyle E, 1996, J LIPID RES, V37, P764; Brockman H.L., 1984, P3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; Charles M, 2000, J AGR FOOD CHEM, V48, P1810, DOI 10.1021/jf9906533; EKMAN S, 1988, BIOCHIM BIOPHYS ACTA, V959, P343, DOI 10.1016/0005-2760(88)90208-1; FOLCH J, 1957, J BIOL CHEM, V226, P497; GARGOURI Y, 1987, EUR J BIOCHEM, V169, P125, DOI 10.1111/j.1432-1033.1987.tb13588.x; GARGOURI Y, 1986, BIOCHIM BIOPHYS ACTA, V879, P419, DOI 10.1016/0005-2760(86)90234-1; GARGOURI Y, 1986, GASTROENTEROLOGY, V91, P919, DOI 10.1016/0016-5085(86)90695-5; GARGOURI Y, 1986, EUR J BIOCHEM, V156, P305, DOI 10.1111/j.1432-1033.1986.tb09583.x; HAMOSH M, 1979, J BIOL CHEM, V254, P2121; HAMOSH M, 1990, LIGUAL GASTRIC LIPAS; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; HOLCZINGER L, 1959, Acta Histochem, V8, P167; LAU SJ, 1974, J BIOL CHEM, V249, P5878; MILLER KW, 1983, J BIOL CHEM, V258, P3772; MILLER KW, 1980, CIRCULATION, V62, P45; MILLER KW, 1982, J COLLOID INTERF SCI, V89, P466, DOI 10.1016/0021-9797(82)90197-7; MILLER KW, 1987, PLASMA LIPOPROTEINS, P1; PATTON JS, 1982, BIOCHIM BIOPHYS ACTA, V712, P400, DOI 10.1016/0005-2760(82)90359-9; ROULET M, 1980, PEDIATR RES, V14, P1360, DOI 10.1203/00006450-198012000-00019; Roussel A, 1999, J BIOL CHEM, V274, P16995, DOI 10.1074/jbc.274.24.16995; SMALL DM, 1986, HDB LIPID RES PHYSIC, P589; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; SPOONER PJR, 1990, J BIOL CHEM, V265, P12650; TIRUPPATHI C, 1985, INDIAN J BIOCHEM BIO, V22, P111; Winer BJ, 1971, STAT PRINCIPLES EXPT	40	155	157	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28070	28079		10.1074/jbc.M202839200	http://dx.doi.org/10.1074/jbc.M202839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	11940604	hybrid			2022-12-25	WOS:000177189800063
J	Bulock, KG; Beardsley, GP; Anderson, KS				Bulock, KG; Beardsley, GP; Anderson, KS			The kinetic mechanism of the human bifunctional enzyme ATIC (5-amino-4-imidazolecarboxamide ribonucleotide transformylase/inosine 5 '-monophosphate cyclohydrolase) - A surprising lack of substrate channeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBOTIDE TRANSFORMYLASE; GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; IMP CYCLOHYDROLASE; CRYSTAL-STRUCTURE; METHOTREXATE; INHIBITION; SYNTHASE; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; FORMYLTRANSFERASE; POLYGLUTAMATES	5-Amino-4-imidazolecarboxamide ribonucleotide transformylase/IMP cyclohydrolase (ATIC) is a bifunctional protein possessing two enzymatic activities that sequentially catalyze the last two steps in the pathway for de novo synthesis of inosine 5'-monophosphate. This bifunctional enzyme is of particular interest because of its potential as a chemotherapeutic target. Furthermore, these two catalytic activities reside on the same protein throughout all of nature, raising the question of whether there is some kinetic advantage to the bifunctionality. Rapid chemical quench, stopped-flow absorbance, and steady-state kinetic techniques were used to elucidate the complete kinetic mechanism of human ATIC. The kinetic simulation program KINSIM was used to model the kinetic data obtained in this study. The detailed kinetic analysis, in combination with kinetic simulations, provided the following key features of the enzyme reaction pathway. 1) The rate-limiting step in the overall reaction (2.9 +/- 0.4 s(-1)) is likely the release of tetrahydrofolate from the formyltransferase active site or a conformational change associated with tetrahydrofolate release. 2) The rate of the reverse transformylase reaction (6.7 s(-1)) is similar to2-3-fold faster than the forward rate (2.9 s(-1)), whereas the cyclohydrolase reaction is essentially unidirectional in the forward sense. The cyclohydrolase reaction thus draws the overall bifunctional reaction toward the production of inosine monophosphate. 3) There was no kinetic evidence of substrate channeling of the intermediate, the formylaminoimidazole carboxamide ribonucleotide, between the formyltransferase and the cyclohydrolase active sites.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA	Yale University; Yale University	Anderson, KS (corresponding author), LMP 4083, 333 Cedar St, New Haven, CT 06520 USA.				NATIONAL CANCER INSTITUTE [R01CA050721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044630] Funding Source: NIH RePORTER; NCI NIH HHS [CA50721] Funding Source: Medline; NIAID NIH HHS [AI44630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEARDSLEY G P, 1986, P953; Beardsley GP, 1998, ADV EXP MED BIOL, V431, P221; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BEARDSLEY GP, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P1001; BLACK SL, 1978, ANAL BIOCHEM, V90, P397, DOI 10.1016/0003-2697(78)90042-8; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Holden HM, 1999, CELL MOL LIFE SCI, V56, P507, DOI 10.1007/s000180050448; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Rowe P.B, 1971, METHODS ENZYMOL B, V18, P733; RUDOLPH J, 1995, BIOCHEMISTRY-US, V34, P2241, DOI 10.1021/bi00007a019; Sugita T, 1997, J BIOCHEM-TOKYO, V122, P309; Szabados E, 1998, INT J BIOCHEM CELL B, V30, P933, DOI 10.1016/S1357-2725(98)00026-0; SZABADOS E, 1994, ANAL BIOCHEM, V221, P401, DOI 10.1006/abio.1994.1433; Vergis JM, 2001, J BIOL CHEM, V276, P7727, DOI 10.1074/jbc.M009940200; Wall M, 2000, BIOCHEMISTRY-US, V39, P11303, DOI 10.1021/bi0007268; Yamauchi M, 1995, DNA Res, V2, P269, DOI 10.1093/dnares/2.6.269	28	30	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22168	22174		10.1074/jbc.M111964200	http://dx.doi.org/10.1074/jbc.M111964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11948179	hybrid			2022-12-25	WOS:000176313600010
J	Hammet, A; Pike, BL; Heierhorst, J				Hammet, A; Pike, BL; Heierhorst, J			Posttranscriptional regulation of the RAD5 DNA repair gene by the Dun1 kinase and the Pan2-Pan3 poly(A)-nuclease complex contributes to survival of replication blocks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCIBLE GENE; FHA DOMAIN; SACCHAROMYCES-CEREVISIAE; CHECKPOINT PATHWAYS; PROTEIN; YEAST; ATM; TRANSCRIPTION; TRANSLATION; ENCODES	The yeast Dun1 kinase has complex checkpoint functions including DNA damage-dependent cell cycle arrest in G(2)/M, transcriptional induction of repair genes, and regulation of postreplicative DNA repair pathways. Here we report that the Dun1 forkhead-associated domain interacts with the Pan3 subunit of the poly(A)nuclease complex and that dun1pan2 and dun1pan3 double mutants are dramatically hypersensitive to replicational stress. This phenotype was independent of the function of Dun1 in regulating deoxyribonucleotide levels as it was also observed in strains lacking the ribonucleotide reductase inhibitor Sml1. dun1pan2 mutants initially arrested normally in response to replication blocks but died in the presence of persistent replication blocks with considerably delayed kinetics compared with mutants lacking the Rad53 kinase, indicating that the double mutation does not compromise the intra-S phase checkpoint. Interestingly, the RAD5 gene involved in error-free postreplication repair pathways was specifically up-regulated in dun1pan2 double mutants. Moreover, inducible overexpression of RAD5 mimicked the double mutant phenotype by hypersensitizing dun1 mutants to replication blocks. The data indicate that Dun1 and Pan2-Pan3 cooperate to regulate the stoichiometry and thereby the activity of postreplication repair complexes, suggesting that posttranscriptional mechanisms complement the transcriptional response in the regulation of gene expression by checkpoint signaling pathways in Saccharomyces cerevisiae.	Univ Melbourne, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	heier@ariel.its.unimelb.edu.au	Pike, Brietta L./H-5317-2019	Pike, Brietta L./0000-0002-4763-1729				Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; Denis CL, 2001, GENETICS, V158, P627; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fasullo M, 1999, GENETICS, V152, P909; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hammet A, 2000, FEBS LETT, V471, P141, DOI 10.1016/S0014-5793(00)01392-2; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; James P, 1996, GENETICS, V144, P1425; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Li J, 2000, J CELL SCI, V113, P4143; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Otero LJ, 1999, EMBO J, V18, P3153, DOI 10.1093/emboj/18.11.3153; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xiao W, 2000, GENETICS, V155, P1633; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	42	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22469	22474		10.1074/jbc.M202473200	http://dx.doi.org/10.1074/jbc.M202473200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11953437	hybrid			2022-12-25	WOS:000176313600048
J	Hughes, WE; Larijani, B; Parker, PJ				Hughes, WE; Larijani, B; Parker, PJ			Detecting protein-phospholipid interactions - Epidermal growth factor-induced activation of phospholipase D1b in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; LIFETIME IMAGING MICROSCOPY; KINASE-C-ALPHA; PLASMA-MEMBRANE; SECRETORY GRANULES; CELLS; LOCALIZATION; PHOSPHATIDYLINOSITOL; STIMULATION; DOWNSTREAM	Phospholipase D (PLD) proteins have been identified in secretory and endocytic vesicles, consistent with their proposed role in regulating membrane traffic. However, their sites of catalytic action remain obscure. We have developed here a novel, analytical approach to monitor PLD activation in intact cells employing lifetime imaging microscopy to measure fluorescence resonance energy transfer between protein and membrane phospholipid. Verification and application of this technique demonstrates a dispersed endosomal, epidermal growth factor-induced activation of the PLD1b isoform. Application of this approach will facilitate the spatial resolution of many protein-phospholipid interact-ions that are key events in the regulation of cellular processes.	Canc Res United Kingdom London Res Inst, Prot Phosphorylat Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England; Canc Res United Kingdom London Res Inst, Cell Biophys Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Parker, PJ (corresponding author), Canc Res United Kingdom London Res Inst, Prot Phosphorylat Lab, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Larijani, Banafshe/H-3909-2015	Larijani, Banafshe/0000-0003-4735-1169; parker, peter/0000-0002-6218-2933; Hughes, William/0000-0002-7149-3987				BALBOA MA, 1995, J BIOL CHEM, V270, P29843; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; CLEGG RM, 1994, FLUORESCENCE IMAGING, P179; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Dittie AS, 1999, J CELL SCI, V112, P3955; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Freyberg Z, 2001, MOL BIOL CELL, V12, P943, DOI 10.1091/mbc.12.4.943; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Hughes WE, 2001, BIOCHEM J, V356, P727, DOI 10.1042/0264-6021:3560727; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Larijani B, 2001, BIOCHEM J, V356, P495, DOI 10.1042/0264-6021:3560495; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Millar CA, 1999, BIOCHEM BIOPH RES CO, V254, P734, DOI 10.1006/bbrc.1998.0110; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; Squire A, 1999, J MICROSC-OXFORD, V193, P36, DOI 10.1046/j.1365-2818.1999.00427.x; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; WANG P, 1991, J BIOL CHEM, V266, P14877; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Wustner D, 2001, TRAFFIC, V2, P277, DOI 10.1034/j.1600-0854.2001.9o135.x; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907	33	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22974	22979		10.1074/jbc.M201391200	http://dx.doi.org/10.1074/jbc.M201391200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950840	hybrid			2022-12-25	WOS:000176313600111
J	Yurchenko, V; Zybarth, G; O'Connor, M; Dai, WW; Franchin, G; Hao, T; Guo, HM; Hung, HC; Toole, B; Gallay, P; Sherry, B; Bukrinsky, M				Yurchenko, V; Zybarth, G; O'Connor, M; Dai, WW; Franchin, G; Hao, T; Guo, HM; Hung, HC; Toole, B; Gallay, P; Sherry, B; Bukrinsky, M			Active site residues of cyclophilin A are crucial for its signaling activity via CD147	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE INDUCER; COLLAGENASE-STIMULATORY FACTOR; NEUTROPHIL ELASTASE INHIBITOR; CIS-TRANS-ISOMERASES; RHEUMATOID-ARTHRITIS; T-LYMPHOCYTES; EXTRACELLULAR-MATRIX; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES; CELL-LINE	Cyclophilin A (CyPA), a ubiquitously distributed intracellular protein, is a peptidylprolyl cis-trans-isomerase and the major target of the potent immunosuppressive drug cyclosporin A. Although expressed predominantly as an intracellular molecule, CyPA is secreted by cells in response to inflammatory stimuli and is a potent neutrophil and eosinophil chemoattractant in vitro and in vivo. The mechanisms underlying CyPA-mediated signaling and chemotaxis are unknown. Here, we identified CD147 as a cell surface receptor for CyPA and demonstrated that CD147 is an essential component in the CyPA-initiated signaling cascade that culminates in ERK activation. Both signaling and chemotactic activities of CyPA depended also on the presence of heparans, which served as primary binding sites for CyPA on target cells. The proline 180 and glycine 181 residues in the extracellular domain of CD147 were critical for signaling and chemotactic activities mediated by CD147. Also crucial were active site residues of CyPA, because rotamase-defective CyPA mutants failed to initiate signaling events. These results establish cyclophilins as natural ligands for CD147 and suggest an unusual, rotamase-dependent mechanism of signaling.	George Washington Univ, Dept Microbiol & Trop Med, Med Ctr, Washington, DC 20037 USA; Picower Inst Med Res, Manhasset, NY 11030 USA; Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	George Washington University; Northwell Health; Tufts University; Scripps Research Institute	Bukrinsky, M (corresponding author), George Washington Univ, Dept Microbiol & Trop Med, Med Ctr, Ross Hall,Rm 734,2300 Eye St NW, Washington, DC 20037 USA.		Sherry, Barbara/GSD-7179-2022; Franchin, Giovanni/AAC-2398-2020; Yurchenko, Vyacheslav/E-4532-2013	Sherry, Barbara/0000-0003-3119-1463; Franchin, Giovanni/0000-0003-1988-2739; Yurchenko, Vyacheslav/0000-0003-4765-3263; Franchin, Giovanni/0000-0003-2609-7974	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029110, R01AI038245] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 29110, R01 AI 38245] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Allain F, 2002, P NATL ACAD SCI USA, V99, P2714, DOI 10.1073/pnas.052284899; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Billich A, 1997, J EXP MED, V185, P975, DOI 10.1084/jem.185.5.975; BISWAS C, 1995, CANCER RES, V55, P434; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Braaten D, 1997, J VIROL, V71, P2107, DOI 10.1128/JVI.71.3.2107-2113.1997; Carpentier M, 1999, J BIOL CHEM, V274, P10990, DOI 10.1074/jbc.274.16.10990; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; Denys A, 1998, BIOCHEM J, V336, P689, DOI 10.1042/bj3360689; Edwards SW, 1997, IMMUNOL TODAY, V18, P320, DOI 10.1016/S0167-5699(97)01087-6; ELLIS SM, 1989, CANCER RES, V49, P3385; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; GILAT D, 1994, J IMMUNOL, V153, P4899; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Igakura T, 1998, DEV BIOL, V194, P152, DOI 10.1006/dbio.1997.8819; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; Inoue H, 1999, GLIA, V28, P265, DOI 10.1002/(SICI)1098-1136(199912)28:3<265::AID-GLIA10>3.0.CO;2-F; Janusz MJ, 1997, INFLAMM RES, V46, P503, DOI 10.1007/s000110050233; Jin ZG, 2000, CIRC RES, V87, P789, DOI 10.1161/01.RES.87.9.789; KAKIMOTO K, 1995, CELL IMMUNOL, V165, P26, DOI 10.1006/cimm.1995.1183; Kasinrerk W, 1999, IMMUNOLOGY, V96, P184; Kirsch AH, 1997, TISSUE ANTIGENS, V50, P147, DOI 10.1111/j.1399-0039.1997.tb02853.x; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; Konttinen YT, 2000, ARTHRITIS RHEUM, V43, P275, DOI 10.1002/1529-0131(200002)43:2<275::AID-ANR6>3.0.CO;2-#; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; Mutin M, 1997, TISSUE ANTIGENS, V50, P449, DOI 10.1111/j.1399-0039.1997.tb02899.x; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; SEWELL KL, 1993, LANCET, V341, P283, DOI 10.1016/0140-6736(93)92627-6; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; SHERRY B, 1992, P NATL ACAD SCI USA, V89, P3511, DOI 10.1073/pnas.89.8.3511; STOCKINGER H, 1997, LEUKOCYTE TYPING, V6, P760; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Wimazal F, 1999, TISSUE ANTIGENS, V54, P499, DOI 10.1034/j.1399-0039.1999.540507.x; XU Q, 1992, J BIOL CHEM, V267, P11968; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Yurchenko V, 2001, BIOCHEM BIOPH RES CO, V288, P786, DOI 10.1006/bbrc.2001.5847; Zucker S, 1999, ANN NY ACAD SCI, V878, P212, DOI 10.1111/j.1749-6632.1999.tb07687.x; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	49	260	279	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22959	22965		10.1074/jbc.M201593200	http://dx.doi.org/10.1074/jbc.M201593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11943775	hybrid			2022-12-25	WOS:000176313600109
J	Zhang, CS; Stratmann, A; Block, O; Bruckner, R; Podeschwa, M; Altenbach, HJ; Wehmeier, UF; Piepersberg, W				Zhang, CS; Stratmann, A; Block, O; Bruckner, R; Podeschwa, M; Altenbach, HJ; Wehmeier, UF; Piepersberg, W			Biosynthesis of the C-7-cyclitol moiety of acarbose in Actinoplanes species SE50/110 - 7-O-phosphorylation of the initial cyclitol precursor leads to proposal of a new biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSIDASE INHIBITOR ACARBOSE; ANTIBIOTIC-PRODUCING ORGANISMS; STREPTOMYCES-GRISEUS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; VALIDAMYCIN-A; EXPRESSION; CLONING; IDENTIFICATION; PURIFICATION	We have previously demonstrated that the biosynthesis of the C-7-cyclitol, called valienol (or valienamine), of the a-glucosidase inhibitor acarbose starts from the cyclization of sedo-heptulose 7-phosphate to 2-epi-5-epivaliolone (Stratmann, A., Mahmud, T., Lee, S., Distler, J., Floss, H. G., and Piepersberg, W. (1999) J. Biol. Chem. 274, 10889-10896). Synthesis of the intermediate 2-epi-5-epi-valiolone is catalyzed by the cyclase AcbC encoded in the biosynthetic (acb) gene cluster of Actinoplanes sp. SE50/110. The acbC gene lies in a possible transcription unit, acbKLMNOC, cluster encompassing putative biosynthetic genes for cyclitol conversion. All genes were heterologously expressed in strains of Streptomyces lividans 66 strains 1326, TK23, and TK64. The AcbK protein was identified as the acarbose 7-kinase, which had been described earlier (Drepper, A., and Pape, H. (1996) J. Antibiot. (Tokyo) 49, 664-668). The multistep conversion of 2-epi-5-epi-valiolone to the final cyclitol moiety was studied by testing enzymatic mechanisms such as dehydration, reduction, epimerization, and phosphorylation. Thus, a phosphotransferase activity was identified modifying 2-epi-5-epi-valiolone by ATP-dependent phosphorylation. This activity could be attributed to the AcbM protein by verifying this activity in S. lividans strain TK64/pCW4123M, expressing His-tagged AcbM. The His-tagged AcbM protein was purified and subsequently characterized as a 2-epi-5-epi-valiolone 7-kinase, presumably catalyzing the first enzyme reaction in the biosynthetic route, leading to an activated form of the intermediate 1-epi-valienol. The AcbK protein could not catalyze the same reaction nor convert any of the other C-7-cyclitol monomers tested. The 2-epi-5-epi-valiolone 7-phosphate was further converted by the AcbO protein to another isomeric and phosphorylated intermediate, which was likely to be the 2-epimer 5-epi-valiolone 7-phosphate. The products of both enzyme reactions were characterized by mass spectrometric methods. The product of the AcbM-catalyzed reaction, 2-epi-5-epi-valiolone 7-phosphate, was purified on a preparative scale and identified by NAIR spectroscopy. A biosynthetic pathway for the pseudodisaccharidic acarviosyl moiety of acarbose is proposed on the basis of these data.	Berg Univ Wuppertal, Inst Chem Microbiol, D-42097 Wuppertal, Germany; Berg Univ Wuppertal, Inst Organ Chem, D-42097 Wuppertal, Germany; Res Ctr Julich, Inst Biotechnol 1, D-52425 Julich, Germany	University of Wuppertal; University of Wuppertal; Helmholtz Association; Research Center Julich	Piepersberg, W (corresponding author), Berg Univ Wuppertal, Inst Chem Microbiol, Gauss Str 20, D-42097 Wuppertal, Germany.	piepersb@uni-wuppertal.de	Zhang, Changsheng/B-5965-2012	Zhang, Changsheng/0000-0003-2349-3138				BABCOCK MJ, 1988, J BACTERIOL, V170, P2802, DOI 10.1128/jb.170.6.2802-2808.1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; DISTLER J, 1985, FEMS MICROBIOL LETT, V30, P145; Dong HJ, 2001, J AM CHEM SOC, V123, P2733, DOI 10.1021/ja003643n; Doumith M, 2000, MOL GEN GENET, V264, P477, DOI 10.1007/s004380000329; Drepper A, 1996, FEBS LETT, V388, P177, DOI 10.1016/0014-5793(96)00554-6; Drepper A, 1996, J ANTIBIOT, V49, P664, DOI 10.7164/antibiotics.49.664; GOCKE K, 1996, J ANTIBIOT TOKYO, V49, P661; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hemker M, 2001, J BACTERIOL, V183, P4484, DOI 10.1128/JB.183.15.4484-4492.2001; Hopwood D. A., 1985, GENETIC MANIPULATION; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; Mahmud T, 2001, J ORG CHEM, V66, P5066, DOI 10.1021/jo0101003; Mahmud T, 1999, J AM CHEM SOC, V121, P6973, DOI 10.1021/ja991102w; MANSOURI K, 1991, MOL GEN GENET, V228, P459, DOI 10.1007/BF00260640; Mendez C, 2001, RES MICROBIOL, V152, P341, DOI 10.1016/S0923-2508(01)01205-0; MULLER L, 1989, NOVEL MICROBIAL PROD, P109; Piepersberg W., 1997, BIOTECHNOLOGY ANTIBI, P81; Rehm H. J., 1997, BIOTECHNOLOGY, P397; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPRENGER GA, 1995, EUR J BIOCHEM, V230, P525; Stratmann A, 1999, J BIOL CHEM, V274, P10889, DOI 10.1074/jbc.274.16.10889; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Tercero JA, 1996, J BIOL CHEM, V271, P1579, DOI 10.1074/jbc.271.3.1579; Thompson C J, 1995, Biotechnology, V28, P197; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; Volff JN, 1996, MOL MICROBIOL, V21, P1037, DOI 10.1046/j.1365-2958.1996.761428.x; Walker J B, 1975, Methods Enzymol, V43, P429; Wehmeier UF, 2001, FEMS MICROBIOL LETT, V197, P53, DOI 10.1111/j.1574-6968.2001.tb10582.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	56	64	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22853	22862		10.1074/jbc.M202375200	http://dx.doi.org/10.1074/jbc.M202375200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11937512	hybrid			2022-12-25	WOS:000176313600096
J	Aubry, L; Mattei, S; Blot, B; Sadoul, R; Satre, M; Klein, G				Aubry, L; Mattei, S; Blot, B; Sadoul, R; Satre, M; Klein, G			Biochemical characterization of two analogues of the apoptosis-linked gene 2 protein in Dictyostelium discoideum and interaction with a physiological partner in mammals, murine alix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; EF-HAND PROTEINS; CA2+-BINDING PROTEINS; CELL-DEATH; ENTAMOEBA-HISTOLYTICA; ESCHERICHIA-COLI; ALG-2 PROTEIN; FAMILY; IDENTIFICATION; EXPRESSION	Two homologues, Dd-ALG-2a and Dd-ALG-2b, of the mammalian calcium-binding protein ALG-2 (apoptosis-linked gene 2) have been characterized in the cellular slime mold Dictyostelium discoideum. Fluorescence titrations showed that both proteins bind calcium ions with affinities (Ca2+)(0.5) of 30 and 450 mum, respectively, at sites specific to calcium. Calcium ion binding resulted in changes of conformation associated with the unmasking of hydrophobic regions of the proteins. Surface plasmon resonance analysis showed that Dd-ALG-2a homodimers formed (K-D of 1 mum) at calcium ion concentrations similar to those necessary for Ca2+-induced conformational changes. Deletion of the hydrophobic N-terminal sequence or EF-hand 5 of Dd-ALG-2a prevented dimerization. The Dd-ALG-2b homodimer was not detected, and the Dd-ALG-2a/2b heterodimer formed only when DdALG-2b was the immobilized partner. Murine Alix formed a heterodimer (K-D = 0.6 mum) with Dd-ALG-2a but not with Dd-ALG-2b, and the interaction strictly depended upon calcium ions. The DeltaNter construct of Dd-ALG-2a lost its interaction capacity with mouse Alix. The genes encoding both proteins, Dd-alg-2a and -2b, were expressed in growing cells. The levels of mRNA were at a maximum during aggregation (4-8 h) and decreased rapidly thereafter. In contrast, the levels of proteins remained fairly stable. Dd-ALG-2a and DdALG-2b were found to be dispensable for growth and development, based on the finding that single Dd-alg2a(-) or Dd-alg-2b(-) and double Dd-alg2a(-)/Dd-alg-2b(-) mutant cell lines showed normal growth in axenic medium or on bacterial lawns and exhibited unaltered development.	Univ Grenoble 1, Dept Reponse & Dynam Cellulaires Biochim & Biophy, Commiss Energie Atom Grenoble, Lab Biochim & Biophys Syst Integres,CNRS,UMR 5092, F-38054 Grenoble 9, France; Univ Grenoble 1, CHU Grenoble, INSERM, Equipe Mixte EMI 0108, F-38043 Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Klein, G (corresponding author), Univ Grenoble 1, Dept Reponse & Dynam Cellulaires Biochim & Biophy, Commiss Energie Atom Grenoble, Lab Biochim & Biophys Syst Integres,CNRS,UMR 5092, 17 Rue Martyrs, F-38054 Grenoble 9, France.			Aubry, Laurence/0000-0001-7640-1706; SADOUL, Remy/0000-0002-4763-0320				ABE F, 1995, DEV GROWTH DIFFER, V37, P39; Andre B, 1996, FEBS LETT, V382, P198, DOI 10.1016/0014-5793(96)00176-7; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Baskar R, 2000, INT J DEV BIOL, V44, P491; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; CORNILLON S, 1994, J CELL SCI, V107, P2691; COUKELL B, 1995, FEBS LETT, V362, P342, DOI 10.1016/0014-5793(95)00272-B; CUBITT AB, 1995, DEVELOPMENT, V121, P2291; Dorywalska M, 2000, BBA-MOL CELL RES, V1496, P356, DOI 10.1016/S0167-4889(00)00024-0; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; Gilchrist CA, 2001, J BIOL CHEM, V276, P11838, DOI 10.1074/jbc.M007375200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAMADA H, 1988, CANCER RES, V48, P3173; Han YH, 1998, FEBS LETT, V441, P302, DOI 10.1016/S0014-5793(98)01568-3; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Kuspa Adam, 2001, Functional and Integrative Genomics, V1, P279, DOI 10.1007/s101420000033; Levraud JP, 2001, METHOD CELL BIOL, V66, P469; LIU TY, 1992, MOL BIOL CELL, V3, P1403, DOI 10.1091/mbc.3.12.1403; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Lollike K, 2001, J BIOL CHEM, V276, P17762, DOI 10.1074/jbc.M100965200; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Maki M, 1997, BIOCHEM J, V328, P718; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; Nickel R, 2000, FEBS LETT, V486, P112, DOI 10.1016/S0014-5793(00)02245-6; Ohkouchi S, 2001, J BIOCHEM-TOKYO, V130, P207, DOI 10.1093/oxfordjournals.jbchem.a002974; Rosel D, 2000, FEBS LETT, V473, P323, DOI 10.1016/S0014-5793(00)01551-9; Schaap P, 1996, EMBO J, V15, P5177, DOI 10.1002/j.1460-2075.1996.tb00902.x; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Van Driessche N, 2002, DEVELOPMENT, V129, P1543; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WHITTINGHAM WF, 1960, P NATL ACAD SCI USA, V46, P642, DOI 10.1073/pnas.46.5.642; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; Zamparelli C, 2000, BIOCHEMISTRY-US, V39, P658, DOI 10.1021/bi991648v	47	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21947	21954		10.1074/jbc.M201718200	http://dx.doi.org/10.1074/jbc.M201718200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11927596	hybrid			2022-12-25	WOS:000176286000107
J	Franzoni, L; Lucke, C; Perez, C; Cavazzini, D; Rademacher, M; Ludwig, C; Spisni, A; Rossi, GL; Ruterjans, H				Franzoni, L; Lucke, C; Perez, C; Cavazzini, D; Rademacher, M; Ludwig, C; Spisni, A; Rossi, GL; Ruterjans, H			Structure and backbone dynamics of apo- and holo-cellular retinol-binding protein in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; LIGAND-BINDING; X-RAY; CRYSTAL-STRUCTURE; NMR RELAXATION; SPECIFICITY; RESOLUTION; PURIFICATION; MECHANISM; PROGRAM	Retinoid-binding proteins play an important role in regulating transport, storage, and metabolism of vitamin A and its derivatives. The solution structure and backbone dynamics of rat cellular retinol-binding protein type I (CRBP) in the apo- and holo-form have been determined and compared using multidimensional high resolution NMR spectroscopy. The global fold of the protein is consistent with the common motif described for members of the intracellular lipid-binding protein family. The most relevant difference between the NMR structure ensembles of apo- and holoCRBP is the higher backbone disorder, in the ligand-free form, of some segments that frame the putative entrance to the ligand-binding site. These comprise alpha-helix II, the subsequent linker to beta-strand B, the hairpin turn between beta-strands C and D, and the betaE-betaF turn. The internal backbone dynamics, obtained from N-15 relaxation data (T-1, T-2. and heteronuclear nuclear Overhauser effect) at two different fields, indicate several regions with significantly higher backbone mobility in the apoprotein, including the betaC-betaD and betaE-betaF turns. Although apoCRBP contains a binding cavity more shielded than that of any other retinoid carrier, conformational flexibility in the portal region may assist retinol uptake. The stiffening of the backbone in the holoprotein guarantees the stability of the complex during retinol transport and suggests that targeted retinol release requires a transiently open state that is likely to be promoted by the acceptor or the local environment.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Dept Expt Med, Sect Chem & Struct Biochem, I-43100 Parma, Italy; Goethe Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany	University of Parma; University of Parma; Goethe University Frankfurt	Rossi, GL (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci,23-A, I-43100 Parma, Italy.	rossi@unipr.it	Spisni, Alberto/AAY-7778-2020; Cavazzini, Davide/C-8154-2014	Cavazzini, Davide/0000-0002-1743-2390				Bakowies D, 2002, J MOL BIOL, V315, P713, DOI 10.1006/jmbi.2001.5202; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BYCHKOVA VE, 1992, BIOCHEMISTRY-US, V31, P7566, DOI 10.1021/bi00148a018; Bychkova VE, 1998, FOLD DES, V3, P285, DOI 10.1016/S1359-0278(98)00039-X; Cavanagh John, 1996, P243; Chen X, 1998, J MOL BIOL, V278, P641, DOI 10.1006/jmbi.1998.1734; CHENG L, 1991, J BIOL CHEM, V266, P24404; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Elviri L, 2001, RAPID COMMUN MASS SP, V15, P2186, DOI 10.1002/rcm.497; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Gudas Lorraine J., 1994, P443; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Herr FM, 1999, J BIOL CHEM, V274, P9556, DOI 10.1074/jbc.274.14.9556; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; Kuser PR, 2001, ACTA CRYSTALLOGR D, V57, P1863, DOI 10.1107/S090744490101825X; LALONDE JM, 1994, BIOCHEMISTRY-US, V33, P4885, DOI 10.1021/bi00182a017; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LASSEN D, 1995, EUR J BIOCHEM, V230, P266, DOI 10.1111/j.1432-1033.1995.tb20560.x; LEVIN MS, 1990, METHOD ENZYMOL, V189, P506; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; LIU RSH, 1984, TETRAHEDRON, V40, P1931, DOI 10.1016/S0040-4020(01)88435-0; Lu JY, 1999, J MOL BIOL, V286, P1179, DOI 10.1006/jmbi.1999.2544; Lu JY, 2000, J MOL BIOL, V300, P619, DOI 10.1006/jmbi.2000.3883; Lucke C, 2001, BIOCHEM J, V354, P259, DOI 10.1042/0264-6021:3540259; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; Malpeli G, 1998, METH MOL B, V89, P111; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Ong David E., 1994, P283; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Penzes P, 1999, BIOCHEMISTRY-US, V38, P2088, DOI 10.1021/bi982228t; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; Pristovsek P, 2000, EUR J BIOCHEM, V267, P4205, DOI 10.1046/j.1432-1327.2000.01456.x; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; ROSS AC, 1993, J NUTR, V123, P346, DOI 10.1093/jn/123.suppl_2.346; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCAPIN G, 1993, MOL CELL BIOCHEM, V123, P3, DOI 10.1007/BF01076469; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SPECHT B, 1994, J BIOTECHNOL, V33, P259, DOI 10.1016/0168-1656(94)90074-4; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; STUMP DG, 1991, J BIOL CHEM, V266, P4622; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Wang LC, 1997, J BIOL CHEM, V272, P1541, DOI 10.1074/jbc.272.3.1541; Wang LC, 1998, BIOCHEMISTRY-US, V37, P12727, DOI 10.1021/bi9808924; Wang LC, 1998, BIOCHEMISTRY-US, V37, P13021, DOI 10.1021/bi981021x; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	74	48	49	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21983	21997		10.1074/jbc.M201994200	http://dx.doi.org/10.1074/jbc.M201994200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934897	hybrid			2022-12-25	WOS:000176286000111
J	Pilch, J; Habermann, R; Felding-Habermann, B				Pilch, J; Habermann, R; Felding-Habermann, B			Unique ability of integrin alpha(v)beta(3) to support tumor cell arrest under dynamic flow conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BETA-3 INTEGRINS; VITRONECTIN RECEPTOR; PLATELET-AGGREGATION; LIGAND RECOGNITION; P-SELECTIN; IN-VITRO; ALPHA-V; ADHESION; METASTASIS	Shear-resistant arrest of circulating tumor cells is required for metastasis from the blood stream. Arrest during blood flow can be supported by tumor cell interaction with attached, activated platelets. This is mediated by tumor cell integrin alpha(v)beta(3) and cross-linking plasma protein ligands. To analyze the mechanism of tumor cell ligand interactions under dynamic flow conditions, we used real-time video microscopy and tested human melanoma cell binding to fibrinogen, von Willebrand Factor, or fibronectin matrices in a buffer perfusion system. When perfused at venous flow, melanoma cells arrested abruptly and began to spread immediately. This was uniquely mediated by integrin alpha(v)beta(3) on all tested ligands, and required alpha(v)beta(3) activation and actin polymerization. Under static conditions, alpha(v)beta(3) cooperated with alpha(v)beta(1) and alpha(5)beta(1), in supporting melanoma cell adhesion to fibronectin. But even when activated, beta(1), integrins did not contribute to melanoma cell arrest during flow. Soluble ligand served as a cross-linker between attached and circulating tumor cells and enhanced melanoma cell arrest. Cohesion of activated melanoma cells was restricted to the matrix surface and did not occur in suspension. We conclude that the presence of alpha(v)beta(3) in a functionally activated state provides a unique advantage for circulating tumor cells by promoting tumor cell arrest in the presence of flow-dependent shear forces.	Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Felding-Habermann, B (corresponding author), Scripps Res Inst, Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,Mail Drop MEM 175, La Jolla, CA 92037 USA.		Pilch, Jan/AAM-1976-2020; Pilch, Jan/AAJ-3614-2021	Pilch, Jan/0000-0002-6427-5738; Pilch, Jan/0000-0002-2682-4708	NATIONAL CANCER INSTITUTE [R01CA095458] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95458] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Chambers AF, 1995, CANCER METAST REV, V14, P279, DOI 10.1007/BF00690599; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Coller BS, 2001, THROMB HAEMOSTASIS, V86, P427; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; Gailit J, 1996, J INVEST DERMATOL, V106, P102, DOI 10.1111/1523-1747.ep12328177; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Konstantopoulos K, 1997, J CLIN INVEST, V100, pS19; LAM SCT, 1989, J BIOL CHEM, V264, P3742; MARSHALL JF, 1995, J CELL SCI, V108, P1227; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; NIERODZIK ML, 1995, THROMB HAEMOSTASIS, V74, P282; NIIYA K, 1987, BLOOD, V70, P475; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Palumbo JS, 2000, BLOOD, V96, P3302, DOI 10.1182/blood.V96.10.3302; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Savage B, 2001, CURR OPIN HEMATOL, V8, P270, DOI 10.1097/00062752-200109000-00002; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; Sheetz MP, 2001, NAT REV MOL CELL BIO, V2, P392, DOI 10.1038/35073095; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Wang J, 2001, J BIOL CHEM, V276, P14474, DOI 10.1074/jbc.M007324200; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; Wong CW, 2001, CANCER RES, V61, P333; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200	40	74	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21930	21938		10.1074/jbc.M201630200	http://dx.doi.org/10.1074/jbc.M201630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11934894	hybrid			2022-12-25	WOS:000176286000105
J	Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J				Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J			Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers	ONCOGENE			English	Article						HPV E6/E7; p53; human carcinoma; Cidofovir; ionizing radiation	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; ACYCLIC NUCLEOSIDE PHOSPHONATES; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; E7 PROTEIN; INHIBITION; DNA; DEGRADATION	High-risk human papillomaviruses (HPVs) have been associated to the development of cervical and some other human cancers. Most of them express E6 and E7 oncoproteins, able to bind to p53 and retinoblastoma (pRb) tumor suppressor proteins respectively and neutralize their function. Restoration of these pathways by blocking E6 and E7 expression would provide a selective therapeutic effect. Here, we show that a clinically approved antiviral agent Cidofovir reduced E6 and E7 expression in cervical carcinoma Me180 and head and neck squamous cell carcinoma HEP2 cells at the transcriptional level. Cidofovir induced the accumulation of active p53 and pRb associated to induction of cyclin dependent kinase inhibitor p21(WAF1/CIP1) in Me180 and HEP2 cells. p53 induction was also shown in Hela HPV-positive cervical carcinoma cell line. In addition, S phase cell cycle accumulation with concomitant decrease of cyclin A expression were associated to the antiproliferative activity of Cidofovir in HPV-treated cells. Combining Cidofovir to irradiation both in vivo and in nude mice xenografts resulted in a marked radiosensitization in HPV-positive cells, which was not observed in virus negative cells. This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects.	Inst Gustave Roussy, Lab UPRES EA 27 10, F-94805 Villejuif, France; Inst Gustave Roussy, Unite METSI, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab UPRES EA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	THIERY, Jerome/N-2469-2018; Chouaib, Salem/F-7939-2016; Sabri, Siham/K-1101-2015	THIERY, Jerome/0000-0002-0998-3627; deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X				Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Andrei G, 1998, ONCOL RES, V10, P523; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Boyer SN, 1996, CANCER RES, V56, P4620; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chiba I, 1996, ONCOGENE, V12, P1663; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gallardo D, 1996, CANCER RES, V56, P4891; Gillam R, 1999, C++ REP, V11, P9; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; GOUBIN F, 1995, ONCOGENE, V10, P2281; He JK, 1997, CANCER RES, V57, P3993; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; HU GY, 1995, CANCER GENE THER, V2, P19; Hwang ES, 1996, ONCOGENE, V12, P795; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamradt MC, 2000, BRIT J CANCER, V82, P1709; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MORAN E, 1993, CURR OPIN GENE DEV, V13, P261; Neyts J, 1998, CANCER RES, V58, P384; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; Safrin S, 1997, REV MED VIROL, V7, P145, DOI 10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0; Santin AD, 1998, CANCER-AM CANCER SOC, V83, P2346, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2346::AID-CNCR14>3.0.CO;2-G; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; STEELE C, 1992, CANCER RES, V52, P4706; STEELE C, 1993, CANCER RES, V53, P2330; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TAN TMC, 1995, CANCER RES, V55, P4599; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	64	105	108	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2334	2346		10.1038/sj.onc.1205006	http://dx.doi.org/10.1038/sj.onc.1205006			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948417				2022-12-25	WOS:000174635600006
J	Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V				Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V			Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway	ONCOGENE			English	Article						HGF/SF; RAS; ERK; ETS; morphogenesis	RECEPTOR TYROSINE KINASE; SCATTER FACTOR; MAP-KINASE; EPITHELIAL-CELLS; PROTEIN-KINASES; PHOSPHORYLATION; DOMAIN; EXPRESSION; TRANSDUCTION; MOTILITY	Hepatocyte growth factor/scatter factor (HGF/SF) induces scattering and morphogenesis of epithelial cells through the activation of the MET tyrosine kinase receptor. Although the activated MET receptor recruits a number of signaling proteins, little is known of the downstream signaling pathways activated by HGF/SF. In this study, we wished to examine the signaling pathway leading to activation of the ETS1 transcription factor. Using in vitro and in vivo kinase assays, we found that HGF/SF activates the ERK1 MAP kinase, leading to the phosphorylation of the threonine 38 residue of ETS1 within a putative MAP kinase phosphorylation site (PLLT38P). This threonine residue was neither phosphorylated by JNK1, nor by p38 MAP kinases and was required for the induction of transcriptional activity of ETS1 by HGF/SF. Using kinase and transcription assays, we further demonstrated that phosphorylation and activation of ETS1 occurs downstream of a RAS-RAF-MEK-ERK pathway. The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis. These data demonstrated that ETS1 is a downstream target of HGF/SF acting through a RAS-RAF-MEK-ERK pathway and provides a signaling pathway leading to the regulation of gene expression by HGF/SF.	Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Fafeur, V (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, BP 447, F-59021 Lille, France.	veronique.fefeur@ibl.fr	KHERROUCHE, Zoulika/HHN-0213-2022; Fafeur, Veronique/L-9072-2018; Tulasne, David/A-8705-2008; plaza, serge/F-5290-2015; Tulasne, David/AAR-5287-2020; Paumelle, Réjane/R-6675-2018; KHERROUCHE, Zoulika/L-6549-2019	Tulasne, David/0000-0002-6764-7242; Paumelle, Réjane/0000-0002-4489-0717; 				Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; CHEN JH, 1990, ONCOGENE RES, V5, P277; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rabault B, 1996, ONCOGENE, V13, P877; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Terauchi R, 2000, EXP CELL RES, V256, P411, DOI 10.1006/excr.2000.4850; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	44	126	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2309	2319		10.1038/sj.onc.1205297	http://dx.doi.org/10.1038/sj.onc.1205297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948414				2022-12-25	WOS:000174635600003
J	Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH				Ashcroft, M; Ludwig, RL; Woods, DB; Copeland, TD; Weber, HO; MacRae, EJ; Vousden, KH			Phosphorylation of HDM2 by Akt	ONCOGENE			English	Article						HDM2; Akt; P53; phosphorylation	ATM-DEPENDENT PHOSPHORYLATION; NUCLEOLAR-LOCALIZATION; MDM2; P53; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; UBIQUITINATION; PREVENTS	The HDM2 protein is a key regulator of the tumour suppressor, p53. Control of HDM2 function is critical for normal cell proliferation and stress responses, and it is becoming evident that multiple modifications of HDM2 can regulate its function within cells. In this study we show that HDM2 associated with the serinethreonine kinase, Akt, in response to growth factor stimulation of human primary cells. This association was concurrent with phosphorylation of Akt (at Ser 473), and resulted in elevated expression of HDM2 and enhanced nuclear localization. However, analysis of HDM2 proteins mutated at the consensus Akt recognition sites at serines 166 and 186 indicated that modification at these residues was not sufficient for the increased expression of the protein, which was blocked by the PI3 kinase inhibitor LY294002. Tryptic peptide and mutational analyses revealed evidence for an Akt phosphorylation site in HDM2 additional to the two consensus sites.	NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of London; Institute of Cancer Research - UK	Vousden, KH (corresponding author), NCI, FCRDC, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	ashcroft@icr.ac.uk						Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, ONCOGENE, V18, P4586, DOI 10.1038/sj.onc.1202814; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gotz C, 1999, EUR J BIOCHEM, V266, P493, DOI 10.1046/j.1432-1327.1999.00882.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 1997, CANCER RES, V57, P5013; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	166	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1955	1962		10.1038/sj.onc.1205276	http://dx.doi.org/10.1038/sj.onc.1205276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960368				2022-12-25	WOS:000174827000002
J	Kim, EJ; Park, JS; Um, SJ				Kim, EJ; Park, JS; Um, SJ			Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL REPRESSION; COVALENT MODIFICATION; HISTONE DEACETYLASES; DOWN-REGULATION; SAM DOMAIN; GENE; P63; EXPRESSION	To study the biological role of p73alpha, a member of the p53 tumor suppressor family, we performed a yeast two-hybrid screen of a human cDNA library. Using a p73alpha fragment consisting of amino acids 49-636 as bait, we found that p73alpha is functionally associated with the human homologue of mouse and hamster homeodomain-interacting protein kinase 2 (HIPK2). The hamster homologue, also known as haHIPK2 or PKM, was used for further characterization of interactions between HIPK2 and members of the p53 protein family. Systematic yeast two-hybrid assays indicated a physical interaction between the oligomerization domains of p73a and p53 (amino acid regions 345-380 and 319-360, respectively) and amino acid region 812-907 of haHIPK2. This region of haHIPK2 includes a PEST sequence, an Ubc9-binding domain, and a partial speckle retention sequence and is identical to amino acid residues 846-941 of human HIPK2 (hHIPK2). The interaction was confirmed by glutathione S-transferase pull-down assays in vitro and immunoprecipitation assays in vivo. HIPK2 colocalized with p73alpha and p53 in nuclear bodies, as shown by confocal microscopy. Overexpression of HIPK2 stabilized the p53 protein and greatly increased the p73- and p53-induced transcriptional repression of multidrug-resistant and collagenase promoters in Saos2 cells but had little effect on the p73- or p53-mediated transcriptional activation of synthetic p53-responsive and p21WAF1 promoters. Stable expression of HIPK2 in U20S cells enhanced the cisplatin response of sub-G(1) and G(2)/M populations, and it also increased the apoptotic response to cisplatin and adriamycin as demonstrated by fluorescence-activated cell sorter and 4',6-diamidino-2-phenylindole-staining analyses. HIPK2 potentiated the inhibition of colony formation by p73 and p53. These results suggest that physical interactions between HIPK2 and members of the p53 family may determine the roles of these proteins in cell cycle regulation and apoptosis.	Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Kwangjin Gu, Seoul 143747, South Korea; Catholic Univ, Grad Sch, Dept Med Biosci, Seoul, South Korea; Catholic Univ, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea	Sejong University; Catholic University of Korea; Catholic University of Korea	Um, SJ (corresponding author), Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Kwangjin Gu, 98 Kunja Dong, Seoul 143747, South Korea.	umsj@sejong.ac.kr						Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Leach SD, 1998, CANCER RES, V58, P3231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MIYASHITA T, 1994, CANCER RES, V54, P3131; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Park JS, 2001, INT J CANCER, V91, P822, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANG BC, 1994, ONCOGENE, V9, P853; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Wang Y, 2001, BBA-GENE STRUCT EXPR, V1518, P168, DOI 10.1016/S0167-4781(00)00308-0; Webster NJG, 1996, CANCER RES, V56, P2781; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhang LL, 2000, CANCER RES, V60, P3655; Zhao RB, 2000, GENE DEV, V14, P981	67	73	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 30	2002	277	35					32020	32028		10.1074/jbc.M200153200	http://dx.doi.org/10.1074/jbc.M200153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	588UB	11925430	hybrid			2022-12-25	WOS:000177718700090
J	Alfsen, A; Bomsel, M				Alfsen, A; Bomsel, M			HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; TYPE-1 GP41; TRANSMEMBRANE GLYCOPROTEIN; NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; AQUEOUS-SOLUTION; STRUCTURAL BASIS; AMINO-ACIDS; T-CELLS	The initial step in the interaction between human immunodeficiency virus (HIV-1) and epithelial cells is the binding of HIV-1 envelope glycoproteins to the epithelial cell galactosyl. ceramide (GalCer). Here we show that HIV-1 envelope gp41 residues 650-685 bind GalCer in a galactose-specific manner. The gp41 residues that display this lectin activity are highly conserved among HIV-1 isolates and constitute three regions: residues 650-661, which encompass a charged helix; residues 662-667, referred to as the conserved epitope ELDKWA, the epitope recognized by antibodies that neutralize HIV-1 entry in epithelial and CD4(+)-mononucleated cells; and residues 668-685, a hydrophobic Trp-rich sequence that stabilizes the structure of the galactose binding site. Similar to other galactose-specific lectins, the gp41 lectin site is active only as an oligomer. Finally the orientation of the galactose toward the gp41 lectin site appears to be controlled by the lipid microenvironment of the epithelial membrane. From the experimental data we construct a theoretical model of the interaction between gp41 and GalCer based on thermodynamic considerations. This model integrates the dynamics and the spatial organization of the viral envelope glycoproteins, GalCer organized in raft microdomains in the apical region of the epithelial cell membrane and the interfacial water. Characterization of the minimal sequence and structure of gp41 in direct interaction with GalCer may help unravel the still unknown immunogenic determinant able to elicit antibodies against ELDKWA and target of one of the rare neutralizing antibodies against gp41.	Inst Cochin Genet Mol, Dept Biol Cellulaire, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bomsel, M (corresponding author), Inst Cochin Genet Mol, Dept Biol Cellulaire, 22 Rue Mechain, F-75014 Paris, France.		Bomsel, Morgane/GSN-1948-2022	Bomsel, Morgane/0000-0002-9577-7474				Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; ARMSTRONG FA, 1985, Q REV BIOPHYS, V18, P261, DOI 10.1017/S0033583500000366; Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175; BHATTACHARYYA L, 1988, EUR J BIOCHEM, V176, P207, DOI 10.1111/j.1432-1033.1988.tb14270.x; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cantin R, 1997, BLOOD, V90, P1091, DOI 10.1182/blood.V90.3.1091.1091_1091_1100; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN RF, 1969, PHYSICAL PRINCIPLE A, P171; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chermann JC, 1998, AM J REPROD IMMUNOL, V40, P183, DOI 10.1111/j.1600-0897.1998.tb00411.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Fantini J, 1997, J BIOL CHEM, V272, P7245, DOI 10.1074/jbc.272.11.7245; FANTINI J, 1993, M S-MED SCI, V9, P891, DOI 10.4267/10608/3009; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; FRANKS F, 1977, PHILOS T ROY SOC B, V278, P33, DOI 10.1098/rstb.1977.0030; FRANKS F, 1968, EQUILIBRIA REACTION, P32; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GALLAY J, 1981, J BIOL CHEM, V256, P1235; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gorny MK, 2000, J VIROL, V74, P6186, DOI 10.1128/JVI.74.13.6186-6192.2000; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Hansen GH, 1999, GASTROENTEROLOGY, V116, P610, DOI 10.1016/S0016-5085(99)70183-6; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HAROUSE JM, 1995, J VIROL, V69, P7383, DOI 10.1128/JVI.69.12.7383-7390.1995; Hinderliter A, 2001, BIOCHEMISTRY-US, V40, P4181, DOI 10.1021/bi0024299; HOEKSTRA D, 1986, BIOCHEMISTRY-US, V25, P1321, DOI 10.1021/bi00354a020; IMBERTY A, 1993, ADV BIOPH C, V0003; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KLEIN R, 1987, PHOTOCHEM PHOTOBIOL, V45, P55, DOI 10.1111/j.1751-1097.1987.tb08405.x; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LUKU L, 1968, J AM CHEM SOC, V91, P220; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Meng G, 2002, NAT MED, V8, P150, DOI 10.1038/nm0202-150; Mobley PW, 2001, AIDS RES HUM RETROV, V17, P311, DOI 10.1089/08892220150503681; OCHOA JL, 1981, J CHROMATOGR, V215, P351, DOI 10.1016/S0021-9673(00)81414-4; Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STILLINGER FH, 1977, PHILOS T R SOC B, V278, P97, DOI 10.1098/rstb.1977.0033; TATISCHEFF L, 1976, EXCITED STAT BIOL ME, P375; THIAUDIERE E, 1991, EUR J BIOCHEM, V195, P203, DOI 10.1111/j.1432-1033.1991.tb15696.x; THOMAS DJ, 1991, J VIROL, V65, P3797, DOI 10.1128/JVI.65.7.3797-3803.1991; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; VANMEER G, 1992, TRENDS CELL BIOL, V2, P322; Verkade P, 2000, J CELL BIOL, V148, P727, DOI 10.1083/jcb.148.4.727; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; VINCENT M, 1982, BIOCHEM BIOPH RES CO, V107, P914, DOI 10.1016/0006-291X(82)90610-6; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; WEI S, 1999, BIOCHEMISTRY-US, V38, P5378; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; Werling D, 1999, J LEUKOCYTE BIOL, V66, P50, DOI 10.1002/jlb.66.1.50; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; Wyatt R, 1997, J VIROL, V71, P9722, DOI 10.1128/JVI.71.12.9722-9731.1997; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	75	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	2002	277	28					25649	25659		10.1074/jbc.M200554200	http://dx.doi.org/10.1074/jbc.M200554200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	571YP	11940580	hybrid			2022-12-25	WOS:000176747000104
J	Kulkarni, S; Goll, DE; Fox, JEB				Kulkarni, S; Goll, DE; Fox, JEB			Calpain cleaves RhoA generating a dominant-negative form that inhibits integrin-induced actin filament assembly and cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; LEUKOCYTE ADHESION; FOCAL COMPLEXES; STRESS FIBERS; RAC; ACTIVATION; GTPASES; CYTOSKELETON; CDC42; FILOPODIA	Integrin-induced cell adhesion results in transmission of signals that induce cytoskeletal reorganizations and resulting changes in cell behavior. The cytoskeletal reorganizations are regulated by transient activation and inactivation of Rho GTPases. Previously, we identified mu-calpain as an enzyme that is activated by signaling across beta(1) and beta(3) integrins. We showed that it mediates cytoskeletal reorganizations in bovine aortic endothelial (BAE) and Chinese hamster ovary (CHO) cells and does so by acting upstream of Rac1 activation. Here we show that mu-calpain is also involved in inactivating RhoA during integrin-induced signaling. Cleavage of RhoA was detectable in BAE cells plated on an integrin substrate; it did not occur in cells plated on poly-(L)-lysine. Cleavage was inhibited by calpain inhibitors. In vitro, mu-calpain cleaved RhoA generating a fragment of the same size as in intact cells. The cleavage site was identified, an HA-tagged construct expressing calpain-cleaved RhoA generated, and the construct expressed in BAE and CHO cells. Calpain-cleaved RhoA inhibited integrin-induced stress fiber assembly and decreased cell spreading. Together, our data show that calpain cleaves RhoA and generates a form that inhibits integrin-induced stress fiber assembly and cell spreading.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Univ Arizona, Muscle Biol Grp, Tucson, AZ 85721 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University of Arizona; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030657, R23HL030657, R37HL030657, R01HL056264] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bialkowska K, 2000, BLOOD, V96, p241A; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EMORI Y, 1986, J BIOL CHEM, V261, P9465; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; GOLL DE, 1983, PROPERTIES REGULATIO, P19; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; MURACHI T, 1989, BIOCHEM INT, V18, P263; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; SZPACENKO A, 1981, PROTEINASES THEIR IN, P151; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728	36	84	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24435	24441		10.1074/jbc.M203457200	http://dx.doi.org/10.1074/jbc.M203457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964413	hybrid			2022-12-25	WOS:000176611800062
J	Li, HM; Ryan, TJ; Chave, KJ; Van Roey, P				Li, HM; Ryan, TJ; Chave, KJ; Van Roey, P			Three-dimensional structure of human gamma-glutamyl hydrolase - A class I glutamine amidotransferase adapted for a complex substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ELECTRON-DENSITY MAPS; X-RAY-DIFFRACTION; FOLYLPOLYGLUTAMATE SYNTHETASE; CRYSTAL-STRUCTURE; METHOTREXATE; RESISTANCE; DATABASE; POLYGLUTAMYLATION; CLASSIFICATION	gamma-Glutamyl hydrolase catalyzes the cleavage of the gamma-glutamyl chain of folylpoly-gamma-glutamyl substrates and is a central enzyme in folyl and antifolyl poly-gamma-glutamate metabolism. The crystal structure of human gamma-glutamyl hydrolase, determined at 1.6-Angstrom resolution, reveals that the protein is a homodimer. The overall structure of human gamma-glutamyl hydrolase contains 11 a-helices and 14 beta-strands, with a fold in which a central eight-stranded beta-sheet is sandwiched by three and five a-helices on each side. The topology is very similar to that of the class I glutamine amidotransferase domains, with the only major differences consisting of extensions in four loops and at the C terminus. These insertions are important for defining the substrate binding cleft and/or the dimer interface. Two sequence motifs are found in common between human gamma-glutamyl hydrolase and the class I glutamine amidotransferase family and include the catalytically essential residues, Cys-110 and His-220. These residues are located in the center of a large L-shaped cleft that is closed at one end and open at the other. Several conserved residues, including Glu-114, His-171, Gln-218, and Lys-223, may be important for substrate binding. Modeling of a methotrexate thioester intermediate, based on the corresponding complex of the glutamate thioester intermediate of Escherichia coli carbamoyl-phosphate synthetase, indicates that the substrate binds in an orientation with the pteroyl group toward the open end of the cleft.	Wadsworth Ctr, Div Mol Med, Albany, NY 12201 USA	Wadsworth Center	Van Roey, P (corresponding author), Wadsworth Ctr, Div Mol Med, POB 509, Albany, NY 12201 USA.	vanroey@wadsworth.org	Li, Hongmin/ABI-2439-2020	Li, Hongmin/0000-0002-8684-5308	NCI NIH HHS [CA82425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chave KJ, 2000, J BIOL CHEM, V275, P40365, DOI 10.1074/jbc.M007908200; Chave KJ, 1999, BIOCHEM J, V343, P551, DOI 10.1042/0264-6021:3430551; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; GALIVAN J, 1980, MOL PHARMACOL, V17, P105; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huang XY, 1999, BIOCHEMISTRY-US, V38, P15909, DOI 10.1021/bi991805q; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knochel T, 1999, P NATL ACAD SCI USA, V96, P9479, DOI 10.1073/pnas.96.17.9479; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Longo GSA, 1997, ONCOL RES, V9, P259; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIRAN SG, 1991, BIOCHEMISTRY-US, V30, P7901, DOI 10.1021/bi00246a005; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PIZZORNO G, 1995, CANCER RES, V55, P566; RHEE MS, 1993, CANCER RES, V53, P2227; Rhee MS, 1998, MOL PHARMACOL, V53, P1040; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Roussel A, 1991, SILICON GRAPHICS GEO, P81; ROUX B, 1993, BIOCHEMISTRY-US, V32, P3763, DOI 10.1021/bi00065a031; RUMBERGER BG, 1990, CANCER COMMUN, V2, P305; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; Sun XL, 2001, J MOL BIOL, V310, P1067, DOI 10.1006/jmbi.2001.4815; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P16158, DOI 10.1021/bi991741j; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Waltham MC, 1997, MOL PHARMACOL, V51, P825, DOI 10.1124/mol.51.5.825; YAO R, 1995, MOL PHARMACOL, V48, P505; Yao R, 1996, P NATL ACAD SCI USA, V93, P10134, DOI 10.1073/pnas.93.19.10134; Yao R, 1996, J BIOL CHEM, V271, P8525, DOI 10.1074/jbc.271.15.8525	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24522	24529		10.1074/jbc.M202020200	http://dx.doi.org/10.1074/jbc.M202020200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11953431	hybrid			2022-12-25	WOS:000176611800073
J	Vickrey, JF; Herve, G; Evans, DR				Vickrey, JF; Herve, G; Evans, DR			Pseudomonas aeruginosa aspartate transcarbamoylase - Characterization of its catalytic and regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENETIC ORGANIZATION; CARBAMOYLPHOSPHATE SYNTHETASE; PYRIMIDINE BIOSYNTHESIS; MULTIFUNCTIONAL PROTEIN; CARBAMOYLTRANSFERASE; PURIFICATION; ARGININE; SUBUNIT; DOMAIN	Aspartate transcarbamoylase from Pseudomonadaceae is a class A enzyme consisting of six copies of a 36-kDa catalytic chain and six copies of a 45-kDa polypeptide of unknown function. The 45-kDa polypeptide is homologous to dihydroorotase but lacks catalytic activity. Pseudomonas aeruginosa aspartate transcarbamoylase was overexpressed in Escherichia coli. The homogeneous His-tagged protein isolated in high yield, 30 mg/liter of culture, by affinity chromatography and crystallized. Attempts to dissociate the catalytic and pseudo-dihydroorotase (pDHO) subunits or to express catalytic subunits only were unsuccessful suggesting that the pDHO subunits are required for the proper folding and assembly of the complex. As reported previously, the enzyme was inhibited by micromolar concentrations of all nucleotide triphosphates. In the absence of effectors, the aspartate saturation curves were hyperbolic but became strongly sigmoidal in the presence of low concentrations of nucleotide triphosphates. The inhibition was unusual in that only free ATP, not MgATP, inhibits the enzyme. Moreover, kinetic and binding studies with a fluorescent ATP analog suggested that ATP induces a conformational change that interferes with the binding of carbamoyl phosphate but has little effect once carbamoyl phosphate is bound. The peculiar allosteric properties suggest that the enzyme may be a potential target for novel chemotherapeutic agents designed to combat Pseudomonas infection.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Wayne State University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Evans, DR (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	devans@cmb.biosci.wayne.edu						ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; ABDELAL AT, 1983, EUR J BIOCHEM, V129, P697; ADAIR LB, 1972, J BIOL CHEM, V247, P2308; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BERGH ST, 1993, P NATL ACAD SCI USA, V90, P9818, DOI 10.1073/pnas.90.21.9818; BRABSON JS, 1975, J BIOL CHEM, V250, P8664; CONDON S, 1976, J GEN MICROBIOL, V92, P375, DOI 10.1099/00221287-92-2-375; DUTTA PK, 1987, J CHROMATOGR, V385, P119, DOI 10.1016/S0021-9673(01)94627-8; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; GRAYSON DR, 1983, J BIOL CHEM, V258, P4123; HAAS D, 1977, MOL GEN GENET, V154, P7, DOI 10.1007/BF00265571; HOBDEN JA, 1993, ANTIMICROB AGENTS CH, V37, P1856, DOI 10.1128/AAC.37.9.1856; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HUFF JP, 1990, BIOTECHNIQUES, V9, P570; ISAAC JH, 1968, J BACTERIOL, V96, P1732, DOI 10.1128/JB.96.5.1732-1741.1968; ISSALY I, 1982, BIOCHEMISTRY-US, V21, P1612, DOI 10.1021/bi00536a023; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGER D, 1988, BIOCHEMISTRY-US, V27, P4293, DOI 10.1021/bi00412a015; LERNER CG, 1986, J BIOL CHEM, V261, P1156; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEY JA, 1988, MOL GEN GENET, V213, P278, DOI 10.1007/BF00339592; Maniatis T., 1982, MOL CLONING LAB MANU; MERCENIER A, 1980, J BACTERIOL, V144, P159, DOI 10.1128/JB.144.1.159-163.1980; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PALMER DA, 1993, APPL ENVIRON MICROB, V59, P1619, DOI 10.1128/AEM.59.5.1619-1626.1993; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Perrin DD, 1966, BIOCHIM BIOPHYS ACTA, V127, P35, DOI 10.1016/0304-4165(66)90472-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PRESTON MJ, 1993, INFECT IMMUN, V61, P2713, DOI 10.1128/IAI.61.6.2713-2716.1993; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; SCHURR MJ, 1995, J BACTERIOL, V177, P1751, DOI 10.1128/jb.177.7.1751-1759.1995; SHEPHERDSON M, 1993, FEMS MICROBIOL LETT, V114, P201, DOI 10.1111/j.1574-6968.1993.tb06574.x; SHOESMITH JG, 1960, J GEN MICROBIOL, V22, P10, DOI 10.1099/00221287-22-1-10; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; STEVENS RC, 1991, P NATL ACAD SCI USA, V88, P6087, DOI 10.1073/pnas.88.14.6087; TREDGET EE, 1992, CLIN INFECT DIS, V15, P941, DOI 10.1093/clind/15.6.941; VICKREY JF, 1993, THESIS U N TEXAS DEN; Wales ME, 1999, J MOL BIOL, V294, P1387, DOI 10.1006/jmbi.1999.3315; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; WEITZMAN PD, 1966, J BIOL CHEM, V241, P5481; WILD JR, 1990, ANNU REV MICROBIOL, V44, P193; XU GR, 1992, J GEN MICROBIOL, V138, P2459, DOI 10.1099/00221287-138-11-2459; ZHANG YX, 1993, J BACTERIOL, V175, P6451, DOI 10.1128/jb.175.20.6451-6458.1993	50	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24490	24498		10.1074/jbc.M200009200	http://dx.doi.org/10.1074/jbc.M200009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11959858	hybrid			2022-12-25	WOS:000176611800069
J	Gioia, M; Fasciglione, GF; Marini, S; D'Alessio, S; De Sanctis, G; Diekmann, O; Pieper, M; Politi, V; Tschesche, H; Coletta, M				Gioia, M; Fasciglione, GF; Marini, S; D'Alessio, S; De Sanctis, G; Diekmann, O; Pieper, M; Politi, V; Tschesche, H; Coletta, M			Modulation of the catalytic activity of neutrophil collagenase MMP-8 on bovine collagen I - Role of the activation cleavage and of the hemopexin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; MATRIX METALLOPROTEINASES; SUBSTRATE-SPECIFICITY; TRIPLE-HELIX; N-TERMINUS; PROCOLLAGENASE; STROMELYSIN; LEUKOCYTES; GELATINASE; INHIBITOR	The cleavage of bovine collagen I by neutrophil collagenase MMP-8 has been followed at pH 7.4, 37 degreesC. The behavior of the whole enzyme molecule (whMMP-8), displaying both the catalytic domain and the hemopexin-like domain, has been compared under the same experimental conditions with that of the catalytic domain only. The main observation is that whMMP-8 cleaves bovine collagen I only at a single specific site, as already reported by many others (Mallya, S. K., Mookhtiar, K. A., Gao, Y., Brew, K., Dioszegi, M., Birkedal-Hansen, H., and van Wart, H. E. (1990) Biochemistry 29, 10628-10634; Knauper, V., Osthues, A., DeClerk, Y. A., Langley, K. A, Blaser, J., and Tschesche, H. (1993) Biochem. J. 291, 847854; Marini, S., Fasciglione, G. F., De Sanctis, G., D'Alessio, S., Politi, V., and Coletta, M. (2000) J. Biol. Chem. 275, 18657-18663), whereas the catalytic domain lacks this specificity and cleaves the collagen molecule at multiple sites. Furthermore, a meaningful difference is observed for the cleavage features displayed by two forms of the catalytic domain, which differ for the N terminus resulting from the activation process (i.e. the former Met(80)of the proenzyme (MetMMP-8) and the former Phe(79) of the proenzyme (PheMMP-8)). Thus, the PheMMP-8 species is characterized by a much faster k(cat)/K-m, fully attributable to a lower K-m, suggesting that the conformation of the catalytic domain, induced by the insertion of this N-terminal residue in a specific pocket (Reinemer, P., Grams, F., Huber, R., Kleine, T., Schnierer, S., Piper, M., Tschesche, H., and Bode, W. (1994) FEBS Lett. 338, 227-233), brings about a better, although less discriminatory, recognition process of cleavage site(s) on bovine collagen I.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; PoliFarma, I-00155 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy; Univ Bielefeld, Dept Biochem 1, D-33051 Bielefeld, Germany	University of Rome Tor Vergata; University of Camerino; University of Bielefeld	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.		Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022; Gioia, Magda/ABF-8909-2020; Marini, Stefano/B-1161-2012; Fasciglione, Giovanni Francesco/ABF-7738-2020; Danese, Silvio/ABH-9571-2020	Marini, Stefano/0000-0003-1299-6696; Danese, Silvio/0000-0001-7341-1351; COLETTA, Massimiliano/0000-0002-5489-9467; Gioia, Magda/0000-0003-0352-3547				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; BLASER J, 1991, EUR J BIOCHEM, V202, P1223, DOI 10.1111/j.1432-1033.1991.tb16494.x; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1995, STRUCTURE, V3, P527, DOI 10.1016/S0969-2126(01)00185-X; BORKAKOTI N, 1994, NAT STRUCT BIOL, V1, P106, DOI 10.1038/nsb0294-106; BRADFORD MM, 1975, ANAL BIOCHEM, V72, P241; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Cole AA, 1996, J BIOL CHEM, V271, P11023, DOI 10.1074/jbc.271.18.11023; Cole AA, 1995, ACTA ORTHOP SCAND, V66, P98, DOI 10.3109/17453679509157661; Farr M, 1999, BIOCHEMISTRY-US, V38, P7332, DOI 10.1021/bi982618f; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; HASTY KA, 1987, J BIOL CHEM, V262, P10048; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1993, BIOCHEM J, V291, P847; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; Marini S, 2000, J BIOL CHEM, V275, P18657, DOI 10.1074/jbc.M000283200; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; MOOKHTIAR KA, 1990, BIOCHEMISTRY-US, V29, P10620, DOI 10.1021/bi00499a007; MURPHY G, 1977, BIOCHEM J, V162, P195, DOI 10.1042/bj1620195; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; TSCHESCHE H, 1995, METHOD ENZYMOL, V248, P431; Wess TJ, 1998, J MOL BIOL, V275, P255, DOI 10.1006/jmbi.1997.1449	35	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23123	23130		10.1074/jbc.M110873200	http://dx.doi.org/10.1074/jbc.M110873200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11953425	hybrid			2022-12-25	WOS:000176475700005
J	Lu, HS; Forbes, RA; Verma, A				Lu, HS; Forbes, RA; Verma, A			Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; HIGH LACTATE LEVELS; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GLUCOSE-METABOLISM; CERVICAL-CANCER; HUMAN GLIOMAS; TUMOR-CELLS; HIF-ALPHA; EXPRESSION	Cancer cells display high rates of aerobic glycolysis, a phenomenon known historically as the Warburg effect. Lactate and pyruvate, the end products of glycolysis, are highly produced by cancer cells even in the presence of oxygen. Hypoxia-induced gene expression in cancer cells has been linked to malignant transformation. Here we provide evidence that lactate and pyruvate regulate hypoxia-inducible gene expression independently of hypoxia by stimulating the accumulation of hypoxia-inducible Factor 1alpha (HIF-1alpha). In human gliomas and other cancer cell lines, the accumulation of HIF-1a protein under aerobic conditions requires the metabolism of glucose to pyruvate that prevents the aerobic degradation of HIF-1a protein, activates HIF-1 DNA binding activity, and enhances the expression of several HIF-1-activated genes including erythropoietin, vascular endothelial growth factor, glucose transporter 3, and aldolase A. Our findings support a novel role for pyruvate in metabolic signaling and suggest a mechanism by which high rates of aerobic glycolysis can promote the malignant transformation and survival of cancer cells.	Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Verma, A (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	averma@usuhs.mil		Verma, Ajay/0000-0001-7715-0443	NINDS NIH HHS [NS-37814] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037814] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acs G, 2001, CANCER RES, V61, P3561; Akakura N, 2001, CANCER RES, V61, P6548; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8; Birner P, 2000, CANCER RES, V60, P4693; Blagosklonny MV, 2001, INT J ONCOL, V19, P257; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Canesi L, 1999, GEN COMP ENDOCR, V116, P241, DOI 10.1006/gcen.1999.7366; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DOMINGUEZ JE, 1987, METAB BRAIN DIS, V2, P17, DOI 10.1007/BF00999506; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GALARRAGA J, 1986, METAB BRAIN DIS, V1, P279, DOI 10.1007/BF00999357; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lee MS, 2001, CANCER RES, V61, P3290; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; NEWSHOLME EA, 1991, ADV ENZYME REGUL, V31, P225, DOI 10.1016/0065-2571(91)90015-E; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PARADIES G, 1983, CANCER RES, V43, P5068; Richard DE, 2000, J BIOL CHEM, V275, P26765; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Van Veelen C W, 1988, Br J Neurosurg, V2, P257, DOI 10.3109/02688698808992677; Varma SD, 1997, MOL CELL BIOCHEM, V171, P23, DOI 10.1023/A:1006846501081; Walenta S, 1997, AM J PATHOL, V150, P409; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	41	589	623	1	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23111	23115		10.1074/jbc.M202487200	http://dx.doi.org/10.1074/jbc.M202487200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11943784	hybrid			2022-12-25	WOS:000176475700003
J	Stieglitz, KA; Johnson, KA; Yang, HY; Roberts, MF; Seaton, BA; Head, JF; Stec, B				Stieglitz, KA; Johnson, KA; Yang, HY; Roberts, MF; Seaton, BA; Head, JF; Stec, B			Crystal structure of a dual activity IMPase/FBPase (AF2372) from Archaeoglobus fulgidus - The story of a mobile loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 1-PHOSPHATASE; MYOINOSITOL MONOPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; GENOMIC STRUCTURE; LITHIUM; ENZYME; MECHANISM; CLONING; GENE; FRUCTOSE-1,6-BISPHOSPHATASE	Several hyperthermophilic organisms contain an unusual phosphatase that has dual activity toward inositol monophosphates and fructose 1,6-bisphosphate. The structure of the second member of this family, an FBPase/IMPase from Archaeoglobus fulgidus (AF2372), has been solved. This enzyme shares many kinetic and structural similarities with that of a previously solved enzyme from Methanococcus jannaschii (MJ0109). It also shows some kinetic differences in divalent metal ion binding as well as structural variations at the dimer interface that correlate with decreased thermal stability. The availability of different crystal forms allowed us to investigate the effect of the presence of ligands on the conformation of a mobile catalytic loop independently of the crystal packing. This conformational variability in AF2372 is compared with that observed in other members of this structural family that are sensitive or insensitive to submillimolar concentrations of Li+. This analysis provides support for the previously proposed mechanism of catalysis involving three metal ions. A direct correlation of the loop conformation with strength of Li+ inhibition provides a useful system of classification for this extended family of enzymes.	Rice Univ, WM Keck Ctr Computat Biol, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Rice University; Boston College; Boston University	Stec, B (corresponding author), Rice Univ, WM Keck Ctr Computat Biol, Dept Biochem & Cell Biol, Houston, TX 77005 USA.			Stec, Boguslaw/0000-0002-8696-0349; Stieglitz, Kimberly/0000-0001-6086-3682; Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709	NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER; NLM NIH HHS [2T15LM07093] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Albert A, 2000, J MOL BIOL, V295, P927, DOI 10.1006/jmbi.1999.3408; Atack JR, 1996, BRAIN RES REV, V22, P183; ATACK JR, 1995, FEBS LETT, V361, P1, DOI 10.1016/0014-5793(95)00063-F; BONE R, 1994, BIOCHEMISTRY-US, V33, P9468, DOI 10.1021/bi00198a012; BRUNGER AT, 1992, X PLOR VERSION 3 1; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; Chen LJ, 1999, APPL ENVIRON MICROB, V65, P4559; Chen LJ, 1998, APPL ENVIRON MICROB, V64, P2609; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; CHOE YZ, 1998, BIOCHEMISTRY-US, V33, P11441; INHORN RC, 1988, J BIOL CHEM, V263, P14559; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Johnson KA, 2001, BIOCHEMISTRY-US, V40, P618, DOI 10.1021/bi0016422; Jones TA, 1994, 1 MAP FINAL MODEL, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lopez-Corcuera B, 2001, J BIOL CHEM, V276, P43463, DOI 10.1074/jbc.M107438200; Lopez-Coronado JM, 1999, J BIOL CHEM, V274, P16034, DOI 10.1074/jbc.274.23.16034; Martin DD, 1999, APPL ENVIRON MICROB, V65, P1815; MCALLISTER G, 1992, BIOCHEM J, V284, P749, DOI 10.1042/bj2840749; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, OSCILLATION DATA RED, P56; Pappenberger G, 2001, NAT STRUCT BIOL, V8, P452, DOI 10.1038/87624; Patel S, 2002, J MOL BIOL, V315, P677, DOI 10.1006/jmbi.2001.5271; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sjoholt G, 2000, MOL PSYCHIATR, V5, P172, DOI 10.1038/sj.mp.4000681; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968; VADNAL R, 1995, NEUROPSYCHOPHARMACOL, V12, P277, DOI 10.1016/0893-133X(94)00088-H; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; YANG H, 2002, UNPUB; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; YORK JD, 1994, BIOCHEMISTRY-US, V33, P13164, DOI 10.1021/bi00249a002; Yoshikawa T, 2000, MOL PSYCHIATR, V5, P165, DOI 10.1038/sj.mp.4000688; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	38	43	45	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22863	22874		10.1074/jbc.M201042200	http://dx.doi.org/10.1074/jbc.M201042200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11940584	hybrid			2022-12-25	WOS:000176313600097
J	Weiss, KK; Bambara, RA; Kim, B				Weiss, KK; Bambara, RA; Kim, B			Mechanistic role of residue Gln(151) in error prone DNA synthesis by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) - Pre-steady state kinetic study of the Q151N HIV-1 RT mutant with increased fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I KLENOW; REPLICATION FIDELITY; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; O-HELIX; MUTAGENESIS; FRAGMENT; ETA; PROCESSIVITY; SELECTION	It has previously been reported that mutations in the Gln(151) residue of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) greatly enhance RT fidelity. In this study, we employed pre-steady state kinetic assays to elucidate the mechanistic role of residue Gln(151) in highly error prone DNA synthesis by HIV-1 RT. Using our Q151N high fidelity mutant, which is structurally altered in its ability to interact with the 3'-OH on the sugar moiety of the incoming deoxynuelcotide triphosphate (dNTP), we examined how this change in RT-dNTP interaction affects HIV-1 RT fidelity. First, we found the binding affinity (K-D) of wild type and Q151N RT proteins to different template/primers to be similar. These results indicate that the Gln(151) residue is not involved in the formation of the binary complex (RT.template/primer) during DNA polymerization. We also found that by changing residue 151 from a Gln-->Asn, the maximum rate of dNTP incorporation (k(pol)) for both correct and incorrect dNTPs was not affected. In contrast, the ability of the Q151N mutant to bind both correct and incorrect dNTPs (K-d) was diminished. The Q151N mutant was 120-fold less efficient at binding correct dNTP than wild type RT, and its decrease in binding was such that we were unable to measure the actual binding affinity of Q151N for incorrect dNTPs. Presumably, the fidelity increase observed during the steady state is explained by this defect in Q151N binding to incorrect dNTP. In wild type RT, residue Gln(151) is important for tight binding of incorrect dNTPs and may contribute to the low fidelity nature of HIV-1 RT. Since the Q151N mutation also alters RT binding to correct dNTPs, the wild type Gln(151) residue may play an important role in efficient binding of RT to correct dNTPs. Our findings suggest that residue Gln(151) is an important element for the execution of both highly error prone and efficient DNA synthesis by HIV-1 RT.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM29573, GM55500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Coffin J. M., 1990, VIROLOGY, P1437; Diamond TL, 2001, J BIOL CHEM, V276, P23624, DOI 10.1074/jbc.M102496200; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; FITZGIBBON JE, 1993, AIDS RES HUM RETROV, V9, P833, DOI 10.1089/aid.1993.9.833; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; VARATNIAN JP, 1991, J VIROL, V65, P1779; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	34	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22662	22669		10.1074/jbc.M200202200	http://dx.doi.org/10.1074/jbc.M200202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11927582	hybrid			2022-12-25	WOS:000176313600073
J	Balla, Z; Hoch, B; Karczewski, P; Blasig, IE				Balla, Z; Hoch, B; Karczewski, P; Blasig, IE			Calcium/calmodulin-dependent protein kinase II delta(2) and gamma isoforms regulate potassium currents of rat brain capillary endothelial cells under hypoxic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CURRENT; VASCULAR ENDOTHELIUM; SMOOTH-MUSCLE; ION CHANNELS; CALCIUM; EXPRESSION; CALMODULIN; MEMBRANE; HEART; ACTIVATION	Endothelial K+ and Ca2+ homeostasis plays an important role in the regulation of tissue supply and metabolism under normal and pathological conditions. However, the exact molecular mechanism of how Ca2+ is involved in the regulation of K+ homeostasis in capillary endothelial cells, especially under oxidative stress, is not clear. To reveal Ca2+-triggered pathways, which modulate K+ homeostasis, Ca2+/calmodulin-dependent protein kinase II and voltage-gated outward K+ currents were studied in rat brain capillary endothelial cells under hypoxia. Whole cell voltage-clamp measurements showed voltage-gated outward K+ current with transient and sustained components. mRNA and protein of Ca2+/calmodulin-dependent protein kinase II delta(2) and two gamma isoenzymes were identified. Activation of the isoforms (autophosphorylation) was typically achieved by the Ca2+ ionophore ionomycin, which was prevented by the Ca2+/calmodulin-dependent protein kinase II-specific inhibitor KN-93. Hypoxia resulted in autophosphorylation of the delta(2) and gamma(B) isoforms, augmented the current amplitude, increased the inactivation time constant, and decreased the extent of inactivation of the transient current. KN-93 prevented both the activation of the isoforms and the alterations in the K+ current characteristics. It is concluded that the activation of Ca2+/calmodulin-dependent protein kinase II decreases inactivation of the voltage-gated outward K+ current, thereby counteracting depolarization of the hypoxic endothelium.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Blasig, IE (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.							ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; BKAILY G, 1993, BRIT J PHARMACOL, V110, P519, DOI 10.1111/j.1476-5381.1993.tb13841.x; Blasig IE, 2001, MICROVASC RES, V62, P114, DOI 10.1006/mvre.2001.2318; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; BOSSU JL, 1992, FEBS LETT, V299, P239, DOI 10.1016/0014-5793(92)80123-X; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUSSE R, 1993, CIRCULATION, V87, P18; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; CANNELL MB, 1989, J PHYSIOL-LONDON, V419, P555, DOI 10.1113/jphysiol.1989.sp017886; DAUT J, 1994, J CARDIOVASC ELECTR, V5, P154, DOI 10.1111/j.1540-8167.1994.tb01156.x; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DITTRICH M, 1999, J PHYSL, V277, pH119; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; GIESE H, 1995, NEUROSCI LETT, V191, P169, DOI 10.1016/0304-3940(95)11584-J; Hagemann D, 1999, J CELL BIOCHEM, V74, P202; HE P, 1991, AM J PHYSIOL, V261, pH1246, DOI 10.1152/ajpheart.1991.261.4.H1246; Hoch B, 2000, J CELL BIOCHEM, V79, P293, DOI 10.1002/1097-4644(20001101)79:2<293::AID-JCB120>3.3.CO;2-H; Hoch B, 1998, J CELL BIOCHEM, V68, P259, DOI 10.1002/(SICI)1097-4644(19980201)68:2<259::AID-JCB12>3.0.CO;2-A; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Ikeda M, 1998, CELL CALCIUM, V24, P49, DOI 10.1016/S0143-4160(98)90088-4; Jovanovic S, 2001, INT J MOL MED, V7, P639; Jow F, 1999, J MEMBRANE BIOL, V167, P53, DOI 10.1007/s002329900471; KINGSTON RE, 1994, CURR PROTOCOLS MOL B, V1; Koh SD, 1999, J PHYSIOL-LONDON, V517, P75, DOI 10.1111/j.1469-7793.1999.0075z.x; Kwiatkowski AP, 2000, ARCH BIOCHEM BIOPHYS, V378, P377, DOI 10.1006/abbi.2000.1846; Langheinrich U, 1998, PFLUG ARCH EUR J PHY, V435, P435, DOI 10.1007/s004240050536; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; Ledoux J, 1999, J PHARMACOL EXP THER, V290, P1165; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; Mazzoni MC, 1995, INT J MICROCIRC, V15, P265, DOI 10.1159/000179028; Mertsch K, 1998, BIOCHEM PHARMACOL, V56, P945, DOI 10.1016/S0006-2952(98)00103-8; MERTSCH K, 1995, CELL MOL BIOL, V41, P243; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; POPP R, 1992, BIOCHIM BIOPHYS ACTA, V1108, P59, DOI 10.1016/0005-2736(92)90114-2; POPP R, 1992, J PHYSL, DOI UNSP 454435; Roeper J, 1997, J NEUROSCI, V17, P3379; Schroeter ML, 2001, NEUROREPORT, V12, P2513, DOI 10.1097/00001756-200108080-00045; SCHULMAN H, 1995, CURR OPIN NEUROBIOL, V5, P375, DOI 10.1016/0959-4388(95)80051-4; Singer HA, 1997, J BIOL CHEM, V272, P9393; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; TAKEDA K, 1987, PFLUG ARCH EUR J PHY, V410, P385, DOI 10.1007/BF00586515; Tessier S, 1999, CIRC RES, V85, P810, DOI 10.1161/01.RES.85.9.810; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; Uese K, 1999, J MOL CELL CARDIOL, V31, P1975, DOI 10.1006/jmcc.1999.1028; Walsh KB, 1998, AM J PHYSIOL-HEART C, V274, pH506, DOI 10.1152/ajpheart.1998.274.2.H506; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; WARD BJ, 1989, J MOL CELL CARDIOL, V12, P1337; WATSKY MA, 1992, J MEMBRANE BIOL, V128, P123	51	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21306	21314		10.1074/jbc.M200553200	http://dx.doi.org/10.1074/jbc.M200553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925434	hybrid			2022-12-25	WOS:000176286000026
J	Calderwood, DA; Yan, BX; de Pereda, JM; Alvarez, BG; Fujioka, Y; Liddington, RC; Ginsberg, MH				Calderwood, DA; Yan, BX; de Pereda, JM; Alvarez, BG; Fujioka, Y; Liddington, RC; Ginsberg, MH			The phosphotyrosine binding-like domain of talin activates Integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; CHICKEN-EMBRYO FIBROBLASTS; AMYLOID PRECURSOR PROTEIN; SURFACE-PLASMON RESONANCE; BETA-CYTOPLASMIC DOMAINS; FERM DOMAIN; PTB DOMAIN; TYROSINE PHOSPHORYLATION; STRUCTURAL BASIS; PHORBOL ESTER	Cellular regulation of the ligand binding affinity of integrin adhesion receptors (integrin activation) depends on the integrin beta cytoplasmic domains (tails). The head domain of talin binds to several integrin beta tails and activates integrins. This head domain contains a predicted FERM domain composed of three subdomains (F1, F2, and F3). An integrin-activating talin fragment was predicted to contain the F2 and F3 subdomains. Both isolated subdomains bound specifically to the integrin beta(3) tail. However, talin F3 bound the beta(3) tail with a 4-fold higher affinity than talin F2. Furthermore, expression of talin F3 (but not F2) in cells led to activation of integrin alpha(IIb)beta(3). A molecular model of talin F3 indicated that it resembles a phosphotyrosine-binding (PTB) domain. PTB domains recognize peptide ligands containing beta turns, often formed by NPXY motifs. NPX(Y/F) motifs are highly conserved in integrin beta tails, and mutations that disrupt this motif interfere with both integrin activation and talin binding. Thus, integrin binding to talin resembles the interactions of PTB domains with peptide ligands. These resemblances suggest that the activation of integrins requires the presence of a beta turn at NPX(Y/F) motifs conserved in integrin beta cytoplasmic domains.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, La Jolla, CA 92037 USA; Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol, CVN Rm 231,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	de Pereda, Jose M/AAE-5226-2022; Calderwood, David A/AAC-6954-2019; de Pereda, Jose M/F-1733-2010; Garcia-Alvarez, Begoña/K-1409-2016	de Pereda, Jose M/0000-0002-8912-6739; Calderwood, David A/0000-0002-0791-4142; de Pereda, Jose M/0000-0002-8912-6739; Garcia-Alvarez, Begoña/0000-0003-3774-1999	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728, HL-30915] Funding Source: Medline; NIAMS NIH HHS [AR-27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BECKERLE MC, 1990, CELL REGUL, V1, P227, DOI 10.1091/mbc.1.2.227; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P896; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; TAPLEY P, 1989, ONCOGENE, V4, P325; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; VRIEND G, 1990, J MOL GRAPHICS, V1, P99; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Xing BD, 2001, J BIOL CHEM, V276, P44373, DOI 10.1074/jbc.M108587200; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	48	305	312	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21749	21758		10.1074/jbc.M111996200	http://dx.doi.org/10.1074/jbc.M111996200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11932255	hybrid			2022-12-25	WOS:000176286000083
J	Weinberg, RB; Anderson, RA; Cook, VR; Emmanuel, F; Denefle, P; Tall, AR; Steinmetz, A				Weinberg, RB; Anderson, RA; Cook, VR; Emmanuel, F; Denefle, P; Tall, AR; Steinmetz, A			Interfacial exclusion pressure determines the ability of apolipoprotein A-IV truncation mutants to activate cholesterol ester transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; LIPID TRANSFER PROTEIN; HUMAN-PLASMA; TRANSGENIC MICE; ACYLTRANSFERASE; LECITHIN; EFFLUX; POLYMORPHISM; METABOLISM; BINDING	We used a panel of recombinant human apolipoprotein (apo) A-IV truncation mutants, in which pairs of 22-mer alpha-helices were sequentially deleted along the primary sequence, to examine the impact of protein structure and interfacial activity on the ability of apoA-IV to activate cholesterol ester transfer protein. Circular dichroism and fluorescence spectroscopy revealed that the secondary structure, conformation, and molecular stability of recombinant human apoA-lV were identical to the native protein. However, deletion of any of the a-helical domains in apoA-IV disrupted its tertiary structure and impaired its molecular stability. Surprisingly, determination of the water/phospholipid interfacial exclusion pressure of the apoA-lV truncation mutants revealed that, for most, deletion of amphipathic a-helical domains increased their affinity for phospholipid monolayers. All of the truncation mutants activated the transfer of fluorescent-labeled cholesterol esters between high and low density lipoproteins at a rate higher than native apoA-lV. There was a strong positive correlation (r = 0.790, P = 0.002) between the rate constant for cholesterol ester transfer and interfacial exclusion pressure. We conclude that molecular interfacial exclusion pressure, rather than specific helical domains, determines the degree to which apoA-lV, and likely other apolipoproteins, facilitate cholesterol ester transfer protein-mediated lipid exchange.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Aventis Pharma, Cardiovasc Dept, Gencell Div, F-94403 Vitry Sur Seine, France; Aventis Pharma, Funct Genom Ctr, F-94403 Vitry Sur Seine, France; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Univ Bonn, St Nikolaus Stiftshosp Teaching Hosp, D-56626 Andernach, Germany	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Columbia University; University of Bonn	Weinberg, RB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Tall, Alan/AAT-8528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL30897, R01 HL030897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER PJ, 1988, BIOCHEM J, V254, P179, DOI 10.1042/bj2540179; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BISGAIER CL, 1985, J LIPID RES, V26, P11; BISGAIER CL, 1987, J LIPID RES, V28, P693; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; Campos H, 1997, ARTERIOSCL THROM VAS, V17, P1074, DOI 10.1161/01.ATV.17.6.1074; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; EMMANUEL F, 1994, J BIOL CHEM, V269, P29883; Fournier N, 2000, ARTERIOSCL THROM VAS, V20, P1283, DOI 10.1161/01.ATV.20.5.1283; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1979, J CLIN INVEST, V64, P233, DOI 10.1172/JCI109444; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; GUYARDDANGREMONT V, 1994, J LIPID RES, V35, P982; HAYASHI H, 1990, J LIPID RES, V31, P1613; HESLER CB, 1987, J BIOL CHEM, V262, P2275; Kalogeris TJ, 1997, J NUTR, V127, pS537, DOI 10.1093/jn/127.3.537S; KAMBOH MI, 1992, HUM BIOL, V64, P605; KAMBOH MI, 1991, ATHEROSCLEROSIS, V91, P25, DOI 10.1016/0021-9150(91)90184-5; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1990, J LIPID RES, V31, P1569; LEFEVRE M, 1984, J LIPID RES, V25, P1603; MAIN LA, 1996, BIOCHIM BIOPHYS ACTA, V29, P17; MILNER TG, 1991, BIOCHIM BIOPHYS ACTA, V1082, P71, DOI 10.1016/0005-2760(91)90301-W; OHNISHI T, 1993, BIOCHEMISTRY-US, V32, P5029, DOI 10.1021/bi00070a009; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P6093, DOI 10.1021/bi00186a008; Ostos MA, 2000, ATHEROSCLEROSIS, V153, P209, DOI 10.1016/S0021-9150(00)00400-7; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; RYAN RO, 1990, J LIPID RES, V31, P1725; SEGREST JP, 1992, J LIPID RES, V33, P141; SHORE B, 1969, BIOCHEMISTRY-US, V8, P4510, DOI 10.1021/bi00839a043; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; TALL A, 1986, J CLIN INVEST, V77, P1163, DOI 10.1172/JCI112417; TALL AR, 1993, J LIPID RES, V34, P1255; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; VONECKARDSTEIN A, 1994, ARTERIOSCLER THROMB, V14, P1114, DOI 10.1161/01.ATV.14.7.1114; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1983, J LIPID RES, V24, P52; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; WEINBERG RB, 1985, J LIPID RES, V26, P26; WEINBERG RB, 1995, BIOCHEM BIOPH RES CO, V211, P840, DOI 10.1006/bbrc.1995.1888; WEINBERG RB, 1986, BIOCHEM BIOPH RES CO, V135, P756, DOI 10.1016/0006-291X(86)90993-9; Weinberg RB, 2002, CURR OPIN LIPIDOL, V13, P125, DOI 10.1097/00041433-200204000-00003; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; Weinberg RB, 1996, METHOD ENZYMOL, V263, P282; WEINBERG RB, 1990, J BIOL CHEM, V265, P8081; WEINBERG RB, 1987, BIOCHIM BIOPHYS ACTA, V918, P299, DOI 10.1016/0005-2760(87)90234-7; WEINBERG RB, 1988, BIOCHEMISTRY-US, V27, P1515, DOI 10.1021/bi00405a018; Weinberg RB, 2000, J LIPID RES, V41, P1419; Weinberg RB, 2000, J LIPID RES, V41, P1410; WEINBERG RB, 1992, 3 INT S PLASM HIGH D, P89; WEISGRABER KH, 1978, BIOCHEM BIOPH RES CO, V85, P287, DOI 10.1016/S0006-291X(78)80041-2	59	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21549	21553		10.1074/jbc.M202197200	http://dx.doi.org/10.1074/jbc.M202197200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11940599	hybrid			2022-12-25	WOS:000176286000057
J	Bradshaw, JM; Hudmon, A; Schulman, H				Bradshaw, JM; Hudmon, A; Schulman, H			Chemical quenched flow kinetic studies indicate an intraholoenzyme autophosphorylation mechanism for Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAM-KINASE; LIGHT-SCATTERING; ELECTRON-MICROSCOPY; SELF-ASSOCIATION; CALMODULIN; CA2+; NEURONS; ALPHA; CA2+-CALMODULIN; PHOSPHORYLATION	Autophosphorylation of alpha-Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) at Thr-286 generates Ca2+-independent activity that outlasts the initial Ca2+ stimulus. Previous studies suggested that this autophosphorylation occurs between subunits within each CaM kinase II holoenzyme. However, electron microscopy studies have questioned this mechanism because a large distance separates a kinase domain from its neighboring subunit. Moreover, the recently discovered ability of CaM kinase II holoenzymes to self-associate has raised questions about data interpretation in previous investigations of autophosphorylation. In this work, we characterize the mechanism of CaM kinase II autophosphorylation. To eliminate ambiguity arising from kinase aggregation, we used dynamic light scattering to establish the monodispersity of all enzyme solutions. We then found using chemical quenched flow kinetics that the autophosphorylation rate was independent of the CaM kinase II concentration, results corroborating intraholoenzyme activation. Experiments with a monomeric CaM kinase II showed that phosphorylation of this construct is intermolecular, supporting intersubunit phosphorylation within a holoenzyme. The autophosphorylation rate at 30 degreesC was similar to12 s(-1), more than 10-fold faster than past estimates. The ability of CaM kinase II to autophosphorylate through an intraholoenzyme, intersubunit mechanism is likely central to its functions of decoding Ca2+ spike frequency and providing a sustained response to Ca2+ signals.	Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Dept Neurobiol, 299 Campus Dr W,Fairchild Bldg, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM30179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030179, R37GM030179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dosemeci A, 2000, J NEUROSCI, V20, P3076, DOI 10.1523/JNEUROSCI.20-09-03076.2000; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gutfreund H., 1995, KINETICS LIFE SCI RE; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; Hudmon A, 1996, J BIOL CHEM, V271, P8800, DOI 10.1074/jbc.271.15.8800; Hudmon A, 2001, J NEUROCHEM, V76, P1364, DOI 10.1046/j.1471-4159.2001.00119.x; HUDMON A, 2002, IN PRESS ANN REV BIO, V71; IKEDA A, 1991, J BIOL CHEM, V266, P11582; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; Kolodziej SJ, 2000, J BIOL CHEM, V275, P14354, DOI 10.1074/jbc.275.19.14354; Kubota Y, 1999, NEUROCOMPUTING, V26-7, P29, DOI 10.1016/S0925-2312(99)00085-5; Kubota Y, 2001, J COMPUT NEUROSCI, V11, P263, DOI 10.1023/A:1013727331979; KURET J, 1985, J BIOL CHEM, V260, P6427; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; LOU LL, 1989, J NEUROSCI, V9, P2020; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Morris EP, 2001, J MOL BIOL, V308, P1, DOI 10.1006/jmbi.2001.4584; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; Okamoto H, 2000, BIOL CYBERN, V82, P35, DOI 10.1007/PL00007960; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; Schonfeld HJ, 1998, BIOCHEM SOC T, V26, P753, DOI 10.1042/bst0260753; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Singla SI, 2001, J BIOL CHEM, V276, P29353, DOI 10.1074/jbc.M101744200; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Tao-Cheng JH, 2001, NEUROSCIENCE, V106, P69, DOI 10.1016/S0306-4522(01)00262-7; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; WOODGETT JR, 1983, EUR J BIOCHEM, V136, P481, DOI 10.1111/j.1432-1033.1983.tb07766.x; Zhabotinsky AM, 2000, BIOPHYS J, V79, P2211, DOI 10.1016/S0006-3495(00)76469-1	46	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20991	20998		10.1074/jbc.M202154200	http://dx.doi.org/10.1074/jbc.M202154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11925447	hybrid			2022-12-25	WOS:000176204500114
J	He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS				He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS			Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway	ONCOGENE			English	Article						ER-stress; thapsigargin; death receptors; caspases; apoptosis; TRAIL	GENE-EXPRESSION; GENOTOXIC STRESS; KILLER/DR5 GENE; RELEASE; PROTEIN; INHIBITOR; LIGAND	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, has been shown to induce apoptosis. The molecular mechanisms of Ca2+ perturbation-induced apoptosis are not fully understood. In this study, we demonstrate for the first time that TG-mediated perturbations in Ca2+ homeostasis are coupled with activation of the death receptor 5 (DR5)-dependent apoptotic pathway in human cancer cells. TG selectively upregulated DR5 but had no effect on the expression 4 the other TRAIL receptor, DR4. TG also upregulated the expression of the DR5 ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), albeit in a cell-type specific manner. TG-induced apoptosis has been shown to be associated with activation of the mitochondrial pathway. We found that TG upregulation of DR5 and TRAIL was coupled with caspase 8 activation and Bid cleavage, suggesting that the TG-regulated DR5 pathway could be linked to the mitochondrial pathway. TG enhanced not only DR5 mRNA stability but also increased induction of the DR5 genomic promoter-reporter gene. The TG-induced increase in DR5 expression appeared to occur as a consequence of TG-induced endoplasmic reticulum (ER) Ca2+ pool depletion. Thus, we report our novel findings that ER Ca2+ pool depletion-induced apoptotic signals are mediated, at least in part, via a DR5-dependent apoptotic pathway and there appears to be a cross-talk between the death receptor and mitochondrial pathways.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Maryland, Sch Med, Dept Biochem, Greenebaum Canc Ctr,Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Penn, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Sch Med, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Pennsylvania	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER; NCI NIH HHS [CA89043] Funding Source: Medline; NHLBI NIH HHS [P01HL27867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; FURUYA Y, 1994, CANCER RES, V54, P6167; Griffith TS, 1999, J IMMUNOL, V162, P2597; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang Y, 2001, CANCER RES, V61, P6918; JACKMAN J, 1994, CANCER RES, V54, P5656; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ruth JH, 1999, AM J RESP CELL MOL, V21, P621, DOI 10.1165/ajrcmb.21.5.3694; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Wei MC, 2000, GENE DEV, V14, P2060; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	28	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2623	2633		10.1038/sj.onc.1205345	http://dx.doi.org/10.1038/sj.onc.1205345			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965535				2022-12-25	WOS:000174996500002
J	Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP				Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP			Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways	ONCOGENE			English	Article						growth factor; cytokine; signal transduction; cell proliferation	FACTOR SCATTER FACTOR; C-MET; TYROSINE KINASE; FACTOR ISOFORMS; FACTOR-RECEPTOR; MAP KINASE; CELLS; TRANSDUCTION; ACTIVATION; HGF/SF	Hepatocyte growth factor (HGF) regulates various physiological and developmental processes in concerti with other growth factors, cytokines and hormones. We examined interactions between cell signaling events elicited by HGF and the cytokine interleukin (IL)-4, in the IL-3-dependent murine myeloid cell line 32D transfected with the human HGF receptor, c-Met. HGF was a potent mitogen in these cells, and prevented apoptosis in response to IL-3 withdrawal. IL-4 showed modest anti-apoptotic activity, but no significant mitogenic activity. IL-4 synergistically enhanced HGF-stimulated DNA synthesis, whereas only additive prevention of apoptosis was observed. IL-4 did not enhance HGF-dependent tyrosine phosphorylation of c-Met or She. In contrast, HGF-stimulated activation of MAP kinases was enhanced by IL-4, suggesting that the IL-4 and HGF signaling pathways converge upstream of these events. Although phosphatidylinositol 3-kinase (PI3K) inhibitors diminished HGF-induced mitogenesis, antiapoptosis, and MAP kinase activation, IL-4 enhanced HGF signaling persisted even in the presence of these inhibitors. IL-4 enhancement of HGF signaling was partially blocked in 32D/c-Met cells treated with inhibitors of MEK1 or c-Src kinases, completely blocked by expression of a catalytically inactive mutant of Janus kinase 3 (Jak3), and increased in 32D/c,Met cells overexpressing STAT6. Our results suggest that the IL-4 and HGF pathways converge at multiple levels, and that IL-4-dependent Jak3 and STAT6 activities modulate signaling events independent of PI3K to enhance, HGF-dependent mitogenesis in myeloid cells, and possibly other common cellular targets.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Natl Inst Hlth, Bethesda, MD USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bottaro, DP (corresponding author), EntreMed Inc, Dept Cell & Mol Biol, Rockville, MD 20850 USA.	donb@entremed.com	Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balkovetz DF, 1999, INT REV CYTOL, V186, P225; BARDELLI A, 1992, ONCOGENE, V7, P1973; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Borset M, 1999, LEUKEMIA LYMPHOMA, V32, P249, DOI 10.3109/10428199909167385; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; DELANEY B, 1993, LIFE SCI, V53, pPL89, DOI 10.1016/0024-3205(93)90654-L; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOHDA E, 1995, LEUKEMIA LYMPHOMA, V19, P197; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassuneh MR, 1997, BLOOD, V89, P610, DOI 10.1182/blood.V89.2.610; HOON DSB, 1991, CANCER RES, V51, P5687; Iguchi T, 1999, STEM CELLS, V17, P82, DOI 10.1002/stem.170082; Ikehara S, 1996, LEUKEMIA LYMPHOMA, V23, P297, DOI 10.3109/10428199609054832; IKIZAWA K, 1994, J ALLERGY CLIN IMMUN, V94, P620, DOI 10.1016/0091-6749(94)90138-4; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KMIECIK TE, 1992, BLOOD, V80, P2454; Machide M, 1998, J NEUROCHEM, V71, P592; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MORISAKI T, 1992, CANCER RES, V52, P6059; MORISAKI T, 1994, CANCER RES, V54, P1113; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAUL WE, 1991, BLOOD, V77, P1859; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schaper F, 1997, FEBS LETT, V405, P99, DOI 10.1016/S0014-5793(97)00167-1; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SOON L, 1999, MOL CELL BIOL, V38, P16; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Streit ACE, 1997, CIBA F SYMP, V212, P155; Sunitha I, 1999, EXP CELL RES, V250, P86, DOI 10.1006/excr.1999.4550; TORIGOE T, 1992, BLOOD, V80, P617; Uchiyama A, 1996, J CELL BIOCHEM, V62, P443, DOI 10.1002/(SICI)1097-4644(19960915)62:4<443::AID-JCB2>3.3.CO;2-H; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Weimar IS, 1998, EXP HEMATOL, V26, P885; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yashiro M, 1996, INT J CANCER, V67, P289, DOI 10.1002/(SICI)1097-0215(19960717)67:2<289::AID-IJC22>3.0.CO;2-5; Yu CZ, 1998, STEM CELLS, V16, P66, DOI 10.1002/stem.160066; Zamorano J, 1996, J IMMUNOL, V157, P4926; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	61	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2201	2211		10.1038/sj.onc.1205289	http://dx.doi.org/10.1038/sj.onc.1205289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948403				2022-12-25	WOS:000174555300009
J	Krutovskikh, VA; Piccoli, C; Yamasaki, H				Krutovskikh, VA; Piccoli, C; Yamasaki, H			Gap junction intercellular communication propagates cell death in cancerous cells	ONCOGENE			English	Article						gap junctions; apoptosis; Connexin43	CONNEXIN GENES; CALCIUM; GROWTH; TUMORIGENICITY; LOCALIZATION; HEMICHANNELS; SUPPRESSION; INHIBITION; EXPRESSION; TUMORS	Gap junction intercellular communication (GJIC) or cell coupling has an important function in maintaining tissue homeostasis and is thus a critical factor in the life and death balance of cells. While the role of GJIC in cell growth regulation has been much studied, its involvement in apoptosis remains unclear. In this study we elucidated the possibility that cell death is propagated via gap junctions, employing the rat bladder carcinoma cell line BC31. BC31 cells proliferate quickly, are tumorigenic, and are well-coupled via gap junctions that contain the gap junction protein Connexin43 (Cx43). In addition, these cells are predisposed to spontaneous death by apoptosis, particularly upon achieving confluency. We found that many dying BC31 cells express Cx43 just as their non-apoptotic counterparts do. Furthermore, Cx43 in apoptotic cells could be functionally competent, supporting coupling of these cells with their non-apoptotic neighbors, and as a result, clusters of coordinately dying cells were observed. The role of Cx43 and GJIC in propagating cell death was shown by analysing clones of BC31 cells expressing a mutant of Cx43 that is a dominant negative inhibitor of GJIC, and by using beta-glycyrrhetinic acid to inhibit intrinsic cell coupling in BC31 cells: in both cases the formation of clusters of dying cells was abrogated, and the intensity of cell death was considerably decreased. These results suggest that GJIC spreads cell-killing signals initially generated by a single cell that spontaneously initiates apoptosis, into healthy surrounding cells, thus increasing the level of cell death. Treatment of BC31 cells with the sleep-inducing lipid Oleamide, which selectively restricts gap junction permeability to Ca2+ ions, did not abrogate coordinated cell death by clusters, indicating that Ca2+ ions are the most probable cell-killing signals spread through gap junctions.	Int Agcy Res Canc, Unit Gene Environm Interact, F-69372 Lyon, France; Kwansei Gakuin Univ, Nishinomiya, Hyogo 6628501, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Kwansei Gakuin University	Krutovskikh, VA (corresponding author), Int Agcy Res Canc, Unit Gene Environm Interact, 150 Cours Albert Thomas, F-69372 Lyon, France.	krutovskikh@iarc.fr						ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; Blanc EM, 1998, J NEUROCHEM, V70, P958; Budd SL, 1998, NAT NEUROSCI, V1, P431, DOI 10.1038/2147; CHIPMAN TK, 1995, HUM EXP TOXICOL, V14, P539; CORTINA ML, 1998, J NEUROSCI, V18, P2520; DAVIDSON JS, 1986, BIOCHEM BIOPH RES CO, V134, P29, DOI 10.1016/0006-291X(86)90522-X; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Estin D, 1999, NEUROSURGERY, V44, P361, DOI 10.1097/00006123-199902000-00068; FITZGERALD DJ, 1983, CANCER RES, V43, P3614; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; Guan XJ, 1996, MOL CARCINOGEN, V16, P157; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Jorgensen NR, 1997, J CELL BIOL, V139, P497, DOI 10.1083/jcb.139.2.497; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LOEWENSTEIN WR, 1992, SEMIN CELL BIOL, V2, P59; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Mehta P, 1999, DEV GENET, V24, P91, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<91::AID-DVG10>3.0.CO;2-#; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Pfahnl A, 1999, PFLUG ARCH EUR J PHY, V437, P345, DOI 10.1007/s004240050788; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Reznikov K, 2000, FASEB J, V14, P1754, DOI 10.1096/fj.99-0890com; WOLSZON LR, 1994, J NEUROSCI, V14, P3437; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang ZQ, 1998, CARCINOGENESIS, V19, P1889, DOI 10.1093/carcin/19.11.1889	31	170	183	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1989	1999		10.1038/sj.onc.1205187	http://dx.doi.org/10.1038/sj.onc.1205187			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960371				2022-12-25	WOS:000174827000005
J	Rehm, M; Dussmann, H; Janicke, RU; Tavare, JM; Kogel, D; Prehn, JHM				Rehm, M; Dussmann, H; Janicke, RU; Tavare, JM; Kogel, D; Prehn, JHM			Single-cell fluorescence resonance energy transfer analysis demonstrates that caspase activation during apoptosis is a rapid process - Role of caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DEPENDENT PROTEIN-KINASE; DRUG-INDUCED APOPTOSIS; MITOCHONDRIAL DEPOLARIZATION; APAF-1 APOPTOSOME; STRUCTURAL BASIS; ENDONUCLEASE-G; DEATH; CLEAVAGE; PROCASPASE-9	Activation of effector caspases is considered to be the final step in many apoptosis pathways. We transfected HeLa cells with a recombinant caspase substrate composed of cyan and yellow fluorescent protein and a linker peptide containing the caspase cleavage sequence DEVD, and we examined the cleavage kinetics at the single-cell level by fluorescence resonance energy transfer (FRET) analysis. Caspase activation in response to tumor necrosis factor-alpha, staurosporine, or etoposide resulted in cleavage of the linker peptide and subsequent disruption of the FRET signal. The time to caspase activation varied among individual cells, depending on the type of treatment and concentration used. However, once initiated, disruption of the FRET signal was always rapid (less than or equal to15 min) and largely independent of these parameters. In contrast, FRET probe cleavage was significantly slower in the caspase-3-deficient MCF-7 cells, particularly at low concentrations of the pro-apoptotic agents. Under these conditions, MCF-7 cells required up to 90 min for the FRET probe cleavage, whereas MCF-7/Casp-3 cells displayed rapid cleavage kinetics. Interestingly, we could still observe comparable cell death rates in MCF-7 and MCF-7/Casp-3 cells. Our results suggest that caspase activation during apoptosis occurs in an "all or nothing" fashion. Caspase-3 is required for rapid cleavage kinetics when the onset of apoptosis is slow, suggesting the existence of caspase-3-dependent feedback loops.	Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res, D-48149 Munster, Germany; Univ Munster, Dept Expt Dermatol, Div Cell Biol & Immunol, D-48149 Munster, Germany; Univ Munster, Dept Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Munster; University of Munster; University of Munster; University of Bristol	Prehn, JHM (corresponding author), Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res, Rontgenstr 21, D-48149 Munster, Germany.	prehn@uni-muenster.de	Rehm, Markus/C-3398-2012; Prehn, Jochen HM/A-3928-2010	Rehm, Markus/0000-0001-6149-9261; Prehn, Jochen HM/0000-0003-3479-7794; Kogel, Donat/0000-0003-1209-0210; Dussmann, Heiko/0000-0002-3582-8057				Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Blanc C, 2000, CANCER RES, V60, P4386; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luetjens CM, 2001, MOL PHARMACOL, V60, P1008, DOI 10.1124/mol.60.5.1008; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P38, DOI 10.1038/sj.cdd.4400800; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tyas L, 2000, EMBO REP, V1, P266, DOI 10.1093/embo-reports/kvd050; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang XD, 2001, CANCER RES, V61, P7339; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	70	251	258	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24506	24514		10.1074/jbc.M110789200	http://dx.doi.org/10.1074/jbc.M110789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11964393	hybrid			2022-12-25	WOS:000176611800071
J	Cortajarena, AL; Goni, FM; Ostolaza, H				Cortajarena, AL; Goni, FM; Ostolaza, H			His-859 is an essential residue for the activity and pH dependence of Escherichia coli RTX toxin alpha-hemolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TOXIN; SELF-AGGREGATION; BINDING; CALCIUM; CONFORMATION; ERYTHROCYTES; PURIFICATION; MEMBRANES; INSERTION; MECHANISM	Escherichia coli a-hemolysin (HlyA) is a toxin protein that, in common with other members of the RTX family, contains a calcium-binding domain consisting of a number of Gly- and Asp-rich nonapeptides (17 in this case) repeated in tandem. Amino acid number 6 in these nonapeptides is almost invariably Asp, and occasionally Asn, but HlyA contains a His residue (number 859 in the chain) in position 6 of the last-but-one nonapeptide. HlyA mutants have been prepared, by site-directed mutagenesis, in which His-859 has been replaced by an Asn (H859N) or by Asp (H859D). HlyA exists in aqueous media in an aggregate-monomer equilibrium, but only the monomer containing bound Ca2+ (HlyA-Ca) appears to be competent to achieve target membrane insertion and subsequent lysis. In mutant H859N, equilibrium appears to be shifted toward the aggregate, therefore the protein does not exchange Ca2+ with the aqueous environment, no HlyA-Ca monomers are detected, and the protein lacks any membrane lytic activity. Mutant H859D in turn is almost indistinguishable from the wild-type regarding its calcium binding and membrane lytic activity, however, it differs significantly in its pH dependence. Wild-type HlyA activity decreases sigmoidally with pH, following rather closely the protonation curve of a His residue (apparent pK(a) approximate to 6.5). With mutant H859D activity decreases almost linearly with pH and to a smaller extent. It can be concluded that His-859 plays a critical role in several aspects of HlyA activity, namely self-aggregation properties, calcium binding, hemolysis, and pH dependence.	Univ Basque Country, CSIC, UPV EHU, Bilbao 48080, Spain; Univ Basque Country, Dept Bioquim, Bilbao 48080, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country, CSIC, UPV EHU, Unidad Biofis, Bilbao 48080, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Bakas L, 1998, BBA-BIOMEMBRANES, V1368, P225, DOI 10.1016/S0005-2736(97)00181-8; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BOEHM DF, 1990, INFECT IMMUN, V58, P1959, DOI 10.1128/IAI.58.6.1959-1964.1990; COOTE JG, 1996, REV MED MICROBIOL, V7, P53, DOI [10.1097/00013542-199601000-00006, DOI 10.1097/00013542-199601000-00006]; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P285, DOI 10.1021/bi00350a001; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; GONZALEZCARRERO MI, 1985, MOL GEN GENET, V199, P106, DOI 10.1007/BF00327518; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; OSTOLAZA H, 1995, FEBS LETT, V371, P303, DOI 10.1016/0014-5793(95)00927-2; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; OSTOLAZA H, 1997, J MEMBRANE BIOL, V158, P1; Pereira FB, 1997, BIOPHYS J, V73, P1977, DOI 10.1016/S0006-3495(97)78228-6; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; WLECH RA, 2001, CURR OPIN MICROBIOL, V257, P85; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3; ZABALA JC, 1984, MOL GEN GENET, V197, P90, DOI 10.1007/BF00327927	23	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23223	23229		10.1074/jbc.M202028200	http://dx.doi.org/10.1074/jbc.M202028200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11940597	hybrid			2022-12-25	WOS:000176475700018
J	Poock, SR; Leach, ER; Moir, JWB; Cole, JA; Richardson, DJ				Poock, SR; Leach, ER; Moir, JWB; Cole, JA; Richardson, DJ			Respiratory detoxification of nitric oxide by the cytochrome c nitrite reductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; GENE-EXPRESSION; FLAVOHEMOGLOBIN; NITRATE; BACTERIA; BINDING; IDENTIFICATION; INTERMEDIATE; DIOXYGENASE; CATALYZES	Nitric oxide is a key element in host defense against invasive pathogens. The periplasmic cytochrome c nitrite reductase (NrfA) of Escherichia coli catalyzes the respiratory reduction of nitrite, but in vitro studies have shown that it can also reduce nitric oxide. The physiological significance of the latter reaction in vivo has never been assessed. In this study the reduction of nitric oxide by Escherichia coli was measured in strains active or deficient in periplasmic nitrite reduction. Nrf(+) cells, harvested from cultures grown anaerobically, possessed a nitric-oxide reductase activity with physiological electron donation of 60 nmol min(-1) mg dry wt(-1), and an in vivo turnover number of NrfA of 390 NO. s(-1) was calculated. Nitric-oxide reductase activity could not be detected in Nrf(-) strains. Comparison of the anaerobic growth of Nrf(+) and Nrf(-) strains revealed a higher sensitivity to nitric oxide in the NrfA(-) strains. A higher sensitivity to the nitrosating agent S-nitroso-N-acetyl penicillamine (SNAP) was also observed in agar plate disk-diffusion assays. Oxygen respiration by E. coli was also more sensitive to nitric oxide in the Nrf(-) strains compared with the Nrf(+) parent strain. The results demonstrate that active periplasmic cytochrome c nitrite reductase can confer the capacity for nitric oxide reduction and detoxification on E. coli. Genomic analysis of many pathogenic enteric bacteria reveals the presence of nrf genes. The present study raises the possibility that this reflects an important role for the cytochrome c nitrite reductase in nitric oxide management in oxygen-limited environments.	Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of East Anglia; University of Birmingham; University of Sheffield	Richardson, DJ (corresponding author), Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.		Richardson, David J/E-2275-2011	Moir, James/0000-0003-2972-5235				Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BELL LC, 1992, J GEN MICROBIOL, V138, P437, DOI 10.1099/00221287-138-3-437; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; Contreras I, 1997, MICROBIOL-UK, V143, P2665, DOI 10.1099/00221287-143-8-2665; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gronberg KLC, 1999, BIOCHEMISTRY-US, V38, P13780, DOI 10.1021/bi9916426; HARBORNE NR, 1992, MOL MICROBIOL, V6, P2805, DOI 10.1111/j.1365-2958.1992.tb01460.x; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hendriks J, 1998, BIOCHEMISTRY-US, V37, P13102, DOI 10.1021/bi980943x; Kim SO, 1999, FEBS LETT, V445, P389, DOI 10.1016/S0014-5793(99)00157-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POPE NR, 1984, J GEN MICROBIOL, V130, P1279; Potter L, 2001, ADV MICROB PHYSIOL, V45, P51, DOI 10.1016/S0065-2911(01)45002-8; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; Richardson DJ, 1999, CURR OPIN CHEM BIOL, V3, P207, DOI 10.1016/S1367-5931(99)80034-9; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Watmough NJ, 1999, BBA-BIOENERGETICS, V1411, P456, DOI 10.1016/S0005-2728(99)00032-8	32	156	161	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23664	23669		10.1074/jbc.M200731200	http://dx.doi.org/10.1074/jbc.M200731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11960983	hybrid			2022-12-25	WOS:000176475700074
J	Gevrey, JC; Cordier-Bussat, M; Nemoz-Gaillard, E; Chayvialle, JA; Abello, J				Gevrey, JC; Cordier-Bussat, M; Nemoz-Gaillard, E; Chayvialle, JA; Abello, J			Co-requirement of cyclic AMP- and calcium-dependent protein kinases for transcriptional activation of cholecystokinin gene by protein hydrolysates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; PROGLUCAGON GENE; PEPTONES STIMULATE; STC-1 CELLS; RESPONSIVE ELEMENT; MAP KINASE; CROSS-TALK; EXPRESSION; GLUCOSE; CREB	Little is known about the mechanisms by which protein-derived nutrients regulate hormone gene expression in the intestine. We have previously reported that protein hydrolysates (i.e. peptones), which are representative of the protein fraction in the lumen, increased cholecystokinin (CCK) gene transcription in the STC-1 enteroendocrine cell line. In the present work, we examined the intracellular events evoked by peptones to stimulate CCK gene transcription. In STC-1 cells, peptones stimulated cyclic AMP production and protein kinase A (PKA) activity. This was associated with a nuclear translocation of the PKA catalytic subunit and with a PKA-dependent phosphorylation of the CRE-binding protein (CREB) at Ser(133). Using transient transfection experiments and reporter luciferase assays, we show that peptone-stimulated transcriptional activity of the CCK gene promoter was significantly decreased when the PKA pathway was inhibited. Furthermore, the intracellular calcium chelator 1,2-bis-(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-tetra(acetoxymethyl) ester completely inhibited peptone-induced stimulation of the CCK gene promoter activity, phosphorylation of CREB, and PKA activity. Peptones increased, in a calcium-dependent manner, the phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and the MEK inhibitor PD98059 decreased the peptone-induced stimulation of CCK gene promoter activity. This stimulation was also reduced by 30% in the presence of the calcium/calmodulin-dependent protein kinase (CaMK) inhibitor KN-93. Total inhibition was obtained when the PKA, ERK, and CaMK pathways were simultaneously blocked with appropriate inhibitors to these pathways. These results demonstrate the simultaneous involvement of cAMP- and calcium-dependent protein kinases in the stimulation of intestinal CCK gene transcription by protein-derived nutrients.	Hop Edouard Herriot, INSERM, U45, F-69437 Lyon 3, France; Hop Edouard Herriot, IFR 62, F-69437 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Abello, J (corresponding author), Hop Edouard Herriot, INSERM, U45, Pavillon H, F-69437 Lyon 3, France.		Cordier-Bussat, Martine/G-4019-2014					Barsacchi R, 1999, FEBS LETT, V461, P273, DOI 10.1016/S0014-5793(99)01468-4; BENTOUIMOU N, 1995, GASTROEN CLIN BIOL, V19, P659; Bernard C, 2001, ENDOCRINOLOGY, V142, P721, DOI 10.1210/en.142.2.721; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Buchan AMJ, 1999, AM J PHYSIOL-GASTR L, V277, pG1103, DOI 10.1152/ajpgi.1999.277.6.G1103; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Cordier-Bussat M, 1998, DIABETES, V47, P1038, DOI 10.2337/diabetes.47.7.1038; CordierBussat M, 1997, ENDOCRINOLOGY, V138, P1137, DOI 10.1210/en.138.3.1137; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; CUBER JC, 1992, J PHYSIOL-LONDON, V449, P37, DOI 10.1113/jphysiol.1992.sp019073; CUBER JC, 1990, AM J PHYSIOL, V259, pG191, DOI 10.1152/ajpgi.1990.259.2.G191; Deavall DG, 2000, AM J PHYSIOL-GASTR L, V279, pG605, DOI 10.1152/ajpgi.2000.279.3.G605; DRUCKER DJ, 1989, P NATL ACAD SCI USA, V86, P3953, DOI 10.1073/pnas.86.11.3953; DRUCKER DJ, 1994, MOL ENDOCRINOL, V8, P1646, DOI 10.1210/me.8.12.1646; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Garrel G, 1997, ENDOCRINOLOGY, V138, P2259, DOI 10.1210/en.138.6.2259; Gevrey JC, 2001, FEBS LETT, V503, P19, DOI 10.1016/S0014-5793(01)02683-7; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Groneberg DA, 2001, AM J PHYSIOL-GASTR L, V281, pG697, DOI 10.1152/ajpgi.2001.281.3.G697; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hansen TV, 1999, MOL ENDOCRINOL, V13, P466, DOI 10.1210/me.13.3.466; HAUN RS, 1990, J BIOL CHEM, V265, P15455; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; LIDDLE RA, 1988, J CLIN INVEST, V81, P2015, DOI 10.1172/JCI113552; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Murai A, 2000, EUR J PHARMACOL, V394, P27, DOI 10.1016/S0014-2999(00)00076-5; Nemoz-Gaillard E, 1998, ENDOCRINOLOGY, V139, P932, DOI 10.1210/en.139.3.932; Pursiheimo JP, 2000, P NATL ACAD SCI USA, V97, P168, DOI 10.1073/pnas.97.1.168; Reimer RA, 1997, J NUTR, V127, P1923, DOI 10.1093/jn/127.10.1923; RINDI G, 1990, AM J PATHOL, V136, P1349; Roche E, 1999, DIABETES, V48, P2007, DOI 10.2337/diabetes.48.10.2007; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHIOTANI A, 1995, AM J PHYSIOL-GASTR L, V269, pG458, DOI 10.1152/ajpgi.1995.269.3.G458; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; TSENG CC, 1994, AM J PHYSIOL, V266, pG887, DOI 10.1152/ajpgi.1994.266.5.G887; Turgeman H, 1998, FEBS LETT, V428, P183, DOI 10.1016/S0014-5793(98)00513-4; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; WALSH JH, 1994, PHYSL GASTROINTESTIN, P49; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023	49	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22407	22413		10.1074/jbc.M201624200	http://dx.doi.org/10.1074/jbc.M201624200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11950843	hybrid			2022-12-25	WOS:000176313600039
J	Shuttleworth, TL; Wilson, MD; Wicklow, BA; Wilkins, JA; Triggs-Raine, BL				Shuttleworth, TL; Wilson, MD; Wicklow, BA; Wilkins, JA; Triggs-Raine, BL			Characterization of the murine hyaluronidase gene region reveals complex organization and cotranscription of Hyal1 with downstream genes, Fus2 and Hyal3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CHROMOSOME 3P21.3; TUMOR-SUPPRESSOR GENE; EXPRESSION ANALYSIS; GENOMIC STRUCTURE; PLASMA-MEMBRANE; CANDIDATE; PROTEIN; SPERM; MOUSE; MUTATIONS	Hyaluronidases are required for the breakdown of hyaluronan (HA), an abundant component of the extracellular matrix of vertebrate tissues. Multiple hyaluronidase genes have been identified, but the only clue to the function of their products has come from the identification of hyaluronidase 1 deficiency in a single patient,with a mild clinical phenotype. As a first step in the generation of mice with hyaluronidase deficiency, we have used experimental and bioinformatic approaches to examine the organization of the mouse chromosome 9 region containing, in order, Hyal2, Hyal1, and Hyal3. This region was found to be complex, with Fus2 partially embedded in Hyal3, and Ifrd2 immediately downstream from Hyal3. The Hyal genes were all found to have four exons, and exons 2-4 exhibited the highest sequence conservation. Northern blot analysis demonstrated that the tissue expression profile for Hyal1 was similar in mice and humans, but a greater number of transcripts was detected in mouse tissues. Hyal3 was expressed more broadly in mice compared with humans and again exhibited additional transcripts. Reverse transcription-PCR demonstrated that some of the larger Hyal1 transcripts, seen on the Northern blot, were the result of cotranscription of Hyal1 with downstream genes, Fus2 or Hyal3. In vitro transcription/translation of one of the high abundance bicistronic transcripts produced Hyal1, suggesting that Hyal1 could be produced from all of the bicistronic transcripts. Characterization of the region including mouse Hyal1 and Hyal3 revealed complex organization and transcription that must be considered in the development and interpretation of mouse models involving genes in this region.	Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med & Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Victoria, Dept Biol, Ctr Environm Hlth, Victoria, BC V8W 3N5, Canada	University of Manitoba; University of Manitoba; University of Victoria	Triggs-Raine, BL (corresponding author), Univ Manitoba, Dept Biochem & Med Genet, 770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.	traine@ms.umanitoba.ca	Wilson, Michael D/K-6294-2014; Triggs-Raine, Barbara/AAF-6209-2021	Wilson, Michael D/0000-0002-4015-3066; Triggs-Raine, Barbara/0000-0003-4719-6779				BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka TB, 1998, GENOMICS, V48, P63, DOI 10.1006/geno.1997.5158; Deng XN, 1997, MAMM GENOME, V8, P94, DOI 10.1007/s003359900365; FRASER JRE, 1997, J INTERN MED, V242, P23; Frost GI, 1997, BIOCHEM BIOPH RES CO, V236, P10, DOI 10.1006/bbrc.1997.6773; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; Gray TA, 1999, P NATL ACAD SCI USA, V96, P5616, DOI 10.1073/pnas.96.10.5616; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JONES MH, 1995, GENOMICS, V29, P796, DOI 10.1006/geno.1995.9931; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lerman MI, 2000, CANCER RES, V60, P6116; Li MW, 1997, MOL REPROD DEV, V48, P356; LIN Y, 1994, J CELL BIOL, V125, P1157, DOI 10.1083/jcb.125.5.1157; MCDONALD JN, 1995, J PHYSIOL-LONDON, V485, P179, DOI 10.1113/jphysiol.1995.sp020722; Natowicz MR, 1996, NEW ENGL J MED, V335, P1029, DOI 10.1056/NEJM199610033351405; Osoegawa K, 2000, GENOME RES, V10, P116; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Ritchie H, 1997, BIOCHEM BIOPH RES CO, V231, P425, DOI 10.1006/bbrc.1997.6126; SAMBROOK J, 1989, MOL CLONING LAB MANU, P779; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Strobl B, 1998, GENOMICS, V53, P214, DOI 10.1006/geno.1998.5472; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296; Wei MH, 1996, CANCER RES, V56, P1487; Zheng Y, 1999, MOL REPROD DEV, V54, P8, DOI 10.1002/(SICI)1098-2795(199909)54:1&lt;8::AID-MRD2&gt;3.0.CO;2-D	33	27	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					23008	23018		10.1074/jbc.M108991200	http://dx.doi.org/10.1074/jbc.M108991200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11929860	hybrid			2022-12-25	WOS:000176313600116
J	Ten Hagen, KG; Tran, DT				Ten Hagen, KG; Tran, DT			A UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase is essential for viability in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; ALPHA-D-GALACTOSAMINE; CDNA CLONING; MOLECULAR-CLONING; EXPRESSION; GLYCOSYLATION; HOMOLOG; FAMILY; GENE; N-ACETYLGALACTOSAMINYLTRANSFERASE-T3	We report the first demonstration that the activity of a member of the LTDP-GalNAc:polypeptide N-acetylgaIactosaminyltransferase gene family is necessary for viability in Drosophila melanogaster. Expression of the wild-type recombinant pgant35A gene in COS7 cells resulted in in vitro activity against peptide and glycopeptide substrates, demonstrating that this gene encodes a biochemically active transferase. Previous mutagenesis studies identified recessive lethal mutations that were rescued by a genomic fragment containing the pgant35A gene; however, the presence of additional open reading frames within this fragment left open the possibility that another gene was responsible for rescue of the observed lethality. Here, we have determined the molecular nature of the mutations in three independent mutant alleles. Two of the mutant alleles contain premature stop codons within the coding region of pgant35A. The third mutant contains an arginine to tryptophan amino acid change, which, when expressed in COS7 cells, resulted in a dramatic reduction of transferase activity in vitro. PCR amplification of this gene from Drosophila cDNA panels and Northern analysis revealed that it is expressed throughout embryonic, larval, and pupal stages as well as in adult males and females. This study provides the first direct evidence for the involvement of a member of this conserved multigene family in eukaryotic development and viability.	NIDDK, Sect Biol Chem, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ten Hagen, KG (corresponding author), NIDDK, Sect Biol Chem, NIH, 9000 Rockville Pike,Bldg 50,Rm 4120, Bethesda, MD 20892 USA.	Kelly.Tenhagen@nih.gov						ALBONE EF, 1994, J BIOL CHEM, V269, P16845; Ashburner M, 1999, GENETICS, V153, P179; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Casso David, 2000, Mechanisms of Development, V91, P451, DOI 10.1016/S0925-4773(00)00248-3; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; Flores C, 1999, P NATL ACAD SCI USA, V96, P2964, DOI 10.1073/pnas.96.6.2964; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hiki Y, 2001, KIDNEY INT, V59, P1077, DOI 10.1046/j.1523-1755.2001.00591.x; HOMA FL, 1993, J BIOL CHEM, V268, P12609; KONGSUWAN K, 1985, NATURE, V317, P555, DOI 10.1038/317555a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; McManus AM, 1999, BIOCHEMISTRY-US, V38, P705, DOI 10.1021/bi981956d; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEKELS LL, 1995, BIOCHEM J, V311, P775, DOI 10.1042/bj3110775; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Westerman EL, 1999, GLYCOBIOLOGY, V9, P1121; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	32	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22616	22622		10.1074/jbc.M201807200	http://dx.doi.org/10.1074/jbc.M201807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11925446	hybrid			2022-12-25	WOS:000176313600068
J	Whitsett, JA; Clark, JC; Picard, L; Tichelaar, JW; Wert, SE; Itoh, N; Perl, AKT; Stahlman, MT				Whitsett, JA; Clark, JC; Picard, L; Tichelaar, JW; Wert, SE; Itoh, N; Perl, AKT; Stahlman, MT			Fibroblast growth factor 18 influences proximal programming during lung morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHING MORPHOGENESIS; TRANSGENIC MICE; MOUSE LUNG; MESSENGER-RNA; FACTOR FAMILY; IN-VIVO; EXPRESSION; GENE; LIMB; DIFFERENTIATION	The structure and functions of the airways of the lung change dramatically along their lengths. Large-diameter conducting airways are supported by cartilaginous rings and smooth muscle tissue and are lined by ciliated and secretory epithelial cells that are involved in mucociliary clearance. Smaller peripheral airways formed during branching morphogenesis are lined by cuboidal and squamous cells that facilitate gas exchange to a network of fine capillaries. The factors that mediate formation of these changing cell types and structures along the length of the airways are unknown. We report here that conditional expression of fibroblast growth factor (FGF)-18 in epithelial cells of the developing lung caused the airway to adopt structural features of proximal airways. Peripheral lung tubules were markedly diminished in numbers, whereas the size and extent of conducting airways were increased. Abnormal smooth muscle and cartilage were found in the walls of expanded distal airways, which were accompanied by atypically large pulmonary blood vessels. Expression of proteins normally expressed in peripheral lung tubules, including SP-B and pro-SP-C, was inhibited. FGF-18 mRNA was detected in normal mouse lung in stromal cells surrounding proximal airway cartilage and in peripheral lung mesenchyme. Effects were unique to FGF-18 because expression of other members of the FGF family had different consequences. These data show that FGF-18 is capable of enhancing proximal and inhibiting peripheral programs during lung morphogenesis.	Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Kyoto 6068501, Japan; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA	Cincinnati Children's Hospital Medical Center; Kyoto University; Vanderbilt University	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@chmcc.org	Perl, Anne-Karina T/M-7174-2013; Tichelaar, Jay/B-9148-2011	Perl, Anne-Karina T/0000-0002-8445-4565; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P50HL056387, P01HL056387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Colvin JS, 2001, DEVELOPMENT, V128, P2095; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; HORLICK RA, 1992, GENE, V120, P291, DOI 10.1016/0378-1119(92)90108-2; Hu MCT, 1998, MOL CELL BIOL, V18, P6063, DOI 10.1128/MCB.18.10.6063; KLINT P, 1999, FRONT BIOSCI, V4, P165; KORHONEN J, 1992, INT J DEV BIOL, V36, P323; Luo YD, 1998, BIOCHEMISTRY-US, V37, P16506, DOI 10.1021/bi9816599; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Minowada G, 1999, DEVELOPMENT, V126, P4465; MUENKE M, 2001, CRANIOSYNOSTOSIS SYN, V4, P6117; Ohbayashi N, 1998, J BIOL CHEM, V273, P18161, DOI 10.1074/jbc.273.29.18161; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; Powell PP, 1998, AM J RESP CELL MOL, V19, P563, DOI 10.1165/ajrcmb.19.4.2994; SANNES PL, 1992, AM J RESP CELL MOL, V7, P230, DOI 10.1165/ajrcmb/7.2.230; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; SHANNON JM, 1994, DEV BIOL, V166, P600, DOI 10.1006/dbio.1994.1340; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tichelaar JW, 1999, J HISTOCHEM CYTOCHEM, V47, P823, DOI 10.1177/002215549904700612; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; Wang O, 2001, DEVELOPMENT, V128, P3867; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Xu JS, 2000, DEVELOPMENT, V127, P1833; Zhao BH, 2001, P NATL ACAD SCI USA, V98, P5898, DOI 10.1073/pnas.101116598; Zhou L, 1996, AM J PHYSIOL-LUNG C, V271, pL987, DOI 10.1152/ajplung.1996.271.6.L987	43	65	68	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22743	22749		10.1074/jbc.M202253200	http://dx.doi.org/10.1074/jbc.M202253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11927601	hybrid			2022-12-25	WOS:000176313600083
J	Amano, T; Kaji, N; Ohashi, K; Mizuno, K				Amano, T; Kaji, N; Ohashi, K; Mizuno, K			Mitosis-specific activation of LIM motif-containing protein kinase and roles of cofilin phosphorylation and dephosphorylation in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIN REORGANIZATION; CYTOSKELETAL DYNAMICS; DEPOLYMERIZING FACTOR; CLEAVAGE FURROW; CELL-CYCLE; CYTOKINESIS; RHO; IDENTIFICATION; LIM-KINASE-1; REGULATORS	Actin filament dynamics play a critical role in mitosis and cytokinesis. LIM motif-containing protein kinase 1 (LIMK1) regulates actin reorganization by phosphorylating and inactivating cofilin, an actin-depolymerizing and -severing protein. To examine the role of LIMK1 and cofilin during the cell cycle, we measured cell cycle-associated changes in the kinase activity of LIMK1 and in the level of cofilin phosphorylation. Using synchronized HeLa cells, we found that LIMK1 became hyper-phosphorylated. and activated in prometaphase and metaphase, then gradually returned to the basal level as cells entered into telophase and cytokinesis. Although Rho-associated kinase and p21-activated protein kinase phosphorylate and activate LIMK1, they are not likely to be involved in mitosis-specific activation and phosphorylation of LIMK1. Immunoblot and immunofluorescence analyses using an anti-phosphocofilin-specific antibody revealed that the level of cofilin phosphorylation, similar to levels of LIMK1 activity, increased during prometaphase and metaphase then gradually declined in telophase and cytokinesis. Ectopic expression of LIMK1 increased the level of cofilin phosphorylation throughout the cell cycle and induced the formation of multinucleate cells. These results suggest that LIMK1 is involved principally in control of mitosis-specific cofilin phosphorylation and that dephosphorylation and reactivation of cofilin at later stages of mitosis play a critical role in cytokinesis of mammalian cells.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan	Tohoku University	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Aoba Ku, Aramaki Aza Aoba, Sendai, Miyagi 9808578, Japan.		Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Amano T, 2001, BIOCHEM J, V354, P149, DOI 10.1042/0264-6021:3540149; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Chernoff J, 1999, NAT CELL BIOL, V1, pE115, DOI 10.1038/12942; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; FISHKIND DJ, 1995, CURR OPIN CELL BIOL, V7, P23, DOI 10.1016/0955-0674(95)80041-7; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Nagata K, 1999, BIOCHEM J, V343, P99, DOI 10.1042/0264-6021:3430099; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Takahashi T, 2001, DEV BIOL, V229, P554, DOI 10.1006/dbio.2000.9999; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	40	74	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					22093	22102		10.1074/jbc.M201444200	http://dx.doi.org/10.1074/jbc.M201444200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11925442	hybrid			2022-12-25	WOS:000176286000122
J	Gaille, C; Kast, P; Haas, D				Gaille, C; Kast, P; Haas, D			Salicylate biosynthesis in Pseudomonas aeruginosa - Purification and characterization of PchB, a novel bifunctional enzyme displaying isochorismate pyruvate-lyase and chorismate mutase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MENAQUINONE VITAMIN-K-2 BIOSYNTHESIS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; MYCOBACTERIUM-SMEGMATIS; PYOCHELIN BIOSYNTHESIS; MOLECULAR-CLONING; ACID; GENES; ENTEROBACTIN; SIDEROPHORE	Isochorismate pyruvate-lyase (IPL), the second enzyme of pyochelin biosynthesis and the product of the pchB gene, was purified to homogeneity from Pseudomonas aeruginosa. In the reaction catalyzed by this enzyme, isochorismate salicylate + pyruvate, no cofactors appear to be required. At the pH optimum (pH 6.8), the enzyme displayed Michaelis-Menten kinetics, with an apparent K-m of 12.5 muM for isochorismate and a k(cat) of 106 min(-1), calculated per monomer. The native enzyme behaved as a homodimer, as judged by molecular sieving chromatography, electrophoresis under nondenaturing conditions, and cross-linking experiments. PchB has approximately 20% amino acid sequence identity with AroQ-class chorismate mutases (CMs). Chorismate was shown to be converted to prephenate by purified PchB in vitro, with an apparent K-m of 150 muM and a k(cat) of 7.8 min(-1). An oxabicyclic diacid transition state analog and well characterized inhibitor of CMs competitively inhibited both IPL and CM activities of PchB. Moreover, a CM-deficient Escherichia coli mutant, which is auxotrophic for phenylalanine and tyrosine, was functionally complemented by the cloned P. aeruginosa pchB gene for growth in minimal medium. A mutant form of PchB, in which isoleucine 88 was changed to threonine, had no detectable IPL activity, but retained wild-type CM activity. In conclusion, the 11.5-kDa subunit of PchB appears to contain a single active site involved in both IPL and CM activity.	Univ Lausanne, Lab Biol Microbienne, CH-1015 Lausanne, Switzerland; Swiss Fed Inst Technol, Organ Chem Lab, CH-8093 Zurich, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; ETH Zurich	Haas, D (corresponding author), Univ Lausanne, Lab Biol Microbienne, CH-1015 Lausanne, Switzerland.							Adilakshmi T, 2000, J BACTERIOL, V182, P264, DOI 10.1128/JB.182.2.264-271.2000; AHMAD S, 1988, MOL BIOL EVOL, V5, P282; ANKENBAUER RG, 1988, J BACTERIOL, V170, P5364, DOI 10.1128/jb.170.11.5364-5367.1988; ANKENBAUER RG, 1988, J BACTERIOL, V170, P5344, DOI 10.1128/jb.170.11.5344-5351.1988; BARTLETT PA, 1988, J ORG CHEM, V53, P3195, DOI 10.1021/jo00249a013; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALHOUN DH, 2001, GENOME BIOL, V2; Chin-A-Woeng TFC, 2001, MOL PLANT MICROBE IN, V14, P1006, DOI 10.1094/MPMI.2001.14.8.1006; COTTON RGH, 1965, BIOCHIM BIOPHYS ACTA, V100, P76, DOI 10.1016/0304-4165(65)90429-0; COX CD, 1981, P NATL ACAD SCI-BIOL, V78, P4256, DOI 10.1073/pnas.78.7.4256; Dahm C, 1998, BBA-GEN SUBJECTS, V1425, P377, DOI 10.1016/S0304-4165(98)00089-0; Daruwala R, 1997, J BACTERIOL, V179, P3133, DOI 10.1128/jb.179.10.3133-3138.1997; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; ESSAR DW, 1990, J BACTERIOL, V172, P884, DOI 10.1128/jb.172.2.884-900.1990; FARINHA MA, 1990, FEMS MICROBIOL LETT, V70, P221, DOI 10.1016/S0378-1097(05)80043-6; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; GIBSON F, 1964, BIOCHEM J, V90, P256, DOI 10.1042/bj0900256; GORISCH H, 1978, BIOCHEMISTRY-US, V17, P3700, DOI 10.1021/bi00611a004; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; HEIDE E, 1978, BIOCHEMISTRY-US, V17, P1573; HUDSON A T, 1970, Tetrahedron Letters, V24, P2077; HUDSON AT, 1970, BIOCHEMISTRY-US, V9, P3984, DOI 10.1021/bi00822a017; Kast P, 1996, TETRAHEDRON LETT, V37, P2691, DOI 10.1016/0040-4039(96)00338-3; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Kwon O, 1996, J BACTERIOL, V178, P3252, DOI 10.1128/jb.178.11.3252-3259.1996; LAMMELI UK, 1973, J MOL BIOL, V80, P575; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MacBeath G, 1998, BIOCHEMISTRY-US, V37, P10062, DOI 10.1021/bi980449t; MARSHALL BJ, 1971, BIOCHIM BIOPHYS ACTA, V230, P643, DOI 10.1016/0304-4165(71)90201-7; MARSHALL BJ, 1972, BIOCHIM BIOPHYS ACTA, V264, P106, DOI 10.1016/0304-4165(72)90122-5; Mattei P, 1999, EUR J BIOCHEM, V261, P25, DOI 10.1046/j.1432-1327.1999.00169.x; Mercado-Blanco J, 2001, J BACTERIOL, V183, P1909, DOI 10.1128/JB.183.6.1909-1920.2001; OKUJO N, 1994, BIOMETALS, V7, P109; PATEL N, 1977, J BIOL CHEM, V252, P5839; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Reimmann C, 1998, MICROBIOL-UK, V144, P3135, DOI 10.1099/00221287-144-11-3135; Reimmann C, 2001, J BACTERIOL, V183, P813, DOI 10.1128/JB.183.3.813-820.2001; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rowland BM, 1996, J BACTERIOL, V178, P854, DOI 10.1128/jb.178.3.854-861.1996; RUSNAK F, 1990, BIOCHEMISTRY-US, V29, P1425, DOI 10.1021/bi00458a013; Sambrook J., 2002, MOL CLONING LAB MANU; SAXENA B, 1986, J GEN MICROBIOL, V132, P2219; SCHMIDT K, 1995, BIOTECHNOL BIOENG, V45, P285, DOI 10.1002/bit.260450402; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; Serino L, 1997, J BACTERIOL, V179, P248, DOI 10.1128/jb.179.1.248-257.1997; SOKOL PA, 1992, J MED MICROBIOL, V36, P184, DOI 10.1099/00222615-36-3-184; TIETZ D, 1987, ANAL BIOCHEM, V161, P395, DOI 10.1016/0003-2697(87)90468-4; van Tegelen LJP, 1999, PLANT PHYSIOL, V119, P705, DOI 10.1104/pp.119.2.705; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WALSH CT, 1990, CHEM REV, V90, P1105, DOI 10.1021/cr00105a003; XIA TH, 1993, J BACTERIOL, V175, P4729, DOI 10.1128/JB.175.15.4729-4737.1993; YOUNG IG, 1969, BIOCHIM BIOPHYS ACTA, V177, P389, DOI 10.1016/0304-4165(69)90301-8; ZHAO GS, 1992, J BIOL CHEM, V267, P2487	56	96	103	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21768	21775		10.1074/jbc.M202410200	http://dx.doi.org/10.1074/jbc.M202410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11937513	hybrid			2022-12-25	WOS:000176286000085
J	Hahn, JS; Thiele, DJ				Hahn, JS; Thiele, DJ			Regulation of the Saccharomyces cerevisiae Slt2 kinase pathway by the stress-inducible Sdp1 dual specificity phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-WALL INTEGRITY; FUS3 MAP KINASE; TYROSINE PHOSPHATASES; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; OSMOTIC-STRESS; YEAST; HOG1	The Slt2/Mpk1 mitogen-activated protein kinase (MAPK) cell integrity pathway is involved in maintenance of cell shape and integrity during vegetative growth and mating in Saccharomyces cerevisiae. Slt2 is activated by dual phosphorylation of a threonine and tyrosine residue in response to several environmental stresses that perturb cell integrity. Negative regulation of Slt2 is achieved via dephosphorylation by two protein-tyrosine phosphatases, Ptp2 and Ptp3, and a dual specificity phosphatase, Msg5. In this study, we provide genetic and biochemical evidence that the stress-inducible dual specificity phosphatase, Sdp1, negatively regulates Slt2 by direct dephosphorylation. Deletion of SDP1 exacerbated growth defects due to overexpression of Mkk1(p386), a constitutively active mutant of Slt2 MAPK kinase, whereas overexpression of Sdp1 suppressed lethality caused by Mkk1(p386). overexpression. The heat shock-induced phosphorylation level of Slt2 was elevated in an sdp1Delta strain compared with that of the wild type, and heat shock-activated phospho-Slt2 was dephosphorylated by recombinant Sdp1 in vitro. Under normal growth conditions, an Sdp1-GFP fusion protein was localized to both the nucleus and cytoplasm. However, the Sdp1-GFP protein translocated to punctate spots throughout the cell after heat shock. SDP1 transcription was induced by several stress conditions in an Msn2/4-dependent manner but independent of the Rlm1 transcription factor, a downstream target activated by Slt2. Induction of SLT2 by high osmolarity was dependent on Rlm1 transcription factor and Hog1 kinase, suggesting cross-talk between Slt2 and Hog1 MAPK pathways. These studies demonstrate regulation of Slt2 activity and gene expression in coordination with other stress signaling pathways.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.		Rho, Hyunji/R-6242-2016	Rho, Hyunji/0000-0001-7650-8933	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059911] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Davenport KD, 1999, GENETICS, V153, P1091; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fox D, 1999, MOL MICROBIOL, V34, P451, DOI 10.1046/j.1365-2958.1999.01606.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HUANG KN, 1995, GENETICS, V141, P1275; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jacoby T, 1997, J BIOL CHEM, V272, P17749, DOI 10.1074/jbc.272.28.17749; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Mattison CP, 1999, MOL CELL BIOL, V19, P7651; Mattison CP, 2000, GENE DEV, V14, P1229; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x; Zhan XL, 1997, GENE DEV, V11, P1690, DOI 10.1101/gad.11.13.1690; Zhan XL, 1999, GENE DEV, V13, P2811, DOI 10.1101/gad.13.21.2811	41	95	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21278	21284		10.1074/jbc.M202557200	http://dx.doi.org/10.1074/jbc.M202557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923319	hybrid			2022-12-25	WOS:000176286000022
J	Zheng, XM; Resnick, RJ; Shalloway, D				Zheng, XM; Resnick, RJ; Shalloway, D			Mitotic activation of protein-tyrosine phosphatase alpha and regulation of its Src-mediated transforming activity by its sites of protein kinase C phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTP-ALPHA; RPTP-ALPHA; PP60(C-SRC); ASSOCIATION; PP60C-SRC; ADAPTER; GRB2; OVEREXPRESSION; FAMILY; DOMAIN	During mitosis, the catalytic activity of protein-tyrosine phosphatase (PTP) alpha is enhanced, and its inhibitory binding to Grb2, which specifically blocks Src dephosphorylation, is decreased. These effects act synergistically to activate Src in mitosis. We show here that these effects are abrogated by mutation of Ser(180) and/or Ser(204), the sites of protein kinase C-mediated phosphorylation within PTPalpha. Moreover, either a Ser-to-Ala substitution or serine dephosphorylation specifically eliminated the ability of PTPalpha to dephosphorylate and activate Src even during interphase. This explains why the substitutions eliminated PTPalpha transforming activity, even though PTPalpha interphase dephosphorylation of nonspecific substrates was only slightly decreased. This occurred without change in the phosphorylation of PTPalpha at Tyr(789), which is required for "phosphotyrosine displacement" during Src dephosphorylation. Thus, in addition to increasing PTPalpha nonspecific catalytic activity, Ser(180) and Ser(204) phosphorylation (along with Tyr(789) phosphorylation) regulates PTPalpha substrate specificity. This involves serine phosphorylation-dependent differential modulation of the affinity of Tyr(P)(789) for the Src and Grb2 SH2 domains. The results suggest that protein kinase C may participate in the mitotic activation of PTPalpha and Src and that there are intramolecular interactions between the PTPalpha C-terminal and membrane-proximal regions that are regulated, at least in part, by serine phosphorylation.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Shalloway, D (corresponding author), Cornell Univ, Dept Mol Biol & Genet, 265 Biotechnol Bldg, Ithaca, NY 14883 USA.	dis2@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA032317] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA032317, CA32317] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BLACK JD, 2001, FRONT BIOSCI, V5, P406; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILMER T, 1994, J BIOL CHEM, V269, P31711; HARDIE G, 1995, PROTEIN KINASE FACTS, P240; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Ogura K, 1999, J MOL BIOL, V289, P439, DOI 10.1006/jmbi.1999.2792; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Petrone A, 2000, J CELL SCI, V113, P2345; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; Shalloway D, 1997, TRENDS CELL BIOL, V7, P215; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stetak A, 2001, BIOCHEM BIOPH RES CO, V285, P483, DOI 10.1006/bbrc.2001.5199; Stetak A, 2001, BIOCHEM BIOPH RES CO, V288, P564, DOI 10.1006/bbrc.2001.5811; STOVER DR, 1994, J BIOL CHEM, V269, P26885; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	40	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21922	21929		10.1074/jbc.M201394200	http://dx.doi.org/10.1074/jbc.M201394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11923305	Green Accepted, hybrid			2022-12-25	WOS:000176286000104
J	Ponimaskin, EG; Profirovic, J; Vaiskunaite, R; Richter, DW; Voyno-Yasenetskaya, TA				Ponimaskin, EG; Profirovic, J; Vaiskunaite, R; Richter, DW; Voyno-Yasenetskaya, TA			5-hydroxytryptamine 4(a) receptor is coupled to the G alpha subunit of heterotrimeric G(13) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; LYSOPHOSPHATIDIC ACID; NEURITE OUTGROWTH; THALAMIC NEURONS; P115 RHOGEF; SF9 CELLS; SEROTONIN; ACTIVATION; GROWTH; BINDING	Serotonin (5-hydroxytryptamine (5-HT)) is an important neurotransmitter that regulates multiple events in the central nervous system. Many of the 5-HT functions are mediated via G protein-coupled receptors that are coupled to multiple heterotrimeric G proteins, including G(s), G(j), and G(q) subfamilies (Martin, G. R., Eglen, R. M., Hamblin, M. W.,Hoyer, D., and Yocca, F. (1998) Trends Pharmacol, Sci 19, 2-4). Here we show for the first time that the 5-hydroxytryptamine 4(a) receptor (5-HT4(a)) is coupled not only to heterotrimeric G(s) but also to G(13) protein, as assessed both by biochemical and functional assays. Using reconstitution of 5-HT4(a) receptor with different G proteins in Spodoptera frugiperda (Sf.9) cells, we have proved that agonist stimulation of receptor-induced guanosine 5'-(3-O-thio)triphosphate binding to Galpha(13) protein. We then determined that expression of 5-HT4(a) receptor in mammalian cells induced constitutive- as well as agonist-promoted activation of a transcription factor, serum response element, through the activation of Gals and RhoA. Finally, we have determined that expression of 5-HT4(a) receptor in neuroblastoma x glioma NIE-115 cells cause RhoA-dependent neurite retraction and cell rounding under basal conditions and after agonist stimulation. These data suggest that by activating 5-HT4(a) receptor-G(13) pathway, serotonin plays a prominent role in regulating neuronal architecture in addition to its classical role in neurotransmission.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Gottingen, Inst Physiol, Abt Neuro & Sinnesphysiol, D-37073 Gottingen, Germany	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Gottingen	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Ponimaskin, evgeni/0000-0002-4570-5130	NIGMS NIH HHS [GM56159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; BAKER MW, 1993, BRAIN RES, V623, P311, DOI 10.1016/0006-8993(93)91444-W; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BONHOMME N, 1995, BRAIN RES, V675, P215, DOI 10.1016/0006-8993(95)00067-Z; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Claeysen S, 1999, MOL PHARMACOL, V55, P910; DIEFENBACH TJ, 1995, DEV BIOL, V167, P282, DOI 10.1006/dbio.1995.1023; EGLEN RM, 1995, TRENDS PHARMACOL SCI, V16, P391, DOI 10.1016/S0165-6147(00)89081-1; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GOLDBERG JI, 1991, J NEUROBIOL, V22, P182, DOI 10.1002/neu.480220208; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; IGARASHI M, 1995, J NEUROSCI, V15, P5660; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Koert CE, 2001, J NEUROSCI, V21, P5597, DOI 10.1523/JNEUROSCI.21-15-05597.2001; Kostner E., 1995, Society for Neuroscience Abstracts, V21, P862; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kranenburg O, 1997, J CELL SCI, V110, P2417; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lieske V, 1999, NEUROSCIENCE, V90, P967, DOI 10.1016/S0306-4522(98)00501-6; LIMA L, 1994, J NEUROSCI RES, V38, P444, DOI 10.1002/jnr.490380410; LIU JP, 1991, DEV BRAIN RES, V62, P297, DOI 10.1016/0165-3806(91)90180-Q; Lotto B, 1999, NEUROSCI LETT, V269, P87, DOI 10.1016/S0304-3940(99)00422-X; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MarchettiGauthier E, 1997, NEUROPHARMACOLOGY, V36, P697, DOI 10.1016/S0028-3908(97)00058-0; Mercer AR, 1996, J NEUROBIOL, V29, P49, DOI 10.1002/(SICI)1097-4695(199601)29:1<49::AID-NEU4>3.0.CO;2-7; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; NIU J, 2001, CURR BIOL, V11, P1; Pauwels PJ, 1996, N-S ARCH PHARMACOL, V354, P136; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; Ponimaskin EG, 2002, J BIOL CHEM, V277, P2534, DOI 10.1074/jbc.M106529200; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Scott JD, 2000, ADV PHARMACOL, V47, P175; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Tigyi G, 1996, J NEUROCHEM, V66, P549; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wong EHF, 1996, BEHAV BRAIN RES, V73, P249; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Wu-Wong JR, 1998, J CARDIOVASC PHARM, V31, pS185, DOI 10.1097/00005344-199800001-00053; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837	53	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20812	20819		10.1074/jbc.M112216200	http://dx.doi.org/10.1074/jbc.M112216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11923294	hybrid			2022-12-25	WOS:000176204500091
J	Zhang, HJ; Zhao, WL; Venkataraman, S; Robbins, MEC; Buettner, GR; Kregel, KC; Oberley, LW				Zhang, HJ; Zhao, WL; Venkataraman, S; Robbins, MEC; Buettner, GR; Kregel, KC; Oberley, LW			Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED PEPTIDE SEQUENCE; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; CYSTEINE-SWITCH; CU,ZN-SUPEROXIDE DISMUTASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; IV COLLAGENASE; GLIOMA-CELLS	Matrix metalloproteinases (MMPs) participate in cell migration and remodeling processes by affecting the extracellular matrix. MMP-2 is thought to be involved in cancer cell invasiveness. It has been proposed that the activity of MMP-2 can be modulated by intracellular reactive oxygen species (ROS)/reactive nitrogen species. We hypothesized that manganese superoxide dismutase (MnSOD) could mediate MMP-2 activity by changing the intracellular ROS level and that nitric oxide (NO) may be involved in this process. Human breast cancer MCF-7 cells were stably transfected with plasmids containing MnSOD cDNA. A 2-30-fold increase of MnSOD protein and activity was observed in four clones. Our data demonstrated that overexpression of MnSOD stimulated the activation of MMP-2 with a corresponding elevation of ROS. A decrease in ROS by ebselen, a glutathione peroxidase mimetic, or by transduction of adenovirus containing human catalase or glutathione peroxidase cDNA abolished the effect of MnSOD on MMP-2 activation. Treatment of MCF-7 cells with antimycin A or rotenone increased intracellular ROS production and MMP-2 activation simultaneously. Our data also showed a suppression of endothelial nitric-oxide synthase expression that was accompanied by decreased (NO)-N-. production in MnSOD-overexpressing cells. However, the changes in endothelial nitric-oxide synthase and (NO)-N-. did not correlate with the MnSOD activity. Corresponding changes of MMP-2 activity after the addition of a NOS inhibitor (N-G--amino-L-arginine) or a (NO)-N-. donor ((Z)-1-[(2-aminoethyl) -N-(2-ammonioethyl) amino]diazen-1-ium-1,2-diolate) to the cells suggested the possibility that (NO)-N-. may be involved in the MnSOD-mediated MMP2 activation pathway. These results indicate that MnSOD induces MMP-2 activity by regulation of intracellular ROS and imply that signaling pathways involving (NO)-N-. may also be involved in the MnSOD mediation of MMP-2 activity.	Univ Iowa, Dept Radiat Oncol, Free Radical & Radiat Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Exercise Sci, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Oberley, LW (corresponding author), Univ Iowa, Dept Radiat Oncol, Free Radical & Radiat Biol Program, B180 ML, Iowa City, IA 52242 USA.			Buettner, Garry/0000-0002-5594-1903	NCI NIH HHS [P01 CA 660841, CA84462] Funding Source: Medline; NIA NIH HHS [AG 14687, AG 12350] Funding Source: Medline; NIDDK NIH HHS [DK 51612] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014687, R01AG012350, R29AG012350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; BASS DA, 1983, J IMMUNOL, V130, P1910; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Camhi S L, 1995, New Horiz, V3, P170; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CRAWFORD HC, 1994, INVAS METAST, V14, P234; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; LOTTA LA, 1984, AM J PATHOL, V117, P339; MAIORINO M, 1988, BIOCHEM PHARMACOL, V37, P2267, DOI 10.1016/0006-2952(88)90591-6; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; MELCHIORI A, 1992, CANCER RES, V52, P2353; NOMURA K, 1993, FEBS LETT, V321, P84, DOI 10.1016/0014-5793(93)80626-6; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 1986, FREE RADICALS AGING, P352; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PARHAM MJ, 1987, BIOCHEM PHARMACOL, V36, P3095; PARK AJ, 1991, J BIOL CHEM, V266, P1584; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SEFTOR REB, 1994, ELECTROPHORESIS, V15, P454, DOI 10.1002/elps.1150150162; Siwik DA, 2001, AM J PHYSIOL-CELL PH, V280, pC53, DOI 10.1152/ajpcell.2001.280.1.C53; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1991, AM J MED SCI, V302, P163, DOI 10.1097/00000441-199109000-00009; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; SUN Y, 1988, FREE RADICAL RES COM, V5, P67, DOI 10.3109/10715768809066913; Thomas Patricia A, 1997, Pathol Oncol Res, V3, P278; Vanden Hoek Terry L., 1997, Journal of Molecular and Cellular Cardiology, V29, P2441, DOI 10.1006/jmcc.1997.0481; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Yan T, 1996, CANCER RES, V56, P2864; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhao W, 2000, INT J RADIAT BIOL, V76, P391, DOI 10.1080/095530000138736; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	49	164	170	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20919	20926		10.1074/jbc.M109801200	http://dx.doi.org/10.1074/jbc.M109801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11929863	hybrid			2022-12-25	WOS:000176204500105
J	Artz, JD; Schmidt, B; McCracken, JL; Marletta, MA				Artz, JD; Schmidt, B; McCracken, JL; Marletta, MA			Effects of nitroglycerin on soluble guanylate cyclase - Implications for nitrate tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DONORS; ANGINA-PECTORIS; CARBON-MONOXIDE; BOVINE LUNG; NO DONORS; ACTIVATION; HEME; OXYHEMOGLOBIN; THERAPY; RELAXATION	Soluble guanylate cyclase (sGC) is a heterodimeric hemoprotein that catalyzes the conversion of GTP to cGMP. Upon binding NO to its heme cofactor, purified sGC was activated 300-fold. sGC was only activated 67-fold by nitroglycerin (GTN) and Cys; and in the absence of Cys, GTN did not activate sGC. Electronic absorption spectroscopy studies showed that upon NO binding, the Soret of ferrous sGC shifted from 431 to 399 nm. The data also revealed that activation of sGC by GTN/Cys was not via the expected ferrous heme-NO species as indicated by the absence of the 399 nm heme Soret. Furthermore, EPR studies of the reaction of GTN/Cys with sGC confirmed that no ferrous heme-NO species was formed but that there was heme oxidation. Potassium ferricyanide is known to oxidize ferrous sGC to the ferric oxidation state. Spectroscopic and activity data for the reactions of sGC with GTN alone or with K3Fe(CN)(6) were indistinguishable. These data suggest the following: 1) GTN/Cys do not activate sGC via GTN biotransformation to NO in vitro, and 2) in the absence of added thiol, GTN oxidizes sGC.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Michigan State University	Marletta, MA (corresponding author), Univ Calif Berkeley, Dept Chem, 211 Lewis Hall, Berkeley, CA 94720 USA.		Artz, Jennifer/G-5515-2014	Artz, Jennifer/0000-0003-0500-6156	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054065] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54065] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams J, 1998, AM J CARDIOL, V81, p3A, DOI 10.1016/S0002-9149(97)00992-2; Artz JD, 1998, CHEM RES TOXICOL, V11, P1393, DOI 10.1021/tx980205+; Artz JD, 2001, BIOCHEMISTRY-US, V40, P9256, DOI 10.1021/bi002885x; BOHYN M, 1991, CARDIOVASC DRUG THER, V5, P457, DOI 10.1007/BF03029770; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; CHONG S, 1991, BIOCHEM PHARMACOL, V42, P1433; CHUNG SJ, 1993, BIOCHEM PHARMACOL, V45, P157; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DUNSTAN I, 1965, J CHEM SOC, P1319, DOI 10.1039/jr9650001319; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; GRUETTER CA, 1986, CAN J PHYSIOL PHARM, V64, P1395, DOI 10.1139/y86-236; IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Marsh N, 2000, CLIN EXP PHARMACOL P, V27, P313, DOI 10.1046/j.1440-1681.2000.03240.x; MUNZEL T, 1995, J CLIN INVEST, V95, P187, DOI 10.1172/JCI117637; NEEDLEMAN P, 1972, J PHARMACOL EXP THER, V181, P489; Parker JD, 1998, NEW ENGL J MED, V338, P520, DOI 10.1056/NEJM199802193380807; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1996, BIOCHEMISTRY-US, V35, P3258, DOI 10.1021/bi952386+; Stone JR, 1998, CHEM BIOL, V5, P255, DOI 10.1016/S1074-5521(98)90618-4; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Thatcher RGJ, 1998, CHEM SOC REV, V27, P331; WALDMAN SA, 1986, BIOCHEM PHARMACOL, V35, P3525, DOI 10.1016/0006-2952(86)90622-2; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhao YD, 2000, BIOCHEMISTRY-US, V39, P10848, DOI 10.1021/bi9929296	35	38	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18253	18256		10.1074/jbc.C200170200	http://dx.doi.org/10.1074/jbc.C200170200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11937497	hybrid			2022-12-25	WOS:000175975800003
J	Hochedlinger, K; Wagner, EF; Sabapathy, K				Hochedlinger, K; Wagner, EF; Sabapathy, K			Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis	ONCOGENE			English	Article						JNK; c-Jun; apoptosis; UV irradiation; TNF-alpha; sorbitol	C-JUN; ACTIVATION; KINASE; ABSENCE	The c-Jun N-terminal kinases (JNKs) are activated by a variety of stress inducing agents and are thought to regulate apoptosis in a cell type and signal-specific manner. We have used fibroblasts lacking JNK1 or JNK2 to define their roles in response to different stress signals. Lack of JNK1 results in reduced c-Jun phosphorylation and resistance to UV-induced cell death. JNK2 deficient cells show increased sensitivity to UV irradiation which correlates with elevated and sustained phosphorylation of JNK1 and c-Jun. On the contrary, both Jnk1(-/-) and Jnk2(-1) cells were more sensitive to tumor necrosis factor - alpha (TNF-alpha) and sorbitol-induced cell death. Treatment of Jnk1(-/-) cells with these reagents resulted in reduced JNK activity and a concomitant reduction of c-Jun phosphorylation, suggesting that phosphorylation of c-Jun does not influence TNF-alpha and sorbitol-induced apoptosis in fibroblasts. Moreover, both JNK1 and JNK2 appear to negatively regulate apoptosis independent of c-Jun phosphorylation. These data provide genetic evidence that although the JNK pathway is activated by a plethora of signals, it is required only for the induction of UV-induced cell death in a c-Jun phosphorylation-dependent manner, but not for TNF-alpha and sorbitol-induced apoptosis.	Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, Singapore 169610, Singapore; Res Inst Mol Pathol, A-1030 Vienna, Austria	National Cancer Centre Singapore (NCCS); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sabapathy, K (corresponding author), Natl Canc Ctr, Mol Carcinogenesis Lab, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	emrksb@nccs.com.sg		Wagner, Erwin F/0000-0001-7872-0196				Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	15	88	90	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2441	2445		10.1038/sj.onc.1205348	http://dx.doi.org/10.1038/sj.onc.1205348			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948429				2022-12-25	WOS:000174635600018
J	Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M				Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M			Bloom's syndrome protein response to ultraviolet-C radiation and hydroxyurea-mediated DNA synthesis inhibition	ONCOGENE			English	Article						Bloom's syndrome; UVC radiation; hydroxyurea-mediated DNA synthesis inhibition; cell cycle checkpoints; phosphorylation	SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; SYNDROME FIBROBLASTS; IONIZING-RADIATION; REPLICATION; CELLS; CHECKPOINT; P53; PHOSPHORYLATION; P21(WAF1/CIP1)	Bloom's syndrome (BS) arises through mutations in both copies of the BLM gene that encodes a RecQ 3'-5' DNA helicase. BS patients are predisposed to developing all the cancers that affect the general population, and BS cells exhibit marked genetic instability. We showed recently that BLM protein contributes to the cellular response to ionizing radiation by acting as downstream ATM kinase effector. We now show that following UVC treatment, BLM-deficient cells exhibit a reduction in the number of replicative cells, a partial escape from the G2/M cell cycle checkpoint, and have an altered p21 response. Surprisingly, we found that hydroxyureatreated BLM-deficient cells exhibit an intact S phase arrest, proper recovery from the S phase arrest, and intact p53 and p21 responses. We also show that the level of BLM falls sharply in response to UVC radiation. This UVC-induced reduction in BLM does not require a functional ATM gene and does not result from a subcellular compartment change. Finally, we demonstrate that exposure to UVC and hydroxyurea treatment both induce BLM phosphorylation via an ATM-independent pathway. These results are discussed in the light of their potential physiological significance with regard to the role of BLM in the cellular pathways activated by UVC radiation or HU-mediated inhibition of DNA synthesis.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Cytometr Flux, IFR 54, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	amor@igr.fr		ababou, mouna/0000-0003-4276-3754				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; ANDO T, 2001, J BIOL CHEM, V14, P14; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HAND R, 1977, HUM GENET, V38, P297, DOI 10.1007/BF00402156; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAMADA A, 1989, PHOTODERMATOLOGY, V6, P124; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang SC, 2001, CANCER RES, V61, P2838; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	43	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2079	2088		10.1038/sj.onc.1205246	http://dx.doi.org/10.1038/sj.onc.1205246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960380				2022-12-25	WOS:000174827000014
J	Maher, P				Maher, P			Phorbol esters inhibit fibroblast growth factor-2-stimulated fibroblast proliferation by a p38 MAP kinase dependent pathway	ONCOGENE			English	Article						FGF; p38 MAPK; ERK; PKC; proliferation; fibroblasts	ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR-1; CYTOSKELETAL REORGANIZATION; TYROSINE PHOSPHORYLATION; CELL-PROLIFERATION; NEURITE OUTGROWTH; MITOGEN; PHOSPHATASE; EXPRESSION; ROLES	Treatment of fibroblasts with the phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA), specifically inhibits fibroblast growth factor-2 (FGF-2) induced proliferation. TPA treatment has little or no effect on FGF receptor activation but specifically inhibits the activation of p38 MAPK but not other downstream signaling pathways implicated in cell proliferation. p38 MAPK was recently shown to be required for the FGF-2-stimulated proliferation of fibroblasts. The effect of TPA on both p38 MAPK activation and cell proliferation can be reversed by treatment with the PKC inhibitor Go6983. The TPA-mediated inhibition of p38 MAPK activation requires phosphatase activity and is at least partially mediated by ERKs since it is reduced by treatment with the MEK inhibitor PD98059. In contrast, the FGF-2-stimulated differentiation of PC12 cells, which express the same FGF receptor as Swiss 3T3 fibroblasts, is not affected by TPA treatment, consistent with a lack of involvement of p38 MAPK activity in this process. These data indicate that the effects of TPA treatment on cellular function are not only cell type but also stimulus specific and are dependent upon the distinct pathways activated downstream of each stimulus.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Maher, P (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pmaher@scripps.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054604] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54604] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARITA Y, 1994, INT J CANCER, V56, P229, DOI 10.1002/ijc.2910560215; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cross MJ, 2000, J CELL SCI, V113, P643; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; KLINT P, 1999, FRONT BIOSCI, V4, P165; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS TS, 1998, CANCER RES, P47; Lin HY, 1996, J NEUROSCI, V16, P4579; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; Presta M, 1998, J BIOL CHEM, V273, P7911, DOI 10.1074/jbc.273.14.7911; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SIGMUND O, 1990, J BIOL CHEM, V265, P2257; Skaletz-Rorowski A, 1999, ARTERIOSCL THROM VAS, V19, P1608, DOI 10.1161/01.ATV.19.7.1608; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Tanaka K, 1999, JPN J CANCER RES, V90, P647, DOI 10.1111/j.1349-7006.1999.tb00796.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Weinstein IB, 1997, ADV EXP MED BIOL, V400, P313; Weiss RH, 1996, AM J PHYSIOL-CELL PH, V270, pC619, DOI 10.1152/ajpcell.1996.270.2.C619; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; ZACHARY I, 1985, CANCER SURV, V4, P729; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	56	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1978	1988		10.1038/sj.onc.1205268	http://dx.doi.org/10.1038/sj.onc.1205268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960370				2022-12-25	WOS:000174827000004
J	Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM				Sarafan-Vasseur, N; Lamy, A; Bourguignon, J; Le Pessot, F; Hieter, P; Sesboue, R; Bastard, C; Frebourg, T; Flaman, JM			Overexpression of B-type cyclins alters chromosomal segregation	ONCOGENE			English	Article						genetic instability; chromosomes; Clb5; cyclin B; yeast	CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; KINETOCHORE PROTEIN; MESSENGER-RNA; MUTATIONS; ANAPHASE; GENE; TRANSFORMATION; INSTABILITY; PROMOTERS	To identify genes which overexpression results into chromosomal instability (CIN), we developed a biological approach based on a yeast indicator strain in which CIN can be detected by a sectoring phenotype. Screening in this strain of a yeast genomic Library cloned into a high copy vector led us to identify, among the clones generating 100% of sectoring colonies, Clb5, one of the six B-type cyclins present in yeast. Overexpression of cyclin B2 and cyclin B1, the two human homologs of Clb5, in the CIN indicator strain resulted also into a sectoring phenotype and induced, like overexpression of Clb5, an abnormal sensitivity to benomyl, indicating that overexpression of B-type cyclins alters the spindle checkpoint. In a series of 38 primary colorectal cancers, we detected in five tumors (13%) an accumulation of cyclin B1, which was neither related to mRNA overexpression nor to mutation within the coding region, and in five other tumors (13%) a 2-10-fold increase of cyclin B2 mRNA which was not related to gene amplification. These results suggest that overexpression of cyclins B, resulting from different mechanisms, could contribute, through an alteration of the spindle checkpoint, to the chromosomal instability observed in cancer.	IFRMP, INSERM, EMI 9906, Fac Med & Pharm, F-76183 Rouen, France; Ctr Hosp Univ, Serv Anat & Cytol Pathol, F-76031 Rouen, France; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Rouen; University of British Columbia	Frebourg, T (corresponding author), IFRMP, INSERM, EMI 9906, Fac Med & Pharm, 22 Blvd Gambetta, F-76183 Rouen, France.	Frebourg@chu-rouen.fr	Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018	Flaman, Jean-Michel/0000-0003-3544-0199				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hyland KM, 1999, J CELL BIOL, V145, P15, DOI 10.1083/jcb.145.1.15; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Kotani T, 2001, MOL REPROD DEV, V59, P199, DOI 10.1002/mrd.1023; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; OHSUMI K, 1994, J CELL SCI, V107, P3005; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Segal M, 1998, J CELL BIOL, V143, P135, DOI 10.1083/jcb.143.1.135; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Soria JC, 2000, CANCER RES, V60, P4000; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Yin XY, 2001, CANCER RES, V61, P6487; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	32	61	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2051	2057		10.1038/sj.onc.1205257	http://dx.doi.org/10.1038/sj.onc.1205257			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960377				2022-12-25	WOS:000174827000011
